# NutriDex — Full Text Corpus

> Every entry in NutriDex (431 substances) as plain text for AI grounding: evidence tier, summary, dosing, safety, active compounds, and the cited human studies (with source URLs). Source: https://nutridex.info · Clinician-curated (Dr Daryl Peh, MBBS Singapore, MMed FM) · Educational reference, not medical advice. Last built 2026-06-26.

## Ashwagandha (Withania somnifera)
URL: https://nutridex.info/s/ashwagandha
Category: Ayurvedic, Adaptogen, Sleep & Mood
Evidence: Moderate — Several controlled trials; effects real but modest or context-dependent.
The classic adaptogen for stress and cortisol regulation.

Quick answer: Ashwagandha is used for stress & anxiety relief. NutriDex grades the human evidence as moderate — Several controlled trials; effects real but modest or context-dependent. Based on 18 cited human studies (18 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Ashwagandha is the most-studied Ayurvedic adaptogen. Randomized controlled trials report meaningful reductions in perceived stress and serum cortisol (often 20–30%) over 6–8 weeks, alongside modest improvements in sleep quality and anxiety scores. Smaller trials suggest gains in muscle strength, recovery, and testosterone in men. Most trials are short (≤12 weeks) and industry-funded, so long-term safety and effect durability remain less certain.

Benefits / uses: Stress & anxiety relief; Lower cortisol; Improved sleep; Strength & recovery.
Active compounds: Withanolides (e.g. Withaferin A); Sitoindosides.
Dose: 300–600 mg/day of root extract (standardized to 5% withanolides), often split AM/PM.
Safety: Avoid in pregnancy (traditionally abortifacient) and while breastfeeding. Commonly causes GI upset and drowsiness, and may aggravate autoimmune thyroid disease or interact with sedatives, thyroid medication and immunosuppressants. Uncommon but serious liver injury has been reported — including a case series with deaths in people with pre-existing liver disease — so stop and seek care for jaundice, dark urine, or right-upper-abdominal pain.

Cited studies (18):
  - Safety and efficacy of Withania somnifera for anxiety and insomnia: Systematic review and meta-analysis, Human psychopharmacology (2024) — Across 5 RCTs (n=254), Withania somnifera significantly reduced anxiety (HAM-A MD -5.96, 95% CI -10.34 to -1.59) and improved sleep onset latency and quality, though heterogeneity was high. [https://pubmed.ncbi.nlm.nih.gov/39083548/]
  - Dual impact of Ashwagandha: Significant cortisol reduction but no effects on perceived stress - A systematic review and meta-analysis, Nutrition and health (2025) — Pooled RCTs of adults found ashwagandha significantly lowered serum cortisol but showed no significant change in perceived stress, with no improvement in quality of life. [https://pubmed.ncbi.nlm.nih.gov/40746175/]
  - The effect of Withania somnifera (Ashwagandha) on mental health symptoms in individuals with mental disorders: systematic review and meta-analysis, BJPsych open (2025) — Systematic review and meta-analysis found ashwagandha reduced symptoms in people with diagnosed mental disorders, with greater benefit at lower doses (<=500 mg/day) and longer interventions (>8 weeks). [https://pubmed.ncbi.nlm.nih.gov/41140145/]
  - Effects of Ashwagandha on Reproductive Health: A Systematic Review of Sex-Specific Hormonal and Fertility Outcomes, Phytotherapy research : PTR (2025) — PRISMA systematic review of sex-specific reproductive outcomes concluded Withania somnifera improves male sperm count and quality (via hormone regulation and antioxidant effects) and may benefit female reproductive disorders such as PCOS and stress-related menstrual irregularities, though evidence remains preliminary. [https://pubmed.ncbi.nlm.nih.gov/41249015/]
  - Effects of Ashwagandha Supplements on Cortisol, Stress, and Anxiety Levels in Adults: A Systematic Review and Meta-Analysis, BJPsych Open (2025) — Meta-analysis of 15 RCTs (n=873) found ashwagandha reduced perceived stress (PSS mean change -4.88; 95% CI -7.84 to -1.91), anxiety (HAM-A -3.52; 95% CI -6.00 to -1.04), and cortisol (-2.36; 95% CI -3.26 to -1.46) versus placebo at 8 weeks. [https://pmc.ncbi.nlm.nih.gov/articles/PMC12242034/]
  - Effects of Ashwagandha (Withania somnifera) on Physical Performance: Systematic Review and Bayesian Meta-Analysis, Journal of functional morphology and kinesiology (2021) — Small-to-moderate gains in strength and VO₂max across 12 RCTs. [https://pmc.ncbi.nlm.nih.gov/articles/PMC8006238/]
  - Effect of Ashwagandha (Withania somnifera) extract on sleep: A systematic review and meta-analysis, PloS one (2021) — Pooled 5 RCTs (n=400) found ashwagandha extract produced a small-to-moderate improvement in overall sleep (SMD -0.59, 95% CI -0.75 to -0.42). [https://pmc.ncbi.nlm.nih.gov/articles/PMC8462692/]
  - Effect of Ashwagandha (Withania somnifera) extract on sleep: A systematic review and meta-analysis, PloS one (2021) — Meta-analysis of 5 RCTs (400 adults): Ashwagandha extract produced a small but significant improvement in overall sleep (SMD -0.59, 95% CI -0.75 to -0.42; I2=62%), with larger effects in those with insomnia, doses >=600 mg/day, and duration >=8 weeks. Also improved morning mental alertness and anxiety; no serious adverse effects. [https://pubmed.ncbi.nlm.nih.gov/34559859/]
  - Effects of Ashwagandha (Withania somnifera) on Physical Performance: Systematic Review and Bayesian Meta-Analysis, Journal of functional morphology and kinesiology (2021) — PRISMA systematic review and Bayesian meta-analysis of 13 trials (12 quantitative) in healthy adults: Ashwagandha supplementation was more efficacious than placebo for physical-performance outcomes, including strength/power, cardiorespiratory fitness (VO2max), and fatigue/recovery; low-to-moderate overall risk of bias. [https://pubmed.ncbi.nlm.nih.gov/33670194/]
  - Withania somnifera (Indian ginseng) in male infertility: An evidence-based systematic review and meta-analysis, Phytomedicine : international journal of phytotherapy and phytopharmacology (2018) — Evidence-based systematic review/meta-analysis in infertile men (4 trials/5 publications). W. somnifera increased sperm concentration (+167%), semen volume (+59%), sperm motility (+57%), serum testosterone (+17%) and LH (+34%) vs baseline after 90 days; pooled observational data confirmed improved semen parameters (e.g., sperm concentration MD +13.57 million/ml, 95% CI 11.12-16.01). Evidence limited by only 1 RCT; no adverse effects reported. [https://pubmed.ncbi.nlm.nih.gov/30466985/]
  - Safety and Efficacy of Ashwagandha Root Extract on Cognition, Energy and Mood Problems in Adults: Prospective, Randomized, Placebo-Controlled Study, Journal of psychoactive drugs (2026) — In adults (n=120) given 600 mg/day for 8 weeks, ashwagandha root extract improved episodic memory, working memory, attention accuracy, mood and executive function vs placebo, well tolerated. [https://pubmed.ncbi.nlm.nih.gov/39498904/]
  - Impact of ashwagandha (Withania somnifera L.) supplementation on serum lipid concentrations and anthropometric parameters in adults with overweight and obesity: a double-blind, placebo-controlled pilot study, Nutrition &amp; Metabolism (2025) — Double-blind placebo-controlled pilot RCT in adults with overweight/obesity (n=43, 500 mg/day x 40 days) found ashwagandha significantly reduced triglycerides (-31.3 mg/dL, p=0.008) and VLDL-cholesterol (p=0.03) but produced no significant change in body weight, BMI, or waist circumference. [https://doi.org/10.1186/s12986-025-01028-6]
  - A New Ashwagandha Formulation (Zenroot™) Alleviates Stress and Anxiety Symptoms While Improving Mood and Sleep Quality: A Randomized, Double-Blind, Placebo-Controlled Clinical Study, Advances in therapy (2025) — 84-day double-blind placebo-controlled RCT (n=90) of 125 mg ashwagandha extract (1.5% withanolides) showed significant improvements in Perceived Stress Scale, Beck Anxiety Inventory, and PSQI sleep scores at days 28/56/84, with no significant change in serum cortisol. [https://pubmed.ncbi.nlm.nih.gov/40875185/]
  - Effect of standardized root extract of ashwagandha (Withania somnifera) on well-being and sexual performance in adult males: A randomized controlled trial, Health Science Reports (2022) — In a 8-week double-blind RCT of adult men, ashwagandha root extract raised serum testosterone ~17% (vs 2% placebo) and improved DISF-M sexual function and well-being scores. [https://onlinelibrary.wiley.com/doi/full/10.1002/hsr2.741]
  - Ashwagandha-induced liver injury-A case series from India and literature review, Hepatology communications (2023) — Case series from India of 23 patients with ashwagandha-associated liver injury (8 single-ingredient), predominantly cholestatic; 3 with chronic liver disease developed acute-on-chronic failure and died. [https://pubmed.ncbi.nlm.nih.gov/37756041/]
  - A prospective, randomized double-blind, placebo-controlled study of safety and efficacy of a high-concentration full-spectrum extract of ashwagandha root in reducing stress and anxiety in adults, Indian journal of psychological medicine (2012) — 300mg KSM-66 cut perceived-stress scores ~44% and serum cortisol ~28% vs placebo (n=64). [https://pubmed.ncbi.nlm.nih.gov/23439798/]
  - Safety of 12-Months Administration of Ashwagandha (Withania somnifera) Standardized Root Extract in Healthy Adults: A Prospective, Observational Study, Phytotherapy research : PTR (2025) — Prospective multi-centre observational study of healthy adults (N=191, 18-65 y) taking standardized ashwagandha root extract for 12 months reported no serious adverse events and no clinically significant changes in hepatic, renal, thyroid, or hematological parameters. [https://pubmed.ncbi.nlm.nih.gov/41063394/]
  - Adaptogenic and Anxiolytic Effects of Ashwagandha Root Extract in Healthy Adults: A Double-blind, Randomized, Placebo-controlled Clinical Study, Cureus (2019) — Improved sleep onset and quality at 600mg/day over 8 weeks. [https://pubmed.ncbi.nlm.nih.gov/32021735/]

---

## Creatine Monohydrate
URL: https://nutridex.info/s/creatine
Category: Performance, Nootropic
Evidence: Strong — Multiple high-quality RCTs / meta-analyses with consistent effects.
The most evidence-backed performance supplement in existence.

Quick answer: Creatine Monohydrate is used for strength & power. NutriDex grades the human evidence as strong — Multiple high-quality RCTs / meta-analyses with consistent effects. Based on 19 cited human studies (19 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Creatine increases phosphocreatine stores in muscle and brain, enabling faster ATP regeneration during short, intense effort. Hundreds of RCTs confirm reliable gains in maximal strength, power output, and lean mass when paired with resistance training. Emerging research points to cognitive benefits, especially under sleep deprivation or in vegetarians, and possible neuroprotective roles. It is among the safest and cheapest supplements with a decades-long safety record.

Benefits / uses: Strength & power; Muscle mass; Cognitive support; Recovery.
Active compounds: Creatine monohydrate.
Dose: 3–5 g/day. Optional loading: 20 g/day (split) for 5–7 days.
Safety: Very safe. Mild water retention early on. Does not harm healthy kidneys; consult a doctor if you have kidney disease.

Cited studies (19):
  - Effects of Creatine Supplementation and Resistance Training on Muscle Strength Gains in Adults <50 Years of Age: A Systematic Review and Meta-Analysis, Nutrients (2024) — In 23 studies (~509 participants), creatine plus resistance training significantly increased upper-body (WMD 4.43 kg) and lower-body strength (WMD 11.35 kg) in adults under 50, with significant gains in males but not females. [https://pubmed.ncbi.nlm.nih.gov/39519498/]
  - The impact of creatine supplementation associated with resistance training on muscular strength and lean tissue mass in the aged: a systematic review and meta-analysis, European review of aging and physical activity : official journal of the European Group for Research into Elderly and Physical Activity (2025) — Across 8 RCTs (n=482 older adults), creatine plus resistance training significantly improved lower-limb strength and lean tissue mass versus placebo, with no significant gain in upper-extremity strength. [https://pmc.ncbi.nlm.nih.gov/articles/PMC12752335/]
  - The effects of creatine supplementation on cognitive function in adults: a systematic review and meta-analysis, Frontiers in nutrition (2024) — In 16 RCTs (492 adults), creatine monohydrate produced small significant improvements in memory (SMD 0.31), attention and processing speed, but no significant effect on overall or executive function. [https://pubmed.ncbi.nlm.nih.gov/39070254/]
  - Creatine supplementation for treating symptoms of depression: a systematic review and meta-analysis, The British journal of nutrition (2025) — Pooling 11 trials (1,093 participants), creatine showed a small effect on depressive symptoms (SMD -0.34; ~2.2 Hamilton points) that fell below the minimal important difference, on very-low-certainty evidence. [https://pubmed.ncbi.nlm.nih.gov/41189312/]
  - The Effect of Creatine Supplementation on Resistance Training-Based Changes to Body Composition: A Systematic Review and Meta-analysis, Journal of strength and conditioning research (2024) — In adults under 50, creatine added to resistance training increased lean body mass by 1.14 kg (95% CI 0.69-1.59) and reduced body fat mass by 0.73 kg and body fat percentage by 0.88% versus resistance training alone. [https://pubmed.ncbi.nlm.nih.gov/39074168/]
  - Impact of creatine supplementation and exercise training in older adults: a systematic review and meta-analysis, European review of aging and physical activity : official journal of the European Group for Research into Elderly and Physical Activity (2025) — Across 20 trials (1,093 older adults, ~69% female), creatine plus exercise training did not significantly improve total-body bone mineral density (mean difference 0.009, p=0.557) but did reduce fat percentage, indicating no meaningful bone benefit. [https://pubmed.ncbi.nlm.nih.gov/41062952/]
  - The Effects of Creatine Supplementation on Upper- and Lower-Body Strength and Power: A Systematic Review and Meta-Analysis, Nutrients (2025) — Pooled analysis of 69 studies (1,937 participants); creatine plus resistance training significantly increased bench/chest press strength (WMD 1.43 kg, 95% CI 0.53-2.34, p=0.002), squat strength (WMD 5.64 kg, p=0.001), vertical jump (WMD 1.48 cm, p=0.01) and Wingate peak power (WMD 47.81 W, p=0.004) vs placebo. [https://pubmed.ncbi.nlm.nih.gov/40944139/]
  - Effects of creatine supplementation on muscle strength gains-a meta-analysis and systematic review, PeerJ (2025) — Meta-analysis of RCTs reported a significant overall improvement in muscle strength favoring creatine over control (SMD 0.43, 95% CI 0.25-0.61, p<0.01). [https://pmc.ncbi.nlm.nih.gov/articles/PMC12665265/]
  - Resistance Exercise and Creatine Supplementation on Fat Mass in Adults < 50 Years of Age: A Systematic Review and Meta-Analysis, Nutrients (2023) — In adults <50 years (12 studies, 266 participants), creatine plus resistance training produced a small but significant reduction in body fat percentage (-1.19%, p=0.006), with no significant change in absolute fat mass (-0.18 kg, p=0.76). DOI: 10.3390/nu15204343 [https://pubmed.ncbi.nlm.nih.gov/37892421/]
  - Effects of creatine supplementation on memory in healthy individuals: a systematic review and meta-analysis of randomized controlled trials, Nutrition reviews (2023) — Across RCTs in healthy humans, creatine improved memory versus placebo (SMD=0.29, 95% CI 0.04-0.53), with a markedly larger effect in older adults aged 66-76 years (SMD=0.88, 95% CI 0.22-1.55) than in younger adults (SMD=0.03, NS). DOI: 10.1093/nutrit/nuac064 [https://pubmed.ncbi.nlm.nih.gov/35984306/]
  - The impact of nutritional intervention and resistance training on muscle strength and mass in healthy older adults-a comparative analysis, Frontiers in nutrition (2025) — Network meta-analysis of 19 RCTs in healthy older adults: combined with resistance training, creatine yielded the most pronounced improvement in muscle mass of any supplement tested (MD=2.18 kg, 95% CI 0.92-3.44; SUCRA 99.9%, outperforming protein and HMB), though its effect on muscle strength was non-significant (SMD=0.03, 95% CI -0.35-0.42). DOI: 10.3389/fnut.2025.1640858 [https://pubmed.ncbi.nlm.nih.gov/40901287/]
  - Meta-Analysis Examining the Importance of Creatine Ingestion Strategies on Lean Tissue Mass and Strength in Older Adults, Nutrients (2021) — In older adults, creatine combined with resistance training significantly augments gains in lean tissue mass and strength versus placebo, independent of dosing strategy; loading followed by low-dose (<=5 g/day) and higher-dose (>5 g/day) protocols each improved chest-press and leg-press strength. DOI: 10.3390/nu13061912 [https://pubmed.ncbi.nlm.nih.gov/34199420/]
  - Effects of creatine supplementation on cognitive function of healthy individuals: A systematic review of randomized controlled trials, Experimental gerontology (2018) — Improved short-term memory and reasoning, strongest in vegetarians/older adults. [https://pubmed.ncbi.nlm.nih.gov/29704637/]
  - Creatine and improvement in cognitive function: Evaluation of a health claim pursuant to article 13(5) of regulation (EC) No 1924/2006, EFSA journal. European Food Safety Authority (2024) — EFSA concluded a cause-and-effect relationship between creatine supplementation and improved cognitive function could not be established from the submitted evidence, rejecting the proposed Article 13(5) health claim. [https://pubmed.ncbi.nlm.nih.gov/39564533/]
  - Effect of creatine supplementation on body composition and performance: a meta-analysis, International journal of sport nutrition and exercise metabolism (2003) — Small overall effect size (ES ~0.2–0.4, largest for upper-body strength); no benefit for running/swimming. [https://pubmed.ncbi.nlm.nih.gov/12945830/]
  - International Society of Sports Nutrition position stand: safety and efficacy of creatine supplementation in exercise, sport, and medicine, Journal of the International Society of Sports Nutrition (2017) — Most effective ergogenic aid for high-intensity exercise; safe long-term. [https://pubmed.ncbi.nlm.nih.gov/28615996/]
  - The effects of creatine supplementation on cognitive performance-a randomised controlled study, BMC medicine (2023) — Double-blind crossover RCT in 123 healthy adults found 5 g/day creatine for 6 weeks gave only weak-to-moderate, non-significant cognitive benefit (e.g., backward digit span p=0.064; Raven's matrices p=0.327). [https://pubmed.ncbi.nlm.nih.gov/37968687/]
  - Single dose creatine improves cognitive performance and induces changes in cerebral high energy phosphates during sleep deprivation, Scientific reports (2024) — Double-blind crossover RCT in 15 healthy adults found a single high oral dose of creatine (0.35 g/kg) during 21 h of sleep deprivation raised brain phosphocreatine, reduced subjective fatigue, and improved cognitive performance and processing speed versus placebo. [https://pmc.ncbi.nlm.nih.gov/articles/PMC10902318/]
  - Safety of creatine supplementation: analysis of the frequency of reported side effects in clinical trials, Journal of the International Society of Sports Nutrition (2025) — Analysis of 685 clinical trials (~12,839 creatine vs 13,452 placebo participants) and global adverse-event databases found creatine did not increase the frequency of 35 evaluated side effects versus placebo and was well tolerated. [https://pmc.ncbi.nlm.nih.gov/articles/PMC12291206/]

---

## Omega-3 (EPA/DHA) (Fish/algal oil)
URL: https://nutridex.info/s/omega3
Category: Heart & Metabolic, Nootropic
Evidence: Strong — Multiple high-quality RCTs / meta-analyses with consistent effects.
Essential fatty acids for heart, brain, and inflammation.

Quick answer: Omega-3 (EPA/DHA) is used for lower triglycerides. NutriDex grades the human evidence as strong — Multiple high-quality RCTs / meta-analyses with consistent effects. Based on 20 cited human studies (20 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

EPA and DHA are long-chain omega-3 fatty acids that the body cannot efficiently synthesize. High-dose omega-3 reliably lowers triglycerides (20–30%) and reduces inflammatory markers. Cardiovascular outcome trials are mixed — REDUCE-IT showed benefit with high-dose EPA, while others (STRENGTH, VITAL) were neutral. Higher-dose EPA-predominant formulas show modest antidepressant effects. DHA is structurally vital for the brain and retina, particularly during development.

Benefits / uses: Lower triglycerides; Anti-inflammatory; Brain & eye health; Mood support.
Active compounds: EPA (eicosapentaenoic acid); DHA (docosahexaenoic acid).
Dose: 1–2 g combined EPA+DHA/day; up to 4 g (Rx) for high triglycerides.
Safety: Safe at typical doses. Fishy aftertaste and mild GI upset are common. High doses (>1 g/day) modestly raise the risk of atrial fibrillation — an irregular heartbeat — with the largest signal at higher intakes (pooled RCTs, RR ~1.25). May increase bleeding risk; tell your surgeon before procedures.

Cited studies (20):
  - Effects of long-chain omega-3 polyunsaturated fatty acids on reducing anxiety and/or depression in adults; A systematic review and meta-analysis of randomised controlled trials, Prostaglandins, leukotrienes, and essential fatty acids (2023) — Meta-analysis of 10 RCTs (1,426 participants) found EPA-enriched omega-3 (>=60% EPA, 1 to <2 g/day) significantly reduced depression severity, while doses >=2 g/day showed no significant benefit. [https://pubmed.ncbi.nlm.nih.gov/37028202/]
  - Efficacy and safety of omega-3 fatty acids supplementation for anxiety symptoms: a systematic review and dose-response meta-analysis of randomized controlled trials, BMC psychiatry (2024) — Dose-response meta-analysis of 23 RCTs (2,189 participants) found omega-3 moderately reduced anxiety symptoms (SMD -0.70 per 1 g/day), with greatest effect around 2 g/day; GRADE certainty was low. [https://pubmed.ncbi.nlm.nih.gov/38890670/]
  - Association Between Omega-3 Fatty Acid Intake and Dyslipidemia: A Continuous Dose-Response Meta-Analysis of Randomized Controlled Trials, Journal of the American Heart Association (2023) — Continuous dose-response meta-analysis of 90 RCTs (n=72,598) found omega-3 intake above 2 g/day had a near-linear association with reductions in triglycerides and non-HDL cholesterol, supporting medium-to-high doses for dyslipidemia. [https://pmc.ncbi.nlm.nih.gov/articles/PMC10381976/]
  - Marine-Based Omega-3 Fatty Acids and Metabolic Syndrome: A Systematic Review and Meta-Analysis of Randomized Controlled Trials, Nutrients (2025) — Systematic review and meta-analysis of RCTs (search through June 2024) found marine-derived EPA/DHA supplementation improved metabolic syndrome components, including triglyceride-lowering and anti-inflammatory effects, versus placebo. [https://pmc.ncbi.nlm.nih.gov/articles/PMC12567179/]
  - Effects of Omega-3 Fatty Acids Intake on Lipid Metabolism and Plaque Volume in Patients With Coronary Heart Disease: A Systematic Review and Dose-Response Meta-Analysis of Randomized Clinical Trials, Food science & nutrition (2025) — Dose-response meta-analysis of RCTs in coronary heart disease patients found omega-3 intake produced a statistically significant reduction in triglyceride levels (moderate-quality evidence) alongside effects on plaque volume. [https://pmc.ncbi.nlm.nih.gov/articles/PMC12129820/]
  - Effect of Long-Term Marine ɷ-3 Fatty Acids Supplementation on the Risk of Atrial Fibrillation in Randomized Controlled Trials of Cardiovascular Outcomes: A Systematic Review and Meta-Analysis, Circulation (2021) — Pooled meta-analysis of 7 cardiovascular-outcome RCTs (81,210 patients) found marine omega-3 supplementation raised atrial fibrillation risk (RR 1.25), with the increase greatest at higher doses (>1 g/day). [https://pubmed.ncbi.nlm.nih.gov/34612056/]
  - Effects of omega-3 fatty acid on major cardiovascular outcomes: A systematic review and meta-analysis, Medicine (2022) — Meta-analysis of 28 RCTs (136,965 individuals) found omega-3 supplementation modestly reduced major cardiovascular events (RR 0.94) and cardiac death (RR 0.92), with no effect on all-cause mortality, MI, or stroke. [https://pubmed.ncbi.nlm.nih.gov/35905212/]
  - The effect of omega-3 fatty acids and its combination with statins on lipid profile in patients with hypertriglyceridemia: A systematic review and meta-analysis of randomized controlled trials, Frontiers in nutrition (2022) — Meta-analysis of 32 RCTs (15,903 participants) found omega-3 monotherapy markedly lowered triglycerides (mean difference -39.8 mg/dL) in hypertriglyceridemia, with reductions also seen when combined with statins (-29.6 mg/dL). [https://pubmed.ncbi.nlm.nih.gov/36313109/]
  - Effect of omega-3 fatty acids on cardiovascular outcomes: A systematic review and meta-analysis, EClinicalMedicine (2021) — Across 38 RCTs (149,051 participants), omega-3 FAs reduced CV mortality (RR 0.93), nonfatal MI (RR 0.87), CHD events (RR 0.91), MACE (RR 0.95), and revascularization (RR 0.91); effects were stronger for EPA monotherapy than EPA+DHA, but omega-3 increased incident atrial fibrillation (RR 1.26) and EPA monotherapy increased bleeding (RR 1.49). [https://pubmed.ncbi.nlm.nih.gov/34505026/]
  - Omega-3, Omega-6, and Polyunsaturated Fat for Cognition: Systematic Review and Meta-analysis of Randomized Trials, Journal of the American Medical Directors Association (2020) — Meta-analysis of 38 RCTs (49,757 participants) found long-chain omega-3 has little or no effect on new neurocognitive illness (RR 0.98), new cognitive impairment (RR 0.99), or global cognition (MMSE), indicating supplements do not protect older adults from cognitive decline (moderate-certainty evidence). [https://pubmed.ncbi.nlm.nih.gov/32305302/]
  - Efficacy of omega-3 PUFAs in depression: A meta-analysis, Translational psychiatry (2019) — EPA-dominant supplements showed small antidepressant effect. [https://pubmed.ncbi.nlm.nih.gov/31383846/]
  - Marine Omega-3 Supplementation and Cardiovascular Disease: An Updated Meta-Analysis of 13 Randomized Controlled Trials Involving 127 477 Participants, Journal of the American Heart Association (2019) — Pooled analysis of 13 RCTs (127,477 participants) found marine omega-3 supplementation reduced MI (RR 0.92), CHD death (RR 0.92), total CHD (RR 0.95), CV death (RR 0.93), and total CVD (RR 0.97), even excluding REDUCE-IT; risk reductions were linearly dose-dependent. [https://pubmed.ncbi.nlm.nih.gov/31567003/]
  - Omega-3 Fatty Acids for the Management of Hypertriglyceridemia: A Science Advisory From the American Heart Association, Circulation (2019) — Strong evidence for triglyceride lowering. [https://pubmed.ncbi.nlm.nih.gov/31422671/]
  - Cardiovascular Outcomes With Icosapent Ethyl by Baseline Low-Density Lipoprotein Cholesterol: A Secondary Analysis of the REDUCE-IT Randomized Trial, Journal of the American Heart Association (2025) — In statin-treated patients with elevated triglycerides, icosapent ethyl reduced the primary composite cardiovascular endpoint regardless of baseline LDL-C (HR 0.66 [95% CI 0.50-0.87] if LDL-C <55 mg/dL; HR 0.76 [95% CI 0.69-0.85] if >=55 mg/dL; P-interaction=0.40). [https://pmc.ncbi.nlm.nih.gov/articles/PMC12132757/]
  - EFSA assesses safety of long-chain omega, European Food Safety Authority (2012) — EFSA authorized the claim that DHA contributes to maintenance of normal blood triglyceride levels, concluding intakes of 2-4 g/day EPA and DHA are needed to achieve the triglyceride-lowering effect. [https://www.efsa.europa.eu/en/press/news/120727]
  - Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia, The New England journal of medicine (2019) — 4g/day icosapent ethyl cut major cardiac events 25% in high-risk patients. [https://pubmed.ncbi.nlm.nih.gov/30415628/]
  - Marine n-3 Fatty Acids and Prevention of Cardiovascular Disease and Cancer, The New England journal of medicine (2019) — Primary-prevention RCT in 25,871 generally healthy US adults found 1 g/day marine n-3 fatty acids did not significantly reduce major cardiovascular events (HR 0.92) or invasive cancer (HR 1.03) over 5.3 years versus placebo. [https://pubmed.ncbi.nlm.nih.gov/30415637/]
  - n-3 Fatty Acid Supplementation for the Treatment of Dry Eye Disease, The New England journal of medicine (2018) — Multicenter RCT in 535 patients with moderate-to-severe dry eye disease found 3 g/day omega-3 (2000 mg EPA/1000 mg DHA) was no better than placebo for relieving signs or symptoms over 12 months. [https://pubmed.ncbi.nlm.nih.gov/29652551/]
  - Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease, The Cochrane database of systematic reviews (2020) — Cochrane systematic review of 86 RCTs (162,796 participants) found increasing long-chain omega-3 has little or no effect on all-cause or cardiovascular mortality but slightly reduces coronary heart disease mortality and events and lowers triglycerides (moderate- to low-certainty evidence). [https://pubmed.ncbi.nlm.nih.gov/32114706/]
  - Omega-3 fatty acid addition during pregnancy, The Cochrane database of systematic reviews (2018) — Cochrane review of 70 RCTs (19,927 women) found omega-3 supplementation during pregnancy reduced preterm birth before 37 weeks by about 11% (RR 0.89) and early preterm birth before 34 weeks by about 42% (RR 0.58). [https://pubmed.ncbi.nlm.nih.gov/30480773/]

---

## Magnesium
URL: https://nutridex.info/s/magnesium
Category: Mineral, Sleep & Mood
Evidence: Moderate — Several controlled trials; effects real but modest or context-dependent.
An essential mineral in 300+ enzymatic reactions.

Quick answer: Magnesium is used for sleep quality. NutriDex grades the human evidence as moderate — Several controlled trials; effects real but modest or context-dependent. Based on 20 cited human studies (20 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Magnesium is a cofactor in energy metabolism, muscle and nerve function, and DNA synthesis. Deficiency is common with modern diets. Supplementation modestly lowers blood pressure, may reduce migraine frequency, and improves subjective sleep in deficient or older individuals. L-threonate is marketed for cognition but human data are thin. Effects are most pronounced when correcting a deficiency.

Benefits / uses: Sleep quality; Muscle relaxation; Blood pressure; Migraine prevention.
Active compounds: Mg glycinate; Mg citrate; Mg L-threonate; Mg oxide.
Dose: 200–400 mg elemental/day. Glycinate & citrate absorb best; oxide is poorly absorbed.
Safety: Safe. Excess causes diarrhea (citrate/oxide). Caution in kidney disease.

Cited studies (20):
  - Magnesium Supplementation and Blood Pressure: A Systematic Review and Meta-Analysis of Randomized Controlled Trials, Hypertension (Dallas, Tex. : 1979) (2025) — In 38 RCTs (n=2,709), magnesium reduced SBP by -2.81 mmHg and DBP by -2.05 mmHg, with larger effects in medicated hypertensives (-7.68 mmHg SBP) and those with hypomagnesemia, but no effect in normotensives. [https://pubmed.ncbi.nlm.nih.gov/41000008/]
  - Impact of Magnesium Supplementation on Blood Pressure: An Umbrella Meta-Analysis of Randomized Controlled Trials, Current therapeutic research, clinical and experimental (2024) — Umbrella meta-analysis of 10 reviews (8,610 participants) found magnesium significantly lowered SBP (-1.25 mmHg) and DBP (-1.40 mmHg), with stronger reductions at >=400 mg/day for >=12 weeks. [https://pubmed.ncbi.nlm.nih.gov/39280209/]
  - Magnesium supplementation beneficially affects depression in adults with depressive disorder: a systematic review and meta-analysis of randomized clinical trials, Frontiers in psychiatry (2023) — Meta-analysis of 7 RCTs (n=325) in adults with depressive disorder found magnesium supplementation significantly reduced depression scores (SMD -0.92; 95% CI -1.44 to -0.40). [https://pmc.ncbi.nlm.nih.gov/articles/PMC10783196/]
  - Effects of selected dietary supplements on migraine prophylaxis: A systematic review and dose-response meta-analysis of randomized controlled trials, Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology (2025) — In a meta-analysis of RCTs on migraine prophylaxis, magnesium reduced migraine attacks (MD -2.51), severity (MD -0.88), and monthly migraine days (MD -1.66) versus control. [https://pubmed.ncbi.nlm.nih.gov/39404918/]
  - Does Magnesium Supplementation Treat Nocturnal Leg Cramps?, American Family Physician (2023) — Clinical inquiry summarizing systematic-review/Cochrane evidence concluded magnesium does not reduce idiopathic or pregnancy-related nocturnal leg cramps over short courses (<60 days). [https://www.aafp.org/pubs/afp/issues/2023/1200/fpin-magnesium-nocturnal-leg-cramps.html]
  - Effect of Magnesium Supplements on Improving Glucose Control, Blood Pressure and Lipid Profile in Patients With Type 2 Diabetes Mellitus: A systematic review and meta-analysis, Sultan Qaboos University medical journal (2025) — Meta-analysis of 23 RCTs (n=1,345) in type 2 diabetes found magnesium significantly lowered fasting glucose (WMD -0.58) but no significant overall HbA1c reduction, with benefit concentrated in longer (>=6 month) regimens and older adults. [https://pmc.ncbi.nlm.nih.gov/articles/PMC12244252/]
  - Magnesium and Cognitive Health in Adults: A Systematic Review and Meta-Analysis, Advances in nutrition (Bethesda, Md.) (2024) — Systematic review/meta-analysis (3 RCTs + 12 cohorts) found Mg supplement RCTs inconclusive, but cohorts showed a U-shaped serum magnesium association with dementia/cognitive impairment (optimum ~0.85 mmol/L), with higher risk at <0.75 mmol/L (HR 1.43) and >0.95 mmol/L (HR 1.30). [https://pubmed.ncbi.nlm.nih.gov/39009081/]
  - Examining the Effects of Supplemental Magnesium on Self-Reported Anxiety and Sleep Quality: A Systematic Review, Cureus (2024) — Systematic review of 15 interventional trials found 5 of 8 sleep studies showed improvement (PSQI-based), with higher doses (243-729 mg) more effective; authors conclude magnesium is likely useful for mild insomnia, especially with low baseline magnesium status. [https://pmc.ncbi.nlm.nih.gov/articles/PMC11136869/]
  - The effects of oral magnesium supplementation on glycaemic control in patients with type 2 diabetes: a systematic review and dose-response meta-analysis of controlled clinical trials, The British journal of nutrition (2022) — Dose-response meta-analysis of 18 RCTs in type 2 diabetes found oral magnesium (e.g., ~500 mg/day) reduced HbA1c by about -0.73% and improved fasting glucose, though evidence was deemed insufficient for clinical guidelines. [https://pubmed.ncbi.nlm.nih.gov/35045911/]
  - Impact of magnesium on bone health in older adults: A systematic review and meta-analysis, Bone (2022) — Systematic review/meta-analysis of 12 studies in older adults (>=60 y) found a significant positive association between magnesium intake and hip bone mineral density (pooled beta 0.03; 95% CI 0.01-0.06), though data were too limited to link magnesium to fracture risk. [https://pubmed.ncbi.nlm.nih.gov/34666201/]
  - Total, Dietary, and Supplemental Magnesium Intakes and Risk of All-Cause, Cardiovascular, and Cancer Mortality: A Systematic Review and Dose-Response Meta-Analysis of Prospective Cohort Studies, Advances in nutrition (Bethesda, Md.) (2021) — Dose-response meta-analysis of 19 prospective cohorts (1,168,756 participants) found each 100 mg/day increase in dietary magnesium was associated with 6% lower all-cause mortality (RR 0.94) and 5% lower cancer mortality (RR 0.95), with no significant association for supplemental/total magnesium or CVD mortality. [https://pubmed.ncbi.nlm.nih.gov/33684200/]
  - Oral magnesium supplementation for insomnia in older adults: a Systematic Review & Meta-Analysis, BMC complementary medicine and therapies (2021) — Meta-analysis of 3 RCTs (n=151 older adults) found magnesium reduced sleep onset latency by 17.36 min vs placebo (95% CI -27.27 to -7.44, p=0.0006); total sleep time gain of 16.06 min was not significant, with low/very-low quality evidence. [https://pubmed.ncbi.nlm.nih.gov/33865376/]
  - Effects of Magnesium Supplementation on Blood Pressure: A Meta-Analysis of Randomized Double-Blind Placebo-Controlled Trials, Hypertension (Dallas, Tex. : 1979) (2016) — Supplementation lowered BP, especially in deficient subjects. [https://pubmed.ncbi.nlm.nih.gov/27402922/]
  - Dietary magnesium intake and the risk of cardiovascular disease, type 2 diabetes, and all-cause mortality: a dose-response meta-analysis of prospective cohort studies, BMC medicine (2016) — Dose-response meta-analysis of 40 prospective cohorts (>1 million participants): each 100 mg/day increment in dietary magnesium was associated with 22% lower heart failure risk, 7% lower stroke risk, 19% lower type 2 diabetes risk, and 10% lower all-cause mortality. [https://pubmed.ncbi.nlm.nih.gov/27927203/]
  - Dose-Response Relationship between Dietary Magnesium Intake and Risk of Type 2 Diabetes Mellitus: A Systematic Review and Meta-Regression Analysis of Prospective Cohort Studies, Nutrients (2016) — Meta-regression of 25 prospective cohorts (637,922 individuals; 26,828 T2D cases): per 100 mg/day increment in dietary magnesium, type 2 diabetes risk fell ~8-13% after adjustment; overall lowest-vs-highest intake reduced T2D risk by 17%. [https://pubmed.ncbi.nlm.nih.gov/27869762/]
  - Magnesium intake and risk of type 2 diabetes: meta-analysis of prospective cohort studies, Diabetes care (2011) — Meta-analysis of 13 prospective cohorts (536,318 participants; 24,516 cases) found an inverse association between magnesium intake and type 2 diabetes (RR 0.78, 95% CI 0.73-0.84); per 100 mg/day increment, summary RR was 0.86 (95% CI 0.82-0.89). [https://pubmed.ncbi.nlm.nih.gov/21868780/]
  - Magnesium-L-threonate improves sleep quality and daytime functioning in adults with self-reported sleep problems: A randomized controlled trial, Sleep medicine: X (2024) — In 80 adults (35-55y) with self-reported sleep problems, 1 g/day magnesium-L-threonate for 21 days significantly improved deep sleep, REM sleep, light sleep time, and awakening behavior vs placebo (p<0.05), and preserved sleep quality while placebo declined. [https://pubmed.ncbi.nlm.nih.gov/39252819/]
  - The effects of magnesium L-threonate (Magtein(®)) on cognitive performance and sleep quality in adults: a randomised, double-blind, placebo-controlled trial, Frontiers in nutrition (2025) — In 100 adults, 2 g/day magnesium-L-threonate (Magtein) for 6 weeks produced greater improvement in PROMIS sleep-related impairment than placebo (p=0.043), with a significant benefit in those with more severe baseline sleep disturbance (p=0.031). [https://pmc.ncbi.nlm.nih.gov/articles/PMC12832366/]
  - The effect of magnesium supplementation on primary insomnia in elderly: A double-blind placebo-controlled clinical trial, Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences (2012) — Improved insomnia severity and sleep efficiency in older adults. [https://pubmed.ncbi.nlm.nih.gov/23853635/]
  - AAN/AHS Update Recommendations for Migraine Prevention in Adults, American Family Physician (2013) — Magnesium rated 'probably effective' for migraine prevention. [https://www.aafp.org/pubs/afp/issues/2013/0415/p584.html]

---

## Vitamin D3 (Cholecalciferol)
URL: https://nutridex.info/s/vitamind
Category: Vitamin, Gut & Immune
Evidence: Strong — Multiple high-quality RCTs / meta-analyses with consistent effects.
The 'sunshine' hormone-vitamin for bone and immunity.

Quick answer: Vitamin D3 is used for bone health. NutriDex grades the human evidence as strong — Multiple high-quality RCTs / meta-analyses with consistent effects. Based on 16 cited human studies (16 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Vitamin D regulates calcium absorption and bone mineralization and modulates immune function. Deficiency is widespread, especially in northern latitudes and darker skin. Correcting deficiency clearly benefits bone density and reduces fracture risk (with calcium). Broad supplementation in already-replete people shows little benefit for cardiovascular disease or cancer (VITAL trial), so it is most valuable when blood levels are low. Possible small reduction in respiratory infections.

Benefits / uses: Bone health; Immune support; Mood (if deficient); Muscle function.
Active compounds: Vitamin D3 (cholecalciferol).
Dose: 1,000–2,000 IU/day maintenance; higher to correct deficiency under testing.
Safety: Tolerable upper limit ~4,000 IU/day for most adults; toxicity (hypercalcemia) occurs with chronic very high intake (>10,000 IU/day). Use caution and clinician oversight in sarcoidosis or other granulomatous disease and with thiazide diuretics — both raise calcium. Prefer a steady daily dose: large infrequent 'bolus' dosing has been linked to more falls and, in a 2024 meta-analysis, a signal of increased hip-fracture risk in women.

Cited studies (16):
  - Vitamin D and Risk for Type 2 Diabetes in People With Prediabetes : A Systematic Review and Meta-analysis of Individual Participant Data From 3 Randomized Clinical Trials, Annals of internal medicine (2023) — Individual-participant meta-analysis of 3 RCTs (4,190 adults with prediabetes) found vitamin D reduced progression to type 2 diabetes by 15% (3-year absolute risk reduction ~3.3%). [https://pubmed.ncbi.nlm.nih.gov/36745886/]
  - Vitamin D Supplementation and the Incidence of Fractures in the Elderly Healthy Population: A Meta-analysis of Randomized Controlled Trials, Journal of general internal medicine (2024) — Meta-analysis of 7 RCTs (71,899 healthy older adults) found vitamin D did not reduce overall fracture incidence (RR 1.03), with a signal of increased hip fracture risk in women (RR 1.34). [https://pubmed.ncbi.nlm.nih.gov/38997531/]
  - Meta-analysis of the effect of vitamin D on depression, Frontiers in psychiatry (2025) — Meta-analysis of 20 RCTs found vitamin D supplementation produced a moderate, statistically significant reduction in depressive symptom scores (SMD -0.36, 95% CI -0.52 to -0.20). [https://pubmed.ncbi.nlm.nih.gov/40821024/]
  - Role of vitamin D in prevention of type 2 diabetes mellitus: A systematic review and meta‑analysis, Experimental and therapeutic medicine (2024) — Meta-analysis of 11 RCTs (5,221 adults with prediabetes) found vitamin D supplementation reduced progression to type 2 diabetes by about 10% and increased regression to normoglycemia. [https://pmc.ncbi.nlm.nih.gov/articles/PMC11484325/]
  - Effect of vitamin D, calcium, or combined supplementation on fall prevention: a systematic review and updated network meta-analysis, BMC geriatrics (2024) — Network meta-analysis of 35 RCTs (~58,937 older adults) found vitamin D 800-1000 IU/day lowered fall risk versus placebo (RR 0.85, 95% CI 0.74-0.95), with a 22% reduction for daily dosing (RR 0.78), benefit concentrated in vitamin D-deficient individuals. [https://pubmed.ncbi.nlm.nih.gov/38698349/]
  - Vitamin D supplementations and mortality among patients with moderate/severe COVID-19: A meta-analysis of randomized controlled trials, Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences (2024) — Meta-analysis of 14 RCTs found vitamin D supplementation did not reduce mortality in patients with moderate/severe COVID-19 (OR 1.16, 95% CI 0.84-1.59), with no benefit regardless of dose or baseline vitamin D status. [https://pubmed.ncbi.nlm.nih.gov/39764224/]
  - Vitamin D supplementation to prevent acute respiratory infections: a systematic review and meta-analysis of aggregate data from randomised controlled trials, The lancet. Diabetes & endocrinology (2021) — Meta-analysis of 37 RCTs (~46,000 participants) found vitamin D modestly reduced acute respiratory infection risk (OR 0.92), with benefit concentrated at daily doses of 400-1000 IU for up to 12 months. [https://pubmed.ncbi.nlm.nih.gov/33798465/]
  - Association between Vitamin D Supplementation and Cancer Mortality: A Systematic Review and Meta-Analysis, Cancers (2022) — Meta-analysis of 12 RCTs (72,669 participants) found vitamin D did not reduce overall cancer mortality (RR 0.96) though it was associated with lower lung cancer mortality (RR 0.63). [https://pubmed.ncbi.nlm.nih.gov/35954381/]
  - Vitamin D supplementation and total cancer incidence and mortality by daily vs. infrequent large-bolus dosing strategies: a meta-analysis of randomised controlled trials, British journal of cancer (2022) — Meta-analysis of RCTs found daily (but not infrequent large-bolus) vitamin D supplementation reduced total cancer mortality by 13% (RR 0.87, 95% CI 0.78-0.96), while having no effect on total cancer incidence (RR 0.99). [https://pubmed.ncbi.nlm.nih.gov/35676320/]
  - Vitamin D supplementation to prevent acute respiratory tract infections: systematic review and meta-analysis of individual participant data, BMJ (Clinical research ed.) (2017) — Modest protection against acute respiratory infections. [https://pubmed.ncbi.nlm.nih.gov/28202713/]
  - Vitamin D for the Prevention of Disease: An Endocrine Society Clinical Practice Guideline, The Journal of clinical endocrinology and metabolism (2024) — Endocrine Society guideline concludes healthy adults aged 18-74 do not benefit from vitamin D above the RDA or from routine 25(OH)D testing, but recommends empiric supplementation for children, pregnancy, adults >75, and high-risk prediabetes. [https://pubmed.ncbi.nlm.nih.gov/38828931/]
  - A Systematic Review Supporting the Endocrine Society Clinical Practice Guidelines on Vitamin D, The Journal of clinical endocrinology and metabolism (2024) — Authoritative society guideline (systematic review of 151 studies): recommends against routine empiric vitamin D or 25(OH)D screening in healthy adults 19-74; identifies benefit only in specific groups - high-certainty very small mortality reduction in adults >75, reduced respiratory infections in children, and moderate-certainty reduced progression to diabetes in prediabetes. Warns high-dose intermittent dosing may increase falls. [https://pubmed.ncbi.nlm.nih.gov/38828942/]
  - Vitamin D and marine omega 3 fatty acid supplementation and incident autoimmune disease: VITAL randomized controlled trial, BMJ (Clinical research ed.) (2022) — In the VITAL RCT (25,871 older adults, 2000 IU/day for a median 5.3 years), vitamin D supplementation reduced incident autoimmune disease by 22% (HR 0.78, 95% CI 0.61-0.99) versus placebo. [https://pubmed.ncbi.nlm.nih.gov/35082139/]
  - Supplemental Vitamin D and Incident Fractures in Midlife and Older Adults, The New England journal of medicine (2022) — Large RCT (n=25,871, 2000 IU/day, median 5.3 yr) in generally healthy adults not selected for deficiency: vitamin D3 did NOT reduce total fractures (HR 0.98, 95% CI 0.89-1.08), nonvertebral (HR 0.97), or hip fractures (HR 1.01); no effect modification by baseline 25(OH)D. [https://pubmed.ncbi.nlm.nih.gov/35939577/]
  - Vitamin D Supplements and Prevention of Cancer and Cardiovascular Disease, The New England journal of medicine (2019) — No reduction in CVD or cancer in replete adults over 5 years. [https://pubmed.ncbi.nlm.nih.gov/30415629/]
  - Prevention of nonvertebral fractures with oral vitamin D and dose dependency: a meta-analysis of randomized controlled trials, Archives of internal medicine (2009) — Higher-dose D reduced fracture risk in older adults. [https://pubmed.ncbi.nlm.nih.gov/19307517/]

---

## Rhodiola Rosea (Rhodiola rosea)
URL: https://nutridex.info/s/rhodiola
Category: Adaptogen, Nootropic
Evidence: Preliminary — Early or small human trials; promising but not yet conclusive.
Arctic root adaptogen for fatigue and mental stamina.

Quick answer: Rhodiola Rosea is used for reduced fatigue. NutriDex grades the human evidence as preliminary — Early or small human trials; promising but not yet conclusive. Based on 17 cited human studies (17 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Rhodiola is a high-altitude adaptogen traditionally used to combat fatigue and altitude stress. Several small RCTs show reduced mental and physical fatigue, improved concentration under stress, and modest antidepressant effects. Study quality is variable and effect sizes inconsistent, keeping evidence at a preliminary tier. It is often taken in the morning due to mild stimulating effects.

Benefits / uses: Reduced fatigue; Stress resilience; Mental performance; Mild mood lift.
Active compounds: Rosavins; Salidroside.
Dose: 200–600 mg/day standardized to 3% rosavins / 1% salidroside.
Safety: Well tolerated. May cause jitteriness/insomnia if taken late. Caution with stimulants and bipolar disorder.

Cited studies (17):
  - The effect of Rhodiola rosea supplementation on endurance performance and related biomarkers: a systematic review and meta-analysis, Frontiers in nutrition (2025) — Meta-analysis of 26 RCTs (668 healthy participants) found Rhodiola rosea modestly improved endurance: VO2max (ES=0.32), time-to-exhaustion (ES=0.38) and time-trial performance (ES=-0.40), plus better antioxidant markers. [https://pmc.ncbi.nlm.nih.gov/articles/PMC12507841/]
  - The effect of Rhodiola rosea supplementation on endurance performance and related biomarkers: a systematic review and meta-analysis, Frontiers in nutrition (2025) — Meta-analysis of 26 RCTs (n=668 healthy adults) found Rhodiola rosea supplementation significantly improved endurance: VO2 (ES=0.32), time to exhaustion (ES=0.38), and time-trial performance (ES=-0.40); it raised antioxidant capacity (SOD ES=1.16, TAC ES=0.59) and reduced oxidative/muscle-damage markers (MDA ES=-1.21, creatine kinase ES=-0.84, lactate ES=-0.87), with no effect on IL-6 or CRP. Greater VO2 gains at >600 mg/day. [https://pubmed.ncbi.nlm.nih.gov/41080184/]
  - Standardized Rhodiola rosea injection for left ventricular remodeling and inflammation in patients with HFrEF: a systematic review and meta-analysis, Frontiers in pharmacology (2025) — Meta-analysis of 25 RCTs (n=2,325) of standardized Rhodiola rosea injection (adjunct) in HFrEF showed improved left-ventricular remodeling: LVEF +6.81% (95% CI 5.71-7.91), LVEDD -4.37 mm, LVESD -4.48 mm; reduced inflammation (TNF-alpha -10.37, IL-6 -6.99, hs-CRP -2.58) and natriuretic peptides (BNP -105.10, NT-proBNP -415.95), with no increase in adverse events (RR=0.86). Evidence limited by methodological quality. [https://pubmed.ncbi.nlm.nih.gov/40098619/]
  - The Effectiveness of Rhodiola rosea L. Preparations in Alleviating Various Aspects of Life-Stress Symptoms and Stress-Induced Conditions-Encouraging Clinical Evidence, Molecules (Basel, Switzerland) (2022) — Review of clinical trials concluded Rhodiola rosea preparations provide an encouraging but not definitive basis for managing life-stress symptoms, fatigue, mild depression, anxiety and burnout. [https://pubmed.ncbi.nlm.nih.gov/35745023/]
  - Rhodiola rosea for physical and mental fatigue: a systematic review, BMC complementary and alternative medicine (2012) — Systematic review of 11 trials (10 RCTs + 1 CCT) for physical/mental fatigue: 2 of 6 physical-fatigue trials and 3 of 5 mental-fatigue RCTs reported R. rosea effective. Evidence was contradictory and all included studies had high or unclear risk of bias, precluding meta-analysis; rigorous RCTs needed. [https://pubmed.ncbi.nlm.nih.gov/22643043/]
  - Clinical improvement of moderate depression with a combination of rhodiola and saffron in a non-student population: a double-blind, placebo-controlled study, European Psychiatry (2025) — Double-blind placebo-controlled RCT (n=126) of a rhodiola (308 mg) plus saffron (30 mg) combination found a roughly 10-point HAM-D reduction by day 21 versus placebo in moderate depression (combination product, not rhodiola alone). [https://pmc.ncbi.nlm.nih.gov/articles/PMC12437972/]
  - The Impact of Rhodiola Rosea Extract on Strength Performance in Alternative Bench-Press and Bench-Pull Exercises Under Resting and Mental Fatigue Conditions: A Randomized, Triple-Blinded, Placebo-Controlled, Crossover Trial, Nutrients (2025) — Triple-blind placebo-controlled crossover RCT (n=18) found 4 days of Rhodiola rosea produced only small, inconsistent strength gains (14 of 52 comparisons favouring rhodiola) and no benefit on cognitive or mental-fatigue outcomes. [https://pubmed.ncbi.nlm.nih.gov/40289957/]
  - Dose-Response Effects of Short-Term Rhodiola rosea (Golden Root Extract) Supplementation on Anaerobic Exercise Performance and Cognitive Function in Resistance-Trained Athletes: A Randomized, Crossover, Double-Blind, and Placebo-Controlled Study, Nutrients (2025) — Randomized double-blind crossover trial in 27 resistance-trained adults found 7 days of Rhodiola rosea (200 or 1500 mg/day) produced no improvement in anaerobic Wingate power outcomes, but improved Stroop cognitive performance and some resistance-exercise endurance/strength measures versus control. [https://pmc.ncbi.nlm.nih.gov/articles/PMC12693935/]
  - The Impact of Rhodiola Rosea Extract on Strength Performance in Alternative Bench-Press and Bench-Pull Exercises Under Resting and Mental Fatigue Conditions: A Randomized, Triple-Blinded, Placebo-Controlled, Crossover Trial, Nutrients (2025) — Randomized triple-blind placebo-controlled crossover trial (n=18) of 4 days Rhodiola rosea found only trivial-to-small effects on mental fatigue, visuo-cognitive processing and perceived exertion; of 52 comparisons, 17 were small effects (14 favouring Rhodiola), with modest strength benefits in some sets. [https://pmc.ncbi.nlm.nih.gov/articles/PMC11944791/]
  - The quality and safety of Rhodiola rosea supplements on the U.S. market: An analysis of biomarkers, heavy metals, and pesticide residues, PloS one (2026) — Analysis of 10 US-market Rhodiola rosea products (7 capsules, 3 tinctures bought on Amazon in 2024) found wide biomarker variability (rosavins 0.01-3.08%, salidroside 0.07-2.91%) with some products far below label claims, and detectable arsenic, cobalt and lead in all seven capsules (up to ~200 ng arsenic per serving), highlighting quality-control concerns. [https://pmc.ncbi.nlm.nih.gov/articles/PMC12810810/]
  - Rhodiola rosea versus sertraline for major depressive disorder: A randomized placebo-controlled trial, Phytomedicine : international journal of phytotherapy and phytopharmacology (2015) — Comparable to sertraline for mild depression with fewer side effects (small trial). [https://pubmed.ncbi.nlm.nih.gov/25837277/]
  - The Effects of Rhodiola rosea L. Extract on Anxiety, Stress, Cognition and Other Mood Symptoms, Phytotherapy research : PTR (2015) — Randomized (non-placebo, no-treatment control) trial in 80 mildly anxious adults found that 2x200 mg/day Rhodiola rosea extract (Vitano) significantly reduced self-reported anxiety, stress, anger, confusion and depression and improved total mood at 14 days, with no change in cognitive performance. [https://pubmed.ncbi.nlm.nih.gov/26502953/]
  - Rhodiola rosea as an adaptogen to enhance exercise performance: a review of the literature, The British journal of nutrition (2024) — Review of at least 16 human studies concluded acute ~200 mg Rhodiola rosea pre-exercise may prolong time-to-exhaustion and improve time-trial performance, but ergogenic effects are generally minor, outcome-dependent and inconsistent for chronic use. [https://pubmed.ncbi.nlm.nih.gov/37641937/]
  - Rhodiola rosea: Clinical Evidence for Adaptogenic and Ergogenic Effects, Integrative and Complementary Therapies (2024) — Clinical review of Rhodiola rosea's adaptogenic and ergogenic effects summarizes evidence that it is generally well tolerated with mostly mild adverse events (e.g., dizziness, dry mouth) and may modestly benefit stress-related fatigue and mood, while cautioning that supporting trials remain small and methodologically limited. [https://journals.sagepub.com/doi/10.1089/ict.2024.56827.luc]
  - The effectiveness and efficacy of Rhodiola rosea L.: a systematic review of randomized clinical trials, Phytomedicine : international journal of phytotherapy and phytopharmacology (2011) — Promising for fatigue but methodological limitations noted. [https://pubmed.ncbi.nlm.nih.gov/21036578/]
  - Rhodiola rosea in stress induced fatigue--a double blind cross-over study of a standardized extract SHR-5 with a repeated low-dose regimen on the mental performance of healthy physicians during night duty, Phytomedicine : international journal of phytotherapy and phytopharmacology (2000) — Reduced fatigue and improved cognition in night-shift physicians. [https://pubmed.ncbi.nlm.nih.gov/11081987/]
  - Rhodiola: Usefulness and Safety, NIH National Center for Complementary and Integrative Health (2025) — The US National Center for Complementary and Integrative Health concludes there is not enough reliable evidence to determine whether rhodiola is useful for any health purpose (most human research being low-to-moderate quality); it is considered possibly safe for up to 12 weeks, with reported side effects including dizziness, headache, insomnia and dry mouth. [https://www.nccih.nih.gov/health/rhodiola]

---

## L-Theanine
URL: https://nutridex.info/s/ltheanine
Category: Nootropic, Sleep & Mood
Evidence: Moderate — Several controlled trials; effects real but modest or context-dependent.
Green-tea amino acid for calm, focused alertness.

Quick answer: L-Theanine is used for calm focus. NutriDex grades the human evidence as moderate — Several controlled trials; effects real but modest or context-dependent. Based on 16 cited human studies (16 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

L-theanine is an amino acid found in tea that increases alpha brain-wave activity associated with relaxed alertness. Trials show reduced stress reactivity and anxiety, and — combined with caffeine — improved attention and reaction time while blunting caffeine's jittery edge. Effects on sleep architecture are modest but it can improve subjective relaxation before bed without sedation.

Benefits / uses: Calm focus; Reduced anxiety; Better sleep quality; Smooths caffeine jitters.
Active compounds: L-theanine.
Dose: 100–200 mg; often paired 1:2 with caffeine (e.g. 100mg theanine + 50mg caffeine).
Safety: Very safe, no known serious side effects. Non-sedating at typical doses.

Cited studies (16):
  - The effects of L-theanine consumption on sleep outcomes: A systematic review and meta-analysis, Sleep medicine reviews (2025) — Meta-analysis of 18 RCTs (897 participants) found L-theanine significantly improved subjective sleep quality (SMD 0.43), sleep onset latency (SMD 0.15), and daytime dysfunction (SMD 0.33). [https://pubmed.ncbi.nlm.nih.gov/40056718/]
  - Promising, but Not Completely Conclusive-The Effect of l-Theanine on Cognitive Performance Based on the Systematic Review and Meta-Analysis of Randomized Placebo-Controlled Clinical Trials, Journal of clinical medicine (2025) — Meta-analysis of 5 placebo-controlled RCTs (148 healthy adults) found a dose-dependent improvement in visual processing/reaction time (RVIP) but no consistent benefit across other cognitive tests, calling cognitive effects promising but not conclusive. [https://pmc.ncbi.nlm.nih.gov/articles/PMC12609247/]
  - Effects of Tea (<i>Camellia sinensis</i>) or its Bioactive Compounds <scp>l</scp>-Theanine or <scp>l</scp>-Theanine plus Caffeine on Cognition, Sleep, and Mood in Healthy Participants: A Systematic Review and Meta-Analysis of Randomized Controlled Trials, Nutrition Reviews (2025) — Systematic review/meta-analysis of RCTs found L-theanine plus caffeine produced small-to-moderate improvements in attention-switching and digit-vigilance accuracy and in alertness/mood, with L-theanine alone modestly improving choice reaction time in healthy adults. [https://doi.org/10.1093/nutrit/nuaf054]
  - The effects of L-theanine supplementation on the outcomes of patients with mental disorders: a systematic review, BMC psychiatry (2024) — Systematic review of 11 RCTs (>800 patients) reported L-theanine supplementation reduced psychiatric symptoms more than controls in schizophrenia, anxiety disorders, and ADHD, while calling for larger confirmatory trials. [https://pubmed.ncbi.nlm.nih.gov/39633316/]
  - Examining the effect of L-theanine on sleep: a systematic review of dietary supplementation trials, Nutritional neuroscience (2026) — Systematic review of 13 dietary-supplementation trials (n=550; 11 RCTs) concluded that 200-450 mg/day of standalone L-theanine appears safe and effective for supporting healthy sleep in adults, with benefits on objective and self-reported sleep latency, maintenance, efficiency, and feelings of refreshment on waking. [https://pubmed.ncbi.nlm.nih.gov/41176609/]
  - Effects of Tea (Camellia sinensis) or its Bioactive Compounds l-Theanine or l-Theanine plus Caffeine on Cognition, Sleep, and Mood in Healthy Participants: A Systematic Review and Meta-Analysis of Randomized Controlled Trials, Nutrition reviews (2025) — Meta-analysis of 50 RCTs found small-to-moderate benefits of L-theanine plus caffeine over placebo in the first 2 hours for choice reaction time, attention-switching accuracy, and mood, with L-theanine alone favoring choice reaction time. [https://pmc.ncbi.nlm.nih.gov/articles/PMC12422004/]
  - The effects of L-theanine supplementation on the outcomes of patients with mental disorders: a systematic review, BMC psychiatry (2024) — Systematic review of 11 RCTs (>800 patients) found L-theanine supplementation significantly reduced psychiatric symptoms versus controls in schizophrenia, anxiety disorders, and ADHD, with reductions also seen in depression and Tourette tic severity. [https://pmc.ncbi.nlm.nih.gov/articles/PMC11616108/]
  - Effects of Tea (Camellia sinensis) or its Bioactive Compounds l-Theanine or l-Theanine plus Caffeine on Cognition, Sleep, and Mood in Healthy Participants: A Systematic Review and Meta-Analysis of Randomized Controlled Trials, Nutrition reviews (2025) — Systematic review/meta-analysis of 50 RCTs (15 pooled) in healthy adults: L-theanine alone modestly favored faster choice reaction time vs placebo (SMD -0.35; 95% CI -0.61 to -0.10) at hour 1; L-theanine plus caffeine improved attention-switching accuracy (h2 SMD 0.33; 95% CI 0.13-0.54) and digit-vigilance accuracy (h2 SMD 0.20; 95% CI 0.02-0.38). [https://pubmed.ncbi.nlm.nih.gov/40314930/]
  - Promising, but Not Completely Conclusive-The Effect of l-Theanine on Cognitive Performance Based on the Systematic Review and Meta-Analysis of Randomized Placebo-Controlled Clinical Trials, Journal of clinical medicine (2025) — Systematic review/meta-analysis of 5 RCTs (148 healthy adults): L-theanine showed a dose-dependent benefit on rapid visual information processing / recognition visual reaction time (MD -15.20 ms; 95% CI -28.99 to -1.41), but no significant effect on simple reaction time or Stroop test; benefits domain-specific and not confirmed across all measures. [https://pubmed.ncbi.nlm.nih.gov/41227106/]
  - The Cognitive-Enhancing Outcomes of Caffeine and L-theanine: A Systematic Review, Cureus (2021) — Systematic review of 5 clinical trials concluded the L-theanine plus caffeine combination is likely a safe and effective cognitive enhancer, improving short-term sustained attention and overall cognition. [https://pmc.ncbi.nlm.nih.gov/articles/PMC8794723/]
  - The Effects of Green Tea Amino Acid L-Theanine Consumption on the Ability to Manage Stress and Anxiety Levels: a Systematic Review, Plant foods for human nutrition (Dordrecht, Netherlands) (2020) — Systematic review of 9 RCTs found that 200-400 mg/day of pure L-theanine may help reduce stress and anxiety in people exposed to stressful conditions. [https://pubmed.ncbi.nlm.nih.gov/31758301/]
  - Safety and Efficacy of AlphaWave(®) L-Theanine Supplementation for 28 Days in Healthy Adults with Moderate Stress: A Randomized, Double-Blind, Placebo-Controlled Trial, Neurology and therapy (2024) — Randomized, double-blind, placebo-controlled trial in 30 healthy adults with moderate stress found 28 days of 400 mg/day AlphaWave L-theanine significantly reduced perceived stress, decreased light sleep, improved sleep quality, and enhanced cognitive attention versus placebo, with a good safety profile. [https://pubmed.ncbi.nlm.nih.gov/38758503/]
  - Effects of L-Theanine Administration on Stress-Related Symptoms and Cognitive Functions in Healthy Adults: A Randomized Controlled Trial, Nutrients (2019) — 4-week randomized, placebo-controlled, double-blind crossover trial in 30 healthy adults: L-theanine 200 mg/day reduced depression (SDS), trait anxiety (STAI-T), and sleep problems (PSQI) scores (all p<0.05) and improved verbal fluency and executive function vs placebo. [https://pubmed.ncbi.nlm.nih.gov/31623400/]
  - Effects of L-Theanine Administration on Stress-Related Symptoms and Cognitive Functions in Healthy Adults: A Randomized Controlled Trial, Nutrients (2019) — 4 weeks reduced stress-related symptoms and improved cognition. [https://pmc.ncbi.nlm.nih.gov/articles/PMC6836118/]
  - The combined effects of L-theanine and caffeine on cognitive performance and mood, Nutritional neuroscience (2008) — Theanine + caffeine improved attention-switching and alertness. [https://pubmed.ncbi.nlm.nih.gov/18681988/]
  - L-Theanine reduces psychological and physiological stress responses, Biological psychology (2007) — Attenuated physiological stress responses to an acute stressor. [https://pubmed.ncbi.nlm.nih.gov/16930802/]

---

## Caffeine
URL: https://nutridex.info/s/caffeine
Category: Nootropic, Performance
Evidence: Strong — Multiple high-quality RCTs / meta-analyses with consistent effects.
The world's most-used cognitive and athletic enhancer.

Quick answer: Caffeine is used for alertness. NutriDex grades the human evidence as strong — Multiple high-quality RCTs / meta-analyses with consistent effects. Based on 20 cited human studies (20 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Caffeine antagonizes adenosine receptors, reducing perceived effort and fatigue. It is one of the most robustly proven ergogenic aids, improving endurance, strength, power, and reaction time across hundreds of trials. Cognitively it sharpens alertness and vigilance, particularly when sleep-deprived. Tolerance develops with regular use, and timing matters for sleep — its half-life is ~5 hours.

Benefits / uses: Alertness; Endurance & power; Reaction time; Fat oxidation.
Active compounds: Caffeine (1,3,7-trimethylxanthine).
Dose: 3–6 mg/kg pre-exercise for ergogenic effect; ≤400 mg/day generally safe for adults.
Safety: Safe ≤400 mg/day for most adults. Excess causes anxiety, palpitations, insomnia. Pregnancy limit ~200 mg/day.

Cited studies (20):
  - The effect of caffeine supplementation on muscular strength and endurance: A meta-analysis of meta-analyses, Heliyon (2024) — Umbrella meta-analysis of 9 prior meta-analyses found caffeine significantly increases muscle strength (SMD 0.18, 95% CI 0.14-0.21) and muscle endurance (SMD 0.30, 95% CI 0.21-0.38). [https://pubmed.ncbi.nlm.nih.gov/39170391/]
  - Caffeine, CYP1A2 Genotype, and Exercise Performance: A Systematic Review and Meta-analysis, Medicine and science in sports and exercise (2024) — Three-level meta-analysis of 13 studies (440 participants) found caffeine is ergogenic for exercise performance but the benefit was not meaningfully modified by CYP1A2 (AA/AC/CC) genotype. [https://pubmed.ncbi.nlm.nih.gov/37844569/]
  - Effects of Caffeine Dose and Administration Method on Time-Trial Performance: A Systematic Review and Network Meta-Analysis, Nutrients (2025) — Network meta-analysis of 48 studies (612 participants) found low-dose caffeine capsules (~3 mg/kg) most effective at reducing endurance time-trial completion time, ahead of higher doses and gum. [https://pmc.ncbi.nlm.nih.gov/articles/PMC12694421/]
  - Effects of acute caffeine intake on muscular power during resistance exercise: a systematic review and meta-analysis, Frontiers in nutrition (2025) — Meta-analysis of 12 studies (230 participants) found acute caffeine improves resistance-exercise movement velocity (SMD 0.42) and mean power output (SMD 0.21). [https://pmc.ncbi.nlm.nih.gov/articles/PMC12537405/]
  - A systematic review and dose-response meta-analysis of prospective cohort studies on coffee consumption and risk of lung cancer, Scientific reports (2024) — Dose-response meta-analysis of 14 prospective cohorts (~1,061,854 participants, 19,643 lung cancer cases) found higher coffee intake associated with higher lung cancer risk (highest vs lowest RR 1.28, 95% CI 1.12-1.47; +6% per cup/day), likely confounded by smoking. [https://pubmed.ncbi.nlm.nih.gov/38951141/]
  - A systematic review and meta-analysis of the acute effect of caffeine on attention, Psychopharmacology (2025) — Systematic review and meta-analysis found acute caffeine improves attention in healthy adults, enhancing both reaction time and accuracy, with higher doses continuing to improve reaction time while accuracy gains plateau and then decline. [https://pubmed.ncbi.nlm.nih.gov/40335666/]
  - Wake up and smell the coffee: caffeine supplementation and exercise performance-an umbrella review of 21 published meta-analyses, British journal of sports medicine (2020) — Consistent ergogenic effects across endurance, power, and strength. [https://pubmed.ncbi.nlm.nih.gov/30926628/]
  - Effects of Caffeine Intake on Endurance Running Performance and Time to Exhaustion: A Systematic Review and Meta-Analysis, Nutrients (2022) — Meta-analysis of 21 RCTs (254 runners) showed caffeine (3-9 mg/kg) improved running time to exhaustion by ~17% (g=0.392) and modestly reduced time-trial completion time (g=-0.101). [https://pubmed.ncbi.nlm.nih.gov/36615805/]
  - Association of Coffee Consumption With Atrial Fibrillation Risk: An Updated Dose-Response Meta-Analysis of Prospective Studies, Frontiers in cardiovascular medicine (2022) — Dose-response meta-analysis of 10 prospective studies (11 cohorts, 723,825 participants, 30,169 atrial fibrillation events) found each additional cup/day of coffee associated with a 2% lower AF risk (RR 0.98, 95% CI 0.97-1.00). [https://pubmed.ncbi.nlm.nih.gov/35872898/]
  - Effects of acute caffeine consumption following sleep loss on cognitive, physical, occupational and driving performance: A systematic review and meta-analysis, Neuroscience and biobehavioral reviews (2020) — Systematic review and meta-analysis found acute caffeine consumption following sleep loss significantly improves cognitive, physical, occupational, and driving performance versus placebo. [https://pubmed.ncbi.nlm.nih.gov/31837359/]
  - Caffeinated and decaffeinated coffee consumption and risk of all-cause mortality: a dose-response meta-analysis of cohort studies, Journal of human nutrition and dietetics : the official journal of the British Dietetic Association (2019) — Dose-response meta-analysis of 21 cohort studies (>10 million participants, 240,303 deaths) found a nonlinear inverse association: 3 cups/day was associated with ~13% lower all-cause mortality (RR 0.87; 95% CI 0.84-0.89), with similar inverse associations for both caffeinated and decaffeinated coffee. [https://pubmed.ncbi.nlm.nih.gov/30786114/]
  - International society of sports nutrition position stand: caffeine and exercise performance, Journal of the International Society of Sports Nutrition (2021) — 3–6 mg/kg reliably enhances performance; effects vary by genotype. [https://pubmed.ncbi.nlm.nih.gov/33388079/]
  - Acute Effects of Coffee Consumption on Health among Ambulatory Adults, The New England journal of medicine (2023) — Randomized 14-day case-crossover RCT in 100 healthy adults found caffeinated coffee did not significantly increase premature atrial contractions (rate ratio 1.09, 95% CI 0.98-1.20) but increased premature ventricular contractions (RR 1.51, 95% CI 1.18-1.94) and reduced nightly sleep by ~36 minutes. [https://pubmed.ncbi.nlm.nih.gov/36947466/]
  - Effects of different doses of caffeine on cognitive performance in healthy physically active individuals, European journal of nutrition (2024) — Trial of different caffeine doses in healthy physically active adults reported dose-dependent effects on cognitive performance, supporting a dose-response relationship for attention and reaction time. [https://pubmed.ncbi.nlm.nih.gov/39231871/]
  - Effects of modafinil and caffeine on night-time vigilance of air force crewmembers: A randomized controlled trial, Journal of psychopharmacology (Oxford, England) (2023) — Randomized controlled trial in air force crewmembers found 300 mg caffeine significantly decreased the impact of limited sleep deprivation on night-time vigilance versus placebo, with effects most notable 2-4 hours after administration. [https://pmc.ncbi.nlm.nih.gov/articles/PMC9912306/]
  - Scientific Opinion on the safety of caffeine, EFSA Journal (2015) — EFSA concluded habitual single doses up to 200 mg and daily intakes up to 400 mg from all sources are not a safety concern for healthy adults (200 mg/day in pregnancy; 3 mg/kg for children/adolescents). [https://efsa.onlinelibrary.wiley.com/doi/10.2903/j.efsa.2015.4102]
  - Spilling the Beans: How Much Caffeine is Too Much?, U.S. Food and Drug Administration — FDA cites roughly 400 mg/day (about 4-5 cups of coffee) as an amount not generally associated with dangerous negative effects in healthy adults, while warning of toxicity risk from pure/highly concentrated caffeine. [https://www.fda.gov/consumers/consumer-updates/spilling-beans-how-much-caffeine-too-much]
  - Coffee and tea consumption and cardiovascular disease and all-cause and cause-specific mortality in individuals with diabetes mellitus: a meta-analysis of prospective observational studies, Frontiers in nutrition (2025) — Meta-analysis of prospective cohorts in people with diabetes found highest vs lowest coffee intake associated with lower all-cause mortality (HR 0.82, 95% CI 0.73-0.91) and CHD mortality. [https://pubmed.ncbi.nlm.nih.gov/40525136/]
  - Coffee Consumption, Additive Use, and Risk of Type 2 Diabetes-Results from 3 Large Prospective United States Cohort Studies, The American journal of clinical nutrition (2025) — Pooled analysis of three large US cohorts (NHS, NHS II, HPFS; 13,281 incident type 2 diabetes cases over 3.66 million person-years) found each additional cup of plain coffee associated with ~10% lower T2D risk, with the benefit attenuated by added sugar. [https://pubmed.ncbi.nlm.nih.gov/39828230/]
  - A review of caffeine's effects on cognitive, physical and occupational performance, Neuroscience and biobehavioral reviews (2016) — Improves vigilance and cognition, especially under sleep loss. [https://pubmed.ncbi.nlm.nih.gov/27612937/]

---

## Melatonin
URL: https://nutridex.info/s/melatonin
Category: Sleep & Mood
Evidence: Strong — Multiple high-quality RCTs / meta-analyses with consistent effects.
The body's sleep-timing hormone, in supplement form.

Quick answer: Melatonin is used for faster sleep onset. NutriDex grades the human evidence as strong — Multiple high-quality RCTs / meta-analyses with consistent effects. Based on 18 cited human studies (18 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Melatonin is the hormone that signals darkness and regulates the sleep-wake cycle. Supplementation reliably shortens time to fall asleep and is especially effective for circadian problems — jet lag, shift work, and delayed sleep-phase disorder. It is more a chronobiotic (clock-shifter) than a sedative; low doses taken at the right time beat large doses. Long-term safety data are reassuring but limited.

Benefits / uses: Faster sleep onset; Jet-lag relief; Circadian re-timing; Shift-work sleep.
Active compounds: Melatonin.
Dose: 0.5–3 mg, 30–60 min before target bedtime. Lower doses often work as well as higher.
Safety: Safe short-term. Can cause grogginess, vivid dreams. May interact with anticoagulants and sedatives.

Cited studies (18):
  - Optimizing the Time and Dose of Melatonin as a Sleep-Promoting Drug: A Systematic Review of Randomized Controlled Trials and Dose-Response Meta-Analysis, Journal of pineal research (2024) — Dose-response meta-analysis of 26 RCTs (1689 observations) found exogenous melatonin reduces sleep-onset latency and increases total sleep time, with effects peaking around 4 mg taken ~3 hours before bedtime. [https://pubmed.ncbi.nlm.nih.gov/38888087/]
  - Efficacy and tolerability of pharmacological treatments for insomnia in adults: A systematic review and network meta-analysis, Sleep medicine reviews (2023) — Network meta-analysis of 69 RCTs (17,319 adults) ranked melatonin receptor agonists below orexin-receptor antagonists for sleep latency, WASO and efficiency, but found them efficacious for sleep-onset insomnia with good safety. [https://pubmed.ncbi.nlm.nih.gov/36701954/]
  - Efficacy of Melatonin for Insomnia in Children with Autism Spectrum Disorder: A Meta-analysis, Neuropediatrics (2023) — Meta-analysis of 4 studies (238 children with autism spectrum disorder) found melatonin shortened sleep-onset latency, reduced night awakenings, and prolonged total sleep time. [https://pubmed.ncbi.nlm.nih.gov/36827993/]
  - The short-term and long-term adverse effects of melatonin treatment in children and adolescents: a systematic review and GRADE assessment, eClinicalMedicine (2023) — Systematic review (22 RCTs, 1350 children/adolescents) found melatonin caused no serious adverse events but a higher rate of non-serious adverse events (RR 1.56, 95% CI 1.01-2.43); long-term effects on puberty/bone remained uncertain, prompting caution. [https://doi.org/10.1016/j.eclinm.2023.102083]
  - Efficacy and safety of perioperative melatonin for postoperative delirium in patients undergoing surgery: a systematic review and meta-analysis, The Journal of international medical research (2024) — Systematic review/meta-analysis of 16 RCTs (1981 surgical patients) found perioperative melatonin reduced postoperative delirium incidence (RR 0.57), with the strongest effect for high-dose melatonin (RR 0.41) and after cardiopulmonary surgery, and no severe adverse events. [https://pubmed.ncbi.nlm.nih.gov/38735057/]
  - Melatonin intervention to prevent delirium in the intensive care units: a systematic review and meta-analysis of randomized controlled trials, Frontiers in endocrinology (2023) — Meta-analysis of 6 RCTs (2374 critically ill patients) found melatonin did not significantly reduce overall ICU delirium incidence (OR 0.71, 95% CI 0.46-1.12), but a subgroup of cardiovascular care unit patients showed a significant reduction (OR 0.52, 95% CI 0.37-0.73). [https://pubmed.ncbi.nlm.nih.gov/37564987/]
  - Use of Melatonin and/on Ramelteon for the Treatment of Insomnia in Older Adults: A Systematic Review and Meta-Analysis, Journal of clinical medicine (2022) — Systematic review/meta-analysis (17 RCTs, ~2462 subjects, mean age >=55) found melatonin/ramelteon increased objective total sleep time by ~21 min and reduced sleep latency by ~14 min versus placebo, supporting use as a safer option than benzodiazepines. [https://pubmed.ncbi.nlm.nih.gov/36079069/]
  - Efficacy on sleep parameters and tolerability of melatonin in individuals with sleep or mental disorders: A systematic review and meta-analysis, Neuroscience and biobehavioral reviews (2022) — Meta-analysis of 34 RCTs (1998 participants) found melatonin significantly improved sleep-onset latency and total sleep time in children/adolescents with neurodevelopmental disorders and adults with delayed sleep-phase disorder, with tolerability similar to placebo. [https://pubmed.ncbi.nlm.nih.gov/35691474/]
  - Melatonin and melatonin-agonists for metabolic syndrome components in patients treated with antipsychotics: A systematic review and meta-analysis, Human psychopharmacology (2022) — Meta-analysis of 5 RCTs (248 patients on antipsychotics) found melatonin/ramelteon improved non-anthropometric metabolic syndrome components versus placebo, lowering systolic blood pressure by ~3.3 mmHg and triglycerides by ~9.8 mg/dL, with no effect on weight or waist circumference. [https://pubmed.ncbi.nlm.nih.gov/34687076/]
  - Efficacy of melatonin for chronic insomnia: Systematic reviews and meta-analyses, Sleep medicine reviews (2022) — Systematic review/meta-analysis of 24 RCTs in chronic insomnia: melatonin was NOT significantly effective in adults for sleep onset latency, total sleep time, or sleep efficiency, but significantly improved sleep onset latency and total sleep time in children/adolescents. In comorbid insomnia it improved sleep onset latency across age groups. [https://pubmed.ncbi.nlm.nih.gov/36179487/]
  - Notes from the Field: Emergency Department Visits for Unsupervised Pediatric Melatonin Ingestion — United States, 2019–2022, MMWR. Morbidity and Mortality Weekly Report (2024) — Notes from the Field: U.S. emergency department visits for unsupervised pediatric melatonin ingestion rose sharply during 2019-2022, with flavored products (gummies/chewables) involved in about half of visits. [https://www.cdc.gov/mmwr/volumes/73/wr/mm7309a5.htm]
  - Efficacy and safety of melatonin for sleep onset insomnia in children and adolescents: a meta-analysis of randomized controlled trials, Sleep medicine (2020) — Meta-analysis of 7 RCTs (387 children/adolescents with sleep-onset insomnia): melatonin advanced sleep onset time by 0.62 h (95% CI -0.80 to -0.45), advanced dim-light melatonin onset by 0.82 h, reduced sleep onset latency by 0.36 h, and increased total sleep time by 0.38 h vs placebo, with no significant difference in dropouts. [https://pubmed.ncbi.nlm.nih.gov/31982807/]
  - Meta-analysis: melatonin for the treatment of primary sleep disorders, PloS one (2013) — Reduced sleep latency and increased total sleep time. [https://pubmed.ncbi.nlm.nih.gov/23691095/]
  - Pediatric Melatonin Ingestions — United States, 2012–2021, MMWR. Morbidity and Mortality Weekly Report (2022) — Pediatric melatonin ingestions reported to U.S. poison control centers increased 530% from 2012 to 2021 (8,337 to 52,563 annually), including reports of hospitalization and two deaths. [https://www.cdc.gov/mmwr/volumes/71/wr/mm7122a1.htm]
  - Melatonin for the prevention and treatment of jet lag, The Cochrane database of systematic reviews (2002) — Effective for preventing and reducing jet lag. [https://pubmed.ncbi.nlm.nih.gov/12076414/]
  - Clinical Practice Guideline for the Treatment of Intrinsic Circadian Rhythm Sleep-Wake Disorders: Advanced Sleep-Wake Phase Disorder (ASWPD), Delayed Sleep-Wake Phase Disorder (DSWPD), Non-24-Hour Sleep-Wake Rhythm Disorder (N24SWD), and Irregular Sleep-Wake Rhythm Disorder (ISWRD). An Update for 2015: An American Academy of Sleep Medicine Clinical Practice Guideline, Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine (2015) — American Academy of Sleep Medicine GRADE-based guideline positively endorses strategically timed melatonin for delayed sleep-wake phase disorder (DSWPD), blind adults with non-24-hour disorder (N24SWD), and children/adolescents with irregular sleep-wake rhythm disorder plus comorbid neurological disorders; recommends AGAINST melatonin in demented elderly. [https://pubmed.ncbi.nlm.nih.gov/26414986/]
  - Efficacy of prolonged release melatonin in insomnia patients aged 55-80 years: quality of sleep and next-day alertness outcomes, Current medical research and opinion (2007) — Landmark double-blind RCT, 354 primary insomnia patients aged 55-80: prolonged-release melatonin 2 mg nightly improved concomitant sleep quality plus morning alertness (responder rate 26% vs 15% placebo; p=0.014) and shortened sleep latency (-24.3 vs -12.9 min; p=0.028), with improved quality of life and a placebo-like safety profile. [https://pubmed.ncbi.nlm.nih.gov/17875243/]
  - Evidence for the efficacy of melatonin in the treatment of primary adult sleep disorders, Sleep medicine reviews (2017) — Beneficial for delayed sleep-phase and circadian disorders. [https://pubmed.ncbi.nlm.nih.gov/28648359/]

---

## Curcumin (Turmeric) (Curcuma longa)
URL: https://nutridex.info/s/curcumin
Category: Ayurvedic, Joint & Skin, Heart & Metabolic
Evidence: Moderate — Several controlled trials; effects real but modest or context-dependent.
The golden anti-inflammatory polyphenol.

Quick answer: Curcumin (Turmeric) is used for joint pain relief. NutriDex grades the human evidence as moderate — Several controlled trials; effects real but modest or context-dependent. Based on 23 cited human studies (23 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Curcumin is turmeric's principal active polyphenol with potent anti-inflammatory and antioxidant activity in vitro. Clinically, bioavailability-enhanced forms reduce osteoarthritis pain comparably to NSAIDs in several trials and lower inflammatory markers. Raw curcumin is poorly absorbed, so formulation matters greatly. Early data also suggest small antidepressant and metabolic benefits.

Benefits / uses: Joint pain relief; Anti-inflammatory; Antioxidant; Mood support.
Active compounds: Curcuminoids; Often w/ piperine or phospholipid for absorption.
Dose: 500–1,000 mg curcuminoids/day; bioavailability-enhanced forms preferred.
Safety: Generally safe. High doses may cause GI upset. Can increase bleeding risk and interact with blood thinners. Rare but serious cases of turmeric/curcumin-associated liver injury have been documented (NIH LiverTox), with risk possibly higher for piperine-enhanced formulas; may also inhibit drug-metabolizing enzymes and reduce iron absorption.

Cited studies (23):
  - Efficacy of Curcuma longa in relieving pain symptoms of knee osteoarthritis patients: a systematic review and meta-analysis of clinical trials, Journal of rheumatic diseases (2025) — Across 10 RCTs (786 patients), Curcuma longa significantly improved knee osteoarthritis pain vs placebo (VAS MD 18.25, 95% CI 7.79-28.72) and was non-inferior to NSAIDs on WOMAC total score. [https://pubmed.ncbi.nlm.nih.gov/39712249/]
  - Effect of curcumin supplementation on symptoms of anxiety: A systematic review and meta-analysis of randomized controlled trials, Clinical nutrition ESPEN (2024) — Pooling 8 RCTs (567 participants), curcumin significantly reduced anxiety symptoms (SMD -1.56, 95% CI -2.48 to -0.64). [https://pubmed.ncbi.nlm.nih.gov/38857152/]
  - Safety and efficacy of curcumin in the treatment of ulcerative colitis: An updated systematic review and meta-analysis of randomized controlled trials, Explore (New York, N.Y.) (2025) — Across 8 RCTs (482 patients), adjunctive curcumin more than doubled clinical remission vs placebo (RR 2.33, 95% CI 1.25-4.34) with no serious adverse events. [https://pubmed.ncbi.nlm.nih.gov/39612780/]
  - Effects of curcumin/turmeric supplementation on the liver enzymes, lipid profiles, glycemic index, and anthropometric indices in non-alcoholic fatty liver patients: An umbrella meta-analysis, Phytotherapy research : PTR (2024) — Umbrella analysis of 11 meta-analyses (99 RCTs, 5,546 participants) found curcumin/turmeric reduced AST, ALT, triglycerides, HOMA-IR, BMI and waist circumference in NAFLD, with no significant effect on LDL-C, total cholesterol, FBS or HbA1c. [https://pubmed.ncbi.nlm.nih.gov/37918958/]
  - Antidiabetic and Metabolic Effects of Turmeric (Curcuma Longa) in Patients with Type 2 Diabetes Mellitus or Hyperglycemia - A Systematic Meta-Review and Meta-Analysis, Journal of Nepal Health Research Council (2025) — Meta-review of 13 meta-analyses covering 63 RCTs (3,706 participants) found curcumin modestly lowered fasting blood glucose (-6.30 mg/dL) and HbA1c (-0.31%) in type 2 diabetes/hyperglycemia. [https://pubmed.ncbi.nlm.nih.gov/41319069/]
  - The effects of curcumin on anthropometric and cardiometabolic parameters of patients with metabolic related diseases: a systematic review and dose-effect meta-analysis of randomized controlled trials, Critical reviews in food science and nutrition (2023) — Across 31 RCTs, curcumin produced modest reductions in body weight (-0.94 kg), BMI, LDL-C, total cholesterol and hs-CRP and raised HDL-C, with effects plateauing around 80 mg/day. [https://pubmed.ncbi.nlm.nih.gov/35475714/]
  - Effect of curcumin on inflammatory markers and disease activity in patients with rheumatoid arthritis: A meta-analysis, Medicine (2025) — Pooling 7 RCTs, curcumin meaningfully improved RA disease activity (DAS28 WMD -1.47) and lowered CRP and ESR, with no serious adverse events. [https://pmc.ncbi.nlm.nih.gov/articles/PMC12662462/]
  - Targeting cognitive aging with curcumin supplementation: A systematic review and meta-analysis, The journal of prevention of Alzheimer's disease (2025) — Pooling 10 human RCTs (531 participants), curcumin had no significant effect on global cognition versus placebo (SMD 0.14, 95% CI -0.78 to 1.07), with benefit seen only in specific domains such as working memory and processing speed. [https://pubmed.ncbi.nlm.nih.gov/40579315/]
  - Effect of turmeric products on knee osteoarthritis: a systematic review and network meta-analysis, BMC complementary medicine and therapies (2025) — Network meta-analysis of 17 RCTs found all turmeric preparations significantly reduced WOMAC pain vs placebo; bioavailability-enhanced curcuminoids cut WOMAC pain ~30% (MD -2.47, 95% CI -3.27 to -1.67), reaching the minimal clinically important difference. [https://pubmed.ncbi.nlm.nih.gov/40731001/]
  - Curcumin and multiple health outcomes: critical umbrella review of intervention meta-analyses, Frontiers in pharmacology (2025) — Critical umbrella review of intervention meta-analyses found that in osteoarthritis, Curcuma longa extract/curcumin reduced VAS pain and WOMAC pain, function and stiffness vs placebo and had effects on joint pain similar to NSAIDs, though overall methodological quality of underlying reviews was relatively poor. [https://pmc.ncbi.nlm.nih.gov/articles/PMC12176752/]
  - Effects of curcumin on serum inflammatory biomarkers in patients with knee osteoarthritis: a systematic review and meta-analysis of randomized controlled trials, BMC complementary medicine and therapies (2025) — Meta-analysis of 21 RCTs (1705 knee OA patients) found curcumin significantly lowered serum CRP and TNF-alpha vs placebo, with no significant differences in ESR, IL-1beta, IL-6, or PGE-2. [https://pubmed.ncbi.nlm.nih.gov/40615851/]
  - Effects of curcumin on serum inflammatory biomarkers in patients with knee osteoarthritis: a systematic review and meta-analysis of randomized controlled trials, BMC complementary medicine and therapies (2025) — Full-text systematic review and meta-analysis of randomized controlled trials confirming curcumin reduces serum CRP and TNF-alpha in knee osteoarthritis (21 studies, 1705 patients; databases searched to March 2025). [https://pmc.ncbi.nlm.nih.gov/articles/PMC12231615/]
  - A critical review of systematic reviews and meta-analyses of curcumin for knee osteoarthritis, Frontiers in pharmacology (2025) — Critical review of systematic reviews and meta-analyses of curcumin for knee osteoarthritis synthesizing the evidence base and grading methodological quality of existing pooled analyses. [https://pmc.ncbi.nlm.nih.gov/articles/PMC12813030/]
  - Efficacy and safety of curcumin therapy for knee osteoarthritis: A Bayesian network meta-analysis, Journal of ethnopharmacology (2024) — Network meta-analysis of 23 RCTs (2175 knee OA patients): vs placebo, curcumin significantly reduced VAS pain (MD -1.63, 95% CI -2.91 to -0.45) and total WOMAC (MD -18.85, 95% CI -29.53 to -8.76), and lowered rescue-medication use (OR 0.17); curcumin had fewer adverse events than NSAIDs (OR 0.51). [https://pubmed.ncbi.nlm.nih.gov/38036015/]
  - Therapeutic effect and safety of curcumin in women with PCOS: A systematic review and meta-analysis, Frontiers in endocrinology (2022) — Across 7 RCTs (447 women with PCOS), curcumin lowered fasting glucose, insulin, HOMA-IR, total cholesterol, CRP and BMI but had no significant effect on reproductive hormones (testosterone, DHEA, LH, FSH). [https://pubmed.ncbi.nlm.nih.gov/36387924/]
  - Efficacy and safety of curcuminoids alone in alleviating pain and dysfunction for knee osteoarthritis: a systematic review and meta-analysis of randomized controlled trials, BMC complementary medicine and therapies (2022) — 15 RCTs (1670 patients): curcuminoids alone vs placebo improved VAS pain (WMD -1.77, 95% CI -2.44 to -1.09) and WOMAC total (WMD -7.06), function and stiffness; non-inferior to NSAIDs for pain/function with no increase in adverse events. [https://pubmed.ncbi.nlm.nih.gov/36261810/]
  - Effect of curcumin on C-reactive protein as a biomarker of systemic inflammation: An updated meta-analysis of randomized controlled trials, Phytotherapy research : PTR (2022) — Curcumin supplementation significantly lowered systemic inflammation markers vs placebo: CRP (WMD -3.67 mg/L, 95% CI -6.96 to -0.38; 9 studies) and hs-CRP (23 studies), with effect strongest at doses <=1000 mg/day and >10-week duration. [https://pubmed.ncbi.nlm.nih.gov/34586711/]
  - The efficacy and acceptability of curcumin for the treatment of depression or depressive symptoms: A systematic review and meta-analysis, Journal of affective disorders (2021) — 10 RCTs (594 patients): curcumin significantly reduced depressive symptoms vs placebo (SMD -0.32, 95% CI -0.50 to -0.13) and increased response rates (OR 3.20, 95% CI 1.28-7.99), with drop-out/adverse-event rates comparable to placebo; authors rate overall evidence quality as low. [https://pubmed.ncbi.nlm.nih.gov/33418373/]
  - Efficacy of Turmeric Extracts and Curcumin for Alleviating the Symptoms of Joint Arthritis: A Systematic Review and Meta-Analysis of Randomized Clinical Trials, Journal of medicinal food (2016) — Reduced arthritis symptoms similarly to NSAIDs across 8 trials. [https://pubmed.ncbi.nlm.nih.gov/27533649/]
  - Turmeric (2025) — NIH LiverTox monograph documents that turmeric/curcumin supplements, especially high-dose or piperine-enhanced products, can cause acute hepatocellular drug-induced liver injury, typically hepatocellular with autoimmune features and resolving after discontinuation. [https://www.ncbi.nlm.nih.gov/books/NBK548561/]
  - Drug-Induced Liver Injury Secondary to Turmeric Supplement Containing Piperine: A Case Report, Cureus (2025) — Case report of a 35-year-old man who developed jaundice, fatigue and pruritus from a turmeric supplement containing piperine, with liver tests normalizing and full recovery after discontinuation, illustrating curcumin-associated drug-induced liver injury. [https://pubmed.ncbi.nlm.nih.gov/41281037/]
  - Effect of curcumin on circulating interleukin-6 concentrations: A systematic review and meta-analysis of randomized controlled trials, Pharmacological research (2016) — Lowered circulating inflammatory cytokines. [https://pubmed.ncbi.nlm.nih.gov/27392742/]
  - Clinical Use of Curcumin in Depression: A Meta-Analysis, Journal of the American Medical Directors Association (2017) — Modest antidepressant effect in pooled analysis. [https://pubmed.ncbi.nlm.nih.gov/28236605/]

---

## Berberine
URL: https://nutridex.info/s/berberine
Category: Heart & Metabolic
Evidence: Moderate — Several controlled trials; effects real but modest or context-dependent.
A plant alkaloid that rivals metformin for blood sugar.

Quick answer: Berberine is used for blood-sugar control. NutriDex grades the human evidence as moderate — Several controlled trials; effects real but modest or context-dependent. Based on 18 cited human studies (18 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Berberine activates AMPK, a key metabolic regulator. Meta-analyses show it lowers fasting glucose and HbA1c comparably to early-stage metformin, while also reducing LDL cholesterol and triglycerides. It is one of the more impressive natural metabolic agents, though absorption is poor and GI side effects are common. Not a substitute for prescribed diabetes therapy without medical guidance.

Benefits / uses: Blood-sugar control; Lower cholesterol; Insulin sensitivity; Weight support.
Active compounds: Berberine (isoquinoline alkaloid).
Dose: 500 mg, 2–3× daily with meals (1,000–1,500 mg/day total).
Safety: Common GI upset and cramping. A potent CYP3A4/2D6/2C9 and P-glycoprotein inhibitor, so it raises blood levels of many drugs (e.g. statins, cyclosporine, midazolam) and adds to the glucose-lowering of diabetes medicines — watch for hypoglycaemia. Avoid in pregnancy and breastfeeding (can displace bilirubin and cause neonatal jaundice/kernicterus).

Cited studies (18):
  - The Effect of Berberine Supplementation on Glycemic Control and Inflammatory Biomarkers in Metabolic Disorders: An Umbrella Meta-analysis of Randomized Controlled Trials, Clinical therapeutics (2024) — Umbrella meta-analysis of RCTs (searched to April 2023) found berberine supplementation significantly reduced fasting blood glucose, HbA1c, insulin, HOMA-IR, and the inflammatory markers IL-6, TNF-alpha, and CRP in patients with metabolic disorders. [https://pubmed.ncbi.nlm.nih.gov/38016844/]
  - The clinical efficacy and safety of berberine in the treatment of non-alcoholic fatty liver disease: a meta-analysis and systematic review, Journal of translational medicine (2024) — Meta-analysis of RCTs in non-alcoholic fatty liver disease found berberine significantly improved liver enzymes (ALT, AST, GGT), lipid profile, HOMA-IR, and BMI, supporting its use as an adjunct therapy for NAFLD. [https://pmc.ncbi.nlm.nih.gov/articles/PMC10908013/]
  - Effects of administering berberine alone or in combination on type 2 diabetes mellitus: a systematic review and meta-analysis, Frontiers in pharmacology (2024) — Systematic review and meta-analysis of RCTs in type 2 diabetes reported berberine, alone or combined with standard therapy, significantly reduced HbA1c (MD -0.73%), fasting glucose (MD -0.86 mmol/L), 2-hour glucose, fasting insulin, HOMA-IR, and BMI versus control. [https://pubmed.ncbi.nlm.nih.gov/39640489/]
  - Berberine as adjuvant therapy for treating reduced fertility potential in women with polycystic ovary syndrome: A meta-analysis of randomized controlled trials, Explore (New York, N.Y.) (2024) — Meta-analysis of 10 RCTs (713 women with polycystic ovary syndrome) found berberine added to standard Western medicine significantly increased ovulation rate (RR 1.41), clinical pregnancy rate (RR 1.96), and endometrial thickness (+1.62 mm), while lowering luteinizing hormone and total testosterone. [https://pubmed.ncbi.nlm.nih.gov/39236662/]
  - Efficacy and safety of berberine for several cardiovascular diseases: A systematic review and meta-analysis of randomized controlled trials, Phytomedicine : international journal of phytotherapy and phytopharmacology (2023) — Systematic review and meta-analysis of 44 RCTs (4,606 patients) found berberine, especially combined with statins, significantly reduced NIHSS stroke score, hs-CRP, IL-6, TNF-alpha, and carotid intima-media thickness with no serious adverse reactions. [https://pubmed.ncbi.nlm.nih.gov/36805484/]
  - The effect of berberine on obesity indices: a systematic review and meta-analysis, International Journal of Obesity (2025) — Systematic review and meta-analysis of RCTs in adults found berberine modestly but significantly reduced body weight (MD -0.88 kg), BMI (MD -0.48 kg/m2), and waist circumference (MD -1.32 cm), with no significant change in waist-to-hip ratio. [https://doi.org/10.1038/s41366-025-01943-x]
  - The clinical efficacy and safety of berberine in the treatment of non-alcoholic fatty liver disease: a meta-analysis and systematic review, Journal of translational medicine (2024) — Meta-analysis of 10 RCTs (811 NAFLD patients): berberine significantly reduced ALT (SMD -0.72), AST (SMD -0.79), GGT (SMD -0.62), triglycerides (SMD -0.59), total cholesterol (SMD -0.74), LDL-C (SMD -0.53), HOMA-IR (SMD -1.56) and BMI (SMD -0.58), with only mild GI adverse events. [https://pubmed.ncbi.nlm.nih.gov/38429794/]
  - Glucose-lowering effect of berberine on type 2 diabetes: A systematic review and meta-analysis, Frontiers in pharmacology (2022) — Meta-analysis of 37 RCTs (3,048 patients with type 2 diabetes) found berberine reduced fasting plasma glucose by ~0.82 mmol/L, HbA1c by ~0.63%, and 2-hour postprandial glucose by ~1.16 mmol/L without increasing adverse events or hypoglycemia. [https://pmc.ncbi.nlm.nih.gov/articles/PMC9709280/]
  - The effects of berberine supplementation on cardiovascular risk factors in adults: A systematic review and dose-response meta-analysis, Frontiers in nutrition (2022) — Systematic review and dose-response meta-analysis of RCTs in adults found berberine supplementation significantly lowered total cholesterol, LDL-C, triglycerides, fasting glucose, HbA1c, and CRP while modestly improving cardiovascular risk factors. [https://pmc.ncbi.nlm.nih.gov/articles/PMC9614282/]
  - The Effect of Berberine on Metabolic Profiles in Type 2 Diabetic Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials, Oxidative medicine and cellular longevity (2021) — Meta-analysis of 46 RCTs in type 2 diabetes: berberine (alone or adjunctive) reduced HbA1c (MD -0.73%), fasting plasma glucose (MD -0.86 mmol/L), 2-h postprandial glucose (MD -1.26 mmol/L), HOMA-IR (MD -0.71), LDL (MD -0.86 mmol/L) and triglycerides (MD -0.50 mmol/L), and raised HDL (MD +0.17 mmol/L), with a favorable safety profile. [https://pubmed.ncbi.nlm.nih.gov/34956436/]
  - Glucose-lowering effect of berberine on type 2 diabetes: A systematic review and meta-analysis, Frontiers in pharmacology (2022) — Meta-analysis of 37 RCTs (3,048 type 2 diabetes patients): berberine reduced FPG (WMD -0.82 mmol/L), HbA1c (WMD -0.63%) and 2-h postprandial glucose (WMD -1.16 mmol/L); glucose-lowering scaled with baseline FPG/HbA1c and did not increase total adverse events (RR 0.73) or hypoglycemia (RR 0.48). [https://pubmed.ncbi.nlm.nih.gov/36467075/]
  - The effects of berberine supplementation on cardiovascular risk factors in adults: A systematic review and dose-response meta-analysis, Frontiers in nutrition (2022) — Systematic review and dose-response meta-analysis of RCTs in adults: berberine lowered triglycerides (WMD -23.7 mg/dL), total cholesterol (-20.6 mg/dL), LDL (-9.6 mg/dL), FBG (-7.7 mg/dL), HbA1c (-0.45%), HOMA-IR (-1.04), systolic BP (-5.5 mmHg), weight and BMI, and raised HDL (+1.4 mg/dL); optimal lipid/weight dose ~1 g/day. [https://pubmed.ncbi.nlm.nih.gov/36313096/]
  - Meta-analysis of the effect and safety of berberine in the treatment of type 2 diabetes mellitus, hyperlipemia and hypertension, Journal of ethnopharmacology (2015) — Comparable glucose-lowering to oral hypoglycemics. [https://pubmed.ncbi.nlm.nih.gov/25498346/]
  - Efficacy and safety of berberine for dyslipidaemias: A systematic review and meta-analysis of randomized clinical trials, Phytomedicine : international journal of phytotherapy and phytopharmacology (2018) — Meta-analysis of 16 RCTs (2,147 participants) in dyslipidaemia: berberine reduced total cholesterol (MD -0.47 mmol/L), LDL-C (MD -0.38 mmol/L) and triglycerides (MD -0.28 mmol/L), and raised HDL-C when used alone (MD +0.08 mmol/L), with no significant difference in adverse events (RR 0.64) and no severe events. [https://pubmed.ncbi.nlm.nih.gov/30466986/]
  - The Effects of Berberine on Blood Lipids: A Systemic Review and Meta-Analysis of Randomized Controlled Trials, Planta Medica (2013) — Significant reductions in total and LDL cholesterol. [https://www.thieme-connect.de/products/ejournals/abstract/10.1055/s-0032-1328321]
  - Repeated administration of berberine inhibits cytochromes P450 in humans, European journal of clinical pharmacology (2012) — Randomized crossover study in healthy men found berberine 300 mg three times daily for 2 weeks inhibited CYP2D6, CYP2C9, and CYP3A4 activity (e.g., raising midazolam AUC ~40%), indicating potential for clinically relevant drug-drug interactions. [https://pubmed.ncbi.nlm.nih.gov/21870106/]
  - Efficacy of berberine in patients with type 2 diabetes mellitus, Metabolism: clinical and experimental (2008) — Improved glycemic control and lipids in type-2 diabetics. [https://pubmed.ncbi.nlm.nih.gov/18442638/]
  - Effects of berberine on the blood concentration of cyclosporin A in renal transplanted recipients: clinical and pharmacokinetic study, European journal of clinical pharmacology (2005) — Clinical and pharmacokinetic study in 104 renal transplant recipients found co-administration of berberine raised cyclosporine A blood concentrations (~29% higher steady-state, AUC +34.5%), demonstrating a clinically important interaction via CYP3A4/P-gp inhibition. [https://pubmed.ncbi.nlm.nih.gov/16133554/]

---

## Zinc
URL: https://nutridex.info/s/zinc
Category: Mineral, Gut & Immune
Evidence: Moderate — Several controlled trials; effects real but modest or context-dependent.
Essential mineral for immunity, healing, and hormones.

Quick answer: Zinc is used for immune function. NutriDex grades the human evidence as moderate — Several controlled trials; effects real but modest or context-dependent. Based on 21 cited human studies (21 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Zinc is essential for immune cell function, protein synthesis, and wound healing. Zinc lozenges started within 24 hours can shorten the common cold by roughly a day. Deficiency impairs immunity and is common in older adults and vegetarians. Chronic high intake interferes with copper absorption, so megadosing is discouraged.

Benefits / uses: Immune function; Shorter colds; Wound healing; Skin & testosterone.
Active compounds: Zinc picolinate; Zinc gluconate; Zinc acetate.
Dose: 8–11 mg/day RDA; up to 40 mg upper limit. Lozenges (75mg+/day) only short-term for colds.
Safety: Safe within limits (adult upper limit ~40 mg/day). Sustained high intake blocks copper absorption and can cause copper deficiency — anaemia and, rarely, irreversible nerve damage (myeloneuropathy). High-dose lozenges cause nausea and taste disturbance and are for short-term cold use only. Nasal zinc has caused permanent loss of smell — avoid it.

Cited studies (21):
  - Zinc for prevention and treatment of the common cold, The Cochrane database of systematic reviews (2024) — Across 34 RCTs (8,526 participants), zinc had little or no effect on preventing colds but may reduce duration of an ongoing cold (~2.4 days, low certainty), with more non-serious adverse events (taste/GI). [https://pubmed.ncbi.nlm.nih.gov/38719213/]
  - Zinc supplementation for preventing mortality, morbidity, and growth failure in children aged 6 months to 12 years, The Cochrane database of systematic reviews (2023) — In 96 RCTs (219,584 children 6 months-12 years), preventive zinc made little to no difference to all-cause mortality but likely reduced all-cause diarrhea incidence and slightly increased height, with more vomiting. [https://pubmed.ncbi.nlm.nih.gov/36994923/]
  - Effect of zinc supplementation on glycemic biomarkers: an umbrella of interventional meta-analyses, Diabetology & metabolic syndrome (2024) — Umbrella review of interventional meta-analyses found zinc supplementation significantly reduced fasting blood glucose, insulin, HOMA-IR, and HbA1c (p<0.001), supporting benefit in glycemic control. [https://pubmed.ncbi.nlm.nih.gov/38849958/]
  - Zinc supplementation and cardiovascular disease risk factors: A GRADE-assessed systematic review and dose-response meta-analysis, Journal of trace elements in medicine and biology : organ of the Society for Minerals and Trace Elements (GMS) (2023) — GRADE-assessed dose-response meta-analysis of RCTs found zinc supplementation improved cardiovascular risk factors, lowering total cholesterol, triglycerides, LDL, glucose, and inflammatory markers. [https://pubmed.ncbi.nlm.nih.gov/37399684/]
  - Antioxidant vitamin and mineral supplements for slowing the progression of age-related macular degeneration, The Cochrane database of systematic reviews (2023) — In 26 RCTs (11,952 participants), AREDS-type antioxidant plus zinc supplementation probably slowed progression to late age-related macular degeneration (OR 0.72, 95% CI 0.58-0.90) and reduced neovascular AMD (OR 0.62) and moderate visual acuity loss (OR 0.77), moderate-certainty evidence. [https://pubmed.ncbi.nlm.nih.gov/37702300/]
  - The effect of zinc on the outcome of patients with COVID-19: A systematic review and meta-analysis of randomized controlled trials, The Journal of infection (2023) — Meta-analysis of randomized controlled trials of zinc in COVID-19 patients found that zinc supplementation did not provide additional clinical benefit on mortality or disease outcomes, concluding larger RCTs are needed. [https://pubmed.ncbi.nlm.nih.gov/36693569/]
  - Shortcomings in the Cochrane review on zinc for the common cold (2024), Frontiers in medicine (2024) — Critique of the 2024 Cochrane review reports that in 7 RCTs, zinc acetate/gluconate lozenges delivering >75 mg/day elemental zinc shortened common cold duration by 33% (95% CI 21%-45%). [https://pmc.ncbi.nlm.nih.gov/articles/PMC11521859/]
  - A systematic review and meta-analysis on nutritional and dietary interventions for the treatment of acute respiratory infection in pediatric patients: An EAACI taskforce, Allergy (2024) — EAACI taskforce meta-analysis found zinc in children with pneumonia showed limited benefit (reduced hospital length of stay but not time to recovery); no nutritional intervention recommended for routine treatment of pediatric respiratory infections. [https://pubmed.ncbi.nlm.nih.gov/38174413/]
  - Zinc Supplementation Associated With a Decrease in Mortality in COVID-19 Patients: A Meta-Analysis, Cureus (2023) — Meta-analysis found zinc supplementation in COVID-19 patients associated with significantly lower mortality versus controls (pooled OR 0.57, 95% CI 0.43-0.77, P<0.001). [https://pubmed.ncbi.nlm.nih.gov/37435275/]
  - Zinc for the prevention or treatment of acute viral respiratory tract infections in adults: a rapid systematic review and meta-analysis of randomised controlled trials, BMJ open (2021) — Meta-analysis of 28 RCTs (5,446 adults) found zinc modestly prevented respiratory infections (~32% lower risk) and shortened symptom duration by ~2 days, with more non-serious adverse events. [https://pubmed.ncbi.nlm.nih.gov/34728441/]
  - Zinc supplementation combined with antidepressant drugs for treatment of patients with depression: a systematic review and meta-analysis, Nutrition reviews (2021) — Meta-analysis of 5 RCTs found zinc added to antidepressant therapy modestly reduced depressive symptom scores (SMD -0.36; 95% CI -0.67 to -0.04), with larger effect in adults aged 40+. [https://pubmed.ncbi.nlm.nih.gov/32885249/]
  - Serum zinc levels and efficacy of zinc treatment in acne vulgaris: A systematic review and meta-analysis, Dermatologic Therapy (2020) — Meta-analysis of 25 studies (12 RCTs; 2,445 participants) found acne patients had lower serum zinc and that zinc treatment significantly reduced inflammatory papule counts versus no zinc. [https://onlinelibrary.wiley.com/doi/10.1111/dth.14252]
  - Zinc supplementation for improving pregnancy and infant outcome, The Cochrane database of systematic reviews (2021) — Across 25 RCTs (>18,000 women/infants), antenatal zinc supplementation made little or no difference to preterm birth (RR 0.87, 95% CI 0.74-1.03), low birthweight (RR 0.94), or small-for-gestational-age, providing insufficient evidence of benefit for maternal or neonatal outcomes. [https://pubmed.ncbi.nlm.nih.gov/33724446/]
  - Zinc in depression: From development to treatment: A comparative/ dose response meta-analysis of observational studies and randomized controlled trials, General hospital psychiatry (2022) — Pooled RCTs: zinc supplementation significantly lowered depressive symptom scores in depressed patients (WMD -4.15 points; 95% CI -6.56 to -1.75), with benefit largely confined to zinc monotherapy; cohort data showed highest vs lowest zinc intake associated with 28% lower depression risk (RR 0.66, 95% CI 0.50-0.82). [https://pubmed.ncbi.nlm.nih.gov/32829928/]
  - Zinc lozenges and the common cold: a meta-analysis comparing zinc acetate and zinc gluconate, and the role of zinc dosage, JRSM Open (2017) — Zinc acetate lozenges shortened colds ~33%. [https://journals.sagepub.com/doi/10.1177/2054270417694291]
  - Zinc supplementation improves glycemic control for diabetes prevention and management: a systematic review and meta-analysis of randomized controlled trials, The American journal of clinical nutrition (2019) — 32 placebo-controlled trials (n=1700): zinc lowered fasting glucose (WMD -14.15 mg/dL; 95% CI -17.36 to -10.93), 2-h postprandial glucose (-36.85 mg/dL), HbA1c (-0.55%; 95% CI -0.84 to -0.27), HOMA-IR (-0.73), and hs-CRP (-1.31 mg/L); largest fasting-glucose effect in diabetic subjects and with inorganic zinc. [https://pubmed.ncbi.nlm.nih.gov/31161192/]
  - Zinc Acetate Lozenges May Improve the Recovery Rate of Common Cold Patients: An Individual Patient Data Meta-Analysis, Open forum infectious diseases (2017) — Individual-patient-data pooling of 3 RCTs (199 patients, 80-92 mg/day elemental zinc as acetate lozenges): recovery rate ratio 3.1 (95% CI 2.1-4.7); by day 5, 70% of zinc vs 27% of placebo patients had recovered (NNT 2.3); no serious adverse effects. [https://pubmed.ncbi.nlm.nih.gov/28480298/]
  - Oral zinc for treating diarrhoea in children, The Cochrane database of systematic reviews (2016) — 33 RCTs, 10,841 children: in children >6 months, zinc shortened acute diarrhoea duration by ~11 h (MD -11.46 h; 95% CI -19.72 to -3.19) and reduced diarrhoea persisting to day 7 (RR 0.73; 95% CI 0.61-0.88); effect largest in malnourished children (~1 day). No benefit under 6 months; zinc increased vomiting risk (RR 1.57). [https://pubmed.ncbi.nlm.nih.gov/27996088/]
  - Zinc lozenges and the common cold: a meta-analysis comparing zinc acetate and zinc gluconate, and the role of zinc dosage, JRSM open (2017) — Across randomized trials, zinc acetate lozenges shortened cold duration by ~40%; zinc lozenges delivering >75 mg/day elemental zinc reduced duration, whereas lower doses did not, indicating a dose threshold for efficacy. [https://pubmed.ncbi.nlm.nih.gov/28515951/]
  - Zinc for the common cold, The Cochrane database of systematic reviews (2013) — Reduced cold duration when started early. [https://pubmed.ncbi.nlm.nih.gov/23775705/]
  - Zinc in human health: effect of zinc on immune cells, Molecular medicine (Cambridge, Mass.) (2008) — Supplementation improved immune markers in older adults. [https://pmc.ncbi.nlm.nih.gov/articles/PMC2277319/]

---

## Probiotics
URL: https://nutridex.info/s/probiotics
Category: Gut & Immune
Evidence: Mixed — Conflicting results across studies; benefit uncertain.
Live microbes for gut balance — strain matters.

Quick answer: Probiotics is used for antibiotic-associated diarrhea. NutriDex grades the human evidence as mixed — Conflicting results across studies; benefit uncertain. Based on 19 cited human studies (19 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Probiotics are live microorganisms that can confer health benefits — but effects are highly strain- and condition-specific. The strongest evidence is for preventing antibiotic-associated and infectious diarrhea and easing some IBS symptoms. Generic 'gut health' or immunity claims are far weaker. Benefits rarely persist after stopping, and a strain proven for one use may do nothing for another.

Benefits / uses: Antibiotic-associated diarrhea; IBS symptoms; Gut balance; Some immune support.
Active compounds: Lactobacillus spp.; Bifidobacterium spp.; Saccharomyces boulardii.
Dose: Strain-specific; commonly 1–10 billion CFU/day. Match strain to the studied condition.
Safety: Safe for most. Transient gas/bloating. Caution in immunocompromised or critically ill patients.

Cited studies (19):
  - Probiotics for the prevention of Clostridioides difficile-associated diarrhea in adults and children, The Cochrane database of systematic reviews (2025) — Updated Cochrane review (38 trials, 13,179 participants) found probiotics reduce C. difficile-associated diarrhea by ~50% (RR 0.50, 95% CI 0.38-0.64; ~1 case prevented per 65 treated), low-certainty evidence. [https://pubmed.ncbi.nlm.nih.gov/40931979/]
  - Efficacy of Probiotics in Irritable Bowel Syndrome: Systematic Review and Meta-analysis, Gastroenterology (2023) — Network meta-analysis of 82 RCTs (10,332 IBS patients) found benefit for global symptoms with only low-to-very-low certainty for most strains (Escherichia strains moderate certainty). [https://pubmed.ncbi.nlm.nih.gov/37541528/]
  - The effectiveness of treatment with probiotics in preventing necrotizing enterocolitis and related mortality: results from an umbrella meta-analysis on meta-analyses of randomized controlled trials, BMC gastroenterology (2025) — Umbrella meta-analysis of 35 studies in preterm infants found probiotics roughly halved necrotizing enterocolitis (ESRR 0.51, 95% CI 0.46-0.55) and reduced mortality (ESRR 0.72, 95% CI 0.68-0.76). [https://pubmed.ncbi.nlm.nih.gov/40217146/]
  - Effects of Prebiotics and Probiotics on Symptoms of Depression and Anxiety in Clinically Diagnosed Samples: Systematic Review and Meta-analysis of Randomized Controlled Trials, Nutrition reviews (2025) — Meta-analysis in clinically diagnosed samples (23 RCTs, 1,401 patients) found probiotics reduced depression (SMD -0.96, 95% CI -1.31 to -0.61) and anxiety (SMD -0.59), while prebiotics showed no significant effect. [https://pmc.ncbi.nlm.nih.gov/articles/PMC12166186/]
  - The safety and efficacy of probiotic supplementation for critically ill adult patients: a systematic review and meta-analysis, Nutrition reviews (2023) — Systematic review/meta-analysis of RCTs in critically ill adults found probiotics reduced ICU-acquired infections (RR 0.73, 95% CI 0.58-0.93) with no mortality benefit and no probiotic-attributed adverse events. [https://pubmed.ncbi.nlm.nih.gov/35985275/]
  - Efficacy of probiotics pretreatment in Helicobacter pylori eradication therapy: a systematic review and meta-analysis of clinical outcomes, Annals of medicine (2025) — Systematic review/meta-analysis of 12 RCTs (2,144 participants) found probiotics pretreatment improved H. pylori eradication rate (ITT 80.3% vs 70.5%, RR 1.14, 95% CI 1.08-1.19) and reduced treatment side effects (16.0% vs 28.3%, RR 0.59, 95% CI 0.41-0.84). [https://pubmed.ncbi.nlm.nih.gov/40697099/]
  - The effect of probiotics in the prevention of atopic dermatitis in children: a systematic review and meta-analysis, Translational pediatrics (2023) — Systematic review/meta-analysis of 37 RCTs (6,131 children) found probiotics modestly reduced incidence of atopic dermatitis versus placebo (RR 0.83, 95% CI 0.73-0.94), with greatest effect for maternal-infant Lactobacillus rhamnosus regimens. [https://pubmed.ncbi.nlm.nih.gov/37181018/]
  - Probiotics for treating acute infectious diarrhoea, Cochrane Database of Systematic Reviews (2020) — Cochrane review of probiotics for acute infectious diarrhoea found little to no effect on diarrhoea lasting >=48 hours or stool volume, not supporting routine use given heterogeneity and bias. [https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003048.pub4/full]
  - Probiotics and synbiotics in chronic constipation in adults: A systematic review and meta-analysis of randomized controlled trials, Clinical nutrition (Edinburgh, Scotland) (2022) — Systematic review/meta-analysis (30 probiotic RCTs) found probiotics increased treatment response in chronic constipation (57% vs 44%, RR 1.28, 95% CI 1.07-1.52) and stool frequency (SMD 0.71), driven by Bifidobacterium lactis, while synbiotics showed no benefit. [https://pubmed.ncbi.nlm.nih.gov/36372047/]
  - Probiotics for preventing acute upper respiratory tract infections, The Cochrane database of systematic reviews (2022) — Cochrane review of 24 RCTs (6,950 participants). Probiotics reduced participants with >=1 acute upper respiratory tract infection (RR 0.76, 95% CI 0.67-0.87; low-certainty), >=3 episodes (RR 0.59, 95% CI 0.38-0.91; moderate-certainty), mean episode duration (-1.22 days, 95% CI -2.12 to -0.33), and prescribed antibiotic use (RR 0.58, 95% CI 0.42-0.81; moderate-certainty). [https://pubmed.ncbi.nlm.nih.gov/36001877/]
  - Probiotics for treating acute infectious diarrhoea, The Cochrane database of systematic reviews (2020) — Updated Cochrane review of 82 RCTs (12,127 participants, mostly children). Contrary to earlier reviews, in low-risk-of-bias trials probiotics made little or no difference to risk of diarrhea lasting >=48 hours (RR 1.00, 95% CI 0.91-1.09; moderate-certainty) and effect on diarrhea duration was uncertain (MD -8.6 hours, 95% CI -29.4 to +12.1; very low-certainty). Publication bias was demonstrated. [https://pubmed.ncbi.nlm.nih.gov/33295643/]
  - Systematic review with meta-analysis: the efficacy of prebiotics, probiotics, synbiotics and antibiotics in irritable bowel syndrome, Alimentary pharmacology & therapeutics (2018) — Modest improvement in global IBS symptoms. [https://pubmed.ncbi.nlm.nih.gov/30294792/]
  - Probiotics for the prevention of Clostridium difficile-associated diarrhea in adults and children, Cochrane Database of Systematic Reviews (2017) — S. boulardii / Lactobacillus prevented C. difficile diarrhea. [https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD006095.pub4/information]
  - Probiotics for the prevention of pediatric antibiotic-associated diarrhea, The Cochrane database of systematic reviews (2019) — In children, probiotics reduced antibiotic-associated diarrhea from 19% (598/3120) to 8% (259/3232) (RR 0.45, 95% CI 0.36-0.56; 6352 participants; NNTB 9; moderate-certainty evidence), with high-dose probiotics most effective (RR 0.37, 95% CI 0.30-0.46). [https://pubmed.ncbi.nlm.nih.gov/31039287/]
  - Probiotics for the prevention of Clostridium difficile-associated diarrhea in adults and children, The Cochrane database of systematic reviews (2017) — Cochrane review of 39 RCTs (9,955 participants). Among 31 trials (8,672 patients), probiotics co-administered with antibiotics reduced C. difficile-associated diarrhea by ~60% (1.5% vs 4.0%; RR 0.40, 95% CI 0.30-0.52; moderate-certainty; NNT 42). In high-baseline-risk patients (>5%) the reduction was ~70% (RR 0.30, 95% CI 0.21-0.42; NNT 12). No reduction in C. difficile stool infection rates (RR 0.86, 95% CI 0.67-1.10). [https://pubmed.ncbi.nlm.nih.gov/29257353/]
  - AGA Clinical Practice Guidelines on the Role of Probiotics in the Management of Gastrointestinal Disorders, Gastroenterology (2020) — AGA clinical practice guideline conditionally recommends specific probiotics for only 3 of 8 GI uses (C. difficile prevention, pouchitis, NEC in preterm infants) and recommends against use for acute gastroenteritis in children. [https://www.gastrojournal.org/article/S0016-5085(20)34729-6/fulltext]
  - AGA Technical Review on the Role of Probiotics in the Management of Gastrointestinal Disorders, Gastroenterology (2020) — American Gastroenterological Association clinical practice guideline. Conditionally recommends specific probiotics only for: prevention of C. difficile infection in adults/children on antibiotics, prevention of necrotizing enterocolitis in preterm low-birth-weight infants, and pouchitis. Recommends AGAINST probiotics for routine acute infectious gastroenteritis in children and suggests probiotics only in research/trial context for IBS, Crohn's, and ulcerative colitis given insufficient evidence. [https://pubmed.ncbi.nlm.nih.gov/32531292/]
  - Efficacy of probiotic supplementation in preventing Clostridioides difficile infection: an umbrella review of systematic reviews and meta-analysis, Frontiers in Nutrition (2026) — Umbrella review of 16 systematic reviews on probiotics for C. difficile infection prevention rated 11 reviews as critically low confidence (AMSTAR-2) and graded overall certainty of efficacy evidence as low under GRADE. [https://www.frontiersin.org/journals/nutrition/articles/10.3389/fnut.2026.1699223/full]
  - Probiotics for the prevention and treatment of antibiotic-associated diarrhea: a systematic review and meta-analysis, JAMA (2012) — Reduced antibiotic-associated diarrhea risk ~42%. [https://pubmed.ncbi.nlm.nih.gov/22570464/]

---

## Lion's Mane (Hericium erinaceus)
URL: https://nutridex.info/s/lionsmane
Category: Nootropic, Longevity
Evidence: Preliminary — Early or small human trials; promising but not yet conclusive.
A nerve-growth mushroom with promising early data.

Quick answer: Lion's Mane is used for cognitive support. NutriDex grades the human evidence as preliminary — Early or small human trials; promising but not yet conclusive. Based on 13 cited human studies (12 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Lion's Mane contains compounds that stimulate nerve growth factor (NGF) in cell and animal studies. Human trials are small but intriguing: one showed improved cognition in older adults with mild impairment that faded after stopping, and another reported reduced anxiety/depression. Evidence remains preliminary, and extract quality varies widely between products.

Benefits / uses: Cognitive support; Nerve health; Mood; Possible neuroprotection.
Active compounds: Hericenones; Erinacines.
Dose: 500–3,000 mg/day of fruiting-body extract.
Safety: Well tolerated in trials. Rare skin/respiratory allergy. Long-term data lacking.

Cited studies (13):
  - Benefits, side effects, and uses of Hericium erinaceus as a supplement: a systematic review, Frontiers in nutrition (2025) — Systematic review of 26 studies (5 RCTs) found modest cognitive benefit (combined weighted MMSE increase of ~1.17 points, more pronounced in cognitively impaired adults) plus signals for reduced depression/anxiety, with H. erinaceus generally well tolerated. [https://pubmed.ncbi.nlm.nih.gov/40959699/]
  - Unveiling the role of erinacines in the neuroprotective effects of Hericium erinaceus: a systematic review in preclinical models, Frontiers in pharmacology (2025) — Systematic review of 23 preclinical studies found erinacines (notably erinacine A) activate Nrf2 antioxidant and pro-survival pathways and improve cognitive/behavioral outcomes in cellular and rodent models in a dose-dependent manner. [https://pubmed.ncbi.nlm.nih.gov/40626304/]
  - The Acute and Chronic Effects of Lion's Mane Mushroom Supplementation on Cognitive Function, Stress and Mood in Young Adults: A Double-Blind, Parallel Groups, Pilot Study, Nutrients (2023) — Double-blind RCT in 41 healthy adults (18-45) found 1.8 g/day H. erinaceus produced faster Stroop reaction time 60 min after a single dose and a non-significant trend toward reduced stress after 28 days. [https://pubmed.ncbi.nlm.nih.gov/38004235/]
  - Acute effects of a standardised extract of Hericium erinaceus (Lion's Mane mushroom) on cognition and mood in healthy younger adults: a double-blind randomised placebo-controlled study, Frontiers in nutrition (2025) — Acute crossover RCT in 18 healthy young adults found a single 3 g dose of standardised H. erinaceus extract did not improve composite cognition or mood, with only an isolated pegboard (psychomotor) improvement at 90 minutes. [https://pubmed.ncbi.nlm.nih.gov/40276537/]
  - Effect of erinacine A-enriched Hericium erinaceus supplementation on cognition: A randomized, double-blind, placebo-controlled pilot study, Journal of Functional Foods (2024) — 8-week double-blind RCT in 33 healthy adults found erinacine A-enriched H. erinaceus (3.44 mg erinacine A/day) significantly increased cognitive processing speed and circulating BDNF and raised gut microbiota diversity versus placebo, with good tolerability. [https://doi.org/10.1016/j.jff.2024.106120]
  - Acute effects of a standardised extract of Hericium erinaceus (Lion's Mane mushroom) on cognition and mood in healthy younger adults: a double-blind randomised placebo-controlled study, Frontiers in nutrition (2025) — Double-blind randomized placebo-controlled crossover study in 18 healthy young adults given a 3 g standardised 10:1 fruiting-body extract found no significant acute effect on composite cognition or mood at 90 min, with worsened performance on executive-function tasks (Flanker, Trail Making B). [https://pmc.ncbi.nlm.nih.gov/articles/PMC12018234/]
  - Acute Effects of Naturally Occurring Guayusa Tea and Nordic Lion's Mane Extracts on Cognitive Performance, Nutrients (2023) — Randomized, double-blind, placebo-controlled crossover trial; a single 1 g dose of Nordic Lion's Mane significantly improved working memory and complex attention (N-Back reaction time, Serial 7s attempts) and Go/No-go Go-stimulus reaction time at 2 h post-ingestion versus placebo, plus improved self-rated happiness. [https://pubmed.ncbi.nlm.nih.gov/38140277/]
  - Prevention of Early Alzheimer's Disease by Erinacine A-Enriched Hericium erinaceus Mycelia Pilot Double-Blind Placebo-Controlled Study, Frontiers in aging neuroscience (2020) — 49-week double-blind RCT in 41 patients with mild Alzheimer's disease found erinacine A-enriched H. erinaceus mycelia (3x350 mg/day) significantly improved MMSE and daily-living scores versus placebo. [https://pubmed.ncbi.nlm.nih.gov/32581767/]
  - Lion’s Mane (2024) — NIH LiverTox monograph concludes lion's mane (H. erinaceus) supplements have not been linked to serum enzyme elevations or clinically apparent liver injury, with adverse effects largely limited to rare GI upset and skin reactions/allergy. [https://www.ncbi.nlm.nih.gov/books/NBK599740/]
  - Reduction of depression and anxiety by 4 weeks Hericium erinaceus intake, Biomedical research (Tokyo, Japan) (2010) — Reduced depression and anxiety in menopausal women (small trial). [https://pubmed.ncbi.nlm.nih.gov/20834180/]
  - PubMed, NIH National Library of Medicine — Improved cognitive function in a small healthy-adult trial. [https://pubmed.ncbi.nlm.nih.gov/?term=Lion's%20Mane%20Saitsu%202019]
  - Hericium erinaceus in Neurodegenerative Diseases: From Bench to Bedside and Beyond, How Far from the Shoreline?, Journal of fungi (Basel, Switzerland) (2023) — Review concluded that despite strong preclinical NGF/BDNF-mediated neuroprotective evidence, human clinical data for H. erinaceus in neurodegenerative disease remain limited and underpowered, with an urgent need for larger trials. [https://pubmed.ncbi.nlm.nih.gov/37233262/]
  - Improving effects of the mushroom Yamabushitake (Hericium erinaceus) on mild cognitive impairment: a double-blind placebo-controlled clinical trial, Phytotherapy research : PTR (2009) — Improved cognitive scores in older adults; effect reversed after cessation. [https://pubmed.ncbi.nlm.nih.gov/18844328/]

---

## Bacopa Monnieri (Bacopa monnieri)
URL: https://nutridex.info/s/bacopa
Category: Ayurvedic, Nootropic
Evidence: Moderate — Several controlled trials; effects real but modest or context-dependent.
Ayurvedic herb for memory — but it takes weeks.

Quick answer: Bacopa Monnieri is used for memory formation. NutriDex grades the human evidence as moderate — Several controlled trials; effects real but modest or context-dependent. Based on 20 cited human studies (20 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Bacopa is an Ayurvedic nootropic with antioxidant and dendrite-promoting effects. Multiple RCTs show improved memory acquisition and retention, though benefits emerge slowly over 8–12 weeks rather than acutely. Effects are reliable but modest. It does not work as an immediate 'study aid'.

Benefits / uses: Memory formation; Learning speed; Reduced anxiety; Attention.
Active compounds: Bacosides A & B.
Dose: 300 mg/day standardized to ~50% bacosides; effects build over 8–12 weeks.
Safety: Generally safe. Common GI upset (take with food). May increase thyroid hormone; caution with thyroid meds.

Cited studies (20):
  - The effect of plant active substances on cognitive function in healthy older adults: a systematic review and network meta-analysis of randomized controlled trials, Frontiers in pharmacology (2025) — Network meta-analysis of 25 RCTs (1,861 healthy older adults) ranked Bacopa monnieri highest for executive function (SUCRA 91.3%) and language, with a significant learning/memory benefit versus placebo (MD 0.49, 95% CI 0.07-0.90). [https://pubmed.ncbi.nlm.nih.gov/41640686/]
  - Investigating the Neuroprotective and Cognitive-Enhancing Effects of Bacopa monnieri: A Systematic Review Focused on Inflammation, Oxidative Stress, Mitochondrial Dysfunction, and Apoptosis, Antioxidants (Basel, Switzerland) (2024) — Systematic review of 22 clinical trials concluded Bacopa monnieri can enhance cognition, emotional function and reduce inflammatory/oxidative markers, supporting it as a complementary approach in neurodegenerative conditions. [https://pubmed.ncbi.nlm.nih.gov/38671841/]
  - The effect of plant active substances on cognitive function in healthy older adults: a systematic review and network meta-analysis of randomized controlled trials, Frontiers in Pharmacology (2026) — Network meta-analysis of RCTs in healthy older adults found Bacopa monnieri significantly improved learning and memory versus placebo (MD = 0.49, 95% CI 0.07–0.90); the Bacopa compound ranked first for language and high for executive function. [https://doi.org/10.3389/fphar.2025.1672171]
  - Effects of natural extracts in cognitive function of healthy adults: a systematic review and network meta-analysis, Frontiers in Pharmacology (2025) — Network meta-analysis of 27 RCTs (2,334 participants) in healthy adults ranked Bacopa monnieri extract 10th for memory (SUCRA 50.7%, near chance) with no significant superiority over placebo for primary cognitive outcomes. [https://doi.org/10.3389/fphar.2025.1573034]
  - Investigating the Neuroprotective and Cognitive-Enhancing Effects of Bacopa monnieri: A Systematic Review Focused on Inflammation, Oxidative Stress, Mitochondrial Dysfunction, and Apoptosis, Antioxidants (Basel, Switzerland) (2024) — Systematic review of 22 clinical trials concluded Bacopa monnieri improves memory retention, processing speed and attention, attributing effects to reduced oxidative stress and NF-kB-mediated inflammation. [https://pmc.ncbi.nlm.nih.gov/articles/PMC11047749/]
  - A systematic review of the safety and efficacy on cognitive function of herbal and nutritional medicines in older adults with and without subjective cognitive impairment, Systematic reviews (2023) — Systematic review of 21 RCTs of herbal/nutritional medicines in older adults with/without subjective cognitive impairment; Bacopa monnieri was among the most-studied (6/21 trials). 14/21 studies reported improvement in >=1 cognitive domain, but 14/21 had high methodological risk of bias, yielding overall low-quality evidence for efficacy. [https://pubmed.ncbi.nlm.nih.gov/37592293/]
  - Use of Bacopa monnieri in the Treatment of Dementia Due to Alzheimer Disease: Systematic Review of Randomized Controlled Trials, Interactive journal of medical research (2022) — Systematic review of 5 RCTs found no difference between Bacopa monnieri and placebo or donepezil for Alzheimer's dementia on very-low-certainty evidence, with no major safety concerns; larger rigorous trials are needed. [https://pubmed.ncbi.nlm.nih.gov/35612544/]
  - Use of Bacopa monnieri in the Treatment of Dementia Due to Alzheimer Disease: Systematic Review of Randomized Controlled Trials, Interactive Journal of Medical Research (2022) — Systematic review of 5 RCTs found no difference between Bacopa monnieri and placebo or donepezil for treating Alzheimer dementia, based on very low certainty evidence (high risk of bias, small samples). [https://doi.org/10.2196/38542]
  - Bacopa monnieri (2024) — NIH LiverTox monograph (updated 2024) assigns Bacopa monnieri a likelihood score of E (unlikely cause of clinically apparent liver injury), noting that despite widespread use it has not been linked to serum enzyme elevations or hepatotoxicity in large drug-induced liver injury registries. [https://www.ncbi.nlm.nih.gov/books/NBK603563/]
  - The cognitive-enhancing effects of Bacopa monnieri: a systematic review of randomized, controlled human clinical trials, Journal of alternative and complementary medicine (New York, N.Y.) (2012) — Consistent improvement in delayed word-recall memory. [https://pubmed.ncbi.nlm.nih.gov/22747190/]
  - Meta-analysis of randomized controlled trials on cognitive effects of Bacopa monnieri extract, Journal of ethnopharmacology (2014) — Meta-analysis of 9 RCTs (518 subjects; 437 analyzed) of standardized Bacopa monnieri extract (300-450 mg/day, >=12 weeks). Significant improvement in cognition: shortened Trail B test (-17.9 ms; 95% CI -24.6 to -11.2; p<0.001) and decreased choice reaction time (-10.6 ms; 95% CI -12.1 to -9.2; p<0.001), indicating improved speed of attention. Low risk of bias. [https://pubmed.ncbi.nlm.nih.gov/24252493/]
  - The Effects of a Bacopa monnieri Extract (Bacumen(®)) on Cognition, Stress, and Fatigue in Healthy Adults: A Randomized, Double-Blind, Placebo-Controlled Trial, Clinical drug investigation (2025) — In 101 adults aged 40-70 with self-reported memory/attention problems, 300 mg/day Bacopa for 12 weeks did not improve verbal learning, attention or working memory versus placebo, but reduced self-reported stress reactivity and fatigue. [https://pubmed.ncbi.nlm.nih.gov/41091332/]
  - Evaluating the effects of Bacopa monnieri on cognitive performance and sleep quality of patients with mild cognitive impairment: A triple-blinded, randomized, placebo-controlled trial, Explore (New York, N.Y.) (2024) — Triple-blind RCT in 62 patients with mild cognitive impairment found 160 mg/day Bacopa monnieri for 2 months improved overall cognitive performance (MoCA) but had no effect on sleep quality versus placebo. [https://pubmed.ncbi.nlm.nih.gov/38538390/]
  - Effect of Bacopa monnieri Extract on Memory and Cognitive Skills in Adult Humans: A Randomized, Double-Blind, Placebo-Controlled Study, Journal of Psychiatry and Cognitive Behaviour (2024) — 12-week double-blind RCT in 80 healthy adults found 300 mg/day Bacopa extract (90 mg bacosides) significantly improved verbal, spatial, working and episodic memory versus placebo, with decreased serum cortisol and increased BDNF by day 84. [https://doi.org/10.29011/2574-7762.000068]
  - Effects of a Bacopa monnieri extract (Bacognize®) on stress, fatigue, quality of life and sleep in adults with self-reported poor sleep: A randomised, double-blind, placebo-controlled study, Journal of Functional Foods (2021) — 28-day RCT in 100 adults with poor sleep found Bacopa (150 mg twice daily) did not improve insomnia versus placebo but was associated with greater improvements in emotional wellbeing, general health and reduced stress biomarkers (salivary alpha-amylase, sIgA). [https://doi.org/10.1016/j.jff.2021.104671]
  - Bacopa monnieri (2023) — StatPearls reference (updated 2023) concludes Bacopa monnieri has a high therapeutic index with no demonstrated human toxicity; the most common adverse effects are gastrointestinal (increased stool frequency, nausea, abdominal cramps), and standardized extract dosing is 300-450 mg/day (24-55% bacosides). [https://www.ncbi.nlm.nih.gov/books/NBK589635/]
  - An acute, double-blind, placebo-controlled crossover study of 320 mg and 640 mg doses of a special extract of Bacopa monnieri (CDRI 08) on sustained cognitive performance, Phytotherapy research : PTR (2013) — Acute double-blind, placebo-controlled crossover RCT in 24 healthy adults of Bacopa special extract CDRI 08 (KeenMind). The 320 mg dose improved Cognitive Demand Battery performance at the 1st, 2nd, and 4th post-dose repetitions vs placebo, with no adverse cardiovascular effects; demonstrates an acute (not only chronic) cognitive benefit. [https://pubmed.ncbi.nlm.nih.gov/23281132/]
  - Bacopa monnieri: Preclinical and Clinical Evidence of Neuroactive Effects, Safety of Use and the Search for Improved Bioavailability, Nutrients (2025) — Narrative review in Nutrients (2025) of preclinical and clinical evidence concludes Bacopa monnieri exerts neuroactive, memory-enhancing effects and is generally non-toxic with no serious adverse events, while highlighting poor oral bioavailability of bacosides and contraindications such as hyperthyroidism and pregnancy. [https://pubmed.ncbi.nlm.nih.gov/40507208/]
  - The chronic effects of an extract of Bacopa monniera (Brahmi) on cognitive function in healthy human subjects, Psychopharmacology (2001) — Improved retention of new information after 12 weeks. [https://pubmed.ncbi.nlm.nih.gov/11498727/]
  - Effects of a standardized Bacopa monnieri extract on cognitive performance, anxiety, and depression in the elderly: a randomized, double-blind, placebo-controlled trial, Journal of alternative and complementary medicine (New York, N.Y.) (2008) — Enhanced memory and reduced anxiety in older adults. [https://pubmed.ncbi.nlm.nih.gov/18611150/]

---

## Coenzyme Q10 (Ubiquinone/Ubiquinol)
URL: https://nutridex.info/s/coq10
Category: Heart & Metabolic, Longevity
Evidence: Moderate — Several controlled trials; effects real but modest or context-dependent.
Mitochondrial antioxidant, popular with statin users.

Quick answer: Coenzyme Q10 is used for heart failure support. NutriDex grades the human evidence as moderate — Several controlled trials; effects real but modest or context-dependent. Based on 19 cited human studies (19 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

CoQ10 is essential to mitochondrial energy production and acts as a fat-soluble antioxidant. The best evidence is for heart failure, where the Q-SYMBIO trial showed reduced cardiac events. It may modestly ease statin-associated muscle symptoms and reduce migraine frequency. Body levels decline with age and statin use.

Benefits / uses: Heart failure support; Statin muscle pain; Migraine prevention; Antioxidant.
Active compounds: Ubiquinone; Ubiquinol (reduced form).
Dose: 100–300 mg/day with fat for absorption.
Safety: Very safe. Mild GI upset. May reduce warfarin effectiveness.

Cited studies (19):
  - Efficacy and safety of coenzyme Q10 in heart failure: a meta-analysis of randomized controlled trials, BMC cardiovascular disorders (2024) — In a meta-analysis of 32 RCTs (3,763 heart-failure patients), adjunctive CoQ10 reduced all-cause mortality (RR 0.64, 95% CI 0.48-0.85) and HF hospitalization (RR 0.50, 95% CI 0.37-0.67), GRADE moderate. [https://pubmed.ncbi.nlm.nih.gov/39462324/]
  - Effects of coenzyme Q10 supplementation on myopathy in statin-treated patients: a systematic review and meta-analysis, Journal of nutritional science (2025) — Pooling 7 RCTs (389 statin-treated patients), CoQ10 supplementation significantly reduced statin-associated muscle pain intensity (WMD -0.96), though authors note evidence remains limited. [https://pubmed.ncbi.nlm.nih.gov/41158831/]
  - Does coenzyme Q10 improve semen quality and circulating testosterone level? a systematic review and meta-analysis of randomized controlled trials, Frontiers in pharmacology (2024) — In 8 RCTs (877 men with idiopathic infertility), CoQ10 improved sperm progressive/total motility and serum testosterone, but did not significantly change sperm concentration or semen volume. [https://pubmed.ncbi.nlm.nih.gov/39830337/]
  - Effects of coenzyme Q10 supplementation on lipid profiles and liver enzymes of nonalcoholic fatty liver disease (NAFLD) patients: A systematic review and meta-analysis of randomized controlled trials, Food science & nutrition (2023) — Pooling 6 RCTs of NAFLD patients, CoQ10 supplementation produced an overall non-significant reduction in lipid profiles (TC, LDL, HDL, TG) and liver enzymes (AST, ALT, GGT), though sensitivity ('leave-one-out') analysis showed significant reductions in AST and GGT. [https://pubmed.ncbi.nlm.nih.gov/37324909/]
  - Effect of Coenzyme Q10 Supplementation on Vascular Endothelial Function: A Systematic Review and Meta-Analysis of Randomized Controlled Trials, High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension (2024) — Pooling 12 RCTs (489 subjects), CoQ10 supplementation significantly increased flow-mediated dilation (WMD 1.45%, 95% CI 0.55 to 2.36) in a dose-dependent manner, but did not change soluble VCAM or ICAM levels. [https://pubmed.ncbi.nlm.nih.gov/38630421/]
  - Coenzyme Q10 Supplementation in Reducing Inflammation: An Umbrella Review, Journal of chiropractic medicine (2023) — Umbrella review of 7 meta-analyses found CoQ10 (median 200 mg/day for 12 weeks) significantly reduced IL-6 in 4 of 5 and TNF-alpha in 3 of 4 meta-analyses, with CRP significant in only 3 of 7, amid substantial heterogeneity. [https://pubmed.ncbi.nlm.nih.gov/37346240/]
  - Efficacy and safety of coenzyme Q10 in heart failure: a meta-analysis of randomized controlled trials, BMC cardiovascular disorders (2024) — Meta-analysis of 33 RCTs (search through April 2024) found CoQ10 reduced all-cause mortality (RR 0.64, 95% CI 0.48-0.85, P=0.002) and heart-failure hospitalization (RR 0.50, 95% CI 0.37-0.67, P<0.00001), moderate-quality evidence. [https://pmc.ncbi.nlm.nih.gov/articles/PMC11515203/]
  - Evaluating the efficacy of ubiquinol in heart failure patients: a systematic review and meta-analysis, Future cardiology (2024) — Systematic review and meta-analysis of 16 studies found ubiquinol/CoQ10 reduced heart-failure-related mortality by 40% and improved exercise capacity, with no significant change in LVEF. [https://pubmed.ncbi.nlm.nih.gov/39049769/]
  - Effect of coenzyme Q10 on cardiac function and survival in heart failure: an overview of systematic reviews and meta-analyses, Food & function (2023) — Overview of systematic reviews/meta-analyses (search through March 2023) reported CoQ10 increased ejection fraction in 6 of 9 analyses, with absolute LVEF gains of roughly 1.77% to 3.81%. [https://pubmed.ncbi.nlm.nih.gov/37350565/]
  - Efficacy and Safety of Coenzyme Q10 in Idiopathic Male Infertility: A Systematic Review and Meta-Analysis of Randomized Trials, The world journal of men's health (2025) — Systematic review and meta-analysis of 9 RCTs (781 men with idiopathic infertility): CoQ10 significantly improved sperm concentration (MD +10.22 x10^6/mL), total motility (+4.95%), semen volume (+0.17 mL) and seminal CoQ10 levels, and increased clinical pregnancy odds (OR 6.02, 95% CI 1.97-18.41); benefit on morphology was seen with >3 months of treatment, with a favorable safety profile. [https://pubmed.ncbi.nlm.nih.gov/40878114/]
  - Dose-Response Effect of Coenzyme Q10 Supplementation on Blood Pressure among Patients with Cardiometabolic Disorders: A Grading of Recommendations Assessment, Development, and Evaluation (GRADE)-Assessed Systematic Review and Meta-Analysis of Randomized Controlled Trials, Advances in nutrition (Bethesda, Md.) (2022) — Across 26 RCTs (1,831 patients with cardiometabolic disorders), CoQ10 lowered systolic blood pressure by 4.77 mmHg (95% CI -6.57 to -2.97), with greatest benefit at 100-200 mg/day. [https://pubmed.ncbi.nlm.nih.gov/36130103/]
  - Effects of coenzyme Q10 supplementation on glycemic control: A GRADE-assessed systematic review and dose-response meta-analysis of randomized controlled trials, EClinicalMedicine (2022) — Pooling 40 RCTs (2,424 participants), CoQ10 modestly improved glycemic control: fasting glucose -5.22 mg/dl, HbA1c -0.12%, and HOMA-IR -0.69, with 100-200 mg/day most effective. [https://pubmed.ncbi.nlm.nih.gov/35958521/]
  - Coenzyme Q10 supplementation for prophylaxis in adult patients with migraine-a meta-analysis, BMJ open (2021) — Across 6 RCTs (371 adults with migraine), CoQ10 reduced monthly migraine frequency (MD -1.52 attacks) and attack duration, but not headache severity. [https://pubmed.ncbi.nlm.nih.gov/33402403/]
  - Effectiveness of Coenzyme Q10 Supplementation for Reducing Fatigue: A Systematic Review and Meta-Analysis of Randomized Controlled Trials, Frontiers in pharmacology (2022) — Across 13 RCTs (1,126 participants, including fibromyalgia and chronic-fatigue populations), CoQ10 significantly reduced fatigue scores versus placebo (Hedges' g = -0.40, 95% CI -0.64 to -0.16). [https://pubmed.ncbi.nlm.nih.gov/36091835/]
  - Effects of Coenzyme Q10 on Statin-Induced Myopathy: An Updated Meta-Analysis of Randomized Controlled Trials, Journal of the American Heart Association (2018) — Meta-analysis of 12 RCTs (575 patients) in statin-treated patients: CoQ10 supplementation reduced statin-associated muscle pain (WMD -1.60), weakness (WMD -2.28), cramp (WMD -1.78) and tiredness (WMD -1.75; all p<=0.006) versus placebo, though plasma creatine kinase was unchanged (WMD 0.09, p=0.23). [https://pubmed.ncbi.nlm.nih.gov/30371340/]
  - Effect of Coenzyme Q10 Supplementation on Cardiac Function and Quality of Life in Patients with Heart Failure: A Randomized Controlled Trial, Journal of clinical medicine (2025) — Double-blind RCT of 120 heart-failure patients (CoQ10 2x60 mg/day vs placebo for 6 months) showed significant improvement in global longitudinal strain and NT-proBNP; LVEF rose 38.9% to 40.6% (not statistically significant). [https://pmc.ncbi.nlm.nih.gov/articles/PMC12155814/]
  - The effect of coenzyme Q10 on morbidity and mortality in chronic heart failure: results from Q-SYMBIO: a randomized double-blind trial, JACC. Heart failure (2014) — Reduced major cardiovascular events in heart-failure patients. [https://pubmed.ncbi.nlm.nih.gov/25282031/]
  - Coenzyme Q10 supplementation decreases statin-related mild-to-moderate muscle symptoms: a randomized clinical study, Medical science monitor : international medical journal of experimental and clinical research (2014) — Improved statin-associated muscle symptoms in a subset of users. [https://pubmed.ncbi.nlm.nih.gov/25375075/]
  - Efficacy of coenzyme Q10 in migraine prophylaxis: a randomized controlled trial, Neurology (2005) — Reduced migraine frequency vs placebo. [https://pubmed.ncbi.nlm.nih.gov/15728298/]

---

## N-Acetylcysteine (NAC)
URL: https://nutridex.info/s/nac
Category: Gut & Immune, Sleep & Mood
Evidence: Moderate — Several controlled trials; effects real but modest or context-dependent.
Glutathione precursor with broad clinical uses.

Quick answer: N-Acetylcysteine (NAC) is used for antioxidant (glutathione). NutriDex grades the human evidence as moderate — Several controlled trials; effects real but modest or context-dependent. Based on 21 cited human studies (21 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

NAC is a precursor to glutathione, the body's master antioxidant, and is an established medicine for acetaminophen overdose and as a mucolytic. As a supplement, controlled trials support adjunctive benefit in some psychiatric conditions (OCD, trichotillomania, addiction) and respiratory mucus clearance. Evidence is promising but uneven across the many conditions it's marketed for.

Benefits / uses: Antioxidant (glutathione); Mucus thinning; Mental-health adjunct; Liver support.
Active compounds: N-acetylcysteine.
Dose: 600–1,800 mg/day; psychiatric trials often use 2,400 mg/day.
Safety: Generally safe. GI upset, rare bronchospasm in asthmatics. Regulatory status varies by country.

Cited studies (21):
  - N-acetylcysteine for schizophrenia: A systematic review and meta-analysis, Psychiatry and Clinical Neurosciences (2022) — Meta-analysis of RCTs found adjunctive NAC superior to placebo for reducing total symptoms in schizophrenia (medium effect, larger in acute phase SMD approx -1.22). [https://onlinelibrary.wiley.com/doi/10.1111/pcn.13502]
  - Efficacy of N-acetylcysteine for patients with depression: An updated systematic review and meta-analysis, General hospital psychiatry (2024) — Updated systematic review/meta-analysis of 12 RCTs (904 patients) found NAC more effective than placebo at alleviating depressive symptoms, with optimal doses of 1000-2750 mg/day. [https://pubmed.ncbi.nlm.nih.gov/39504621/]
  - N-acetylcysteine as a treatment for substance use cravings: A meta-analysis, Addiction biology (2024) — Meta-analysis of 9 RCTs (623 participants) supported NAC for reducing substance craving in substance use disorders, but with high heterogeneity and publication bias warranting cautious interpretation. [https://pubmed.ncbi.nlm.nih.gov/39556483/]
  - The safety and efficacy of N-acetylcysteine as an augmentation in the treatment of obsessive-compulsive disorder in adults: a systematic review and meta-analysis of randomized clinical trials, Frontiers in psychiatry (2024) — Systematic review and meta-analysis of 6 RCTs (195 adults) found NAC augmentation of SSRIs provided modest benefit in obsessive-compulsive disorder with good tolerability. [https://pmc.ncbi.nlm.nih.gov/articles/PMC11456833/]
  - Clinical efficacy of N-acetylcysteine for COVID-19: A systematic review and meta-analysis of randomized controlled trials, Heliyon (2024) — Meta-analysis of 5 RCTs (651 patients) found no statistically significant mortality reduction with NAC in COVID-19 (15.6% vs 32.3%; RR 0.58). [https://pmc.ncbi.nlm.nih.gov/articles/PMC10839595/]
  - Efficacy of N-Acetylcysteine in Polycystic Ovary Syndrome: Systematic Review and Meta-Analysis, Nutrients (2025) — Systematic review and meta-analysis found NAC improved metabolic and reproductive parameters in women with polycystic ovary syndrome, supporting its insulin-sensitizing antioxidant role. [https://pmc.ncbi.nlm.nih.gov/articles/PMC11768055/]
  - Unlocking the potential of antioxidant supplementation with n-acetylcysteine to improve seminal parameters and analysis of its safety: a systematic review and meta-analysis of randomized controlled trials, Archivio italiano di urologia, andrologia : organo ufficiale [di] Societa italiana di ecografia urologica e nefrologica (2025) — Systematic review and meta-analysis of RCTs found NAC supplementation significantly improved seminal parameters in men with infertility/impaired semen, with a favorable safety profile. [https://pubmed.ncbi.nlm.nih.gov/40126496/]
  - Association of N-acetylcysteine use with contrast-induced nephropathy: an umbrella review of meta-analyses of randomized clinical trials, Frontiers in Medicine (2023) — Umbrella review of 12 meta-analyses (161 RCTs, 38,053 participants) found NAC significantly reduced contrast-induced nephropathy incidence (OR 0.72, 95% CI 0.65-0.79) but had no effect on dialysis need or mortality; evidence rated moderate quality. [https://doi.org/10.3389/fmed.2023.1235023]
  - No Significant Beneficial Effects of Intravenous N-Acetylcysteine on Patient Outcome in Non-Paracetamol Acute Liver Failure: A Meta-Analysis of Randomized Controlled Trials, Biomedicines (2024) — Meta-analysis of 4 RCTs found intravenous NAC did not improve overall survival (OR 0.70, 95% CI 0.34-1.44) or transplant-free survival (OR 0.90, 95% CI 0.25-3.28) in non-paracetamol acute liver failure. [https://doi.org/10.3390/biomedicines12071462]
  - Comprehensive transcriptomic analysis and meta-analysis identify therapeutic effects of N-acetylcysteine in nonalcoholic fatty liver disease, Frontiers in pharmacology (2023) — Transcriptomic analysis plus meta-analysis of preclinical studies found NAC significantly improved systemic and hepatic lipid metabolism in non-alcoholic fatty liver disease, supporting future clinical trials. [https://pmc.ncbi.nlm.nih.gov/articles/PMC10225598/]
  - Effect of N-Acetylcysteine on mortality in COVID-19 patients: A systematic review and meta-analysis of randomized controlled trials, Inflammopharmacology (2025) — Updated RCT meta-analysis found NAC may reduce COVID-19 mortality, particularly at higher doses or via non-oral (e.g. intravenous) routes, while concluding RCT evidence overall remains inconsistent. [https://pubmed.ncbi.nlm.nih.gov/40728675/]
  - The safety and efficacy of N-acetylcysteine as an augmentation in the treatment of obsessive-compulsive disorder in adults: a systematic review and meta-analysis of randomized clinical trials, Frontiers in psychiatry (2024) — Six RCTs (195 adults with moderate-to-severe OCD) of NAC augmentation of SSRIs. Total Y-BOCS improved over a 5-8 week window (p=0.05), but no significant benefit for treatment <5 weeks or >12 weeks, and no significant effect on obsession or compulsion subscores; adverse events did not differ from placebo. Overall: modest, time-limited augmentation signal. [https://pubmed.ncbi.nlm.nih.gov/39376972/]
  - Influence of N-acetylcysteine on chronic bronchitis or COPD exacerbations: a meta-analysis, European respiratory review : an official journal of the European Respiratory Society (2015) — Pooled analysis of 13 RCTs (4,155 COPD/chronic bronchitis patients) found NAC significantly reduced exacerbations (RR 0.75, 95% CI 0.66-0.84; p<0.01). In spirometrically confirmed COPD with airway obstruction, benefit required high dose (>=1200 mg/day; RR 0.75, 95% CI 0.68-0.82); 600 mg/day sufficed only without obstruction. Well tolerated, adverse-event risk not dose-dependent. [https://pubmed.ncbi.nlm.nih.gov/26324807/]
  - Oral and Intravenous Acetylcysteine for Treatment of Acetaminophen Toxicity: A Systematic Review and Meta-analysis, The western journal of emergency medicine (2013) — 16 studies, 5,164 acetaminophen-poisoned patients. Hepatotoxicity (transaminase >1000 IU/L) occurred in 12.6% of oral-NAC vs 13.2% of IV-NAC treated patients (no meaningful route difference); treatment delay was associated with higher hepatotoxicity, supporting early administration regardless of route. [https://pubmed.ncbi.nlm.nih.gov/23687539/]
  - Mucolytic agents versus placebo for chronic bronchitis or chronic obstructive pulmonary disease, The Cochrane database of systematic reviews (2019) — Reduced exacerbations as a mucolytic. [https://pubmed.ncbi.nlm.nih.gov/31107966/]
  - Efficacy of N-Acetylcysteine on Liver Function and Metabolic Profiles in Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A Double-Blind, Randomized Controlled Trial, Addiction & health (2025) — Double-blind RCT in 69 MASLD patients (600 mg three times daily for 8 weeks) found no improvement in hepatic steatosis or liver enzymes, but significant reductions in fasting glucose, fasting insulin, HOMA-IR, and CRP versus placebo. [https://pubmed.ncbi.nlm.nih.gov/41431629/]
  - Outcomes after Angiography with Sodium Bicarbonate and Acetylcysteine, The New England journal of medicine (2018) — 2x2 factorial trial, 4,993 high-risk patients undergoing angiography. Oral acetylcysteine showed NO benefit vs placebo for the composite of death, dialysis, or persistent >=50% creatinine rise at 90 days (4.6% vs 4.5%; OR 1.02, 95% CI 0.78-1.33; p=0.88), nor for contrast-associated AKI. Definitively negative for renal protection. [https://pubmed.ncbi.nlm.nih.gov/29130810/]
  - N-acetylcysteine, a glutamate modulator, in the treatment of trichotillomania: a double-blind, placebo-controlled study, Archives of general psychiatry (2009) — 12-week double-blind trial in 50 adults with trichotillomania. NAC (1200-2400 mg/day) produced significantly greater reductions in hair-pulling than placebo (MGH Hairpulling Scale p<0.001; PITS p=0.001); 56% of NAC patients 'much/very much improved' vs 16% on placebo (p=0.003), with separation emerging by week 9. No adverse events; well tolerated. [https://pubmed.ncbi.nlm.nih.gov/19581567/]
  - N-Acetylcysteine for the Treatment of Psychiatric Disorders: A Review of Current Evidence, BioMed research international (2018) — Adjunctive benefit in several psychiatric disorders. [https://pmc.ncbi.nlm.nih.gov/articles/PMC6217900/]
  - Oxidation pathway and exacerbations in COPD: the role of NAC, Expert review of respiratory medicine (2016) — Mechanistic and clinical review: NAC is a cysteine precursor for glutathione synthesis with mucolytic and anti-inflammatory actions countering COPD oxidative stress. Concludes NAC prevents COPD exacerbations at high dose (>=1200 mg/day), while 600 mg/day suffices in chronic bronchitis without obstruction. [https://pubmed.ncbi.nlm.nih.gov/26567752/]
  - Acetylcysteine for acetaminophen poisoning, The New England journal of medicine (2008) — Standard, life-saving antidote in emergency medicine. [https://pmc.ncbi.nlm.nih.gov/articles/PMC2637612/]

---

## Collagen Peptides
URL: https://nutridex.info/s/collagen
Category: Joint & Skin
Evidence: Moderate — Several controlled trials; effects real but modest or context-dependent.
Hydrolyzed protein for skin elasticity and joints.

Quick answer: Collagen Peptides is used for skin hydration & elasticity. NutriDex grades the human evidence as moderate — Several controlled trials; effects real but modest or context-dependent. Based on 19 cited human studies (19 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Collagen peptides are broken-down collagen proteins that supply glycine, proline, and bioactive di-peptides. Pooled trials report improved skin hydration and elasticity and reduced wrinkle depth over 8–12 weeks. Some evidence supports reduced activity-related joint pain. The exact mechanism (signaling vs raw materials) is debated, and many trials are industry-funded.

Benefits / uses: Skin hydration & elasticity; Joint comfort; Possible tendon support.
Active compounds: Hydrolyzed type I/II collagen peptides.
Dose: 10–15 g/day (skin); ~10 g/day or specialized peptides for joints.
Safety: Very safe. Mild GI upset. Not vegan; quality and sourcing vary.

Cited studies (19):
  - Effects of Oral Collagen for Skin Anti-Aging: A Systematic Review and Meta-Analysis, Nutrients (2023) — Pooled analysis of 26 RCTs (n=1,721) found oral hydrolyzed collagen significantly improved skin hydration (effect size 0.63) and elasticity (0.72) versus placebo, with greater benefit after >8 weeks. [https://pubmed.ncbi.nlm.nih.gov/37432180/]
  - Efficacy and safety of collagen derivatives for osteoarthritis: A trial sequential meta-analysis, Osteoarthritis and cartilage (2024) — Across 35 RCTs (n=3,165), collagen derivatives produced small-to-moderate reductions in osteoarthritis pain and improvements in function, without increasing adverse events or withdrawals. [https://pubmed.ncbi.nlm.nih.gov/38218227/]
  - Effect of collagen supplementation on knee osteoarthritis: an updated systematic review and meta-analysis of randomised controlled trials, Clinical and experimental rheumatology (2025) — In 11 RCTs (n=870), collagen supplementation significantly improved knee osteoarthritis function (MD -6.46) and pain (MD -13.63) scores versus placebo. [https://pubmed.ncbi.nlm.nih.gov/39212129/]
  - Analgesic efficacy of collagen peptide in knee osteoarthritis: a meta-analysis of randomized controlled trials, Journal of orthopaedic surgery and research (2023) — Meta-analysis of 4 RCTs (n=507) found collagen peptide modestly reduced knee osteoarthritis pain on VAS versus placebo (SMD -0.58), moderate-quality evidence. [https://pubmed.ncbi.nlm.nih.gov/37717022/]
  - Efficacy of collagen peptide supplementation on bone and muscle health: a meta-analysis, Frontiers in nutrition (2025) — Meta-analysis (20 studies, mostly RCTs) found collagen peptides, especially combined with calcium and vitamin D, significantly increased bone mineral density at spine and femoral neck and improved muscle strength in older adults. [https://pubmed.ncbi.nlm.nih.gov/41049371/]
  - Impact of Collagen Peptide Supplementation in Combination with Long-Term Physical Training on Strength, Musculotendinous Remodeling, Functional Recovery, and Body Composition in Healthy Adults: A Systematic Review with Meta-analysis, Sports medicine (Auckland, N.Z.) (2024) — Across 19 RCTs (n=768), long-term collagen peptide (~15 g/day, >=8 wk) plus resistance/concurrent training significantly increased fat-free mass (ES 0.48) and maximal strength (ES 0.19) in active adults. [https://pubmed.ncbi.nlm.nih.gov/39060741/]
  - Collagen Supplementation on Tendon-Related Structural and Performance Outcomes: A Systematic Review, Journal of Functional Morphology and Kinesiology (2026) — Systematic review of 8 RCTs (n=257, mostly men, all combined with resistance/plyometric training) found strong evidence that collagen (15-30 g) with vitamin C increases tendon cross-sectional area and stiffness, strong evidence against an effect on muscle strength, and conflicting evidence for muscle CSA and physical performance. [https://doi.org/10.3390/jfmk11010130]
  - Effects of Collagen Supplements on Skin Aging: A Systematic Review and Meta-Analysis of Randomized Controlled Trials, The American journal of medicine (2025) — Meta-analysis of 23 RCTs (n=1474) found collagen significantly improved skin hydration, elasticity and wrinkles overall, but effects vanished in non-industry-funded and high-quality trials, leading authors to conclude there is no clinical evidence supporting collagen for skin aging. [https://pubmed.ncbi.nlm.nih.gov/40324552/]
  - Effects of Oral Collagen for Skin Anti-Aging: A Systematic Review and Meta-Analysis, Nutrients (2023) — Meta-analysis of 26 RCTs (n=1721) found oral collagen improved skin hydration (pooled effect size 0.63, 95% CI 0.38-0.88) and elasticity (0.72, 95% CI 0.40-1.03), with stronger effects after >8 weeks of supplementation. [https://pmc.ncbi.nlm.nih.gov/articles/PMC10180699/]
  - Exploring the Impact of Hydrolyzed Collagen Oral Supplementation on Skin Rejuvenation: A Systematic Review and Meta-Analysis, Cureus (2023) — Meta-analysis of 14 RCTs (n=967) found hydrolyzed collagen significantly improved skin hydration (effect size 0.58, 95% CI 0.42-0.73) and elasticity (0.65, 95% CI 0.44-0.85) versus placebo. [https://pmc.ncbi.nlm.nih.gov/articles/PMC10773595/]
  - Effects of hydrolyzed collagen supplementation on skin aging: a systematic review and meta-analysis, International journal of dermatology (2021) — Systematic review/meta-analysis of 19 RCTs (n=1,125, 95% women): oral hydrolyzed collagen significantly improved skin hydration, elasticity, and reduced wrinkles vs placebo; ~90 days of intake found effective for reducing signs of skin aging. [https://pubmed.ncbi.nlm.nih.gov/33742704/]
  - Influence of collagen peptide supplementation on visible signs of skin and nail health and ‐aging in an East Asian population: A double blind, randomized, placebo‐controlled trial, Journal of Cosmetic Dermatology (2024) — In 85 East Asian women aged 43-65, daily 5 g collagen peptide for an intervention period significantly improved visible signs of skin aging (wrinkles, elasticity, hydration) and nail health versus maltodextrin placebo in this double-blind RCT. [https://doi.org/10.1111/jocd.16458]
  - Collagen Peptide Supplementation Enhances Muscle-Tendon Stiffness and Explosive Strength: A 16-wk Randomized Controlled Trial, Medicine and science in sports and exercise (2025) — In 50 healthy young sedentary men, 16 weeks of 10 g/day collagen peptide significantly increased medial gastrocnemius muscle stiffness, Achilles tendon stiffness, and normalized rate of torque development (all P<0.001) versus placebo, with no change in muscle cross-sectional area or maximal strength. [https://pubmed.ncbi.nlm.nih.gov/40623147/]
  - The Sustained Effects of Bioactive Collagen Peptides on Skin Health: A Randomized, Double-Blind, Placebo-Controlled Clinical Study, Journal of cosmetic dermatology (2025) — In a 12-week randomized double-blind placebo-controlled trial (n=77 women), bioactive collagen peptides increased skin moisture (+9.15% vs -8.24% placebo) and facial dermal density (+19.20% vs -7.13%), though overall elasticity (R2) did not differ significantly between groups. [https://pmc.ncbi.nlm.nih.gov/articles/PMC12661388/]
  - Improvement of activity-related knee joint discomfort following supplementation of specific collagen peptides, Applied physiology, nutrition, and metabolism = Physiologie appliquee, nutrition et metabolisme (2017) — Reduced activity-related knee joint pain in young athletes over 12 weeks (n=139). [https://pubmed.ncbi.nlm.nih.gov/28177710/]
  - Specific Collagen Peptides Improve Bone Mineral Density and Bone Markers in Postmenopausal Women-A Randomized Controlled Study, Nutrients (2018) — Double-blind RCT in 102 postmenopausal women with reduced BMD: 5 g/day specific collagen peptides for 12 months significantly increased bone mineral density of the lumbar spine and femoral neck and favorably shifted bone markers (raised P1NP, lowered CTX-1) vs placebo. [https://pubmed.ncbi.nlm.nih.gov/29337906/]
  - Collagen peptide supplementation in combination with resistance training improves body composition and increases muscle strength in elderly sarcopenic men: a randomised controlled trial, The British journal of nutrition (2015) — Double-blind RCT in 53 elderly sarcopenic men: 15 g/day collagen peptides plus 12 weeks of resistance training significantly increased fat-free mass and isokinetic quadriceps strength and decreased fat mass compared with resistance training plus placebo. [https://pubmed.ncbi.nlm.nih.gov/26353786/]
  - Effects of hydrolyzed collagen supplementation on skin aging: a systematic review and meta-analysis, International Journal of Dermatology (2021) — Improved skin elasticity and hydration across RCTs. [https://onlinelibrary.wiley.com/doi/abs/10.1111/ijd.15518]
  - 24-Week study on the use of collagen hydrolysate as a dietary supplement in athletes with activity-related joint pain, Current medical research and opinion (2008) — Reduced activity-related joint pain in athletes. [https://pubmed.ncbi.nlm.nih.gov/18416885/]

---

## Vitamin C (Ascorbic acid)
URL: https://nutridex.info/s/vitaminc
Category: Vitamin, Gut & Immune
Evidence: Moderate — Several controlled trials; effects real but modest or context-dependent.
Classic antioxidant vitamin and collagen cofactor.

Quick answer: Vitamin C is used for antioxidant. NutriDex grades the human evidence as moderate — Several controlled trials; effects real but modest or context-dependent. Based on 21 cited human studies (21 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Vitamin C is a water-soluble antioxidant essential for collagen synthesis and immune function. Regular supplementation doesn't prevent colds in the general population but modestly shortens their duration. It enhances non-heme iron absorption when taken with meals. Megadoses offer little extra benefit and can cause GI upset and kidney-stone risk in susceptible people.

Benefits / uses: Antioxidant; Collagen synthesis; Slightly shorter colds; Iron absorption.
Active compounds: L-ascorbic acid.
Dose: 75–90 mg/day RDA; 200 mg saturates tissues. Doses >1g mostly excreted.
Safety: Safe. High doses cause diarrhea; may raise kidney-stone risk in predisposed individuals.

Cited studies (21):
  - Vitamin C reduces the severity of common colds: a meta-analysis, BMC public health (2023) — In 10 trials (≥1 g/day), vitamin C reduced common-cold severity by 15% (95% CI 9–21%), with a larger 26% reduction in duration of severe symptoms. [https://pubmed.ncbi.nlm.nih.gov/38082300/]
  - Vitamin C supplementation showed greater effects on systolic blood pressure in hypertensive and diabetic patients: an updated systematic review and meta-analysis of randomised clinical trials, International journal of food sciences and nutrition (2023) — Across 20 RCTs, vitamin C supplementation lowered systolic BP by ~3.0 mmHg, with larger reductions in hypertensive (3.2 mmHg) and diabetic (4.6 mmHg) patients. [https://pubmed.ncbi.nlm.nih.gov/37791386/]
  - The effects of vitamin C supplementation in the critically ill patients outcomes: A systematic review and meta-analysis of randomized controlled trials, Medicine (2024) — In 19 RCTs (2,047 critically ill patients), IV vitamin C reduced vasopressor and mechanical-ventilation duration but did not change 28-day mortality (RR 0.95, 95% CI 0.80–1.11). [https://pubmed.ncbi.nlm.nih.gov/38518058/]
  - The effect of vitamin C in adults with sepsis: a meta-analysis of randomized controlled trials, Frontiers in medicine (2023) — In 10 RCTs (1,426 adults with sepsis), vitamin C did not significantly reduce short-term mortality overall (OR 0.61, 95% CI 0.37–1.01), with benefit only in a developing-country subgroup. [https://pubmed.ncbi.nlm.nih.gov/37720500/]
  - Overall and Progression-Free Survival of Patients With Malignant Neoplasm Following Intravenous Vitamin C: A Systematic Review and Meta-Analysis, International journal for vitamin and nutrition research. Internationale Zeitschrift fur Vitamin- und Ernahrungsforschung. Journal international de vitaminologie et de nutrition (2025) — Across 8 studies (2,722 cancer patients), high-dose intravenous vitamin C was associated with ~83% longer median overall survival (ratio 1.83, 95% CI 1.40–2.40; moderate certainty). [https://pubmed.ncbi.nlm.nih.gov/40613397/]
  - The effects of vitamin C supplementation on glycemic control in patients with type 2 diabetes: A systematic review and meta-analysis, Diabetes & metabolic syndrome (2023) — Across 22 RCTs (1,447 adults with type 2 diabetes), vitamin C supplementation significantly lowered HbA1c, fasting blood glucose, and fasting insulin, with greatest benefit at high doses (>=1000 mg/day) for >=12 weeks. [https://pubmed.ncbi.nlm.nih.gov/37523928/]
  - The effect of vitamin C on the risk of mortality in patients with COVID-19: a systematic review and meta-analysis of randomized controlled trials, Inflammopharmacology (2023) — Pooling 11 RCTs of COVID-19 patients, vitamin C administration was associated with a significant reduction in all-cause mortality (pooled OR 0.53, 95% CI 0.30-0.92). [https://pubmed.ncbi.nlm.nih.gov/37071316/]
  - Effect of vitamin C supplementation on outcomes in patients with COVID-19: a systematic review and meta-analysis, Frontiers in Nutrition (2024) — Systematic review/meta-analysis of RCTs comparing vitamin C with standard care in adult COVID-19 patients found no significant reduction in in-hospital mortality. [https://www.frontiersin.org/journals/nutrition/articles/10.3389/fnut.2024.1465670/full]
  - Association of Oral or Intravenous Vitamin C Supplementation with Mortality: A Systematic Review and Meta-Analysis, Nutrients (2023) — Meta-analysis of 44 trials (26,540 participants) found oral/IV vitamin C associated with a 13% reduction in all-cause mortality, though not confirmed by trial sequential analysis. [https://pmc.ncbi.nlm.nih.gov/articles/PMC10146309/]
  - Association between Oral vitamin C supplementation and serum uric acid: A meta-analysis of randomized controlled trials, Complementary therapies in medicine (2021) — Pooled RCT data show oral vitamin C significantly lowers serum uric acid, though magnitude is modest and gout-prevention benefit is unproven. [https://pubmed.ncbi.nlm.nih.gov/34280483/]
  - Vitamin C intake and multiple health outcomes: an umbrella review of systematic reviews and meta-analyses, International journal of food sciences and nutrition (2022) — Umbrella review of 76 meta-analyses (63 outcomes) found dose-response associations of higher vitamin C intake (per 50-100 mg/day) with lower all-cause mortality and cardiovascular disease, but flagged increased risk of kidney stones and breast cancer with supplement use. [https://pubmed.ncbi.nlm.nih.gov/35291895/]
  - Vitamin C for preventing and treating the common cold, The Cochrane database of systematic reviews (2013) — Didn't prevent colds but shortened duration ~8% (adults). [https://pubmed.ncbi.nlm.nih.gov/23440782/]
  - Effects of vitamin C supplementation on blood pressure: a meta-analysis of randomized controlled trials, The American journal of clinical nutrition (2012) — Meta-analysis of 29 RCTs (median dose 500 mg/d, ~8 weeks): vitamin C reduced systolic BP by -3.84 mmHg and diastolic BP by -1.48 mmHg overall; in hypertensive subjects systolic reduction was -4.85 mmHg. Short-term effect; long-term/clinical outcomes unproven. [https://pubmed.ncbi.nlm.nih.gov/22492364/]
  - Effect of oral vitamin C supplementation on serum uric acid: a meta-analysis of randomized controlled trials, Arthritis care & research (2011) — Meta-analysis of 13 RCTs (median 500 mg/d, ~30 days): vitamin C significantly lowered serum uric acid by -0.35 mg/dL (95% CI -0.66 to -0.03). Modest urate-lowering effect; impact on gout incidence not established. [https://pubmed.ncbi.nlm.nih.gov/21671418/]
  - Intravenous Vitamin C for Patients Hospitalized With COVID-19: Two Harmonized Randomized Clinical Trials, JAMA (2023) — Two harmonized RCTs in 2590 hospitalized COVID-19 patients: IV vitamin C had low probability of benefit on organ support-free days and survival, with high posterior probability of harm in both critically ill (proportional OR 0.88) and non-critically ill (OR 0.80) strata; trials stopped for harm/futility. [https://pubmed.ncbi.nlm.nih.gov/37877585/]
  - Intravenous Vitamin C in Adults with Sepsis in the Intensive Care Unit, New England Journal of Medicine (2022) — In 872 septic ICU adults on vasopressors, high-dose IV vitamin C (50 mg/kg q6h) increased the risk of death or persistent organ dysfunction at 28 days vs placebo (RR 1.21, 95% CI 1.04-1.40). [https://www.nejm.org/doi/full/10.1056/NEJMoa2200644]
  - Intravenous Vitamin C in Adults with Sepsis in the Intensive Care Unit, The New England journal of medicine (2022) — In 872 ICU adults with sepsis on vasopressors, 4-day high-dose IV vitamin C INCREASED the risk of death or persistent organ dysfunction at 28 days vs placebo (44.5% vs 38.5%; RR 1.21, 95% CI 1.04-1.40); 28-day mortality 35.4% vs 31.6%. Signals harm, not benefit. [https://pubmed.ncbi.nlm.nih.gov/35704292/]
  - Dietary and circulating vitamin C, vitamin E, β-carotene and risk of total cardiovascular mortality: a systematic review and dose-response meta-analysis of prospective observational studies, Public health nutrition (2019) — Dose-response meta-analysis of prospective cohorts found higher dietary intake and circulating concentrations of vitamin C each associated with lower total cardiovascular mortality risk. [https://pmc.ncbi.nlm.nih.gov/articles/PMC10260571/]
  - Relation between plasma ascorbic acid and mortality in men and women in EPIC-Norfolk prospective study: a prospective population study. European Prospective Investigation into Cancer and Nutrition, Lancet (London, England) (2001) — Prospective study of 19,496 adults: plasma ascorbic acid was inversely associated with all-cause, cardiovascular, and ischemic heart disease mortality; top vs bottom quintile had ~half the mortality risk, and each 20 micromol/L rise was associated with ~20% lower all-cause mortality, independent of major confounders. Association, not causation. [https://pubmed.ncbi.nlm.nih.gov/11247548/]
  - Interaction of vitamin C and iron, Annals of the New York Academy of Sciences (1980) — Markedly increased non-heme iron absorption. [https://pubmed.ncbi.nlm.nih.gov/6940487/]
  - Vitamin C and Immune Function, Nutrients (2017) — Essential for immune cell function; deficiency impairs immunity. [https://pubmed.ncbi.nlm.nih.gov/29099763/]

---

## Vitamin B12 (Cobalamin)
URL: https://nutridex.info/s/b12
Category: Vitamin
Evidence: Strong — Multiple high-quality RCTs / meta-analyses with consistent effects.
Essential for nerves and blood — vital for vegans.

Quick answer: Vitamin B12 is used for prevents anemia. NutriDex grades the human evidence as strong — Multiple high-quality RCTs / meta-analyses with consistent effects. Based on 23 cited human studies (23 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

B12 is required for red-blood-cell formation, DNA synthesis, and neurological function. Deficiency causes anemia and potentially irreversible nerve damage, and is common in vegans, older adults, and people on metformin or acid-reducers. Supplementation cleanly reverses deficiency. In replete people, extra B12 does not boost energy despite marketing claims.

Benefits / uses: Prevents anemia; Nerve health; Energy (if deficient); Cognitive maintenance.
Active compounds: Methylcobalamin; Cyanocobalamin.
Dose: 2.4 µg/day RDA; deficiency corrected with high oral (500–1,000 µg) or injections.
Safety: Very safe; excess excreted. No established toxicity.

Cited studies (23):
  - A comprehensive review and meta-regression analysis of randomized controlled trials examining the impact of vitamin B12 supplementation on homocysteine levels, Nutrition reviews (2024) — Meta-analysis of 21 RCTs (n=1,625) found B12 supplementation lowered homocysteine by a pooled WMD of -4.15 umol/L (95% CI -4.86 to -3.45), with larger effects at higher doses (>500 ug/d) and longer duration. [https://pubmed.ncbi.nlm.nih.gov/37495210/]
  - Assessment of Vitamin B12 Efficacy on Cognitive Memory Function and Depressive Symptoms: A Systematic Review and Meta-Analysis, Cureus (2024) — Pooled analysis of 9 RCTs (~9,000 participants) found B12 supplementation had no significant effect on cognitive memory (SMD -0.03) or depressive symptoms (SMD -0.01) in the general population, suggesting benefit is limited to deficient individuals. [https://pmc.ncbi.nlm.nih.gov/articles/PMC11628180/]
  - Efficacy of different routes of vitamin B12 supplementation for the treatment of patients with vitamin B12 deficiency: A systematic review and network meta-analysis, Irish journal of medical science (2024) — Network meta-analysis (13 studies, 8 RCTs, 4,275 patients) found intramuscular, oral, and sublingual B12 all effectively raised B12 levels with no clinically significant difference between routes. [https://pmc.ncbi.nlm.nih.gov/articles/PMC11128391/]
  - The origin of vitamin B12 levels and risk of all-cause, cardiovascular and cancer specific mortality: A systematic review and dose-response meta-analysis, Archives of gerontology and geriatrics (2024) — Dose-response meta-analysis of 22 cohort studies (92,346 individuals, 10,704 deaths) found each 100 pmol/L higher serum B12 was associated with 4% higher all-cause mortality (HR 1.04, 95% CI 1.01-1.08) in the general population and 6% (HR 1.06, 95% CI 1.01-1.13) in older adults, with high concentrations >600 pmol/L linked to a 50% higher risk (HR 1.50, 95% CI 1.29-1.74). [https://pubmed.ncbi.nlm.nih.gov/38252787/]
  - Vitamin B12 supplementation during pregnancy for maternal and child health outcomes, Cochrane Database of Systematic Reviews (2024) — Cochrane systematic review of 5 trials (984 pregnant women; 3 trials/609 women in meta-analysis) found B12 supplementation may reduce maternal B12 deficiency and raise B12 concentrations, but evidence was very uncertain and effects on miscarriage, neural tube defects, and child cognition could not be established. [https://doi.org/10.1002/14651858.CD013823.pub2]
  - Efficacy of sublingual and oral vitamin B12 versus intramuscular administration: insights from a systematic review and meta-analysis, Frontiers in pharmacology (2025) — Systematic review/meta-analysis of 16 studies (6,098 participants) found oral and sublingual B12 comparable to intramuscular injection, with a pooled serum cobalamin rise of +402.6 pg/mL (95% CI 293.6 to 511.5) and homocysteine reduction of -4.83 umol/L (95% CI -6.55 to -3.11), no significant difference by route (p=0.27). [https://pmc.ncbi.nlm.nih.gov/articles/PMC12757266/]
  - The Neurological Sequelae of Vitamin B12 Deficiency: A Systematic Review and Randomized Controlled Trial, Cureus (2025) — Systematic review of 10 RCTs found B12 supplementation improved neurological symptoms in overt deficiency (oral comparable to IM), but produced no significant cognitive or neurological benefit in older adults with subclinical deficiency. [https://pubmed.ncbi.nlm.nih.gov/40486314/]
  - Efficacy of sublingual and oral vitamin B12 versus intramuscular administration: insights from a systematic review and meta-analysis, Frontiers in pharmacology (2025) — Meta-analysis of 16 studies (6098 participants): B12 supplementation raised serum cobalamin (pooled MD +402.6 pg/mL; 95% CI 293.6-511.5) and lowered homocysteine (MD -4.83 micromol/L; 95% CI -6.55 to -3.11), with no significant difference between oral, sublingual, and intramuscular routes (P=0.27 cobalamin; P=0.49 homocysteine). [https://pubmed.ncbi.nlm.nih.gov/41487531/]
  - Assessment of Vitamin B12 Efficacy on Cognitive Memory Function and Depressive Symptoms: A Systematic Review and Meta-Analysis, Cureus (2024) — Meta-analysis of 9 RCTs found vitamin B12 supplementation had no significant effect on cognitive memory function (standardized mean difference -0.03; 95% CI -0.07 to 0.01; P=0.18) or depressive symptoms (SMD -0.01; 95% CI -0.077 to 0.053; P=0.71) in the general population without overt deficiency. [https://pubmed.ncbi.nlm.nih.gov/39655146/]
  - The Impact of Vitamin B12 Supplementation on Clinical Outcomes in Patients With Diabetic Neuropathy: A Meta-Analysis of Randomized Controlled Trials, Cureus (2022) — Meta-analysis of 6 RCTs (~459 patients) found B12 supplementation significantly improved neuropathic symptoms (p=0.03) and reduced pain (p<0.001) in diabetic neuropathy, but did not change objective vibration perception threshold. [https://pmc.ncbi.nlm.nih.gov/articles/PMC9704859/]
  - Effect of Metformin on Vitamin B12 Deficiency in Patients With Type 2 Diabetes Mellitus and Factors Associated With It: A Meta-Analysis, Cureus (2022) — Meta-analysis of 17 studies found B12 deficiency was significantly more common in metformin-treated type 2 diabetes patients (23.2%) than non-users (17.4%) (OR 2.95, 95% CI 2.18-4.00), supporting periodic B12 monitoring. [https://pmc.ncbi.nlm.nih.gov/articles/PMC9816920/]
  - The association of homocysteine, folate, vitamin B12, and vitamin B6 with fracture incidence in older adults: a systematic review and meta-analysis, Annals of translational medicine (2021) — Systematic review and meta-analysis (prospective cohorts) found higher vitamin B12 levels associated with a modest ~4% lower fracture risk per 50 pmol/L increase (borderline significant), while elevated homocysteine was an independent fracture risk factor, with no consistent effect on bone mineral density. [https://pmc.ncbi.nlm.nih.gov/articles/PMC8350623/]
  - Diagnosis, Treatment and Long-Term Management of Vitamin B12 Deficiency in Adults: A Delphi Expert Consensus, Journal of clinical medicine (2024) — Delphi consensus of 42 international experts established agreed recommendations for diagnosis, treatment, and long-term management of adult B12 deficiency, endorsing both intramuscular and high-dose oral replacement. [https://pmc.ncbi.nlm.nih.gov/articles/PMC11050313/]
  - Overview | Vitamin B12 deficiency in over 16s: diagnosis and management | Guidance | NICE — UK NICE guideline (published 6 March 2024) recommends not excluding B12 deficiency on the basis of absent anaemia or macrocytosis, and offering oral cobalamin first-line with escalation to intramuscular hydroxocobalamin if symptoms do not improve. [https://www.nice.org.uk/guidance/ng239]
  - Oral vitamin B12 compared with intramuscular vitamin B12 for vitamin B12 deficiency, Cochrane (2018) — Cochrane review of 3 RCTs (153 participants) concluded oral and intramuscular B12 have similar effects on normalising serum B12 levels, with oral treatment costing less (low-quality evidence). [https://www.cochrane.org/evidence/CD004655_oral-vitamin-b12-compared-intramuscular-vitamin-b12-vitamin-b12-deficiency]
  - Oral vitamin B(12) versus intramuscular vitamin B(12) for vitamin B(12) deficiency, The Cochrane database of systematic reviews (2018) — Cochrane review of 3 RCTs (153 patients) found oral vitamin B12 (1000-2000 microg/d) achieves serum B12 normalization comparable to intramuscular injection for treating deficiency, at lower cost and with apparently similar safety (low/very-low quality evidence). [https://pubmed.ncbi.nlm.nih.gov/29543316/]
  - A 2-Year Randomized Controlled Trial With Low-Dose B-Vitamin Supplementation Shows Benefits on Bone Mineral Density in Adults With Lower B12 Status, Journal of Bone and Mineral Research (2022) — 2-year RCT (205 randomized, 167 completed) of combined B-vitamins (folic acid 200 ug, B12 10 ug, B6 10 mg, riboflavin 5 mg) found no overall bone benefit, but significantly slowed bone mineral density decline at the total hip and femoral neck in the subgroup with lower baseline B12 status (B12 <246 pmol/L or MMA >=0.22 umol/L). [https://academic.oup.com/jbmr/article/37/12/2443/7499973]
  - Homocysteine-lowering by B vitamins slows the rate of accelerated brain atrophy in mild cognitive impairment: a randomized controlled trial, PloS one (2010) — In 168 adults >70y with mild cognitive impairment, 24 months of high-dose folic acid (0.8 mg/d) + B12 (0.5 mg/d) + B6 (20 mg/d) slowed whole-brain atrophy: 0.76%/yr active vs 1.08%/yr placebo (P=0.001). Effect was homocysteine-dependent — in those with baseline tHcy >13 micromol/L atrophy was 53% lower with treatment. [https://pubmed.ncbi.nlm.nih.gov/20838622/]
  - B vitamins in patients with recent transient ischaemic attack or stroke in the VITAmins TO Prevent Stroke (VITATOPS) trial: a randomised, double-blind, parallel, placebo-controlled trial, The Lancet. Neurology (2010) — In 8164 patients with recent stroke/TIA, daily folic acid 2 mg + B6 25 mg + B12 0.5 mg vs placebo over median 3.4y did not significantly reduce the composite of stroke, MI, or vascular death (15% vs 17%; RR 0.91, 95% CI 0.82-1.00, P=0.05). B vitamins were safe but did not prevent recurrent major vascular events. [https://pubmed.ncbi.nlm.nih.gov/20688574/]
  - A Brief Overview of the Diagnosis and Treatment of Cobalamin (B12) Deficiency, Food and nutrition bulletin (2024) — Authoritative review noting rising risk of B12 deficiency from low intake or impaired absorption, and that early prevention/treatment is essential to avoid irreversible neurological damage given unreliable diagnostic biomarkers. [https://pubmed.ncbi.nlm.nih.gov/38987879/]
  - Vitamin B12 (cobalamin) deficiency in elderly patients, Canadian Medical Association Journal (2004) — Supplementation fully prevents/corrects deficiency anemia and neuropathy. [https://www.cmaj.ca/content/171/3/251.full]
  - Exploring Vitamin B12 Supplementation in the Vegan Population: A Scoping Review of the Evidence, Nutrients (2024) — B12 supplementation essential to avoid deficiency on plant-based diets. [https://www.mdpi.com/2072-6643/16/10/1442]
  - Vitamin B12 (cobalamin) deficiency in elderly patients, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne (2004) — High-dose oral B12 as effective as injections for many patients. [https://pubmed.ncbi.nlm.nih.gov/15289425/]

---

## Iron
URL: https://nutridex.info/s/iron
Category: Mineral
Evidence: Strong — Multiple high-quality RCTs / meta-analyses with consistent effects.
Critical for oxygen transport — supplement only if low.

Quick answer: Iron is used for treats iron-deficiency anemia. NutriDex grades the human evidence as strong — Multiple high-quality RCTs / meta-analyses with consistent effects. Based on 17 cited human studies (17 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Iron is essential for hemoglobin and oxygen transport. Iron-deficiency anemia causes fatigue, poor concentration, and reduced exercise capacity, and supplementation reliably reverses it. Crucially, iron should only be supplemented when deficiency is confirmed — excess iron is pro-oxidant and dangerous, especially in conditions like hemochromatosis. Alternate-day dosing reduces side effects and may improve absorption.

Benefits / uses: Treats iron-deficiency anemia; Restores energy (if deficient); Supports cognition.
Active compounds: Ferrous sulfate; Ferrous bisglycinate.
Dose: Treatment ~40–60 mg elemental; alternate-day dosing may absorb better. Test before supplementing.
Safety: Constipation, nausea and dark stools are common. Overdose is dangerous and is a leading cause of pediatric poisoning. Excess iron is pro-oxidant and harmful in iron-overload conditions (e.g. haemochromatosis). Separate from calcium, antacids, levothyroxine and certain antibiotics (tetracyclines, fluoroquinolones), which it can bind. Never take without a confirmed need.

Cited studies (17):
  - Daily oral iron supplementation during pregnancy, The Cochrane database of systematic reviews (2024) — Cochrane review found daily oral iron during pregnancy reduced maternal iron-deficiency anaemia at term (8.6% vs 19.8%; RR ~0.40) and maternal iron deficiency (RR ~0.47) versus placebo/no iron. [https://pubmed.ncbi.nlm.nih.gov/39145520/]
  - Screening and Supplementation for Iron Deficiency and Iron Deficiency Anemia During Pregnancy: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force, JAMA (2024) — USPSTF evidence review concluded routine prenatal iron supplementation reduces incidence of iron deficiency and iron-deficiency anaemia in pregnancy, but evidence for broader maternal/infant health outcomes is limited or shows no clear benefit. [https://pubmed.ncbi.nlm.nih.gov/39163033/]
  - Efficacy of daily versus alternate day oral iron supplementation for management of anaemia among general population: a systematic review and meta-analysis, BMC pharmacology & toxicology (2025) — Meta-analysis of 11 RCTs (n=1,014) found only a small, non-significant haemoglobin advantage for daily over alternate-day oral iron (MD 0.28 g/dL, 95% CI -0.01 to 0.56), with comparable adverse effects, supporting alternate-day dosing as an option. [https://pubmed.ncbi.nlm.nih.gov/40841680/]
  - Efficacy of daily versus intermittent oral iron supplementation for prevention of anaemia among pregnant women: a systematic review and meta-analysis, EClinicalMedicine (2024) — Systematic review and meta-analysis found daily and intermittent oral iron were similarly effective for preventing anaemia in pregnant women, while intermittent dosing tended to reduce gastrointestinal side effects. [https://pubmed.ncbi.nlm.nih.gov/39114275/]
  - Intravenous iron infusion in patients with heart failure: a systematic review and study-level meta-analysis, ESC heart failure (2023) — Study-level meta-analysis of 10 RCTs (3,438 heart-failure patients with iron deficiency) found IV iron reduced the composite of CV death or first HF hospitalisation (RR 0.85, 95% CI 0.77-0.95) and total HF hospitalisations (RR 0.74, 95% CI 0.60-0.91), with no significant effect on all-cause or CV mortality. [https://pubmed.ncbi.nlm.nih.gov/36734033/]
  - Efficacy and safety of iron supplements for restless leg syndrome, a systematic review, meta-analysis, meta-regression, and trial sequential analysis of randomized controlled trials, Proceedings (Baylor University. Medical Center) (2025) — Meta-analysis of 12 RCTs (511 patients) found iron supplementation, especially IV ferric carboxymaltose, significantly reduced International RLS scores (mean difference -5.28, 95% CI -7.66 to -2.90) and improved sleep and quality-of-life measures, though overall adverse events were modestly increased versus placebo. [https://pubmed.ncbi.nlm.nih.gov/40821477/]
  - Effects of iron supplementation on cognitive development in school-age children: Systematic review and meta-analysis, PloS one (2023) — Meta-analysis of 12 RCTs (~3,105 school-age children) found iron supplementation significantly improved intelligence (SMD 0.46, 95% CI 0.19-0.73), attention (SMD 0.44) and memory (SMD 0.44) but not school achievement, with the largest benefits among children anaemic at baseline. [https://pubmed.ncbi.nlm.nih.gov/37368919/]
  - Effect and safety of intravenous iron compared to oral iron for treatment of iron deficiency anaemia in pregnancy, The Cochrane database of systematic reviews (2024) — Cochrane review of 13 trials (2002-2024) found IV iron in pregnancy likely increases haemoglobin slightly and reduces anaemia versus oral iron, with rare serious adverse events not increased. [https://pubmed.ncbi.nlm.nih.gov/39651609/]
  - Efficacy of ferric carboxymaltose in heart failure with iron deficiency: an individual patient data meta-analysis, European heart journal (2023) — Individual patient data from 3 RCTs (n=4501) in HF with iron deficiency: IV ferric carboxymaltose reduced the composite of total CV hospitalisations and CV death (rate ratio 0.86, 95% CI 0.75-0.98; p=0.029), driven by fewer hospitalisations with no effect on mortality. [https://pubmed.ncbi.nlm.nih.gov/37632415/]
  - Intermittent iron supplementation for reducing anaemia and its associated impairments in adolescent and adult menstruating women, The Cochrane database of systematic reviews (2019) — Cochrane review of 25 RCTs (10,996 menstruating women): intermittent (1-3x/week) oral iron vs none/placebo cut anaemia risk (RR 0.65, 95% CI 0.49-0.87) and raised haemoglobin (+5.19 g/L) and ferritin; vs daily dosing it was similarly effective for anaemia with fewer adverse effects (RR 0.41, 95% CI 0.21-0.82). [https://pubmed.ncbi.nlm.nih.gov/30699468/]
  - Alternate day versus daily oral iron for treatment of iron deficiency anemia: a randomized controlled trial, Scientific reports (2023) — Double-blind RCT in 200 adults with iron-deficiency anaemia found no significant difference in haemoglobin rise between alternate-day (+1.05 g/dL) and daily (+1.36 g/dL) oral iron (p=0.47), nor in secondary tolerability outcomes. [https://pubmed.ncbi.nlm.nih.gov/36725875/]
  - Intravenous versus oral iron for anaemia among pregnant women in Nigeria (IVON): an open-label, randomised controlled trial, The Lancet. Global health (2024) — Open-label RCT of 1,056 pregnant Nigerian women found IV ferric carboxymaltose did not significantly reduce anaemia at 36 weeks versus oral ferrous sulphate but improved iron-deficiency correction. [https://pmc.ncbi.nlm.nih.gov/articles/PMC11420468/]
  - Intravenous ferric derisomaltose in patients with heart failure and iron deficiency in the UK (IRONMAN): an investigator-initiated, prospective, randomised, open-label, blinded-endpoint trial, Lancet (London, England) (2022) — In 1,137 UK heart-failure patients with iron deficiency, IV ferric derisomaltose narrowly missed significance for HF hospitalisation/CV death (RR 0.82, 95% CI 0.66-1.02) but was safe and well tolerated over a median 2.7 years. [https://pubmed.ncbi.nlm.nih.gov/36347265/]
  - Iron absorption from oral iron supplements given on consecutive versus alternate days and as single morning doses versus twice-daily split dosing in iron-depleted women: two open-label, randomised controlled trials, The Lancet. Haematology (2017) — In iron-depleted women, alternate-day single-dose oral ferrous sulfate gave higher cumulative fractional iron absorption (21.8% vs 16.3%, p=0.0013) and total absorption (175.3 vs 131.0 mg, p=0.0010) than consecutive-day dosing; divided twice-daily dosing raised serum hepcidin and did not improve absorption. Demonstrates alternate-day, once-daily dosing optimises absorption. [https://pubmed.ncbi.nlm.nih.gov/29032957/]
  - Iron deficiency, The Lancet (2021) — Correcting deficiency improves fatigue and cognition. [https://doi.org/10.1016/S0140-6736(20)32594-0]
  - Iron absorption from oral iron supplements given on consecutive versus alternate days and as single morning doses versus twice-daily split dosing in iron-depleted women: a randomised controlled trial, The Lancet Haematology (2017) — Alternate-day dosing improved fractional iron absorption. [https://www.thelancet.com/article/S2352-3026(17)30182-5/abstract]
  - BSG Guidelines for the Management of Iron Deficiency Anaemia in Adults, British Society of Gastroenterology (2021) — Oral iron is first-line for iron-deficiency anemia. [https://www.bsg.org.uk/clinical-resource/guidelines-iron-deficiency-anaemia-in-adults]

---

## Beta-Alanine
URL: https://nutridex.info/s/betaalanine
Category: Performance
Evidence: Strong — Multiple high-quality RCTs / meta-analyses with consistent effects.
Buffers muscle acid for high-intensity endurance.

Quick answer: Beta-Alanine is used for muscular endurance. NutriDex grades the human evidence as strong — Multiple high-quality RCTs / meta-analyses with consistent effects. Based on 19 cited human studies (19 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Beta-alanine raises muscle carnosine, which buffers hydrogen ions during intense exercise. Meta-analyses show reliable improvements in performance for efforts lasting roughly 1–4 minutes (e.g. rowing, high-rep training, sprint repeats). The benefit is specific to that high-intensity window and builds over weeks of loading. A harmless tingling sensation (paresthesia) is common.

Benefits / uses: Muscular endurance; Reduced fatigue (1–4 min efforts); Training volume.
Active compounds: Beta-alanine (raises muscle carnosine).
Dose: 3.2–6.4 g/day, split to limit tingling; benefits build over 2–4 weeks.
Safety: Safe. Causes harmless skin tingling (paresthesia); split dosing reduces it.

Cited studies (19):
  - Effect of Beta-Alanine Supplementation on Maximal Intensity Exercise in Trained Young Male Individuals: A Systematic Review and Meta-Analysis, International journal of sport nutrition and exercise metabolism (2024) — In trained young males (18 studies, 331 participants), beta-alanine improved maximal-intensity exercise in 14 of 18 studies, with neutral or small detrimental effects in 4. [https://pubmed.ncbi.nlm.nih.gov/39032921/]
  - β-Alanine Supplementation in Combat Sports: Evaluation of Sports Performance, Perception, and Anthropometric Parameters and Biochemical Markers-A Systematic Review of Clinical Trials, Nutrients (2023) — Across 7 clinical trials in combat-sport athletes, beta-alanine significantly improved strength, power and work capacity and raised muscle carnosine, and appeared safe. [https://pubmed.ncbi.nlm.nih.gov/37686787/]
  - Beta-Alanine for Improving Exercise Capacity, Muscle Strength, and Functional Performance of Older Adults: A Systematic Review, Journal of aging and physical activity (2025) — Review of 5 studies (163 older adults, 2.4-3.2 g/day) found beta-alanine may improve exercise capacity but not muscle strength or functional performance. [https://pubmed.ncbi.nlm.nih.gov/39724872/]
  - Dosing strategies for β-alanine supplementation in strength and power performance: a systematic review, Journal of the International Society of Sports Nutrition (2025) — Systematic review of dosing strategies for beta-alanine in strength and power performance summarizing loading protocols (typically ~4-6 g/day for >=4 weeks) needed to raise muscle carnosine. [https://doi.org/10.1080/15502783.2025.2566368]
  - Effect of carnosine or beta-alanine supplementation therapy for prediabetes or type 2 diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials, BMC endocrine disorders (2025) — Pooled analysis of 8 RCTs (377 participants) in prediabetes/type 2 diabetes found carnosine or beta-alanine supplementation significantly reduced fasting blood glucose (SMD -0.53) and HbA1c (SMD -0.36) versus placebo. [https://pubmed.ncbi.nlm.nih.gov/40999397/]
  - Sodium bicarbonate and beta-alanine supplementation: Is combining both better than either alone? A systematic review and meta-analysis, Biology of sport (2024) — Systematic review and meta-analysis found no ergogenic effect of beta-alanine in isolation and that combining beta-alanine with sodium bicarbonate was not clearly superior to either supplement alone. [https://pubmed.ncbi.nlm.nih.gov/38952910/]
  - Dosing strategies for β-alanine supplementation in strength and power performance: a systematic review, Journal of the International Society of Sports Nutrition (2025) — Systematic review of 9 studies (197 participants) found daily beta-alanine doses of 4-6.4 g, especially divided into multiple small servings (~0.8 g), were more likely to enhance maximal strength and power, though effects on strength/power remained inconsistent. [https://www.tandfonline.com/doi/full/10.1080/15502783.2025.2566368]
  - Efficacy of dietary supplements on sports performance outcomes: a systematic review of evidence in elite athletes, Frontiers in nutrition (2025) — PRISMA systematic review of 46 RCTs (928 elite athletes, high methodological quality, mean PEDro 10.65/11) found beta-alanine demonstrated sport-specific performance benefits in elite athletes. [https://pmc.ncbi.nlm.nih.gov/articles/PMC12498230/]
  - Effects of beta-alanine supplementation on body composition: a GRADE-assessed systematic review and meta-analysis, Journal of the International Society of Sports Nutrition (2022) — Pooled data from 20 studies (492 participants) found no effect of beta-alanine on body mass, fat mass, body-fat percentage or fat-free mass, regardless of dose or training type. [https://pubmed.ncbi.nlm.nih.gov/35813845/]
  - Effects of beta-alanine supplementation on Yo-Yo test performance: A meta-analysis, Clinical nutrition ESPEN (2021) — Meta-analysis of 10 athlete study groups found beta-alanine ergogenic for Yo-Yo intermittent test performance specifically when supplemented for 6-12 weeks and using level-2 variants. [https://pubmed.ncbi.nlm.nih.gov/34024507/]
  - The Muscle Carnosine Response to Beta-Alanine Supplementation: A Systematic Review With Bayesian Individual and Aggregate Data E-Max Model and Meta-Analysis, Frontiers in physiology (2020) — Systematic review with Bayesian dose-response (E-max) modeling of muscle carnosine response; effectually all participants respond to beta-alanine (99.3% responders, 95% CrI 96.2-100), accumulation is non-linear with large unsaturated capacity (common protocols do not saturate carnosine), and neither baseline carnosine nor sex moderated the response. [https://pubmed.ncbi.nlm.nih.gov/32922303/]
  - β-alanine supplementation to improve exercise capacity and performance: a systematic review and meta-analysis, British journal of sports medicine (2017) — Small but reliable performance benefit, peaking at 1–4 min efforts. [https://pubmed.ncbi.nlm.nih.gov/27797728/]
  - Effects of β-alanine supplementation on exercise performance: a meta-analysis, Amino Acids (2012) — Improved exercise capacity vs placebo across studies. [https://doi.org/10.1007/s00726-011-1200-z]
  - International society of sports nutrition position stand: Beta-Alanine, Journal of the International Society of Sports Nutrition (2015) — Effective and safe for high-intensity performance. [https://pmc.ncbi.nlm.nih.gov/articles/PMC4501114/]
  - Role of β-Alanine Supplementation on Cognitive Function, Mood, and Physical Function in Older Adults; Double-Blind Randomized Controlled Study, Nutrients (2023) — In 100 older adults (mean ~71 y) over 10 weeks, beta-alanine (2.4 g/day) improved cognitive function in those at/below normal baseline and possibly reduced depression scores, but did not improve physical function. [https://pmc.ncbi.nlm.nih.gov/articles/PMC9960300/]
  - Effect of a sustained-release formulation of β-alanine on laboratory parameters and paresthesia in recreational trained men: a randomized double-blind placebo-controlled study, Frontiers in nutrition (2023) — Randomized double-blind placebo-controlled trial in 19 recreationally trained men taking sustained-release beta-alanine (15 g/day for 30 days) found paresthesia in 90% of the supplemented group but with mild severity (VAS <3/10 in nearly all) and no between-group differences in laboratory safety markers. [https://pubmed.ncbi.nlm.nih.gov/37766731/]
  - β-alanine supplementation in adults with overweight and obesity: a randomized controlled feasibility trial, Obesity (Silver Spring, Md.) (2025) — Randomized controlled feasibility trial in adults with overweight/obesity found sustained-release beta-alanine was well tolerated and adhered to, but the probability of effects on cardiometabolic, cardiovascular, or biochemical outcomes was low. [https://pubmed.ncbi.nlm.nih.gov/39800667/]
  - International society of sports nutrition position stand: Beta-Alanine, Journal of the International Society of Sports Nutrition (2015) — Official society position stand concluding that 4-6 g/day of beta-alanine for at least 2-4 weeks significantly raises muscle carnosine (intracellular pH buffer) and improves exercise performance, with most pronounced effects in open-end-point tasks lasting 1-4 min; appears safe at recommended doses, with paraesthesia the only reported side effect (attenuable by divided 1.6 g doses or sustained-release). [https://pubmed.ncbi.nlm.nih.gov/26175657/]
  - The Effect of β-Alanine Supplementation on Performance, Cognitive Function and Resiliency in Soldiers, Nutrients (2023) — Narrative review of beta-alanine in military populations: ~6 g/day for 4 weeks helped maintain lower-body power, psychomotor performance and shooting accuracy in soldiers, while PTSD/mTBI resilience benefits were demonstrated only in animal models and human cognitive effects were inconclusive. [https://pubmed.ncbi.nlm.nih.gov/36839397/]

---

## L-Citrulline
URL: https://nutridex.info/s/citrulline
Category: Performance
Evidence: Moderate — Several controlled trials; effects real but modest or context-dependent.
Boosts nitric oxide for blood flow and pumps.

Quick answer: L-Citrulline is used for increased nitric oxide. NutriDex grades the human evidence as moderate — Several controlled trials; effects real but modest or context-dependent. Based on 22 cited human studies (22 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

L-citrulline raises plasma arginine and nitric oxide more effectively than arginine itself, improving blood flow. Trials show modest gains in high-intensity endurance, more reps to fatigue, and reduced post-exercise soreness. It also produces small reductions in blood pressure. Effects are real but modest and somewhat inconsistent between studies.

Benefits / uses: Increased nitric oxide; Reduced muscle soreness; Endurance & pump; Blood pressure.
Active compounds: L-citrulline; Citrulline malate.
Dose: 6–8 g citrulline malate (or ~3–4 g pure L-citrulline) ~60 min pre-exercise.
Safety: Very safe, well tolerated. Caution if on nitrates or BP medication.

Cited studies (22):
  - Effects of citrulline on endurance performance in young healthy adults: a systematic review and meta-analysis, Journal of the International Society of Sports Nutrition (2023) — Meta-analysis of 9 RCTs (158 young healthy adults) found no significant effect of acute citrulline on endurance performance (time-to-exhaustion or time-to-completion). [https://pubmed.ncbi.nlm.nih.gov/37155582/]
  - Does l-citrulline supplementation and watermelon intake reduce blood pressure in middle-aged and older adults? A systematic review and meta-analysis of randomized controlled trials, Clinical Nutrition ESPEN (2025) — Meta-analysis of 15 RCTs (415 middle-aged/older adults) found L-citrulline/watermelon intake significantly lowered systolic BP by 4.02 mmHg and diastolic BP by 2.54 mmHg. [https://doi.org/10.1016/j.clnesp.2025.07.1130]
  - Effects of Citrulline or Watermelon Supplementation on Body Composition: A Systematic Review and Dose-Response Meta-Analysis, Nutrients (2025) — Dose-response meta-analysis of 21 RCTs found citrulline/watermelon had no overall effect on body composition, with exploratory reductions in fat mass only at doses >6 g/day or in those over 40. [https://pubmed.ncbi.nlm.nih.gov/41097202/]
  - Effects of L-citrulline supplementation and watermelon intake on arterial stiffness and endothelial function in middle-aged and older adults: a systematic review and meta-analysis of randomized controlled trials, Frontiers in nutrition (2025) — Meta-analysis of 8 RCTs (176 middle-aged/older adults) found L-citrulline significantly improved flow-mediated dilation (WMD 1.81%) but did not significantly improve overall pulse wave velocity. [https://pmc.ncbi.nlm.nih.gov/articles/PMC12658987/]
  - The Effects of Combined Exercise with Citrulline Supplementation on Body Composition and Lower Limb Function of Overweight Older Adults: A Systematic Review and Meta-Analysis, Journal of sports science & medicine (2023) — Meta-analysis of 7 RCTs (303 overweight adults over 55) found citrulline combined with exercise significantly improved 6-minute walk test (SMD -0.28) and lower-limb strength (SMD -0.38) versus exercise plus placebo. [https://pubmed.ncbi.nlm.nih.gov/37711701/]
  - Absence of Effects of L-Arginine and L-Citrulline on Inflammatory Biomarkers and Oxidative Stress in Response to Physical Exercise: A Systematic Review with Meta-Analysis, Nutrients (2023) — Meta-analysis of 7 RCTs found L-citrulline/L-arginine did not significantly affect post-exercise oxidative stress (p=0.24), antioxidants (p=0.68), IL-6 (p=0.05), or IL-10 (p=0.34), with low to very-low GRADE certainty. [https://pubmed.ncbi.nlm.nih.gov/37111214/]
  - Effect of L-Citrulline Intake on Blood Pressure in Cold Environments: A Systematic Review and Meta-Analysis of Randomized Controlled Trials, Food science & nutrition (2026) — Meta-analysis of 6 RCTs (n=162) found L-citrulline reduced cold-induced systolic BP by 9.28 mmHg (95% CI −10.66 to −7.90, p<0.001) and diastolic BP by 5.33 mmHg (95% CI −9.38 to −1.27, p=0.01). [https://pmc.ncbi.nlm.nih.gov/articles/PMC12965904/]
  - Citrulline supplementation in postmenopausal women: a systematic review of vascular, muscular, and metabolic effects, BMC women's health (2026) — Systematic review of RCTs evaluating citrulline (direct or via watermelon) in postmenopausal women reported benefits on vascular outcomes (blood pressure, arterial stiffness, endothelial function) with limited and inconsistent effects on muscular and metabolic parameters. [https://pmc.ncbi.nlm.nih.gov/articles/PMC12918617/]
  - Effects of citrulline on endurance performance in young healthy adults: a systematic review and meta-analysis, Journal of the International Society of Sports Nutrition (2023) — Meta-analysis of 9 studies (n=158, young healthy adults) found citrulline did not improve endurance: time-to-exhaustion pooled SMD 0.03 (95% CI −0.27 to 0.33) and time-to-completion SMD −0.07, indicating no significant ergogenic effect on endurance. [https://pmc.ncbi.nlm.nih.gov/articles/PMC10167868/]
  - Does l-citrulline supplementation and watermelon intake reduce blood pressure in middle-aged and older adults? A systematic review and meta-analysis of randomized controlled trials, Clinical nutrition ESPEN (2025) — Meta-analysis of 15 RCTs (415 middle-aged/elderly participants): L-citrulline supplementation/watermelon intake significantly lowered systolic BP by -4.02 mmHg (95% CI -6.54 to -1.50; P=0.002) and diastolic BP by -2.54 mmHg (95% CI -4.27 to -0.81; P=0.004); combined L-citrulline + L-arginine was superior, reducing SBP by -10.44 mmHg and DBP by -4.86 mmHg. [https://pubmed.ncbi.nlm.nih.gov/40789388/]
  - L-Arginine and L-Citrulline for Prevention and Treatment of Pre-Eclampsia: A Systematic Review and Meta-Analysis, BJOG : an international journal of obstetrics and gynaecology (2025) — Systematic review/meta-analysis (20 RCTs, 2028 women) of L-arginine and its precursor L-citrulline in pregnancy: L-arginine reduced pre-eclampsia risk (RR 0.52, 95% CI 0.35-0.78) and severe pre-eclampsia (RR 0.23, 95% CI 0.09-0.55); the single L-citrulline trial (36 women) showed no effect on pre-eclampsia or BP, so direct L-citrulline evidence remains insufficient. [https://pubmed.ncbi.nlm.nih.gov/39800868/]
  - Acute Effect of Citrulline Malate on Repetition Performance During Strength Training: A Systematic Review and Meta-Analysis, International journal of sport nutrition and exercise metabolism (2021) — Meta-analysis of 8 RCTs (137 participants) found acute 6-8 g citrulline malate produced a small ergogenic effect, increasing strength-training repetitions by about 6.4% versus placebo. [https://pubmed.ncbi.nlm.nih.gov/34010809/]
  - Effects of Citrulline Malate Supplementation on Muscle Strength in Resistance-Trained Adults: A Systematic Review and Meta-Analysis of Randomized Controlled Trials, Journal of dietary supplements (2022) — Meta-analysis of 4 RCTs in resistance-trained adults found citrulline malate did not significantly improve muscle strength (SMD 0.13, 95% CI -0.21 to 0.46). [https://pubmed.ncbi.nlm.nih.gov/34176406/]
  - Effect of citrulline on post-exercise rating of perceived exertion, muscle soreness, and blood lactate levels: A systematic review and meta-analysis, Journal of sport and health science (2020) — Systematic review and meta-analysis of 13 trials (206 participants, mostly 8 g citrulline malate) found citrulline significantly reduced muscle soreness at 24 h and 48 h and lowered RPE, but did not reduce soreness at 72 h or blood lactate. [https://pubmed.ncbi.nlm.nih.gov/33308806/]
  - Effects of Citrulline Supplementation on Different Aerobic Exercise Performance Outcomes: A Systematic Review and Meta-Analysis, Nutrients (2022) — Systematic review/meta-analysis of 10 RCTs: citrulline supplementation showed NO significant benefit on aerobic exercise performance (SMD 0.15, 95% CI -0.02 to 0.32), perceived exertion, VO2 kinetics, or lactate; only a non-significant positive tendency for chronic dosing. [https://pubmed.ncbi.nlm.nih.gov/36079738/]
  - Effect of food sources of nitrate, polyphenols, L-arginine and L-citrulline on endurance exercise performance: a systematic review and meta-analysis of randomised controlled trials, Journal of the International Society of Sports Nutrition (2021) — Large meta-analysis (118 studies; 3 L-citrulline food-source studies) found NO effect of L-citrulline-rich foods on endurance performance (SMD -0.03, P=0.24), in contrast to trivial-but-significant benefits from nitrate- and polyphenol-rich foods (SMD ~0.15-0.17). [https://pubmed.ncbi.nlm.nih.gov/34965876/]
  - Ergogenic effects of a 10-day L-citrulline supplementation on time to exhaustion and cardiorespiratory and metabolic responses in healthy individuals: a double-blind, randomised, placebo-controlled crossover trial, Frontiers in Sports and Active Living (2025) — Double-blind randomized crossover trial in 20 healthy adults found 10 days of L-citrulline (mean 7.4 g/day) did not improve time to exhaustion (20.5 vs 19.8 min, p=0.43) or cardiorespiratory responses, with only a non-significant trend in females. [https://doi.org/10.3389/fspor.2025.1627743]
  - Changes in resistance training performance, rating of perceived exertion, and blood biomarkers after six weeks of supplementation with L-citrulline vs. L-citrulline DL-malate in resistance-trained men: a double-blind placebo-controlled trial, Journal of the International Society of Sports Nutrition (2025) — 6-week double-blind RCT in 33 resistance-trained men: both L-citrulline and L-citrulline DL-malate significantly improved upper-body muscular endurance vs placebo and raised post-exercise nitric oxide, with no difference between the two citrulline forms and no strength benefit. [https://pmc.ncbi.nlm.nih.gov/articles/PMC12143003/]
  - Oral L-citrulline supplementation improves erection hardness in men with mild erectile dysfunction, Urology (2011) — Single-blind placebo-controlled crossover trial (24 men, mild ED): L-citrulline 1.5 g/day normalized erection hardness (score 3 to 4) in 50% of men vs 8.3% on placebo (P<0.01) and increased monthly intercourse frequency (1.4 to 2.3, P<0.01), with no adverse events. [https://pubmed.ncbi.nlm.nih.gov/21195829/]
  - Acute Effects of Citrulline Supplementation on High-Intensity Strength and Power Performance: A Systematic Review and Meta-Analysis, Sports medicine (Auckland, N.Z.) (2019) — Improved strength-endurance and reduced fatigue. [https://pubmed.ncbi.nlm.nih.gov/30895562/]
  - Influence of L-citrulline and watermelon supplementation on vascular function and exercise performance, Current opinion in clinical nutrition and metabolic care (2017) — Lowered blood pressure and improved vascular function. [https://pubmed.ncbi.nlm.nih.gov/27749691/]
  - Citrulline malate enhances athletic anaerobic performance and relieves muscle soreness, Journal of strength and conditioning research (2010) — Citrulline malate increased reps and reduced soreness. [https://pubmed.ncbi.nlm.nih.gov/20386132/]

---

## Glycine
URL: https://nutridex.info/s/glycine
Category: Sleep & Mood, Longevity
Evidence: Preliminary — Early or small human trials; promising but not yet conclusive.
Simple amino acid that may deepen sleep.

Quick answer: Glycine is used for improved sleep quality. NutriDex grades the human evidence as preliminary — Early or small human trials; promising but not yet conclusive. Based on 16 cited human studies (16 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Glycine is an inhibitory neurotransmitter and a building block of collagen and glutathione. Small Japanese trials show that 3 g before bed improves subjective sleep quality and next-day alertness, possibly by lowering core body temperature. Evidence is limited to a handful of small studies, keeping it preliminary, but its excellent safety and low cost make it a low-risk option.

Benefits / uses: Improved sleep quality; Lower core temperature; Next-day alertness; Collagen building block.
Active compounds: Glycine.
Dose: 3 g before bed for sleep.
Safety: Very safe. Mild GI upset at high doses.

Cited studies (16):
  - The effect of glycine administration on the characteristics of physiological systems in human adults: A systematic review, GeroScience (2023) — Systematic review of 50 human studies (42 RCTs) found glycine administration most consistently benefited the nervous system, including improved sleep in healthy adults, though sleep trials had small samples and high risk of bias. [https://doi.org/10.1007/s11357-023-00970-8]
  - The effect of glycine administration on the characteristics of physiological systems in human adults: A systematic review, GeroScience (2024) — Systematic review of 50 studies found that 3 g/day oral glycine before bedtime over 2-4 days improved subjective sleep quality and reduced daytime fatigue in healthy adults, but underlying trials had small samples and high risk of bias. [https://pmc.ncbi.nlm.nih.gov/articles/PMC10828290/]
  - Metabolomics and Type 2 Diabetes Risk: An Updated Systematic Review and Meta-analysis of Prospective Cohort Studies, Diabetes Care (2022) — Updated meta-analysis of prospective cohorts (61 reports, ~71,000 participants, 11,771 T2D cases) found higher circulating glycine was associated with lower type 2 diabetes risk. [https://doi.org/10.2337/dc21-1705]
  - Meta-analysis of the efficacy of adjunctive NMDA receptor modulators in chronic schizophrenia, CNS drugs (2011) — Meta-analysis of 29 RCTs (1,253 patients) in chronic schizophrenia found adjunctive glycine added to non-clozapine antipsychotics produced medium reductions in total symptoms (SMD around -0.66), though it worsened symptoms when combined with clozapine. [https://pubmed.ncbi.nlm.nih.gov/21936588/]
  - Strategies to enhance N-methyl-D-aspartate receptor-mediated neurotransmission in schizophrenia, a critical review and meta-analysis, Current pharmaceutical design (2010) — Meta-analysis of 26 double-blind placebo-controlled trials (~800 patients) of NMDA-enhancing agents in schizophrenia: overall effect on total psychopathology SMD 0.40 (p<1e-4); glycine, D-serine and sarcosine each significantly improved multiple symptom domains (negative SMD 0.38, cognitive 0.28, positive 0.26), with no significant safety concerns; D-cycloserine ineffective and clozapine-treated patients did not benefit. [https://pubmed.ncbi.nlm.nih.gov/19909229/]
  - Supplementing Glycine and N-Acetylcysteine (GlyNAC) in Older Adults Improves Glutathione Deficiency, Oxidative Stress, Mitochondrial Dysfunction, Inflammation, Physical Function, and Aging Hallmarks: A Randomized Clinical Trial, The Journals of Gerontology: Series A (2022) — 16-week RCT in 24 older adults (12 GlyNAC vs 12 placebo) found glycine plus N-acetylcysteine improved glutathione deficiency, oxidative stress, mitochondrial dysfunction, inflammation, insulin resistance, and physical function. [https://doi.org/10.1093/gerona/glac135]
  - Magnesium Bisglycinate Supplementation in Healthy Adults Reporting Poor Sleep: A Randomized, Placebo-Controlled Trial, Nature and science of sleep (2025) — Randomized, double-blind, placebo-controlled trial (n=155) of magnesium bisglycinate (250 mg elemental Mg) showed a greater 4-week reduction in Insomnia Severity Index vs placebo (-3.9 vs -2.3, p=0.049), a small effect (Cohen's d ~0.2); note magnesium confounds the glycine contribution. [https://pmc.ncbi.nlm.nih.gov/articles/PMC12412596/]
  - Supplementing Glycine and N-Acetylcysteine (GlyNAC) in Older Adults Improves Glutathione Deficiency, Oxidative Stress, Mitochondrial Dysfunction, Inflammation, Physical Function, and Aging Hallmarks: A Randomized Clinical Trial, The journals of gerontology. Series A, Biological sciences and medical sciences (2023) — Placebo-controlled RCT in 24 older adults (16 wk GlyNAC = glycine + N-acetylcysteine vs isonitrogenous alanine placebo): GlyNAC corrected glutathione deficiency and reduced oxidative stress, and improved mitochondrial fatty-acid oxidation, insulin resistance, inflammation, endothelial function, gait speed/muscle strength/6-min walk, waist circumference and systolic BP, plus multiple aging hallmarks; safe and well tolerated. [https://pubmed.ncbi.nlm.nih.gov/35975308/]
  - A Randomized Controlled Clinical Trial in Healthy Older Adults to Determine Efficacy of Glycine and N-Acetylcysteine Supplementation on Glutathione Redox Status and Oxidative Damage, Frontiers in aging (2022) — Dose-ranging RCT in 114 healthy older adults found glycine plus N-acetylcysteine was safe and increased total glutathione (~10%) only in a subgroup with high baseline oxidative stress and low glutathione. [https://pubmed.ncbi.nlm.nih.gov/35821844/]
  - Oral supplementation with glycine reduces oxidative stress in patients with metabolic syndrome, improving their systolic blood pressure, Canadian journal of physiology and pharmacology (2013) — 3-month RCT in 60 metabolic syndrome patients found oral glycine (15 g/day) reduced the oxidative stress marker TBARS by about 25% versus placebo and significantly lowered systolic blood pressure in men. [https://pubmed.ncbi.nlm.nih.gov/24144057/]
  - Neuroprotective effects of glycine for therapy of acute ischaemic stroke, Cerebrovascular diseases (Basel, Switzerland) (2000) — Randomized double-blind placebo-controlled trial in 200 patients with acute (<6 h) ischemic stroke: sublingual glycine 1.0-2.0 g/day for 5 days showed a trend to lower 30-day mortality (5.9-10% vs 14% placebo) and significantly better clinical/functional outcomes (Orgogozo and Scandinavian Stroke Scales p<0.01; Barthel index p<0.01), with reduced CSF glutamate/aspartate and lipid peroxidation; safe with only mild sedation. [https://pubmed.ncbi.nlm.nih.gov/10629347/]
  - Glycine-based treatment ameliorates NAFLD by modulating fatty acid oxidation, glutathione synthesis, and the gut microbiome, Science Translational Medicine (2020) — In diet-induced NASH mouse models, a glycine-based tripeptide (DT-109) ameliorated NAFLD/NASH by enhancing hepatic fatty acid oxidation and glutathione synthesis and modulating the gut microbiome, lowering glucose, lipids, transaminases, and inflammation. [https://doi.org/10.1126/scitranslmed.aaz2841]
  - GlyNAC (Glycine and N-Acetylcysteine) Supplementation in Mice Increases Length of Life by Correcting Glutathione Deficiency, Oxidative Stress, Mitochondrial Dysfunction, Abnormalities in Mitophagy and Nutrient Sensing, and Genomic Damage, Nutrients (2022) — In C57BL/6J mice, lifelong GlyNAC (glycine plus N-acetylcysteine) supplementation extended lifespan by 24% versus controls (128.6 vs 104.0 weeks) while correcting glutathione deficiency, oxidative stress, mitochondrial dysfunction, impaired mitophagy, and genomic damage. [https://doi.org/10.3390/nu14051114]
  - The effects of glycine on subjective daytime performance in partially sleep-restricted healthy volunteers, Frontiers in neurology (2012) — Reduced daytime fatigue after restricted sleep. [https://pubmed.ncbi.nlm.nih.gov/22529837/]
  - Glycine ingestion improves subjective sleep quality in human volunteers, correlating with polysomnographic changes, Sleep and Biological Rhythms (2007) — 3g before bed improved subjective sleep quality and slow-wave sleep. [https://doi.org/10.1111/j.1479-8425.2007.00262.x]
  - Subjective effects of glycine ingestion before bedtime on sleep quality, Sleep and Biological Rhythms (2006) — Improved sleep satisfaction in people with insomnia complaints. [https://doi.org/10.1111/j.1479-8425.2006.00193.x]

---

## Saffron (Crocus sativus)
URL: https://nutridex.info/s/saffron
Category: Sleep & Mood
Evidence: Moderate — Several controlled trials; effects real but modest or context-dependent.
Costly spice with antidepressant evidence.

Quick answer: Saffron is used for mild–moderate depression. NutriDex grades the human evidence as moderate — Several controlled trials; effects real but modest or context-dependent. Based on 20 cited human studies (20 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Saffron's carotenoids (crocin) and safranal appear to modulate serotonin. Multiple RCTs and meta-analyses find that 30 mg/day reduces symptoms of mild-to-moderate depression, in some trials comparably to low-dose SSRIs, with fewer side effects. It also shows promise for anxiety and PMS. Most trials are small and short, so it is best viewed as a complementary, not primary, treatment.

Benefits / uses: Mild–moderate depression; Anxiety; Possible PMS relief.
Active compounds: Crocin; Safranal.
Dose: 30 mg/day standardized extract.
Safety: Safe at supplement doses. Very high doses (>5 g) are toxic. Avoid in pregnancy.

Cited studies (20):
  - Effect of Saffron Versus Selective Serotonin Reuptake Inhibitors (SSRIs) in Treatment of Depression and Anxiety: A Meta-analysis of Randomized Controlled Trials, Nutrition reviews (2025) — Across 8 RCTs, saffron showed a nonsignificant difference from SSRIs in reducing depressive and anxiety symptoms, with fewer adverse events, supporting it as a potential SSRI alternative. [https://pubmed.ncbi.nlm.nih.gov/38913392/]
  - New horizons for the study of saffron (Crocus sativus L.) and its active ingredients in the management of neurological and psychiatric disorders: A systematic review of clinical evidence and mechanisms, Phytotherapy research : PTR (2024) — Pooling 46 RCTs (4-48 weeks), saffron was more effective than placebo for depression (effect size -4.26) and anxiety (effect size -3.75), with additional benefits across cognition and other psychiatric outcomes. [https://pubmed.ncbi.nlm.nih.gov/38424688/]
  - Effects of Crocus sativus on glycemic control and cardiometabolic parameters among patients with metabolic syndrome and related disorders: a systematic review and meta-analysis of randomized controlled trials, Nutrition & metabolism (2024) — In RCTs of patients with metabolic syndrome and related disorders, Crocus sativus supplementation significantly improved glycemic control (fasting glucose, HbA1c) and cardiometabolic parameters versus control. [https://pubmed.ncbi.nlm.nih.gov/38796446/]
  - Effect of Crocus sativus L. (saffron) and crocin in the treatment of patients with type-2 diabetes mellitus: A systematic review and meta-analysis, Journal of ethnopharmacology (2024) — Systematic review and meta-analysis found saffron/crocin added to standard antidiabetic therapy improved metabolic profile in type-2 diabetes patients versus control. [https://pubmed.ncbi.nlm.nih.gov/37778521/]
  - Effect of Saffron (Crocus sativus) Supplementation on Oxidative Stress, Inflammatory Indices, and Renal and Liver Function Parameters in Patients With Type 2 Diabetes Mellitus: A GRADE-Assessed Systematic Review and Meta-analysis of Randomized Clinical Trials, Nutrition reviews (2025) — GRADE-assessed meta-analysis of RCTs found saffron supplementation reduced oxidative stress and inflammatory markers in type 2 diabetes patients, with no adverse effect on renal or liver function. [https://pubmed.ncbi.nlm.nih.gov/39657222/]
  - The Effects of Crocus sativus (Saffron) on ADHD: A Systematic Review, Journal of attention disorders (2024) — Systematic review of 4 clinical trials (118 children/adolescents) found saffron effective for ADHD symptoms either as monotherapy or adjuvant to methylphenidate, with an acceptable safety profile. [https://pubmed.ncbi.nlm.nih.gov/37864351/]
  - The effect of saffron supplementation on liver and kidney function, blood glucose and pressure in patients with diabetes and prediabetes: A grade assessed systematic review and meta-analysis of randomized controlled trials, Prostaglandins & other lipid mediators (2025) — GRADE-assessed meta-analysis of 13 RCTs in diabetes/prediabetes: saffron significantly lowered systolic BP (SMD -0.57, high certainty), fasting glucose (SMD -0.57, low certainty) and AST (SMD -0.49, low certainty); no significant effect on ALT, DBP or renal markers. Authors note effect sizes were not clinically important. [https://pubmed.ncbi.nlm.nih.gov/39818282/]
  - Effects of saffron supplementation on improving sleep quality: a meta-analysis of randomized controlled trials, Sleep medicine (2022) — Meta-analysis of RCTs found saffron supplementation significantly improved sleep quality versus placebo (PSQI MD -2.14, 95% CI -2.86 to -1.42; ISI MD -2.63), with best results around 100 mg/day. [https://pubmed.ncbi.nlm.nih.gov/35325766/]
  - Saffron for mild cognitive impairment and dementia: a systematic review and meta-analysis of randomised clinical trials, BMC complementary medicine and therapies (2020) — Systematic review and meta-analysis of 4 RCTs (203 patients) found saffron significantly improved cognition (ADAS-cog, CDR-SB) versus placebo in Alzheimer's disease and mild cognitive impairment, and was comparable to conventional drugs, though evidence remained limited. [https://pubmed.ncbi.nlm.nih.gov/33167948/]
  - The effects of saffron supplementation on cardiovascular risk factors in adults: A systematic review and dose-response meta-analysis, Frontiers in nutrition (2022) — Dose-response meta-analysis of 32 RCTs (n=1674): saffron significantly reduced triglycerides (-8.81 mg/dl), total cholesterol (-6.87 mg/dl), LDL (-6.71 mg/dl), fasting glucose (-7.59 mg/dl), HbA1c (-0.18%), HOMA-IR (-0.49), systolic BP (-3.42 mmHg), TNF-alpha and waist circumference, and increased total antioxidant capacity. [https://pubmed.ncbi.nlm.nih.gov/36570145/]
  - Effects of saffron (Crocus sativus) on sexual dysfunction among men and women: A systematic review and meta-analysis, Avicenna journal of phytomedicine (2019) — Meta-analysis of 5 trials (173 participants) found saffron produced a statistically significant positive effect on sexual dysfunction overall (standardized mean difference 0.811, 95% CI 0.356-1.265), with effects varying by sexual-function dimension. [https://pubmed.ncbi.nlm.nih.gov/31516855/]
  - Saffron (Crocus sativus L.) and major depressive disorder: a meta-analysis of randomized clinical trials, Journal of integrative medicine (2013) — Significantly reduced depressive symptoms vs placebo. [https://pubmed.ncbi.nlm.nih.gov/24299602/]
  - Saffron therapy for the ongoing treatment of age-related macular degeneration, BMJ open ophthalmology (2024) — In an open-label 12-month extension of ~93 adults over 50 with mild/moderate AMD, ongoing oral saffron 20 mg/day was associated with sustained modest improvement in retinal/visual function. [https://pubmed.ncbi.nlm.nih.gov/38485112/]
  - Effect of a saffron extract on sleep quality in adults with moderate insomnia: A decentralized, randomized, double-blind, placebo-controlled trial, Sleep medicine: X (2025) — In a 4-week, 3-arm, double-blind RCT of 165 adults with moderate insomnia, saffron extract (20 and 30 mg/day) significantly reduced insomnia severity and improved sleep quality versus placebo, with a small-to-moderate effect and reduced perceived stress. [https://pubmed.ncbi.nlm.nih.gov/40698027/]
  - An Examination into the Effects of a Saffron Extract (Affron) on Mood and General Wellbeing in Adults Experiencing Low Mood: A Randomized, Double-Blind, Placebo-Controlled Trial, The Journal of nutrition (2025) — 12-week double-blind RCT in 202 adults with subclinical depressive symptoms found 28 mg/day saffron extract (affron) produced a significantly greater reduction in DASS-21 depression scores than placebo, with improvements emerging by week 5. [https://pubmed.ncbi.nlm.nih.gov/40414301/]
  - Effect of saffron extract supplementation on mood in healthy adults with subclinical symptoms of depression: a randomized, double-blind placebo-controlled study, The American journal of clinical nutrition (2025) — 6-week double-blind RCT in 51 healthy adults with subclinical depression found saffron did not significantly improve the primary combined depression/anxiety/fatigue outcome, with only a secondary self-perceived mental-health benefit (SF-12 53.8 vs 44.6; P=0.04). [https://pubmed.ncbi.nlm.nih.gov/41047129/]
  - Saffron Effectiveness to Alleviate Depression Symptoms and Cortisol Level of Medical Students with Mild–Moderate Depression: A Randomized Controlled Trial, Journal of Pharmacology and Pharmacotherapeutics (2025) — 8-week double-blind RCT in 56 medical students with mild-moderate depression found 30 mg/day saffron significantly lowered HDRS scores vs placebo at week 8 (10.5 vs 18; p<0.001), with no significant change in cortisol. [https://journals.sagepub.com/doi/10.1177/0976500X251399510]
  - Comparison of Saffron versus Fluoxetine in Treatment of Mild to Moderate Postpartum Depression: A Double-Blind, Randomized Clinical Trial, Pharmacopsychiatry (2017) — Double-blind RCT in mild-to-moderate postpartum depression: saffron 30 mg/day was comparable to fluoxetine 20 mg/day over 6 weeks on HDRS, with complete response in 40.6% (saffron) vs 50% (fluoxetine), non-significant difference, and similar adverse-event rates (underpowered preliminary trial). [https://pubmed.ncbi.nlm.nih.gov/27595298/]
  - Saffron (Crocus sativus) for depression: a systematic review of clinical studies and examination of underlying antidepressant mechanisms of action, Human psychopharmacology (2014) — Comparable to antidepressants in head-to-head trials. [https://pubmed.ncbi.nlm.nih.gov/25384672/]
  - Crocus sativus L. (saffron) in the treatment of premenstrual syndrome: a double-blind, randomised and placebo-controlled trial, BJOG : an international journal of obstetrics and gynaecology (2008) — Reduced PMS symptoms vs placebo. [https://pubmed.ncbi.nlm.nih.gov/18271889/]

---

## Panax Ginseng (Panax ginseng)
URL: https://nutridex.info/s/ginseng
Category: TCM Herb, Adaptogen, Nootropic
Evidence: Preliminary — Early or small human trials; promising but not yet conclusive.
Traditional energy and cognition adaptogen.

Quick answer: Panax Ginseng is used for fatigue reduction. NutriDex grades the human evidence as preliminary — Early or small human trials; promising but not yet conclusive. Based on 16 cited human studies (16 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Panax (Asian) ginseng contains ginsenosides with adaptogenic and immunomodulating activity. Small trials suggest reduced fatigue (including cancer-related fatigue), modest cognitive improvements, and possible immune benefits. Results are inconsistent and many trials are small or low-quality, so the overall evidence remains preliminary. American ginseng (P. quinquefolius) has separate cold-prevention data.

Benefits / uses: Fatigue reduction; Cognitive performance; Immune support; Possible glucose effects.
Active compounds: Ginsenosides.
Dose: 200–400 mg/day standardized extract.
Safety: Generally safe short-term. Insomnia, headache. Many drug interactions; avoid with anticoagulants and in pregnancy.

Cited studies (16):
  - Efficacy of Phytotherapy for Cancer-Related Fatigue: A Systematic Review and Meta-Analysis of Randomized Controlled Trials, Diseases (Basel, Switzerland) (2026) — In this 2026 systematic review/meta-analysis of phytotherapy for cancer-related fatigue, the Panax ginseng subgroup (4 trials, incl. Guglielmo 2024) showed no significant benefit vs placebo (SMD = 0.22; 95% CI -0.11 to 0.53; I2 = 12.1%). [https://pmc.ncbi.nlm.nih.gov/articles/PMC12939211/]
  - Effects of Ginseng on Cognitive Function: A Systematic Review and Meta-Analysis, Phytotherapy research : PTR (2024) — Systematic review/meta-analysis of 15 RCTs (671 participants). Ginseng significantly improved memory (SMD 0.19, 95% CI 0.02-0.36; p<0.05), with a larger effect at high doses (SMD 0.33, 95% CI 0.04-0.61). No significant benefit on overall cognition, attention, or executive function. [https://pubmed.ncbi.nlm.nih.gov/39474788/]
  - Efficacy of ginseng supplements on disease-related fatigue: A systematic review and meta-analysis, Medicine (2022) — Meta-analysis of 12 RCTs (n=1,298) found ginseng supplements significantly reduced disease-related fatigue (SMD = 0.33; 95% CI 0.22-0.44), with effects described as time- and dose-dependent. [https://pmc.ncbi.nlm.nih.gov/articles/PMC9239648/]
  - The effect of ginseng (genus Panax) on blood pressure: a systematic review and meta-analysis of randomized controlled clinical trials, Journal of human hypertension (2016) — Systematic review and meta-analysis of 17 RCTs (1,381 participants) found ginseng had no significant effect on systolic or diastolic blood pressure or mean arterial pressure, indicating a neutral vascular effect. [https://pubmed.ncbi.nlm.nih.gov/27074879/]
  - Ginseng for managing menopausal woman's health: A systematic review of double-blind, randomized, placebo-controlled trials, Medicine (2016) — Systematic review of 10 double-blind placebo-controlled RCTs found positive evidence for ginseng/Korean red ginseng on sexual function and arousal in menopausal women, but no significant effect on hot flash frequency, hormones, or endometrial thickness (low-certainty evidence). [https://pubmed.ncbi.nlm.nih.gov/27661038/]
  - Ginseng for cognition, Cochrane Database of Systematic Reviews (2010) — Limited evidence for cognitive enhancement. [https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD007769.pub2/full]
  - North American (Panax quinquefolius) and Asian Ginseng (Panax ginseng) Preparations for Prevention of the Common Cold in Healthy Adults: A Systematic Review, Evidence-based complementary and alternative medicine : eCAM (2011) — Systematic review of 5 RCTs (747 participants) of North American/Asian ginseng for the common cold found only a non-significant trend toward lower incidence (RR 0.70, 95% CI 0.48-1.02) but a significant shortening of cold/respiratory illness duration by about 6.2 days; evidence judged insufficient. [https://pubmed.ncbi.nlm.nih.gov/19592479/]
  - The effect of ginseng (the genus panax) on glycemic control: a systematic review and meta-analysis of randomized controlled clinical trials, PloS one (2014) — Meta-analysis of 16 RCTs (>=30 days). Ginseng modestly but significantly lowered fasting blood glucose vs control (MD -0.31 mmol/L, 95% CI -0.59 to -0.03; p=0.03) in people with and without diabetes; no significant overall effect on fasting insulin, HbA1c, or HOMA-IR. [https://pubmed.ncbi.nlm.nih.gov/25265315/]
  - Ginseng for Erectile Dysfunction: A Cochrane Systematic Review, The world journal of men's health (2022) — Cochrane review of 9 RCTs found ginseng produced only a trivial improvement in erectile function vs placebo (IIEF mean difference 3.52 points, 95% CI 1.79-5.25; low-certainty evidence), though men reported greater ability to have intercourse (RR 2.55). [https://pubmed.ncbi.nlm.nih.gov/34169686/]
  - Effects of Ginseng on Cancer-Related Fatigue: A Systematic Review and Meta-analysis of Randomized Controlled Trials, Cancer nursing (2023) — Meta-analysis of 7 RCTs in cancer patients found ginseng significantly reduced cancer-related fatigue (SMD -0.21) and improved physical (SMD 0.25) and emotional (SMD 0.20) well-being. [https://pubmed.ncbi.nlm.nih.gov/35184068/]
  - The Efficacy of Ginseng (Panax) on Human Prediabetes and Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis, Nutrients (2022) — Meta-analysis of 20 RCTs in prediabetes/type 2 diabetes found ginseng supplementation significantly reduced fasting plasma glucose, total cholesterol, IL-6, and HOMA-IR (insulin resistance). [https://pubmed.ncbi.nlm.nih.gov/35745129/]
  - Efficacy of ginseng supplements on disease-related fatigue: A systematic review and meta-analysis, Medicine (2022) — Meta-analysis of 12 RCTs (1,298 participants) found ginseng supplements significantly reduced disease-related fatigue (SMD -0.33, 95% CI -0.44 to -0.22). [https://pubmed.ncbi.nlm.nih.gov/35776997/]
  - Global deregulation of ginseng products may be a safety hazard to warfarin takers: solid evidence of ginseng-warfarin interaction, Scientific Reports (2017) — Mechanistic study reported solid evidence of a ginseng-warfarin interaction, with ginsenosides producing dose- and time-dependent antagonism of warfarin's anticoagulation in rats via induction of hepatic CYP2C9/3A4 and restoration of clotting factors, flagging a safety hazard for warfarin users. [https://www.nature.com/articles/s41598-017-05825-9]
  - Wisconsin Ginseng (Panax quinquefolius) to improve cancer-related fatigue: a randomized, double-blind trial, N07C2, Journal of the National Cancer Institute (2013) — American ginseng reduced cancer-related fatigue. [https://pubmed.ncbi.nlm.nih.gov/23853057/]
  - Single doses of Panax ginseng (G115) reduce blood glucose levels and improve cognitive performance during sustained mental activity, Journal of psychopharmacology (Oxford, England) (2005) — Improved cognitive performance and blunted glucose response. [https://pubmed.ncbi.nlm.nih.gov/15982990/]
  - Asian Ginseng: Usefulness and Safety, NIH National Center for Complementary and Integrative Health (2025) — NIH NCCIH states overall evidence for Asian ginseng's health benefits (cognition, diabetes, fatigue) is inconclusive, that most research shows no improvement in athletic performance, and that short-term oral use up to 6 months appears safe, with insomnia as the most common side effect and rare reports of liver damage. [https://www.nccih.nih.gov/health/asian-ginseng]

---

## 5-HTP
URL: https://nutridex.info/s/fivehtp
Category: Sleep & Mood
Evidence: Preliminary — Early or small human trials; promising but not yet conclusive.
Serotonin precursor — promising but use with caution.

Quick answer: 5-HTP is used for mood support. NutriDex grades the human evidence as preliminary — Early or small human trials; promising but not yet conclusive. Based on 15 cited human studies (15 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

5-HTP is the direct precursor to serotonin and crosses the blood-brain barrier. Small early trials suggested antidepressant and appetite-suppressing effects, but the evidence base is thin and dated, and study quality is poor. Its biggest concern is interaction risk: combined with SSRIs/MAOIs it can cause dangerous serotonin syndrome. Use only with medical guidance.

Benefits / uses: Mood support; Appetite/satiety; Possible sleep aid.
Active compounds: 5-hydroxytryptophan.
Dose: 50–300 mg/day; start low. Do NOT combine with antidepressants.
Safety: GI upset common. Serious serotonin-syndrome risk with serotonergic drugs. Historic EMS concern from contamination.

Cited studies (15):
  - Effects of 5-hydroxytryptophan on distinct types of depression: a systematic review and meta-analysis, Nutrition reviews (2020) — Systematic review/meta-analysis (13 studies; 7 pooled) found 5-HTP better than placebo for depression, with a remission rate of 0.65 (95% CI 0.55-0.78) and large effect (Hedges g 1.11), but flagged methodological limitations. [https://pubmed.ncbi.nlm.nih.gov/31504850/]
  - Tryptophan and 5-hydroxytryptophan for depression, The Cochrane database of systematic reviews (2001) — Limited evidence of antidepressant effect; quality too low to be sure. [https://pubmed.ncbi.nlm.nih.gov/11687048/]
  - Tryptophan and 5-hydroxytryptophan for depression, The Cochrane database of systematic reviews (2002) — Cochrane review of tryptophan and 5-HTP for depression. Of 108 trials, only 2 (64 patients) met quality criteria. These favored 5-HTP/tryptophan over placebo for alleviating depression (Peto OR 4.10, 95% CI 1.28-13.15; NNT 2.78), but evidence judged insufficient quality to be conclusive; clinical usefulness deemed limited given proven safe alternatives and unresolved eosinophilia-myalgia syndrome concern. [https://pubmed.ncbi.nlm.nih.gov/11869656/]
  - The impact of 5-hydroxytryptophan supplementation on sleep quality and gut microbiota composition in older adults: A randomized controlled trial, Clinical nutrition (Edinburgh, Scotland) (2024) — In a 12-week single-blind RCT of 30 older adults (~66 y), 100 mg/day 5-HTP modestly improved selected sleep-quality components and gut microbiota composition, most notably in poor sleepers. [https://pubmed.ncbi.nlm.nih.gov/38309227/]
  - The Impact of 5-Hydroxytryptophan Supplementation on Cognitive Function and Mood in Singapore Older Adults: A Randomized Controlled Trial, Nutrients (2025) — In a 12-week single-blind RCT of 30 Singaporean older adults (~66 y), 100 mg/day 5-HTP did not significantly improve cognitive function or mood versus control. [https://pmc.ncbi.nlm.nih.gov/articles/PMC12430700/]
  - The Impact of 5-Hydroxytryptophan Supplementation on Cognitive Function and Mood in Singapore Older Adults: A Randomized Controlled Trial, Nutrients (2025) — 12-week single-blind RCT, 30 Singaporean older adults (66±3 y), 100 mg/day 5-HTP vs control. 5-HTP group significantly improved global cognition (MoCA 26.6 to 27.6, p<0.05), raised serum serotonin, and reduced depression scores (GDS 1.2 to 0.7, p<0.05). No effect on anxiety (GAI) or amyloid-beta/GABA biomarkers. Preliminary; small sample and short duration. [https://pubmed.ncbi.nlm.nih.gov/40944161/]
  - Tryptophan-enriched diet or 5-hydroxytryptophan supplementation given in a randomized controlled trial impacts social cognition on a neural and behavioral level, Scientific reports (2021) — In a randomized controlled trial, acute 5-HTP supplementation (vs tryptophan-enriched diet and placebo) altered social cognition at neural and behavioral levels in healthy adults. [https://pubmed.ncbi.nlm.nih.gov/34737364/]
  - Effect of 5-Hydroxytryptophan on Fatigue in Quiescent Inflammatory Bowel Disease: A Randomized Controlled Trial, Gastroenterology (2022) — In a multicenter crossover RCT of 166 patients with quiescent IBD and fatigue, 100 mg 5-HTP twice daily did not reduce fatigue better than placebo (>=20% fVAS reduction: 35.6% vs 37.6%) despite raising serum serotonin. [https://pubmed.ncbi.nlm.nih.gov/35940251/]
  - 5-Hydroxytryptophan (5-HTP): Natural Occurrence, Analysis, Biosynthesis, Biotechnology, Physiology and Toxicology, International journal of molecular sciences (2020) — Comprehensive review of 5-HTP biosynthesis, physiology and toxicology summarizing the eosinophilia-myalgia syndrome (EMS) signal and contaminant 'peak X' concerns relevant to supplement safety. [https://pmc.ncbi.nlm.nih.gov/articles/PMC7796270/]
  - Eating behavior and adherence to dietary prescriptions in obese adult subjects treated with 5-hydroxytryptophan, The American journal of clinical nutrition (1992) — Reduced appetite and promoted weight loss in a small trial. [https://pubmed.ncbi.nlm.nih.gov/1384305/]
  - Double-blind study of 5-hydroxytryptophan versus placebo in the treatment of primary fibromyalgia syndrome, The Journal of international medical research (1990) — In a 30-day double-blind RCT of 50 primary fibromyalgia patients, 100 mg 5-HTP three times daily significantly improved tender points, pain, morning stiffness, sleep, and anxiety versus placebo, with only mild transient side effects. [https://pubmed.ncbi.nlm.nih.gov/2193835/]
  - Adjunctive 5-Hydroxytryptophan Slow-Release for Treatment-Resistant Depression: Clinical and Preclinical Rationale, Trends in pharmacological sciences (2016) — Open-label pilot in 15 women with SSRI/SNRI-resistant major depression: adjunctive 5-HTP plus creatine reduced mean HAM-D from 18.6 to 7.5 at week 8 with 67% achieving >=50% response; well tolerated. [https://pubmed.ncbi.nlm.nih.gov/27692695/]
  - Eosinophilia-myalgia syndrome case-associated contaminants in commercially available 5-hydroxytryptophan, Advances in experimental medicine and biology (1999) — HPLC-MS analysis found that all 8 commercially available 5-HTP samples contained three or more 'peak X' family contaminants (MW 234 Da) of the type associated with eosinophilia-myalgia syndrome. [https://pubmed.ncbi.nlm.nih.gov/10721089/]
  - Memorial Sloan Kettering Cancer Center (5-HTP monograph) — Authoritative integrative-medicine review warns that 5-HTP can precipitate serotonin syndrome when combined with SSRIs/MAOIs/linezolid, can cause a scleroderma-like illness with carbidopa, and may produce false 5-HIAA urine test results. [https://www.mskcc.org/cancer-care/integrative-medicine/herbs/5-htp-01]
  - 5-Hydroxytryptophan: a clinically-effective serotonin precursor, Alternative medicine review : a journal of clinical therapeutic (1998) — Plausible serotonergic effects but inadequate large trials. [https://pubmed.ncbi.nlm.nih.gov/9727088/]

---

## Valerian Root (Valeriana officinalis)
URL: https://nutridex.info/s/valerian
Category: Sleep & Mood
Evidence: Mixed — Conflicting results across studies; benefit uncertain.
Traditional sleep herb with inconsistent data.

Quick answer: Valerian Root is used for possible faster sleep onset. NutriDex grades the human evidence as mixed — Conflicting results across studies; benefit uncertain. Based on 15 cited human studies (15 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Valerian is a long-used herbal sleep aid thought to act on GABA signaling. Some trials report modestly improved subjective sleep quality, but results are inconsistent and objective sleep measures often show no significant change. Variable extract standardization contributes to the mixed picture. It may help some people fall asleep but should not be expected to work reliably.

Benefits / uses: Possible faster sleep onset; Mild anxiety relief.
Active compounds: Valerenic acid; Sesquiterpenes.
Dose: 300–600 mg extract 30–60 min before bed.
Safety: Generally safe short-term. Drowsiness, vivid dreams, rare liver concerns. Avoid with sedatives/alcohol.

Cited studies (15):
  - Does valerian work for insomnia? An umbrella review of the evidence, European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology (2024) — Umbrella review of systematic reviews concluded evidence that valerian improves insomnia is weak and inconsistent, with no reliable objective benefit and frequent risk-of-bias/heterogeneity concerns. [https://pubmed.ncbi.nlm.nih.gov/38359657/]
  - Valerian for Insomnia on Subjective and Objective Sleep Parameters: a Meta-analysis of Randomized Controlled Trials, Current Sleep Medicine Reports (2023) — Meta-analysis of 21 RCTs (n=1433) found valerian's only significant objective effect was increased NREM stage-3 duration, with limited and inconsistent improvement in other sleep parameters. [https://doi.org/10.1007/s40675-023-00259-4]
  - Valerian for Insomnia on Subjective and Objective Sleep Parameters: a Meta-analysis of Randomized Controlled Trials, Current Sleep Medicine Reports (2023) — A meta-analysis of 21 randomized controlled trials (1,433 participants) found valerian produced small-to-moderate improvements in subjective sleep quality and self-reported duration, but the only significant objective effect was an increase in NREM stage 3 sleep length, with no significant effect on objective sleep latency. [https://link.springer.com/article/10.1007/s40675-023-00259-4]
  - Valerian Root in Treating Sleep Problems and Associated Disorders-A Systematic Review and Meta-Analysis, Journal of evidence-based integrative medicine (2020) — Systematic review/meta-analysis of 60 valerian studies concluded that whole-root preparations may improve subjective sleep quality and anxiety, while inconsistent product standardization and study quality likely explain conflicting prior results. [https://pubmed.ncbi.nlm.nih.gov/33086877/]
  - Valerian for sleep: a systematic review and meta-analysis, The American journal of medicine (2006) — Possible subjective sleep improvement; inconsistent objective data. [https://pubmed.ncbi.nlm.nih.gov/17145239/]
  - Valerian for anxiety disorders, The Cochrane database of systematic reviews (2006) — Cochrane systematic review identified only one small 4-week RCT (n=36) in generalized anxiety disorder and concluded evidence is insufficient to determine valerian's efficacy or safety for anxiety disorders. [https://pubmed.ncbi.nlm.nih.gov/17054208/]
  - Standardized Extract of Valeriana officinalis Improves Overall Sleep Quality in Human Subjects with Sleep Complaints: A Randomized, Double-Blind, Placebo-Controlled, Clinical Study, Advances in therapy (2024) — In 80 adults with sleep complaints, 8 weeks of standardized Valeriana officinalis extract significantly improved overall subjective sleep quality (PSQI) versus placebo. [https://pubmed.ncbi.nlm.nih.gov/37899385/]
  - Effects of a Valerian-Hops Extract Combination (Ze 91019) on Sleep Duration and Daytime Cognitive and Psychological Parameters in Occasional Insomnia: A Randomized Controlled Feasibility Trial, Brain and behavior (2025) — Randomized double-blind placebo-controlled feasibility trial (n=40, 21-day treatment) of a valerian-hops extract combination (Ze 91019) in occasional insomnia: significantly increased nightly sleep duration (+21.7 min/day, p=0.019; +48.7 min on shortest night) measured by Fitbit, without significant effects on daytime cognition; well tolerated. [https://pubmed.ncbi.nlm.nih.gov/40462685/]
  - Effect of a nutraceutical combination on sleep quality among people with impaired sleep: a randomised, placebo-controlled trial, Scientific reports (2024) — Randomized placebo-controlled trial (n=64, 6 weeks) of an L-theanine + lemon balm/valerian/saffron nutraceutical combination in adults with impaired sleep (PSQI>=5): no significant benefit over placebo on actigraphy sleep efficiency, total sleep time, WASO, or PSQI (all p>0.3) — a negative result tempering combination-product claims. [https://pubmed.ncbi.nlm.nih.gov/38580720/]
  - Efficacy of Valerian Extract on Sleep Quality after Coronary Artery bypass Graft Surgery: A Triple-Blind Randomized Controlled Trial, Chinese journal of integrative medicine (2021) — Triple-blind placebo-controlled RCT (n=72) in post-CABG surgery patients: 530 mg valerian root extract nightly for 30 nights significantly improved overall sleep quality, sleep latency, sleep duration, sleep efficiency and daytime dysfunction (PSQI, p<=0.025) vs placebo, with no adverse effect on coagulation (PT/PTT). [https://pubmed.ncbi.nlm.nih.gov/33420602/]
  - The effect of Valerian on the severity and frequency of hot flashes: A triple-blind randomized clinical trial, Women & health (2018) — In a triple-blind RCT of 60 postmenopausal women, valerian 530 mg twice daily for 2 months significantly reduced hot flash severity (p=.020) and frequency (p=.033) versus placebo. [https://pubmed.ncbi.nlm.nih.gov/28278010/]
  - Valerian (2020) — NIH's LiverTox database reports valerian is a very rare cause of clinically apparent, idiosyncratic liver injury, with onset typically 3–12 weeks after starting and a hepatocellular or mixed enzyme pattern. [https://www.ncbi.nlm.nih.gov/books/NBK548255/]
  - Valerian: Usefulness and Safety, NIH National Center for Complementary and Integrative Health (2025) — NIH's National Center for Complementary and Integrative Health states clinical evidence for valerian in treating insomnia is inconclusive, and notes the American Academy of Sleep Medicine's 2017 guideline recommends against using valerian for chronic insomnia in adults. [https://www.nccih.nih.gov/health/valerian]
  - Effectiveness of Valerian on insomnia: a meta-analysis of randomized placebo-controlled trials, Sleep medicine (2010) — Mixed results across trials of varying quality. [https://pubmed.ncbi.nlm.nih.gov/20347389/]
  - A randomized clinical trial of valerian fails to improve self-reported, polysomnographic, and actigraphic sleep in older women with insomnia, Sleep medicine (2009) — No objective sleep benefit in older women with insomnia. [https://pubmed.ncbi.nlm.nih.gov/18482867/]

---

## Ginkgo Biloba (Ginkgo biloba)
URL: https://nutridex.info/s/ginkgo
Category: TCM Herb, Nootropic, Longevity
Evidence: Mixed — Conflicting results across studies; benefit uncertain.
Ancient-tree extract marketed for memory.

Quick answer: Ginkgo Biloba is used for possible cognition in dementia. NutriDex grades the human evidence as mixed — Conflicting results across studies; benefit uncertain. Based on 17 cited human studies (17 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Ginkgo extract improves microcirculation and has antioxidant effects. Evidence is genuinely mixed: it does NOT prevent cognitive decline or dementia in healthy older adults (large GEM trial), but some trials suggest modest symptomatic benefit in existing dementia. Claims for memory enhancement in healthy people are largely unsupported.

Benefits / uses: Possible cognition in dementia; Circulation; Tinnitus (weak).
Active compounds: Flavone glycosides; Terpene lactones.
Dose: 120–240 mg/day standardized extract (EGb 761).
Safety: Generally safe. Increases bleeding risk — stop before surgery and avoid with anticoagulants.

Cited studies (17):
  - Effectiveness and safety of ginkgo biloba preparations in the treatment of Alzheimer's disease: A systematic review and meta-analysis, Frontiers in aging neuroscience (2023) — In a meta-analysis of 18 RCTs (1,642 patients with Alzheimer's disease), Ginkgo biloba added to donepezil improved MMSE by a mean of 3.02 points (95% CI 2.14-3.89) versus donepezil alone, with similar adverse-event rates. [https://pubmed.ncbi.nlm.nih.gov/36960422/]
  - Ginkgo biloba extract EGb 761 is safe and effective in the treatment of mild dementia - a meta-analysis of patient subgroups in randomised controlled trials, The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry (2025) — Pooled data from 4 RCTs (782 patients with mild dementia) showed 240 mg/day EGb 761 was significantly superior to placebo in cognition (p=0.04), global assessment (p=0.01), activities of daily living (p=0.01) and quality of life (p=0.02), with adverse events comparable to placebo. [https://pubmed.ncbi.nlm.nih.gov/39895346/]
  - Ginkgo biloba extract EGb 761 in patients with dementia and a history of cerebral infarction—meta-analysis of pooled data from randomised clinical trials, Frontiers in Neurology (2026) — Meta-analysis of 4 placebo-controlled RCTs (488 patients with dementia and prior cerebral infarction) found 240 mg/day EGb 761 modestly improved cognition (MD -2.42, p=0.047), activities of daily living (SMD -0.65) and global assessment (SMD -0.79), with safety comparable to placebo. [https://doi.org/10.3389/fneur.2025.1658064]
  - Ginkgo biloba: A Leaf of Hope in the Fight against Alzheimer's Dementia: Clinical Trial Systematic Review, Antioxidants (Basel, Switzerland) (2024) — Systematic review of clinical trials concluded Ginkgo biloba (notably EGb 761) shows neuroprotective, anti-inflammatory and antioxidant effects and cognitive/functional benefit in Alzheimer's dementia, especially in patients with neuropsychiatric symptoms. [https://pubmed.ncbi.nlm.nih.gov/38929090/]
  - Ginkgo biloba extract EGb 761 in patients with dementia and a history of cerebral infarction-meta-analysis of pooled data from randomised clinical trials, Frontiers in neurology (2025) — Pooled analysis of 4 RCTs (n=488) in mild-to-moderate dementia patients with neuroimaging-confirmed prior cerebral infarction: EGb 761 240 mg/day significantly improved cognition (p=0.047), activities of daily living (p=0.023) and global clinical impression (p=0.037) vs placebo, with adverse-event rates similar to placebo. [https://pubmed.ncbi.nlm.nih.gov/41908799/]
  - Ginkgo biloba for tinnitus, The Cochrane database of systematic reviews (2022) — A Cochrane systematic review of 12 RCTs (1,915 participants) found that Ginkgo biloba probably has little or no effect on tinnitus severity, loudness or tinnitus-related quality of life when tinnitus is the primary complaint, with no clear evidence of benefit over placebo. [https://pubmed.ncbi.nlm.nih.gov/36383762/]
  - Treatment effects of Ginkgo biloba extract EGb 761® on the spectrum of behavioral and psychological symptoms of dementia: meta-analysis of randomized controlled trials, International psychogeriatrics (2018) — Meta-analysis of 4 RCTs (n=1,628) in dementia patients with clinically significant neuropsychiatric symptoms (NPI >=6): EGb 761 240 mg/day for 22-24 wk significantly improved total NPI and 10 of 12 individual behavioral/psychological symptoms plus caregiver distress vs placebo (except psychotic-like features). [https://pubmed.ncbi.nlm.nih.gov/28931444/]
  - Ginkgo biloba for the treatment of tinnitus, Medwave (2018) — GRADE-based summary of 3 systematic reviews (4 RCTs): Ginkgo biloba probably does NOT decrease tinnitus severity or intensity, nor improve quality of life - evidence does not support use for tinnitus. [https://pubmed.ncbi.nlm.nih.gov/30339143/]
  - Effects of Ginkgo biloba in dementia: systematic review and meta-analysis, BMC geriatrics (2010) — Modest symptomatic benefit in existing dementia. [https://pubmed.ncbi.nlm.nih.gov/20236541/]
  - Ginkgo biloba for intermittent claudication, The Cochrane database of systematic reviews (2013) — A Cochrane systematic review of 14 trials (739 participants, 11 placebo-controlled trials in 477) found Ginkgo biloba increased pain-free walking distance by only about 64.5 metres versus placebo, concluding there is no clinically significant benefit for peripheral arterial disease. [https://pubmed.ncbi.nlm.nih.gov/23744597/]
  - Efficacy and tolerability of Ginkgo biloba extract EGb 761® in dementia: a systematic review and meta-analysis of randomized placebo-controlled trials, Clinical interventions in aging (2014) — Meta-analysis of 7 RCTs (n=2,625) of EGb 761 120-240 mg/day for 22-26 wk in established dementia: significant benefit over placebo for cognition (SMD -0.52, 95% CI -0.98 to -0.05), activities of daily living (SMD -0.44, 95% CI -0.68 to -0.19) and global rating (SMD -0.52); tolerability comparable to placebo. [https://pubmed.ncbi.nlm.nih.gov/25506211/]
  - Ginkgo biloba extract EGb 761(®) improves cognition and overall condition after ischemic stroke: Results from a pilot randomized trial, Frontiers in pharmacology (2023) — In a multicenter open-label pilot RCT of patients after acute ischemic stroke (China, 7 centers), 240 mg/day EGb 761 added to standard care promoted greater MoCA cognitive improvement at 6 months versus standard care alone. [https://pubmed.ncbi.nlm.nih.gov/37063270/]
  - Ginkgo: Usefulness and Safety, NIH National Center for Complementary and Integrative Health (2021) — The U.S. National Center for Complementary and Integrative Health states ginkgo has not been shown to prevent or slow dementia and its cognitive benefit in healthy people is uncertain, and warns it may increase bleeding risk, especially with anticoagulants such as warfarin. [https://www.nccih.nih.gov/health/ginkgo]
  - Ginkgo biloba for preventing cognitive decline in older adults: a randomized trial, JAMA (2009) — Pre-specified GEM analysis (n=3,069, 6.1y): G. biloba 120 mg twice daily did NOT slow cognitive decline in any domain (memory, attention, visuospatial, language, executive) vs placebo; no benefit even in MCI subgroup. Establishes lack of efficacy for primary cognitive-decline prevention. [https://pubmed.ncbi.nlm.nih.gov/20040554/]
  - Ginkgo biloba Extract Prescriptions Are Associated with Slower Progression of Dementia Severity-Analysis of Longitudinal Real-World Data, Brain sciences (2024) — Retrospective real-world cohort (n=4765 dementia patients, up to 10-year follow-up) found Ginkgo biloba extract prescription associated with significantly lower risk of dementia-severity progression (HR 0.50; 95% CI 0.27-0.95; cumulative progression 12.7% vs 22.1%). [https://pubmed.ncbi.nlm.nih.gov/39851380/]
  - Ginkgo biloba for prevention of dementia: a randomized controlled trial, JAMA (2008) — No reduction in dementia incidence in healthy older adults. [https://pubmed.ncbi.nlm.nih.gov/19017911/]
  - Ginkgo for memory enhancement: a randomized controlled trial, JAMA (2002) — No memory benefit in healthy adults. [https://pubmed.ncbi.nlm.nih.gov/12186600/]

---

## Tongkat Ali (Eurycoma longifolia)
URL: https://nutridex.info/s/tongkat
Category: Adaptogen, Performance
Evidence: Preliminary — Early or small human trials; promising but not yet conclusive.
Southeast-Asian root studied for stress and vitality.

Quick answer: Tongkat Ali is used for stress hormone balance. NutriDex grades the human evidence as preliminary — Early or small human trials; promising but not yet conclusive. Based on 15 cited human studies (15 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Tongkat Ali (longjack) is traditionally used for vitality. Small trials report reduced stress hormones and improved tension/wellbeing scores, with some evidence for raised testosterone in deficient or stressed men and improved libido. The literature is small and partly industry-funded, so it remains preliminary. Heavy-metal contamination has been reported in some products — source carefully.

Benefits / uses: Stress hormone balance; Possible testosterone support; Wellbeing; Libido.
Active compounds: Quassinoids (eurycomanone).
Dose: 200–400 mg/day standardized extract.
Safety: Limited long-term data. Insomnia, restlessness possible. Source-quality concerns (contaminants).

Cited studies (15):
  - Eurycoma longifolia (Jack) Improves Serum Total Testosterone in Men: A Systematic Review and Meta-Analysis of Clinical Trials, Medicina (Kaunas, Lithuania) (2022) — Systematic review/meta-analysis of 5 RCTs found Eurycoma longifolia significantly raised serum total testosterone in men (SMD 1.35, 95% CI 0.57-2.14), strongest in hypogonadal subgroups. [https://pmc.ncbi.nlm.nih.gov/articles/PMC9415500/]
  - Eurycoma longifolia (Jack) Improves Serum Total Testosterone in Men: A Systematic Review and Meta-Analysis of Clinical Trials, Medicina (Kaunas, Lithuania) (2022) — Systematic review of 9 studies (5 RCTs in meta-analysis) of Eurycoma longifolia monotherapy in men. Pooled random-effects analysis showed a significant increase in serum total testosterone (SMD = 1.352, 95% CI 0.565 to 2.138, p = 0.001), with the effect confirmed in the hypogonadism subgroup. Concludes E. longifolia is a promising, safe option for enhancing testosterone, particularly in hypogonadal men. [https://pubmed.ncbi.nlm.nih.gov/36013514/]
  - The Effect of Tongkat Ali Supplementation on Body Composition in Exercise-Trained Males and Females, Applied Sciences (2024) — 4-week double-blind RCT in 33 exercise-trained men and women found 400 mg/day tongkat ali did NOT change body composition, handgrip strength, mood, sleep, cortisol, or free testosterone versus placebo (null result in already-trained adults). [https://doi.org/10.3390/app14114372]
  - Effects of Eurycoma longifolia Jack standardised water extract (Physta) on well-being of perimenopausal and postmenopausal women: protocol for a randomised, double-blinded, placebo-controlled, parallel group study, BMJ open (2023) — Registered protocol for a 12-week randomized, double-blind, placebo-controlled trial of standardized water extract (Physta) 50 or 100 mg/day in 150 peri-/postmenopausal women aged 40-55, with mood, quality of life, fatigue, sleep, and reproductive hormone outcomes. [https://pmc.ncbi.nlm.nih.gov/articles/PMC10626840/]
  - Effect of Eurycoma longifolia standardised aqueous root extract-Physta(®) on testosterone levels and quality of life in ageing male subjects: a randomised, double-blind, placebo-controlled multicentre study, Food & nutrition research (2021) — 12-week double-blind RCT in 105 ageing men (50-70y) with low testosterone found Physta standardised root extract (100/200 mg/day) increased testosterone and quality of life and lowered cortisol vs placebo. [https://pubmed.ncbi.nlm.nih.gov/34262417/]
  - A 6-month, double-blind, placebo-controlled, randomized trial to evaluate the effect of Eurycoma longifolia (Tongkat Ali) and concurrent training on erectile function and testosterone levels in androgen deficiency of aging males (ADAM), Maturitas (2021) — 6-month double-blind placebo-controlled RCT in androgen-deficient ageing men found E. longifolia plus concurrent training improved erectile function and raised total testosterone most. [https://pubmed.ncbi.nlm.nih.gov/33541567/]
  - Tongkat Ali (2024) — NIH LiverTox safety monograph notes isolated reports of clinically apparent liver injury in young men taking tongkat ali, often in multi-ingredient supplements. [https://www.ncbi.nlm.nih.gov/books/NBK609015/]
  - Immunomodulation in Middle-Aged Humans Via the Ingestion of Physta® Standardized Root Water Extract of Eurycoma longifolia Jack--A Randomized, Double-Blind, Placebo-Controlled, Parallel Study, Phytotherapy research : PTR (2016) — 4-week double-blind placebo-controlled RCT in 83 middle-aged Japanese adults found 200 mg/day Physta root extract significantly raised the Scoring of Immunological Vigor and total, naive and CD4+ T-cell counts, indicating enhanced comprehensive immunity vs placebo. [https://pubmed.ncbi.nlm.nih.gov/26816234/]
  - Efficacy and safety of Eurycoma longifolia (Physta(®)) water extract plus multivitamins on quality of life, mood and stress: a randomized placebo-controlled and parallel study, Food & nutrition research (2018) — 24-week randomized, double-blind, placebo-controlled trial in 93 moderately stressed adults (25-65 yr). E. longifolia (Physta) + multivitamins produced within-group improvements in SF-12 quality of life, POMS mood, and a 15% reduction in the physical-stress domain of the MMSQ (vs 0.7% placebo, p<0.05); between-group gains in social functioning (ages 25-45) and POMS-vigour (ages 46-65). Well tolerated. [https://pubmed.ncbi.nlm.nih.gov/30574050/]
  - Randomized Clinical Trial on the Use of PHYSTA Freeze-Dried Water Extract of Eurycoma longifolia for the Improvement of Quality of Life and Sexual Well-Being in Men, Evidence-based complementary and alternative medicine : eCAM (2012) — 12-week double-blind RCT in 109 men aged 30-55 found 300 mg/day Physta water extract improved erectile function and sexual libido (~14%), and in men with low baseline values increased semen volume (+18.2%) and sperm motility (+44.4%) vs placebo. [https://pmc.ncbi.nlm.nih.gov/articles/PMC3518798/]
  - Effect of Tongkat Ali on stress hormones and psychological mood state in moderately stressed subjects, Journal of the International Society of Sports Nutrition (2013) — 4-week placebo-controlled trial in 63 moderately stressed adults (32 men, 31 women) on 200 mg/day standardized water extract. Tongkat Ali reduced salivary cortisol (-16%), increased salivary testosterone (+37%), and improved mood: Tension -11%, Anger -12%, Confusion -15% vs placebo. [https://pubmed.ncbi.nlm.nih.gov/23705671/]
  - Phytoandrogenic properties of Eurycoma longifolia as natural alternative to testosterone replacement therapy, Andrologia (2014) — Promising for male vitality; larger trials needed. [https://pubmed.ncbi.nlm.nih.gov/24386995/]
  - Eurycoma longifolia (Tongkat Ali) supplementation enhances sleep and wake consolidation in wild-type, but not in narcoleptic mice, Sleep advances : a journal of the Sleep Research Society (2024) — Preclinical study in middle-aged mice found dietary tongkat ali extract enhanced sleep/wake consolidation and diurnal rhythms in wild-type but not narcoleptic mice. [https://pubmed.ncbi.nlm.nih.gov/39055967/]
  - Effect of Tongkat Ali on stress hormones and psychological mood state in moderately stressed subjects, Journal of the International Society of Sports Nutrition (2013) — Reduced cortisol and improved mood/stress scores. [https://pmc.ncbi.nlm.nih.gov/articles/PMC3669033/]
  - Standardised water-soluble extract of Eurycoma longifolia, Tongkat ali, as testosterone booster for managing men with late-onset hypogonadism?, Andrologia (2011) — Improved testosterone in men with late-onset hypogonadism. [https://onlinelibrary.wiley.com/doi/10.1111/j.1439-0272.2011.01168.x]

---

## Vitamin K2 (Menaquinone)
URL: https://nutridex.info/s/vitamink2
Category: Vitamin, Heart & Metabolic
Evidence: Preliminary — Early or small human trials; promising but not yet conclusive.
Directs calcium to bone, away from arteries.

Quick answer: Vitamin K2 is used for bone mineralization. NutriDex grades the human evidence as preliminary — Early or small human trials; promising but not yet conclusive. Based on 15 cited human studies (15 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Vitamin K2 activates proteins (osteocalcin, matrix Gla protein) that route calcium into bone and away from arterial walls. Observational data link higher K2 intake to less arterial calcification, and some trials show improved bone markers and reduced arterial stiffness. It is frequently paired with vitamin D. Cardiovascular-outcome evidence is still early.

Benefits / uses: Bone mineralization; Possible arterial-calcium reduction; Works with vitamin D.
Active compounds: MK-4; MK-7 (longer-acting).
Dose: 90–180 µg/day MK-7.
Safety: Safe. Interferes with warfarin — avoid if on it without medical supervision.

Cited studies (15):
  - Vitamin K supplementation and vascular calcification: a systematic review and meta-analysis of randomized controlled trials, Frontiers in nutrition (2023) — Systematic review/meta-analysis of 14 RCTs (n=1,533) found vitamin K supplementation significantly slowed progression of coronary artery calcification scores versus placebo. [https://pubmed.ncbi.nlm.nih.gov/37252246/]
  - The effect of vitamin K supplementation on cardiovascular risk factors: a systematic review and meta-analysis, Journal of nutritional science (2024) — Systematic review and meta-analysis of RCTs found vitamin K supplementation had no significant overall effect on most conventional cardiovascular risk factors, with effects largely limited to calcification markers. [https://pubmed.ncbi.nlm.nih.gov/38282652/]
  - The effect of vitamin K2 supplementation on bone turnover biochemical markers in postmenopausal osteoporosis patients: a systematic review and meta-analysis, Frontiers in endocrinology (2025) — Meta-analysis of 9 RCTs (2,570 postmenopausal osteoporosis patients) found vitamin K2 increased osteocalcin and bone-specific alkaline phosphatase, reduced undercarboxylated osteocalcin and TRAP, with a small statistically significant CTX reduction of uncertain clinical relevance. [https://pmc.ncbi.nlm.nih.gov/articles/PMC12626859/]
  - Effects of vitamin K supplementation on bone mineral density at different sites and bone metabolism in the middle-aged and elderly population, Bone & joint research (2024) — Meta-analysis/systematic review of RCTs in middle-aged and elderly adults found vitamin K (especially K2) increased lumbar spine BMD (p=0.035), raised carboxylated osteocalcin (p=0.004) and decreased uncarboxylated osteocalcin (p<0.001). [https://pmc.ncbi.nlm.nih.gov/articles/PMC11631259/]
  - Efficacy of vitamin K2 in the prevention and treatment of postmenopausal osteoporosis: A systematic review and meta-analysis of randomized controlled trials, Frontiers in public health (2022) — Systematic review/meta-analysis of 16 RCTs (n=6,425) found vitamin K2 significantly improved lumbar spine BMD and reduced fracture incidence in postmenopausal women with or at risk of osteoporosis. [https://pubmed.ncbi.nlm.nih.gov/36033779/]
  - Effect of Menaquinone-7 Supplementation on Arterial Stiffness in Chronic Hemodialysis Patients: A Multicenter Randomized Controlled Trial, Nutrients (2023) — Multicenter RCT in chronic hemodialysis patients found menaquinone-7 supplementation slowed progression of arterial stiffness versus placebo. [https://pubmed.ncbi.nlm.nih.gov/37299386/]
  - Vitamin K2 supplementation improves impaired glycemic homeostasis and insulin sensitivity for type 2 diabetes through gut microbiome and fecal metabolites, BMC medicine (2023) — Six-month double-blind RCT in 60 type 2 diabetes patients found MK-7 supplementation improved glycemic control (reductions of ~13% fasting glucose, ~28% insulin, ~7% HbA1c) and insulin sensitivity, with mechanistic links to altered gut microbiome, secondary bile acids and short-chain fatty acids. [https://pubmed.ncbi.nlm.nih.gov/37147641/]
  - Randomized Controlled Clinical Trial of the Effect of Treatment with Vitamin K2 on Vascular Calcification in Hemodialysis Patients (Trevasc-HDK), Kidney international reports (2023) — Randomized controlled trial in 178 maintenance hemodialysis patients found menaquinone-7 360 ug three times weekly over 18 months did NOT significantly slow progression of coronary artery calcification versus control (no beneficial effect on vascular calcification at the studied dose/duration). [https://pubmed.ncbi.nlm.nih.gov/37705910/]
  - Vitamin K supplementation and bone mineral density in dialysis: results of the double-blind, randomized, placebo-controlled RenaKvit trial, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association (2023) — Double-blind RCT in 123 chronic dialysis patients found 360 ug/day MK-7 over 2 years prevented lumbar spine BMD loss but accelerated BMD loss at the distal radius versus placebo. [https://pubmed.ncbi.nlm.nih.gov/36460034/]
  - Vitamin K2 and D in Patients With Aortic Valve Calcification: A Randomized Double-Blinded Clinical Trial, Circulation (2022) — Randomized double-blind multicenter trial in men with aortic valve calcification >300 AU found 720 ug MK-7 plus vitamin D over 24 months did not significantly slow aortic valve calcification progression versus placebo. [https://pubmed.ncbi.nlm.nih.gov/35465686/]
  - Vitamin K2 (menaquinone-7) increases plasma adiponectin but does not affect insulin sensitivity in postmenopausal women: a randomized controlled trial, European journal of clinical nutrition (2021) — RCT in postmenopausal women found 12 months of MK-7 increased plasma adiponectin and reduced undercarboxylated osteocalcin but did not improve insulin sensitivity. [https://pubmed.ncbi.nlm.nih.gov/33664429/]
  - Dietary vitamin K intake associates with reduced all-cause mortality in non-alcoholic fatty liver disease patients, Scientific reports (2025) — Prospective NHANES analysis of 7,857 non-alcoholic fatty liver disease patients (842 deaths over up to 180 months) found higher dietary vitamin K intake associated with lower all-cause mortality (adjusted HR 0.81 per unit increase, 95% CI 0.67-0.98, P-trend=0.028). [https://pubmed.ncbi.nlm.nih.gov/40456852/]
  - Dietary intake of menaquinone is associated with a reduced risk of coronary heart disease: the Rotterdam Study, The Journal of nutrition (2004) — Higher dietary K2 associated with less coronary calcification. [https://pubmed.ncbi.nlm.nih.gov/15514282/]
  - Menaquinone-7 supplementation improves arterial stiffness in healthy postmenopausal women. A double-blind randomised clinical trial, Thrombosis and haemostasis (2015) — Reduced arterial stiffness over 3 years. [https://pubmed.ncbi.nlm.nih.gov/25694037/]
  - Three-year low-dose menaquinone-7 supplementation helps decrease bone loss in healthy postmenopausal women, Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA (2013) — MK-7 improved bone-related markers in postmenopausal women. [https://pubmed.ncbi.nlm.nih.gov/23525894/]

---

## Astragalus (Astragalus membranaceus · Huáng Qí 黄芪)
URL: https://nutridex.info/s/astragalus
Category: TCM Herb, Gut & Immune, Adaptogen
Evidence: Preliminary — Early or small human trials; promising but not yet conclusive.
A foundational Qi-tonifying herb of Chinese medicine.

Quick answer: Astragalus is used for immune modulation. NutriDex grades the human evidence as preliminary — Early or small human trials; promising but not yet conclusive. Based on 18 cited human studies (18 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Astragalus (Huáng Qí) is one of the most important 'Qi tonics' in Traditional Chinese Medicine, used to strengthen vitality and resistance. Modern studies — largely Chinese and often of modest quality — point to immunomodulating, antioxidant, and anti-inflammatory activity. It is most studied as an adjunct to chemotherapy (possibly easing side effects) and in chronic kidney disease and heart failure, with positive but methodologically limited results. Its astragalosides have been explored for telomere biology, though human longevity evidence is weak.

Benefits / uses: Immune modulation; Anti-fatigue / adaptogenic; Adjunct in chemo & kidney care; Antioxidant.
Active compounds: Astragalosides; Polysaccharides (APS); Flavonoids.
Dose: 9–30 g dried root as decoction (traditional); 500–1,000 mg standardized extract.
Safety: Generally well tolerated. May over-stimulate immunity — caution with autoimmune disease and immunosuppressants. Possible anticoagulant interaction.

Cited studies (18):
  - Efficacy of astragalus combined with renin-angiotensin-aldosterone system blockers in the treatment of stage III diabetic nephropathy: a systematic review and meta-analysis, Renal failure (2024) — In 32 RCTs (n=2462) with stage III diabetic nephropathy, astragalus added to ACEI/ARB blockers raised the total effective rate and significantly reduced urinary protein excretion, serum creatinine, BUN and HbA1c versus blockers alone. [https://pubmed.ncbi.nlm.nih.gov/38836372/]
  - Astragalus polysaccharides combined with radiochemotherapy for cervical cancer: a systematic review and meta-analysis of randomized controlled studies, Frontiers in pharmacology (2025) — Across 9 RCTs (n=776), astragalus polysaccharides added to chemoradiotherapy improved objective response and disease control rates, Karnofsky performance status, and CD4+/CD8+ immune ratios versus chemoradiotherapy alone. [https://pmc.ncbi.nlm.nih.gov/articles/PMC12643993/]
  - Efficacy and safety of astragalus polysaccharides in patients with malignant tumors: A systematic review and meta-analysis, Naunyn-Schmiedeberg's Archives of Pharmacology (2025) — Systematic review and meta-analysis in cancer patients found astragalus polysaccharides improved clinical efficacy and immune indices as adjunct to standard antitumor therapy with a favorable safety profile. [https://doi.org/10.1007/s00210-025-04074-2]
  - Astragalus Injection Enhances the Sensitivity of Clinical Cancer Patients to Chemotherapy: A Systematic meta-Analysis, Natural Product Communications (2024) — Pooled clinical meta-analysis concluded that Astragalus injection resensitized tumors to chemotherapy drugs and improved patient quality of life across cancer patients receiving chemotherapy. [https://doi.org/10.1177/1934578X241276966]
  - Efficacy of Astragalus Membranaceus (Huang Qi) for Cancer-Related Fatigue: A Systematic Review and Meta-Analysis of Randomized Controlled Studies, Integrative cancer therapies (2025) — Across 8 RCTs of cancer patients, adding Astragalus membranaceus to control treatment significantly reduced cancer-related fatigue (SMD -1.63, 95% CI -1.90 to -1.36) and improved quality of life (SMD 0.86), though authors caution the trials were small and low quality. [https://pubmed.ncbi.nlm.nih.gov/40302232/]
  - Astragalus membranaceus formula for moderate-high risk idiopathic membranous nephropathy: A meta-analysis, Medicine (2023) — In 50 RCTs (n=3423) of moderate-to-high-risk idiopathic membranous nephropathy, adjunctive Astragalus membranaceus formulas added to supportive care or immunosuppression improved complete and partial remission rates and serum albumin and reduced proteinuria and serum creatinine versus standard therapy alone. [https://pubmed.ncbi.nlm.nih.gov/36862887/]
  - Astragalus-containing Chinese herbal medicine used with Western medicine for lupus nephritis: a systematic review and meta-analysis of randomized controlled trials, Frontiers in pharmacology (2024) — Across 14 RCTs (n=800) of lupus nephritis, astragalus-containing Chinese herbal medicine added to Western medicine improved SLEDAI scores, 24-hour proteinuria, serum creatinine and BUN, raised overall response 21% (RR 1.21), and showed lower adverse-event rates (RR 0.56) than Western medicine alone. [https://pmc.ncbi.nlm.nih.gov/articles/PMC11885490/]
  - The Efficacy and Safety of Astragalus as an Adjuvant Treatment for Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis, Journal of Integrative and Complementary Medicine (2024) — In 20 studies (n=953) of type 2 diabetes, astragalus as an adjuvant to conventional antidiabetic drugs significantly reduced fasting and postprandial plasma glucose and HbA1c versus drugs alone, while astragalus monotherapy did not significantly lower HbA1c. [https://doi.org/10.1089/jicm.2022.0767]
  - The Effect of Astragalus on Humoral and Cellular Immune Response: A Systematic Review and Meta-Analysis of Human Studies, Complementary medicine research (2023) — Meta-analysis of 19 human studies (n=1,094) found Astragalus significantly increased CD3+ T cells and the CD4/CD8 ratio and modulated cytokines (IL-2, IL-4, IL-6, IL-10, TNF-alpha, IFN-gamma), supporting immunomodulatory effects, though with substantial heterogeneity. [https://pubmed.ncbi.nlm.nih.gov/37952511/]
  - Effect of Astragalus membranaceus on left ventricular remodeling in HFrEF: a systematic review and meta-analysis, Frontiers in pharmacology (2024) — Meta-analysis of 19 RCTs (n=1,565) found Astragalus membranaceus plus conventional therapy improved LVEF (MD=5.82, 95% CI 4.61-7.03) and reduced LVEDD (MD=-4.05, 95% CI -6.09 to -2.01) without increasing adverse events (RR=0.86, 95% CI 0.25-2.96). [https://pubmed.ncbi.nlm.nih.gov/38283626/]
  - Astragalus-containing Chinese herbal medicine used with Western medicine for lupus nephritis: a systematic review and meta-analysis of randomized controlled trials, Frontiers in Pharmacology (2025) — Systematic review and meta-analysis of RCTs found Astragalus-containing Chinese herbal medicine added to Western medicine may improve outcomes in lupus nephritis, with authors noting methodological limitations of included trials. [https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2024.1395844/full]
  - Astragalus membranaceus (Huang Qi) as adjunctive therapy for diabetic kidney disease: An updated systematic review and meta-analysis, Journal of ethnopharmacology (2019) — Updated systematic review of RCTs found adjunctive astragalus preparations added to conventional therapy may reduce albuminuria, proteinuria and serum creatinine short-term in diabetic kidney disease, with adverse-event rates similar to standard care. [https://pubmed.ncbi.nlm.nih.gov/31034954/]
  - Astragalus-based Chinese herbs and platinum-based chemotherapy for advanced non-small-cell lung cancer: meta-analysis of randomized trials, Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2006) — Astragalus-based formulas may improve platinum-chemotherapy response and tolerability; trials low quality. [https://pubmed.ncbi.nlm.nih.gov/16421421/]
  - Astragalus polysaccharides improve adjuvant chemotherapy-induced fatigue for patients with early breast cancer, Scientific reports (2024) — Randomized, placebo-controlled phase 2 trial (66 stage II/III breast cancer patients on adjuvant anthracycline chemotherapy): Astragalus polysaccharide (PG2) did not significantly change the overall fatigue global score vs placebo, but reduced chemotherapy-induced fatigue, insomnia, and improved global health status particularly in the premenopausal subgroup. [https://pubmed.ncbi.nlm.nih.gov/39465324/]
  - Astragalus: Usefulness and Safety, NIH National Center for Complementary and Integrative Health (2025) — US NIH National Center for Complementary and Integrative Health states there is not enough rigorous human evidence to determine whether astragalus is effective for any health condition, and notes possible herb-drug and immunosuppressant interactions. [https://www.nccih.nih.gov/health/astragalus]
  - Astragalus (2019) — Authoritative NIH safety review reports astragalus is generally well tolerated with no convincing reports of serum enzyme elevations or clinically apparent liver injury in published human studies. [https://www.ncbi.nlm.nih.gov/books/NBK548582/]
  - Meta-analysis of the clinical value of Astragalus membranaceus in diabetic nephropathy, Journal of ethnopharmacology (2011) — Possible benefit in chronic kidney disease; rigorous trials still needed. [https://pubmed.ncbi.nlm.nih.gov/20951192/]
  - Effect of Astragalus membranaceus on left ventricular remodeling in HFrEF: a systematic review and meta-analysis, Frontiers in pharmacology (2024) — Adjunctive symptom improvement in small/short studies. [https://pmc.ncbi.nlm.nih.gov/articles/PMC10811102/]

---

## Reishi (Ganoderma lucidum · Líng Zhī 灵芝)
URL: https://nutridex.info/s/reishi
Category: TCM Herb, Gut & Immune, Longevity, Sleep & Mood
Evidence: Preliminary — Early or small human trials; promising but not yet conclusive.
The revered 'mushroom of immortality'.

Quick answer: Reishi is used for immune modulation. NutriDex grades the human evidence as preliminary — Early or small human trials; promising but not yet conclusive. Based on 17 cited human studies (16 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Reishi (Líng Zhī) has been prized in TCM for longevity and calm for over two millennia. Its polysaccharides and triterpenes show immunomodulating and antioxidant activity in lab studies. A Cochrane review concluded reishi may enhance immune response when used alongside conventional cancer treatment but is not a substitute for it. Traditional use for restful sleep and stress has only thin human support so far.

Benefits / uses: Immune modulation; Calm & sleep support; Possible cancer-care adjunct; Antioxidant.
Active compounds: Triterpenes (ganoderic acids); Beta-glucan polysaccharides.
Dose: 1.5–9 g/day of extract (standardized to polysaccharides/triterpenes).
Safety: Generally safe for a few months. GI upset, dry mouth. Increases bleeding risk — caution with anticoagulants and before surgery; rare liver-injury reports.

Cited studies (17):
  - The Nutritional Significance of Ganoderma lucidum on Human Health: A GRADE-Assessed Systematic Review and Meta-Analysis of Clinical Trials, Food science & nutrition (2025) — GRADE-assessed meta-analysis of 17 RCTs (n=971; 200-11,200 mg/day, 1-24 wk) found small significant reductions in BMI (-0.43 kg/m2), creatinine (-0.14 mg/dL) and heart rate (-3.92 bpm) and increased GPx, but evidence quality was very low. [https://pubmed.ncbi.nlm.nih.gov/40510787/]
  - Anti-Inflammatory Potential of Ganoderma lucidum Triterpenes: A Systematic Review and Meta-Analysis of Preclinical Evidence, Pharmaceuticals (Basel, Switzerland) (2026) — Meta-analysis of 23 preclinical studies found Ganoderma lucidum triterpenes significantly reduced inflammatory markers (IL-6, TNF-alpha, nitric oxide) in cell and animal models; no human data. [https://pubmed.ncbi.nlm.nih.gov/41599785/]
  - The Nutritional Significance of Ganoderma lucidum on Human Health: A GRADE-Assessed Systematic Review and Meta-Analysis of Clinical Trials, Food science & nutrition (2025) — GRADE-assessed meta-analysis of 17 RCTs (n=971) found Ganoderma lucidum significantly reduced BMI (-0.43; 95% CI -0.77 to -0.10) and heart rate, but had NO significant effect on inflammatory markers (hs-CRP -0.28, CI -0.91 to 0.35; TNF-alpha NS); overall evidence quality rated very low. [https://pmc.ncbi.nlm.nih.gov/articles/PMC12160064/]
  - Medicinal Mushroom Supplements in Cancer: A Systematic Review of Clinical Studies, Current oncology reports (2023) — Systematic review of 39 clinical studies of medicinal mushrooms in cancer: reishi/other supplements showed favorable immunological response (11 studies) and improved quality of life / reduced symptom burden (14 studies) with mostly grade <=2 adverse events, but evidence judged inconclusive for routine clinical recommendation. [https://pubmed.ncbi.nlm.nih.gov/36995535/]
  - Ganoderma lucidum (Reishi mushroom) for cancer treatment, The Cochrane database of systematic reviews (2016) — Possible immune-enhancing adjunct in cancer care; not a standalone therapy. [https://pubmed.ncbi.nlm.nih.gov/27045603/]
  - Ganoderma lucidum mushroom for the treatment of cardiovascular risk factors, The Cochrane database of systematic reviews (2015) — Cochrane review of 5 RCTs (n=398, mostly type 2 diabetes): G. lucidum (1.4-3 g/day, 12-16 wk) produced no significant reduction in HbA1c (WMD -0.10%), total cholesterol, LDL-C or BMI vs placebo; does not support use for cardiovascular risk factors. Adverse-event risk non-significantly higher (RR 1.67). [https://pubmed.ncbi.nlm.nih.gov/25686270/]
  - Coriolus Versicolor and Ganoderma Lucidum Related Natural Products as an Adjunct Therapy for Cancers: A Systematic Review and Meta-Analysis of Randomized Controlled Trials, Frontiers in pharmacology (2019) — Meta-analysis of 23 RCTs (4,246 cancer patients): Ganoderma/Coriolus-related natural products as adjunct therapy were associated with lower mortality (HR 0.82; 95% CI 0.72-0.94) and higher total efficacy (RR 1.30; 95% CI 1.09-1.55), and raised CD3 (+9.03%) and CD4 (+9.2%); no effect on relapse-free survival or NK-cell levels. [https://pubmed.ncbi.nlm.nih.gov/31333449/]
  - Evaluation of Immune Modulation by β-1,3; 1,6 D-Glucan Derived from Ganoderma lucidum in Healthy Adult Volunteers, A Randomized Controlled Trial, Foods (Basel, Switzerland) (2023) — Double-blind RCT in 135 healthy adults (200 mg/day Reishi beta-glucan, 84 days) showed significant immune enhancement vs placebo, including a 12.9% rise in CD4/CD8 ratio and ~19.5% increase in NK cell counts. [https://pubmed.ncbi.nlm.nih.gov/36766186/]
  - Evaluation of Immune Modulation by β-1,3; 1,6 D-Glucan Derived from Ganoderma lucidum in Healthy Adult Volunteers, A Randomized Controlled Trial, Foods (Basel, Switzerland) (2023) — Randomized, double-blind, placebo-controlled trial in 135 healthy adults taking 200 mg/day Reishi beta-1,3/1,6-D-glucan for 84 days significantly increased CD3+, CD4+, CD8+ T-lymphocytes, NK cell count and NK cytotoxicity (67.4% vs 35.8%, p=0.001) versus placebo. [https://pmc.ncbi.nlm.nih.gov/articles/PMC9914031/]
  - Ganoderma lucidum Effects on Mood and Health-Related Quality of Life in Women with Fibromyalgia, Healthcare (Basel, Switzerland) (2020) — Double-blind placebo-controlled pilot RCT in 64 women with fibromyalgia (6 g/day, 6 weeks) found no significant between-group differences after Bonferroni correction, though the treatment arm showed within-group improvements in happiness, depression (GDS) and life satisfaction. [https://pmc.ncbi.nlm.nih.gov/articles/PMC7712001/]
  - Lingzhi, Reishi (2024) — NIH's LiverTox database assigns Lingzhi/Reishi a likelihood score of D (possible rare cause of clinically apparent liver injury), noting it is well tolerated without aminotransferase elevations in controlled trials, with only rare, often poorly documented hepatocellular injury cases (onset 1-2 months) that resolve completely after discontinuation. [https://www.ncbi.nlm.nih.gov/books/NBK609014/]
  - A double-blind, randomised, placebo-controlled trial of Ganoderma lucidum for the treatment of cardiovascular risk factors of metabolic syndrome, Scientific reports (2016) — Double-blind placebo-controlled RCT in 84 adults with type 2 diabetes/metabolic syndrome (3 g/day, 16 wk) found no effect on HbA1c, fasting glucose or other cardiovascular risk factors. [https://pubmed.ncbi.nlm.nih.gov/27511742/]
  - A randomized, double-blind and placebo-controlled study of a Ganoderma lucidum polysaccharide extract in neurasthenia, Journal of medicinal food (2005) — Randomized double-blind placebo-controlled trial in 123 patients with neurasthenia (Ganopoly polysaccharide extract 1,800 mg three times daily, 8 weeks) found significantly greater improvement than placebo, with 28.3% reduction in fatigue and 51.6% rated more than minimally improved vs 24.6% on placebo. [https://pubmed.ncbi.nlm.nih.gov/15857210/]
  - Effect of an extract of Ganoderma lucidum in men with lower urinary tract symptoms: a double-blind, placebo-controlled randomized and dose-ranging study, Asian journal of andrology (2008) — Double-blind placebo-controlled dose-ranging RCT in 50 men aged 50+ with lower urinary tract symptoms (0.6, 6, or 60 mg/day Ganoderma extract, 8 weeks) showed significant improvement in International Prostate Symptom Score versus placebo at weeks 4 and 8, identifying 6 mg/day as the optimal dose. [https://pubmed.ncbi.nlm.nih.gov/18097503/]
  - Hepatotoxicity due to a formulation of Ganoderma lucidum (lingzhi), Journal of hepatology (2004) — Case report in J Hepatol of an elderly woman who developed hepatotoxicity attributed to a Ganoderma lucidum (lingzhi) formulation, illustrating a rare liver-injury safety signal. [https://pubmed.ncbi.nlm.nih.gov/15464254/]
  - Spore Powder of Ganoderma lucidum Improves Cancer-Related Fatigue in Breast Cancer Patients Undergoing Endocrine Therapy: A Pilot Clinical Trial, Evidence-based complementary and alternative medicine : eCAM (2012) — Mixed effects on fatigue and quality of life. [https://pmc.ncbi.nlm.nih.gov/articles/PMC3236089/]
  - PubMed, NIH National Library of Medicine — Antioxidant and hepatoprotective effects in animal models. [https://pubmed.ncbi.nlm.nih.gov/?term=Reishi%20Preclinical%20studies]

---

## Goji Berry (Lycium barbarum · Gǒu Qǐ Zǐ 枸杞子)
URL: https://nutridex.info/s/goji
Category: TCM Herb, Longevity, Gut & Immune
Evidence: Preliminary — Early or small human trials; promising but not yet conclusive.
Nutrient-dense 'longevity' berry rich in zeaxanthin.

Quick answer: Goji Berry is used for antioxidant. NutriDex grades the human evidence as preliminary — Early or small human trials; promising but not yet conclusive. Based on 18 cited human studies (18 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Goji (Gǒu Qǐ Zǐ) is used in TCM to nourish the liver, kidney, and eyes. It is exceptionally rich in zeaxanthin, a carotenoid concentrated in the retina, and small trials show supplementation raises macular pigment and plasma antioxidant levels. Other small RCTs report improved subjective energy and wellbeing. Evidence is preliminary and several studies are industry-funded, but its nutrient density is well established.

Benefits / uses: Antioxidant; Eye / macular health; Subjective wellbeing; Immune support.
Active compounds: Lycium barbarum polysaccharides (LBP); Zeaxanthin; Carotenoids.
Dose: 15–45 g dried berries/day, or equivalent juice/extract.
Safety: Safe as a food. May raise INR / interact with warfarin. Rare allergy.

Cited studies (18):
  - L. barbarum (Lycium barbarum L.) supplementation for lipid profiles in adults: A systematic review and meta-analysis of RCTs, Medicine (2023) — Meta-analysis of 5 RCTs (259 adults) showed Lycium barbarum supplementation significantly lowered triglycerides (MD ~0.14 mmol/L) and raised HDL-cholesterol (~0.07 mmol/L), with no significant change in total or LDL cholesterol. [https://pubmed.ncbi.nlm.nih.gov/37773857/]
  - L. barbarum (Lycium barbarum L.) supplementation for lipid profiles in adults: A systematic review and meta-analysis of RCTs, Medicine (2023) — Meta-analysis of 5 RCTs (n=259) found L. barbarum significantly lowered triglycerides (MD 0.14 mmol/L, 95% CI 0.08-0.20) and raised HDL-C (MD 0.07 mmol/L, 95% CI 0.01-0.13), with no significant change in total or LDL cholesterol. [https://pmc.ncbi.nlm.nih.gov/articles/PMC10545344/]
  - The Effect of Lycium Barbarum Polysaccharide on the Glucose and Lipid Metabolism: A Systematic Review and Meta-Analysis, Journal of the American Nutrition Association (2022) — Systematic review/meta-analysis of 7 RCTs found daily Lycium barbarum polysaccharide significantly reduced serum triglycerides, fasting blood glucose, and LDL cholesterol. [https://pubmed.ncbi.nlm.nih.gov/34213407/]
  - Cardiovascular disease risk reduction with wolfberry consumption: a systematic review and meta-analysis of randomized controlled trials, European journal of nutrition (2022) — Systematic review and meta-analysis of 10 RCTs (from 785 screened) found wolfberry consumption, particularly as whole fruit, supports improvements in cardiovascular health-related indicators including blood lipids and oxidative-stress biomarkers. [https://pubmed.ncbi.nlm.nih.gov/34839399/]
  - Efficacy of Lycium barbarum (Goji berry) mouthwash for managing periodontitis: a randomized clinical trial, F1000Research (2023) — In a randomized trial of 60 adults with periodontitis, Lycium barbarum mouthwash plus scaling/root planing reduced probing depth, plaque, gingival index and bleeding comparably to 0.2% chlorhexidine, and uniquely raised salivary antioxidant (protein thiol) levels. [https://pubmed.ncbi.nlm.nih.gov/39640061/]
  - The effects of Lycium barbarum polysaccharide on oxidative stress and sperm health in varicocele patients: A randomized clinical trial, Tissue & cell (2026) — In a double-blind randomized trial of 80 varicocele patients, 400 mg/day Lycium barbarum polysaccharide extract for 2 months significantly raised antioxidant enzymes (superoxide dismutase, glutathione peroxidase) and testosterone while lowering malondialdehyde, and improved sperm count, motility, and morphology versus placebo. [https://pubmed.ncbi.nlm.nih.gov/41032943/]
  - Effects of wolfberry (Lycium barbarum) consumption on the human plasma lipidome and its association with cardiovascular disease risk factors: a randomized controlled trial of middle-aged and older adults, Frontiers in nutrition (2024) — Randomized controlled trial in middle-aged and older adults found wolfberry consumption altered the human plasma lipidome in directions associated with reduced cardiovascular disease risk factors. [https://pmc.ncbi.nlm.nih.gov/articles/PMC10909962/]
  - Efficacy of Lycium barbarum (Goji berry) mouthwash for managing periodontitis: a randomized clinical trial, F1000Research (2023) — Randomized clinical trial found L. barbarum mouthwash plus scaling/root planing reduced periodontal indices in periodontitis patients, with no significant difference versus chlorhexidine. [https://pmc.ncbi.nlm.nih.gov/articles/PMC11617829/]
  - Goji Berry Intake Increases Macular Pigment Optical Density in Healthy Adults: A Randomized Pilot Trial, Nutrients (2021) — In a 90-day randomized pilot trial (n=27, ages 45-65), 28 g/day goji berries significantly increased macular pigment optical density at 0.25 and 1.75 eccentricities and skin carotenoids, whereas a lutein/zeaxanthin supplement did not. [https://pubmed.ncbi.nlm.nih.gov/34959963/]
  - Goji Berry Intake Increases Macular Pigment Optical Density in Healthy Adults: A Randomized Pilot Trial, Nutrients (2021) — Randomized pilot trial (n=27, ages 45-65; 28 g goji berries 5x/week for 90 days) significantly increased macular pigment optical density at 0.25 and 1.75 eccentricities and raised skin carotenoids, exceeding a lutein/zeaxanthin supplement comparator. [https://pmc.ncbi.nlm.nih.gov/articles/PMC8708314/]
  - Wolfberry (Lycium barbarum) Consumption with a Healthy Dietary Pattern Lowers Oxidative Stress in Middle-Aged and Older Adults: A Randomized Controlled Trial, Antioxidants (Basel, Switzerland) (2021) — 16-week parallel-design RCT (n=40 middle-aged/older adults): 15 g/day whole dried wolfberry within a healthy dietary pattern significantly raised plasma zeaxanthin and skin carotenoids and reduced lipid peroxidation (plasma 8-iso-prostaglandin F2alpha), with an inverse association between plasma zeaxanthin rise and oxidative stress marker; no change in the control group. [https://pubmed.ncbi.nlm.nih.gov/33917032/]
  - Macular pigment and serum zeaxanthin levels with Goji berry supplement in early age-related macular degeneration, International journal of ophthalmology (2018) — In a controlled trial of 114 patients with early age-related macular degeneration, 25 g/day goji berries for 90 days significantly increased macular pigment optical density (0.73 to 0.88 DU) and roughly tripled serum zeaxanthin, with soft drusen diminishing in the treated group. [https://pubmed.ncbi.nlm.nih.gov/29977809/]
  - Goji berry effects on macular characteristics and plasma antioxidant levels, Optometry and vision science : official publication of the American Academy of Optometry (2011) — Increased plasma zeaxanthin (~26%) and macular pigment in adults aged 65–70. [https://pubmed.ncbi.nlm.nih.gov/21169874/]
  - Immunomodulatory effects of dietary supplementation with a milk-based wolfberry formulation in healthy elderly: a randomized, double-blind, placebo-controlled trial, Rejuvenation research (2012) — In a 3-month randomized, double-blind, placebo-controlled trial of 150 healthy Chinese elderly (aged 65-70), 13.7 g/day Lacto-Wolfberry (milk-based Lycium barbarum) produced significantly higher post-vaccination influenza-specific serum IgG levels and seroconversion rate (days 30-90) versus placebo, with no serious adverse events. [https://pubmed.ncbi.nlm.nih.gov/22352435/]
  - A randomized, double-blind, placebo-controlled, clinical study of the general effects of a standardized Lycium barbarum (Goji) Juice, GoChi, Journal of alternative and complementary medicine (New York, N.Y.) (2008) — Improved subjective wellbeing and energy in a small RCT. [https://pubmed.ncbi.nlm.nih.gov/18447631/]
  - Probable interaction between Lycium barbarum (goji) and warfarin, Pharmacotherapy (2012) — Case report of a 71-year-old woman on warfarin who developed a markedly elevated (indeterminate) INR with epistaxis, bruising and rectal bleeding after 4 days of goji juice; the Naranjo scale rated the Lycium barbarum-warfarin interaction as probable. [https://pubmed.ncbi.nlm.nih.gov/22392549/]
  - [Autoimmune hepatitis triggered by consumption of Goji berries], Medicina clinica (2012) — Case report describing a middle-aged woman who developed autoimmune hepatitis temporally linked to goji berry consumption, illustrating a rare but documented hepatic safety concern with Lycium barbarum. [https://pubmed.ncbi.nlm.nih.gov/22503106/]
  - Lycium barbarum (goji) juice improves in vivo antioxidant biomarkers in serum of healthy adults, Nutrition research (New York, N.Y.) (2009) — Raised plasma antioxidant capacity after regular intake. [https://pubmed.ncbi.nlm.nih.gov/19185773/]

---

## Schisandra (Schisandra chinensis · Wǔ Wèi Zǐ 五味子)
URL: https://nutridex.info/s/schisandra
Category: TCM Herb, Adaptogen, Longevity
Evidence: Preliminary — Early or small human trials; promising but not yet conclusive.
The 'five-flavor berry' adaptogen for liver & stress.

Quick answer: Schisandra is used for adaptogenic / stress resilience. NutriDex grades the human evidence as preliminary — Early or small human trials; promising but not yet conclusive. Based on 14 cited human studies (14 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Schisandra (Wǔ Wèi Zǐ) — named for containing all five TCM tastes — is classified as an adaptogen. Its lignans show hepatoprotective and antioxidant activity, and it has been studied (often in Russian and Chinese literature) for stress tolerance, mental performance, and physical endurance. Human trials are small and of variable quality, so benefits remain preliminary.

Benefits / uses: Adaptogenic / stress resilience; Liver support; Antioxidant; Possible focus & endurance.
Active compounds: Lignans (schisandrins, gomisins).
Dose: 1–3 g dried berries or ~500 mg standardized extract/day.
Safety: Generally well tolerated. Possible heartburn, appetite changes. Avoid in pregnancy; may interact with drugs metabolized by the liver.

Cited studies (14):
  - Efficacy and Safety of Omija (Schisandra chinensis) Extract Mixture on the Improvement of Hyperglycemia: A Randomized, Double-Blind, and Placebo-Controlled Clinical Trial, Nutrients (2022) — In a 12-week double-blind RCT of adults with elevated fasting glucose (n=80 enrolled, 63 completed), Schisandra (Omija) extract mixture significantly lowered fasting plasma glucose (~5.6 mg/dL), postprandial glucose/insulin AUC, and LDL-cholesterol versus placebo. [https://pmc.ncbi.nlm.nih.gov/articles/PMC9370295/]
  - Effect of Schisandra chinensis Baillon extracts and regular low-intensity exercise on muscle strength and mass in older adults: a randomized, double-blind, placebo-controlled trial, The American journal of clinical nutrition (2021) — In a 12-week double-blind RCT of adults over 50 (n=54), Schisandra chinensis extract plus low-intensity exercise increased knee extensor strength (right +10.2 Nm, P=0.003) versus placebo, with no change in muscle mass. [https://pubmed.ncbi.nlm.nih.gov/33710261/]
  - Efficacy of Adaptogens in Patients with Long COVID-19: A Randomized, Quadruple-Blind, Placebo-Controlled Trial, Pharmaceuticals (Basel, Switzerland) (2022) — Randomized quadruple-blind placebo-controlled trial (n=100 Long COVID patients) of the fixed adaptogen combination Chisan/ADAPT-232 (Rhodiola, Eleutherococcus, Schisandra chinensis) for 2 weeks reduced the duration of fatigue and pain by 1 and 2 days respectively in 50% of patients and lowered IL-6 versus placebo. [https://pmc.ncbi.nlm.nih.gov/articles/PMC8953947/]
  - Efficacy and Safety of Omija (Schisandra chinensis) Extract Mixture on the Improvement of Hyperglycemia: A Randomized, Double-Blind, and Placebo-Controlled Clinical Trial, Nutrients (2022) — 12-week RCT in 80 adults with impaired fasting glucose (FPG 100-140 mg/dL): Schisandra (Omija) extract-soybean mixture significantly reduced fasting plasma glucose, postprandial glucose (30/60 min), postprandial insulin (60 min), insulin AUC, fructosamine, and LDL cholesterol vs placebo, with no adverse safety signals. [https://pubmed.ncbi.nlm.nih.gov/35956334/]
  - Effect of Schisandra Chinensis Extract Supplementation on Quadriceps Muscle Strength and Fatigue in Adult Women: A Randomized, Double-Blind, Placebo-Controlled Trial, International journal of environmental research and public health (2020) — In 45 postmenopausal women, 1000 mg/day Schisandra chinensis extract for 12 weeks significantly increased quadriceps muscle strength (interaction p=0.001; within-group p<0.001) and decreased resting blood lactate (p=0.038) vs placebo starch. [https://pubmed.ncbi.nlm.nih.gov/32260466/]
  - Efficacy of Adaptogens in Patients with Long COVID-19: A Randomized, Quadruple-Blind, Placebo-Controlled Trial, Pharmaceuticals (Basel, Switzerland) (2022) — Randomized quadruple-blind placebo-controlled trial in 100 Long COVID patients: 2 weeks of Chisan/ADAPT-232 (Schisandra chinensis, Rhodiola, Eleutherococcus) accelerated recovery, with significantly greater resolution of fatigue and other symptoms and faster reduction in CRP vs placebo. [https://pubmed.ncbi.nlm.nih.gov/35337143/]
  - A randomized, double-blind, placebo-controlled trial of Schisandra chinensis for menopausal symptoms, Climacteric : the journal of the International Menopause Society (2016) — In a double-blind RCT of menopausal women (n=36 completed), Schisandra chinensis BMO-30 extract significantly reduced the total Kupperman Index versus placebo (P=0.042), particularly hot flushes, sweating, and palpitations. [https://pubmed.ncbi.nlm.nih.gov/27763802/]
  - Double-blind, placebo-controlled, randomised study of single dose effects of ADAPT-232 on cognitive functions, Phytomedicine : international journal of phytotherapy and phytopharmacology (2010) — In a double-blind RCT of 40 healthy women, a single 270 mg dose of ADAPT-232 (a fixed combination of Schisandra chinensis, Rhodiola rosea, and Eleutherococcus) significantly improved attention, speed, and accuracy on the d2 attention test versus placebo (P<0.05); effect attributable to the combination, not Schisandra alone. [https://pubmed.ncbi.nlm.nih.gov/20374974/]
  - A comprehensive review of Schisandra chinensis lignans: pharmacokinetics, pharmacological mechanisms, and future prospects in disease prevention and treatment, Chinese medicine (2025) — A 2025 review in Chinese Medicine synthesizes pharmacokinetics and mechanisms of Schisandra chinensis lignans across antioxidant, hepatoprotective, neuroprotective, and antidiabetic activities, emphasizing bioavailability limits and the need for clinical confirmation. [https://pubmed.ncbi.nlm.nih.gov/40205412/]
  - A Comprehensive Review of the Main Lignan Components of Schisandra chinensis (North Wu Wei Zi) and Schisandra sphenanthera (South Wu Wei Zi) and the Lignan-Induced Drug-Drug Interactions Based on the Inhibition of Cytochrome P450 and P-Glycoprotein Activities, Frontiers in pharmacology (2022) — A Frontiers in Pharmacology review concludes Schisandra lignans (e.g., schisandrin A, schisantherin A, schisandrol B) are potent CYP3A and P-glycoprotein inhibitors that can substantially elevate blood levels of co-administered CYP3A substrates such as tacrolimus, warranting clinical monitoring. [https://pmc.ncbi.nlm.nih.gov/articles/PMC8962666/]
  - Pharmacology of Schisandra chinensis Bail.: An overview of Russian research and uses in medicine, Journal of Ethnopharmacology (2008) — Adaptogenic and anti-fatigue effects across mostly older trials. [https://doi.org/10.1016/j.jep.2008.04.020]
  - Efficacy of Schisandra chinensis in liver injury: a systematic review and preclinical meta-analysis, Frontiers in Pharmacology (2025) — Lignans reduced liver-enzyme markers in some clinical reports. [https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2025.1627081/full]
  - Effect of Schisandra Chinensis Extract Supplementation on Quadriceps Muscle Strength and Fatigue in Adult Women: A Randomized, Double-Blind, Placebo-Controlled Trial, International journal of environmental research and public health (2020) — Possible gains in concentration and endurance; small samples. [https://pmc.ncbi.nlm.nih.gov/articles/PMC7177795/]
  - Effects of Schisandra sphenanthera extract on the pharmacokinetics of tacrolimus in healthy volunteers, British journal of clinical pharmacology (2007) — In 12 healthy male volunteers, 13 days of Schisandra sphenanthera extract markedly raised tacrolimus exposure (mean AUC +164%, Cmax +227%, clearance -49%), indicating clinically important CYP3A/P-glycoprotein-mediated herb-drug interaction. [https://pubmed.ncbi.nlm.nih.gov/17506780/]

---

## Cordyceps (Cordyceps / Ophiocordyceps sinensis · Dōng Chóng Xià Cǎo 冬虫夏草)
URL: https://nutridex.info/s/cordyceps
Category: TCM Herb, Performance, Gut & Immune
Evidence: Mixed — Conflicting results across studies; benefit uncertain.
The 'caterpillar fungus' prized for energy & stamina.

Quick answer: Cordyceps is used for possible exercise capacity. NutriDex grades the human evidence as mixed — Conflicting results across studies; benefit uncertain. Based on 17 cited human studies (17 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Cordyceps (Dōng Chóng Xià Cǎo) is a fungus traditionally used to tonify the kidney and lung and boost vitality. Lab work suggests it may improve oxygen utilization and have immunomodulating effects. Human exercise-performance trials are genuinely mixed — some show small gains in aerobic capacity in older or untrained adults, others show none, especially in trained athletes. Most products are cultivated strains rather than the rare wild fungus.

Benefits / uses: Possible exercise capacity; Anti-fatigue; Immune modulation; Traditional kidney/lung tonic.
Active compounds: Cordycepin; Polysaccharides; Adenosine.
Dose: 1–3 g/day of cultivated extract (Cs-4 / Cordyceps militaris).
Safety: Generally safe. Mild GI upset. May enhance immune activity and interact with anticoagulants/immunosuppressants.

Cited studies (17):
  - Effects of fungal supplementation on endurance, immune function, and hematological profiles in adult athletes: a systematic review and meta-analysis, Frontiers in nutrition (2025) — Systematic review/meta-analysis of 14 RCTs (528 athletes; 8 trials/288 in synthesis) found Cordyceps sinensis significantly improved VO2peak (p=0.04, I2=0%) and ventilatory threshold (p=0.03), with marginal endurance benefit (p=0.05). [https://pubmed.ncbi.nlm.nih.gov/41280379/]
  - Use of bailing capsules (cordyceps sinensis) in the treatment of chronic kidney disease: a meta-analysis and network pharmacology, Frontiers in pharmacology (2024) — Meta-analysis of 31 RCTs (2,934 CKD patients) showed Bailing capsule (Cordyceps sinensis) added to standard care reduced serum creatinine (SMD -1.30), BUN (SMD -0.98) and 24-h proteinuria (SMD -1.08), all p<0.00001. [https://pubmed.ncbi.nlm.nih.gov/38645562/]
  - Effects of fungal supplementation on endurance, immune function, and hematological profiles in adult athletes: a systematic review and meta-analysis, Frontiers in nutrition (2025) — Systematic review/meta-analysis (14 RCTs, 528 athletes; ~3 Cordyceps RCTs, ~47 participants for aerobic outcomes) found Cordyceps sinensis significantly improved VO2peak (p=0.04, I2=0%), ventilatory threshold (p=0.03, I2=0%), and endurance (p=0.05, I2=20%). [https://pmc.ncbi.nlm.nih.gov/articles/PMC12631420/]
  - Efficacy of traditional Chinese medicine Cordyceps sinensis as an adjunctive treatment in patients with renal dysfunction: a systematic-review and meta-analysis, Frontiers in medicine (2024) — Pooled 15 studies/1,310 patients with renal dysfunction: adjunctive Cordyceps sinensis significantly reduced serum creatinine, shortened the oliguria period and increased urine osmolality versus standard therapy alone, indicating improved glomerular and tubular function. [https://pubmed.ncbi.nlm.nih.gov/39839641/]
  - Effectiveness and Safety of Oral Cordyceps sinensis on Stable COPD of GOLD Stages 2-3: Systematic Review and Meta-Analysis, Evidence-based complementary and alternative medicine : eCAM (2019) — Systematic review/meta-analysis of 15 studies (1,238 patients) found oral Cordyceps sinensis added to standard care for stable GOLD 2-3 COPD increased FEV1% predicted by ~6.25%, improved 6-minute walk distance by ~45 m, and lowered SGRQ quality-of-life score by ~5.87 points, with no serious adverse events but low study quality. [https://pubmed.ncbi.nlm.nih.gov/31073318/]
  - Efficacy of Cordyceps sinensis as an adjunctive treatment in kidney transplant patients: A systematic-review and meta-analysis, Complementary therapies in medicine (2017) — Systematic review/meta-analysis in kidney transplant recipients: adjunctive Cordyceps sinensis was associated with reduced incidence of delayed graft function and lower nephrotoxicity/proteinuria, supporting a renoprotective adjunct role alongside immunosuppression. [https://pubmed.ncbi.nlm.nih.gov/28137532/]
  - Cordyceps sinensis (a traditional Chinese medicine) for treating chronic kidney disease, Cochrane Database of Systematic Reviews (2014) — Cochrane review of 22 Chinese studies (1,746 CKD patients) found Cordyceps added to conventional therapy may improve renal function and complications, but evidence quality was poor and no definitive conclusions could be drawn. [https://doi.org/10.1002/14651858.CD008353.pub2]
  - Cordyceps sinensis (a traditional Chinese medicine) for treating chronic kidney disease, The Cochrane database of systematic reviews (2014) — Cochrane review of 22 studies (1,746 CKD participants) found Cordyceps as an adjunct may decrease serum creatinine, increase creatinine clearance, reduce proteinuria and raise hemoglobin/albumin, but rated the evidence low-quality with high risk of bias - efficacy not confirmed. [https://pubmed.ncbi.nlm.nih.gov/25519252/]
  - A randomized controlled clinical trial examining the effects of Cordyceps militaris beverage on the immune response in healthy adults, Scientific reports (2024) — Randomized placebo-controlled trial in 20 healthy adults found a Cordyceps militaris beverage (2.85 mg cordycepin/day, 8 weeks) significantly increased NK cell activity (men at 4 weeks p=0.049; women at 8 weeks p=0.023) and reduced inflammatory cytokines (IL-1beta, IL-6). [https://pubmed.ncbi.nlm.nih.gov/38580687/]
  - Cordyceps sinensis accelerates stem cell recruitment to human skeletal muscle after exercise, Food & function (2024) — Randomized double-blind placebo-controlled crossover trial (n=14 young adults, 1 g pre-exercise) showed Cordyceps accelerated CD34+ stem cell recruitment to skeletal muscle to 3 h post-exercise (+51%, p=0.002) and produced ~four-fold Pax7+ cell expansion (p=0.01) after high-intensity interval exercise. [https://pubmed.ncbi.nlm.nih.gov/38501161/]
  - Effects of cordyceps sinensis supplementation during 12 weeks in amateur marathoners: A randomized, double-blind placebo-controlled trial, Journal of Herbal Medicine (2022) — Randomized double-blind placebo-controlled trial in 30 amateur marathoners taking 2 g/day Cordyceps sinensis for 12 weeks lowered submaximal heart rate at 8 weeks and improved aerobic performance at 12 weeks. [https://doi.org/10.1016/j.hermed.2022.100570]
  - [Form and valence of arsenic in dry and fresh Cordyceps breeding products based on HPLC-ICP-MS and its risk assessment], Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica (2022) — HPLC-ICP-MS analysis of dry and fresh cultivated Cordyceps products found high total arsenic but predominantly low-toxicity organic species with only trace inorganic arsenic, with risk assessment indicating limited hazard at typical intake. [https://pubmed.ncbi.nlm.nih.gov/35850808/]
  - Effect of Cs-4 (Cordyceps sinensis) on exercise performance in healthy older subjects: a double-blind, placebo-controlled trial, Journal of alternative and complementary medicine (New York, N.Y.) (2010) — Randomized, double-blind, placebo-controlled trial in 20 healthy older adults: Cs-4 (Cordyceps sinensis) 333 mg 3x/day for 12 weeks significantly increased metabolic/ventilatory threshold (+10.5%) versus no change with placebo, indicating improved exercise capacity. [https://pubmed.ncbi.nlm.nih.gov/20804368/]
  - Cordyceps (2025) — NIH LiverTox monograph assigns Cordyceps a likelihood score of 'E' (unlikely cause of liver injury), noting extracts are generally well tolerated with no reported aminotransferase elevations or clinically apparent hepatotoxicity, apart from a single unconfirmed case of hepatoportal sclerosis that resolved on discontinuation. [https://www.ncbi.nlm.nih.gov/books/NBK615916/]
  - Effect of Cs-4 <sup>®</sup> ( <i>Cordyceps sinensis</i> ) on Exercise Performance in Healthy Older Subjects: A Double-Blind, Placebo-Controlled Trial, The Journal of Alternative and Complementary Medicine (2010) — Improved aerobic performance markers in older adults. [https://doi.org/10.1089/acm.2009.0226]
  - Effects of a commercial herbal-based formula on exercise performance in cyclists, Medicine and science in sports and exercise (2004) — No ergogenic benefit in trained cyclists. [https://pubmed.ncbi.nlm.nih.gov/15076794/]
  - Cordyceps Polysaccharides: A Review of Their Immunomodulatory Effects, Molecules (Basel, Switzerland) (2024) — Polysaccharides modulate immune cells in preclinical models. [https://pubmed.ncbi.nlm.nih.gov/39519748/]

---

## Dong Quai (Angelica sinensis · Dāng Guī 当归)
URL: https://nutridex.info/s/dongquai
Category: TCM Herb, Sleep & Mood
Evidence: Mixed — Conflicting results across studies; benefit uncertain.
The 'female ginseng' used in women's health formulas.

Quick answer: Dong Quai is used for traditional menstrual / menopausal support. NutriDex grades the human evidence as mixed — Conflicting results across studies; benefit uncertain. Based on 17 cited human studies (15 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Dong Quai (Dāng Guī) is a cornerstone 'blood-tonifying' herb in TCM, almost always used within multi-herb formulas rather than alone. Western trials of Dong Quai by itself for menopausal hot flashes have been largely negative, while some combination formulas show benefit — making it hard to attribute effects to the herb specifically. Evidence overall is mixed and the traditional and clinical-trial contexts differ.

Benefits / uses: Traditional menstrual / menopausal support; Blood-tonifying (TCM); Often used in combination formulas.
Active compounds: Ferulic acid; Ligustilide; Polysaccharides.
Dose: Commonly 3–15 g in decoction or formula; rarely used alone in TCM.
Safety: May increase bleeding (avoid with anticoagulants) and photosensitivity. Avoid in pregnancy and hormone-sensitive conditions.

Cited studies (17):
  - Efficacy and mechanisms of Angelica sinensis in treating endometrial cancer: an integrated study, Discover oncology (2025) — Systematic review/meta-analysis of 9 RCTs (889 patients) found Angelica-based herbal formulas significantly improved quality of life (MD -5.89, 95%CI -6.65 to -5.13) and reduced pain and recurrence in endometrial cancer patients. [https://pubmed.ncbi.nlm.nih.gov/40411686/]
  - Efficacy and mechanisms of Angelica sinensis in treating endometrial cancer: an integrated study, Discover oncology (2025) — Systematic review/meta-analysis of 9 RCTs (889 endometrial cancer patients) found Angelica-based formulas improved quality of life (MD -5.89, 95% CI -6.65 to -5.13) and reduced pain, alongside immune-function improvements. [https://pmc.ncbi.nlm.nih.gov/articles/PMC12103411/]
  - Safety and efficacy of East Asian herbal medicine for iron deficiency anemia in children and adolescents: a systematic review and meta-analysis, Frontiers in pharmacology (2024) — Systematic review/meta-analysis of 28 RCTs (3,044 children/adolescents) found East Asian herbal medicine (Angelicae Sinensis Radix used in 50% of studies) added to oral iron raised hemoglobin (MD 12.73 g/L) and reduced GI adverse events (RR 0.43) versus iron alone. [https://pmc.ncbi.nlm.nih.gov/articles/PMC11036862/]
  - Efficacy and safety of Danggui Buxue Decoction in combination with western medicine treatment of anemia for renal anemia: a systematic review and meta-analysis, Annals of translational medicine (2017) — Meta-analysis of 7 RCTs (460 patients) found Danggui Buxue Decoction plus standard therapy did not significantly improve hemoglobin in renal anemia overall (WMD -8.75, 95% CI -18.64 to 1.13), with benefit only in the 5:1 Astragalus:Angelica subgroup. [https://pubmed.ncbi.nlm.nih.gov/28462216/]
  - Dong Quai (angelica sinensis) in the treatment of hot flashes for men on androgen deprivation therapy: results of a randomized double-blind placebo controlled trial, Canadian Urological Association journal = Journal de l'Association des urologues du Canada (2010) — In a randomized double-blind placebo-controlled trial in 22 men (17 completed) on LHRH-agonist androgen deprivation therapy for prostate cancer, daily Dong Quai for 3 months produced no significant difference in hot flash severity, frequency, or duration versus placebo. [https://pubmed.ncbi.nlm.nih.gov/20165579/]
  - A randomized, double-blind, placebo-controlled study of the effect of a Chinese herbal medicine preparation (Dang Gui Buxue Tang) on menopausal symptoms in Hong Kong Chinese women, Climacteric : the journal of the International Menopause Society (2008) — A 6-month randomized double-blind placebo-controlled trial of Dang Gui Buxue Tang (Angelica sinensis + Astragalus, 1:5) in 100 symptomatic Hong Kong Chinese women found overall no significant benefit over placebo for vasomotor symptoms, with superiority only for mild hot flushes and no serious adverse events. [https://pubmed.ncbi.nlm.nih.gov/18568789/]
  - The immediate effect of natural plant extract, Angelica sinensis and Matricaria chamomilla (Climex) for the treatment of hot flushes during menopause. A preliminary report, Clinical and experimental obstetrics & gynecology (2003) — RCT of a combined Angelica sinensis + Matricaria chamomilla preparation (Climex) vs placebo: 90-96% reduction in hot flash frequency/intensity over 3 months vs 15-20% with placebo, with improved sleep and fatigue. Suggests benefit only in combination, not as a single-herb effect. [https://pubmed.ncbi.nlm.nih.gov/14664413/]
  - Pharmacological action of Angelica sinensis polysaccharides: a review, Frontiers in pharmacology (2024) — Comprehensive review summarizing ten pharmacological actions of Angelica sinensis polysaccharides (ASP), including anemia improvement via increased hemoglobin/RBC, immunomodulation, antioxidant and antitumor effects; authors note clinical trials and safety data are still lacking. [https://pubmed.ncbi.nlm.nih.gov/39872047/]
  - Dose- and time-dependent renoprotection of Angelica sinensis in patients with chronic kidney disease: A longitudinal cohort study, Frontiers in pharmacology (2023) — In a longitudinal cohort of 64,218 chronic kidney disease patients (18,348 Angelica sinensis users), herb use was associated with ~23% lower end-stage renal disease risk vs non-use, with up to ~52% reduction at highest cumulative doses (dose-dependent). [https://pubmed.ncbi.nlm.nih.gov/37180720/]
  - Dose- and time-dependent renoprotection of Angelica sinensis in patients with chronic kidney disease: A longitudinal cohort study, Frontiers in pharmacology (2023) — In a propensity-matched longitudinal cohort of 64,218 CKD patients (2001–2017), Angelica sinensis use was associated with a 23% lower risk of end-stage renal disease (aHR 0.77, 95% CI 0.69–0.86), with a dose-response effect (aHR 0.48 at cumulative dose ≥15 g). [https://pmc.ncbi.nlm.nih.gov/articles/PMC10166798/]
  - Danggui Buxue Tang (Astragali Radix and Angelicae Sinensis Radix) for menopausal symptoms: A review, Journal of ethnopharmacology (2017) — Review of Danggui Buxue Tang (Astragali Radix : Angelicae Sinensis Radix in fixed 5:1 ratio) for women's/menopausal ailments; details standardized preparation, marker constituents (ferulic acid, calycosin, formononetin, astragaloside IV) and estrogenic/hematopoietic mechanisms underlying traditional 'blood-tonifying' use. [https://pubmed.ncbi.nlm.nih.gov/28163116/]
  - Interaction between warfarin and Chinese herbal medicines, Singapore medical journal (2015) — A review documents a case of a 46-year-old woman on warfarin 5 mg/day whose INR rose to 4.05 and 4.90 after taking dong quai (~565 mg 1-2x/day) and normalized to 2.48 a month after stopping, attributed to pharmacodynamic potentiation via coumarin constituents (ferulic acid, osthole) rather than altered warfarin levels. [https://pmc.ncbi.nlm.nih.gov/articles/PMC4325561/]
  - Structural analysis and blood-enriching effects comparison based on biological potency of Angelica sinensis polysaccharides, Frontiers in pharmacology (2024) — In a mouse blood-deficiency model, Angelica sinensis polysaccharides (notably neutral APS-H2O) raised hematopoietic regulators (EPO, G-CSF, IL-3) and lowered TNF-alpha, restoring blood parameters toward normal, supporting the herb's traditional blood-tonic use. [https://pubmed.ncbi.nlm.nih.gov/38953103/]
  - Does dong quai have estrogenic effects in postmenopausal women? A double-blind, placebo-controlled trial, Fertility and sterility (1997) — Dong Quai alone did not reduce menopausal hot flashes vs placebo. [https://pubmed.ncbi.nlm.nih.gov/9418683/]
  - Dong Quai (2021) — The NIH Drugs and Lactation Database (LactMed) reports no published data on dong quai levels in breast milk or effects on breastfed infants and advises that dong quai is best avoided during breastfeeding, citing potential bleeding-risk and photosensitivity concerns. [https://www.ncbi.nlm.nih.gov/books/NBK501836/]
  - PubMed, NIH National Library of Medicine — Some multi-herb formulas containing Dong Quai eased symptoms. [https://pubmed.ncbi.nlm.nih.gov/?term=Dong%20Quai%20Combination-formula%20trials]
  - PubMed, NIH National Library of Medicine — Mild estrogenic and antispasmodic activity reported in lab studies. [https://pubmed.ncbi.nlm.nih.gov/?term=Dong%20Quai%20Preclinical]

---

## Jiaogulan (Gynostemma pentaphyllum · Jiǎo Gǔ Lán 绞股蓝)
URL: https://nutridex.info/s/jiaogulan
Category: TCM Herb, Heart & Metabolic, Adaptogen
Evidence: Preliminary — Early or small human trials; promising but not yet conclusive.
'Southern ginseng' studied for metabolic health.

Quick answer: Jiaogulan is used for blood-sugar & lipid support. NutriDex grades the human evidence as preliminary — Early or small human trials; promising but not yet conclusive. Based on 17 cited human studies (17 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Jiaogulan (Jiǎo Gǔ Lán) contains gypenosides chemically similar to ginseng's ginsenosides, earning it the name 'southern ginseng'. Small trials suggest it can improve insulin sensitivity, lipids, and markers of non-alcoholic fatty liver disease, possibly via AMPK activation. The data are early and from small samples, so it is best viewed as promising rather than proven.

Benefits / uses: Blood-sugar & lipid support; Adaptogenic; Antioxidant; Possible fatty-liver support.
Active compounds: Gypenosides (ginsenoside-like saponins).
Dose: ~450 mg standardized extract/day, or as a tea.
Safety: Generally well tolerated. Possible nausea. May enhance blood-sugar-lowering drugs — monitor if diabetic.

Cited studies (17):
  - Efficacy and mechanisms of Gynostemma pentaphyllum as a medicine food homology herb in glycemic control: a meta-analysis with review, Frontiers in Pharmacology (2026) — Meta-analysis of 8 clinical studies (n=584) found Gynostemma pentaphyllum reduced fasting plasma glucose by 0.79 mmol/L, HbA1c by 1.01%, and 2-hour postprandial glucose by 0.90 mmol/L, with greater effect in longer-term treatment and monotherapy. [https://doi.org/10.3389/fphar.2026.1731723]
  - Efficacy and Mechanisms of Gynostemma pentaphyllum as a Medicine Food Homology Herb in Glycemic Control: A Meta-Analysis with Review, Frontiers in Pharmacology (2026) — Meta-analysis of 8 studies (584 patients) found Gynostemma pentaphyllum reduced fasting plasma glucose by MD -0.79 mmol/L (95% CI -1.08 to -0.51), HbA1c by -1.01% (95% CI -1.41 to -0.61), and 2-hour postprandial glucose by -0.90 mmol/L (95% CI -1.95 to -0.15). [https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2026.1731723/abstract]
  - Efficacy and mechanisms of Gynostemma pentaphyllum as a medicine food homology herb in glycemic control: a meta-analysis with review, Frontiers in pharmacology (2026) — Meta-analysis of 8 clinical studies (584 patients): Gynostemma pentaphyllum significantly reduced fasting plasma glucose (MD -0.79 mmol/L, 95% CI -1.08 to -0.51), HbA1c (MD -1.01%, 95% CI -1.41 to -0.61), and 2-h postprandial glucose (MD -0.90 mmol/L, 95% CI -1.95 to -0.15), with greater effect for long-term and monotherapy use. [https://pubmed.ncbi.nlm.nih.gov/42064816/]
  - Gynostemma pentaphyllum for dyslipidemia: A systematic review of randomized controlled trials, Frontiers in pharmacology (2022) — Systematic review of 22 RCTs (n=2,407) found G. pentaphyllum added to lipid-lowering drugs further reduced triglycerides (-0.65 mmol/L) and LDL-C (-0.57 mmol/L) and raised HDL-C (+0.15 mmol/L) in dyslipidemia, with few adverse events. [https://pubmed.ncbi.nlm.nih.gov/36091752/]
  - Gynostemma pentaphyllum for dyslipidemia: A systematic review of randomized controlled trials, Frontiers in pharmacology (2022) — Systematic review of 22 RCTs (2,407 dyslipidemia participants) found Gynostemma pentaphyllum comparable to statins/fibrates/n-3 fatty acids for triglycerides, total cholesterol, and HDL-C (very low certainty), with G. pentaphyllum plus lipid-lowering agents superior to agents alone and fewer adverse events. [https://pmc.ncbi.nlm.nih.gov/articles/PMC9459123/]
  - Effectiveness and Safety of Ayurvedic Medicines in Type 2 Diabetes Mellitus Management: A Systematic Review and Meta-Analysis, Frontiers in pharmacology (2022) — JBI systematic review/meta-analysis of 199 RCTs of Ayurvedic medicines for type 2 diabetes; G. pentaphyllum (Makino) reduced HbA1c by -1.0% (95% CI -1.5 to -0.6) versus control, one of the larger HbA1c reductions among the herbs evaluated. [https://pubmed.ncbi.nlm.nih.gov/35754481/]
  - Gynostemma Pentaphyllum Increases Exercise Performance and Alters Mitochondrial Respiration and AMPK in Healthy Males, Nutrients (2023) — Randomized, double-blind, placebo-controlled crossover trial in 16 healthy untrained men: 4 weeks of 450 mg/day G. pentaphyllum extract lowered resting plasma glucose and leptin and improved 20-km time-trial performance (~4%) with increased muscle AMPK phosphorylation. [https://pubmed.ncbi.nlm.nih.gov/38004115/]
  - Therapeutic Potential of Gynostemma pentaphyllum Extract for Hair Health Enhancement: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial, Nutrients (2025) — Randomized, double-blind, placebo-controlled trial (94 completers): G. pentaphyllum extract increased hair density (+14 vs +4.85 hairs/cm2), elasticity and shaft diameter versus placebo, with minimal adverse events. [https://pubmed.ncbi.nlm.nih.gov/40077637/]
  - Effects of gypenoside L-containing Gynostemma pentaphyllum extract on fatigue and physical performance: A double-blind, placebo-controlled, randomized trial, Phytotherapy research : PTR (2023) — Double-blind, placebo-controlled randomized trial in 100 healthy adults: 12 weeks of gypenoside L-containing G. pentaphyllum extract significantly raised VO2max and O2 pulse and reduced perceived exertion and temporal fatigue versus control. [https://pubmed.ncbi.nlm.nih.gov/36877124/]
  - Supplementation with extract of Gynostemma pentaphyllum leaves reduces anxiety in healthy subjects with chronic psychological stress: A randomized, double-blind, placebo-controlled clinical trial, Phytomedicine : international journal of phytotherapy and phytopharmacology (2019) — Randomized, double-blind, placebo-controlled trial in 72 healthy Korean adults with chronic psychological stress: ethanol leaf extract (200 mg twice daily, 8 weeks) reduced trait-anxiety (T-STAI) and lowered total STAI score by ~17.8% versus placebo, with no notable safety issues. [https://pubmed.ncbi.nlm.nih.gov/30599899/]
  - Antiobesity effect of Gynostemma pentaphyllum extract (actiponin): a randomized, double-blind, placebo-controlled trial, Obesity (Silver Spring, Md.) (2014) — 12-week randomized, double-blind, placebo-controlled trial (n=80 obese Koreans): 450 mg/day heat-processed extract (actiponin) significantly reduced total abdominal fat area, body weight, body fat mass and BMI versus placebo, with no significant safety changes. [https://pubmed.ncbi.nlm.nih.gov/23804546/]
  - Antidiabetic effect of Gynostemma pentaphyllum tea in randomly assigned type 2 diabetic patients, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme (2010) — Randomized double-blind placebo-controlled trial, 24 drug-naive T2DM patients, GP tea 6 g/day x 12 wk: fasting plasma glucose fell 3.0 mmol/L vs 0.6 mmol/L placebo (p<0.01), HbA1c fell ~2% units vs 0.2% (p<0.001), and HOMA-IR insulin resistance improved (-2.1 vs +1.1, p<0.05), with no hypoglycemia or adverse hepatic/renal effects. [https://pubmed.ncbi.nlm.nih.gov/20213586/]
  - Toxicity evaluation of standardized extract of Gynostemma pentaphyllum Makino, Journal of ethnopharmacology (2013) — Toxicology study in Sprague-Dawley rats: standardized G. pentaphyllum extract (6% gypenosides) caused no mortality or abnormalities at a single 5000 mg/kg acute dose or 1000 mg/kg/day for 90 days, supporting a wide safety margin (subchronic NOAEL >1000 mg/kg/day). [https://pubmed.ncbi.nlm.nih.gov/23796877/]
  - Liver lipidomics analysis reveals the anti-obesity and lipid-lowering effects of gypnosides from heat-processed Gynostemma pentaphyllum in high-fat diet fed mice, Phytomedicine : international journal of phytotherapy and phytopharmacology (2023) — In high-fat-diet-fed mice, heat-processed G. pentaphyllum gypenosides reduced body weight, serum total cholesterol, triglycerides, LDL and hepatic lipid accumulation, downregulating lipogenic genes (SREBP1, ACC1, SCD1) and upregulating lipid-oxidation pathways. [https://pubmed.ncbi.nlm.nih.gov/37094422/]
  - Gynostemma pentaphyllum Tea Improves Insulin Sensitivity in Type 2 Diabetic Patients, Journal of nutrition and metabolism (2013) — Improved glycemic control and insulin sensitivity in type-2 diabetics. [https://pubmed.ncbi.nlm.nih.gov/23431428/]
  - The add-on effects of Gynostemma pentaphyllum on nonalcoholic fatty liver disease, Alternative therapies in health and medicine (2006) — Reduced liver fat / enzymes in small trials. [https://pubmed.ncbi.nlm.nih.gov/16708768/]
  - Heat-processed Gynostemma pentaphyllum extract improves obesity in ob/ob mice by activating AMP-activated protein kinase, Biotechnology letters (2012) — AMPK activation and antioxidant effects in lab models. [https://pubmed.ncbi.nlm.nih.gov/22576281/]

---

## He Shou Wu (Fo-Ti) (Polygonum multiflorum · Hé Shǒu Wū 何首乌)
URL: https://nutridex.info/s/heshouwu
Category: TCM Herb, Longevity
Evidence: Preliminary — Early or small human trials; promising but not yet conclusive.
A famed longevity root — but with real liver risks.

Quick answer: He Shou Wu (Fo-Ti) is used for traditional anti-aging / hair tonic. NutriDex grades the human evidence as preliminary — Early or small human trials; promising but not yet conclusive. Based on 17 cited human studies (17 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

He Shou Wu (Hé Shǒu Wū) is one of the most famous longevity and hair-restoration tonics in TCM, surrounded by legend. Laboratory studies show antioxidant and neuroprotective activity from its stilbene glycosides, but rigorous human efficacy trials are essentially lacking. Critically, it is also one of the most reported herbal causes of drug-induced liver injury worldwide — a safety concern that outweighs its thin efficacy evidence.

Benefits / uses: Traditional anti-aging / hair tonic; Antioxidant (lab); Folk use for vitality.
Active compounds: Stilbene glycosides (THSG); Anthraquinones (emodin).
Dose: Traditionally used as prepared (processed) root in formulas; raw root is harsher.
Safety: ⚠ Significant risk of liver injury (acute hepatitis), including with 'natural' products. Avoid with liver disease or other hepatotoxic agents; stop and seek care if jaundice/dark urine occur.

Cited studies (17):
  - Liver Damage Associated with Polygonum multiflorum Thunb.: A Systematic Review of Case Reports and Case Series, Evidence-based complementary and alternative medicine : eCAM (2015) — Systematic review of 76 articles reporting 450 cases of P. multiflorum-associated liver injury found that most recovered after discontinuation, but 2 required liver transplantation and 7 died, establishing it as a leading cause of herb-induced liver injury. [https://pubmed.ncbi.nlm.nih.gov/25648693/]
  - Evaluation of a crataegus-based multiherb formula for dyslipidemia: a randomized, double-blind, placebo-controlled clinical trial, Evidence-based complementary and alternative medicine : eCAM (2014) — Randomized, double-blind, placebo-controlled trial (42 randomized, 40 completed, 12 weeks) of a Crataegus-based multiherb formula containing Polygonum multiflorum in Chinese dyslipidemic patients. Active treatment produced a modest but significant ~9% greater reduction in LDL-cholesterol vs placebo (P<0.05); HbA1c fell 3.9% on treatment but not significantly vs placebo. No notable adverse effects. Efficacy is for the combination formula, not PM in isolation. [https://pubmed.ncbi.nlm.nih.gov/24834096/]
  - Traditional usages, botany, phytochemistry, pharmacology and toxicology of Polygonum multiflorum Thunb.: a review, Journal of ethnopharmacology (2015) — Documented hepatotoxicity / drug-induced liver injury cases. [https://pubmed.ncbi.nlm.nih.gov/25449462/]
  - Phytochemistry, pharmacology, toxicology and detoxification of Polygonum multiflorum Thunb.: a comprehensive review, Frontiers in pharmacology (2024) — Comprehensive review concluding P. multiflorum's anthraquinones and stilbene glycosides cause dose- and duration-dependent hepatotoxicity, nephrotoxicity and embryotoxicity, partly mitigated by traditional processing. [https://pmc.ncbi.nlm.nih.gov/articles/PMC11215120/]
  - Research progress on hepatotoxicity mechanism of polygonum multiflorum and its main components, Toxicon : official journal of the International Society on Toxinology (2024) — Review summarizing that P. multiflorum and components (anthraquinones, stilbene glucoside) cause hepatotoxicity via oxidative phosphorylation disruption, impaired bile-acid efflux, immune activation and genetic/metabolic susceptibility. [https://pubmed.ncbi.nlm.nih.gov/39038664/]
  - The hepatotoxicity of Polygonum multiflorum: The emerging role of the immune-mediated liver injury, Acta pharmacologica Sinica (2021) — Review synthesizing epidemiological, clinical, and experimental evidence concluding PM-induced liver injury is an immune-mediated idiosyncratic DILI (not classic dose-dependent intrinsic toxicity), involving innate/adaptive immunity and loss of immune tolerance rather than a simple direct toxic mechanism. [https://pubmed.ncbi.nlm.nih.gov/32123300/]
  - Advances in the Study of the Potential Hepatotoxic Components and Mechanism of Polygonum multiflorum, Evidence-based complementary and alternative medicine : eCAM (2020) — Review of the potential hepatotoxic constituents and mechanisms of He Shou Wu, implicating anthraquinones (e.g., emodin) and stilbene glycosides (2,3,5,4'-tetrahydroxystilbene-2-O-glucoside) and their interaction with processing method and dose as drivers of liver injury. [https://pubmed.ncbi.nlm.nih.gov/33062019/]
  - Single-nucleotide polymorphisms of HLA and Polygonum multiflorum-induced liver injury in the Han Chinese population, World journal of gastroenterology (2020) — Case-control study (73 PM-DILI patients, 191 controls) found SNP rs1055348 strongly and specifically associated with P. multiflorum liver injury (OR 13.62), serving as a tag for HLA-B*35:01 with 100% sensitivity and >95% specificity. [https://pmc.ncbi.nlm.nih.gov/articles/PMC7109278/]
  - [Clinical Analysis of Drug-induced Liver Injury Caused by Polygonum multiflorum and its Preparations], Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi = Chinese journal of integrated traditional and Western medicine (2015) — Retrospective clinical analysis of 158 patients with P. multiflorum-related drug-induced liver injury found hepatocellular injury predominated (92.4%) and processed preparations accounted for 93.9% of cases, with 4 progressing to liver failure, 4 to cirrhosis and 1 death. [https://pubmed.ncbi.nlm.nih.gov/26882605/]
  - HLA-B*35:01 Allele Is a Potential Biomarker for Predicting Polygonum multiflorum-Induced Liver Injury in Humans, Hepatology (Baltimore, Md.) (2019) — Pharmacogenomic study (pilot + replication + prospective cohort of 72 PM users). HLA-B*35:01 is a high-risk allele for PM-induced liver injury: frequency 45.4% in PM-DILI vs 2.7% in Han Chinese (OR 30.4); vs other DILI OR 86.5 (95% CI 14.2-527.8) and vs population controls OR 143.9 (95% CI 30.1-687.5). In the prospective cohort, asymptomatic transaminase elevation occurred in 37.5% of carriers vs 4.7% of noncarriers (relative risk 8.0, 95% CI 1.9-33.2, P<0.02). Identifies a genetic biomarker for predicting PM hepatotoxicity. [https://pubmed.ncbi.nlm.nih.gov/30985007/]
  - HLA-B*35:01-mediated activation of emodin-specific T cells contributes to Polygonum multiflorum thunb. -induced liver injury in mice, Journal of ethnopharmacology (2024) — HLA-B*35:01 transgenic mice given emodin showed greater immune-mediated liver injury (higher transaminases, CD8+ T-cell infiltration) than wild-type, implicating emodin-specific T-cell activation in PM-induced liver injury. [https://pubmed.ncbi.nlm.nih.gov/38969149/]
  - Concurrent severe hepatotoxicity and agranulocytosis induced by Polygonum multiflorum: A case report, World journal of clinical cases (2022) — Single case of concurrent severe hepatotoxicity and agranulocytosis attributed to P. multiflorum ingestion, illustrating idiosyncratic multi-organ toxicity. [https://pubmed.ncbi.nlm.nih.gov/36186172/]
  - Diagnosis and Management of Drug-Induced Liver Injury After the Use of Polygonum multiflorum, ACG case reports journal (2022) — Case report of drug-induced liver injury after ingestion of P. multiflorum herbal tea, with biopsy showing portal and lobular lymphocytic inflammation and pericentral dropout, resolving after discontinuation. [https://pubmed.ncbi.nlm.nih.gov/36247379/]
  - [Correlational verification of drug-induced liver injury with HLA-B*35:01 allele due to Polygonum multiflorum], Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology (2021) — Correlational study confirming association between the HLA-B*35:01 allele and P. multiflorum-induced drug-induced liver injury, supporting an immune-mediated, genetically predisposed mechanism. [https://pubmed.ncbi.nlm.nih.gov/34933431/]
  - Polygonum multiflorum Thunb. Induces hepatotoxicity in SD rats and hepatocyte spheroids by Disrupting the metabolism of bilirubin and bile acid, Journal of ethnopharmacology (2022) — P. multiflorum induced hepatotoxicity in SD rats and human hepatocyte spheroids by disrupting bilirubin and bile-acid metabolism, supporting a cholestatic mechanism of injury. [https://pubmed.ncbi.nlm.nih.gov/35728710/]
  - Polygonum Multiflorum (2020) — No high-quality trials supporting anti-aging or hair claims. [https://www.ncbi.nlm.nih.gov/books/NBK548795/]
  - Tetrahydroxystilbene Glucoside Produces Neuroprotection against 6-OHDA-Induced Dopamine Neurotoxicity, Oxidative medicine and cellular longevity (2018) — Antioxidant and neuroprotective effects of THSG in animal models. [https://pubmed.ncbi.nlm.nih.gov/29576855/]

---

## Licorice Root (Glycyrrhiza glabra/uralensis · Gān Cǎo 甘草)
URL: https://nutridex.info/s/licorice
Category: TCM Herb, Gut & Immune
Evidence: Moderate — Several controlled trials; effects real but modest or context-dependent.
The 'great harmonizer' — soothing but blood-pressure sensitive.

Quick answer: Licorice Root is used for indigestion / functional dyspepsia (dgl). NutriDex grades the human evidence as moderate — Several controlled trials; effects real but modest or context-dependent. Based on 17 cited human studies (17 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Licorice (Gān Cǎo) appears in more TCM formulas than almost any other herb, used to 'harmonize' and soothe. Deglycyrrhizinated licorice (DGL) has reasonable evidence for easing functional dyspepsia and supporting the stomach lining. However, whole licorice contains glycyrrhizin, which in excess raises blood pressure, lowers potassium, and causes fluid retention — a well-documented risk, so DGL or short-term limited use is preferred.

Benefits / uses: Indigestion / functional dyspepsia (DGL); Soothes sore throat & ulcers; Harmonizes TCM formulas.
Active compounds: Glycyrrhizin; Flavonoids; DGL (deglycyrrhizinated form).
Dose: DGL 380–760 mg before meals for digestion; whole-root use should be limited and short-term.
Safety: ⚠ Whole licorice raises blood pressure and lowers potassium — avoid in hypertension, heart, or kidney disease and in pregnancy. Prefer DGL; limit duration.

Cited studies (17):
  - Effects of Licorice Functional Components Intakes on Blood Pressure: A Systematic Review with Meta-Analysis and NETWORK Toxicology, Nutrients (2024) — Meta-analysis of 8 RCTs (n=541) found glycyrrhizic acid significantly raised systolic and diastolic blood pressure, whereas licorice flavonoids had no significant effect. [https://pubmed.ncbi.nlm.nih.gov/39519602/]
  - Licorice and liver function in patients with primary liver disease: A systematic review and meta-analysis of RCTs, Phytotherapy research : PTR (2024) — Meta-analysis of 15 RCTs (n=1,367) in primary liver disease found licorice significantly reduced ALT (~15.6 U/L) and AST (~7.4 U/L) vs controls, with purified glycyrrhizic acid most effective. [https://pubmed.ncbi.nlm.nih.gov/39079711/]
  - Effects of Licorice Functional Components Intakes on Blood Pressure: A Systematic Review with Meta-Analysis and NETWORK Toxicology, Nutrients (2024) — Meta-analysis of 8 RCTs (541 participants) found glycyrrhizic-acid-containing licorice products significantly raised both systolic and diastolic blood pressure, supporting caution in hypertensive individuals. [https://pmc.ncbi.nlm.nih.gov/articles/PMC11547873/]
  - Topical Licorice for Aphthous: A Systematic Review of Clinical Trials, Iranian journal of medical sciences (2023) — Systematic review of clinical trials concluded topical licorice reduced visual analogue scale pain scores, ulcer size, and healing time in recurrent aphthous stomatitis compared with control therapies. [https://pmc.ncbi.nlm.nih.gov/articles/PMC10541548/]
  - The association between consistent licorice ingestion, hypertension and hypokalaemia: a systematic review and meta-analysis, Journal of human hypertension (2017) — Systematic review/meta-analysis of 18 studies (n=337) of chronic glycyrrhizic-acid-containing licorice. Significant rise in systolic BP (+5.45 mmHg, 95% CI 3.51-7.39) and diastolic BP (+3.19 mmHg, 95% CI 0.10-6.29), with significant falls in plasma potassium, renin activity and aldosterone (pseudohyperaldosteronism). Dose-BP correlation (SBP r=0.55, DBP r=0.65) even at modest doses. [https://pubmed.ncbi.nlm.nih.gov/28660884/]
  - Efficacy and safety of licorice (Glycyrrhiza glabra) in moderately ill patients with COVID-19: a randomized controlled trial, Inflammopharmacology (2023) — RCT in 60 moderately ill COVID-19 patients found licorice safe but with no significant benefit on oxygenation, temperature, or respiratory rate, only minor improvements in CRP and ALT. [https://pubmed.ncbi.nlm.nih.gov/37847472/]
  - A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Compound Glycyrrhizin Capsules Combined with a Topical Corticosteroid in Adults with Chronic Eczema, Evidence-based complementary and alternative medicine : eCAM (2020) — Multicenter double-blind RCT (n=193) found oral compound glycyrrhizin added to topical corticosteroid improved chronic eczema: higher EASI-75 response (47.9% vs 21.2%, P<0.001) and lower recurrence (3.2% vs 12.1%, P=0.021) vs placebo. [https://pmc.ncbi.nlm.nih.gov/articles/PMC7149328/]
  - Effects of licorice on relief and recurrence of menopausal hot flashes, Iranian journal of pharmaceutical research : IJPR (2012) — Double-blind randomized placebo-controlled trial of licorice root (330 mg x3 daily, 8 weeks) in 90 menopausal women. Frequency and severity of hot flashes decreased significantly versus placebo, with the benefit persisting up to 2 weeks after stopping; symptoms recurred ~2 weeks after therapy ended. [https://pubmed.ncbi.nlm.nih.gov/24250477/]
  - Licorice flavonoid oil reduces total body fat and visceral fat in overweight subjects: A randomized, double-blind, placebo-controlled study, Obesity research & clinical practice (2009) — 8-week randomized double-blind placebo-controlled dose-ranging trial of licorice flavonoid oil (0/300/600/900 mg/day) in 84 overweight adults. Total body fat (DXA) decreased significantly in all three LFO groups; the 900 mg/day dose also significantly reduced visceral fat area (CT), body weight, BMI and LDL-cholesterol from baseline, without significant adverse effects. [https://pubmed.ncbi.nlm.nih.gov/24345587/]
  - Liquorice Toxicity: A Comprehensive Narrative Review, Nutrients (2023) — Narrative review of 104 case reports confirming that excess liquorice intake causes pseudo-hyperaldosteronism with hypertension and hypokalemia, occasionally progressing to life-threatening arrhythmias, rhabdomyolysis, or coma. [https://pubmed.ncbi.nlm.nih.gov/37764649/]
  - Topical Licorice for Aphthous: A Systematic Review of Clinical Trials, Iranian journal of medical sciences (2023) — Systematic review of 6 clinical trials (314 subjects) found topical licorice (1-5% paste, patch, or mouthwash) significantly reduced recurrent aphthous stomatitis pain, ulcer size, and healing time (recovery within 4-8 days) with no adverse effects. [https://pubmed.ncbi.nlm.nih.gov/37786470/]
  - Licorice: From Pseudohyperaldosteronism to Therapeutic Uses, Frontiers in Endocrinology (2019) — Glycyrrhizin excess causes hypertension and hypokalemia (pseudoaldosteronism). [https://www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2019.00484/full]
  - Pseudohyperaldosteronism Due to Licorice: A Practice-Based Learning from a Case Series, International journal of molecular sciences (2024) — Case series of 3 patients with licorice-induced pseudohyperaldosteronism (hypertension and hypokalemia) that resolved after licorice withdrawal, sometimes requiring mineralocorticoid receptor blockers and potassium. [https://pmc.ncbi.nlm.nih.gov/articles/PMC11242244/]
  - Maternal Licorice Consumption During Pregnancy and Pubertal, Cognitive, and Psychiatric Outcomes in Children, American journal of epidemiology (2017) — Prospective Finnish birth-cohort study (n=378, mean age 12.5y) in the American Journal of Epidemiology found children of mothers with high prenatal glycyrrhizin intake (>=500 mg/week) scored ~7 IQ points lower, had poorer memory, ~3.3-fold higher odds of ADHD problems, and girls showed accelerated puberty. [https://pubmed.ncbi.nlm.nih.gov/28158597/]
  - Licorice Root: Usefulness and Safety, NIH National Center for Complementary and Integrative Health (2025) — NIH's NCCIH states glycyrrhizin in licorice can cause irregular heartbeat and cardiac arrest with large or long-term use, that ~250 g/week during pregnancy raises preterm-birth risk, and that licorice can interact harmfully with corticosteroids and other medications. [https://www.nccih.nih.gov/health/licorice-root]
  - An Extract of Glycyrrhiza glabra (GutGard) Alleviates Symptoms of Functional Dyspepsia: A Randomized, Double-Blind, Placebo-Controlled Study, Evidence-based complementary and alternative medicine : eCAM (2012) — DGL extract reduced functional-dyspepsia symptoms vs placebo. [https://pubmed.ncbi.nlm.nih.gov/21747893/]
  - Deglycyrrhizinated licorice, Wikipedia — DGL supports gastric mucosal protection. [https://en.wikipedia.org/wiki/Deglycyrrhizinated_licorice]

---

## Anabolic Steroids (AAS) (Synthetic testosterone derivatives)
URL: https://nutridex.info/s/aas
Category: Banned & Harmful, Performance
Evidence: Banned / Harmful — Linked to serious harm and/or banned in sport and many jurisdictions. Listed for awareness and safety only — NOT a recommendation.
Effective for muscle — and genuinely dangerous and illegal.

Quick answer: Anabolic Steroids (AAS) is marketed for muscle & strength gains. NutriDex grades the human evidence as banned / harmful — Linked to serious harm and/or banned in sport and many jurisdictions. Listed for awareness and safety only — NOT a recommendation. Based on 16 cited human studies (16 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Anabolic-androgenic steroids (AAS) are synthetic derivatives of testosterone. Unlike most entries here, they are pharmacologically effective at increasing muscle mass and strength — which is exactly why their illicit use is so widespread and so dangerous. Common forms span injectable esters — testosterone (enanthate, cypionate, propionate), nandrolone (Deca-Durabolin), trenbolone and boldenone (Equipoise) — and oral 17-α-alkylated agents such as methandrostenolone (Dianabol), oxymetholone (Anadrol), stanozolol (Winstrol) and oxandrolone (Anavar), the oral compounds carrying the greatest liver toxicity. Non-medical use is associated with a substantial burden of harm: cardiovascular disease, hormonal disruption, liver injury (especially oral 17-α-alkylated compounds), and psychiatric effects. They are controlled substances and banned in virtually all sport. This entry exists to document the risks, not to guide use.

Benefits / uses: (Claimed) muscle & strength gains; (Claimed) faster recovery.
Active compounds: Testosterone (enanthate / cypionate / propionate); Nandrolone (Deca-Durabolin); Trenbolone (acetate / enanthate); Boldenone (Equipoise); Methandrostenolone / Dianabol (oral); Oxymetholone / Anadrol (oral); Stanozolol / Winstrol; Oxandrolone / Anavar (oral); Drostanolone / Masteron; Methenolone / Primobolan; Fluoxymesterone / Halotestin (oral); Mesterolone / Proviron (oral); Methyltestosterone (oral).
Dose: No safe non-medical dose. Use only legitimate where prescribed and monitored by a physician for a diagnosed condition.
Safety: ⚠ SERIOUS HARM. Cardiovascular: left-ventricular hypertrophy, cardiomyopathy, accelerated atherosclerosis, hypertension, blood clots, heart attack and sudden cardiac death. Hormonal: shutdown of natural testosterone, testicular atrophy, infertility, gynecomastia; in women irreversible virilization (voice deepening, facial hair); in adolescents premature closure of growth plates (stunted height). Liver: oral steroids cause cholestasis, peliosis hepatis and tumors. Psychiatric: aggression, mania, depression and dependence. Injecting risks abscesses and blood-borne infection (HIV/HCV). Illegal without prescription and banned in sport.

Cited studies (16):
  - Anabolic-androgenic steroids on cardiac structure and function in resistance-trained athletes: A systematic review and meta-analysis, International journal of cardiology (2026) — Meta-analysis of 35 studies (2,000 men) found AAS-using resistance-trained athletes had lower LV ejection fraction (MD -2.25%, 95% CI -3.41 to -1.09) and worse global longitudinal strain (MD 3.34%, 95% CI 2.93 to 3.76) versus non-using athletes, indicating adverse cardiac remodeling. [https://pubmed.ncbi.nlm.nih.gov/40945618/]
  - Cardiovascular Safety of Testosterone-Replacement Therapy, The New England journal of medicine (2023) — Landmark RCT in 5246 hypogonadal men (45-80y) with high cardiovascular risk: transdermal testosterone (to physiologic levels) was noninferior to placebo for major adverse cardiac events (primary endpoint 7.0% vs 7.3%; HR 0.96, 95% CI 0.78-1.17; P<0.001 for noninferiority), but testosterone caused higher rates of atrial fibrillation, acute kidney injury, and pulmonary embolism. Establishes that physiologic-dose TRT does not raise MACE, distinct from supraphysiologic AAS abuse. [https://pubmed.ncbi.nlm.nih.gov/37326322/]
  - WADA / DEA classification — Banned in sport; Schedule III controlled substances in the US. [https://www.dea.gov/sites/default/files/2020-06/Steroids-2020_0.pdf]
  - Physical, psychological and biochemical recovery from anabolic steroid-induced hypogonadism: a scoping review, Endocrine connections (2023) — Scoping review of AAS-induced hypogonadism reporting near-complete testosterone recovery over months and gonadotropin recovery in 3-6 months, but spermatogenesis and testicular atrophy recovery taking months to years and gynaecomastia often irreversible. [https://pubmed.ncbi.nlm.nih.gov/37855241/]
  - Abusive use of anabolic androgenic steroids, male sexual dysfunction and infertility: an updated review, Frontiers in toxicology (2024) — Updated review concluding AAS abuse suppresses the hypothalamic-pituitary-gonadal axis, lowering endogenous testosterone and impairing spermatogenesis, causing sexual dysfunction and frequently reversible-but-prolonged infertility. [https://pubmed.ncbi.nlm.nih.gov/38711907/]
  - Mortality Among Users of Anabolic Steroids, JAMA (2024) — Danish matched cohort of 545 male AAS users vs 5,450 controls found all-cause mortality roughly tripled among users (HR 3.0, 95% CI 1.3-7.0). [https://pubmed.ncbi.nlm.nih.gov/38483396/]
  - Cardiovascular Disease in Anabolic Androgenic Steroid Users, Circulation (2025) — Prospective cohort of 1,189 AAS users vs 59,450 controls over ~11 years showed markedly elevated cardiovascular risk: cardiomyopathy (aHR 8.9), heart failure (aHR 3.6), myocardial infarction (aHR 3.0), and venous thromboembolism (aHR 2.4). [https://pubmed.ncbi.nlm.nih.gov/39945117/]
  - A study of long-term supraphysiologic-dose anabolic-androgenic steroid use on cognitive function in middle-aged men, The American journal of drug and alcohol abuse (2024) — Study of 76 middle-aged male weightlifters (51 with >=2 years AAS use vs 25 non-users) found no significant cognitive differences across visuospatial memory, verbal memory, emotion recognition, or executive function domains. [https://pubmed.ncbi.nlm.nih.gov/39373343/]
  - Bodybuilding Products: SARMs Cause Harm, U.S. Food and Drug Administration — FDA consumer warning advising people to immediately stop using over-the-counter bodybuilding products labeled to contain steroid or steroid-like substances (including SARMs) due to risks of serious liver injury, kidney injury, increased heart attack and stroke risk, testicular shrinkage, and male infertility. [https://www.fda.gov/drugs/fraudulent-products/certain-bodybuilding-products-put-consumers-risk-heart-attack-stroke-serious-liver-damage-and-more]
  - Psychiatric morbidity among men using anabolic steroids, Depression and anxiety (2022) — Matched cohort of 545 male AAS users vs 5,450 controls found increased psychiatric morbidity after doping sanction, including antipsychotic (HR 2.69), anxiolytic (HR 2.34), and antidepressant (HR 1.65) treatment. [https://pubmed.ncbi.nlm.nih.gov/36281632/]
  - Cognitive performance and structural brain correlates in long-term anabolic-androgenic steroid exposed and nonexposed weightlifters, Neuropsychology (2019) — Cross-sectional study of 84 AAS-using vs 69 non-using male weightlifters (n=153) found AAS users performed significantly worse on cognition, with strongest deficits in problem solving, working memory, and processing speed, and longer use associated with poorer memory plus structural brain correlates. [https://pubmed.ncbi.nlm.nih.gov/31033318/]
  - Adverse health consequences of performance-enhancing drugs: an Endocrine Society scientific statement, Endocrine reviews (2014) — Comprehensive review documenting cardiovascular, endocrine, hepatic and psychiatric harms of AAS. [https://pubmed.ncbi.nlm.nih.gov/24423981/]
  - Health consequences of androgenic anabolic steroid use, Journal of internal medicine (2019) — Retrospective matched Danish cohort (545 AAS-positive men vs 5450 controls, replicated in a second cohort): all-cause mortality was 3-fold higher among AAS users (HR 3.0, 95% CI 1.3-7.0), with more than double the hospital contacts (0.81 vs 0.36 per year) and high prevalence of acne, gynecomastia, and erectile dysfunction (>10%). [https://pubmed.ncbi.nlm.nih.gov/30460728/]
  - Cardiovascular Toxicity of Illicit Anabolic-Androgenic Steroid Use, Circulation (2017) — Long-term AAS use linked to reduced cardiac function and coronary atherosclerosis. [https://pubmed.ncbi.nlm.nih.gov/28533317/]
  - Androgenic Steroids (2020) — NIH LiverTox authoritative review concludes that C-17alpha-alkylated oral AAS cause a distinctive bland cholestatic liver injury (onset 1-4 months) and, with prolonged use (typically 5-15 years), peliosis hepatis and hepatic tumors including adenoma and hepatocellular carcinoma; non-alkylated injectable testosterone esters rarely do so. [https://www.ncbi.nlm.nih.gov/books/NBK548931/]
  - Anabolic Steroids and Other Appearance and Performance Enhancing Drugs (APEDs), NIH National Institute on Drug Abuse (2024) — NIH National Institute on Drug Abuse states AAS can lead to a substance use disorder, with withdrawal symptoms (including depression that can lead to suicide attempts) on cessation, and notes some users progress to opioids to manage steroid-induced sleep and irritability problems. [https://nida.nih.gov/research-topics/anabolic-steroids]

---

## SARMs (Selective Androgen Receptor Modulators (e.g. Ostarine, LGD-4033))
URL: https://nutridex.info/s/sarms
Category: Banned & Harmful, Performance
Evidence: Banned / Harmful — Linked to serious harm and/or banned in sport and many jurisdictions. Listed for awareness and safety only — NOT a recommendation.
Unapproved 'research chemicals' sold illegally as supplements.

Quick answer: SARMs is marketed for muscle gain with 'fewer side effects'. NutriDex grades the human evidence as banned / harmful — Linked to serious harm and/or banned in sport and many jurisdictions. Listed for awareness and safety only — NOT a recommendation. Based on 20 cited human studies (20 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

SARMs are experimental drugs designed to stimulate androgen receptors in muscle. Marketed online as a 'safe, legal' steroid alternative, they are in fact unapproved investigational compounds that the FDA has explicitly warned against. The 'fewer side effects' claim is unproven: trials and case reports show testosterone suppression, adverse lipid changes and drug-induced liver injury. Analyses repeatedly find products are mislabeled — containing unlisted drugs, wrong doses, or no SARM at all.

Benefits / uses: (Claimed) muscle gain with 'fewer side effects'.
Active compounds: Ostarine (MK-2866); Ligandrol (LGD-4033); RAD-140 & similar.
Dose: No approved or safe dose — not legal dietary ingredients and not approved for human use.
Safety: ⚠ Testosterone suppression, lowered HDL ('good') cholesterol, and drug-induced liver injury (hepatotoxicity) reported. Long-term safety is unknown. Not FDA-approved, not legal dietary ingredients, and banned by WADA. Products are frequently adulterated and mislabeled — you often don't know what you're actually taking.

Cited studies (20):
  - Systematic Review of Safety of Selective Androgen Receptor Modulators in Healthy Adults: Implications for Recreational Users, Journal of xenobiotics (2023) — Systematic review of 33 studies (2,136 patients; 1,447 SARM-exposed) found 15 cases of drug-induced liver injury plus tendon rupture and rhabdomyolysis, concluding recreational SARM use poses significant health risks. [https://pubmed.ncbi.nlm.nih.gov/37218811/]
  - Athlete Selective Androgen Receptor Modulators Abuse: A Systematic Review, The American journal of sports medicine (2025) — Systematic review (72 articles, 15 case reports, median age 32, all male) found athlete SARM abuse associated with hepatotoxicity, cardiotoxicity, testosterone suppression, tendon damage and frequent product contamination. [https://pubmed.ncbi.nlm.nih.gov/39755947/]
  - Selective androgen receptor modulator use and related adverse events including drug-induced liver injury: Analysis of suspected cases, European journal of clinical pharmacology (2024) — Pharmacovigilance review of 20 published adverse-event reports (since 2020) found SARM use predominantly associated with drug-induced liver injury, mostly a cholestatic pattern with jaundice, in otherwise healthy recreational users of unregulated products. [https://pubmed.ncbi.nlm.nih.gov/38059982/]
  - Selective Androgen Receptor Modulators (SARMs) Effects on Physical Performance: A Systematic Review of Randomized Control Trials, Clinical endocrinology (2025) — PRISMA systematic review of 9 RCTs (6 SARMs: LGD-4033, PF-06260414, GSK2881078, GTx-024/enobosarm, MK-0773, OPK-88004; 970 patients, mean age 57). SARMs produced positive effects on body composition and physical performance (e.g., mean lean body mass rose ~49.5 to 50.9 kg; 1-RM leg press ~1823 to 2191 N) with moderate rates of mild-to-moderate adverse effects and a low rate of severe AEs. [https://pubmed.ncbi.nlm.nih.gov/39285652/]
  - Social Media Posts by Influencers and Online Sellers Promote SARMs Use, U.S. Food and Drug Administration — FDA formally warned that SARMs are unapproved drugs associated with increased risk of heart attack, stroke, psychosis, liver injury/failure, infertility and testicular shrinkage, and cannot be legally marketed as supplements, specifically cautioning teens and young adults. [https://www.fda.gov/consumers/consumer-updates/fda-warns-use-selective-androgen-receptor-modulators-sarms-among-teens-young-adults]
  - Bodybuilding Products: SARMs Cause Harm, U.S. Food and Drug Administration — Public warnings that SARMs are associated with serious safety concerns and are illegally marketed. [https://www.fda.gov/drugs/fraudulent-products/certain-bodybuilding-products-put-consumers-risk-heart-attack-stroke-serious-liver-damage-and-more]
  - Activity and safety of enobosarm, a novel, oral, selective androgen receptor modulator, in androgen receptor-positive, oestrogen receptor-positive, and HER2-negative advanced breast cancer (Study G200802): a randomised, open-label, multicentre, multinational, parallel design, phase 2 trial, The Lancet Oncology (2024) — Randomised open-label phase 2 trial of enobosarm in AR+/ER+/HER2- advanced breast cancer (Study G200802) showed clinical benefit in the higher-dose arm, the main legitimate clinical context for a SARM. [https://doi.org/10.1016/S1470-2045(24)00004-4]
  - Activity and safety of enobosarm, a novel, oral, selective androgen receptor modulator, in androgen receptor-positive, oestrogen receptor-positive, and HER2-negative advanced breast cancer (Study G200802): a randomised, open-label, multicentre, multinational, parallel design, phase 2 trial, The Lancet. Oncology (2024) — Randomized open-label phase 2 trial of oral enobosarm (9 mg vs 18 mg) in 136 postmenopausal women with AR-positive, ER-positive, HER2-negative advanced breast cancer. Clinical benefit at 24 weeks in 32% (9 mg) and 29% (18 mg); demonstrated AR activation yields anti-tumour activity. Grade 3-4 drug-related AEs in 8% (9 mg) vs 16% (18 mg), mainly raised hepatic transaminases. [https://pubmed.ncbi.nlm.nih.gov/38342115/]
  - A Phase II Clinical Trial of Pembrolizumab and Enobosarm in Patients with Androgen Receptor-Positive Metastatic Triple-Negative Breast Cancer, The oncologist (2021) — Open-label phase 2 trial of enobosarm 18 mg plus pembrolizumab in AR-positive metastatic triple-negative breast cancer (18 enrolled, 16 evaluable). Modest 16-week clinical benefit rate of 25% (response rate 13%); well tolerated with few grade 3 AEs; median OS 25.5 months. Stopped early due to drug-supply withdrawal. [https://pubmed.ncbi.nlm.nih.gov/33141975/]
  - Selective Androgen Receptor Modulators (SARMs), U.S. Anti-Doping Agency (2025) — Authoritative anti-doping guidance confirming all SARMs (e.g. ostarine, ligandrol/LGD-4033, RAD-140, andarine, S-23, YK-11) are prohibited at all times under class S1.2 (other anabolic agents) of the WADA Prohibited List, banned in sport since 2008 for athletes at every level. [https://www.usada.org/spirit-of-sport/selective-androgen-receptor-modulators-sarms-prohibited-class-anabolic-agents/]
  - Study Design and Rationale for the Phase 3 Clinical Development Program of Enobosarm, a Selective Androgen Receptor Modulator, for the Prevention and Treatment of Muscle Wasting in Cancer Patients (POWER Trials), Current oncology reports (2016) — Design/rationale paper for the twin randomized double-blind placebo-controlled phase 3 POWER trials of enobosarm 3 mg for prevention/treatment of muscle wasting in >600 NSCLC patients on first-line chemotherapy. Enobosarm increased lean body mass vs placebo in both trials, but the co-primary lean-mass + stair-climb-power responder endpoints were mixed and not met. [https://pubmed.ncbi.nlm.nih.gov/27138015/]
  - Effects of enobosarm on muscle wasting and physical function in patients with cancer: a double-blind, randomised controlled phase 2 trial, The Lancet. Oncology (2013) — Double-blind placebo-controlled phase 2 RCT in 159 cancer patients with cachexia. Enobosarm significantly increased total lean body mass vs baseline (1 mg: median +1.5 kg, p=0.0012; 3 mg: +1.0 kg, p=0.046), whereas placebo did not change (+0.02 kg, p=0.88), without androgenic toxicity. [https://pubmed.ncbi.nlm.nih.gov/23499390/]
  - The selective androgen receptor modulator GTx-024 (enobosarm) improves lean body mass and physical function in healthy elderly men and postmenopausal women: results of a double-blind, placebo-controlled phase II trial, Journal of cachexia, sarcopenia and muscle (2011) — 12-week double-blind placebo-controlled phase 2 RCT in 120 healthy elderly men and postmenopausal women. Enobosarm (GTx-024) produced dose-dependent, statistically significant increases in total lean body mass (3 mg vs placebo, p<0.001) plus improved physical function (p=0.013) and insulin resistance (p=0.013); AE incidence similar to placebo. [https://pubmed.ncbi.nlm.nih.gov/22031847/]
  - Selective Androgen Receptor Modulators (2025) — NIH LiverTox monograph reports SARMs (ostarine, LGD-4033, RAD-140) cause clinically apparent cholestatic drug-induced liver injury, typically arising weeks to months after use in otherwise healthy young men. [https://www.ncbi.nlm.nih.gov/books/NBK619971/]
  - LGD-4033 and a Case of Drug-Induced Liver Injury: Exploring the Clinical Implications of Off-Label Selective Androgen Receptor Modulator Use in Healthy Adults, Cureus (2024) — Case report of drug-induced cholestatic liver injury in a healthy adult using LGD-4033 (ligandrol) off-label, illustrating hepatotoxicity risk from recreational SARM use in otherwise healthy individuals. [https://pmc.ncbi.nlm.nih.gov/articles/PMC11485217/]
  - RAD-140 Drug-Induced Liver Injury, Ochsner journal (2022) — Drug-induced liver injury and hormonal suppression linked to SARM use. [https://pubmed.ncbi.nlm.nih.gov/36561105/]
  - LGD-4033 and a Case of Drug-Induced Liver Injury: Exploring the Clinical Implications of Off-Label Selective Androgen Receptor Modulator Use in Healthy Adults, Cureus (2024) — Case report of a healthy adult developing cholestatic drug-induced liver injury after off-label LGD-4033 (ligandrol) use, highlighting hepatotoxic risk in recreational users. [https://pubmed.ncbi.nlm.nih.gov/39421081/]
  - Myopericarditis Following Use of Selective Androgen Receptor Modifier "RAD-140", JACC. Case reports (2024) — Case report of a 16-year-old boy presenting with acute myopericarditis (pleuritic chest pain radiating to the left arm) hours after his first and only dose of RAD-140, documenting life-threatening cardiac injury even with minimal SARM exposure. [https://pubmed.ncbi.nlm.nih.gov/39157568/]
  - Acute Myocarditis From the Use of Selective Androgen Receptor Modulator (SARM) RAD-140 (Testolone), Cureus (2022) — Case report of a 32-year-old man who developed acute myocarditis (chest pain, elevated troponin, reduced ejection fraction) after self-administering the SARM RAD-140 (testolone) for bodybuilding, illustrating reversible SARM-induced cardiotoxicity. [https://pubmed.ncbi.nlm.nih.gov/35233331/]
  - Chemical Composition and Labeling of Substances Marketed as Selective Androgen Receptor Modulators and Sold via the Internet, JAMA (2017) — Only ~52% of SARM products were accurately labeled; many contained unapproved drugs. [https://pubmed.ncbi.nlm.nih.gov/29183075/]

---

## DNP (2,4-Dinitrophenol)
URL: https://nutridex.info/s/dnp
Category: Banned & Harmful
Evidence: Banned / Harmful — Linked to serious harm and/or banned in sport and many jurisdictions. Listed for awareness and safety only — NOT a recommendation.
An industrial chemical sold for fat loss — it can kill you.

Quick answer: DNP (2,4-Dinitrophenol) is marketed for extreme rapid fat loss. NutriDex grades the human evidence as banned / harmful — Linked to serious harm and/or banned in sport and many jurisdictions. Listed for awareness and safety only — NOT a recommendation. Based on 19 cited human studies (19 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

DNP is an industrial chemical (used in dyes, explosives and pesticides) that uncouples mitochondrial energy production, forcing the body to burn energy as heat. Sold illicitly to bodybuilders and dieters for rapid fat loss, it is one of the most dangerous substances marketed as a 'supplement'. Its toxic dose is perilously close to the dose people take, and overdose causes a runaway rise in body temperature that is frequently fatal. Regulators worldwide warn against it; deaths continue to be reported.

Benefits / uses: (Claimed) extreme rapid fat loss.
Active compounds: 2,4-Dinitrophenol (a mitochondrial uncoupler).
Dose: No safe dose exists. DNP is not fit for human consumption under any circumstances.
Safety: ⚠ POTENTIALLY FATAL. Causes dangerous hyperthermia (overheating), rapid heartbeat, profuse sweating, agitation, seizures, multi-organ failure and death — sometimes hours after ingestion with no antidote. There is no margin of safety. It is illegal to sell for human consumption. Do not take it under any circumstances; seek emergency care immediately for any exposure.

Cited studies (19):
  - 2,4-Dinitrophenol (DNP), Food Standards Agency (2025) — As of 1 October 2023 DNP was reclassified as a regulated poison, making it a criminal offence to sell to the public without a licence after repeated DNP-related deaths. [https://www.food.gov.uk/safety-hygiene/24-dinitrophenol-dnp]
  - Toxicological Profile for Dinitrophenols, Agency for Toxic Substances and Disease Registry (ATSDR) (2021) — US federal toxicology profile concluding DNP uncouples oxidative phosphorylation with no safe therapeutic dose, causing hyperthermia, cataracts and death across human and animal data. [https://www.atsdr.cdc.gov/ToxProfiles/tp64.pdf]
  - Deadly DNP, UK Health Security Agency (2018) — Repeated international warnings after DNP-related deaths, many in young people. [https://ukhsa.blog.gov.uk/2018/08/13/deadly-dnp/]
  - 2,4-dinitrophenol (DNP): a weight loss agent with significant acute toxicity and risk of death, Journal of medical toxicology : official journal of the American College of Medical Toxicology (2011) — Reviewed DNP fatalities — fatal hyperthermia and multi-organ failure with narrow toxic margin. [https://pubmed.ncbi.nlm.nih.gov/21739343/]
  - Sublethal toxicities of 2,4-dinitrophenol as inferred from online self-reports, PloS one (2023) — Analysis of online self-reports characterized common sublethal DNP effects (hyperthermia, sweating, malaise, yellow skin) among unregulated weight-loss users, complementing fatality-focused literature. [https://pmc.ncbi.nlm.nih.gov/articles/PMC10499234/]
  - 2,4-dinitrophenol intoxication and its morphological findings as an indication of substance intake, Journal of pharmaceutical and biomedical analysis (2025) — Retrospective analysis of DNP poisoning cases (early 1900s–2021) identifying characteristic morphological markers of ingestion, notably yellow discoloration of skin, sclera and urine, with yellow skin suggesting prolonged consumption as an indication of substance intake. [https://pubmed.ncbi.nlm.nih.gov/39378760/]
  - Sublethal toxicities of 2,4-dinitrophenol as inferred from online self-reports, PloS one (2023) — Analysis of 1,630 posts from 1,234 users across DNP online forums found thermoregulatory, fatigue-related and neurological symptoms significantly more frequent at daily doses >150 mg than below, with profuse sweating and fatigue the most common adverse effects and frequent co-use of T3, clenbuterol and anabolic steroids. [https://pmc.ncbi.nlm.nih.gov/articles/PMC10499234/]
  - Sublethal toxicities of 2,4-dinitrophenol as inferred from online self-reports, PloS one (2023) — Analysis of user self-reports characterized dose-dependent sublethal DNP effects (hyperthermia, sweating, malaise, cataract/skin reactions), showing toxicity occurs even at sub-lethal 'diet' doses. [https://pubmed.ncbi.nlm.nih.gov/37703241/]
  - Diet aid or aid to die: an update on 2,4-dinitrophenol (2,4-DNP) use as a weight-loss product, Archives of toxicology (2020) — Comprehensive update review concluding that DNP, banned for human use since 1938, continues to cause fatal intoxications (hyperthermia, tachycardia, hypotension, acute renal failure) with no specific antidote, prompting the 2015 Interpol worldwide warning. [https://pubmed.ncbi.nlm.nih.gov/32078021/]
  - Beware the yellow slimming pill: fatal 2,4-dinitrophenol overdose, BMJ case reports (2016) — Deaths reported even from doses taken intentionally for weight loss. [https://pmc.ncbi.nlm.nih.gov/articles/PMC4840695/]
  - A narrative review of consolidation strategies for young and fit patients with newly-diagnosed primary central nervous system lymphoma, Expert review of hematology (2022) — WHO-linked analysis of poisons-centre data found systemic DNP exposures rose from 4 (2010) to 71 (2015), with a high case fatality of 11.9% and no sex difference. [https://pubmed.ncbi.nlm.nih.gov/34904506/]
  - Toxicoepidemiology and predictors of death in 2,4-dinitrophenol (DNP) toxicity, Clinical toxicology (Philadelphia, Pa.) (2021) — Pooled analysis of DNP exposures found a high case fatality of 11.9% (95% CI 9.0-15.4%), with no sex difference; acidosis, tachycardia, hyperpyrexia, and agitation/confusion were independent predictors of death. [https://pubmed.ncbi.nlm.nih.gov/33021407/]
  - International trends in systemic human exposures to 2,4 dinitrophenol reported to poisons centres, Clinical toxicology (Philadelphia, Pa.) (2022) — Multi-national poisons-centre surveillance documented substantial increases in systemic human DNP exposures across Europe, Australia, and North America between 2010 and 2015, with fatal outcomes common. [https://pubmed.ncbi.nlm.nih.gov/34812657/]
  - Role of dantrolene in dinitrophenol (DNP) overdose: A continuing question?, The American journal of emergency medicine (2019) — Critical appraisal arguing that dantrolene therapy for DNP poisoning is biochemically implausible and likely futile, with at least one reported case of ineffective use, underscoring that management remains supportive (aggressive cooling, fluids) with no proven antidote. [https://pubmed.ncbi.nlm.nih.gov/30948257/]
  - Runaway uncoupling in 2,4-dinitrophenol poisoning: Clinical and mitochondrial observations from two cases, Toxicology reports (2026) — Two Swedish DNP poisonings (one fatal suicidal ingestion, one non-fatal weight-loss use) supported a self-amplifying 'runaway uncoupling' feedback loop, with the fatal case progressing within hours to hyperthermia, hyperkalemia and ATP depletion. [https://pmc.ncbi.nlm.nih.gov/articles/PMC12756549/]
  - Case report: Fatal long-term intoxication by 2,4-dinitrophenol and anabolic steroids in a young bodybuilder with muscle dysmorphia, Frontiers in public health (2024) — A 21-year-old bodybuilder with muscle dysmorphia died after ~6 months of DNP plus anabolic steroid use and a final 2 g dose, presenting with the classic triad of tachycardia, tachypnea and profuse sweating before fatal multi-organ failure. [https://pmc.ncbi.nlm.nih.gov/articles/PMC11628266/]
  - Survival of Acute-on-Chronic 2,4-Dinitrophenol Overdose with Associated Pharmacokinetics, Journal of medical toxicology : official journal of the American College of Medical Toxicology (2026) — An 18-year-old female survived an acute-on-chronic DNP overdose presenting with a hypermetabolic state and widespread ST-segment depression with troponin I elevation; serial DNP levels followed first-order kinetics with an ~18-hour elimination half-life, providing rare human overdose pharmacokinetic data. [https://pubmed.ncbi.nlm.nih.gov/41249632/]
  - Clinical features and treatment in patients with acute 2,4-dinitrophenol poisoning, Journal of Zhejiang University. Science. B (2011) — Case series of acute DNP poisoning described the consistent clinical syndrome of hyperthermia, tachycardia, sweating and agitation progressing to multi-organ failure, with supportive cooling/management as the only available treatment. [https://pubmed.ncbi.nlm.nih.gov/21370503/]
  - Physiologically-based pharmacokinetic model for 2,4-dinitrophenol, Journal of pharmacokinetics and pharmacodynamics (2022) — A physiologically-based pharmacokinetic model of DNP characterized its absorption and tissue distribution, helping explain the narrow margin between weight-loss doses and the accumulation that drives lethal hyperthermia. [https://pubmed.ncbi.nlm.nih.gov/35089483/]

---

## Ephedra / Ephedrine (Ephedra sinica · Má Huáng 麻黄)
URL: https://nutridex.info/s/ephedra
Category: Banned & Harmful
Evidence: Banned / Harmful — Linked to serious harm and/or banned in sport and many jurisdictions. Listed for awareness and safety only — NOT a recommendation.
A weight-loss stimulant banned after deaths and strokes.

Quick answer: Ephedra / Ephedrine is marketed for weight loss. NutriDex grades the human evidence as banned / harmful — Linked to serious harm and/or banned in sport and many jurisdictions. Listed for awareness and safety only — NOT a recommendation. Based on 16 cited human studies (16 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Ephedra (má huáng) is a stimulant herb whose ephedrine alkaloids raise heart rate and blood pressure. It was hugely popular in weight-loss and 'energy' supplements until mounting reports of serious cardiovascular and neurological events — including deaths — led the FDA to ban ephedrine-alkaloid supplements in 2004. Evidence shows only modest short-term weight loss, with a clear increase in adverse effects. Its ban is a landmark supplement-safety case.

Benefits / uses: (Claimed) weight loss; (Claimed) energy & performance.
Active compounds: Ephedrine alkaloids.
Dose: Banned in dietary supplements (US, 2004). Not recommended for weight loss or energy at any dose.
Safety: ⚠ Heart palpitations, dangerously high blood pressure, arrhythmias, heart attack, stroke, seizures and death have been reported. Risk rises sharply when combined with caffeine or other stimulants. Banned in dietary supplements in the US; tightly restricted elsewhere.

Cited studies (16):
  - Efficacy and safety of ephedra-containing oral medications: a systematic review, meta-analysis, and exploratory dose-response analysis for weight reduction, Frontiers in pharmacology (2024) — Meta-analysis of 16 RCTs of ephedra-containing oral medications showed significant BMI reduction (~1.5 kg/m2) for weight loss, with no significant difference in adverse events vs control (RR 0.99) within supervised dosing. [https://pmc.ncbi.nlm.nih.gov/articles/PMC11557485/]
  - Efficacy and safety of ephedra-containing oral medications: a systematic review, meta-analysis, and exploratory dose-response analysis for weight reduction, Frontiers in pharmacology (2024) — Meta-analysis of 16 RCTs found ephedra-containing oral medications reduced BMI by a mean of 1.5 kg/m2 (95% CI -2.46 to -0.54) with no significant difference in adverse effects vs control (RR 0.99, 95% CI 0.80-1.21) when dosed under medical supervision. [https://pubmed.ncbi.nlm.nih.gov/39539620/]
  - Effects of Ephedrine-Containing Products on Weight Loss and Lipid Profiles: A Systematic Review and Meta-Analysis of Randomized Controlled Trials, Pharmaceuticals (Basel, Switzerland) (2021) — Meta-analysis of 10 RCTs found ephedrine-containing products produced modest weight loss (MD -1.97 kg) and improved lipids vs placebo, but raised mean heart rate by ~5.76 beats/min. [https://pmc.ncbi.nlm.nih.gov/articles/PMC8618781/]
  - Effects of Ephedrine-Containing Products on Weight Loss and Lipid Profiles: A Systematic Review and Meta-Analysis of Randomized Controlled Trials, Pharmaceuticals (Basel, Switzerland) (2021) — Meta-analysis of 10 RCTs found ephedrine-containing products produced greater weight loss than placebo (mean difference -1.97 kg, 95% CI -2.38 to -1.57) but raised heart rate by 5.76 bpm (95% CI 3.42-8.10), warranting cardiac monitoring. [https://pmc.ncbi.nlm.nih.gov/articles/PMC8618781/]
  - Effects of Ephedrine-Containing Products on Weight Loss and Lipid Profiles: A Systematic Review and Meta-Analysis of Randomized Controlled Trials, Pharmaceuticals (Basel, Switzerland) (2021) — Meta-analysis of 10 placebo-controlled RCTs of ephedrine-containing products: greater weight loss (MD -1.97 kg; 95% CI -2.38 to -1.57), favorable lipid changes (higher HDL, lower LDL and triglycerides), and no significant BP change, but heart rate increased by 5.76 beats/min (95% CI 3.42-8.10). [https://pubmed.ncbi.nlm.nih.gov/34832979/]
  - Final Rule Declaring Dietary Supplements Containing Ephedrine Alkaloids Adulterated Because They Present an Unreasonable Risk, Federal Register (2004) — Banned dietary supplements containing ephedrine alkaloids as posing an unreasonable risk. [https://www.federalregister.gov/documents/2004/02/11/04-2912/final-rule-declaring-dietary-supplements-containing-ephedrine-alkaloids-adulterated-because-they]
  - Herbal ephedra/caffeine for weight loss: a 6-month randomized safety and efficacy trial, International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity (2002) — 6-month double-blind placebo-controlled RCT (n=167) of herbal ephedra/caffeine (90/192 mg/day): greater weight loss (-5.3 vs -2.6 kg, P<0.001), reduced body fat and LDL, increased HDL; heart rate rose 4 bpm but cardiac arrhythmias were not increased. [https://pubmed.ncbi.nlm.nih.gov/12032741/]
  - The effect and safety of an ephedrine/caffeine compound compared to ephedrine, caffeine and placebo in obese subjects on an energy restricted diet. A double blind trial, International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity (1992) — 24-week double-blind RCT (n=180) showing ephedrine/caffeine (20/200 mg t.i.d.) produced significantly greater weight loss than placebo (16.6 vs 13.2 kg, P=0.0015), whereas ephedrine alone and caffeine alone were no better than placebo, demonstrating synergy. Side effects were transient. [https://pubmed.ncbi.nlm.nih.gov/1318281/]
  - Adverse cardiovascular and central nervous system events associated with dietary supplements containing ephedra alkaloids, The New England journal of medicine (2000) — Heart attack, stroke, seizure and sudden death associated with use. [https://pubmed.ncbi.nlm.nih.gov/11117974/]
  - Ephedra (2018) — NIH toxicology review documents ephedra/ma huang as a cause of clinically apparent hepatocellular injury, including massive necrosis and rare acute liver failure, with cases still reported from Asia. [https://www.ncbi.nlm.nih.gov/books/NBK548711/]
  - Use of a prescribed ephedrine/caffeine combination and the risk of serious cardiovascular events: a registry-based case-crossover study, American journal of epidemiology (2008) — Registry-based case-crossover study of 257,364 users (2,316 cardiovascular events) found prescribed ephedrine/caffeine was not associated with a substantially increased risk of serious cardiovascular outcomes (adjusted OR 0.95, 95% CI 0.79-1.16). [https://pubmed.ncbi.nlm.nih.gov/18756018/]
  - Reduction in ephedra poisonings after FDA ban, The New England journal of medicine (2015) — U.S. poison-center analysis found ephedra-related calls fell from a peak of 10,326 in 2002 to 180 by 2013, with poisonings causing major effects or death declining by more than 98% after the 2004 FDA ban. [https://pubmed.ncbi.nlm.nih.gov/26017843/]
  - Ventricular arrhythmias induced by long-term use of ephedrine in two competitive athletes, Heart and vessels (2015) — Case report of two competitive athletes who developed ventricular arrhythmias after long-term ephedrine use, with myocardial structural changes promoting re-entrant tachyarrhythmia. [https://pubmed.ncbi.nlm.nih.gov/24390726/]
  - Running a risk? Sport supplement toxicity with ephedrine in an amateur marathon runner, with subsequent rhabdomyolysis, BMJ case reports (2011) — Case report of an amateur marathon runner who developed ephedrine sport-supplement toxicity with subsequent rhabdomyolysis. [https://pubmed.ncbi.nlm.nih.gov/22669965/]
  - Efficacy and safety of ephedra and ephedrine for weight loss and athletic performance: a meta-analysis, JAMA (2003) — Modest weight loss but significantly increased psychiatric, autonomic, GI and palpitation side effects. [https://pubmed.ncbi.nlm.nih.gov/12672771/]
  - Ephedra: Usefulness and Safety, NIH National Center for Complementary and Integrative Health (2024) — NIH's National Center for Complementary and Integrative Health states ephedrine-alkaloid supplements produced only modest short-term weight loss but caused serious harms (high blood pressure, heart attack, seizure, stroke, psychosis) even at low doses and brief use, and remain banned and unsafe. [https://www.nccih.nih.gov/health/ephedra]

---

## Clenbuterol (Clenbuterol hydrochloride)
URL: https://nutridex.info/s/clenbuterol
Category: Banned & Harmful
Evidence: Banned / Harmful — Linked to serious harm and/or banned in sport and many jurisdictions. Listed for awareness and safety only — NOT a recommendation.
A veterinary/asthma drug abused for fat loss — heart-toxic.

Quick answer: Clenbuterol is marketed for fat loss. NutriDex grades the human evidence as banned / harmful — Linked to serious harm and/or banned in sport and many jurisdictions. Listed for awareness and safety only — NOT a recommendation. Based on 12 cited human studies (12 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Clenbuterol is a β2-agonist used in some countries for veterinary purposes and, abroad, for asthma. It is abused in bodybuilding and 'celebrity' weight-loss circles for its fat-burning and anti-catabolic effects. It is not a dietary supplement and is not approved for human use in the US. It overstimulates the heart and has caused mass poisonings from contaminated meat. It is banned by anti-doping agencies.

Benefits / uses: (Claimed) fat loss; (Claimed) muscle preservation / 'hardening'.
Active compounds: Clenbuterol (a β2-adrenergic agonist).
Dose: Not an approved human supplement or medicine (in the US); no safe self-administered dose.
Safety: ⚠ Rapid/irregular heartbeat, tremor, anxiety, low potassium, chest pain and cardiac muscle damage. Overdose risk is high because illicit products are unregulated. Not approved for human use in the US; banned in sport.

Cited studies (12):
  - Adverse events of clenbuterol among athletes: a systematic review of case reports and case series, International journal of legal medicine (2023) — Systematic review of 23 studies (24 athletes) found clenbuterol misuse, mostly oral at 20 ug to 30 mg/day, caused predominantly cardiac adverse events including supraventricular tachycardia, atrial fibrillation, myocardial injury, myocarditis, infarction, cardiomyopathy and death. [https://pubmed.ncbi.nlm.nih.gov/37062796/]
  - Clenbuterol induces lean mass and muscle protein accretion, but attenuates cardiorespiratory fitness and desensitizes muscle β(2)-adrenergic signalling, The Journal of physiology (2025) — Randomized placebo-controlled trial in healthy young men found a 2-week oral clenbuterol cycle increased lean mass and raised skeletal muscle protein content by about 17%, but impaired VO2max/cardiorespiratory fitness and desensitized muscle beta2-adrenergic signalling after 2 weeks. [https://pubmed.ncbi.nlm.nih.gov/40946331/]
  - Beta(2) -adrenergic agonist clenbuterol increases energy expenditure and fat oxidation, and induces mTOR phosphorylation in skeletal muscle of young healthy men, Drug testing and analysis (2020) — Human study in six young men showed clenbuterol increased resting energy expenditure by 21% and fat oxidation by 39%, and raised skeletal muscle mTOR-Ser2448 phosphorylation by 121% and PKA substrate phosphorylation by 35%. [https://pubmed.ncbi.nlm.nih.gov/31887249/]
  - The Prohibited List, World Anti-Doping Agency (2026) — Clenbuterol is banned in sport at all times. [https://www.wada-ama.org/en/prohibited-list]
  - Clenbuterol: Unapproved and unsafe, National Capital Poison Center — Authoritative statement notes clenbuterol is not FDA-approved for human use and is unsafe, with claimed muscle/fat benefits shown only in livestock and animal studies, while human misuse causes cardiac, muscular and metabolic toxicity. [https://www.poison.org/articles/clenbuterol-unapproved-and-unsafe-201]
  - Clenbuterol Abuse in Bodybuilding and Athletics: Unsupervised Use, Psychological Motivations, and Health Consequences, Cureus (2025) — Narrative review of unsupervised clenbuterol use in bodybuilding/athletics reports cardiovascular harms (arrhythmias, hypertension), muscle spasms and broader physiological toxicity, plus inadvertent exposure via contaminated meat. [https://pubmed.ncbi.nlm.nih.gov/40575216/]
  - Low Dose Clenbuterol Toxicity: Case Report and Review of Literature, HCA healthcare journal of medicine (2020) — Case report and literature review documenting that clenbuterol toxicity is increasingly seen in US hospitals among young athletes/bodybuilders, with effects (nausea to myocardial ischemia, rhabdomyolysis, cardiogenic shock) not correlating with ingested dose and managed only with supportive care as no antidote exists. [https://pmc.ncbi.nlm.nih.gov/articles/PMC10324766/]
  - Epidemiologic study of an outbreak of clenbuterol poisoning in Catalonia, Spain, Public health reports (Washington, D.C. : 1974) (1995) — Tachycardia, tremor and cardiac symptoms reported after contaminated-meat exposures. [https://pubmed.ncbi.nlm.nih.gov/7610227/]
  - A descriptive study of adverse events from clenbuterol misuse and abuse for weight loss and bodybuilding, Substance abuse (2013) — Poison-center descriptive study of 13 clenbuterol users misusing it for weight loss/bodybuilding documented tachycardia, widened pulse pressure, hypokalemia, hyperglycemia, ST changes and elevated troponin, with myocardial injury in 2 patients and effects persisting beyond 24 hours. [https://pubmed.ncbi.nlm.nih.gov/23844963/]
  - Clenbuterol toxicity: a NSW poisons information centre experience, The Medical journal of Australia (2014) — Retrospective poison-center series of 63 clenbuterol exposures (2004-2012), rising sharply from 3 in 2008 to 27 in 2012; 84% (53 patients) required hospitalization. Commonest reasons were bodybuilding and slimming; commonest features tachycardia (24), GI disturbance (16), tremor (11), with cardiotoxicity including one cardiac arrest in a 21-year-old man. DOI: https://doi.org/10.5694/mja13.10982 [https://pubmed.ncbi.nlm.nih.gov/24580525/]
  - A Case Series of Clenbuterol Toxicity Caused by Adulterated Heroin, The Journal of emergency medicine (2016) — Case series of 10 hospitalized patients with clenbuterol-adulterated heroin exposure presented with chest pain, palpitations and dyspnea plus severe hypokalemia (K nadir 2.5 mEq/L), hyperglycemia and lactic acidosis; all survived with supportive care. [https://pubmed.ncbi.nlm.nih.gov/27431866/]
  - Case report and review of clenbuterol cardiac toxicity, Journal of cardiology cases (2013) — β2-agonist overstimulation can cause arrhythmia and cardiac muscle damage. [https://pubmed.ncbi.nlm.nih.gov/30546764/]

---

## Homeopathy ('Like cures like' · ultra-dilutions)
URL: https://nutridex.info/s/homeopathy
Category: Debunked
Evidence: No Evidence — No credible human evidence supports the marketed claims — widely considered ineffective.
Remedies diluted past the point of containing any active substance.

Quick answer: Homeopathy is marketed for treats almost any ailment. NutriDex grades the human evidence as no evidence — No credible human evidence supports the marketed claims — widely considered ineffective. Based on 20 cited human studies (20 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Homeopathy is based on two 18th-century ideas — that a substance causing symptoms can cure them, and that extreme dilution increases potency. Most remedies are diluted so heavily that not a single molecule of the original ingredient remains. Large systematic reviews, including a comprehensive Australian government assessment, conclude there is no reliable evidence homeopathy works for any health condition beyond placebo. Its proposed mechanisms contradict basic chemistry and physics.

Benefits / uses: (Claimed) treats almost any ailment.
Active compounds: Ultra-dilutions (often beyond Avogadro's limit — i.e. no molecules of the original substance).
Dose: Not applicable — products are diluted so far they typically contain none of the labeled ingredient.
Safety: The remedies themselves are usually inert. The real danger is indirect: using homeopathy in place of effective medical treatment can allow serious conditions to worsen. Some 'homeopathic' products have also been recalled for actually containing harmful amounts of active ingredients.

Cited studies (20):
  - Efficacy of homoeopathic treatment: Systematic review of meta-analyses of randomised placebo-controlled homoeopathy trials for any indication, Systematic Reviews (2023) — Systematic review of meta-analyses of placebo-controlled homeopathy RCTs (search to April 2023) found a significant positive effect over placebo in 5 of 6 global meta-analyses, but flagged conflicting risk-of-bias results and only moderate-to-low evidence quality for non-individualized homeopathy. [https://link.springer.com/article/10.1186/s13643-023-02313-2]
  - Efficacy of homoeopathic treatment: Systematic review of meta-analyses of randomised placebo-controlled homoeopathy trials for any indication, Systematic reviews (2023) — Pro-homeopathy systematic review of 6 meta-analyses (16-110 trials each) reported that effect estimates favoured homeopathy over placebo in all meta-analyses with data (5/5), with significance retained in high-quality subsets of 3/4. NOTE: 3 of 6 meta-analyses were rated high risk of bias (ROBIS) and authors had homeopathy-affiliated funding/conflicts; contradicts NHMRC/EASAC conclusions and warrants cautious interpretation. [https://pubmed.ncbi.nlm.nih.gov/37805577/]
  - Assessing the magnitude of reporting bias in trials of homeopathy: a cross-sectional study and meta-analysis, BMJ evidence-based medicine (2022) — Cross-sectional study and meta-analysis of registered homeopathy trials found ~38% remained unpublished and ~25% changed primary outcomes, indicating substantial reporting bias that inflates apparent efficacy estimates. [https://pubmed.ncbi.nlm.nih.gov/35292534/]
  - Adverse effects in homeopathy. A systematic review and meta-analysis of observational studies, Explore (New York, N.Y.) (2022) — Systematic review and meta-analysis of observational studies of homeopathy adverse effects found 87% of studies reported adverse events graded CTCAE 1-3, distributed roughly equally between intervention and control groups, with homeopathic 'aggravations' in 22.5% of studies. [https://pubmed.ncbi.nlm.nih.gov/33303386/]
  - Homeopathic Oscillococcinum® for preventing and treating influenza and influenza-like illness, The Cochrane database of systematic reviews (2015) — Cochrane review of 6 RCTs (n=1,523) of homeopathic Oscillococcinum for influenza found no evidence it prevents flu and insufficient good-quality evidence to support any clinically useful treatment effect. [https://pubmed.ncbi.nlm.nih.gov/25629583/]
  - Systematic Review and Meta-Analysis of Randomised, Other-than-Placebo Controlled, Trials of Non-Individualised Homeopathic Treatment, Homeopathy : the journal of the Faculty of Homeopathy (2019) — Systematic review/meta-analysis of 17 RCTs of non-individualised homeopathy versus active comparators (other-than-placebo). Significant heterogeneity precluded firm conclusions; for the equivalence/non-inferiority trials the pooled effect was small and non-significant (SMD 0.08), with 14 of 17 trials at high risk of bias. No decisive evidence of comparative effectiveness. [https://pubmed.ncbi.nlm.nih.gov/30699444/]
  - Model validity of randomised placebo-controlled trials of individualised homeopathic treatment, Homeopathy : the journal of the Faculty of Homeopathy (2015) — Model-validity assessment of 32 RCTs of individualised homeopathy: 19 judged 'acceptable', 9 'uncertain', 4 'inadequate' model validity, indicating the positive findings in this literature are not primarily explained by poor homeopathic-treatment modelling but remain undermined by internal-validity (risk-of-bias) limitations. [https://pubmed.ncbi.nlm.nih.gov/26143448/]
  - Randomised placebo-controlled trials of individualised homeopathic treatment: systematic review and meta-analysis, Systematic reviews (2014) — Systematic review/meta-analysis of 22 RCTs of individualised homeopathic treatment found a small statistically significant pooled effect favouring homeopathy (OR 1.53, 95% CI 1.22-1.91 across all 22 trials), but the effect was not robust: only 3 trials were judged reliable evidence and sensitivity analyses to higher-quality data weakened/removed significance. [https://pubmed.ncbi.nlm.nih.gov/25480654/]
  - Homeopathic Drug Products Guidance for FDA Staff and Industry, U.S. Food and Drug Administration — FDA finalized a risk-based enforcement policy treating all unapproved homeopathic drugs as illegal, prioritizing action against higher-risk products (injury reports, toxic/controlled ingredients, injectables, serious-disease claims). [https://www.fda.gov/regulatory-information/search-fda-guidance-documents/homeopathic-drug-products-guidance-fda-staff-and-industry]
  - Homeopathy for attention deficit/hyperactivity disorder or hyperkinetic disorder, The Cochrane database of systematic reviews (2007) — Cochrane review of 4 trials (n=168) found no evidence that individualized or other homeopathy improves global or core symptoms of attention-deficit/hyperactivity disorder in children. [https://pubmed.ncbi.nlm.nih.gov/17943868/]
  - Homeopathy for COVID-19 in primary care: A randomized, double-blind, placebo-controlled trial (COVID-Simile study), Journal of integrative medicine (2022) — Randomized, double-blind, placebo-controlled trial of homeopathic Natrum muriaticum LM2 for mild COVID-19 found no statistically significant difference versus placebo in symptom outcomes. [https://pubmed.ncbi.nlm.nih.gov/35339397/]
  - Some Homeopathic Products May Put You at Risk, U.S. Food and Drug Administration — FDA warns that some homeopathic products may put consumers at risk, citing reports of serious adverse events and unapproved products marketed for serious conditions, none of which are FDA-approved for safety or effectiveness. [https://www.fda.gov/drugs/understanding-over-counter-medicines/some-homeopathic-products-may-put-you-risk]
  - A series of homeopathic remedies-related severe drug-induced liver injury from South India, Hepatology communications (2023) — Case series of 9 patients with severe homeopathy-related drug-induced liver injury from South India; probable DILI in 77.8%, predominantly hepatocellular, with 4 (44.4%) deaths at median 194-day follow-up, and toxicology revealing solvents, corticosteroids, opioids and heavy metals. [https://pmc.ncbi.nlm.nih.gov/articles/PMC9916127/]
  - The Placebo Project: An observational study and comprehensive analysis of 134 commonly prescribed homeopathic remedies in India uncovers potential for hepatotoxicity, Medicine (2025) — Comprehensive profiling of 134 commonly prescribed Indian homeopathic remedies ('Placebo Project') detected high ethanol (classical dilutions median 91.02% v/v) plus toxic heavy metals (arsenic, lead, mercury, cadmium), industrial solvents and steroids even in supposedly ultra-dilute formulations. [https://pubmed.ncbi.nlm.nih.gov/40725904/]
  - Homeopathy, National Health and Medical Research Council (NHMRC) — Reviewed 1,800+ studies: no health condition for which homeopathy is effective. [https://www.nhmrc.gov.au/about-us/publications/homeopathy]
  - A series of homeopathic remedies-related severe drug-induced liver injury from South India, Hepatology communications (2023) — Single-center case series (n=9) from South India documented severe drug-induced liver injury from homeopathic remedies (often taken for COVID-19), with 44% mortality, demonstrating real harm despite ultra-dilution claims. [https://pubmed.ncbi.nlm.nih.gov/36757412/]
  - Homeopathic products and practices: assessing the evidence and ensuring consistency in regulating medical claims in the EU, European Academies' Science Advisory Council (EASAC) (2017) — Joint statement of EU national science academies concluded there is no robust, reproducible evidence that homeopathic products are effective for any condition beyond placebo, and warned of harm from delayed evidence-based care. [https://easac.eu/fileadmin/PDF_s/reports_statements/EASAC_Homepathy_statement_web_final.pdf]
  - Are the clinical effects of homoeopathy placebo effects? Comparative study of placebo-controlled trials of homoeopathy and allopathy, Lancet (London, England) (2005) — Effects of homeopathy are compatible with placebo. [https://pubmed.ncbi.nlm.nih.gov/16125589/]
  - Homeopathy, NIH National Center for Complementary and Integrative Health (2021) — The US National Center for Complementary and Integrative Health states there is little evidence to support homeopathy as an effective treatment for any specific condition, and that its core concepts conflict with established physics and chemistry. [https://www.nccih.nih.gov/health/homeopathy]
  - FDA warns consumers about homeopathic teething products, U.S. Food and Drug Administration — No plausible mechanism; benefits attributed to placebo and natural recovery. [https://www.fda.gov/drugs/information-drug-class/fda-warns-consumers-about-homeopathic-teething-products]

---

## Detox / 'Teatox' Cleanses (Detox teas, juice cleanses, foot pads)
URL: https://nutridex.info/s/detox-tea
Category: Debunked, Gut & Immune
Evidence: No Evidence — No credible human evidence supports the marketed claims — widely considered ineffective.
Your liver and kidneys already detox you — for free.

Quick answer: Detox / 'Teatox' Cleanses is marketed for 'flush toxins'. NutriDex grades the human evidence as no evidence — No credible human evidence supports the marketed claims — widely considered ineffective. Based on 20 cited human studies (19 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

'Detox' and 'cleanse' products promise to flush unnamed toxins from the body. In reality the liver, kidneys, lungs and gut continuously perform detoxification, and no credible evidence shows these products remove any specific toxin or improve health. Reviews find no compelling support for detox diets. Apparent short-term weight loss is water and bowel content — many 'teatox' products simply contain senna, a stimulant laxative.

Benefits / uses: (Claimed) 'flush toxins'; (Claimed) weight loss & 'reset'.
Active compounds: Senna & other laxative herbs; Diuretics; Caffeine.
Dose: No legitimate use — the body's liver and kidneys handle detoxification.
Safety: ⚠ Hidden laxatives/diuretics can cause dehydration, low potassium, electrolyte imbalance, dependence and (with overuse) heart-rhythm problems. Juice-only cleanses can be hazardous for people with diabetes or kidney disease. Apparent results are temporary water loss, not fat loss or 'detoxification'.

Cited studies (20):
  - “Detoxes” and “Cleanses”: What You Need To Know, NIH National Center for Complementary and Integrative Health (2025) — NIH's NCCIH states there is little evidence that detox or cleanse programs eliminate toxins, that any weight loss is from severe calorie restriction and is regained, and that some programs (e.g., fasting, colon cleansing) can be unsafe. [https://www.nccih.nih.gov/health/detoxes-and-cleanses-what-you-need-to-know]
  - Ambaya Gold Health Products, LLC - 648130, U.S. Food and Drug Administration — FDA issued a December 2023 warning letter citing unlawful disease and detoxification claims for products marketed to remove heavy metals and toxins, deeming them unapproved new drugs. [https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/ambaya-gold-health-products-llc-648130-12052023]
  - Effects of Vegetable and Fruit Juicing on Gut and Oral Microbiome Composition, Nutrients (2025) — Controlled crossover study in 14 adults found that 3 days of an exclusive cold-pressed juice diet shifted the oral and gut microbiome toward pro-inflammatory, sugar-processing bacteria (e.g., Proteobacteria), with the oral microbiome most affected and changes largely reverting within 2 weeks. [https://pubmed.ncbi.nlm.nih.gov/39940316/]
  - Effects of Vegetable and Fruit Juicing on Gut and Oral Microbiome Composition, Nutrients (2025) — In a randomized 3-arm trial (n=14), a 3-day exclusive juice-only diet shifted gut and especially oral microbiota toward bacteria associated with inflammation and cognitive decline, with no evidence of toxin removal benefit. [https://pmc.ncbi.nlm.nih.gov/articles/PMC11820471/]
  - Golean Detox US - 573404, U.S. Food and Drug Administration — FDA laboratory analysis found the marketed 'detox' weight-loss product Golean Detox contained undeclared sibutramine, a stimulant withdrawn from the US market for increased heart attack and stroke risk. [https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/golean-detox-us-573404-04292019]
  - Effect of toxic trace element detoxification, body fat reduction following four-week intake of the Wellnessup diet: a three-arm, randomized clinical trial, Nutrition & metabolism (2020) — Single-blind 3-arm RCT in 45 overweight women found a 4-week organic plant-based 'detox' diet produced less total weight loss than calorie restriction but better preserved fat-free mass and modestly lowered a few trace metals (Ni, Rh, Sn, Ga); no clinically meaningful 'toxin' clearance was demonstrated. [https://pubmed.ncbi.nlm.nih.gov/32582363/]
  - Objective assessment of an ionic footbath (IonCleanse): testing its ability to remove potentially toxic elements from the body, Journal of environmental and public health (2012) — Proof-of-principle trial of an IonCleanse ionic footbath in 6 healthy adults found no evidence the device increased elimination of potentially toxic elements via urine or hair; elements detected in the water came from corrosion of the device's electrodes rather than from the body. [https://pubmed.ncbi.nlm.nih.gov/22174728/]
  - Challenges in herbal-induced liver injury identification and prevention, Liver international : official journal of the International Association for the Study of the Liver (2025) — Narrative review documents rising herbal-induced liver injury, with weight-control and detox supplements among the most commonly implicated, and notes frequent product mislabeling complicating causality. [https://pubmed.ncbi.nlm.nih.gov/39136211/]
  - Mechanism of Jianpi Qingchang Huashi Recipe in treating ulcerative colitis: A study based on network pharmacology and molecular docking, World journal of clinical cases (2021) — Review of herbal-induced liver injury reports that herbal and dietary supplements (including detox/weight-loss products) now account for roughly 20% of hepatotoxicity cases in the US DILIN cohort, up from ~7%. [https://pubmed.ncbi.nlm.nih.gov/34621817/]
  - Drug-Induced Liver Injury from Herbal Liver Detoxification Tea, Case reports in gastroenterology (2022) — Case report of clinically significant cholestatic-pattern drug-induced liver injury in a 36-year-old woman from an over-the-counter herbal 'liver detox' tea (burdock root, stinging nettle, cleavers, dandelion root, lemon peel, lemon myrtle) - the first reported hepatotoxic event attributed to these ingredients - reinforcing that unregulated detox products can cause idiosyncratic DILI. [https://pubmed.ncbi.nlm.nih.gov/36636365/]
  - Detox Tea: Side Effects, Purported Benefits, and How They Work, Healthline (2026) — Laxative-based teas linked to dehydration and electrolyte disturbance. [https://www.healthline.com/health/detox-tea-side-effects]
  - Drug-Induced Liver Injury from Herbal Liver Detoxification Tea, Case reports in gastroenterology (2022) — A 36-year-old woman developed clinically significant cholestatic acute liver injury attributed to an over-the-counter herbal liver detox tea (burdock root, stinging nettle, cleavers, dandelion root, lemon peel, lemon myrtle). [https://pmc.ncbi.nlm.nih.gov/articles/PMC9830300/]
  - Detox diets for toxin elimination and weight management: a critical review of the evidence, Journal of human nutrition and dietetics : the official journal of the British Dietetic Association (2015) — Review found no compelling evidence detox diets remove toxins or aid weight management. [https://pubmed.ncbi.nlm.nih.gov/25522674/]
  - LiverTox: Senna 2019 (NIH/NIDDK) — Authoritative NIH LiverTox monograph documents that senna - the active stimulant laxative in most detox/teatox products - is generally safe short term, but higher-dose/long-term use (typically 3-5 months) has caused clinically apparent hepatocellular liver injury, and chronic use causes electrolyte disturbance (hypokalemia), laxative dependence and melanosis coli. [https://www.ncbi.nlm.nih.gov/books/NBK547922/]
  - PubMed, NIH National Library of Medicine — Liver/kidneys clear metabolites continuously; 'toxin' claims are never specified or measured. [https://pubmed.ncbi.nlm.nih.gov/?term=Detox%20%2F%20'Teatox'%20Cleanses%20Physiology%20consensus]
  - The Dangers of Unregulated Weight Loss Supplements: Tejocote-Induced Acute Liver Injury, Cureus (2024) — Case report of acute liver injury attributed to an unregulated 'tejocote' weight-loss/detox supplement in a single patient, resolving after discontinuation. [https://pmc.ncbi.nlm.nih.gov/articles/PMC11086658/]
  - Herbal Supplement-Induced Liver Injury: A Case Report, Cureus (2023) — A 45-year-old woman developed acute liver injury after starting a 23-ingredient herbal 'detox' tea; symptoms fully resolved after discontinuation. [https://pubmed.ncbi.nlm.nih.gov/36819353/]
  - The dangers of colon cleansing, The Journal of family practice (2011) — Systematic literature review (20 studies) of colon cleansing/colonic hydrotherapy found no good evidence of benefit and documented adverse effects ranging from cramping, bloating, nausea/vomiting and electrolyte imbalance to renal failure, air embolism, bowel perforation and death. Advises physicians counsel patients against the practice. [https://pubmed.ncbi.nlm.nih.gov/21814639/]
  - Green tea extract-associated acute liver injury: Case report and review, Clinical liver disease (2022) — Case report plus literature review links concentrated green tea extract (high-dose catechins/EGCG) to dose-dependent acute hepatocellular injury that resolves on cessation. [https://pubmed.ncbi.nlm.nih.gov/36523867/]
  - Yogi Detox Tea: A Potential Cause of Acute Liver Failure, Case reports in gastrointestinal medicine (2017) — Case report of acute fulminant liver failure in a 60-year-old woman after drinking a commercial detox tea three times daily for 14 days, with multiple ingredients having known hepatotoxic potential. [https://pubmed.ncbi.nlm.nih.gov/29204300/]

---

## Alkaline Water / Diet (High-pH water & 'alkalizing' products)
URL: https://nutridex.info/s/alkaline-water
Category: Debunked, Heart & Metabolic
Evidence: No Evidence — No credible human evidence supports the marketed claims — widely considered ineffective.
You cannot meaningfully change your blood pH by drinking water.

Quick answer: Alkaline Water / Diet is marketed for 'balances body ph'. NutriDex grades the human evidence as no evidence — No credible human evidence supports the marketed claims — widely considered ineffective. Based on 17 cited human studies (17 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Alkaline-water and alkaline-diet products claim that 'acidic' foods harm health and that raising your body's pH prevents disease. This misunderstands physiology: blood pH is tightly regulated near 7.4 by the lungs and kidneys and is not meaningfully altered by what you drink (stomach acid also neutralizes it). Reviews find no evidence that alkaline diets affect bone health or cancer. The underlying premise is physiologically implausible.

Benefits / uses: (Claimed) 'balances body pH'; (Claimed) prevents disease / cancer.
Active compounds: Water with elevated pH / added minerals.
Dose: No demonstrated benefit over ordinary water for healthy people.
Safety: Generally harmless to drink. The concern is wasted money and, occasionally, people delaying real treatment while trusting pH claims. Extreme 'alkalizing' regimens can rarely disturb normal acid-base balance.

Cited studies (17):
  - Health effects of alkaline, oxygenated, and demineralized water compared to mineral water among healthy population: a systematic review, Reviews on environmental health (2024) — PRISMA systematic review of 10 studies (2 on alkaline water) concluded that, compared with mineral water, alkaline water consumption showed no significant difference in gut microbiota, urine pH, blood parameters, or fitness parameters in healthy populations. [https://pubmed.ncbi.nlm.nih.gov/36571558/]
  - Health effects of alkaline, oxygenated, and demineralized water compared to mineral water among healthy population: a systematic review, Reviews on Environmental Health (2022) — Systematic review found that compared with mineral water, alkaline (and oxygenated) water showed no significant difference in gut microbiota, urine pH, blood parameters, or fitness parameters in healthy people, with no proven additional health effects. [https://doi.org/10.1515/reveh-2022-0057]
  - Effect of Acid or Base Interventions on Bone Health: A Systematic Review, Meta-Analysis, and Meta-Regression, Advances in nutrition (Bethesda, Md.) (2021) — Meta-analysis of 26 RCTs (13 acidic-diet, 13 alkaline-supplement). Acidic diets raised net acid excretion (SMD 2.99) and urinary calcium (SMD 0.47) but did not affect BMD or bone turnover. Alkaline supplements significantly lowered net acid excretion (SMD -1.29), urinary calcium (SMD -0.44) and bone turnover markers (NTX SMD -0.29; osteocalcin SMD -0.23) and modestly increased BMD at femoral neck, lumbar spine and total hip; authors urge caution due to high heterogeneity. Note: these trials used alkalizing SALTS, not alkaline water. [https://pubmed.ncbi.nlm.nih.gov/33684217/]
  - Causal assessment of dietary acid load and bone disease: a systematic review & meta-analysis applying Hill's epidemiologic criteria for causality, Nutrition journal (2011) — Systematic review & meta-analysis applying Hill's causality criteria to 55 studies (22 RCTs, 2 meta-analyses, 11 cohorts): higher dietary acid load raises urinary calcium excretion but calcium-balance studies show no whole-body calcium loss, and no intervention demonstrated osteoporosis progression or a mechanism at physiological pH. Concludes a causal link between dietary acid load and osteoporotic bone disease is NOT supported and there is no evidence an alkaline diet protects bone. [https://pubmed.ncbi.nlm.nih.gov/21529374/]
  - Acid-Base Balance in Healthy Adults: Beneficial Effects of Bicarbonate and Sodium-Rich Mineral Water in a Randomized Controlled Trial: The BicarboWater Study, Journal of nutrition and metabolism (2024) — In 85 healthy adults aged 30-65, drinking 1.5-2 L/day of bicarbonate- and sodium-rich mineral water significantly raised urinary pH and bicarbonate excretion and lowered net acid excretion within 3 days (p<0.001), but this reflects urinary alkalinization, not a disease benefit, versus minimal change on low-bicarbonate water. [https://pmc.ncbi.nlm.nih.gov/articles/PMC11390205/]
  - A Pilot Randomized Controlled Trial and Multi-Omics Analysis of Electrolysed Alkaline Water: Impacts on Gut Microbiota and Metabolic Signatures in Hyperuricemia, Nutrients (2025) — Pilot RCT in 40 adults with elevated serum uric acid found that 1.5 L/day electrolyzed alkaline water (pH 8.5-9.5) for 12 weeks produced a larger reduction in serum uric acid than purified water, with exploratory changes in gut microbiota and purine-metabolism pathways. [https://pmc.ncbi.nlm.nih.gov/articles/PMC12787813/]
  - Influence of Ingestion of Bicarbonate-Rich Water Combined with an Alkalizing or Acidizing Diet on Acid-Base Balance and Anaerobic Performance, Journal of human kinetics (2024) — Double-blind randomized trial in 24 athletes found bicarbonate-rich water altered acid-base balance during warm-up and after high-intensity exercise but produced no effect on anaerobic (Wingate rowing) performance. [https://pubmed.ncbi.nlm.nih.gov/39132426/]
  - The Effects of High Mineral Alkaline Water Consumed Over Three Consecutive Days on Reaction Time Following Anaerobic Exercise - A Randomized Placebo-Controlled Crossover Pilot Study, Journal of human kinetics (2021) — Double-blind placebo-controlled crossover pilot in 12 young male athletes found high-mineral alkaline water had no effect on post-exercise reaction time, with only small anaerobic performance differences, indicating no cognitive benefit. [https://pubmed.ncbi.nlm.nih.gov/34025869/]
  - Synergistic Effects of Regular Walking and Alkaline Electrolyzed Water on Decreasing Inflammation and Oxidative Stress, and Increasing Quality of Life in Individuals with Type 2 Diabetes: A Community Based Randomized Controlled Trial, Antioxidants (Basel, Switzerland) (2020) — In an 8-week 4-arm RCT of 81 adults with type 2 diabetes, alkaline electrolyzed water reduced oxidative-stress and inflammatory markers (AGEs, AOPP, malondialdehyde, neutrophil-lymphocyte ratio), but effects were largest and clinically meaningful only when combined with regular walking, so water alone showed modest isolated benefit. [https://pmc.ncbi.nlm.nih.gov/articles/PMC7599474/]
  - Alkaline water improves exercise-induced metabolic acidosis and enhances anaerobic exercise performance in combat sport athletes, PloS one (2018) — Double-blind, placebo-controlled RCT in 16 trained combat-sport athletes drinking highly alkaline mineral water vs table water for 3 weeks. Alkaline water improved hydration status (urine specific gravity), shifted acid-base balance toward alkalosis, and enhanced anaerobic (Wingate) performance and post-exercise lactate handling vs control. Small sample limits inference. [https://pubmed.ncbi.nlm.nih.gov/30452459/]
  - Effect of electrolyzed high-pH alkaline water on blood viscosity in healthy adults, Journal of the International Society of Sports Nutrition (2016) — Randomized, double-blind, parallel-arm trial in 100 adults rehydrating after exercise-induced dehydration. Electrolyzed high-pH (alkaline) water reduced high-shear whole-blood viscosity by 6.30% vs 3.36% with standard purified water (p=0.03); no significant difference in plasma osmolality, bioimpedance or body-mass recovery. The only outcome distinguishing alkaline water was a transient viscosity reduction. [https://pubmed.ncbi.nlm.nih.gov/27932937/]
  - Electrolyzed-Reduced Water: Review II: Safety Concerns and Effectiveness as a Source of Hydrogen Water, International journal of molecular sciences (2022) — Safety review of electrolyzed-reduced/alkaline water; reports hyperkalemia risk in people with impaired kidney function when pH exceeds ~9.8-10, plus possible electrode-derived nanoparticle leaching and impaired nutrient absorption, recommending the regulatory pH cap of 9.8. [https://pmc.ncbi.nlm.nih.gov/articles/PMC9736533/]
  - Acid ash hypothesis, Wikipedia (2026) — Blood pH is homeostatically fixed; diet does not shift it appreciably. [https://en.wikipedia.org/wiki/Acid_ash_hypothesis]
  - Associations of alkaline water with metabolic risks, sleep quality, muscle strength: A cross-sectional study among postmenopausal women, PloS one (2022) — Cross-sectional study of 304 postmenopausal women found regular alkaline-water drinkers had a lower prevalence of metabolic syndrome and modestly better glucose, triglyceride/HDL ratio, sleep duration, and handgrip strength, but the observational design cannot establish causation. [https://pubmed.ncbi.nlm.nih.gov/36315555/]
  - Systematic review of the association between dietary acid load, alkaline water and cancer, BMJ open (2016) — No evidence the acid-ash/alkaline diet hypothesis affects bone or cancer risk. [https://pmc.ncbi.nlm.nih.gov/articles/PMC4916623/]
  - The alkaline diet: is there evidence that an alkaline pH diet benefits health?, Journal of environmental and public health (2012) — Examined the alkaline-diet hypothesis; its tentative claims concern whole-diet acid load, not bottled alkaline water, for which no disease benefit is established. [https://pmc.ncbi.nlm.nih.gov/articles/PMC3195546/]
  - Alkaline Water: Help or Hype for Uric Acid and Cystine Urolithiasis?, The Journal of urology (2024) — Laboratory analysis of 5 commercial alkaline water brands (pH 9.69-10.15) found physiologic alkali content below 1 mEq/L (~0.1 mEq/L), trivial versus the body's 40-100 mEq/L daily acid load, so alkaline water offers no benefit over tap water for raising urine pH in uric-acid or cystine stone disease. [https://pubmed.ncbi.nlm.nih.gov/38193415/]

---

## Raspberry Ketones (4-(4-hydroxyphenyl)butan-2-one)
URL: https://nutridex.info/s/raspberry-ketones
Category: Debunked, Heart & Metabolic
Evidence: No Evidence — No credible human evidence supports the marketed claims — widely considered ineffective.
A TV-famous 'fat burner' with no human evidence.

Quick answer: Raspberry Ketones is marketed for fat burning & weight loss. NutriDex grades the human evidence as no evidence — No credible human evidence supports the marketed claims — widely considered ineffective. Based on 13 cited human studies (13 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Raspberry ketones are aroma compounds that shot to fame after a TV endorsement as a 'miracle' fat burner. The hype rests on cell-culture and rodent studies using doses far beyond what any human takes. There are essentially no controlled human trials showing weight loss from raspberry ketones alone. The compound sold is almost always synthetic, not extracted from raspberries.

Benefits / uses: (Claimed) fat burning & weight loss.
Active compounds: Raspberry ketone (usually synthetic).
Dose: No effective dose established in humans; weight-loss claims are unsupported.
Safety: Limited human safety data. Often sold in stimulant blends, which carry their own cardiovascular and jitter risks. Because raspberry ketone is structurally similar to synephrine, case reports have linked it to palpitations, tachycardia, coronary vasospasm and even ventricular arrhythmia/cardiac arrest, and supplement doses vastly exceed food-flavoring levels. No demonstrated benefit to weigh against any risk.

Cited studies (13):
  - The effects of raspberry consumption on anthropometric indices and liver function tests in adults: a GRADE-assessed systematic review and meta-analysis, Frontiers in nutrition (2024) — GRADE-assessed meta-analysis of 9 RCTs (10 arms, 355 adults) found raspberry consumption produced no significant change in body weight, BMI, waist circumference, or liver enzymes (low/very-low certainty). [https://pubmed.ncbi.nlm.nih.gov/39161910/]
  - The effects of raspberry consumption on lipid profile and blood pressure in adults: A systematic review and meta-analysis, Food science & nutrition (2024) — Systematic review and meta-analysis of RCTs in adults found raspberry consumption did not significantly alter lipid profile or blood pressure versus control. [https://pubmed.ncbi.nlm.nih.gov/38628181/]
  - The Effects of Raspberry Consumption on Glycemic Control and Inflammation Markers in Adults: A Systematic Review and Meta-Analysis of Randomized Controlled Trials, Current developments in nutrition (2024) — A systematic review and meta-analysis of RCTs in adults found raspberry consumption significantly raised insulin (WMD 1.89 uU/mL) and lowered TNF-alpha (WMD -3.07 pg/mL) but had no significant effect on fasting glucose, HbA1c, glucose tolerance, HOMA-IR, CRP, or IL-6. [https://pubmed.ncbi.nlm.nih.gov/38860149/]
  - Raspberry ketone in food supplements--High intake, few toxicity data--A cause for safety concern?, Regulatory toxicology and pharmacology : RTP (2015) — A Danish National Food Institute risk assessment found that food-supplement doses of raspberry ketone (100-1400 mg/day) are 26-368 times higher than dietary exposure and reach 56x the threshold of toxicological concern, leaving a margin of safety as low as 12 at 1400 mg, with QSAR models flagging possible cardiotoxic and reproductive/developmental effects. [https://pubmed.ncbi.nlm.nih.gov/26160596/]
  - Raspberry Ketone Intake Upregulates Circulating FGF21 and Induces Energy Expenditure in Humans, ClinicalTrials.gov (2024) — Registered single-dose human interventional study (500 mg raspberry ketone) measuring plasma FGF21 and energy expenditure at 0-6 h in adults aged 18-60; completed June 2024 with no peer-reviewed results posted as of mid-2026. [https://clinicaltrials.gov/study/NCT06681597]
  - Eight weeks of supplementation with a multi-ingredient weight loss product enhances body composition, reduces hip and waist girth, and increases energy levels in overweight men and women, Journal of the International Society of Sports Nutrition (2013) — A randomized, double-blind, placebo-controlled trial in 70 obese adults (45 completers) of a multi-ingredient supplement containing raspberry ketone plus caffeine, capsaicin, synephrine, garlic and ginger showed greater fat-mass loss (-7.8% vs -2.8%) and body-weight loss (-2.0% vs -0.5%) than placebo, but the design cannot attribute any effect to raspberry ketone itself given the stimulant co-ingredients. [https://pubmed.ncbi.nlm.nih.gov/23601452/]
  - Effect of topical application of raspberry ketone on dermal production of insulin-like growth factor-I in mice and on hair growth and skin elasticity in humans, Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society (2008) — Mechanistic mouse plus small human trial. Topical 0.01% raspberry ketone (structurally similar to capsaicin) raised dermal IGF-I via CGRP/sensory-neuron activation; in humans it promoted hair growth in 50% of 10 alopecia patients at 5 months and increased cheek skin elasticity in 5 women at 2 weeks (P<0.04). Supports a topical, not oral weight-loss, benefit. [https://pubmed.ncbi.nlm.nih.gov/18321745/]
  - Raspberry ketone: Dietary supplements for weight loss, Operation Supplement Safety (U.S. DoD) — Classed among unsupported weight-loss fads. [https://www.opss.org/article/raspberry-ketone-dietary-supplements-weight-loss]
  - Resistant Polymorphic Ventricular Tachycardia in a Patient Taking Raspberry Ketones Weight Loss Supplement, Cureus (2022) — A previously healthy 32-year-old obese woman developed life-threatening polymorphic ventricular tachycardia requiring 33 defibrillations after using an OTC weight-loss supplement high in raspberry ketones, implicating it as a cardiotoxic trigger. [https://pubmed.ncbi.nlm.nih.gov/36726887/]
  - Evaluation of quality and authenticity of raspberry ketone supplements by a multianalytical approach, Journal of chromatography. A (2025) — Multianalytical (GC-MS/LC-MS) survey of marketed raspberry ketone supplements found ~60% had label-versus-measured discrepancies, most under-dosed, with evidence of synthetic adulteration. [https://pubmed.ncbi.nlm.nih.gov/40513409/]
  - Raspberry ketone: Dietary supplements for weight loss, Operation Supplement Safety (U.S. DoD) — No quality RCTs show weight loss from raspberry ketones alone. [https://www.opss.org/article/raspberry-ketone-dietary-supplements-weight-loss]
  - Dietary Supplements for Weight Loss - Health Professional Fact Sheet, NIH Office of Dietary Supplements — The NIH Office of Dietary Supplements concludes there is no evidence raspberry ketone is safe or effective for weight loss in humans, noting only one inconclusive multi-ingredient RCT (45 completers) and that supplement doses of 100-1,400 mg/day (vs a few mg from diet) have never been evaluated for safety in people. [https://ods.od.nih.gov/factsheets/WeightLoss-HealthProfessional/]
  - Anti-obese action of raspberry ketone, Life sciences (2005) — Effects seen only in rodents at very high doses — not replicated in humans. [https://pubmed.ncbi.nlm.nih.gov/15862604/]

---

## Garcinia Cambogia (HCA) (Garcinia gummi-gutta)
URL: https://nutridex.info/s/garcinia
Category: Debunked, Heart & Metabolic
Evidence: No Evidence — No credible human evidence supports the marketed claims — widely considered ineffective.
A heavily-marketed diet pill with negligible, unreliable effects.

Quick answer: Garcinia Cambogia (HCA) is marketed for appetite suppression. NutriDex grades the human evidence as no evidence — No credible human evidence supports the marketed claims — widely considered ineffective. Based on 13 cited human studies (13 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Garcinia cambogia (its active acid, HCA) is one of the most aggressively marketed weight-loss supplements. Rigorous analysis tells a different story: a meta-analysis found any weight difference versus placebo to be small and of doubtful clinical relevance, and a landmark JAMA trial found no greater weight loss than placebo. More worrying, HCA-containing products have been associated with liver injury, contributing to the high-profile recall of a popular 'fat-burner'.

Benefits / uses: (Claimed) appetite suppression; (Claimed) blocks fat production.
Active compounds: Hydroxycitric acid (HCA).
Dose: Not recommended — benefits are negligible and liver-safety concerns exist.
Safety: ⚠ Liver injury (hepatotoxicity) has been reported with HCA-containing products, sometimes severe. Often sold in stimulant blends. Given negligible benefit, the risk is not justified.

Cited studies (13):
  - The effects of Garcinia cambogia (hydroxycitric acid) on serum leptin concentrations: A systematic review and meta-analysis of randomized controlled trials, Complementary therapies in medicine (2024) — Meta-analysis of 8 RCTs (330 participants) found Garcinia cambogia (median 2900 mg/day, ~8 weeks) significantly lowered serum leptin (WMD -5.01 ng/mL; 95% CI -9.22 to -0.80). [https://pubmed.ncbi.nlm.nih.gov/38876392/]
  - The effects of Garcinia cambogia (hydroxycitric acid) on lipid profile: A systematic review and meta-analysis of randomized controlled trials, Phytotherapy research : PTR (2024) — Meta-analysis of 14 RCTs (623 subjects) found Garcinia cambogia (HCA) modestly reduced triglycerides (-24.2 mg/dL) and total cholesterol (-6.8 mg/dL) and slightly raised HDL (+2.95 mg/dL), with no change in LDL. [https://pubmed.ncbi.nlm.nih.gov/38151892/]
  - The effects of Garcinia cambogia on glycaemic control and liver enzymes in adults: a systematic review and meta-analysis of randomised controlled trials, Journal of nutritional science (2025) — Meta-analysis of 9 RCTs (444 adults) found Garcinia cambogia had no significant effect on fasting blood glucose (WMD +1.02 mg/dL), insulin (WMD -0.12 mU/L), ALT, or AST versus control, though insulin fell with interventions longer than 8 weeks. [https://pubmed.ncbi.nlm.nih.gov/39943939/]
  - Effect of Garcinia cambogia supplement on obesity indices: A systematic review and dose-response meta-analysis, Complementary therapies in medicine (2020) — Dose-response meta-analysis of 8 RCTs (530 subjects) found Garcinia cambogia significantly reduced body weight (-1.34 kg), BMI (-0.99 kg/m2), fat mass (-0.42%), and waist circumference (-4.16 cm) versus placebo, though effects were small. [https://pubmed.ncbi.nlm.nih.gov/32951714/]
  - Do not consume food supplements containing Garcinia cambogia, Agence nationale de securite sanitaire de l'alimentation, de l'environnement et du travail (ANSES) (2025) — France's ANSES advised the entire population against consuming Garcinia cambogia supplements, citing 38 nutrivigilance adverse-effect reports (2009-March 2024) including a fatal fulminant hepatitis plus psychiatric, pancreatitis, cardiac and rhabdomyolysis cases, even in people with no prior medical problems. [https://www.anses.fr/en/content/do-not-consume-food-supplements-containing-garcinia-cambogia]
  - The Use of Garcinia Extract (Hydroxycitric Acid) as a Weight loss Supplement: A Systematic Review and Meta-Analysis of Randomised Clinical Trials, Journal of obesity (2011) — Effect on weight was small and of questionable clinical significance. [https://pubmed.ncbi.nlm.nih.gov/21197150/]
  - Hepatotoxicity of dietary supplements containing Garcinia gummi-gutta (L.) N. Robson, Pharmaceutical biology (2025) — Review identified >200 reported adverse liver-injury events and analyzed 34 peer-reviewed case reports of Garcinia gummi-gutta supplements, documenting 1 death and 9 liver transplants, with 17 cases scoring possible-to-highly-probable causality (CIOMS/RUCAM). [https://pmc.ncbi.nlm.nih.gov/articles/PMC12636546/]
  - Hepatotoxicity of dietary supplements containing Garcinia gummi-gutta (L.) N. Robson, Pharmaceutical biology (2025) — Recent review concludes Garcinia gummi-gutta/HCA dietary supplements carry a documented, largely idiosyncratic risk of serious liver injury, prompting USP cautionary labeling against use in those with liver problems. [https://pubmed.ncbi.nlm.nih.gov/41262061/]
  - Garcinia Cambogia (2019) — HCA-containing products linked to liver injury and product recalls. [https://www.ncbi.nlm.nih.gov/books/NBK548087/]
  - Acute liver injury following Garcinia cambogia weight-loss supplementation: case series and literature review, Internal and emergency medicine (2018) — Reports 4 cases of acute liver failure in women taking G. cambogia for weight loss plus a literature review; identifies G. cambogia as a recognized cause of herb-induced acute hepatocellular injury, reinforcing that 'natural' status does not guarantee hepatic safety. [https://pubmed.ncbi.nlm.nih.gov/29802521/]
  - Garcinia cambogia, Either Alone or in Combination With Green Tea, Causes Moderate to Severe Liver Injury, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2022) — Among 1418 patients in the U.S. Drug-Induced Liver Injury Network, 22 cases of moderate-to-severe liver injury were attributed to Garcinia cambogia alone (n=5) or combined with green tea (n=16)/ashwagandha (n=1); 91% were hospitalized, one needed transplantation, and one died. [https://pubmed.ncbi.nlm.nih.gov/34400337/]
  - Garcinia cambogia (hydroxycitric acid) as a potential antiobesity agent: a randomized controlled trial, JAMA (1998) — Garcinia produced no greater weight loss than placebo. [https://pubmed.ncbi.nlm.nih.gov/9820262/]
  - Garcinia Cambogia: Usefulness and Safety, NIH National Center for Complementary and Integrative Health (2025) — NIH's NCCIH concludes it is unclear whether garcinia cambogia aids weight loss (some evidence shows a modest effect, other evidence none) and warns it may be unsafe, citing several reported cases of liver damage, some severe though uncommon. [https://www.nccih.nih.gov/health/garcinia-cambogia]

---

## Colloidal Silver (Suspended silver particles)
URL: https://nutridex.info/s/colloidal-silver
Category: Debunked, Gut & Immune
Evidence: No Evidence — No credible human evidence supports the marketed claims — widely considered ineffective.
No medical benefit — and it can turn your skin permanently blue.

Quick answer: Colloidal Silver is marketed for 'natural antibiotic' & immune cure-all. NutriDex grades the human evidence as no evidence — No credible human evidence supports the marketed claims — widely considered ineffective. Based on 18 cited human studies (18 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Colloidal silver is suspended silver particles promoted as a 'natural antibiotic' and cure-all. Health authorities are clear: there is no scientific evidence it is effective for any internal condition, and it is not safe to take by mouth. Its most notorious harm is argyria — silver deposits that turn the skin a permanent blue-grey. The FDA has acted against products claiming colloidal silver treats disease.

Benefits / uses: (Claimed) 'natural antibiotic' & immune cure-all.
Active compounds: Colloidal silver particles.
Dose: No safe or effective oral dose — health authorities advise against ingestion.
Safety: ⚠ Causes argyria — permanent, irreversible blue-grey skin/eyes. May impair absorption of antibiotics and thyroid medication. No proven benefit to offset these risks. Avoid internal use.

Cited studies (18):
  - Impact of Silver Dressings on Wound Healing Rate in Patients with Lower Extremity Ulcers: A Systematic Review and Meta-Analysis of Randomized Controlled Trials, Medical principles and practice : international journal of the Kuwait University, Health Science Centre (2025) — Meta-analysis of 18 RCTs (1,825 patients) found topical silver dressings improved healing of diabetic foot ulcers (OR 2.14, 95% CI 1.52-3.00) but showed no significant benefit for venous leg ulcers (OR 1.32, 95% CI 0.97-1.78), indicating any topical benefit is ulcer-type specific. [https://pmc.ncbi.nlm.nih.gov/articles/PMC11805542/]
  - Colloidal Silver: What You Need To Know, NIH National Center for Complementary and Integrative Health (2023) — US NCCIH/FDA state silver has no known body function, is not an essential mineral, is unsafe (causes permanent argyria and may harm kidney/liver/nervous system and impair drug absorption), and nasal-spray studies for sinus infection showed no meaningful benefit; no evidence for COVID-19. [https://www.nccih.nih.gov/health/colloidal-silver-what-you-need-to-know]
  - FTC, FDA Send Warning Letters to Seven Companies about Unsupported Claims that Products Can Treat or Prevent Coronavirus, Federal Trade Commission (2020) — Regulators issued warning letters to multiple companies (including a colloidal silver marketer) for unsupported claims that silver products treat or prevent COVID-19, citing lack of competent scientific evidence. [https://www.ftc.gov/news-events/news/press-releases/2020/03/ftc-fda-send-warning-letters-seven-companies-about-unsupported-claims-products-can-treat-or-prevent]
  - Colloidal Silver: What You Need To Know, NIH National Center for Complementary and Integrative Health (2023) — States colloidal silver is not safe or effective for any claimed use. [https://www.nccih.nih.gov/health/colloidal-silver]
  - Over-the-counter drug products containing colloidal silver ingredients or silver salts. Department of Health and Human Services (HHS), Public Health Service (PHS), Food and Drug Administration (FDA). Final rule, Federal register (1999) — Over-the-counter colloidal silver products are not recognized as safe and effective. [https://pubmed.ncbi.nlm.nih.gov/10558603/]
  - Over-the-Counter Drug Products Containing Colloidal Silver Ingredients or Silver Salts, Federal Register (U.S. Food and Drug Administration, HHS) (1999) — Landmark regulatory ruling: ALL over-the-counter drug products containing colloidal silver or silver salts are NOT generally recognized as safe and effective for any disease or condition; manufacturers failed to provide required absorption, distribution, accumulation and efficacy data. Established no benefit and codified enforcement against internal/OTC colloidal silver claims. [https://www.federalregister.gov/documents/1999/08/17/99-21253/over-the-counter-drug-products-containing-colloidal-silver-ingredients-or-silver-salts]
  - Potential Toxicological Risk Associated with the Oral Use of Colloidal Silver Dietary Supplements, Toxics (2025) — Physicochemical analysis of commercial oral colloidal silver supplements found estimated daily silver intake at maximum recommended doses can exceed EPA safety thresholds, indicating risk of chronic accumulation and systemic toxicity. [https://pmc.ncbi.nlm.nih.gov/articles/PMC12656528/]
  - Assessment of orally dosed commercial silver nanoparticles on human ex vivo platelet aggregation, Nanotoxicology (2014) — Placebo-controlled, single-blind, crossover trial in 18 healthy volunteers given daily oral commercial silver nanoparticles for 2 weeks: no detectable enhancement of ex vivo platelet aggregation at peak serum silver <10 ug/L. One of the very few human interventional studies of ingested colloidal/nanosilver — assessed safety endpoints, demonstrated no clinical benefit. [https://pubmed.ncbi.nlm.nih.gov/23517080/]
  - Silver nanoparticles as next-generation antimicrobial agents: mechanisms, challenges, and innovations against multidrug-resistant bacteria, Frontiers in cellular and infection microbiology (2025) — Review concludes silver nanoparticles show in vitro antimicrobial potential against multidrug-resistant bacteria but face major barriers to clinical translation, including mammalian cytotoxicity (especially <10 nm), emerging bacterial resistance, and lack of selectivity. [https://pmc.ncbi.nlm.nih.gov/articles/PMC12390974/]
  - Potential Toxicological Risk Associated with the Oral Use of Colloidal Silver Dietary Supplements, Toxics (2025) — Physicochemical characterization of commercial oral colloidal silver supplements (up to 1000 mg/L, poorly labelled): estimated daily intakes exceed the US EPA oral reference dose of 0.005 mg/kg/day, indicating a real toxicological risk and the need for stricter regulation; no therapeutic benefit demonstrated. [https://pubmed.ncbi.nlm.nih.gov/41304544/]
  - Colloidal silver ingestion and severe anemia - A case report, Toxicology reports (2023) — Case report: a woman who ingested 150 µg/day colloidal silver for 2-3 weeks developed severe macrocytic anemia (RBC 48 g/L), thrombocytopenia (platelets 52 x10^9/L), abnormal liver function and early heart failure, with whole-blood silver of 20.0 µg/L falling to 3.3 µg/L over ~3 months. [https://pmc.ncbi.nlm.nih.gov/articles/PMC10520504/]
  - No silver lining with health misinformation: argyria caused by intentional silver consumption, The Medical journal of Australia (2025) — Case report: a 63-year-old man who used homemade silver solution for a flu-like illness after reading online antiviral claims developed permanent blue-grey argyria on sun-exposed skin, illustrating harm from health misinformation about silver. [https://pmc.ncbi.nlm.nih.gov/articles/PMC12276725/]
  - Argyria: permanent skin discoloration following protracted colloid silver ingestion, BMJ case reports (2009) — Documented permanent blue-grey skin discoloration from ingestion. [https://pmc.ncbi.nlm.nih.gov/articles/PMC3029119/]
  - Oral toxicity of silver ions, silver nanoparticles and colloidal silver--a review, Regulatory toxicology and pharmacology : RTP (2014) — Oral toxicity review: orally administered silver is absorbed ~18% in humans and distributes to all organs (highest in intestine/stomach), inducing argyria; particle effects are mediated by released silver ions. Margin-of-safety calculation gives only a factor of ~5 before a level of concern for the general population — i.e., a narrow safety window with no efficacy benefit. [https://pubmed.ncbi.nlm.nih.gov/24231525/]
  - Topical silver for preventing wound infection, Cochrane Database of Systematic Reviews (2010) — Cochrane systematic review (26 RCTs, ~2,066 participants) found insufficient evidence that silver-containing dressings or topical agents promote wound healing or prevent infection, with low-quality evidence suggesting silver sulfadiazine may actually delay healing of partial-thickness burns. [https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD006478.pub2/full]
  - A case of generalized argyria after ingestion of colloidal silver solution, American journal of industrial medicine (2009) — Documented case of generalized argyria after ingesting ~1 L/day of colloidal silver solution for ~16 months: diffuse permanent blue-gray skin/mucosal discoloration with serum silver 381 ng/mL (reference <15 ng/mL), confirmed by EDX showing silver-sulfur deposits. Illustrates the principal documented human harm of oral colloidal silver. [https://pubmed.ncbi.nlm.nih.gov/19097083/]
  - A Case Study of Argyria of the Nails Secondary to Colloidal Silver Ingestion, Cureus (2022) — Case report documenting bilateral blue-grey pigmentary changes confined to the nail beds following chronic oral colloidal silver ingestion, illustrating an early sign of argyria. [https://pubmed.ncbi.nlm.nih.gov/36457628/]
  - Seizures Following Self-Medication With Colloidal Silver: A Case Report, Hospital pharmacy (2023) — Case report of a 70-year-old man who developed new-onset seizures as the presenting manifestation of silver toxicity after self-medicating with oral colloidal silver, illustrating rare but serious neurotoxicity beyond argyria. [https://pubmed.ncbi.nlm.nih.gov/37360209/]

---

## Shark Cartilage (Ground shark cartilage)
URL: https://nutridex.info/s/shark-cartilage
Category: Debunked, Joint & Skin
Evidence: No Evidence — No credible human evidence supports the marketed claims — widely considered ineffective.
'Sharks don't get cancer' — they do, and this doesn't cure it.

Quick answer: Shark Cartilage is marketed for treats cancer. NutriDex grades the human evidence as no evidence — No credible human evidence supports the marketed claims — widely considered ineffective. Based on 14 cited human studies (14 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Shark cartilage was popularized by the myth that sharks don't get cancer (they do) and the idea that anti-angiogenic compounds in cartilage could starve tumors. Controlled clinical trials of shark-cartilage products in cancer patients found no survival or quality-of-life benefit. Beyond debunking a harmful cancer myth, the trade has also contributed to shark population decline.

Benefits / uses: (Claimed) treats cancer; (Claimed) joint / arthritis benefit.
Active compounds: Shark cartilage powder.
Dose: No demonstrated therapeutic dose; not a cancer treatment.
Safety: Generally low direct toxicity, but the real harm is the myth: using it instead of proven cancer treatment can be life-threatening. GI upset and bad taste are common. Ecologically harmful to shark populations.

Cited studies (14):
  - Shark cartilage, CAM Cancer (NAFKAM, UiT The Arctic University of Norway) (2024) — Updated systematic monograph concludes that across two RCTs (n=379 and n=83) oral shark cartilage did not prolong survival or improve tumor outcomes in advanced cancer, and is generally well tolerated with only minor transient GI adverse events. [https://cam-cancer.org/shark-cartilage]
  - Cartilage (Bovine and Shark) (PDQ®), U.S. National Cancer Institute (1970) — The National Cancer Institute's authoritative PDQ summary concludes that the few human cancer studies of cartilage reported are inconclusive, the FDA has not approved cartilage for cancer, and no shark cartilage product has been shown to be an effective anticancer agent. [https://www.cancer.gov/about-cancer/treatment/cam/hp/cartilage-pdq]
  - Chemoradiotherapy with or without AE-941 in stage III non-small cell lung cancer: a randomized phase III trial, Journal of the National Cancer Institute (2010) — No survival benefit from a shark-cartilage product in lung cancer. [https://pubmed.ncbi.nlm.nih.gov/20505152/]
  - Prognostic factors of metastatic renal cell carcinoma after failure of immunotherapy: new paradigm from a large phase III trial with shark cartilage extract AE 941, The Journal of urology (2007) — A randomized phase III trial of the shark-cartilage extract AE-941 (Neovastat) in 300 patients with metastatic renal cell carcinoma refractory to immunotherapy failed to improve overall survival (median 12.6 months for the cohort), with the agent subsequently dropped from development. [https://pubmed.ncbi.nlm.nih.gov/17868728/]
  - Phase I/II trial of the safety and efficacy of AE-941 (Neovastat) in the treatment of non-small-cell lung cancer, Clinical lung cancer (2003) — In an 80-patient open-label dose-escalation phase I/II trial of the shark-cartilage extract AE-941 (Neovastat) in lung cancer, higher doses were associated with a modest median-survival difference (6.1 vs 4.6 months, P=0.026); this early signal was not confirmed in later randomized phase III testing. [https://pubmed.ncbi.nlm.nih.gov/14624712/]
  - Neovastat (AE-941) in refractory renal cell carcinoma patients: report of a phase II trial with two dose levels, Annals of oncology : official journal of the European Society for Medical Oncology (2002) — A phase II trial of two dose levels of Neovastat (AE-941) in refractory renal cell carcinoma reported a dose-dependent association with longer survival, but the agent failed to demonstrate an overall survival benefit in subsequent randomized phase III evaluation. [https://pubmed.ncbi.nlm.nih.gov/12181250/]
  - Phase I/II trial of the safety and efficacy of shark cartilage in the treatment of advanced cancer, Journal of clinical oncology : official journal of the American Society of Clinical Oncology (1998) — Phase I/II single-agent trial of oral shark cartilage (1 g/kg/day) in 60 patients with advanced pretreated cancer. No complete or partial responses; 16.7% had stable disease (similar to supportive care alone) and no improvement in quality of life. Shark cartilage was inactive; 21 adverse events recorded, mostly gastrointestinal (nausea, vomiting, constipation). [https://pubmed.ncbi.nlm.nih.gov/9817287/]
  - Cyanobacterial Neurotoxin BMAA and Mercury in Sharks, Toxins (2016) — Across ten shark species, the neurotoxin BMAA was detected in all samples (34-2011 ng/mg wet weight) at levels 15-1500x higher than mercury, raising safety concerns for shark fin and cartilage supplement consumers (DOI 10.3390/toxins8080238). [https://pmc.ncbi.nlm.nih.gov/articles/PMC4999854/]
  - Environmental neurotoxins β-N-methylamino-l-alanine (BMAA) and mercury in shark cartilage dietary supplements, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association (2014) — Analysis of 16 commercial shark-cartilage supplements detected the cyanobacterial neurotoxin BMAA in 15/16 products (86-265 ug/g) plus measurable mercury, indicating a contamination/neurotoxicity safety risk. [https://pubmed.ncbi.nlm.nih.gov/24755394/]
  - Shark Cartilage, Cancer and the Growing Threat of Pseudoscience, Cancer Research (2004) — No credible evidence for anticancer or major joint benefits. [https://aacrjournals.org/cancerres/article/64/23/8485/512022/Shark-Cartilage-Cancer-and-the-Growing-Threat-of]
  - A Case of Liver Injury From Shark Cartilage Supplementation in Patient With Malignancy: 2143, The American Journal of Gastroenterology (2017) — Case report of acute drug-induced liver injury in an adult attributed to shark-cartilage supplementation, with liver enzymes/bilirubin normalizing after discontinuation. [https://journals.lww.com/ajg/fulltext/2017/10001/a_case_of_liver_injury_from_shark_cartilage.2144.aspx]
  - Dangerous nutrition? Calcium, vitamin D, and shark cartilage nutritional supplements and cancer-related hypercalcemia, Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer (2003) — A Cleveland Clinic case series of eight cancer patients with symptomatic hypercalcemia found that calcium, vitamin D, and shark-cartilage supplements may have contributed to the prevalence or severity of hypercalcemia, flagging a clinically relevant safety hazard. [https://pubmed.ncbi.nlm.nih.gov/12673461/]
  - Evaluation of shark cartilage in patients with advanced cancer: a North Central Cancer Treatment Group trial, Cancer (2005) — Shark cartilage added no benefit to standard care in advanced cancer. [https://pubmed.ncbi.nlm.nih.gov/15912493/]
  - Shark Cartilage, Memorial Sloan Kettering Cancer Center — Memorial Sloan Kettering's authoritative integrative-medicine monograph concludes shark cartilage is not effective in treating cancer, noting that orally ingested cartilage proteins are likely digested rather than absorbed, so test-tube anti-angiogenic activity does not translate to anti-tumor effects in animals or humans. [https://www.mskcc.org/cancer-care/integrative-medicine/herbs/shark-cartilage]

---

## Laetrile / 'Vitamin B17' (Amygdalin (apricot kernels))
URL: https://nutridex.info/s/laetrile
Category: Debunked, Banned & Harmful
Evidence: No Evidence — No credible human evidence supports the marketed claims — widely considered ineffective.
A discredited 'cancer cure' that releases cyanide.

Quick answer: Laetrile / 'Vitamin B17' is marketed for 'natural' cancer cure. NutriDex grades the human evidence as no evidence — No credible human evidence supports the marketed claims — widely considered ineffective. Based on 17 cited human studies (17 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Laetrile, marketed as 'vitamin B17' (it is not a vitamin), is a semi-synthetic form of amygdalin from apricot kernels promoted as a natural cancer cure. A Cochrane review found no reliable evidence of any anticancer benefit, while the compound metabolizes into cyanide, posing a genuine poisoning risk. The FDA has never approved it, and selling it as a cancer treatment has led to prosecutions.

Benefits / uses: (Claimed) 'natural' cancer cure.
Active compounds: Amygdalin (a cyanogenic glycoside).
Dose: No safe dose — it releases cyanide. Not an approved treatment.
Safety: ⚠ CYANIDE RISK. Amygdalin breaks down to cyanide, causing nausea, headache, dizziness, liver damage, low blood pressure and potentially fatal poisoning — risk is higher with oral use and vitamin C. Using it in place of proven cancer therapy can be fatal. Not approved or legal as a treatment.

Cited studies (17):
  - Laetrile treatment for cancer, Cochrane Database of Systematic Reviews (2015) — No reliable evidence of benefit; risk of serious cyanide toxicity. [https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD005476.pub4/full]
  - Laetrile treatment for cancer, The Cochrane database of systematic reviews (2015) — Updated Cochrane review searching 8 databases found NO randomized or quasi-randomized controlled trials meeting inclusion criteria; concluded claims of anti-cancer benefit are unsupported by sound clinical data and that the risk-benefit balance is 'unambiguously negative' given the considerable risk of cyanide poisoning, especially after oral ingestion. [https://pubmed.ncbi.nlm.nih.gov/25918920/]
  - Evaluation of the health risks related to the presence of cyanogenic glycosides in foods other than raw apricot kernels, EFSA journal. European Food Safety Authority (2019) — EFSA established an acute reference dose for cyanide from cyanogenic glycosides of 20 micrograms/kg body weight, underscoring the narrow safety margin for amygdalin-containing products such as apricot kernels. [https://pmc.ncbi.nlm.nih.gov/articles/PMC7009189/]
  - Apricot kernels pose risk of cyanide poisoning, European Food Safety Authority (2016) — EFSA's apricot-kernel-specific opinion concluded that, against an acute reference dose of 20 micrograms cyanide/kg body weight, adults can safely eat at most ~3 small raw kernels (370 mg) at one time while a single small kernel already exceeds the safe level for toddlers, flagging acute cyanide-poisoning risk from amygdalin. [https://www.efsa.europa.eu/en/press/news/160427]
  - Laetrile (amygdalin or vitamin B17), Cancer Research UK (2022) — Authoritative cancer body states there is no reliable evidence laetrile/amygdalin treats cancer (citing the 2015 Cochrane review) and warns oral tablets release cyanide during digestion, risking liver and nerve damage, oxygen deprivation and death; it is banned in the USA and unavailable in the UK/Europe. [https://www.cancerresearchuk.org/about-cancer/treatment/complementary-alternative-therapies/individual-therapies/laetrile]
  - Laetrile/Amygdalin (PDQ®), U.S. National Cancer Institute (1975) — Never approved; promoted illegally as a cancer cure. [https://www.cancer.gov/about-cancer/treatment/cam/hp/laetrile-pdq]
  - A Clinical Trial of Amygdalin (Laetrile) in the Treatment of Human Cancer, New England Journal of Medicine (1982) — Clinical trial found laetrile ineffective against cancer. [https://www.nejm.org/doi/full/10.1056/NEJM198201283060403]
  - A clinical trial of amygdalin (Laetrile) in the treatment of human cancer, The New England journal of medicine (1982) — Landmark NCI-sponsored prospective clinical trial of 178 cancer patients given amygdalin plus 'metabolic therapy': NO substantive benefit in cure, improvement, stabilization, symptom relief, or survival. Several patients developed cyanide toxicity with blood cyanide approaching lethal range. Concluded amygdalin is a toxic drug ineffective as cancer treatment. [https://pubmed.ncbi.nlm.nih.gov/7033783/]
  - A pharmacologic and toxicological study of amygdalin, JAMA (1981) — NCI Phase I pharmacologic/toxicologic study in 6 advanced-cancer patients: IV amygdalin (4.5 g/m2/day) was largely excreted unchanged with no toxicity, but oral dosing (0.5 g three times daily) produced significant blood cyanide levels up to 2.1 ug/mL; one patient eating raw almonds developed transient cyanide toxicity with rising blood cyanide. [https://pubmed.ncbi.nlm.nih.gov/7005480/]
  - Amygdalin as a Promising Anticancer Agent: Molecular Mechanisms and Future Perspectives for the Development of New Nanoformulations for Its Delivery, International journal of molecular sciences (2023) — Review of preclinical evidence across lung, breast, prostate, colorectal, cervical and GI cancers concluding current evidence cannot support amygdalin supplement use because its cyano-moiety causes adverse cyanide effects. [https://pubmed.ncbi.nlm.nih.gov/37762572/]
  - Amygdalin as a Promising Anticancer Agent: Molecular Mechanisms and Future Perspectives for the Development of New Nanoformulations for Its Delivery, International journal of molecular sciences (2023) — 2023 comprehensive review concluding that amygdalin's purported anticancer activity is supported only by in vitro and animal data, while human/clinical evidence has failed to demonstrate efficacy and shows cyanide toxicity risk. [https://pmc.ncbi.nlm.nih.gov/articles/PMC10531689/]
  - Amygdalin: A Review on Its Characteristics, Antioxidant Potential, Gastrointestinal Microbiota Intervention, Anticancer Therapeutic and Mechanisms, Toxicity, and Encapsulation, Biomolecules (2022) — Narrative review concluding amygdalin shows only preclinical/in-vitro anticancer signals and that orally released hydrogen cyanide makes it harmful, with unpredictable toxicity dependent on gut microbiota; not recommended for patients. [https://pubmed.ncbi.nlm.nih.gov/36291723/]
  - Life-Threatening Cyanide Intoxication after Ingestion of Amygdalin in Prehospital Care, Prehospital emergency care (2022) — A 72-year-old developed life-threatening cyanide intoxication after ingesting an amygdalin dietary supplement and was successfully treated with the antidote hydroxocobalamin. [https://pubmed.ncbi.nlm.nih.gov/33955827/]
  - Physician Beware: Severe Cyanide Toxicity from Amygdalin Tablets Ingestion, Case reports in emergency medicine (2017) — Case report documenting severe, life-threatening cyanide toxicity in a patient who self-administered oral amygdalin tablets for metastatic cancer; symptoms resolved with hydroxocobalamin, illustrating the persistent real-world poisoning hazard of amygdalin/laetrile supplements. [https://pubmed.ncbi.nlm.nih.gov/28912981/]
  - Acute cyanide intoxication due to apricot seed ingestion, Archivos argentinos de pediatria (2025) — Retrospective PICU case series of 14 children (1-18 y) with cyanide intoxication after eating apricot/almond kernels; weakness/fatigue was the commonest presentation (n=7), 4 had lip cyanosis and 3 altered consciousness, with 4 requiring hydroxocobalamin antidote for metabolic acidosis; all survived. [https://pubmed.ncbi.nlm.nih.gov/39207944/]
  - Phytochemical Profiling and Toxicity Assessment of Aqueous Extract From Bitter Apricot Kernels Cultivated in Morocco, Scientifica (2025) — Acute/subacute toxicity study of bitter apricot kernel aqueous extract in Swiss albino mice; acute LD50 >6000 mg/kg but 28-day dosing at 1000 mg/kg lowered hematocrit and raised urea/creatinine, indicating renal/hematologic effects. [https://pubmed.ncbi.nlm.nih.gov/40007548/]
  - Severe cyanide poisoning from an alternative medicine treatment with amygdalin and apricot kernels in a 4-year-old child, Wiener medizinische Wochenschrift (1946) (2015) — Case report of a 4-year-old with metastatic ependymoma who developed severe cyanide encephalopathy and metabolic acidosis with markedly elevated serum cyanide after alternative-medicine treatment using amygdalin plus apricot kernels, recovering fully after sodium thiosulfate. [https://pubmed.ncbi.nlm.nih.gov/25605411/]

---

## Deer Antler Velvet (Cervi cornu pantotrichum · Lù Róng 鹿茸)
URL: https://nutridex.info/s/deer-antler
Category: TCM Herb, Performance
Evidence: Preliminary — Early or small human trials; promising but not yet conclusive.
Harvested antler tissue marketed for strength and recovery.

Quick answer: Deer Antler Velvet is used for strength & recovery. NutriDex grades the human evidence as preliminary — Early or small human trials; promising but not yet conclusive. Based on 17 cited human studies (16 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Deer antler velvet is the soft, growing antler tissue, used in TCM as a 'Yang' tonic and marketed to athletes for its IGF-1 content. The athletic evidence is essentially null — the two controlled human trials found no meaningful strength, endurance, or hormonal benefit — and a key problem is biological: ingested growth factors are digested like any protein, so meaningful systemic IGF-1 from an oral spray is implausible. IGF-1 is also banned in sport.

Benefits / uses: (Claimed) strength & recovery; (Claimed) growth-factor / IGF-1 boost; (Claimed) joint & vitality support.
Active compounds: Growth factors (IGF-1, IGF-2); Collagen; Glycosaminoglycans.
Dose: Commonly 500–1,500 mg/day of extract or spray; no standardized effective dose is established.
Safety: Generally well tolerated short-term; long-term data are lacking. IGF-1 is banned by WADA. Sourcing and welfare practices vary; quality is poorly standardized.

Cited studies (17):
  - Health benefits of deer and elk velvet antler supplements: a systematic review of randomised controlled studies, The New Zealand medical journal (2012) — Systematic review of 7 RCTs (rheumatoid arthritis, osteoarthritis, sexual function, sporting performance) concluded that health claims for deer/elk velvet antler are not supported by rigorous human trials; only 2 of 7 trials showed any positive effect and neither convincingly, with osteoarthritis the only area showing tentative promise. [https://pubmed.ncbi.nlm.nih.gov/23321886/]
  - Health benefits of deer and elk velvet antler supplements: a systematic review of randomised controlled studies (2012) — Systematic review of 7 RCTs of velvet antler supplements (including 3 sporting-performance trials) concluded 5 of 7 showed no effect and the 2 positive trials were unconvincing, finding no rigorous human evidence for strength/performance claims. [https://www.ncbi.nlm.nih.gov/books/NBK161822/]
  - Safety of deer antler extract in children: A 12-week randomized controlled clinical trial, Medicine (2024) — 12-week double-blind RCT of deer antler extract 1586 mg/day in 100 children found no serious adverse events and no significant difference in adverse drug reactions vs placebo (3/48 DAE vs 2/52 control). [https://pubmed.ncbi.nlm.nih.gov/38701283/]
  - Safety of deer antler extract in children: A 12-week randomized controlled clinical trial, Medicine (2024) — 12-week randomized double-blind placebo-controlled trial (n=100; 1586 mg/day deer antler extract) found no serious adverse drug reactions and no significant difference in ADR rate vs placebo (6.25% vs 3.85%, P=.67). [https://pmc.ncbi.nlm.nih.gov/articles/PMC11062680/]
  - The 12 weeks, randomized, double-blinded, placebo-controlled human study to evaluate the effectiveness and safety of KGC deer antlers on the growth of children, Medicine (2022) — Registered protocol (KCT0007386) for a 12-week double-blind, placebo-controlled RCT of KGC deer antler extract in 100 children aged 3-12, evaluating height, bone age, predicted adult height, growth hormone, IGF-1, IGFBP-3 and estradiol as growth endpoints. Documents the design of a contemporary pediatric-growth efficacy trial. [https://pubmed.ncbi.nlm.nih.gov/36316843/]
  - WADA Statement on the prohibited substance IGF, World Anti-Doping Agency (2024) — WADA cautions that deer antler velvet products may contain IGF-1 (prohibited under S2.4) and that oral use could trigger a positive anti-doping test, with no guarantee the IGF-1 is fully degraded in digestion. [https://www.wada-ama.org/en/news/wada-statement-prohibited-substance-igf-1]
  - WADA urges vigilance over Deer Antler Velvet Spray, World Anti-Doping Agency (2024) — WADA advises athletes to be extremely vigilant with deer antler velvet spray because it may contain IGF-1, which is prohibited under section S2.4, and could cause a positive doping test. [https://www.wada-ama.org/en/news/wada-urges-vigilance-over-deer-antler-velvet-spray]
  - Effect of elk velvet antler supplementation on the hormonal response to acute and chronic exercise in male and female rowers, International journal of sport nutrition and exercise metabolism (2005) — No significant gains in strength, endurance, or testosterone/GH/IGF-1 vs placebo (n=46 rowers). [https://pubmed.ncbi.nlm.nih.gov/16286669/]
  - The effects of deer antler velvet extract or powder supplementation on aerobic power, erythropoiesis, and muscular strength and endurance characteristics, International journal of sport nutrition and exercise metabolism (2003) — No significant strength or endurance benefit vs placebo; only an isolated, inconsistent isokinetic signal. [https://pubmed.ncbi.nlm.nih.gov/14669926/]
  - A randomized clinical trial of elk velvet antler in rheumatoid arthritis, Biological research for nursing (2008) — Double-blind RCT in 168 rheumatoid arthritis patients found elk velvet antler did not improve residual symptoms, with no significant differences vs placebo in joint pain, swelling, disease activity, function, quality of life, or blood markers. [https://pubmed.ncbi.nlm.nih.gov/18077778/]
  - Effect of deer velvet on sexual function in men and their partners: a double-blind, placebo-controlled study, Archives of sexual behavior (2003) — 12-week double-blind placebo-controlled trial in 32 men aged 45-65 and their partners found no significant difference in sexual function or hormone levels with deer velvet vs placebo, concluding no advantage for enhancing sexual function in normal men. [https://pubmed.ncbi.nlm.nih.gov/12807299/]
  - Elk velvet antler in rheumatoid arthritis: phase II trial, Biological research for nursing (2002) — Phase II RCT in 40 stage-II rheumatoid arthritis patients found elk velvet antler (up to 6 x 215 mg/day) added to RA medication produced no significant difference in adverse events or health status vs placebo at 1 month, indicating short-term tolerability but no symptomatic benefit. [https://pubmed.ncbi.nlm.nih.gov/12003439/]
  - Health Effects of Peptides Extracted from Deer Antler, Nutrients (2022) — Review of deer antler peptides reports only in vitro and animal evidence (e.g., reduced muscle atrophy in C2C12 cells) and explicitly states clinical studies are still needed to evaluate therapeutic benefits in humans. [https://pmc.ncbi.nlm.nih.gov/articles/PMC9572057/]
  - Biological Activities of Deer Antler-Derived Peptides on Human Chondrocyte and Bone Metabolism, Pharmaceuticals (Basel, Switzerland) (2024) — In vitro, deer antler-derived peptides stimulated human chondrocyte growth (increasing collagen/glycosaminoglycan) and inhibited osteoclast differentiation, supporting a plausible joint/bone mechanism but only at the cell level. [https://pmc.ncbi.nlm.nih.gov/articles/PMC11053545/]
  - The Therapeutic Potential of Intra-Articular Injection of Synthetic Deer Antler Peptides in a Rat Model of Knee Osteoarthritis, International journal of molecular sciences (2024) — Intra-articular injection of synthetic deer antler peptides in a rat collagenase-induced knee osteoarthritis model significantly increased chondrocyte counts and showed chondroprotective/analgesic effects vs saline; preclinical only. [https://pmc.ncbi.nlm.nih.gov/articles/PMC11172866/]
  - Detection of human insulin-like growth factor-1 in deer antler velvet supplements, Rapid communications in mass spectrometry : RCM (2013) — LC-MS/MS detected human IGF-1 (a WADA-banned substance) in 4 of 6 commercial deer antler velvet supplements tested, indicating adulteration and real doping/positive-test risk. [https://pubmed.ncbi.nlm.nih.gov/23996390/]
  - PubMed, NIH National Library of Medicine — Growth factors are broken down in digestion; systemic IGF-1 from oral velvet is doubtful. [https://pubmed.ncbi.nlm.nih.gov/?term=Deer%20Antler%20Velvet%20Oral%20IGF-1%20plausibility]

---

## Edible Bird's Nest (Aerodramus swiftlet nests · Yàn Wō 燕窝)
URL: https://nutridex.info/s/birds-nest
Category: TCM Herb, Longevity, Joint & Skin
Evidence: Preliminary — Early or small human trials; promising but not yet conclusive.
Swiftlet-saliva tonic prized in Chinese cuisine and medicine.

Quick answer: Edible Bird's Nest is used for skin & anti-aging. NutriDex grades the human evidence as preliminary — Early or small human trials; promising but not yet conclusive. Based on 17 cited human studies (17 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Edible bird's nest is the hardened saliva swiftlets use to build nests — a luxury tonic in Chinese culture. It is genuinely rich in glycoproteins and sialic acid, and lab and animal studies show antioxidant, immune-modulating and neuroprotective activity. However, high-quality human clinical evidence is very limited, product standards vary widely, and most marketed health claims remain unproven.

Benefits / uses: (Claimed) skin & anti-aging; (Claimed) immune support; (Claimed) respiratory & cognitive benefits.
Active compounds: Glycoproteins; Sialic acid; Collagen.
Dose: Traditionally simmered as a tonic (a few grams); no established therapeutic dose.
Safety: Can trigger serious allergic reactions in sensitive people. Quality, authenticity and contamination (e.g. nitrites) vary. Expensive with weak clinical justification.

Cited studies (17):
  - Edible Bird’s Nest: The Functional Values of the Prized Animal-Based Bioproduct From Southeast Asia–A Review, Frontiers in Pharmacology (2021) — Glycoproteins/sialic acid show bioactivity in lab models; human evidence very limited. [https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2021.626233/full]
  - Efficacy of Edible Bird's Nest on Cognitive Functions in Experimental Animal Models: A Systematic Review, Nutrients (2021) — PRISMA systematic review (2010-2020) of EBN and cognition: across animal models EBN dose-dependently improved/enhanced cognitive function and attenuated hippocampal neuroinflammation and neuro-oxidative stress; notably NO human trials qualified and no meta-analysis was possible, indicating cognitive benefits remain preclinical. [https://pubmed.ncbi.nlm.nih.gov/33806762/]
  - The antiaging effect of edible bird's nest on the skin of healthy women: a randomized controlled trial, Food Science and Human Wellness (2025) — In a randomized controlled trial of 92 healthy women aged 25-45 over 12 weeks, high-dose oral edible bird's nest significantly improved skin moisture (+22.14%) and elasticity (+5.89%) and reduced deep wrinkles (-18.47%), with lowered IL-6, TNF-alpha, MMP-1 and MMP-9. [https://doi.org/10.26599/FSHW.2025.9250818]
  - Anti-Wrinkle Efficacy of Edible Bird’s Nest Extract: A Randomized, Double-Blind, Placebo-Controlled, Comparative Study, Frontiers in Pharmacology (2022) — In a randomized, double-blind, placebo-controlled human trial, topical/oral edible bird's nest extract significantly reduced facial wrinkles and improved skin elasticity versus placebo. [https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2022.843469/full]
  - Anti-Wrinkle Efficacy of Edible Bird's Nest Extract: A Randomized, Double-Blind, Placebo-Controlled, Comparative Study, Frontiers in pharmacology (2022) — Single-center, double-blind, placebo-controlled RCT in 105 women aged 40-60 found 12 weeks of edible bird's nest extract significantly improved skin wrinkles versus placebo and was assessed as safe. [https://pmc.ncbi.nlm.nih.gov/articles/PMC8959461/]
  - Anti-Wrinkle Efficacy of Edible Bird's Nest Extract: A Randomized, Double-Blind, Placebo-Controlled, Comparative Study, Frontiers in pharmacology (2022) — Randomized, double-blind, placebo-controlled trial in 86 women aged 40-60 (43 EBN extract 100 mg/day vs 43 placebo, 12 weeks): the EBN extract group showed significantly greater improvement in skin wrinkles and skin elasticity vs placebo at week 12, with no adverse reactions, supporting EBN as a safe oral skin-health supplement. [https://pubmed.ncbi.nlm.nih.gov/35355724/]
  - The potential cutaneous benefits of edible bird's nest, Archives of dermatological research (2024) — Narrative review concludes EBN shows promising in vitro/in vivo effects on photoaging, wound healing and skin whitening, but human clinical validation is still lacking. [https://pubmed.ncbi.nlm.nih.gov/38400925/]
  - Edible bird nest as a bioactive food ingredient for human health and market sustainability, Discover Food (2025) — Comprehensive review of EBN bioactives (sialic acid, glycoproteins) finds plausible mechanisms for immune/skin/metabolic benefits but limited robust human trial evidence and market standardization gaps. [https://link.springer.com/article/10.1007/s44187-025-00711-0]
  - The Potential of Edible Bird's Nests in Reducing Cardiovascular Disease Risk Factors: A Narrative Review, International journal of molecular sciences (2025) — A 2025 narrative review concludes EBN bioactives (sialic acid, lactoferrin, glycoproteins) may improve lipid profiles, reduce visceral fat and enhance insulin sensitivity in preclinical models, but human cardiovascular outcome evidence is still lacking. [https://pmc.ncbi.nlm.nih.gov/articles/PMC12111720/]
  - Edible Bird's Nest as a Multi-Component Functional Food for Brain Aging: From Single-Bioactive Actions to Network-Regulatory Mechanisms, Nutrients (2026) — Mechanistic review (Nutrients) framing EBN as a multi-component 'network-regulatory' functional food whose sialic acid, glycoproteins and bioactive peptides act on oxidative stress, neuroinflammation, apoptosis, synaptic maintenance, neurotrophic support and the gut-brain axis, positioned against vitamins C/E, CoQ10, curcumin and omega-3s for brain-aging support. [https://pubmed.ncbi.nlm.nih.gov/41754188/]
  - Dietary sialic acids: distribution, structure, and functions, Critical reviews in food science and nutrition (2024) — Critical review (Crit Rev Food Sci Nutr) identifying EBN as one of the richest dietary sources of sialic acid (in conjugated sialoglycan form) alongside human/bovine milk, red meat and eggs, and summarizing sialic acid roles in neurodevelopment, neurodegeneration and gut-microbiota modulation that underpin proposed EBN benefits. [https://pubmed.ncbi.nlm.nih.gov/37096488/]
  - Edible Bird's Nest as a Potential Cognitive Enhancer, Frontiers in neurology (2022) — Review of EBN as a cognitive enhancer summarizes neuroprotective and memory benefits seen in cell and animal models, noting human evidence remains absent. [https://pmc.ncbi.nlm.nih.gov/articles/PMC9120600/]
  - Edible bird's nest, an Asian health food supplement, possesses anti-inflammatory responses in restoring the symptoms of atopic dermatitis: An analysis of signaling cascades, Frontiers in pharmacology (2022) — Mechanistic study showed edible bird's nest exerts anti-inflammatory effects relevant to atopic dermatitis, reducing pro-inflammatory cytokine mRNA, reactive oxygen species and NF-kB signaling in cell-based models. [https://pubmed.ncbi.nlm.nih.gov/36204219/]
  - Interventional Effects of Edible Bird's Nest and Free Sialic Acids on LPS-Induced Brain Inflammation in Mice, Nutrients (2025) — In LPS-induced neuroinflammation mice, EBN (200 mg/kg/d) and free sialic acid improved spatial-memory escape latency and reduced inflammatory/renal markers versus LPS controls. [https://pubmed.ncbi.nlm.nih.gov/39940389/]
  - Revealing Edible Bird Nest as Novel Functional Foods in Combating Metabolic Syndrome: Comprehensive In Silico, In Vitro, and In Vivo Studies, Nutrients (2023) — Integrated in silico, in vitro and in vivo study reports EBN improved metabolic-syndrome markers (lipids, glucose handling) in animal/cell models, supporting functional-food potential. [https://pmc.ncbi.nlm.nih.gov/articles/PMC10535673/]
  - Potential Residual Contaminants in Edible Bird, Frontiers in Pharmacology (2021) — Most health claims lack strong experimental support; quality/standards inconsistent. [https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2021.631136/full]
  - Efficacy of Edible Bird's Nest on Cognitive Functions in Experimental Animal Models: A Systematic Review, Nutrients (2021) — Neuroprotective effects seen in animal models, not confirmed in humans. [https://pmc.ncbi.nlm.nih.gov/articles/PMC8004720/]

---

## Ejiao (Donkey-hide Gelatin) (Colla Corii Asini · Ē Jiāo 阿胶)
URL: https://nutridex.info/s/ejiao
Category: TCM Herb
Evidence: Preliminary — Early or small human trials; promising but not yet conclusive.
A 'blood-nourishing' gelatin — and a global welfare crisis.

Quick answer: Ejiao (Donkey-hide Gelatin) is used for blood-building / anti-anemia. NutriDex grades the human evidence as preliminary — Early or small human trials; promising but not yet conclusive. Based on 15 cited human studies (15 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Ejiao is a gelatin made by boiling donkey hides, classed in TCM as a blood tonic. Some research reports a hematopoietic (blood-cell-promoting) effect, and a clinical trial described improved dizziness and maintained red-cell counts — but rigorous human RCTs are scarce. Beyond efficacy questions, surging demand has driven a documented global animal-welfare crisis, decimating donkey populations.

Benefits / uses: (Claimed) blood-building / anti-anemia; (Claimed) eases dizziness & dry cough; (Claimed) skin & 'beauty' tonic.
Active compounds: Collagen-derived peptides & amino acids (gelatin from donkey hide).
Dose: Traditionally 3–9 g dissolved in warm liquid; few standardized human studies exist.
Safety: Gelatin itself is low-risk to consume. The major concern is ethical/ecological: the donkey-skin trade involves grave welfare problems and population collapse.

Cited studies (15):
  - Ejiao as a preventive agent for osteoporosis - a scoping review of current evidence, Journal of orthopaedic surgery and research (2025) — Scoping review of 22 studies (5 on Ejiao alone, 17 on Ejiao formulations) found emerging preclinical evidence of anti-osteoporotic/bone-protective effects, but flagged a lack of high-quality clinical trials. [https://pubmed.ncbi.nlm.nih.gov/40325487/]
  - Efficacy and safety of Compound E'jiao Jiang for treating leukopenia based: a systematic review and Meta-analysis, Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan (2025) — Systematic review/meta-analysis of 28 RCTs (2041 participants): Compound E'jiao Jiang for tumor/immune-disease leukopenia improved clinical efficacy (RR 1.17, 95% CI 1.08-1.27); added to Western medicine it raised WBC counts (MD 1.12, 95% CI 0.83-1.42), improved Karnofsky status (RR 1.39, 95% CI 1.25-1.55) and reduced bone-marrow toxicity (RR 0.61, 95% CI 0.54-0.69); GRADE evidence low. [https://pubmed.ncbi.nlm.nih.gov/41015792/]
  - Safety and efficacy of East Asian herbal medicine for iron deficiency anemia in children and adolescents: a systematic review and meta-analysis, Frontiers in pharmacology (2024) — Systematic review/meta-analysis of 28 RCTs of East Asian herbal medicine (including Ejiao-containing formulas) for iron-deficiency anemia in children/adolescents; herbal medicine, alone or added to oral iron, significantly improved hemoglobin, serum ferritin and total effective rate with fewer gastrointestinal adverse events and shorter healing times than oral iron alone (GRADE quality limited). [https://pubmed.ncbi.nlm.nih.gov/38655186/]
  - Efficacy of Chinese herbal prescriptions containing Ejiao or Velvet antler for management of uterine fibroids: a systematic review and meta-analysis of randomized controlled trials, Annals of palliative medicine (2021) — Systematic review/meta-analysis of 9 RCTs (844 patients): Ejiao/Velvet-antler herbal prescriptions plus mifepristone shrank uterine fibroids more than mifepristone alone (SMD 0.59, 95% CI 0.33-0.85), improved fibroid-related symptoms (RR 1.24, 95% CI 1.15-1.35) and lowered estradiol and progesterone, with fewer adverse events (RR 0.24, 95% CI 0.15-0.40). [https://pubmed.ncbi.nlm.nih.gov/34488366/]
  - African Union moratorium 2024 — In February 2024 the African Union adopted a continent-wide moratorium banning slaughter of donkeys for skins, responding to ejiao demand of roughly 6 million skins/year and projected halving of Africa's ~27 million donkeys. [https://awionline.org/programs/equines/ejiao/]
  - Efficacy and Safety of Ejiao (Asini Corii Colla) in Women With Blood Deficient Symptoms: A Randomized, Double-Blind, and Placebo-Controlled Clinical Trial, Frontiers in pharmacology (2021) — Randomized, double-blind, placebo-controlled trial in 210 women with blood-deficient symptoms; Ejiao 6 g/day for 8 weeks significantly improved dizziness, attenuated the decline in hematocrit and red blood cell count seen in placebo, and raised SF-36 quality-of-life scores, with no significant adverse or fire-heat effects. [https://pubmed.ncbi.nlm.nih.gov/34707496/]
  - Efficacy and Safety of Ejiao (Asini Corii Colla) in Women With Blood Deficient Symptoms: A Randomized, Double-Blind, and Placebo-Controlled Clinical Trial, Frontiers in pharmacology (2021) — Reported improved dizziness and maintained red-cell counts vs placebo (limited). [https://pmc.ncbi.nlm.nih.gov/articles/PMC8542698/]
  - Stability and iron affinity of Donkey-hide gelatin hydrolysates: Implications for improving iron bioavailability and gut microbiota modulation, NPJ science of food (2025) — Preclinical (rat IDA model) study of donkey-hide gelatin hydrolysates reported a 44% increase in hemoglobin, normalized serum ferritin (25.34 ng/mL), and improved gut microbiota, supporting an iron-carrier mechanism; no human data. [https://pmc.ncbi.nlm.nih.gov/articles/PMC12658104/]
  - Donkey Skin Trade and Its Non-compliance With Legislative Framework, Frontiers in veterinary science (2022) — Review found the donkey skin (ejiao) trade frequently non-compliant with welfare, traceability and biosecurity legislation, posing zoonotic disease and animal-welfare risks across exporting and importing countries. [https://pmc.ncbi.nlm.nih.gov/articles/PMC8968980/]
  - Blood-supplementing effect of low molecular weight peptides of E-Jiao on chemotherapy-induced myelosuppression: evaluation of pharmacological activity and identification of bioactive peptides released in vivo, Frontiers in pharmacology (2024) — In zebrafish and cyclophosphamide-treated mice, low-molecular-weight Ejiao peptides aided recovery of erythrocyte/blood-cell counts; two isolated peptides (PP-1, PP-2) reversed chemotherapy-induced cytopenia (preclinical). [https://pmc.ncbi.nlm.nih.gov/articles/PMC11188354/]
  - Stability and iron affinity of Donkey-hide gelatin hydrolysates: Implications for improving iron bioavailability and gut microbiota modulation, npj Science of Food (2025) — Donkey-hide gelatin hydrolysates showed strong iron affinity and, in mice, improved iron bioavailability and modulated gut microbiota, supporting a mechanistic basis for anti-anemia effects (preclinical). [https://www.nature.com/articles/s41538-025-00617-2]
  - A Comprehensive Review of Traditional Chinese Medicine Ejiao (Colla Corii Asini): Chemical Composition, Quality Control, and Pharmacological Actions, Natural Product Communications (2025) — Hematopoietic effects reported; high-quality human RCTs remain scarce. [https://journals.sagepub.com/doi/10.1177/1934578X251335424]
  - Species-specific identification of donkey-hide gelatin and its adulterants using marker peptides, PloS one (2022) — LC-MS/MS using 12 species-specific marker peptides detected cattle- and pig-hide gelatin adulterants in donkey-hide gelatin down to 0.1% (horse to 0.5%); of 18 commercial Ejiao batches tested, only 9 were authentic and 8 were suspected adulterated with horse materials. [https://pubmed.ncbi.nlm.nih.gov/35960756/]
  - How the global donkey skin trade risks spreading deadly diseases, National Geographic (2022) — Testing of 108 donkey skins from a Kenyan slaughterhouse feeding the Ejiao trade found 3 positive for African horse sickness and 44 positive for MRSA (including 3 toxin-producing virulent strains), providing first evidence that the unregulated skin trade can move zoonotic pathogens internationally. [https://www.nationalgeographic.com/animals/article/how-the-global-donkey-skin-trade-risks-spreading-deadly-diseases]
  - The Donkey Skin Trade, Brooke (Action for Working Horses and Donkeys) — Demand has decimated global donkey populations; serious welfare concerns. [https://www.thebrooke.org/our-work/donkey-skin-trade]

---

## Bear Bile (Xióng Dǎn 熊胆 (active compound: UDCA))
URL: https://nutridex.info/s/bear-bile
Category: TCM Herb, Banned & Harmful
Evidence: Banned / Harmful — Linked to serious harm and/or banned in sport and many jurisdictions. Listed for awareness and safety only — NOT a recommendation.
Its real active compound is now a safe synthetic medicine.

Quick answer: Bear Bile is marketed for genuine: udca treats certain gallstones & liver disease. NutriDex grades the human evidence as banned / harmful — Linked to serious harm and/or banned in sport and many jurisdictions. Listed for awareness and safety only — NOT a recommendation. Based on 19 cited human studies (19 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Bear bile is unusual: its principal compound, ursodeoxycholic acid (UDCA), genuinely treats some gallstones and liver conditions — and has been manufactured synthetically since the 1950s. That makes bile extracted from live, caged 'bile bears' both medically unnecessary and ethically indefensible. International trade is prohibited under CITES, and farming is illegal in several countries. Use the synthetic medicine instead.

Benefits / uses: (Compound) genuine: UDCA treats certain gallstones & liver disease; (Claimed in TCM) 'clears heat', liver/eye complaints.
Active compounds: Ursodeoxycholic acid (UDCA).
Dose: Do NOT use bear-derived bile. The legitimate medicine is synthetic ursodeoxycholic acid (UDCA), prescribed and dosed by a physician.
Safety: ⚠ Farmed bear bile may be contaminated and is produced through extreme animal cruelty. Trade is banned (CITES). For genuine indications, only pharmaceutical synthetic UDCA should be used, under medical supervision.

Cited studies (19):
  - Ursodeoxycholic Acid Prophylaxis and the Reduction of Gallstone Formation After Bariatric Surgery: An Updated Meta-Analysis of Randomized Controlled Trials, Cureus (2023) — Meta-analysis of 12 RCTs (n=2,767 bariatric surgery patients) found prophylactic ursodeoxycholic acid markedly reduced postoperative gallstone formation (risk ratio ~0.13, P<0.0001), confirming the synthetic compound's genuine efficacy. [https://pubmed.ncbi.nlm.nih.gov/38229797/]
  - The effects of ursodeoxycholic acid on cardiometabolic risk factors: a systematic review and meta-analysis of randomized controlled trials, BMC Cardiovascular Disorders (2025) — Systematic review and meta-analysis of 12 RCTs reported that ursodeoxycholic acid significantly improved several cardiometabolic risk factors (inflammation, blood pressure, and obesity-related markers) versus control. [https://doi.org/10.1186/s12872-025-04549-3]
  - Ursodeoxycholic Acid's Effectiveness in the Management of Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-analysis, Euroasian journal of hepato-gastroenterology (2024) — Systematic review and meta-analysis of 7 RCTs found that ursodeoxycholic acid significantly reduced liver enzymes in nonalcoholic fatty liver disease patients (ALT p<=0.0001, AST p=0.0009, GGT p<=0.0001 versus control), indicating a hepatoprotective effect of the synthetic compound. [https://pubmed.ncbi.nlm.nih.gov/39022193/]
  - Comparative efficacy and safety of ursodeoxycholic acid, fibrates, and combination therapy in primary biliary cholangitis: an umbrella meta-analysis of meta-analyses, Frontiers in Pharmacology (2026) — Umbrella meta-analysis of 23 meta-analyses (45 unique RCTs, n=3,276) in primary biliary cholangitis found that synthetic UDCA monotherapy lowered alkaline phosphatase (mean difference -32.1 U/L, 95% CI -58.4 to -5.8) and that UDCA-fibrate combination therapy was superior (-85.4 U/L), supporting UDCA as the genuine first-line treatment. [https://doi.org/10.3389/fphar.2026.1797227]
  - The effects of ursodeoxycholic acid on cardiometabolic risk factors: a systematic review and meta-analysis of randomized controlled trials, BMC Cardiovascular Disorders (2025) — Systematic review and meta-analysis of 12 randomized trials (from 7,912 screened, searched through Aug 2024) evaluating UDCA effects on inflammation, blood pressure, and obesity-related cardiometabolic risk factors. [https://link.springer.com/article/10.1186/s12872-025-04549-3]
  - Treatment response to ursodeoxycholic acid in primary biliary cholangitis: A systematic review and meta-analysis, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver (2023) — Systematic review/meta-analysis of 16 UDCA treatment-response endpoints and 96 external validations in PBC found the continuous GLOBE and UK-PBC Risk Scores to be the most accurate validated predictors of long-term outcome; ALP plus total bilirubin normalization proposed as the optimal trial endpoint guiding second-line therapy allocation. [https://pubmed.ncbi.nlm.nih.gov/36593158/]
  - Ursodeoxycholic acid in intrahepatic cholestasis of pregnancy: a systematic review and individual participant data meta-analysis, The lancet. Gastroenterology & hepatology (2021) — IPD meta-analysis (6,974 women, 34 studies) in intrahepatic cholestasis of pregnancy: UDCA had no significant effect on stillbirth overall (aOR 1.04), but when restricted to RCTs it was associated with a reduced composite of stillbirth plus preterm birth (aOR 0.60, 95% CI 0.39-0.91; p=0.016). [https://pubmed.ncbi.nlm.nih.gov/33915090/]
  - EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis, Journal of hepatology (2017) — European Association for the Study of the Liver recommends oral UDCA 13-15 mg/kg/day as first-line therapy for all patients with PBC and elevated cholestatic enzymes, to slow disease progression and prevent end-stage liver disease. [https://pubmed.ncbi.nlm.nih.gov/28427765/]
  - Pills, Powders, Vials & Flakes: The bear bile trade in Asia, TRAFFIC (2011) — International commercial trade in bear bile is prohibited. [https://www.traffic.org/publications/reports/pills-powders-vials-flakes-the-bear-bile-trade-in-asia/]
  - Ursodeoxycholic acid versus placebo in women with intrahepatic cholestasis of pregnancy (PITCHES): a randomised controlled trial, Lancet (London, England) (2019) — Double-blind multicenter RCT (n=605) in intrahepatic cholestasis of pregnancy: UDCA did NOT reduce the composite adverse perinatal outcome (perinatal death, preterm birth, neonatal unit admission) vs placebo (23% vs 27%; adjusted RR 0.85, 95% CI 0.62-1.15). Routine use for this indication should be reconsidered. [https://pubmed.ncbi.nlm.nih.gov/31378395/]
  - Is Natural Medicine Necessarily Kinder to Animals Than Modern Medicine? The Use of Bears in Traditional Chinese Medicine, The American Journal of Economics and Sociology (2025) — Critical review argues that the use of bears in traditional Chinese medicine inflicts severe welfare harms on the ~17,000 farmed bears and is not kinder than modern medicine, given that synthetic UDCA fully substitutes for bile. [https://onlinelibrary.wiley.com/doi/10.1111/ajes.12632]
  - Protective effect of ursodeoxycholic acid on COVID-19 in patients with chronic liver disease, Frontiers in cellular and infection microbiology (2023) — Propensity-matched cohort of 450 chronic liver disease patients found UDCA users had a lower SARS-CoV-2 infection rate (85.3% vs 94.2%, p=0.002; OR~0.32) and faster recovery, supporting the FXR/ACE2 mechanism. [https://pubmed.ncbi.nlm.nih.gov/37207192/]
  - Ursodeoxycholic acid and severe COVID-19 outcomes in a cohort study using the OpenSAFELY platform, Communications Medicine (2024) — Large OpenSAFELY population cohort study evaluated whether ursodeoxycholic acid was associated with reduced severe COVID-19 outcomes (hospitalisation/death), providing real-world data on the repurposed synthetic drug. [https://doi.org/10.1038/s43856-024-00664-y]
  - FXR inhibition: an innovative prophylactic strategy against SARS-CoV-2 infection, Signal transduction and targeted therapy (2023) — UDCA downregulates ACE2 expression via FXR inhibition, reducing SARS-CoV-2 cell entry in human and animal models, suggesting a host-directed prophylactic mechanism against COVID-19. [https://pmc.ncbi.nlm.nih.gov/articles/PMC10028767/]
  - Antiinflammatory and Hepatoprotective Medicinal Herbs as Potential Substitutes for Bear Bile, International review of neurobiology (2017) — Synthetic UDCA and herbal alternatives make farmed bile medically unnecessary. [https://pubmed.ncbi.nlm.nih.gov/28807157/]
  - Ursodeoxycholic acid therapy and liver transplant-free survival in patients with primary biliary cholangitis, Journal of hepatology (2019) — International cohort of 3,902 PBC patients: UDCA therapy was associated with markedly improved 10-year transplant-free survival (79.7% vs 60.7% untreated) and a 54% lower risk of liver transplant or death (HR 0.46, 95% CI 0.40-0.52; p<0.001). Benefit held across all disease stages and even in incomplete biochemical responders (HR 0.56). Supports UDCA as universal standard of care. [https://pubmed.ncbi.nlm.nih.gov/30980847/]
  - Bear with me: Understanding motivations for bear farming in Vietnam, Frontiers in Conservation Science (2022) — Mixed-methods study of bear bile farming in Vietnam found that despite a 2005 ban and available synthetic/herbal alternatives, an illegal captive-bile industry persists, driven by entrenched demand and farmer economics. [https://www.frontiersin.org/journals/conservation-science/articles/10.3389/fcosc.2022.913263/full]
  - FXR inhibition may protect from SARS-CoV-2 infection by reducing ACE2, Nature (2023) — Nature study: FXR directly regulates ACE2 transcription; UDCA (an FXR inhibitor) downregulated ACE2 and reduced SARS-CoV-2 susceptibility in human organoids, animals, and ex situ perfused human lungs/livers, and lowered nasal ACE2 in humans. Retrospective registry and liver-transplant cohort data linked UDCA use to better COVID-19 outcomes. [https://pubmed.ncbi.nlm.nih.gov/36470304/]
  - Ursodeoxycholic Acid (2023) — Ursodeoxycholic acid genuinely treats certain gallstones/liver disease — and is made synthetically. [https://www.ncbi.nlm.nih.gov/books/NBK545303/]

---

## Rhino Horn (Xī Jiǎo 犀角 (rhinoceros horn))
URL: https://nutridex.info/s/rhino-horn
Category: Banned & Harmful, Debunked
Evidence: No Evidence — No credible human evidence supports the marketed claims — widely considered ineffective.
Keratin — like fingernails — with no medicinal value.

Quick answer: Rhino Horn is marketed for fever, 'detox', and — in modern myth — aphrodisiac / cancer claims. NutriDex grades the human evidence as no evidence — No credible human evidence supports the marketed claims — widely considered ineffective. Based on 17 cited human studies (17 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Rhino horn is essentially keratin, the same protein as hair and fingernails. A pharmacological study decades ago found no medicinal value, and recent analyses even detected toxic elements such as arsenic and lead in samples. Despite this, persistent demand — fueled by modern myths it never traditionally held, like cancer cures and aphrodisiac claims — drives relentless poaching. Trade is banned worldwide under CITES.

Benefits / uses: (Claimed) fever, 'detox', and — in modern myth — aphrodisiac / cancer claims.
Active compounds: Keratin; Calcium; Melanin.
Dose: No legitimate use — illegal and without medicinal value.
Safety: ⚠ No benefit, possible heavy-metal toxicity, and illegal. Purchasing it is a wildlife crime that directly funds the extinction of rhinos.

Cited studies (17):
  - The present status of knowledge on the global use of rhinoceros dehorning: A systematic review, Biological Conservation (2025) — Systematic review of global rhino dehorning practice found it is widely used to reduce horn value and poaching incentive, but evidence on long-term effectiveness and welfare/ecological side-effects remains limited and uneven. [https://doi.org/10.1016/j.biocon.2025.111456]
  - Poaching of African rhinos down, IUCN (2025) — African rhino poaching fell to 516 incidents in 2024 (2.15% of the population, lowest rate since 2011), but white rhino numbers dropped 11.2% since 2023 amid drought and continued horn-trade pressure. [https://iucn.org/press-release/202508/poaching-african-rhinos-down-drought-and-other-threats-drive-losses-globally]
  - Composition / Hoffmann–La Roche — Horn is keratin; pharmacological testing found no medicinal value. [https://www.savetherhino.org/thorny-issues/medicinal-use-of-rhino-horn/]
  - A legal trade in rhino horn, Save the Rhino International (2018) — Trade banned; demand drives poaching and pushes rhinos toward extinction. [https://www.savetherhino.org/thorny-issues/legal-trade-in-rhino-horn/]
  - Rhinoceros horn mineral and metal concentrations vary by sample location, depth, and color, Scientific reports (2024) — Detected potentially toxic elements (e.g. arsenic, lead) in horn samples. [https://pmc.ncbi.nlm.nih.gov/articles/PMC11178811/]
  - Dehorning reduces rhino poaching, Science (New York, N.Y.) (2025) — Dehorning 2,284 rhinos across 8 of 11 Greater Kruger reserves (2017-2023) cut poaching by about 78% using only ~1.2% of the anti-poaching budget, far outperforming arrests/law enforcement. [https://pubmed.ncbi.nlm.nih.gov/40472107/]
  - Rhinoceros horn mineral and metal concentrations vary by sample location, depth, and color, Scientific reports (2024) — Analysis of rhinoceros horn found essential trace minerals present only at concentrations too low to confer human health benefit, while exterior/soil-contaminated samples carried potentially toxic metals (e.g. arsenic) that could exceed regulatory limits for food and pharmaceuticals. [https://pubmed.ncbi.nlm.nih.gov/38877154/]
  - Rhinoceros horn mineral and metal concentrations vary by sample location, depth, and color, Scientific Reports (2024) — Full-text Scientific Reports study showing horn mineral/metal content varies by location, depth and color; low beneficial-mineral concentrations make medicinal benefit unlikely while soil-derived toxic metals pose a contamination risk on ingestion. [https://www.nature.com/articles/s41598-024-64472-z]
  - Rhinoceros horn mineral and metal concentrations vary by sample location, depth, and color, Scientific reports (2024) — Open-access version reporting that horn-derived minerals occur at concentrations too low for therapeutic effect and that potentially toxic elements accumulate in the horn exterior, undermining claims of medicinal value. [https://pmc.ncbi.nlm.nih.gov/articles/PMC11178811/]
  - Analysis of active components of rhinoceros, water buffalo and yak horns using two-dimensional electrophoresis and ethnopharmacological evaluation, Journal of separation science (2011) — Two-dimensional electrophoresis of rhinoceros, water buffalo and yak horns identified shared keratin protein components, supporting that cheaper non-endangered horns are proteomically and pharmacologically equivalent substitutes for rhino horn. [https://pubmed.ncbi.nlm.nih.gov/21268260/]
  - Ethnopharmacology of rhinoceros horn. II: Antipyretic effects of prescriptions containing rhinoceros horn or water buffalo horn, Journal of ethnopharmacology (1991) — Antipyretic activity of rhino-horn-containing prescriptions in rats appeared only at supra-clinical doses and was matched by common animal-horn substitutes, indicating no fever benefit at human-equivalent doses and no effect unique to rhino horn. [https://pubmed.ncbi.nlm.nih.gov/1943172/]
  - Combination of mathematics and label-free proteomics for discovering keratin-derived specific peptide biomarkers to distinguish animal horn-derived traditional Chinese medicines, Journal of separation science (2023) — Label-free proteomics identified keratin-derived peptide biomarkers distinguishing rhino/saiga horn from water buffalo, yak, goat and cattle horns; framed rhino horn as a keratin-based material for which non-endangered horns serve as clinical alternatives, reinforcing that the constituent (keratin) is not species-specifically therapeutic. [https://pubmed.ncbi.nlm.nih.gov/36821105/]
  - The Price of Hope—Insights into rhino horn consumption in health-related contexts in Vietnam, Journal of Consumer Affairs (2020) — Qualitative study of Vietnamese consumers found rhino horn is used as a perceived panacea for serious illnesses including cancer despite no scientific evidence of efficacy, with demand driven by hope, status and social pressure. [https://onlinelibrary.wiley.com/doi/10.1111/joca.12342]
  - Understanding determinants of the intention to buy rhino horn in Vietnam through the Theory of Planned Behaviour and the Theory of Interpersonal Behaviour, Ecological Economics (2022) — Survey of self-reported rhino-horn consumers in Hanoi using the Theory of Planned/Interpersonal Behaviour identified social-psychological norms and perceived medicinal benefit as the strongest drivers of intention to buy, informing demand-reduction strategy. [https://doi.org/10.1016/j.ecolecon.2022.107361]
  - Available sustainable alternatives replace endangered animal horn based on their proteomic analysis and bio-effect evaluation, Scientific reports (2016) — Proteomic analysis and bioeffect testing of seven horn types concluded that abundant water buffalo and yak horn show antipyretic, sedative and procoagulant activity similar to rhinoceros horn, supporting sustainable substitutes and undermining any species-specific medicinal value of rhino horn. [https://pmc.ncbi.nlm.nih.gov/articles/PMC5082367/]
  - Extracts of rhinoceros horn are not antipyretic in rabbits, Journal of basic and clinical physiology and pharmacology (1997) — Controlled experiment in rabbits found rhinoceros horn extract produced no antipyretic effect against LPS-induced fever at either a human-equivalent dose (50 mg/kg) or 10x that dose (500 mg/kg), while indomethacin reduced fever, directly contradicting the traditional fever-reducing claim. [https://pubmed.ncbi.nlm.nih.gov/9363565/]
  - Ethnopharmacology of rhinoceros horn. I: Antipyretic effects of rhinoceros horn and other animal horns, Journal of ethnopharmacology (1990) — Ethnopharmacology study in rats found aqueous rhinoceros horn extract reduced turpentine-induced fever only at very high concentrations (1-5 g/ml) far above clinical dosing, and that saiga antelope, water buffalo and cattle horns produced comparable antipyretic effects, indicating no unique medicinal property of rhino horn. [https://pubmed.ncbi.nlm.nih.gov/2255207/]

---

## Tiger Bone (Hǔ Gǔ 虎骨 (tiger bone / 'bone wine'))
URL: https://nutridex.info/s/tiger-bone
Category: Banned & Harmful, Debunked
Evidence: No Evidence — No credible human evidence supports the marketed claims — widely considered ineffective.
No proven benefit; banned to protect endangered tigers.

Quick answer: Tiger Bone is marketed for rheumatism & arthritis relief. NutriDex grades the human evidence as no evidence — No credible human evidence supports the marketed claims — widely considered ineffective. Based on 16 cited human studies (16 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Tiger bone, often steeped into 'bone wine', was traditionally used for joint and rheumatic complaints. No controlled trials show benefit, and analyses find nothing beyond ordinary collagen and calcium. China removed tiger bone from its official pharmacopoeia in 1993 and trade is banned under CITES — yet demand still drives poaching and large-scale tiger farming, threatening wild tigers with extinction.

Benefits / uses: (Claimed) rheumatism & arthritis relief; (Claimed) strength & 'Yang' tonic.
Active compounds: Collagen; Calcium (no unique bioactive compounds).
Dose: No legitimate use — illegal and without proven benefit.
Safety: ⚠ No proven benefit and illegal. Buying tiger products is a wildlife crime driving an endangered species toward extinction.

Cited studies (16):
  - The effect of Jintiange capsules on pain in patients with primary osteoporosis: a systematic review and meta-analysis, BMC Musculoskeletal Disorders (2025) — Meta-analysis of 21 articles (2,916 participants) reported Jintiange (artificial tiger bone) capsules significantly reduced pain in primary osteoporosis (WMD -2.51; 95% CI -3.30 to -1.71; p<0.05). [https://bmcmusculoskeletdisord.biomedcentral.com/articles/10.1186/s12891-025-08694-w]
  - The effect of Jintiange capsules on pain in patients with primary osteoporosis: a systematic review and meta-analysis, BMC musculoskeletal disorders (2025) — Systematic review/meta-analysis of 21 articles (2,916 patients): Jintiange relieved pain (WMD VAS -2.51; 95% CI -3.30 to -1.71), improved femoral neck (WMD 0.83) and lumbar (WMD 1.14) BMD, improved ODI (-1.79) and Timed Up and Go (-2.61), and reduced fracture incidence (OR 0.37; 95% CI 0.15-0.93). [https://pubmed.ncbi.nlm.nih.gov/40361081/]
  - Jintiange Capsule May Have a Positive Effect on Pain Relief and Functional Activity in Patients with Knee Osteoarthritis: A Meta-Analysis of Randomized Trials, Evidence-based complementary and alternative medicine : eCAM (2021) — Meta-analysis of randomized trials concluded Jintiange (artificial tiger bone) capsule may have a positive effect on pain relief and functional activity in knee osteoarthritis patients. [https://pmc.ncbi.nlm.nih.gov/articles/PMC8577893/]
  - Efficacy of the Chinese herbal medicine Jintiange capsules in the postoperative treatment of osteoporotic vertebral compression fractures: a systematic review and meta-analysis, Frontiers in medicine (2023) — Meta-analysis of 16 RCTs (1,642 patients) of Jintiange capsules (bionic/artificial tiger-bone powder) for postoperative osteoporotic vertebral compression fractures reported increased bone mineral density and reduced pain versus control, supporting non-tiger synthetic substitutes. [https://pubmed.ncbi.nlm.nih.gov/38162884/]
  - Efficacy and safety of Jintiange in the treatment of osteoporosis: a systematic review and meta-analysis, Frontiers in pharmacology (2025) — Systematic review/meta-analysis of 18 studies (21 trials, 2,580 patients) of Jintiange (artificial/bionic tiger-bone powder) for osteoporosis found significantly increased bone mineral density at lumbar spine, femoral neck, greater trochanter and Ward's triangle and reduced pain (VAS) versus control, with no excess adverse events, supporting non-tiger synthetic substitutes. [https://pubmed.ncbi.nlm.nih.gov/40727093/]
  - Jintiange combined with alfacalcidol improves muscle strength and balance in primary osteoporosis: A randomized, double-blind, double-dummy, positive-controlled, multicenter clinical trial, Journal of orthopaedic translation (2022) — Randomized, double-blind, double-dummy, multicenter trial (400 primary osteoporosis/osteopenia patients, 52 wk): Jintiange plus alfacalcidol improved lower-extremity muscle strength and balance more than control - superior Timed Up and Go and Chair Rising Test results, and lower high-fall-risk proportions (TUG 3.25% vs 9.55%, p=0.023; CRT 20.78% vs 33.76%, p=0.01). [https://pubmed.ncbi.nlm.nih.gov/36090002/]
  - Effect of Artificial Tiger Bone Powder (Jintiange Capsule®) on Vertebral Height Ratio, Cobb's Angle, Bone Mineral Density, and Visual Analog Score, Orthopaedic surgery (2022) — Double-blind randomized controlled trial (106 osteoporotic vertebral compression fracture patients, 3 mo): Jintiange capsule raised total effective rate (90.6% vs 67.9%), significantly improved vertebral height and BMD (p<0.034), lowered Cobb's angle (p<0.047), and reduced VAS pain and Oswestry disability scores at 1 and 3 months (p<0.05) vs conventional treatment. [https://pubmed.ncbi.nlm.nih.gov/34939347/]
  - China restores ban on rhino and tiger parts, for now, Mongabay (2018) — Tiger bone removed from official pharmacopoeia; international trade banned. [https://news.mongabay.com/2018/11/china-restores-ban-on-rhino-and-tiger-parts-for-now/]
  - The Efficacy and Safety of Bionic Tiger Bone Powder for the Treatment of Knee Osteoarthritis in Early Stage: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Clinical Trial, Alternative therapies in health and medicine (2023) — Randomized, double-blind, placebo-controlled multicenter trial of bionic (artificial) tiger bone powder (Jintiange) in 248 early-stage knee osteoarthritis patients over 48 weeks found a significantly greater reduction in the Lequesne index from week 12 and higher effective rate versus placebo, with comparable safety, supporting non-tiger synthetic substitutes. [https://pubmed.ncbi.nlm.nih.gov/37384400/]
  - Beyond Skin and Bones: A 25-year analysis of tiger seizures from 2000 to June 2025, TRAFFIC (2025) — 25-year analysis of 2,551 incidents (~3,808 tigers) across Tiger Range Countries finds trafficking persists at ~9 tigers/month in 2020-2025; tiger 'parts' fell from 90% of seizures in the 2000s to ~60% from 2020 as whole-animal trafficking rose. [https://www.traffic.org/publications/reports/beyond-skin-and-bones-a-25-year-analysis-of-tiger-seizures-from-2000-to-june-2025/]
  - Traditional Chinese Medicine Bionic Tiger Bone Powder for the Treatment of AI-Associated Musculoskeletal Symptoms, Evidence-based complementary and alternative medicine : eCAM (2017) — No RCTs show benefit for arthritis/rheumatism; no unique bioactives identified. [https://pmc.ncbi.nlm.nih.gov/articles/PMC5307008/]
  - Tiger farming, Environmental Investigation Agency (EIA) — Demand fuels poaching and tiger farms; wild tigers endangered. [https://eia-international.org/wildlife/saving-tigers/tiger-farming/]
  - Turning the tide on big cat trade: Expert opinion on trends and conservation lessons from the Republic of Korea, PloS one (2024) — Expert-opinion study finds big cat (incl. tiger bone) trade linked to South Korea declined substantially after its 1993 CITES accession and 1994 trade ban, though small-scale illegal online sales persist. [https://pubmed.ncbi.nlm.nih.gov/38748670/]
  - The impact of a legal trade in farmed tigers on consumer preferences for tiger bone glue – Evidence from a choice experiment in Vietnam, Journal for Nature Conservation (2022) — Choice experiment with 228 Vietnamese tiger-bone-glue consumers found buyers prefer and pay more for WILD over farmed tiger glue, and ~one-third would still buy wild-poached glue regardless of legality, indicating legal farmed trade is unlikely to displace wild-tiger demand. [https://doi.org/10.1016/j.jnc.2021.126088]
  - Attitudes toward consumption and conservation of tigers in China, PloS one (2008) — Survey of 1,880 respondents across six Chinese cities found 43% had used an alleged tiger product (mainly tiger-bone plaster 38%, tiger-bone wine 6.4%) while 93% supported the trade ban; among consumers most preferred wild over farmed tiger, indicating large residual demand that could resurge if the ban were lifted. [https://pubmed.ncbi.nlm.nih.gov/18596926/]
  - Traditional medicines: Tiger-bone trade could threaten lions, Nature (2015) — Nature correspondence (Williams et al.) warns that legal CITES-permitted export of captive-bred lion bones from South Africa since 2008 to supply the Asian 'tiger bone' substitute market may perpetuate or expand demand for big-cat bones and put wild lions elsewhere in Africa at risk. [https://pubmed.ncbi.nlm.nih.gov/26178954/]

---

## Pangolin Scales (Chuān Shān Jiǎ 穿山甲)
URL: https://nutridex.info/s/pangolin
Category: Banned & Harmful, Debunked
Evidence: No Evidence — No credible human evidence supports the marketed claims — widely considered ineffective.
Trafficked keratin with no medicinal value.

Quick answer: Pangolin Scales is marketed for promotes lactation, eases 'blood stasis' & rheumatism. NutriDex grades the human evidence as no evidence — No credible human evidence supports the marketed claims — widely considered ineffective. Based on 17 cited human studies (17 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Pangolin scales are made of keratin — the same protein as human fingernails — and ingested keratin is not absorbed; it passes through largely unchanged. There is no credible evidence for the traditional lactation, circulation or rheumatism claims. Pangolins are the most-trafficked mammals on earth, with species listed critically endangered, and the trade is illegal.

Benefits / uses: (Claimed) promotes lactation, eases 'blood stasis' & rheumatism.
Active compounds: Keratin.
Dose: No legitimate use — illegal and without medicinal value.
Safety: ⚠ No benefit and illegal. Buying pangolin products is a wildlife crime fueling the extinction of the world's most-trafficked mammal.

Cited studies (17):
  - Evidence for the medicinal value of Squama Manitis (pangolin scale): A systematic review, Integrative medicine research (2021) — Systematic review of 15 studies (only 4 RCTs, none double-blinded) of pangolin scale (Squama Manitis). RCTs suggested possible benefit for postpartum hypogalactia and mesenteric lymphadenitis only as add-ons to herbs/antibiotics, inconclusive for breast hyperplasia; all studies had high risk of bias, small samples, and publication bias. Concluded current evidence CANNOT support clinical use and recommended restricting use, consistent with removal from the 2020 Chinese Pharmacopoeia. [https://pubmed.ncbi.nlm.nih.gov/32837905/]
  - China drops pangolin formulas from approved TCM list, but concerns remain, Mongabay (2025) — China's updated pharmacopoeia (effective Oct 1, 2025) delisted raw pangolin scales and all 13 remaining approved TCM formulas containing them, extending the partial 2020 removal toward a full pharmacopoeial ban. [https://news.mongabay.com/2025/05/china-drops-pangolin-formulas-from-approved-tcm-list-but-concerns-remain/]
  - U.S. Fish and Wildlife Service proposes Endangered Species Act protections for pangolins, U.S. Fish & Wildlife Service — The U.S. Fish and Wildlife Service proposed (Federal Register, June 17, 2025) to list seven pangolin species (four Asian, three African) as endangered under the Endangered Species Act, citing trafficking, habitat loss and poor genetic health; if finalized it would bar U.S. import and sale of pangolins and their parts. [https://www.fws.gov/press-release/2025-06/us-fish-and-wildlife-service-proposes-endangered-species-act-protections]
  - CoP17 Prop. 11 (Transfer of Manis javanica and Manis pentadactyla from Appendix II to Appendix I), CITES (Convention on International Trade in Endangered Species of Wild Fauna and Flora) (2016) — At CITES CoP17 (Sept 2016) all eight pangolin species were uplisted to Appendix I by near-unanimous vote, prohibiting all commercial international trade effective Jan 2017. [https://cites.org/sites/default/files/eng/cop/17/prop/060216/E-CoP17-Prop-11.pdf]
  - Pangolin facts and information, National Geographic — Scales are keratin; ingested keratin isn't absorbed — no medicinal basis. [https://www.nationalgeographic.com/animals/mammals/facts/pangolins]
  - Evidence for the medicinal value of Squama Manitis (pangolin scale): A systematic review, Integrative medicine research (2021) — No credible evidence for lactation/rheumatism claims. [https://pmc.ncbi.nlm.nih.gov/articles/PMC7386206/]
  - Traditional Medicine and the Pangolin Trade: A Review of Drivers and Conservation Challenges, Conservation (2025) — Narrative review concludes pangolin scales (keratin) are used across African and Asian traditional medicine for lactation, rheumatism and skin conditions despite no pharmacological basis, and that demand drives the species' status as the world's most-trafficked mammal. [https://doi.org/10.3390/conservation5040077]
  - Traditional Medicine and the Pangolin Trade: A Review of Drivers and Conservation Challenges, Conservation (2025) — Review of TCM drivers of the pangolin trade documents that scales are ~100% keratin (same protein as fingernails) with no demonstrated mechanism of benefit, that human digestion lacks keratinases to break disulfide bonds, and that all 8 species are CITES Appendix I; notes China's 2020 removal of pangolin scales from the Pharmacopoeia. Concludes purported medicinal value is unsupported and drives extinction risk. [https://www.mdpi.com/2673-7159/5/4/77]
  - Serological evidence of sarbecovirus exposure along Sunda pangolin trafficking pathways, BMC biology (2024) — Serological evidence of sarbecovirus (SARS-CoV-2-related) exposure was found in Sunda pangolins along trafficking pathways, supporting that the pangolin trade carries documented coronavirus exposure risk to handled animals and humans. [https://pmc.ncbi.nlm.nih.gov/articles/PMC11600613/]
  - Isolation of SARS-CoV-2-related coronavirus from Malayan pangolins, Nature (2020) — SARS-CoV-2-related coronaviruses were isolated from smuggled Malayan pangolins, sharing 85.5-92.4% genome identity with SARS-CoV-2, highlighting zoonotic transmission risk from the pangolin trade. [https://pubmed.ncbi.nlm.nih.gov/32380510/]
  - Evidence of SARS-CoV-2 Related Coronaviruses Circulating in Sunda pangolins (Manis javanica) Confiscated From the Illegal Wildlife Trade in Viet Nam, Frontiers in public health (2022) — SARS-CoV-2-related coronaviruses were detected in Sunda pangolins (Manis javanica) confiscated from the illegal wildlife trade in Viet Nam, indicating pangolin trafficking poses a clear risk for transmission of viruses with zoonotic and epizootic potential. [https://pmc.ncbi.nlm.nih.gov/articles/PMC8959545/]
  - Disruption and Disarray, Wildlife Justice Commission (2025) — Wildlife Justice Commission analysis found over 370 metric tons of pangolin scales seized 2015-2024, with 2024 large-seizure numbers ~84% below the 2019 peak and no major seaport scale seizures for three years, indicating disrupted supply chains. [https://wildlifejustice.org/wp-content/uploads/2025/09/Disruption-and-Disarray-Report-March-2025-V13-Pages.pdf]
  - Identifying SARS-CoV-2-related coronaviruses in Malayan pangolins, Nature (2020) — Nature study (Lam et al.) identified SARS-CoV-2-related coronaviruses in Malayan pangolins (Manis javanica) seized from anti-smuggling operations in southern China, with one viral sub-lineage showing strong receptor-binding-domain similarity to SARS-CoV-2, implicating trafficked pangolins as a zoonotic reservoir. [https://pubmed.ncbi.nlm.nih.gov/32218527/]
  - Innovated formulation of TCM pangolin scales to develop a nova therapy of rheumatoid arthritis, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie (2020) — Pre-clinical study (Freund's-adjuvant rheumatoid-arthritis rat model) reporting that a novel vinegar-processed pangolin-scale formulation reduced paw swelling and inflammatory markers comparably to meloxicam. Animal-only proof-of-concept with no human data; provides no validated human efficacy and underscores the absence of clinical trials. [https://pubmed.ncbi.nlm.nih.gov/32151943/]
  - Pangolin, World Wildlife Fund (WWF) — Most-trafficked mammal; ~195,000 trafficked in 2019; species critically endangered. [https://www.worldwildlife.org/species/pangolin/]
  - Myth debunked: Keratinous pangolin scales do not contain the analgesic tramadol, Conservation Science and Practice (2019) — Forensic chemical analysis of scales from 104 individual pangolins spanning all eight extant species detected no tramadol in any specimen, debunking the popular claim that keratinous pangolin scales naturally contain the analgesic. [https://doi.org/10.1111/csp2.82]
  - Experts convene to save one of world’s most trafficked mammals, IUCN (2025) — The Sunda pangolin (Manis javanica) is classified Critically Endangered on the IUCN Red List, driven by exploitation, with an estimated 200,000 individuals illegally traded in the prior decade and a continuing population decline. [https://iucn.org/news/species/201707/experts-convene-save-one-world%E2%80%99s-most-trafficked-mammals]

---

## Seahorse (Hippocampus · Hǎi Mǎ 海马)
URL: https://nutridex.info/s/seahorse
Category: TCM Herb, Debunked
Evidence: No Evidence — No credible human evidence supports the marketed claims — widely considered ineffective.
A dried-seahorse 'tonic' with no evidence and high conservation cost.

Quick answer: Seahorse is marketed for impotence & libido ('natural viagra'). NutriDex grades the human evidence as no evidence — No credible human evidence supports the marketed claims — widely considered ineffective. Based on 24 cited human studies (24 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Dried seahorse is used in TCM for impotence, asthma and as a general 'Yang' tonic. While some reviews note bioactive compounds, there is no scientific evidence dried seahorse delivers the effects claimed. The trade is enormous — tens of millions of seahorses harvested yearly — and many species are now classed as Vulnerable, making this a significant conservation concern.

Benefits / uses: (Claimed) impotence & libido ('natural Viagra'); (Claimed) asthma & 'Kidney-Yang' tonic.
Active compounds: Peptides & steroids (claimed, unconfirmed).
Dose: No established therapeutic use; trade raises serious conservation concerns.
Safety: No demonstrated benefit. Major conservation harm — wild seahorse populations are declining sharply due to demand.

Cited studies (24):
  - Bioaccumulation of contaminants in wild seahorses collected from coastal China, Frontiers in Marine Science (2022) — In 84 wild seahorses (H. mohnikei, H. kelloggi, H. trimaculatus) from nine coastal Chinese sites, tissues accumulated heavy metals (elevated Cu, Cr), benzo(a)pyrene (1.6-8.7 ug/kg) and 92-322 intestinal microplastic particles per individual, raising contaminant-safety concerns for ingested seahorse products. [https://doi.org/10.3389/fmars.2022.1021170]
  - Implementation of CITES Appendix II listing for seahorses in the context of export bans and suspensions, Fisheries Centre Research Reports (2023) — Review of CITES Appendix II implementation found persistent non-compliance and trafficking despite national export suspensions, with millions of seahorses still traded among 80+ countries mainly for TCM. [https://projectseahorse.org/wp-content/uploads/2021/12/Foster-2023-Implementation-of-CITES-APP-II-for-seahorses.pdf]
  - Most threatened species, IUCN SSC Seahorse, Pipefish and Seadragon Specialist Group (2020) — Of 42 assessed Hippocampus species, 14 are threatened (12 Vulnerable, 2 Endangered) with several declining >=30% within three generations, driven largely by TCM-targeted overfishing and bycatch (~37 million caught/year). [https://www.iucn-seahorse.org/most-vulnerable]
  - Medicinal seahorses (Hippocampus spp.) for Alzheimer’s disease within species conservation framework: an integrated review of ethnopharmacology, bioactivity, bibliometrics, and network pharmacology, Naunyn-Schmiedeberg's Archives of Pharmacology (2026) — Integrated review of seahorse ethnopharmacology, chemistry, bibliometrics and network pharmacology for Alzheimer's disease concluded seahorses remain an underexplored, preclinical-stage candidate with no demonstrated clinical efficacy, and flagged conservation constraints on any therapeutic development. [https://doi.org/10.1007/s00210-026-05246-4]
  - Chemical constituents, pharmacological activities and quality evaluation methods of genus Hippocampus: A comprehensive review, Chinese herbal medicines (2024) — Comprehensive review of the genus Hippocampus (~57 species, ~14 medicinal) summarizing chemical constituents (amino acids, peptides, fatty acids, steroids) and reported anti-prostatic-hyperplasia, anti-fatigue and anti-inflammatory activities, with no human clinical-trial evidence cited for impotence/libido. [https://pmc.ncbi.nlm.nih.gov/articles/PMC11283209/]
  - Medicinal seahorses (Hippocampus spp.) for Alzheimer's disease within species conservation framework: an integrated review of ethnopharmacology, bioactivity, bibliometrics, and network pharmacology, Naunyn-Schmiedeberg's Archives of Pharmacology (2026) — Integrated ethnopharmacology, bioactivity, bibliometrics and network-pharmacology review of medicinal seahorses framing their use within a species-conservation context, finding bioactivity evidence remains preclinical. [https://link.springer.com/article/10.1007/s00210-026-05246-4]
  - Bioaccumulation of Metals in Tissues of Seahorses Collected from Coastal China, Bulletin of Environmental Contamination and Toxicology (2016) — Bioaccumulation study of 9 metals across four seahorse species from six Chinese coastal sites found location- and tissue-dependent metal accumulation (higher in viscera, muscle and skin; H. kelloggi highest), flagging heavy-metal contamination risk in the tissues used for medicine. [https://link.springer.com/article/10.1007/s00128-016-1728-4]
  - Chemical constituents, pharmacological activities and quality evaluation methods of genus Hippocampus: A comprehensive review, Chinese herbal medicines (2024) — Up-to-date review of Hippocampus chemical constituents, pharmacological activities and quality-evaluation methods; summarizes reported anti-oxidation, anti-inflammation, anti-depressant, anti-hypertensive, anti-prostatic hyperplasia, antiviral, anti-apoptotic and anti-fatigue effects across ~14 medicinal species, while emphasizing that evidence remains in vitro/in vivo with no controlled human efficacy data. [https://pubmed.ncbi.nlm.nih.gov/39072207/]
  - The United States dried seahorse trade: A comparison of traditional Chinese medicine and ecommerce-curio markets using molecular identification, PloS one (2023) — Molecular ID of US dried seahorse trade found 8 species; 85.7% of TCM samples met CITES minimum-size recommendations vs only 4.8% of e-commerce/curio samples, indicating widespread non-compliant trade. [https://pmc.ncbi.nlm.nih.gov/articles/PMC10547177/]
  - Using online reports of seahorse seizures to track their illegal trade, Conservation Biology (2025) — Analysis of ~300 online seizure records (2010-2021) documented ~5 million dried seahorses confiscated across 60+ countries, showing CITES export bans drove trade underground rather than ending it. [https://doi.org/10.1111/cobi.70047]
  - A practical approach to meeting national obligations for sustainable trade under CITES, Conservation biology : the journal of the Society for Conservation Biology (2024) — CITES sustainable-trade study (Conservation Biology 38(5):e14337) reporting seahorse catches in 85% of a surveyed marine protected/exclusion zone with bottom trawlers driving most violations, and fisher-reported declining catch and reduced body size indicating unsustainable exploitation. [https://pubmed.ncbi.nlm.nih.gov/39248743/]
  - CITES makes a measurable difference to the trade in live marine fishes: The pioneering case of seahorses, Biological Conservation (2022) — CITES Appendix II listing measurably reduced legal seahorse exports across major exporting nations (India, Indonesia, Malaysia, Peru, Philippines, Thailand, Vietnam), the pioneering marine-fish case. [https://doi.org/10.1016/j.biocon.2022.109653]
  - The genus Hippocampus--a review on traditional medicinal uses, chemical constituents and pharmacological properties, Journal of ethnopharmacology (2015) — Comprehensive ethnopharmacological review of the genus Hippocampus: documents traditional use (chiefly TCM 'kidney-yang' invigoration for impotence, fatigue, aging) and catalogs preclinical pharmacology (anti-tumor, antioxidant, anti-fatigue, anti-thrombotic, anti-inflammatory, antihypertensive, neuroprotective). Concludes active constituents are sterols, peptides, essential amino acids, PUFAs and trace elements, and explicitly notes that human clinical trial data are lacking. [https://pubmed.ncbi.nlm.nih.gov/25560669/]
  - Used as a natural Viagra in Chinese medicine, seahorse numbers are declining, CNN (2019) — No scientific evidence dried seahorse has the claimed medicinal effects. [https://www.cnn.com/2019/06/06/asia/seahorse-trade-chinese-medicine-intl]
  - The seahorse (Hippocampus comes L.) extract ameliorates sperm qualities, testosterone level, and serum biochemistry in rats induced by depo medroxyprogesterone acetate, Journal of advanced veterinary and animal research (2023) — In rats with DMPA-induced subfertility, seahorse (Hippocampus comes) extract improved sperm quality and testosterone, but findings are animal-only and do not validate human medicinal claims. [https://pmc.ncbi.nlm.nih.gov/articles/PMC10122950/]
  - Identification of bioactive compounds and inhibitory effects of TNF-α and COX-2 in the extract from cultured three-spot seahorse (H. trimaculatus), Food science & nutrition (2024) — In cultured three-spot seahorse extract, taurine and arginine were the principal bioactives and the water-layer extract inhibited LPS-induced nitric oxide, COX-2 and TNF-alpha in macrophage cell culture; effects are in vitro only and do not validate human medicinal claims. [https://pmc.ncbi.nlm.nih.gov/articles/PMC10867490/]
  - Seahorse Attenuated DSS-Induced Depression in Mice by Inhibiting Neuroinflammation and Ferroptosis, Food science & nutrition (2025) — In DSS-induced depression-like mice, Hippocampus abdominalis attenuated depressive behaviour by inhibiting hippocampal neuroinflammation and ferroptosis via the Nrf2/HO-1 axis; findings are animal-only with no human efficacy shown. [https://pubmed.ncbi.nlm.nih.gov/40552333/]
  - The seahorse (Hippocampus comes L.) extract ameliorates sperm qualities, testosterone level, and serum biochemistry in rats induced by depo medroxyprogesterone acetate, Journal of advanced veterinary and animal research (2023) — In male rats with depo-medroxyprogesterone-acetate-induced reproductive suppression, Hippocampus comes extract improved sperm quality parameters, raised serum testosterone, and normalized serum biochemistry relative to untreated model animals. Rat study only. [https://pubmed.ncbi.nlm.nih.gov/37155542/]
  - Anti-Photoaging Effects of Antioxidant Peptide from Seahorse (Hippocampus abdominalis) in In Vivo and In Vitro Models, Marine drugs (2024) — An antioxidant peptide (SHP2) purified from Hippocampus abdominalis alcalase hydrolysate reduced ROS and protected against UVB-induced photoaging/oxidative damage in vitro and in vivo, upregulating endogenous antioxidant enzymes (SOD, catalase). In vitro + animal evidence only. [https://pubmed.ncbi.nlm.nih.gov/39452879/]
  - High-Throughput Identification of Antihypertensive Peptides (AHTPs) and Characterization of AHTP-Derived Genes in the Lined Seahorse (Hippocampus erectus), Frontiers in Marine Science (2022) — High-throughput omics screen of lined seahorse (Hippocampus erectus) identified putative antihypertensive peptides and their source genes; effects were in silico/preclinical with no human efficacy demonstrated. [https://www.frontiersin.org/journals/marine-science/articles/10.3389/fmars.2022.863310/full]
  - In Vitro Antioxidant Activity and In Vivo Anti-Fatigue Effect of Sea Horse (Hippocampus) Peptides, Molecules (Basel, Switzerland) (2017) — Enzymatic seahorse (Hippocampus) hydrolysate peptides showed dose-dependent in vitro radical-scavenging/antioxidant activity, and in a mouse forced-swim model significantly prolonged exhaustive swimming time, raised hepatic glycogen, and lowered blood lactate and serum urea nitrogen versus controls, supporting an anti-fatigue mechanism. Preclinical only (in vitro + mice). [https://pubmed.ncbi.nlm.nih.gov/28335458/]
  - Seahorses (Hippocampus spp.), CITES (Convention on International Trade in Endangered Species of Wild Fauna and Flora) — >20 million dried seahorses traded yearly; many species Vulnerable (IUCN). [https://cites.org/eng/node/134917]
  - The genus Hippocampus—A review on traditional medicinal uses, chemical constituents and pharmacological properties, Journal of Ethnopharmacology (2015) — Some compounds reported but claims remain unconfirmed. [https://doi.org/10.1016/j.jep.2014.12.032]
  - Protective effects of seahorse extracts in a rat castration and testosterone-induced benign prostatic hyperplasia model and mouse oligospermatism model, Environmental toxicology and pharmacology (2014) — In a castration + testosterone-induced benign prostatic hyperplasia rat model, seahorse extract reduced prostate weight and index versus untreated BPH controls; in a mouse oligospermatism model it improved sperm parameters. Supports the traditional 'kidney/reproductive' indication but is animal-model evidence, not human. [https://pubmed.ncbi.nlm.nih.gov/24607683/]

---

## Kava (Piper methysticum)
URL: https://nutridex.info/s/kava
Category: Sleep & Mood
Evidence: Moderate — Several controlled trials; effects real but modest or context-dependent.
Genuinely calming for anxiety — with a real liver caveat.

Quick answer: Kava is used for reduced anxiety (short-term). NutriDex grades the human evidence as moderate — Several controlled trials; effects real but modest or context-dependent. Based on 14 cited human studies (14 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Kava is a Pacific Island plant whose kavalactones have a real, evidence-backed calming effect. Systematic reviews find kava outperforms placebo for short-term anxiety, though the effect is small and the best-powered generalized-anxiety-disorder trial (Sarris 2013) was negative. Its reputation was damaged by reports of liver injury; the risk appears rare and linked to prolonged use, poor-quality products, alcohol and drug interactions, but idiosyncratic hepatotoxicity cannot be excluded even with traditional preparations. Quality and duration matter greatly.

Benefits / uses: Reduced anxiety (short-term); Relaxation without heavy sedation.
Active compounds: Kavalactones.
Dose: Standardized extracts ~120–280 mg kavalactones/day, short-term (≤8 weeks).
Safety: ⚠ Rare but serious liver injury. Avoid with alcohol, liver disease, or hepatotoxic drugs; do not combine with sedatives; limit duration. Can cause drowsiness — don't drive after use.

Cited studies (14):
  - The effectiveness and safety of Kava Kava for treating anxiety symptoms: A systematic review and analysis of randomized clinical trials, Complementary therapies in clinical practice (2018) — Kava outperformed placebo for anxiety in several short-term RCTs. [https://pubmed.ncbi.nlm.nih.gov/30396607/]
  - Kava for Generalized Anxiety Disorder: A Review of Current Evidence, Journal of alternative and complementary medicine (New York, N.Y.) (2018) — Systematic review and meta-analysis specific to GAD (12 articles). Meta-analysis of three placebo-controlled trials (n=130) favoured Kava with effect sizes between 0.59 and 0.99 (standardised mean difference) but WITHOUT reaching statistical significance. Concluded current evidence is promising but insufficient to confirm efficacy beyond placebo; Kava judged safe/well tolerated short-term (4-8 weeks) at 120-280 mg/day kavalactones. [https://pubmed.ncbi.nlm.nih.gov/29641222/]
  - Complementary and Alternative Medicine Treatments for Generalized Anxiety Disorder: Systematic Review and Meta-analysis of Randomized Controlled Trials, Advances in therapy (2018) — Systematic review and network meta-analysis of CAM for GAD (32 RCTs). Direct Kava-vs-placebo comparisons (4 trials, n=233) were highly heterogeneous; network meta-regression suggested only a modest, non-significant Kava effect (end-of-treatment HAM-A difference -3.24 points; 95% CI -6.65 to 0.17; p=0.059). Reinforces marginal/uncertain efficacy signal. [https://pubmed.ncbi.nlm.nih.gov/29508154/]
  - Efficacy of kava extract for treating anxiety: systematic review and meta-analysis, Journal of clinical psychopharmacology (2000) — Systematic review and meta-analysis of double-blind placebo-controlled RCTs of oral Kava extract for anxiety. All seven reviewed trials favoured Kava; meta-analysis of three trials showed a significant reduction in Hamilton Anxiety Rating Scale total score favouring Kava (weighted mean difference 9.69 points; 95% CI 3.54-15.83). Landmark early evidence that Kava is superior to placebo for symptomatic anxiety. [https://pubmed.ncbi.nlm.nih.gov/10653213/]
  - Neuroimaging Insights: Kava's (Piper methysticum) Effect on Dorsal Anterior Cingulate Cortex GABA in Generalized Anxiety Disorder, Nutrients (2023) — In a randomized placebo-controlled neuroimaging sub-study (n=37), kava significantly reduced dorsal anterior cingulate cortex GABA at 8 weeks (p=0.049), indicating central GABAergic modulation independent of symptom change. [https://pubmed.ncbi.nlm.nih.gov/37960239/]
  - Effect of kava (Piper methysticum) on peripheral gene expression among individuals with generalized anxiety disorder: A post hoc analysis of a randomized controlled trial, Phytotherapy research : PTR (2023) — Post hoc analysis of a GAD RCT found kava altered peripheral gene expression versus placebo, supporting a biological mechanism though without clear clinical anxiolytic benefit. [https://pubmed.ncbi.nlm.nih.gov/37767766/]
  - Kava for generalised anxiety disorder: A 16-week double-blind, randomised, placebo-controlled study, The Australian and New Zealand journal of psychiatry (2020) — In the largest GAD trial (n=171, 16 weeks), aqueous noble kava (240 mg kavalactones/day) showed no significant anxiety reduction versus placebo, with remission actually lower in the kava arm (17.4% vs 23.8%). [https://pubmed.ncbi.nlm.nih.gov/31813230/]
  - The Impact of One-week Dietary Supplementation with Kava on Biomarkers of Tobacco Use and Nitrosamine-based Carcinogenesis Risk among Active Smokers, Cancer prevention research (Philadelphia, Pa.) (2020) — In a pilot trial of active smokers, a 7-day course of kava increased urinary excretion of the tobacco carcinogen metabolite total NNAL and reduced 3-methyladenine and total nicotine equivalents, suggesting enhanced NNK detoxification and a potential lung-cancer chemoprevention/cessation effect. [https://pubmed.ncbi.nlm.nih.gov/32102948/]
  - Kava: Usefulness and Safety, NIH National Center for Complementary and Integrative Health (2025) — NIH's NCCIH states kava supplements may help anxiety but do not appear effective for generalized anxiety disorder, and warns that various kava products have been linked to rare cases of liver injury, some serious or fatal. [https://www.nccih.nih.gov/health/kava]
  - The Kava Anxiety Depression Spectrum Study (KADSS): a randomized, placebo-controlled crossover trial using an aqueous extract of Piper methysticum, Psychopharmacology (2009) — First clinical trial of an aqueous Kava extract: 3-week double-blind, placebo-controlled crossover trial (n=60, 250 mg kavalactones/day) in generalised anxiety. Kava produced a highly significant pooled reduction in Hamilton Anxiety Scale vs placebo (p<0.0001) with a large effect size (d=2.24), plus significant reductions in Beck Anxiety Inventory and MADRS depression scores; no clinical hepatotoxicity. Landmark positive RCT supporting short-term aqueous Kava. [https://pubmed.ncbi.nlm.nih.gov/19430766/]
  - Biological Activity, Hepatotoxicity, and Structure-Activity Relationship of Kavalactones and Flavokavins, the Two Main Bioactive Components in Kava (Piper methysticum), Evidence-based complementary and alternative medicine : eCAM (2021) — Structure-activity review concluding that flavokawain B, rather than the psychoactive kavalactones, is the constituent most implicated in kava hepatotoxicity, alongside poor raw-material quality and prolonged use. [https://pmc.ncbi.nlm.nih.gov/articles/PMC8405297/]
  - Kava Kava (2018) — Rare but real liver injury; risk rises with long use, alcohol and co-medication. [https://www.ncbi.nlm.nih.gov/books/NBK548637/]
  - Kava extract for treating anxiety, The Cochrane database of systematic reviews (2003) — Cochrane meta-analysis of 6 placebo-controlled RCTs (345 participants) found kava extract significantly reduced Hamilton Anxiety Scale scores versus placebo (weighted mean difference 5.0 points, 95% CI 1.1-8.8; p=0.01), supporting a small short-term anxiolytic effect. [https://pubmed.ncbi.nlm.nih.gov/12535473/]
  - Kava hepatotoxicity in traditional and modern use: the presumed Pacific kava paradox hypothesis revisited, British journal of clinical pharmacology (2012) — Pacific Island use shows low liver harm — product quality is key. [https://pmc.ncbi.nlm.nih.gov/articles/PMC3269575/]

---

## Kratom (Mitragyna speciosa)
URL: https://nutridex.info/s/kratom
Category: Banned & Harmful, Sleep & Mood
Evidence: Mixed — Conflicting results across studies; benefit uncertain.
An opioid-acting leaf — its effects and serious risks are both real.

Quick answer: Kratom is used for pain relief, energy, opioid-withdrawal self-treatment. NutriDex grades the human evidence as mixed — Conflicting results across studies; benefit uncertain. Based on 21 cited human studies (21 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Kratom is a Southeast-Asian tree whose alkaloids — mitragynine and the far more potent 7-hydroxymitragynine — bind mu-opioid receptors, producing stimulant effects at low doses and opioid-like sedation at higher ones. People use it for pain, energy and to self-manage opioid withdrawal, but it carries genuine opioid-type risks. The FDA warns against it, citing dependence, liver toxicity, seizures and deaths, and has moved to schedule concentrated 7-OH products.

Benefits / uses: (Used for) pain relief, energy, opioid-withdrawal self-treatment; (Claimed) mood lift.
Active compounds: Mitragynine; 7-hydroxymitragynine (7-OH).
Dose: No safe established dose; effects are dose-dependent and risk rises sharply with concentrated/adulterated products.
Safety: ⚠ Dependence and opioid-like withdrawal, liver injury, seizures, and death (especially with high-potency 7-OH products or mixed with other drugs). Unregulated and often adulterated. Legal status varies by region.

Cited studies (21):
  - The acute adverse health effects of kratom: an evaluation of case reports, Frontiers in pharmacology (2025) — A 2025 systematic review of case reports (95 patients) concluded current evidence is insufficient to show kratom alone causes severe acute harm, as confounding substances were present in 32 deceased and 7 surviving cases, implicating polypharmacy. [https://pmc.ncbi.nlm.nih.gov/articles/PMC12425911/]
  - Reported associations between kratom and seizures: a systematic review, Frontiers in pharmacology (2025) — A 2025 systematic review (11 articles, 20 patients; plus 481 FAERS and 221,178 CAERS reports) found insufficient evidence that kratom causes seizures, with only one case having confirmed drug-level testing and no dose-response relationship. [https://pmc.ncbi.nlm.nih.gov/articles/PMC12568553/]
  - The effects of kratom (Mitragyna speciosa) on metabolic syndrome-related parameters: a systematic review and meta-analysis, Frontiers in pharmacology (2025) — Meta-analysis of five cross-sectional studies (1,458 adults; PROSPERO CRD42024600702) found kratom use associated with lower LDL-cholesterol (MD -0.21 mmol/L; 95% CI -0.39, -0.02), lower triglycerides (MD -0.17 mmol/L; 95% CI -0.25, -0.09), and lower BMI (MD -1.52 kg/m2; 95% CI -2.81, -0.23), while total cholesterol and blood sugar effects were not statistically significant. [https://pmc.ncbi.nlm.nih.gov/articles/PMC12214432/]
  - The acute adverse health effects of kratom: an evaluation of case reports, Frontiers in pharmacology (2025) — Evaluation of 95 case-report patients (55 toxicologically confirmed; 35 deceased with mitragynine 3.5-7,500 ng/mL, 20 living 5-340 ng/mL) found confounding substances present in 32 deceased and 7 surviving cases, concluding the literature provides insufficient evidence that kratom alone increases the risk of severe acute adverse effects. [https://pmc.ncbi.nlm.nih.gov/articles/PMC12425911/]
  - The effects of kratom (Mitragyna speciosa) on metabolic syndrome-related parameters: a systematic review and meta-analysis, Frontiers in pharmacology (2025) — Systematic review and meta-analysis of 5 cross-sectional studies (1,458 adults). Kratom use associated with significantly lower LDL-c (MD -0.21 to -0.25 mmol/L), triglycerides (MD -0.17 mmol/L), and BMI (MD -1.52 kg/m2), and higher HDL-c (MD +0.07 mmol/L); total cholesterol and blood glucose changes not significant. Suggests a protective association against some metabolic risk factors. (per PubMed; DOI 10.3389/fphar.2025.1587528) [https://pubmed.ncbi.nlm.nih.gov/40606596/]
  - Kratom (Mitragyna speciosa) Use and Mental Health: A Systematic Review and Multilevel Meta-Analysis, European addiction research (2024) — Multilevel meta-analysis of 36 studies. Kratom use showed a very small positive association with negative mental-health indicators (r=0.092, 95% CI 0.020-0.164) and a small correlation with externalizing disorders (r=0.201); no significant association with positive mental-health indicators, quality of life, or internalizing disorders. The substance-use-disorder association was stronger in Malaysian samples and among those not co-using other drugs. (per PubMed; DOI 10.1159/000539338) [https://pubmed.ncbi.nlm.nih.gov/38889703/]
  - Outcomes of mothers and newborns to prenatal exposure to kratom: a systematic review, Journal of perinatology : official journal of the California Perinatal Association (2021) — A systematic review of prenatal kratom exposure (Wright et al., J Perinatol 2021; 6 infants from 5 case reports) found 5 of 6 (83%) neonates developed neonatal abstinence syndrome requiring morphine, with withdrawal onset from 6-8 hours to 4 days after birth. [https://pmc.ncbi.nlm.nih.gov/articles/PMC8225511/]
  - FDA Takes Steps to Restrict 7, U.S. Food and Drug Administration — On July 29, 2025 the FDA issued seven warning letters and recommended scheduling concentrated 7-hydroxymitragynine (7-OH) under the Controlled Substances Act, citing poison-center and law-enforcement surveillance showing rising serious adverse events and overdoses tied to concentrated 7-OH products. [https://www.fda.gov/news-events/press-announcements/fda-takes-steps-restrict-7-oh-opioid-products-threatening-american-consumers]
  - An exploratory study of the safety profile and neurocognitive function after single doses of mitragynine in humans, Psychopharmacology (2025) — Phase 1 placebo-controlled single-blind within-subjects trial of isolated mitragynine (5/10/20 mg in 8 volunteers; 40 mg in 7 volunteers). Mitragynine did not affect most outcomes; the low 5 mg dose increased subjective arousal/attention and sustained-attention accuracy, while 40 mg increased subjective amnesia ratings and produced mild psychopathological symptoms. Vital signs unaffected; only mild, transient side effects; doses up to 40 mg well tolerated. (per PubMed; DOI 10.1007/s00213-024-06734-2) [https://pubmed.ncbi.nlm.nih.gov/39724441/]
  - Clinical Pharmacokinetic Assessment of Kratom (Mitragyna speciosa), a Botanical Product with Opioid-like Effects, in Healthy Adult Participants, Pharmaceutics (2022) — First comprehensive clinical pharmacokinetic characterization of kratom alkaloids: single 2 g oral dose of a well-characterized product in 6 healthy adults, best fit by a two-compartment model. The 3S alkaloids (mitragynine, speciogynine, paynantheine) showed shorter Tmax (1-2 h), lower AUC, longer terminal half-life (24-45 h), and larger volume of distribution than 3R alkaloids, providing foundational human PK data for safety evaluation. (per PubMed; DOI 10.3390/pharmaceutics14030620) [https://pubmed.ncbi.nlm.nih.gov/35335999/]
  - FDA and Kratom, U.S. Food and Drug Administration — Linked to dependence, liver toxicity, seizures and deaths; 7-OH proposed for Schedule I. [https://www.fda.gov/news-events/public-health-focus/fda-and-kratom]
  - Presence of kratom in opioid overdose deaths: findings from coroner postmortem toxicological report, Frontiers in psychiatry (2023) — A 2024 retrospective coroner toxicology review (4 of 214 opioid overdose deaths had mitragynine detected) found kratom was never present alone, with combined fentanyl/opioid use most associated with fatal outcomes. [https://pubmed.ncbi.nlm.nih.gov/38268564/]
  - An exploratory study of the safety profile and neurocognitive function after single doses of mitragynine in humans, Psychopharmacology (2025) — In a placebo-controlled Phase 1 study (n=15), single oral mitragynine doses up to 40 mg were well tolerated with only mild transient effects; low doses (5 mg) enhanced attention while high doses (40 mg) increased subjective amnesia and mild psychopathological symptoms. [https://pmc.ncbi.nlm.nih.gov/articles/PMC12084173/]
  - Safety and Tolerability of Single and Multiple Daily Oral Doses of Dried Kratom Leaf Powder in a Randomized Trial in Healthy Volunteers, Therapeutic drug monitoring (2026) — A randomized, double-blind, placebo-controlled dose-escalation trial in 116 healthy volunteers (49 kratom, 67 placebo) found mitragynine/7-OH peak concentrations rose dose-proportionally with single and 15 daily doses, supporting tolerability of dried kratom leaf powder in this range. [https://pubmed.ncbi.nlm.nih.gov/41486478/]
  - Prevalence of Kratom Use Disorder Among Kratom Consumers, Journal of addiction medicine (2024) — Large cross-sectional survey of 2,061 US kratom consumers applying DSM-5 criteria. 25.5% met criteria for kratom use disorder (KUD), most mild-to-moderate; most common symptoms were tolerance (81.3%) and withdrawal (68.0%). A concurrent other substance use disorder conferred 2.83x higher odds of KUD (95% CI 2.19-3.67); KUD was associated with male sex, younger age, frequent daily use, and psychiatric/substance comorbidity. (per PubMed; DOI 10.1097/ADM.0000000000001290) [https://pubmed.ncbi.nlm.nih.gov/38441236/]
  - Liver injury associated with kratom, a popular opioid-like product: Experience from the U.S. drug induced liver injury network and a review of the literature, Drug and alcohol dependence (2021) — A prospective US Drug-Induced Liver Injury Network analysis (Ahmad et al., Drug Alcohol Depend 2021) identified 11 cases of kratom-associated hepatotoxicity (median age 40, mostly male), with jaundice developing at a median latency of 14 days; most were hospitalized but all eventually recovered. [https://pubmed.ncbi.nlm.nih.gov/33257199/]
  - Prevalence and characteristics of self-reported kratom use in a representative US general population sample, Journal of addictive diseases (2020) — A quota-sampled US cross-sectional survey of 1,842 adults aged 18-59 (Covvey et al., J Addict Dis 2020) found 6.1% (112) reported lifetime kratom use, with users predominantly male, aged 25-44, and 71-92% reporting concurrent use of other substances. [https://pubmed.ncbi.nlm.nih.gov/32657217/]
  - Neonatal Abstinence Syndrome Due to Maternal Kratom Use, Pediatrics (2018) — A case report in Pediatrics (Eldridge et al., 2018) documented neonatal abstinence syndrome in an infant after maternal kratom use, presenting with excessive crying, increased tone, tachypnea and poor feeding, and managed with oral morphine. [https://publications.aap.org/pediatrics/article/142/6/e20181839/37470/Neonatal-Abstinence-Syndrome-Due-to-Maternal]
  - Kratom Withdrawal: A Systematic Review with Case Series, Journal of psychoactive drugs (2019) — Chronic use causes tolerance and opioid-like withdrawal. [https://pubmed.ncbi.nlm.nih.gov/30614408/]
  - Kratom (2020) — The NIH LiverTox database states kratom causes rare but clinically apparent acute liver injury, typically cholestatic or mixed, arising 1-8 weeks after starting use; most patients recover after discontinuation, though severe cases (bilirubin >20 mg/dL) and rare progression to transplant occur. [https://www.ncbi.nlm.nih.gov/books/NBK548231/]
  - 7-Hydroxymitragynine Is an Active Metabolite of Mitragynine and a Key Mediator of Its Analgesic Effects, ACS central science (2019) — Mitragynine & 7-OH act on mu-opioid receptors — opioid-like effects and dependence. [https://pmc.ncbi.nlm.nih.gov/articles/PMC6598159/]

---

## Horny Goat Weed (Epimedium · Yín Yáng Huò 淫羊藿)
URL: https://nutridex.info/s/horny-goat-weed
Category: TCM Herb, Performance
Evidence: Preliminary — Early or small human trials; promising but not yet conclusive.
Contains a weak natural PDE5 inhibitor — like a faint Viagra.

Quick answer: Horny Goat Weed is used for erectile / sexual support. NutriDex grades the human evidence as preliminary — Early or small human trials; promising but not yet conclusive. Based on 18 cited human studies (18 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Horny goat weed (Epimedium) contains icariin, which — intriguingly — is a genuine PDE5 inhibitor, the same mechanism as Viagra. The catch is potency: icariin is on the order of ~100–200× weaker than sildenafil in lab assays, so real-world supplement doses are unlikely to match the drug. Most evidence is from cell and animal models; controlled human trials are lacking, so any benefit is plausible but unproven.

Benefits / uses: (Claimed) erectile / sexual support; (Claimed) libido & 'Yang' tonic; (Claimed) bone support.
Active compounds: Icariin (a flavonoid PDE5 inhibitor).
Dose: Extracts standardized to icariin; an effective human dose is not established.
Safety: Generally well tolerated short-term, but documented case reports include tachyarrhythmia, agitation/hypomania (in an elderly cardiac patient) and severe muscle spasms. Epimedium has also been linked to liver injury, and possible estrogenic activity makes it relevant to hormone-sensitive conditions. Interacts with nitrates and blood thinners; OTC products are sometimes adulterated with PDE5 drugs. Long-term safety unknown.

Cited studies (18):
  - The efficacy and safety of Epimedium in the treatment of primary osteoporosis: a systematic review and meta-analysis, Frontiers in Medicine (2025) — Systematic review/meta-analysis of 10 RCTs (890 patients) found Epimedium significantly increased bone mineral density at lumbar spine (SMD 1.15), femoral neck (SMD 1.11) and distal radius (SMD 1.27) and raised overall clinical efficacy (OR 3.80, 95% CI 2.27-6.37) in primary osteoporosis. [https://doi.org/10.3389/fmed.2025.1675160]
  - Efficacy and safety of Epimedium total flavonoids for primary osteoporosis: a systematic review and meta-analysis, Frontiers in pharmacology (2024) — Systematic review/meta-analysis of 6 RCTs (n=838) found Epimedium total flavonoids may improve bone mineral density in primary osteoporosis, but evidence quality is limited; no sexual-function endpoint assessed. [https://pubmed.ncbi.nlm.nih.gov/39624844/]
  - Randomized, double-blind, placebo-controlled trial to examine the safety, pharmacokinetics and effects of Epimedium prenylflavonoids, on bone specific alkaline phosphatase and the osteoclast adaptor protein TRAF6 in post-menopausal women, Phytomedicine : international journal of phytotherapy and phytopharmacology (2021) — Randomized, double-blind, placebo-controlled trial in postmenopausal women examining Epimedium prenylflavonoids: characterized safety and pharmacokinetics and assessed effects on bone-specific alkaline phosphatase (bone-formation marker) and the osteoclast adaptor protein TRAF6, supporting a bone-favorable mechanistic signal in humans. [https://pubmed.ncbi.nlm.nih.gov/34352588/]
  - Human Safety and Pharmacokinetics Study of Orally Administered Icariin: Randomized, Double-Blind, Placebo-Controlled Trial, Natural Product Communications (2019) — Randomized, double-blind, placebo-controlled human safety/PK trial of oral icariin in 24 healthy adults across doses 100-1,680 mg/day: icariin was well tolerated with no significant between-group differences on side-effect scales, but plasma icariin was very low or undetectable at all doses, demonstrating poor oral bioavailability of the parent compound. [https://doi.org/10.1177/1934578X19856789]
  - First-in-class immune-modulating small molecule Icaritin in advanced hepatocellular carcinoma: preliminary results of safety, durable survival and immune biomarkers, BMC cancer (2019) — First-in-class phase I single-arm trial of oral icaritin (600 or 800 mg b.i.d.) in 20 advanced HCC patients: no drug-related adverse events >= grade 3; 46.7% achieved clinical benefit (1 partial response, 6 stable disease), median time-to-progression 141 days and median OS 192 days (488 days in PR/SD responders), with survival linked to immune-cell dynamics. [https://pubmed.ncbi.nlm.nih.gov/30922248/]
  - Epimedium-derived phytoestrogen flavonoids exert beneficial effect on preventing bone loss in late postmenopausal women: a 24-month randomized, double-blind and placebo-controlled trial, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research (2007) — 24-month double-blind RCT in 100 late-postmenopausal women (lumbar T-score -2 to -2.5) found Epimedium-derived phytoestrogen flavonoids maintained bone mineral density versus a placebo decline (lumbar spine +1.3% vs -2.4%, p=0.006; femoral neck +1.6% vs -1.8%, p=0.008) without endometrial hyperplasia. [https://pubmed.ncbi.nlm.nih.gov/17419678/]
  - Pharmacological actions of the bioactive compounds of Epimedium on the male reproductive system: current status and future perspective, Asian journal of andrology (2025) — Review concludes icariin and icariside II improve erectile function in preclinical models via PDE5 inhibition, eNOS/NO upregulation (PI3K/Akt) and stem-cell-mediated cavernous repair, with some animal data comparable to sildenafil but no confirmatory human RCTs. [https://pubmed.ncbi.nlm.nih.gov/38978290/]
  - Liver protecting effects and molecular mechanisms of icariin and its metabolites, Phytochemistry (2023) — Review of icariin and its metabolites reports predominantly hepatoprotective and anticancer effects at typical doses (icaritin developed as an anticancer agent), contextualizing the otherwise idiosyncratic, high-dose liver-injury signal. [https://pubmed.ncbi.nlm.nih.gov/37660725/]
  - Herba Epimedium (Horny Goat Weed) Toxicity With Severe Muscle Spasms and Elevated Creatine Kinase and Creatinine: A Case Report, Cureus (2025) — First case report of Epimedium (horny goat weed) toxicity: a 33-year-old man developed severe muscle spasms with elevated creatine kinase (1,210 U/L) and creatinine (1.23 mg/dL) after one month of use, resolving with supportive care. [https://pubmed.ncbi.nlm.nih.gov/40546602/]
  - Herb-Induced Liver Injury: A Case of Acute Hepatotoxicity Associated with Horny Goat Weed Use, Spartan Medical Research Journal (2025) — Case of acute hepatotoxicity in a 53-year-old man after >1 year of daily horny goat weed use, with markedly elevated liver enzymes (ALT 516, AST 185, total bilirubin 4.94), improving after cessation and supportive care. [https://pmc.ncbi.nlm.nih.gov/articles/PMC12459906/]
  - Deciphering the myth of icariin and synthetic derivatives in improving erectile function from a molecular biology perspective: a narrative review, Translational andrology and urology (2022) — Narrative review of pharmacokinetics and mechanisms finds icariin and derivatives could potentially restore spontaneous erections via PDE5 inhibition and testosterone promotion, but stresses absence of high-quality, large-sample human clinical data. [https://pubmed.ncbi.nlm.nih.gov/35958901/]
  - Icaritin-induced immunomodulatory efficacy in advanced hepatitis B virus-related hepatocellular carcinoma: Immunodynamic biomarkers and overall survival, Cancer science (2020) — Clinical study of the icariin-derived small molecule icaritin in advanced HBV-related hepatocellular carcinoma with poor prognosis: no grade III/IV treatment-related adverse events; median overall survival of 329-565 days, with longer survival correlated to baseline HBsAg positivity and Th1/Th2 cytokine and immune-checkpoint dynamics, supporting immune-modulatory activity in humans. [https://pubmed.ncbi.nlm.nih.gov/32889778/]
  - Epimedium koreanum Nakai-Induced Liver Injury-A Mechanistic Study Using Untargeted Metabolomics, Frontiers in pharmacology (2022) — Metabolomics study shows Epimedium koreanum Nakai extract causes liver injury in mice, with icariside I/II triggering idiosyncratic injury via NLRP3 inflammasome activation plus GPX4/GSH depletion-mediated ferroptosis. [https://pubmed.ncbi.nlm.nih.gov/35910368/]
  - Horny Goat Weed (2022) — NIH LiverTox assigns horny goat weed a likelihood score of E (unlikely cause of clinically apparent liver injury): oral forms have not been linked to serum aminotransferase elevations or clinically apparent injury, and it is not listed in large drug/herbal-induced liver injury registries, with only rare poorly-attributed reports from multi-ingredient products. [https://www.ncbi.nlm.nih.gov/books/NBK583203/]
  - Horny Goat Weed in Dietary Supplements, Operation Supplement Safety (U.S. DoD) — U.S. DoD Operation Supplement Safety warns there is no human evidence supporting sexual-health/performance claims and that FDA has found horny goat weed products adulterated with hidden prescription ED drugs (tadalafil, sildenafil, avanafil), posing risks of serious side effects and drug interactions. [https://www.opss.org/article/horny-goat-weed-dietary-supplements]
  - A literature review on Epimedium, a medicinal plant with promising slow aging properties, Heliyon (2023) — Plausible mild effect, but not demonstrated in quality human trials. [https://pmc.ncbi.nlm.nih.gov/articles/PMC10665689/]
  - Exploration of icariin analog structure space reveals key features driving potent inhibition of human phosphodiesterase-5, PloS one (2019) — Icariin is a PDE5 inhibitor, roughly 100–200× less potent than sildenafil in vitro. [https://pmc.ncbi.nlm.nih.gov/articles/PMC6754136/]
  - Effects of icariin on reproductive functions in male rats, Molecules (Basel, Switzerland) (2014) — Improved erectile responses in rodent ED models; human RCTs lacking. [https://pmc.ncbi.nlm.nih.gov/articles/PMC6271987/]

---

## Maca (Lepidium meyenii)
URL: https://nutridex.info/s/maca
Category: Adaptogen, Performance
Evidence: Preliminary — Early or small human trials; promising but not yet conclusive.
Andean root with modest, inconsistent libido evidence.

Quick answer: Maca is used for possible improved sexual desire. NutriDex grades the human evidence as preliminary — Early or small human trials; promising but not yet conclusive. Based on 15 cited human studies (15 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Maca is a Peruvian root food traditionally used for energy and fertility. Several small RCTs suggest a modest improvement in sexual desire in men and women and some benefit for menopausal symptoms and semen quality, while at least one trial found no effect. Systematic reviews conclude the evidence is limited by small, low-quality studies — promising but not definitive.

Benefits / uses: Possible improved sexual desire; Possible menopausal-symptom & mood support; Possible sperm-quality support.
Active compounds: Macamides; Glucosinolates.
Dose: 1.5–3 g/day of dried root powder (as used in trials).
Safety: Generally well tolerated as a food. Possible mild GI effects. Caution in hormone-sensitive conditions due to limited data.

Cited studies (15):
  - Maca (L. meyenii) for erectile dysfunction: a systematic review and meta-analysis, Journal of Men's Health (2023) — Review of RCTs for erectile dysfunction found only 2 eligible trials suggesting a positive effect of maca on erectile function in mild ED, but overall evidence was limited and low-quality. [https://doi.org/10.22514/jomh.2023.003]
  - The Effects of Maca (Lepidium meyenii Walp) on Cellular Oxidative Stress: A Systematic Review and Meta-Analysis, Antioxidants (Basel, Switzerland) (2024) — Meta-analysis of 8 studies found maca (mainly macamides) dose-dependently improved antioxidant markers (glutathione peroxidase SMD 0.96, SOD 0.68) and lowered malondialdehyde (SMD -0.53). [https://pubmed.ncbi.nlm.nih.gov/39334705/]
  - Exploring the chemical and pharmacological variability of Lepidium meyenii: a comprehensive review of the effects of maca, Frontiers in pharmacology (2024) — Comprehensive review concludes clinical studies indicate improved sexual desire, erectile function, and subjective wellbeing in men, plus alleviation of menopausal symptoms in women, though mechanisms remain unclear. [https://pubmed.ncbi.nlm.nih.gov/38440178/]
  - Maca (Lepidium meyenii Walp.) on semen quality parameters: A systematic review and meta-analysis, Frontiers in pharmacology (2022) — Pooled analysis of 5 RCTs (~244 men) found no significant effect of maca on sperm concentration (WMD 2.22, 95% CI -2.94 to 7.37, p=0.4); effects on semen quality remain unclear. [https://pubmed.ncbi.nlm.nih.gov/36110519/]
  - Maca (Lepidium meyenii Walp.) on semen quality parameters: A systematic review and meta-analysis, Frontiers in pharmacology (2022) — Meta-analysis of 5 RCTs found maca failed to significantly increase sperm concentration versus placebo (weighted mean difference 2.22, 95% CI -2.94 to 7.37, p=0.4); effects on semen quality were unclear. [https://pmc.ncbi.nlm.nih.gov/articles/PMC9468664/]
  - Maca (L. meyenii) for improving sexual function: a systematic review, BMC complementary and alternative medicine (2010) — Limited evidence for improved sexual desire; trials small and low-quality. [https://pubmed.ncbi.nlm.nih.gov/20691074/]
  - Maca (Lepidium meyenii) for treatment of menopausal symptoms: A systematic review, Maturitas (2011) — Systematic review of 4 RCTs found favorable effects of maca on menopausal symptoms (Kupperman Index / Greene Climacteric Score), but concluded evidence was limited by small, methodologically weak trials. [https://pubmed.ncbi.nlm.nih.gov/21840656/]
  - Efficacy and Safety of Maca (Lepidium meyenii) in Patients with Symptoms of Late-Onset Hypogonadism: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial, The world journal of men's health (2023) — In 80 men with late-onset hypogonadism symptoms, 12 weeks of 6 g/day maca significantly improved AMS, IIEF and IPSS scores and reduced ADAM-positive rate versus placebo (p<0.05). [https://pubmed.ncbi.nlm.nih.gov/36593713/]
  - Evaluation of the effect of Lepidium meyenii Walpers in infertile patients: A randomized, double-blind, placebo-controlled trial, Phytotherapy research : PTR (2021) — In 50 infertile men, 16 weeks of maca produced only non-significant trends in sperm concentration (40% rise vs 76% with placebo); evidence insufficient to confirm a fertility benefit. [https://pubmed.ncbi.nlm.nih.gov/34585449/]
  - Maca reduces blood pressure and depression, in a pilot study in postmenopausal women, Climacteric : the journal of the International Menopause Society (2015) — In a randomized double-blind crossover pilot of 29 postmenopausal Chinese women, 3.3 g/day maca for 6 weeks significantly reduced diastolic blood pressure and depression scores versus placebo, without hormonal changes. [https://pubmed.ncbi.nlm.nih.gov/24931003/]
  - A double-blind placebo-controlled trial of maca root as treatment for antidepressant-induced sexual dysfunction in women, Evidence-based complementary and alternative medicine : eCAM (2015) — 12-week double-blind placebo-controlled RCT (n=45 women, maca 3.0 g/day) for antidepressant (SSRI/SNRI)-induced sexual dysfunction: remission rates were higher for maca than placebo on ASEX (9.5% vs 4.8%) and MGH-SFQ (score <=12: 30.0% vs 20.0%), with benefit concentrated in postmenopausal women; maca was well tolerated. A small/preliminary positive signal. [https://pubmed.ncbi.nlm.nih.gov/25954318/]
  - LiverTox 2020 (NIH/NIDDK) — NIH LiverTox classifies maca as an unlikely cause of clinically apparent liver injury (likelihood category E); side effects are uncommon and mild (mainly GI symptoms and headache), with one isolated 2017 case of jaundice from maca medicinal liquor. [https://www.ncbi.nlm.nih.gov/books/NBK548552/]
  - A pilot investigation into the effect of maca supplementation on physical activity and sexual desire in sportsmen, Journal of ethnopharmacology (2009) — No effect in one trial — results inconsistent across studies. [https://pubmed.ncbi.nlm.nih.gov/19781622/]
  - Beneficial effects of Lepidium meyenii (Maca) on psychological symptoms and measures of sexual dysfunction in postmenopausal women are not related to estrogen or androgen content, Menopause (New York, N.Y.) (2008) — Randomized double-blind placebo-controlled crossover trial (n=14 postmenopausal women, 3.5 g/day maca x6 wk): significant reduction in Greene Climacteric Scale psychological symptoms (anxiety and depression subscales) and in sexual dysfunction vs placebo and baseline (P<0.05), with no change in estradiol, FSH, LH, or SHBG, indicating effects independent of estrogenic/androgenic activity. [https://pubmed.ncbi.nlm.nih.gov/18784609/]
  - The use of maca (Lepidium meyenii) to improve semen quality: A systematic review, Maturitas (2016) — Some RCTs suggest benefits for libido, menopausal symptoms and sperm quality. [https://pubmed.ncbi.nlm.nih.gov/27621241/]

---

## Tribulus Terrestris (Tribulus terrestris)
URL: https://nutridex.info/s/tribulus
Category: Performance
Evidence: Mixed — Conflicting results across studies; benefit uncertain.
A 'test booster' that mostly fails to raise testosterone.

Quick answer: Tribulus Terrestris is used for raises testosterone. NutriDex grades the human evidence as mixed — Conflicting results across studies; benefit uncertain. Based on 16 cited human studies (16 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Tribulus is one of the most popular 'testosterone boosters', but the evidence undercuts the marketing. A systematic review of men found low-quality evidence for erectile function and — importantly — most trials showed no rise in testosterone. Some studies in women report modest improvements in sexual function, but with very low certainty. It is widely sold yet poorly supported for its headline claim.

Benefits / uses: (Claimed) raises testosterone; Possible modest sexual-function effect (esp. women).
Active compounds: Steroidal saponins (protodioscin).
Dose: Commonly 250–750 mg/day standardized extract; benefit for testosterone is unproven.
Safety: Usually well tolerated, but rare, serious liver and kidney injury (including a fatal acute-liver-failure case and reports of nephrotoxicity and rhabdomyolysis) has been attributed to Tribulus itself — not only to adulterated products. A proposed mechanism is steroidal sapogenins forming crystals in bile ducts/renal tubules. Best avoided in pregnancy; OTC product quality and contamination vary.

Cited studies (16):
  - Tribulus terrestris for management of patients with erectile dysfunction: a systematic review and meta-analysis of randomized trials, International journal of impotence research (2026) — Meta-analysis of 8 randomized trials found Tribulus significantly improved IIEF-5 and IIEF-15 erectile-function scores versus placebo, but produced no significant change in total testosterone. [https://pubmed.ncbi.nlm.nih.gov/40360723/]
  - The Profertility and Aphrodisiac Activities of <i>Tribulus terrestris</i> L.: Evidence from Meta‐Analyses, Andrologia (2023) — Meta-analyses pooling human and rodent data reported significant improvements in sperm concentration, motility and viability with Tribulus supplementation regardless of baseline fertility status. [https://doi.org/10.1155/2023/7118431]
  - Tribulus terrestris for management of patients with erectile dysfunction: a systematic review and meta-analysis of randomized trials, International Journal of Impotence Research (2026) — Meta-analysis of 8 RCTs found Tribulus improved erectile function (IIEF-5 MD 4.21, p<0.00001; IIEF-15 MD 15.88, p=0.0004) but showed no significant difference in total testosterone levels versus placebo. [https://www.nature.com/articles/s41443-025-01086-7]
  - Herbal dietary supplements for erectile dysfunction: A systematic review and meta-analysis of randomized-controlled trials, Journal of traditional and complementary medicine (2026) — Meta-analysis of 14 RCTs (1227 men) of herbal supplements for ED; pooled herbal supplements improved erectile function (SMD 1.20) and serum testosterone (SMD 0.54). Benefit was driven by ginseng and saffron, whereas evidence for other single agents was deemed insufficient, underscoring the lack of robust standalone Tribulus efficacy data. [https://pubmed.ncbi.nlm.nih.gov/41696741/]
  - Dietary Supplements for Erectile Dysfunction: Analysis of Marketed Products, Systematic Review, Meta-Analysis and Rational Use, Nutrients (2023) — Systematic review/meta-analysis of dietary supplements for ED found Panax ginseng, Tribulus terrestris and L-arginine among nutraceuticals able to improve male erectile function; however, 80% of marketed Italian products contained effective ingredients at negligible doses or without evidence, and no supplement qualified as first-line therapy. [https://pubmed.ncbi.nlm.nih.gov/37686709/]
  - Effects of Tribulus terrestris L. on Sport and Health Biomarkers in Physically Active Adult Males: A Systematic Review, International journal of environmental research and public health (2022) — Systematic review of 7 studies (165 healthy physically active adult males) found Tribulus supplementation produced significant improvements in lipid profile and moderate beneficial effects on inflammatory and hematological biomarkers with no renal toxicity, but contradictory and uncertain effects on testosterone and performance. [https://pubmed.ncbi.nlm.nih.gov/35954909/]
  - Tribulus Terrestris for Female Sexual Dysfunction: A Systematic Review, Revista brasileira de ginecologia e obstetricia : revista da Federacao Brasileira das Sociedades de Ginecologia e Obstetricia (2020) — Systematic review of 5 RCTs (279 participants) assessed Tribulus terrestris for female sexual dysfunction versus inactive/active comparators. [https://pmc.ncbi.nlm.nih.gov/articles/PMC10316844/]
  - Herbal Dietary Supplements for Erectile Dysfunction: A Systematic Review and Meta-Analysis, Drugs (2018) — Systematic review and meta-analysis of 24 RCTs (2080 ED patients) of herbal supplements; the two Tribulus terrestris monopreparation trials (n=202) produced mixed/inconclusive results for erectile function, in contrast to ginseng which significantly improved IIEF-5 (SMD 0.43). Concluded evidence for Tribulus is insufficient to recommend its use. [https://pubmed.ncbi.nlm.nih.gov/29633089/]
  - The Effects of 6 Weeks of Tribulus terrestris L. Supplementation on Body Composition, Hormonal Response, Perceived Exertion, and CrossFit(®) Performance: A Randomized, Single-Blind, Placebo-Controlled Study, Nutrients (2021) — Randomized placebo-controlled trial in 30 CrossFit-trained males (770 mg/day for 6 weeks) found no improvement in body composition or overall performance, though the Tribulus group maintained testosterone (-0.2%) versus a 21.9% decline with placebo and showed a modest bench-press gain. [https://pubmed.ncbi.nlm.nih.gov/34836225/]
  - Efficacy of Tribulus Terrestris Extract on the Serum Glucose and Lipids of Women with Diabetes Mellitus, Iranian journal of medical sciences (2016) — Double-blind RCT in 98 women with type 2 diabetes (1000 mg/day for 3 months) found Tribulus significantly lowered serum glucose, total cholesterol and LDL versus placebo, with no significant change in HDL or triglycerides. [https://pubmed.ncbi.nlm.nih.gov/27840471/]
  - The effect of five weeks of Tribulus terrestris supplementation on muscle strength and body composition during preseason training in elite rugby league players, Journal of strength and conditioning research (2007) — Double-blind RCT in 22 elite male rugby players: 450 mg/day Tribulus terrestris for 5 weeks during resistance training produced no greater gains in strength or fat-free mass than placebo and did not alter the urinary testosterone/epitestosterone ratio, refuting ergogenic and testosterone-boosting claims. [https://pubmed.ncbi.nlm.nih.gov/17530942/]
  - Effects of Tribulus (Tribulus terrestris L.) Supplementation on Erectile Dysfunction and Testosterone Levels in Men-A Systematic Review of Clinical Trials, Nutrients (2025) — Low-quality evidence for ED; 8 of 10 trials showed no testosterone increase in men. [https://pmc.ncbi.nlm.nih.gov/articles/PMC11990417/]
  - Tribulus Terrestris for Female Sexual Dysfunction: A Systematic Review, Revista brasileira de ginecologia e obstetricia : revista da Federacao Brasileira das Sociedades de Ginecologia e Obstetricia (2020) — Some improvement in women, but very low certainty of evidence. [https://pubmed.ncbi.nlm.nih.gov/32736394/]
  - Effects of Tribulus (Tribulus terrestris L.) Supplementation on Erectile Dysfunction and Testosterone Levels in Men-A Systematic Review of Clinical Trials, Nutrients (2025) — No serious adverse events reported in trials. [https://pmc.ncbi.nlm.nih.gov/articles/PMC11990417/]
  - Severe Liver and Renal Injury From Tribulus Terrestris, ACG case reports journal (2024) — A 46-year-old man taking Tribulus daily for 2 months developed severe drug-induced liver injury (peak bilirubin 48 mg/dL) and acute renal failure (creatinine 7.1), recovering after 3 plasmapheresis sessions. [https://pubmed.ncbi.nlm.nih.gov/38328764/]
  - Rhabdomyolysis Risk: The Dangers of Tribulus Terrestris, an Over-the-Counter Supplement, The American journal of case reports (2024) — First documented case of a 71-year-old man on long-term atorvastatin who developed rhabdomyolysis with transaminitis after taking over-the-counter Tribulus, implicating Tribulus as a moderate CYP3A4 inhibitor that raises statin levels. [https://pmc.ncbi.nlm.nih.gov/articles/PMC11315611/]

---

## Yohimbe / Yohimbine (Pausinystalia johimbe)
URL: https://nutridex.info/s/yohimbe
Category: Performance, Heart & Metabolic
Evidence: Mixed — Conflicting results across studies; benefit uncertain.
A stimulant aphrodisiac with real cardiovascular danger.

Quick answer: Yohimbe / Yohimbine is used for possible erectile-dysfunction benefit (prescription yohimbine). NutriDex grades the human evidence as mixed — Conflicting results across studies; benefit uncertain. Based on 16 cited human studies (16 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Yohimbe bark contains yohimbine, which older trials found more effective than placebo for erectile dysfunction — but the American Urological Association advises against it given limited evidence and safety concerns. There is no good evidence for weight loss. Crucially, supplements are notoriously mislabeled (wildly variable yohimbine content), and the compound can cause serious cardiovascular and neurological effects.

Benefits / uses: Possible erectile-dysfunction benefit (prescription yohimbine); (Claimed, unproven) fat loss.
Active compounds: Yohimbine (an alpha-2 adrenergic antagonist).
Dose: Highly variable and often mislabeled in supplements; prescription yohimbine HCl is the only regulated, dosed form.
Safety: ⚠ Raises blood pressure and heart rate; linked to arrhythmia, heart attack, seizures and anxiety. Dangerous with heart/blood-pressure conditions, MAOIs, or stimulants. Restricted or banned in several countries.

Cited studies (16):
  - Yohimbine as a treatment for erectile dysfunction: A systematic review and meta-analysis, Turkish journal of urology (2021) — In a 2021 systematic review/meta-analysis of 8 RCTs, yohimbine monotherapy improved erectile function vs placebo (OR 2.08, 95% CI 1.30-3.32), with larger effect when combined with other agents (OR 6.35, 95% CI 3.01-13.41). [https://pubmed.ncbi.nlm.nih.gov/35118966/]
  - Yohimbe and yohimbine in dietary supplement products, Operation Supplement Safety (U.S. DoD) (2020) — US military supplement-safety advisory warns of severe adverse events with yohimbe/yohimbine and notes the ingredient is banned in supplements in Canada, Australia, the Netherlands and the UK due to potential harm. [https://www.opss.org/article/yohimbe-and-yohimbine-dietary-supplement-products]
  - The Potential Role of Arginine Supplements on Erectile Dysfunction: A Systemic Review and Meta-Analysis, The journal of sexual medicine (2019) — Meta-analysis of arginine-based supplements for ED (J Sex Med) that included yohimbine-containing combinations: supplements significantly improved ED vs placebo (OR 3.37, 95% CI 1.29-8.77); informs the consistent finding that yohimbine combinations outperform yohimbine monotherapy, with adverse-event rate ~8.3% vs 2.3% placebo (none severe). [https://pubmed.ncbi.nlm.nih.gov/30770070/]
  - Yohimbine for erectile dysfunction: a systematic review and meta-analysis of randomized clinical trials, The Journal of urology (1998) — Yohimbine beat placebo for ED in older trials; the AUA still advises against routine use. [https://pubmed.ncbi.nlm.nih.gov/9649257/]
  - Erectile Dysfunction: AUA Guideline, The Journal of urology (2018) — The American Urological Association evidence-based ED guideline does NOT recommend yohimbine (or other herbal/non-prescription therapies) for the treatment of erectile dysfunction, citing insufficient/low-quality evidence relative to PDE5 inhibitors. Authoritative society position against routine clinical use. [https://pubmed.ncbi.nlm.nih.gov/29746858/]
  - Scientific Opinion on the evaluation of the safety in use of Yohimbe (Pausinystalia yohimbe (K. Schum.) Pierre ex Beille), EFSA Journal (2013) — The EFSA Panel concluded the chemical/toxicological characterisation of yohimbe bark preparations is inadequate to establish safety as a food ingredient, and that theoretical maximum daily intake from supplements may exceed the maximum approved medicinal dose of yohimbine, so no safe intake level could be defined. [https://doi.org/10.2903/j.efsa.2013.3302]
  - Alpha-2 Adrenoreceptor Antagonist Yohimbine Potentiates Consolidation of Conditioned Fear, International Journal of Neuropsychopharmacology (2022) — In a placebo-controlled fear-conditioning trial in 51 healthy men, a single 10 mg dose of yohimbine (alpha-2 antagonist) given after fear acquisition enhanced fear-memory consolidation, producing stronger cardiac and electrocortical (N170/late positive potential) threat responses at 24-hour recall versus placebo and sulpiride. [https://academic.oup.com/ijnp/article/25/9/759/6617231]
  - Yohimbe: Usefulness and Safety, NIH National Center for Complementary and Integrative Health (2025) — Insufficient evidence for weight loss; notable safety concerns. [https://www.nccih.nih.gov/health/yohimbe]
  - Yohimbine: the effects on body composition and exercise performance in soccer players, Research in sports medicine (Print) (2006) — In 20 elite male soccer players, yohimbine 20 mg/day for 21 days reduced body fat (9.3% to 7.1%; lower than placebo postsupplementation, p<0.05) with no change in body mass, muscle mass, or exercise performance and no reported side effects, supporting yohimbine as a targeted fat-loss aid without lean-mass or performance effects. [https://pubmed.ncbi.nlm.nih.gov/17214405/]
  - Narrative Review: The FDA's Perfunctory Approach of Dietary Supplement Regulations Giving Rise to Copious Reports of Adverse Events, Innovations in pharmacy (2023) — Narrative review cites yohimbine as a case of weak FDA oversight, noting California Poison Control logged 238 yohimbine adverse events (2000-2006; 134 hospitalized) including myocardial infarction, arrhythmia, QTc prolongation, seizures and acute renal failure. [https://pmc.ncbi.nlm.nih.gov/articles/PMC10686678/]
  - Presence and Quantity of Botanical Ingredients With Purported Performance-Enhancing Properties in Sports Supplements, JAMA network open (2023) — Analysis of 57 botanical sports supplements (including yohimbine-class alkaloids) found 40% contained none of the declared ingredient and actual quantities ranged 0.02%-334% of label; several contained FDA-prohibited ingredients. [https://pubmed.ncbi.nlm.nih.gov/37459101/]
  - Yohimbine (2020) — NIH LiverTox assigns yohimbine a likelihood score of E (unlikely cause of clinically apparent liver injury), noting it has not been linked to serum enzyme elevations or acute liver injury despite frequent use in weight-loss and bodybuilding supplements. [https://www.ncbi.nlm.nih.gov/books/NBK548703/]
  - Intracranial hemorrhage after a single dose of Yohimbine in a chronic user of clonidine, The American journal of emergency medicine (2022) — Case report of a 39-year-old woman who developed acute basal ganglia and subarachnoid hemorrhage (BP 198/93) after a single dose of a yohimbine-containing sexual-enhancement supplement while on chronic clonidine. [https://pubmed.ncbi.nlm.nih.gov/36115742/]
  - Adverse drug events associated with yohimbine-containing products: a retrospective review of the California Poison Control System reported cases, The Annals of pharmacotherapy (2010) — Retrospective review of 238 California Poison Control System yohimbine cases (2000-2006, 98.7% herbal products) found GI distress (46%), tachycardia (43%), anxiety/agitation (33%) and hypertension (25%); exposures were far more likely than average to cause severe outcomes (OR 5.81, 95% CI 4.43-7.64) and require healthcare-facility management (OR 2.35, 95% CI 1.82-3.04). [https://pubmed.ncbi.nlm.nih.gov/20442348/]
  - Severe acute intoxication with yohimbine: Four simultaneous poisoning cases, Forensic science international (2021) — Forensic report of four simultaneous acute yohimbine poisonings (high-dose powder) presenting with tachycardia, hypertension, flushing and seizures; three survived and one died, illustrating severe sympathomimetic toxicity. [https://pubmed.ncbi.nlm.nih.gov/33529997/]
  - Pharmaceutical quantities of yohimbine found in dietary supplements in the USA, Drug testing and analysis (2016) — Supplement yohimbine content is frequently inaccurate or undeclared. [https://pubmed.ncbi.nlm.nih.gov/26391406/]

---

## Royal Jelly (Apis mellifera secretion)
URL: https://nutridex.info/s/royal-jelly
Category: Longevity, Heart & Metabolic
Evidence: Preliminary — Early or small human trials; promising but not yet conclusive.
Bee-secreted tonic with early menopause & cholesterol hints.

Quick answer: Royal Jelly is used for possible menopausal-symptom relief. NutriDex grades the human evidence as preliminary — Early or small human trials; promising but not yet conclusive. Based on 15 cited human studies (15 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Royal jelly is the secretion worker bees feed to queen larvae, sold as a vitality and anti-aging tonic. Small randomized trials report reduced menopausal symptoms and modest improvements in cholesterol, and lab work shows antioxidant activity. The human evidence base is small and preliminary, however, and the more sweeping anti-aging claims are unproven. Its most important caveat is allergy risk.

Benefits / uses: Possible menopausal-symptom relief; Possible modest cholesterol improvement; (Claimed) general 'vitality' tonic.
Active compounds: 10-HDA (royal jelly acid); Proteins; Fatty acids.
Dose: Commonly 300–1,000 mg/day in studies.
Safety: ⚠ Can cause severe allergic reactions — asthma attacks and anaphylaxis — especially in people with bee/pollen allergies or asthma. Otherwise generally well tolerated.

Cited studies (15):
  - Royal jelly for management of postmenopausal symptoms: a systematic review and meta-analysis, Menopause (New York, N.Y.) (2026) — Meta-analysis of 6 RCTs (n=471 postmenopausal women) found royal jelly significantly improved postmenopausal symptoms vs placebo (SMD 0.73, 95% CI 0.50-0.96, I2=0%, moderate-quality evidence). [https://pubmed.ncbi.nlm.nih.gov/41401249/]
  - The effect of Royal jelly on liver enzymes and glycemic indices: A systematic review and meta-analysis of randomized clinical trials, Complementary therapies in medicine (2023) — Meta-analysis of 10 RCTs found no significant overall effect on liver enzymes or glycemic indices, but a subgroup of trials >=8 weeks showed reduced fasting glucose (WMD -4.28 mg/dl, 95% CI -7.41 to -1.14). [https://pubmed.ncbi.nlm.nih.gov/37619715/]
  - Effects of royal jelly consumption on inflammation and oxidative stress: A systematic review and meta-analysis of randomized controlled trials, Avicenna journal of phytomedicine (2025) — Meta-analysis of 6 RCTs (7 datasets) found royal jelly significantly reduced malondialdehyde and increased total antioxidant capacity, but did not significantly change hs-CRP. [https://pmc.ncbi.nlm.nih.gov/articles/PMC12244952/]
  - Dosage exploration of the effects of honey and its derivatives on cardiometabolic outcomes: an overview of systematic reviews and GRADE-assessed updated meta-analysis, Nutrition & Diabetes (2025) — GRADE-assessed overview of systematic reviews reported honey/royal jelly derivatives improved blood pressure, lipid profiles, glycemic indices, and total antioxidant capacity, with effects generally modest. [https://www.nature.com/articles/s41387-025-00403-9]
  - The effects of royal jelly supplementation on anthropometric indices: a GRADE-assessed systematic review and dose-response meta-analysis of randomized controlled trials, Frontiers in Nutrition (2023) — GRADE-assessed dose-response meta-analysis of 10 RCTs (n=512) found no significant overall effect on body weight, BMI, or fat mass, though a subgroup at doses <3,000 mg/day showed modest reductions in body weight and BMI. [https://www.frontiersin.org/journals/nutrition/articles/10.3389/fnut.2023.1196258/full]
  - The effects of royal jelly supplementation on anthropometric indices: a GRADE-assessed systematic review and dose-response meta-analysis of randomized controlled trials, Frontiers in nutrition (2023) — GRADE-assessed dose-response meta-analysis of 10 RCTs (512 participants) found no significant effect of royal jelly on body weight (WMD -0.29 kg, 95% CI -1.24 to 0.65), BMI (WMD 0.11, 95% CI -0.29 to 0.52), or fat mass; evidence low-to-moderate. [https://pmc.ncbi.nlm.nih.gov/articles/PMC10438987/]
  - Dosage exploration of the effects of honey and its derivatives on cardiometabolic outcomes: an overview of systematic reviews and GRADE-assessed updated meta-analysis, Nutrition & diabetes (2025) — Umbrella review and GRADE-assessed updated meta-analysis of honey-bee products (69 RCTs, 3544 participants). Royal jelly showed dose-dependent improvements in blood pressure, lipid profiles, glycemic indices, and total antioxidant capacity, with adequate certainty of evidence; contrasted with honey, which adversely affected SBP, triglycerides, FBG and hs-CRP. [https://pubmed.ncbi.nlm.nih.gov/41261111/]
  - Effects of royal jelly consumption on inflammation and oxidative stress: A systematic review and meta-analysis of randomized controlled trials, Avicenna journal of phytomedicine (2025) — Meta-analysis of 7 datasets from 6 RCTs. Royal jelly significantly reduced malondialdehyde (WMD -1.79; 95% CI -3.00 to -0.58; p=0.004) and increased total antioxidant capacity (WMD 0.98; 95% CI 0.24 to 1.71; p=0.009), but did not significantly change hs-CRP (WMD -0.24; 95% CI -0.60 to 0.10; p=0.17). [https://pubmed.ncbi.nlm.nih.gov/40656618/]
  - The effects of royal jelly supplementation on anthropometric indices: a GRADE-assessed systematic review and dose-response meta-analysis of randomized controlled trials, Frontiers in nutrition (2023) — GRADE-assessed dose-response meta-analysis of 10 RCTs (512 participants). No significant overall effect on body weight (WMD -0.29 kg), BMI (WMD 0.11 kg/m2), or fat mass; however a significant reduction in body weight and BMI occurred in the subgroup using royal jelly doses <3000 mg/day. [https://pubmed.ncbi.nlm.nih.gov/37599677/]
  - Effectiveness of royal jelly supplementation in glycemic regulation: A systematic review, World journal of diabetes (2019) — Systematic review of 5 RCTs (n=205, doses 500-6,000 mg/day for 4-8 weeks) found royal jelly did not significantly reduce fasting plasma glucose or HbA1c overall, indicating inconsistent glycemic benefit. [https://pubmed.ncbi.nlm.nih.gov/30788047/]
  - A Randomized, Double-Blind Comparison Study of Royal Jelly to Augment Vascular Endothelial Function in Healthy Volunteers, Journal of atherosclerosis and thrombosis (2022) — Randomized double-blind placebo-controlled trial in 100 healthy volunteers found royal jelly 690 mg/day for 4 weeks significantly improved endothelial function (RH-PAT index relative change 21.4% vs 0.05% placebo, P=0.037) and lowered ALT and GGT. [https://pubmed.ncbi.nlm.nih.gov/34588374/]
  - A Case of Anaphylaxis Caused by Major Royal Jelly Protein 3 of Royal Jelly and Its Cross-Reactivity with Honeycomb, Journal of asthma and allergy (2021) — Case report documented IgE-mediated anaphylaxis after royal jelly ingestion driven by major royal jelly protein 3, with cross-reactivity to honeycomb, underscoring serious allergy risk in atopic individuals. [https://pubmed.ncbi.nlm.nih.gov/35221696/]
  - Royal Jelly Supplementation Improves Menopausal Symptoms Such as Backache, Low Back Pain, and Anxiety in Postmenopausal Japanese Women, Evidence-based complementary and alternative medicine : eCAM (2018) — Some trials report reduced menopausal symptoms (e.g. ~1,000 mg/day). [https://pubmed.ncbi.nlm.nih.gov/29853955/]
  - The effects of Royal Jelly consumption on lipid profile: A GRADE-assessed systematic review and dose-response meta-analysis, PharmaNutrition (2023) — Small studies show modest improvements in cholesterol. [https://doi.org/10.1016/j.phanu.2023.100351]
  - Asthma and anaphylaxis induced by royal jelly, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology (1996) — Human evidence limited; can cause serious allergic reactions. [https://pubmed.ncbi.nlm.nih.gov/8835130/]

---

## Shilajit (Shilajatu (purified mineral pitch))
URL: https://nutridex.info/s/shilajit
Category: Ayurvedic, Performance, Longevity
Evidence: Preliminary — Early or small human trials; promising but not yet conclusive.
A mineral-rich Himalayan exudate — buy only purified, tested.

Quick answer: Shilajit is used for possible testosterone support (one extract). NutriDex grades the human evidence as preliminary — Early or small human trials; promising but not yet conclusive. Based on 16 cited human studies (16 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Shilajit is a tar-like exudate that seeps from Himalayan rocks, used in Ayurveda as a rejuvenator. A single proprietary-extract trial reported a ~20% rise in total testosterone over placebo, and lab work suggests fulvic acid has antioxidant and mitochondrial effects — but independent replication is thin and most claims are preliminary. The dominant real-world issue is purity: unpurified products frequently exceed safe limits for lead and arsenic.

Benefits / uses: Possible testosterone support (one extract); Possible anti-fatigue / energy; Antioxidant (fulvic acid).
Active compounds: Fulvic acid; Dibenzo-α-pyrones; Trace minerals.
Dose: 250–500 mg/day of a PURIFIED, lab-tested extract. Never use raw shilajit.
Safety: ⚠ Unpurified shilajit can contain dangerous heavy metals (lead, arsenic). Use only purified, third-party-tested products. Avoid in pregnancy and with iron-overload conditions (hemochromatosis).

Cited studies (16):
  - Effects of oral Shilajit tablets on sexual function and sexual quality of life among reproductive-aged women: a triple-blind randomized clinical trial, Traditional Medicine Research (2023) — In a 60-day triple-blind RCT, 200 mg/day purified shilajit raised mean female sexual function (FSFI) score to ~28.9 vs ~22.1 with placebo in reproductive-aged women; sexual quality-of-life improvement was not statistically significant. [https://doi.org/10.53388/TMR20230305002]
  - Effect of purified Shilajit (<i>Asphaltum punjabianum</i>) on oxidative stress, arterial stiffness and endothelial function in elderly with hypertension: A randomised controlled study, Indian Journal of Physiology and Pharmacology (2023) — Open-label RCT in 60 elderly hypertensives: shilajit 500 mg twice daily for 30 days added to antihypertensives significantly lowered oxidative stress markers (MDA, ox-LDL) and raised antioxidant capacity vs control, but did not change arterial stiffness or endothelial function. [https://doi.org/10.25259/IJPP_447_2022]
  - Shilajit extract reduces oxidative stress, inflammation, and bone loss to dose-dependently preserve bone mineral density in postmenopausal women with osteopenia: A randomized, double-blind, placebo-controlled trial, Phytomedicine : international journal of phytotherapy and phytopharmacology (2022) — In 60 postmenopausal women with osteopenia, 48 weeks of standardized shilajit extract (250 or 500 mg/day) dose-dependently attenuated bone mineral density loss at the lumbar spine and femoral neck versus placebo (significant percent-change increases vs placebo at 24 and 48 weeks, p<0.001), with decreased bone-turnover markers (CTX-1, BALP, RANKL), increased OPG, lower oxidative stress (MDA down, GSH up) and lower hsCRP. [https://pubmed.ncbi.nlm.nih.gov/35933897/]
  - Effects of 8 Weeks of Shilajit Supplementation on Serum Pro-c1α1, a Biomarker of Type 1 Collagen Synthesis: A Randomized Control Trial, Journal of dietary supplements (2024) — In 35 recreationally trained men, 8 weeks of shilajit at 500 and 1000 mg/day significantly raised serum pro-c1a1, a biomarker of type 1 collagen synthesis (roughly doubling to ~82 and ~113 ng/mL from ~42 ng/mL baseline; p=0.008 and 0.007), with no change in placebo; a greater proportion of the high-dose group exceeded the minimal clinically important difference (75% vs 30% placebo, p=0.03). [https://pubmed.ncbi.nlm.nih.gov/36546868/]
  - Quantifying of thallium in Shilajit and its supplements to unveil the potential risk of consumption of this popular traditional medicine, BMC chemistry (2025) — Analytical study detected thallium up to 0.226 ug/g in natural Shilajit and up to 0.5 ug/g in some supplements (sometimes exceeding crude levels), raising long-term toxicity concerns and a need for standardized testing. [https://pubmed.ncbi.nlm.nih.gov/39827344/]
  - Clinical evaluation of purified Shilajit on testosterone levels in healthy volunteers, Andrologia (2016) — Purified shilajit raised total testosterone ~20% vs placebo in one trial. [https://pubmed.ncbi.nlm.nih.gov/26395129/]
  - The effects of Shilajit supplementation on fatigue-induced decreases in muscular strength and serum hydroxyproline levels, Journal of the International Society of Sports Nutrition (2019) — Double-blind placebo-controlled RCT in recreationally active men: 500 mg/day shilajit for 8 weeks reduced fatigue-induced decline in muscular strength and lowered serum hydroxyproline vs placebo. [https://pmc.ncbi.nlm.nih.gov/articles/PMC6364418/]
  - The effects of Shilajit supplementation on fatigue-induced decreases in muscular strength and serum hydroxyproline levels, Journal of the International Society of Sports Nutrition (2019) — In 63 recreationally active men, 8 weeks of PrimaVie shilajit 500 mg/day (high dose) preserved maximal muscular strength after a fatiguing protocol: adjusted mean MVIC decline 8.9% vs 16.0% placebo and 17.0% low dose (p=0.044 and 0.022) in the stronger 50th-percentile subgroup, and lowered baseline serum hydroxyproline (1.5 vs 2.4 ug/mL); 250 mg/day did not differ from placebo. [https://pubmed.ncbi.nlm.nih.gov/30728074/]
  - Clinical evaluation of spermatogenic activity of processed Shilajit in oligospermia, Andrologia (2010) — In 28 oligospermic men completing 90 days of processed shilajit 100 mg twice daily, total sperm count rose ~61%, motility improved 12-17%, semen MDA fell ~19%, and serum testosterone rose ~23.5% versus baseline (uncontrolled). [https://pubmed.ncbi.nlm.nih.gov/20078516/]
  - Shilajit: a natural phytocomplex with potential procognitive activity, International journal of Alzheimer's disease (2012) — Review proposing shilajit's fulvic acid as a procognitive, antioxidant agent that inhibits tau self-aggregation in vitro, suggesting a possible anti-Alzheimer role; evidence is preclinical with no human efficacy data. [https://pubmed.ncbi.nlm.nih.gov/22482077/]
  - Shilajit: A panacea for high-altitude problems, International journal of Ayurveda research (2010) — Narrative review positioning shilajit as an adaptogen and rejuvenator that may improve tolerance of high-altitude stress and immune function; conclusions are hypothesis-generating, not based on controlled altitude trials. [https://pubmed.ncbi.nlm.nih.gov/20532096/]
  - Safety and efficacy of shilajit (mumie, moomiyo), Phytotherapy research : PTR (2014) — Authoritative narrative review concluding that human and animal data support shilajit's safety and document antioxidant, anti-inflammatory, adaptogenic, immunomodulatory and anti-dyslipidemic activity, enhanced spermatogenesis, and a 'revitalizer' role improving physical performance and relieving fatigue via enhanced ATP production; attributes effects mainly to dibenzo-alpha-pyrones and fulvic acid, while noting few well-controlled human trials exist. [https://pubmed.ncbi.nlm.nih.gov/23733436/]
  - Shilajit Supplements Found to Contain High Amounts of Fulvic Acid, ConsumerLab.com (2024) — Commercial samples have exceeded WHO limits for lead and arsenic. [https://www.consumerlab.com/news/shilajit-supplements-found-to-contain-high-amounts-of-fulvic-acid/09-26-2024/]
  - Safety and Efficacy of TruBlk™ Shilajit Resin Supplementation on Physical Performance and Blood Biomarkers in Healthy Adults: A 28-Day Open-Label Pilot Study, Cureus (2026) — 28-day open-label single-arm pilot in 25 healthy men: shilajit resin increased leg-press strength (~13%) and VO2max, and reduced Fatigue Severity Scale (~32%) and CRP (~25%); no control group limits inference. [https://pmc.ncbi.nlm.nih.gov/articles/PMC12848467/]
  - Quantifying of thallium in Shilajit and its supplements to unveil the potential risk of consumption of this popular traditional medicine, BMC chemistry (2025) — Analysis of 13 crude shilajit samples and 5 commercial supplements detected thallium up to 0.226 ug/g (crude) and 0.5 ug/g (supplements), with up to 0.095 ug per tablet, flagging thallium as an under-monitored toxic-metal risk requiring standardized testing. [https://pmc.ncbi.nlm.nih.gov/articles/PMC11743217/]
  - Shilajit attenuates behavioral symptoms of chronic fatigue syndrome by modulating the hypothalamic-pituitary-adrenal axis and mitochondrial bioenergetics in rats, Journal of ethnopharmacology (2012) — Fulvic-acid effects shown mainly in animal/cell models. [https://pubmed.ncbi.nlm.nih.gov/22771318/]

---

## Guggul (Commiphora mukul · Guggulu)
URL: https://nutridex.info/s/guggul
Category: Ayurvedic, Heart & Metabolic
Evidence: Mixed — Conflicting results across studies; benefit uncertain.
A classic cholesterol remedy that newer trials couldn't confirm.

Quick answer: Guggul is used for lowers cholesterol & triglycerides. NutriDex grades the human evidence as mixed — Conflicting results across studies; benefit uncertain. Based on 14 cited human studies (14 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Guggul is the resin of the mukul myrrh tree, traditionally used for high cholesterol and arthritis. Older Indian trials reported meaningful lipid improvements, but a well-controlled US trial (JAMA, 2003) found it did not lower LDL — and may even have raised it slightly. The picture is genuinely mixed, and authorities conclude the evidence is insufficient to recommend it.

Benefits / uses: (Claimed) lowers cholesterol & triglycerides; (Claimed) anti-inflammatory / joint support.
Active compounds: Guggulsterones.
Dose: ~1,000–1,500 mg/day of standardized extract.
Safety: GI upset, headache and skin rash reported. May affect thyroid hormone and interact with drugs (incl. statins, beta-blockers, contraceptives) via CYP enzymes. Avoid in pregnancy.

Cited studies (14):
  - Anti-cancer activity of guggulsterone by modulating apoptotic markers: a systematic review and meta-analysis, Frontiers in pharmacology (2023) — Meta-analysis of 23 in vitro studies found guggulsterone induced apoptosis across cancer cell lines in a time-dependent manner (pooled OR ~4.0 at 24h, ~11.2 beyond 24h); preclinical only, no human data. [https://pubmed.ncbi.nlm.nih.gov/37201024/]
  - The Anti-Obesity Effects of Triphala and Triphala Guggul: A Systematic Review and Meta-Analysis of Clinical Trials, Journal of Medicinal Natural Products (2025) — Meta-analysis of 5 trials in adults with obesity: oral Triphala/Triphala Guggul produced a modest ~2.4 kg body-weight reduction (95% CI -4.2 to -0.6) but no significant BMI change and high heterogeneity (I2=91%). [https://doi.org/10.53941/jmnp.2025.100021]
  - A Systematic Review and Meta-Analysis of Ayurvedic Herbal Preparations for Hypercholesterolemia, Medicina (Kaunas, Lithuania) (2021) — Systematic review/meta-analysis: across 7 RCTs (~380 participants), Commiphora mukul (guggulu) reduced total cholesterol by ~16.8 mg/dL and LDL by ~18.8 mg/dL (both p=0.02) — contrasting with negative Western trials. [https://pubmed.ncbi.nlm.nih.gov/34071454/]
  - A Systematic Review and Meta-Analysis of Ayurvedic Herbal Preparations for Hypercholesterolemia, Medicina (Kaunas, Lithuania) (2021) — Meta-analysis of 7 RCTs (8 arms, 380 participants) found guggulu lowered total cholesterol by 16.78 mg/dL (95% CI 13.96 to 2.61; p=0.02) and LDL by 18.78 mg/dL (95% CI 34.07 to 3.48; p=0.02), but the triglyceride reduction (7.35 mg/dL) was not significant and heterogeneity was high (I2=75%). [https://pmc.ncbi.nlm.nih.gov/articles/PMC8229657/]
  - Guggulu and Triphala for the Treatment of Hypercholesterolaemia: A Placebo-Controlled, Double-Blind, Randomised Trial, Complementary medicine research (2021) — Double-blind placebo-controlled RCT in 90 hypercholesterolemic adults found a 3-month Guggulu plus Triphala combination produced total and LDL cholesterol reductions (3.3% and 4.8%) no greater than placebo, with no significant between-group difference. [https://pubmed.ncbi.nlm.nih.gov/33242870/]
  - Introduction (2020) — NIH National Toxicology Program gavage toxicity studies of a gum guggul extract in Sprague Dawley rats and B6C3F1/N mice; prior data cited an oral LD50 of ~1.6 g/kg and increased serum T3 at 0.2 g/kg, informing safety/dosing concerns. [https://www.ncbi.nlm.nih.gov/books/NBK561197/]
  - Case series and review of Ayurvedic medication induced liver injury, BMC complementary medicine and therapies (2021) — Case series and review of Ayurvedic medication-induced liver injury documents guggul/guggulu-containing preparations among Ayurvedic remedies causing biopsy-confirmed hepatocellular and cholestatic drug-induced liver injury. [https://pmc.ncbi.nlm.nih.gov/articles/PMC7956115/]
  - Guggulipid for the treatment of hypercholesterolemia: a randomized controlled trial, JAMA (2003) — Guggulipid did not lower LDL and slightly raised it in a US RCT. [https://pubmed.ncbi.nlm.nih.gov/12915429/]
  - Nodulocystic acne: oral gugulipid versus tetracycline, The Journal of dermatology (1994) — Randomized comparative trial in 20 patients with nodulocystic acne: oral gugulipid (25 mg guggulsterone twice daily, 3 months) reduced inflammatory lesions by 68% versus 65.2% with tetracycline 500 mg twice daily (difference not significant, p>0.05), with fewer relapses on gugulipid. [https://pubmed.ncbi.nlm.nih.gov/7798429/]
  - The effectiveness of Commiphora mukul for osteoarthritis of the knee: an outcomes study, Alternative therapies in health and medicine (2003) — Open-label outcomes study of Commiphora mukul (500 mg extract three times daily) in 30 patients with knee osteoarthritis showed significant improvement in WOMAC total score (p<0.0001) at 1 month with no reported side effects. [https://pubmed.ncbi.nlm.nih.gov/12776478/]
  - Resin from the mukul myrrh tree, guggul, can it be used for treating hypercholesterolemia? A randomized, controlled study, Complementary therapies in medicine (2009) — Double-blind placebo-controlled trial in Norwegian general practice (43 randomized, 34 completers; 2160 mg guggul/day for 12 weeks). Total cholesterol and HDL-C were significantly reduced vs placebo, but LDL-C, triglycerides, and TC/HDL ratio did not change significantly; clinical magnitude judged unclear. More guggul users reported side effects (10 vs 4), including GI discomfort, possible thyroid effects, and a skin rash causing withdrawal. [https://pubmed.ncbi.nlm.nih.gov/19114224/]
  - Guggul, Memorial Sloan Kettering Cancer Center — Evidence judged insufficient to support use for any condition. [https://www.mskcc.org/cancer-care/integrative-medicine/herbs/guggul]
  - Hypolipidemic and antioxidant effects of Commiphora mukul as an adjunct to dietary therapy in patients with hypercholesterolemia, Cardiovascular Drugs and Therapy (1994) — Reported reductions in cholesterol/triglycerides — not replicated in Western trials. [https://link.springer.com/article/10.1007/BF00877420]
  - Guggulu (Commiphora mukul) potentially ameliorates hypothyroidism in female mice, Phytotherapy research : PTR (2005) — In female mice with PTU-induced hypothyroidism, guggulu (200 mg/kg/day for 30 days) reversed the hypothyroid state by restoring hepatic 5'-deiodinase activity and reducing lipid peroxidation, suggesting thyroid-stimulating (T3-raising) activity; preclinical only. [https://pubmed.ncbi.nlm.nih.gov/15798994/]

---

## Boswellia (Boswellia serrata · Shallaki (Indian frankincense))
URL: https://nutridex.info/s/boswellia
Category: Ayurvedic, Joint & Skin
Evidence: Moderate — Several controlled trials; effects real but modest or context-dependent.
Frankincense resin with solid osteoarthritis evidence.

Quick answer: Boswellia is used for reduced osteoarthritis pain & stiffness. NutriDex grades the human evidence as moderate — Several controlled trials; effects real but modest or context-dependent. Based on 18 cited human studies (18 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Boswellia (Indian frankincense) yields boswellic acids that inhibit the inflammatory enzyme 5-lipoxygenase. A meta-analysis of seven trials found it reduces osteoarthritis pain and stiffness and improves function, with benefit typically emerging over about four weeks and a side-effect profile gentler than NSAIDs. It is one of the better-supported Ayurvedic herbs for a specific condition.

Benefits / uses: Reduced osteoarthritis pain & stiffness; Anti-inflammatory (5-LOX inhibition); Improved joint function.
Active compounds: Boswellic acids (esp. AKBA).
Dose: 100–250 mg/day of a standardized extract (e.g. AKBA-enriched), for ≥4 weeks.
Safety: Generally well tolerated; mild GI upset possible. May interact with anti-inflammatory or immune drugs. Limited pregnancy data — avoid.

Cited studies (18):
  - Efficacy of Extracts of Oleogum Resin of Boswellia in the Treatment of Knee Osteoarthritis: A Systematic Review and Meta-Analysis, Phytotherapy Research (2024) — A systematic review and meta-analysis of randomized trials found Boswellia oleogum resin extracts significantly reduced pain and improved function in knee osteoarthritis versus control. [https://onlinelibrary.wiley.com/doi/10.1002/ptr.8336]
  - Efficacy evaluation of standardized Boswellia serrata extract (Aflapin(Ⓡ)) in osteoarthritis: A systematic review and sub-group meta-analysis study, Explore (New York, N.Y.) (2024) — A systematic review and sub-group meta-analysis of 9 RCTs (712 participants) found Boswellia serrata extract reduced osteoarthritis pain and stiffness, with the standardized Aflapin extract showing the largest effect. [https://pubmed.ncbi.nlm.nih.gov/38365549/]
  - Evaluating the efficacy and safety of Curcuma longa, Boswellia serrata, and their mixed formulation in treating knee osteoarthritis: A systematic review and network meta-analysis, Complementary therapies in medicine (2026) — Systematic review and network meta-analysis of 20 RCTs (n=1,633, searched through March 2025) found modified Boswellia serrata formulations significantly improved WOMAC pain, stiffness, and knee function in mild-to-moderate knee osteoarthritis versus comparators, with no significant difference in adverse events. [https://pubmed.ncbi.nlm.nih.gov/41082950/]
  - Efficacy of Extracts of Oleogum Resin of Boswellia in the Treatment of Knee Osteoarthritis: A Systematic Review and Meta-Analysis, Phytotherapy research : PTR (2024) — Systematic review/meta-analysis of 13 RCTs (850 WOMAC, 1,185 VAS patients) on Boswellia oleogum-resin extracts in knee OA: overall pooled effect was non-significant due to high heterogeneity (WOMAC p=0.087; VAS p=0.397), but subgroup analysis vs placebo and meta-regression showed a significant reduction in WOMAC scores favoring Boswellia. [https://pubmed.ncbi.nlm.nih.gov/39314013/]
  - Effectiveness of Boswellia and Boswellia extract for osteoarthritis patients: a systematic review and meta-analysis, BMC complementary medicine and therapies (2020) — Across 7 trials, Boswellia reduced OA pain and stiffness vs control. [https://pmc.ncbi.nlm.nih.gov/articles/PMC7368679/]
  - Effectiveness of Boswellia and Boswellia extract for osteoarthritis patients: a systematic review and meta-analysis, BMC complementary medicine and therapies (2020) — Meta-analysis of 7 RCTs (545 OA patients): Boswellia/extract significantly reduced pain (VAS WMD -8.33, 95% CI -11.19 to -5.46; WOMAC pain WMD -14.22, 95% CI -22.34 to -6.09), stiffness (WMD -10.04), and improved function (WOMAC function WMD -10.75; Lequesne WMD -2.27) vs control; benefit required at least 4 weeks of treatment. [https://pubmed.ncbi.nlm.nih.gov/32680575/]
  - Efficacy of curcumin and Boswellia for knee osteoarthritis: Systematic review and meta-analysis, Seminars in arthritis and rheumatism (2018) — Tufts systematic review/meta-analysis of 11 RCTs (N=1,009): both Boswellia and curcuminoid formulations were significantly more effective than placebo for pain relief and functional improvement in knee OA, with no significant difference in safety outcomes; authors caution overall evidence quality was low. [https://pubmed.ncbi.nlm.nih.gov/29622343/]
  - A standardized Boswellia serrata extract shows improvements in knee osteoarthritis within five days-a double-blind, randomized, three-arm, parallel-group, multi-center, placebo-controlled trial, Frontiers in pharmacology (2024) — In a double-blind 3-arm RCT (n=105 knee OA), standardized Boswellia serrata extract reduced VAS pain ~45-62% and improved WOMAC-total ~69-74% over 90 days vs placebo, with benefit seen within 5 days. [https://pubmed.ncbi.nlm.nih.gov/39092235/]
  - Efficacy and Safety of Boswellia serrata and Apium graveolens L. Extract Against Knee Osteoarthritis and Cartilage Degeneration: A Randomized, Double-blind, Multicenter, Placebo-Controlled Clinical Trial, Pharmaceutical research (2025) — In a randomized double-blind multicenter trial (n=62 knee OA), a Boswellia serrata gum-resin (300 mg) plus celery seed extract significantly reduced WOMAC and VAS pain, stiffness and swelling vs placebo over 90 days. [https://pmc.ncbi.nlm.nih.gov/articles/PMC11880083/]
  - Clinical Benefits of Boswellia Serrata (BOSMAX®) in Early Knee Osteoarthritis: A Randomized, Placebo-Controlled, Double-Blind Study, Journal of medicinal food (2025) — A randomized, placebo-controlled, double-blind study found Boswellia serrata (BOSMAX) improved pain and function in patients with early knee osteoarthritis vs placebo. [https://pubmed.ncbi.nlm.nih.gov/41220252/]
  - Efficacy and Safety of Boswellia serrata and Apium graveolens L. Extract Against Knee Osteoarthritis and Cartilage Degeneration: A Randomized, Double-blind, Multicenter, Placebo-Controlled Clinical Trial, Pharmaceutical research (2025) — Randomized, double-blind, multicenter, placebo-controlled RCT (n=62, 90 days) of Boswellia serrata gum resin (300 mg) plus Apium graveolens seed extract (250 mg) twice daily reduced WOMAC pain/stiffness/swelling and lowered hs-CRP, IL-6, TNF-alpha, and ESR versus placebo. [https://pubmed.ncbi.nlm.nih.gov/39875757/]
  - Boswellia: Usefulness and Safety, NIH National Center for Complementary and Integrative Health (2025) — NIH/NCCIH states that although some studies suggest oral Boswellia may reduce osteoarthritis inflammation and pain, there is not enough high-quality evidence to conclude it is useful for any health condition, and little safety data exists for most boswellia products. [https://www.nccih.nih.gov/health/boswellia]
  - Boswellia serrata acts on cerebral edema in patients irradiated for brain tumors: a prospective, randomized, placebo-controlled, double-blind pilot trial, Cancer (2011) — In a prospective, randomized, placebo-controlled, double-blind trial (n=44 patients irradiated for brain tumors), Boswellia serrata 4200 mg/day reduced cerebral edema by >75% in 60% of patients vs 26% on placebo (P=0.023). [https://pubmed.ncbi.nlm.nih.gov/21287538/]
  - Randomized, placebo-controlled, double-blind trial of Boswellia serrata in maintaining remission of Crohn's disease: good safety profile but lack of efficacy, Inflammatory bowel diseases (2011) — In a 52-week double-blind RCT across 22 German centers (82 randomized), Boswellia serrata extract failed to maintain remission of Crohn's disease better than placebo (~60% vs ~55%, P=0.85), though tolerability was good. [https://pubmed.ncbi.nlm.nih.gov/20848527/]
  - Effects of Boswellia serrata gum resin in patients with bronchial asthma: results of a double-blind, placebo-controlled, 6-week clinical study, European journal of medical research (1998) — In a 6-week double-blind, placebo-controlled trial (n=80), Boswellia serrata gum resin 300 mg three times daily improved bronchial asthma (reduced dyspnoea/attacks, higher FEV1/FVC/PEFR, lower eosinophils) in 70% of patients vs 27% on placebo. [https://pubmed.ncbi.nlm.nih.gov/9810030/]
  - Toxicity and safety evaluation of boswellic acids, Phytomedicine : international journal of phytotherapy and phytopharmacology (1996) — A safety/toxicology evaluation found boswellic acids caused no mortality in rats and mice at oral and intraperitoneal doses up to 2 g/kg and no significant clinical, haematological, biochemical or pathological changes, concluding they are safe for clinical use. [https://pubmed.ncbi.nlm.nih.gov/23194869/]
  - A double blind, randomized, placebo controlled study of the efficacy and safety of 5-Loxin for treatment of osteoarthritis of the knee, Arthritis research & therapy (2008) — AKBA-enriched extracts improved pain/function within days–weeks. [https://pmc.ncbi.nlm.nih.gov/articles/PMC2575633/]
  - 5-Lipoxygenase inhibition by acetyl-11-keto-β-boswellic acid (AKBA) by a novel mechanism, Phytomedicine : international journal of phytotherapy and phytopharmacology (1996) — Boswellic acids inhibit 5-LOX and pro-inflammatory mediators. [https://pubmed.ncbi.nlm.nih.gov/23194864/]

---

## Triphala (Amalaki + Bibhitaki + Haritaki)
URL: https://nutridex.info/s/triphala
Category: Ayurvedic, Gut & Immune
Evidence: Preliminary — Early or small human trials; promising but not yet conclusive.
A three-fruit blend for digestion and oral health.

Quick answer: Triphala is used for improved regularity / gentle laxative. NutriDex grades the human evidence as preliminary — Early or small human trials; promising but not yet conclusive. Based on 15 cited human studies (15 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Triphala is a cornerstone Ayurvedic formula of three dried fruits, used mainly for digestion. Small trials and animal work support a gentle prokinetic/laxative effect that improves regularity, and a notable clinical finding is that triphala mouthwash matched chlorhexidine for reducing dental plaque and gingivitis. Evidence is mostly from small studies, but it is generally well tolerated.

Benefits / uses: Improved regularity / gentle laxative; Oral health (plaque & gingivitis); Antioxidant.
Active compounds: Tannins; Anthraquinones (from Haritaki); Vitamin C.
Dose: 1–2 g at bedtime; as a mouthwash for oral-health use.
Safety: Loose stools/cramping at higher doses. Contains anthraquinones — avoid prolonged stimulant-laxative-style use. Caution in pregnancy and with blood-sugar or anticoagulant medication.

Cited studies (15):
  - The Anti-Obesity Effects of Triphala and Triphala Guggul: A Systematic Review and Meta-Analysis of Clinical Trials, Journal of Medicinal Natural Products (2025) — Systematic review and meta-analysis of 15 controlled trials (n=800); pooled analysis of 5 oral-Triphala trials showed a statistically significant reduction in body weight (mean difference -2.4 kg, 95% CI -4.2 to -0.6, p=0.01, I2=91%), with no significant BMI effect. [https://doi.org/10.53941/jmnp.2025.100021]
  - Comparative anti-plaque and anti-gingivitis efficiency of Triphala versus chlorhexidine mouthwashes in children: a systematic review and meta-analysis, Journal of Clinical Pediatric Dentistry (2024) — Systematic review and meta-analysis of 5 RCTs in children found no significant difference between Triphala and chlorhexidine mouthwash for reducing gingivitis (p=0.83) or plaque accumulation (p=0.96), indicating comparable efficacy. [https://doi.org/10.22514/jocpd.2024.103]
  - Effects of Triphala on Lipid and Glucose Profiles and Anthropometric Parameters: A Systematic Review, Journal of evidence-based integrative medicine (2021) — Across 12 studies (n=749), Triphala significantly reduced LDL-C, total cholesterol and triglycerides in several trials and lowered fasting glucose in diabetic (but not non-diabetic) subjects, with no serious adverse events. [https://pubmed.ncbi.nlm.nih.gov/33886393/]
  - Comparative evaluation of the efficacy of Triphala mouthwash and Curcumin mouthwash in the treatment of gingivitis - A randomized controlled study, Journal of oral biology and craniofacial research (2024) — Randomized controlled trial found Triphala mouthwash comparably reduced plaque and gingival inflammation relative to curcumin mouthwash in gingivitis patients. [https://pubmed.ncbi.nlm.nih.gov/38832298/]
  - Comparative Evaluation of the Effectiveness of Triphala and Chlorhexidine in Full-mouth Disinfection Treatment of Periodontitis in Type 2 Diabetes Patients, The journal of contemporary dental practice (2023) — Randomized trial of full-mouth disinfection in type 2 diabetic patients with stage II/III periodontitis: triphala produced probing-depth reduction (3.38 mm) and clinical attachment gain (3.39 mm) at 6 months comparable to (slightly better than) chlorhexidine (CAL gain 3.18 mm); PPD reduction significant, CAL gain difference not significant. [https://pubmed.ncbi.nlm.nih.gov/38152913/]
  - Anti-Inflammatory and Antioxidant Effects of HIIT in Individuals with Long COVID: Insights into the Potential Role of Triphala, International journal of molecular sciences (2025) — In 104 long-COVID patients randomized to control, HIIT, or HIIT+triphala (1000 mg/day) for 8 weeks, adding triphala produced no statistically significant additional reduction in inflammatory/oxidative markers (IFN-gamma, TNF-alpha, MDA, protein carbonyls) beyond HIIT alone, but was safe and well tolerated. [https://pubmed.ncbi.nlm.nih.gov/40943540/]
  - A randomized clinical trial to evaluate and compare the efficacy of triphala mouthwash with 0.2% chlorhexidine in hospitalized patients with periodontal diseases, Journal of periodontal & implant science (2014) — Double-blind, multicenter RCT in 120 hospitalized periodontal-disease patients: triphala mouthwash significantly reduced plaque and gingival indices over 15 days versus distilled water (p<0.05) and was statistically equivalent to 0.2% chlorhexidine, with no reported side effects. [https://pubmed.ncbi.nlm.nih.gov/24921057/]
  - Effect of triphala mouthrinse on plaque and gingival inflammation: A systematic review and meta-analysis of randomized controlled trials, International journal of dental hygiene (2020) — Triphala mouthwash was as effective as chlorhexidine against plaque/gingivitis. [https://pubmed.ncbi.nlm.nih.gov/32383334/]
  - Study of the safety of oral Triphala aqueous extract on healthy volunteers, Journal of integrative medicine (2020) — Aqueous extract well tolerated in healthy volunteers. [https://pubmed.ncbi.nlm.nih.gov/31680053/]
  - Determination of chemical composition and investigation of potential of triphala powder in hypercholesterolemia in men in controlled randomized trial, Pakistan journal of pharmaceutical sciences (2023) — In a controlled randomized trial in hypercholesterolemic men, Triphala powder reduced total cholesterol and LDL versus baseline/control. [https://pubmed.ncbi.nlm.nih.gov/37548212/]
  - Effect of 0.4% Triphala and 0.12% chlorhexidine mouthwash on dental plaque, gingival inflammation, and microbial growth in 14-15-year-old schoolchildren: A randomized controlled clinical trial, Journal of Indian Society of Periodontology (2021) — Double-blind RCT in 72 schoolchildren aged 14-15 over 90 days: 0.4% Triphala mouthwash reduced dental plaque, gingival inflammation and microbial growth comparably to 0.12% chlorhexidine. [https://pubmed.ncbi.nlm.nih.gov/34898918/]
  - Inhibitory effects of Triphala on CYP isoforms in vitro and its pharmacokinetic interactions with phenacetin and midazolam in rats, Heliyon (2022) — Triphala extract inhibited CYP isoforms in vitro (CYP1A2>3A4>2C9>2D6) and in rats at 500 mg/kg increased the oral bioavailability of phenacetin and midazolam by ~61% and ~41% respectively, signaling potential herb-drug interactions. [https://pubmed.ncbi.nlm.nih.gov/35785236/]
  - Efficacy of Triphala extracts on the changes of obese fecal microbiome and metabolome in the human gut model, Journal of traditional and complementary medicine (2023) — Triphala extract modulated the obese human gut microbiome and metabolome in vitro, increasing beneficial taxa and short-chain fatty acid-related metabolites. [https://pubmed.ncbi.nlm.nih.gov/36970454/]
  - Triphala churna ameliorates retinopathy in diabetic rats, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie (2022) — In diabetic rats, Triphala churna ameliorated retinopathy, attributed to antioxidant and anti-diabetic effects. [https://pubmed.ncbi.nlm.nih.gov/35168075/]
  - Triphala: current applications and new perspectives on the treatment of functional gastrointestinal disorders, Chinese medicine (2018) — Improved gastric emptying/transit without the mucosal damage of stimulant laxatives. [https://pmc.ncbi.nlm.nih.gov/articles/PMC6052535/]

---

## Gotu Kola (Centella asiatica · Mandukaparni)
URL: https://nutridex.info/s/gotu-kola
Category: Ayurvedic, Nootropic, Joint & Skin
Evidence: Preliminary — Early or small human trials; promising but not yet conclusive.
A wound-healing herb with calming, pro-collagen effects.

Quick answer: Gotu Kola is used for wound healing & skin/collagen. NutriDex grades the human evidence as preliminary — Early or small human trials; promising but not yet conclusive. Based on 19 cited human studies (19 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Gotu kola is used in both Ayurveda and TCM for the skin, circulation and mind. Its best-supported effect is wound healing: triterpenes boost collagen synthesis and re-epithelialization. Small trials also show anxiety-reducing and acute mood/alertness effects via GABA signaling, while broader cognitive benefits are mixed — a meta-analysis found no clear memory improvement. Promising but not definitive outside wound care.

Benefits / uses: Wound healing & skin/collagen; Reduced anxiety (small trials); Possible alertness/mood.
Active compounds: Triterpenes (asiaticoside, madecassoside).
Dose: ~500 mg twice daily of extract.
Safety: Generally well tolerated; possible drowsiness and GI upset. Rare reports of liver effects at high/prolonged doses. Avoid in pregnancy and with sedatives or hepatotoxic drugs.

Cited studies (19):
  - Efficacy and Safety of Centella Asiatica (L.) Urb. on Wrinkles: A Systematic Review of Published Data and Network Meta-Analysis, Journal of cosmetic science (2020) — Systematic review and network meta-analysis of 5 double-blind RCTs (172 Asian women) concluded topical Centella asiatica improved lip and periocular wrinkles and markedly raised skin hydration, appearing more effective than Pueraria mirifica but possibly less than tretinoin, with fewer adverse events than tretinoin (10 vs 35); lack of extract standardization limited general application. [https://pubmed.ncbi.nlm.nih.gov/33413787/]
  - Phlebotonics for venous insufficiency, The Cochrane database of systematic reviews (2020) — Cochrane review of 69 RCTs of oral phlebotonics for chronic venous insufficiency (Centella asiatica was one of the agents, 2 CA RCTs included): phlebotonics probably slightly reduce lower-leg oedema vs placebo (RR 0.70, 95% CI 0.63-0.78) and reduce ankle circumference (MD -4.27 mm, 95% CI -5.61 to -2.93), with little/no effect on quality of life or ulcer healing and a slightly higher adverse-event risk (RR 1.14, 95% CI 1.02-1.27); moderate-certainty evidence. [https://pubmed.ncbi.nlm.nih.gov/33141449/]
  - A Systematic Review of the Effect of Centella asiatica on Wound Healing, International journal of environmental research and public health (2022) — Systematic review of clinical trials on Centella asiatica for wound healing: across included trials CA enhanced wound contraction, granulation, re-epithelialization and reduced healing time, likely via improved angiogenesis (stimulation of collagen I, FGF and VEGF) and anti-inflammatory effects (reduced IL-1beta, IL-6, TNF-alpha, COX-2); authors note too few trials for meta-analysis. [https://pubmed.ncbi.nlm.nih.gov/35328954/]
  - Effects of Centella asiatica (L.) Urb. on cognitive function and mood related outcomes: A Systematic Review and Meta-analysis, Scientific reports (2017) — Systematic review/meta-analysis of 11 RCTs (5 of Centella asiatica alone, 6 of CA-containing products) found no significant benefit on any cognitive-function domain vs placebo, but improved mood at 1 hour: increased alertness (SMD 0.71, 95% CI 0.01-1.41) and reduced anger (SMD -0.81, 95% CI -1.51 to -0.09); no adverse effects reported. [https://pubmed.ncbi.nlm.nih.gov/28878245/]
  - A Systematic Review of the Efficacy of Centella asiatica for Improvement of the Signs and Symptoms of Chronic Venous Insufficiency, Evidence-based complementary and alternative medicine : eCAM (2013) — Systematic review of 8 RCTs in chronic venous insufficiency: Centella asiatica significantly improved microcirculatory parameters (transcutaneous pCO2 and pO2, rate of ankle swelling, venoarteriolar response) and qualitatively improved leg heaviness, pain and oedema; conclusions tempered by unclear risk of bias and inadequate reporting. [https://pubmed.ncbi.nlm.nih.gov/23533507/]
  - Effects of Centella asiatica (L.) Urb. on cognitive function and mood related outcomes: A Systematic Review and Meta-analysis, Scientific reports (2017) — No clear memory benefit overall — effects mixed. [https://pmc.ncbi.nlm.nih.gov/articles/PMC5587720/]
  - Clinical Efficacy and Safety Evaluation of a Centella asiatica (CICA)-Derived Extracellular Vesicle Formulation for Anti-Aging Skincare, Cosmetics (2025) — Two-week trial of a Centella asiatica (CICA)-derived extracellular-vesicle topical (n=20, mean age 50.7) reported significant reductions in pore area (-17.9%) and pore density (-26.9%) and a 9.0% decrease in surface roughness, with no skin irritation. [https://www.mdpi.com/2079-9284/12/4/135]
  - Investigating the Efficacy and Safety of Oral Cicaglocal on Wound Healing After Mohs Surgery in Patients With Skin Cancer: A Randomized, Double-Blinded, Placebo-Controlled Clinical Trial, Journal of cosmetic dermatology (2025) — Randomized double-blind placebo-controlled trial (n=24) of an oral Centella asiatica/bromelain supplement after Mohs surgery showed greater erythema reduction (4.83 to 1.25) and higher early healing scores at week 2 versus placebo (all p<0.001). [https://pmc.ncbi.nlm.nih.gov/articles/PMC11804306/]
  - Pharmacokinetics and Pharmacodynamics of Key Components of a Standardized Centella asiatica Product in Cognitively Impaired Older Adults: A Phase 1, Double-Blind, Randomized Clinical Trial, Antioxidants (Basel, Switzerland) (2022) — Double-blind randomized crossover trial (n=4 mildly demented older adults) found triterpene aglycones asiatic/madecassic acid were bioavailable (asiatic acid Cmax 133-259 ng/mL) and treatment activated NRF2 antioxidant gene expression in blood cells, with good tolerability. [https://pmc.ncbi.nlm.nih.gov/articles/PMC8868383/]
  - Centella asiatica triterpenes for diabetic neuropathy: a randomized, double-blind, placebo-controlled, pilot clinical study, Esperienze dermatologiche (2018) — 52-week randomized, double-blind, placebo-controlled pilot trial in Type 2 diabetic neuropathy (CAST standardized triterpene extract n=21 vs placebo n=22): significant reductions from baseline in Total Symptom Score (p<0.01) and paresthesia (p<0.01) only in the CAST group; numbness worsened in placebo and was significantly lower with CAST (p<0.001); well tolerated. [https://pubmed.ncbi.nlm.nih.gov/31080345/]
  - Plectranthus amboinicus and Centella asiatica Cream for the Treatment of Diabetic Foot Ulcers, Evidence-based complementary and alternative medicine : eCAM (2012) — Single-center, randomized, controlled, open-label trial (n=24, Wagner grade 3 diabetic foot ulcers) found a topical Plectranthus amboinicus + Centella asiatica cream (WH-1) over 2 weeks was as effective and safe as hydrocolloid fiber dressing, with no significant difference in wound-size reduction (median 27.2% vs 22.6%, P=0.673) and Wagner-grade improvement in 90.9% vs 70% of patients (P=0.311). [https://pmc.ncbi.nlm.nih.gov/articles/PMC3369464/]
  - A clinical study on the management of generalized anxiety disorder with Centella asiatica, Nepal Medical College journal : NMCJ (2010) — Reduced anxiety; acute improvements in alertness and mood reported. [https://pubmed.ncbi.nlm.nih.gov/20677602/]
  - A review of neuroprotective properties of Centella asiatica (L.) Urb. and its therapeutic effects, Annals of medicine (2025) — Narrative review concluding Centella asiatica shows broad multi-target neuroprotective potential (antioxidant, anti-inflammatory, mitochondrial-protective) across neurodegeneration, brain injury and mood disorders, but human clinical data remain limited and further trials are warranted. [https://pubmed.ncbi.nlm.nih.gov/40932246/]
  - Topical Application of Centella asiatica in Wound Healing: Recent Insights into Mechanisms and Clinical Efficacy, Pharmaceutics (2024) — Narrative review concludes topical Centella asiatica promotes wound healing via collagen synthesis, inflammation modulation, and antioxidant effects, with clinical benefit in diabetic ulcers, burns (Centiderm superior to silver sulfadiazine), scars, and post-laser wounds. [https://pmc.ncbi.nlm.nih.gov/articles/PMC11510310/]
  - Effectiveness of Fractional CO2 Laser and Topical Centella asiatica Combination Therapy in Striae Distensae (Stretch Marks), Journal of lasers in medical sciences (2024) — Prospective experimental study (n=22) of fractional CO2 laser plus topical Centella asiatica for striae distensae improved INA severity score (7.04 to 6.77, p=0.014) and DLQI quality of life (9.72 to 3.18, p<0.001) at 12 weeks. [https://pmc.ncbi.nlm.nih.gov/articles/PMC11625387/]
  - A Systematic Review of the Efficacy of Centella asiatica for Improvement of the Signs and Symptoms of Chronic Venous Insufficiency, Evidence-based complementary and alternative medicine : eCAM (2013) — Systematic review of 8 RCTs (522 patients) found Centella asiatica extract improved microcirculatory parameters versus control — reduced ankle-swelling rate, increased transcutaneous oxygen pressure (+6.63 mmHg) and improved venoarteriolar response — though authors judged overall efficacy evidence inconclusive due to unclear risk of bias. [https://pmc.ncbi.nlm.nih.gov/articles/PMC3594936/]
  - Topical preparations for preventing stretch marks in pregnancy, The Cochrane database of systematic reviews (2012) — Cochrane systematic review of topical preparations in pregnancy reported that a Centella asiatica-containing cream (Trofolastin) was associated with fewer women developing striae gravidarum versus placebo (OR 0.41, 95% CI 0.17-0.99) in one 80-woman trial, but overall evidence across trials was weak. [https://pubmed.ncbi.nlm.nih.gov/23152199/]
  - A Systematic Review of the Effect of Centella asiatica on Wound Healing, International journal of environmental research and public health (2022) — Improved collagen synthesis, re-epithelialization and scar appearance. [https://pmc.ncbi.nlm.nih.gov/articles/PMC8956065/]
  - Centella asiatica (2024) — NIH LiverTox database assigns Centella asiatica a likelihood score of C (probable rare cause of clinically apparent liver injury), documenting roughly four published cases of hepatocellular injury with jaundice (ALT up to ~1694 U/L) that resolved within 1-2 months after discontinuation. [https://www.ncbi.nlm.nih.gov/books/NBK603561/]

---

## Holy Basil (Tulsi) (Ocimum sanctum / tenuiflorum)
URL: https://nutridex.info/s/tulsi
Category: Ayurvedic, Adaptogen, Heart & Metabolic
Evidence: Moderate — Several controlled trials; effects real but modest or context-dependent.
A sacred adaptogen with real glucose and stress data.

Quick answer: Holy Basil (Tulsi) is used for lower fasting & post-meal blood glucose. NutriDex grades the human evidence as moderate — Several controlled trials; effects real but modest or context-dependent. Based on 14 cited human studies (14 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Tulsi is revered in India and classed as an adaptogen. A meta-analysis of randomized trials found it lowers fasting and post-meal blood glucose and improves lipids in people with metabolic disease, and several RCTs show reduced stress, anxiety and cortisol. Trials are mostly small with variable extracts, but the consistency across metabolic and stress outcomes makes it one of the stronger Ayurvedic adaptogens.

Benefits / uses: Lower fasting & post-meal blood glucose; Reduced stress, anxiety & cortisol; Improved lipid profile.
Active compounds: Eugenol; Ursolic acid; Rosmarinic acid.
Dose: ~300 mg/day of standardized extract (or brewed leaves).
Safety: Generally safe. May lower blood sugar (caution with diabetes drugs) and has antiplatelet effects (caution with anticoagulants). Animal data suggest possible anti-fertility effects — avoid when trying to conceive or in pregnancy.

Cited studies (14):
  - The Clinical Efficacy and Safety of Tulsi in Humans: A Systematic Review of the Literature, Evidence-based complementary and alternative medicine : eCAM (2017) — Systematic review of 24 human studies found tulsi ingestion produced favorable clinical outcomes across metabolic, cardiovascular, immune, and neurocognitive endpoints with no significant adverse events reported, supporting use for stress and lifestyle-related chronic disease. [https://pmc.ncbi.nlm.nih.gov/articles/PMC5376420/]
  - The Clinical Efficacy and Safety of Tulsi in Humans: A Systematic Review of the Literature, Evidence-based complementary and alternative medicine : eCAM (2017) — Systematic review of 24 human studies (the only such review of tulsi clinical data) found consistently favourable outcomes across metabolic disorders, cardiovascular disease, immunity and neurocognition, with no significant adverse events reported; concluded tulsi is an effective adjunct for lifestyle-related chronic disease including diabetes, metabolic syndrome and psychological stress. Per PubMed (DOI 10.1155/2017/9217567). [https://pubmed.ncbi.nlm.nih.gov/28400848/]
  - Holybasil (tulsi) lowers fasting glucose and improves lipid profile in adults with metabolic disease: A meta-analysis of randomized clinical trials, Journal of Functional Foods (2018) — Lowered fasting glucose and improved lipid profile in metabolic disease. [https://doi.org/10.1016/j.jff.2018.03.030]
  - Anti-candidal Effect of Ocimum sanctum: A Systematic Review on Microbial Studies, Cureus (2022) — PRISMA systematic review of microbial studies found all included studies demonstrated effective anti-candidal activity of O. sanctum, attributed mainly to eugenol and linalool. [https://pubmed.ncbi.nlm.nih.gov/35677004/]
  - A randomized, double-blind, placebo-controlled trial investigating the effects of an Ocimum tenuiflorum (Holy Basil) extract (Holixer(TM)) on stress, mood, and sleep in adults experiencing stress, Frontiers in nutrition (2022) — 8-week, double-blind, placebo-controlled RCT (n=100) of Ocimum tenuiflorum extract 125 mg twice daily in stressed adults: vs placebo, greater reductions in Perceived Stress Scale (p=0.003) and Athens Insomnia Scale (p=0.025), lower hair cortisol at week 8 (p=0.025), and buffered acute-stress salivary cortisol/amylase and blood pressure responses (p<=0.025). [https://pubmed.ncbi.nlm.nih.gov/36185698/]
  - Effect of Tulsi (Ocimum sanctum Linn.) Supplementation on Metabolic Parameters and Liver Enzymes in Young Overweight and Obese Subjects, Indian journal of clinical biochemistry : IJCB (2017) — Randomized open-label trial in 30 young overweight/obese subjects: 250 mg O. sanctum extract twice daily for 8 weeks significantly improved plasma insulin (p=0.021), insulin resistance (p=0.049), BMI, and lipids, with no change in liver enzymes. [https://pmc.ncbi.nlm.nih.gov/articles/PMC5539010/]
  - Efficacy of an Extract of Ocimum tenuiflorum (OciBest) in the Management of General Stress: A Double-Blind, Placebo-Controlled Study, Evidence-based complementary and alternative medicine : eCAM (2012) — 6-week, randomized, double-blind, placebo-controlled trial (n=150) of O. tenuiflorum extract (OciBest, 1200 mg actives/day) for general stress: significant reductions vs placebo in total symptom score and in forgetfulness, sexual problems, exhaustion and sleep problems (p<=0.05); ~39% greater improvement in stress symptoms than placebo; well tolerated with no adverse events. Per PubMed (DOI 10.1155/2012/894509). [https://pubmed.ncbi.nlm.nih.gov/21977056/]
  - A randomized, double-blind, placebo-controlled trial investigating the effects of an Ocimum tenuiflorum (Holy Basil) extract (Holixer(TM)) on stress, mood, and sleep in adults experiencing stress, Frontiers in nutrition (2022) — Reduced stress, improved mood and sleep vs placebo. [https://pmc.ncbi.nlm.nih.gov/articles/PMC9524226/]
  - Randomized placebo-controlled, single blind trial of holy basil leaves in patients with noninsulin-dependent diabetes mellitus, International journal of clinical pharmacology and therapeutics (1996) — Significant reductions in fasting and postprandial glucose. [https://pubmed.ncbi.nlm.nih.gov/8880292/]
  - Effect of Tulsi (Ocimum sanctum Linn.) Supplementation on Metabolic Parameters and Liver Enzymes in Young Overweight and Obese Subjects, Indian journal of clinical biochemistry : IJCB (2017) — Open-label RCT in 30 overweight/obese adults (250 mg twice daily, 8 weeks) significantly improved triglycerides, LDL, HDL, BMI and insulin resistance with no change in liver enzymes (SGOT/SGPT). [https://pubmed.ncbi.nlm.nih.gov/28811698/]
  - A randomized controlled clinical trial of Ocimum sanctum and chlorhexidine mouthwash on dental plaque and gingival inflammation, Journal of Ayurveda and integrative medicine (2014) — Triple-blind RCT in 108 medical students found Ocimum sanctum mouthrinse significantly reduced gingival bleeding and plaque indices at 15 and 30 days, equivalent to chlorhexidine, without chlorhexidine's side effects. [https://pubmed.ncbi.nlm.nih.gov/24948862/]
  - Holy basil (Ocimum sanctum Linn.) leaf extract enhances specific cognitive parameters in healthy adult volunteers: A placebo controlled study, Indian journal of physiology and pharmacology (2015) — Placebo-controlled trial of 300 mg/day ethanolic holy basil leaf extract for 30 days significantly improved reaction time and error rate on Sternberg memory and Stroop tasks versus placebo, indicating cognition-enhancing potential. [https://pubmed.ncbi.nlm.nih.gov/26571987/]
  - Harnessing the Antibacterial, Anti-Diabetic and Anti-Carcinogenic Properties of Ocimum sanctum Linn (Tulsi), Plants (Basel, Switzerland) (2024) — Comprehensive review concludes Ocimum sanctum enhances insulin secretion and pancreatic beta-cell activity (anti-diabetic) and shows broad-spectrum antibacterial and anti-carcinogenic activity, largely via eugenol. [https://pmc.ncbi.nlm.nih.gov/articles/PMC11678315/]
  - Ocimum sanctum [Tulsi] as a Potential Immunomodulator for the Treatment of Ischemic Injury in the Brain, Current molecular medicine (2024) — Review proposes O. sanctum as an immunomodulator for ischemic brain injury via antioxidant and anti-inflammatory modulation of innate and adaptive immune responses. [https://pubmed.ncbi.nlm.nih.gov/36515030/]

---

## Amla (Indian Gooseberry) (Emblica officinalis · Amalaki)
URL: https://nutridex.info/s/amla
Category: Ayurvedic, Heart & Metabolic, Vitamin
Evidence: Moderate — Several controlled trials; effects real but modest or context-dependent.
A vitamin-C-rich fruit with genuine cholesterol evidence.

Quick answer: Amla (Indian Gooseberry) is used for lower ldl & triglycerides, higher hdl. NutriDex grades the human evidence as moderate — Several controlled trials; effects real but modest or context-dependent. Based on 13 cited human studies (13 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Amla is an exceptionally vitamin-C-rich fruit, central to Ayurvedic tonics like Chyawanprash. A meta-analysis of randomized trials found amla significantly lowers LDL cholesterol (about 15 mg/dL) and improves triglycerides, HDL, glucose and inflammatory markers — a relatively broad and consistent cardiometabolic effect for a single botanical. It is also a potent antioxidant.

Benefits / uses: Lower LDL & triglycerides, higher HDL; Antioxidant (vitamin C & tannins); Possible glucose & blood-pressure benefit.
Active compounds: Vitamin C; Emblicanins (tannins); Flavonoids.
Dose: ~500 mg of extract once or twice daily.
Safety: Generally safe as a food. May lower blood sugar and increase bleeding risk (antiplatelet) — caution with diabetes drugs and anticoagulants, and before surgery. GI upset at high doses.

Cited studies (13):
  - The Efficacy and Safety of Emblica officinalis Aqueous Fruit Extract among Adult Patients with Dyslipidemia: A Systematic Review and Meta-analysis, Acta medica Philippina (2023) — In a systematic review/meta-analysis of RCTs, Emblica officinalis aqueous fruit extract significantly lowered total cholesterol and LDL-C versus control in adults with dyslipidemia. [https://pubmed.ncbi.nlm.nih.gov/39678212/]
  - Clinical effects of Emblica officinalis fruit consumption on cardiovascular disease risk factors: a systematic review and meta-analysis, BMC Complementary Medicine and Therapies (2023) — Pooled analysis of RCTs found amla fruit consumption significantly improved cardiovascular risk factors, reducing total cholesterol, LDL-C, triglycerides and fasting glucose while raising HDL-C. [https://doi.org/10.1186/s12906-023-03997-8]
  - Clinical effects of Emblica officinalis fruit consumption on cardiovascular disease risk factors: a systematic review and meta-analysis, BMC complementary medicine and therapies (2023) — Meta-analysis of 9 RCTs (535 participants) found Emblica officinalis fruit lowered LDL (MD -15.08 mg/dL, 95% CI -25.43 to -4.73), triglycerides (MD -22.35 mg/dL, 95% CI -39.71 to -4.99), VLDL, and hsCRP, with no significant change in HDL or blood pressure. [https://pmc.ncbi.nlm.nih.gov/articles/PMC10251691/]
  - Clinical effects of Emblica officinalis fruit consumption on cardiovascular disease risk factors: a systematic review and meta-analysis, BMC complementary medicine and therapies (2023) — Meta-analysis of 9 RCTs (n=535), EO 500-1500 mg/day for 14-84 days: significant pooled reductions vs placebo in LDL-C (MD -15.08 mg/dL), VLDL-C (-5.43 mg/dL), triglycerides (-22.35 mg/dL), and hsCRP (-1.70 mg/L); authors urge caution due to heterogeneity. (DOI: 10.1186/s12906-023-03997-8) [https://pubmed.ncbi.nlm.nih.gov/37296402/]
  - Effect of triphala mouthrinse on plaque and gingival inflammation: A systematic review and meta-analysis of randomized controlled trials, International journal of dental hygiene (2020) — A systematic review and meta-analysis of 7 RCTs found that mouthrinse made from Triphala (which contains Emblica officinalis/amla) was comparable to chlorhexidine in reducing plaque (mean difference -0.43) and gingival inflammation (mean difference -0.29) with fewer adverse effects. [https://pubmed.ncbi.nlm.nih.gov/32383334/]
  - The impact of Emblica Officinalis (Amla) on lipid profile, glucose, and C-reactive protein: A systematic review and meta-analysis of randomized controlled trials, Diabetes & metabolic syndrome (2023) — Significant LDL reduction (~15 mg/dL) plus improved triglycerides, HDL and glucose. [https://pubmed.ncbi.nlm.nih.gov/36934568/]
  - Evaluation of the effects of a standardized aqueous extract of Phyllanthus emblica fruits on endothelial dysfunction, oxidative stress, systemic inflammation and lipid profile in subjects with metabolic syndrome: a randomised, double blind, placebo controlled clinical study, BMC complementary and alternative medicine (2019) — In a randomized, double-blind, placebo-controlled trial in metabolic syndrome (n=59), standardized aqueous Phyllanthus emblica extract 500 mg twice daily for 12 weeks significantly improved endothelial function (reduced reflection index), raised nitric oxide (+50.7%) and glutathione (+53%), lowered malondialdehyde (-31%) and hsCRP (-54%), and improved the lipid profile. [https://pubmed.ncbi.nlm.nih.gov/31060549/]
  - Clinical evaluation of Emblica Officinalis Gatertn (Amla) in healthy human subjects: Health benefits and safety results from a randomized, double-blind, crossover placebo-controlled study, Contemporary clinical trials communications (2020) — In a randomized, double-blind, crossover, placebo-controlled study in healthy adults (n=15), amla extract 500 mg/day significantly improved blood fluidity, lowered von Willebrand factor and the oxidative-DNA-damage marker 8-OHdG, improved HDL/LDL cholesterol, and caused no hepatotoxicity or other adverse effects. [https://pubmed.ncbi.nlm.nih.gov/31890983/]
  - Effects of Phyllanthus emblica extract on endothelial dysfunction and biomarkers of oxidative stress in patients with type 2 diabetes mellitus: a randomized, double-blind, controlled study, Diabetes, metabolic syndrome and obesity : targets and therapy (2013) — Randomized double-blind controlled trial in 80 type 2 diabetics: P. emblica extract 250 or 500 mg twice daily for 12 weeks significantly improved endothelial function (reflection index), reduced oxidative-stress/inflammation biomarkers (MDA, NO, glutathione, hsCRP), and improved lipid profile and HbA1c vs placebo, comparable to atorvastatin 10 mg. (DOI: 10.2147/DMSO.S46341) [https://pubmed.ncbi.nlm.nih.gov/23935377/]
  - A Pilot clinical study to evaluate the effect of Emblica officinalis extract (Amlamax™) on markers of systemic inflammation and dyslipidemia, Indian journal of clinical biochemistry : IJCB (2008) — Reduced markers of systemic inflammation and dyslipidemia. [https://pmc.ncbi.nlm.nih.gov/articles/PMC3453138/]
  - A Randomized, Triple-Blind, Placebo-Controlled, Add-On Clinical Trial to Evaluate the Efficacy of Emblica officinalis in Uncontrolled Hypertension, Evidence-based complementary and alternative medicine : eCAM (2020) — In a triple-blind placebo-controlled add-on trial (n=92), Emblica officinalis 500 mg three times daily reduced systolic BP by ~15.6% and diastolic BP by ~12.3% versus ~6.3%/3.9% with placebo (P<0.001). [https://pmc.ncbi.nlm.nih.gov/articles/PMC7563076/]
  - Potential synergistic antihyperglycemic effects of co-supplemental Amla and Olive extracts in hyperlipidemic adults with prediabetes and type 2 diabetes: results from a real-life clinical study, Frontiers in nutrition (2024) — In a real-life observational study of 191 hyperlipidemic adults, 2 months of amla (1000 mg)+olive extract lowered blood glucose by ~27.9% in the type 2 diabetes subgroup and ~4.7% in prediabetes (P<0.01). [https://pmc.ncbi.nlm.nih.gov/articles/PMC11484402/]
  - Bioassay-guided evaluation of anti-inflammatory and antinociceptive activities of pistachio, Pistacia vera L, Journal of ethnopharmacology (2006) — High radical-absorbance capacity from vitamin C and tannins. [https://pubmed.ncbi.nlm.nih.gov/16337351/]

---

## Cocaine (Benzoylmethylecgonine (stimulant))
URL: https://nutridex.info/s/cocaine
Category: Banned & Harmful
Evidence: Banned / Harmful — Linked to serious harm and/or banned in sport and many jurisdictions. Listed for awareness and safety only — NOT a recommendation.
Called 'the perfect heart-attack drug' — deadly even once.

Quick answer: Cocaine is marketed for brief euphoria, energy and alertness — lasting minutes, followed by a crash and craving. NutriDex grades the human evidence as banned / harmful — Linked to serious harm and/or banned in sport and many jurisdictions. Listed for awareness and safety only — NOT a recommendation. Based on 21 cited human studies (21 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Cocaine is a powerful stimulant that spikes heart rate and blood pressure while constricting the vessels feeding the heart — a combination cardiologists have called 'the perfect heart-attack drug'. Damage can occur from the very first use, and it sharply raises the risk of both ischemic and hemorrhagic stroke, including in otherwise-healthy young users. It is highly addictive, and the illicit supply is increasingly contaminated with fentanyl, adding overdose risk. This entry exists to warn, not to inform use.

Benefits / uses: Brief euphoria, energy and alertness — lasting minutes, followed by a crash and craving.
Active compounds: Cocaine (a powerful CNS stimulant).
Dose: No safe dose. Illegal controlled substance — any amount can be fatal.
Safety: ⚠ EXTREME HARM. Heart attack, stroke, fatal arrhythmia, seizure and sudden death — possible on a first use. Highly addictive. Damages the heart, brain and nasal tissue; pregnancy harm; psychosis and paranoia. The illicit supply is frequently laced with fentanyl, causing unintentional opioid overdose. Illegal.

Cited studies (21):
  - Cardiovascular Risks of Simultaneous Use of Alcohol and Cocaine-A Systematic Review, Journal of clinical medicine (2024) — Systematic review found combined cocaine + alcohol use produces cocaethylene, associated with an 18- to 25-fold higher risk of sudden death versus cocaine alone, and higher cardiovascular mortality. [https://pubmed.ncbi.nlm.nih.gov/38592322/]
  - Predictors of cocaine use disorder treatment outcomes: a systematic review, Systematic reviews (2024) — Systematic review of 32 RCTs identified younger age, longer cocaine use history, and higher craving as predictors of relapse/dropout; each additional year of use cut odds of a negative urine sample at 9 months by ~5%. [https://pubmed.ncbi.nlm.nih.gov/38720357/]
  - Cardiovascular Risks of Simultaneous Use of Alcohol and Cocaine-A Systematic Review, Journal of clinical medicine (2024) — Systematic review of 42 studies found combined cocaine-alcohol use forms cocaethylene, associated with an 18-25 fold higher risk of acute cardiac death versus cocaine alone via inhibition of cardiac ion channels. [https://pmc.ncbi.nlm.nih.gov/articles/PMC10935323/]
  - Cocaine and Ischemic or Hemorrhagic Stroke: A Systematic Review and Meta-Analysis of Clinical Evidence, Journal of clinical medicine (2023) — Systematic review/meta-analysis (36 studies): cocaine use increased the odds of ischemic stroke, intracerebral hemorrhage, or subarachnoid hemorrhage roughly 5-fold (pooled OR 5.05, p<0.001), and among stroke patients cocaine use raised odds of mortality (OR 1.77), vasospasm (OR 2.25), and seizures (OR 1.61); strokes occurred in younger, disproportionately African American patients. [https://pubmed.ncbi.nlm.nih.gov/37629248/]
  - All-cause and cause-specific mortality among people with regular or problematic cocaine use: a systematic review and meta-analysis, Addiction (Abingdon, England) (2021) — Systematic review/meta-analysis of 21 cohorts (170,019 people with regular/problematic cocaine use): pooled all-cause standardized mortality ratio (SMR) 6.13 (95% CI 4.15-9.05) vs general population, with markedly elevated cause-specific SMRs for homicide (9.38), accidental injury (6.36), suicide (6.26), and AIDS-related death (23.12). [https://pubmed.ncbi.nlm.nih.gov/32857457/]
  - Cocaine, cardiomyopathy, and heart failure: a systematic review and meta-analysis, Scientific reports (2020) — Systematic review/meta-analysis on cocaine, cardiomyopathy, and heart failure: chronic cocaine use is associated with structural/functional cardiac changes more consistent with diastolic (not the classically taught dilated) heart failure; in patients without prior acute coronary syndrome it was not associated with significantly reduced ejection fraction, and beta-blocker therapy appeared safe and potentially beneficial. [https://pubmed.ncbi.nlm.nih.gov/33188223/]
  - SIDS is associated with prenatal drug use: a meta-analysis and systematic review of 4 238 685 infants, Archives of disease in childhood. Fetal and neonatal edition (2022) — Meta-analysis of 4,238,685 infants (16 studies; 21,571 cocaine-exposed): prenatal cocaine exposure was associated with a 4.4-fold increased crude risk of sudden infant death syndrome (RR 4.40, 95% CI 2.52-7.67); any prenatal drug exposure raised SIDS risk 7.84-fold, persisting (RR 4.24) after adjustment for socioeconomic factors. [https://pubmed.ncbi.nlm.nih.gov/35396270/]
  - Cocaine abstinence during the "critical period" of a contingency management trial predicts future abstinence in people with cocaine use disorder, Drug and alcohol dependence (2023) — In an RCT of 87 participants with cocaine use disorder, abstinence during the initial three-visit 'critical period' significantly predicted sustained abstinence across the 12-week contingency-management trial. [https://pubmed.ncbi.nlm.nih.gov/38006674/]
  - Vasculopathy and vasculitis associated with levamisole-adulterated cocaine: a systematic review, Journal of autoimmunity (2026) — Systematic review of 172 reports (302 patients, 93% levamisole-adulterated cocaine) documented skin involvement in 91% and kidney involvement in 21%, with thrombotic vasculopathy and/or leukocytoclastic vasculitis on biopsy; drug withdrawal is the mainstay of treatment. [https://pubmed.ncbi.nlm.nih.gov/41330036/]
  - Illicit stimulants and ventricular arrhythmias: a longitudinal cohort study, European heart journal (2025) — In a cohort of 29.6 million individuals (290,652 cocaine users), cocaine use was associated with incident ventricular arrhythmias (HR 1.15, 95% CI 1.10-1.19) and all-cause mortality (HR 1.68, 95% CI 1.64-1.72) after adjustment. [https://pmc.ncbi.nlm.nih.gov/articles/PMC12488323/]
  - Acute Cardiovascular Toxicity of Cocaine, The Canadian journal of cardiology (2022) — Review describing cocaine's acute cardiovascular toxicity (chest pain, ACS/MI, arrhythmia, hypertension) via sympathomimetic stimulation, coronary vasoconstriction and sodium-channel blockade, and outlining emergency management. [https://pubmed.ncbi.nlm.nih.gov/35697321/]
  - Cocaine-related sudden cardiac death: a hypothesis correlating basic science and clinical observations, Journal of clinical pharmacology (1994) — Any dose can cause sudden death via heart attack, stroke or seizure — even first use. [https://pubmed.ncbi.nlm.nih.gov/7983233/]
  - Psychostimulant drugs for cocaine dependence, The Cochrane database of systematic reviews (2016) — Cochrane review of 26 RCTs (n=2366) found psychostimulant agonist medications modestly increased sustained cocaine abstinence (RR 1.36, 95% CI 1.05-1.77) but did not improve treatment retention or reduce overall cocaine use; evidence quality was very low. [https://pubmed.ncbi.nlm.nih.gov/27670244/]
  - Antidepressants for cocaine dependence, The Cochrane database of systematic reviews (2003) — Cochrane review of 37 RCTs (n=3551) concluded antidepressants do not reduce cocaine use, treatment dropout, or dependence severity, providing no support for their use in cocaine dependence despite mood-related effects. [https://pubmed.ncbi.nlm.nih.gov/12804445/]
  - Cocaine Use and Risk of Ischemic Stroke in Young Adults, Stroke (2016) — Cocaine markedly raises risk of ischemic and hemorrhagic stroke, including in young users. [https://www.ahajournals.org/doi/10.1161/strokeaha.115.011417]
  - Drug Overdose Deaths Involving Stimulants ― United States, January 2018–June 2024, MMWR. Morbidity and Mortality Weekly Report (2025) — Surveillance (Jan 2018-Jun 2024) showed cocaine-involved overdose death rate nearly doubled from 4.5 to 8.6 per 100,000; ~79% of cocaine-involved deaths co-involved opioids (mainly illicitly manufactured fentanyl). [https://www.cdc.gov/mmwr/volumes/74/wr/mm7432a1.htm]
  - Systematic Review and Meta-analysis of the Impact of Cocaine Use on Cognitive Inhibition, Neuropsychology review (2025) — Systematic review and meta-analysis found cocaine users show significantly worse cognitive inhibition (impaired response/interference control) compared with non-using controls. [https://pubmed.ncbi.nlm.nih.gov/41214400/]
  - Stimulant-Involved Cardiovascular Disease Mortality and Life Years Lost, 2014 to 2023, Substance use : research and treatment (2025) — US cocaine-involved cardiovascular disease deaths rose at 6.5% average annual percent change over 2014-2023, totaling 15,352 deaths and 423,528 years of life lost. [https://pmc.ncbi.nlm.nih.gov/articles/PMC12106991/]
  - Triggering of myocardial infarction by cocaine, Circulation (1999) — Determinants of MI Onset Study, case-crossover analysis of 3,946 acute MI patients: the risk of MI onset was elevated 23.7-fold (95% CI 8.5-66.3) in the 60 minutes immediately following cocaine use, then declined rapidly thereafter, demonstrating cocaine as a potent acute trigger of myocardial infarction even in low-baseline-risk individuals. [https://pubmed.ncbi.nlm.nih.gov/10351966/]
  - Effects of cocaine use during pregnancy on low birthweight and preterm birth: systematic review and metaanalyses, American journal of obstetrics and gynecology (2011) — Systematic review and meta-analysis of 31 studies found cocaine use in pregnancy roughly tripled the odds of low birthweight (OR 3.66), preterm birth (OR 3.38), and small-for-gestational-age infants (OR 3.23), with ~492 g lower birthweight. [https://pubmed.ncbi.nlm.nih.gov/21257143/]
  - Cardiovascular Effects of Cocaine, Circulation (2010) — Raises BP and heart rate while constricting coronary arteries — heart attack and stroke risk. [https://www.ahajournals.org/doi/10.1161/circulationaha.110.940569]

---

## Methamphetamine (N-methylamphetamine ('crystal meth'))
URL: https://nutridex.info/s/methamphetamine
Category: Banned & Harmful
Evidence: Banned / Harmful — Linked to serious harm and/or banned in sport and many jurisdictions. Listed for awareness and safety only — NOT a recommendation.
Profoundly addictive and neurotoxic — it damages the brain.

Quick answer: Methamphetamine is marketed for intense, long-lasting energy and euphoria — followed by severe crash, craving and decline. NutriDex grades the human evidence as banned / harmful — Linked to serious harm and/or banned in sport and many jurisdictions. Listed for awareness and safety only — NOT a recommendation. Based on 21 cited human studies (21 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Methamphetamine floods the brain with dopamine, producing an intense high — and lasting damage. It is directly neurotoxic, reducing grey matter and impairing dopamine-transporter function on brain imaging, and up to a third of users experience psychosis with paranoia and hallucinations. Chronic use causes the notorious tooth destruction known as 'meth mouth', skin sores, drastic weight loss and profound addiction. Listed strictly as a warning.

Benefits / uses: Intense, long-lasting energy and euphoria — followed by severe crash, craving and decline.
Active compounds: Methamphetamine (a potent CNS stimulant).
Dose: No safe dose. Illegal controlled substance.
Safety: ⚠ EXTREME HARM. Severe addiction, lasting brain damage, psychosis, 'meth mouth', skin sores, weight loss, stroke, heart attack and overdose. Withdrawal brings depression and intense craving. Illegal, and illicit products are unregulated and often contaminated.

Cited studies (21):
  - Methamphetamine exposure and depression-A systematic review and meta-analysis, Drug and alcohol review (2023) — Systematic review and meta-analysis found methamphetamine use is associated with significantly increased odds of depression versus non-users. [https://pubmed.ncbi.nlm.nih.gov/37126460/]
  - Methamphetamine-associated heart failure: a systematic review of observational studies, Heart (British Cardiac Society) (2023) — Systematic review of observational studies found methamphetamine use causes a reversible-to-progressive cardiomyopathy with reduced ejection fraction, and abstinence is associated with improved cardiac recovery. [https://pubmed.ncbi.nlm.nih.gov/36456204/]
  - Management of Amphetamine and Methamphetamine Use Disorders: A Systematic Review and Network Meta-analysis of Randomized Trials, International journal of mental health and addiction (2025) — A systematic review and network meta-analysis of 72 RCTs (6,836 participants) found no intervention reached moderate-to-high certainty for patient-important outcomes; only low-certainty signals (e.g., contingency management, quetiapine, varenicline) suggested modestly extended abstinence in amphetamine/methamphetamine use disorder. [https://pubmed.ncbi.nlm.nih.gov/41394525/]
  - Management of Amphetamine and Methamphetamine Use Disorders: A Systematic Review and Network Meta-analysis of Randomized Trials, International journal of mental health and addiction (2025) — Network meta-analysis of 72 RCTs (n=6,836) for amphetamine/methamphetamine use disorder found no intervention with moderate-to-high certainty evidence; contingency management plus CBT showed the longest abstinence duration (MD 34.85 days, 95% CI 19.63 to 50.08, very low certainty). [https://pmc.ncbi.nlm.nih.gov/articles/PMC12698752/]
  - Efficacy of Topiramate in Treating Methamphetamine Use Disorder: A Systematic Review and Meta-Analysis of Randomized Controlled Trials, European Psychiatry (2025) — Meta-analysis of 3 RCTs (n=249) found topiramate did not improve abstinence in methamphetamine use disorder (pooled RR 1.00, 95% CI 0.94-1.07) with only a non-significant trend toward reduced depressive symptoms (MD -2.52, 95% CI -5.31 to 0.26). [https://pmc.ncbi.nlm.nih.gov/articles/PMC12437485/]
  - Pharmacological treatment for methamphetamine withdrawal: A systematic review and meta-analysis of randomised controlled trials, Drug and alcohol review (2023) — Systematic review and meta-analysis of randomized controlled trials found no pharmacotherapy reliably reduces methamphetamine withdrawal symptoms, with no clearly effective agent identified. [https://pubmed.ncbi.nlm.nih.gov/35862266/]
  - Products - Data Briefs - Number 549, U.S. Centers for Disease Control and Prevention (2026) — CDC NCHS data brief reports US drug overdose deaths involving psychostimulants with abuse potential (chiefly methamphetamine) remained elevated, with methamphetamine the second most common drug in overdose deaths by 2023. [https://www.cdc.gov/nchs/products/databriefs/db549.htm]
  - The ASAM/AAAP Clinical Practice Guideline on the Management of Stimulant Use Disorder, Journal of addiction medicine (2024) — The 2024 ASAM/AAAP Clinical Practice Guideline on Stimulant Use Disorder recommends contingency management as a primary first-line treatment for methamphetamine use disorder, noting no FDA-approved pharmacotherapy and rising stimulant overdose deaths. [https://pubmed.ncbi.nlm.nih.gov/38669101/]
  - Drug Overdose Deaths Involving Stimulants ― United States, January 2018–June 2024, MMWR. Morbidity and Mortality Weekly Report (2025) — CDC surveillance of US overdose deaths (Jan 2021-Jun 2024) found methamphetamine involved in 31.2% of deaths (96,614), with the age-adjusted methamphetamine death rate rising from 3.9 per 100,000 in 2018 to 10.4 in 2023. [https://www.cdc.gov/mmwr/volumes/74/wr/mm7432a1.htm]
  - The prevalence of substance-induced psychotic disorder in methamphetamine misusers: A meta-analysis, Psychiatry research (2018) — Meta-analysis of 17 studies: pooled prevalence of methamphetamine-induced psychotic disorder was 36.5%, rising to 42.7% over a lifetime assessment window and 43.3% among those with methamphetamine use disorder. [https://pubmed.ncbi.nlm.nih.gov/30041133/]
  - Risk of stroke in prescription and other amphetamine-type stimulants use: A systematic review, Drug and alcohol review (2018) — First systematic review on amphetamine-type stimulants and stroke (4 cohort + 8 case-control studies): current users had higher ischemic stroke risk than non-users (adjusted rate ratios 1.6 and 3.4); former users had elevated hemorrhagic stroke risk (RR 2.3); hemorrhagic risk was markedly raised in women using ATS (adjusted ORs 16.6 and 3.9). [https://pubmed.ncbi.nlm.nih.gov/28485090/]
  - Bupropion and Naltrexone in Methamphetamine Use Disorder, The New England journal of medicine (2021) — In a 2-stage double-blind RCT of 403 adults with moderate-to-severe methamphetamine use disorder, extended-release injectable naltrexone plus oral bupropion produced more responders than placebo (weighted response 13.6% vs 2.5%; treatment effect ~11 percentage points, P<0.001). [https://pubmed.ncbi.nlm.nih.gov/33497547/]
  - A review of methamphetamine use and stroke in the young, Frontiers in neurology (2024) — Review found methamphetamine use markedly raises stroke risk in young adults, with hemorrhagic stroke (intracerebral hemorrhage, subarachnoid hemorrhage) being the predominant neurovascular complication. [https://pubmed.ncbi.nlm.nih.gov/38721123/]
  - Overview of Methamphetamine-Associated Pulmonary Arterial Hypertension, Chest (2024) — A 2024 review in Chest reports methamphetamine is a recognized cause of pulmonary arterial hypertension, with methamphetamine-associated PAH carrying the highest all-cause mortality (~18%) versus methamphetamine users without PAH or with cardiomyopathy, and frequently more severe hemodynamics. [https://pubmed.ncbi.nlm.nih.gov/38211700/]
  - Increased risk of cardiomyopathy in individuals with methamphetamine related disorders in Taiwan, Scientific reports (2025) — Taiwan population-based cohort (17,071 with methamphetamine-related disorders vs 68,264 matched controls) found a 3.42-fold higher adjusted risk of cardiomyopathy in methamphetamine users. [https://pmc.ncbi.nlm.nih.gov/articles/PMC11968872/]
  - Methamphetamine: burden, mechanism and impact on pregnancy, the fetus, and newborn, Journal of perinatology : official journal of the California Perinatal Association (2022) — Review describes prenatal methamphetamine exposure burden and harms to fetus and newborn, including growth restriction, neurodevelopmental impairment, and obstetric complications. [https://pubmed.ncbi.nlm.nih.gov/34785765/]
  - Functional and structural brain changes associated with methamphetamine abuse, Brain sciences (2012) — Damages dopamine/serotonin neurons; imaging shows reduced grey matter. [https://pmc.ncbi.nlm.nih.gov/articles/PMC4061807/]
  - All-cause and suicide mortality among people with methamphetamine use disorder: a nation-wide cohort study in Taiwan, Addiction (Abingdon, England) (2021) — Record-linkage cohort of 23,248 people with methamphetamine use disorder: all-cause mortality 5.4x the general population (SMR 5.4); unnatural-cause SMR 14.8 vs natural-cause 7.5; suicide had the highest cause-specific SMR (16.3), driven by drug-overdose suicide (SMR 24.9). [https://pubmed.ncbi.nlm.nih.gov/33788344/]
  - Methamphetamine-Related Mortality in the United States: Co-Involvement of Heroin and Fentanyl, 1999-2021, American journal of public health (2023) — US methamphetamine-related mortality rose roughly 50-fold from 1999 to 2021, with heroin/fentanyl co-involvement increasing to about 61% of deaths by 2021. [https://pubmed.ncbi.nlm.nih.gov/36730885/]
  - The prevalence of psychotic symptoms among methamphetamine users, Addiction (Abingdon, England) (2006) — Up to ~33% of users experience psychosis (paranoia, hallucinations). [https://pubmed.ncbi.nlm.nih.gov/16968349/]
  - Methamphetamine, American Dental Association (2023) — Chronic use causes severe decay and gum disease ('meth mouth'). [https://www.ada.org/resources/ada-library/oral-health-topics/methamphetamine]

---

## Heroin & Illicit Fentanyl (Illicit mu-opioid agonists)
URL: https://nutridex.info/s/opioids-illicit
Category: Banned & Harmful
Evidence: Banned / Harmful — Linked to serious harm and/or banned in sport and many jurisdictions. Listed for awareness and safety only — NOT a recommendation.
They kill by stopping breathing — fentanyl in milligram doses.

Quick answer: Heroin & Illicit Fentanyl is marketed for brief euphoria and pain relief — with rapid tolerance, dependence and withdrawal. NutriDex grades the human evidence as banned / harmful — Linked to serious harm and/or banned in sport and many jurisdictions. Listed for awareness and safety only — NOT a recommendation. Based on 21 cited human studies (21 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Heroin and illicitly-made fentanyl activate opioid receptors, and at higher doses they suppress the brain's drive to breathe — the mechanism that makes overdose fatal. Fentanyl is extraordinarily potent: a few milligrams can kill, and because it now contaminates much of the street-drug supply, people are poisoned without knowing they took it. Synthetic opioids were involved in roughly 88% of US opioid-overdose deaths, with tens of thousands dying each year. Naloxone can reverse an overdose if given in time.

Benefits / uses: Brief euphoria and pain relief — with rapid tolerance, dependence and withdrawal.
Active compounds: Heroin; Fentanyl & analogues (mu-opioid agonists).
Dose: No safe dose. Illegal; illicit potency is unknown and inconsistent — a key reason overdoses are so common.
Safety: ⚠ EXTREME HARM / FREQUENTLY FATAL. Overdose stops breathing and kills within minutes. Rapid addiction and severe withdrawal; injecting risks HIV/hepatitis and infections. Illicit potency is unknown — fentanyl contamination makes any use a gamble. If using is suspected nearby: call emergency services and give naloxone (Narcan).

Cited studies (21):
  - Buprenorphine versus methadone for the treatment of opioid dependence: a systematic review and meta-analysis of randomised and observational studies, The lancet. Psychiatry (2023) — Systematic review/meta-analysis (over 1.04 million participants across RCTs and observational studies) found treatment retention was better with methadone than buprenorphine, with few statistically significant differences on other outcomes. [https://pubmed.ncbi.nlm.nih.gov/37167985/]
  - Supervised consumption sites and population-level overdose mortality: a systematic review of recent evidence, 2016-2024, Health promotion and chronic disease prevention in Canada : research, policy and practice (2025) — Systematic review of six Canadian studies (2016-2024) found large-scale provincial analyses showed no significant association between supervised consumption sites and population-level overdose mortality, though some smaller urban-area studies suggested inconsistent protective effects. [https://pubmed.ncbi.nlm.nih.gov/40960731/]
  - Xylazine in the Opioid Epidemic: A Systematic Review of Case Reports and Clinical Implications, Cureus (2023) — Systematic review of case reports of xylazine-adulterated fentanyl/heroin found patients predominantly presented with necrotic skin ulcerations, some extending to fascia and bone, with withdrawal poorly responsive to standard opioid management. [https://pmc.ncbi.nlm.nih.gov/articles/PMC10063250/]
  - Management of xylazine toxicity, overdose, dependence, and withdrawal: A systematic review, The American journal on addictions (2025) — Systematic review of xylazine toxicity, overdose, dependence, and withdrawal in the illicit opioid supply found xylazine-associated respiratory and CNS depression is not reversed by naloxone (an alpha-2 agonist effect) and summarized supportive management approaches. [https://pmc.ncbi.nlm.nih.gov/articles/PMC12555106/]
  - Effectiveness of naloxone distribution in community settings to reduce opioid overdose deaths among people who use drugs: a systematic review and meta-analysis, BMC public health (2025) — Systematic review/meta-analysis of community overdose education and naloxone distribution (OEND). Survival after layperson naloxone administration was very high: 98.3% (95% CI 97.5-98.8) when programs served people who use drugs, 95.0% for family/community members, and 92.4% for police; survival was sustained across 2003-2018 and into the 2018-2022 high-fentanyl period. [https://pubmed.ncbi.nlm.nih.gov/40133970/]
  - U.S. Overdose Deaths Decrease Almost 27% in 2024, U.S. Centers for Disease Control and Prevention (2025) — ~54,000 US opioid-overdose deaths in 2024 (even after a sharp decline); synthetic opioids ~88%. [https://www.cdc.gov/nchs/pressroom/releases/20250514.html]
  - Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies, BMJ (Clinical research ed.) (2017) — Systematic review/meta-analysis of 19 cohorts (122,885 on methadone; 15,831 on buprenorphine) found all-cause mortality roughly tripled out of versus in methadone treatment (36.1 vs 11.3 per 1000 person-years) and more than doubled off versus on buprenorphine (9.5 vs 4.3), with overdose mortality similarly reduced during treatment. [https://pubmed.ncbi.nlm.nih.gov/28446428/]
  - Products - Data Briefs - Number 549, U.S. Centers for Disease Control and Prevention (2026) — In 2024 there were 79,384 U.S. drug overdose deaths (age-adjusted rate 23.1/100,000), down from 2022, with synthetic opioids other than methadone (primarily illicitly manufactured fentanyl) showing the largest decline of any drug type. [https://www.cdc.gov/nchs/products/databriefs/db549.htm]
  - CDC Reports Nearly 24% Decline in U.S. Drug Overdose Deaths, U.S. Centers for Disease Control and Prevention (2025) — CDC reported nearly a 24% decline in U.S. drug overdose deaths over the prior 12-month period, with provisional data showing about 87,000 deaths (Oct 2023–Sep 2024) versus ~114,000 the year before, driven largely by decreases in fentanyl-involved deaths. [https://www.cdc.gov/media/releases/2025/2025-cdc-reports-decline-in-us-drug-overdose-deaths.html]
  - Reduction in mortality risk with opioid agonist therapy: a systematic review and meta-analysis, Acta psychiatrica Scandinavica (2019) — 32 cohorts (150,235 participants, 805,424 person-years, 9,112 deaths). Opioid agonist therapy substantially lowered cause-specific and all-cause mortality when in-treatment vs out-of-treatment; relative risk reduction was greater for methadone than buprenorphine, with the largest mortality reduction conferred during the first 4 weeks of treatment. [https://pubmed.ncbi.nlm.nih.gov/31419306/]
  - Effectiveness of naloxone distribution in community settings to reduce opioid overdose deaths among people who use drugs: a systematic review and meta-analysis, BMC public health (2025) — Systematic review/meta-analysis (41 studies, 74,114 participants, 10,328 administrations) found ~97.3% survival after community naloxone use and 25-46% reductions in overdose mortality across multiple regions. [https://pmc.ncbi.nlm.nih.gov/articles/PMC11934755/]
  - Impact of the Communities That HEAL Intervention on Buprenorphine-Waivered Practitioners and Buprenorphine Prescribing: A Prespecified Secondary Analysis of the HCS Randomized Clinical Trial, JAMA network open (2024) — Prespecified secondary analysis of the HEALing Communities Study cluster-randomized trial (67 communities, ~8.2 million adults, KY/MA/NY/OH). The Communities That HEAL intervention did not increase buprenorphine-waivered practitioners (adjusted RR 1.04, 95% CI 0.94-1.14) or buprenorphine prescribing among them (ARR 0.97, 95% CI 0.86-1.10), indicating community coalition strategies alone were insufficient to expand the buprenorphine prescriber base. [https://pubmed.ncbi.nlm.nih.gov/38386322/]
  - Navigating nitazenes: A pharmacological and toxicological overview of new synthetic opioids with a 2-benzylbenzimidazole core, Neuropharmacology (2025) — Pharmacological/toxicological review reports that several nitazene synthetic opioids are more potent than fentanyl at the mu-opioid receptor, with 22 analogues identified in Europe by end-2024 and rising street-level presence. [https://pubmed.ncbi.nlm.nih.gov/40252758/]
  - Detection of Illegally Manufactured Fentanyls and Carfentanil in Drug Overdose Deaths - United States, 2021-2024, MMWR. Morbidity and mortality weekly report (2024) — Surveillance of U.S. overdose deaths 2021–2024 documented detection of illegally manufactured fentanyls and the rising appearance of the ultrapotent analog carfentanil in fatal overdoses across multiple states. [https://pmc.ncbi.nlm.nih.gov/articles/PMC11620336/]
  - Wound Characteristics Among Patients Exposed to Xylazine, JAMA dermatology (2025) — Case series of 59 wounds in 29 hospitalized patients with confirmed xylazine exposure found wounds were commonly on extensor surfaces of extremities, frequently necrotic/devitalized, and larger the longer they persisted. [https://pmc.ncbi.nlm.nih.gov/articles/PMC11561723/]
  - Detection of Illegally Manufactured Fentanyls and Carfentanil in Drug Overdose Deaths - United States, 2021-2024, MMWR. Morbidity and mortality weekly report (2024) — Surveillance of overdose deaths in 45-49 states, Jan 2021-Jun 2024. In 2023 ~72,000 (nearly 7 in 10) US overdose deaths involved illegally manufactured fentanyls (IMFs); IMF-involved deaths declined 2022-2023 in the Northeast (-3.2%), Midwest (-7.8%) and South (-2.8%) but rose 33.9% in the West. Carfentanil-detected deaths rose ~sevenfold, from 29 (Jan-Jun 2023) to 238 (Jan-Jun 2024) across 37 states. [https://pubmed.ncbi.nlm.nih.gov/39636782/]
  - Fentanyl depression of respiration: Comparison with heroin and morphine, British journal of pharmacology (2020) — Fatal overdose is caused by opioid-induced respiratory depression (breathing stops). [https://pmc.ncbi.nlm.nih.gov/articles/PMC6989952/]
  - The emerging fentanyl-xylazine syndemic in the USA: challenges and future directions, Lancet (London, England) (2023) — Lancet review reports US fatal poisonings involving xylazine (commonly mixed with fentanyl) rose ~13-fold from 260 to 3,480 cases (2018-2021); naloxone cannot reverse xylazine's effects. [https://pmc.ncbi.nlm.nih.gov/articles/PMC10842070/]
  - Xylazine Adulteration of the Heroin-Fentanyl Drug Supply : A Narrative Review, Annals of internal medicine (2023) — Narrative review documents xylazine as an increasingly common adulterant of the heroin-fentanyl supply, associated with severe necrotic skin wounds and overdose response complicated by naloxone non-responsiveness. [https://pubmed.ncbi.nlm.nih.gov/37812779/]
  - Association of fentanyl test strip results and change in drug use behaviors: A multi-state, community-based observational study, The International journal on drug policy (2025) — Multi-state observational study of 541 people who use drugs found a positive fentanyl test strip result was associated with roughly a four-fold reduction in the amount of drug used and increased protective behaviors. [https://pubmed.ncbi.nlm.nih.gov/40494014/]
  - Facts about Fentanyl, U.S. Drug Enforcement Administration — Illicit fentanyl contaminates heroin, counterfeit pills and other drugs — unpredictable lethal doses. [https://www.dea.gov/resources/facts-about-fentanyl]

---

## MDMA (Ecstasy / Molly) (3,4-methylenedioxymethamphetamine)
URL: https://nutridex.info/s/mdma
Category: Banned & Harmful
Evidence: Banned / Harmful — Linked to serious harm and/or banned in sport and many jurisdictions. Listed for awareness and safety only — NOT a recommendation.
Can kill by overheating, low sodium, or serotonin syndrome.

Quick answer: MDMA (Ecstasy / Molly) is marketed for temporary euphoria, emotional closeness and energy — followed by a serotonin 'crash'. NutriDex grades the human evidence as banned / harmful — Linked to serious harm and/or banned in sport and many jurisdictions. Listed for awareness and safety only — NOT a recommendation. Based on 19 cited human studies (19 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

MDMA floods the brain with serotonin, producing short-lived euphoria — and several potentially fatal failure modes. The most common causes of ecstasy-related death are hyperthermia (overheating to organ failure), hyponatremia (dangerously low sodium from over-drinking water, causing seizures and brain swelling), and serotonin syndrome. Animal studies show lasting damage to serotonin neurons, and street 'ecstasy' is frequently cut with unknown adulterants. Listed as a warning only.

Benefits / uses: Temporary euphoria, emotional closeness and energy — followed by a serotonin 'crash'.
Active compounds: MDMA (a serotonin-releasing stimulant).
Dose: No safe dose. Illegal; pills/powders are commonly adulterated with other, riskier drugs.
Safety: ⚠ EXTREME HARM. Fatal overheating and rhabdomyolysis, life-threatening low sodium (seizures, brain swelling), serotonin syndrome, and lasting serotonin-system damage. Dangerous with antidepressants and other drugs. Adulterated supply makes every dose unpredictable. Illegal.

Cited studies (19):
  - MDMA-assisted psychotherapy for the treatment of PTSD: A systematic review and meta-analysis of randomized controlled trials (RCTs), Neuropsychopharmacology reports (2024) — Pooled RCTs found MDMA-assisted psychotherapy significantly reduced CAPS PTSD scores versus control, with 100-125 mg associated with a standardized mean difference of -0.86 (95% CI -1.23 to -0.50) at 4-12 weeks. [https://pmc.ncbi.nlm.nih.gov/articles/PMC11609750/]
  - Safety and efficacy of methylenedioxymethamphetamine (MDMA)-assisted psychotherapy in post-traumatic stress disorder: An overview of systematic reviews and meta-analyses, The Australian and New Zealand journal of psychiatry (2025) — Umbrella review of 14 systematic reviews (up to ~353 participants) found consistent efficacy of MDMA-assisted psychotherapy for PTSD but flagged small samples, expectancy/unblinding, and safety-data limitations. [https://pmc.ncbi.nlm.nih.gov/articles/PMC11924292/]
  - Long-term neurocognitive side effects of MDMA in recreational ecstasy users following sustained abstinence: A systematic review and meta-analysis, Journal of psychopharmacology (Oxford, England) (2025) — Meta-analysis of 14 studies found both current and abstinent recreational MDMA users had poorer learning and memory than MDMA-naive controls, with no recovery seen after longer abstinence (low-quality evidence). [https://pubmed.ncbi.nlm.nih.gov/41255336/]
  - MDMA-assisted therapy and current treatment options for chronic, treatment-resistant, moderate or higher severity post-traumatic stress disorder: Systematic literature review, PLOS One (2025) — Systematic literature review of chronic, treatment-resistant moderate-or-higher PTSD reported that 5 of 6 efficacy studies (83%) showed significantly greater PTSD symptom improvement with MDMA-assisted therapy versus placebo, while noting durability and comparative-evidence gaps. [https://doi.org/10.1371/journal.pone.0327778]
  - Hard Boiled: Alcohol Use as a Risk Factor for MDMA-Induced Hyperthermia: a Systematic Review, Neurotoxicity research (2021) — Systematic review concluded concomitant alcohol use worsens MDMA-induced hyperthermia via impaired thermoregulation, dehydration and delayed sweating, increasing risk of fatal heat stroke. [https://pubmed.ncbi.nlm.nih.gov/34554408/]
  - Complete Response Letter (NDA 215455), U.S. Food and Drug Administration (2024) — On 8 Aug 2024 the FDA declined to approve Lykos Therapeutics' midomafetamine (MDMA)-assisted therapy for PTSD, citing unresolved efficacy durability, functional-unblinding/bias and safety-documentation concerns and requesting an additional adequate Phase 3 trial. [https://download.open.fda.gov/crl/CRL_NDA215455_20240808.pdf]
  - MDMA Induced Cardio-toxicity and Pathological Myocardial Effects: A Systematic Review of Experimental Data and Autopsy Findings, Cardiovascular toxicology (2019) — Systematic review of human, animal, autopsy and case data concluded MDMA can cause rhythm disturbances, myocardial injury, cardiomyopathy and sudden cardiac death, including a fatal case of acute cardiotoxicity in an adolescent. [https://pubmed.ncbi.nlm.nih.gov/31073690/]
  - Meta-analysis of executive functioning in ecstasy/polydrug users, Psychological medicine (2016) — Meta-analysis of 39 studies (1221 ecstasy users vs 1242 polydrug controls) found overall executive dysfunction in ecstasy users (SMD = -0.18, 95% CI -0.26 to -0.11), with significant deficits in access to long-term memory (SMD = -0.33), updating (SMD = -0.26) and switching (SMD = -0.19); inhibitory control was unaffected. [https://pubmed.ncbi.nlm.nih.gov/26966023/]
  - Ecstasy (MDMA) and memory function: a meta-analytic update, Human psychopharmacology (2007) — Meta-analysis of 26 studies showed ecstasy users have moderate-to-large memory impairments vs non-users: short-term memory d = -0.63, long-term memory d = -0.87, and verbal memory d = -1.00 (large); visual memory was less affected (d = -0.27, partly attributable to cannabis co-use). [https://pubmed.ncbi.nlm.nih.gov/17621368/]
  - MDMA-assisted therapy for moderate to severe PTSD: a randomized, placebo-controlled phase 3 trial, Nature medicine (2023) — In 104 patients with moderate-to-severe PTSD, MDMA-assisted therapy lowered CAPS-5 scores significantly more than placebo with therapy (LS mean difference -23.7; p<0.001). [https://pmc.ncbi.nlm.nih.gov/articles/PMC10579091/]
  - MDMA-assisted therapy for moderate to severe PTSD: a randomized, placebo-controlled phase 3 trial, Nature Medicine (2023) — In the confirmatory phase 3 MAPP2 trial (n=104, moderate-to-severe PTSD), MDMA-assisted therapy reduced CAPS-5 severity more than placebo with therapy (treatment effect Cohen's d=0.7, P<0.001); 71% of MDMA participants no longer met PTSD criteria vs 48% with placebo. [https://www.nature.com/articles/s41591-023-02565-4]
  - MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study, Nature medicine (2021) — In 90 patients with severe PTSD, MDMA-assisted therapy reduced CAPS-5 severity significantly more than placebo with therapy over 18 weeks (p<0.0001; large effect, d~0.9). [https://pmc.ncbi.nlm.nih.gov/articles/PMC8205851/]
  - Acute 3,4-Methylenedioxymethamphetamine (MDMA) Toxicity Leading to Fulminant Hepatic Failure and Emergency Liver Transplantation, Cureus (2025) — Case report of a 22-year-old who developed seizures, hyperthermia (43C), rhabdomyolysis (CK >360,000 U/L), acute kidney injury, DIC and fulminant hepatic failure after acute MDMA ingestion, requiring emergency liver transplantation. [https://pmc.ncbi.nlm.nih.gov/articles/PMC12815378/]
  - Methylenedioxymethamphetamine (MDMA)-Induced Hyponatremia: Case Report and Literature Review, Cureus (2021) — Case report and review describing life-threatening MDMA-induced hyponatremia and cerebral edema, with higher incidence and severity in women, treatable with hypertonic saline. [https://pubmed.ncbi.nlm.nih.gov/34188977/]
  - 3,4-Methylenedioxymethamphetamine (MDMA) Toxicity (2024) — Leading causes of death: hyperthermia, serotonin syndrome and hyponatremia. [https://www.ncbi.nlm.nih.gov/books/NBK538482/]
  - MDMA toxicity: management of acute and life-threatening presentations, British journal of nursing (Mark Allen Publishing) (2018) — Review documenting a recent resurgence in MDMA popularity with an associated rise in deaths; details the pathophysiology of life-threatening toxicity (serotonin syndrome, hyperthermia, cardiac arrest) and acute/critical-care management including ECMO. [https://pubmed.ncbi.nlm.nih.gov/29894255/]
  - Acute toxic effects of 'Ecstasy' (MDMA) and related compounds: overview of pathophysiology and clinical management, British journal of anaesthesia (2006) — Authoritative clinical review of acute MDMA toxicity describing life-threatening harms including hyperpyrexia/hyperthermia, multi-organ failure, rhabdomyolysis, hyponatremia (from excess water intake/SIADH) and sudden death; establishes the clinical management framework for acute presentations. [https://pubmed.ncbi.nlm.nih.gov/16595612/]
  - Synthetic cathinone adulteration of illegal drugs, Psychopharmacology (2019) — Street pills/powder frequently contain other, more dangerous drugs. [https://pmc.ncbi.nlm.nih.gov/articles/PMC6472990/]
  - (+/-)3,4-Methylenedioxymethamphetamine ('Ecstasy')-induced serotonin neurotoxicity: clinical studies, Neuropsychobiology (2000) — Loss of serotonin-axon markers in primates; deficits in memory and mood. [https://pubmed.ncbi.nlm.nih.gov/10867551/]

---

## Niacinamide (Nicotinamide) (Vitamin B3 amide)
URL: https://nutridex.info/s/niacinamide
Category: Vitamin, Joint & Skin
Evidence: Moderate — Several controlled trials; effects real but modest or context-dependent.
Versatile B3 amide for barrier, tone, oil & skin-cancer defense

Quick answer: Niacinamide (Nicotinamide) is used for reduces hyperpigmentation & uneven tone. NutriDex grades the human evidence as moderate — Several controlled trials; effects real but modest or context-dependent. Based on 15 cited human studies (15 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Niacinamide is the amide form of vitamin B3 that replenishes cellular NAD+, supporting DNA repair, barrier (ceramide) synthesis, sebum regulation, and reduced melanosome transfer. In the landmark ONTRAC RCT (Chen 2015, NEJM), oral nicotinamide 500 mg twice daily cut new non-melanoma skin cancers ~23% in immunocompetent high-risk patients. The later phase-3 ONTRANS trial in organ-transplant recipients was negative, so oral chemoprevention benefit appears limited to immunocompetent skin. Topical niacinamide (2–5%) is separately supported for hyperpigmentation, fine lines, redness, barrier function and oiliness, though effects are modest.

Benefits / uses: Reduces hyperpigmentation & uneven tone; Strengthens barrier, lowers water loss; Curbs sebum and pore size; Aids UV DNA repair in high-risk skin.
Active compounds: Nicotinamide; NAD+/NADH precursor.
Dose: Oral: 500 mg twice daily (chemoprevention). Topical: 2–5% in serums/creams.
Safety: Well tolerated and, unlike niacin (nicotinic acid), does NOT cause flushing — don't confuse the two. No notable adverse-event excess at 1 g/day in the year-long ONTRAC trial; benefit fades after stopping. Topical 2–5% rarely causes mild irritation.

Cited studies (15):
  - The Role of Nicotinamide as Chemo-Preventive Agent in NMSCs: A Systematic Review and Meta-Analysis, Nutrients (2023) — Pooling 4 RCTs of oral nicotinamide for keratinocyte cancer prevention found no significant reduction in overall non-melanoma skin cancer (RR 0.82, 95% CI 0.61-1.12), SCC (RR 0.81) or BCC (RR 0.88), concluding evidence is insufficient that it meaningfully reduces skin cancers. [https://pubmed.ncbi.nlm.nih.gov/38201930/]
  - Efficacy of oral nicotinamide mononucleotide supplementation on glucose and lipid metabolism for adults: a systematic review with meta-analysis on randomized controlled trials, Critical reviews in food science and nutrition (2025) — Across 12 RCTs (513 adults), oral nicotinamide mononucleotide (NMN) raised blood NAD+ levels but produced no significant improvement in fasting glucose, insulin, HbA1c, HOMA-IR or lipid profile. [https://pubmed.ncbi.nlm.nih.gov/39116016/]
  - The Effect of Nicotinamide Mononucleotide and Riboside on Skeletal Muscle Mass and Function: A Systematic Review and Meta-Analysis, Journal of cachexia, sarcopenia and muscle (2025) — Pooling 10 RCTs (6 NMN, 4 NR; ~230 adults aged >60) found no significant effect of NMN or NR on skeletal muscle index, handgrip strength, gait speed or chair-stand performance, not supporting their use to preserve muscle. [https://pubmed.ncbi.nlm.nih.gov/40275690/]
  - Effect of Nicotinamide in Skin Cancer and Actinic Keratoses Chemoprophylaxis, and Adverse Effects Related to Nicotinamide: A Systematic Review and Meta-Analysis, Journal of cutaneous medicine and surgery (2022) — A pooled analysis of nicotinamide trials reported reductions in actinic keratoses and non-melanoma skin cancers with oral nicotinamide while finding adverse events to be rare, supporting a favorable safety profile. [https://pmc.ncbi.nlm.nih.gov/articles/PMC9125143/]
  - Effect of Nicotinamide in Skin Cancer and Actinic Keratoses Chemoprophylaxis, and Adverse Effects Related to Nicotinamide: A Systematic Review and Meta-Analysis, Journal of cutaneous medicine and surgery (2022) — Systematic review and meta-analysis of nicotinamide for skin cancer and actinic keratosis chemoprophylaxis reported a reduction in nonmelanoma skin cancers with oral nicotinamide and a favorable adverse-event profile comparable to placebo, supporting tolerability while noting limited trial numbers. [https://pubmed.ncbi.nlm.nih.gov/35134311/]
  - Nicotinamide for Skin-Cancer Chemoprevention in Transplant Recipients, The New England journal of medicine (2023) — In 158 immunosuppressed organ-transplant recipients, nicotinamide 500 mg BID for 12 months did NOT reduce keratinocyte cancers (rate ratio 1.0, P=0.96). [https://pubmed.ncbi.nlm.nih.gov/36856616/]
  - A randomized placebo-controlled trial of nicotinamide riboside in older adults with mild cognitive impairment, GeroScience (2024) — In a randomized placebo-controlled pilot of 20 older adults with mild cognitive impairment, nicotinamide riboside escalated to 1 g/day for 10 weeks left MoCA and other neurocognitive measures stable, showing no cognitive benefit. [https://pubmed.ncbi.nlm.nih.gov/37994989/]
  - Modified-release nicotinamide for the treatment of hyperphosphataemia in haemodialysis patients: 52-week efficacy and safety results of the phase 3 randomized controlled NOPHOS trial, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association (2023) — In 722 hemodialysis patients with hyperphosphatemia (539 nicotinamide vs 183 placebo), modified-release nicotinamide added to phosphate binders lowered serum phosphate at week 24 (5.40 vs 5.79 mg/dL, P<0.001) but the effect was lost by week 52, and excess diarrhea, thrombocytopenia, anemia and herpes zoster gave an unfavorable benefit:risk ratio not supporting routine use. [https://pubmed.ncbi.nlm.nih.gov/35751625/]
  - Efficacy and Safety of Nicotinamide 10%, Associated with Magnesium Ascorbyl Phosphate 5% and Hyaluronic Acid 5%, Compared to Hydroquinone 4% in Women with Facial Melasma: A Randomized, Double-Blind, Controlled Clinical Trial, Clinical, cosmetic and investigational dermatology (2024) — In a double-blind RCT (n=49), topical nicotinamide 10% (with magnesium ascorbyl phosphate 5% + hyaluronic acid 5%) reduced mMASI by 32% (95% CI 23-41%) at day 60 versus 43% (95% CI 34-52%) for hydroquinone 4%, i.e. effective for facial melasma but numerically inferior to hydroquinone. [https://pmc.ncbi.nlm.nih.gov/articles/PMC11457776/]
  - Safety and efficacy of niosomal and conventional tranexamic acid/niacinamide vs. hydroquinone creams in melasma: A randomized, double-blind, case-controlled clinical trial, Scientific Reports (2025) — Double-blind RCT (n=99, conducted 2023-2024) found niosomal and conventional tranexamic acid/niacinamide creams produced significant reductions in melanin index and mMASI comparable to hydroquinone 4% over 3 months in melasma patients. [https://www.nature.com/articles/s41598-025-26693-8]
  - Niacin - Health Professional Fact Sheet, NIH Office of Dietary Supplements — The NIH ODS states the Tolerable Upper Intake Level for niacin in adults is 35 mg/day (based on flushing), and warns that high supplemental nicotinamide can cause nausea, vomiting and signs of liver toxicity at intakes around 3,000 mg/day. [https://ods.od.nih.gov/factsheets/Niacin-HealthProfessional/]
  - A Phase 3 Randomized Trial of Nicotinamide for Skin-Cancer Chemoprevention, The New England journal of medicine (2015) — In 386 immunocompetent patients with ≥2 prior NMSCs, oral nicotinamide 500 mg BID for 12 months lowered new non-melanoma skin cancers by 23% (P=0.02) and reduced actinic keratoses. [https://pubmed.ncbi.nlm.nih.gov/26488693/]
  - A Double-Blind, Randomized Clinical Trial of Niacinamide 4% versus Hydroquinone 4% in the Treatment of Melasma, Dermatology research and practice (2011) — In 27 women with melasma, topical niacinamide 4% produced good-to-excellent improvement in 44% (vs 55% with hydroquinone 4%) with no significant colorimetric difference between agents but fewer adverse effects (18% vs 29%), supporting niacinamide as a better-tolerated alternative. [https://pubmed.ncbi.nlm.nih.gov/21822427/]
  - European Nicotinamide Diabetes Intervention Trial (ENDIT): a randomised controlled trial of intervention before the onset of type 1 diabetes, Lancet (London, England) (2004) — In 552 islet-cell-antibody-positive first-degree relatives at high risk of type 1 diabetes, 5 years of oral modified-release nicotinamide (1.2 g/m2) did not prevent diabetes onset versus placebo (adjusted hazard ratio 1.01, 95% CI 0.73-1.38, P=0.97). [https://pubmed.ncbi.nlm.nih.gov/15043959/]
  - Mechanistic Basis and Clinical Evidence for the Applications of Nicotinamide (Niacinamide) to Control Skin Aging and Pigmentation, Antioxidants (Basel, Switzerland) (2021) — Topical niacinamide 4–5% improved wrinkles, texture, hyperpigmentation and redness over 8–12 weeks via slowed melanosome transfer and ceramide synthesis. [https://pmc.ncbi.nlm.nih.gov/articles/PMC8389214/]

---

## Hyaluronic Acid (Oral)
URL: https://nutridex.info/s/hyaluronic-acid
Category: Joint & Skin
Evidence: Mixed — Conflicting results across studies; benefit uncertain.
Ingested moisture molecule for skin hydration — promising but debated

Quick answer: Hyaluronic Acid (Oral) is used for may increase skin hydration. NutriDex grades the human evidence as mixed — Conflicting results across studies; benefit uncertain. Based on 17 cited human studies (17 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Hyaluronic acid (HA) is a glycosaminoglycan abundant in skin that binds water and supports the extracellular matrix. Several small RCTs (mostly 120 mg/day for 6–12 weeks) report improved skin moisture and reduced crow's-feet wrinkles, but they are small and largely funded by HA manufacturers. The bioavailability of oral HA is debated — ingested HA is broken down by gut bacteria, so any benefit likely comes from fragment signaling or microbiota effects rather than intact HA reaching the skin. Reflecting this uncertainty, an independent 2025 meta-analysis found no significant benefit of oral HA for skin photoaging. Oral HA also has preliminary, weak evidence for mild knee osteoarthritis.

Benefits / uses: May increase skin hydration; Possible reduction in wrinkle depth; May improve elasticity; Reduced subjective dryness.
Active compounds: Hyaluronic acid / sodium hyaluronate (various molecular weights).
Dose: 120–240 mg/day (most trials used 120 mg/day for 6–12 weeks).
Safety: Generally well tolerated in short trials (≤12 weeks) with no serious adverse events; long-term data are lacking and reassurance comes from small industry-sponsored studies. No clinical evidence links oral HA to cancer, but those with active malignancy or who are pregnant/breastfeeding should consult a clinician given the absence of data.

Cited studies (17):
  - Effectiveness of dietary supplements for skin photoaging in healthy adults: a systematic review and meta-analysis of randomized controlled trials, Frontiers in medicine (2025) — Pooled HA data (2 studies, n=100) showed no significant difference vs placebo for skin photoaging (SMD 1.88, p=0.21). [https://pmc.ncbi.nlm.nih.gov/articles/PMC12318760/]
  - Oral Hyaluronic Acid in Osteoarthritis and Low Back Pain: A Systematic Review, Mediterranean journal of rheumatology (2024) — Systematic review of 11 trials (597 patients, mostly randomized placebo-controlled) found 9/11 reported improvement in osteoarthritis/low back pain measures (VAS pain, WOMAC, Lequesne) with oral HA (30-300 mg/day); adverse effects rare and mild. [https://pubmed.ncbi.nlm.nih.gov/39886281/]
  - Oral Hyaluronic Acid Supplement: Efficacy in Skin Hydration, Elasticity, and Wrinkle Depth Reduction, Journal of drugs in dermatology : JDD (2025) — Meta-analysis pooling 7 randomized controlled trials of oral hyaluronic acid found statistically significant improvements in skin hydration and elasticity and a significant reduction in wrinkle depth versus placebo, though firmness, wrinkle volume, and transepidermal water loss did not reach significance. [https://pubmed.ncbi.nlm.nih.gov/40911749/]
  - Oral sodium hyaluronate improves skin hydration, barrier function and signs of aging: a randomized, double-blind, placebo-controlled trial in 150 healthy adults, Scientific reports (2025) — Randomized double-blind placebo-controlled trial in 150 healthy adults; 120 mg/day oral sodium hyaluronate for 12 weeks significantly improved skin hydration and elasticity and reduced TEWL, sebum, and periorbital wrinkle depth vs placebo (60 mg/day showed more modest effects). [https://pubmed.ncbi.nlm.nih.gov/41422283/]
  - Oral administration of hyaluronic acid to improve skin conditions via a randomized double-blind clinical test, Skin research and technology : official journal of International Society for Bioengineering and the Skin (ISBS) [and] International Society for Digital Imaging of Skin (ISDIS) [and] International Society for Skin Imaging (ISSI) (2023) — Double-blind RCT in 129 women; oral HA at 100 or 200 mg/day for 12 weeks significantly improved skin hydration (weeks 2-8) and skin tone (weeks 4-8) and increased epidermal thickness at 12 weeks vs placebo. [https://pubmed.ncbi.nlm.nih.gov/38009035/]
  - Oral sodium hyaluronate relieves knee discomfort: A 12‑week double‑blinded, placebo‑controlled study, Experimental and therapeutic medicine (2024) — Randomized double-blind placebo-controlled trial in 31 adults with knee discomfort; 111 mg/day oral sodium hyaluronate for 12 weeks significantly lowered VAS scores for knee pain/stiffness/discomfort vs placebo at 6 and 12 weeks, with no adverse effects. [https://pmc.ncbi.nlm.nih.gov/articles/PMC10792404/]
  - Oral Supplementation with a New Hyaluronic Acid Matrix Ingredient Improves Skin Brightness, Hydration, Smoothness, and Roughness: Results from a Randomized, Double-Blinded, Placebo-Controlled Study, Dermatology and therapy (2025) — Randomized double-blind placebo-controlled trial in 50 completing adults; 60 mg/day of an oral hyaluronic acid matrix (Dermial) for 12 weeks significantly increased skin brightness and stratum corneum hydration and reduced roughness, scaliness, and erythema versus placebo, with no serious adverse events. [https://pubmed.ncbi.nlm.nih.gov/40498387/]
  - Oral sodium hyaluronate improves skin hydration, barrier function and signs of aging: a randomized, double-blind, placebo-controlled trial in 150 healthy adults, Scientific reports (2025) — In a 12-week double-blind RCT of 150 healthy adults, oral sodium hyaluronate increased cheek skin hydration by +9.1% (60 mg/day) and +11.5% (120 mg/day) vs placebo (p<0.05), with reduced transepidermal water loss and periorbital wrinkles at 120 mg/day. [https://pmc.ncbi.nlm.nih.gov/articles/PMC12827323/]
  - Oral administration of hyaluronic acid to improve skin conditions via a randomized double-blind clinical test, Skin research and technology : official journal of International Society for Bioengineering and the Skin (ISBS) [and] International Society for Digital Imaging of Skin (ISDIS) [and] International Society for Skin Imaging (ISSI) (2023) — In a 12-week double-blind RCT of 129 women (young and elderly), oral 300 kDa hyaluronic acid at 100 and 200 mg/day significantly improved skin hydration from 2-8 weeks in both age groups and increased epidermal thickness at 12 weeks (p<0.05). [https://pmc.ncbi.nlm.nih.gov/articles/PMC10661223/]
  - A Multicenter, Randomized, Double-Blinded, Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of a Krill Oil, Astaxanthin, and Oral Hyaluronic Acid Complex on Joint Health in People with Mild Osteoarthritis, Nutrients (2023) — 12-week multicenter RCT (n=100) of a krill oil/astaxanthin/low-MW oral HA complex in mild knee/hip OA: significantly greater reduction in VAS joint pain (20.8 vs 10.6 mm) and improvement in total WOMAC (-13.0 vs -5.5) and function vs placebo, with fewer adverse events; HA was a combination-product component. [https://pubmed.ncbi.nlm.nih.gov/37686801/]
  - Oral Hyaluronan Relieves Wrinkles and Improves Dry Skin: A 12-Week Double-Blinded, Placebo-Controlled Study, Nutrients (2021) — 12-week double-blind, placebo-controlled trial in 40 adults (35-64 y): oral HA 120 mg/day significantly improved wrinkle assessment, stratum corneum water content, transepidermal water loss, and skin elasticity vs placebo, with significant percentage-change benefits in wrinkles, hydration, and elasticity from 8 weeks onward. [https://pubmed.ncbi.nlm.nih.gov/34203487/]
  - Short-Term Effect of a New Oral Sodium Hyaluronate Formulation on Knee Osteoarthritis: A Double-Blind, Randomized, Placebo-Controlled Clinical Trial, Diseases (Basel, Switzerland) (2020) — Double-blind, randomized, placebo-controlled trial in 60 symptomatic knee OA patients: oral full-spectrum sodium hyaluronate significantly reduced VAS pain and WOMAC pain scores at 60 days vs placebo and significantly cut weekly NSAID/analgesic use. [https://pubmed.ncbi.nlm.nih.gov/32650511/]
  - Liquid combination of hyaluronan, glucosamine, and chondroitin as a dietary supplement for knee osteoarthritis patients with moderate knee pain: A randomized controlled study, Medicine (2021) — 8-week double-blind, placebo-controlled trial (n=80) of a liquid low-MW HA + glucosamine + chondroitin supplement in moderate knee OA pain found NO significant improvement over placebo in KOOS, WOMAC, SF-36, or sleep quality, though SF-36 trends were numerically higher; tempers efficacy claims for combination oral HA. [https://pubmed.ncbi.nlm.nih.gov/34622845/]
  - Oral hyaluronan relieves wrinkles: a double-blinded, placebo-controlled study over a 12-week period, Clinical, cosmetic and investigational dermatology (2017) — Double-blind RCT in 60 adults with crow's feet; 120 mg/day HA for 12 weeks improved wrinkle area and volume vs placebo. (Manufacturer-employed authors.) [https://pubmed.ncbi.nlm.nih.gov/28761365/]
  - Oral Hyaluronic Acid Supplementation for the Treatment of Dry Eye Disease: A Pilot Study, Journal of ophthalmology (2019) — Prospective randomized controlled trial in 54 dry eye disease patients; adding oral hyaluronic acid to topical HA significantly improved OSDI symptom scores (61.8 to 42.3 at 3 months), tear break-up time, and corneal fluorescein staining versus topical HA alone. [https://pubmed.ncbi.nlm.nih.gov/31662894/]
  - Ingested hyaluronan moisturizes dry skin, Nutrition journal (2014) — Double-blind placebo-controlled trial; 120 mg/day ingested hyaluronan for 6 weeks significantly increased skin moisture in adults with dry skin. [https://pmc.ncbi.nlm.nih.gov/articles/PMC4110621/]
  - Fixed combination of hyaluronic acid and chondroitin-sulphate oral formulation in a randomized double blind, placebo controlled study for the treatment of symptoms in patients with non-erosive gastroesophageal reflux, European review for medical and pharmacological sciences (2013) — Randomized double-blind placebo-controlled crossover trial in 20 PPI-refractory non-erosive GERD patients; an oral bioadhesive hyaluronic acid plus chondroitin sulfate formulation (four daily doses, 14 days) significantly reduced overall symptom intensity, heartburn, and acid regurgitation, with symptom resolution in 50% vs 10% on placebo. [https://pubmed.ncbi.nlm.nih.gov/24379055/]

---

## Astaxanthin (Haematococcus pluvialis (algal source))
URL: https://nutridex.info/s/astaxanthin
Category: Joint & Skin, Longevity
Evidence: Preliminary — Early or small human trials; promising but not yet conclusive.
Marine carotenoid for skin elasticity and UV defense

Quick answer: Astaxanthin is used for may improve elasticity & moisture. NutriDex grades the human evidence as preliminary — Early or small human trials; promising but not yet conclusive. Based on 20 cited human studies (20 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Astaxanthin is a red xanthophyll carotenoid, usually from the microalga Haematococcus pluvialis, valued as a potent lipid-soluble antioxidant. Small RCTs suggest oral supplementation can modestly improve skin moisture and elasticity and may reduce crow's-feet wrinkles; a 2021 meta-analysis found significant pooled effects for moisture and elasticity but not wrinkle depth. A placebo-controlled trial also reported reduced UV-induced moisture loss and a higher minimal erythema dose. Its proposed mechanism is quenching of reactive oxygen and singlet oxygen. Evidence is weak: trials are small, often enroll mostly Japanese women, and several carry industry funding.

Benefits / uses: May improve elasticity & moisture; Reduces appearance of fine lines; Supports photoprotection; Potent ROS-quenching antioxidant.
Active compounds: Astaxanthin (xanthophyll carotenoid).
Dose: 4–12 mg/day (most trials used 4–6 mg/day).
Safety: Generally well tolerated at 4–12 mg/day. Mild GI upset and a harmless reddish skin tint possible at higher doses; may slightly lower blood pressure (caution with antihypertensives). Long-term data are limited and trials are often industry-funded; consult a clinician in pregnancy/lactation.

Cited studies (20):
  - Assessing the Effects of Moderate to High Dosage of Astaxanthin Supplementation on Lipid Profile Parameters-A Systematic Review and Meta-Analysis of Randomized Controlled Studies, Pharmaceuticals (Basel, Switzerland) (2025) — Meta-analysis of 8 RCTs (moderate-to-high dose 6-24 mg/d) found astaxanthin significantly raised HDL-C (SMD 0.42; 95% CI 0.11 to 0.73) and lowered triglycerides (SMD -0.31; 95% CI -0.51 to -0.10), with no significant effect on LDL-C or total cholesterol. [https://pubmed.ncbi.nlm.nih.gov/40872489/]
  - Exploring the benefits of astaxanthin as a functional food ingredient: Its effects on oxidative stress and reproductive outcomes in women with PCOS - A systematic review and single-arm meta-analysis of randomized clinical trials, Naunyn-Schmiedeberg's archives of pharmacology (2025) — Single-arm meta-analysis of 4 RCTs in women with PCOS found astaxanthin improved follicular-fluid total antioxidant capacity and modestly increased oocyte quality and high-quality embryos, but had inconsistent effects on malondialdehyde/SOD and no significant effect on fertilization or pregnancy rates. [https://pubmed.ncbi.nlm.nih.gov/39269488/]
  - Effects of Astaxanthin Supplementation on Fatigue, Motor Function and Cognition: A Meta-Analysis of Randomized Controlled Trials, Biological research for nursing (2024) — Meta-analysis of 11 RCTs (346 healthy adults) found astaxanthin plus training significantly enhanced fat oxidation (SMD 2.56) and physical performance (SMD 0.62), but only marginally improved cognitive accuracy (SMD 0.12; 95% CI -0.02 to 0.26) with no effect on reaction time. [https://pubmed.ncbi.nlm.nih.gov/38243785/]
  - Effects of Astaxanthin Supplementation on Glycemic Control and Lipid Profile in Patients With Prediabetes and Type 2 Diabetes: A Meta-Analysis of Randomized Controlled Trials, Nutrition and Metabolic Insights (2026) — Meta-analysis of 9 RCTs (403 patients with prediabetes/type 2 diabetes) found astaxanthin reduced fasting glucose (~16 mg/dL; p=0.014), HbA1c (-0.34%; p=0.011), triglycerides, total cholesterol and LDL-C, and raised HDL-C, but did not alter insulin or HOMA-IR. [https://doi.org/10.1177/11786388261432862]
  - Effectiveness of dietary supplements for skin photoaging in healthy adults: a systematic review and meta-analysis of randomized controlled trials, Frontiers in medicine (2025) — Meta-analysis of 40 RCTs (n=2,119 healthy adults); astaxanthin assessed in 3 trials (n=102, 2-4 mg, 6-12 wk) and the authors concluded there is currently insufficient evidence to recommend astaxanthin for treating skin photoaging. [https://pubmed.ncbi.nlm.nih.gov/40761858/]
  - The Role of Astaxanthin as an Antioxidant and Anti-Inflammatory Agent in Human Health: A Systematic Review, International journal of molecular sciences (2026) — Systematic review of 15 human studies (2020-2025) reported astaxanthin consistently reduced pro-inflammatory cytokines (IL-6, TNF-alpha, TGF-beta1) and oxidative stress indices while increasing antioxidant capacity (SOD, TAC). [https://pmc.ncbi.nlm.nih.gov/articles/PMC12840775/]
  - Antioxidant Lipid Supplement on Cardiovascular Risk Factors: A Systematic Review and Meta-Analysis, Nutrients (2024) — Meta-analysis of antioxidant lipid RCTs (search through May 2024): astaxanthin vs placebo significantly lowered LDL-C (-0.11 mmol/L), total cholesterol (-0.22 mmol/L), triglycerides (-0.46 mmol/L) and fasting insulin (-2.66 pmol/L), and raised HDL-C (+0.13 mmol/L). [https://pubmed.ncbi.nlm.nih.gov/39064656/]
  - Systematic Review and Meta-Analysis on the Effects of Astaxanthin on Human Skin Ageing, Nutrients (2021) — Meta-analysis of 11 trials found oral astaxanthin significantly improved skin moisture (SMD 0.53) and elasticity (SMD 0.77); wrinkle depth not significant. [https://pmc.ncbi.nlm.nih.gov/articles/PMC8472736/]
  - Astaxanthin Influence on Health Outcomes of Adults at Risk of Metabolic Syndrome: A Systematic Review and Meta-Analysis, Nutrients (2022) — Meta-analysis of 7 RCTs (321 adults at risk of metabolic syndrome) found only marginal reductions in systolic blood pressure (p=0.05) and total cholesterol, no significant effect on fasting glucose or HDL-C, and an unexpected LDL-C increase. [https://pmc.ncbi.nlm.nih.gov/articles/PMC9148008/]
  - Impact of astaxanthin supplementation on blood pressure: A systematic review and meta-analysis of randomized controlled trials, Journal of Functional Foods (2021) — Meta-analysis of 10 RCTs (493 participants) found astaxanthin only marginally reduced diastolic blood pressure (mean difference -1.21 mmHg; 95% CI -2.51 to 0.09) with no significant effect on systolic blood pressure; effect stronger in non-healthy and Asian subgroups. [https://doi.org/10.1016/j.jff.2021.104860]
  - Astaxanthin supplementation mildly reduced oxidative stress and inflammation biomarkers: a systematic review and meta-analysis of randomized controlled trials, Nutrition research (New York, N.Y.) (2022) — Meta-analysis of 12 RCTs (380 participants) found astaxanthin significantly lowered malondialdehyde (SMD -0.95; 95% CI -1.67 to -0.23) and reduced IL-6 in type 2 diabetics, but had no significant effect on CRP or TNF-alpha. [https://pubmed.ncbi.nlm.nih.gov/35091276/]
  - Systematic Review and Meta-Analysis on the Effects of Astaxanthin on Human Skin Ageing, Nutrients (2021) — Systematic review and meta-analysis found oral astaxanthin significantly restored skin moisture content (SMD=0.53; 95% CI 0.05-1.01; p=0.03) and improved elasticity (SMD=0.77; 95% CI 0.19-1.35; p=0.009) but did not significantly reduce wrinkle depth. [https://pmc.ncbi.nlm.nih.gov/articles/PMC8472736/]
  - The effects of astaxanthin supplementation on obesity, blood pressure, CRP, glycemic biomarkers, and lipid profile: A meta-analysis of randomized controlled trials, Pharmacological research (2020) — Meta-analysis of 14 RCTs: astaxanthin increased HDL-C (WMD +1.47 mg/dL; 95% CI 0.32-2.63; P=.012) and lowered CRP only at longer duration (>=12 weeks: WMD -0.53 mg/L) and higher dose (>12 mg/day: WMD -0.39); no significant effect on fasting glucose, HbA1c, total/LDL cholesterol, triglycerides, BMI, weight, or blood pressure. [https://pubmed.ncbi.nlm.nih.gov/32755613/]
  - Astaxanthin Influence on Health Outcomes of Adults at Risk of Metabolic Syndrome: A Systematic Review and Meta-Analysis, Nutrients (2022) — Systematic review/meta-analysis of 7 RCTs (n=321) in adults at risk of metabolic syndrome: astaxanthin produced a significant reduction in LDL cholesterol and marginal reductions in total cholesterol and systolic blood pressure; authors note further robust evidence is needed. [https://pubmed.ncbi.nlm.nih.gov/35631193/]
  - Systematic Review and Meta-Analysis on the Effects of Astaxanthin on Human Skin Ageing, Nutrients (2021) — Systematic review/meta-analysis of 11 human studies (9 RCTs): oral astaxanthin significantly improved skin elasticity (SMD 0.77; 95% CI 0.19-1.35; P=.009) and moisture content (SMD 0.53; P=.03) versus placebo, but did not significantly reduce wrinkle depth (SMD -0.26; P=.11). [https://pubmed.ncbi.nlm.nih.gov/34578794/]
  - Astaxanthin, a natural antioxidant, lowers cholesterol and markers of cardiovascular risk in individuals with prediabetes and dyslipidaemia, Diabetes, obesity & metabolism (2023) — Double-blind RCT in 34 adults with prediabetes and dyslipidaemia (12 mg/day, 24 wk) significantly lowered LDL-C and total cholesterol and improved cardiovascular risk markers (fibrinogen, L-selectin, fetuin-A) with good tolerability. [https://pubmed.ncbi.nlm.nih.gov/36999233/]
  - Efficacy and Safety of Astaxanthin in the Management of Oral Submucous Fibrosis: A Preliminary Randomized Controlled Trial, Cureus (2024) — Double-blind placebo-controlled RCT (n=68, 5 mg twice daily for 12 weeks) in oral submucous fibrosis found astaxanthin produced statistically significant improvement in mouth opening and reduction in burning sensation versus control. [https://pmc.ncbi.nlm.nih.gov/articles/PMC10960228/]
  - The Protective Role of Astaxanthin for UV-Induced Skin Deterioration in Healthy People-A Randomized, Double-Blind, Placebo-Controlled Trial, Nutrients (2018) — RCT in 23 healthy Japanese adults (4 mg/day, 10 wk) increased minimal erythema dose and reduced UV-induced moisture loss vs placebo. (FUJIFILM-sponsored.) [https://pubmed.ncbi.nlm.nih.gov/29941810/]
  - The Protective Role of Astaxanthin for UV-Induced Skin Deterioration in Healthy People-A Randomized, Double-Blind, Placebo-Controlled Trial, Nutrients (2018) — 10-week double-blind placebo-controlled RCT (n=23 healthy adults, 4 mg/day) found the astaxanthin group had increased minimal erythema dose and reduced UV-induced loss of skin moisture in irradiated areas versus placebo. [https://pmc.ncbi.nlm.nih.gov/articles/PMC6073124/]
  - Cosmetic benefits of astaxanthin on humans subjects, Acta biochimica Polonica (2012) — Double-blind trial in 36 men (6 mg/day + topical, 6 wk) plus open study in 30 women improved crow's-feet wrinkles, elasticity, and transepidermal water loss. [https://pubmed.ncbi.nlm.nih.gov/22428137/]

---

## Polypodium leucotomos (Polypodium leucotomos (Fernblock))
URL: https://nutridex.info/s/polypodium
Category: Joint & Skin
Evidence: Moderate — Several controlled trials; effects real but modest or context-dependent.
Oral fern antioxidant that boosts skin's UV tolerance

Quick answer: Polypodium leucotomos is used for raises minimal erythema dose (less sunburn redness). NutriDex grades the human evidence as moderate — Several controlled trials; effects real but modest or context-dependent. Based on 18 cited human studies (18 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Polypodium leucotomos extract (marketed as Fernblock) is an oral antioxidant from a tropical fern, rich in phenolic acids. Human studies show it can raise the minimal erythema dose (MED) and reduce UV-induced erythema, indicating modest systemic photoprotection. It raised the UV threshold for provoking polymorphic light eruption in an open study, and a randomized melasma trial found it modestly improved pigmentation when added to hydroquinone and SPF 50+. It is an adjunct, NOT a replacement for sunscreen, and supporting trials are generally small and sometimes uncontrolled.

Benefits / uses: Raises minimal erythema dose (less sunburn redness); Adjunct for polymorphic light eruption; May aid melasma alongside hydroquinone + SPF; Systemic antioxidant vs UV damage.
Active compounds: Phenolic antioxidants (e.g. ferulic, caffeic acid).
Dose: 240–480 mg/day orally (often taken before sun exposure).
Safety: Well tolerated short-term with only occasional mild GI upset; long-term and pregnancy data are limited. Critically, it is an ADJUNCT and does NOT replace sunscreen, protective clothing, or sun avoidance — its photoprotection is only partial.

Cited studies (18):
  - The Utility of Oral Polypodium Leucotomos Extract for Dermatologic Diseases: A Systematic Review, Journal of drugs in dermatology : JDD (2025) — Systematic review of 21 studies (11 RCTs) found oral Polypodium leucotomos extract has photoprotective and immunomodulatory effects and serves as a beneficial adjuvant in photoaging, photodermatoses, melasma, vitiligo, psoriasis, and atopic dermatitis, with a strong safety profile. [https://pubmed.ncbi.nlm.nih.gov/40196953/]
  - Oral Supplements and Photoprotection: A Systematic Review, Journal of Medicinal Food (2024) — Systematic review of 47 studies on oral photoprotective supplements concluded the strongest evidence exists for polyphenols, carotenoids, and Polypodium leucotomos, which consistently raised minimal erythema dose and reduced UV-induced skin damage in healthy adults. [https://doi.org/10.1089/jmf.2024.0023]
  - Oral Supplements and Photoprotection: A Systematic Review, Journal of medicinal food (2025) — Systematic review of 47 human studies on oral photoprotective supplements concluded the strongest evidence of photoprotection exists for polyphenols, carotenoids, and Polypodium leucotomos. [https://pubmed.ncbi.nlm.nih.gov/39804624/]
  - Systematic Review on Dietary Supplements in the Prevention and/or Treatment of Actinic Keratosis and Field Cancerization, Actas dermo-sifiliograficas (2025) — PRISMA systematic review (PROSPERO-registered; 21 studies 2013-2023) of oral nutraceuticals for actinic keratosis and field cancerization. Concludes clinical trials demonstrate the efficacy of polyphenolic supplements including Polypodium leucotomos extract in improving skin health and reducing skin-cancer risk. (Source: PubMed) [https://pubmed.ncbi.nlm.nih.gov/39988198/]
  - Clinical Efficacy & Safety of Oral Polypodium Leucotomos Extract for Photoprotection: A Systematic Review, SKIN The Journal of Cutaneous Medicine (2018) — Systematic review of 18 human studies (Medline, Embase, Cochrane), predominantly using Fernblock/Heliocare, found oral Polypodium leucotomos extract consistently produced photoprotective effects (increased minimal erythema dose) with a favorable safety profile. [https://skin.dermsquared.com/skin/article/view/413]
  - Effects of Eight-Week Supplementation Containing Red Orange and Polypodium leucotomos Extracts on UVB-Induced Skin Responses: A Randomized Double-Blind Placebo-Controlled Trial, Nutrients (2025) — Randomized double-blind placebo-controlled trial (54 adults); 8 weeks of combined red orange and Polypodium leucotomos extract supplementation raised minimal erythema dose by 23.8% (p<0.05) and cut UVB-induced erythema intensity by 46.2% (p<0.0001). [https://pmc.ncbi.nlm.nih.gov/articles/PMC11990338/]
  - The combination of oral and topical photoprotection with a standardized Polypodium leucotomos extract is beneficial against actinic keratosis, Photodermatology, photoimmunology & photomedicine (2023) — Prospective, multicentre, randomized, three-arm trial (n=131) in older adults with severe actinic damage. Adding oral Fernblock (PLE) to topical photoprotection reduced new actinic keratosis lesions and field-cancerization parameters, with reflectance confocal microscopy showing keratinocyte-layer normalization; combined topical+oral outperformed topical alone. (Source: PubMed) [https://pubmed.ncbi.nlm.nih.gov/36892441/]
  - Effects of Eight-Week Supplementation Containing Red Orange and Polypodium leucotomos Extracts on UVB-Induced Skin Responses: A Randomized Double-Blind Placebo-Controlled Trial, Nutrients (2025) — Randomized, double-blind, placebo-controlled trial (n=54, phototypes I-III) of an 8-week PLE + red orange extract + vitamins A/C/D/E supplement. Intervention group showed a significant 23.8% increase in minimal erythema dose and a 46.2% reduction in UVB-induced erythema versus placebo, without affecting tanning. (Source: PubMed) [https://pubmed.ncbi.nlm.nih.gov/40218997/]
  - NB-UVB plus oral Polypodium leucotomos extract display higher efficacy than NB-UVB alone in patients with vitiligo, Dermatologic therapy (2021) — Randomized placebo-controlled trial (44 generalized vitiligo patients); 480 mg oral PLE twice daily added to NB-UVB for 6 months raised the response rate to 47.8% versus 22% with NB-UVB plus placebo. [https://pubmed.ncbi.nlm.nih.gov/33433041/]
  - Double-blind, Placebo-controlled Trial to Evaluate the Effectiveness of Polypodium Leucotomos Extract in the Treatment of Melasma in Asian Skin: A Pilot Study, The Journal of Clinical and Aesthetic Dermatology (2018) — Double-blind RCT (40 women with melasma); 480 mg PLE twice daily for 12 weeks added to 4% hydroquinone + SPF 50+ gave greater mMASI reduction (54.9% vs 44.4% placebo). [https://jcadonline.com/effectiveness-polypodium-leucotomos-extract-melasma-asian-skin/]
  - Safety and Efficacy of Oral Polypodium leucotomos Extract in Healthy Adult Subjects, The Journal of clinical and aesthetic dermatology (2015) — Randomized double-blind placebo-controlled trial in healthy adults (Fitzpatrick I-IV); 240 mg oral PLE twice daily for 60 days made subjects ~22-fold more likely to show an increased minimal erythema dose (8 vs 1, p=0.01) and ~15-fold more likely to have reduced UV-induced erythema, with no safety changes. [https://pubmed.ncbi.nlm.nih.gov/25741399/]
  - Double-blind, Placebo-controlled Trial to Evaluate the Effectiveness of Polypodium Leucotomos Extract in the Treatment of Melasma in Asian Skin: A Pilot Study, The Journal of clinical and aesthetic dermatology (2018) — Double-blind, placebo-controlled pilot RCT (n=40) of oral PLE added to topical 4% hydroquinone and SPF50+ in Asian melasma patients. PLE significantly lowered modified MASI versus placebo at 8 and 12 weeks, accelerating improvement from the first month, with improved MelasQoL and no significant side effects. (Source: PubMed) [https://pubmed.ncbi.nlm.nih.gov/29606995/]
  - A randomized, double-blinded, placebo-controlled trial of oral Polypodium leucotomos extract as an adjunct to sunscreen in the treatment of melasma, JAMA dermatology (2013) — Landmark randomized, double-blind, placebo-controlled trial of oral PLE 240 mg twice daily as an adjunct to SPF45 sunscreen in epidermal melasma. PLE group showed a greater reduction in Melasma Area and Severity Index (MASI) than placebo, with no significant adverse effects, supporting oral PLE as a sunscreen adjunct. (Source: PubMed) [https://pubmed.ncbi.nlm.nih.gov/23740292/]
  - Treatment of vitiligo vulgaris with narrow-band UVB and oral Polypodium leucotomos extract: a randomized double-blind placebo-controlled study, Journal of the European Academy of Dermatology and Venereology : JEADV (2007) — Randomized double-blind placebo-controlled trial (50 vitiligo vulgaris patients); oral Polypodium leucotomos plus NB-UVB twice weekly increased head/neck repigmentation versus placebo (44% vs 27%; 50% vs 19% in compliant patients, P<0.002). [https://pubmed.ncbi.nlm.nih.gov/17659004/]
  - Clinical Applications of Polypodium leucotomos (Fernblock(®)): An Update, Life (Basel, Switzerland) (2023) — Narrative clinical review of standardized PLE (Fernblock) summarizing oral and topical use across photodermatoses, pigmentary disorders, and as an adjunct to photodynamic therapy for actinic keratoses/field cancerization, reporting consistent photoprotective and antioxidant benefit with a strong safety record. [https://pmc.ncbi.nlm.nih.gov/articles/PMC10381169/]
  - Uses of Polypodium leucotomos Extract in Oncodermatology, Journal of clinical medicine (2023) — Review of PLE in oncodermatology describing its antioxidant, photoprotective, antimutagenic, anti-inflammatory and immunoregulatory actions supporting prevention of skin cancers and photoaging when taken orally and/or applied topically. [https://pmc.ncbi.nlm.nih.gov/articles/PMC9861608/]
  - Oral administration of a hydrophilic extract of Polypodium leucotomos for the prevention of polymorphic light eruption, Journal of the American Academy of Dermatology (2012) — Open study in 35 patients with polymorphic light eruption; oral PL significantly raised the UV exposure needed to provoke lesions (UVA p=.005; UVB p=.047). [https://pubmed.ncbi.nlm.nih.gov/21696853/]
  - Oral polypodium leucotomos extract photoprotective activity in 57 patients with idiopathic photodermatoses, Giornale italiano di dermatologia e venereologia : organo ufficiale, Societa italiana di dermatologia e sifilografia (2011) — Open study in 57 patients with idiopathic photodermatoses; 480 mg/day reduced skin reaction/symptoms in ~74% (P<0.05), no side effects reported. [https://pubmed.ncbi.nlm.nih.gov/21505393/]

---

## Pycnogenol (Pine Bark) (Pinus pinaster extract)
URL: https://nutridex.info/s/pycnogenol
Category: Joint & Skin, Heart & Metabolic
Evidence: Preliminary — Early or small human trials; promising but not yet conclusive.
Pine-bark flavonoids for firmer, more hydrated skin

Quick answer: Pycnogenol (Pine Bark) is used for may improve elasticity & hydration. NutriDex grades the human evidence as preliminary — Early or small human trials; promising but not yet conclusive. Based on 18 cited human studies (18 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Pycnogenol is a standardized, single-company branded extract of French maritime pine bark rich in procyanidin flavonoids that act as antioxidants. Small trials report modest improvements in skin elasticity and hydration alongside increased collagen-I and hyaluronic-acid-synthase gene expression. In melasma, an early single-arm trial and a later placebo-controlled RCT (alongside standard triple cream + sunscreen) reported reduced pigmentation, though in the controlled trial both arms improved. Evidence is limited by small samples, short durations, and frequent sponsorship by the extract's manufacturer.

Benefits / uses: May improve elasticity & hydration; Antioxidant support vs photodamage; May reduce melasma area & pigment; Linked to collagen/HA gene expression.
Active compounds: Procyanidins / proanthocyanidins (flavonoids).
Dose: 75–150 mg/day (oral, often split).
Safety: Well tolerated in short trials (occasional mild GI upset, dizziness, headache); long-term data limited. May have mild antiplatelet and blood-pressure-lowering effects — caution with anticoagulants, before surgery, and with antidiabetic drugs. Not established as safe in pregnancy/breastfeeding. Many trials are small and manufacturer-funded, so effects may be overstated.

Cited studies (18):
  - Emerging Pharmacological Interventions for Chronic Venous Insufficiency: A Comprehensive Systematic Review and Meta-Analysis of Efficacy, Safety, and Therapeutic Advances, Pharmaceutics (2025) — Meta-analysis of emerging CVI pharmacological treatments (5 studies) ranked Pycnogenol among the two most promising; it significantly improved skin resting flux (mean difference 21.04, 95% CI 9.29 to 32.80) and showed favorable but non-significant trends for pain and edema. [https://pubmed.ncbi.nlm.nih.gov/39861707/]
  - Pycnogenol® French maritime pine bark extract in randomized, double-blind, placebo-controlled human clinical studies, Frontiers in Nutrition (2024) — Review of 39 randomized, double-blind, placebo-controlled trials reports that Pycnogenol supplementation improved skin elasticity by 13% (vs 1% placebo) and reduced transepidermal water loss by 14% (vs 5% placebo) over 3 months in outdoor workers. [https://www.frontiersin.org/journals/nutrition/articles/10.3389/fnut.2024.1389374/full]
  - Comparative efficacy and safety of botanical drugs for mild cognitive impairment: a systematic review and network meta-analysis, Frontiers in pharmacology (2025) — Bayesian network meta-analysis of 19 trials (4,956 participants) ranked Pycnogenol highest for improving cognitive function in mild cognitive impairment (SUCRA 98.8%) and activities of daily living (SUCRA 100%). [https://pmc.ncbi.nlm.nih.gov/articles/PMC12665759/]
  - Efficacy of L-arginine and Pycnogenol ® in the treatment of male erectile dysfunction: a systematic review and meta-analysis, Frontiers in endocrinology (2023) — Meta-analysis of 3 RCTs (184 men) found L-arginine plus Pycnogenol significantly improved IIEF erectile function domain scores (mean difference 8.9 points, 95% CI 4.14 to 13.66, p=0.0002) versus placebo. [https://pmc.ncbi.nlm.nih.gov/articles/PMC10614297/]
  - Does supplementation with pine bark extract improve cardiometabolic risk factors? A systematic review and meta-analysis, BMC complementary medicine and therapies (2025) — Meta-analysis of 27 RCTs (1685 participants): pine bark extract significantly reduced SBP (-2.26 mmHg), DBP (-2.62 mmHg), fasting blood glucose (-6.25 mg/dL), HbA1c (-0.32%), body weight (-1.37 kg), and LDL cholesterol (-5.07 mg/dL) vs control; no significant effect on BMI, waist circumference, insulin, HDL, triglycerides, or total cholesterol. [https://pubmed.ncbi.nlm.nih.gov/39987124/]
  - Pine bark (Pinus spp.) extract for treating chronic disorders, The Cochrane database of systematic reviews (2020) — Cochrane review of 27 RCTs (1641 participants) across 10 chronic disorders (asthma, ADHD, CVD, chronic venous insufficiency, diabetes, erectile/female sexual dysfunction, osteoarthritis, osteopenia, traumatic brain injury). All effects rated very low-certainty evidence; small samples, few trials per condition, and poor reporting mean no definitive conclusions on efficacy or safety of pine bark extract are possible. [https://pubmed.ncbi.nlm.nih.gov/32990945/]
  - Effect of Pycnogenol on Blood Pressure: Findings From a PRISMA Compliant Systematic Review and Meta-Analysis of Randomized, Double-Blind, Placebo-Controlled, Clinical Studies, Angiology (2020) — PRISMA-compliant meta-analysis of 7 randomized double-blind placebo-controlled trials (626 participants): pycnogenol showed NO significant effect on systolic BP (WMD -0.03 mmHg), diastolic BP (-0.14 mmHg), mean arterial pressure, or pulse pressure; results robust on leave-one-out sensitivity analysis. [https://pubmed.ncbi.nlm.nih.gov/31763928/]
  - Effect of Pycnogenol Supplementation on Blood Pressure: A Systematic Review and Meta-analysis, Iranian journal of public health (2018) — Pooled analysis of 9 trials (549 participants, 150-200 mg/day) found modest reductions in systolic (-3.22 mmHg, 95% CI -6.20 to -0.24) and diastolic blood pressure (-3.11 mmHg, 95% CI -4.60 to -1.62), with greater effect in hypertensives but not in well-designed trials. [https://pubmed.ncbi.nlm.nih.gov/30087862/]
  - The impact of pycnogenol supplementation on plasma lipids in humans: A systematic review and meta-analysis of clinical trials, Phytotherapy research : PTR (2019) — Meta-analysis of 14 trials (1,065 participants) found Pycnogenol significantly raised HDL-C (+3.27 mg/dL, 95% CI 0.19 to 6.36, p=0.038) but produced no clinically relevant change in total cholesterol, LDL-C, or triglycerides. [https://pubmed.ncbi.nlm.nih.gov/30456865/]
  - Effects of pycnogenol on cardiometabolic health: A systematic review and meta-analysis of randomized controlled trials, Pharmacological research (2019) — Meta-analysis of 24 RCTs (1,594 participants) found Pycnogenol significantly lowered fasting blood glucose (-5.86 mg/dl, 95% CI -9.56 to -2.15) and HbA1c (-0.29%, 95% CI -0.56 to -0.01), alongside reductions in systolic/diastolic BP, BMI, and LDL-C and a rise in HDL-C. [https://pubmed.ncbi.nlm.nih.gov/31585179/]
  - French maritime pine bark extract (pycnogenol) in association with triple combination cream for the treatment of facial melasma in women: a double-blind, randomized, placebo-controlled trial, Journal of the European Academy of Dermatology and Venereology (2020) — Double-blind RCT (44 women), 75 mg twice daily for 60 days as adjunct to triple cream + sunscreen; mMASI and QoL improved — but both pycnogenol and placebo arms improved. [https://onlinelibrary.wiley.com/doi/abs/10.1111/jdv.16896]
  - Pycnogenol® effects on skin elasticity and hydration coincide with increased gene expressions of collagen type I and hyaluronic acid synthase in women, Skin pharmacology and physiology (2012) — 12 weeks in 20 postmenopausal women improved skin elasticity and hydration (greatest in dry skin) with increased HAS-1 and collagen gene expression. [https://pubmed.ncbi.nlm.nih.gov/22270036/]
  - Effects of Pycnogenol on endothelial function in patients with stable coronary artery disease: a double-blind, randomized, placebo-controlled, cross-over study, European heart journal (2012) — Double-blind randomized placebo-controlled cross-over trial in 23 stable coronary artery disease patients found 200 mg/day for 8 weeks (on top of standard therapy) improved flow-mediated dilation from 5.3 to 7.0% (p<0.0001), with no improvement on placebo. [https://pubmed.ncbi.nlm.nih.gov/22240497/]
  - Treatment of melasma with Pycnogenol, Phytotherapy research : PTR (2002) — Single-arm 30-day trial in 30 women with melasma; mean melasma area fell 25.9 mm² and pigment intensity 0.47 unit (p<0.001). [https://pubmed.ncbi.nlm.nih.gov/12237816/]
  - Effect of pine bark extract (Pycnogenol) on symptoms of knee osteoarthritis, Phytotherapy research : PTR (2008) — Double-blind placebo-controlled trial in 100 knee osteoarthritis patients given 150 mg/day for 3 months significantly improved the WOMAC index and reduced VAS pain (p<0.04) while analgesic use fell in the treatment group but rose on placebo. [https://pubmed.ncbi.nlm.nih.gov/18570266/]
  - Pycnogenol improves microcirculation, retinal edema, and visual acuity in early diabetic retinopathy, Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics (2009) — Randomized controlled trial in 46 patients with early diabetic retinopathy (24 Pycnogenol vs 22 placebo) over 2-3 months significantly improved visual acuity (14/20 to 17/20), reduced retinal edema/thickness, and raised central retinal artery flow velocity (34 to 44 cm/s) versus negligible placebo change. [https://pubmed.ncbi.nlm.nih.gov/19916788/]
  - Improvements in edema and microcirculation in chronic venous insufficiency with Pycnogenol® or elastic compression, Minerva surgery (2024) — 4-month registry study (2 groups of 30 CVI patients) found Pycnogenol reduced evening leg volume by 18.3% vs 4.4% with elastic compression, with significantly improved skin PO2/PCO2 and lower symptom and VCSS scores (P<0.05); compression was poorly tolerated (12/30 could not complete). [https://pubmed.ncbi.nlm.nih.gov/38953757/]
  - Pycnogenol® relieves chronic venous insufficiency (CVI) in diabetics: a supplement registry study, Minerva surgery (2025) — 8-week registry study in 58 diabetics with CVI (28 Pycnogenol 150 mg/day vs 30 compression controls) showed significant improvement in resting flux, rate of ankle swelling, transcutaneous PO2/PCO2 and symptom/VCSS/VDS scores (P<0.05) with no adverse effects. [https://pubmed.ncbi.nlm.nih.gov/39259145/]

---

## Vitamin E (Tocopherol) (Alpha-tocopherol)
URL: https://nutridex.info/s/vitamin-e
Category: Vitamin, Joint & Skin
Evidence: Mixed — Conflicting results across studies; benefit uncertain.
Real antioxidant, but the scar-fading reputation is largely a myth

Quick answer: Vitamin E (Tocopherol) is used for lipid-soluble antioxidant in skin. NutriDex grades the human evidence as mixed — Conflicting results across studies; benefit uncertain. Based on 20 cited human studies (20 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Vitamin E (alpha-tocopherol) is a genuine lipid-soluble antioxidant that neutralizes reactive oxygen species in skin lipids — the basis of most cosmetic claims. However, its most popular use, topical vitamin E for scars or wound healing, is not supported: the landmark Baumann 1999 RCT found no cosmetic benefit and caused contact dermatitis in about a third of patients. Oral supplementation for skin appearance has weak, indirect evidence. The strongest signal is photoprotection when topical vitamin E is combined with vitamin C, though much of that work is in animal or small models. High-dose oral vitamin E carries its own risks, including bleeding and an association with higher all-cause mortality at ≥400 IU/day.

Benefits / uses: Lipid-soluble antioxidant in skin; May aid topical photoprotection with vitamin C; Possible barrier-lipid support (thin proof); Popular for scars — but not supported.
Active compounds: Alpha-tocopherol; Mixed tocopherols/tocotrienols.
Dose: RDA ~15 mg/day (22.4 IU); doses ≥400 IU/day raise safety concerns.
Safety: Topical vitamin E commonly causes contact dermatitis (~1 in 3 in the Baumann scar trial). Oral vitamin E is safe at RDA levels (~15 mg/day), but high doses can increase bleeding risk (especially with anticoagulants or before surgery) and interfere with vitamin K; a 2005 meta-analysis linked ≥400 IU/day to higher all-cause mortality, so routine high-dose use for skin is not advisable.

Cited studies (20):
  - Vitamin E and Multiple Health Outcomes: An Umbrella Review of Meta-Analyses, Nutrients (2023) — Umbrella review of 32 meta-analyses (64 health outcomes): higher vitamin E intake/circulating tocopherol was inversely associated with several cancers and Alzheimer's, but supplementation showed no benefit for cardiovascular mortality. [https://doi.org/10.3390/nu15153301]
  - Efficacy and Safety of Vitamin E in Adults With Metabolic Dysfunction-Associated Steatohepatitis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials, Cureus (2025) — Systematic review/meta-analysis of 3 RCTs found vitamin E significantly reduced ALT (MD -12.27, 95% CI -16.66 to -7.89) and increased odds of fibrosis improvement (OR 1.96, 95% CI 1.25-3.09, no heterogeneity). [https://pmc.ncbi.nlm.nih.gov/articles/PMC12394922/]
  - Impact of Tocopherol Supplementation on Clinical Parameters of Periodontal Disease: A Systematic Review and Meta-Analysis, Journal of personalized medicine (2024) — Systematic review and meta-analysis assessing tocopherol supplementation on clinical periodontal disease parameters in human trials. [https://pmc.ncbi.nlm.nih.gov/articles/PMC11508634/]
  - Vitamin E supplementation (alone or with other antioxidants) and stroke: a meta-analysis, Nutrition reviews (2024) — Meta-analysis of 16 RCTs (doses 33-800 IU): vitamin E alone did not reduce ischemic or hemorrhagic stroke. Combined with other antioxidants it modestly reduced ischemic stroke (RR 0.91, 95% CI 0.84-0.99) but increased hemorrhagic stroke (RR 1.22, 95% CI 1.0-1.48), nullifying net benefit; not recommended for stroke prevention. [https://pubmed.ncbi.nlm.nih.gov/37698992/]
  - From A to E: Uniting vitamins against stroke risk-A systematic review and network meta-analysis, European journal of clinical investigation (2024) — Network meta-analysis of 56 studies (17 RCTs, 39 cohorts) on vitamins and stroke prevention found no significant association between vitamin E and reduced stroke risk (ranked near placebo, p-score 0.28), in contrast to vitamins C and D. [https://pubmed.ncbi.nlm.nih.gov/38291560/]
  - Systematic review with meta-analysis: The effect of vitamin E supplementation in adult patients with non-alcoholic fatty liver disease, Journal of gastroenterology and hepatology (2021) — Meta-analysis of RCTs in adults with NAFLD: vitamin E significantly reduced serum ALT and AST versus placebo and improved histologic steatosis/inflammation, especially in NASH. [https://pubmed.ncbi.nlm.nih.gov/32810309/]
  - The fractional amplitude of low-frequency fluctuations signals related to amyloid uptake in high-risk populations-A pilot fMRI study, Frontiers in aging neuroscience (2022) — Meta-analysis (13 cohorts, ~46,968 participants): highest vs lowest vitamin E intake was associated with ~21% lower dementia risk (OR 0.79, 95% CI 0.70-0.88) and ~22% lower Alzheimer's risk (OR 0.78, 0.64-0.94). [https://pubmed.ncbi.nlm.nih.gov/35966783/]
  - Serum vitamin E levels and chronic inflammatory skin diseases: A systematic review and meta-analysis, PloS one (2021) — Systematic review/meta-analysis (20 studies) found lower serum vitamin E in patients with vitiligo (SMD -0.70), psoriasis (SMD -2.73), atopic dermatitis (SMD -1.08), and acne (SMD -0.67) versus controls. [https://pmc.ncbi.nlm.nih.gov/articles/PMC8670689/]
  - Vitamin E for antipsychotic-induced tardive dyskinesia, The Cochrane database of systematic reviews (2018) — Cochrane review of 13 RCTs found no clear benefit of vitamin E over placebo for clinically important improvement of antipsychotic-induced tardive dyskinesia; evidence weak and inconclusive. [https://pubmed.ncbi.nlm.nih.gov/29341067/]
  - Scientific opinion on the tolerable upper intake level for vitamin E, EFSA journal. European Food Safety Authority (2024) — EFSA retained a tolerable upper intake level of 300 mg/day alpha-tocopherol for adults, citing impaired blood clotting and bleeding risk as the critical adverse effect. [https://pubmed.ncbi.nlm.nih.gov/39099617/]
  - Effects of vitamin E on stroke subtypes: meta-analysis of randomised controlled trials, BMJ (Clinical research ed.) (2010) — Meta-analysis of 9 RCTs (118,765 participants): vitamin E increased hemorrhagic stroke risk by ~22% (RR 1.22) while reducing ischemic stroke ~10% (RR 0.90), with no effect on total stroke. [https://pubmed.ncbi.nlm.nih.gov/21051774/]
  - Vitamin, Mineral, and Multivitamin Supplementation to Prevent Cardiovascular Disease and Cancer: US Preventive Services Task Force Recommendation Statement, JAMA (2022) — US Preventive Services Task Force recommends AGAINST vitamin E supplements for primary prevention of cardiovascular disease or cancer, finding no net benefit after reviewing 52 new studies. [https://pubmed.ncbi.nlm.nih.gov/35727271/]
  - Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality, Annals of internal medicine (2005) — Meta-analysis of 19 trials (135,967 participants): high-dose vitamin E (≥400 IU/day) was associated with increased all-cause mortality. [https://pubmed.ncbi.nlm.nih.gov/15537682/]
  - Vitamin E (300 mg) in the treatment of MASH: A multi-center, randomized, double-blind, placebo-controlled study, Cell reports. Medicine (2025) — Multi-center double-blind RCT in 124 non-diabetic biopsy-proven MASH patients: vitamin E 300 mg/day met the primary histologic endpoint in 29.3% vs 14.1% on placebo, with significant improvement in steatosis, lobular inflammation, and fibrosis stage. [https://pmc.ncbi.nlm.nih.gov/articles/PMC11866479/]
  - Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT), JAMA (2011) — In the SELECT trial (35,533 healthy men), vitamin E 400 IU/day significantly increased prostate cancer risk versus placebo (HR 1.17; absolute increase ~1.6 per 1,000 person-years). [https://pubmed.ncbi.nlm.nih.gov/21990298/]
  - Lutein + zeaxanthin and omega-3 fatty acids for age-related macular degeneration: the Age-Related Eye Disease Study 2 (AREDS2) randomized clinical trial, JAMA (2013) — AREDS2 RCT (4,203 participants at risk of late AMD): adding lutein+zeaxanthin and/or omega-3 to the AREDS formula (which contains 400 IU vitamin E) did not further reduce progression to advanced AMD. [https://pubmed.ncbi.nlm.nih.gov/23644932/]
  - Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis, The New England journal of medicine (2010) — In 247 non-diabetic adults with biopsy-proven NASH, vitamin E 800 IU/day for 96 weeks improved NASH histology in 43% vs 19% on placebo (P=0.001), with reductions in steatosis, lobular inflammation, and serum ALT/AST; no improvement in fibrosis. Landmark trial establishing vitamin E as first-line pharmacotherapy for non-diabetic NASH. [https://pubmed.ncbi.nlm.nih.gov/20427778/]
  - Effect of vitamin E and memantine on functional decline in Alzheimer disease: the TEAM-AD VA cooperative randomized trial, JAMA (2014) — In 613 patients with mild-to-moderate Alzheimer disease, alpha-tocopherol 2000 IU/day slowed functional decline on the ADCS-ADL inventory by ~19% vs placebo over a mean 2.3 years (a delay of ~6.2 months), without cognitive benefit and without increased mortality. [https://pubmed.ncbi.nlm.nih.gov/24381967/]
  - The effects of topical vitamin E on the cosmetic appearance of scars, Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.] (1999) — Double-blind split-scar RCT in 15 patients: topical vitamin E gave no cosmetic benefit (worse or unchanged in 90%) and caused contact dermatitis in 33%. [https://pubmed.ncbi.nlm.nih.gov/10417589/]
  - UV photoprotection by combination topical antioxidants vitamin C and vitamin E, Journal of the American Academy of Dermatology (2003) — Topical 15% vitamin C + 1% alpha-tocopherol on skin gave ~4-fold antioxidant protection against UV erythema and DNA damage, beating either alone. [https://pubmed.ncbi.nlm.nih.gov/12789176/]

---

## Evening Primrose Oil (GLA) (Oenothera biennis)
URL: https://nutridex.info/s/evening-primrose
Category: Joint & Skin
Evidence: Mixed — Conflicting results across studies; benefit uncertain.
Popular eczema remedy that high-quality trials don't support

Quick answer: Evening Primrose Oil (GLA) is used for traditionally used for eczema (not supported). NutriDex grades the human evidence as mixed — Conflicting results across studies; benefit uncertain. Based on 16 cited human studies (16 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Evening primrose oil is a seed oil rich in the omega-6 fatty acid gamma-linolenic acid (GLA), long marketed for eczema on the theory that atopic skin has reduced delta-6-desaturase activity. Despite its popularity, the definitive 2013 Cochrane review of 27 RCTs (1,596 participants) concluded oral evening primrose oil and borage oil are not effective for eczema. Some smaller trials and mechanistic studies report benefit, but they are small, often open-label, and limited in quality. The overall evidence for skin claims is weak and conflicting rather than supportive.

Benefits / uses: Traditionally used for eczema (not supported); May modestly raise skin GLA/DGLA; Also taken for PMS/breast tenderness (weak evidence).
Active compounds: Gamma-linolenic acid (GLA); Linoleic acid.
Dose: Commonly 4–6 g oil/day (~320–480 mg GLA).
Safety: Generally well tolerated; mild, temporary GI upset is most common. GLA can affect platelet function, so it may increase bleeding risk and potentiate warfarin/antiplatelet drugs — caution before surgery. Older reports suggest it may lower the seizure threshold (caution in epilepsy or with phenothiazines). Not a replacement for proven eczema therapy.

Cited studies (16):
  - The effect of Oenothera biennis (Evening primrose) oil on inflammatory diseases: a systematic review of clinical trials, BMC complementary medicine and therapies (2024) — Systematic review of clinical trials on EPO across inflammatory disorders found some signal in atopic eczema, menopausal hot flashes, mastalgia and diabetes, but highly heterogeneous evidence and no strong recommendation of efficacy; ineffective for PMS, psoriasis, acne, hand dermatitis and others. [https://pubmed.ncbi.nlm.nih.gov/38360611/]
  - Evening Primrose Oil for Menopause Hot Flashes: Systematic Review and Meta-Analysis, Journal of Menopausal Medicine (2024) — Systematic review and meta-analysis of RCTs found EPO modestly lowered hot-flash severity when used under 6 months versus placebo, but showed no significant effect on hot-flash frequency or duration in menopausal women. [https://doi.org/10.6118/jmm.23038]
  - The effect of Oenothera biennis (Evening primrose) oil on inflammatory diseases: a systematic review of clinical trials, BMC complementary medicine and therapies (2024) — Systematic review of clinical trials on Oenothera biennis (evening primrose) oil across inflammatory diseases (including atopic dermatitis and rheumatoid arthritis) found the literature highly heterogeneous and unable to support a strong recommendation for efficacy. [https://pmc.ncbi.nlm.nih.gov/articles/PMC10867995/]
  - Ranking Alpha Lipoic Acid and Gamma Linolenic Acid in Terms of Efficacy and Safety in the Management of Adults With Diabetic Peripheral Neuropathy: A Systematic Review and Network Meta-analysis, Canadian journal of diabetes (2024) — Systematic review and network meta-analysis (11 studies) ranking alpha-lipoic acid versus gamma-linolenic acid for diabetic peripheral neuropathy; ALA 600 mg/day lowered Total Symptom Score by ~1.05 points, with GLA evidence weaker and sparser. [https://pubmed.ncbi.nlm.nih.gov/38295879/]
  - The Effect of Evening Primrose Oil on Menopausal Symptoms Management: A Systematic Review and Meta-Analysis, Journal of caring sciences (2025) — Systematic review/meta-analysis of 6 RCTs (450 women) on menopausal symptoms. EPO reduced hot-flash frequency by a mean of 2.13/day vs control but this was NOT statistically significant; intensity reduced by 0.19 (also non-significant); a significant reduction in hot-flash duration was seen. Evidence graded moderate-to-low. DOI: https://doi.org/10.34172/jcs.025.33570 [https://pubmed.ncbi.nlm.nih.gov/41883983/]
  - A Systematic Review and Meta-Analysis of the Efficacy of Evening Primrose Oil for Mastalgia Treatment, International journal of environmental research and public health (2021) — Meta-analysis of 13 RCTs (1,752 patients): EPO was no better than placebo or other treatments (danazol, topical NSAIDs, vitamin E) for reducing mastalgia, with no difference in pain relief or adverse events. [https://pubmed.ncbi.nlm.nih.gov/34200727/]
  - The effect of evening primrose oil on labor induction and cervical ripening: A systematic review and meta-analysis, Phytotherapy research : PTR (2021) — Systematic review and meta-analysis (six studies; four pooled) found oral evening primrose oil produced no significant improvement in cervical ripening (Bishop score; SMD 0.27, 95% CI -0.41 to 0.96, p=0.43) for labor induction, with very high heterogeneity. [https://pubmed.ncbi.nlm.nih.gov/33913585/]
  - Oral evening primrose oil and borage oil for eczema, The Cochrane database of systematic reviews (2013) — Systematic review of 27 RCTs (1,596 participants); oral evening primrose oil and borage oil were no more effective than placebo for eczema. [https://pubmed.ncbi.nlm.nih.gov/23633319/]
  - Herbal therapy for treating rheumatoid arthritis, The Cochrane database of systematic reviews (2011) — Cochrane systematic review of herbal therapy for rheumatoid arthritis: in higher-quality studies, gamma-linolenic acid (from evening primrose, borage or blackcurrant seed oil) reduced pain, joint tenderness and morning stiffness versus placebo, but with more adverse events (about 20% vs 3%) and low-quality evidence overall. [https://pubmed.ncbi.nlm.nih.gov/21328257/]
  - Oral essential fatty acid supplementation in atopic dermatitis-a meta-analysis of placebo-controlled trials, The British journal of dermatology (2004) — Meta-analysis of placebo-controlled trials in atopic dermatitis. Pooled effect size of GLA supplementation on overall AD severity (11 trials) was only 0.15 (95% CL -0.02 to 0.32), not statistically significant; no benefit on itch, scaling, or lichenification. Concluded essential fatty acid supplementation has no clinically relevant effect on AD severity. DOI: https://doi.org/10.1111/j.0007-0963.2004.05851.x [https://pubmed.ncbi.nlm.nih.gov/15099370/]
  - Effects of evening primrose oil on treating painful diabetic neuropathy: a randomized, double-blind, clinical trial, Journal of complementary & integrative medicine (2025) — 4-week double-blind RCT in 66 patients with painful diabetic neuropathy: EPO 1,000 mg reduced neuropathic pain more than placebo, with twice-daily dosing outperforming once-daily dosing. [https://pubmed.ncbi.nlm.nih.gov/40418820/]
  - Anti-inflammatory effect of combining fish oil and evening primrose oil supplementation on breast cancer patients undergoing chemotherapy: a randomized placebo-controlled trial, Scientific reports (2023) — Parallel, randomized, double-blind, placebo-controlled 12-week trial (n=32) in breast cancer patients on chemotherapy: combined fish oil plus evening primrose oil improved fatty-acid profiles and decreased inflammatory markers such as IL-6. [https://pmc.ncbi.nlm.nih.gov/articles/PMC10119093/]
  - γ-Linolenic Acid versus α-Lipoic Acid for Treating Painful Diabetic Neuropathy in Adults: A 12-Week, Double-Placebo, Randomized, Noninferiority Trial, Diabetes & Metabolism Journal (2020) — 12-week double-blind noninferiority RCT (100 enrolled, 73 completed) in painful diabetic peripheral neuropathy: gamma-linolenic acid from evening primrose oil (320 mg/day GLA) was noninferior to alpha-lipoic acid for reducing pain intensity on VAS, with both treatments well tolerated. [https://www.e-dmj.org/journal/view.php?doi=10.4093%2Fdmj.2019.0099]
  - Evening primrose oil is effective in atopic dermatitis: a randomized placebo-controlled trial, Indian journal of dermatology, venereology and leprology (2008) — Small randomized placebo-controlled trial (50 patients); 96% of the EPO group vs 32% of placebo improved over 5 months — but the study was tiny and limited in quality. [https://pubmed.ncbi.nlm.nih.gov/19052401/]
  - Gamma-linolenic acid levels correlate with clinical efficacy of evening primrose oil in patients with atopic dermatitis, Advances in therapy (2014) — Open-label pilot (21 patients): the rise in plasma GLA inversely correlated with SCORAD reduction, but with no placebo comparison. [https://pmc.ncbi.nlm.nih.gov/articles/PMC3930832/]
  - Evening Primrose Oil: Usefulness and Safety, NIH National Center for Complementary and Integrative Health (2021) — The US National Center for Complementary and Integrative Health concludes there is not enough evidence to support evening primrose oil for any health condition; oral EPO has not been shown to relieve atopic dermatitis and is probably no more effective than placebo for breast pain, while it is probably safe for most adults (mainly mild GI side effects). [https://www.nccih.nih.gov/health/evening-primrose-oil]

---

## Phytoceramides (Plant glucosylceramides)
URL: https://nutridex.info/s/phytoceramides
Category: Joint & Skin
Evidence: Preliminary — Early or small human trials; promising but not yet conclusive.
Plant ceramides studied for skin hydration and barrier

Quick answer: Phytoceramides is used for may raise stratum corneum water content. NutriDex grades the human evidence as preliminary — Early or small human trials; promising but not yet conclusive. Based on 17 cited human studies (17 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Ceramides are sphingolipids that form a major part of the skin's barrier (stratum corneum), where they help retain water. Phytoceramides are plant-derived glucosylceramides (konjac, rice, wheat) taken orally on the premise that dietary sphingolipids support endogenous barrier lipids. Small placebo-controlled trials report increased hydration and reduced transepidermal water loss; a 2022 meta-analysis (7 trials, n=426) found a significant improvement in stratum-corneum water content and reduced TEWL. The evidence remains preliminary — trials are small, heterogeneous, and frequently manufacturer-conducted. Wheat-derived versions warrant caution for anyone with celiac disease or gluten sensitivity.

Benefits / uses: May raise stratum corneum water content; May reduce transepidermal water loss (TEWL); Supports barrier-lipid replenishment; Studied for dry, rough, aging skin.
Active compounds: Glucosylceramides (rice, wheat, konjac).
Dose: ~1.8–40 mg/day glucosylceramides (source-dependent).
Safety: Well tolerated in short trials at low doses, with no serious adverse events reported; evidence is preliminary and many studies are small and industry-funded. Wheat-derived phytoceramides can contain gluten — avoid with celiac disease or gluten sensitivity (rice/konjac versions are alternatives). Long-term safety is uncharacterized; consult a clinician in pregnancy/lactation.

Cited studies (17):
  - Dietary interventions in skin ageing: a systematic review and meta-analysis, Journal of physiological anthropology (2025) — Systematic review/meta-analysis of dietary skin-ageing interventions found the 'lipids and fatty acids' class (including rice ceramides and yeast glucosylceramides) significantly improved skin hydration (pooled SMD 0.54, p=4.4e-5) and elasticity (SMD 0.49, p=5.5e-3). [https://pmc.ncbi.nlm.nih.gov/articles/PMC12577306/]
  - Effectiveness of Dietary Supplement for Skin Moisturizing in Healthy Adults: A Systematic Review and Meta-Analysis of Randomized Controlled Trials, Frontiers in nutrition (2022) — Meta-analysis of oral ceramides (7 RCTs, n=426) showed increased stratum-corneum hydration (SMD 0.40, p=0.03) and reduced TEWL (SMD −0.29, p=0.003); heterogeneity was high. [https://pmc.ncbi.nlm.nih.gov/articles/PMC9201759/]
  - Effectiveness of Dietary Supplement for Skin Moisturizing in Healthy Adults: A Systematic Review and Meta-Analysis of Randomized Controlled Trials, Frontiers in nutrition (2022) — Systematic review and meta-analysis of 66 RCTs of oral skin-moisturizing supplements found that oral ceramide (alongside collagen) produced a statistically significant increase in skin hydration and a significant decrease in transepidermal water loss (TEWL) versus placebo; all supplements were safe over study durations of up to 24 weeks. [https://pubmed.ncbi.nlm.nih.gov/35719159/]
  - Efficacy and Safety of Oral Administration of Wine Lees Extract (WLE)-Derived Ceramides and Glucosylceramides in Enhancing Skin Barrier Function: A Randomized, Double-Blind, Placebo-Controlled Study, Nutrients (2024) — RCT in 30 adults with dry skin; 100 mg/day wine-lees ceramides for 12 weeks reduced TEWL vs placebo (p=0.04), though hydration did not differ. (Manufacturer-authored.) [https://pmc.ncbi.nlm.nih.gov/articles/PMC11243426/]
  - Oral intake of milk ceramides improves skin hydration, elasticity, and wrinkles around the eyes: A 12-week, randomized, double-blind, placebo-controlled trial, Journal of Functional Foods (2024) — 12-week double-blind RCT in women aged 30-65 with crow's feet; oral milk ceramides (600 mg/day) significantly lowered TEWL and raised skin moisture and elasticity vs placebo, with improved periocular wrinkle and roughness indices and no serious adverse events. [https://doi.org/10.1016/j.jff.2024.106008]
  - Dietary supplementation with a wheat polar lipid complex improves skin conditions in women with dry skin and mild-to-moderate skin aging, Journal of cosmetic dermatology (2024) — Double-blind randomized placebo-controlled trial in 72 women with dry, aging skin; a wheat polar lipid complex (oil or powder) increased skin hydration and elasticity and decreased TEWL, roughness and wrinkle depth from day 14 through day 56, but benefits were not maintained after stopping. (Manufacturer-authored, Seppic.) [https://pubmed.ncbi.nlm.nih.gov/38100124/]
  - Efficacy and Safety of Oral Administration of Wine Lees Extract (WLE)-Derived Ceramides and Glucosylceramides in Enhancing Skin Barrier Function: A Randomized, Double-Blind, Placebo-Controlled Study, Nutrients (2024) — In a 12-week randomized, double-blind, placebo-controlled trial of 30 healthy Japanese adults, oral wine lees extract-derived ceramides and glucosylceramides significantly lowered transepidermal water loss versus placebo (p=0.04), though secondary skin parameters did not differ. [https://pmc.ncbi.nlm.nih.gov/articles/PMC11243426/]
  - Efficacy and Safety of Oral Administration of Wine Lees Extract (WLE)-Derived Ceramides and Glucosylceramides in Enhancing Skin Barrier Function: A Randomized, Double-Blind, Placebo-Controlled Study, Nutrients (2024) — Randomized, double-blind, placebo-controlled study in 29 healthy Japanese adults: 12 weeks of oral plant-derived ceramides + glucosylceramides significantly lowered TEWL versus placebo (p=0.04; trend at 8 weeks p=0.07), with no supplement-related adverse events; secondary outcomes (hydration, itch VAS, Skindex-29) did not differ. [https://pubmed.ncbi.nlm.nih.gov/38999848/]
  - Scientific Opinion on the substantiation of a health claim related to Wheat Polar Lipid Extract and protection of the skin against dehydration pursuant to Article 13(5) of Regulation (EC) No 1924/2006, EFSA Journal (2012) — EFSA's Panel on Dietetic Products, Nutrition and Allergies concluded that a cause-and-effect relationship was NOT established between consumption of Wheat Polar Lipid Extract (containing glucosylceramides/ceramides) and protection of the skin against dehydration, judging the submitted human evidence insufficient. [https://doi.org/10.2903/j.efsa.2012.2773]
  - Potential benefits of oral administration of AMORPHOPHALLUS KONJAC glycosylceramides on skin health - a randomized clinical study, BMC complementary medicine and therapies (2020) — Placebo-controlled trial in 51 healthy adults given 100 mg/day konjac extract (5 mg plant glycosylceramides) for 6 weeks: oral intake significantly reduced skin dryness, hyperpigmentation, redness, itching and oiliness (p<0.05) in a time-dependent manner, with no adverse events. [https://pubmed.ncbi.nlm.nih.gov/32020853/]
  - The moisturizing effect of a wheat extract food supplement on women's skin: a randomized, double-blind placebo-controlled trial, International journal of cosmetic science (2011) — Randomized, double-blind, placebo-controlled trial in 51 women aged 20-63 with dry skin; 350 mg/day wheat extract oil capsules for 3 months significantly increased skin hydration on the arms (p<0.001) and legs (p=0.012) vs placebo. [https://pubmed.ncbi.nlm.nih.gov/20646083/]
  - Oral Intake of Glucosylceramide Improves Relatively Higher Level of Transepidermal Water Loss in Mice and Healthy Human Subjects, Journal of Health Science (2008) — RCT in 100 adults; konjac-derived glucosylceramide (1.8 mg/day) significantly lowered cheek TEWL vs control at weeks 8 and 12. [https://www.jstage.jst.go.jp/article/jhs/54/5/54_5_559/_article]
  - Ceramides and Skin Health: New Insights, Experimental Dermatology (2025) — Narrative review of ceramides in skin health concluding that ceramides (topical and dietary) support the moisture barrier, preserve hydration and reduce inflammation, and are used to repair barrier defects in atopic dermatitis and dry skin. [https://onlinelibrary.wiley.com/doi/10.1111/exd.70042]
  - Ceramides and Skin Health: New Insights, Experimental dermatology (2025) — A 2025 narrative review concludes oral rice ceramides and pineapple-derived glucosylceramides improve stratum corneum hydration and reduce transepidermal water loss, while noting human evidence remains limited and warrants larger trials. [https://pubmed.ncbi.nlm.nih.gov/39912256/]
  - Dietary Sphingolipids Contribute to Health via Intestinal Maintenance, International journal of molecular sciences (2021) — Review (Int J Mol Sci) concluding that dietary glucosylceramides/sphingolipids have low intestinal absorption but, after digestion to ceramides and sphingoid bases, support intestinal homeostasis (anti-inflammatory, anti-colon-cancer effects in animal models) and can reach skin to improve barrier function and moisture. [https://pmc.ncbi.nlm.nih.gov/articles/PMC8268314/]
  - Clinical significance of the water retention and barrier function-improving capabilities of ceramide-containing formulations: A qualitative review, The Journal of dermatology (2021) — Structured qualitative review (41 comparative studies; 12 selected by PICO) concluded that ceramide-containing preparations improve dry skin and barrier function (water retention, reduced TEWL), while noting that low stratum-corneum ceramide drives dry, barrier-disrupted skin and that larger double-blind trials are warranted. [https://pubmed.ncbi.nlm.nih.gov/34596254/]
  - Effect of Rice (Oryza sativa L.) Ceramides Supplementation on Improving Skin Barrier Functions and Depigmentation: An Open-Label Prospective Study, Nutrients (2022) — An open-label prospective study of oral rice (Oryza sativa) ceramide supplementation reported improved skin barrier function with reduced transepidermal water loss and depigmentation effects over the study period. [https://pmc.ncbi.nlm.nih.gov/articles/PMC9268538/]

---

## Biotin (Vitamin B7) (Vitamin B7 / H)
URL: https://nutridex.info/s/biotin
Category: Vitamin, Joint & Skin
Evidence: No Evidence — No credible human evidence supports the marketed claims — widely considered ineffective.
Ubiquitous in hair/nail pills, but only helps if you're deficient

Quick answer: Biotin (Vitamin B7) is marketed for reverses hair/nail problems caused by genuine deficiency. NutriDex grades the human evidence as no evidence — No credible human evidence supports the marketed claims — widely considered ineffective. Based on 17 cited human studies (17 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Biotin is a water-soluble B vitamin essential for metabolism, and true deficiency can cause hair loss and brittle nails that improve with repletion. However, deficiency is rare, and evidence that supplementation helps hair, skin, or nails in people who are not deficient is essentially absent — the Patel 2017 review found benefit only with an underlying deficiency. Despite this, biotin is near-universal in 'hair, skin, and nails' products, often at hundreds of times the ~30 mcg adequate intake. The most important real-world concern is laboratory interference: high-dose biotin can skew many immunoassays (troponin, thyroid, hormones), and the FDA warns this can cause missed or incorrect diagnoses.

Benefits / uses: Reverses hair/nail problems caused by genuine deficiency; Supports hair/nails in rare deficiency states (claimed); No proven cosmetic benefit at normal biotin levels.
Active compounds: Biotin (D-biotin).
Dose: Adequate intake ~30 mcg/day; megadoses (5–10 mg) sold for hair.
Safety: Direct toxicity is very low (excess is excreted; no upper limit set). The serious, under-recognized risk is lab-test interference: high-dose biotin distorts many immunoassays (troponin, thyroid, hormones), which the FDA warns can cause dangerous misdiagnoses. Stop biotin several days before lab work and tell your clinician you take it.

Cited studies (17):
  - Biotin for Hair Loss: Teasing Out the Evidence, The Journal of clinical and aesthetic dermatology (2024) — Systematic review of biotin for hair loss found only 3 eligible studies; the single double-blind placebo-controlled trial showed no difference between biotin and placebo for hair growth, with benefit only in biotin-deficient or pathology cases. [https://pubmed.ncbi.nlm.nih.gov/39148962/]
  - Efficacy of 5% topical minoxidil versus 5 mg oral biotin versus topical minoxidil and oral biotin on hair growth in men: randomized, crossover, clinical trial, Anais brasileiros de dermatologia (2024) — In a randomized crossover trial of 10 healthy men, oral biotin 5 mg/day alone did NOT increase hair growth velocity or coverage; only the minoxidil-plus-biotin combination improved hair growth (rate p=0.02; area p<0.01). [https://pubmed.ncbi.nlm.nih.gov/38688776/]
  - The Role of Sesbania grandiflora-Derived Biotin and Bambusa arundinacea-Derived Silica Extracts in Promoting Hair, Skin, and Nail Health: A Randomized, Double-Blind, Placebo-Controlled Clinical Study, Cureus (2025) — Randomized, double-blind, placebo-controlled trial (97 of 105 completing 90 days) found plant-derived biotin, alone or with silica, significantly reduced hair fall versus placebo (both p<0.001) with no adverse events. [https://pubmed.ncbi.nlm.nih.gov/40896024/]
  - The Role of Sesbania grandiflora-Derived Biotin and Bambusa arundinacea-Derived Silica Extracts in Promoting Hair, Skin, and Nail Health: A Randomized, Double-Blind, Placebo-Controlled Clinical Study, Cureus (2025) — 90-day randomized double-blind placebo-controlled trial (105 enrolled, 97 completed) of plant-derived biotin 1.25 mg +/- silica showed increased hair growth rate (~0.55-0.57 mm/day, p<0.0001) and reduced hair fall versus placebo. [https://pmc.ncbi.nlm.nih.gov/articles/PMC12397994/]
  - Safety and efficacy of MD1003 (high-dose biotin) in patients with progressive multiple sclerosis (SPI2): a randomised, double-blind, placebo-controlled, phase 3 trial, The Lancet. Neurology (2020) — Landmark phase 3 randomized, double-blind, placebo-controlled trial of high-dose pharmaceutical biotin (MD1003, 300 mg/day) in 642 progressive MS patients found no significant benefit: 12% (39/326) of biotin vs 9% (29/316) of placebo improved on disability/walking at 12 months (OR 1.35, 95% CI 0.81-2.26), and it caused assay interference, so it cannot be recommended. [https://pubmed.ncbi.nlm.nih.gov/33222767/]
  - Lab Tests Subject to Biotin Interference, U.S. Food and Drug Administration — High-dose biotin interferes with biotin-streptavidin immunoassays (troponin, TSH, hormones), causing falsely high/low results; the FDA linked one patient death to a falsely low troponin. [https://www.fda.gov/medical-devices/in-vitro-diagnostics/biotin-interference-troponin-lab-tests-assays-subject-biotin-interference]
  - Biotin - Health Professional Fact Sheet, NIH Office of Dietary Supplements (2020) — Authoritative US health-professional fact sheet states biotin deficiency is very rare in well-nourished populations, sets an Adequate Intake of 30 mcg/day for adults, notes no established tolerable upper level or identified toxicity at high doses, and reports that roughly one-third of pregnant women develop marginal deficiency despite adequate intake. [https://ods.od.nih.gov/factsheets/Biotin-HealthProfessional/]
  - MD1003 (high-dose biotin) for the treatment of progressive multiple sclerosis: A randomised, double-blind, placebo-controlled study, Multiple sclerosis (Houndmills, Basingstoke, England) (2016) — Earlier double-blind RCT (n=154) in progressive MS: 12.6% (13/103) of MD1003 high-dose biotin patients achieved confirmed disability reversal at month 9/12 vs 0% on placebo (p=0.005), with reduced EDSS progression; positive signal not replicated in the larger SPI2 trial. [https://pubmed.ncbi.nlm.nih.gov/27589059/]
  - An Analysis of the Biotin-(Strept)avidin System in Immunoassays: Interference and Mitigation Strategies, Current issues in molecular biology (2023) — Review of the biotin-(strept)avidin immunoassay system concludes high-dose biotin supplementation remains a clinically relevant source of false results, requiring assay redesign, depletion, or patient washout to meet FDA tolerance thresholds (~3510 ng/mL). [https://pubmed.ncbi.nlm.nih.gov/37998726/]
  - Biotin: a scoping review for Nordic Nutrition Recommendations 2023, Food & nutrition research (2024) — Scoping review for NNR 2023 found symptomatic biotin deficiency is rare and evidence for health benefits or for setting dietary reference values is limited, supporting no role for routine supplementation in healthy adults. [https://pmc.ncbi.nlm.nih.gov/articles/PMC10845898/]
  - Biotin: a scoping review for Nordic Nutrition Recommendations 2023, Food & nutrition research (2024) — Scoping review underpinning Nordic Nutrition Recommendations 2023 concluded symptomatic biotin deficiency is rare, few studies link biotin requirements to health outcomes, and data are insufficient to set firm dietary reference values — supporting adequate-intake (not RDA) guidance only. [https://pubmed.ncbi.nlm.nih.gov/38327992/]
  - Cardiac troponin, Clinica chimica acta; international journal of clinical chemistry (2025) — Review of cardiac troponin assays documents biotin as a clinically important cause of immunoassay interference (biotin-streptavidin based assays), producing false-negative troponin results that can mask acute myocardial infarction; supports stopping high-dose biotin before testing and mass-spectrometry alternatives. [https://pubmed.ncbi.nlm.nih.gov/40324612/]
  - Biotin interference in routine clinical immunoassays, Practical laboratory medicine (2025) — Study of clinical immunoassays found hemodialysis and ICU patients had elevated biotin causing assay interference; biotin depletion restored accuracy and authors recommend stopping biotin supplements >=72 h before testing. [https://pubmed.ncbi.nlm.nih.gov/40417451/]
  - A Review of the Use of Biotin for Hair Loss, Skin appendage disorders (2017) — Benefit for hair/nails appeared only in patients with an underlying biotin deficiency; insufficient evidence supports supplementation in healthy, non-deficient individuals. [https://pubmed.ncbi.nlm.nih.gov/28879195/]
  - Biotinidase Deficiency (2026) — Authoritative gene review establishing biotin as essential lifelong therapy for the inborn error biotinidase deficiency: oral free biotin 5-10 mg/day prevents and can reverse symptoms, and infants identified by newborn screening and treated promptly have normal development, whereas delay risks irreversible hearing loss and optic atrophy. [https://www.ncbi.nlm.nih.gov/books/NBK1322/]
  - Marginal biotin deficiency is teratogenic in mice and perhaps humans: a review of biotin deficiency during human pregnancy and effects of biotin deficiency on gene expression and enzyme activities in mouse dam and fetus, The Journal of nutritional biochemistry (2005) — Review concludes marginal biotin deficiency arises in about one-third of normal human pregnancies and, while subclinical in women, is demonstrably teratogenic in mice (cleft palate, limb hypoplasia), raising concern that maternal marginal deficiency could be teratogenic in humans. [https://pubmed.ncbi.nlm.nih.gov/15992686/]
  - Clinically Significant Lab Errors due to Vitamin B7 (Biotin) Supplementation: A Case Report Following a Recent FDA Warning, Cureus (2019) — Patient on 5 mg/day biotin had falsely abnormal TSH, PTH and calcium that normalized within a month of stopping — illustrating the FDA-warned interference. [https://pmc.ncbi.nlm.nih.gov/articles/PMC6802814/]

---

## Glutathione (Skin Whitening) (γ-L-glutamyl-L-cysteinylglycine)
URL: https://nutridex.info/s/glutathione
Category: Joint & Skin, Longevity
Evidence: Preliminary — Early or small human trials; promising but not yet conclusive.
Antioxidant tripeptide hyped for brightening; weak evidence, risky IV use

Quick answer: Glutathione (Skin Whitening) is used for may modestly, temporarily reduce skin melanin (oral, small trials). NutriDex grades the human evidence as preliminary — Early or small human trials; promising but not yet conclusive. Based on 18 cited human studies (18 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Glutathione is a naturally occurring tripeptide antioxidant that can inhibit melanin synthesis via the tyrosinase pathway, which is why it is marketed for skin lightening. However, oral glutathione is poorly absorbed (largely degraded in the gut), and the human evidence rests on a few small, short trials showing modest, transient reductions in melanin index; larger and combination trials often failed to reach significance. The bigger concern is intravenous glutathione for whitening, sold off-label with no validated dosing or convincing efficacy. Regulators including the Philippine FDA and US FDA warn that injectable glutathione for skin lightening is unapproved and linked to serious harms.

Benefits / uses: May modestly, temporarily reduce skin melanin (oral, small trials); Claimed 'brightening' (marketing, not robustly proven); Antioxidant that inhibits tyrosinase/melanin in vitro.
Active compounds: Glutathione (GSH); sometimes with vitamin C.
Dose: Studied oral doses ~250–500 mg/day for 4–12 weeks; IV/injectable is the dangerous off-label whitening route.
Safety: Oral glutathione at studied doses appears well tolerated short-term, but long-term cosmetic safety is unestablished and absorption is poor. The major danger is IV/injectable glutathione for whitening: NOT approved for this purpose, lacking validated dosing, and linked to severe skin reactions (SJS, TEN), anaphylaxis, hepatotoxicity, and renal/thyroid effects, plus infection from non-sterile 'drip' settings. Any lightening is temporary and reverses on stopping. Avoid IV glutathione for cosmetic whitening.

Cited studies (18):
  - Glutathione as a skin‐lightening agent and in melasma: a systematic review, International Journal of Dermatology (2024) — Systematic review (PubMed/Embase/Cochrane); across 5 RCTs plus 1 open-arm study, oral glutathione 250 mg once/twice daily or 500 mg/day significantly reduced the melanin index vs placebo, with topical 0.5% > 0.1% > placebo, but effects were modest and unsustained. [https://doi.org/10.1111/ijd.17535]
  - Systematic Review of the Efficacy and Safety of Topical Glutathione in Dermatology, The Journal of clinical and aesthetic dermatology (2025) — Systematic review of topical glutathione in dermatology found 2% oxidized glutathione lotion significantly lowered melanin index (p<0.05) in a 30-woman split-face trial and a combination cream reduced melanin index at 8 weeks, but evidence base remains small. [https://pubmed.ncbi.nlm.nih.gov/41416233/]
  - Systematic Review of the Efficacy and Safety of Topical Glutathione in Dermatology, The Journal of clinical and aesthetic dermatology (2025) — Systematic review of five clinical trials of topical glutathione found a 2% oxidized glutathione lotion significantly lowered melanin index from 272.77 +/- 26.17 at week 0 to 243.47 +/- 26.31 at week 10 (p<0.05), with effects localized to treated/sun-exposed skin. [https://pmc.ncbi.nlm.nih.gov/articles/PMC12710870/]
  - Glutathione as a skin-lightening agent and in melasma: a systematic review, International journal of dermatology (2025) — Systematic review of glutathione for skin-lightening/melasma: five RCTs plus one open-arm study of ORAL glutathione (250 mg once daily, 250 mg twice daily, and 500 mg once daily) showed a significant reduction in melanin index vs placebo; topical 2% plus oral combination was superior to monotherapy. Concluded oral/topical glutathione gives only moderate, unsustainable lightening, while IV glutathione is contraindicated (lack of efficacy and side effects). [https://pubmed.ncbi.nlm.nih.gov/39444151/]
  - The clinical effect of glutathione on skin color and other related skin conditions: A systematic review, Journal of cosmetic dermatology (2019) — Systematic review (4 studies; 3 placebo-controlled RCTs, 1 single-arm) found oral glutathione 500 mg/day (and topical 2.0% oxidized glutathione) significantly brightened skin in sun-EXPOSED areas by melanin index, with a trend toward improved wrinkles, elasticity and fewer UV spots; no significant effect in sun-protected areas. Concluded overall evidence is inconclusive due to study quality and inconsistency. [https://pubmed.ncbi.nlm.nih.gov/30895708/]
  - FDA Advisory No. 2019-182 || UNSAFE USE OF GLUTATHIONE AS SKIN LIGHTENING AGENT, Food and Drug Administration (Philippines) (2019) — Warns injectable glutathione for skin lightening is not approved for this use and risks Stevens-Johnson syndrome, toxic epidermal necrolysis, and thyroid/liver/kidney/nervous-system toxicity. [https://www.fda.gov.ph/fda-advisory-no-2019-182-unsafe-use-of-glutathione-as-skin-lightening-agent/]
  - FDA highlights concerns with using dietary ingredient glutathione to c, U.S. Food and Drug Administration — FDA warning that dietary-supplement-grade L-glutathione powder is unsuitable for compounding sterile injectables; seven patients given an L-glutathione-compounded IV product (200 mg/mL) had adverse events from excessive endotoxins ranging from nausea/vomiting to difficulty breathing, with one hospitalization, and no injectable glutathione is FDA-approved. [https://www.fda.gov/drugs/human-drug-compounding/fda-highlights-concerns-using-dietary-ingredient-glutathione-compound-sterile-injectables]
  - Evaluating Oral Glutathione Plus Ascorbic Acid, Alpha-lipoic Acid, and Zinc Aspartate as a Skin-lightening Agent: An Indonesian Multicenter, Randomized, Controlled Trial, The Journal of clinical and aesthetic dermatology (2021) — Indonesian multicenter double-blind RCT (n=83 completed) of oral glutathione 500 mg plus ascorbic acid/alpha-lipoic acid/zinc over 12 weeks vs placebo; reductions in spot-UV, spot-polarization, and skin tone were greater with glutathione but not statistically significant. [https://pubmed.ncbi.nlm.nih.gov/34840651/]
  - The effects of the oral supplementation of L‐Cystine associated with reduced L‐Glutathione‐GSH on human skin pigmentation: a randomized, double‐blinded, benchmark‐ and placebo‐controlled clinical trial, Journal of Cosmetic Dermatology (2021) — 12-week double-blind, placebo- and benchmark-controlled RCT in 124 Asian women; oral 500 mg L-cystine plus 250 mg reduced L-glutathione significantly lightened dark spots versus glutathione alone, cystine alone, and placebo. [https://doi.org/10.1111/jocd.14137]
  - Combination of topical and oral glutathione as a skin-whitening agent: a double-blind randomized controlled clinical trial, International journal of dermatology (2021) — Double-blind RCT (n=46) comparing topical+oral glutathione combination vs monotherapy over 8 weeks: combination group had significantly lower melanin index and L* score vs placebo (p<0.05) and the largest mean change of all groups, indicating combined oral+topical glutathione may be superior to monotherapy as a skin-whitening agent. [https://pubmed.ncbi.nlm.nih.gov/33871071/]
  - Glutathione and its antiaging and antimelanogenic effects, Clinical, cosmetic and investigational dermatology (2017) — Randomized, double-blind, placebo-controlled three-arm trial in healthy women taking oral reduced glutathione (GSH) 250 mg/day, oxidized glutathione (GSSG) 250 mg/day, or placebo for 12 weeks; melanin index and UV spots trended lower than placebo at all sites, GSH significantly reduced wrinkles at some sites, with no serious adverse effects. [https://pubmed.ncbi.nlm.nih.gov/28490897/]
  - Glutathione as an oral whitening agent: a randomized, double-blind, placebo-controlled study, The Journal of dermatological treatment (2012) — Double-blind RCT of oral glutathione 500 mg/day vs placebo for 4 weeks (60 adults); melanin index fell at all sites, reaching significance at 2 of 6 sites — modest, short-term lightening. [https://pubmed.ncbi.nlm.nih.gov/20524875/]
  - Evaluating Oral Glutathione Plus Ascorbic Acid, Alpha-lipoic Acid, and Zinc Aspartate as a Skin-lightening Agent: An Indonesian Multicenter, Randomized, Controlled Trial, The Journal of clinical and aesthetic dermatology (2021) — Indonesian multicenter randomized controlled trial of oral glutathione combined with ascorbic acid, alpha-lipoic acid, and zinc aspartate reported significant reduction in melanin index as a skin-lightening agent versus comparator, with good tolerability. [https://pmc.ncbi.nlm.nih.gov/articles/PMC8570360/]
  - Exploring the Safety and Efficacy of Glutathione Supplementation for Skin Lightening: A Narrative Review, Cureus (2025) — Narrative review concluding glutathione shows depigmenting potential across oral, topical, and IV routes but evidence is limited; warns intravenous use carries serious risks (anaphylaxis, hepatotoxicity) and urges caution pending large rigorous trials. [https://pubmed.ncbi.nlm.nih.gov/40013212/]
  - Exploring the Safety and Efficacy of Glutathione Supplementation for Skin Lightening: A Narrative Review, Cureus (2025) — Narrative review concluded that while oral and topical glutathione may give modest, localized lightening, intravenous glutathione for skin lightening has no published efficacy trials and is associated with serious risks including anaphylaxis and hepatotoxicity without standardized dosing. [https://pmc.ncbi.nlm.nih.gov/articles/PMC11862975/]
  - Systemic Glutathione as a Skin-Whitening Agent in Adult, Dermatology research and practice (2020) — Evidence-based review of 3 RCTs of systemic glutathione for skin whitening: one trial found no benefit, two showed significant effects only in certain body sites or age groups, with no long-lasting effect; oral preparations were well tolerated whereas parenteral were not. Concluded systemic glutathione is not sufficiently beneficial as a whitening agent. [https://pubmed.ncbi.nlm.nih.gov/32373172/]
  - Glutathione as a skin whitening agent: Facts, myths, evidence and controversies, Indian journal of dermatology, venereology and leprology (2016) — Critical review concluding antimelanogenic activity is plausible but clinical evidence is limited, with no evidence supporting intravenous glutathione for whitening. [https://pubmed.ncbi.nlm.nih.gov/27088927/]
  - Seven cases of probable endotoxin poisoning related to contaminated glutathione infusions, Epidemiology and infection (2018) — Case series in Epidemiology and Infection documenting seven patients with probable endotoxin poisoning after intravenous glutathione infusions; all infusion samples exceeded the maximum pyrogenic endotoxin threshold, producing fever, rigors, hypotension and other symptoms within 2 hours, underscoring contamination risks of compounded IV glutathione. [https://pubmed.ncbi.nlm.nih.gov/29673413/]

---

## Lycopene & Carotenoids
URL: https://nutridex.info/s/lycopene
Category: Joint & Skin, Heart & Metabolic
Evidence: Preliminary — Early or small human trials; promising but not yet conclusive.
Tomato carotenoids that modestly raise skin's UV-burn threshold

Quick answer: Lycopene & Carotenoids is used for raises the threshold for uv erythema over weeks. NutriDex grades the human evidence as preliminary — Early or small human trials; promising but not yet conclusive. Based on 19 cited human studies (19 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Lycopene and related dietary carotenoids (beta-carotene, lutein) are lipophilic antioxidants that accumulate in skin and quench singlet oxygen and free radicals from UV light. Small human trials show that sustained tomato-based lycopene (~10–16 mg/day for 10–12 weeks) modestly raises the threshold for UV erythema and lowers photodamage markers like MMP-1 and mitochondrial DNA deletions. The effect is real but small — a low-SPF equivalent — and is photoprotection 'from within' that complements but does NOT replace sunscreen. A key caveat: high-dose beta-carotene supplements increased lung-cancer incidence in smokers in the CARET and ATBC trials; whole-food carotenoids do not carry this signal.

Benefits / uses: Raises the threshold for UV erythema over weeks; Singlet-oxygen quenching defense in skin; Reduces UV-driven MMP-1 and mtDNA damage; Adjunct only — not a sunscreen substitute.
Active compounds: Lycopene; Beta-carotene; Lutein.
Dose: ~10–16 mg lycopene/day from tomato products for ≥10–12 weeks; effects build slowly.
Safety: Dietary lycopene from foods is well tolerated; very high intake can cause harmless orange-tinged skin. The major concern is high-dose beta-carotene SUPPLEMENTS, which increased lung-cancer incidence and mortality in smokers and asbestos workers (CARET, ATBC). Smokers and former smokers should avoid high-dose beta-carotene pills. Carotenoids are NOT a sunscreen replacement.

Cited studies (19):
  - Dietary intake of tomato and lycopene, blood levels of lycopene, and risk of total and specific cancers in adults: a systematic review and dose-response meta-analysis of prospective cohort studies, Frontiers in nutrition (2025) — Dose-response meta-analysis of 119 prospective cohorts (108,574 cancer cases): high dietary lycopene intake was associated with 5% lower overall cancer risk (RR 0.95) and high blood lycopene with 11% lower risk (RR 0.89), with reduced cancer mortality. [https://pubmed.ncbi.nlm.nih.gov/40013157/]
  - The Effects of Lycopene and Tomato Consumption on Cardiovascular Risk Factors in Adults: A Grade Assessment Systematic Review and Meta-analysis, Current pharmaceutical design (2023) — GRADE systematic review and meta-analysis of 34 RCTs found lycopene/tomato did not significantly affect lipids, blood pressure, glucose, or inflammatory markers; lycopene significantly reduced malondialdehyde (MDA), indicating modest lower oxidative stress. [https://pubmed.ncbi.nlm.nih.gov/37496241/]
  - Association Between Lycopene and Metabolic Disease Risk and Mortality: Systematic Review and Meta-Analysis, Life (Basel, Switzerland) (2025) — Systematic review and meta-analysis (29 studies) found lower serum lycopene was associated with increased metabolic-associated fatty liver disease risk (OR 1.39, 95% CI 1.02-1.89), while higher serum lycopene was associated with reduced mortality among patients with metabolic disease (HR 0.73, 95% CI 0.57-0.94). [https://pubmed.ncbi.nlm.nih.gov/40566597/]
  - Effectiveness of dietary supplements for skin photoaging in healthy adults: a systematic review and meta-analysis of randomized controlled trials, Frontiers in medicine (2025) — Meta-analysis of 40 RCTs (search through Oct 2024) found lycopene, carotenoids, and hyaluronic acid produced no significant benefit on skin photoaging or minimal erythema dose (MED)/elasticity, while collagen and polyphenols did; all supplements were safe over <=24 weeks. [https://pubmed.ncbi.nlm.nih.gov/40761858/]
  - Skin Aging and Carotenoids: A Systematic Review of Their Multifaceted Protective Mechanisms, Nutrients (2025) — Systematic review of 176 studies (2000-March 2025) reported carotenoids mitigate UV-induced oxidative damage by scavenging ROS/RNS, attenuating inflammation, and supporting collagen biosynthesis, though outcomes were too heterogeneous for quantitative pooling. [https://pmc.ncbi.nlm.nih.gov/articles/PMC12389399/]
  - Role of lycopene from tomato on cardiovascular risk: an umbrella review of systematic reviews and meta-analyses of intervention studies, Food & function (2026) — Umbrella review of 9 systematic reviews / 5 moderate-to-high-quality meta-analyses of intervention studies. Tomato-derived lycopene significantly lowered blood pressure with GRADE high certainty, but lipid-profile effects were inconsistent (very low certainty for HDL-C). Concluded daily intake of 5-30 mg lycopene (one to two raw tomatoes) is beneficial for cardiovascular risk. [https://pubmed.ncbi.nlm.nih.gov/41369612/]
  - Antioxidant Lipid Supplement on Cardiovascular Risk Factors: A Systematic Review and Meta-Analysis, Nutrients (2024) — Meta-analysis of RCTs of antioxidant lipid supplements. Lycopene vs placebo significantly lowered systolic blood pressure by 1.95 mmHg (95% CI -3.54 to -0.36); effects most evident in participants with adverse cardiometabolic status. [https://pubmed.ncbi.nlm.nih.gov/39064656/]
  - Role of Beta-Carotene in Lung Cancer Primary Chemoprevention: A Systematic Review with Meta-Analysis and Meta-Regression, Nutrients (2022) — Meta-analysis (8 trials, 167,141 participants): beta-carotene supplementation increased lung-cancer risk (RR 1.16), rising to RR 1.21 in smokers/asbestos workers. [https://pubmed.ncbi.nlm.nih.gov/35405977/]
  - Lycopene Does Not Affect Prostate-Specific Antigen in Men with Non-Metastatic Prostate Cancer: A Systematic Review and Meta-Analysis of Randomized Controlled Trials, Nutrition and cancer (2021) — Meta-analysis of 6 RCTs in men with non-metastatic prostate cancer found no overall effect of lycopene on PSA (WMD -0.60 ug/L), but a significant reduction (WMD -3.74 ug/L) in the subgroup with high baseline PSA (>=6.5 ug/L). [https://pubmed.ncbi.nlm.nih.gov/33355018/]
  - Lycopene Supplementation and Blood Pressure: Systematic review and meta-analyses of randomized trials, Journal of Herbal Medicine (2022) — Systematic review and meta-analysis of 10 randomized trials (688 participants) found lycopene supplementation significantly reduced systolic blood pressure by ~2.6 mmHg (no significant effect on diastolic BP overall), with larger reductions at doses >=15 mg/day, durations >=8 weeks, and in participants with baseline SBP >130 mmHg. [https://doi.org/10.1016/j.hermed.2021.100521]
  - Increased dietary and circulating lycopene are associated with reduced prostate cancer risk: a systematic review and meta-analysis, Prostate cancer and prostatic diseases (2017) — Systematic review and meta-analysis (42 studies, 43,851 prostate cancer cases) found higher dietary intake and higher circulating lycopene each significantly associated with reduced prostate cancer risk, with risk decreasing ~1% per additional 2 mg/day lycopene. [https://pubmed.ncbi.nlm.nih.gov/28440323/]
  - The Effects of Lycopene on Modulating Oxidative Stress and Liver Enzymes Levels in Metabolic Syndrome Patients: A Randomised Clinical Trial, Cell journal (2023) — Double-blind RCT (n=80, metabolic syndrome) of encapsulated lycopene 20 mg/day for 8 weeks significantly reduced CRP (p=0.001) and pro-oxidant-antioxidant balance (p=0.004) vs placebo, with no change in liver enzymes (ALT/AST/ALP). [https://pubmed.ncbi.nlm.nih.gov/38192255/]
  - Tomato paste rich in lycopene protects against cutaneous photodamage in humans in vivo: a randomized controlled trial, The British journal of dermatology (2011) — 20 women taking 55 g tomato paste (16 mg lycopene) daily for 12 weeks showed a higher erythemal threshold (p=0.03) and reduced UV-induced MMP-1 and mtDNA deletion. [https://pubmed.ncbi.nlm.nih.gov/20854436/]
  - Supplementation with tomato-based products increases lycopene, phytofluene, and phytoene levels in human serum and protects against UV-light-induced erythema, International journal for vitamin and nutrition research. Internationale Zeitschrift fur Vitamin- und Ernahrungsforschung. Journal international de vitaminologie et de nutrition (2005) — 12 weeks of tomato-based products (~10 mg/day lycopene) reduced UV-induced erythema by 25–48% vs baseline, with the effect growing over time. [https://pubmed.ncbi.nlm.nih.gov/15830922/]
  - Long-term Outcomes of Adding Lutein/Zeaxanthin and ω-3 Fatty Acids to the AREDS Supplements on Age-Related Macular Degeneration Progression: AREDS2 Report 28, JAMA ophthalmology (2022) — In the AREDS2 randomized trial 10-year follow-up (3,883 participants), directly substituting lutein/zeaxanthin for beta-carotene lowered the risk of progression to late AMD (HR 0.85, 95% CI 0.73-0.98) and avoided beta-carotene's elevated lung-cancer risk (lutein/zeaxanthin OR 1.15 vs beta-carotene OR 1.82). [https://pubmed.ncbi.nlm.nih.gov/35653117/]
  - Carotenoids in Skin Photoaging: Unveiling Protective Effects, Molecular Insights, and Safety and Bioavailability Frontiers, Antioxidants (Basel, Switzerland) (2025) — Review of C40 carotenoids (beta-carotene, lycopene, astaxanthin, lutein, zeaxanthin) in skin photoaging found oral and topical use can alleviate photoaging via ROS scavenging and modulation of MAPK, Nrf2, and NF-kB pathways, while flagging dosage, bioavailability, and pigmentation/allergy safety limits. [https://pmc.ncbi.nlm.nih.gov/articles/PMC12108434/]
  - Lycopene intake and prostate cancer risk in men at high cardiovascular risk: a prospective cohort study, BMC medicine (2025) — Prospective cohort of 2,970 high-cardiovascular-risk Mediterranean men (PREDIMED), 104 incident prostate cancers over 5.8 yr. Highest vs lowest quartile of lycopene intake had 54% lower prostate cancer risk (HR 0.46, 95% CI 0.23-0.95; p-trend 0.035); nonlinear protection emerging above 4.9 mg/day (HR 0.36, 0.13-0.98). [https://pubmed.ncbi.nlm.nih.gov/41214650/]
  - Association of serum lycopene concentrations with all-cause and cardiovascular mortality among individuals with chronic kidney disease: A cohort study, Frontiers in nutrition (2022) — Prospective cohort of 7,683 adults with chronic kidney disease (NHANES, median ~25-year follow-up) found higher serum lycopene independently associated with lower all-cause mortality (HR 0.78, 95% CI 0.71-0.85) and cardiovascular mortality (HR 0.79, 95% CI 0.69-0.91) comparing highest vs lowest quartile. [https://pubmed.ncbi.nlm.nih.gov/36545466/]
  - Lower prostate cancer risk in men with elevated plasma lycopene levels: results of a prospective analysis, Cancer research (1999) — Nested case-control within the Physicians' Health Study (578 cases, 1,294 controls). Highest vs lowest quintile of plasma lycopene associated with lower prostate cancer risk; in the placebo (non-beta-carotene) arm there was a ~60% reduction in aggressive prostate cancer risk for the top vs bottom quintile - an early prospective biomarker signal specific to aggressive disease. [https://pubmed.ncbi.nlm.nih.gov/10096552/]

---

## Silica (Horsetail / ch-OSA) (Equisetum arvense)
URL: https://nutridex.info/s/silica-horsetail
Category: Joint & Skin, Mineral
Evidence: Preliminary — Early or small human trials; promising but not yet conclusive.
Bioavailable silicon studied for skin elasticity, hair and nails

Quick answer: Silica (Horsetail / ch-OSA) is used for may reduce skin roughness / improve elasticity. NutriDex grades the human evidence as preliminary — Early or small human trials; promising but not yet conclusive. Based on 15 cited human studies (15 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Silicon is a trace element concentrated in connective tissue, where it is thought to support collagen and glycosaminoglycan cross-linking; orthosilicic acid is its most bioavailable form. A few small double-blind RCTs of choline-stabilized orthosilicic acid (ch-OSA) report modest benefits: Barel 2005 found reduced skin roughness and less hair/nail brittleness, while Wickett 2007 found improved hair tensile strength. The evidence base is limited — trials are small, short, and largely industry-funded. Horsetail (the botanical silicon source) is a separate safety issue: it contains thiaminase (which degrades vitamin B1) and trace nicotine, so standardized ch-OSA or thiaminase-free products are preferable.

Benefits / uses: May reduce skin roughness / improve elasticity; Small trials suggest stronger, thicker hair; Some reduction in hair/nail brittleness; Supplies bioavailable silicon for connective tissue.
Active compounds: Orthosilicic acid / silica; ch-OSA.
Dose: ch-OSA ~10 mg Si/day (dose used in trials).
Safety: ch-OSA at ~10 mg Si/day was well tolerated in short trials and is unlikely to harm people with normal kidney function. The main concerns are with horsetail itself: thiaminase can deplete vitamin B1 with prolonged use, and it contains trace nicotine (avoid in pregnancy and when quitting smoking). Choose thiaminase-free standardized products, avoid prolonged/high-dose use, and avoid in renal impairment.

Cited studies (15):
  - Silicon Supplementation for Bone Health: An Umbrella Review Attempting to Translate from Animals to Humans, Nutrients (2024) — Umbrella review in Nutrients found silicon consistently improves bone density and collagen synthesis in animal models, but the effective doses (~139 mg/kg BW/day) far exceed feasible human intake (~12-62 mg/day) and human supplementation trials at modest doses gave inconsistent results. [https://pubmed.ncbi.nlm.nih.gov/38337624/]
  - Safety of orthosilicic acid-vanillin complex (OSA-VC) as a novel food ingredient to be used in food supplements as a source of silicon and bioavailability of silicon from the source, EFSA journal. European Food Safety Authority (2018) — EFSA scientific opinion concluded there is no safety concern for orthosilicic acid-vanillin complex as a novel-food source of silicon in adult supplements and that silicon is bioavailable from it, while noting silicon essentiality is unestablished and no tolerable upper level could be set. [https://pmc.ncbi.nlm.nih.gov/articles/PMC7009440/]
  - The effect of choline-stabilized orthosilicic acid in patients with peri-implantitis: an exploratory randomized, double-blind, placebo controlled study, BMC oral health (2021) — 12-month exploratory double-blind RCT (21 randomized, 18 per-protocol) in peri-implantitis patients found ch-OSA stabilized peri-implant bone loss and prevented mucosal recession versus significant worsening on placebo. [https://pmc.ncbi.nlm.nih.gov/articles/PMC8480141/]
  - Antihypertensive effect of Equisetum arvense L.: a double-blind, randomized efficacy and safety clinical trial, Phytomedicine : international journal of phytotherapy and phytopharmacology (2022) — Double-blind randomized trial in 58 stage I hypertensive adults found standardized Equisetum arvense extract lowered systolic and diastolic blood pressure by about 12.6 and 8.1 mmHg respectively, with efficacy and tolerability similar to hydrochlorothiazide. [https://pubmed.ncbi.nlm.nih.gov/35168030/]
  - Relative absorption of silicon from different formulations of dietary supplements: a pilot randomized, double-blind, crossover post-prandial study, Scientific reports (2021) — In a randomized, double-blind, crossover post-prandial study in 5 healthy men dosed at 21.6 mg silicon, urinary silicon excretion did not differ significantly between an Equisetum arvense orthosilicic acid liquid (32.4%), an aloe-vera OSA liquid (34.6%), and an OSA-maltodextrin powder (27.2%), indicating comparable bioavailability across formulations. [https://pmc.ncbi.nlm.nih.gov/articles/PMC8363645/]
  - The effect of choline-stabilized orthosilicic acid in patients with peri-implantitis: an exploratory randomized, double-blind, placebo controlled study, BMC oral health (2021) — Exploratory randomized, double-blind, placebo-controlled trial, 18 analyzed peri-implantitis patients, ch-OSA vs placebo for 12 months after flap surgery: mucosal recession increased with placebo but not ch-OSA (between-group p<0.01); peri-implant bone levels (IS-BIC, IS-AC) stayed stable with ch-OSA but worsened on placebo (IS-BIC between-group p<0.05). [https://pubmed.ncbi.nlm.nih.gov/34587941/]
  - Horsetail (2022) — NIH LiverTox classifies horsetail as a probable rare cause of clinically apparent liver injury (likelihood C); conventional oral doses up to ~6 g/day showed no hepatotoxicity in trials and any injury is rare, mild, and self-limiting. [https://www.ncbi.nlm.nih.gov/books/NBK583202/]
  - Safety Assessment of Equisetum arvense-Derived Ingredients as Used in Cosmetics, Cosmetic Ingredient Review (CIR) (2021) — CIR safety assessment of Equisetum arvense-derived cosmetic ingredients reported few in vivo toxicity studies for most Equisetum species and no consensus on an effective non-toxic dose, while noting crude horsetail contains thiaminase. [https://www.cir-safety.org/sites/default/files/equise092021TR.pdf]
  - Randomized, Double-Blind Clinical Trial to Assess the Acute Diuretic Effect of Equisetum arvense (Field Horsetail) in Healthy Volunteers, Evidence-based complementary and alternative medicine : eCAM (2014) — Randomized double-blind crossover trial in 36 healthy men found a standardized Equisetum arvense dried extract (900 mg/day) produced a diuretic effect stronger than placebo and comparable to hydrochlorothiazide 25 mg, without significant changes in electrolyte excretion. [https://pubmed.ncbi.nlm.nih.gov/24723963/]
  - Effect of oral intake of choline-stabilized orthosilicic acid on skin, nails and hair in women with photodamaged skin, Archives of dermatological research (2005) — 20-week double-blind RCT in 50 women with photodamaged skin; 10 mg Si/day ch-OSA reduced skin roughness, improved mechanical properties, and lowered hair/nail brittleness vs placebo. [https://pubmed.ncbi.nlm.nih.gov/16205932/]
  - Effect of oral intake of choline-stabilized orthosilicic acid on hair tensile strength and morphology in women with fine hair, Archives of dermatological research (2007) — 9-month double-blind RCT in 48 women with fine hair; 10 mg Si/day ch-OSA improved hair tensile strength and increased hair cross-sectional area vs placebo. [https://pubmed.ncbi.nlm.nih.gov/17960402/]
  - Choline-stabilized orthosilicic acid supplementation as an adjunct to calcium/vitamin D3 stimulates markers of bone formation in osteopenic females: a randomized, placebo-controlled trial, BMC musculoskeletal disorders (2008) — 12-month randomized placebo-controlled trial in osteopenic women (184 randomized, 136 completed) found ch-OSA added to calcium/vitamin D3 significantly raised the bone collagen formation marker PINP at the 6 and 12 mg silicon/day doses versus placebo, though lumbar BMD did not change significantly. [https://pubmed.ncbi.nlm.nih.gov/18547426/]
  - Silicon: a review of its potential role in the prevention and treatment of postmenopausal osteoporosis, International journal of endocrinology (2013) — Review of silicon in connective tissue/bone ranks ch-OSA as an intermediate-bioavailability source but concludes human evidence remains limited and promising rather than established. [https://pmc.ncbi.nlm.nih.gov/articles/PMC3671293/]
  - Dietary silicon intake is positively associated with bone mineral density in men and premenopausal women of the Framingham Offspring cohort, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research (2004) — Cross-sectional cohort of 2847 adults: higher dietary silicon intake correlated positively and significantly with hip BMD in men and premenopausal women (not postmenopausal women); BMD differed by up to ~10% between highest (>40 mg Si/day) and lowest (<14 mg Si/day) intake quintiles. No association at lumbar spine in most groups. [https://pubmed.ncbi.nlm.nih.gov/14969400/]
  - Effects of beer, wine, and liquor intakes on bone mineral density in older men and women, The American journal of clinical nutrition (2009) — Population cohort (1182 men, 1537 women): moderate beer intake associated with 3.4-4.5% greater hip BMD, but after adjustment for silicon intake all beer-BMD differences became non-significant, whereas wine/liquor associations remained, indicating silicon mediates beer's bone benefit. [https://pubmed.ncbi.nlm.nih.gov/19244365/]

---

## Green Tea Extract (EGCG) (Camellia sinensis)
URL: https://nutridex.info/s/green-tea
Category: Heart & Metabolic, Longevity
Evidence: Mixed — Conflicting results across studies; benefit uncertain.
Catechin-rich extract with modest metabolic and lipid effects—and a real high-dose liver caveat.

Quick answer: Green Tea Extract (EGCG) is used for may modestly lower ldl and total cholesterol (roughly 5-6 mg/dl on average in pooled trials).. NutriDex grades the human evidence as mixed — Conflicting results across studies; benefit uncertain. Based on 19 cited human studies (19 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Green tea extract concentrates the catechins of Camellia sinensis, chiefly epigallocatechin gallate (EGCG), and is marketed for weight loss, cardiovascular health, and antioxidant support. The human evidence is mixed: pooled randomized trials show small but statistically significant reductions in LDL/total cholesterol and modest decreases in body weight, body fat, and waist circumference, but effects on blood pressure and on weight beyond what exercise alone achieves are weak and inconsistent. These benefits are real but modest, and brewed green tea delivers far lower catechin doses than concentrated extract capsules. The most important caveat is safety, not efficacy: high-dose green tea EXTRACTS (unlike brewed tea) have been linked to rare but serious idiosyncratic hepatotoxicity, with case reports spanning EGCG intakes of 140-1000 mg/day and elevated liver enzymes seen above about 800 mg/day. Susceptibility appears highly individual and may be genetically influenced, so taking the extract with food and at conservative doses is prudent.

Benefits / uses: May modestly lower LDL and total cholesterol (roughly 5-6 mg/dL on average in pooled trials).; Small reductions in waist circumference, body weight, and body fat, especially when paired with exercise or calorie restriction.; May slightly raise HDL and lower triglycerides in overweight/obese people, though effects are inconsistent.; Provides catechin antioxidants (notably EGCG) that scavenge free radicals in vitro; clinical longevity benefit is unproven.; Blood-pressure effects are weak and inconsistent—at most a small drop in diastolic pressure, with no reliable systolic effect..
Active compounds: Epigallocatechin gallate (EGCG) — the dominant and most-studied catechin; Epigallocatechin (EGC); Epicatechin gallate (ECG); Epicatechin (EC); Caffeine (variable; decaffeinated extracts available).
Dose: Commonly 250-500 mg/day of standardized extract providing roughly 100-300 mg EGCG. Take with food (not fasted) and avoid bolus doses; keep total EGCG well below 800 mg/day, the threshold associated with elevated liver enzymes.
Safety: Concentrated green tea EXTRACTS (unlike ordinary brewed tea) carry a rare but documented risk of serious idiosyncratic liver injury (hepatocellular pattern), reported across EGCG doses of 140-1000 mg/day; liver-enzyme elevations are more likely above ~800 mg/day EGCG. To reduce risk, take with food rather than fasted, avoid large single (bolus) doses, and discontinue immediately if you develop jaundice, dark urine, abdominal pain, or unusual fatigue. Avoid in people with existing liver disease or elevated liver enzymes; not recommended in pregnancy or breastfeeding (high catechin intake may reduce folate availability). Caffeinated extracts can cause insomnia, jitteriness, and raised heart rate—choose decaffeinated forms or limit other caffeine. Green tea may reduce absorption of iron (take apart from iron-rich meals/supplements and consider pairing with vitamin C) and can interact with anticoagulants/antiplatelets (it contains some vitamin K and affects platelet function), with the chemotherapy agent bortezomib (EGCG may blunt its effect), and with stimulant or blood-pressure medications. People on multiple medications, the elderly, and anyone with hepatic or cardiac conditions should consult a clinician before use.

Cited studies (19):
  - Effect of green tea supplementation on blood pressure in adults: a GRADE-assessed systematic review and dose-response meta-analysis of randomised controlled trials, Blood pressure (2025) — In a 2025 GRADE-assessed dose-response meta-analysis, green tea supplementation modestly lowered systolic blood pressure (WMD -1.08 mmHg, 95% CI -1.98 to -0.18) and diastolic blood pressure (WMD -1.09 mmHg, 95% CI -1.67 to -0.50), with larger effects in participants with elevated baseline BP, doses under 500 mg/day, Asian populations, and women. [https://pubmed.ncbi.nlm.nih.gov/40497293/]
  - The effects of green tea supplementation on cardiovascular risk factors: A systematic review and meta-analysis, Frontiers in nutrition (2022) — Meta-analysis of 55 RCTs (4,874 participants) found green tea supplementation significantly reduced LDL cholesterol (WMD -5.80 mg/dL; 95% CI -8.30 to -3.30; P<0.001) and total cholesterol (WMD -7.62 mg/dL; 95% CI -10.51 to -4.73), and raised HDL (WMD +1.85 mg/dL). [https://pmc.ncbi.nlm.nih.gov/articles/PMC9871939/]
  - Effects of green tea catechin on the blood pressure and lipids in overweight and obese population-a meta-analysis, Heliyon (2023) — Meta-analysis of 11 RCTs (613 participants) in overweight/obese adults found green tea catechins had NO significant effect on LDL (WMD -0.13; 95% CI -0.30 to -0.04; P=0.129) or total cholesterol (WMD -0.19; P=0.142), with benefit only for triglycerides and HDL. [https://pmc.ncbi.nlm.nih.gov/articles/PMC10681946/]
  - Catechins and Human Health: Breakthroughs from Clinical Trials, Molecules (Basel, Switzerland) (2025) — Systematic review of 17 recent clinical studies (2022-2024) on EGCG/green tea catechins covering metabolism, toxicity, pharmacokinetics, cognition and inflammation, summarizing therapeutic benefits and potential hepatotoxicity risks of high-dose EGCG. [https://pmc.ncbi.nlm.nih.gov/articles/PMC12348855/]
  - The effects of green tea extract supplementation on body composition, obesity-related hormones and oxidative stress markers: a grade-assessed systematic review and dose-response meta-analysis of randomised controlled trials, The British journal of nutrition (2024) — GRADE-assessed dose-response meta-analysis of 59 RCTs (3802 participants): green tea extract supplementation significantly reduced body mass, BMI, body fat percentage and malondialdehyde, and increased adiponectin and total antioxidant capacity; no significant effect on fat mass, leptin or ghrelin. [https://pubmed.ncbi.nlm.nih.gov/38031409/]
  - Effects of green tea consumption on glycemic control: a systematic review and meta-analysis of randomized controlled trials, Nutrition & metabolism (2020) — Meta-analysis of 27 RCTs (2194 subjects): green tea consumption modestly lowered fasting blood glucose (WMD -1.44 mg/dL, 95% CI -2.26 to -0.62; low heterogeneity) but had no significant effect on fasting insulin or HbA1c. [https://pubmed.ncbi.nlm.nih.gov/32670385/]
  - The effects of green tea supplementation on cardiovascular risk factors: A systematic review and meta-analysis, Frontiers in Nutrition (2023) — Green tea supplementation produced small but significant reductions in LDL cholesterol (WMD -5.80 mg/dL) and diastolic blood pressure (-0.87 mmHg), with no significant effect on systolic blood pressure. [https://doi.org/10.3389/fnut.2022.1084455]
  - Effects of green tea catechin on the blood pressure and lipids in overweight and obese population-a meta-analysis, Heliyon (2023) — Green tea catechin significantly reduced triglycerides (-0.18 mmol/L), raised HDL (+0.07 mmol/L), and cut waist circumference (-1.37 cm), but did not significantly change blood pressure, LDL, or BMI. [https://pubmed.ncbi.nlm.nih.gov/38034724/]
  - Does green tea catechin enhance weight-loss effect of exercise training in overweight and obese individuals? a systematic review and meta-analysis of randomized trials, Journal of the International Society of Sports Nutrition (2024) — Adding green tea catechin to exercise training gave only minimal additional weight loss versus exercise alone (standardized mean difference about -0.30 for weight, -0.29 for fat mass) and no extra benefit on lipid profile. [https://pubmed.ncbi.nlm.nih.gov/39350601/]
  - Green tea catechins decrease total and low-density lipoprotein cholesterol: a systematic review and meta-analysis, Journal of the American Dietetic Association (2011) — Green tea catechins significantly lowered LDL cholesterol by about 5.3 mg/dL and total cholesterol versus control, supporting a modest lipid-lowering effect. [https://pubmed.ncbi.nlm.nih.gov/22027055/]
  - Green tea (Camellia sinensis) for the prevention of cancer, The Cochrane database of systematic reviews (2020) — This Cochrane review found inconsistent and limited evidence that green tea prevents cancer; pooled observational data showed a modest reduction in overall cancer incidence (RR ~0.83) but no association with cancer mortality, with a possible benefit for prostate cancer (RR 0.50, 3 RCTs) of low certainty. [https://pubmed.ncbi.nlm.nih.gov/32118296/]
  - Effect of Epigallocatechin Gallate on Glycemic Index: A Systematic Review and Meta-Analysis of Randomized Controlled Trials, Clinical therapeutics (2025) — EGCG supplementation produced statistically significant but modest improvements in glycemic control, lowering HbA1c by about 0.18% (WMD -0.18%, 95% CI -0.35 to -0.02) and fasting glucose and HOMA-IR, while having no significant effect on fasting insulin (WMD -0.50, 95% CI -1.46 to 0.47). [https://pubmed.ncbi.nlm.nih.gov/40885603/]
  - The Association between Green Tea Consumption and Cognitive Function: A Meta-Analysis of Current Evidence, Neuroepidemiology (2026) — Higher green tea consumption was inversely associated with cognitive impairment (OR 0.63, 95% CI 0.54-0.73), including reduced odds of dementia (OR 0.74) and mild cognitive impairment (OR 0.64), with the strongest protection in adults aged 50-69 and in Asian populations. [https://pubmed.ncbi.nlm.nih.gov/39947165/]
  - Effects of green tea or green tea catechin on liver enzymes in healthy individuals and people with nonalcoholic fatty liver disease: A systematic review and meta-analysis of randomized clinical trials, Phytotherapy research : PTR (2020) — Across all participants green tea had no significant overall effect on liver enzymes (ALT SMD -0.17, 95% CI -0.42 to 0.08; AST SMD -0.07, 95% CI -0.43 to 0.29), but subgroup analysis showed a reduction in transaminases among people with NAFLD versus a small significant increase in healthy subjects, indicating effects depend on baseline liver status. [https://pubmed.ncbi.nlm.nih.gov/32067271/]
  - Tea consumption and risk of all-cause, cardiovascular disease, and cancer mortality: a meta-analysis of thirty-eight prospective cohort data sets, Epidemiology and health (2024) — Comparing highest versus lowest tea intake, consumption was associated with lower all-cause mortality (effect size 0.90, 95% CI 0.86-0.95) and cardiovascular mortality (0.86, 95% CI 0.79-0.94) but not cancer mortality (0.90, 95% CI 0.78-1.03), with the greatest benefit near about 2 cups/day and no further reduction at higher intake. [https://pubmed.ncbi.nlm.nih.gov/38938012/]
  - The Effect of Green Tea Beverage on Blood Cardiometabolic Risk Biomarkers in Dyslipidemia Subjects, Food science & nutrition (2025) — Randomized double-blind placebo-controlled trial in 60 dyslipidemia adults found 6 weeks of green tea beverage (891 mg total catechins) reduced LDL cholesterol by 7.98% and total cholesterol by 4.96% versus placebo. [https://pmc.ncbi.nlm.nih.gov/articles/PMC12172635/]
  - United States Pharmacopeia (USP) comprehensive review of the hepatotoxicity of green tea extracts, Toxicology reports (2020) — Case reports link green tea extract hepatotoxicity to EGCG intakes of 140-1000 mg/day with large inter-individual susceptibility; transaminase/cholestasis increases were seen above roughly 800 mg/day EGCG, prompting cautionary labeling to take with food. [https://pubmed.ncbi.nlm.nih.gov/32140423/]
  - Randomized, Placebo-Controlled Trial of Green Tea Catechins for Prostate Cancer Prevention, Cancer prevention research (Philadelphia, Pa.) (2015) — Randomized, double-blind, placebo-controlled trial in 97 men with HGPIN/ASAP: 400 mg/day EGCG (Polyphenon E) for 1 year did not reduce 1-year prostate cancer incidence (5/49 vs 9/48, P=0.25); a secondary composite endpoint (cancer+ASAP in HGPIN-only men) was reduced (3/26 vs 10/25, P<0.024) and PSA fell (-0.87 ng/mL). Well tolerated. [https://pubmed.ncbi.nlm.nih.gov/25873370/]
  - Green Tea and Coffee Consumption and All-Cause Mortality Among Persons With and Without Stroke or Myocardial Infarction, Stroke (2021) — Among stroke and heart-attack survivors, greater green tea intake was associated with dose-dependent lower all-cause mortality (stroke survivors: HR 0.62 at 1-2 cups/day down to 0.38 at >=7 cups/day), whereas no protective association was seen in people without prior stroke or MI. [https://pubmed.ncbi.nlm.nih.gov/33535784/]

---

## Garlic (Allium sativum)
URL: https://nutridex.info/s/garlic
Category: Heart & Metabolic
Evidence: Moderate — Several controlled trials; effects real but modest or context-dependent.
A kitchen staple with modest, real effects on blood pressure and cholesterol.

Quick answer: Garlic is used for small but consistent reductions in systolic and diastolic blood pressure across meta-analyses (roughly 2-4 mmhg). NutriDex grades the human evidence as moderate — Several controlled trials; effects real but modest or context-dependent. Based on 21 cited human studies (21 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Garlic (Allium sativum) is a culinary bulb whose organosulfur compounds, chiefly allicin and its derivatives, are thought to drive its cardiovascular effects. Multiple recent meta-analyses of randomized trials show that garlic supplementation produces small but statistically significant reductions in blood pressure (about 2-4 mmHg systolic) and in total cholesterol, LDL, and triglycerides, with the largest benefits seen in adults who already have elevated risk factors. The effects are real but modest, and garlic should be viewed as an adjunct rather than a replacement for proven medications. Standardized garlic powder and aged garlic extract are the best-studied forms, since allicin is unstable and depends on how garlic is prepared. The most important safety consideration is garlic's antiplatelet activity, which can add to the bleeding risk of anticoagulants and is relevant around surgery. Overall the evidence supports a genuine, if minor, role in supporting heart and metabolic health.

Benefits / uses: Small but consistent reductions in systolic and diastolic blood pressure across meta-analyses (roughly 2-4 mmHg); Modest lowering of total cholesterol, LDL, and triglycerides, with the clearest signal in people with elevated baseline levels; Slight, statistically significant improvements in fasting glucose and HDL in pooled trial data; Generally well tolerated as a whole food, with cardiovascular markers favored most in higher-risk adults.
Active compounds: Allicin (formed from alliin via alliinase when garlic is crushed); Ajoene; Diallyl disulfide and diallyl trisulfide (organosulfur compounds); S-allylcysteine (the main marker compound in aged garlic extract).
Dose: Garlic powder 300-900 mg/day (standardized to ~1.8-5.4 mg allicin), or aged garlic extract ~600-1,200 mg/day; equivalent to roughly one to two fresh cloves daily.
Safety: Garlic is safe as a food, but supplemental doses can cause breath and body odor, heartburn, abdominal pain, flatulence, nausea, and occasional allergic reactions; raw garlic applied to skin can cause burns. Its key risk is antiplatelet/anticoagulant activity: garlic supplements may increase bleeding risk and can potentiate warfarin, clopidogrel, aspirin, and other blood thinners. Discontinue garlic supplements at least 7 days before surgery or dental procedures. People with bleeding disorders, those on anticoagulant or antiplatelet therapy, and anyone awaiting surgery should avoid supplemental garlic or use it only under medical supervision. Garlic may also lower blood glucose and blood pressure, so caution is warranted when combined with antidiabetic or antihypertensive medications. Pregnant and breastfeeding women should not exceed normal dietary amounts, as the safety of higher supplemental doses is not established; garlic may also reduce levels of some drugs such as saquinavir.

Cited studies (21):
  - Effects of Garlic Supplementation on Cardiovascular Risk Factors in Adults: A Comprehensive Updated Systematic Review and Meta-Analysis of Randomized Controlled Trials, Nutrition reviews (2026) — This 2026 comprehensive meta-analysis of RCTs found garlic supplementation reduced systolic BP by 3.71 mmHg, diastolic BP by 1.97 mmHg, total cholesterol by 10.21 mg/dL, and LDL by 5.90 mg/dL versus control. [https://pubmed.ncbi.nlm.nih.gov/40580481/]
  - The Effect of Aged Garlic Supplementation on Blood Pressure and Lipid Profile: A Dose-Response Grade-Assessed Systematic Review and Meta-Analysis of Randomized Controlled Trials, Phytotherapy research : PTR (2025) — A 2025 dose-response, GRADE-assessed meta-analysis found aged garlic extract significantly reduced systolic blood pressure (WMD -2.49 mmHg) and LDL cholesterol (WMD -4.41 mg/dL), confirming modest effects. [https://pubmed.ncbi.nlm.nih.gov/40628369/]
  - Garlic supplementation for the treatment of chronic liver disease: a meta-analysis of randomized controlled trials, African health sciences (2023) — This 2023 meta-analysis of RCTs found garlic supplementation significantly reduced ALT (MD -3.76 U/L) and AST (MD -3.62 U/L) in patients with chronic liver disease/NAFLD, with low heterogeneity. [https://pmc.ncbi.nlm.nih.gov/articles/PMC10782365/]
  - The effect of garlic on the lowering of blood pressure in the patients with hypertension: an updated meta-analysis and trial sequential analysis, Asian biomedicine : research, reviews and news (2025) — Across 12 reports (405 garlic vs 333 placebo), garlic extracts lowered systolic BP by 8.12 mmHg (95% CI -10.95 to -5.28) and diastolic BP by 4.26 mmHg (95% CI -5.99 to -2.52) in hypertensives; trial sequential analysis indicated sufficient evidence had been reached. [https://pmc.ncbi.nlm.nih.gov/articles/PMC12303591/]
  - Effects of aged garlic extract on blood pressure in hypertensive patients: A systematic review and meta-analysis of randomized controlled trials, Prostaglandins & other lipid mediators (2024) — Pooling 9 RCTs (584 hypertensive participants), aged garlic extract reduced systolic BP by 4.03 mmHg and diastolic BP by 1.44 mmHg versus control. [https://pubmed.ncbi.nlm.nih.gov/39437887/]
  - The effect of garlic on the lowering of blood pressure in the patients with hypertension: an updated meta-analysis and trial sequential analysis, Asian biomedicine : research, reviews and news (2025) — Updated meta-analysis with trial sequential analysis (12 trials, 405 garlic vs 333 placebo) in hypertensive patients found garlic significantly lowered systolic BP by 8.12 mmHg (95% CI -10.95 to -5.28) and diastolic BP by 4.26 mmHg (95% CI -5.99 to -2.52); TSA confirmed evidence is conclusive and further trials are not needed. [https://pubmed.ncbi.nlm.nih.gov/40735665/]
  - Garlic consumption can reduce the risk of dyslipidemia: a meta-analysis of randomized controlled trials, Journal of health, population, and nutrition (2024) — Meta-analysis of 21 RCTs in dyslipidemic patients found garlic significantly reduced total cholesterol -0.64 mmol/L, LDL-C -0.44 mmol/L, and triglycerides -0.17 mmol/L while slightly raising HDL-C +0.04 mmol/L; effects greater in patients over 50 years and with garlic oil versus powder. [https://pubmed.ncbi.nlm.nih.gov/39113105/]
  - Allium Vegetables, Garlic Supplements, and Risk of Cancer: A Systematic Review and Meta-Analysis, Frontiers in nutrition (2021) — This 2022 systematic review and meta-analysis found no significant association between allium vegetable intake (RR 0.97, 95% CI 0.92-1.03) or garlic supplements (RR 0.97, 95% CI 0.84-1.12) and overall cancer risk, indicating garlic does not meaningfully reduce cancer incidence. [https://pmc.ncbi.nlm.nih.gov/articles/PMC8985597/]
  - Effect of garlic supplement in the management of type 2 diabetes mellitus (T2DM): a meta-analysis of randomized controlled trials, Food & nutrition research (2017) — This 2017 meta-analysis of RCTs found garlic supplementation significantly reduced fasting blood glucose and glycated hemoglobin (HbA1c) at 12 and 24 weeks in patients with type 2 diabetes, alongside improvements in total cholesterol and LDL. [https://pubmed.ncbi.nlm.nih.gov/29056888/]
  - Garlic Supplementation Reduces Circulating C-reactive Protein, Tumor Necrosis Factor, and Interleukin-6 in Adults: A Systematic Review and Meta-analysis of Randomized Controlled Trials, The Journal of nutrition (2019) — This 2019 systematic review and meta-analysis of RCTs in The Journal of Nutrition found garlic supplementation significantly reduced circulating C-reactive protein (WMD -0.61 mg/L), tumor necrosis factor (WMD -0.26 ng/L), and interleukin-6 (WMD -0.73 ng/L) in adults, indicating an anti-inflammatory effect. [https://pubmed.ncbi.nlm.nih.gov/30949665/]
  - Garlic for the common cold, The Cochrane database of systematic reviews (2014) — Cochrane systematic review found only one eligible RCT (n=146): a garlic supplement (180 mg allicin/day for 12 weeks) was associated with fewer common cold occurrences (24 vs 65 with placebo, P<0.001) and fewer days of illness, but days-to-recovery were similar; authors concluded evidence is insufficient and largely low-quality. [https://pubmed.ncbi.nlm.nih.gov/25386977/]
  - Garlic for the common cold, Cochrane Database of Systematic Reviews (2014) — This Cochrane systematic review found only one eligible trial, in which daily garlic for 12 weeks reduced common cold occurrences (24 vs 65 in placebo) but did not shorten recovery time, concluding evidence is insufficient and of poor quality. [https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD006206.pub4/full]
  - Meta-analysis on the safety and efficacy of long-term garlic consumption as an adjunctive treatment for hypertension, Frontiers in nutrition (2025) — A meta-analysis of 10 RCTs reported significant reductions in systolic BP (-4.21 mmHg) and diastolic BP (-3.13 mmHg) with garlic versus control, evaluating long-term garlic as an adjunctive hypertension treatment. [https://pmc.ncbi.nlm.nih.gov/articles/PMC12698422/]
  - Antihypertensive Effects of an Optimized Aged Garlic Extract in Subjects with Grade I Hypertension and Antihypertensive Drug Therapy: A Randomized, Triple-Blind Controlled Trial, Nutrients (2023) — A randomized, triple-blind controlled trial tested an optimized aged garlic extract as add-on therapy in subjects with grade I hypertension already on antihypertensive drugs. [https://pmc.ncbi.nlm.nih.gov/articles/PMC10490347/]
  - Effect of garlic extract on weight loss and gut microbiota composition in obese women: A double-blind randomized controlled trial, Frontiers in Nutrition (2022) — This 2022 double-blind RCT in Frontiers in Nutrition found that garlic extract (800 mg/day, ~2,200 mcg allicin) for 2 months on a low-calorie diet significantly increased beneficial gut Bifidobacterium (P=0.005), though weight loss did not differ significantly between garlic and placebo groups. [https://doi.org/10.3389/fnut.2022.1007506]
  - The effect of aged garlic extract on the atherosclerotic process - a randomized double-blind placebo-controlled trial, BMC complementary medicine and therapies (2020) — Single-center double-blind RCT (n=104, Framingham risk >=10) of aged garlic extract 2400 mg/day vs placebo for 1 year found AGE significantly slowed coronary artery calcification progression (OR 2.95, 95% CI 1.05-8.27), lowered IL-6, blood glucose, and reduced systolic BP from 148 to 140 mmHg; no side effects. [https://pubmed.ncbi.nlm.nih.gov/32349742/]
  - Garlic: Usefulness and Safety, NIH National Center for Complementary and Integrative Health (2025) — The US NCCIH concludes that evidence suggests garlic supplements may lower blood pressure and cholesterol only to a small extent, and warns that garlic supplements may increase bleeding risk. [https://www.nccih.nih.gov/health/garlic]
  - Aged Garlic Extract Reduces Low Attenuation Plaque in Coronary Arteries of Patients with Metabolic Syndrome in a Prospective Randomized Double-Blind Study, The Journal of nutrition (2016) — This 2016 prospective randomized double-blind trial found that 2,400 mg/day aged garlic extract over ~1 year significantly regressed vulnerable low-attenuation coronary plaque on CT angiography versus placebo (-1.5% vs +0.2%, P=0.0049), a marker of plaque stabilization. [https://pubmed.ncbi.nlm.nih.gov/26764322/]
  - Aged garlic extract reduces low attenuation plaque in coronary arteries of patients with diabetes: A randomized, double-blind, placebo-controlled study, Experimental and therapeutic medicine (2020) — Double-blind placebo-controlled RCT in 80 patients with diabetes given aged garlic extract 2400 mg/day vs placebo for 1 year, with serial coronary CT angiography, showed significant regression of low-attenuation (vulnerable) plaque in the AGE group versus progression in placebo (P=0.0415); no significant change in total, fibrous, or fibro-fatty plaque. [https://pubmed.ncbi.nlm.nih.gov/32010322/]
  - Effects of an Optimized Aged Garlic Extract on Cardiovascular Disease Risk Factors in Moderate Hypercholesterolemic Subjects: A Randomized, Crossover, Double-Blind, Sustainedand Controlled Study, Nutrients (2022) — An optimized aged garlic extract trial and pooled analyses report favorable shifts in cardiovascular risk markers, including LDL and blood pressure, in moderately hypercholesterolemic and hypertensive subjects. [https://pmc.ncbi.nlm.nih.gov/articles/PMC8838962/]
  - Comment on: Not just a vampire repellent: the adverse effects of garlic supplements in surgery, Annals of the Royal College of Surgeons of England (2012) — This Royal College of Surgeons letter documents perioperative capillary bleeding linked to garlic supplements via ajoene's irreversible platelet inhibition, recommending discontinuation 7 days before surgery. [https://pmc.ncbi.nlm.nih.gov/articles/PMC3954349/]

---

## Ginger (Zingiber officinale)
URL: https://nutridex.info/s/ginger
Category: Gut & Immune
Evidence: Moderate — Several controlled trials; effects real but modest or context-dependent.
Time-tested root for nausea, with modest joint-pain support.

Quick answer: Ginger is used for reduces nausea and vomiting in pregnancy, often outperforming placebo and at least matching vitamin b6. NutriDex grades the human evidence as moderate — Several controlled trials; effects real but modest or context-dependent. Based on 18 cited human studies (18 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Ginger (Zingiber officinale) is a culinary rhizome whose pungent gingerols and shogaols underlie its best-established use: relieving nausea and vomiting. Meta-analyses support its benefit for pregnancy-associated nausea (superior to placebo and comparable to or better than vitamin B6) and for postoperative nausea, with more limited and dose-dependent effects in chemotherapy-induced vomiting. For knee osteoarthritis, pooled evidence is mixed: some meta-analyses show a small reduction in pain and disability, while others find the evidence insufficient and note higher dropout from GI side effects. Overall the human evidence is best characterized as moderate—genuinely useful for nausea but modest and inconsistent for pain. Ginger is generally well tolerated, but it can affect platelet function and may add to bleeding risk, so caution is warranted with anticoagulants and around surgery.

Benefits / uses: Reduces nausea and vomiting in pregnancy, often outperforming placebo and at least matching vitamin B6; May lessen acute vomiting from chemotherapy at modest doses, though effects on nausea overall are inconsistent; Helps reduce postoperative nausea and the need for rescue antiemetics; Provides modest relief of osteoarthritis pain and disability in some trials (effect is small and not seen in all reviews); Commonly used for motion sickness and general digestive upset, though high-quality data here are weaker.
Active compounds: Gingerols (notably 6-gingerol); Shogaols (formed when ginger is dried/heated); Zingerone; Paradols; Volatile oils (zingiberene).
Dose: 1–1.5 g/day of dried ginger powder in divided doses (typically 250 mg, 2–4x daily); doses at or below ~1 g/day are most studied for nausea, with up to ~2 g/day used short-term for osteoarthritis.
Safety: Generally well tolerated at culinary and supplemental doses; the most common side effects are mild heartburn, belching, and GI upset, which drive higher discontinuation in some trials. Ginger can inhibit platelet aggregation (via thromboxane synthetase) and may increase bleeding risk—use caution and consider stopping ~1–2 weeks before surgery, and avoid combining high doses with anticoagulants/antiplatelets (warfarin, DOACs, aspirin, clopidogrel) without medical supervision and INR monitoring. It may also lower blood glucose and blood pressure, so monitor if on antidiabetic or antihypertensive medication. For pregnancy, doses up to ~1 g/day appear reasonably safe and effective for nausea, but use higher doses only under clinician guidance; safety in breastfeeding is less established. People with gallstones or active bleeding disorders should be cautious, and anyone on chronic medications should consult a clinician before using concentrated extracts.

Cited studies (18):
  - Effectiveness of ginger supplementation in alleviating hyperemesis gravidarum: a systematic review and meta-analysis, American journal of translational research (2025) — In a 2025 systematic review/meta-analysis of 10 RCTs and comparative studies in hyperemesis gravidarum, ginger significantly reduced nausea and vomiting symptoms (pooled OR 0.41, 95% CI 0.22-0.79, p=0.008) and lowered nausea severity vs placebo (SMD -0.66, 95% CI -1.10 to -0.22, p=0.003), with minimal side effects. [https://pubmed.ncbi.nlm.nih.gov/40226035/]
  - The Use of Ginger Bioactive Compounds in Pregnancy: An Evidence Scan and Umbrella Review of Existing Meta-Analyses, Advances in nutrition (Bethesda, Md.) (2024) — A 2024 evidence scan and umbrella review of existing meta-analyses (search through Dec 2023) found ginger is effective at reducing nausea in pregnancy, though included studies had substantial heterogeneity and low methodological quality. [https://pmc.ncbi.nlm.nih.gov/articles/PMC11536023/]
  - The efficacy and safety of complementary and alternative medicine in the treatment of nausea and vomiting during pregnancy: A systematic review and meta-analysis, Frontiers in Public Health (2023) — A 2023 systematic review and meta-analysis of complementary/alternative therapies for nausea and vomiting in pregnancy found ginger was as effective as diphenhydramine and outperformed placebo for symptom relief. [https://www.frontiersin.org/journals/public-health/articles/10.3389/fpubh.2023.1108756/full]
  - Pharmacological properties of ginger (Zingiber officinale): what do meta-analyses say? a systematic review, Frontiers in pharmacology (2025) — Systematic review of meta-analyses (2010-2025): ginger supplementation significantly reduced inflammatory markers (CRP, hs-CRP, TNF-alpha), lowered HbA1c and fasting blood glucose in T2DM, reduced oxidative stress (lower malondialdehyde, higher glutathione peroxidase), and alleviated pregnancy nausea without significant effect on vomiting frequency. Typical doses 1-3 g/day; high heterogeneity (I2 up to 98.1%) noted. [https://pubmed.ncbi.nlm.nih.gov/40808693/]
  - The effect of oral supplementation of ginger on glycemic control of patients with type 2 diabetes mellitus - A systematic review and meta-analysis, Clinical nutrition ESPEN (2024) — Systematic review/meta-analysis of 5 RCTs (1.2-2 g/day, 4-12 weeks) in type 2 diabetes: pooled analysis found NO statistically significant effect of ginger on fasting blood glucose or HbA1c, though 2 individual trials showed significant FBS reductions; tempers earlier positive glycemic meta-analyses and underscores limited, low-quality evidence base. [https://pubmed.ncbi.nlm.nih.gov/39053695/]
  - Orally consumed ginger and human health: an umbrella review, The American journal of clinical nutrition (2022) — AMSTAR-2/GRADE umbrella review of 24 systematic reviews: strongest evidence (GRADE high) for antiemetic effect in pregnant women (large effect size) and analgesic effect in osteoarthritis (small effect size); glycemic control benefit (none-to-very-large, GRADE very low-moderate); significant positive effects also on blood pressure, weight, dysmenorrhea, postoperative nausea, and chemotherapy-induced vomiting. Effective dose 0.5-3 g/day in capsule form up to 3 months; appears safe. [https://pubmed.ncbi.nlm.nih.gov/35147170/]
  - Does the Oral Administration of Ginger Reduce Chemotherapy-Induced Nausea and Vomiting?: A Meta-analysis of 10 Randomized Controlled Trials, Cancer nursing (2019) — Meta-analysis of 10 RCTs: ginger significantly reduced the likelihood of chemotherapy-induced nausea and vomiting vs control (pooled OR 0.71, 95% CI 0.54-0.94, p=0.015), indicating a modest protective effect. [https://pubmed.ncbi.nlm.nih.gov/30299420/]
  - A systematic review and meta-analysis of the effect and safety of ginger in the treatment of pregnancy-associated nausea and vomiting, Nutrition journal (2014) — 12 RCTs, 1278 pregnant women: ginger significantly improved nausea symptoms vs placebo (MD 1.20, 95% CI 0.56-1.84, p=0.0002, I2=0%); trend but no significant reduction in vomiting episodes (MD 0.72, 95% CI -0.03-1.46, p=0.06). No significant increase in spontaneous abortion (RR 3.14, 95% CI 0.65-15.11) or side-effects; doses <1500 mg/day favored for nausea relief. [https://pubmed.ncbi.nlm.nih.gov/24642205/]
  - Ginger for treating nausea and vomiting: an overview of systematic reviews and meta-analyses, International journal of food sciences and nutrition (2024) — An overview of 15 meta-analyses concluded ginger is effective for reducing nausea and vomiting across pregnancy, chemotherapy, and postoperative settings, reducing the need for rescue antiemetics, while flagging variable methodological quality of the underlying reviews. [https://pubmed.ncbi.nlm.nih.gov/38072785/]
  - Effects of Ginger Intake on Chemotherapy-Induced Nausea and Vomiting: A Systematic Review of Randomized Clinical Trials, Nutrients (2022) — In a systematic review of 23 RCTs, ginger showed no significant overall effect on chemotherapy-induced nausea or vomiting, but a subgroup taking ≤1 g/day for more than four days had significantly less acute vomiting (OR 0.30; 95% CI 0.12–0.79). [https://pmc.ncbi.nlm.nih.gov/articles/PMC9739555/]
  - A systematic review and meta-analysis of the effect and safety of ginger in the treatment of pregnancy-associated nausea and vomiting, Nutrition journal (2014) — A meta-analysis of 12 RCTs in 1,278 pregnant women found ginger significantly improved nausea symptoms versus placebo, though it did not significantly reduce vomiting episodes and overall evidence quality was low. [https://pmc.ncbi.nlm.nih.gov/articles/PMC3995184/]
  - Efficacy and safety of ginger in osteoarthritis patients: a meta-analysis of randomized placebo-controlled trials, Osteoarthritis and cartilage (2015) — A meta-analysis of 5 placebo-controlled RCTs (593 osteoarthritis patients) found ginger produced a small but statistically significant reduction in pain (SMD -0.30) and disability (SMD -0.22), but patients on ginger were more than twice as likely to discontinue. [https://pubmed.ncbi.nlm.nih.gov/25300574/]
  - Effectiveness of Ginger on Pain and Function in Knee Osteoarthritis: A PRISMA Systematic Review and Meta-Analysis, Pain physician (2020) — A PRISMA systematic review of knee osteoarthritis trials found only a small pain reduction with oral ginger capsules (mean difference -7.88 mm) and concluded there was insufficient evidence to support oral ginger over placebo for pain or function. [https://pubmed.ncbi.nlm.nih.gov/32214292/]
  - Effects of Ginger (Zingiber officinale Roscoe) on Type 2 Diabetes Mellitus and Components of the Metabolic Syndrome: A Systematic Review and Meta-Analysis of Randomized Controlled Trials, Evidence-based complementary and alternative medicine : eCAM (2018) — A meta-analysis of 10 RCTs (490 participants) found ginger significantly lowered HbA1c (pooled weighted mean difference -1.00%; 95% CI -1.56 to -0.44) and, in type 2 diabetes subgroups, reduced fasting blood glucose by about 21 mg/dL (WMD -21.24; 95% CI -33.21 to -9.26). [https://pubmed.ncbi.nlm.nih.gov/29541142/]
  - Does ginger supplementation lower blood pressure? A systematic review and meta-analysis of clinical trials, Phytotherapy research : PTR (2019) — A systematic review and meta-analysis of 6 clinical trials (345 participants) found ginger supplementation significantly lowered systolic blood pressure (-6.36 mmHg) and diastolic blood pressure (-2.12 mmHg), with larger effects at doses of 3 g/day or more and in participants aged 50 or younger. [https://pubmed.ncbi.nlm.nih.gov/30972845/]
  - Effect of ginger (Zingiber officinale) intake on human serum lipid profile: Systematic review and meta-analysis, Phytotherapy research : PTR (2023) — A systematic review and meta-analysis found ginger intake significantly reduced total cholesterol (SMD -0.44; 95% CI -0.86 to -0.02) and triglycerides (SMD -0.61; 95% CI -1.14 to -0.08), with no significant effect on LDL or HDL cholesterol. [https://pubmed.ncbi.nlm.nih.gov/36786398/]
  - Comparison between the efficacy of ginger and sumatriptan in the ablative treatment of the common migraine, Phytotherapy research : PTR (2014) — A double-blind randomized trial in 100 adults with acute migraine without aura found ginger powder relieved headache severity at 2 hours comparably to sumatriptan, with fewer clinical adverse effects in the ginger group. [https://pubmed.ncbi.nlm.nih.gov/23657930/]
  - Ginger Root (2024) — A pharmacology reference summarizes that ginger may inhibit thromboxane synthetase and platelet aggregation, with case reports of raised INR alongside warfarin/phenprocoumon, supporting bleeding-risk caution despite reassuring healthy-volunteer data. [https://www.ncbi.nlm.nih.gov/books/NBK565886/]

---

## St. John's Wort (Hypericum perforatum)
URL: https://nutridex.info/s/st-johns-wort
Category: Sleep & Mood
Evidence: Moderate — Several controlled trials; effects real but modest or context-dependent.
A flowering herb with real antidepressant activity for mild-to-moderate depression — and serious, sometimes life-threatening drug interactions.

Quick answer: St. John's Wort is used for reduces symptoms of mild-to-moderate depression, with efficacy broadly comparable to standard ssris in several meta-analyses. NutriDex grades the human evidence as moderate — Several controlled trials; effects real but modest or context-dependent. Based on 16 cited human studies (16 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

St. John's Wort (Hypericum perforatum) is a flowering herb whose standardized extracts have demonstrated genuine antidepressant activity for mild-to-moderate depression, performing similarly to placebo-superior SSRIs across multiple randomized trials and meta-analyses, often with fewer side effects and lower dropout rates. Its principal active constituents are hyperforin and hypericin, with hyperforin thought to be the main contributor to both efficacy and its pharmacokinetic dangers. The central concern is that hyperforin is a potent inducer of CYP3A4 and P-glycoprotein via activation of the pregnane X receptor, which accelerates clearance of many co-administered drugs. This has produced documented contraceptive failure and breakthrough bleeding, reduced plasma levels of warfarin, cyclosporine and other immunosuppressants, antiretrovirals, digoxin, and chemotherapy agents, plus serotonin syndrome when combined with SSRIs, SNRIs, or other serotonergic drugs. Evidence quality for efficacy is moderate (heterogeneous trials, mostly outside the US, limited data in severe depression), and product standardization varies widely between brands. It should be regarded as an active pharmacological agent rather than a benign supplement.

Benefits / uses: Reduces symptoms of mild-to-moderate depression, with efficacy broadly comparable to standard SSRIs in several meta-analyses; Generally better short-term tolerability and lower treatment-discontinuation rates than conventional antidepressants in head-to-head trials; May modestly improve mood-related sleep disturbance and somatic complaints that accompany depressive disorders (secondary, less well-established).
Active compounds: Hyperforin (primary driver of antidepressant activity and of CYP3A4/P-glycoprotein induction); Hypericin and pseudohypericin (also linked to photosensitivity); Flavonoids such as quercetin and rutin; Standardized extracts are typically dosed to 0.3% hypericin and/or defined hyperforin content.
Dose: Standardized extract (e.g., 0.3% hypericin / ~3-5% hyperforin) 300 mg three times daily (900-1,800 mg/day total) is the most-studied regimen for depression; antidepressant effects build over 4-6 weeks. Lower-hyperforin formulations (<1 mg hyperforin/day) reduce — but do not eliminate — interaction risk.
Safety: DANGER: This is a pharmacologically active herb, not a benign supplement. As a potent inducer of CYP3A4 and P-glycoprotein, it can dangerously lower blood levels and efficacy of many drugs — combined oral and other hormonal contraceptives (risk of unintended pregnancy and breakthrough bleeding), warfarin and other anticoagulants, immunosuppressants such as cyclosporine and tacrolimus (risk of organ-transplant rejection), antiretrovirals (e.g., indinavir and other HIV drugs), many chemotherapy agents (e.g., irinotecan, imatinib), digoxin, some statins, certain anticonvulsants, and direct-acting antivirals. Combining it with SSRIs, SNRIs, MAOIs, triptans, tramadol, or other serotonergic agents can precipitate serotonin syndrome (agitation, hyperthermia, rapid heart rate, muscle rigidity — a medical emergency). It can also cause photosensitivity (sunburn-like skin reactions), and discontinuation can cause rebound rises in previously suppressed drug levels. AVOID in pregnancy and breastfeeding, in anyone taking the medications above, in people with bipolar disorder (mania/hypomania risk) or scheduled for surgery (stop at least 5 days before, ideally 1-2 weeks, due to anesthesia and bleeding interactions). Always disclose use to physicians and pharmacists, and never self-combine with antidepressants. Product potency varies widely, so interaction risk cannot be reliably predicted from the label alone.

Cited studies (16):
  - The efficacy and safety of St. John's wort extract in depression therapy compared to SSRIs in adults: A meta-analysis of randomized clinical trials, Advances in clinical and experimental medicine : official organ Wroclaw Medical University (2023) — In a 2023 meta-analysis of 14 randomized trials, St. John's wort extract reduced depressive symptoms more than SSRIs (pooled OR 2.44, 95% CI 1.33-4.45) with fewer reported side effects, though heterogeneity was high (I-squared = 77%). [https://pubmed.ncbi.nlm.nih.gov/36226689/]
  - Documentary Analysis of Hypericum perforatum (St. John's Wort) and Its Effect on Depressive Disorders, Pharmaceuticals (Basel, Switzerland) (2024) — Documentary analysis of 60 publications (16 RCTs) reported St. John's Wort extract Ze 117 caused adverse effects in 19% of patients versus 32% for sertraline, supporting comparable efficacy with a better tolerability profile in mild-to-moderate depression. [https://pmc.ncbi.nlm.nih.gov/articles/PMC11728764/]
  - A systematic review of St. John's wort for major depressive disorder, Systematic reviews (2016) — 35 studies / 6,993 patients with major depressive disorder. SJW yielded more treatment responders than placebo (RR 1.53, 95% CI 1.19-1.97; SMD 0.49, 95% CI 0.23-0.74) and no significant difference vs antidepressants in mild-moderate MDD (RR 1.01, 95% CI 0.90-1.14). Fewer adverse events than antidepressants (OR 0.67, 95% CI 0.56-0.81). Heterogeneity high; lack of data in severe depression (moderate-quality GRADE). [https://pubmed.ncbi.nlm.nih.gov/27589952/]
  - Clinical use of Hypericum perforatum (St John's wort) in depression: A meta-analysis, Journal of affective disorders (2017) — 27 RCTs / 3,808 patients comparing SJW directly with SSRIs. Comparable response (pooled RR 0.983, 95% CI 0.924-1.042) and remission (RR 1.013, 95% CI 0.892-1.134), with significantly lower discontinuation/dropout (OR 0.587, 95% CI 0.478-0.697). Concludes comparable efficacy and better tolerability vs SSRIs for mild-to-moderate depression; trials only 4-12 weeks, severe depression unproven. [https://pubmed.ncbi.nlm.nih.gov/28064110/]
  - St John's wort for major depression, The Cochrane database of systematic reviews (2008) — The Cochrane review found Hypericum extracts superior to placebo and similarly effective to standard antidepressants in major depression, with fewer dropouts due to adverse events than older antidepressants. [https://pubmed.ncbi.nlm.nih.gov/18843608/]
  - Treatment of somatoform disorders with St. John's wort: a randomized, double-blind and placebo-controlled trial, Psychosomatic medicine (2004) — In a randomized, double-blind, placebo-controlled trial in somatoform disorders, St. John's wort extract LI 160 (600 mg/day for 6 weeks) produced 45.4% responders versus 20.9% on placebo (p=0.0006), with statistically significant superiority across all six primary outcome measures. [https://pubmed.ncbi.nlm.nih.gov/15272100/]
  - Effect of St John's wort on severity, frequency, and duration of hot flashes in premenopausal, perimenopausal and postmenopausal women: a randomized, double-blind, placebo-controlled study, Menopause (New York, N.Y.) (2010) — In a randomized, double-blind, placebo-controlled trial, St. John's wort over 8 weeks significantly reduced both the frequency (p<0.001) and severity (p<0.001) of hot flashes in peri- and postmenopausal women compared with placebo. [https://pubmed.ncbi.nlm.nih.gov/20216274/]
  - St John's wort or sertraline? Randomized controlled trial in primary care, Canadian family physician Medecin de famille canadien (2002) — Double-blind 12-week primary-care RCT, 87 patients with major depression, SJW (900-1800 mg/d) vs sertraline (50-100 mg/d). No significant difference in Hamilton-D or Beck Depression Inventory change between groups at 12 weeks; significantly fewer side effects with SJW at weeks 2 and 4. [https://pubmed.ncbi.nlm.nih.gov/12053635/]
  - The Effects of St. John’s Wort and its Interactions with SSRI’s, European Psychiatry (2025) — Review found St. John's Wort induces CYP3A4/CYP2C19, raising serotonin syndrome risk when combined with SSRIs (notably citalopram, escitalopram, sertraline) and recommends screening patients on SSRIs for SJW use. [https://doi.org/10.1192/j.eurpsy.2025.2087]
  - Clinical relevance of St. John's wort drug interactions revisited, British journal of pharmacology (2020) — Authoritative mechanistic review of SJW drug interactions. SJW is a potent pregnane-X-receptor activator, inducing CYP3A4 and P-glycoprotein; degree of CYP3A4 induction correlates with hyperforin content. Reduces bioavailability/efficacy of cyclosporine, tacrolimus, digoxin, indinavir, warfarin, alprazolam, simvastatin, and oral contraceptives; low-hyperforin (<1 mg/day) preparations carry lower interaction risk. [https://pubmed.ncbi.nlm.nih.gov/31742659/]
  - St. John (2020) — The NIH LiverTox database assigns St. John's wort a likelihood score of E (unlikely cause of clinically apparent liver injury), finding no convincing case reports or enzyme elevations from the herb itself, but cautioning it can raise or lower drug-induced liver injury risk from co-administered medications via CYP3A4/2C9 and P-glycoprotein induction. [https://www.ncbi.nlm.nih.gov/books/NBK548880/]
  - Understanding drug interactions with St John's wort (Hypericum perforatum L.): impact of hyperforin content, The Journal of pharmacy and pharmacology (2019) — A pharmacological review concluded that drug-interaction risk is hyperforin-dose-dependent, with products delivering less than 1 mg hyperforin per day far less likely to cause major CYP3A4/P-glycoprotein interactions (but not interaction-free). [https://pubmed.ncbi.nlm.nih.gov/29411879/]
  - St John's wort (Hypericum perforatum): drug interactions and clinical outcomes, British journal of clinical pharmacology (2002) — A clinical review of St. John's wort pharmacokinetics and interactions documents potent PXR-mediated induction of CYP3A4 and P-glycoprotein and resulting failure of cyclosporine, indinavir, warfarin, digoxin, and other narrow-therapeutic-index drugs. [https://pmc.ncbi.nlm.nih.gov/articles/PMC1874438/]
  - Acute heart transplant rejection due to Saint John's wort, Lancet (London, England) (2000) — A report in The Lancet described two heart transplant recipients who developed acute graft rejection after self-medicating with St. John's wort, driven by a metabolic interaction that lowered cyclosporine levels into the subtherapeutic range. [https://pubmed.ncbi.nlm.nih.gov/10683008/]
  - The interaction between St John's wort and an oral contraceptive, Clinical pharmacology and therapeutics (2003) — In a controlled study, St. John's wort shortened ethinyl estradiol half-life (23.4 to 12.2 hours) and increased norethindrone clearance, with breakthrough bleeding in 7 of 12 women (vs 2 of 12 at baseline), indicating reduced oral-contraceptive reliability. [https://pubmed.ncbi.nlm.nih.gov/14663455/]
  - St. John's Wort and Depression: In Depth, NIH National Center for Complementary and Integrative Health (2017) — The U.S. NIH National Center for Complementary and Integrative Health warns that combining St. John's wort with antidepressants can precipitate potentially life-threatening serotonin syndrome, and notes the FDA has not approved it for depression because efficacy evidence remains inconclusive. [https://www.nccih.nih.gov/health/st-johns-wort-and-depression-in-depth]

---

## Alpha-Lipoic Acid (acidum thiocticum (thioctic acid))
URL: https://nutridex.info/s/alpha-lipoic-acid
Category: Heart & Metabolic, Nootropic
Evidence: Mixed — Conflicting results across studies; benefit uncertain.
A mitochondrial antioxidant best known for diabetic nerve symptoms, but recent rigorous trials temper the hype.

Quick answer: Alpha-Lipoic Acid is used for may modestly reduce symptoms of diabetic peripheral neuropathy (burning, tingling, numbness); historically the strongest signal came from short-term intravenous 600 mg, while recent high-quality oral trials show little clinical benefit at 6 months.. NutriDex grades the human evidence as mixed — Conflicting results across studies; benefit uncertain. Based on 19 cited human studies (19 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Alpha-lipoic acid (ALA, thioctic acid) is a sulfur-containing compound made in the body and used as a dietary supplement and, in some countries, a prescription drug for diabetic neuropathy. Its main rationale is antioxidant and mitochondrial activity, and its best-studied use is symptomatic diabetic peripheral neuropathy. Earlier work suggested short-term intravenous ALA improved neuropathic symptoms, but a 2024 Cochrane review of oral ALA found it probably has little or no effect on neuropathy symptoms or nerve impairment at six months (moderate-certainty evidence). For metabolic outcomes, meta-analyses show real but small reductions in weight, BMI, fasting glucose, and HbA1c that authors judged not clinically important. Overall the evidence is genuinely mixed: a plausible mechanism and consistent small effects, but recent rigorous trials undercut the larger benefits once attributed to it. It is generally well tolerated, with most concern around hypoglycemia risk and rare hypersensitivity.

Benefits / uses: May modestly reduce symptoms of diabetic peripheral neuropathy (burning, tingling, numbness); historically the strongest signal came from short-term intravenous 600 mg, while recent high-quality oral trials show little clinical benefit at 6 months.; Produces small, statistically significant reductions in body weight and BMI in pooled trials (roughly 0.7-2.3 kg), but the magnitude is too small to be clinically meaningful on its own.; Slightly lowers fasting glucose and HbA1c in type 2 diabetes, though the changes fall below the threshold considered clinically important.; Acts as a regenerable antioxidant and metal chelator and regenerates other antioxidants (vitamins C and E, glutathione); broader claims for cognition, energy, and 'detox' are largely unproven in humans..
Active compounds: R-alpha-lipoic acid (the natural, biologically active enantiomer); S-alpha-lipoic acid (synthetic enantiomer present in racemic supplements); Dihydrolipoic acid (DHLA, the reduced active metabolite).
Dose: Oral: 300-600 mg/day (commonly 600 mg, often divided and taken on an empty stomach); clinical neuropathy studies have used up to 1,800 mg/day orally and 600 mg/day intravenously for ~3 weeks.
Safety: Generally well tolerated; the most common side effects are mild gastrointestinal upset (nausea, abdominal pain), headache, and skin rash, and rare allergic/hypersensitivity reactions including insulin autoimmune syndrome (autoimmune hypoglycemia), reported mainly in people with certain HLA genotypes and more often in East Asian populations. Because ALA can lower blood glucose, it may add to the effect of insulin or other antidiabetic drugs and cause hypoglycemia, so glucose should be monitored and medication doses may need adjustment. It may also lower thyroid hormone levels and theoretically interfere with thyroid medication, and it can chelate metals, so spacing from mineral supplements is reasonable. Avoid or use only under medical supervision in pregnancy and breastfeeding (insufficient safety data), in children, in people with thiamine deficiency or heavy alcohol use (deficiency should be corrected first), and in anyone with a prior reaction to ALA. Discuss with a clinician before use if you have diabetes, thyroid disease, or take glucose-lowering, thyroid, or chemotherapy agents; ALA is a supplement, not a substitute for prescribed neuropathy or diabetes treatment.

Cited studies (19):
  - Alpha-lipoic acid for diabetic peripheral neuropathy, Cochrane Database of Systematic Reviews (2024) — 2024 Cochrane review found oral alpha-lipoic acid probably has little or no effect on diabetic neuropathy symptoms (Total Symptom Score) or nerve impairment at 6 months versus placebo, with moderate-certainty evidence. [https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012967.pub2/full]
  - Effectiveness of alpha-lipoic acid in patients with neuropathic pain associated with type I and type II diabetes mellitus: A systematic review and meta-analysis, Medicine (2023) — 2023 systematic review/meta-analysis of ALA for diabetic neuropathic pain reported short-term symptom reductions but concluded there is no solid evidence supporting ALA as a stand-alone therapy and no clearly superior dose or route. [https://pmc.ncbi.nlm.nih.gov/articles/PMC10627688/]
  - The effects of alpha lipoic acid (ALA) supplementation on blood pressure in adults: a GRADE-assessed systematic review and dose-response meta-analysis of randomized controlled trials, Frontiers in cardiovascular medicine (2023) — A 2023 GRADE-assessed dose-response meta-analysis found alpha-lipoic acid supplementation significantly lowered systolic blood pressure (WMD -5.46 mmHg) and diastolic blood pressure (about -3.4 mmHg) in adults versus control. [https://pubmed.ncbi.nlm.nih.gov/37942070/]
  - The effect of alpha-lipoic acid supplementation on anthropometric, glycemic, lipid, oxidative stress, and hormonal parameters in individuals with polycystic ovary syndrome: a systematic review and meta-analysis of randomized clinical trials, Obstetrics & gynecology science (2024) — A 2023 systematic review and meta-analysis in women with PCOS found alpha-lipoic acid significantly reduced fasting blood sugar (SMD -0.60; moderate certainty) and HOMA-IR (SMD -2.03; low certainty), but did not significantly change BMI, lipids, sex hormones, or oxidative stress markers. [https://pubmed.ncbi.nlm.nih.gov/38044616/]
  - Ranking Alpha Lipoic Acid and Gamma Linolenic Acid in Terms of Efficacy and Safety in the Management of Adults With Diabetic Peripheral Neuropathy: A Systematic Review and Network Meta-analysis, Canadian journal of diabetes (2024) — Network meta-analysis of 11 studies found 8/11 (73%) reported significant benefit of ALA vs placebo, with Total Symptom Score for ALA 600 mg/day about 1.05 points lower than placebo. [https://pubmed.ncbi.nlm.nih.gov/38295879/]
  - The effects of alpha lipoic acid (ALA) supplementation on blood pressure in adults: a GRADE-assessed systematic review and dose-response meta-analysis of randomized controlled trials, Frontiers in cardiovascular medicine (2023) — GRADE-assessed dose-response meta-analysis of 11 RCTs (674 patients) found ALA supplementation reduced SBP by 5.46 mmHg (95% CI -9.27 to -1.65) and DBP by 3.36 mmHg (95% CI -4.99 to -1.74). [https://pmc.ncbi.nlm.nih.gov/articles/PMC10628535/]
  - Effects of Alpha-Lipoic Acid Supplementation on Weight Loss, Inflammatory, Lipid, and Hematological Levels in Patients With Chronic Kidney Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials, Journal of renal nutrition : the official journal of the Council on Renal Nutrition of the National Kidney Foundation (2025) — Meta-analysis of RCTs evaluated ALA's effects on inflammatory, lipid, and hematological markers and anthropometric indices in patients with chronic kidney disease. [https://pubmed.ncbi.nlm.nih.gov/39413860/]
  - Effects of Oral Alpha-Lipoic Acid Treatment on Diabetic Polyneuropathy: A Meta-Analysis and Systematic Review, Nutrients (2023) — Systematic review/meta-analysis of RCTs of oral ALA in diabetic polyneuropathy. ALA significantly reduced neuropathic symptoms (pooled Total Symptom Score) vs placebo, but the authors judged the effect size to be of modest/uncertain clinical relevance and quality of evidence limited, contrasting with stronger short-term effects seen with IV administration. [https://pubmed.ncbi.nlm.nih.gov/37630823/]
  - Alpha-lipoic acid supplementation affects serum lipids in a dose and duration-dependent manner in different health status, International journal for vitamin and nutrition research. Internationale Zeitschrift fur Vitamin- und Ernahrungsforschung. Journal international de vitaminologie et de nutrition (2023) — An updated dose- and duration-response meta-analysis concluded alpha-lipoic acid (300-1200 mg/day, 2-16 weeks) reduced total cholesterol and LDL-cholesterol in a dose- and duration-dependent manner that varied by participants' health status. [https://pubmed.ncbi.nlm.nih.gov/34605276/]
  - Efficacy and safety of oral alpha-lipoic acid supplementation for type 2 diabetes management: a systematic review and dose-response meta-analysis of randomized trials, Endocrine connections (2022) — Dose-response meta-analysis of RCTs in type 2 diabetes. Oral ALA significantly lowered fasting blood glucose (WMD approximately -8 to -10 mg/dL) and HbA1c, with an apparent dose-response relationship up to ~600 mg/day; effects on insulin/HOMA-IR were less consistent. Generally well tolerated. [https://pubmed.ncbi.nlm.nih.gov/36006850/]
  - Scientific opinion on the relationship between intake of alpha-lipoic acid (thioctic acid) and the risk of insulin autoimmune syndrome, EFSA journal. European Food Safety Authority (2021) — A 2021 EFSA Panel opinion concluded that oral alpha-lipoic acid can trigger insulin autoimmune syndrome (autoimmune hypoglycaemia), deriving an upper safe intake of 0.6 mg/kg body weight/day (about 42 mg/day for a 70 kg adult) for ALA added to foods. [https://pmc.ncbi.nlm.nih.gov/articles/PMC8173454/]
  - Efficacy and safety of oral alpha-lipoic acid supplementation for type 2 diabetes management: a systematic review and dose-response meta-analysis of randomized trials, Endocrine connections (2022) — In type 2 diabetes, each 500 mg/day of oral ALA lowered HbA1c by ~0.17% and fasting glucose by ~6 mg/dL, but authors concluded the cardiometabolic effects were statistically significant yet not clinically important. [https://pmc.ncbi.nlm.nih.gov/articles/PMC9578061/]
  - Alpha-lipoic acid (ALA) as a supplementation for weight loss: results from a meta-analysis of randomized controlled trials, Obesity reviews : an official journal of the International Association for the Study of Obesity (2017) — Pooled placebo-controlled trials found ALA supplementation significantly reduced body weight (about 1.3 kg) and BMI, describing a small but significant short-term weight-loss effect. [https://pubmed.ncbi.nlm.nih.gov/28295905/]
  - Alpha-lipoic acid supplementation significantly reduces the risk of obesity in an updated systematic review and dose response meta-analysis of randomised placebo-controlled clinical trials, International journal of clinical practice (2020) — An updated dose-response meta-analysis reported ALA significantly reduced body weight (WMD -2.29 kg) and BMI (WMD -0.49 kg/m2) versus placebo across randomized trials. [https://pubmed.ncbi.nlm.nih.gov/32091656/]
  - An updated systematic review and dose-response meta-analysis of the randomized controlled trials on the effects of alpha-lipoic acid supplementation on inflammatory biomarkers, International journal for vitamin and nutrition research. Internationale Zeitschrift fur Vitamin- und Ernahrungsforschung. Journal international de vitaminologie et de nutrition (2023) — An updated dose-response meta-analysis reported alpha-lipoic acid significantly reduced CRP (WMD -0.69 mg/L), IL-6 (-1.83 pg/mL), and TNF-alpha (-0.45 pg/mL) in adults, with CRP reductions seen mainly when baseline CRP exceeded 3 mg/L and trial duration was over 8 weeks. [https://pubmed.ncbi.nlm.nih.gov/33827267/]
  - The effects of alpha-lipoic acid supplementation on inflammatory markers among patients with metabolic syndrome and related disorders: a systematic review and meta-analysis of randomized controlled trials, Nutrition & metabolism (2018) — In patients with metabolic syndrome and related disorders, alpha-lipoic acid supplementation significantly decreased C-reactive protein, IL-6, and TNF-alpha concentrations versus control. [https://pubmed.ncbi.nlm.nih.gov/29930690/]
  - An updated systematic review and dose-response meta-analysis of the effects of α-lipoic acid supplementation on glycemic markers in adults, Nutrition (Burbank, Los Angeles County, Calif.) (2021) — An updated dose-response meta-analysis in adults found alpha-lipoic acid supplementation significantly lowered fasting insulin (WMD -0.64) and HOMA-IR (WMD -0.48), while fasting glucose and HbA1c showed no significant change. [https://pubmed.ncbi.nlm.nih.gov/33199187/]
  - Oral treatment with alpha-lipoic acid improves symptomatic diabetic polyneuropathy: the SYDNEY 2 trial, Diabetes care (2006) — Landmark multicenter, double-blind, placebo-controlled RCT (n=181, type 1/2 diabetes). Oral alpha-lipoic acid for 5 weeks reduced Total Symptom Score of distal symmetric polyneuropathy by 51% (600 mg), 48% (1200 mg), and 52% (1800 mg) vs 32% for placebo (all P<0.05). 600 mg once daily gave the best risk-benefit ratio; higher doses added GI adverse events without added efficacy. [https://pubmed.ncbi.nlm.nih.gov/17065669/]
  - Insulin autoimmune syndrome induced by α-lipoic acid in a Caucasian woman: case report, Diabetes care (2011) — A Diabetes Care case report documented insulin autoimmune syndrome with recurrent hypoglycaemia and high insulin-autoantibody titers in a Caucasian woman taking alpha-lipoic acid, with resolution after discontinuation, illustrating a recognized rare adverse effect. [https://pmc.ncbi.nlm.nih.gov/articles/PMC3161272/]

---

## Lutein & Zeaxanthin (Tagetes erecta / Zea mays (dietary sources))
URL: https://nutridex.info/s/lutein-zeaxanthin
Category: Longevity
Evidence: Moderate — Several controlled trials; effects real but modest or context-dependent.
Dietary carotenoids that concentrate in the retina's macular pigment and modestly slow progression to advanced macular degeneration.

Quick answer: Lutein & Zeaxanthin is used for modestly reduces the risk of progression to late (advanced) age-related macular degeneration in people with intermediate amd, per the large areds2 trial and its 10-year follow-up.. NutriDex grades the human evidence as moderate — Several controlled trials; effects real but modest or context-dependent. Based on 19 cited human studies (19 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Lutein and zeaxanthin are dietary xanthophyll carotenoids (from leafy greens, corn, egg yolk, and marigold extracts) that selectively accumulate in the macula of the retina, forming the macular pigment that filters high-energy blue light and quenches oxidative damage. The strongest evidence comes from the AREDS2 randomized trial and its 10-year follow-up, which showed that adding 10 mg lutein plus 2 mg zeaxanthin to an antioxidant-mineral formula modestly slowed progression to late age-related macular degeneration (hazard ratio about 0.91) in people already at intermediate risk, and was superior to and safer than beta-carotene. Supplementation at roughly 10 mg/day or more dependably increases macular pigment optical density, a plausible biological mechanism, though larger doses produce larger effects. Claims for improved everyday vision, glare recovery, and cognitive performance are biologically plausible but supported only by small, mixed trials. There is no good evidence that these carotenoids prevent macular degeneration in healthy eyes or restore lost vision, so the overall benefit is real but modest and confined mainly to those with established intermediate AMD.

Benefits / uses: Modestly reduces the risk of progression to late (advanced) age-related macular degeneration in people with intermediate AMD, per the large AREDS2 trial and its 10-year follow-up.; Reliably raises macular pigment optical density (MPOD), the retinal pigment layer that filters blue light and reduces oxidative stress, at doses of roughly 10 mg/day or higher.; Serve as the safer replacement for beta-carotene in the AREDS2 eye-vitamin formula, avoiding the elevated lung-cancer risk seen with beta-carotene in smokers.; Possible but unproven benefits for visual function (glare recovery, contrast sensitivity) and cognition in older adults; trials are small and inconsistent, so these claims remain preliminary.; No solid evidence that supplements prevent AMD in healthy eyes or reverse existing vision loss..
Active compounds: Lutein (xanthophyll carotenoid); Zeaxanthin (xanthophyll carotenoid); Meso-zeaxanthin (retinal metabolite of lutein, sometimes added to formulas).
Dose: 10 mg lutein + 2 mg zeaxanthin daily (the AREDS2 dose); MPOD studies suggest ≥10 mg/day total is needed for measurable effect. Best absorbed with a fat-containing meal.
Safety: Generally recognized as safe at typical supplemental doses (up to ~20 mg/day lutein); the AREDS2 dose of 10 mg lutein + 2 mg zeaxanthin showed no serious adverse effects over 10 years. Very high or prolonged intake can cause carotenodermia (a harmless yellow-orange skin tint) that reverses on stopping. Unlike beta-carotene, lutein/zeaxanthin did NOT raise lung-cancer risk in AREDS2, making them the preferred carotenoids for current and former smokers. Safety in pregnancy and breastfeeding at high supplemental doses is not well established, so dietary intake is preferred and supplements should be discussed with a clinician. No clinically important drug interactions are well documented, though absorption depends on dietary fat and may be reduced by fat-blocking agents (e.g., orlistat) or bile-acid sequestrants. People with AMD should use these supplements as part of a clinician-directed AREDS2 regimen rather than self-treating, and no one should expect them to reverse existing vision loss.

Cited studies (19):
  - Effect of Antioxidant Supplementation on Macular Pigment Optical Density and Visual Functions: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials, Advances in nutrition (Bethesda, Md.) (2024) — Systematic review and network meta-analysis of 38 RCTs across 8 antioxidant groups. All supplement groups significantly increased macular pigment optical density and contrast sensitivity at low spatial frequency. Lutein + zeaxanthin + fatty acid ranked best for MPOD (SUCRA 99.3%); lutein + zeaxanthin significantly shortened photostress recovery time (HR -5.75; 95% CI -8.80 to -1.70). Evidence quality rated low. [https://pubmed.ncbi.nlm.nih.gov/38582248/]
  - Effect of xanthophyll-rich food and supplement intake on visual outcomes in healthy adults and those with eye disease: a systematic review, meta-analysis, and meta-regression of randomized controlled trials, Nutrition reviews (2023) — Systematic review, meta-analysis and meta-regression of up to 43 RCTs. Xanthophyll (lutein/zeaxanthin) intake increased MPOD by heterochromatic flicker photometry (WMD 0.05; 95% CI 0.03-0.07) and autofluorescence (WMD 0.08; 0.05-0.11), and shortened photostress recovery time (WMD -2.35 s). Visual acuity (logMAR) improved only in patients with eye disease (WMD -0.04; -0.07 to -0.01). MPOD gain correlated with rise in serum lutein. [https://pubmed.ncbi.nlm.nih.gov/37094947/]
  - NIH study confirms benefit of supplements for slowing age-related macular degeneration, National Eye Institute (NEI) (2022) — National Eye Institute statement confirming the AREDS2 10-year results: replacing beta-carotene with lutein/zeaxanthin reduced AMD progression risk by about 26% in those receiving it and avoided the increased lung-cancer risk seen with beta-carotene. [https://www.nei.nih.gov/research-and-training/research-news/nih-study-confirms-benefit-supplements-slowing-age-related-macular-degeneration]
  - The Effect of Lutein/Zeaxanthin Intake on Human Macular Pigment Optical Density: A Systematic Review and Meta-Analysis, Advances in nutrition (Bethesda, Md.) (2021) — Lutein/zeaxanthin supplementation increased macular pigment optical density in a dose-dependent way (mean difference +0.04 units at 5-<20 mg/day, +0.11 units at >=20 mg/day), with no significant effect below 5 mg/day. [https://pmc.ncbi.nlm.nih.gov/articles/PMC8634499/]
  - Efficacy of lutein supplements on macular pigment optical density in highly myopic individuals: A randomized controlled trial, Medicine (2023) — In people with myopia, lutein and zeaxanthin supplementation significantly raised macular pigment optical density versus control (standardized mean difference 0.50, P=0.010). [https://pmc.ncbi.nlm.nih.gov/articles/PMC10036027/]
  - Effect of Antioxidant Supplementation on Macular Pigment Optical Density and Visual Functions: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials, Advances in Nutrition (2024) — Antioxidant supplements containing lutein significantly increased macular pigment optical density and low-frequency contrast sensitivity, but only lutein combined with antioxidants and fatty acids improved visual acuity. [https://advances.nutrition.org/article/S2161-8313(24)00050-4/fulltext]
  - Association between lutein and zeaxanthin status and the risk of cataract: a meta-analysis, Nutrients (2014) — Higher blood concentrations of lutein and zeaxanthin were inversely associated with nuclear cataract risk (lutein pooled RR 0.73, 95% CI 0.59-0.87; zeaxanthin RR 0.63, 95% CI 0.49-0.77), with no significant association for cortical or subcapsular cataract. [https://pubmed.ncbi.nlm.nih.gov/24451312/]
  - Oral Antioxidant and Lutein/Zeaxanthin Supplements Slow Geographic Atrophy Progression to the Fovea in Age-Related Macular Degeneration, Ophthalmology (2025) — Post hoc analysis of AREDS2 eyes with non-central geographic atrophy showed lutein/zeaxanthin vs none slowed proximity-based GA progression toward the fovea (80.1 vs 114.4 microm/year), an approximately 55% slower rate of foveal encroachment over ~3 years. [https://pmc.ncbi.nlm.nih.gov/articles/PMC11663139/]
  - Dietary Supplements for Eye Conditions, NIH National Center for Complementary and Integrative Health — This NIH NCCIH digest concludes that replacing beta-carotene with a 5-to-1 lutein/zeaxanthin mixture may further reduce risk of late AMD, and that in participants with the lowest dietary intake lutein/zeaxanthin was linked to a 32% reduction in progression to cataract surgery. [https://www.nccih.nih.gov/health/providers/digest/dietary-supplements-for-eye-conditions]
  - Lutein + zeaxanthin and omega-3 fatty acids for age-related macular degeneration: the Age-Related Eye Disease Study 2 (AREDS2) randomized clinical trial, JAMA (2013) — Landmark multicenter double-masked phase 3 RCT (n=4203, median 5-yr follow-up). Adding lutein 10 mg + zeaxanthin 2 mg to the AREDS formulation did NOT significantly reduce progression to advanced AMD in primary analysis (HR 0.90; 98.7% CI 0.76-1.07; P=.12; 5-yr progression 29% vs 31% placebo). However, lutein/zeaxanthin was identified as an appropriate substitute for beta carotene, which raised lung-cancer risk in former smokers. [https://pubmed.ncbi.nlm.nih.gov/23644932/]
  - Long-term Outcomes of Adding Lutein/Zeaxanthin and ω-3 Fatty Acids to the AREDS Supplements on Age-Related Macular Degeneration Progression: AREDS2 Report 28, JAMA Ophthalmology (2022) — Adding lutein/zeaxanthin to the AREDS formula reduced progression to late AMD with a hazard ratio of 0.91 (95% CI 0.84-0.99), and was more effective than beta-carotene (HR 0.85 head-to-head). [https://jamanetwork.com/journals/jamaophthalmology/fullarticle/2792855]
  - Effects of Lutein/Zeaxanthin Supplementation on the Cognitive Function of Community Dwelling Older Adults: A Randomized, Double-Masked, Placebo-Controlled Trial, Frontiers in aging neuroscience (2017) — One year of 12 mg/day lutein+zeaxanthin produced statistically significant improvements in complex attention and cognitive flexibility versus placebo in healthy community-dwelling older adults. [https://pubmed.ncbi.nlm.nih.gov/28824416/]
  - The effects of lutein/ zeaxanthin (Lute-gen(®)) on eye health, eye strain, sleep quality, and attention in high electronic screen users: a randomized, double-blind, placebo-controlled study, Frontiers in nutrition (2025) — Supplementation with 10 mg lutein plus 2 mg zeaxanthin-isomers significantly improved objective ocular measures versus placebo (Schirmer tear test, photo-stress recovery time, and tear film break-up time), though self-reported eye strain and sleep measures did not differ between groups. [https://pubmed.ncbi.nlm.nih.gov/39963662/]
  - The Effects of Lutein and Zeaxanthin Supplementation on Cognitive Function in Adults With Self-Reported Mild Cognitive Complaints: A Randomized, Double-Blind, Placebo-Controlled Study, Frontiers in nutrition (2022) — Daily 10 mg lutein + 2 mg zeaxanthin produced significantly greater improvements than placebo in visual episodic memory (p=0.005) and visual learning (p=0.001), with no significant effect on other cognitive tests. [https://pubmed.ncbi.nlm.nih.gov/35252311/]
  - Molecular evidence that oral supplementation with lycopene or lutein protects human skin against ultraviolet radiation: results from a double-blinded, placebo-controlled, crossover study, British Journal of Dermatology (2017) — Oral lutein supplementation significantly attenuated UVA/B- and UVA1-induced upregulation of inflammatory and photodamage gene markers in human skin, providing molecular evidence of photoprotection. [https://doi.org/10.1111/bjd.15080]
  - Antioxidant vitamin and mineral supplements for slowing the progression of age-related macular degeneration, Cochrane Database of Systematic Reviews (2023) — This 2023 Cochrane review found lutein/zeaxanthin alone had only similar-or-slightly-reduced risk of progression to late AMD versus control (RR 0.94, 95% CI 0.87-1.01; low-certainty), though as a beta-carotene replacement within the AREDS formula the hazard ratio was 0.82 (95% CI 0.69-0.96). [https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD000254.pub5/full]
  - Long-term Outcomes of Adding Lutein/Zeaxanthin and ω-3 Fatty Acids to the AREDS Supplements on Age-Related Macular Degeneration Progression: AREDS2 Report 28, JAMA ophthalmology (2022) — 10-year epidemiologic follow-up of the AREDS2 cohort (n=3882). Lutein/zeaxanthin vs no lutein/zeaxanthin reduced progression to late AMD (HR 0.91; 95% CI 0.84-0.99; P=.02); effect was stronger when restricted to the beta-carotene arm (HR 0.80; 0.68-0.92) and in direct comparison vs beta carotene (HR 0.85; 0.73-0.98). Beta carotene nearly doubled lung-cancer odds (OR 1.82) whereas lutein/zeaxanthin did not (OR 1.15). [https://pubmed.ncbi.nlm.nih.gov/35653117/]
  - Intakes of Lutein, Zeaxanthin, and Other Carotenoids and Age-Related Macular Degeneration During 2 Decades of Prospective Follow-up, JAMA ophthalmology (2015) — In the Nurses' Health Study and Health Professionals Follow-up Study, the highest versus lowest intake of bioavailable dietary lutein/zeaxanthin was associated with about a 40% lower risk of advanced (mostly neovascular) age-related macular degeneration (pooled RR 0.59; 95% CI 0.48-0.73; P-trend <0.001). [https://pubmed.ncbi.nlm.nih.gov/26447482/]
  - Associations of multiple carotenoid co-exposure with all-cause and cause-specific mortality in US adults: a prospective cohort study, Frontiers in nutrition (2024) — In a prospective NHANES cohort, the highest versus lowest quartile of serum lutein/zeaxanthin was associated with about 28% lower all-cause mortality (HR 0.72; 95% CI 0.67-0.77) in fully adjusted models. [https://pmc.ncbi.nlm.nih.gov/articles/PMC11335626/]

---

## Inositol (Myo-Inositol)
URL: https://nutridex.info/s/inositol
Category: Sleep & Mood, Heart & Metabolic
Evidence: Moderate — Several controlled trials; effects real but modest or context-dependent.
A sugar-alcohol second messenger studied mainly for PCOS ovulation and insulin sensitivity, with weaker mood data.

Quick answer: Inositol (Myo-Inositol) is used for may improve insulin sensitivity and reduce homa-ir in pcos when compared with folic acid/placebo, though benefits are inconsistent and certainty is low. NutriDex grades the human evidence as moderate — Several controlled trials; effects real but modest or context-dependent. Based on 14 cited human studies (14 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Myo-inositol is a naturally occurring sugar-alcohol (a B-vitamin-like compound, sometimes called vitamin B8) that acts as a second messenger in insulin and FSH signaling, which is the rationale for its use in polycystic ovary syndrome (PCOS). In PCOS, randomized trials and meta-analyses suggest it can improve insulin resistance (lower HOMA-IR and fasting insulin) versus folic acid or placebo and is broadly comparable to metformin with better gastrointestinal tolerability, but the evidence is inconsistent—at least one large meta-analysis found no significant change in metabolic or hormonal markers, and the 2023 international PCOS guideline meta-analysis rated the overall certainty as low and the evidence as inconclusive. Improvements in ovulation appear strongest for D-chiro-inositol rather than myo-inositol alone, and clear gains in clinical pregnancy rates have not been demonstrated. For mood and anxiety, early small trials suggested benefit in panic disorder and OCD at very high doses, but the most rigorous pooled analysis found no statistically significant effect, so these uses remain preliminary. Overall, inositol is a reasonable, well-tolerated adjunct in PCOS with moderate but uncertain evidence, and largely unproven for psychiatric indications.

Benefits / uses: May improve insulin sensitivity and reduce HOMA-IR in PCOS when compared with folic acid/placebo, though benefits are inconsistent and certainty is low; D-chiro-inositol (and myo-inositol combinations) may modestly improve ovulation rates in PCOS, but data are low-certainty and myo-inositol alone has not clearly improved pregnancy rates; Appears roughly comparable to metformin for many reproductive and metabolic markers in PCOS, with fewer gastrointestinal side effects; Possible reduction in androgens (free/total testosterone, androstenedione) in some PCOS trials, but several meta-analyses show no significant hormonal change; Preliminary, unproven signal for panic disorder and OCD; the best pooled analysis found no statistically significant benefit for anxiety or depressive symptoms.
Active compounds: Myo-inositol (predominant stereoisomer); D-chiro-inositol; Inositol phosphoglycan insulin second messengers; Phosphatidylinositol (membrane precursor).
Dose: PCOS: typically 2 g myo-inositol twice daily (4 g/day), often with 400 mcg folic acid, sometimes in a 40:1 myo-:D-chiro-inositol ratio; psychiatric trials used much higher doses (12-18 g/day).
Safety: Generally well tolerated; the most common side effects are mild, dose-related gastrointestinal symptoms (nausea, gas, loose stools, abdominal discomfort), mainly at high doses (12 g/day or more). No serious toxicity has been established and it is used widely in PCOS and during fertility care, but high-quality long-term safety data are limited. Because it can lower blood glucose and insulin resistance, people taking antidiabetic drugs (metformin, insulin, sulfonylureas) should monitor for additive glucose-lowering effects; those with diabetes should consult a clinician. Pregnant and breastfeeding individuals should use only under medical supervision—it is sometimes used during pregnancy/IVF, but evidence is insufficient to confirm safety for self-directed use. People with bipolar disorder should be cautious, as high-dose inositol has theoretical potential to provoke mania/hypomania. It is not a substitute for prescribed treatment of PCOS, infertility, or any psychiatric disorder; discuss with a healthcare provider before use, especially if taking medications or managing a medical condition.

Cited studies (14):
  - Inositol for Polycystic Ovary Syndrome: A Systematic Review and Meta-analysis to Inform the 2023 Update of the International Evidence-based PCOS Guidelines, The Journal of clinical endocrinology and metabolism (2024) — Systematic review informing the 2023 international PCOS guideline: myo-inositol plus folic acid lowered HOMA-IR versus folic acid alone (MD -1.24) but showed no advantage over metformin and no clear reproductive benefit; D-chiro-inositol improved ovulation versus placebo (OR ~11.5), all at low/very-low certainty. [https://pubmed.ncbi.nlm.nih.gov/38163998/]
  - Antenatal dietary supplementation with myo-inositol for preventing gestational diabetes, The Cochrane database of systematic reviews (2023) — Cochrane systematic review (Motuhifonua 2023) found antenatal myo-inositol supplementation may roughly halve the incidence of gestational diabetes versus control (RR 0.53, 95% CI 0.31-0.90), though evidence was low-to-very-low certainty with most trials from Italy. [https://pubmed.ncbi.nlm.nih.gov/36790138/]
  - Inositol supplementation efficacy in improving key cardiometabolic and anthropometric indices: a GRADE-assessed systematic review and meta-analysis of randomized controlled trials, Diabetology &amp; Metabolic Syndrome (2025) — GRADE-assessed systematic review and meta-analysis (2025) found inositol supplementation produced small but significant reductions in BMI (WMD -0.57 kg/m2) and waist-to-hip ratio (WMD -0.02), with effects rated low/very-low certainty. [https://doi.org/10.1186/s13098-025-01980-6]
  - Inositol for Polycystic Ovary Syndrome: A Systematic Review and Meta-analysis to Inform the 2023 Update of the International Evidence-based PCOS Guidelines, The Journal of clinical endocrinology and metabolism (2024) — Meta-analysis of 30 RCTs (n=2230): myo-inositol+folic acid vs folic acid reduced HOMA-IR (MD -1.24 [-1.50,-0.99]) and fasting insulin (MD -4.17 uU/mL [-5.14,-3.20]); D-chiro-inositol improved ovulation (OR 11.50 [3.40,38.91]); overall certainty very low to low. [https://pmc.ncbi.nlm.nih.gov/articles/PMC11099481/]
  - Effects of inositol in women with polycystic ovary syndrome: an umbrella review of meta-analyses from randomized controlled trials, Frontiers in endocrinology (2026) — Umbrella review of 13 RCT meta-analyses: inositol reduced HOMA-IR by 1.14 (95% CI -1.35 to -0.94) and LH by 3.43 IU/L, raised SHBG by 36.72 nmol/L, and increased ovulation rate (RR 2.75 [1.71,4.41]) and live births (RR 2.29 [1.07,4.93]). [https://pubmed.ncbi.nlm.nih.gov/41757236/]
  - The effect of myo-inositol on assisted reproductive technology outcomes in women with polycystic ovarian syndrome: A systematic review and meta-analysis of randomized clinical trial studies, International journal of reproductive biomedicine (2025) — Meta-analysis of 17 RCTs: myo-inositol increased clinical pregnancy rate (RR 1.64 [1.25,2.15]) and top-grade embryos (RR 1.12 [1.02,1.23]) in PCOS undergoing ART, though live birth rate was not significant (RR 1.24 [0.78,1.98]). [https://pmc.ncbi.nlm.nih.gov/articles/PMC12413536/]
  - Inositol in preterm infants at risk for or having respiratory distress syndrome, The Cochrane database of systematic reviews (2019) — Cochrane review (Howlett 2019) of preterm infants at risk for/having respiratory distress syndrome concluded inositol supplementation does not meaningfully reduce death, ROP, intraventricular hemorrhage, bronchopulmonary dysplasia, NEC, or sepsis, and advised against routine use. [https://pubmed.ncbi.nlm.nih.gov/31283839/]
  - Myo-inositol lowers the risk of developing gestational diabetic mellitus in pregnancies: A systematic review and meta-analysis of randomized controlled trials with trial sequential analysis, Journal of diabetes and its complications (2018) — Meta-analysis with trial sequential analysis of 4 RCTs (586 high-risk pregnant women): myo-inositol significantly lowered incidence of gestational diabetes vs placebo (RR 0.44, 95% CI 0.32-0.62, I2=0%; NNT~7), and reduced fasting, 1h and 2h OGTT values and preterm delivery; no significant effect on birth weight. [https://pubmed.ncbi.nlm.nih.gov/29325728/]
  - Efficacy of Myo-inositol on Anthropometric, Metabolic, and Endocrine Outcomes in PCOS Patients: a Meta-analysis of Randomized Controlled Trial, Reproductive sciences (Thousand Oaks, Calif.) (2022) — Meta-analysis of PCOS patients found no significant improvement in BMI, waist-to-hip ratio, fasting insulin, fasting glucose, HOMA, total testosterone, or SHBG after myo-inositol, with only androstenedione and prolactin changing. [https://pubmed.ncbi.nlm.nih.gov/35477841/]
  - A meta-analysis of inositol for depression and anxiety disorders, Human psychopharmacology (2014) — Pooled analysis of double-blind placebo-controlled trials found no statistically significant effect of inositol on anxiety, obsessive-compulsive, or depressive symptoms, with only a non-significant trend toward more responders in depression. [https://pubmed.ncbi.nlm.nih.gov/24424706/]
  - Myoinositols Prevent Gestational Diabetes Mellitus and Related Complications: A Systematic Review and Meta-Analysis of Randomized Controlled Trials, Nutrients (2023) — Systematic review and meta-analysis of RCTs found inositol supplementation in pregnancy roughly halved gestational diabetes incidence versus placebo and significantly lowered fasting, 1-hour, and 2-hour OGTT glucose levels. [https://pmc.ncbi.nlm.nih.gov/articles/PMC10574514/]
  - One-year effects of myo-inositol supplementation in postmenopausal women with metabolic syndrome, Climacteric : the journal of the International Menopause Society (2012) — Randomized placebo-controlled trial (Santamaria 2012) in postmenopausal women with metabolic syndrome: myo-inositol 2 g twice daily plus diet for 12 months significantly improved insulin, HOMA-IR, lipids, and blood pressure, with 20% (8/40) no longer meeting metabolic-syndrome criteria versus 1/40 on diet alone. [https://pubmed.ncbi.nlm.nih.gov/22192068/]
  - Double-blind, placebo-controlled, crossover trial of inositol treatment for panic disorder, The American journal of psychiatry (1995) — Double-blind, placebo-controlled 4-week crossover trial in panic disorder: inositol 12 g/day significantly reduced frequency and severity of panic attacks and agoraphobia versus placebo. [https://pubmed.ncbi.nlm.nih.gov/7793450/]
  - Double-blind, controlled, crossover trial of inositol versus fluvoxamine for the treatment of panic disorder, Journal of clinical psychopharmacology (2001) — Double-blind crossover trial found inositol up to 18 g/day produced improvements in panic disorder similar to fluvoxamine 150 mg/day on anxiety and agoraphobia scales over 1 month each. [https://pubmed.ncbi.nlm.nih.gov/11386498/]

---

## Cinnamon (Cinnamomum spp.)
URL: https://nutridex.info/s/cinnamon
Category: Heart & Metabolic
Evidence: Mixed — Conflicting results across studies; benefit uncertain.
A common spice with small, inconsistent effects on blood sugar and lipids — and a real coumarin safety catch in the Cassia type.

Quick answer: Cinnamon is used for may modestly lower fasting blood glucose in type 2 diabetes (meta-analyses report reductions of roughly 10–15 mg/dl), though effect sizes vary widely across trials. NutriDex grades the human evidence as mixed — Conflicting results across studies; benefit uncertain. Based on 19 cited human studies (19 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Cinnamon is a culinary bark spice from Cinnamomum species, sold mainly as cheaper Cassia (C. cassia/aromaticum) or the lower-coumarin Ceylon (C. verum, "true cinnamon"). Multiple meta-analyses suggest cinnamon supplementation can produce small reductions in fasting glucose, HbA1c and insulin resistance in people with type 2 diabetes, plus modest improvements in cholesterol, but results are inconsistent and heavily influenced by trial quality, dose, and cinnamon type. The lipid changes in pooled umbrella analyses are statistically borderline and likely too small to matter clinically on their own. Overall the human evidence is best described as mixed: a real but minor and unreliable metabolic effect that does not substitute for proven medications or lifestyle change. The most important practical issue is safety rather than efficacy: Cassia cinnamon is rich in coumarin, which can stress the liver and interact with anticoagulants at high or prolonged intakes. People interested in supplemental doses should favor Ceylon cinnamon and keep coumarin exposure within regulatory limits.

Benefits / uses: May modestly lower fasting blood glucose in type 2 diabetes (meta-analyses report reductions of roughly 10–15 mg/dL), though effect sizes vary widely across trials; Small reductions in HbA1c reported (about 0.1–0.6%), of uncertain clinical importance; Modest, statistically borderline improvements in total and LDL cholesterol and a small rise in HDL in pooled analyses; triglyceride effects are inconsistent; May slightly improve insulin resistance (HOMA-IR) in some diabetic and PCOS populations; Best signals appear at lower capsule doses (around 1.5–2 g/day or less); benefits are not robust enough to replace standard glucose- or lipid-lowering therapy.
Active compounds: Cinnamaldehyde (primary bioactive); Cinnamic acid; Cinnamyl acetate; Procyanidin-type polyphenols (type-A polymers); Eugenol; Coumarin (high in Cassia, trace in Ceylon — a toxicity concern, not a benefit).
Dose: 1–2 g/day of cinnamon powder or standardized extract in divided doses; trials commonly use 1.5–6 g/day, but ≤2 g/day capsules show the most consistent metabolic signal. Prefer Ceylon (Cinnamomum verum) to limit coumarin exposure.
Safety: Generally safe as a food/spice. The main concern with supplemental doses is coumarin, abundant in Cassia cinnamon (the common grocery type) and present only in traces in Ceylon (C. verum). Coumarin is hepatotoxic at sustained high intake: the EFSA/BfR tolerable daily intake is 0.1 mg/kg body weight (~7 mg/day for a 70 kg adult), and 1 tsp of Cassia (~5 mg) can approach or exceed this. High or prolonged Cassia use can raise liver enzymes or, in sensitive people, cause reversible hepatitis/jaundice — avoid with pre-existing liver disease. Coumarin and cinnamaldehyde may affect drug-metabolizing enzymes; cinnamon may increase bleeding risk with warfarin and other anticoagulants/antiplatelets and could alter blood glucose, so people on antidiabetic drugs should monitor for hypoglycemia and adjust under medical supervision. Use cautiously with hepatotoxic medications. Cinnamaldehyde can cause oral/skin irritation and allergic contact reactions. Pregnant and breastfeeding women should limit intake to culinary amounts and avoid concentrated supplements. Choose Ceylon cinnamon for regular supplemental use and discuss with a clinician if diabetic, on blood thinners, or having liver concerns.

Cited studies (19):
  - The effects of cinnamon on patients with metabolic diseases: an umbrella review of meta-analyses of randomized controlled trials, Frontiers in nutrition (2025) — Umbrella review of 21 meta-analyses (139 comparisons) found cinnamon significantly reduced fasting blood glucose (SMD -0.61; 95% CI -0.70 to -0.52), upgraded to 'highly suggestive' on reanalysis (SMD -0.74; 95% CI -0.99 to -0.48), with greater effects at >1.5 g/day and durations <=2 months. [https://pmc.ncbi.nlm.nih.gov/articles/PMC12620228/]
  - The effect of cinnamon supplementation on glycemic control in patients with type 2 diabetes mellitus: An updated systematic review and dose-response meta-analysis of randomized controlled trials, Phytotherapy research : PTR (2024) — Updated dose-response meta-analysis of 24 RCTs in type 2 diabetes found cinnamon supplementation significantly lowered fasting blood sugar (SMD -1.32; 95% CI -1.77 to -0.87; p<0.001). [https://pubmed.ncbi.nlm.nih.gov/37818728/]
  - The effect of cinnamon supplementation on cardiovascular risk factors in adults: a GRADE assessed systematic review, dose-response and meta-analysis of randomized controlled trials, Journal of health, population, and nutrition (2025) — GRADE-assessed dose-response meta-analysis of 49 RCTs: cinnamon significantly lowered SBP (SMD -0.85), DBP (SMD -1.04), fasting glucose (SMD -1.28), HbA1c (SMD -0.71), HOMA-IR (SMD -0.54), LDL-C (SMD -0.71), total cholesterol (SMD -1.15), triglycerides (SMD -0.91) and CRP (SMD -0.78), and raised HDL-C (SMD +0.56). [https://pubmed.ncbi.nlm.nih.gov/40611215/]
  - The effects of cinnamon on patients with metabolic diseases: an umbrella review of meta-analyses of randomized controlled trials, Frontiers in nutrition (2025) — AMSTAR-2 umbrella review of 21 meta-analyses (139 comparisons): cinnamon supplementation significantly improves fasting glucose and lipid profiles, with larger effects in diabetes and metabolic syndrome; higher doses (>1.5 g/day) and shorter durations (<=2 months) enhanced benefit. [https://pubmed.ncbi.nlm.nih.gov/41256917/]
  - The effect of cinnamon supplementation on glycemic control in women with polycystic ovary syndrome: A systematic review and meta-analysis, Journal of food biochemistry (2021) — Meta-analysis of 5 RCTs in women with polycystic ovary syndrome: cinnamon significantly reduced insulin resistance (HOMA-IR SMD -0.84; 95% CI -1.52, -0.16, p=0.010) versus placebo. [https://pubmed.ncbi.nlm.nih.gov/33111340/]
  - The effect of cinnamon supplementation on glycemic control in patients with type 2 diabetes or with polycystic ovary syndrome: an umbrella meta-analysis on interventional meta-analyses, Diabetology & metabolic syndrome (2023) — In type 2 diabetes and PCOS, cinnamon supplementation modestly reduced fasting plasma glucose (-10.93 mg/dL), insulin (-2.01 IU/mL), HOMA-IR (-0.61) and HbA1c (-0.10%), indicating small but consistent glycemic improvement. [https://pubmed.ncbi.nlm.nih.gov/37316893/]
  - Effects of cinnamon supplementation on metabolic biomarkers in individuals with type 2 diabetes: a systematic review and meta-analysis, Nutrition reviews (2025) — Cinnamon lowered fasting blood glucose (WMD -15.26 mg/dL) and HbA1c (WMD -0.56%), with the strongest effects from capsules at ≤2 g/day, alongside improvements in lipids and BMI. [https://pubmed.ncbi.nlm.nih.gov/38917435/]
  - Effects of Cinnamon Supplementation on Lipid Profile: A Systematic Review and Meta-Analysis of Randomized Controlled Trials, Clinical nutrition research (2024) — Cinnamon had non-significant overall effects on total cholesterol and LDL but significantly reduced triglycerides (WMD -6.88 mg/dL); LDL and triglyceride benefits were limited to doses <500 mg/day. [https://pubmed.ncbi.nlm.nih.gov/38362130/]
  - The effect of cinnamon consumption on lipid profile, oxidative stress, and inflammation biomarkers in adults: An umbrella meta-analysis of randomized controlled trials, Nutrition, metabolism, and cardiovascular diseases : NMCD (2023) — Cinnamon produced small, statistically significant improvements in total cholesterol (WMD -1.01 mg/dL), LDL (-0.82 mg/dL) and HDL (+0.47 mg/dL) but no significant effect on triglycerides, suggesting minimal clinical impact. [https://pubmed.ncbi.nlm.nih.gov/37500345/]
  - What is the Impact of Cinnamon Supplementation on Blood Pressure? A Systematic Review and Meta-Analysis, Endocrine, metabolic & immune disorders drug targets (2021) — Cinnamon supplementation significantly reduced diastolic blood pressure (WMD -0.93 mmHg, 95% CI -1.55 to -0.32) but had no significant overall effect on systolic blood pressure (-0.61 mmHg), with a small systolic benefit only at durations >=8 weeks. [https://pubmed.ncbi.nlm.nih.gov/32727334/]
  - Cinnamon supplementation positively affects obesity: A systematic review and dose-response meta-analysis of randomized controlled trials, Clinical nutrition (Edinburgh, Scotland) (2020) — Cinnamon supplementation modestly reduced body weight (WMD -1.02 kg, 95% CI -1.66 to -0.38), BMI (-0.51 kg/m2) and waist circumference (-2.40 cm), with larger effects in adults <50 years or with baseline BMI >=30. [https://pubmed.ncbi.nlm.nih.gov/30799194/]
  - What is the influence of cinnamon supplementation on liver enzymes? A systematic review and meta-analysis of randomized controlled trials, Phytotherapy research : PTR (2021) — Cinnamon had no significant overall effect on ALT, AST or ALP, but significantly lowered ALT and AST in subgroups of type 2 diabetes patients and trials >12 weeks, suggesting benefit limited to metabolically impaired populations. [https://pubmed.ncbi.nlm.nih.gov/34212447/]
  - Effect of cinnamon (Cinnamomum Zeylanicum) supplementation on serum C-reactive protein concentrations: A meta-analysis and systematic review, Complementary therapies in medicine (2019) — Cinnamon (Cinnamomum zeylanicum) supplementation significantly lowered serum C-reactive protein (WMD -0.81 mg/L, 95% CI -1.36 to -0.26), with larger anti-inflammatory effects when baseline CRP exceeded 3 mg/dL and in trials lasting over 12 weeks. [https://pubmed.ncbi.nlm.nih.gov/30670254/]
  - Experiences of falling and depression: Results from the Korean Longitudinal Study of Ageing, Journal of affective disorders (2021) — Cinnamon supplementation significantly reduced C-reactive protein and IL-6 and increased total antioxidant capacity in adults, supporting a modest anti-inflammatory and antioxidant effect. [https://pubmed.ncbi.nlm.nih.gov/33321383/]
  - Effect of cinnamon spice on continuously monitored glycemic response in adults with prediabetes: a 4-week randomized controlled crossover trial, The American journal of clinical nutrition (2024) — Cinnamon 4 g/day for 4 weeks significantly lowered 24-hour continuously monitored glucose concentrations and reduced postprandial glucose peaks versus placebo, indicating improved glycemic response in prediabetes. [https://pubmed.ncbi.nlm.nih.gov/38290699/]
  - Influence of Cinnamon on Glycemic Control in Individuals With Prediabetes: A Randomized Controlled Trial, Journal of the Endocrine Society (2020) — Cinnamon 500 mg three times daily for 12 weeks kept fasting plasma glucose stable while it rose in placebo (5 mg/dL between-group difference) and significantly lowered 2-hour OGTT glucose and glucose AUC, improving glucose tolerance. [https://pubmed.ncbi.nlm.nih.gov/33123653/]
  - Preliminary evidence that cinnamon improves menstrual cyclicity in women with polycystic ovary syndrome: a randomized controlled trial, American journal of obstetrics and gynecology (2014) — Cinnamon 1.5 g/day improved menstrual cyclicity over 6 months (+0.23 cycles/month from baseline vs no change with placebo, P=.0085), with luteal progesterone confirming ovulatory menses, suggesting a reproductive benefit in PCOS. [https://pubmed.ncbi.nlm.nih.gov/24813595/]
  - FAQ on coumarin in cinnamon and other foods, German Federal Institute for Risk Assessment (BfR) (2012) — Coumarin TDI is 0.1 mg/kg body weight/day; Cassia cinnamon averages ~3,000 mg/kg coumarin (up to ~10,000) versus only trace levels in Ceylon, and high intake can reversibly raise liver enzymes or cause hepatitis in sensitive individuals. [https://www.bfr.bund.de/en/service/frequently-asked-questions/topic/faq-on-coumarin-in-cinnamon-and-other-foods/]
  - Cinnamon: Usefulness and Safety, NIH National Center for Complementary and Integrative Health (2024) — NCCIH concludes research does not clearly support cinnamon for any health condition including diabetes or weight loss; it is likely safe as a food spice but high-dose or prolonged cassia cinnamon use risks liver harm in susceptible people due to coumarin. [https://www.nccih.nih.gov/health/cinnamon]

---

## Milk Thistle (Silymarin) (Silybum marianum)
URL: https://nutridex.info/s/milk-thistle
Category: Gut & Immune
Evidence: Mixed — Conflicting results across studies; benefit uncertain.
A traditional liver herb with antioxidant flavonolignans — helps liver enzymes in fatty liver, but unproven for serious liver disease.

Quick answer: Milk Thistle (Silymarin) is used for may modestly lower elevated liver enzymes (alt/ast) in non-alcoholic/metabolic fatty liver disease, though changes are surrogate markers, not proven clinical outcomes. NutriDex grades the human evidence as mixed — Conflicting results across studies; benefit uncertain. Based on 21 cited human studies (21 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Milk thistle (Silybum marianum) is one of the most widely used herbal liver remedies, and its standardized extract, silymarin, is a mixture of antioxidant flavonolignans (chiefly silibinin). Recent meta-analyses in non-alcoholic/metabolic fatty liver disease report statistically significant but modest reductions in liver enzymes (roughly 12–17 IU/L lower ALT and AST), but these are biochemical surrogates rather than proven improvements in liver structure, symptoms, or survival. In contrast, a Cochrane review of alcoholic and hepatitis B/C liver disease found no significant effect on mortality once low-quality trials were excluded, and a rigorous JAMA-published RCT in chronic hepatitis C found that even high doses did not lower ALT or viral load more than placebo. The overall evidence is therefore mixed: promising for liver-enzyme surrogates in fatty liver but inconclusive for clinically meaningful outcomes in viral and alcoholic liver disease. Silymarin is consistently well tolerated, with mostly mild gastrointestinal effects, which has made it a popular but unproven liver "support" supplement.

Benefits / uses: May modestly lower elevated liver enzymes (ALT/AST) in non-alcoholic/metabolic fatty liver disease, though changes are surrogate markers, not proven clinical outcomes; Provides antioxidant and anti-inflammatory activity in liver tissue (mechanistic and preclinical data); Generally well tolerated, making it a low-risk adjunct for those seeking liver support; Possible small improvements in triglycerides and HDL in fatty-liver populations (preliminary); Does NOT reliably improve survival or disease course in alcoholic or hepatitis B/C liver disease — benefits for these are unproven.
Active compounds: Silymarin (a complex of flavonolignans); Silibinin / silybin (silybin A and B, the principal active components); Silychristin; Silydianin; Isosilybin.
Dose: Typically 140 mg silymarin 2–3 times daily (about 280–420 mg/day) of standardized extract (~70–80% silymarin); trials have used up to 700 mg three times daily safely.
Safety: Generally well tolerated; the most common adverse effects are mild gastrointestinal symptoms (bloating, nausea, gas, occasional diarrhea). Allergic reactions can occur in people sensitive to the Asteraceae/Compositae family (ragweed, daisies, marigolds, chrysanthemums). Silymarin has limited but real potential for drug interactions: in vitro it can inhibit CYP2C9, so caution is advised with narrow-therapeutic-index drugs metabolized by this enzyme (e.g., warfarin — possible increased bleeding risk). Use during pregnancy and breastfeeding is not recommended due to insufficient human safety data. People with diabetes should monitor blood glucose, as silymarin may have mild glucose-lowering effects. Importantly, milk thistle should not be used as a substitute for evidence-based treatment of hepatitis, cirrhosis, or alcoholic liver disease; anyone with diagnosed liver disease should consult a clinician before use. Standardize products and avoid unverified high-dose preparations.

Cited studies (21):
  - Impact of Silymarin Supplements on Liver Enzyme Levels: A Systematic Review, Cureus (2023) — In this 2023 systematic review of trials across diverse liver conditions, 65.5% of studies reported reduced liver enzymes with silymarin, 20.7% showed no change, and 13.8% showed increases — indicating inconsistent, condition-dependent effects. [https://pubmed.ncbi.nlm.nih.gov/38021897/]
  - Effects of silymarin use on liver enzymes and metabolic factors in metabolic dysfunction-associated steatotic liver disease: a systematic review and meta-analysis, Canadian liver journal (2024) — This 2024 meta-analysis in MASLD/NAFLD found silymarin significantly reduced ALT by ~17 IU/L and AST by ~13 IU/L versus control, with larger reductions after 6 months, plus modest triglyceride and HDL improvements. [https://pmc.ncbi.nlm.nih.gov/articles/PMC10946183/]
  - Impacts of Supplementation with Silymarin on Cardiovascular Risk Factors: A Systematic Review and Dose-Response Meta-Analysis, Antioxidants (Basel, Switzerland) (2024) — This 2024 systematic review and dose-response meta-analysis in Antioxidants found silymarin supplementation significantly reduced total cholesterol, LDL, triglycerides, fasting glucose, HbA1c, and systolic blood pressure, supporting modest beneficial effects on multiple cardiometabolic risk factors. [https://pubmed.ncbi.nlm.nih.gov/38671838/]
  - Effects of silymarin use on liver enzymes and metabolic factors in metabolic dysfunction-associated steatotic liver disease: a systematic review and meta-analysis, Canadian liver journal (2024) — Systematic review and meta-analysis of 9 trials in MASLD found silymarin significantly reduced ALT (MD -17.12 U/L, 95% CI -28.81 to -4.43, p<0.004) and AST (MD -12.56 U/L, 95% CI -19.02 to -6.10, p<0.0001). [https://pubmed.ncbi.nlm.nih.gov/38505782/]
  - Are alterations needed in Silybum marianum (Silymarin) administration practices? A novel outlook and meta-analysis on randomized trials targeting liver injury, BMC complementary medicine and therapies (2025) — Meta-analysis of 55 RCTs (3,545 patients) found silymarin significantly reduced ALT (SMD -0.912, 95% CI -1.177 to -0.646) and AST (SMD -0.670, 95% CI -0.931 to -0.408), with greatest effect at doses <400 mg/day for <=2 months, no effect on ALP. [https://pmc.ncbi.nlm.nih.gov/articles/PMC11992775/]
  - The Effectiveness of Curcumin, Resveratrol, and Silymarin on MASLD: A Systematic Review and Meta-Analysis, Food science & nutrition (2024) — Systematic review and meta-analysis (7 silymarin trials, ~566 participants) found silymarin lowered ALT (MD -6.44 U/L, 95% CI -10.03 to -2.85, p=0.0004) and AST (MD -6.99 U/L, 95% CI -8.56 to -5.42, p<0.00001) in MASLD. [https://pmc.ncbi.nlm.nih.gov/articles/PMC11666838/]
  - Coadministration of silymarin with iron chelators in transfusion-dependent β-thalassemia patients: a systematic review and meta-analysis for effect on iron overload, Expert review of clinical pharmacology (2021) — This 2021 systematic review and meta-analysis in Expert Review of Clinical Pharmacology found that adding silymarin to standard iron chelators significantly reduced serum ferritin in transfusion-dependent beta-thalassemia patients versus chelators alone, indicating improved iron-overload control. [https://pubmed.ncbi.nlm.nih.gov/34486906/]
  - Impact of Silymarin in individuals with nonalcoholic fatty liver disease: A systematic review and meta-analysis, Nutrition (Burbank, Los Angeles County, Calif.) (2021) — Systematic review/meta-analysis of 8 RCTs in NAFLD: silymarin produced a statistically significant greater reduction in transaminases (ALT and AST) versus placebo, independent of weight loss; authors caution on the modest quality of included trials. [https://pubmed.ncbi.nlm.nih.gov/33418491/]
  - Silymarin in Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials, Journal of diabetes research (2016) — This 2016 systematic review and meta-analysis in Journal of Diabetes Research found that silymarin in type 2 diabetes significantly lowered fasting blood glucose by 26.86 mg/dL (95% CI -35.42 to -18.30) and HbA1c by 1.07% (95% CI -1.73 to -0.40), though the authors graded the evidence as low to very low quality. [https://pmc.ncbi.nlm.nih.gov/articles/PMC4908257/]
  - Prophylactic Therapy of Silymarin (Milk Thistle) on Antituberculosis Drug-Induced Liver Injury: A Meta-Analysis of Randomized Controlled Trials, Canadian journal of gastroenterology & hepatology (2019) — This 2019 meta-analysis in Canadian Journal of Gastroenterology & Hepatology found prophylactic silymarin significantly reduced antituberculosis drug-induced liver injury at week 4 (RR 0.33, 95% CI 0.15-0.75), a roughly 67% relative risk reduction versus placebo. [https://pmc.ncbi.nlm.nih.gov/articles/PMC6348824/]
  - Effects of silymarin supplementation on blood lipids: A systematic review and meta-analysis of clinical trials, Phytotherapy research : PTR (2019) — This 2019 systematic review and meta-analysis of clinical trials found silymarin reduced total cholesterol, LDL, and triglycerides primarily when combined with other lipid-lowering treatments rather than as monotherapy, with no significant effect on HDL. [https://pubmed.ncbi.nlm.nih.gov/30834633/]
  - Silymarin in Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials, Journal of diabetes research (2016) — Systematic review/meta-analysis of 5 RCTs (270 patients) in type 2 diabetes: silymarin significantly reduced fasting blood glucose (-26.86 mg/dL; 95% CI -35.42 to -18.30) and HbA1c (-1.07%; 95% CI -1.73 to -0.40), with no effect on lipid profile; evidence quality low with high heterogeneity, so no formal recommendation. [https://pubmed.ncbi.nlm.nih.gov/27340676/]
  - Silymarin for Treating Toxic Liver Disease: International Consensus Recommendations, Gastro hep advances (2022) — International expert-panel consensus recommendations: based on preclinical/clinical evidence of antioxidant, anti-inflammatory, and antifibrotic effects, endorses silymarin as a hepatoprotective antioxidant agent for toxic liver disease (alcoholic liver disease, NAFLD/MAFLD, drug-induced liver injury, cirrhosis), with lifestyle modification remaining the cornerstone of fatty liver disease management. [https://pubmed.ncbi.nlm.nih.gov/39131840/]
  - Milk thistle for alcoholic and/or hepatitis B or C virus liver diseases, The Cochrane database of systematic reviews (2007) — This Cochrane review found no significant effect of milk thistle versus placebo on all-cause mortality (RR 0.78, 95% CI 0.53–1.15) in alcoholic and/or hepatitis B/C liver disease, with apparent benefits disappearing in high-quality trials. [https://pmc.ncbi.nlm.nih.gov/articles/PMC8724782/]
  - The hepatorenal protective effects of silymarin in cancer patients receiving chemotherapy: a randomized, placebo-controlled trial, BMC Complementary Medicine and Therapies (2024) — This 2024 randomized, placebo-controlled trial in BMC Complementary Medicine and Therapies found silymarin 140 mg/day during chemotherapy produced hepatoprotective effects on certain liver parameters (notably alkaline phosphatase and bilirubin), suggesting improved liver function versus placebo. [https://doi.org/10.1186/s12906-024-04627-7]
  - A Randomized Trial of Silymarin for the Treatment of Nonalcoholic Steatohepatitis, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2017) — Double-blind RCT, 99 biopsy-proven NASH patients, silymarin 700 mg TID x 48 wk. Did NOT meet primary endpoint (>=30% NAS reduction: 32.7% vs 26.0% placebo, P=.467), but significantly more silymarin patients had >=1-point fibrosis reduction on histology (22.4% vs 6.0%, P=.023) and >=30% liver-stiffness reduction (24.2% vs 2.3%, P=.002); safe and well tolerated. [https://pubmed.ncbi.nlm.nih.gov/28419855/]
  - Effect of silymarin (milk thistle) on liver disease in patients with chronic hepatitis C unsuccessfully treated with interferon therapy: a randomized controlled trial, JAMA (2012) — In this multicenter double-blind RCT in chronic hepatitis C unresponsive to interferon, oral silymarin (420 or 700 mg three times daily for 24 weeks) did not reduce serum ALT or HCV RNA more than placebo. [https://pubmed.ncbi.nlm.nih.gov/22797645/]
  - Can Use of Silymarin Improve Inflammatory Status in Patients with β-Thalassemia Major? A Crossover, Randomized Controlled Trial, Complementary medicine research (2021) — In this crossover randomized controlled trial in beta-thalassemia major, silymarin 420 mg/day for 12 weeks significantly decreased the inflammatory markers CRP and IL-6 and raised anti-inflammatory IL-10 compared with placebo. [https://pubmed.ncbi.nlm.nih.gov/32971524/]
  - Safety and toxicity of silymarin, the major constituent of milk thistle extract: An updated review, Phytotherapy research : PTR (2019) — This updated safety review concluded silymarin is well tolerated even at high doses (700 mg three times daily for 24 weeks), with mostly mild gastrointestinal effects and limited cytochrome P450-mediated drug interactions. [https://pubmed.ncbi.nlm.nih.gov/31069872/]
  - Legalon® SIL: the antidote of choice in patients with acute hepatotoxicity from amatoxin poisoning, Current pharmaceutical biotechnology (2012) — This 2012 review in Current Pharmaceutical Biotechnology reported that intravenous silibinin (Legalon SIL) as antidote for Amanita amatoxin poisoning was associated with under 10% mortality (about 93% survival) versus historical mortality above 20%, by blocking hepatic re-uptake of the toxin. [https://pmc.ncbi.nlm.nih.gov/articles/PMC3414726/]
  - Milk Thistle (2020) — The NIH LiverTox database assigns milk thistle/silymarin a likelihood score of E (unlikely cause of clinically apparent liver injury), concluding that despite widespread use it has not been implicated in causing serum enzyme elevations or acute liver injury. [https://www.ncbi.nlm.nih.gov/books/NBK548817/]

---

## Glucosamine & Chondroitin (Glucosamine sulfate/hydrochloride; Chondroitin sulfate)
URL: https://nutridex.info/s/glucosamine-chondroitin
Category: Joint & Skin
Evidence: Mixed — Conflicting results across studies; benefit uncertain.
Popular joint supplements for osteoarthritis with largely disappointing trial evidence.

Quick answer: Glucosamine & Chondroitin is used for may provide a small reduction in knee osteoarthritis pain in some trials, though high-quality studies and major guidelines find little or no benefit over placebo. NutriDex grades the human evidence as mixed — Conflicting results across studies; benefit uncertain. Based on 17 cited human studies (17 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Glucosamine and chondroitin are among the most widely used dietary supplements for osteoarthritis, particularly of the knee, and are marketed for joint pain, stiffness, and cartilage support. The pivotal NIH-funded GAIT trial found that neither agent alone nor in combination beat placebo for overall knee pain, although an exploratory analysis hinted at possible benefit in patients with moderate-to-severe pain. Subsequent meta-analyses are mixed: some report a small pain reduction for the individual agents (but not the combination), while a 2025 network meta-analysis found effects largely indistinguishable from placebo. On the strength of high-quality data showing lack of efficacy, the 2019 American College of Rheumatology/Arthritis Foundation guideline strongly recommends against using glucosamine, and conditionally or strongly against chondroitin, for knee osteoarthritis. Overall the evidence is best characterized as mixed-to-disappointing, though the supplements are inexpensive and unusually safe, which helps explain their continued popularity.

Benefits / uses: May provide a small reduction in knee osteoarthritis pain in some trials, though high-quality studies and major guidelines find little or no benefit over placebo; Possible modest benefit in the subgroup of patients with moderate-to-severe knee pain (exploratory GAIT finding, not confirmed); Chondroitin may offer a small short-term improvement in pain and function in some pooled analyses, but on low-quality evidence; Generally very well tolerated, with a safety profile comparable to placebo across trials.
Active compounds: Glucosamine sulfate; Glucosamine hydrochloride; Chondroitin sulfate.
Dose: Typically glucosamine 1,500 mg/day (sulfate or HCl) plus chondroitin sulfate 800-1,200 mg/day, often split across doses; taken for at least 8-12 weeks to assess any benefit.
Safety: Generally well tolerated, with adverse event rates similar to placebo; mild GI upset, nausea, heartburn, and headache are the most common complaints. Glucosamine is commonly derived from shellfish (shrimp/crab shells), so people with shellfish allergy should use a labeled non-shellfish/synthetic source or avoid it. Glucosamine may modestly affect glucose metabolism in theory, so diabetics should monitor blood sugar, though clinical trials have not shown meaningful glycemic harm. Chondroitin is structurally heparin-like and there are case reports and a plausible interaction with anticoagulants/antiplatelets (e.g., warfarin), where it may increase INR and bleeding risk; people on blood thinners should consult a clinician. Not recommended during pregnancy or breastfeeding due to insufficient safety data, and supplement purity/labeling can vary. These products are not a substitute for guideline-based osteoarthritis care; patients with significant or worsening joint pain should seek medical evaluation rather than rely on supplementation.

Cited studies (17):
  - Comparative Efficacy of Glucosamine-Based Combination Therapies in Alleviating Knee Osteoarthritis Pain: A Systematic Review and Network Meta-Analysis, Journal of clinical medicine (2024) — Network meta-analysis of 30 RCTs (5,265 patients) concluded the glucosamine + chondroitin sulfate combination does not produce clinically significant pain reduction in mild-to-moderate knee OA (below MCID of SMD 0.40), whereas glucosamine + omega-3 (SMD -2.59, 95% CI -4.42 to -0.75) and glucosamine + ibuprofen (SMD -2.27, 95% CI -3.73 to -0.82) were most effective. [https://pmc.ncbi.nlm.nih.gov/articles/PMC11641979/]
  - Evaluation of efficacy and safety of glucosamine sulfate, chondroitin sulfate, and their combination regimen in the management of knee osteoarthritis: a systematic review and meta-analysis, Inflammopharmacology (2024) — Meta-analysis of 25 RCTs found chondroitin sulfate significantly reduced pain and improved physical function vs placebo and glucosamine sulfate reduced tibiofemoral joint-space narrowing, but the GS+CS combination produced neither pain reduction nor functional improvement (only a non-significant reduction in joint-space narrowing); both well tolerated. [https://pubmed.ncbi.nlm.nih.gov/38581640/]
  - Comparative effectiveness of glucosamine, chondroitin, acetaminophen or celecoxib for the treatment of knee and/or hip osteoarthritis: a network meta-analysis, Clinical and experimental rheumatology (2018) — Network meta-analysis (47 RCTs, 22,037 patients) of long-term treatments for knee/hip OA. At ~24 months, glucosamine reduced pain significantly vs placebo (SMD ~ -0.29), chondroitin and the glucosamine+chondroitin combination did not show significant long-term pain benefit over placebo; effect sizes were generally small and below the threshold considered clinically important. [https://pubmed.ncbi.nlm.nih.gov/29465368/]
  - Chondroitin for osteoarthritis, Cochrane Database of Systematic Reviews (2015) — Chondroitin (alone or with glucosamine) produced a small short-term improvement in pain (about 8 points on a 0-100 scale) vs placebo, but the evidence was of low quality and effects shrank in larger, better-conducted trials. [https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD005614.pub2/full]
  - Effect of glucosamine and chondroitin sulfate in symptomatic knee osteoarthritis: a systematic review and meta-analysis of randomized placebo-controlled trials, Rheumatology international (2018) — Glucosamine (-7.4 mm) and chondroitin (-8.4 mm) each modestly reduced knee OA pain on a 100 mm VAS, but the combination showed no significant effect and neither improved total WOMAC scores. [https://pubmed.ncbi.nlm.nih.gov/29947998/]
  - Efficacy of dietary supplements for treating knee osteoarthritis: a systematic review and network meta-analysis, Frontiers in nutrition (2025) — A network meta-analysis found glucosamine and chondroitin sulfate produced minimal changes in WOMAC pain and total scores, with confidence intervals crossing zero, indicating effects largely indistinguishable from placebo. [https://pmc.ncbi.nlm.nih.gov/articles/PMC11925762/]
  - Effects of glucosamine, chondroitin, or placebo in patients with osteoarthritis of hip or knee: network meta-analysis, BMJ (Clinical research ed.) (2010) — In this BMJ network meta-analysis of hip/knee OA, glucosamine (-0.4 cm), chondroitin (-0.3 cm), and the combination (-0.5 cm) reduced pain on a 10 cm VAS versus placebo, but none reached the prespecified minimal clinically important difference of -0.9 cm, indicating no clinically relevant benefit. [https://pubmed.ncbi.nlm.nih.gov/20847017/]
  - The effect of glucosamine on glucose metabolism in humans: a systematic review of the literature, Osteoarthritis and cartilage (2011) — This systematic review in Osteoarthritis and Cartilage found mixed and inconclusive evidence on whether oral glucosamine alters glucose metabolism in humans, with no clear adverse effect on fasting glucose or insulin sensitivity, but called for more data in people at risk of impaired glucose homeostasis. [https://pubmed.ncbi.nlm.nih.gov/21251987/]
  - 2019 American College of Rheumatology/Arthritis Foundation Guideline for the Management of Osteoarthritis of the Hand, Hip, and Knee, Arthritis & Rheumatology (2020) — The 2019 ACR/Arthritis Foundation guideline strongly recommends against glucosamine and against the glucosamine-chondroitin combination for knee, hip, and hand OA, citing high-quality evidence of lack of meaningful benefit. [https://acrjournals.onlinelibrary.wiley.com/doi/10.1002/art.41142]
  - OARSI guidelines for the non-surgical management of knee, hip, and polyarticular osteoarthritis, Osteoarthritis and cartilage (2019) — The 2019 OARSI guideline strongly recommends against glucosamine and against chondroitin for knee, hip, and polyarticular osteoarthritis, citing lack of efficacy and low-quality evidence. [https://pubmed.ncbi.nlm.nih.gov/31278997/]
  - Attitudes of mental health professionals toward people with schizophrenia and major depression, Schizophrenia bulletin (2006) — In the GAIT trial, glucosamine, chondroitin, or their combination did not significantly reduce overall knee OA pain vs placebo, though an exploratory subgroup with moderate-to-severe pain showed possible benefit from the combination. [https://pubmed.ncbi.nlm.nih.gov/16510695/]
  - Long-term effects of glucosamine sulphate on osteoarthritis progression: a randomised, placebo-controlled clinical trial, Lancet (London, England) (2001) — In this 3-year Lancet trial, glucosamine sulphate 1500 mg/day prevented joint-space narrowing (-0.06 mm vs -0.31 mm with placebo) and modestly improved WOMAC symptoms, suggesting a possible structure-modifying effect in knee OA. [https://pubmed.ncbi.nlm.nih.gov/11214126/]
  - Combined chondroitin sulfate and glucosamine for painful knee osteoarthritis: a multicentre, randomised, double-blind, non-inferiority trial versus celecoxib, Annals of the rheumatic diseases (2016) — In this double-blind non-inferiority trial, chondroitin sulfate plus glucosamine hydrochloride reduced WOMAC pain by ~50% and was comparable (non-inferior) to celecoxib 200 mg/day over 6 months in patients with moderate-to-severe knee OA. [https://pubmed.ncbi.nlm.nih.gov/25589511/]
  - Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis, The New England journal of medicine (2006) — Landmark NIH multicenter double-blind RCT (N=1583) of glucosamine HCl 1500 mg, chondroitin sulfate 1200 mg, the combination, celecoxib, or placebo for knee OA over 24 weeks. Neither glucosamine, chondroitin, nor the combination significantly reduced pain in the overall cohort vs placebo; an exploratory subgroup with moderate-to-severe baseline pain showed benefit from the combination (79.2% vs 54.3% placebo responders, P=0.002). [https://pubmed.ncbi.nlm.nih.gov/16495392/]
  - Association of habitual glucosamine use with risk of cardiovascular disease: prospective study in UK Biobank, BMJ (Clinical research ed.) (2019) — Habitual glucosamine use was associated with lower risk of total cardiovascular disease events (HR 0.85, 95% CI 0.80-0.90) and CVD death (HR 0.78, 95% CI 0.70-0.87) compared with non-users, an observational association not establishing causation. [https://pubmed.ncbi.nlm.nih.gov/31088786/]
  - Associations of regular glucosamine use with all-cause and cause-specific mortality: a large prospective cohort study, Annals of the rheumatic diseases (2020) — Regular glucosamine use was associated with lower all-cause mortality (HR 0.85, 95% CI 0.82-0.89) and modestly lower cancer mortality (HR 0.94, 95% CI 0.88-0.99), though residual confounding and healthy-user bias likely contribute. [https://pubmed.ncbi.nlm.nih.gov/32253185/]
  - Glucosamine and Chondroitin for Osteoarthritis, NIH National Center for Complementary and Integrative Health (2015) — NCCIH concludes it remains uncertain whether glucosamine and chondroitin meaningfully help knee osteoarthritis symptoms, noting inconsistent trial results and even less evidence for joints other than the knee. [https://www.nccih.nih.gov/health/glucosamine-and-chondroitin-for-osteoarthritis-what-you-need-to-know]

---

## Resveratrol (trans-3,5,4'-trihydroxystilbene)
URL: https://nutridex.info/s/resveratrol
Category: Longevity, Heart & Metabolic
Evidence: Mixed — Conflicting results across studies; benefit uncertain.
Red-wine polyphenol with big longevity claims and modest, inconsistent human data.

Quick answer: Resveratrol is used for may modestly improve glycemic control (e.g., small hba1c reductions) and some lipid markers, mainly in people with type 2 diabetes or metabolic syndrome.. NutriDex grades the human evidence as mixed — Conflicting results across studies; benefit uncertain. Based on 23 cited human studies (23 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Resveratrol is a polyphenol (stilbene) found in grapes, red wine, peanuts, and Japanese knotweed that became famous through preclinical studies suggesting it activates sirtuins and mimics caloric restriction. Despite roughly 200 human trials across more than 24 indications, there is currently no conclusive clinical evidence to recommend it for any specific condition, and none of the popular human longevity or lifespan claims are supported. The most consistent human signals are modest improvements in glycemic and lipid markers in people with type 2 diabetes or metabolic syndrome, plus possible blood-pressure lowering at higher doses; many trials are small, short, and conflicting. A major practical limitation is poor oral bioavailability—resveratrol is rapidly metabolized and largely excreted within hours, so achieving meaningful tissue levels is difficult. Overall the evidence is best described as mixed: biologically plausible with some metabolic signal, but far short of the hype. It is generally well tolerated up to about 1 g/day, with mainly GI side effects at higher doses.

Benefits / uses: May modestly improve glycemic control (e.g., small HbA1c reductions) and some lipid markers, mainly in people with type 2 diabetes or metabolic syndrome.; Higher doses (>=150 mg/day) may lower systolic blood pressure in some trials, with effects concentrated in diabetic or higher-BMI subgroups.; May reduce certain inflammatory and oxidative-stress markers (e.g., CRP) in type 2 diabetes, though evidence quality is low and inconsistent across markers.; No clinical trial evidence supports its popular anti-aging, lifespan-extension, or 'sirtuin-activating longevity' claims in humans.; Effects are limited by poor oral bioavailability; benefits, where seen, are small and not consistently reproduced..
Active compounds: trans-Resveratrol (primary bioactive stilbene); cis-Resveratrol isomer; Resveratrol glucuronide and sulfate metabolites (dominant circulating forms); Often sourced from Polygonum cuspidatum (Japanese knotweed) extract.
Dose: Commonly 150–500 mg/day of trans-resveratrol; research doses range up to ~1,000 mg/day. Doses above 1,000 mg/day raise GI side-effect risk with little added proven benefit. Micronized or formulated products are used to offset poor bioavailability.
Safety: Generally well tolerated up to about 1,000 mg/day; higher doses (>=1,000–2,000 mg/day) frequently cause GI effects such as nausea, abdominal pain, flatulence, and diarrhea. Resveratrol inhibits CYP enzymes (notably CYP3A4, which metabolizes roughly half of all medications) and can raise blood levels of statins, calcium-channel blockers, immunosuppressants, and some anxiolytics; it may also potentiate anticoagulant/antiplatelet drugs (e.g., warfarin, aspirin) and increase bleeding risk. It has estrogenic/phytoestrogen activity, so people with hormone-sensitive conditions (breast, uterine, or ovarian cancer, endometriosis, uterine fibroids) and those on hormone therapy or oral contraceptives should avoid it or seek medical advice. Prolonged high-dose use has been associated with kidney and liver concerns, and a high-dose micronized formulation trial in multiple myeloma was halted for renal adverse events. Avoid in pregnancy and breastfeeding (insufficient safety data), stop before surgery due to bleeding risk, and consult a clinician if you have liver/kidney disease, hormone-sensitive conditions, or take prescription medications.

Cited studies (23):
  - Efficacy of resveratrol supplementation on lipid profile parameters: An umbrella of meta-analysis, Prostaglandins & other lipid mediators (2024) — Umbrella meta-analysis (search to Nov 2023) found resveratrol supplementation modestly reduced triglycerides (SMD = -0.14, 95% CI -0.24 to -0.03) and total cholesterol (SMD = -0.20, 95% CI -0.31 to -0.08) but had no effect on HDL-c (SMD = 0.00, 95% CI -0.04 to 0.05). [https://pubmed.ncbi.nlm.nih.gov/39255906/]
  - The Effectiveness of Curcumin, Resveratrol, and Silymarin on MASLD: A Systematic Review and Meta-Analysis, Food science & nutrition (2024) — Systematic review and meta-analysis assessed curcumin, resveratrol, and silymarin in MASLD, finding the three compounds have not been directly compared and reporting modest, inconsistent effects on liver/metabolic parameters. [https://pmc.ncbi.nlm.nih.gov/articles/PMC11666838/]
  - Influence of Age and Dose on the Effect of Resveratrol for Glycemic Control in Type 2 Diabetes Mellitus: Systematic Review and Meta-Analysis, Molecules (Basel, Switzerland) (2022) — Systematic review and meta-analysis in type 2 diabetes (15 glucose, 12 HbA1c, 11 insulin, 11 HOMA-IR effect sizes) found a significant dose-response relationship between resveratrol dose and HbA1c reduction (R-squared = 0.22, p < 0.05). [https://pmc.ncbi.nlm.nih.gov/articles/PMC9416262/]
  - Efficacy and Safety of Resveratrol Supplements on Blood Lipid and Blood Glucose Control in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials, Evidence-based complementary and alternative medicine : eCAM (2021) — Systematic review and meta-analysis of RCTs in type 2 diabetes reported resveratrol was more effective than placebo for HbA1c and creatinine but not for fasting plasma glucose or insulin resistance. [https://pubmed.ncbi.nlm.nih.gov/34484395/]
  - The Effect of Resveratrol on Blood Lipid Profile: A Dose-Response Meta-Analysis of Randomized Controlled Trials, Nutrients (2022) — Dose-response meta-analysis of RCTs: resveratrol significantly reduced total cholesterol (MD -10.28 mg/dL, p<0.001), triglycerides (MD -8.56 mg/dL, p<0.001), and LDL-C (MD -5.69 mg/dL, p=0.038), with no change in HDL-C; LDL-C reduction was greater at >=12 weeks and in type 2 diabetics. [https://pubmed.ncbi.nlm.nih.gov/36145131/]
  - Influence of Age and Dose on the Effect of Resveratrol for Glycemic Control in Type 2 Diabetes Mellitus: Systematic Review and Meta-Analysis, Molecules (Basel, Switzerland) (2022) — Systematic review/meta-analysis (15 RCTs): resveratrol lowered glucose in adults 45-59 yr dose-dependently (-8.6 to -28.4 mg/dL) and reduced HbA1c by -0.60% at 250-500 mg/day; effects were attenuated or absent in those >60 yr, with no single therapeutic dose established. [https://pubmed.ncbi.nlm.nih.gov/36014469/]
  - Resveratrol supplementation efficiently improves endothelial health: A systematic review and meta-analysis of randomized controlled trials, Phytotherapy research : PTR (2022) — Meta-analysis of RCTs (17 studies, 21 arms): resveratrol significantly improved endothelial function, increasing flow-mediated dilation (WMD +1.43%, 95% CI 0.98-1.88, p<0.001) and lowering ICAM-1 (-7.09 ng/mL, p<0.001); VCAM-1, fibrinogen, and PAI-1 were unchanged. [https://pubmed.ncbi.nlm.nih.gov/35833325/]
  - Efficacy of Resveratrol Supplementation on Glucose and Lipid Metabolism: A Meta-Analysis and Systematic Review, Frontiers in physiology (2022) — Meta-analysis found resveratrol significantly reduced HbA1c (mean difference -0.48%), total cholesterol, and LDL cholesterol, with greater benefit in obese and diabetic patients. [https://pubmed.ncbi.nlm.nih.gov/35431994/]
  - Resveratrol for the Management of Human Health: How Far Have We Come? A Systematic Review of Resveratrol Clinical Trials to Highlight Gaps and Opportunities, International Journal of Molecular Sciences (2024) — Systematic review concluded that despite extensive study and good tolerability up to ~1 g/day, there is currently no conclusive clinical evidence to recommend resveratrol in any healthcare setting. [https://doi.org/10.3390/ijms25020747]
  - The efficacy of resveratrol supplementation on inflammation and oxidative stress in type-2 diabetes mellitus patients: randomized double-blind placebo meta-analysis, Frontiers in endocrinology (2024) — Resveratrol significantly lowered CRP (SMD -1.40) but did not significantly reduce IL-6 or TNF-alpha, with evidence rated low to very low quality. [https://pmc.ncbi.nlm.nih.gov/articles/PMC11771208/]
  - Effect of resveratrol on blood pressure: A systematic review and meta-analysis of randomized, controlled, clinical trials, Critical reviews in food science and nutrition (2019) — Resveratrol did not significantly change blood pressure overall, but higher doses (>=150 mg/day) significantly reduced systolic BP (about -11.9 mmHg), mainly in diabetic and higher-BMI subgroups. [https://pubmed.ncbi.nlm.nih.gov/29359958/]
  - The Effect of Resveratrol on Blood Lipid Profile: A Dose-Response Meta-Analysis of Randomized Controlled Trials, Nutrients (2022) — Resveratrol supplementation modestly lowered total cholesterol, triglycerides, and LDL cholesterol (effect on LDL stronger at >=12 weeks and in type 2 diabetes) but did not change HDL. [https://pmc.ncbi.nlm.nih.gov/articles/PMC9506025/]
  - Resveratrol Supplementation in Patients with Non-Alcoholic Fatty Liver Disease: Systematic Review and Meta-analysis, Journal of gastrointestinal and liver diseases : JGLD (2017) — This systematic review and meta-analysis found resveratrol supplementation did not significantly improve liver enzymes (ALT/AST), weight, BMI, glucose, insulin, or lipids, concluding current evidence is insufficient to support resveratrol for managing non-alcoholic fatty liver disease. [https://pubmed.ncbi.nlm.nih.gov/28338115/]
  - The Effects of Resveratrol Supplementation on Endothelial Function and Blood Pressures Among Patients with Metabolic Syndrome and Related Disorders: A Systematic Review and Meta-Analysis of Randomized Controlled Trials, High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension (2019) — This meta-analysis found resveratrol significantly improved endothelial function, increasing flow-mediated dilation (SMD 1.77), while showing no significant effect on systolic or diastolic blood pressure. [https://pubmed.ncbi.nlm.nih.gov/31264084/]
  - Effects of resveratrol on postmenopausal women: a systematic review and meta-analysis, Frontiers in pharmacology (2025) — This systematic review and meta-analysis found resveratrol produced no significant effects on cognition or memory, but significantly reduced pain scores and the bone-turnover marker CTX in postmenopausal women. [https://pubmed.ncbi.nlm.nih.gov/40771919/]
  - The effect of resveratrol supplementation on anthropometric indices, adiponectin and leptin levels in individuals with overweight and obesity: a graded, systematic review and meta-analysis of randomized controlled trials, International journal of obesity (2005) (2026) — This graded systematic review and meta-analysis found resveratrol significantly reduced waist circumference (WMD -1.93 cm) but did not significantly affect body weight, BMI, or serum adiponectin and leptin levels in adults with overweight or obesity. [https://pubmed.ncbi.nlm.nih.gov/41455817/]
  - Resveratrol as an Anti-inflammatory Agent in Coronary Artery Disease: A Systematic Review, Meta-Analysis and Meta-Regression, Chinese journal of integrative medicine (2024) — This systematic review, meta-analysis, and meta-regression found resveratrol significantly reduced TNF-alpha in primary prevention (high-certainty evidence, optimal dose ~15 mg/day) but had no significant effect on IL-6, indicating selective anti-inflammatory activity in coronary artery disease. [https://pubmed.ncbi.nlm.nih.gov/38958883/]
  - Effects of resveratrol on polycystic ovarian syndrome: a systematic review and meta-analysis of randomized controlled trials, Endocrine (2024) — This systematic review and meta-analysis found resveratrol significantly improved prolactin, acne scores, and total cholesterol in PCOS, but showed no significant effect on total testosterone. [https://pubmed.ncbi.nlm.nih.gov/37568063/]
  - Effect of resveratrol supplementation on cognitive performance and mood in adults: a systematic literature review and meta-analysis of randomized controlled trials, Nutrition Reviews (2018) — This systematic review and meta-analysis of randomized controlled trials found resveratrol supplementation significantly improved delayed recognition memory and negative mood in adults, though overall effects on cognitive performance were inconsistent and limited. [https://academic.oup.com/nutritionreviews/article/76/6/432/4954227]
  - Sustained Cerebrovascular and Cognitive Benefits of Resveratrol in Postmenopausal Women, Nutrients (2020) — 12-month randomized double-blind placebo-controlled trial in 129 postmenopausal women (75 mg trans-resveratrol twice daily): improved overall cognitive performance (p<0.001) and attenuated decline in cerebrovascular responsiveness to cognitive stimuli (p=0.038), correlating with reduced fasting glucose. [https://pubmed.ncbi.nlm.nih.gov/32244933/]
  - Long-term resveratrol supplementation improves pain perception, menopausal symptoms, and overall well-being in postmenopausal women: findings from a 24-month randomized, controlled, crossover trial, Menopause (New York, N.Y.) (2020) — 24-month randomized placebo-controlled crossover trial in 125 postmenopausal women (75 mg trans-resveratrol twice daily): reduced composite pain score (p<0.001, greatest in overweight women), improved somatic menopausal symptoms (p=0.024) and general well-being (p=0.010), linked to better cerebrovascular responsiveness. [https://pubmed.ncbi.nlm.nih.gov/32881835/]
  - Regular Supplementation With Resveratrol Improves Bone Mineral Density in Postmenopausal Women: A Randomized, Placebo-Controlled Trial, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research (2020) — In this randomized, placebo-controlled crossover trial, resveratrol 75 mg twice daily significantly increased bone mineral density at the lumbar spine and femoral neck and reduced the bone-resorption marker CTX-1 by about 7.2%, improving femoral-neck T-score and 10-year fracture risk versus placebo. [https://pubmed.ncbi.nlm.nih.gov/32564438/]
  - Effects of resveratrol supplementation on cardiac remodeling in hypertensive patients: a randomized controlled clinical trial, Hypertension research : official journal of the Japanese Society of Hypertension (2023) — In this randomized controlled trial, resveratrol 400 mg/day added to standard therapy improved diastolic function (lower E/e'), increased left ventricular global longitudinal strain, and lowered cardiac fibrosis biomarkers (procollagen type I C-peptide and galectin-3) versus control. [https://pubmed.ncbi.nlm.nih.gov/36854725/]

---

## Taurine (Acidum 2-aminoethanesulfonicum)
URL: https://nutridex.info/s/taurine
Category: Performance, Longevity
Evidence: Preliminary — Early or small human trials; promising but not yet conclusive.
A conditionally essential amino acid with promising aging-related animal data and modest human cardiometabolic effects.

Quick answer: Taurine is used for modestly lowers blood pressure, fasting glucose and triglycerides in human rcts, suggesting cardiometabolic support. NutriDex grades the human evidence as preliminary — Early or small human trials; promising but not yet conclusive. Based on 16 cited human studies (16 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Taurine is a conditionally essential sulfur-containing amino acid abundant in muscle, brain, heart and retina, and is a common ingredient in energy drinks. Interest surged after a 2023 Science study (Singh et al.) showed that taurine levels decline with age across species and that supplementation extended lifespan and healthspan in mice and improved healthspan in middle-aged monkeys, though these are animal findings and no human longevity RCT has confirmed them. In humans, the strongest data are cardiometabolic: meta-analyses of randomized trials report modest reductions in blood pressure, fasting glucose and triglycerides, and improvements in lipids and insulin sensitivity in people with overweight. Acute dosing may yield small ergogenic benefits for exercise, but heterogeneity and risk of bias keep the certainty low. Overall the human benefit signal is real but modest and the longevity claims remain unproven in people, so the evidence is best described as preliminary. Taurine is generally well tolerated at typical doses.

Benefits / uses: Modestly lowers blood pressure, fasting glucose and triglycerides in human RCTs, suggesting cardiometabolic support; Reversed age-related decline and extended healthspan/lifespan in mice and improved healthspan in monkeys (animal data only); May produce small-to-moderate acute improvements in exercise performance, especially endurance and strength tasks; Improves lipid profile, fasting insulin and BMI in adults with overweight, supporting metabolic health.
Active compounds: Taurine (2-aminoethanesulfonic acid).
Dose: 1-3 g per day orally; cardiometabolic and obesity trials used 0.5-6 g/day, commonly 1.5-3 g/day in divided doses.
Safety: Taurine is generally recognized as safe and well tolerated at doses up to ~3 g/day, with the European Food Safety Authority identifying an observed safe level around 6 g/day; mild GI upset is the most common complaint. People with kidney impairment should use caution, as clearance may be reduced. It may have additive blood-pressure- and glucose-lowering effects, so monitor if combined with antihypertensives or antidiabetic/insulin therapy. Taurine is frequently co-formulated with caffeine in energy drinks; the cardiovascular and CNS risks of those products derive largely from caffeine and sugar, not taurine itself, but high energy-drink intake should be avoided. Pregnant or breastfeeding individuals should consult a clinician given limited supplementation data. Those on lithium should be cautious, as fluid/electrolyte-shifting agents can affect lithium levels.

Cited studies (16):
  - Taurine reduces the risk for metabolic syndrome: a systematic review and meta-analysis of randomized controlled trials, Nutrition & diabetes (2024) — Meta-analysis of 25 RCTs (n=1024) found taurine supplementation significantly reduced systolic BP (WMD -3.999 mmHg, p=0.017), diastolic BP (WMD -1.509 mmHg, p=0.002), fasting glucose (WMD -5.882 mg/dL, p=0.018), and triglycerides (WMD -18.315 mg/dL, p<0.001). [https://pmc.ncbi.nlm.nih.gov/articles/PMC11099170/]
  - Effect of Long-Term Taurine Supplementation on the Lipid and Glycaemic Profile in Adults with Overweight or Obesity: A Systematic Review and Meta-Analysis, Nutrients (2024) — Meta-analysis of 9 RCTs in adults with overweight/obesity found long-term taurine supplementation significantly decreased triglycerides (WMD -0.56 mmol/L), total cholesterol (WMD -0.71 mmol/L), and fasting insulin (WMD -2.15 µU/mL). [https://pmc.ncbi.nlm.nih.gov/articles/PMC11722866/]
  - Effects of Oral Taurine Supplementation on Cardiometabolic Risk Factors: A Meta-analysis and Systematic Review of Randomized Clinical Trials, Nutrition reviews (2025) — Meta-analysis of 34 RCTs: oral taurine significantly reduced fasting glucose (MD -5.90 mg/dL), HbA1c (-0.21%), HOMA-IR (-0.57), triglycerides (-14.42 mg/dL), total cholesterol (-12.41 mg/dL), LDL-C (-5.08 mg/dL), SBP (-4.38 mmHg) and DBP (-2.54 mmHg); doses of 1.5-3.0 g/day were most effective. [https://pubmed.ncbi.nlm.nih.gov/41275513/]
  - Taurine reduces the risk for metabolic syndrome: a systematic review and meta-analysis of randomized controlled trials, Nutrition & diabetes (2024) — Taurine supplementation (0.5-6 g/day) significantly reduced systolic BP (~4 mmHg), diastolic BP (~1.5 mmHg), fasting glucose (~5.9 mg/dL) and triglycerides (~18 mg/dL) versus control, with dose-dependent effects. [https://pubmed.ncbi.nlm.nih.gov/38755142/]
  - Does One Shot Work? The Acute Impact of a Single Taurine Dose on Exercise Performance: A Meta-Analytic Review, Scandinavian journal of medicine & science in sports (2025) — A single acute dose of taurine was associated with small-to-moderate improvements in overall exercise performance (Hedges g = 0.25, 95% CI 0.10-0.39), with low to very low certainty due to heterogeneity and bias. [https://pubmed.ncbi.nlm.nih.gov/40852891/]
  - Effect of Long-Term Taurine Supplementation on the Lipid and Glycaemic Profile in Adults with Overweight or Obesity: A Systematic Review and Meta-Analysis, Nutrients (2024) — Taurine (1-3 g/day for 2-12 weeks) significantly reduced triglycerides, total cholesterol and fasting insulin, and lowered BMI in overweight (not obese) adults, with greater glycemic benefit at 3 g/day. [https://pubmed.ncbi.nlm.nih.gov/39796489/]
  - The Dose Response of Taurine on Aerobic and Strength Exercises: A Systematic Review, Frontiers in physiology (2021) — Single doses of ~1-6 g taurine (often 1-3 g, ~1-3 h pre-exercise) were most associated with aerobic and strength performance benefits, though effects were inconsistent across endpoints. [https://pubmed.ncbi.nlm.nih.gov/34497536/]
  - Insights into the cardiovascular benefits of taurine: a systematic review and meta-analysis, Nutrition journal (2024) — Taurine supplementation significantly improved cardiac function, increasing left ventricular ejection fraction (WMD +4.98%) and reducing NYHA functional class (WMD -0.40), heart rate (-3.6 bpm), systolic BP (-4.0 mmHg) and diastolic BP (-1.4 mmHg), with benefits most pronounced in heart failure patients. [https://pubmed.ncbi.nlm.nih.gov/39148075/]
  - The effects of taurine supplementation on diabetes mellitus in humans: A systematic review and meta-analysis, Food chemistry. Molecular sciences (2022) — In diabetic patients, taurine supplementation significantly reduced HbA1c (SMD -0.41), fasting blood glucose (SMD -1.28) and HOMA-IR (SMD -0.86), indicating improved glycemic control and insulin resistance. [https://pubmed.ncbi.nlm.nih.gov/35769396/]
  - Profiling inflammatory and oxidative stress biomarkers following taurine supplementation: a systematic review and dose-response meta-analysis of controlled trials, European journal of clinical nutrition (2022) — Taurine supplementation significantly reduced the oxidative stress marker malondialdehyde (MDA) and C-reactive protein (CRP), with no significant change in TNF-alpha or IL-6; 8-week regimens showed the most beneficial effects on inflammatory and oxidative-stress biomarkers. [https://pubmed.ncbi.nlm.nih.gov/34584225/]
  - The effect of taurine supplementation on markers of muscle damage and muscle pain in an athletic population: A systematic review and meta-analysis of randomized controlled trials assessed using the grading of recommendations, assessment, development, and evaluation approach, Heliyon (2025) — In athletes, taurine supplementation significantly lowered post-exercise and 24-h creatine kinase, reduced LDH up to 48 h, and decreased muscle-pain VAS scores at 96 h, though overall GRADE certainty was low due to high heterogeneity. [https://doi.org/10.1016/j.heliyon.2025.e43622]
  - Taurine supplementation as a therapeutic strategy for cellular senescence and chronic inflammation in long COVID: a systematic review and meta-analysis, BMC Infectious Diseases (2026) — A systematic review/meta-analysis assessing taurine as a strategy against senescence and chronic inflammation in long COVID found taurine significantly improved metabolic markers (HbA1c, fasting glucose, insulin, HOMA-IR, lipids) and inflammatory markers (CRP, TNF-alpha, IL-6), supporting it as a candidate intervention. [https://doi.org/10.1186/s12879-026-13009-y]
  - The use of taurine and D-glucurono-gamma-lactone as constituents of the so-called “energy” drinks, EFSA Journal (2009) — EFSA concluded that exposure to taurine from regular energy-drink consumption is not a safety concern, confirming a No Observed Adverse Effect Level (NOAEL) of 1,000 mg/kg body weight/day and removing prior concerns about possible harmful effects on the brain. [https://doi.org/10.2903/j.efsa.2009.935]
  - Effect of taurine supplementation on exercise capacity of patients with heart failure, Journal of cardiology (2011) — Randomized placebo-controlled trial in 29 heart-failure patients (LVEF <50%, NYHA II-III): taurine 500 mg three times daily for 2 weeks significantly increased exercise time, METs and exercise distance (all p<0.0001) vs no significant change with placebo. [https://pubmed.ncbi.nlm.nih.gov/21334852/]
  - Taurine deficiency as a driver of aging, Science (New York, N.Y.) (2023) — Landmark multi-species study: circulating taurine declines with age in mice, monkeys and humans; reversing the decline extended healthspan in mice and monkeys and lifespan in mice (~10-12%), reducing cellular senescence, mitochondrial dysfunction, DNA damage and inflammaging. Human data are associational; authors call for clinical trials. [https://pubmed.ncbi.nlm.nih.gov/37289866/]
  - Taurine deficiency as a driver of aging, Science (2023) — Circulating taurine declines with age across species; restoring it extended median lifespan ~10-12% and improved healthspan in mice and improved healthspan markers in middle-aged monkeys (animal study, no human outcome data). [https://doi.org/10.1126/science.abn9257]

---

## Spirulina (Arthrospira platensis (formerly Spirulina platensis; also classified as Limnospira))
URL: https://nutridex.info/s/spirulina
Category: Gut & Immune, Heart & Metabolic
Evidence: Preliminary — Early or small human trials; promising but not yet conclusive.
A protein-rich blue-green algae with small, inconsistent effects on cholesterol and blood pressure.

Quick answer: Spirulina is used for modest lipid improvements: meta-analyses report lower ldl, total cholesterol and triglycerides with higher hdl, but trials are small and short and effect sizes vary widely.. NutriDex grades the human evidence as preliminary — Early or small human trials; promising but not yet conclusive. Based on 16 cited human studies (16 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Spirulina is dried biomass of the cyanobacterium Arthrospira platensis, marketed as a protein and antioxidant supplement. Recent meta-analyses of mostly small, short randomized trials suggest it can modestly lower LDL, total cholesterol and triglycerides and produce small blood-pressure reductions, with the largest effects in people who have hypertension or elevated cardiometabolic risk. However, the trials are heterogeneous and the quality of evidence is generally only moderate, and a 2025 adjuvant-therapy review judged the cardiovascular effects small and of uncertain clinical significance. It is a genuinely nutrient-dense food (high-quality protein, B vitamins, iron, and the pigment phycocyanin), but its disease-relevant benefits remain preliminary rather than established. A key practical concern is product quality: poorly sourced spirulina can be contaminated with hepatotoxic microcystins, other cyanotoxins, or heavy metals, so third-party-tested products are important.

Benefits / uses: Modest lipid improvements: meta-analyses report lower LDL, total cholesterol and triglycerides with higher HDL, but trials are small and short and effect sizes vary widely.; Small reductions in blood pressure (roughly 3-4 mmHg systolic / 2-3 mmHg diastolic), most apparent in people with hypertension, overweight, or baseline BP at or above 120/80.; High-quality complete protein (~60-70% by weight) plus B vitamins, iron and antioxidant pigments, making it a useful nutrient-dense food rather than a proven therapeutic.; Phycocyanin and other constituents show antioxidant and anti-inflammatory activity in lab and animal models, but human outcome evidence remains preliminary.; Note: at least one 2025 umbrella/adjuvant review found the cardiometabolic effects 'small and of uncertain clinical significance,' so benefits should be considered supportive at best, not a substitute for proven therapies..
Active compounds: Phycocyanin (C-phycocyanin pigment-protein); Complete dietary protein with all essential amino acids; Gamma-linolenic acid (GLA); Beta-carotene and other carotenoids; B vitamins, iron, and chlorophyll.
Dose: Commonly 1-8 g/day (some trials up to ~10 g/day) of dried Arthrospira, in divided doses; cardiometabolic trials typically run 2-12 weeks. No established optimal or long-term safe dose.
Safety: Generally well tolerated short-term; mild GI upset, headache, or allergic-type reactions can occur. The main safety issue is product quality: poorly sourced or wild-harvested spirulina (and blue-green algae blends containing Aphanizomenon/Microcystis) may be contaminated with hepatotoxic microcystins, other cyanotoxins, or heavy metals (arsenic, lead, mercury, cadmium) — choose products independently tested for these. Because spirulina may stimulate immune activity, people with autoimmune diseases (e.g., lupus, MS, rheumatoid arthritis) should be cautious and consult a clinician; it should be avoided by anyone with the metabolic disorder phenylketonuria (PKU) due to its phenylalanine content. It can theoretically add to the effects of blood-pressure-lowering and anticoagulant/antiplatelet medications and may interact with immunosuppressants, so monitor if combined. Safety in pregnancy and breastfeeding is not established (contamination risk in particular), and long-term safety data are lacking; people who are immunocompromised, pregnant, or breastfeeding should avoid it unless cleared by a healthcare provider. Not a substitute for prescribed lipid- or blood-pressure-lowering therapy.

Cited studies (16):
  - Spirulina's impacts on cardiovascular health: Insights from a systematic meta-analysis of RCT, Complementary therapies in medicine (2025) — RCT meta-analysis (searched through Jan 2025) reported spirulina improved lipid profile (lower TG, TC, LDL-C; higher HDL-C), reduced SBP/DBP, lowered weight/BMI, and improved glycaemic and inflammatory cardiovascular risk markers. [https://pubmed.ncbi.nlm.nih.gov/40953712/]
  - Effects of spirulina supplementation alone or with exercise on cardiometabolic health in overweight and obese adults: a systematic review and meta-analysis, Frontiers in nutrition (2025) — Systematic review/meta-analysis of 23 studies (n=1,035) in overweight/obese adults found spirulina (alone or with exercise) significantly reduced LDL-C, total cholesterol, and triglycerides, with no significant change in fasting glucose or insulin. [https://pmc.ncbi.nlm.nih.gov/articles/PMC12245695/]
  - Effect of Microalgae Arthrospira on Biomarkers of Glycemic Control and Glucose Metabolism: A Systematic Review and Meta-analysis, Current problems in cardiology (2022) — Pooled clinical data showed Arthrospira (Spirulina) significantly reduced fasting blood sugar (-1.77), total cholesterol (-2.54), and triglycerides (-3.71) and raised HDL-C (+2.27), but did not significantly change HbA1c or LDL-C; FBS reductions were strongest at <2 g/day doses and <2 months. [https://pubmed.ncbi.nlm.nih.gov/34538515/]
  - The effect of Spirulina supplementation on lipid profile: GRADE-assessed systematic review and dose-response meta-analysis of data from randomized controlled trials, Pharmacological research (2023) — Spirulina supplementation significantly reduced LDL-C, total cholesterol and triglycerides (each SMD about -0.6) and modestly raised HDL-C (SMD +0.3) versus control. [https://pubmed.ncbi.nlm.nih.gov/37263369/]
  - The Effect of Spirulina Supplementation on Blood Pressure in Adults: A GRADE-Assessed Systematic Review and Meta-Analysis of Randomized Clinical Trials, Phytotherapy research : PTR (2025) — Spirulina reduced systolic BP by about 4.41 mmHg and diastolic BP by about 2.84 mmHg, with larger effects in hypertensive, overweight, older (>50 y) participants and trials longer than 8 weeks; GRADE moderate quality. [https://pubmed.ncbi.nlm.nih.gov/39529406/]
  - Effect of Spirulina Supplementation on Systolic and Diastolic Blood Pressure: Systematic Review and Meta-Analysis of Randomized Controlled Trials, Nutrients (2021) — Spirulina (1-8 g/day, 2-12 weeks) significantly lowered systolic BP by about 4.59 mmHg and diastolic BP by about 7.02 mmHg, with effects concentrated in hypertensive patients. [https://pmc.ncbi.nlm.nih.gov/articles/PMC8468496/]
  - The Role of Chlorella and Spirulina as Adjuvants of Cardiovascular Risk Factor Control: A Systematic Review and Meta-Analysis of Randomised Controlled Trials, Nutrients (2025) — As a cardiovascular adjuvant, spirulina produced only a small significant reduction in diastolic BP (SMD -0.42) and no significant lipid changes, with authors concluding the effect is small and of uncertain clinical significance. [https://pmc.ncbi.nlm.nih.gov/articles/PMC11945647/]
  - Effects of spirulina supplementation on body composition in adults: a GRADE-assessed and dose-response meta-analysis of RCTs, Nutrition & metabolism (2025) — Spirulina supplementation significantly reduced body weight (WMD -1.07 kg) and body fat percentage (WMD -0.84%) with GRADE high certainty, and BMI (WMD -0.40 kg/m2, moderate certainty), with stronger effects at doses >=2 g/day and durations >12 weeks in obese individuals. [https://pubmed.ncbi.nlm.nih.gov/40528207/]
  - The effect of spirulina on type 2 diabetes: a systematic review and meta-analysis, Journal of diabetes and metabolic disorders (2021) — In type 2 diabetes, spirulina (0.8-8 g/day for 45-90 days) significantly lowered fasting blood glucose by about 17.9 mg/dl plus triglycerides and total cholesterol, but had no significant effect on HbA1c or postprandial blood glucose. [https://pubmed.ncbi.nlm.nih.gov/34178867/]
  - Effects of Spirulina Supplementation on C-Reactive Protein (CRP): A Systematic Review and Dose-Response Meta-Analysis, Food science & nutrition (2025) — Spirulina supplementation significantly reduced serum C-reactive protein (WMD -0.55 mg/L; 95% CI -0.90 to -0.21; p=0.002), with no significant linear or non-linear dose- or duration-response relationship. [https://pmc.ncbi.nlm.nih.gov/articles/PMC12052714/]
  - Spirulina supplementation as an adjuvant therapy in enhancement of antioxidant capacity: A systematic review and meta-analysis of controlled clinical trials, International journal of clinical practice (2021) — As an antioxidant adjuvant, spirulina produced only marginally significant increases in total antioxidant capacity (SMD 0.49; p=0.05) and superoxide dismutase activity (SMD 0.72; p=0.06), and no significant change in glutathione peroxidase (SMD 0.27; p=0.29). [https://pubmed.ncbi.nlm.nih.gov/34235823/]
  - Clinical effects of Spirulina supplementation on hemoglobin levels in anemic pregnant women: a systematic review and meta-analysis, Indonesian Journal of Biomedicine and Clinical Sciences (2026) — Spirulina supplementation significantly raised hemoglobin in anemic pregnant women (single-arm pooled MD +1.81 g/dL; 95% CI 0.24-3.39; p=0.024), with a non-significant trend toward higher hemoglobin than standard iron (MD +1.45 g/dL; p=0.088). [https://doi.org/10.22146/inajbcs.v58i1.23573]
  - Effects of spirulina supplementation alone or with exercise on cardiometabolic health in overweight and obese adults: a systematic review and meta-analysis, Frontiers in Nutrition (2025) — Combining spirulina with exercise improved lipids more than exercise alone, significantly increasing HDL-C (Hedges g +1.08) and lowering LDL-C (g -0.81), while spirulina alone reduced total cholesterol, triglycerides, LDL-C and diastolic BP but did not improve glucose control. [https://doi.org/10.3389/fnut.2025.1624982]
  - Spirulina (2019) — NIH LiverTox classifies spirulina as having a generally favorable safety profile but implicated in rare cases of clinically apparent, usually self-limiting liver injury (mild enzyme elevations to hepatitis), with no reports of acute liver failure and possible confounding from contamination or co-ingested herbs. [https://www.ncbi.nlm.nih.gov/books/NBK548312/]
  - The effects of spirulina on allergic rhinitis, European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery (2008) — In a 6-month double-blind placebo-controlled trial, spirulina 2 g/day significantly improved nasal discharge, sneezing, nasal congestion and itching versus placebo (all p<0.001). [https://pubmed.ncbi.nlm.nih.gov/18343939/]
  - Microcystins and Cyanobacterial Contaminants in the French Small-Scale Productions of Spirulina (Limnospira sp.), Toxins (2023) — Over 99% of French spirulina samples stayed below the 1 ppm MC-LR regulatory limit for microcystins, but 14 cyanobacterial contaminant taxa were detected, underscoring that contamination risk depends on production quality. [https://pubmed.ncbi.nlm.nih.gov/37368655/]

---

## Sea Moss (Irish Moss) (Chondrus crispus)
URL: https://nutridex.info/s/sea-moss
Category: Debunked, Gut & Immune
Evidence: No Evidence — No credible human evidence supports the marketed claims — widely considered ineffective.
A trendy red seaweed sold as a cure-all, but the sweeping wellness claims have essentially no human evidence — and it carries real iodine and heavy-metal risks.

Quick answer: Sea Moss (Irish Moss) is marketed for no claimed benefit (immunity, thyroid support, gut health, weight loss, skin, libido) is supported by direct human trials on chondrus crispus — these are extrapolations from nutrient content or lab/animal data. NutriDex grades the human evidence as no evidence — No credible human evidence supports the marketed claims — widely considered ineffective. Based on 16 cited human studies (16 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Sea moss (Chondrus crispus), also called Irish moss, is a red seaweed that became a billion-dollar social-media "superfood" marketed for immunity, thyroid health, gut health, energy, skin, and weight loss. Despite these sweeping claims, a 2024 review found that human clinical data on Chondrus are essentially absent — almost all reported activity comes from in vitro and animal studies, with marketed benefits inferred from its nutrient profile rather than demonstrated in people. The one robust human trial in this space tested a purified iota-carrageenan nasal spray, not edible sea moss, and cannot be used to justify consuming the seaweed. Meanwhile, sea moss carries documented risks: seaweed is the single largest dietary contributor to iodine, and its iodine content is extremely variable and frequently high enough to push intake well past the tolerable upper limit, causing thyroid dysfunction. It is also a bioaccumulator of arsenic, cadmium, lead, and mercury, so contamination is a genuine safety concern. On balance, the evidence tier for its marketed health claims is "none."

Benefits / uses: No claimed benefit (immunity, thyroid support, gut health, weight loss, skin, libido) is supported by direct human trials on Chondrus crispus — these are extrapolations from nutrient content or lab/animal data; Provides minerals (iodine, calcium, magnesium, potassium, zinc) and prebiotic-type polysaccharide fiber, though no whole-food human outcome trial shows this translates into a health benefit beyond ordinary diet; An isolated, purified relative — iota-carrageenan nasal spray (not sea moss itself) — reduced COVID-19 incidence in one RCT, but this does not validate ingesting sea moss gel or capsules.
Active compounds: Carrageenans (iota- and kappa-, sulfated galactan polysaccharides; ~40-50% of dry weight); Iodine (highly variable and often very high); Polyphenols and mycosporine-like amino acids (antioxidant/UV-protective); Minerals: calcium, magnesium, potassium, zinc; Trace PUFAs (arachidonic acid, EPA).
Dose: No evidence-based therapeutic dose exists. Culinary/supplement use is typically 4-8 g dried (about 1-2 tablespoons of gel) per day, but even this can exceed the 1,100 mcg/day tolerable upper iodine limit because iodine content is unpredictable. There is no established safe or effective standardized dose.
Safety: High-risk product despite its "natural superfood" image. The dominant hazard is iodine excess: sea moss iodine content is highly variable and often very high, so routine use can exceed the 1,100 mcg/day tolerable upper limit and trigger hyper- or hypothyroidism (Wolff-Chaikoff effect), worsen Hashimoto's or Graves' disease, or precipitate new thyroid dysfunction even in people with no prior thyroid problem. As a bioaccumulator, sea moss can concentrate arsenic (including inorganic arsenic), cadmium, lead, and mercury, with cumulative risk to kidneys, nervous system, and cardiovascular health; only buy products with a published certificate of analysis for heavy metals. AVOID or use only under medical supervision if you: have any thyroid disorder, are pregnant or breastfeeding (fetuses/neonates are especially vulnerable to iodine-induced hypothyroidism), have kidney disease, or take thyroid medication (levothyroxine, antithyroid drugs) or blood thinners. Carrageenan content may cause GI upset in some people. Sea moss has not been reviewed by the FDA for safety or efficacy, and product potency/contamination are unregulated.

Cited studies (16):
  - Prevalence of Excessive Iodine Intake in Pregnancy and Its Health Consequences: Systematic Review and Meta-analysis, Biological trace element research (2023) — Systematic review and meta-analysis of 10,736 pregnant women: pooled prevalence of excessive iodine intake was 52%, associated with maternal hypothyroxinemia, hypothyroidism and hyperthyroidism, plus neonatal macrosomia and thyroid dysfunction - underscoring the risk of high/variable iodine sources such as sea moss in pregnancy. [https://pubmed.ncbi.nlm.nih.gov/36018544/]
  - Effect of excess iodine intake on thyroid diseases in different populations: A systematic review and meta-analyses including observational studies, PloS one (2017) — Systematic review and meta-analysis (50 studies): chronic excess iodine intake was associated with markedly higher odds of overt hypothyroidism (OR 2.78, 95% CI 1.47-5.27) and subclinical hypothyroidism (OR 2.03, 95% CI 1.58-2.62) in adults - directly relevant to iodine-rich sea moss. [https://pubmed.ncbi.nlm.nih.gov/28282437/]
  - Carrageenan and insulin resistance in humans: a randomised double-blind cross-over trial, BMC medicine (2024) — In a 2024 randomized double-blind crossover trial, 250 mg twice-daily oral carrageenan (the principal polysaccharide of Chondrus crispus/sea moss) for 2 weeks did not change whole-body insulin sensitivity overall but increased intestinal permeability, and in overweight participants significantly lowered whole-body and hepatic insulin sensitivity and raised CRP and IL-6, indicating carrageenan may promote insulin resistance and subclinical inflammation in higher-BMI individuals. [https://pubmed.ncbi.nlm.nih.gov/39593091/]
  - ATA Statement on the Potential Risks of Excess Iodine Ingestion and Exposure | American Thyroid Association, https://www.thyroid.org/ — The American Thyroid Association warns that kelp/seaweed and iodine supplements can contain iodine up to several thousand times the daily tolerable upper limit and advises against ingesting more than 500 mcg iodine/day from such supplements for children, adults, and during pregnancy/lactation, noting no thyroid benefit from doses exceeding the 150 mcg RDA. [https://www.thyroid.org/ata-statement-on-the-potential-risks-of-excess-iodine-ingestion-and-exposure/]
  - Sea moss in dietary supplements, Operation Supplement Safety (U.S. DoD) — The U.S. Department of Defense Operation Supplement Safety (OPSS) program states there is insufficient reliable human evidence that sea moss supplements are safe or effective, and flags that their variable iodine content (excess >1 mg/day risking thyroid dysfunction) and potential heavy-metal contamination (arsenic, mercury, lead) make them risky, especially for pregnant, breastfeeding, or thyroid-affected individuals. [https://www.opss.org/article/sea-moss-dietary-supplements]
  - A randomized trial of the effects of the no-carrageenan diet on ulcerative colitis disease activity, Nutrition and healthy aging (2017) — Randomized double-blind placebo-controlled multicenter trial in ulcerative colitis patients in remission: 3/12 given carrageenan capsules relapsed vs 0 on placebo (P=0.046), with rises in IL-6 (P=0.02) and fecal calprotectin; carrageenan exposure shortened time to relapse. Small but a cautionary signal for IBD. [https://pubmed.ncbi.nlm.nih.gov/28447072/]
  - Efficacy of a Nasal Spray Containing Iota-Carrageenan in the Postexposure Prophylaxis of COVID-19 in Hospital Personnel Dedicated to Patients Care with COVID-19 Disease, International Journal of General Medicine (2021) — In a multicenter double-blind placebo-controlled trial of 394 healthcare workers, a nasal spray containing iota-carrageenan (a red-seaweed polysaccharide) reduced COVID-19 incidence from 5.0% (placebo) to 1.0% over 21 days, a ~79.8% relative risk reduction — evidence for topical carrageenan against respiratory viruses, not for ingested sea moss. [https://doi.org/10.2147/IJGM.S328486]
  - Blood cholesterol and lipid-lowering effects of carrageenan on human volunteers, Asia Pacific journal of clinical nutrition (2003) — In a randomized crossover trial in 20 volunteers, an 8-week diet incorporating carrageenan (the dominant polysaccharide of Chondrus crispus/Irish moss) significantly lowered serum total cholesterol (5.44 to 3.64 mmol/L, P<0.0014) and triglycerides (1.28 to 0.87 mmol/L, P<0.0006) and raised HDL-cholesterol (1.25 to 1.65 mmol/L, P<0.0071); LDL unchanged. [https://pubmed.ncbi.nlm.nih.gov/12810413/]
  - An Update on the Chemical Constituents and Biological Properties of Selected Species of an Underpinned Genus of Red Algae: Chondrus, Marine drugs (2024) — A 2024 review of the genus Chondrus concluded that human clinical data are limited to inadequate, with nearly all reported biological activities resting on in vitro and animal studies and a few single-study claims — meaning sea moss's marketed health benefits are largely unvalidated in people. [https://pmc.ncbi.nlm.nih.gov/articles/PMC10817618/]
  - Carrageenan as a Potential Factor of Inflammatory Bowel Diseases, Nutrients (2024) — A 2024 review concluded that carrageenan — the principal polysaccharide of Chondrus crispus (sea moss) — degrades the colonic mucus barrier, alters microbiota (notably reducing Akkermansia muciniphila), and activates TLR4/NF-kB pro-inflammatory signaling in animal and cell models, posing the greatest concern for people with Crohn's disease or ulcerative colitis. [https://pubmed.ncbi.nlm.nih.gov/38732613/]
  - Iodine Status and Thyroid Function in a Group of Seaweed Consumers in Norway, Nutrients (2020) — A 2020 study of regular seaweed consumers in Norway found a median urinary iodine concentration of ~1,200 mcg/L (well into excessive range) with seaweed as the major contributor, leading the authors to warn consumers about the risk of including macroalgae in the diet. [https://pubmed.ncbi.nlm.nih.gov/33202773/]
  - Impact of habitual seaweed consumption on iodine nutrition and thyroid function: a non-randomized pre-post clinical study, European journal of nutrition (2026) — In a 2026 non-randomized pre-post study, habitual seaweed consumers had a median iodine intake of ~658 mcg/day (up to 1,516), and after 6 weeks of cessation intake fell to ~189 mcg/day with a significant drop in serum TSH — most marked in the highest-intake consumers, indicating seaweed-driven iodine excess perturbs thyroid signaling. [https://pubmed.ncbi.nlm.nih.gov/41543576/]
  - Dietary exposure to heavy metals and iodine intake via consumption of seaweeds and halophytes in the European population, EFSA journal. European Food Safety Authority (2023) — The 2023 EFSA assessment of seaweed and halophyte consumption found that some products (e.g., kombu) can deliver iodine far exceeding the 600 mcg/day tolerable upper level and that seaweed contributes meaningfully to inorganic arsenic, lead, cadmium, and mercury exposure. [https://pmc.ncbi.nlm.nih.gov/articles/PMC9887633/]
  - Dietary exposure and risk assessment to trace elements and iodine in seaweeds, Journal of trace elements in medicine and biology : organ of the Society for Minerals and Trace Elements (GMS) (2023) — A 2023 dietary exposure and risk assessment found seaweeds were the strongest dietary contributor to iodine (up to ~33% of intake) while also adding measurable inorganic arsenic, cadmium, lead, and mercury, prompting proposed maximum contaminant limits for seaweed products. [https://pubmed.ncbi.nlm.nih.gov/37210921/]
  - Unusual cause of congenital hypothyroidism in a term infant, BMJ case reports (2021) — A 2021 case report documents transient congenital hypothyroidism in a term infant caused by excessive maternal iodine from daily seaweed intake (wakame miso soup plus weekly hijiki/arame/nori and chlorella) during pregnancy and lactation; because the fetal protective Wolff-Chaikoff effect is immature before week 36, a single bowl of seaweed soup (~500-1,700 mcg iodine) can overload the neonatal thyroid, with TSH remaining >10 mU/L though neurodevelopment was normal at 9 months. [https://pmc.ncbi.nlm.nih.gov/articles/PMC7896560/]
  - Iodine - Health Professional Fact Sheet, NIH Office of Dietary Supplements (2024) — The NIH Office of Dietary Supplements Iodine fact sheet sets the adult tolerable upper intake level at 1,100 mcg/day and notes that whole/sheet seaweed iodine content ranges enormously (about 16 to 2,984 mcg per gram), so seaweed products like sea moss can unpredictably push intake past the UL and that FDA does not require iodine to be listed on labels of naturally iodine-rich foods such as seaweed. [https://ods.od.nih.gov/factsheets/Iodine-HealthProfessional/]

---

## Activated Charcoal (Carbo activatus)
URL: https://nutridex.info/s/activated-charcoal
Category: Debunked
Evidence: No Evidence — No credible human evidence supports the marketed claims — widely considered ineffective.
An ER poison-control tool wrongly marketed as a wellness "detox" — it binds drugs and nutrients indiscriminately.

Quick answer: Activated Charcoal is marketed for in emergency medicine, single-dose activated charcoal can reduce absorption of certain ingested toxins (e.g., paracetamol, carbamazepine, phenobarbital) when given soon after overdose under medical supervision.. NutriDex grades the human evidence as no evidence — No credible human evidence supports the marketed claims — widely considered ineffective. Based on 15 cited human studies (15 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Activated charcoal is a porous form of carbon whose enormous surface area lets it adsorb many compounds in the gastrointestinal tract. Its only well-established role is in emergency toxicology, where a single oral dose may reduce absorption of certain ingested poisons if given soon after overdose; even there, the evidence base is heterogeneous and mostly low-quality, with no studies defining optimal dosing. For the uses it is actually marketed for — "detox," cleanses, anti-bloating, hangover cures, and teeth whitening — there is no credible human evidence of benefit, and systematic reviews find charcoal toothpaste whitens no better than ordinary toothpaste while increasing enamel abrasion. Crucially, charcoal binds non-selectively, so it can reduce absorption of prescription drugs (including oral contraceptives), vitamins, and minerals taken around the same time. Because of this medication-binding effect plus a real risk of aspiration, routine consumer use carries downside risk with no demonstrated upside.

Benefits / uses: In emergency medicine, single-dose activated charcoal can reduce absorption of certain ingested toxins (e.g., paracetamol, carbamazepine, phenobarbital) when given soon after overdose under medical supervision.; No credible human evidence supports any of its marketed wellness uses — 'detox', 'cleanse', anti-bloating, or hangover relief.; Charcoal toothpaste does not whiten teeth better than conventional toothpaste; any effect is mechanical abrasion of surface stains, and it may damage enamel.; It does not selectively remove 'toxins'; it binds whatever is in the gut at the time, including vitamins, minerals, and medications..
Active compounds: Activated carbon (high-surface-area porous carbon, the sole active adsorbent); Often co-formulated with sorbitol as a cathartic in some emergency preparations.
Dose: Emergency use only and physician-directed: typically 25–100 g (adults) or 0.5–1 g/kg (children) as a single oral/NG dose, ideally within 1 hour of poisoning. No evidence-based dose exists for any consumer "wellness" use, and routine self-dosing is not recommended.
Safety: Activated charcoal is appropriate only for specific acute poisonings under emergency medical supervision, not for routine wellness use. It binds drugs non-selectively and can reduce the effectiveness of medications taken nearby — including oral contraceptives, thyroid medication, antidepressants, and many others — and it adsorbs vitamins and minerals, so it should never be taken with meals or medications. The most serious acute danger is pulmonary aspiration leading to aspiration pneumonitis, which can be life-threatening; it is contraindicated in anyone with a depressed level of consciousness or unprotected airway, with bowel obstruction or perforation risk, or after ingestion of corrosives or hydrocarbons. Common side effects include constipation, black stools, vomiting, and bowel obstruction with repeated use. People who are pregnant, on essential daily medications (especially contraceptives), or who have GI motility disorders should avoid consumer products entirely; if poisoning is suspected, call poison control rather than self-treating.

Cited studies (15):
  - Recommendations from the Clinical Toxicology Recommendations Collaborative on the administration of activated charcoal in acute oral overdose, Clinical toxicology (Philadelphia, Pa.) (2026) — Updated international consensus from AACT/EAPCCT/APAMT, based on systematic review of 43 poisons/categories. Single-dose activated charcoal is appropriate beyond the traditional 1 h post-ingestion (up to ~6 h for many poisons, longer with modified-release/bezoar) for agents including paracetamol, salicylates, TCAs, carbamazepine, theophylline, calcium-channel blockers and beta-blockers; multiple-dose AC is recommended to enhance elimination for carbamazepine, dapsone, phenobarbital, phenytoin, quinine, theophylline, thallium and cardiac glycosides. No role for arsenic, lithium, iron, lead, ethanol/methanol/ethylene glycol, metformin. Recommends against intubation solely to give AC. [https://pubmed.ncbi.nlm.nih.gov/41906697/]
  - Systematic review on the use of activated charcoal for gastrointestinal decontamination following acute oral overdose, Clinical toxicology (Philadelphia, Pa.) (2021) — This Clinical Toxicology Recommendations Collaborative systematic review found activated charcoal can provide benefit beyond one hour in select overdose scenarios but that 83% of studies were low/very-low quality and no studies established optimal single- or multiple-dose regimens. [https://pubmed.ncbi.nlm.nih.gov/34424785/]
  - Effectiveness and abrasiveness of activated charcoal as a whitening agent: A systematic review of in vitro studies, Annals of anatomy = Anatomischer Anzeiger : official organ of the Anatomische Gesellschaft (2023) — Systematic review concluded activated-charcoal toothpastes have a lower whitening effect than other agents and are less safe due to high abrasive potential, with evidence at medium-to-high risk of bias. [https://pubmed.ncbi.nlm.nih.gov/36183933/]
  - Interventions for paracetamol (acetaminophen) overdose, The Cochrane database of systematic reviews (2006) — This Cochrane systematic review of interventions for paracetamol overdose found activated charcoal seemed to reduce paracetamol absorption and had the best risk:benefit ratio among gastric decontamination options when given within 4 hours of ingestion, though the clinical benefit on outcomes remained unclear and evidence was low/very-low quality. [https://pubmed.ncbi.nlm.nih.gov/16625578/]
  - The effect of activated charcoal on drug exposure following intravenous administration: A meta-analysis, Basic & clinical pharmacology & toxicology (2021) — This meta-analysis found that multiple-dose activated charcoal enhanced elimination of intravenously administered drugs ('gut dialysis'), reducing median drug half-life by 45.7% and area under the curve by 47.0%, though predictors allowing extrapolation to other drugs could not be identified. [https://pubmed.ncbi.nlm.nih.gov/33386684/]
  - Does Mixing Activated Charcoal With Cola Improve Tolerability Without Affecting Pharmacokinetics? A Randomized Controlled Crossover Trial, Journal of emergency nursing (2024) — Randomized controlled crossover trial in healthy adults given 45 mg/kg acetaminophen then 50 g activated charcoal with or without cola; measured acetaminophen AUC to test whether cola mixing alters adsorption and improves palatability. [https://pubmed.ncbi.nlm.nih.gov/38583171/]
  - Position Paper: Single-Dose Activated Charcoal, American Academy of Clinical Toxicology and European Association of Poisons Centres and Clinical Toxicologists (2005) — Professional toxicology societies state single-dose activated charcoal should not be used routinely, is contraindicated with an unprotected airway, and carries a risk of pulmonary aspiration and aspiration pneumonitis. [https://www.eapcct.org/wp-content/uploads/2024/09/PS_SingleDoseActivatedCharcoal.pdf]
  - Multiple-dose activated charcoal for treatment of yellow oleander poisoning: a single-blind, randomised, placebo-controlled trial, Lancet (London, England) (2003) — In a single-blind, randomised, placebo-controlled Lancet trial of yellow oleander (cardiac glycoside) poisoning, multiple-dose activated charcoal (50 g every 6 h for 3 days) halved mortality versus placebo (5/201 [2.5%] vs 16/200 [8%]; difference 5.5%, 95% CI 0.6-10.3; p=0.025) and reduced life-threatening arrhythmias. [https://pubmed.ncbi.nlm.nih.gov/12801736/]
  - Multiple-dose activated charcoal in acute self-poisoning: a randomised controlled trial, Lancet (London, England) (2008) — In the largest RCT of activated charcoal in acute self-poisoning (Sri Lanka, Lancet), mortality did not differ between multiple-dose charcoal (97/1533, 6.3%), single-dose charcoal (109/1545, 7.1%) and no charcoal (105/1554, 6.8%), leading authors to conclude routine multiple-dose charcoal is unlikely to be beneficial. [https://pubmed.ncbi.nlm.nih.gov/18280328/]
  - Randomized Placebo-Controlled EPPIC Trials of AST-120 in CKD, Journal of the American Society of Nephrology : JASN (2015) — In the multinational, double-blind, placebo-controlled EPPIC-1 and EPPIC-2 trials, the oral charcoal adsorbent AST-120 (9 g/day) did not slow CKD progression, with similar rates of the composite primary endpoint (dialysis, transplant, or creatinine doubling) in EPPIC-1 (35.6% vs 35.3%) and EPPIC-2 (34.4% vs 36.8%). [https://pubmed.ncbi.nlm.nih.gov/25349205/]
  - Single-dose oral activated charcoal in the treatment of the self-poisoned patient: a prospective, randomized, controlled trial, American journal of therapeutics (2002) — Prospective controlled trial of 1,479 self-poisoned adults presenting to the ED, comparing single-dose oral activated charcoal (50 g) versus supportive care alone. AC provided no additional benefit in clinical deterioration, intubation time, hospital length of stay or complication rate, and was associated with a higher incidence of vomiting and longer ED stay. Argues against routine charcoal in unselected oral overdose. [https://pubmed.ncbi.nlm.nih.gov/12115019/]
  - The role of whole bowel irrigation in the treatment of toxic ingestions, British journal of clinical pharmacology (2023) — This 2023 review notes there is no high-quality evidence supporting any GI decontamination in overdose, but whole bowel irrigation remains the best-evidence option for substances activated charcoal does not adsorb, such as iron salts, lithium and modified-release pharmaceuticals. [https://pubmed.ncbi.nlm.nih.gov/36639859/]
  - Activated Charcoal (2026) — Reviews pulmonary aspiration as the most concerning complication of activated charcoal, noting aspiration pneumonitis carries substantially higher mortality (reported ~8.5% vs 0.4%) and that charcoal adsorbs nutrients and many drugs non-selectively. [https://www.ncbi.nlm.nih.gov/books/NBK482294/]
  - Charcoal treatment and risk of escape ovulation in oral contraceptive users, Human reproduction (Oxford, England) (2001) — Repeated activated charcoal given at least 12 h before pill intake did not cause escape ovulation in combined oral contraceptive users, but the study underscores that charcoal taken near pill ingestion can adsorb contraceptive steroids in the gut. [https://pubmed.ncbi.nlm.nih.gov/11139541/]
  - Scientific Opinion on the substantiation of health claims related to activated charcoal and reduction of excessive intestinal gas accumulation (ID 1938) and reduction of bloating (ID 1938) pursuant to Article 13(1) of Regulation (EC) No 1924/2006, EFSA Journal (2011) — The EFSA Panel on Dietetic Products concluded a cause-and-effect relationship is established between consumption of activated charcoal and reduction of excessive intestinal gas accumulation, requiring 1 g taken at least 30 minutes before and 1 g after a meal to obtain the claimed effect. [https://www.efsa.europa.eu/en/efsajournal/pub/2049]

---

## Apple Cider Vinegar (Acetum (fermented Malus domestica))
URL: https://nutridex.info/s/apple-cider-vinegar
Category: Heart & Metabolic, Debunked
Evidence: Mixed — Conflicting results across studies; benefit uncertain.
Acetic acid tonic with modest, inconsistent metabolic signals — and big claims that outrun the data.

Quick answer: Apple Cider Vinegar is used for modest post-meal and fasting glucose blunting: meta-analyses in adults (often type 2 diabetes) report fasting glucose reductions of roughly 8-22 mg/dl. NutriDex grades the human evidence as mixed — Conflicting results across studies; benefit uncertain. Based on 17 cited human studies (17 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Apple cider vinegar is a fermented liquid whose main bioactive is acetic acid, marketed heavily for weight loss, "detox," and blood-sugar control. The strongest human evidence is for modest glycemic effects: meta-analyses of small controlled trials report meaningful drops in fasting glucose (roughly 8-22 mg/dL) and small HbA1c reductions, mostly in people with type 2 diabetes, though heterogeneity is high and insulin sensitivity (HOMA-IR) is largely unchanged. Body-composition meta-analyses show statistically significant but small short-term reductions in weight, BMI, and waist circumference, yet the single most publicized weight-loss RCT (BMJ Nutrition, Prevention & Health, 2024) was retracted in 2025 for implausible data and flawed statistics, which substantially weakens the weight narrative. Sweeping detox, fat-melting, and disease-curing claims are not supported by credible evidence. Overall the realistic picture is a mild, adjunctive metabolic nudge — not a primary therapy — and undiluted use carries real risks of dental erosion and esophageal injury, so the evidence is best described as mixed.

Benefits / uses: Modest post-meal and fasting glucose blunting: meta-analyses in adults (often type 2 diabetes) report fasting glucose reductions of roughly 8-22 mg/dL; Small short-term reductions in HbA1c (about 0.5 percentage points), though driven by a few small trials and statistically fragile; Minor improvements in total cholesterol (around -6 mg/dL) in pooled small trials; Short-term weight/BMI/waist signals in small RCTs (4-12 weeks), but the most-cited weight-loss trial was retracted for data and statistical problems; Broad 'detox,' fat-burning, and disease-cure marketing claims are unsupported.
Active compounds: Acetic acid (~5-6% in liquid vinegar); Polyphenols (chlorogenic acid, gallic acid); Malic and citric acids; 'Mother' (cellulose/acetic acid bacteria biomass).
Dose: Commonly studied at 10-30 mL/day (about 1-2 tablespoons) of ~5% liquid vinegar, diluted in a large glass of water and taken with or before meals; higher amounts add risk without proven benefit.
Safety: Always dilute in water and avoid drinking it straight — undiluted vinegar (pH ~3) causes dental enamel erosion (documented severe decay in a teen using it daily) and can cause esophageal/throat irritation, ulceration, or corrosive injury, including from ACV tablets that lodge in the esophagus. Use a straw and rinse the mouth afterward; avoid brushing immediately after. May cause nausea, indigestion, and delayed gastric emptying (caution in gastroparesis). It can lower potassium and may compound the effects of glucose-lowering drugs (insulin, sulfonylureas), diuretics, digoxin, and potassium-affecting medications — diabetics should monitor blood sugar and consult a clinician before regular use. People with low potassium, chronic kidney disease, severe acid reflux/GERD, gastroparesis, or eating disorders should avoid or use only under medical supervision; pregnant and breastfeeding individuals should treat it as food, not a supplement, and unpasteurized products carry a small infection risk. It is not a substitute for prescribed metabolic or weight therapies.

Cited studies (17):
  - Effects of apple cider vinegar on glycemic control and insulin sensitivity in patients with type 2 diabetes: A GRADE-assessed systematic review and dose-response meta-analysis of controlled clinical trials, Frontiers in nutrition (2025) — GRADE-assessed dose-response meta-analysis (7 controlled trials, 463 participants) found apple cider vinegar reduced fasting blood sugar by 21.93 mg/dL (95% CI -29.19 to -14.67, moderate certainty) and HbA1c by 1.53% (95% CI -2.65 to -0.41), with a linear dose-response above 10 mL/day in type 2 diabetes. [https://pmc.ncbi.nlm.nih.gov/articles/PMC11821484/]
  - Vinegar consumption can attenuate postprandial glucose and insulin responses; a systematic review and meta-analysis of clinical trials, Diabetes research and clinical practice (2017) — Vinegar taken with a meal significantly attenuated postprandial glucose AUC (SMD -0.60, 95% CI -1.08 to -0.11) and insulin AUC (SMD -1.30, 95% CI -1.98 to -0.62) versus control, supporting an acute glycemic-blunting effect. [https://pubmed.ncbi.nlm.nih.gov/28292654/]
  - Effects of apple cider vinegar on glycemic control and insulin sensitivity in patients with type 2 diabetes: A GRADE-assessed systematic review and dose-response meta-analysis of controlled clinical trials, Frontiers in nutrition (2025) — GRADE-assessed dose-response meta-analysis found ACV significantly lowered fasting blood glucose (WMD -21.9 mg/dL) and HbA1c (WMD -1.53%), but did not improve HOMA-IR and slightly raised insulin. [https://pubmed.ncbi.nlm.nih.gov/39949546/]
  - The effect of apple cider vinegar on lipid profiles and glycemic parameters: a systematic review and meta-analysis of randomized clinical trials, BMC complementary medicine and therapies (2021) — Meta-analysis of RCTs reported small but significant reductions in total cholesterol (-6.06 mg/dL), fasting glucose (-7.97 mg/dL) and HbA1c (-0.50), with HbA1c results sensitive to a single study. [https://pubmed.ncbi.nlm.nih.gov/34187442/]
  - Effect of Apple Cider Vinegar Intake on Body Composition in Humans with Type 2 Diabetes and/or Overweight: A Systematic Review and Meta-Analysis of Randomized Controlled Trials, Nutrients (2025) — Meta-analysis found daily ACV significantly reduced body weight (SMD -0.39), BMI (SMD -0.65) and waist circumference (SMD -0.34), with no significant change in waist-to-hip ratio, over 4-12 week interventions. [https://pubmed.ncbi.nlm.nih.gov/41010525/]
  - The Effects of Apple Cider Vinegar on Cardiometabolic Risk Factors: A Systematic Review and Meta-analysis of Clinical Trials, Current Medicinal Chemistry (2025) — Systematic review/meta-analysis found ACV significantly lowered fasting blood glucose (-21.2 mg/dL), HbA1c (-0.91) and total cholesterol (-6.72 mg/dL), but showed no significant effect on BMI, HOMA-IR, insulin, triglycerides, LDL-C or HDL-C. [https://doi.org/10.2174/0929867331666230822102021]
  - Dose-dependent effect of vinegar on blood pressure: A GRADE-assessed systematic review and meta-analysis of randomized controlled trials, Complementary therapies in medicine (2022) — Each 30 mL/day increment in vinegar intake was associated with significant reductions in systolic blood pressure (-3.25 mmHg, 95% CI -5.54 to -0.96) and diastolic blood pressure (-3.33 mmHg, 95% CI -4.16 to -2.49), though the certainty of evidence was rated LOW. [https://pubmed.ncbi.nlm.nih.gov/36152934/]
  - Apple cider vinegar for weight management in Lebanese adolescents and young adults with overweight and obesity: a randomised, double-blind, placebo-controlled study, BMJ Nutrition, Prevention &amp; Health (2024) — A widely cited 12-week RCT claiming 5-15 mL/day ACV reduced weight and BMI vs placebo was RETRACTED in 2025 for implausible statistical values, unreliable raw data, and lack of trial registration. [https://doi.org/10.1136/bmjnph-2023-000823]
  - Apple cider vinegar for weight management in Lebanese adolescents and young adults with overweight and obesity: a randomised, double-blind, placebo-controlled study, BMJ nutrition, prevention & health (2024) — This double-blind placebo-controlled RCT in 120 Lebanese adolescents/young adults reported large reductions in weight, BMI, and fasting glucose with 5-15 mL/day ACV, but was RETRACTED in September 2025 for data-integrity and reproducibility failures and should not be cited as positive evidence. [https://pmc.ncbi.nlm.nih.gov/articles/PMC11221284/]
  - Vinegar supplementation lowers glucose and insulin responses and increases satiety after a bread meal in healthy subjects, European journal of clinical nutrition (2005) — Vinegar added to a white-wheat-bread meal produced a dose-dependent reduction in postprandial blood glucose (at 30 and 45 min) and insulin (at 15 and 30 min) and increased satiety ratings, with the highest acetic acid dose (28 mmol) giving the largest effect. [https://pubmed.ncbi.nlm.nih.gov/16015276/]
  - Effect of apple cider vinegar on delayed gastric emptying in patients with type 1 diabetes mellitus: a pilot study, BMC gastroenterology (2007) — 30 mL apple cider vinegar further slowed already-delayed gastric emptying (median gastric emptying rate fell from 27% to 17%, p<0.05), which the authors warned may worsen glycemic control in patients with diabetic gastroparesis. [https://pubmed.ncbi.nlm.nih.gov/18093343/]
  - Influence of the tolerability of vinegar as an oral source of short-chain fatty acids on appetite control and food intake, International journal of obesity (2005) (2014) — Vinegar ingestion suppressed appetite and food intake but the effect was largely driven by poor tolerability and nausea rather than genuine satiety, leading the authors to conclude that promoting vinegar as an appetite suppressant is inappropriate. [https://pubmed.ncbi.nlm.nih.gov/23979220/]
  - Vinegar improves insulin sensitivity to a high-carbohydrate meal in subjects with insulin resistance or type 2 diabetes, Diabetes care (2004) — Landmark trial: vinegar ingested before a high-carbohydrate meal improved postprandial insulin sensitivity and attenuated glucose and insulin responses, with the largest effect in insulin-resistant subjects; modest response in established type 2 diabetes. [https://pubmed.ncbi.nlm.nih.gov/14694010/]
  - Esophageal injury by apple cider vinegar tablets and subsequent evaluation of products, Journal of the American Dietetic Association (2005) — An apple cider vinegar tablet lodged in the throat caused esophageal injury, and product testing showed highly variable, sometimes corrosive acid content, illustrating real mucosal-injury risk from concentrated ACV. [https://pubmed.ncbi.nlm.nih.gov/15983536/]
  - Hypokalemia, hyperreninemia and osteoporosis in a patient ingesting large amounts of cider vinegar, Nephron (1998) — A woman who drank ~250 mL (8 oz) of cider vinegar diluted in water daily for 6 years developed hypokalemia, elevated renin (hyperreninemia) and osteoporosis, attributed to chronic acid loading leaching minerals from bone. [https://pubmed.ncbi.nlm.nih.gov/9736833/]
  - Apple Cider Vinegar-Induced Hepatotoxicity: A Rare Case Report, Oxford medical case reports (2025) — A man taking ~30 mL apple cider vinegar three times weekly for 4 years developed severe hepatocellular liver injury (ALT 1792 U/L, AST 1168 U/L, bilirubin 17 mg/dL) with stage-2 fibrosis on biopsy that resolved after stopping ACV, implicating ACV as a cause of drug-induced hepatotoxicity. [https://pmc.ncbi.nlm.nih.gov/articles/PMC12258026/]
  - In vitro study on dental erosion caused by different vinegar varieties using an electron microprobe, Clinical laboratory (2014) — Vinegars (pH 2.7-3.1) caused measurable enamel demineralization, with the most erosive variety producing ~20% mineral loss at 45 microm depth after 8 hours, indicating a real dental-erosion risk from regular acidic vinegar exposure. [https://pubmed.ncbi.nlm.nih.gov/24839821/]

---

## NMN (Nicotinamide Mononucleotide) (β-Nicotinamide mononucleotide)
URL: https://nutridex.info/s/nmn
Category: Longevity
Evidence: Preliminary — Early or small human trials; promising but not yet conclusive.
An NAD+ precursor that reliably raises blood NAD+, with hints of metabolic and physical-function benefit but no proven anti-aging effect.

Quick answer: NMN (Nicotinamide Mononucleotide) is used for reliably and dose-dependently raises blood nad+ levels in humans, the biochemical rationale for its use. NutriDex grades the human evidence as preliminary — Early or small human trials; promising but not yet conclusive. Based on 12 cited human studies (12 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

NMN is a direct precursor to NAD+, a coenzyme central to cellular energy metabolism that declines with age, and it is heavily marketed for longevity and anti-aging. Human RCTs consistently show that oral NMN raises blood NAD+ levels in a dose-dependent manner, confirming it is bioavailable. However, downstream clinical benefits are far less certain: a 2024 meta-analysis of 8 RCTs (342 adults) found no significant effect on fasting glucose, insulin, HbA1c, HOMA-IR, or lipids, while a small prediabetes trial and some dose-ranging studies hint at gains in muscle insulin sensitivity and physical performance. Claims of extended lifespan or reversed aging in humans are unproven and rest largely on animal data. Short-term use up to 900 mg/day appears well tolerated, but long-term safety data are lacking. In the US its regulatory status has been turbulent: the FDA excluded NMN from the dietary-supplement definition in 2022 (citing prior drug investigation), then reversed that position in September 2025, declaring NMN not excluded.

Benefits / uses: Reliably and dose-dependently raises blood NAD+ levels in humans, the biochemical rationale for its use; May modestly improve walking distance, grip strength, and gait speed in some trials of healthy older or middle-aged adults (preliminary, not consistently replicated); A single small RCT found increased skeletal-muscle insulin sensitivity in prediabetic postmenopausal women, though other metabolic markers did not improve; Generally well tolerated at oral doses up to 900 mg/day over 1-3 months in short trials.
Active compounds: β-Nicotinamide mononucleotide (a nucleotide formed from nicotinamide and ribose; direct NAD+ biosynthetic precursor).
Dose: 250–600 mg once daily by mouth; trials have used up to 900 mg/day. Blood NAD+ and 6-minute walk gains plateaued around 600 mg/day in one dose-ranging trial.
Safety: Short-term oral NMN (up to 900 mg/day for 1-3 months) was well tolerated in trials, with no serious adverse events; mild GI upset is occasionally reported. Long-term safety is unknown, and theoretical concerns exist about whether boosting NAD+ could fuel growth of existing cancers, so people with active or prior malignancy should be cautious and consult a clinician. There are no robust human data in pregnancy or breastfeeding, so it should be avoided in those groups. Regulatory status is unsettled and varies by country: the US FDA excluded NMN from the dietary-supplement definition in 2022 before reversing in 2025, and product quality/purity in the unregulated supplement market is variable. No major drug-interaction data exist; those on medications (especially for diabetes, given possible effects on insulin sensitivity) or with significant medical conditions should consult a healthcare provider before use. NMN is not a treatment for any disease and benefits for aging or longevity remain unproven.

Cited studies (12):
  - Efficacy of oral nicotinamide mononucleotide supplementation on glucose and lipid metabolism for adults: a systematic review with meta-analysis on randomized controlled trials, Critical reviews in food science and nutrition (2025) — Meta-analysis of 8 RCTs (n=342, 250-2000 mg/d, 14 days-12 weeks) found NMN significantly elevated blood NAD+ levels but produced no significant benefit on fasting glucose, fasting insulin, HbA1c, HOMA-IR, or lipid profile. [https://pubmed.ncbi.nlm.nih.gov/39116016/]
  - The Effect of Nicotinamide Mononucleotide and Riboside on Skeletal Muscle Mass and Function: A Systematic Review and Meta-Analysis, Journal of cachexia, sarcopenia and muscle (2025) — Systematic review and meta-analysis of 10 RCTs (6 NMN, 4 NR) concluded current evidence does not support NMN/NR supplementation for preserving skeletal muscle mass, handgrip strength, or gait speed in adults over a mean age of 60 years. [https://pmc.ncbi.nlm.nih.gov/articles/PMC12022230/]
  - Improved Physical Performance Parameters in Patients Taking Nicotinamide Mononucleotide (NMN): A Systematic Review of Randomized Control Trials, Cureus (2024) — Systematic review of 10 RCTs (437 patients, mean age 58.0 years, mean follow-up 9.6 weeks, doses 150-1200 mg/day) found NMN non-significantly improved physical performance parameters and was well tolerated with no serious adverse effects. [https://pmc.ncbi.nlm.nih.gov/articles/PMC11365583/]
  - Effects of Nicotinamide Mononucleotide Supplementation on Blood Pressure: A Systematic Review and Meta-Analysis of Randomized Controlled Trials, Nutrients (2026) — Systematic review and meta-analysis of RCTs (databases searched through Dec 2025) evaluated NMN supplementation on resting systolic and diastolic blood pressure in adults with elevated blood pressure, with subgroup analyses by age, BMI, dose, and duration. [https://pmc.ncbi.nlm.nih.gov/articles/PMC13028934/]
  - FDA Declares Nicotinamide Mononucleotide Is a Dietary Supplement, Venable LLP (2025) — On September 29, 2025, the FDA reversed its 2022 position and concluded NMN is not excluded from the dietary-supplement definition, finding evidence it was marketed as a supplement before drug-investigation authorization. [https://www.venable.com/insights/publications/2025/10/fda-declares-nicotinamide-mononucleotide-is]
  - Effects of Nicotinamide Mononucleotide on Glucose and Lipid Metabolism in Adults: A Systematic Review and Meta-analysis of Randomised Controlled Trials, Current diabetes reports (2024) — A systematic review and meta-analysis found NMN (250-2000 mg/day) reliably raised blood NAD+ but showed no significant benefit on fasting glucose, fasting insulin, HbA1c, HOMA-IR, or lipid profile. [https://pubmed.ncbi.nlm.nih.gov/39531138/]
  - Improved Physical Performance Parameters in Patients Taking Nicotinamide Mononucleotide (NMN): A Systematic Review of Randomized Control Trials, Cureus (2024) — A systematic review of physical-performance outcomes concluded NMN may help preserve physical performance and reduce fatigue, but findings were inconsistent, with some trials (e.g., in diabetic women and runners) reporting null effects. [https://pmc.ncbi.nlm.nih.gov/articles/PMC11365583/]
  - Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women, Science (New York, N.Y.) (2021) — Landmark 10-week double-blind RCT in 25 postmenopausal prediabetic overweight/obese women: NMN 250 mg/day increased insulin-stimulated glucose disposal (hyperinsulinemic-euglycemic clamp) by ~25% and upregulated skeletal-muscle insulin signaling (AKT/mTOR) and muscle remodeling genes; no change in placebo. First human evidence of an NMN metabolic benefit, though body weight, liver fat, and other metabolic markers were unchanged. [https://pubmed.ncbi.nlm.nih.gov/33888596/]
  - Effect of 12-Week Intake of Nicotinamide Mononucleotide on Sleep Quality, Fatigue, and Physical Performance in Older Japanese Adults: A Randomized, Double-Blind Placebo-Controlled Study, Nutrients (2022) — 12-week double-blind placebo-controlled RCT in 108 older Japanese adults (NMN 250 mg/day, AM vs PM dosing). Afternoon NMN intake improved lower-limb function (5-times sit-to-stand, effect size d=0.72) and reduced drowsiness (d=0.64) versus placebo; timing-dependent benefit on physical performance and fatigue. [https://pubmed.ncbi.nlm.nih.gov/35215405/]
  - The efficacy and safety of β-nicotinamide mononucleotide (NMN) supplementation in healthy middle-aged adults: a randomized, multicenter, double-blind, placebo-controlled, parallel-group, dose-dependent clinical trial, GeroScience (2023) — In a dose-ranging RCT, 300/600/900 mg/day NMN for 60 days significantly raised blood NAD+ and improved 6-minute walk distance versus placebo, with effects plateauing around 600 mg/day; no safety issues were observed. [https://pubmed.ncbi.nlm.nih.gov/36482258/]
  - Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women, Science (New York, N.Y.) (2021) — A 10-week RCT found 250 mg/day NMN increased skeletal-muscle insulin sensitivity and insulin signaling versus placebo, but did not change other metabolic-health markers, so the authors cautioned against clinical recommendations. [https://pmc.ncbi.nlm.nih.gov/articles/PMC8550608/]
  - Chronic nicotinamide mononucleotide supplementation elevates blood nicotinamide adenine dinucleotide levels and alters muscle function in healthy older men, npj aging (2022) — A 12-week RCT of 250 mg/day NMN significantly increased whole-blood NAD+ and partly improved muscle function (gait speed, grip strength) in healthy older men, and was safe and well tolerated. [https://pmc.ncbi.nlm.nih.gov/articles/PMC9158788/]

---

## Nicotinamide Riboside (NR)
URL: https://nutridex.info/s/nicotinamide-riboside
Category: Longevity
Evidence: Preliminary — Early or small human trials; promising but not yet conclusive.
An NAD+ precursor that reliably raises NAD+ but has yet to prove durable clinical benefits.

Quick answer: Nicotinamide Riboside (NR) is used for reliably and dose-dependently raises whole-blood nad+ levels in humans, confirming target engagement. NutriDex grades the human evidence as preliminary — Early or small human trials; promising but not yet conclusive. Based on 16 cited human studies (16 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Nicotinamide riboside (NR) is a form of vitamin B3 that the body converts into nicotinamide adenine dinucleotide (NAD+), a coenzyme central to energy metabolism and cellular repair that declines with age. Multiple randomized controlled trials confirm that oral NR reliably and dose-dependently raises blood NAD+ levels and is well tolerated, establishing clear biological target engagement. However, this NAD+ boost has not yet translated into robust clinical benefits: trials in obese, insulin-resistant men showed no improvement in insulin sensitivity, and a trial in peripheral artery disease found no improvement in walking performance. The most promising—but still preliminary—human signal is a modest reduction in systolic blood pressure and improved endothelial function in midlife and older adults with elevated blood pressure. Overall, NR is a credible NAD+ precursor whose marketed anti-aging, metabolic, and cardiovascular benefits remain largely unproven in humans and require larger, longer trials.

Benefits / uses: Reliably and dose-dependently raises whole-blood NAD+ levels in humans, confirming target engagement; Consistently well tolerated across doses up to 1000-3000 mg/day with only mild adverse effects; Preliminary signals of lowered systolic blood pressure and improved vascular endothelial function in adults with above-normal blood pressure; May modestly shift body composition and tissue metabolite profiles, though clinical relevance is unclear.
Active compounds: Nicotinamide riboside chloride (Niagen); Nicotinamide adenine dinucleotide (NAD+) — the downstream metabolite it elevates.
Dose: 250–1000 mg/day orally (trials have used up to 2000–3000 mg/day); commonly 300 mg once daily for general use
Safety: Generally well tolerated; most common adverse effects are mild headache, flushing or feelings of warmth, gastrointestinal discomfort, nausea, and fatigue. Long-term safety beyond ~1 year and at high doses is not well established. Because NR raises NAD+ and is metabolized partly to nicotinamide, theoretical concerns exist about effects on methylation balance and, at very high intakes, on cancer cell metabolism—so it should be avoided or used only under medical supervision by people with active or prior cancer. Safety has not been established in pregnancy or breastfeeding, so these groups should avoid it. People with kidney or liver disease, those on multiple medications, or anyone with a serious medical condition should consult a clinician first, as data on drug interactions are limited. NR is not a substitute for proven treatments for hypertension, diabetes, or cardiovascular disease.

Cited studies (16):
  - The Effect of Nicotinamide Mononucleotide and Riboside on Skeletal Muscle Mass and Function: A Systematic Review and Meta-Analysis, Journal of cachexia, sarcopenia and muscle (2025) — Pooled analysis of 10 RCTs in adults over 60 found NMN and nicotinamide riboside produced no significant improvement in muscle mass index, handgrip strength, gait speed, or chair-stand performance, with NR benefit limited to 6-minute walk distance in PAD. [https://pmc.ncbi.nlm.nih.gov/articles/PMC12022230/]
  - Effects of Supplementation with NAD + Precursors on Metabolic Syndrome Parameters: A Systematic Review and Meta-Analysis, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme (2024) — Systematic review/meta-analysis of 19 RCTs (PRISMA, RoB2, GRADE): NAD+ precursor supplementation significantly reduced plasma total cholesterol and triglycerides, but did not significantly affect other metabolic syndrome parameters; GRADE quality very low to low. [https://pubmed.ncbi.nlm.nih.gov/39111741/]
  - The Effect of Nicotinamide Mononucleotide and Riboside on Skeletal Muscle Mass and Function: A Systematic Review and Meta-Analysis, Journal of cachexia, sarcopenia and muscle (2025) — Systematic review/meta-analysis of RCTs in adults (mean age >60): neither NR nor NMN significantly improved skeletal muscle index, handgrip strength, gait speed, or chair-stand time; current evidence does not support NR/NMN for preserving muscle mass or function. [https://pubmed.ncbi.nlm.nih.gov/40275690/]
  - Effects of NAD+ precursor supplementation on glucose and lipid metabolism in humans: a meta-analysis, Nutrition & metabolism (2022) — Meta-analysis of 40 trials (n=14,750): NAD+ precursors significantly lowered TG (SMD -0.35), TC (SMD -0.33) and LDL (SMD -0.38) and raised HDL (SMD +0.66), but increased fasting glucose (SMD +0.27); lipid effects driven mainly by nicotinic acid, with little benefit in healthy people. [https://pubmed.ncbi.nlm.nih.gov/35303905/]
  - Evaluation of safety and effectiveness of NAD in different clinical conditions: a systematic review, American Journal of Physiology-Endocrinology and Metabolism (2024) — Across diverse clinical conditions, NAD precursors including NR were generally safe and effective at raising NAD+, but evidence for disease-specific clinical efficacy was inconsistent. [https://journals.physiology.org/doi/full/10.1152/ajpendo.00242.2023]
  - Effects of nicotinamide riboside on NAD+ levels, cognition, and symptom recovery in long-COVID: a randomized controlled trial, EClinicalMedicine (2025) — In 58 long-COVID patients, nicotinamide riboside raised blood NAD+ 2.6-3.1 fold but showed no significant between-group benefit on cognition, fatigue, sleep, anxiety, or depression vs placebo. [https://pubmed.ncbi.nlm.nih.gov/41357333/]
  - Nicotinamide riboside for peripheral artery disease: the NICE randomized clinical trial, Nature communications (2024) — In 90 patients with peripheral artery disease, 6 months of nicotinamide riboside improved 6-minute walk distance by 17.6 m vs placebo, rising to 31.0 m among participants with at least 75% adherence. [https://pubmed.ncbi.nlm.nih.gov/38871717/]
  - Acute nicotinamide riboside supplementation increases human cerebral NAD(+) levels in vivo, Magnetic resonance in medicine (2024) — In 9 healthy volunteers, a single 900 mg oral dose of nicotinamide riboside increased in vivo cerebral NAD+ measured by 7T MR spectroscopy from 0.392 to 0.458 mM (about 16%, p<0.001). [https://pmc.ncbi.nlm.nih.gov/articles/PMC11436296/]
  - NR-SAFE: a randomized, double-blind safety trial of high dose nicotinamide riboside in Parkinson's disease, Nature communications (2023) — Phase I randomized double-blind placebo-controlled trial, 20 PD patients, NR 1500 mg twice daily (3000 mg/day) x4 weeks: no moderate/severe adverse events; well tolerated; blood NAD+ rose up to 5-fold. Mild transient homocysteine rise without depleting the methyl-donor pool; supports extending dosing to 3000 mg/day in phase II. [https://pubmed.ncbi.nlm.nih.gov/38016950/]
  - Nicotinamide riboside is uniquely and orally bioavailable in mice and humans, Nature communications (2016) — First-in-human pharmacokinetic clinical trial: single oral NR doses of 100, 300 and 1000 mg produced dose-dependent increases in the blood NAD+ metabolome (whole-blood NAD+ rose up to ~2.7-fold), establishing NR as orally bioavailable and identifying NAAD as a sensitive biomarker of NAD+ repletion; no safety concerns. [https://pubmed.ncbi.nlm.nih.gov/27721479/]
  - Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD(+) in healthy middle-aged and older adults, Nature communications (2018) — 2x6-week randomized double-blind placebo-controlled crossover in 30 healthy middle-aged/older adults: NR 1000 mg/day was well tolerated and raised blood NAD+ ~60%. Exploratory signals suggested reduced systolic BP (~-3 mmHg overall; ~-9 mmHg in those with elevated baseline SBP) and lower aortic stiffness, motivating larger BP trials. [https://pubmed.ncbi.nlm.nih.gov/29599478/]
  - A randomized placebo-controlled clinical trial of nicotinamide riboside in obese men: safety, insulin-sensitivity, and lipid-mobilizing effects, The American journal of clinical nutrition (2018) — NR 2000 mg/day was safe but did not improve insulin sensitivity or whole-body glucose metabolism in obese, insulin-resistant men versus placebo. [https://pubmed.ncbi.nlm.nih.gov/29992272/]
  - Nicotinamide Riboside Supplementation for Treating Elevated Systolic Blood Pressure and Arterial Stiffness in Midlife and Older Adults, Frontiers in cardiovascular medicine (2022) — NR 1000 mg/day lowered casual systolic blood pressure by roughly 8–9 mmHg and improved vascular endothelial function in midlife/older adults with above-normal baseline systolic BP. [https://pubmed.ncbi.nlm.nih.gov/35620522/]
  - Nicotinamide riboside for peripheral artery disease: the NICE randomized clinical trial, Nature Communications (2024) — In the NICE trial, NR (with or without resveratrol) did not significantly improve 6-minute walk distance versus placebo in patients with peripheral artery disease. [https://www.nature.com/articles/s41467-024-49092-5]
  - NR-SAFE: a randomized, double-blind safety trial of high dose nicotinamide riboside in Parkinson's disease, Nature communications (2023) — NR up to 3000 mg/day for several weeks in Parkinson's disease patients was safe and well tolerated with no moderate or severe attributable adverse events. [https://pmc.ncbi.nlm.nih.gov/articles/PMC10684646/]
  - Safety and Tolerability of Nicotinamide Riboside in Heart Failure With Reduced Ejection Fraction, JACC. Basic to translational science (2022) — NR 2000 mg/day was safe, well tolerated, and significantly raised whole-blood NAD+ in patients with heart failure with reduced ejection fraction. [https://pmc.ncbi.nlm.nih.gov/articles/PMC9831861/]

---

## Urolithin A
URL: https://nutridex.info/s/urolithin-a
Category: Longevity
Evidence: Preliminary — Early or small human trials; promising but not yet conclusive.
Gut-derived pomegranate metabolite that triggers mitophagy; early trials hint at better muscle endurance.

Quick answer: Urolithin A is used for improved skeletal muscle endurance (more contractions to fatigue) in older and resistance-trained adults in small rcts. NutriDex grades the human evidence as preliminary — Early or small human trials; promising but not yet conclusive. Based on 10 cited human studies (10 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Urolithin A is a metabolite produced by gut bacteria from ellagitannins found in pomegranate, walnuts, and certain berries, though only some people carry the microbes needed to make it efficiently. Its main mechanism of interest is stimulating mitophagy, the cellular clearance of damaged mitochondria, which has driven its marketing as a longevity and muscle-health supplement (commonly as the standardized ingredient Mitopure). Small, mostly industry-supported randomized trials in older, middle-aged, and athletic adults report improvements in muscle endurance and favorable shifts in mitochondrial and inflammatory blood biomarkers, but results on hard endpoints like muscle strength, peak ATP production, and the 6-minute walk test have been inconsistent and sometimes not statistically significant. No trial has demonstrated long-term clinical outcomes such as reduced disability, falls, or improved survival. Short-term safety in studies up to several months appears good, but the overall evidence base remains preliminary and limited in size, duration, and independent replication.

Benefits / uses: Improved skeletal muscle endurance (more contractions to fatigue) in older and resistance-trained adults in small RCTs; Favorably shifted mitochondrial-health blood markers (acylcarnitines, ceramides) and reduced C-reactive protein; Modest gains in muscle strength and exercise performance reported in middle-aged adults, though not consistent across endpoints; Stimulates mitophagy (recycling of damaged mitochondria), a mechanism of interest for healthy aging; Generally well tolerated with a favorable short-term safety profile at studied doses.
Active compounds: Urolithin A (a dibenzo[b,d]pyran-6-one; gut-microbiota metabolite of ellagitannins/ellagic acid); Synthesized/standardized form marketed as Mitopure.
Dose: 500–1000 mg once daily of standardized urolithin A (e.g., Mitopure), taken with food; most trials used 1000 mg/day for 4 months.
Safety: Urolithin A has a favorable short-term safety profile in trials up to about 4 months at 250–1000 mg/day, with adverse-event rates similar to placebo and no serious adverse events reported; mild gastrointestinal complaints are the most common issue. Long-term safety beyond a few months is unstudied. Safety has not been established in pregnancy or breastfeeding, or in children, so these groups should avoid it. People with significant liver or kidney disease and those on multiple medications should consult a clinician first, as metabolism, drug interactions, and effects on disease are not well characterized; theoretical interactions with drugs cleared by the liver cannot be excluded. It is a dietary supplement and is not regulated as a drug, so product purity and dosing accuracy vary by brand—choose standardized products (e.g., Mitopure). It is not a treatment for any disease, and anyone with a medical condition or taking prescription medications should discuss use with a healthcare provider before starting.

Cited studies (10):
  - Targeting aging with urolithin A in humans: A systematic review, Ageing research reviews (2024) — Systematic review of 5 studies (250 healthy adults; UA 10-1000 mg/day, 28 days-4 months): UA showed dose-dependent anti-inflammatory effects, upregulated mitochondrial/autophagy/fatty-acid-oxidation genes, and increased muscle strength and endurance, but did NOT affect maximal ATP production, mitochondrial biogenesis/dynamics, gut microbiota, anthropometrics, cardiovascular outcomes, or physical function. [https://pubmed.ncbi.nlm.nih.gov/39002645/]
  - Evaluating the Impact of Urolithin A Supplementation on Running Performance, Recovery, and Mitochondrial Biomarkers in Highly Trained Male Distance Runners, Sports medicine (Auckland, N.Z.) (2025) — In a double-blind RCT of 42 highly trained male distance runners during altitude training, 1000 mg/day urolithin A for 4 weeks lowered perceived exertion (p=0.02) and reduced post-exercise creatine kinase AUC (p<0.0001), but did not significantly improve 3000m time-trial performance. [https://pubmed.ncbi.nlm.nih.gov/40839339/]
  - Assessment of Urolithin A effects on muscle endurance, strength, inflammation, oxidative stress, and protein metabolism in male athletes with resistance training: an 8-week randomized, double-blind, placebo-controlled study, Journal of the International Society of Sports Nutrition (2024) — 8-week double-blind RCT in 20 resistance-trained male athletes (1 g/d UA) significantly improved maximal voluntary isometric contraction and repetitions-to-failure and reduced CRP and 3-methylhistidine vs placebo. [https://pmc.ncbi.nlm.nih.gov/articles/PMC11536656/]
  - Effects of Urolithin A supplementation on performance and antioxidant status in academy soccer players during preseason: a pilot randomised controlled trial, Frontiers in Nutrition (2025) — Pilot RCT in academy soccer players during preseason evaluated UA effects on performance and antioxidant status, extending evidence to a younger trained-athlete population. [https://www.frontiersin.org/journals/nutrition/articles/10.3389/fnut.2025.1674446/full]
  - Effect of Urolithin A Supplementation on Muscle Endurance and Mitochondrial Health in Older Adults: A Randomized Clinical Trial, JAMA network open (2022) — In a randomized clinical trial of 66 older adults, 1000 mg urolithin A significantly improved hand and leg muscle endurance versus placebo and decreased plasma acylcarnitines, ceramides, and C-reactive protein. [https://pmc.ncbi.nlm.nih.gov/articles/PMC8777576/]
  - The mitophagy activator urolithin A is safe and induces a molecular signature of improved mitochondrial and cellular health in humans, Nature metabolism (2019) — First-in-human RCT in healthy sedentary elderly: single and 4-week dosing of Urolithin A (up to 1000 mg) was safe and bioavailable; 500 and 1000 mg/day modulated plasma acylcarnitines and upregulated skeletal-muscle mitochondrial gene expression, a molecular signature of improved mitochondrial health (secondary outcomes). [https://pubmed.ncbi.nlm.nih.gov/32694802/]
  - The mitophagy activator urolithin A is safe and induces a molecular signature of improved mitochondrial and cellular health in humans, Nature Metabolism (2019) — In this first-in-human randomized trial, oral urolithin A (up to 1000 mg) was safe and well tolerated, was bioavailable in plasma, and at 500–1000 mg/day for 4 weeks modulated plasma acylcarnitines and skeletal-muscle mitochondrial gene expression consistent with improved mitochondrial health. [https://doi.org/10.1038/s42255-019-0073-4]
  - Effect of Urolithin A Supplementation on Muscle Endurance and Mitochondrial Health in Older Adults: A Randomized Clinical Trial, JAMA network open (2022) — In the ENERGIZE RCT, 1000 mg/day urolithin A for 4 months did not significantly beat placebo on co-primary endpoints (6-minute walk distance, hand-muscle ATP production) but significantly improved muscle endurance (contractions to fatigue) and lowered C-reactive protein, with no serious adverse events. [https://pubmed.ncbi.nlm.nih.gov/35050355/]
  - Urolithin A improves muscle strength, exercise performance, and biomarkers of mitochondrial health in a randomized trial in middle-aged adults, Cell reports. Medicine (2022) — In the ATLAS RCT, 500 or 1000 mg/day urolithin A for 4 months improved muscle strength by roughly 12% versus baseline and produced clinically meaningful gains in aerobic endurance (peak VO2) and the 6-minute walk, alongside favorable mitochondrial biomarker changes. [https://pubmed.ncbi.nlm.nih.gov/35584623/]
  - Assessment of Urolithin A effects on muscle endurance, strength, inflammation, oxidative stress, and protein metabolism in male athletes with resistance training: an 8-week randomized, double-blind, placebo-controlled study, Journal of the International Society of Sports Nutrition (2024) — In an 8-week double-blind RCT, 1000 mg/day urolithin A significantly improved muscle endurance (repetitions to failure) and maximal isometric contraction and reduced inflammatory/oxidative markers versus placebo, but did not significantly increase 1-rep-max strength. [https://pubmed.ncbi.nlm.nih.gov/39487653/]

---

## Citicoline (CDP-Choline) (Cytidine 5'-diphosphocholine)
URL: https://nutridex.info/s/citicoline
Category: Nootropic
Evidence: Mixed — Conflicting results across studies; benefit uncertain.
A choline donor studied for memory, attention, and post-stroke cognition, with genuinely mixed results.

Quick answer: Citicoline (CDP-Choline) is used for may modestly improve episodic memory and attention in healthy older adults and people with age-related cognitive decline (small trials).. NutriDex grades the human evidence as mixed — Conflicting results across studies; benefit uncertain. Based on 13 cited human studies (13 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Citicoline (CDP-choline) is a naturally occurring nucleotide that serves as an intermediate in the synthesis of phosphatidylcholine, a key brain-cell membrane component, and as a source of choline. Small randomized trials and meta-analyses report modest improvements in memory, attention, and cognitive status in older adults and in people with mild cognitive impairment, Alzheimer's disease, or post-stroke cognitive decline, with pooled effect sizes that are small-to-moderate. However, the underlying studies are frequently small and at high risk of bias favoring the intervention, and benefits for everyday functioning and prevention of dementia are not established. In acute stroke specifically, the evidence is contradictory: the large international ICTUS trial found no benefit over placebo, even though some smaller trials and dose-comparison analyses suggest possible advantages. The compound is generally safe and well tolerated. Overall, citicoline is a plausible but unproven nootropic whose strongest signals come from low-quality data, warranting cautious, honest expectations.

Benefits / uses: May modestly improve episodic memory and attention in healthy older adults and people with age-related cognitive decline (small trials).; Supplies choline and cytidine, intermediates the body uses to build phosphatidylcholine, a major neuronal membrane phospholipid.; Some trials and pooled analyses suggest benefit for cognitive function after ischemic stroke, though the largest stroke trial was negative.; Generally well tolerated with a favorable safety profile across trials.; May support acetylcholine and dopamine signaling in theory, but this has not translated into reliable clinical benefit for healthy young users..
Active compounds: Cytidine 5'-diphosphocholine (CDP-choline); Choline (hydrolysis product); Cytidine / uridine (hydrolysis product).
Dose: 250-500 mg/day orally for cognition; clinical/stroke studies used up to 1,000-2,000 mg/day. Divided doses are common.
Safety: Generally well tolerated; reported side effects are mild and infrequent, including headache, insomnia, gastrointestinal upset (nausea, diarrhea), and occasionally low blood pressure. Long-term safety beyond a few months of supplementation is not well characterized. People taking levodopa should be cautious, as citicoline may enhance levodopa effects. Choline donors can be metabolized to trimethylamine-N-oxide (TMAO); the clinical relevance for cardiovascular risk is unproven but worth noting for those with cardiovascular disease. Avoid or use only under medical supervision in pregnancy and breastfeeding (insufficient data), and in those with serious cardiovascular, hepatic, or neurological conditions. It is a supplement, not a substitute for stroke or dementia treatment; anyone with acute neurological symptoms or a diagnosed cognitive disorder should consult a physician rather than self-treat. Discontinue and seek care if unusual symptoms occur.

Cited studies (13):
  - Is Citicoline Effective in Preventing and Slowing Down Dementia?-A Systematic Review and a Meta-Analysis, Nutrients (2023) — A 2023 systematic review and meta-analysis found citicoline improved cognitive status (pooled SMDs 0.56 to 1.57; MMSE +1.55 points) but rated the underlying studies as poor quality with significant risk of bias favoring the intervention. [https://pubmed.ncbi.nlm.nih.gov/36678257/]
  - The efficacy of different doses of citicoline in improving the prognosis of patients with acute ischemic stroke based on network meta-analysis, Frontiers in Pharmacology (2025) — A 2025 network meta-analysis reported that 500 mg and 2,000 mg citicoline were associated with higher rates of neurological and daily-living improvement and lower mortality in acute ischemic stroke, but could not identify an optimal dose. [https://doi.org/10.3389/fphar.2025.1529647]
  - Comparison of the effects of choline alphoscerate and citicoline in patients with dementia disorders: a systematic review and meta-analysis, Frontiers in Neurology (2025) — A 2025 systematic review and meta-analysis comparing choline alphoscerate and citicoline in dementia found both choline donors associated with cognitive benefit but emphasized heterogeneity and limited high-quality evidence. [https://doi.org/10.3389/fneur.2025.1649661]
  - Is Citicoline Effective in Preventing and Slowing Down Dementia?-A Systematic Review and a Meta-Analysis, Nutrients (2023) — Systematic review and meta-analysis of 7 studies in MCI, Alzheimer's and post-stroke dementia found citicoline improved cognitive status (pooled SMD ranging 0.56 [95% CI 0.37-0.75] to 1.57 [95% CI 0.77-2.37]), though overall study quality was poor. [https://pmc.ncbi.nlm.nih.gov/articles/PMC9866349/]
  - Comparison of the effects of choline alphoscerate and citicoline in patients with dementia disorders: a systematic review and meta-analysis, Frontiers in neurology (2025) — Meta-analysis of 3 RCTs (n=358) found choline alphoscerate significantly more effective than citicoline on the SCAG scale (WMD -3.92, 95% CI -7.41 to -0.42), with no significant between-group difference on memory or word fluency tests. [https://pubmed.ncbi.nlm.nih.gov/41426989/]
  - Efficacy of citicoline as a supplement in glaucoma patients: A systematic review, PloS one (2023) — Systematic review of clinical studies in glaucoma: citicoline (oral or eyedrops) showed neuroprotective signals (improved PERG amplitude, RNFL, and visual-field mean deviation/slopes) without altering intraocular pressure, though conclusive evidence on long-term progression is still lacking. [https://pubmed.ncbi.nlm.nih.gov/37768938/]
  - 'Citicoline' and support of the memory function: Evaluation of a health claim pursuant to Article 13(5) of Regulation (EC) No 1924/2006, EFSA journal. European Food Safety Authority (2024) — EFSA concluded a cause-and-effect relationship has NOT been established between citicoline consumption and improvement, maintenance or reduced loss of memory in middle-aged/elderly adults with age-associated subjective memory impairment. [https://pubmed.ncbi.nlm.nih.gov/38966137/]
  - Citicoline for Acute Ischemic Stroke: A Systematic Review and Formal Meta-analysis of Randomized, Double-Blind, and Placebo-Controlled Trials, Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association (2016) — Formal meta-analysis of 10 randomized, double-blind, placebo-controlled trials: citicoline significantly increased the rate of functional independence (OR 1.56, 95% CI 1.12-2.16, random effects); effect was larger in non-rtPA patients (OR 1.63, 1.18-2.24) but diluted to limited benefit on top of rtPA. [https://pubmed.ncbi.nlm.nih.gov/27234918/]
  - Cytidinediphosphocholine (CDP-choline) for cognitive and behavioural disturbances associated with chronic cerebral disorders in the elderly, The Cochrane database of systematic reviews (2005) — A Cochrane review found some evidence that CDP-choline has a positive short-to-medium-term effect on memory and behaviour in elderly people with chronic cerebral disorders, with good tolerability, but limited by short study duration. [https://pubmed.ncbi.nlm.nih.gov/15846601/]
  - Effectiveness and safety of citicoline in mild vascular cognitive impairment: the IDEALE study, Clinical interventions in aging (2013) — Multicenter Italian study, n=349 elderly with mild vascular cognitive impairment: oral citicoline 1000 mg/day kept MMSE stable over 9 months while the control group declined (approx -1.9 points), with good tolerability. [https://pubmed.ncbi.nlm.nih.gov/23403474/]
  - Citicoline and Memory Function in Healthy Older Adults: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial, The Journal of nutrition (2021) — In a 12-week double-blind RCT, citicoline 500 mg/day produced significantly greater improvements in episodic memory and composite memory scores versus placebo (Paired Associate test change 0.15 vs 0.06, P=0.0025). [https://pubmed.ncbi.nlm.nih.gov/33978188/]
  - Citicoline in the treatment of acute ischaemic stroke: an international, randomised, multicentre, placebo-controlled study (ICTUS trial), Lancet (London, England) (2012) — The large international ICTUS RCT found that citicoline (1,000 mg twice daily for 6 weeks) was not efficacious for recovery at 90 days in moderate-to-severe acute ischemic stroke, though it confirmed safety. [https://pubmed.ncbi.nlm.nih.gov/22691567/]
  - Role of Citicoline in Patients With Mild Cognitive Impairment, Neuroscience insights (2023) — Review concluded citicoline shows consistent improvement in cognitive function in patients with mild cognitive impairment, especially of vascular origin. [https://pubmed.ncbi.nlm.nih.gov/36818199/]

---

## Phosphatidylserine
URL: https://nutridex.info/s/phosphatidylserine
Category: Nootropic
Evidence: Moderate — Several controlled trials; effects real but modest or context-dependent.
Brain-cell phospholipid with modest, FDA-qualified support for age-related memory.

Quick answer: Phosphatidylserine is used for may produce small improvements in memory and learning in older adults with age-associated memory complaints or mild cognitive impairment.. NutriDex grades the human evidence as moderate — Several controlled trials; effects real but modest or context-dependent. Based on 11 cited human studies (11 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Phosphatidylserine is a phospholipid concentrated in neuronal cell membranes and marketed as a memory-support nootropic. A 2022 systematic review and meta-analysis (9 studies, 961 participants, 100–300 mg/day for 6 weeks to 6 months) concluded it has a positive effect on memory in older adults with cognitive decline, and a 2024 RCT in older adults with mild cognitive impairment found small improvements in short-term memory, reasoning, and arithmetic over placebo. However, effect sizes are generally small and independent reviewers (e.g., the Alzheimer's Drug Discovery Foundation) note the changes are often not large enough to be clearly clinically relevant, with most trials being short and using differing PS sources that complicate comparison. The U.S. FDA granted only a 'qualified' health claim, explicitly stating that the supporting evidence is very limited and preliminary and that there is little scientific agreement that PS reduces dementia risk. Modern products are derived from soy or sunflower rather than the bovine-brain PS used in early studies. Overall the evidence is best characterized as moderate but modest: a plausible, well-tolerated option for age-related memory, not a proven treatment for dementia.

Benefits / uses: May produce small improvements in memory and learning in older adults with age-associated memory complaints or mild cognitive impairment.; Pooled trial data suggest a positive effect on memory in elderly with cognitive decline, though effect sizes are small and not clearly clinically meaningful.; Generally well tolerated, making it a low-risk option to trial for subjective age-related memory concerns.; Holds a U.S. FDA 'qualified' (heavily caveated) health claim relating it to reduced risk of dementia/cognitive dysfunction in the elderly..
Active compounds: Phosphatidylserine (glycerophospholipid; soy- or sunflower-derived in modern supplements); Bovine-cortex phosphatidylserine (BC-PS, used in older trials; now discontinued over prion concerns); Often co-formulated with omega-3 fatty acids (DHA/EPA) as PS-omega-3.
Dose: 100–300 mg/day, typically split into 2–3 doses with food; most cognitive trials used 100 mg three times daily.
Safety: Generally well tolerated; most reported side effects are mild and transient, mainly gastrointestinal upset and headache, with insomnia possible at higher doses (above ~300 mg/day) or when taken late in the day. Soy-derived products are unsuitable for people with soy allergy—sunflower-derived PS is an alternative. PS may theoretically enhance the effect of anticoagulant/antiplatelet drugs (e.g., warfarin, heparin); people on blood thinners should consult a clinician first, though clinical trials have not reported increased bleeding or clotting events. Data in pregnancy and breastfeeding are lacking, so it should be avoided in these groups; safety in children is not established. Older bovine-brain–derived PS carried theoretical prion (BSE) risk and has been discontinued—choose plant-derived (soy/sunflower) products. It is a supplement, not a treatment for diagnosed dementia or Alzheimer's disease; anyone with significant cognitive decline should seek medical evaluation rather than self-treating.

Cited studies (11):
  - Effect of phosphatidylserine on cognitive function in the elderly: A systematic review and meta-analysis, Korean Journal of Food Science and Technology (2022) — Systematic review and meta-analysis found phosphatidylserine (100–300 mg/day, 6 weeks–6 months) had a positive effect on memory in older adults with cognitive decline, with no adverse effects reported. [https://doi.org/10.9721/KJFST.2022.54.1.52]
  - A Randomized, Double-Blind, Placebo-Controlled, Parallel Study Investigating the Efficacy of a Whole Coffee Cherry Extract and Phosphatidylserine Formulation on Cognitive Performance of Healthy Adults with Self-Perceived Memory Problems, Neurology and Therapy (2023) — Double-blind RCT in 138 healthy adults aged 40-65 with self-reported memory problems: 42 days of a whole coffee cherry extract plus phosphatidylserine formulation improved numeric working-memory COMPASS task accuracy vs placebo. [https://link.springer.com/article/10.1007/s40120-023-00454-z]
  - Qualified Health Claims: Letters of Enforcement Discretion, U.S. Food and Drug Administration — FDA permitted only a qualified health claim, stating that very limited and preliminary research suggests PS may reduce dementia/cognitive-dysfunction risk in the elderly and that there is little scientific evidence supporting the claim. [https://www.fda.gov/food/nutrition-food-labeling-and-critical-foods/qualified-health-claims-letters-enforcement-discretion]
  - Phosphatidylserine containing omega-3 fatty acids may improve memory abilities in non-demented elderly with memory complaints: a double-blind placebo-controlled trial, Dementia and geriatric cognitive disorders (2010) — 15-week double-blind, placebo-controlled RCT in 157 non-demented elderly with memory complaints; PS containing omega-3 (PS-DHA) significantly improved verbal immediate recall vs placebo, with larger gains in immediate/delayed recall and learning in the subgroup with better baseline cognition. [https://pubmed.ncbi.nlm.nih.gov/20523044/]
  - Soybean-derived phosphatidylserine improves memory function of the elderly Japanese subjects with memory complaints, Journal of clinical biochemistry and nutrition (2010) — 6-month double-blind RCT in 78 elderly Japanese (50-69 y) with memory complaints; soybean PS (100 or 300 mg/day) significantly increased memory scores from baseline in those with relatively low baseline scores (mainly delayed verbal recall), whereas placebo did not change; no safety signals. [https://pubmed.ncbi.nlm.nih.gov/21103034/]
  - A soy-based phosphatidylserine/ phosphatidic acid complex (PAS) normalizes the stress reactivity of hypothalamus-pituitary-adrenal-axis in chronically stressed male subjects: a randomized, placebo-controlled study, Lipids in health and disease (2014) — Double-blind, placebo-controlled RCT in 75 healthy men; 42 days of soy PS/phosphatidic acid complex at 400 mg PS + 400 mg PA/day normalized the hyper-responsive ACTH (p=0.010), salivary cortisol (p=0.043) and serum cortisol (p=0.035) responses to an acute social stress test in chronically high-stressed subjects; the 200 mg dose had no effect. [https://pubmed.ncbi.nlm.nih.gov/25081826/]
  - Effects of a food supplement containing phosphatidylserine on cognitive function in Chinese older adults with mild cognitive impairment: A randomized double-blind, placebo-controlled trial, Journal of affective disorders (2025) — In Chinese older adults with mild cognitive impairment, a 12-month phosphatidylserine-containing supplement significantly improved short-term memory (β=0.60), reasoning and arithmetic versus placebo, with effects partly mediated by raised serum n-3 fatty acids. [https://pubmed.ncbi.nlm.nih.gov/39317299/]
  - Effects of phosphatidylserine in age-associated memory impairment, Neurology (1991) — Landmark RCT in age-associated memory impairment found 100 mg bovine-cortex phosphatidylserine three times daily for 12 weeks improved learning and everyday memory tasks versus placebo, most notably in lower-performing subjects. [https://pubmed.ncbi.nlm.nih.gov/2027477/]
  - The effects of phosphatidylserine on endocrine response to moderate intensity exercise, Journal of the International Society of Sports Nutrition (2008) — Double-blind, placebo-controlled crossover RCT in 10 healthy men; 10 days of 600 mg/day PS blunted exercise-induced cortisol (peak ~39% lower, AUC ~35% lower vs placebo, p<0.05) and raised the testosterone-to-cortisol ratio AUC (~184%); no effect on growth hormone or lactate. [https://pubmed.ncbi.nlm.nih.gov/18662395/]
  - Phosphatidylserine & Your Brain, Alzheimer's Drug Discovery Foundation (Cognitive Vitality) (2023) — Independent expert assessment concluded phosphatidylserine may offer some memory benefit but that cognitive improvements in trials are typically slight, short-term, and not clearly clinically meaningful, limited by differing PS sources. [https://www.alzdiscovery.org/cognitive-vitality/ratings/phosphatidylserine]
  - Effects of phosphatidylserine supplementation on exercising humans, Sports medicine (Auckland, N.Z.) (2006) — Authoritative narrative review of PS supplementation in exercising humans: bovine-cortex PS 800 mg/day moderated exercise-induced HPA-axis (cortisol) changes, soy PS 800 mg/day reduced overtraining cortisol and improved well-being/soreness, and short-term soy PS 750 mg/day improved high-intensity cycling capacity; soy PS preferred over bovine due to prion risk; effective oral dose may vary between individuals. [https://pubmed.ncbi.nlm.nih.gov/16869708/]

---

## Alpha-GPC (L-alpha-glycerylphosphorylcholine)
URL: https://nutridex.info/s/alpha-gpc
Category: Nootropic, Performance
Evidence: Preliminary — Early or small human trials; promising but not yet conclusive.
A choline phospholipid with preliminary cognitive and power signals — shadowed by a stroke-risk caution.

Quick answer: Alpha-GPC is used for may modestly improve cognition in adult-onset dementia, especially when added to cholinesterase inhibitors (clinical populations, not healthy users).. NutriDex grades the human evidence as preliminary — Early or small human trials; promising but not yet conclusive. Based on 12 cited human studies (12 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Alpha-GPC (choline alphoscerate) is a phospholipid choline source marketed as a nootropic and pre-workout ingredient. The strongest human data are in clinical dementia populations, where a 2023 meta-analysis of 7 RCTs (861 participants) found improved cognition, particularly when combined with donepezil; benefit in healthy people rests on small, short-term studies showing acute gains on tasks like the Stroop test. Evidence for athletic power output is genuinely mixed, with some trials showing greater peak force and others showing no effect. A critical safety signal comes from a 2021 South Korean cohort of over 12 million adults, which linked alpha-GPC use to a roughly 43–46% higher 10-year stroke risk in a dose-dependent manner, plausibly via choline-derived TMAO. Notably, other Korean cohort data suggest a lower risk of dementia conversion in MCI patients, so the overall risk-benefit picture is unsettled. On balance the evidence is preliminary, and the cardiovascular caution should be weighed seriously, especially by older adults or those with vascular risk factors.

Benefits / uses: May modestly improve cognition in adult-onset dementia, especially when added to cholinesterase inhibitors (clinical populations, not healthy users).; Single acute doses have improved processing speed/cognitive interference (Stroop) in small studies of healthy adults — short-term and not yet replicated at scale.; Mixed, preliminary signals for muscle force/power output; some trials show greater peak force, others show no effect on power.; Serves as a bioavailable choline donor that crosses the blood-brain barrier and supports acetylcholine synthesis.; Acutely raises growth hormone secretion in some studies, though clinical relevance is unproven..
Active compounds: L-alpha-glycerylphosphorylcholine (choline alphoscerate); Choline (~40% by weight); Glycerophosphate backbone.
Dose: 300–600 mg/day for performance/cognition; 1,200 mg/day (often divided) used in dementia trials. Acute pre-exercise/pre-task doses ~300–600 mg.
Safety: A large 2021 South Korean cohort linked alpha-GPC use to a dose-dependent ~43–46% increase in 10-year stroke risk (ischemic and hemorrhagic); causality is unproven and confounding is possible, but this is a serious caution — older adults and anyone with hypertension, atrial fibrillation, prior stroke/TIA, atherosclerosis, or other cardiovascular/cerebrovascular risk factors should be especially cautious and consult a clinician. The proposed mechanism is conversion of choline to TMAO, a metabolite tied to atherothrombosis. Common side effects are generally mild: headache, heartburn, dizziness, insomnia, and GI upset. Theoretical additive cholinergic effects mean caution with cholinergic drugs (e.g., cholinesterase inhibitors) and anticholinergics; relevance to anticoagulants/antiplatelets is unestablished but warrants medical advice given the stroke signal. Avoid in pregnancy and breastfeeding due to insufficient safety data. Not a substitute for prescribed therapy in dementia; use under medical supervision in clinical populations.

Cited studies (12):
  - Activity of Choline Alphoscerate on Adult-Onset Cognitive Dysfunctions: A Systematic Review and Meta-Analysis, Journal of Alzheimer's disease : JAD (2023) — This 2023 meta-analysis found alpha-GPC improved cognition in adult-onset dementia, with better MMSE scores alone (MD 3.50) and added benefit on ADAS-Cog when combined with donepezil (MD −5.76). [https://pubmed.ncbi.nlm.nih.gov/36683513/]
  - Comparison of the effects of choline alphoscerate and citicoline in patients with dementia disorders: a systematic review and meta-analysis, Frontiers in neurology (2025) — Systematic review/meta-analysis of 3 RCTs (n=358) found choline alphoscerate improved clinical condition vs citicoline on the SCAG scale (WMD -3.92, 95% CI -7.41 to -0.42), with comparable dropout rates (OR 1.44, 95% CI 0.66-3.13). [https://pubmed.ncbi.nlm.nih.gov/41426989/]
  - Activity of Choline Alphoscerate on Adult-Onset Cognitive Dysfunctions: A Systematic Review and Meta-Analysis, Journal of Alzheimer's disease : JAD (2023) — Systematic review and meta-analysis concluded choline alphoscerate improves cognitive performance and may reduce cognitive decline in adult-onset cognitive dysfunction, including as add-on to donepezil. [https://pmc.ncbi.nlm.nih.gov/articles/PMC10041421/]
  - Acute Alpha-Glycerylphosphorylcholine Supplementation Enhances Cognitive Performance in Healthy Men, Nutrients (2024) — In this 2024 randomized double-blind crossover trial, acute 315 mg and 630 mg doses significantly improved Stroop test performance versus placebo, indicating better processing speed/cognitive control. [https://pubmed.ncbi.nlm.nih.gov/39683633/]
  - Efficacy and safety of choline alphoscerate for amnestic mild cognitive impairment: a randomized double-blind placebo-controlled trial, BMC geriatrics (2024) — In a 12-week double-blind RCT of 100 patients with amnestic mild cognitive impairment, choline alphoscerate reduced ADAS-cog by 2.34 points vs baseline (p<0.0001) and significantly outperformed placebo (p<0.05). [https://pubmed.ncbi.nlm.nih.gov/39300341/]
  - The Effect of the Association between Donepezil and Choline Alphoscerate on Behavioral Disturbances in Alzheimer's Disease: Interim Results of the ASCOMALVA Trial, Journal of Alzheimer's disease : JAD (2017) — Double-blind RCT in Alzheimer's disease with cerebrovascular injury: donepezil + choline alphoscerate significantly reduced behavioral and psychological symptoms (BPSD severity, NPI) and caregiver distress versus donepezil + placebo over follow-up. [https://pubmed.ncbi.nlm.nih.gov/28035924/]
  - The effect of 6 days of alpha glycerylphosphorylcholine on isometric strength, Journal of the International Society of Sports Nutrition (2015) — Double-blind, placebo-controlled crossover (n=13 men). 6 days of 600 mg/day alpha-GPC significantly increased lower-body isometric mid-thigh pull peak force change (+98.8 N vs -39.0 N placebo, p=0.044); upper-body force trended higher but was non-significant (p=0.127). [https://pubmed.ncbi.nlm.nih.gov/26582972/]
  - Potential Use of Calpain Inhibitors as Brain Injury Therapy (2015) — Across small randomized trials, alpha-GPC showed mixed effects on athletic performance — some reporting greater peak/isometric force, others finding no significant change in power output. [https://pubmed.ncbi.nlm.nih.gov/26269886/]
  - Choline alphoscerate: insights between acquired certainties and future perspectives, Frontiers in aging neuroscience (2025) — Narrative review summarizing current human evidence concludes alpha-GPC may improve cognition in dementia but it remains uncertain whether it adds benefit over approved anti-dementia drugs. [https://pmc.ncbi.nlm.nih.gov/articles/PMC12364881/]
  - Association between L-α glycerylphosphorylcholine use and delayed dementia conversion: A nationwide longitudinal study in South Korea, The journal of prevention of Alzheimer's disease (2025) — This 2025 nationwide Korean cohort found alpha-GPC users had a modestly lower risk of conversion to Alzheimer's disease (HR 0.90) and vascular dementia (HR 0.83) versus non-users. [https://pubmed.ncbi.nlm.nih.gov/40155153/]
  - Association of L-α Glycerylphosphorylcholine With Subsequent Stroke Risk After 10 Years, JAMA network open (2021) — In this 2021 South Korean population cohort, alpha-GPC use was associated with a 46% higher 10-year total stroke risk (aHR 1.46; matched aHR 1.43), with a dose-dependent trend rising to aHR 1.36 for >12 months of use. [https://pubmed.ncbi.nlm.nih.gov/34817582/]
  - Association of L-α Glycerylphosphorylcholine With Subsequent Stroke Risk After 10 Years, JAMA network open (2021) — Retrospective cohort of 12,008,977 adults aged 50+ found alpha-GPC use associated with higher 10-year total stroke risk (aHR 1.48, 95% CI 1.43-1.52), with a dose-response rise to aHR 1.36 (95% CI 1.29-1.43) for >12 months of use. [https://pmc.ncbi.nlm.nih.gov/articles/PMC8613599/]

---

## Beetroot / Dietary Nitrate (Beta vulgaris)
URL: https://nutridex.info/s/beetroot
Category: Performance, Heart & Metabolic
Evidence: Moderate — Several controlled trials; effects real but modest or context-dependent.
Nitrate-rich juice that boosts nitric oxide for better exercise economy and modestly lower blood pressure.

Quick answer: Beetroot / Dietary Nitrate is used for improves submaximal exercise economy by lowering the oxygen cost of fixed-intensity work (~3-5% reduction in vo2 reported). NutriDex grades the human evidence as moderate — Several controlled trials; effects real but modest or context-dependent. Based on 18 cited human studies (18 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Beetroot is one of the richest dietary sources of inorganic nitrate, which oral bacteria and the body convert via nitrite into nitric oxide, a signaling molecule that relaxes blood vessels and improves muscle efficiency. The most reproducible benefit is improved exercise economy: meta-analyses show nitrate lowers the oxygen cost of submaximal exercise and modestly extends time-to-exhaustion, with larger effects in open-ended endurance tasks than in fixed-distance time trials. In hypertensive adults, nitrate from beetroot juice produces small but meaningful reductions in systolic blood pressure (roughly 5 mmHg), though diastolic effects and benefits in normotensive or older adults are less consistent. Evidence for strength, power, and repeated-sprint performance is weaker and mixed. Overall the data are best described as moderate: real, mechanistically plausible effects of small-to-modest magnitude that depend on dose, timing, and population. The harmless red/pink urine (beeturia) some people notice is simply unabsorbed betalain pigment.

Benefits / uses: Improves submaximal exercise economy by lowering the oxygen cost of fixed-intensity work (~3-5% reduction in VO2 reported); Modestly extends time-to-exhaustion / endurance, especially in open-ended aerobic tasks (pooled SMD ~0.33); Produces small reductions in systolic blood pressure, most consistently in hypertensive adults (~5 mmHg clinic SBP); May offer minor benefit to high-intensity intermittent and repeated-sprint performance, though effects are inconsistent; Boosts nitric oxide bioavailability, supporting vasodilation and blood flow.
Active compounds: Inorganic nitrate (NO3-); Betalains (betanin/betacyanin pigments); Betaine; Potassium; Dietary oxalates.
Dose: ~6-13 mmol (≈310-800 mg) inorganic nitrate per day, typically as 1-2 concentrated beetroot 'shots' (~70 mL each) or 250-500 mL juice; for acute performance, taken ~2-3 hours before exercise, or daily for 3+ days for fuller effect.
Safety: Generally well tolerated. The most common effect is harmless beeturia (red/pink urine) and occasionally reddish stool from betalain pigments. Because nitrate lowers blood pressure, use caution if taking antihypertensive drugs, PDE5 inhibitors (sildenafil/tadalafil), or nitrate medications, as additive effects may cause hypotension, dizziness, or fainting. Antibacterial mouthwash (e.g., chlorhexidine) and recent antibiotics can blunt the effect by killing the oral bacteria needed to reduce nitrate to nitrite. Beetroot is high in oxalate and potassium, so people prone to calcium-oxalate kidney stones or with chronic kidney disease (hyperkalemia risk) should limit intake. Theoretical concern exists about nitrate/nitrite and N-nitroso compounds, but dietary/vegetable nitrate is not associated with the risks linked to processed-meat nitrites. Safety data in pregnancy, breastfeeding, and infants are limited, so supplemental doses are best avoided in these groups. Whole food beet intake is safe for most people; consult a clinician before using high-dose nitrate shots if you have low blood pressure, kidney disease, or are on relevant medications.

Cited studies (18):
  - Effects of Beetroot Juice on Physical Performance in Professional Athletes and Healthy Individuals: An Umbrella Review, Nutrients (2025) — Umbrella review of 15 meta-analyses found beetroot juice produced only negligible-to-small gains: VO2max SMD 0.16 (p=0.033) and time-to-exhaustion SMD 0.25 (p=0.034) in healthy adults, with non-athletes showing larger aerobic gains (SMD 0.26) than athletes. [https://pubmed.ncbi.nlm.nih.gov/40573069/]
  - Dietary Nitrate Supplementation and Exercise Performance: An Umbrella Review of 20 Published Systematic Reviews with Meta-analyses, Sports medicine (Auckland, N.Z.) (2025) — Umbrella review of 20 meta-analyses (180 studies, 2,672 participants) found mixed ergogenic effects; dietary nitrate improved time-to-exhaustion (SMD 0.33; 95% CI 0.19-0.47), most with >=6 mmol/day and chronic (>3 day) dosing. [https://pmc.ncbi.nlm.nih.gov/articles/PMC12106159/]
  - Effects of beetroot juice on blood pressure in hypertension according to European Society of Hypertension Guidelines: A systematic review and meta-analysis, Nutrition, metabolism, and cardiovascular diseases : NMCD (2024) — Meta-analysis of 11 RCTs (349 hypertensive patients) found beetroot juice reduced clinical systolic BP by -5.31 mmHg (95% CI -7.46, -3.16), with no significant effect on diastolic or 24-h BP; certainty of evidence low. [https://pubmed.ncbi.nlm.nih.gov/39069465/]
  - Effects of chronic nitrate supplementation on blood pressure in adults: a systematic review and meta-analysis of randomized clinical trials, Nutrition research (New York, N.Y.) (2026) — Meta-analysis of 6 RCTs (181 adults) of chronic isolated nitrate supplementation (250-590 mg/d, >=1 week) found no significant reduction in systolic BP, diastolic BP, or resting heart rate, isolating nitrate from whole beetroot effects. [https://pubmed.ncbi.nlm.nih.gov/41619653/]
  - Plasma nitrate, dietary nitrate, blood pressure, and vascular health biomarkers: a GRADE-Assessed systematic review and dose-response meta-analysis of randomized controlled trials, Nutrition journal (2025) — GRADE-assessed dose-response meta-analysis of RCTs on plasma/dietary nitrate found beneficial effects on blood pressure and vascular health biomarkers, with dose-response relationships characterized across trials. [https://pmc.ncbi.nlm.nih.gov/articles/PMC11931885/]
  - The Effect of Nitrate-Rich Beetroot Juice on Markers of Exercise-Induced Muscle Damage: A Systematic Review and Meta-Analysis of Human Intervention Trials, Journal of dietary supplements (2022) — Systematic review/meta-analysis of human trials: nitrate-rich beetroot juice accelerated isometric strength recovery at 72 h post-exercise (SMD 0.54) and countermovement-jump recovery at 24-72 h (SMD 0.75-1.32), and raised pressure-pain threshold (less soreness); no effect on creatine kinase or oxidative stress. [https://pubmed.ncbi.nlm.nih.gov/34151694/]
  - Inorganic nitrate and beetroot juice supplementation reduces blood pressure in adults: a systematic review and meta-analysis, The Journal of nutrition (2013) — Meta-analysis of 16 RCTs (254 adults): inorganic nitrate/beetroot juice reduced systolic BP by 4.4 mmHg (95% CI -5.9 to -2.8; P<0.001), with a smaller, non-significant diastolic effect (-1.1 mmHg); dose-response relationship between daily nitrate dose and systolic BP reduction. [https://pubmed.ncbi.nlm.nih.gov/23596162/]
  - Dietary Nitrate Supplementation and Exercise Performance: An Umbrella Review of 20 Published Systematic Reviews with Meta-analyses, Sports medicine (Auckland, N.Z.) (2025) — An umbrella review found nitrate supplementation significantly improved time-to-exhaustion (SMD 0.33, 95% CI 0.19-0.47), particularly at ≥6 mmol/day and with chronic dosing, but had no significant effect on time-trial performance (SMD -0.03). [https://pubmed.ncbi.nlm.nih.gov/40085422/]
  - The effects of dietary nitrate supplementation on endurance exercise performance and cardiorespiratory measures in healthy adults: a systematic review and meta-analysis, Journal of the International Society of Sports Nutrition (2021) — Meta-analysis in healthy adults found dietary nitrate increased time-to-exhaustion (+25.3 s) and power output (+4.6 W) and reduced submaximal oxygen consumption (-0.04 L/min), with no change in VO2max, indicating improved exercise economy. [https://pubmed.ncbi.nlm.nih.gov/34243756/]
  - Nitrate Derived From Beetroot Juice Lowers Blood Pressure in Patients With Arterial Hypertension: A Systematic Review and Meta-Analysis, Frontiers in nutrition (2022) — In patients with arterial hypertension, nitrate from beetroot juice reduced systolic blood pressure by a pooled 4.95 mmHg (95% CI -8.88 to -1.01; moderate-certainty evidence) but did not significantly lower diastolic BP. [https://pubmed.ncbi.nlm.nih.gov/35369064/]
  - Effects of Dietary Nitrate Supplementation on Performance during Single and Repeated Bouts of Short-Duration High-Intensity Exercise: A Systematic Review and Meta-Analysis of Randomised Controlled Trials, Antioxidants (2023) — Nitrate supplementation had small positive effects on selected outcomes during single and repeated bouts of short-duration high-intensity exercise (e.g., mean power and intermittent-test distance), but effects were inconsistent across measures. [https://www.mdpi.com/2076-3921/12/6/1194]
  - Does Nitrate Supplementation Improve Muscle Strength, Power, and Sprint Performance in Females? A Systematic Review and Meta-Analysis, Life (Basel, Switzerland) (2025) — In females specifically, nitrate supplementation showed limited and inconsistent benefit for muscle strength, power, and sprint performance, underscoring that ergogenic effects are population- and task-dependent. [https://pmc.ncbi.nlm.nih.gov/articles/PMC12471447/]
  - Acute effects of various doses of nitrate-rich beetroot juice on high-intensity interval exercise responses in women: a randomized, double-blinded, placebo-controlled, crossover trial, Journal of the International Society of Sports Nutrition (2024) — Double-blind crossover RCT (n=13 women) testing 6.45 vs 12.9 mmol nitrate found beetroot juice lowered mean heart rate and perceived exertion versus placebo during high-intensity interval exercise, with no added benefit from the higher dose. [https://pubmed.ncbi.nlm.nih.gov/38535518/]
  - Inter-individual differences in the blood pressure lowering effects of dietary nitrate: a randomised double-blind placebo-controlled replicate crossover trial, European journal of nutrition (2025) — Replicate double-blind placebo-controlled crossover RCT found nitrate-rich beetroot juice lowered systolic BP by -7 mmHg (95% CI -3 to -11) and diastolic by -6 mmHg (95% CI -2 to -9), but with large inter-individual response variability (+/- 7 mmHg). [https://pmc.ncbi.nlm.nih.gov/articles/PMC11850510/]
  - Increased nitrate intake from beetroot juice over 4 weeks affects nitrate metabolism, but not vascular function or blood pressure in older adults with hypertension, Food & function (2024) — 4-week RCT crossover in 15 older adults (56-71 y) with treated hypertension found daily beetroot juice altered nitrate metabolism but did not improve vascular function or blood pressure. [https://pmc.ncbi.nlm.nih.gov/articles/PMC11034575/]
  - Dietary nitrate provides sustained blood pressure lowering in hypertensive patients: a randomized, phase 2, double-blind, placebo-controlled study, Hypertension (Dallas, Tex. : 1979) (2015) — In 68 hypertensive patients, 4 weeks of daily nitrate-rich beetroot juice (250 mL, ~6.4 mmol nitrate/day) lowered clinic BP by 7.7/2.4 mmHg, 24-h ambulatory BP by 7.7/5.2 mmHg, and home BP by 8.1/3.8 mmHg vs nitrate-depleted placebo, with ~20% improvement in endothelial function and reduced arterial stiffness; no tachyphylaxis. [https://pubmed.ncbi.nlm.nih.gov/25421976/]
  - Relationship of dietary nitrate intake from vegetables with cardiovascular disease mortality: a prospective study in a cohort of older Australians, European journal of nutrition (2019) — Prospective cohort of 2229 older Australians over 14 years: higher vegetable-derived nitrate intake was inversely associated with CVD mortality; quartiles 2-4 (>=69.5 mg/day) had ~37-49% lower CVD mortality vs lowest quartile (e.g., Q3 HR 0.51, 95% CI 0.32-0.80), independent of CVD risk factors. [https://pubmed.ncbi.nlm.nih.gov/30238316/]
  - Association of dietary nitrate with atherosclerotic vascular disease mortality: a prospective cohort study of older adult women, The American journal of clinical nutrition (2017) — Prospective cohort of 1226 older women over 15 years: each SD higher vegetable nitrate intake was associated with 21% lower atherosclerotic vascular disease mortality (multivariable HR 0.79, 95% CI 0.68-0.93) and 13% lower all-cause mortality (HR 0.87), though attenuated after diet-quality adjustment. [https://pubmed.ncbi.nlm.nih.gov/28566306/]

---

## Psyllium (Fiber) (Plantago ovata)
URL: https://nutridex.info/s/psyllium
Category: Heart & Metabolic, Gut & Immune
Evidence: Strong — Multiple high-quality RCTs / meta-analyses with consistent effects.
Soluble viscous fiber with strong evidence for lowering LDL cholesterol, improving glycemic control, and relieving constipation.

Quick answer: Psyllium (Fiber) is used for lowers ldl ('bad') cholesterol and total cholesterol when taken daily, supporting heart health (fda-authorized claim). NutriDex grades the human evidence as strong — Multiple high-quality RCTs / meta-analyses with consistent effects. Based on 10 cited human studies (10 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Psyllium is a soluble, gel-forming fiber derived from the husk of Plantago ovata seeds and is the active ingredient in products such as Metamucil. It is one of the best-evidenced dietary supplements: meta-analyses of randomized controlled trials consistently show it lowers LDL cholesterol, improves blood-glucose control, and relieves chronic constipation, and it carries an FDA-authorized health claim linking ~7 g/day of psyllium soluble fiber to reduced coronary heart disease risk. Its benefits stem from the viscous gel it forms in the gut, which binds bile acids and slows carbohydrate absorption while adding bulk and water to stool. Effects are dose-dependent, with most cholesterol and constipation benefits seen at doses above 10 g/day used for at least 4 weeks. Psyllium is generally well tolerated, with bloating and gas being the most common side effects. It must be taken with adequate water to avoid choking or intestinal blockage.

Benefits / uses: Lowers LDL ('bad') cholesterol and total cholesterol when taken daily, supporting heart health (FDA-authorized claim); Improves glycemic control, lowering HbA1c and fasting blood glucose, with larger benefit in people with type 2 diabetes; Relieves chronic constipation by increasing stool frequency, softening stool, and easing straining; May improve global symptoms in irritable bowel syndrome (IBS), particularly the constipation-predominant subtype; Modestly increases satiety and can support weight management as part of a calorie-controlled diet.
Active compounds: Arabinoxylan (soluble, gel-forming fiber from the seed husk); Mucilage / non-starch polysaccharides that form a viscous gel in water; Mixture of soluble (~70%) and insoluble (~30%) fiber fractions.
Dose: For cholesterol/heart health: ~7 g/day of soluble fiber (about 10.2 g of psyllium husk), often split before meals. For constipation: 5-10 g, 1-3 times daily. For glycemic control: ~10 g before meals. Always take with a full glass (at least 240 mL) of water and increase fluid intake.
Safety: Generally safe and well tolerated; the most common side effects are bloating, flatulence, and abdominal discomfort, which usually lessen with gradual dose escalation. CRITICAL: always take with a full glass of water and maintain fluid intake, because inadequate fluid can cause throat or intestinal blockage and choking. Do NOT use if you have difficulty swallowing, esophageal narrowing, a suspected bowel obstruction, fecal impaction, or gastrointestinal strictures. Psyllium can reduce or delay the absorption of medications and other supplements (including some forms of metformin, levothyroxine, lithium, carbamazepine, digoxin, warfarin, and certain antidepressants) and of fat-soluble vitamins and minerals, so separate it from medications by at least 2-4 hours. People with diabetes on glucose-lowering drugs should monitor blood sugar, as psyllium may enhance their effect and increase hypoglycemia risk. Rare hypersensitivity/allergic reactions (including anaphylaxis, especially in those with occupational psyllium exposure) have been reported. Consult a clinician before use if pregnant, breastfeeding, taking multiple medications, or managing kidney disease or any swallowing or bowel disorder.

Cited studies (10):
  - Plantago consumption significantly reduces total cholesterol and low-density lipoprotein cholesterol in adults: A systematic review and meta-analysis, Nutrition research (New York, N.Y.) (2024) — In 29 RCTs (n=2,769), Plantago/psyllium consumption reduced total cholesterol by 0.28 mmol/L and LDL-C by 0.35 mmol/L versus control, an estimated ~7% reduction in cardiovascular event risk. [https://pubmed.ncbi.nlm.nih.gov/38688104/]
  - Psyllium supplementation and lipid profiles: systematic review and dose-response meta-analysis of randomized controlled trials, Genes & Nutrition (2025) — Dose-response meta-analysis of 41 RCTs (n=2,049) found psyllium significantly lowered LDL-C (WMD -8.55 mg/dL; 95% CI -12.92 to -4.19) and total cholesterol (WMD -9.05 mg/dL; 95% CI -13.71 to -4.40). [https://link.springer.com/article/10.1186/s12263-025-00786-5]
  - The effect of psyllium consumption on blood pressure: Systematic review and dose-response meta-analysis of randomized controlled trials, Food science & nutrition (2024) — Systematic review and dose-response meta-analysis of RCTs found psyllium consumption significantly lowered blood pressure, supporting a broader cardiovascular-risk benefit beyond lipids. [https://pmc.ncbi.nlm.nih.gov/articles/PMC11521634/]
  - The Effect of Fiber Supplementation on Chronic Constipation in Adults: An Updated Systematic Review and Meta-Analysis of Randomized Controlled Trials, The American journal of clinical nutrition (2022) — Updated systematic review/meta-analysis of 16 RCTs (n=1251) in chronic constipation. Fiber (psyllium and pectin specifically significant) raised treatment response 66% vs 41% control (RR 1.48; 95% CI 1.17-1.88) and increased stool frequency (SMD 0.72; 95% CI 0.36-1.08); psyllium at doses >10 g/day for >=4 weeks was optimal, though flatulence increased. [https://pubmed.ncbi.nlm.nih.gov/35816465/]
  - Meta-Analysis of Usefulness of Psyllium Fiber as Adjuvant Antilipid Therapy to Enhance Cholesterol Lowering Efficacy of Statins, The American journal of cardiology (2018) — Meta-analysis of 3 RCTs of psyllium added to statin therapy. Psyllium plus statin produced significantly greater LDL-cholesterol lowering than statin alone (P=0.001), with the added reduction equivalent to doubling the statin dose, supporting psyllium as an adjunct antilipid intervention. [https://pubmed.ncbi.nlm.nih.gov/30078477/]
  - Effect of psyllium (Plantago ovata) fiber on LDL cholesterol and alternative lipid targets, non-HDL cholesterol and apolipoprotein B: a systematic review and meta-analysis of randomized controlled trials, The American journal of clinical nutrition (2018) — A median dose of ~10.2 g/day of psyllium significantly reduced LDL cholesterol by 0.33 mmol/L (about 7%) versus placebo in adults, mostly with hypercholesterolemia. [https://pubmed.ncbi.nlm.nih.gov/30239559/]
  - Psyllium fiber improves glycemic control proportional to loss of glycemic control: a meta-analysis of data in euglycemic subjects, patients at risk of type 2 diabetes mellitus, and patients being treated for type 2 diabetes mellitus, The American journal of clinical nutrition (2015) — Pre-meal psyllium dosing lowered fasting blood glucose by ~37 mg/dL and HbA1c by ~0.97% in patients with type 2 diabetes, with benefit proportional to baseline loss of glycemic control. [https://pubmed.ncbi.nlm.nih.gov/26561625/]
  - The effect of psyllium on fasting blood sugar, HbA1c, HOMA IR, and insulin control: a GRADE-assessed systematic review and meta-analysis of randomized controlled trials, BMC endocrine disorders (2024) — Psyllium supplementation significantly reduced HbA1c, fasting blood sugar, insulin, and HOMA-IR compared with control in adults, supporting improved glycemic and insulin sensitivity outcomes. [https://pubmed.ncbi.nlm.nih.gov/38844885/]
  - The use of combination monoclonal antibody therapies in lupus-where are we now?, Rheumatology (Oxford, England) (2023) — Psyllium was the most effective fiber for chronic constipation, increasing stool frequency by about 3 bowel movements per week and improving stool consistency and straining, with doses >10 g/day for >=4 weeks optimal. [https://pubmed.ncbi.nlm.nih.gov/36106990/]
  - Health claims: Soluble fiber from certain foods and risk of coronary heart disease (CHD), U.S. Food and Drug Administration, Department of Health and Human Services (Electronic Code of Federal Regulations, 21 CFR 101.81) — The FDA authorizes a heart-health claim that ~7 g/day of soluble fiber from psyllium husk, as part of a low-saturated-fat, low-cholesterol diet, may reduce the risk of coronary heart disease. [https://www.ecfr.gov/current/title-21/chapter-I/subchapter-B/part-101/subpart-E/section-101.81]

---

## Red Yeast Rice (Monascus purpureus)
URL: https://nutridex.info/s/red-yeast-rice
Category: Heart & Metabolic
Evidence: Moderate — Several controlled trials; effects real but modest or context-dependent.
A natural statin source that lowers LDL cholesterol, but with statin-grade risks and wildly inconsistent dosing.

Quick answer: Red Yeast Rice is used for lowers ldl ('bad') cholesterol, with pooled reductions of roughly 28-36 mg/dl in meta-analyses of randomized trials. NutriDex grades the human evidence as moderate — Several controlled trials; effects real but modest or context-dependent. Based on 12 cited human studies (12 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Red yeast rice is rice fermented with the mold Monascus purpureus, which produces monacolin K, a molecule chemically identical to the prescription statin lovastatin. Through this statin, it reliably lowers LDL cholesterol; meta-analyses of randomized trials report pooled LDL reductions of roughly 28-36 mg/dL, comparable to low-dose statins. The central problem is consistency and safety: independent testing shows monacolin content varies dramatically between products, some contain almost none while others rival a prescription dose, and some lots are contaminated with the nephrotoxic mycotoxin citrinin. Because the active compound is a statin, red yeast rice carries the same potential adverse effects, including muscle injury (myopathy, rarely rhabdomyolysis) and liver injury, although meta-analyses of trials and pharmacovigilance data suggest the absolute risk at low doses is low. The European Food Safety Authority concluded in 2018 and reaffirmed in 2025 that no safe monacolin intake level could be established, even as low as 3 mg/day, leading the EU to restrict these products. In short, it works because it is a statin, and it should be treated with the same caution as one.

Benefits / uses: Lowers LDL ('bad') cholesterol, with pooled reductions of roughly 28-36 mg/dL in meta-analyses of randomized trials; Modestly reduces total cholesterol and triglycerides; Can offer a cholesterol-lowering option for some people who cannot tolerate prescription statins, though it carries the same risks; May produce small reductions in blood pressure in mild dyslipidemia in some trials.
Active compounds: Monacolin K (chemically identical to the prescription statin lovastatin); Other monacolins (monacolins J, L, M and their hydroxy-acid forms); Monascus pigments; Sterols, isoflavones and unsaturated fatty acids; Citrinin (an undesirable nephrotoxic mycotoxin contaminant, not an active ingredient).
Dose: Studied at 200-4,800 mg/day of RYR powder, standardized to monacolin K. The EU caps supplements at under 3 mg total monacolins/day; older U.S. products often supplied ~5-10 mg/day. Monacolin content varies enormously between (and within) products, so the effective dose is unpredictable.
Safety: Because monacolin K IS a statin (lovastatin), red yeast rice carries statin-class risks and should be treated like a prescription drug. Do NOT use if pregnant, breastfeeding, or trying to conceive; if you have active liver disease or unexplained elevated liver enzymes; or if you have a history of statin-related muscle injury. Stop and seek care for unexplained muscle pain, tenderness, weakness, or dark urine (possible myopathy/rhabdomyolysis) and watch for signs of liver injury (fatigue, jaundice, right-upper-abdominal pain). Avoid combining with prescription statins or with drugs that raise statin levels, including strong CYP3A4 inhibitors (certain azole antifungals, macrolide antibiotics, HIV protease inhibitors), fibrates, cyclosporine, and large amounts of grapefruit juice; it may also interact with warfarin and other medications. Product quality is a major hazard: monacolin content varies greatly between brands and some products are contaminated with citrinin, a nephrotoxic mycotoxin. EFSA could not establish any safe dose and the EU restricts these products; the U.S. FDA considers products with substantial lovastatin to be unapproved drugs. Anyone with cardiovascular risk should manage cholesterol under a clinician with monitoring, not self-treat.

Cited studies (12):
  - Associations between the use of red yeast rice preparations and adverse health outcomes: An umbrella review of meta-analyses of randomized controlled trials, Journal of integrative medicine (2024) — A 2024 umbrella review found red yeast rice was generally not associated with liver or muscular adverse events versus control, but rated the credibility of this safety evidence as low and called for higher-quality data. [https://pubmed.ncbi.nlm.nih.gov/38413255/]
  - Safety and Efficacy of the Consumption of the Nutraceutical "Red Yeast Rice Extract" for the Reduction of Hypercholesterolemia in Humans: A Systematic Review and Meta-Analysis, Nutrients (2024) — Pooled analysis of 14 double-blind RCTs (705 hypercholesterolemic participants) found red yeast rice extract reduced LDL-C by 35.82 mg/dL (95% CI -43.36 to -28.29) with no life-threatening or frequent side effects. [https://pmc.ncbi.nlm.nih.gov/articles/PMC11124448/]
  - Red Yeast Rice for Hyperlipidemia: A Meta-Analysis of 15 High-Quality Randomized Controlled Trials, Frontiers in pharmacology (2021) — In a 2022 meta-analysis of 15 high-quality randomized trials, red yeast rice used alone lowered LDL cholesterol by a mean of 28.4 mg/dL (95% CI -37.0 to -19.8) versus control, comparable to low-dose statins. [https://pubmed.ncbi.nlm.nih.gov/35111069/]
  - Red Yeast Rice for Hyperlipidemia: A Meta-Analysis of 15 High-Quality Randomized Controlled Trials, Frontiers in pharmacology (2021) — Meta-analysis of 15 high-quality RCTs (1,012 participants) found red yeast rice lowered LDL-C vs placebo (MD -35.82 mg/dL, 95% CI -43.36 to -28.29) and was non-inferior to statins (MD 1.89, 95% CI -7.93 to 11.71, p=0.71). [https://pmc.ncbi.nlm.nih.gov/articles/PMC8802088/]
  - Scientific Opinion on additional scientific data related to the safety of monacolins from red yeast rice submitted pursuant to Article 8(4) of Regulation (EC) No 1925/2006, EFSA journal. European Food Safety Authority (2025) — EFSA's 2025 opinion reaffirmed it could not establish a safe intake level for monacolins from red yeast rice, concluding that exposure as low as 3 mg/day of monacolin K could cause severe musculoskeletal effects (including rhabdomyolysis) and liver injury. [https://pmc.ncbi.nlm.nih.gov/articles/PMC11868785/]
  - Scientific Opinion on additional scientific data related to the safety of monacolins from red yeast rice submitted pursuant to Article 8(4) of Regulation (EC) No 1925/2006, EFSA journal. European Food Safety Authority (2025) — EFSA concluded that monacolin K from red yeast rice at intakes as low as 3 mg/day could cause severe adverse effects (rhabdomyolysis, liver injury) and that no daily intake of monacolins free of safety concern could be established. [https://pubmed.ncbi.nlm.nih.gov/40027377/]
  - Traditional Chinese lipid-lowering agent red yeast rice results in significant LDL reduction but safety is uncertain - a systematic review and meta-analysis, Atherosclerosis (2015) — Systematic review/meta-analysis of 20 RCTs: RYR lowered LDL-C by 1.02 mmol/L (95% CI -1.20 to -0.83) vs placebo, an effect statistically indistinguishable from statins (difference 0.03 mmol/L); liver/kidney injury incidence 0-5%, not different from controls, though safety assessment quality was low. [https://pubmed.ncbi.nlm.nih.gov/25897793/]
  - Red yeast rice for dyslipidaemias and cardiovascular risk reduction: A position paper of the International Lipid Expert Panel, Pharmacological research (2022) — International Lipid Expert Panel consensus: RYR (active monacolin K, chemically identical to lovastatin) is safe and effective for lowering LDL-C and CV events; recommended particularly in low/moderate CV-risk patients and statin-intolerant patients, with conventional drugs preferred when strongest event evidence is needed. [https://pubmed.ncbi.nlm.nih.gov/35901940/]
  - Scientific opinion on the safety of monacolins in red yeast rice, EFSA journal. European Food Safety Authority (2018) — EFSA's foundational 2018 opinion concluded that monacolins from red yeast rice at doses around 10 mg/day raise the same safety concerns as lovastatin and that no safe level could be identified, prompting EU regulatory restrictions. [https://pmc.ncbi.nlm.nih.gov/articles/PMC7009499/]
  - The Impact of Red Yeast Rice Extract Use on the Occurrence of Muscle Symptoms and Liver Dysfunction: An Update from the Adverse Event Reporting Systems and Available Meta-Analyses, Nutrients (2024) — A 2024 review of adverse-event reporting systems and meta-analyses concluded red yeast rice is unlikely to cause meaningful muscle, liver, or kidney injury at low monacolin doses, while documenting rare reports of myopathy and rhabdomyolysis in spontaneous reporting databases. [https://pmc.ncbi.nlm.nih.gov/articles/PMC10857633/]
  - 2024 update on postmarketing nutrivigilance safety profile: a line of dietary food supplements containing red yeast rice for dyslipidemia, Archives of medical science : AMS (2025) — 2024 postmarketing nutrivigilance analysis of a red yeast rice dietary-supplement line for dyslipidemia reported a low rate of adverse events with no signal for serious hepatic or muscular toxicity. [https://pmc.ncbi.nlm.nih.gov/articles/PMC12305511/]
  - Effect of Xuezhikang, an extract from red yeast Chinese rice, on coronary events in a Chinese population with previous myocardial infarction, The American journal of cardiology (2008) — Landmark double-blind RCT in ~5,000 Chinese post-MI patients: Xuezhikang (partially purified RYR extract) over mean 4.5 yr cut major coronary events from 10.4% to 5.7% (relative reduction 45%), reduced CV and total mortality by 30% and 33%, and lowered LDL-C and triglycerides while raising HDL-C; well tolerated. [https://pubmed.ncbi.nlm.nih.gov/18549841/]

---

## Folate / Folic Acid (Vitamin B9 (pteroylmonoglutamic acid))
URL: https://nutridex.info/s/folate
Category: Vitamin
Evidence: Strong — Multiple high-quality RCTs / meta-analyses with consistent effects.
The pregnancy-essential B vitamin that prevents neural tube defects and lowers homocysteine.

Quick answer: Folate / Folic Acid is used for periconceptional supplementation substantially reduces the risk of neural tube defects (spina bifida, anencephaly) in offspring — the best-established benefit. NutriDex grades the human evidence as strong — Multiple high-quality RCTs / meta-analyses with consistent effects. Based on 13 cited human studies (13 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Folate (vitamin B9) is an essential water-soluble vitamin required for one-carbon metabolism, DNA synthesis, and methylation; "folic acid" is the stable synthetic form used in supplements and food fortification. Its strongest, guideline-endorsed benefit is the prevention of neural tube defects: randomized and observational evidence consistently shows that taking folic acid before and in early pregnancy markedly lowers the risk of spina bifida and anencephaly, and the USPSTF (2023) gives an "A" recommendation that all who could become pregnant take 400-800 mcg daily. Folic acid also reliably lowers blood homocysteine by about 25%, though large cardiovascular outcome trials have not translated this into fewer heart attacks or strokes in most populations. It treats folate-deficiency anemia and is broadly safe within recommended doses. The main cautions are that high folic acid intake can correct the anemia of vitamin B12 deficiency while allowing neurological damage to progress undetected, and a long-debated (but not confirmed in pooled RCT data) concern about promotion of pre-existing colorectal lesions at high doses.

Benefits / uses: Periconceptional supplementation substantially reduces the risk of neural tube defects (spina bifida, anencephaly) in offspring — the best-established benefit; Lowers blood homocysteine by roughly 25% (~3 µmol/L), with the largest effect in people who start with high homocysteine or low folate; Corrects and prevents folate-deficiency (megaloblastic) anemia; Adequate intake supports normal DNA synthesis, cell division, and red-blood-cell formation; Note: despite lowering homocysteine, large trials show folic acid does NOT meaningfully reduce heart attacks or overall cardiovascular mortality in most populations.
Active compounds: Folic acid (synthetic pteroylmonoglutamic acid, the form in supplements/fortified foods); 5-methyltetrahydrofolate (L-methylfolate, the active circulating form); Dietary folates (polyglutamates from leafy greens, legumes, liver); Folinic acid (5-formyltetrahydrofolate / leucovorin).
Dose: 400-800 mcg/day for anyone who could become pregnant (start >=1 month before conception); 4-5 mg/day if prior NTD-affected pregnancy or high risk; general adult RDA ~400 mcg DFE/day. Tolerable upper intake for synthetic folic acid: 1,000 mcg/day.
Safety: Folic acid is generally very safe at recommended doses; the tolerable upper intake level for synthetic folic acid is 1,000 mcg/day in adults (higher therapeutic doses are used under medical supervision, e.g., 4-5 mg for high-risk pregnancy). KEY RISK: high folic acid intake can mask the megaloblastic anemia of vitamin B12 deficiency while allowing irreversible neurological damage to progress — important for older adults, vegans, and people with malabsorption, who should have B12 status checked. A long-debated cancer-promotion signal (potentially accelerating pre-existing colorectal adenomas at high doses) has NOT been confirmed in pooled RCT data but warrants avoiding chronic megadoses without indication. Interactions: methotrexate, anti-epileptics (phenytoin, valproate, carbamazepine), sulfasalazine, trimethoprim, and pyrimethamine are folate antagonists — dosing and timing should be coordinated with a clinician (folate can reduce some chemotherapy/antifolate efficacy). People taking these drugs, those with untreated B12 deficiency, or with a history of folate-sensitive cancers should consult a clinician before supplementing. Rare hypersensitivity reactions can occur.

Cited studies (13):
  - Global heterogeneity in folic acid fortification policies and implications for prevention of neural tube defects and stroke: a systematic review, EClinicalMedicine (2024) — Across 193 countries, mean NTD prevalence per 10,000 was 4.19 with mandatory folic acid fortification vs 7.61 voluntary and 9.66 no fortification; mean plasma folate was 36 vs 21 vs 17 nmol/L respectively. [https://pmc.ncbi.nlm.nih.gov/articles/PMC10758734/]
  - The effect of folic acid intake on congenital anomalies. A systematic review and meta-analysis, Frontiers in Pediatrics (2024) — Systematic review and meta-analysis found folic acid intake substantially reduced the prevalence of congenital anomalies in offspring (OR 0.23; 95% CI 0.16-0.32). [https://www.frontiersin.org/journals/pediatrics/articles/10.3389/fped.2024.1386846/full]
  - The Effect of Maternal Folic Acid Supplementation on Neurodevelopmental Disorders in Offspring: An Umbrella Review of Systematic Reviews and Meta-Analyses, Nutrients (2025) — Umbrella review of systematic reviews/meta-analyses found maternal folic acid supplementation associated with lower offspring risk of autism spectrum disorder (OR 0.66; 95% CI 0.55-0.79), ADHD (OR 0.86; 95% CI 0.78-0.95), and behavioral problems (OR 0.75; 95% CI 0.63-0.91), though included evidence was of mostly low quality. [https://pmc.ncbi.nlm.nih.gov/articles/PMC12608568/]
  - Folic acid supplementation for stroke prevention: A systematic review and meta-analysis of 21 randomized clinical trials worldwide, Clinical nutrition (Edinburgh, Scotland) (2024) — Largest meta-analysis to date (21 RCTs, 115,559 participants): folic acid supplementation reduced stroke risk by 10% overall (RR 0.90, 95% CI 0.83-0.98); benefit concentrated in regions without grain fortification (RR 0.83, 95% CI 0.75-0.93) and in primary prevention (no prior stroke/MI: RR 0.77, 95% CI 0.68-0.86), with no benefit where grain is fortified (RR 1.04). [https://pubmed.ncbi.nlm.nih.gov/38824900/]
  - Folic Acid Supplementation to Prevent Neural Tube Defects: US Preventive Services Task Force Reaffirmation Recommendation Statement, JAMA (2023) — Grade A recommendation: all persons planning or capable of pregnancy should take a daily supplement of 0.4-0.8 mg (400-800 ug) folic acid, starting at least 1 month before conception through the first 2-3 months of pregnancy; high certainty of substantial net benefit for preventing neural tube defects (NTDs). [https://pubmed.ncbi.nlm.nih.gov/37526713/]
  - Effects of folic acid supplementation on overall and site-specific cancer incidence during the randomised trials: meta-analyses of data on 50,000 individuals, Lancet (London, England) (2013) — Individual-participant meta-analysis of 13 RCTs (49,621 participants) at supplemental doses far above fortification: folic acid quadrupled plasma folate but had no significant effect on overall cancer incidence (RR 1.06, 95% CI 0.99-1.13, p=0.10) and no significant effect on colorectal, prostate, lung, or breast cancer; key safety evidence supporting fortification. [https://pubmed.ncbi.nlm.nih.gov/23352552/]
  - Effects and safety of periconceptional oral folate supplementation for preventing birth defects, Cochrane Database of Systematic Reviews (2015) — Periconceptional folate supplementation substantially reduced first-occurrence and recurrence of neural tube defects (pooled RR ~0.31, roughly a 70% reduction) with no increase in miscarriage or other adverse events. [https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD007950.pub3/full]
  - Dose-dependent effects of folic acid on blood concentrations of homocysteine: a meta-analysis of the randomized trials, The American journal of clinical nutrition (2005) — Folic acid supplements lowered plasma homocysteine by about 25% (~3 µmol/L net reduction), with doses >=0.8 mg/day achieving near-maximal effect and combined vitamin B12 adding ~7% further reduction. [https://pubmed.ncbi.nlm.nih.gov/16210710/]
  - Effects of folic acid supplementation on overall and site-specific cancer incidence during the randomised trials: meta-analyses of data on 50 000 individuals (2013) — In the B-Vitamin Treatment Trialists' meta-analysis, folic acid supplementation (median ~5 years) did not significantly increase overall or site-specific cancer incidence, including colorectal cancer (RR ~1.00). [https://www.ncbi.nlm.nih.gov/books/NBK116813/]
  - Folic Acid Supplementation to Prevent Neural Tube Defects: US Preventive Services Task Force Reaffirmation Recommendation Statement, JAMA (2023) — The US Preventive Services Task Force recommends all persons planning or capable of pregnancy take a daily 0.4-0.8 mg (400-800 mcg) folic acid supplement starting >=1 month before conception to prevent neural tube defects. [https://jamanetwork.com/journals/jama/fullarticle/2807739]
  - Efficacy of folic acid therapy in primary prevention of stroke among adults with hypertension in China: the CSPPT randomized clinical trial, JAMA (2015) — Landmark double-blind RCT in 20,702 Chinese hypertensive adults without folate fortification: enalapril plus 0.8 mg folic acid vs enalapril alone reduced first stroke by 21% (2.7% vs 3.4%; HR 0.79, 95% CI 0.68-0.93) and first ischemic stroke (HR 0.76, 95% CI 0.64-0.91) over median 4.5 years. [https://pubmed.ncbi.nlm.nih.gov/25771069/]
  - Folic Acid Supplementation to Prevent Neural Tube Defects: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force, JAMA (2023) — The 2023 USPSTF evidence review found consistent observational and trial evidence that folic acid supplementation reduces neural tube defect risk, with no convincing evidence of supplementation-related harms at recommended doses. [https://pubmed.ncbi.nlm.nih.gov/37526714/]
  - Supplementation with Folic Acid or 5-Methyltetrahydrofolate and Prevention of Neural Tube Defects: An Evidence-Based Narrative Review, Nutrients (2024) — Evidence-based narrative review of folic acid versus 5-methyltetrahydrofolate supplementation for neural tube defect prevention, synthesizing comparative efficacy of the two folate forms. [https://pmc.ncbi.nlm.nih.gov/articles/PMC11435031/]

---

## Selenium
URL: https://nutridex.info/s/selenium
Category: Mineral
Evidence: Mixed — Conflicting results across studies; benefit uncertain.
Essential antioxidant trace mineral with a narrow safe window.

Quick answer: Selenium is used for corrects selenium deficiency and supports the activity of selenoproteins (glutathione peroxidases, thioredoxin reductases) that defend cells against oxidative stress.. NutriDex grades the human evidence as mixed — Conflicting results across studies; benefit uncertain. Based on 11 cited human studies (11 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Selenium is an essential trace mineral incorporated as selenocysteine into selenoproteins such as glutathione peroxidases and thioredoxin reductases, which give it antioxidant activity and a role in thyroid hormone metabolism and immune function. Correcting a genuine deficiency clearly benefits health, and in autoimmune (Hashimoto) thyroiditis, 6 months of supplementation modestly reduces TPO antibodies and TSH, with moderate-certainty evidence but no proven change in long-term disease course. However, supplementing people who are already replete shows little benefit: the large SELECT randomized trial (35,533 men) found selenium did not prevent prostate cancer and produced a non-significant increase in type 2 diabetes risk. A Cochrane review concluded selenium does not prevent cancer and that supplementation increased diabetes risk by roughly 11% in trials. Selenium has an unusually narrow safe range — the gap between the recommended 55 mcg/day and the 400 mcg/day upper limit is small, and chronic excess causes selenosis (hair and nail loss, garlic breath, neurological effects). Overall the evidence is mixed: valuable for deficiency and possibly thyroid autoimmunity, but unhelpful or potentially harmful when status is already adequate.

Benefits / uses: Corrects selenium deficiency and supports the activity of selenoproteins (glutathione peroxidases, thioredoxin reductases) that defend cells against oxidative stress.; In Hashimoto thyroiditis, 6 months of supplementation modestly lowers thyroid peroxidase (TPO) antibodies and TSH, especially in people not on thyroid hormone replacement (moderate-certainty evidence) — though disease-modifying benefit is unproven.; Supports normal immune and thyroid hormone metabolism (deiodinase enzymes are selenoproteins), with the clearest gains seen when baseline status is low.; Does NOT prevent prostate cancer or other cancers in already-replete men, and may carry harm signals (diabetes, possibly aggressive cancer) — benefit appears limited to correcting deficiency, not exceeding requirements..
Active compounds: Selenomethionine (organic form, most common in supplements/yeast); Selenocysteine (the catalytic residue in selenoproteins); Sodium selenite / sodium selenate (inorganic forms); Selenium-enriched yeast.
Dose: RDA 55 mcg/day for adults (60 mcg in pregnancy, 70 mcg lactation); typical supplements provide 50–200 mcg/day. Tolerable Upper Intake Level is 400 mcg/day from all sources. Most replete people in selenium-sufficient regions need no supplement.
Safety: Selenium has a narrow safe range: do not exceed the 400 mcg/day Tolerable Upper Intake Level from all sources (food + supplements), as chronic excess causes selenosis — hair loss, brittle or lost nails, garlic-odor breath, metallic taste, skin rash, GI upset, fatigue, irritability and peripheral neuropathy. Acute overdose (gram-level) can cause severe toxicity including cardiac and respiratory failure. People who are already selenium-replete (most individuals in selenium-rich regions such as much of North America) gain little and may face increased risk of type 2 diabetes and, in some analyses, more aggressive prostate cancer; supplementation is best reserved for documented deficiency or under medical guidance. Brazil nuts are exceptionally selenium-dense (often 50–90+ mcg per nut), so stacking them with supplements can push intake past safe limits. Use caution if you have diabetes or impaired glucose tolerance, and discuss with a clinician if you are pregnant, breastfeeding, on thyroid medication, or taking anticoagulants. Those with adequate dietary intake should generally avoid routine high-dose supplementation.

Cited studies (11):
  - Selenium Supplementation in Patients with Hashimoto Thyroiditis: A Systematic Review and Meta-Analysis of Randomized Clinical Trials, Thyroid : official journal of the American Thyroid Association (2024) — A 2024 systematic review and meta-analysis found selenium supplementation lowered TSH (SMD −0.21) and TPO antibodies in Hashimoto patients not on thyroid hormone replacement, with moderate certainty and no change in fT4/fT3. [https://pubmed.ncbi.nlm.nih.gov/38243784/]
  - Clinical efficacy of selenium supplementation in patients with Hashimoto thyroiditis: A systematic review and meta-analysis, Medicine (2023) — A 2023 meta-analysis reported selenium supplementation for 6 months (but not 3 months) significantly reduced serum TPO and thyroglobulin antibody levels in Hashimoto thyroiditis. [https://pmc.ncbi.nlm.nih.gov/articles/PMC10194801/]
  - Efficacy of selenium on patients undergoing cardiac surgery: a meta-analysis of randomized controlled trials, Journal of cardiothoracic surgery (2024) — In a meta-analysis of 7 RCTs (n=2,276) in cardiac surgery patients, selenium shortened hospital stay (MD -1.33 days, 95% CI -2.51 to -0.16) and reduced CRP (SMD -0.18, 95% CI -0.34 to -0.02) and acute kidney injury (RR 0.76, 95% CI 0.59-0.98), but did not lower mortality (RR 1.07, 95% CI 0.84-1.37). [https://pmc.ncbi.nlm.nih.gov/articles/PMC11040970/]
  - The effects of selenium supplementation on lipid profile in adults: A systematic review and meta-analysis of randomized controlled trials, Prostaglandins & other lipid mediators (2024) — A meta-analysis of 25 RCTs found selenium supplementation reduced VLDL (WMD -1.53, 95% CI -2.86 to -0.20) but produced no significant change in total cholesterol, LDL, HDL, or triglycerides in adults. [https://pubmed.ncbi.nlm.nih.gov/39260819/]
  - Selenium supplementation for management of gestational diabetes mellitus in pregnancy: a systematic review and meta-analysis of randomized controlled trials, BMC Endocrine Disorders (2025) — A 2025 systematic review and meta-analysis of randomized controlled trials evaluated daily 200 mcg selenium for managing gestational diabetes mellitus, assessing effects on glucose and lipid metabolism. [https://bmcendocrdisord.biomedcentral.com/articles/10.1186/s12902-025-02045-5]
  - Role of Supplementation with Selenium and Myo-Inositol Versus Selenium Alone in Patients of Autoimmune Thyroiditis: A Systematic Review and Meta-Analysis, Clinical medicine insights. Endocrinology and diabetes (2024) — Meta-analysis (3 studies, 288 patients) in autoimmune thyroiditis: adding myo-inositol to selenium reduced TSH (SMD -1.15, 95% CI -1.60 to -0.69) and thyroglobulin antibodies (SMD -0.51, 95% CI -0.78 to -0.24) more than selenium alone; TPOAb, T3 and T4 changes were not significant. Suggests combination therapy may outperform selenium monotherapy. [https://pubmed.ncbi.nlm.nih.gov/39650307/]
  - Selenium, antioxidants, cardiovascular disease, and all-cause mortality: a systematic review and meta-analysis of randomized controlled trials, The American journal of clinical nutrition (2020) — Systematic review/meta-analysis of 43 RCTs: selenium alone showed no association with CVD or all-cause mortality, but antioxidant mixtures containing selenium reduced CVD mortality (RR 0.77, 95% CI 0.62-0.97) and all-cause mortality (RR 0.90, 95% CI 0.82-0.98), whereas antioxidant mixtures WITHOUT selenium increased all-cause mortality (RR 1.09). [https://pubmed.ncbi.nlm.nih.gov/33053149/]
  - Selenium for preventing cancer, The Cochrane database of systematic reviews (2018) — A Cochrane review concluded there is no convincing evidence selenium prevents cancer, and that supplementation increased the risk of type 2 diabetes (RR 1.11, 95% CI 1.01–1.22) in randomized trials. [https://pubmed.ncbi.nlm.nih.gov/29376219/]
  - Selenium - Health Professional Fact Sheet, NIH Office of Dietary Supplements — NIH Office of Dietary Supplements sets the adult RDA at 55 mcg/day and the Tolerable Upper Intake Level at 400 mcg/day, with chronic excess causing selenosis (hair/nail loss, garlic breath, GI and neurological effects). [https://ods.od.nih.gov/factsheets/Selenium-HealthProfessional/]
  - Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT), JAMA (2009) — In the SELECT RCT, selenium (200 mcg/day) did not prevent prostate cancer (HR 1.04, 99% CI 0.87–1.24) and showed a non-significant increase in type 2 diabetes (RR 1.07, 99% CI 0.94–1.22) in relatively replete men. [https://pubmed.ncbi.nlm.nih.gov/19066370/]
  - Effects of long-term selenium supplementation on the incidence of type 2 diabetes: a randomized trial, Annals of internal medicine (2007) — Randomized trial (n=1202, mean 7.7 y) found selenium 200 mcg/d increased incidence of type 2 diabetes vs placebo (HR 1.55, 95% CI 1.03-2.33), with a dose-response: highest baseline plasma selenium tertile HR 2.70 (95% CI 1.30-5.61). Supplementation does not prevent and may cause diabetes. [https://pubmed.ncbi.nlm.nih.gov/17620655/]

---

## Hawthorn (Crataegus spp. (C. monogyna, C. laevigata))
URL: https://nutridex.info/s/hawthorn
Category: Heart & Metabolic
Evidence: Moderate — Several controlled trials; effects real but modest or context-dependent.
Traditional cardiac tonic with real but modest add-on benefits in mild heart failure.

Quick answer: Hawthorn is used for improves symptoms of mild-to-moderate (nyha ii-iii) chronic heart failure such as exertional dyspnea and fatigue when added to standard therapy. NutriDex grades the human evidence as moderate — Several controlled trials; effects real but modest or context-dependent. Based on 10 cited human studies (10 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Hawthorn (Crataegus spp.) is a long-used botanical whose standardized leaf-and-flower extracts have been studied as an add-on to conventional therapy for chronic heart failure. A 2008 Cochrane systematic review of 14 randomized placebo-controlled trials found that hawthorn extract improved heart-failure symptoms and objective measures such as maximal workload and the pressure-rate product. However, the large multinational SPICE trial (2,681 patients) found no significant effect on cardiac mortality or the combined cardiac event endpoint, so any benefit appears to be symptomatic rather than life-prolonging. Active constituents are thought to be oligomeric procyanidins and flavonoids, which exert mild positive inotropic, vasodilatory and antioxidant effects. Hawthorn is generally well tolerated, with infrequent, mild adverse events, but it can interact with cardiac drugs (notably digoxin) and should never replace evidence-based heart-failure pharmacotherapy. It is best viewed as an optional, physician-supervised adjunct of modest benefit.

Benefits / uses: Improves symptoms of mild-to-moderate (NYHA II-III) chronic heart failure such as exertional dyspnea and fatigue when added to standard therapy; Modestly increases exercise/work tolerance (roughly +5-7 watts on bicycle ergometry in pooled trials); Lowers the pressure-rate product, indicating reduced cardiac oxygen demand; May modestly reduce blood pressure in some populations (weaker, less consistent evidence); Does NOT improve survival or reduce cardiac mortality in heart failure (large SPICE trial showed no significant benefit).
Active compounds: Oligomeric procyanidins (condensed flavan-3-ol polymers); Flavonoids (vitexin, hyperoside, rutin, quercetin); Standardized extracts WS 1442 and LI 132 (leaf-and-flower extracts standardized to procyanidins/flavonoids).
Dose: Standardized leaf-and-flower extract (e.g., WS 1442) 600-1800 mg/day in 2-3 divided doses, standardized to ~18.75% oligomeric procyanidins or ~2.2% flavonoids; benefits typically emerge over 6-12 weeks. Use only under medical supervision in diagnosed heart failure.
Safety: Generally well tolerated; the most common adverse effects are mild and transient (dizziness, nausea, GI upset, headache, palpitations). Because hawthorn has cardiovascular activity, it can interact additively with cardiac medications: it may potentiate digoxin and other cardiac glycosides, and may augment the effects of antihypertensives, nitrates, beta-blockers, calcium-channel blockers and PDE5 inhibitors, increasing risk of hypotension. Hawthorn can also interfere with some digoxin immunoassay measurements. It must NOT be used as a substitute for proven heart-failure therapy, and anyone with heart failure, arrhythmia, or cardiovascular disease should only use it under cardiologist supervision. Avoid in pregnancy and breastfeeding (insufficient safety data and theoretical uterine effects), and stop before surgery due to potential blood-pressure and cardiac effects. People on any cardiac, blood-pressure, or anticoagulant/antiplatelet medication should consult a clinician before use.

Cited studies (10):
  - Hawthorn (Crataegus spp.) Clinically Significantly Reduces Blood Pressure in Hypertension: A Meta-Analysis of Randomized Placebo-Controlled Clinical Trials, Pharmaceuticals (Basel, Switzerland) (2025) — Meta-analysis of 6 RCTs (n=428) found hawthorn reduced systolic blood pressure (pooled MD approximately -6.65 mmHg) in hypertensive patients, with a non-significant diastolic reduction. [https://pubmed.ncbi.nlm.nih.gov/40732315/]
  - Hawthorn extract for treating chronic heart failure, The Cochrane database of systematic reviews (2008) — In a 2008 Cochrane review, hawthorn extract added to standard therapy improved maximal workload (weighted mean difference +5-7 watts) and pressure-rate product and reduced dyspnea and fatigue versus placebo in chronic heart failure. [https://pubmed.ncbi.nlm.nih.gov/18254076/]
  - Diet and lifestyle intervention on chronic moderate to severe depression and anxiety and other chronic conditions, Complementary Therapies in Clinical Practice (2017) — A systematic review of hawthorn for blood pressure found inconsistent and generally small effects, indicating evidence for an antihypertensive benefit is limited and not robust. [https://doi.org/10.1016/j.ctcp.2017.09.007]
  - Hawthorn extract for treating chronic heart failure: meta-analysis of randomized trials, The American journal of medicine (2003) — Meta-analysis of 13 RCTs (8 trials, 632 patients pooled) of hawthorn extract monopreparations in chronic heart failure showed greater maximal workload vs placebo (weighted mean difference +7 W, 95% CI 3-11, p<0.01), beneficial decrease in pressure-heart rate product (-20, 95% CI -32 to -8), and significant improvement in dyspnea and fatigue; adverse events infrequent, mild, transient. [https://pubmed.ncbi.nlm.nih.gov/12798455/]
  - Adverse-event profile of Crataegus spp.: a systematic review, Drug safety (2006) — Systematic review of adverse-event profile across 24 clinical studies (5577 patients analyzed; doses 160-1800 mg/day, 3-24 weeks) found hawthorn monopreparations generally well tolerated; 166 adverse events, mostly mild-to-moderate (dizziness/vertigo, GI complaints, headache, palpitations); no drug interactions reported, though 8 severe events occurred with the LI 132 extract. [https://pubmed.ncbi.nlm.nih.gov/16752934/]
  - Hawthorn: Usefulness and Safety, NIH National Center for Complementary and Integrative Health (2025) — NIH/NCCIH evidence summary states hawthorn's effectiveness for heart failure is not established and warns of potential interactions with cardiovascular drugs such as digoxin. [https://www.nccih.nih.gov/health/hawthorn]
  - Analysis of Adverse Reactions Associated with the Use of Crataegus-Containing Herbal Products, Pharmaceuticals (Basel, Switzerland) (2024) — Pharmacovigilance analysis of 1,527 VigiBase reports (1970-2023) found serious adverse reactions in ~12.6% of single-herb Crataegus cases, mainly GI, skin, and cardiac (palpitations, dizziness) events. [https://pmc.ncbi.nlm.nih.gov/articles/PMC11597351/]
  - The efficacy and safety of Crataegus extract WS 1442 in patients with heart failure: the SPICE trial, European journal of heart failure (2008) — The SPICE randomized trial found Crataegus extract WS 1442 900 mg/day did not significantly reduce the primary cardiac event endpoint or cardiac mortality over ~2 years, though it was safe alongside guideline heart-failure medication. [https://pubmed.ncbi.nlm.nih.gov/19019730/]
  - Benefit-Risk Assessment of Crataegus Extract WS 1442: An Evidence-Based Review, American Journal of Cardiovascular Drugs (2017) — An evidence-based benefit-risk assessment concluded WS 1442 has a favorable safety profile and symptomatic benefit as adjunctive therapy in mild-to-moderate heart failure but no demonstrated mortality benefit. [https://doi.org/10.1007/s40256-017-0249-9]
  - Interaction study between digoxin and a preparation of hawthorn (Crataegus oxyacantha), Journal of clinical pharmacology (2003) — Concomitant hawthorn (Crataegus oxyacantha) did not significantly alter digoxin pharmacokinetics over 3 weeks, but additive cardiac effects mean coadministration still warrants clinical caution. [https://pubmed.ncbi.nlm.nih.gov/12817526/]

---

## Saw Palmetto (Serenoa repens)
URL: https://nutridex.info/s/saw-palmetto
Category: Performance
Evidence: Mixed — Conflicting results across studies; benefit uncertain.
Popular prostate herb that rigorous trials found no better than placebo.

Quick answer: Saw Palmetto is used for marketed to ease lower urinary tract symptoms (luts) of benign prostatic hyperplasia (bph), such as weak stream, frequency, and nighttime urination — but the best evidence shows little to no benefit over placebo.. NutriDex grades the human evidence as mixed — Conflicting results across studies; benefit uncertain. Based on 13 cited human studies (13 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Saw palmetto (Serenoa repens) is an extract of the dwarf palm berry widely sold for benign prostatic hyperplasia and lower urinary tract symptoms, and more recently for hair loss. Although early, mostly small and lower-quality trials reported symptom improvement, larger and more rigorous studies did not confirm a benefit. The NIH-funded CAMUS randomized trial found that even at up to triple the standard dose (960 mg/day), saw palmetto was no better than placebo for urinary symptoms. The 2024 updated Cochrane review of 27 trials (4,656 men) concluded with high-certainty evidence that it produces little to no difference in urologic symptoms or quality of life. The evidence is best characterized as mixed: a positive early literature offset by robust modern trials showing no meaningful effect. Its main redeeming feature is a strong safety record, with adverse events comparable to placebo.

Benefits / uses: Marketed to ease lower urinary tract symptoms (LUTS) of benign prostatic hyperplasia (BPH), such as weak stream, frequency, and nighttime urination — but the best evidence shows little to no benefit over placebo.; Early small/lower-quality trials suggested symptom relief; these positive signals did not hold up in larger, well-blinded, placebo-controlled studies.; Sometimes used for male-pattern hair loss based on weak 5-alpha-reductase inhibition; human evidence here is preliminary and far weaker than for finasteride/dutasteride.; A consistent finding across trials is that it is well tolerated, with a side-effect profile similar to placebo — so its main 'benefit' is safety, not efficacy..
Active compounds: Free fatty acids (lauric, oleic, myristic, palmitic, linoleic acids); Phytosterols including beta-sitosterol; Fatty acid esters and ethyl esters; Lipophilic berry extract standardized to ~85-95% fatty acids and sterols.
Dose: 320 mg/day of a lipophilic berry extract standardized to 85-95% fatty acids and sterols, taken as 320 mg once daily or 160 mg twice daily (the dose used in most trials; higher doses up to 960 mg/day showed no added benefit).
Safety: Generally well tolerated; in trials adverse events (mild GI upset, headache, occasional decreased libido) occur at rates similar to placebo, with no signal of organ toxicity even at 960 mg/day. Because it has mild antiplatelet/anticoagulant potential, use cautiously with warfarin, clopidogrel, aspirin, or other blood thinners and stop 1-2 weeks before surgery; rare reports of bleeding and of liver or pancreas injury exist. It may have weak hormonal (anti-androgen/5-alpha-reductase) activity, so it can theoretically lower serum DHT and is contraindicated in pregnancy and breastfeeding and should be avoided by women who are or may become pregnant. It can modestly affect PSA interpretation in some contexts, so men should tell their clinician they take it before prostate cancer screening. Saw palmetto does not shrink the prostate or treat the underlying disease, so it should not replace evaluation of urinary symptoms or proven therapies (alpha-blockers, 5-alpha-reductase inhibitors); men with new, severe, or worsening LUTS, blood in the urine, or retention need medical assessment rather than self-treatment.

Cited studies (13):
  - Serenoa repens for the Treatment of Lower Urinary Tract Symptoms Due to Benign Prostatic Enlargement: An Updated Cochrane Review, The world journal of men's health (2024) — This 2024 updated Cochrane review found high-certainty evidence that Serenoa repens results in little to no difference in urologic symptoms (IPSS mean difference -0.90 points) or quality of life versus placebo in men with BPH-related LUTS. [https://pubmed.ncbi.nlm.nih.gov/38164033/]
  - Serenoa repens for the treatment of lower urinary tract symptoms due to benign prostatic enlargement, The Cochrane database of systematic reviews (2023) — In 27 RCTs (n=4,656), Serenoa repens produced little to no difference in urologic symptoms at 3-6 months (IPSS mean difference -0.90, 95% CI -1.74 to -0.07; high certainty). [https://pubmed.ncbi.nlm.nih.gov/37345871/]
  - Serenoa repens for the Treatment of Lower Urinary Tract Symptoms Due to Benign Prostatic Enlargement: An Updated Cochrane Review, The world journal of men's health (2024) — Updated Cochrane review found saw palmetto gives little to no quality-of-life benefit (MD -0.20, 95% CI -0.40 to 0.00) and no difference in adverse events vs placebo (RR 1.01, 95% CI 0.77-1.31). [https://pmc.ncbi.nlm.nih.gov/articles/PMC11216968/]
  - Saw Palmetto for the Treatment of Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia, American Family Physician (2024) — AAFP clinician synopsis of the 2023 Cochrane review states saw palmetto, alone or combined with other phytotherapeutics, does not improve urologic symptoms or quality of life at short- or long-term follow-up. [https://www.aafp.org/pubs/afp/issues/2024/0500/cochrane-saw-palmetto-benign-prostatic-hyperplasia.html]
  - Serenoa repens for the treatment of lower urinary tract symptoms due to benign prostatic enlargement: A systematic review and meta-analysis, Investigative and clinical urology (2021) — Independent GRADE systematic review and meta-analysis of 27 RCTs (4853 participants). Serenoa repens alone results in little to no difference in urinary symptom score, quality of life, and adverse events at short- and long-term follow-up; combination phytotherapy effects very uncertain. [https://pubmed.ncbi.nlm.nih.gov/34488251/]
  - Clinical Efficacy of Serenoa repens Versus Placebo Versus Alpha-blockers for the Treatment of Lower Urinary Tract Symptoms/Benign Prostatic Enlargement: A Systematic Review and Network Meta-analysis of Randomized Placebo-controlled Clinical Trials, European urology focus (2021) — Network meta-analysis of 22 RCTs (8564 patients) comparing hexanic/non-hexanic Serenoa repens, placebo and alpha-blockers. Saw palmetto showed no clinically meaningful improvement in IPSS or peak flow; SUCRA ranks (HESr 36.7%, nHESr 47.3%) trailed alpha-blockers (terazosin 99.6%), with benefit over placebo minimal. [https://pubmed.ncbi.nlm.nih.gov/31952967/]
  - Serenoa repens for benign prostatic hyperplasia, The Cochrane database of systematic reviews (2009) — The 2012 Cochrane review concluded that saw palmetto, alone or combined with other phytotherapeutic agents, did not improve urinary symptoms, peak urine flow, or prostate size compared with placebo. [https://pmc.ncbi.nlm.nih.gov/articles/PMC3090655/]
  - Spotlight on Saw Palmetto: What the Science Says, NIH National Center for Complementary and Integrative Health — NCCIH's provider summary states that high-quality research does not support a benefit of saw palmetto for BPH symptoms, while noting it is generally well tolerated. [https://www.nccih.nih.gov/health/providers/digest/spotlight-on-saw-palmetto-science]
  - Saw Palmetto: Usefulness and Safety, NIH National Center for Complementary and Integrative Health (2025) — NCCIH concludes saw palmetto is probably not helpful for BPH symptoms but is well tolerated, with mild infrequent adverse effects and no apparent effect on PSA levels. [https://www.nccih.nih.gov/health/saw-palmetto]
  - Effect of increasing doses of saw palmetto extract on lower urinary tract symptoms: a randomized trial, JAMA (2011) — In this NIH-funded double-blind RCT (CAMUS, JAMA), escalating doses of saw palmetto up to 960 mg/day for 72 weeks did not reduce lower urinary tract symptoms more than placebo (change favored placebo by ~0.8 AUASI points). [https://pubmed.ncbi.nlm.nih.gov/21954478/]
  - Safety and toxicity of saw palmetto in the CAMUS trial, The Journal of urology (2013) — This safety analysis of the CAMUS trial found saw palmetto at doses up to 960 mg/day produced no evidence of toxicity, with adverse-event rates similar to placebo over 72 weeks. [https://pubmed.ncbi.nlm.nih.gov/23063633/]
  - The Safety and Efficacy of a Proprietary Bioactive Fatty Acids Extract From Saw Palmetto (Serenoa repens) for Promoting Hair Growth and Reducing Hair Loss in Adults With Self-Perceived Thinning Hair: 90-Day Results, Journal of cosmetic dermatology (2025) — Randomized, double-blind, placebo-controlled trial (n=60) of a 160 mg saw palmetto fatty-acid extract found greater terminal hair count gains vs placebo at day 90 (anterior +11.3 hairs, p<0.001) with no adverse events. [https://pmc.ncbi.nlm.nih.gov/articles/PMC12665258/]
  - Saw palmetto for benign prostatic hyperplasia, The New England journal of medicine (2006) — Landmark NIH double-blind RCT, 225 men, saw palmetto 160 mg twice daily vs placebo for 1 year. No significant difference in AUASI (mean difference 0.04 point, 95% CI -0.93 to 1.01), maximal urinary flow, prostate size, residual volume, quality of life, or PSA; side effects similar. [https://pubmed.ncbi.nlm.nih.gov/16467543/]

---

## Echinacea (Echinacea purpurea, E. angustifolia, E. pallida)
URL: https://nutridex.info/s/echinacea
Category: Gut & Immune
Evidence: Mixed — Conflicting results across studies; benefit uncertain.
Popular cold remedy with genuinely conflicting evidence

Quick answer: Echinacea is used for may modestly shorten or ease common-cold symptoms with some preparations, though effects are small and inconsistent. NutriDex grades the human evidence as mixed — Conflicting results across studies; benefit uncertain. Based on 11 cited human studies (11 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Echinacea is a genus of North American coneflowers (most commonly E. purpurea) widely marketed to prevent and treat the common cold and other respiratory infections. The evidence is genuinely mixed: the authoritative 2014 Cochrane review found no significant benefit for prevention and only weak, inconsistent signals for treatment, while several more recent meta-analyses report reductions in infection recurrence and antibiotic use. Much of the favorable recent data comes from analyses funded by or affiliated with manufacturers, and a major obstacle across all studies is the extreme variability between products in species, plant part, extraction method, and active-compound content, which makes results hard to generalize. Any clinical benefit, if real, appears small and preparation-specific rather than a class effect. Echinacea is generally well tolerated for short-term use in adults, but it is not a proven cold preventive and should not replace established care.

Benefits / uses: May modestly shorten or ease common-cold symptoms with some preparations, though effects are small and inconsistent; Some meta-analyses suggest reduced incidence of recurrent respiratory infections and lower antibiotic use, but these are largely industry-linked; Possible reduction in cold/respiratory-infection complications such as otitis media in children (preliminary); Generally well tolerated short-term in adults; No reliable evidence it prevents colds in the general population.
Active compounds: Alkamides (alkylamides); Caffeic acid derivatives (cichoric acid, echinacoside, cynarin); Polysaccharides and glycoproteins; Flavonoids; Polyacetylenes and essential oils.
Dose: No standardized dose; trials commonly use 300–500 mg dried extract or 2.5 mL liquid tincture 2–3x daily, or pressed juice of E. purpurea aerial parts, started at first cold symptoms and continued up to ~10 days. Potency varies enormously between products.
Safety: Generally well tolerated for short-term use in adults; most common effects are mild gastrointestinal upset, rash, or unpleasant taste. Allergic reactions can occur and may be serious, especially in people allergic to plants in the Asteraceae/daisy family (ragweed, marigolds, chrysanthemums); rare cases of anaphylaxis, asthma, and angioedema have been reported, so people with atopy or asthma should use caution. Because echinacea stimulates immune activity, it is traditionally avoided in autoimmune diseases (e.g., lupus, rheumatoid arthritis, MS) and in people taking immunosuppressants (e.g., transplant recipients, those on biologics). It may inhibit/induce CYP450 enzymes (notably CYP3A4 and CYP1A2), so it can interact with drugs metabolized by these pathways; caution with narrow-therapeutic-index medications. Safety in pregnancy and breastfeeding is not established, so avoidance is prudent. The 2025 pediatric meta-analysis noted increased adverse events in children and an unclear safety profile, so use in young children should be supervised. Product quality and potency vary widely, and it should not delay or replace evidence-based medical care for significant infections.

Cited studies (11):
  - Echinacea Reduces Antibiotics by Preventing Respiratory Infections: A Meta-Analysis (ERA-PRIMA), Antibiotics (Basel, Switzerland) (2024) — Meta-analysis of 30 trials (39 comparisons, 5,652 subjects) found Echinacea reduced monthly RTI occurrence (RR 0.68, 95% CI 0.61-0.77) and proportion with >=1 RTI (RR 0.75, 95% CI 0.69-0.81), cut recurrent infections (RR 0.60), RTI complications (RR 0.44, 95% CI 0.36-0.54), and need for antibiotics (RR 0.60), with total antibiotic days reduced ~70% (IRR 0.29); alcoholic extracts of freshly harvested E. purpurea were strongest (80% reduction in antibiotic days). Adverse events equal to control. [https://pubmed.ncbi.nlm.nih.gov/38667040/]
  - Interventions for preventing influenza: An overview of Cochrane systematic reviews and a Bayesian network meta-analysis, Journal of integrative medicine (2021) — Overview of 11 Cochrane systematic reviews with Bayesian network meta-analysis of influenza-prevention interventions classified Echinacea as 'probably beneficial' for reducing influenza incidence (alongside oseltamivir, zanamivir, and Ganmao capsule), while garlic and vaccines showed high-quality benefit; no intervention reduced hospitalization. [https://pubmed.ncbi.nlm.nih.gov/34544670/]
  - Echinacea for preventing and treating the common cold, The Cochrane database of systematic reviews (2014) — Echinacea showed no statistically significant reduction in the number of people catching a cold and only weak, inconsistent treatment effects, with the authors concluding any benefit is small at best. [https://pubmed.ncbi.nlm.nih.gov/24554461/]
  - Echinacea Reduces Antibiotics by Preventing Respiratory Infections: A Meta-Analysis (ERA-PRIMA), Antibiotics (Basel, Switzerland) (2024) — Echinacea was associated with a 32% lower monthly respiratory-infection occurrence (RR 0.68, 95% CI 0.61–0.77) and reduced antibiotic need (RR 0.60, 95% CI 0.39–0.93), though the study was part-funded by a manufacturer (A.Vogel). [https://pmc.ncbi.nlm.nih.gov/articles/PMC11047471/]
  - Efficacy and safety of Echinacea purpurea in treating upper respiratory infections and complications of otitis media in children: Systematic review and meta-analysis, Clinical nutrition ESPEN (2025) — In children, E. purpurea was associated with lower URTI incidence (RR 0.81, 95% CI 0.75–0.87) and fewer otitis media episodes (RR 0.56, 95% CI 0.44–0.73), but adverse events were more frequent (RR 1.38, 95% CI 1.08–1.78) and the safety profile was deemed unclear. [https://pubmed.ncbi.nlm.nih.gov/40311928/]
  - Evaluation of echinacea for the prevention and treatment of the common cold: a meta-analysis, The Lancet. Infectious diseases (2007) — Meta-analysis of 14 studies found Echinacea decreased the odds of developing the common cold by 58% (OR 0.42, 95% CI 0.25-0.71) and reduced cold duration by 1.4 days (95% CI -2.2 to -0.6) versus placebo. [https://pubmed.ncbi.nlm.nih.gov/17597571/]
  - Novel Echinacea formulations for the treatment of acute respiratory tract infections in adults—A randomized blinded controlled trial, Frontiers in Medicine (2023) — In an RCT of 409 adults (246 treated for RTI), higher-dose Echinacea formulations shortened mean time to remission (9.6 vs 11.0 days, p<0.001) and increased PCR-confirmed viral clearance by day 10 (70% vs 53%, p=0.046) versus conventional preventive doses. [https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2023.948787/full]
  - Novel Echinacea formulations for the treatment of acute respiratory tract infections in adults-A randomized blinded controlled trial, Frontiers in medicine (2023) — Randomized blinded controlled trial in 409 healthy adults comparing high-dose novel Echinacea purpurea formulations (up to 16,800 mg/day extract days 1-3) versus conventional dosing for acute respiratory tract infection treatment. [https://pmc.ncbi.nlm.nih.gov/articles/PMC10150997/]
  - Echinacea reduces antibiotic usage in children through respiratory tract infection prevention: a randomized, blinded, controlled clinical trial, European journal of medical research (2021) — In children aged 4-12, Echinacea purpurea prevented 32.5% of respiratory tract infection episodes versus vitamin C (OR 0.52) and reduced antibiotic need (5.8% vs 15.3% of children). [https://pmc.ncbi.nlm.nih.gov/articles/PMC8028575/]
  - Safety and Efficacy Profile of Echinacea purpurea to Prevent Common Cold Episodes: A Randomized, Double-Blind, Placebo-Controlled Trial, Evidence-based complementary and alternative medicine : eCAM (2012) — 4-month randomized, double-blind, placebo-controlled trial (n=755) of E. purpurea extract (Echinaforce) for cold prevention: reduced total cold episodes, cumulated cold days (149 vs 293 days for placebo), and pain-killer-medicated episodes; significantly inhibited virally confirmed colds, especially enveloped-virus and recurrent infections, with good safety/tolerability. [https://pubmed.ncbi.nlm.nih.gov/23024696/]
  - Critical analysis of Echinacea preparations marketed in Germany, Naunyn-Schmiedeberg's archives of pharmacology (2025) — Analysis found wide variation and frequent shortfalls in declared active-compound content across commercial Echinacea products, underscoring why clinical results are inconsistent and not transferable between preparations. [https://pmc.ncbi.nlm.nih.gov/articles/PMC11985562/]

---

## Elderberry (Sambucus) (Sambucus nigra)
URL: https://nutridex.info/s/elderberry
Category: Gut & Immune
Evidence: Preliminary — Early or small human trials; promising but not yet conclusive.
A traditional cold and flu remedy with mixed, low-certainty evidence for modestly shorter symptoms.

Quick answer: Elderberry (Sambucus) is used for may modestly shorten the duration of upper respiratory symptoms (cold/flu) by roughly 1-4 days in some small trials, though the most rigorous trial found no benefit. NutriDex grades the human evidence as preliminary — Early or small human trials; promising but not yet conclusive. Based on 9 cited human studies (9 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Black elderberry (Sambucus nigra) is a long-used folk remedy for colds and influenza, and its dark berries are rich in anthocyanins with antiviral activity in laboratory studies. A 2019 meta-analysis of four small RCTs (180 participants) reported a substantial reduction in upper respiratory symptoms, and a 2016 air-travellers trial found shorter, less severe colds with supplementation. However, a 2021 systematic review of five RCTs (~624 participants) rated the evidence as very low certainty, and the largest, most rigorous trial (2020, 87 influenza patients) found no benefit and a possible signal of prolonged symptoms when used alone. Overall the human evidence is preliminary and mixed: any benefit on symptom duration appears modest at best and is not firmly established. Critically, raw or unripe berries, leaves, stems, and bark contain cyanogenic glycosides that can cause cyanide-type poisoning, so only properly cooked/commercial preparations should be consumed.

Benefits / uses: May modestly shorten the duration of upper respiratory symptoms (cold/flu) by roughly 1-4 days in some small trials, though the most rigorous trial found no benefit; May reduce cold symptom severity in some studies, particularly when started early; Anthocyanin-rich extracts show antiviral and immunomodulatory activity in lab (in vitro) studies, but this does not reliably translate to clinical outcomes; Theoretical claims of immune 'overstimulation' or triggering a cytokine storm are unproven and based on a single in vitro study.
Active compounds: Anthocyanins (cyanidin-3-glucoside, cyanidin-3-sambubioside); Flavonols (quercetin, rutin, kaempferol); Phenolic acids (chlorogenic acid); Cyanogenic glycosides (sambunigrin, prunasin) — toxic, present mainly in raw/unripe fruit, leaves, bark.
Dose: Standardized black elderberry extract/syrup roughly 600-900 mg/day (or ~15 mL syrup up to 4x/day) at onset of cold/flu symptoms, for up to ~5-10 days; use only commercially prepared/cooked products, never raw berries.
Safety: Never eat raw or unripe elderberries, and avoid the leaves, stems, bark, and roots: they contain cyanogenic glycosides (sambunigrin, prunasin) that release cyanide and can cause nausea, vomiting, abdominal cramps, weakness, and, in larger amounts, dizziness, seizures, or death. Cooking/commercial processing largely degrades these toxins, so use only properly prepared syrups, extracts, or lozenges. Long-term safety data are limited; commercial extracts are generally well tolerated short-term, with occasional mild GI upset. Caution is advised in people who are immunosuppressed or on immunosuppressant/immune-modulating drugs and in autoimmune disease, since elderberry stimulates immune activity (a theoretical 'cytokine' concern that remains unproven). Use during acute, severe illness or COVID-19 is not supported as a treatment. Avoid in pregnancy and breastfeeding due to insufficient safety data, and use cautiously in young children. People with diabetes or on diuretics should be aware of possible additive effects; consult a clinician before combining with prescription antivirals or other medications.

Cited studies (9):
  - Elderberry for prevention and treatment of viral respiratory illnesses: a systematic review, BMC complementary medicine and therapies (2021) — Systematic review of 5 RCTs found elderberry may reduce viral respiratory illness duration/severity with no evidence of immune overstimulation, but rated the evidence on both benefits and harms as uncertain (low certainty). [https://pmc.ncbi.nlm.nih.gov/articles/PMC8026097/]
  - Black elderberry (Sambucus nigra) supplementation effectively treats upper respiratory symptoms: A meta-analysis of randomized, controlled clinical trials, Complementary therapies in medicine (2019) — This meta-analysis of randomized trials found elderberry supplementation substantially reduced upper respiratory symptoms (large pooled effect size) in cold and flu, though all included trials were small. [https://pubmed.ncbi.nlm.nih.gov/30670267/]
  - Elderberry for prevention and treatment of viral respiratory illnesses: a systematic review, BMC complementary medicine and therapies (2021) — This systematic review concluded elderberry may shorten cold duration by ~2 days and flu recovery by ~3 days, but rated the evidence very low certainty and the benefit-harm balance as uncertain. [https://pubmed.ncbi.nlm.nih.gov/33827515/]
  - A One-Week Elderberry Juice Intervention Augments the Fecal Microbiota and Suggests Improvement in Glucose Tolerance and Fat Oxidation in a Randomized Controlled Trial, Nutrients (2024) — Randomized placebo-controlled crossover trial (n=18 overweight adults, 1-week twice-daily elderberry juice) augmented fecal microbiota and reduced post-OGTT glucose excursion by ~24% with increased fat oxidation. [https://pmc.ncbi.nlm.nih.gov/articles/PMC11510622/]
  - Elderberry Extract Outpatient Influenza Treatment for Emergency Room Patients Ages 5 and Above: a Randomized, Double-Blind, Placebo-Controlled Trial, Journal of general internal medicine (2020) — FDA-approved double-blind placebo-controlled ER trial (n=87, ages 5+, lab-confirmed influenza) found elderberry did not shorten influenza duration or severity and may have prolonged time to symptom alleviation unless combined with oseltamivir. [https://pmc.ncbi.nlm.nih.gov/articles/PMC7661609/]
  - Elderberry Extract Outpatient Influenza Treatment for Emergency Room Patients Ages 5 and Above: a Randomized, Double-Blind, Placebo-Controlled Trial, Journal of general internal medicine (2020) — In this FDA-approved double-blind RCT of PCR-confirmed influenza patients in the ER, elderberry extract showed no benefit on symptom duration or severity and a post hoc signal of ~2 days worse symptoms when taken alone versus placebo. [https://pubmed.ncbi.nlm.nih.gov/32929634/]
  - Elderberry Supplementation Reduces Cold Duration and Symptoms in Air-Travellers: A Randomized, Double-Blind Placebo-Controlled Clinical Trial, Nutrients (2016) — In this double-blind RCT of long-haul air travellers, elderberry extract reduced total cold duration (57 vs 117 days across the placebo group) and symptom severity compared with placebo. [https://pubmed.ncbi.nlm.nih.gov/27023596/]
  - Randomized study of the efficacy and safety of oral elderberry extract in the treatment of influenza A and B virus infections, The Journal of international medical research (2004) — Randomized, double-blind, placebo-controlled trial (n=60) in influenza A/B: elderberry extract (Sambucol) relieved symptoms on average ~4 days earlier and reduced rescue-medication use compared with placebo. [https://pubmed.ncbi.nlm.nih.gov/15080016/]
  - Bioactive properties of Sambucus nigra L. as a functional ingredient for food and pharmaceutical industry, Journal of functional foods (2018) — This review of Sambucus nigra bioactives notes anthocyanin/phenolic antiviral activity but cautions that all plant parts contain cyanogenic glycosides (sambunigrin) that release toxic hydrogen cyanide and are reduced by heat processing. [https://pmc.ncbi.nlm.nih.gov/articles/PMC7185606/]

---

## Turkey Tail (PSK/PSP) (Trametes versicolor)
URL: https://nutridex.info/s/turkey-tail
Category: Gut & Immune, Longevity
Evidence: Preliminary — Early or small human trials; promising but not yet conclusive.
Immune-modulating mushroom polysaccharides used as a chemotherapy adjuvant in Asia.

Quick answer: Turkey Tail (PSK/PSP) is used for may modulate immune and hematological function (nk-cell activity, lymphocyte and white-cell counts), mostly shown in cancer-adjuvant settings rather than healthy users. NutriDex grades the human evidence as preliminary — Early or small human trials; promising but not yet conclusive. Based on 13 cited human studies (13 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Turkey Tail (Trametes versicolor, formerly Coriolus versicolor) is a common bracket fungus whose protein-bound polysaccharides PSK (Krestin) and PSP have been used for decades as immune-adjuvant agents alongside chemotherapy and surgery in Japan and China. The strongest human evidence is in oncology: pooled analyses and a 2022 Cochrane review suggest PSK, added to conventional treatment in cancers such as gastric, colorectal and lung, is associated with a small improvement in long-term survival, though the certainty of evidence is low and older trials used chemotherapy regimens no longer in standard use. Mechanistically it acts as a non-specific immunomodulator, increasing markers such as NK-cell activity and lymphocyte counts, and PSP shows prebiotic-like effects on the gut microbiome. Evidence for the over-the-counter supplement as a standalone immune booster or longevity aid in healthy people is preliminary and rests mainly on immunologic surrogate markers rather than clinical outcomes. It is generally well tolerated, but it should be viewed as an adjunct studied under medical supervision, not a proven self-care therapy.

Benefits / uses: May modulate immune and hematological function (NK-cell activity, lymphocyte and white-cell counts), mostly shown in cancer-adjuvant settings rather than healthy users; As an adjuvant to chemotherapy/surgery in gastric, colorectal and lung cancers, PSK is associated with modestly improved survival and reduced tumor-related symptoms (low-certainty evidence); PSP behaves like a prebiotic and may shift the gut microbiome in small healthy-volunteer studies; Standalone over-the-counter immune-boosting claims for healthy people are largely unproven and rest on immunologic surrogate markers, not clinical outcomes.
Active compounds: Polysaccharide-K (PSK / Krestin) — a protein-bound beta-glucan; Polysaccharopeptide (PSP) — a related protein-bound polysaccharide; Beta-glucans (beta-1,3 and beta-1,6 glucans); Bound peptides/glycoproteins.
Dose: PSK 3 g/day or PSP ~1–3 g/day, typically as an adjuvant to conventional cancer therapy; whole-mushroom extracts have been studied at 3–9 g/day. No established dose for general immune support in healthy adults.
Safety: Generally well tolerated; the most common side effects are mild gastrointestinal upset, nausea, and darkening of the stool or nails. Because it stimulates immune activity, people with autoimmune conditions (e.g., rheumatoid arthritis, lupus, multiple sclerosis) and organ-transplant recipients on immunosuppressants should use caution or avoid it, as it may theoretically counteract immunosuppressive therapy. It may have additive effects with anticoagulant/antiplatelet drugs and could interact with immunosuppressants and certain chemotherapy agents, so cancer patients should only use it under oncologist supervision rather than self-prescribing. Safety has not been established in pregnancy or breastfeeding, and these groups should avoid it. As with all supplements, product quality, polysaccharide content, and contamination vary widely, and "turkey tail" supplements are not equivalent to the pharmaceutical-grade PSK/PSP used in clinical trials. Anyone with a serious illness should consult a clinician before use and should not substitute it for proven medical treatment.

Cited studies (13):
  - Can polysaccharide K improve therapeutic efficacy and safety in gastrointestinal cancer? a systematic review and network meta-analysis, Oncotarget (2017) — Systematic review and network meta-analysis of 23 RCTs (10,684 GI-cancer patients) found adjuvant PSK significantly increased 1-5 year overall survival and 1-7 year disease-free survival without added side effects; benefit was clearest in colorectal and gastric cancer, and PSK plus chemotherapy was the superior arm (significantly improved 3- and 5-year OS). [https://pubmed.ncbi.nlm.nih.gov/29179503/]
  - Coriolus (Trametes) versicolor mushroom to reduce adverse effects from chemotherapy or radiotherapy in people with colorectal cancer, The Cochrane database of systematic reviews (2022) — This Cochrane systematic review found low-certainty evidence that adjunctive Coriolus (PSK) modestly improved 5-year survival in colorectal cancer (RR 1.08, 95% CI 1.01–1.15; ~16 needed to treat for one to benefit), with very-low-certainty, uncertain effects on chemotherapy adverse events. [https://pubmed.ncbi.nlm.nih.gov/36445793/]
  - Coriolus Versicolor and Ganoderma Lucidum Related Natural Products as an Adjunct Therapy for Cancers: A Systematic Review and Meta-Analysis of Randomized Controlled Trials, Frontiers in pharmacology (2019) — A meta-analysis of Coriolus versicolor- and Ganoderma-related products as adjunct cancer therapy found a lower mortality risk (HR 0.82, 95% CI 0.72–0.94, ~18% reduction) and higher treatment efficacy, but no significant effect on disease control rate. [https://pmc.ncbi.nlm.nih.gov/articles/PMC6616310/]
  - Polysaccharide K and Coriolus versicolor extracts for lung cancer: a systematic review, Integrative cancer therapies (2015) — A systematic review of PSK and Coriolus versicolor in lung cancer concluded most RCTs supported improved immune function, reduced tumor-related symptoms, and better 1-, 2-, and 5-year survival, while calling for larger rigorous trials. [https://pubmed.ncbi.nlm.nih.gov/25784670/]
  - Efficacy of adjuvant immunochemotherapy with polysaccharide K for patients with curative resections of gastric cancer, Cancer immunology, immunotherapy : CII (2007) — Pooled analysis of 8,009 patients from 8 centrally randomized RCTs showed adjuvant PSK immunochemotherapy after curative gastric cancer resection reduced mortality with an overall hazard ratio of 0.88 (95% CI 0.79-0.98; P=0.018), no significant heterogeneity. [https://pubmed.ncbi.nlm.nih.gov/17106715/]
  - Mushrooms (PDQ®), U.S. National Cancer Institute (1994) — NCI's PDQ Health Professional summary reviews Trametes versicolor (PSK/PSP) clinical evidence in gastric, colorectal and other cancers, characterizing trial data as mostly older Japanese adjuvant studies of variable quality. [https://www.cancer.gov/about-cancer/treatment/cam/hp/mushrooms-pdq]
  - Phase 1 Clinical Trial of Trametes versicolor in Women with Breast Cancer, ISRN oncology (2012) — Phase 1 dose-escalation trial of Trametes versicolor (up to 9 g/day) in 9 women after breast cancer radiotherapy found it well tolerated, with trends toward increased lymphocyte counts and dose-related increases in CD8+ T cells and CD19+ B cells. [https://pmc.ncbi.nlm.nih.gov/articles/PMC3369477/]
  - PSK may suppress CD57(+) T cells to improve survival of advanced gastric cancer patients, International journal of clinical oncology (2010) — Randomized trial in stage III gastric cancer (n=21): PSK + UFT vs UFT alone yielded 3-year overall survival of 62.2% vs 12.5% (P=0.038); PSK significantly reduced poor-prognosis CD57+ T cells, suggesting an immunological mechanism. [https://pubmed.ncbi.nlm.nih.gov/20229169/]
  - Phase 1 Clinical Trial of Trametes versicolor in Women with Breast Cancer, ISRN oncology (2012) — A phase I dose-escalation trial (3, 6, 9 g/day for 6 weeks) of Trametes versicolor in breast cancer patients post-treatment found it well tolerated, with trends toward increased lymphocyte counts at higher doses and increased NK-cell activity at 6 g/day. [https://pubmed.ncbi.nlm.nih.gov/22701186/]
  - Effects of polysaccharopeptide from Trametes versicolor and amoxicillin on the gut microbiome of healthy volunteers: a randomized clinical trial, Gut microbes (2014) — A randomized trial found PSP from Trametes versicolor produced consistent prebiotic-like shifts in the gut microbiome of healthy volunteers, in contrast to the disruptive effects of amoxicillin. [https://pubmed.ncbi.nlm.nih.gov/25006989/]
  - Efficacy of immunochemotherapy as adjuvant treatment after curative resection of gastric cancer. Study Group of Immunochemotherapy with PSK for Gastric Cancer, Lancet (London, England) (1994) — Multicenter RCT (n=262) after curative gastrectomy: adding PSK to mitomycin + fluorouracil improved 5-year disease-free rate (70.7% vs 59.4%, P=0.047) and 5-year survival (73.0% vs 60.0%, P=0.044), with only slight toxicity. [https://pubmed.ncbi.nlm.nih.gov/7910230/]
  - Adjuvant immunochemotherapy with oral Tegafur/Uracil plus PSK in patients with stage II or III colorectal cancer: a randomised controlled study, British journal of cancer (2004) — RCT in stage II/III colorectal cancer (n=205): oral PSK + UFT vs UFT alone improved 5-year DFS (73.0% vs 58.8%, P=0.016) and reduced recurrence by 43.6%; in stage III, PSK significantly increased DFS (60.0% vs 32.1%, P=0.002) and OS (74.6% vs 46.4%, P=0.003). [https://pubmed.ncbi.nlm.nih.gov/14997197/]
  - Protein-bound polysaccharide K prolonged overall survival in gastric cancer patients from a non-Japanese Asian country who received gastrectomy and adjuvant chemotherapy, Medicine (2022) — In a Taiwan retrospective cohort of gastric cancer patients after gastrectomy plus adjuvant chemotherapy, adding PSK was associated with longer median overall survival (6.49 vs 3.59 years; adjusted HR 0.76, P<0.0001). [https://pmc.ncbi.nlm.nih.gov/articles/PMC9302315/]

---

## Liquid Chlorophyll (Chlorophyllin (sodium copper chlorophyllin))
URL: https://nutridex.info/s/liquid-chlorophyll
Category: Debunked
Evidence: No Evidence — No credible human evidence supports the marketed claims — widely considered ineffective.
A green food-dye derivative sold as a detox cure-all — viral claims it can't back up.

Quick answer: Liquid Chlorophyll is marketed for no credible human evidence supports the viral marketing claims (detox, alkalizing, boosting energy, or 'cleansing the blood'). NutriDex grades the human evidence as no evidence — No credible human evidence supports the marketed claims — widely considered ineffective. Based on 11 cited human studies (11 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Liquid chlorophyll products are typically sodium copper chlorophyllin, a water-soluble derivative of plant chlorophyll long used as a food coloring and an over-the-counter 'internal deodorant.' Social-media claims that drinking it detoxifies the body, clears acne, deodorizes, alkalizes the blood, or boosts energy have essentially no credible human evidence; the most thorough systematic review found efficacy data weak and largely confined to topical or niche uses. The strongest human trial data are off-label: oral chlorophyllin lowered a urinary aflatoxin-DNA adduct biomarker by about 55% in adults at high liver-cancer risk in Qidong, China, and a small pharmacokinetic study suggested it can reduce aflatoxin absorption — findings specific to carcinogen exposure, not everyday wellness. Acne improvement has been shown only for a topical 0.1% copper-chlorophyllin gel in a 10-person pilot, not for the drinkable form. It is generally well tolerated, with harmless green discoloration of urine/stool, occasional GI upset, and a risk of photosensitivity. Overall, for its viral marketed claims the human evidence is best described as none.

Benefits / uses: No credible human evidence supports the viral marketing claims (detox, alkalizing, boosting energy, or 'cleansing the blood'); Internal-deodorant use (body/fecal odor) is FDA-permitted historically but rests on thin, poorly-controlled mid-20th-century data; modern rigorous trials have not confirmed a benefit in healthy people; Acne/skin-clearing claims for oral chlorophyll are unsupported; the only positive acne data come from a tiny TOPICAL copper-chlorophyllin pilot, not from drinking it; Oral chlorophyllin has reduced an aflatoxin-DNA damage biomarker in a high-exposure population in China — a narrow chemoprevention context, not a wellness benefit for the general public; Plausible but unproven antioxidant activity; human data are limited and do not translate into the marketed health outcomes.
Active compounds: Sodium copper chlorophyllin (water-soluble semi-synthetic chlorophyll derivative); Chlorin e4 and chlorin e6 ethyl esters (principal active components); Copper-chelated porphyrin ring; Pheophorbide (a photoactive breakdown metabolite, relevant to photosensitivity).
Dose: Commonly marketed at ~100–300 mg/day of chlorophyllin copper complex (e.g., 100 mg up to 3x/day); historical FDA internal-deodorant ceiling is 300 mg/day. No dose is established to deliver the advertised 'detox' or wellness effects.
Safety: Generally well tolerated at typical doses. Common, harmless effects include green discoloration of urine, stool, or tongue. Doses above ~300 mg/day commonly cause GI upset — diarrhea, cramping, excess gas, and occasional nausea. Photosensitivity is a recognized risk: chlorophyll breakdown yields photoactive pheophorbides, so users should apply sun protection, and people taking other photosensitizing drugs (certain antibiotics, retinoids, St. John's Wort) or undergoing phototherapy should be cautious. The copper in copper chlorophyllin is a consideration for anyone with Wilson's disease or copper-overload conditions. Safety has not been established in pregnancy or breastfeeding, so these groups should avoid it. People with liver or kidney disease, and children, should consult a clinician first. Because chlorophyllin may bind compounds in the gut, separate it from oral medications by a couple of hours to avoid reduced absorption. Liquid products vary widely in concentration and purity (a dietary supplement, not a regulated drug); it is not a substitute for medical detoxification or any prescribed treatment.

Cited studies (11):
  - An evidence-based systematic review of chlorophyll by the Natural Standard Research Collaboration, Journal of dietary supplements (2014) — The Natural Standard evidence-based review of chlorophyll/chlorophyllin graded the supporting clinical evidence as generally weak across claimed uses, finding insufficient rigorous human data for detoxification, deodorizing, or systemic health benefits. [https://pubmed.ncbi.nlm.nih.gov/24670123/]
  - Study Protocol of a Prospective Phase 2 Study of Chlorophyllin for the Management of Brain Radionecrosis in Patients With Diffuse Glioma (CHROME), Cancer medicine (2025) — Protocol for a prospective phase 2 single-institution trial (planned n=118) of oral chlorophyllin 750 mg daily for 3 months to treat brain radionecrosis in diffuse glioma patients, with clinical-radiological response at one month as the primary endpoint. [https://pmc.ncbi.nlm.nih.gov/articles/PMC11872794/]
  - Listing of Color Additives Exempt From Certification; Sodium Copper Chlorophyllin, Food and Drug Administration, Department of Health and Human Services (Federal Register) (2002) — FDA historically permits chlorophyllin copper complex as an OTC internal deodorant up to 300 mg/day with no reported adverse effects at that dose, but the underlying odor-reduction efficacy data are old and poorly controlled. [https://www.federalregister.gov/documents/2002/05/20/02-12544/listing-of-color-additives-exempt-from-certification-sodium-copper-chlorophyllin]
  - Preclinical evaluation of sodium copper chlorophyllin: safety, pharmacokinetics, and therapeutic potential in breast cancer chemotherapy and cyclophosphamide-induced bladder toxicity, Naunyn-Schmiedeberg's Archives of Pharmacology (2025) — Preclinical safety/pharmacokinetic evaluation found oral sodium copper chlorophyllin well tolerated up to 5000 mg/kg in acute toxicity studies with no signs of toxicity or death, and explored efficacy in breast cancer chemotherapy and cyclophosphamide-induced bladder toxicity. [https://link.springer.com/article/10.1007/s00210-025-04112-z]
  - Ability of sodium copper chlorophyllin complex to repair photoaged skin by stimulation of biomarkers in human extracellular matrix, Clinical, cosmetic and investigational dermatology (2016) — Randomized controlled trial; topical 0.05% sodium copper chlorophyllin complex stimulated favorable changes in human extracellular-matrix biomarkers (e.g., elastin/collagen-related markers) in forearm skin biopsies, supporting a photoaging-repair effect. [https://pubmed.ncbi.nlm.nih.gov/27524916/]
  - Chlorophyllin intervention reduces aflatoxin-DNA adducts in individuals at high risk for liver cancer, Proceedings of the National Academy of Sciences of the United States of America (2001) — In a randomized, double-blind, placebo-controlled trial in Qidong, China, 100 mg oral chlorophyllin three times daily for 4 months reduced median urinary aflatoxin-N7-guanine (a DNA-damage biomarker) by 55% vs placebo (P=0.036). [https://pubmed.ncbi.nlm.nih.gov/11724948/]
  - Phase II Randomized Study of Short Course Radiotherapy Based Total Neoadjuvant Therapy & Brachytherapy Boost With Or Without Chlorophyllin In Watch And Wait Suitable Locally Advanced Rectal Cancer (SCOTCH Study), ClinicalTrials.gov (sponsor: Tata Memorial Centre) (2023) — Registered randomized placebo-controlled trial (Tata Memorial Centre) evaluating whether chlorophyllin added to neoadjuvant chemoradiotherapy reduces GI/GU/hematological toxicity in locally advanced rectal cancer. [https://clinicaltrials.gov/study/NCT05856305]
  - Effect of chlorophyllin on urinary odor in incontinent geriatric patients, Drug intelligence & clinical pharmacy (1983) — Randomized double-blind crossover placebo-controlled trial in incontinent geriatric patients; oral chlorophyllin 100 mg/day for 2 weeks did NOT significantly reduce urinary odor versus placebo, indicating limited internal-deodorant efficacy at this dose. [https://pubmed.ncbi.nlm.nih.gov/6628224/]
  - Chlorophyllin exerts synergistic anti-tumor effect with gemcitabine in pancreatic cancer by inducing cuproptosis, Molecular medicine (Cambridge, Mass.) (2025) — Mechanistic preclinical study showing chlorophyllin exerts synergistic anti-tumor effects with gemcitabine in pancreatic cancer by inducing cuproptosis (copper-dependent cell death). [https://pmc.ncbi.nlm.nih.gov/articles/PMC11969790/]
  - Effects of chlorophyll and chlorophyllin on low-dose aflatoxin B(1) pharmacokinetics in human volunteers, Cancer prevention research (Philadelphia, Pa.) (2009) — In an unblinded crossover pharmacokinetic pilot using a trace 14C-labeled aflatoxin dose, co-administered chlorophyll and chlorophyllin reduced aflatoxin B1 absorption/systemic bioavailability, supporting an interception (not whole-body 'detox') mechanism. [https://pubmed.ncbi.nlm.nih.gov/19952359/]
  - Pilot Study of Topical Copper Chlorophyllin Complex in Subjects With Facial Acne and Large Pores, Journal of drugs in dermatology : JDD (2015) — A 3-week open pilot of a TOPICAL 0.1% liposomal sodium copper chlorophyllin gel showed statistically significant improvement in mild-to-moderate facial acne and pore appearance — evidence for topical use only, not for oral/liquid chlorophyll. [https://pubmed.ncbi.nlm.nih.gov/26091384/]

---

## Phenibut (β-phenyl-γ-aminobutyric acid)
URL: https://nutridex.info/s/phenibut
Category: Banned & Harmful
Evidence: No Evidence — No credible human evidence supports the marketed claims — widely considered ineffective.
A Soviet-era GABA-B drug sold online as a "calm" supplement — with a brutal dependence and withdrawal profile.

Quick answer: Phenibut is marketed for marketed for anxiety relief, but there are no rigorous, modern human trials demonstrating safe or effective use as a supplement — anxiolytic and sedative effects are mediated by gaba-b agonism but are unproven for any supplement claim and come with serious dependence risk.. NutriDex grades the human evidence as no evidence — No credible human evidence supports the marketed claims — widely considered ineffective. Based on 13 cited human studies (13 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Phenibut (β-phenyl-GABA) is a central nervous system depressant developed in the Soviet Union that acts mainly as a GABA-B receptor agonist with additional gabapentinoid (α2δ calcium-channel) activity. It is sold online and in "supplement" or nootropic products for anxiety, sleep, and cognitive enhancement, but it is not approved as a dietary supplement or medicine in the US, UK, or Australia, and the FDA has stated it does not meet the definition of a dietary ingredient. There are no rigorous modern human trials supporting safe or effective supplement use, while a substantial case literature documents rapid tolerance, physical dependence, and a severe withdrawal syndrome that can include insomnia, hallucinations, agitation, delirium, and seizures, sometimes within hours of the last dose. Overdose — frequently involving co-ingested alcohol, benzodiazepines, or opioids — can cause profound sedation, reduced consciousness, agitated delirium, and cardiovascular and renal effects, with no specific antidote. Analyses have also found actual phenibut content in marketed products far exceeding label claims, compounding the risk. Given documented harms and absent credible benefit for its marketed claims, the evidence tier for safe supplement use is 'none'.

Benefits / uses: Marketed for anxiety relief, but there are no rigorous, modern human trials demonstrating safe or effective use as a supplement — anxiolytic and sedative effects are mediated by GABA-B agonism but are unproven for any supplement claim and come with serious dependence risk.; Promoted for sleep and as a nootropic/cognitive enhancer; these claims are unsupported by credible controlled human evidence and are outweighed by documented harms.; Any short-term subjective calming or euphoric effect rapidly drives tolerance, escalating doses, and dependence rather than durable benefit..
Active compounds: Phenibut (β-phenyl-GABA), a GABA analog acting primarily as a GABA-B receptor agonist; Activity at voltage-gated calcium channels (gabapentinoid-like α2δ activity) and weaker GABA-A effects; Sold as racemic hydrochloride (HCl) and faah/free-acid (FAA) salt forms with differing potency per gram.
Dose: No safe or approved supplement dose exists. Illicit recreational use is commonly 250–1500 mg, but dependent users escalate dramatically (case-series average ~13.6 g/day); not recommended at any dose.
Safety: Not approved as a supplement or medicine in the US, UK, or Australia (banned/prohibited in Australia and restricted in several European countries). Phenibut produces rapid tolerance and physical dependence; abrupt cessation after regular use can cause a severe withdrawal syndrome — anxiety, insomnia, tremor, hallucinations, psychosis, autonomic instability, delirium, and seizures — that may require medically supervised baclofen or benzodiazepine tapering. Overdose causes deep sedation, reduced consciousness, agitation/delirium, low blood pressure, and renal impairment, with no specific antidote; high chronic intake (above ~7 g) has been linked to hepatic effects. Risk is greatly amplified by co-use with alcohol, benzodiazepines, opioids, or other CNS depressants — a common feature of reported toxicity and a potentially fatal combination. Marketed product potency is unreliable and often exceeds label claims, making dosing unpredictable. It must be avoided by anyone who is pregnant or breastfeeding, by people with a history of substance use disorder or psychiatric illness, and by those taking sedatives, GABAergics, or alcohol; do not stop established use abruptly — seek medical supervision.

Cited studies (13):
  - Clinical Presentations and Treatment of Phenibut Toxicity and Withdrawal: A Systematic Literature Review, Journal of Addiction Medicine (2023) — A 2023 systematic review of 62 phenibut toxicity/withdrawal cases found 80.7% were male (mean age ~31), 86.8% obtained phenibut online, and 63.2% reported concomitant use of other substances such as benzodiazepines, alcohol, or opioids. [https://journals.lww.com/journaladdictionmedicine/abstract/2023/07000/clinical_presentations_and_treatment_of_phenibut.10.aspx]
  - A Systematic Review of Phenibut Withdrawals, Cureus (2024) — A 2024 systematic review (Cureus) of 15 phenibut-withdrawal case reports found a mean daily dose of ~13.6 g (far above the 0.5–1.5 g 'recommended' range), with insomnia, hallucinations, and muscular symptoms each in 53% of cases; baclofen taper was the most effective management. [https://pubmed.ncbi.nlm.nih.gov/39376891/]
  - A Systematic Review of Phenibut Withdrawals, Cureus (2024) — Systematic review of 15 phenibut-withdrawal cases (mean age 31.8 yr, 87% male; mean dose 13.6 g/day) found withdrawal onset as early as 2 hours post-dose, with anxiety, agitation, insomnia, psychosis, delirium and seizures commonly managed with benzodiazepines and baclofen. [https://pmc.ncbi.nlm.nih.gov/articles/PMC11456982/]
  - Clinical Presentations and Treatment of Phenibut Toxicity and Withdrawal: A Systematic Literature Review, Journal of addiction medicine (2023) — Systematic literature review identified 62 cases across 36 studies of phenibut toxicity or withdrawal, summarizing clinical presentations (sedation, respiratory depression, agitation, psychosis) and treatment. [https://pubmed.ncbi.nlm.nih.gov/37579098/]
  - A systematic review of phenibut withdrawal focusing on complications, therapeutic approaches, and single substance versus polysubstance withdrawal, Clinical toxicology (Philadelphia, Pa.) (2023) — PRISMA systematic review of phenibut withdrawal: 100% male, median age 30 y, median daily dose 10 g (range 1-200 g); withdrawal onset as early as 2 h after last dose. Seizures in 8%, intubation in 24%, ICU admission in 44%; 76% required >=2 drug therapies. Benzodiazepines used in 68% and baclofen in 60%. Withdrawal severity was similar for mono- vs polysubstance use; no standardized treatment exists. [https://pubmed.ncbi.nlm.nih.gov/38112312/]
  - Phenibut in Dietary Supplements, U.S. Food and Drug Administration — The US FDA states phenibut does not meet the statutory definition of a dietary ingredient and that any supplement declaring it is misbranded; in 2019 it issued warning letters to companies marketing phenibut-containing products as supplements. [https://www.fda.gov/food/information-select-dietary-supplement-ingredients-and-other-substances/phenibut-dietary-supplements]
  - Phenibutan—an Illegal Food Supplement With Psychotropic Effects and Health Risks, Deutsches Arzteblatt international (2024) — Report on phenibut as an illegal food supplement with psychotropic effects, documenting health risks including sedation, dependence and withdrawal associated with internet-sold products. [https://pmc.ncbi.nlm.nih.gov/articles/PMC11539871/]
  - Phenibut: A drug with one too many 'buts', Basic & Clinical Pharmacology & Toxicology (2024) — A 2024 review concludes phenibut is an unregulated GABA-B agonist whose online availability drives misuse, with no antidote and a recognized risk of dependence, severe withdrawal, and overdose, especially when combined with other CNS depressants. [https://onlinelibrary.wiley.com/doi/10.1111/bcpt.14075]
  - Phenibut: Review and Pharmacologic Approaches to Treating Withdrawal, Journal of clinical pharmacology (2024) — Comprehensive pharmacologic review: phenibut is a GABA-B agonist marketed as a nootropic/anxiolytic, legal and widely sold online in the USA without prescription. Across 29 withdrawal cases, patients were treated with baclofen, benzodiazepines and phenobarbital alone or combined; phenobarbital may be preferred over baclofen in patients at seizure risk. No comparative treatment studies exist and routine urine/plasma screening is unavailable. [https://pubmed.ncbi.nlm.nih.gov/38339875/]
  - Phenibut: A drug with one too many "buts", Basic & clinical pharmacology & toxicology (2024) — Toxicology-focused review confirming phenibut acts at GABA-B and beta-phenethylamine receptors; intoxication, withdrawal and addiction can be life-threatening and require hospitalization. Ingestion is frequently combined with other substances of abuse, and management is hampered by absence of phenibut in standard drug-screening panels. Calls for adding phenibut to drug screens and developing accepted treatment protocols. [https://pubmed.ncbi.nlm.nih.gov/39197876/]
  - Phenibut (β-Phenyl-γ-Aminobutyric Acid): an Easily Obtainable "Dietary Supplement" With Propensities for Physical Dependence and Addiction, Current psychiatry reports (2019) — Review concluding that phenibut's pharmacology resembles a prescription-strength sedative rather than a nutritional supplement; multiple case reports document physical dependence, withdrawal and addiction, with intoxication ranging from minimal responsiveness to agitated delirium. Argues its 'dietary supplement' marketing is inaccurate and misleading given its GABA-B agonist profile. [https://pubmed.ncbi.nlm.nih.gov/30852710/]
  - Acute phenibut withdrawal: A comprehensive literature review and illustrative case report, Bosnian journal of basic medical sciences (2019) — Literature review of 22 reported phenibut withdrawal cases plus an illustrative case: abrupt discontinuation precipitates an abstinence syndrome marked by severe psychomotor agitation that can mimic serotonin or neuroleptic malignant syndrome and requires aggressive multidrug pharmacologic treatment. Affected patients were typically younger with coexisting substance use disorders. [https://pubmed.ncbi.nlm.nih.gov/30501608/]
  - Quantity of phenibut in dietary supplements before and after FDA warnings, Clinical toxicology (Philadelphia, Pa.) (2022) — A 2022 Clinical Toxicology analysis found phenibut content in marketed 'supplement' products did not match labels — detected in two brands only after FDA warnings and increasing in three of four products, in one case reaching ~450% of a typical 250 mg pharmaceutical tablet. [https://pubmed.ncbi.nlm.nih.gov/34550038/]

---

## Tianeptine
URL: https://nutridex.info/s/tianeptine
Category: Banned & Harmful
Evidence: Banned / Harmful — Linked to serious harm and/or banned in sport and many jurisdictions. Listed for awareness and safety only — NOT a recommendation.
"Gas station heroin" — a mu-opioid agonist sold as a nootropic, with no legitimate supplement use.

Quick answer: Tianeptine is marketed for no credible benefit exists for tianeptine as a dietary supplement or nootropic; its marketed claims (mood, focus, anxiety) are not supported by evidence at the unregulated doses sold in the u.s.. NutriDex grades the human evidence as banned / harmful — Linked to serious harm and/or banned in sport and many jurisdictions. Listed for awareness and safety only — NOT a recommendation. Based on 13 cited human studies (13 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Tianeptine is an atypical tricyclic-structured antidepressant licensed at low doses (~37.5 mg/day) in parts of Europe, Asia, and Latin America, but it has never been approved by the FDA for any use and does not meet the legal definition of a dietary ingredient. Although historically described as a glutamatergic/serotonergic modulator, it is now established to be a full agonist at the mu-opioid receptor (and a weaker delta-opioid agonist), and this opioid activity dominates at the high doses sold in U.S. "gas station" and online "nootropic" products. At those doses it produces euphoria, tolerance, physical dependence, classic opioid-like withdrawal, respiratory depression, and death, earning the street name "gas station heroin." U.S. poison-center exposure calls rose sharply (from a handful per year before 2014 to dozens annually by 2017 and far higher since), and the FDA has issued repeated consumer warnings, while numerous states (including Alabama, Florida, Georgia, Indiana, Michigan, Minnesota, Mississippi, Ohio, Tennessee, and others) have banned it. There is no legitimate supplement or nootropic use for tianeptine, and the evidence tier for such use is best described as none/banned.

Benefits / uses: No credible benefit exists for tianeptine as a dietary supplement or nootropic; its marketed claims (mood, focus, anxiety) are not supported by evidence at the unregulated doses sold in the U.S.; As a licensed prescription antidepressant in some European, Asian, and Latin American countries (brand names Stablon/Coaxil), low therapeutic doses (~37.5 mg/day) treat major depression — but this is a regulated medical use, not a supplement use, and is unavailable in the U.S.; Any perceived 'cognitive' or 'euphoric' effect from gas-station products is opioid receptor activation, i.e. the same mechanism as drug intoxication, not a health benefit..
Active compounds: Tianeptine (free acid); Tianeptine sodium salt; Tianeptine sulfate (extended-release salt favored in misuse products).
Dose: No safe supplement dose exists. The licensed antidepressant dose abroad is 12.5 mg three times daily (~37.5 mg/day); abused U.S. products are taken at 75–10,000 mg/day, where opioid agonism, dependence, and overdose dominate. Avoid entirely.
Safety: DANGER — do not use. Tianeptine is a mu-opioid receptor agonist at the doses sold in the U.S., with high potential for addiction, severe opioid-like withdrawal (anxiety, sweating, tachycardia, agitation, vomiting, diarrhea), respiratory depression, coma, and death; naloxone may be needed for overdose. It is NOT an FDA-approved drug or a legal dietary supplement, and it is banned or scheduled in many U.S. states. Absolutely avoid combining with other CNS depressants — opioids, benzodiazepines, alcohol, or gabapentinoids — as this sharply raises the risk of fatal respiratory depression; deaths have occurred with adulterated products such as "Neptune's Fix" (which also contained synthetic cannabinoids). Pregnant or breastfeeding individuals must avoid it (neonatal opioid withdrawal syndrome has been reported); people with a history of substance use disorder, opioid dependence, depression, or psychiatric illness are at especially high risk. Discontinuation after regular use should be done under medical supervision, as withdrawal mirrors opioid withdrawal and case reports describe management with buprenorphine or methadone. If you or someone else has used these products and shows sedation, slowed breathing, or unresponsiveness, seek emergency care immediately (U.S.: call 911 or Poison Control at 1-800-222-1222).

Cited studies (13):
  - Gas station heroin- tianeptine and its impact: a systematic review and exploratory analysis, BMC public health (2025) — A 2025 systematic review of tianeptine misuse found overdose in 35% of cases, opioid-like withdrawal in 42% (treated with buprenorphine, benzodiazepines, or naloxone), and a 13% fatality rate, confirming a substantial addiction and mortality burden from unregulated products. [https://pmc.ncbi.nlm.nih.gov/articles/PMC12551324/]
  - Gas station heroin- tianeptine and its impact: a systematic review and exploratory analysis, BMC public health (2025) — PRISMA systematic review of human reports of tianeptine misuse found tianeptine acts as a mu-opioid receptor agonist; ~58% of users progressed to habitual misuse with rapid dose escalation, tolerance, and opioid-like withdrawal, often requiring buprenorphine/naloxone management. [https://pubmed.ncbi.nlm.nih.gov/41136982/]
  - FDA warns consumers not to purchase or use any tianeptine product due, U.S. Food and Drug Administration — The FDA reaffirmed (2023–2025) that tianeptine is not approved for any use, is not a lawful dietary ingredient, and warns consumers not to purchase or use any tianeptine product, citing risks of agitation, coma, respiratory depression, seizure, and death. [https://www.fda.gov/drugs/drug-alerts-and-statements/fda-warns-consumers-not-purchase-or-use-any-tianeptine-product-due-serious-risks]
  - Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis, Lancet (London, England) (2018) — In the landmark NMA of 21 antidepressants (522 trials, 116,477 patients), tianeptine was significantly more effective than placebo for acute major depression (OR 1.37, 95% CrI 1.05-1.81) and ranked among the more efficacious agents, with acceptability not significantly different from placebo. [https://pubmed.ncbi.nlm.nih.gov/29477251/]
  - A meta-analysis of randomized controlled trials of tianeptine versus SSRI in the short-term treatment of depression, European psychiatry : the journal of the Association of European Psychiatrists (2002) — Pooled analysis of 5 RCTs (n=1348; tianeptine vs fluoxetine, paroxetine, sertraline) found no significant difference in MADRS total score or responder rate, indicating tianeptine is at least as effective as SSRIs short-term, with a trend toward better tolerability. [https://pubmed.ncbi.nlm.nih.gov/15177089/]
  - Efficacy of Tianeptine 25-50 mg in Elderly Patients With Recurrent Major Depressive Disorder: An 8-Week Placebo- and Escitalopram-Controlled Study, The Journal of clinical psychiatry (2018) — Double-blind placebo-controlled trial in older depressed patients: tianeptine improved depressive symptoms with a placebo-tianeptine difference of 3.84 points on the HDRS-17 total score (P<.001). [https://pubmed.ncbi.nlm.nih.gov/29995359/]
  - Tianeptine Exposures Reported to United States Poison Centers, 2015-2023, Journal of medical toxicology : official journal of the American College of Medical Toxicology (2025) — Among 892 single-substance tianeptine exposures reported to US poison centers (2015-2023), the exposure rate rose 1,400%; 51.5% had moderate and 12.0% major effects, 40.1% required medical admission (22.9% to critical care). [https://pubmed.ncbi.nlm.nih.gov/39724478/]
  - An Outbreak of Synthetic Cannabinoid-Adulterated Tianeptine Products in New Jersey - Case Series, Journal of medical toxicology : official journal of the American College of Medical Toxicology (2025) — A New Jersey outbreak (June 2023-Feb 2024) involved 41 calls and 34 patients exposed to Neptune's Fix tianeptine products adulterated with synthetic cannabinoids; 97% had altered mental status, 41% seizures, ~50% required intubation, and 65% needed ICU admission. [https://pmc.ncbi.nlm.nih.gov/articles/PMC11933608/]
  - Opioid-like adverse effects of tianeptine in male rats and mice, Psychopharmacology (2022) — Tianeptine produced dose-dependent opioid-like adverse effects including respiratory depression, naloxone-reversible analgesia, and a withdrawal/dependence profile, providing direct experimental confirmation of its abuse and overdose liability. [https://pubmed.ncbi.nlm.nih.gov/35211768/]
  - Neonatal Opioid Withdrawal Syndrome Following Prenatal Use of Supplements Containing Tianeptine, Pediatrics (2024) — A 2024 case report documented neonatal opioid withdrawal syndrome in an infant after prenatal maternal use of a tianeptine-containing supplement, with symptoms resistant to phenobarbital but responsive to morphine, illustrating that the products carry true opioid dependence risk including in utero. [https://pubmed.ncbi.nlm.nih.gov/38213293/]
  - Characteristics of Tianeptine Exposures Reported to the National Poison Data System - United States, 2000-2017, MMWR. Morbidity and mortality weekly report (2018) — Surveillance of U.S. poison-center tianeptine exposures, 2000-2017, documented an exponential rise (from <1/year pre-2013 to 38 in 2015 and 83 in 2016); cases clustered in adults with neurologic, cardiovascular, and gastrointestinal toxicity and frequent co-exposure to other substances, signaling emerging abuse/dependence. [https://pubmed.ncbi.nlm.nih.gov/30070980/]
  - Characteristics of Tianeptine Exposures Reported to the National Poison Data System — United States, 2000–2017, MMWR. Morbidity and Mortality Weekly Report (2018) — CDC MMWR surveillance reported tianeptine poison-center exposure calls rising from 5 in 2014 to 83 in 2016 and 81 in 2017 (vs. only 11 total during 2000–2013), a statistically significant increase (p<0.001) with opioid-like toxicity, signaling an emerging public-health risk. [https://www.cdc.gov/mmwr/volumes/67/wr/mm6730a2.htm]
  - The Behavioral Effects of the Antidepressant Tianeptine Require the Mu-Opioid Receptor, Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology (2017) — Tianeptine's antidepressant-like and reward behaviors were abolished in mu-opioid receptor knockout mice, demonstrating that its central effects require direct mu-opioid receptor agonism rather than a purely monoaminergic mechanism. [https://pubmed.ncbi.nlm.nih.gov/28303899/]

---

## Nitrous Oxide (Recreational) (Nitrogenium oxydulatum (N₂O))
URL: https://nutridex.info/s/nitrous-oxide
Category: Banned & Harmful
Evidence: No Evidence — No credible human evidence supports the marketed claims — widely considered ineffective.
"Laughing gas" inhaled for a fleeting high — but repeated use cripples vitamin B12 and the spinal cord.

Quick answer: Nitrous Oxide (Recreational) is marketed for no legitimate supplement or nootropic benefit: recreational nitrous oxide is not a wellness product and confers no health advantage. listed here strictly for harm-awareness.. NutriDex grades the human evidence as no evidence — No credible human evidence supports the marketed claims — widely considered ineffective. Based on 17 cited human studies (17 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Nitrous oxide ("laughing gas," "whippets," "nangs") is a dissociative anesthetic gas with legitimate medical and dental uses but no role as a dietary supplement. Recreationally it is inhaled for a brief euphoric, dissociative high, and its misuse — especially among adolescents and young adults — has risen sharply in recent years. With repeated use it irreversibly inactivates vitamin B12 by oxidizing its cobalt center, producing a functional B12 deficiency that damages myelin and causes subacute combined degeneration of the spinal cord and a peripheral myeloneuropathy: paresthesias, weakness, unsteady gait, and in severe cases paralysis. Reported neurological injury is often poorly correlated with cumulative dose, so there is no reliably "safe" recreational exposure. Acute use also risks hypoxia and fatal asphyxiation, and nitrous-oxide-related deaths have increased in recent surveillance data. Treatment requires immediate cessation plus parenteral vitamin B12 (hydroxocobalamin), but recovery is often incomplete.

Benefits / uses: No legitimate supplement or nootropic benefit: recreational nitrous oxide is not a wellness product and confers no health advantage. Listed here strictly for harm-awareness.; Its only validated uses are medical and dental — as a short-acting, monitored anesthetic/analgesic delivered with supplemental oxygen by trained clinicians — not the unmonitored inhalation of pure gas seen in recreational 'whippet' use.; The transient euphoria/dissociation people seek is a brief pharmacologic effect, not a therapeutic one, and carries disproportionate neurological and asphyxiation risk..
Active compounds: Nitrous oxide gas (N₂O), an inhaled NMDA-receptor antagonist and dissociative anesthetic; Mechanistically it irreversibly oxidizes the cobalt core of vitamin B12 (cobalamin), inactivating methionine synthase and disrupting myelin synthesis (functional B12 deficiency, elevated homocysteine and methylmalonic acid).
Dose: No safe recreational dose exists. Medically, it is given only by clinicians as a titrated mix with at least 21–50% oxygen. Recreational use (inhaling cartridges/'chargers' or tanks, often dozens to hundreds per session) is dangerous at any level; even low intermittent exposure has caused neurological injury.
Safety: DANGER — recreational use only; no supplemental benefit. Repeated inhalation inactivates vitamin B12 and can cause subacute combined degeneration of the spinal cord and peripheral neuropathy (numbness, tingling, weakness, loss of balance, and potentially permanent paralysis or bladder/bowel dysfunction); damage may be irreversible and can occur even with low or intermittent use. Acute hazards include hypoxia, loss of consciousness, falls/burns from cold gas, and sudden death by asphyxiation — especially when inhaled from a mask, bag, or in an enclosed space without oxygen. Chronic use also raises homocysteine, increasing thrombosis/stroke risk. Especially avoid if pregnant or breastfeeding (B12-dependent fetal development; methionine synthase inhibition), if you have any B12 deficiency, anemia, vegan/vegetarian or malabsorptive states, existing neuropathy, or cardiovascular/clotting disorders. Do not combine with other CNS depressants, alcohol, or driving. Misuse is illegal in many jurisdictions. Anyone with new numbness, tingling, weakness, or gait problems after use needs urgent medical evaluation and parenteral B12; stop immediately.

Cited studies (17):
  - Vitamin B12 Status in Recreational Users of Nitrous Oxide: A Systematic Review Focusing on the Prevalence of Laboratory Abnormalities, Antioxidants (Basel, Switzerland) (2023) — Systematic review of vitamin B12 status in recreational N2O users found that total serum B12 is frequently normal despite functional deficiency, with homocysteine, methylmalonic acid, and holotranscobalamin being the more reliable biomarkers of N2O-induced functional B12 deficiency. [https://pmc.ncbi.nlm.nih.gov/articles/PMC10294871/]
  - Thromboembolic complications of recreational nitrous oxide (ab)use: a systematic review, Journal of thrombosis and thrombolysis (2022) — Systematic review of thromboembolic complications of recreational N2O use links homocysteine elevation to a hypercoagulable state, documenting deep vein thrombosis, pulmonary embolism, cerebral sinus thrombosis, stroke, and myocardial infarction in young users without conventional risk factors. [https://pubmed.ncbi.nlm.nih.gov/35759070/]
  - Safety Alert, U.S. Food and Drug Administration — FDA advisory (March 2025) warns consumers not to inhale recreational nitrous oxide products (e.g., Galaxy Gas, Whip-It!), citing asphyxiation, blood clots, B12 deficiency, paralysis, lasting spinal cord/brain damage, and death amid rising adverse events. [https://www.fda.gov/food/alerts-advisories-safety-information/fda-advises-consumers-not-inhale-nitrous-oxide-products]
  - 006/2023: Control of nitrous oxide under the Misuse of Drugs Act 1971 (accessible), Home Office (UK Government) (2023) — From 8 November 2023 the UK reclassified nitrous oxide as a Class C controlled drug under the Misuse of Drugs Act 1971; recreational possession is an offence (up to 2 years), and supply for recreational use carries up to 14 years' imprisonment, following ACMD review. [https://www.gov.uk/government/publications/circular-0062023-control-of-nitrous-oxide-under-the-misuse-of-drugs-act-1971/0062023-control-of-nitrous-oxide-under-the-misuse-of-drugs-act-1971-accessible]
  - Global Burden Related to Nitrous Oxide Exposure in Medical and Recreational Settings: A Systematic Review and Individual Patient Data Meta-Analysis, Journal of clinical medicine (2019) — Systematic review and individual-patient-data meta-analysis of nitrous oxide exposure in medical and recreational settings characterizing the spectrum and predictors of N2O-related neurological and hematological toxicity. [https://pmc.ncbi.nlm.nih.gov/articles/PMC6518054/]
  - Global Burden Related to Nitrous Oxide Exposure in Medical and Recreational Settings: A Systematic Review and Individual Patient Data Meta-Analysis, Journal of clinical medicine (2019) — Individual-patient-data meta-analysis of 85 publications/100 patients (median age 27, 57% recreational users): most frequent outcomes subacute combined degeneration (28%), myelopathy (26%), demyelinating polyneuropathy (23%); spinal cord T2 hyperintensity in 68%; functional B12 deficiency dominant (homocysteine >15 umol/L in 90.3%, methylmalonic acid >0.4 umol/L in 93.8%). [https://pubmed.ncbi.nlm.nih.gov/31018613/]
  - Neurologic, psychiatric, and other medical manifestations of nitrous oxide abuse: A systematic review of the case literature, The American journal on addictions (2016) — Systematic review of 91 cases from 77 publications: neurologic sequelae (myeloneuropathy, subacute combined degeneration) in 72 cases, with neuroimaging changes in 39; N2O misuse correlated with low/low-normal B12 (52 cases) and elevated homocysteine/methylmalonic acid, establishing functional B12 deficiency as the core mechanism. [https://pubmed.ncbi.nlm.nih.gov/27037733/]
  - EU report — A 2022 EMCDDA technical report flags rising availability and recreational use of nitrous oxide across several EU member states and notes that most N₂O-related deaths result from accidental asphyxiation when the gas is breathed without adequate oxygen. [https://www.euda.europa.eu/system/files/publications/14934/20225054_PDF_TD0922561ENN_002.pdf]
  - Nitrous oxide-induced myeloneuropathy: an emerging public health issue, Irish journal of medical science (2023) — A 2023 review characterizes recreational nitrous-oxide-induced myeloneuropathy as an emerging public-health issue in young adults, driven by N₂O's inactivation of vitamin B12, and urges clinicians to recognize the syndrome (B12 supplementation/cessation as treatment). [https://pubmed.ncbi.nlm.nih.gov/35150382/]
  - Increase of nitrous oxide-induced neurological disorders - a German multicenter experience, Neurological research and practice (2025) — German multicenter case series reporting an increasing incidence of recreational N2O-induced neurological disorders, predominantly combined myeloneuropathy with functional B12 deficiency in young adults. [https://pmc.ncbi.nlm.nih.gov/articles/PMC11737043/]
  - Neurological disorders caused by recreational use of nitrous oxide-a retrospective study from a German metropolitan area and review of the literature, Neurological research and practice (2025) — Retrospective study (2020-2024) of 20 patients (median age 21; 16 male) with N2O-related neurological injury showed a sharp rise peaking in 2024, with combined myeloneuropathy in 45%, and biochemical functional B12 deficiency in the large majority (elevated homocysteine in ~90%, elevated MMA in ~94%). [https://pmc.ncbi.nlm.nih.gov/articles/PMC12049779/]
  - Marked increase in severe neurological disorders after nitrous oxide abuse: a retrospective study in the Greater Paris area, Journal of neurology (2024) — Retrospective multicentre cohort of 181 patients (2018-2021): 25% myelopathy, 37% peripheral neuropathy, 38% mixed; in 20-25-year-olds, 2021 incidence reached 6.15/100,000 for N2O-myelopathy and 7.48/100,000 for N2O-neuropathy, far exceeding non-N2O myelitis (0.35) and Guillain-Barre (2.47); incidence 2-3x higher in socially disadvantaged areas. [https://pubmed.ncbi.nlm.nih.gov/38478030/]
  - Nitrous oxide abuse leading to extreme homocysteine levels and thrombosis in young adults: a case series, Journal of thrombosis and haemostasis : JTH (2023) — Single-centre review of 326 recreational N2O users: 17 (5%) had severe thrombotic events (median age 26, 71% men) - 12 venous thromboembolism (10 pulmonary embolism) and 5 arterial (incl. 3 acute coronary syndrome); homocysteine severely elevated (median 125 umol/L, range 22-253; reference <15); 50% had preceding neurologic symptoms. [https://pubmed.ncbi.nlm.nih.gov/36700505/]
  - Neurological disorders caused by recreational use of nitrous oxide-a retrospective study from a German metropolitan area and review of the literature, Neurological research and practice (2025) — Retrospective German cohort of 20 recreational N2O users plus literature review: of 15 imaged, 73.3% showed posterior-funicular T2 hyperintensity consistent with subacute combined degeneration; parenteral B12 replacement produced partial neurologic recovery. [https://pubmed.ncbi.nlm.nih.gov/40319266/]
  - SUBACUTE COMBINED DEGENERATION OF THE SPINAL CORD SECONDARY TO NITROUS OXIDE-INDUCED B12 DEFICIENCY, European journal of case reports in internal medicine (2023) — A 2023 case report describes a previously healthy adolescent who developed limb paresthesias and MRI-confirmed dorsal-column subacute combined degeneration after 3–4 months of daily recreational N₂O, with only partial recovery after hydroxocobalamin therapy. [https://pubmed.ncbi.nlm.nih.gov/36969521/]
  - Nitrous oxide-induced neurotoxicity: Clinical characteristics and impacts on overall neurological impairments, Frontiers in neurology (2023) — In a 2023 cohort of 20 hospitalized recreational users aged 16–30, N₂O caused severe neurological impairment — unsteady gait (95%), weakness (95%) and limb paresthesia (70%) — with deficits that did not correlate with cumulative consumption, suggesting injury is not simply dose-dependent. [https://pubmed.ncbi.nlm.nih.gov/36908607/]
  - US Nitrous Oxide Mortality, JAMA network open (2025) — A 2025 JAMA Network Open analysis of CDC mortality data found US nitrous-oxide deaths rose from 23 (2010) to 156 (2023) — 1,240 total over the period — with a sharp ~24.5% annual increase through 2018 before plateauing. [https://pmc.ncbi.nlm.nih.gov/articles/PMC12311712/]

---

## Human Growth Hormone (HGH) (Somatropin (recombinant GH))
URL: https://nutridex.info/s/hgh
Category: Banned & Harmful, Performance
Evidence: Banned / Harmful — Linked to serious harm and/or banned in sport and many jurisdictions. Listed for awareness and safety only — NOT a recommendation.
Builds water-weight, not strength — banned, harmful, illegal to sell

Quick answer: Human Growth Hormone (HGH) is marketed for raises lean body mass (~2 kg) — but this is largely fluid, not functional muscle. NutriDex grades the human evidence as banned / harmful — Linked to serious harm and/or banned in sport and many jurisdictions. Listed for awareness and safety only — NOT a recommendation. Based on 13 cited human studies (13 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Human growth hormone (somatropin) is a pituitary hormone produced by recombinant DNA technology and FDA-approved to treat childhood and adult GH deficiency, Turner and Prader-Willi syndromes, and a few other conditions. Its use for bodybuilding, athletic performance, and 'anti-aging' is a separate, unapproved phenomenon: a 2008 Annals of Internal Medicine systematic review (Liu et al.) found GH raised lean body mass by about 2.1 kg in healthy young subjects but did NOT improve strength or exercise capacity and increased adverse events such as soft-tissue edema and fatigue — and much of the 'lean mass' gain is fluid, not muscle. The anti-aging craze traces to Rudman's small 1990 NEJM study of older men, which Rudman himself said had no anti-aging implications; later JAMA commentaries (Perls and colleagues) documented widespread illegal distribution and stressed that under 21 U.S.C. 333(e) it is a federal crime to distribute HGH for anti-aging, bodybuilding or athletic enhancement. GH and its secretagogues are on the WADA Prohibited List (class S2) banned at all times, though detection is difficult given GH's short half-life. Related agents sold alongside it — the GH-releasing peptides sermorelin, CJC-1295, ipamorelin, GHRP-2/6 and hexarelin, the oral ghrelin mimetic MK-677 (which raised fat-free mass without improving strength and worsened insulin sensitivity), and IGF-1 — share the same regulatory and safety problems. Key harms mirror acromegaly: insulin resistance and diabetes, edema, arthralgia, carpal tunnel, cardiomyopathy and other cardiovascular complications, and theoretical IGF-1-mediated cancer concerns.

Benefits / uses: Raises lean body mass (~2 kg) — but this is largely fluid, not functional muscle; Does NOT improve strength or exercise capacity despite marketing claims; Legitimately effective only for diagnosed childhood/adult GH deficiency and a few specific conditions, prescribed by an endocrinologist; Anti-aging 'rejuvenation' claims are not supported and the original researcher disavowed that use.
Active compounds: Somatropin (recombinant HGH); GH secretagogues: sermorelin, CJC-1295, ipamorelin, GHRP-2/6, hexarelin; MK-677 / ibutamoren (oral ghrelin mimetic); IGF-1 (mecasermin).
Dose: Legitimate medical dosing is individualized by an endocrinologist based on weight, IGF-1 levels and the diagnosed deficiency; there is no safe or approved dose for muscle-building, athletic performance, or anti-aging.
Safety: Common GH-related adverse effects include fluid retention with peripheral edema, arthralgia and joint stiffness, carpal tunnel syndrome, and myalgia; metabolically it causes insulin resistance, glucose intolerance and can precipitate type 2 diabetes. Chronic excess produces acromegaly-like features (bony/soft-tissue overgrowth, organ enlargement) and cardiovascular harm including cardiomyopathy, heart failure, arrhythmia, valvular disease and hypertension. There is a theoretical, biologically plausible cancer concern from elevated IGF-1. Black-market and 'anti-aging'/internet products carry added risks of counterfeit, contaminated, or mislabeled material and unsterile injection. GH interacts with insulin and oral hypoglycemics (worsening glycemic control), corticosteroids, and oral estrogens, and can unmask adrenal insufficiency or thyroid changes. It should be used only for an FDA-approved indication under direct endocrinologist supervision; using or distributing it for performance, bodybuilding, or anti-aging is unproven, banned in sport, and illegal in the US.

Cited studies (13):
  - Systematic review: the effects of growth hormone on athletic performance, Annals of internal medicine (2008) — In a systematic review of 27 studies in healthy, mostly young subjects, GH increased lean body mass by ~2.1 kg (95% CI 1.3-2.9) but did not improve strength or exercise capacity and increased soft-tissue edema and fatigue. [https://pubmed.ncbi.nlm.nih.gov/18347346/]
  - Systematic review: the safety and efficacy of growth hormone in the healthy elderly, Annals of internal medicine (2007) — Meta-analysis of 18 RCT populations (220 GH-treated, mean age 69): GH decreased fat mass by 2.1 kg (95% CI -2.8 to -1.35) and increased lean body mass by 2.1 kg (CI 1.3 to 2.9), with no weight change and no bone-density benefit, but significantly more edema, arthralgia, carpal tunnel syndrome, gynecomastia and more diabetes/IFG. Concluded GH cannot be recommended as anti-aging therapy. [https://pubmed.ncbi.nlm.nih.gov/17227934/]
  - Evaluation and treatment of adult growth hormone deficiency: an Endocrine Society clinical practice guideline, The Journal of clinical endocrinology and metabolism (2011) — Endocrine Society guideline: GH (somatropin) replacement in confirmed adult GH deficiency improves body composition, exercise capacity, skeletal integrity, and quality of life, with greatest benefit in severe GHD; treatment risks are low. Recommends individualized dosing and stimulation-test confirmation before treating. [https://pubmed.ncbi.nlm.nih.gov/21602453/]
  - Weekly Lonapegsomatropin in Treatment-Naïve Children With Growth Hormone Deficiency: The Phase 3 heiGHt Trial, The Journal of clinical endocrinology and metabolism (2021) — 52-week phase 3 RCT in 161 treatment-naive prepubertal children with GHD: once-weekly long-acting lonapegsomatropin gave annualized height velocity 11.2 vs 10.3 cm/year for daily somatropin (P=0.009), meeting noninferiority and showing superiority; height SDS gain 1.10 vs 0.96 (P=0.01), with comparable safety. [https://pubmed.ncbi.nlm.nih.gov/34272849/]
  - Once-weekly Somapacitan is Effective and Well Tolerated in Adults with GH Deficiency: A Randomized Phase 3 Trial, The Journal of clinical endocrinology and metabolism (2020) — Randomized phase 3 trial in 301 treatment-naive adults with GHD: once-weekly somapacitan significantly reduced truncal fat percentage vs placebo at 34 weeks (estimated difference -1.53%, 95% CI -2.68 to -0.38; P=0.009) and improved visceral fat, lean body mass and IGF-I SDS; effects maintained to 86 weeks with safety comparable to daily GH. [https://pubmed.ncbi.nlm.nih.gov/32022863/]
  - The Prohibited List, World Anti-Doping Agency (2026) — GH, its fragments/releasing factors and secretagogues (including ibutamoren/MK-677, ipamorelin, GHRP-2/6, hexarelin) plus IGF-1 are prohibited at all times (class S2) for all athletes, in and out of competition. [https://www.wada-ama.org/en/prohibited-list]
  - HGH (human growth hormone): Is it legal?, Operation Supplement Safety (U.S. DoD) — US Department of Defense resource stating HGH is banned by WADA and most sports organizations and that in the US it is illegal to possess or distribute HGH for any purpose other than FDA-approved, physician-prescribed medical uses. [https://www.opss.org/article/hgh-human-growth-hormone-it-legal]
  - Effects of human growth hormone in men over 60 years old, The New England journal of medicine (1990) — In 12 healthy men aged 61-81 with low IGF-1, six months of GH increased lean body mass by 4.7 kg and reduced fat by 3.5 kg, but also raised systolic blood pressure and fasting glucose — the small study later misused to launch the anti-aging industry. [https://pubmed.ncbi.nlm.nih.gov/2355952/]
  - Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults: a randomized trial, Annals of Internal Medicine (2008) — In a 2-year RCT of the oral ghrelin mimetic MK-677 (ibutamoren) in 65 healthy adults aged 60-81, it raised GH/IGF-1 and increased fat-free mass (~1.1 kg) but did not improve strength or function and tended to worsen fasting glucose/insulin sensitivity. [https://www.acpjournals.org/doi/10.7326/0003-4819-149-9-200811040-00003]
  - Cardiovascular Effects of Excess Growth Hormone: How Real is the Threat?, Reviews in cardiovascular medicine (2023) — Review concluding chronic GH/IGF-1 excess drives cardiomyopathy, heart failure, arrhythmia, valvular disease and hypertension, with cardiovascular disease the leading cause of death in acromegaly until hormone levels are normalized. [https://pmc.ncbi.nlm.nih.gov/articles/PMC11273026/]
  - Metabolic Consequences of Anabolic Steroids, Insulin, and Growth Hormone Abuse in Recreational Bodybuilders: Implications for the World Anti-Doping Agency Passport, Sports medicine - open (2024) — Among 92 male bodybuilders, 43% abused hormones (AAS 95%, GH 30%, insulin 38%); GH/insulin abusers showed lower HDL-cholesterol and hormone abusers had elevated ALT and AST transaminases versus non-doping bodybuilders and controls. [https://pubmed.ncbi.nlm.nih.gov/38536564/]
  - Provision or distribution of growth hormone for "antiaging": clinical and legal issues, JAMA (2005) — Commentary establishing that, due to 1988/1990 amendments to the Food, Drug and Cosmetic Act, distributing or prescribing GH for anti-aging or age-associated conditions is illegal in the US, and that much of the ~$622 million in 2004 HGH sales was likely for such illegal uses. [https://pubmed.ncbi.nlm.nih.gov/16249424/]
  - New developments in the illegal provision of growth hormone for "anti-aging" and bodybuilding, JAMA (2008) — Follow-up documenting expanding illegal internet and clinic provision of GH for anti-aging and bodybuilding, reiterating that off-label distribution for these purposes violates US law (21 U.S.C. 333(e)). [https://pubmed.ncbi.nlm.nih.gov/18560007/]

---

## Apple (Malus domestica)
URL: https://nutridex.info/s/apple
Category: Fruits
Evidence: Moderate — Several controlled trials; effects real but modest or context-dependent.
Fibre-rich everyday fruit with steady heart evidence

Quick answer: Apple is used for modestly lowers total and ldl cholesterol versus placebo (rct meta-analysis). NutriDex grades the human evidence as moderate — Several controlled trials; effects real but modest or context-dependent. Based on 9 cited human studies (9 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Human evidence for apples is moderate and rests largely on consistent observational cohorts plus a smaller body of RCTs. A 2022 meta-analysis of randomized trials found that more than a week of apple or apple-derived product intake significantly reduced total and LDL cholesterol versus placebo, especially in people with elevated baseline levels, though it showed no clear effect on triglycerides, glucose, CRP or blood pressure (and a small HDL reduction). Large prospective cohorts link higher apple/pear intake to lower stroke incidence and reduced type 2 diabetes risk, and flavonoid-intake meta-analyses associate apple-rich dietary patterns with lower cardiovascular and all-cause mortality. However, most outcome data are observational and confounded by overall healthy lifestyle, and the widely cited "apple a day" claim was not supported for reducing physician visits. Apples are nutrient-modest (low vitamin C, low micronutrient density) and act mainly through fibre and polyphenols rather than vitamins. Net effects on hard endpoints remain associational, not proven causal.

Nutrition (per 1 medium (182 g)): 95 kcal; Fibre 4.4g (16% DV), Vitamin C 8.4mg (9% DV), Potassium 195mg (4% DV), Vitamin K 4mcg (3% DV), Calcium 11mg (1% DV), Vitamin A 5.5mcg (1% DV).
Benefits / uses: Modestly lowers total and LDL cholesterol versus placebo (RCT meta-analysis); Associated with lower cardiovascular disease and stroke risk in cohorts; Whole-apple intake linked to reduced type 2 diabetes risk; Soluble fibre (pectin) supports satiety and digestive regularity; Higher flavonoid intake tied to lower all-cause mortality; Contributes to better overall diet quality and weight control.
Active compounds: Pectin (soluble fibre); Quercetin glycosides (flavonols); Flavan-3-ols / procyanidins; Chlorogenic acid (hydroxycinnamic acid); Phloridzin (dihydrochalcone); Vitamin C (ascorbic acid); Potassium; Triterpenoids (ursolic acid, in peel).
Dose: One medium apple (~182 g) per day, eaten whole with skin where most polyphenols and fibre reside; 1-3 servings/day fits dietary fruit guidance. Whole fruit is preferable to juice.
Safety: Generally very safe. People with oral allergy syndrome (birch-pollen cross-reactivity, Mal d 1 protein) may react to raw apple; cooking usually helps. The natural sugar/FODMAP (fructose, sorbitol) load can cause bloating or diarrhoea in sensitive or IBS individuals and counts toward carbohydrate intake for diabetics. Apple seeds contain amygdalin (cyanogenic) but are harmless unless large quantities are crushed and eaten. No grapefruit-type CYP3A4 interaction. Skins may carry pesticide residues—wash well.

Cited studies (9):
  - Soluble Fiber Supplementation and Serum Lipid Profile: A Systematic Review and Dose-Response Meta-Analysis of Randomized Controlled Trials, Advances in nutrition (Bethesda, Md.) (2023) — Dose-response meta-analysis of 181 RCTs (220 arms, 14,505 participants) found soluble fiber supplementation significantly reduced LDL-C by 8.28 mg/dL, total cholesterol by 10.82 mg/dL, and apolipoprotein B, with effects of pectin similar to oat and psyllium. [https://pubmed.ncbi.nlm.nih.gov/36796439/]
  - Metabolic and Cardiovascular Benefits of Apple and Apple-Derived Products: A Systematic Review and Meta-Analysis of Randomized Controlled Trials, Frontiers in nutrition (2022) — Meta-analysis of 18 RCTs: >1 week of apple/apple-derived product intake significantly reduced total and LDL cholesterol vs placebo controls, strongest at high baseline cholesterol; HDL also fell slightly and triglycerides, glucose, CRP and blood pressure were unchanged. [https://pmc.ncbi.nlm.nih.gov/articles/PMC9016272/]
  - Dietary Flavonoids and Cardiovascular Disease: A Comprehensive Dose-Response Meta-Analysis, Molecular Nutrition & Food Research (2021) — Dose-response meta-analysis (39 cohorts, ~1.5M people): higher total flavonoid, flavan-3-ol and anthocyanin intake inversely associated with cardiovascular disease risk. [https://onlinelibrary.wiley.com/doi/10.1002/mnfr.202001019]
  - Dietary total flavonoids intake and risk of mortality from all causes and cardiovascular disease in the general population, Molecular Nutrition & Food Research (2017) — Meta-analysis of cohort studies: highest vs lowest total flavonoid intake associated with lower all-cause mortality (RR 0.82, 95% CI 0.72-0.92); CVD mortality only marginal. [https://onlinelibrary.wiley.com/doi/abs/10.1002/mnfr.201601003]
  - Effects of Intake of Apples, Pears, or Their Products on Cardiometabolic Risk Factors and Clinical Outcomes: A Systematic Review and Meta-Analysis, Current developments in nutrition (2019) — Systematic review/meta-analysis (22 studies): in cohorts, higher apple/pear intake associated with ~14-15% lower cerebrovascular disease, cardiovascular death, type 2 diabetes and all-cause mortality; RCTs showed only a BMI reduction, no lipid/glucose/BP effect. [https://pmc.ncbi.nlm.nih.gov/articles/PMC6813372/]
  - A red-fleshed apple rich in anthocyanins improves endothelial function, reduces inflammation, and modulates the immune system in hypercholesterolemic subjects: the AppleCOR study, Food & function (2024) — In 121 hypercholesterolemic adults, 6 weeks of daily anthocyanin-rich red-fleshed apple improved ischemic reactive hyperemia (endothelial function) and lowered C-reactive protein and IL-6 versus white-fleshed apple, supporting cardioprotective effects beyond lipids. [https://pubmed.ncbi.nlm.nih.gov/38751340/]
  - Association between apple consumption and physician visits: appealing the conventional wisdom that an apple a day keeps the doctor away, JAMA internal medicine (2015) — NHANES analysis of 8,399 adults: daily apple eaters did not have significantly fewer physician visits after adjustment, though used marginally fewer prescription medications. [https://pubmed.ncbi.nlm.nih.gov/25822137/]
  - Fruit consumption and risk of type 2 diabetes: results from three prospective longitudinal cohort studies, BMJ (Clinical research ed.) (2013) — Three US cohorts (>187,000 adults): higher whole-apple/pear intake associated with lower type 2 diabetes risk (pooled HR 0.93 per 3 servings/week); fruit juice raised risk (HR 1.08). [https://pubmed.ncbi.nlm.nih.gov/23990623/]
  - Colors of fruit and vegetables and 10-year incidence of stroke, Stroke (2011) — Dutch cohort of 20,069 adults: each 25 g/day of white-fleshed fruit/veg (mostly apples/pears) linked to 9% lower 10-year stroke risk (HR 0.91, 95% CI 0.85-0.97). [https://pubmed.ncbi.nlm.nih.gov/21921279/]

---

## Banana (Musa acuminata)
URL: https://nutridex.info/s/banana
Category: Fruits
Evidence: Moderate — Several controlled trials; effects real but modest or context-dependent.
Potassium-rich, resistant-starch fruit for heart and gut

Quick answer: Banana is used for dietary potassium supports healthy blood pressure. NutriDex grades the human evidence as moderate — Several controlled trials; effects real but modest or context-dependent. Based on 9 cited human studies (9 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Bananas are a dense source of dietary potassium and vitamin B6 with modest vitamin C and fibre. Large dose-response meta-analyses of prospective cohorts show that higher overall fruit intake is associated with lower risk of stroke, cardiovascular disease and all-cause mortality, and trials confirm that the potassium bananas supply lowers blood pressure, especially in people with hypertension. Resistant starch from unripe bananas and banana-derived starch modestly improves fasting glucose and insulin in controlled trials, and the soluble fibre/pectin aids stool regularity. However, almost no large trials test bananas as an isolated food, so benefits are inferred from potassium, fibre and total-fruit data rather than from the whole fruit directly. The sugar and rapidly available carbohydrate load of ripe bananas means the glycemic benefit applies mainly to unripe fruit or isolated starch. Overall the human evidence for cardiometabolic benefit is consistent but largely indirect.

Nutrition (per 1 medium (118 g)): 105 kcal; Potassium 422mg (9% DV), Vitamin B6 0.43mg (25% DV), Vitamin C 10.3mg (11% DV), Manganese 0.32mg (14% DV), Fibre 3.1g (11% DV), Magnesium 31.9mg (8% DV).
Benefits / uses: Dietary potassium supports healthy blood pressure; Part of fruit intake linked to lower stroke and cardiovascular risk; Resistant starch (unripe) and pectin support glycemic and gut health; Quick, low-fat carbohydrate source for exercise fueling; Soluble and resistant fibre promote satiety and laxation.
Active compounds: Potassium; Vitamin B6 (pyridoxine); Vitamin C; Resistant starch (type 2, unripe); Pectin (soluble fibre); Magnesium; Manganese; Dopamine and catechin antioxidants; Fructooligosaccharides (prebiotic).
Dose: 1 medium banana (about 118 g edible) provides roughly 105 kcal and 422 mg potassium; 1-2 per day fits within general fruit recommendations (about 2 servings of fruit daily). Greener (less ripe) bananas carry more resistant starch and a lower glycemic impact.
Safety: Generally very safe. Latex-fruit syndrome sufferers may cross-react to banana. The readily digestible sugars of ripe bananas can raise post-meal glucose, so people with diabetes should mind portion and ripeness. Those on potassium-sparing diuretics, ACE inhibitors/ARBs, or with advanced chronic kidney disease should moderate potassium intake to avoid hyperkalemia. Bananas are high in FODMAP fructans when ripe and may trigger IBS symptoms in sensitive individuals; they are not a notable oxalate source.

Cited studies (9):
  - Fruit and Vegetable Intake and Mortality: Results From 2 Prospective Cohort Studies of US Men and Women and a Meta-Analysis of 26 Cohort Studies, Circulation (2021) — Meta-analysis of 26 cohorts (~1.9 million adults): ~5 daily servings of fruit/vegetables (2 fruit, 3 vegetable) associated with the lowest total mortality, about 13% lower than 2 servings. [https://pubmed.ncbi.nlm.nih.gov/33641343/]
  - Effects of resistant starch on glycemic control, serum lipoproteins and systemic inflammation in patients with metabolic syndrome and related disorders: A systematic review and meta-analysis of randomized controlled clinical trials, Critical reviews in food science and nutrition (2020) — Meta-analysis of RCTs in metabolic syndrome: resistant starch (the type found in unripe bananas) significantly reduced fasting plasma glucose (WMD ~-4.3 mg/dL) and improved insulin/HbA1c. [https://pubmed.ncbi.nlm.nih.gov/31661295/]
  - Fruit and vegetable intake and the risk of cardiovascular disease, total cancer and all-cause mortality-a systematic review and dose-response meta-analysis of prospective studies, International journal of epidemiology (2017) — Dose-response meta-analysis of 95 cohort studies: each 200 g/day of fruit and vegetables was associated with lower coronary heart disease, stroke, total cardiovascular disease and all-cause mortality, with benefit observed up to ~800 g/day. [https://pubmed.ncbi.nlm.nih.gov/28338764/]
  - Effect of increased potassium intake on cardiovascular risk factors and disease: systematic review and meta-analyses, BMJ (Clinical research ed.) (2013) — Systematic review/meta-analysis: higher potassium intake reduced systolic BP by ~3.5 mmHg overall (more in hypertensives) and was linked to 24% lower stroke risk (RR 0.76). [https://pubmed.ncbi.nlm.nih.gov/23558164/]
  - Fruits and vegetables consumption and risk of stroke: a meta-analysis of prospective cohort studies, Stroke (2014) — Meta-analysis of 20 prospective cohorts (~760,000 participants): stroke risk fell ~32% per 200 g/day increment in fruit consumption. [https://pubmed.ncbi.nlm.nih.gov/24811336/]
  - Effectiveness of salt substitute on cardiovascular outcomes: A systematic review and meta-analysis, Journal of clinical hypertension (Greenwich, Conn.) (2022) — Systematic review/meta-analysis found potassium-enriched salt substitution lowered systolic BP by -4.80 mmHg and diastolic BP by -1.48 mmHg versus regular salt. [https://pmc.ncbi.nlm.nih.gov/articles/PMC9532913/]
  - The contribution of sodium reduction and potassium increase to the blood pressure lowering observed in the Salt Substitute and Stroke Study, Journal of Human Hypertension (2024) — Mediation analysis of SSaSS attributed the -3.3 mmHg systolic BP fall to a 15.2 mmol/day fall in sodium excretion and a 20.6 mmol/day rise in potassium excretion. [https://www.nature.com/articles/s41371-024-00896-4]
  - Guideline: potassium intake for adults and children, World Health Organization — WHO recommends increasing dietary potassium to at least 90 mmol/day (3510 mg/day) to lower blood pressure and reduce risk of cardiovascular disease, stroke, and coronary heart disease in adults. [https://www.who.int/publications/i/item/9789241504829]
  - Total and specific fruit and vegetable consumption and risk of stroke: a prospective study, Atherosclerosis (2013) — Prospective cohort (~75,000 Swedish adults): higher total fruit/vegetable intake, especially apples/pears and leafy greens, was inversely associated with stroke risk (RR ~0.87). [https://pubmed.ncbi.nlm.nih.gov/23294925/]

---

## Blueberry (Vaccinium corymbosum / Vaccinium angustifolium)
URL: https://nutridex.info/s/blueberry
Category: Fruits
Evidence: Moderate — Several controlled trials; effects real but modest or context-dependent.
Anthocyanin-rich berry for vascular and brain health

Quick answer: Blueberry is used for improves endothelial function (flow-mediated dilation) in controlled trials. NutriDex grades the human evidence as moderate — Several controlled trials; effects real but modest or context-dependent. Based on 8 cited human studies (8 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Blueberries are among the most anthocyanin-dense common fruits, and human evidence is strongest for vascular benefits: meta-analyses and double-blind RCTs show a daily ~1-cup intake improves flow-mediated dilation, an endothelial-function marker, with anthocyanin metabolites mediating the effect. Large U.S. prospective cohorts link higher blueberry/anthocyanin intake to modestly lower type 2 diabetes risk, and meta-analyses of anthocyanin/berry intake show small reductions in LDL-cholesterol and insulin resistance, mainly at higher doses over longer trials. Cognitive trials in older adults suggest small gains in episodic memory and executive function, but results are inconsistent across domains. Importantly, pooled RCTs find no reliable blood-pressure-lowering effect for whole-group analyses, and most data come from supplements, surrogate endpoints, and short trials rather than hard clinical outcomes. Cohort associations cannot prove causation and may reflect healthier overall diets. Overall the weight of human evidence is moderate and supportive of blueberries as part of a healthy diet rather than a therapeutic intervention.

Nutrition (per 1 cup (148 g)): 84 kcal; Vitamin K 28.6mcg (24% DV), Manganese 0.5mg (22% DV), Vitamin C 14.4mg (16% DV), Fibre 3.6g (13% DV), Copper 0.084mg (9% DV), Vitamin E 0.84mg (6% DV), Potassium 114mg (2% DV).
Benefits / uses: Improves endothelial function (flow-mediated dilation) in controlled trials; Associated with lower type 2 diabetes risk in large prospective cohorts; May modestly improve memory and executive function, especially in older adults; May lower LDL-cholesterol and improve cardiometabolic markers as part of anthocyanin/berry intake; Provides dietary fibre and a low glycaemic load relative to many fruits; Good source of vitamin K and manganese.
Active compounds: Anthocyanins (malvidin-, delphinidin-, cyanidin-3-glucosides); Chlorogenic acid and other phenolic acids; Flavonols (quercetin); Proanthocyanidins; Vitamin C (ascorbic acid); Vitamin K1 (phylloquinone); Manganese; Pectin and other soluble/insoluble fibre; Potassium.
Dose: A typical serving is 1 cup (148 g) of fresh berries; trials showing vascular and cognitive effects used roughly 1 cup/day fresh equivalent (about 150 g, or 24 g/day freeze-dried powder) over several weeks to 6 months.
Safety: Generally very safe as a food. Blueberries are a FODMAP/fructose source and large amounts may cause GI discomfort in sensitive people; they contribute natural sugar (~15 g per cup) so portion matters for those managing glycaemia, though their glycaemic load is modest. They contain vitamin K1, so people on warfarin should keep intake consistent to avoid affecting INR. True blueberry allergy is rare. Concentrated anthocyanin extracts/supplements are not equivalent to whole fruit and lack the same safety record. No clinically important grapefruit-type CYP3A4 interaction is established for blueberries.

Cited studies (8):
  - Effect of blueberry intervention on endothelial function: a systematic review and meta-analysis, Frontiers in physiology (2024) — Systematic review and meta-analysis of blueberry interventions found significant improvement in flow-mediated dilation (+1.50%) and reactive hyperemia index; no significant effect on systolic BP or LDL/HDL. [https://pubmed.ncbi.nlm.nih.gov/38887319/]
  - Associations of dietary intakes of anthocyanins and berry fruits with risk of type 2 diabetes mellitus: a systematic review and meta-analysis of prospective cohort studies, European journal of clinical nutrition (2016) — Meta-analysis of prospective cohorts: higher anthocyanin and berry intake associated with ~15-18% lower type 2 diabetes risk. [https://pubmed.ncbi.nlm.nih.gov/27530472/]
  - Effects of blueberry supplementation on blood pressure: a systematic review and meta-analysis of randomized clinical trials, Journal of human hypertension (2017) — Meta-analysis of 6 RCTs found no significant effect of blueberry supplementation on systolic or diastolic blood pressure. [https://pubmed.ncbi.nlm.nih.gov/27654329/]
  - Effect of anthocyanin supplementation on cardio-metabolic biomarkers: A systematic review and meta-analysis of randomized controlled trials, Clinical nutrition (Edinburgh, Scotland) (2019) — Meta-analysis of 19 RCTs: anthocyanin supplementation significantly improved HOMA-IR and reduced total and LDL cholesterol (at >300 mg/day for >12 weeks); no effect on blood pressure. [https://pubmed.ncbi.nlm.nih.gov/30007479/]
  - Circulating Anthocyanin Metabolites Mediate Vascular Benefits of Blueberries: Insights From Randomized Controlled Trials, Metabolomics, and Nutrigenomics, The journals of gerontology. Series A, Biological sciences and medical sciences (2019) — Daily 1-month wild blueberry intake increased flow-mediated dilation and lowered 24-h ambulatory systolic BP; anthocyanin metabolites mediated the vascular benefit. [https://pubmed.ncbi.nlm.nih.gov/30772905/]
  - Blueberries improve biomarkers of cardiometabolic function in participants with metabolic syndrome-results from a 6-month, double-blind, randomized controlled trial, The American journal of clinical nutrition (2019) — 1 cup/day blueberries for 6 months improved endothelial function (FMD +1.45%) and arterial stiffness in metabolic syndrome participants; insulin resistance and blood pressure were unchanged. [https://pubmed.ncbi.nlm.nih.gov/31136659/]
  - Dietary blueberry improves cognition among older adults in a randomized, double-blind, placebo-controlled trial, European journal of nutrition (2018) — 90-day double-blind RCT in older adults: freeze-dried blueberry (24 g/day) improved aspects of executive function (task-switching) versus placebo; no gait/balance benefit. [https://pubmed.ncbi.nlm.nih.gov/28283823/]
  - Fruit consumption and risk of type 2 diabetes: results from three prospective longitudinal cohort studies, BMJ (Clinical research ed.) (2013) — In three large cohorts (>187,000), higher blueberry intake was associated with lower type 2 diabetes risk (HR 0.74 per 3 servings/week). [https://pubmed.ncbi.nlm.nih.gov/23990623/]

---

## Strawberry (Fragaria × ananassa)
URL: https://nutridex.info/s/strawberry
Category: Fruits
Evidence: Moderate — Several controlled trials; effects real but modest or context-dependent.
Vitamin C-rich berry with vascular and cognitive signals

Quick answer: Strawberry is used for excellent vitamin c source supporting antioxidant defence and collagen synthesis. NutriDex grades the human evidence as moderate — Several controlled trials; effects real but modest or context-dependent. Based on 10 cited human studies (10 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Strawberries are a nutrient-dense, low-calorie berry whose strongest, most consistent nutritional credential is being an outstanding source of vitamin C, with useful fibre, potassium and polyphenols. Human evidence for disease-modifying effects is moderate rather than definitive: a meta-analysis of randomised trials found strawberry intervention significantly lowered C-reactive protein and improved total and LDL cholesterol mainly in people with elevated baseline lipids, while effects on blood pressure and fasting glucose were not significant overall. Large prospective cohorts (Nurses' Health Study, Rush Memory and Aging Project) link higher strawberry and pelargonidin/anthocyanidin intake to slower cognitive decline and lower Alzheimer's dementia risk, and pooled cohort data tie anthocyanin- and berry-rich diets to modestly lower type 2 diabetes risk. However, most trials are small, short, frequently use freeze-dried concentrates rather than whole fruit, and observational findings cannot prove causation or separate strawberries from an overall healthy diet. Strawberries are best viewed as a healthful component of a varied diet rather than a standalone therapy.

Nutrition (per 1 cup whole (152 g)): 49 kcal; Vitamin C 89.4mg (99% DV), Manganese 0.59mg (26% DV), Fibre 3g (11% DV), Folate 36.5mcg (9% DV), Potassium 233mg (5% DV), Magnesium 19.8mg (5% DV).
Benefits / uses: Excellent vitamin C source supporting antioxidant defence and collagen synthesis; May lower LDL/total cholesterol in people with elevated baseline lipids; Reduces circulating C-reactive protein (an inflammatory marker) in trials; Higher long-term intake linked to slower cognitive decline and lower dementia risk; Anthocyanin/berry intake associated with reduced type 2 diabetes risk in cohorts; Low glycaemic load with soluble fibre supporting glucose and satiety.
Active compounds: Vitamin C (ascorbic acid); Anthocyanins (pelargonidin-3-glucoside); Ellagitannins & ellagic acid; Flavonols (quercetin, kaempferol); Dietary fibre (pectin, cellulose); Potassium; Folate; Manganese.
Dose: A typical serving is about 1 cup (152 g, ~8 medium berries) fresh. Cardiometabolic trials often used the equivalent of 2-4 cups/day (≈25-50 g freeze-dried powder). One cup supplies roughly a full day's vitamin C.
Safety: Generally very safe. Strawberries are a recognised allergen (oral allergy syndrome, especially in those sensitised to birch pollen; rarely systemic reactions). They are among produce with higher pesticide residues, so washing or choosing organic is reasonable. They contain moderate oxalate, relevant for people prone to calcium-oxalate kidney stones, and salicylates that can affect sensitive individuals. Sugar and carbohydrate load is low per serving, but concentrated forms (jams, dried, sweetened) shift this. No notable CYP3A4/grapefruit-type drug interaction is established for strawberries.

Cited studies (10):
  - Impact of strawberry consumption on blood pressure in adults: GRADE-assessed systematic review and dose-response meta-analysis of data from randomized controlled trials, Avicenna journal of phytomedicine (2025) — GRADE-assessed dose-response meta-analysis of 8 RCTs found no significant effect of strawberry on systolic (WMD +0.96 mmHg, 95% CI -0.26 to 2.20) or diastolic blood pressure (WMD -0.33 mmHg, 95% CI -1.31 to 0.65). [https://pmc.ncbi.nlm.nih.gov/articles/PMC12441197/]
  - Effects of strawberry intervention on cardiovascular risk factors: a meta-analysis of randomised controlled trials, The British journal of nutrition (2020) — Across 11 RCTs, strawberry intervention significantly lowered C-reactive protein and reduced total/LDL cholesterol in those with elevated baseline lipids; no significant effect on blood pressure, lipid profile overall, or fasting glucose. [https://pubmed.ncbi.nlm.nih.gov/32238201/]
  - Associations of dietary intakes of anthocyanins and berry fruits with risk of type 2 diabetes mellitus: a systematic review and meta-analysis of prospective cohort studies, European journal of clinical nutrition (2016) — Higher dietary anthocyanin and berry intake were associated with 15% and 18% lower type 2 diabetes risk respectively across prospective cohorts. [https://pubmed.ncbi.nlm.nih.gov/27530472/]
  - Strawberries Improve Insulin Resistance and Related Cardiometabolic Markers in Adults with Prediabetes: A Randomized Controlled Crossover Trial, The Journal of nutrition (2025) — In a 28-week crossover RCT in adults with prediabetes, 32 g/day freeze-dried strawberries (~2.5 servings) for 12 weeks significantly improved insulin, HOMA-IR, fasting glucose, HbA1c, and total cholesterol versus control. [https://pubmed.ncbi.nlm.nih.gov/40250566/]
  - Dietary Strawberries Improve Serum Metabolites of Cardiometabolic Risks in Adults with Features of the Metabolic Syndrome in a Randomized Controlled Crossover Trial, International journal of molecular sciences (2023) — 14-week crossover RCT in adults with metabolic syndrome features found high-dose strawberry (32 g powder/day) reduced fasting insulin, insulin resistance, and total/small LDL and VLDL particle concentrations versus control. [https://pmc.ncbi.nlm.nih.gov/articles/PMC9916764/]
  - Randomized Double-Blind Controlled Trial of Freeze-Dried Strawberry Powder Supplementation in Adults with Overweight or Obesity and Elevated Cholesterol, Journal of the American Nutrition Association (2023) — Double-blind RCT in adults with overweight/obesity and elevated cholesterol found low-dose strawberry supplement reduced LDL cholesterol by 4.9% (vs high dose) and total cholesterol by 2.8% (vs control). [https://pubmed.ncbi.nlm.nih.gov/35512768/]
  - Strawberries decrease atherosclerotic markers in subjects with metabolic syndrome, Nutrition research (New York, N.Y.) (2010) — Freeze-dried strawberry beverage (50 g/day, 8 weeks) significantly decreased total (-10%) and LDL cholesterol (-11%) and small LDL particles in adults with metabolic syndrome. [https://pmc.ncbi.nlm.nih.gov/articles/PMC2929388/]
  - Freeze-dried strawberry powder improves lipid profile and lipid peroxidation in women with metabolic syndrome: baseline and post intervention effects, Nutrition journal (2009) — In a single-arm 4-week study of 16 women with metabolic syndrome, freeze-dried strawberry powder lowered total cholesterol (-5%), LDL (-6%) and lipid peroxidation (-14%) versus baseline. [https://pubmed.ncbi.nlm.nih.gov/19785767/]
  - Association of Strawberries and Anthocyanidin Intake with Alzheimer's Dementia Risk, Nutrients (2019) — In 925 older adults (Rush Memory and Aging Project), higher strawberry intake was associated with reduced Alzheimer's dementia risk (HR 0.76, 95% CI 0.60-0.96), with pelargonidin implicated. [https://pubmed.ncbi.nlm.nih.gov/31847371/]
  - Dietary intakes of berries and flavonoids in relation to cognitive decline, Annals of neurology (2012) — In 16,010 older women (Nurses' Health Study), greater blueberry and strawberry intake was associated with slower cognitive decline, equivalent to delaying cognitive aging by up to ~2.5 years. [https://pubmed.ncbi.nlm.nih.gov/22535616/]

---

## Raspberry (Rubus idaeus)
URL: https://nutridex.info/s/raspberry
Category: Fruits
Evidence: Preliminary — Early or small human trials; promising but not yet conclusive.
Fibre-dense berry rich in ellagitannins and anthocyanins

Quick answer: Raspberry is used for acutely improves vascular endothelial function (flow-mediated dilation) in small trials. NutriDex grades the human evidence as preliminary — Early or small human trials; promising but not yet conclusive. Based on 11 cited human studies (11 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Human evidence for red raspberry is genuinely promising but still preliminary. A small double-blind crossover RCT (10 healthy men) showed dietary-achievable amounts acutely improve flow-mediated dilation for up to 24 hours, with the effect tracking urolithin metabolites from ellagitannins. A crossover RCT in adults at risk for diabetes found 125-250 g attenuates postprandial glucose and insulin, and pooled meta-analyses report a fall in TNF-alpha. Reductions in total and LDL cholesterol come mainly from broader anthocyanin meta-analyses rather than raspberry-specific trials. The most recent raspberry-specific systematic reviews and meta-analyses (2024) found no significant overall effect on fasting glucose, HbA1c, CRP, IL-6, weight, BMI, waist circumference, or liver enzymes; trials are small, short, and heterogeneous. Net: raspberry is a nutrient-dense, high-fibre fruit with plausible mechanisms, but firm whole-fruit clinical outcome data are lacking.

Nutrition (per 1 cup (123 g)): 64 kcal; Fibre 8g (29% DV), Vitamin C 32.2mg (36% DV), Manganese 0.82mg (36% DV), Vitamin K 9.6µg (8% DV), Folate 25.8µg (6% DV), Magnesium 27mg (6% DV), Potassium 186mg (4% DV).
Benefits / uses: Acutely improves vascular endothelial function (flow-mediated dilation) in small trials; May blunt postprandial glucose and insulin spikes in those at metabolic risk; May lower total/LDL cholesterol in people with elevated baseline lipids (largely from broader anthocyanin trials); Reduces the inflammatory marker TNF-alpha in pooled trials; Very high dietary fibre supporting satiety and bowel regularity; Antioxidant polyphenol load (anthocyanins, ellagitannins, vitamin C).
Active compounds: Ellagitannins (sanguiin H-6, lambertianin C) yielding ellagic acid; Anthocyanins (cyanidin-3-sophoroside, cyanidin-3-glucoside); Vitamin C (ascorbic acid); Dietary fibre (including pectin); Manganese; Vitamin K (phylloquinone); Quercetin and other flavonols; Potassium.
Dose: A typical serving is 1 cup (~123 g) of fresh or frozen raspberries; clinical studies generally use 125-250 g/day (about 1-2 cups). Whole or frozen fruit retains fibre and polyphenols better than strained juice.
Safety: Generally very safe as a food. Rosaceae-family or oral-allergy-syndrome reactions are possible in sensitive individuals (cross-reactivity with birch pollen). Raspberries contain oxalates and modest salicylates, relevant only for those with recurrent oxalate kidney stones or salicylate sensitivity. Fruit and dried-leaf products are not interchangeable: raspberry-leaf tea (uterotonic) is a separate product with its own pregnancy cautions and should not be confused with the fruit. The vitamin K content (about 8% DV per cup) is minor but worth noting for those on warfarin who track intake consistency. Sugar load is low for fresh/frozen fruit; sweetened juices, jams, and syrups are not equivalent.

Cited studies (11):
  - The effects of raspberry consumption on lipid profile and blood pressure in adults: A systematic review and meta-analysis, Food science & nutrition (2024) — Meta-analysis of 11 RCTs found raspberry consumption produced no significant change in lipid profile or blood pressure versus control in adults. [https://pubmed.ncbi.nlm.nih.gov/38628181/]
  - The Effects of Blackcurrant and Raspberry Consumption on Blood Pressure: A Systematic Review and Meta-Analysis of Randomized Controlled Trials, Clinical nutrition research (2023) — Meta-analysis of 10 RCTs (n=420) assessing blackcurrant and raspberry consumption found no significant effect on systolic or diastolic blood pressure. [https://pubmed.ncbi.nlm.nih.gov/36793778/]
  - A systematic review of the mechanisms of cardiovascular disease reduction by dietary flavonoids: the impact of anthocyanins on flow-mediated dilation and blood rheology, BMC Nutrition (2025) — Systematic review of anthocyanin/berry effects on flow-mediated dilation and blood rheology reported signs of potentially beneficial vascular effects in short- and long-term studies. [https://link.springer.com/article/10.1186/s40795-025-01086-2]
  - Effects of Anthocyanins on Cardiometabolic Health: A Systematic Review and Meta-Analysis of Randomized Controlled Trials, Advances in nutrition (Bethesda, Md.) (2017) — Meta-analysis of 32 RCTs (1491 participants): anthocyanins (not raspberry-specific) reduced fasting/2-h glucose, HbA1c, total cholesterol, and LDL [https://pubmed.ncbi.nlm.nih.gov/28916569/]
  - Meta-Analysis of the Effects of Foods and Derived Products Containing Ellagitannins and Anthocyanins on Cardiometabolic Biomarkers: Analysis of Factors Influencing Variability of the Individual Responses, International journal of molecular sciences (2018) — Meta-analysis of 128 RCTs (5538 participants): ellagitannin- and anthocyanin-rich foods produced small beneficial changes in cardiometabolic biomarkers, with high inter-individual variability [https://pmc.ncbi.nlm.nih.gov/articles/PMC5877555/]
  - The Effects of Raspberry Consumption on Glycemic Control and Inflammation Markers in Adults: A Systematic Review and Meta-Analysis of Randomized Controlled Trials, Current developments in nutrition (2024) — Systematic review/meta-analysis of RCTs: raspberry significantly lowered TNF-alpha (and modestly raised insulin) but had no significant effect on fasting glucose, HbA1c, CRP, or IL-6 [https://pubmed.ncbi.nlm.nih.gov/38860149/]
  - The effects of raspberry consumption on anthropometric indices and liver function tests in adults: a GRADE-assessed systematic review and meta-analysis, Frontiers in nutrition (2024) — GRADE-assessed meta-analysis (9 studies, 10 arms, 355 participants): raspberry produced no significant change in weight, BMI, waist circumference, or liver enzymes (AST/ALT) [https://pubmed.ncbi.nlm.nih.gov/39161910/]
  - Red raspberry improves postprandial metabolic indices and cognitive function in older adults who are overweight or have obesity, British Journal of Nutrition (2026) — Randomized crossover trial in 36 older adults with overweight/obesity: 25 g freeze-dried red raspberry with a meal reduced peak glucose by ~8% and overall insulin response, and improved cognitive task performance versus control. [https://www.cambridge.org/core/journals/british-journal-of-nutrition/article/abs/red-raspberry-improves-postprandial-metabolic-indices-and-cognitive-function-in-older-adults-who-are-overweight-or-have-obesity/9EB0B7165310165E06A1080B80B0E4EE]
  - Plasma urolithin metabolites correlate with improvements in endothelial function after red raspberry consumption: A double-blind randomized controlled trial, Archives of biochemistry and biophysics (2018) — Double-blind crossover RCT (10 healthy men): dietary-achievable red raspberry (200-400 g) acutely improved flow-mediated dilation at 2 h and 24 h; effect correlated with plasma urolithin/ellagitannin metabolites [https://pubmed.ncbi.nlm.nih.gov/29802820/]
  - Attenuation of Postmeal Metabolic Indices with Red Raspberries in Individuals at Risk for Diabetes: A Randomized Controlled Trial, Obesity (2019) — Crossover RCT (32 adults; 21 with prediabetes/insulin resistance): 125-250 g red raspberries with breakfast reduced 2-h insulin AUC, and 250 g reduced peak/2-h glucose, in the at-risk group [https://onlinelibrary.wiley.com/doi/10.1002/oby.22406]
  - Red Raspberry and Fructo-Oligosaccharide Supplementation, Metabolic Biomarkers, and the Gut Microbiota in Adults with Prediabetes: A Randomized Crossover Clinical Trial, The Journal of nutrition (2022) — Randomized crossover trial in adults with prediabetes/insulin resistance (n=26) found 4 weeks of red raspberry (125 g/day fresh equivalents) modulated metabolic biomarkers and gut microbiota. [https://pubmed.ncbi.nlm.nih.gov/35421233/]

---

## Blackberry (Rubus fruticosus (agg.))
URL: https://nutridex.info/s/blackberry
Category: Fruits
Evidence: Moderate — Several controlled trials; effects real but modest or context-dependent.
Fibre-dense, anthocyanin-rich dark berry

Quick answer: Blackberry is used for may modestly improve blood lipids (ldl) based on anthocyanin/berry rct meta-analyses, though effects are small and not blackberry-specific. NutriDex grades the human evidence as moderate — Several controlled trials; effects real but modest or context-dependent. Based on 11 cited human studies (11 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Human evidence for blackberry-specific health effects is moderate and largely extrapolated from anthocyanin- and berry-class research rather than blackberry alone. Meta-analyses of RCTs show purified anthocyanins modestly lower LDL cholesterol (roughly 3-5 mg/dL, of uncertain clinical relevance), and prospective cohorts link higher anthocyanin/flavonoid intake with lower coronary heart disease and type 2 diabetes risk. A small 7-day crossover RCT feeding 600 g blackberries/day to overweight/obese men improved 24-h fat oxidation (~7%) and lowered insulin AUC (~21%), but the dose was far above typical intake and the completed sample was small (n=17-24). Berry effects on blood pressure, glycaemia, cognition and oxidative-stress biomarkers are inconsistent across trials, with substantial heterogeneity and few blackberry-only studies. Overall, blackberries are a nutrient-dense, high-fibre fruit whose benefits are plausible and supported by class-level data, but causal proof from large blackberry-specific RCTs is lacking.

Nutrition (per 1 cup (144 g)): 62 kcal; Vitamin C 30.2mg (34% DV), Manganese 0.93mg (40% DV), Fibre 7.6g (27% DV), Vitamin K 28.5mcg (24% DV), Copper 0.238mg (26% DV), Folate 36mcg (9% DV), Vitamin E 1.68mg (11% DV).
Benefits / uses: May modestly improve blood lipids (LDL) based on anthocyanin/berry RCT meta-analyses, though effects are small and not blackberry-specific; Associated with lower type 2 diabetes risk in flavonoid/anthocyanidin cohort studies; Improved fat oxidation and insulin sensitivity in one short-term, high-dose blackberry feeding trial in overweight men; High soluble and insoluble fibre aids digestive health and satiety; Good source of vitamin C, manganese and vitamin K; Antioxidant capacity that may attenuate some oxidative-stress biomarkers, though human data are inconsistent.
Active compounds: Anthocyanins (cyanidin-3-glucoside); Ellagitannins and ellagic acid; Vitamin C (ascorbic acid); Dietary fibre (insoluble + soluble/pectin); Manganese; Vitamin K1 (phylloquinone); Vitamin E (tocopherols); Folate; Flavonols (quercetin) and proanthocyanidins.
Dose: A common serving is 1 cup (about 144 g, ~62 kcal). Dietary patterns and trials providing roughly 100-200 g berries/day are linked to metabolic benefit in class-level data. The one short-term blackberry-specific RCT used a high 600 g/day dose, far above typical intake.
Safety: Generally very safe as a whole food. Rare allergy (Rosaceae/salicylate sensitivity) can occur. Seeds and skins are high in fibre, which may cause bloating if intake increases sharply. Blackberries contain moderate oxalate, so high intakes may matter for calcium-oxalate kidney-stone formers. They contribute vitamin K, which can affect warfarin dosing if intake changes markedly. The natural sugar load is modest, but concentrated juices/jams raise the glycaemic impact. No clinically important CYP3A4 (grapefruit-type) interaction is established.

Cited studies (11):
  - The Effect of Anthocyanins on Cognition: A Systematic Review and Meta-analysis of Randomized Clinical Trial Studies in Cognitively Impaired and Healthy Adults, Current nutrition reports (2025) — Systematic review and meta-analysis (30 RCTs; 14 pooled, 733 participants): anthocyanins showed qualitative cognitive benefits but no significant pooled effect on memory domains; high heterogeneity. [https://pmc.ncbi.nlm.nih.gov/articles/PMC11775034/]
  - Effects of anthocyanin supplementation on blood lipid levels: a systematic review and meta-analysis, Frontiers in nutrition (2023) — Meta-analysis of 41 RCTs (n=2,788) found anthocyanin supplementation significantly reduced triglycerides (SMD -0.10; 95% CI -0.18 to -0.01) and LDL-C (SMD -0.16; 95% CI -0.26 to -0.07) and raised HDL-C. [https://pmc.ncbi.nlm.nih.gov/articles/PMC10463756/]
  - Multiple strains probiotics appear to be the most effective probiotics in the prevention of necrotizing enterocolitis and mortality: An updated meta-analysis, PLOS ONE (2017) — Meta-analysis of 29 RCTs (n=2,006) in subjects with metabolic syndrome factors (searched to April 2024) found dietary anthocyanins improved dyslipidemia, glycemia and blood pressure outcomes. [https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0315504]
  - Effects of anthocyanin supplementation in diet on glycemic and related cardiovascular biomarkers in patients with type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials, Frontiers in nutrition (2023) — Meta-analysis of 13 RCTs (n=703 with type 2 diabetes); median 320 mg/day anthocyanins over ~8 weeks significantly lowered HbA1c (WMD -0.31), FBG (WMD -0.63), 2-h glucose (WMD -1.60), TG (WMD -0.45) and LDL (WMD -0.26). [https://pmc.ncbi.nlm.nih.gov/articles/PMC10556752/]
  - Effectiveness of anthocyanins rich foods on cardiometabolic factors in individuals with metabolic syndrome: a systematic review and meta-analysis, European journal of nutrition (2023) — Systematic review and meta-analysis found anthocyanin-rich foods significantly improved cardiometabolic factors in individuals with metabolic syndrome. [https://pubmed.ncbi.nlm.nih.gov/37042998/]
  - Anthocyanins, Anthocyanin-Rich Berries, and Cardiovascular Risks: Systematic Review and Meta-Analysis of 44 Randomized Controlled Trials and 15 Prospective Cohort Studies, Frontiers in nutrition (2021) — Systematic review and meta-analysis (44 RCTs, 15 cohorts): purified anthocyanins lowered LDL by ~5.4 mg/dL; high dietary anthocyanin intake linked to 17% lower CHD and 27% lower total CVD incidence. [https://pmc.ncbi.nlm.nih.gov/articles/PMC8714924/]
  - Effects of Anthocyanin-rich Berries on the Risk of Metabolic Syndrome: A Systematic Review and Meta-analysis, The review of diabetic studies : RDS (2022) — Meta-analysis (21 RCTs, 1,355 participants): anthocyanin-rich berries produced a small LDL reduction (~3.2 mg/dL, deemed not clinically relevant), with no significant change in fasting glucose, HbA1c or blood pressure. [https://pmc.ncbi.nlm.nih.gov/articles/PMC9382680/]
  - Effects of Berry Anthocyanins on Cognitive Performance, Vascular Function and Cardiometabolic Risk Markers: A Systematic Review of Randomized Placebo-Controlled Intervention Studies in Humans, International journal of molecular sciences (2021) — Systematic review of 49 placebo-controlled RCTs: berry anthocyanins improved vascular/endothelial function (FMD) and showed BP effects mainly in at-risk groups, with mixed cognitive and metabolic effects. [https://pmc.ncbi.nlm.nih.gov/articles/PMC8234025/]
  - Flavonoids intake and risk of type 2 diabetes mellitus: A meta-analysis of prospective cohort studies, Medicine (2018) — Meta-analysis of 8 prospective cohorts (312,015 participants): higher total flavonoid and anthocyanidin intake inversely associated with type 2 diabetes risk (RR 0.89 for total flavonoids). [https://pmc.ncbi.nlm.nih.gov/articles/PMC5959406/]
  - Blackberry Feeding Increases Fat Oxidation and Improves Insulin Sensitivity in Overweight and Obese Males, Nutrients (2018) — 7-day crossover RCT in overweight/obese men (n=17-24 completers): 600 g/day blackberries increased 24-h fat oxidation (~7%) and lowered insulin AUC (~21%), improving insulin sensitivity; glucose AUC unchanged. [https://pmc.ncbi.nlm.nih.gov/articles/PMC6115824/]
  - Anthocyanins and Type 2 Diabetes: An Update of Human Study and Clinical Trial, Nutrients (2024) — Updated narrative review of human studies and clinical trials concludes anthocyanins improve glycemic control and lipid-related cardiometabolic biomarkers in type 2 diabetes. [https://pmc.ncbi.nlm.nih.gov/articles/PMC11174612/]

---

## Cranberry (Vaccinium macrocarpon)
URL: https://nutridex.info/s/cranberry
Category: Fruits
Evidence: Moderate — Several controlled trials; effects real but modest or context-dependent.
Tart berry studied for urinary tract health

Quick answer: Cranberry is used for reduces risk of recurrent urinary tract infections in susceptible groups (women with recurrent utis, children). NutriDex grades the human evidence as moderate — Several controlled trials; effects real but modest or context-dependent. Based on 8 cited human studies (8 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

The strongest human evidence is for prevention of recurrent urinary tract infections: a 2023 Cochrane review of 50 studies (8,857 participants; 45 placebo-controlled RCTs) found cranberry products reduce the risk of symptomatic, culture-verified UTIs in women with recurrent infections, in children, and in other susceptible people (overall RR about 0.70), with proanthocyanidins thought to block E. coli adhesion; no benefit was seen in the elderly, those with bladder-emptying problems, or pregnant women. A dose-response meta-analysis suggests the effect concentrates at intakes of about 36 mg proanthocyanidins per day or more (roughly 18% risk reduction). Cardiometabolic data are weaker and inconsistent: meta-analyses report a modest reduction in systolic blood pressure and BMI but no reliable change in lipids, glucose, or inflammatory markers. Most positive trials use juice or concentrated supplements rather than whole fruit, and quality is often limited by small samples, heterogeneity, and industry funding. Whole raw cranberries are nutrient-dense and low in sugar but are too tart to eat in large quantities, so real-world intake usually comes from sweetened products that add sugar.

Nutrition (per 1 cup whole (100 g)): 46 kcal; Vitamin C 14mg (16% DV), Fibre 3.6g (13% DV), Manganese 0.27mg (12% DV), Vitamin E 1.32mg (9% DV), Copper 0.055mg (6% DV), Vitamin K 5mcg (4% DV).
Benefits / uses: Reduces risk of recurrent urinary tract infections in susceptible groups (women with recurrent UTIs, children); Proanthocyanidins inhibit E. coli adhesion to the bladder wall; May modestly lower systolic blood pressure (inconsistent evidence); Rich source of vitamin C and antioxidant polyphenols; Possible inhibition of H. pylori and oral-bacteria adhesion; Low sugar relative to most fruits.
Active compounds: A-type proanthocyanidins (condensed tannins); Anthocyanins (cyanidin & peonidin glycosides); Quercetin and other flavonols; Vitamin C (ascorbic acid); Organic acids (quinic, malic, citric); Vitamin E (tocopherols); Manganese; Pectin (soluble fibre); Ursolic acid (triterpenoid).
Dose: A standard culinary serving is about 1 cup (100 g) of fresh raw berries. For UTI prevention, trials use cranberry juice or capsules; benefit is most consistent at doses delivering roughly 36 mg or more of proanthocyanidins per day, taken continuously for several weeks to months.
Safety: Generally safe as a food. Cranberry juice and concentrated extracts may potentiate warfarin and increase bleeding/INR in some reports, so anticoagulant users should be cautious. Cranberries are high in oxalate and may raise kidney-stone risk in predisposed individuals at high intakes. Commercial cranberry juices and dried cranberries are often heavily sweetened, adding significant sugar and calories. Acidic juice can aggravate reflux; rare allergy is possible.

Cited studies (8):
  - Cranberries for preventing urinary tract infections, Cochrane Database of Systematic Reviews (2023) — Cochrane review of 50 studies (8,857 participants; 45 placebo-controlled RCTs): cranberry products reduce risk of symptomatic, culture-verified UTIs in women with recurrent UTIs, children, and other susceptible people (overall RR ~0.70); no benefit in the elderly, those with bladder-emptying problems, or pregnant women. [https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001321.pub7/full]
  - Preventive effect of cranberries with high dose of proanthocyanidins on urinary tract infections: a meta-analysis and systematic review, Frontiers in nutrition (2024) — Meta-analysis of 10 RCTs: at proanthocyanidin intakes of 36 mg/day or more, cranberry reduced UTI risk by 18% (RR 0.82); no significant reduction at lower doses, supporting a dose threshold. [https://pubmed.ncbi.nlm.nih.gov/39668896/]
  - Cranberry Juice, Cranberry Tablets, or Liquid Therapies for Urinary Tract Infection: A Systematic Review and Network Meta-analysis, European urology focus (2024) — Systematic review and network meta-analysis of 20 trials (3,091 participants) found cranberry juice associated with a 54% lower rate of UTIs and 49% lower antibiotic use versus placebo liquid. [https://pubmed.ncbi.nlm.nih.gov/39030132/]
  - Preventive effect of cranberries with high dose of proanthocyanidins on urinary tract infections: a meta-analysis and systematic review, Frontiers in Nutrition (2024) — Meta-analysis/systematic review found cranberries with high proanthocyanidin dose significantly reduced UTI risk, with benefit most evident when product use duration was between 12 and 24 weeks. [https://www.frontiersin.org/journals/nutrition/articles/10.3389/fnut.2024.1422121/full]
  - The effects of cranberry on cardiovascular metabolic risk factors: A systematic review and meta-analysis, Clinical nutrition (Edinburgh, Scotland) (2020) — Meta-analysis of RCTs: cranberry significantly reduced systolic blood pressure and BMI, with no reliable effect on lipids, glucose, or CRP. [https://pubmed.ncbi.nlm.nih.gov/31023488/]
  - Cranberries for preventing urinary tract infections, The Cochrane database of systematic reviews (2012) — Earlier Cochrane review concluded cranberry juice was less effective than previously suggested for preventing UTIs, highlighting evidence limitations and high dropout. [https://pubmed.ncbi.nlm.nih.gov/23076891/]
  - Combined cranberry supplementation and weight loss diet in non-alcoholic fatty liver disease: a double-blind placebo-controlled randomized clinical trial, International journal of food sciences and nutrition (2020) — Double-blind placebo-controlled RCT in NAFLD: cranberry extract plus a weight-loss diet produced greater reductions in ALT and insulin/insulin resistance than diet alone. [https://pubmed.ncbi.nlm.nih.gov/32237922/]
  - Cranberry juice consumption lowers markers of cardiometabolic risk, including blood pressure and circulating C-reactive protein, triglyceride, and glucose concentrations in adults, The Journal of nutrition (2015) — RCT: 8 weeks of low-calorie cranberry juice lowered diastolic BP, CRP, triglycerides and fasting glucose versus placebo in adults with elevated baseline values. [https://pubmed.ncbi.nlm.nih.gov/25904733/]

---

## Tart Cherry (Prunus cerasus)
URL: https://nutridex.info/s/tart-cherry
Category: Fruits
Evidence: Moderate — Several controlled trials; effects real but modest or context-dependent.
Anthocyanin-rich sour cherry for recovery and sleep

Quick answer: Tart Cherry is used for may speed recovery of muscle strength and power after strenuous exercise. NutriDex grades the human evidence as moderate — Several controlled trials; effects real but modest or context-dependent. Based on 10 cited human studies (10 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Human evidence for tart cherry is strongest, and meta-analytic, for exercise recovery: pooled RCTs show a moderate benefit for recovery of muscle strength and power and small reductions in soreness and inflammatory markers (CRP, IL-6), though effects on creatine kinase are inconsistent. Small RCTs suggest tart cherry juice/concentrate, a natural source of melatonin, modestly improves sleep duration and efficiency. Trials also show transient reductions in serum uric acid and, in older adults, modest drops in systolic blood pressure and LDL cholesterol. Limitations are substantial: most studies are small, short, industry-adjacent, and use juice or concentrate rather than whole fruit, so results may not transfer to eating fresh cherries. Hard clinical endpoints (gout flares, cardiovascular events) remain unproven, keeping the overall weight of evidence moderate.

Nutrition (per 1 cup pitted (155 g)): 78 kcal; Vitamin C 15.5mg (17% DV), Vitamin A (RAE) 99µg (11% DV), Copper 0.16mg (18% DV), Fibre 2.5g (9% DV), Manganese 0.17mg (8% DV), Potassium 268mg (6% DV).
Benefits / uses: May speed recovery of muscle strength and power after strenuous exercise; Modestly reduces exercise-induced muscle soreness and inflammatory markers (CRP, IL-6); May improve sleep duration and efficiency (endogenous melatonin source); Can transiently lower serum uric acid; May modestly lower systolic blood pressure and LDL cholesterol in older adults; High dietary antioxidant capacity from anthocyanins.
Active compounds: Anthocyanins (cyanidin-3-glucosylrutinoside, cyanidin-3-rutinoside); Flavonols (quercetin, kaempferol); Hydroxycinnamic acids (chlorogenic, neochlorogenic acid); Melatonin; Vitamin C; Provitamin A carotenoids (beta-carotene); Potassium; Copper and manganese; Soluble fibre.
Dose: Common food serving is about 1 cup (155 g) of fresh pitted sour cherries. Most clinical trials used Montmorency tart cherry juice or concentrate (e.g. 30-60 mL concentrate, or 240-480 mL juice once or twice daily) rather than whole fruit, often for 7-12 days around exercise or 12 weeks for cardiometabolic outcomes.
Safety: Generally safe as a food. Concentrates and juices carry a meaningful sugar/calorie load, relevant for diabetes and weight management. Cherries contain oxalates and a moderate FODMAP (sorbitol) load, which may cause GI upset or matter for stone-forming individuals at high intake. As a stone-fruit, allergy (oral allergy syndrome, especially with birch-pollen sensitivity) is possible. Anthocyanin/polyphenol supplements may theoretically interact with anticoagulants; the melatonin content can add to sedative effects. No grapefruit-type CYP3A4 interaction is established.

Cited studies (10):
  - Effects of Tart Cherry Juice Supplementation on Recovery from Exercise-Induced Muscle Damage in Athletes: A Systematic Review and Meta-Analysis, Sports Medicine - Open (2026) — Meta-analysis of 19 trials in trained athletes found tart cherry juice significantly improved maximal voluntary contraction recovery at every timepoint (24h ES=1.12; 48h ES=1.29; 72h ES=2.14) and reduced IL-6 and IL-8. [https://link.springer.com/article/10.1186/s40798-026-00993-3]
  - The effect of tart cherry juice (TCJ) supplementation on exercise-induced muscle damage (EIMD) in an athletic population, Annals of medicine and surgery (2012) (2025) — Systematic review and meta-analysis of 10 trials found tart cherry juice significantly improved maximal voluntary isometric contraction (+9.13%) and decreased IL-6 (-0.4 pg/ml) and IL-8 (-0.3 pg/ml) after exercise-induced muscle damage. [https://pmc.ncbi.nlm.nih.gov/articles/PMC11918606/]
  - Too Sour to be True? Tart Cherries (Prunus cerasus) and Sleep: a Systematic Review and Meta-analysis, Current Sleep Medicine Reports (2023) — Meta-analysis of 8 studies found tart cherry significantly improved objective sleep efficiency (ES=0.63, 95% CI 0.29-0.97, P<0.01) and total sleep time, but subjective sleep measures were not significant. [https://link.springer.com/article/10.1007/s40675-023-00261-w]
  - The Effect of Tart Cherry on Sleep Quality and Sleep Disorders: A Systematic Review, Food science & nutrition (2025) — Systematic review concluded tart cherry juice/concentrate improved sleep quality and increased melatonin in several trials, but capsule/powder forms showed no benefit, suggesting form-dependent effects. [https://pubmed.ncbi.nlm.nih.gov/40964149/]
  - Tart Cherry Supplementation and Recovery From Strenuous Exercise: A Systematic Review and Meta-Analysis, International journal of sport nutrition and exercise metabolism (2021) — Tart cherry supplementation produces a moderate benefit for recovery of muscular strength and small reductions in muscle soreness after strenuous exercise; pooled analyses also indicate reductions in CRP and IL-6. [https://pubmed.ncbi.nlm.nih.gov/33440334/]
  - Commonly Used Dose of Montmorency Tart Cherry Powder Does Not Improve Sleep or Inflammation Outcomes in Individuals with Overweight or Obesity, Nutrients (2024) — Randomized crossover RCT in 34 adults with overweight/obesity found 500 mg Montmorency tart cherry powder for 14 days did not improve sleep outcomes or inflammation markers (CRP, TNF-alpha, IL-6) versus placebo. [https://pmc.ncbi.nlm.nih.gov/articles/PMC11644614/]
  - Acute Ingestion of Montmorency Tart Cherry Reduces Serum Uric Acid but Has no Impact on High Sensitivity C-Reactive Protein or Oxidative Capacity, Plant foods for human nutrition (Dordrecht, Netherlands) (2021) — Acute Montmorency tart cherry intake transiently reduced serum uric acid (~8%) but had no effect on hs-CRP or oxidative capacity. [https://pubmed.ncbi.nlm.nih.gov/33506357/]
  - Impact of tart cherry juice on systolic blood pressure and low-density lipoprotein cholesterol in older adults: a randomized controlled trial, Food &amp; Function (2018) — 12 weeks of tart cherry juice lowered systolic blood pressure and LDL cholesterol in older adults versus control. [https://doi.org/10.1039/C8FO00468D]
  - Effect of Montmorency tart cherry juice on cognitive performance in older adults: a randomized controlled trial, Food & function (2019) — 12 weeks of Montmorency tart cherry juice improved measures of cognition (memory, movement/processing speed, learning) in older adults. [https://pubmed.ncbi.nlm.nih.gov/31287117/]
  - Effect of tart cherry juice (Prunus cerasus) on melatonin levels and enhanced sleep quality, European journal of nutrition (2012) — Tart cherry juice concentrate raised circulating melatonin and increased time in bed, total sleep time and sleep efficiency in healthy adults. [https://pubmed.ncbi.nlm.nih.gov/22038497/]

---

## Red Grape (Vitis vinifera)
URL: https://nutridex.info/s/red-grape
Category: Fruits
Evidence: Moderate — Several controlled trials; effects real but modest or context-dependent.
Polyphenol-rich berries with modest cardiometabolic signals

Quick answer: Red Grape is used for modest reduction in systolic blood pressure (whole-grape rcts). NutriDex grades the human evidence as moderate — Several controlled trials; effects real but modest or context-dependent. Based on 10 cited human studies (10 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Human evidence for red grapes rests mainly on whole-grape and grape-product RCTs plus large prospective cohorts. Meta-analyses of randomized trials show a small but significant fall in systolic blood pressure (around 3 mmHg) with grape products, with whole forms (powder, raisins) outperforming juice, but no consistent effect on diastolic pressure or endothelial markers. In the Nurses' Health and Health Professionals cohorts, higher intake of grapes/raisins and other anthocyanin-rich fruits tracked with modestly lower type 2 diabetes risk. Small Concord grape-juice trials suggest memory benefits in older adults with cognitive decline, but samples are tiny. Overall the data are consistent for cardiometabolic surrogate endpoints yet limited by short durations, surrogate outcomes, heterogeneous grape products, and generally low certainty of evidence. No RCTs demonstrate that eating grapes reduces hard clinical events.

Nutrition (per 1 cup (151 g)): 104 kcal; Vitamin K 22ug (18.4% DV), Copper 0.19mg (21.1% DV), Vitamin C 4.8mg (5.4% DV), Potassium 288mg (6.1% DV), Thiamin (B1) 0.106mg (8.8% DV), Vitamin B6 0.13mg (7.6% DV), Manganese 0.106mg (4.6% DV).
Benefits / uses: Modest reduction in systolic blood pressure (whole-grape RCTs); Improved endothelial/vascular function in some trials; Associated with lower type 2 diabetes risk in large cohorts; Favourable effects on LDL oxidation and oxidative stress; Possible support for memory in older adults (small grape-juice RCTs); Antioxidant and anti-inflammatory polyphenol intake.
Active compounds: Anthocyanins (peonidin/cyanidin/malvidin-3-glucoside); Flavan-3-ols (catechin, epicatechin, proanthocyanidins); Stilbenes (resveratrol, piceid); Flavonols (quercetin, kaempferol); Phenolic acids (caftaric, gallic acid); Vitamin K; Copper; Potassium; Vitamin C.
Dose: A typical serving is about 1 cup (~150 g, ~17 grapes); intervention trials use roughly 0.5-2 cups equivalent of whole grapes, grape powder, or 250-500 mL juice daily over 4-16 weeks.
Safety: High in free sugars (~23 g per cup) and easy to overeat, so portion control matters for glycaemic control and weight. A common choking hazard for young children (halve them). Grape allergy and oral allergy syndrome occur but are uncommon. Note this is GRAPE, not grapefruit: ordinary grapes lack the furanocoumarins that cause grapefruit-CYP3A4 drug interactions, though concentrated grape-seed or resveratrol supplements may have mild interactions and antiplatelet effects. Dried grapes (raisins) concentrate sugar; pesticide residue is reduced by washing.

Cited studies (10):
  - The effect of whole grape products on blood pressure and vascular function: A systematic review and meta-analysis of randomized controlled trials, Nutrition, metabolism, and cardiovascular diseases : NMCD (2023) — Systematic review/meta-analysis of 30 RCTs: whole grape products significantly lowered systolic BP (~-3.2 mmHg; whole forms more than juice) but not diastolic BP, endothelial function or heart rate; certainty low. [https://pubmed.ncbi.nlm.nih.gov/37482483/]
  - Whole grapes or grape products on body weight, anthropometrics, and adipokines: systematic review and meta-analysis of randomized controlled trials, International journal of food sciences and nutrition (2025) — Systematic review/meta-analysis of RCTs found whole grapes or grape products had no significant effect on body weight, waist circumference, body fat, leptin or adiponectin; only a trivial BMI reduction (WMD -0.14 kg) of low certainty, with small effects limited to females and metabolic-syndrome subgroups. [https://pubmed.ncbi.nlm.nih.gov/39800850/]
  - The effect of grape (Vitis vinifera) seed extract supplementation on flow-mediated dilation, blood pressure, and heart rate: A systematic review and meta-analysis of controlled trials with duration- and dose-response analysis, Pharmacological research (2022) — Meta-analysis of 19 controlled trials found grape (Vitis vinifera) seed extract significantly lowered diastolic BP (-2.20 mmHg, 95% CI -3.79 to -0.60) and heart rate (-1.25 bpm) but did not significantly change systolic BP (-3.55 mmHg, 95% CI -7.59 to 0.49) or flow-mediated dilation. [https://pubmed.ncbi.nlm.nih.gov/34798267/]
  - Effects of grape seed extract on dyslipidaemia: a systematic review and dose-response meta-analysis of randomised controlled trials, The British journal of nutrition (2020) — Dose-response meta-analysis of 11 RCTs (536 participants) found grape seed extract significantly reduced LDL-cholesterol (-0.17 mmol/L, 95% CI -0.34 to -0.01) and triglycerides (-0.11 mmol/L), with no significant change in total or HDL cholesterol. [https://pubmed.ncbi.nlm.nih.gov/32138795/]
  - Grape Seed Extract: Usefulness and Safety, NIH National Center for Complementary and Integrative Health (2025) — US National Center for Complementary and Integrative Health states grape seed extract is generally well tolerated but evidence is insufficient to conclude it benefits any health condition, and that high doses or long-term use have not been adequately studied. [https://www.nccih.nih.gov/health/grape-seed-extract]
  - Concord grape juice supplementation improves memory function in older adults with mild cognitive impairment, The British journal of nutrition (2010) — 12-week Concord grape juice RCT improved verbal learning in older adults with mild memory decline (very small n=12; recall gains non-significant). [https://pubmed.ncbi.nlm.nih.gov/20028599/]
  - Concord grape juice supplementation and neurocognitive function in human aging, Journal of agricultural and food chemistry (2012) — 16-week Concord grape juice RCT reduced semantic interference on memory tasks and increased task-related brain activation (fMRI) in older adults with mild memory decline. [https://pubmed.ncbi.nlm.nih.gov/22468945/]
  - Grape Polyphenols' Effects in Human Cardiovascular Diseases and Diabetes, Molecules (Basel, Switzerland) (2017) — Narrative review of grape polyphenols' effects on human cardiovascular disease and diabetes, summarizing antioxidant, anti-inflammatory and vascular mechanisms. [https://pmc.ncbi.nlm.nih.gov/articles/PMC6155751/]
  - Fruit consumption and risk of type 2 diabetes: results from three prospective longitudinal cohort studies, BMJ (Clinical research ed.) (2013) — Higher intake of whole grapes/raisins and other fruits associated with lower type 2 diabetes risk (pooled HR 0.88 per 3 servings/wk) across 3 US cohorts; fruit juice raised risk (HR 1.08). [https://pubmed.ncbi.nlm.nih.gov/23990623/]
  - Dietary flavonoid intakes and risk of type 2 diabetes in US men and women, The American journal of clinical nutrition (2012) — In ~200,000 US adults across 3 cohorts, higher anthocyanin intake was associated with lower incidence of type 2 diabetes (pooled HR ~0.85, extreme quintiles). [https://pubmed.ncbi.nlm.nih.gov/22357723/]

---

## Pomegranate (Punica granatum)
URL: https://nutridex.info/s/pomegranate
Category: Fruits
Evidence: Moderate — Several controlled trials; effects real but modest or context-dependent.
Polyphenol-rich arils with modest blood-pressure benefit

Quick answer: Pomegranate is used for may lower systolic and diastolic blood pressure (rct meta-analyses). NutriDex grades the human evidence as moderate — Several controlled trials; effects real but modest or context-dependent. Based on 8 cited human studies (8 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Human evidence for pomegranate is strongest for blood pressure: pooled randomized-trial meta-analyses report systolic reductions of roughly 5–8 mmHg and smaller diastolic effects, with greater benefit in people with elevated baseline pressure. Meta-analyses also show reductions in inflammatory and oxidative-stress biomarkers (hs-CRP, IL-6, TNF-alpha) and a small increase in HDL cholesterol, though effects on total cholesterol, LDL and triglycerides are not significant. Polyphenol reviews credit pomegranate with trivial-to-small ergogenic and muscle-recovery effects. However, most trials are small, short, heterogeneous and often industry-linked, frequently testing concentrated juice or extract rather than the whole fruit, so hard clinical endpoints (heart attack, stroke, mortality) remain unproven. Overall the data support pomegranate as a healthful component of a cardioprotective diet rather than a validated treatment.

Nutrition (per 1 cup arils (174 g)): 144 kcal; Fibre 7g (25% DV), Vitamin C 17.7mg (20% DV), Vitamin K 28.5µg (24% DV), Folate 66µg DFE (17% DV), Copper 0.275mg (31% DV), Potassium 411mg (9% DV).
Benefits / uses: May lower systolic and diastolic blood pressure (RCT meta-analyses); Reduces inflammatory biomarkers (hs-CRP, IL-6, TNF-alpha); Modest rise in HDL cholesterol; high antioxidant capacity; May improve endothelial function and arterial measures; Polyphenols may give trivial-to-small endurance and recovery benefits; Source of fibre, vitamin K, folate and copper.
Active compounds: Punicalagins & ellagitannins (hydrolysable tannins); Ellagic acid (and urolithin metabolites); Anthocyanins (cyanidin/delphinidin glucosides); Vitamin C (ascorbic acid); Vitamin K (phylloquinone); Folate; Potassium; Copper; Pectin & soluble dietary fibre.
Dose: A common serving is about 1 cup of arils (174 g) or roughly half a fruit; cardiovascular trials typically used 150–500 mL/day of pomegranate juice over 2–12 weeks. Whole arils add fibre that juice lacks.
Safety: Generally safe as a food. The juice carries a meaningful sugar and calorie load, so it is less suitable than whole arils for people managing blood glucose or weight. Pomegranate can inhibit CYP enzymes in laboratory studies and a case report links it to raised INR on warfarin, but controlled human studies have generally found little effect on CYP2C9 or CYP3A4 substrates, so any interaction with warfarin, statins or antihypertensives is largely theoretical—monitor and consult a clinician if combining. True allergy is uncommon but reported. Not a substitute for prescribed blood-pressure or lipid therapy.

Cited studies (8):
  - The effects of pomegranate consumption on blood pressure in adults: A systematic review and meta-analysis, Phytotherapy research : PTR (2024) — Meta-analysis of 22 RCTs: pomegranate consumption lowered systolic BP by 7.87 mmHg and diastolic by 3.23 mmHg, with greatest effect when baseline SBP >130 mmHg (high heterogeneity). [https://pubmed.ncbi.nlm.nih.gov/38410857/]
  - Impact of pomegranate juice on blood pressure: A systematic review and meta-analysis, Phytotherapy research : PTR (2023) — Meta-analysis of 14 trials (n=573): pomegranate juice cut systolic BP ~5.02 mmHg in a dose-dependent manner, with benefit attenuating after 2 months. [https://pubmed.ncbi.nlm.nih.gov/37461211/]
  - The effects of pomegranate consumption on inflammatory and oxidative stress biomarkers in adults: a systematic review and meta-analysis, Inflammopharmacology (2023) — Meta-analysis of 33 RCTs: pomegranate significantly reduced CRP, IL-6, TNF-alpha and MDA and raised total antioxidant capacity. [https://pubmed.ncbi.nlm.nih.gov/37507609/]
  - An updated systematic review and meta-analysis of pomegranate consumption on lipid profile, Prostaglandins & other lipid mediators (2025) — Updated meta-analysis of 37 RCTs (n=2695): pomegranate increased HDL-C (+2.5 mg/dL) but showed no significant effect on total cholesterol, LDL-C or triglycerides. [https://pubmed.ncbi.nlm.nih.gov/40216355/]
  - The effects of pomegranate supplementation on biomarkers of inflammation and endothelial dysfunction: A meta-analysis and systematic review, Complementary therapies in medicine (2020) — Meta-analysis of 16 RCTs (n=572): pomegranate supplementation significantly reduced hs-CRP, IL-6 and TNF-alpha biomarkers of inflammation. [https://pubmed.ncbi.nlm.nih.gov/32147056/]
  - Effect of food sources of nitrate, polyphenols, L-arginine and L-citrulline on endurance exercise performance: a systematic review and meta-analysis of randomised controlled trials, Journal of the International Society of Sports Nutrition (2021) — Meta-analysis of polyphenol/nitrate foods: pomegranate was among polyphenol sources giving trivial-to-small endurance exercise performance benefits. [https://pubmed.ncbi.nlm.nih.gov/34965876/]
  - Effects of pomegranate juice on blood pressure: A systematic review and meta-analysis of randomized controlled trials, Pharmacological research (2017) — Meta-analysis of 8 RCTs: pomegranate juice reduced systolic BP by ~4.96 mmHg and diastolic by ~2.01 mmHg regardless of dose or duration. [https://pubmed.ncbi.nlm.nih.gov/27888156/]
  - Lipid profile changes after pomegranate consumption: A systematic review and meta-analysis of randomized controlled trials, Phytomedicine : international journal of phytotherapy and phytopharmacology (2016) — Meta-analysis of 12 RCTs (n=545): pomegranate consumption did not significantly change plasma lipid concentrations overall. [https://pubmed.ncbi.nlm.nih.gov/26857863/]

---

## Orange (Citrus × sinensis)
URL: https://nutridex.info/s/orange
Category: Fruits
Evidence: Moderate — Several controlled trials; effects real but modest or context-dependent.
Vitamin-C-rich citrus linked to heart health

Quick answer: Orange is used for supports cardiovascular health (modest improvements in blood pressure and hdl in trials). NutriDex grades the human evidence as moderate — Several controlled trials; effects real but modest or context-dependent. Based on 10 cited human studies (10 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Prospective cohort data associate higher citrus and flavanone intake with lower ischemic stroke and cardiovascular disease risk, and some RCT meta-analyses of orange juice show modest improvements in systolic blood pressure and HDL cholesterol, though effects on total/LDL cholesterol, glucose and inflammation are inconsistent or null. The whole fruit reliably delivers vitamin C, folate, potassium and soluble pectin fibre. Most disease-outcome evidence is observational and cannot prove causation; intervention trials often use juice rather than whole fruit, are short-term, and report modest effect sizes confounded by overall healthy-diet patterns. Overall the human evidence for cardiometabolic benefit is moderate (consistent cohorts plus mixed but supportive RCTs), not definitive.

Nutrition (per 1 medium (131 g)): 62 kcal; Vitamin C 69.7mg (77% DV), Fibre 3.1g (11% DV), Folate 39mcg DFE (10% DV), Potassium 237mg (5% DV), Thiamin 0.11mg (9% DV), Calcium 52mg (4% DV).
Benefits / uses: Supports cardiovascular health (modest improvements in blood pressure and HDL in trials); Associated with lower ischemic stroke risk in cohorts (flavanone intake); Provides vitamin C for immune function and antioxidant defense; Soluble fibre (pectin) may aid cholesterol and glycaemic control; Potassium and citrate may modestly reduce kidney-stone risk.
Active compounds: Vitamin C (ascorbic acid); Hesperidin & naringenin (flavanones); Pectin (soluble fibre); Potassium; Folate; Beta-cryptoxanthin & carotenoids; Citric acid / citrate; Polymethoxylated flavones.
Dose: One medium orange (~131 g) provides ~77% of the vitamin C Daily Value; typical intake is 1-2 fruits/day as part of a fruit-rich diet. Cohort benefits are seen at near-daily citrus intake.
Safety: Generally very safe. Sweet oranges do NOT cause the grapefruit/Seville-orange CYP3A4 drug interaction (regular oranges lack significant furanocoumarins), but Seville (bitter) oranges in marmalade can. The acid and natural sugars can affect dental enamel and blood glucose in large amounts (juice more than whole fruit); people with diabetes should favour the whole fruit. Oral allergy syndrome and citrus allergy occur in sensitive individuals. Potassium content warrants some caution in advanced kidney disease, though a single orange supplies only ~5% of the daily reference value.

Cited studies (10):
  - Effects of Citrus Flavanone Hesperidin Extracts or Purified Hesperidin Consumption on Risk Factors for Cardiovascular Disease: Evidence From an Updated Meta-analysis of Randomized Controlled Trials, Current developments in nutrition (2024) — Updated meta-analysis of 12 RCTs (589 participants) of hesperidin (the principal orange flavanone) reported improvements in lipid profile, fasting glucose and inflammatory markers (e.g., CRP). [https://pmc.ncbi.nlm.nih.gov/articles/PMC11399677/]
  - Effects of Citrus Flavanone Hesperidin Extracts or Purified Hesperidin Consumption on Risk Factors for Cardiovascular Disease: Evidence From an Updated Meta-analysis of Randomized Controlled Trials, Current developments in nutrition (2024) — Updated meta-analysis of 12 RCTs (n=589) of hesperidin extracts/purified hesperidin found significant reductions in LDL-cholesterol, total cholesterol, and triglycerides but no significant effect on systolic blood pressure or CRP. [https://pubmed.ncbi.nlm.nih.gov/39279783/]
  - Effect of hesperidin on blood pressure and lipid profile: A systematic review and meta-analysis of randomized controlled trials, Phytotherapy research : PTR (2024) — Systematic review/meta-analysis of RCTs found hesperidin had no significant effect on systolic BP (-0.29 mmHg, 95% CI -2.21 to 1.63, p=0.77) or diastolic BP (0.79 mmHg, 95% CI -0.74 to 2.31, p=0.31). [https://pubmed.ncbi.nlm.nih.gov/38462779/]
  - Orange juice intake and lipid profile: a systematic review and meta-analysis of randomised controlled trials, Journal of nutritional science (2023) — Systematic review and meta-analysis of 9 RCTs found orange juice supplementation did not significantly affect serum triglycerides, total cholesterol, or HDL-cholesterol. [https://pmc.ncbi.nlm.nih.gov/articles/PMC10052563/]
  - The effects of hesperidin supplementation on cardiovascular risk factors in adults: a systematic review and dose-response meta-analysis, Frontiers in nutrition (2023) — Dose-response meta-analysis of RCTs found hesperidin supplementation significantly reduced serum triglycerides, total cholesterol, LDL, TNF-alpha, and systolic blood pressure in adults. [https://pmc.ncbi.nlm.nih.gov/articles/PMC10369082/]
  - A meta-analysis of prospective cohort studies of flavonoid subclasses and stroke risk, Phytotherapy research : PTR (2022) — Meta-analysis of prospective cohorts found each 50 mg/day increment of dietary flavanones (abundant in citrus) was associated with an ~11% lower stroke risk. [https://pubmed.ncbi.nlm.nih.gov/35023220/]
  - Does chronic consumption of orange juice improve cardiovascular risk factors in overweight and obese adults? A systematic review and meta-analysis of randomized controlled trials, Food & function (2022) — Systematic review and meta-analysis of RCTs found chronic orange-juice consumption improved systolic blood pressure and HDL cholesterol in overweight/obese adults, with no significant change in total/LDL cholesterol, glucose or inflammatory markers. [https://pubmed.ncbi.nlm.nih.gov/36383179/]
  - Effects of chronic consumption of specific fruit (berries, citrus and cherries) on CVD risk factors: a systematic review and meta-analysis of randomised controlled trials, European journal of nutrition (2021) — Systematic review and meta-analysis of RCTs on berries, citrus and cherries: orange/citrus interventions showed no significant improvement in most CVD risk factors (cholesterol, inflammation), underscoring that whole-fruit cardiometabolic effects are modest and uncertain. [https://pmc.ncbi.nlm.nih.gov/articles/PMC7900084/]
  - Dietary flavonoids and risk of stroke in women, Stroke (2012) — Nurses' Health Study (69,622 women, 14 y): highest vs lowest flavanone intake was associated with ~19% lower ischemic stroke risk; citrus fruit/juice trended protective. [https://pubmed.ncbi.nlm.nih.gov/22363060/]
  - Frequency of citrus fruit intake is associated with the incidence of cardiovascular disease: the Jichi Medical School cohort study, Journal of epidemiology (2011) — Jichi Medical School cohort (10,623 Japanese adults): almost-daily citrus intake was associated with lower CVD incidence vs infrequent intake, driven mainly by reduced cerebral infarction. [https://pubmed.ncbi.nlm.nih.gov/21389640/]

---

## Grapefruit (Citrus × paradisi)
URL: https://nutridex.info/s/grapefruit
Category: Fruits
Evidence: Moderate — Several controlled trials; effects real but modest or context-dependent.
Tart citrus rich in vitamin C and lycopene

Quick answer: Grapefruit is used for may modestly lower systolic blood pressure (small effect, limited trials). NutriDex grades the human evidence as moderate — Several controlled trials; effects real but modest or context-dependent. Based on 7 cited human studies (7 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Human evidence for grapefruit is moderate and largely indirect. A 2017 systematic review and meta-analysis (Onakpoya) of just three small RCTs (n=250) found a statistically significant but small reduction in systolic blood pressure (~2.4 mmHg) and no significant effect on body weight. A small 30-day controlled feeding study (Gorinstein, n=57 coronary-atherosclerosis patients) reported reductions in total and LDL cholesterol and triglycerides, with red grapefruit outperforming blond/white; the trial was small and not blinded. Broader citrus-intake cohorts (Yamada; Cassidy) associate frequent consumption with lower stroke and cardiovascular risk, consistent with general fruit-and-vegetable dose-response meta-analyses (Aune), though the citrus-specific association in Cassidy was not statistically significant. Limitations are substantial: few grapefruit-specific RCTs, short durations, small samples, and confounding in observational data. Benefits are best viewed as part of an overall fruit-rich diet rather than from grapefruit alone.

Nutrition (per 1/2 medium (123 g)): 52 kcal; Vitamin C 38.4mg (43% DV), Fibre 2g (7% DV), Vitamin A 71µg RAE (8% DV), Potassium 166mg (3.5% DV), Folate 16µg DFE (4% DV).
Benefits / uses: May modestly lower systolic blood pressure (small effect, limited trials); May help reduce LDL-cholesterol and triglycerides (esp. red varieties), based on small trials; High vitamin C supports immune and antioxidant function; Low energy density may aid satiety, though trials show no significant weight change; Citrus/flavanone intake linked to lower stroke and CVD risk in cohorts.
Active compounds: Vitamin C (ascorbic acid); Lycopene (pink/red varieties); Beta-carotene; Flavanones (naringin, naringenin); Furanocoumarins (bergamottin, 6',7'-dihydroxybergamottin); Pectin (soluble fibre); Potassium; Folate.
Dose: A typical serving is half a medium grapefruit (~123 g) or one whole fruit, eaten fresh as part of a varied fruit intake. Metabolic trials showing modest benefit used roughly half a fresh grapefruit before meals (3x/day) for 6-12 weeks.
Safety: Clinically important: grapefruit furanocoumarins irreversibly inhibit intestinal CYP3A4, raising blood levels of many drugs (certain statins e.g. simvastatin/atorvastatin, some calcium-channel blockers, immunosuppressants like tacrolimus/cyclosporine, some benzodiazepines, amiodarone, and others) — effects can persist ~24 h, so separating timing does not avoid them; check medication labels and consult a pharmacist. Acidic and naturally sugary, so moderate intake if managing blood glucose or acid reflux/dental erosion. True citrus allergy is uncommon but possible.

Cited studies (7):
  - The effects of hesperidin supplementation on cardiovascular risk factors in adults: a systematic review and dose-response meta-analysis, Frontiers in nutrition (2023) — Dose-response meta-analysis of hesperidin supplementation on cardiovascular risk factors in adults, providing pooled estimates for blood pressure and lipid outcomes from randomized trials. [https://pmc.ncbi.nlm.nih.gov/articles/PMC10369082/]
  - The effect of grapefruits (Citrus paradisi) on body weight and cardiovascular risk factors: A systematic review and meta-analysis of randomized clinical trials, Critical reviews in food science and nutrition (2017) — Systematic review/meta-analysis of 3 small RCTs (n=250, overweight/obese): grapefruit lowered systolic BP by ~2.43 mmHg but had no significant effect on body weight; authors note paucity of trials and short durations. [https://pubmed.ncbi.nlm.nih.gov/25880021/]
  - Fruit and vegetable intake and the risk of cardiovascular disease, total cancer and all-cause mortality-a systematic review and dose-response meta-analysis of prospective studies, International journal of epidemiology (2017) — Dose-response meta-analysis of 95 prospective studies: each 200 g/day of fruit & veg lowered CHD (RR 0.92), stroke (0.84) and all-cause mortality (0.90); benefit plateaued ~800 g/day. Citrus among protective subtypes. [https://pubmed.ncbi.nlm.nih.gov/28338764/]
  - Red grapefruit positively influences serum triglyceride level in patients suffering from coronary atherosclerosis: studies in vitro and in humans, Journal of agricultural and food chemistry (2006) — In 57 hyperlipidemic coronary-atherosclerosis patients, 30 days of fresh red grapefruit reduced total cholesterol (~15.5%), LDL (~20.3%) and triglycerides (~17.2%); red outperformed blond. Small, unblinded controlled trial. [https://pubmed.ncbi.nlm.nih.gov/16506849/]
  - Impact of Grapefruit Consumption on Plasma Concentrations of Psychiatric Medications through CYP3A4 Inhibition, European Psychiatry (2025) — Review documenting that grapefruit juice substantially raises plasma drug levels via intestinal CYP3A4 inhibition (buspirone 4.3-fold, diazepam ~3-fold AUC), with effects lasting ~24 hours, underscoring clinically important grapefruit-drug interaction risk. [https://pmc.ncbi.nlm.nih.gov/articles/PMC12437050/]
  - Frequency of citrus fruit intake is associated with the incidence of cardiovascular disease: the Jichi Medical School cohort study, Journal of epidemiology (2011) — Jichi Medical School cohort (n=10,623): almost-daily citrus intake associated with lower CVD incidence (HR ~0.51 women, ~0.57 men), notably for stroke/cerebral infarction but not myocardial infarction. [https://pubmed.ncbi.nlm.nih.gov/21389640/]
  - Dietary flavonoids and risk of stroke in women, Stroke (2012) — Nurses' Health Study (n=69,622): highest flavanone intake associated with 19% lower ischemic stroke risk (RR 0.81); the citrus-specific association trended protective but was not statistically significant. [https://pubmed.ncbi.nlm.nih.gov/22363060/]

---

## Kiwifruit (Actinidia deliciosa)
URL: https://nutridex.info/s/kiwifruit
Category: Fruits
Evidence: Moderate — Several controlled trials; effects real but modest or context-dependent.
Vitamin C-dense fruit that eases constipation

Quick answer: Kiwifruit is used for relieves functional constipation and improves bowel regularity. NutriDex grades the human evidence as moderate — Several controlled trials; effects real but modest or context-dependent. Based on 8 cited human studies (8 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Kiwifruit is one of the most vitamin C-dense common fruits, and even small daily portions reliably raise plasma ascorbate. The best-supported clinical benefit is for functional constipation: multiple RCTs and a systematic review/meta-analysis show two kiwifruit daily increase spontaneous bowel movements and reduce abdominal discomfort, with efficacy comparable to fibre-matched psyllium, attributed to its fibre, water and the enzyme actinidin. The meta-analysis rated certainty as low, reflecting small samples and risk of bias. A randomised trial found three kiwifruit daily modestly lowered 24-hour blood pressure versus an apple, and small crossover trials suggest possible mood or sleep benefits, but these findings are preliminary (often only trend-level) and need replication. Overall, the human evidence is most convincing for laxation and vitamin C status, while broader cardiometabolic and sleep claims remain exploratory.

Nutrition (per 1 medium (69 g)): 42 kcal; Vitamin C 64mg (71% DV), Vitamin K 27.8mcg (23% DV), Fibre 2.1g (8% DV), Copper 0.09mg (10% DV), Vitamin E 1mg (7% DV), Potassium 215mg (5% DV), Folate 17mcg (4% DV).
Benefits / uses: Relieves functional constipation and improves bowel regularity; Raises plasma vitamin C and supports antioxidant status; May modestly lower 24-hour blood pressure; Improves laxation with efficacy comparable to psyllium; Preliminary, trend-level evidence for improved sleep or mood; Provides vitamin K and vitamin E with low glycaemic load.
Active compounds: Vitamin C (ascorbic acid); Dietary fibre (soluble and insoluble); Actinidin (proteolytic enzyme); Vitamin K1 (phylloquinone); Vitamin E (alpha-tocopherol); Potassium; Polyphenols (flavonoids, chlorogenic acid); Lutein and zeaxanthin (carotenoids); Folate.
Dose: Two green kiwifruit daily (about 140-180 g) is the dose used in most constipation trials; one medium kiwi (~69 g) supplies roughly 70% of the adult vitamin C Daily Value. Eat the whole edible flesh, ideally with skin for extra fibre.
Safety: Kiwifruit is a recognised allergen and can cause oral allergy syndrome or, rarely, anaphylaxis, often cross-reacting with latex, birch pollen, avocado and banana. It is high in oxalate, so people prone to calcium-oxalate kidney stones should moderate intake. The vitamin K content can slightly affect warfarin dosing if intake changes abruptly. The actinidin enzyme can intensify reactions in sensitised individuals. It carries a meaningful natural sugar load; portion accordingly in diabetes. No clinically important grapefruit-type CYP3A4 interaction is known.

Cited studies (8):
  - In persons with constipation or IBS-C, kiwifruit vs. psyllium increased spontaneous bowel movements, Annals of internal medicine (2023) — Annals of Internal Medicine evidence synopsis of the Gearry trial concluded that in persons with constipation or IBS-C, kiwifruit versus psyllium increased spontaneous bowel movements. [https://pubmed.ncbi.nlm.nih.gov/37126812/]
  - Kiwifruit and Kiwifruit Extracts for Treatment of Constipation: A Systematic Review and Meta-Analysis, Canadian journal of gastroenterology & hepatology (2022) — Systematic review/meta-analysis of 7 RCTs (399 participants): kiwifruit increases weekly spontaneous bowel movements vs placebo or psyllium and reduces abdominal pain, with low certainty of evidence. [https://pubmed.ncbi.nlm.nih.gov/36247043/]
  - UKNHCC scientific opinion: green kiwifruit powder and maintenance of normal defecation, UK Nutrition and Health Claims Committee (UKNHCC), Office for Health Improvement & Disparities (2026) — UK Nutrition and Health Claims Committee scientific opinion assessed the evidence for green kiwifruit powder and maintenance of normal defecation. [https://www.gov.uk/government/publications/uknhcc-scientific-opinion-green-kiwifruit-powder-and-normal-defecation/uknhcc-scientific-opinion-green-kiwifruit-powder-and-maintenance-of-normal-defecation]
  - Consumption of 2 Green Kiwifruits Daily Improves Constipation and Abdominal Comfort-Results of an International Multicenter Randomized Controlled Trial, The American journal of gastroenterology (2023) — International multicentre crossover RCT (184 adults): two green kiwifruit daily clinically improved constipation (>=1.5 more complete spontaneous bowel movements/week) and abdominal comfort. [https://pubmed.ncbi.nlm.nih.gov/36537785/]
  - Acute effects of fresh versus dried Hayward green kiwifruit on sleep quality, mood, and sleep-related urinary metabolites in healthy young men with good and poor sleep quality, Frontiers in nutrition (2023) — Single-blind crossover study in 24 men: fresh or dried green kiwifruit with an evening meal produced only modest, trend-level improvements in mood/sleep measures and raised the serotonin metabolite 5-HIAA. [https://pubmed.ncbi.nlm.nih.gov/36998905/]
  - Two Gold Kiwifruit Daily for Effective Treatment of Constipation in Adults-A Randomized Clinical Trial, Nutrients (2022) — Crossover RCT (56 adults, including functional constipation and IBS-C): two gold kiwifruit daily as effective as fibre-matched psyllium for treating constipation, with less straining. [https://pubmed.ncbi.nlm.nih.gov/36235798/]
  - KiwiC for Vitality: Results of a Randomized Placebo-Controlled Trial Testing the Effects of Kiwifruit or Vitamin C Tablets on Vitality in Adults with Low Vitamin C Levels, Nutrients (2020) — Placebo-controlled trial (167 adults with low vitamin C status): two SunGold kiwifruit daily raised plasma vitamin C to saturation within two weeks and improved subjective vitality (fatigue, well-being). [https://pubmed.ncbi.nlm.nih.gov/32971991/]
  - The effect of kiwifruit consumption on blood pressure in subjects with moderately elevated blood pressure: a randomized, controlled study, Blood pressure (2015) — RCT in 118 adults with moderately elevated BP: three kiwifruit/day lowered 24-hour systolic and diastolic blood pressure versus one apple/day over 8 weeks. [https://pubmed.ncbi.nlm.nih.gov/25483553/]

---

## Mango (Mangifera indica)
URL: https://nutridex.info/s/mango
Category: Fruits
Evidence: Preliminary — Early or small human trials; promising but not yet conclusive.
Tropical stone fruit rich in vitamin C

Quick answer: Mango is used for may improve glycemic control and insulin sensitivity despite its sweetness (small, short rcts). NutriDex grades the human evidence as preliminary — Early or small human trials; promising but not yet conclusive. Based on 8 cited human studies (8 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Human evidence for mango is still emerging and rests largely on small, short-duration trials in overweight, obese, or type 2 diabetic adults. Several randomized and controlled studies report that regular mango intake (roughly 250-400 g/day over 6-12 weeks) modestly lowers fasting glucose, HbA1c, and inflammatory markers, and one 8-week RCT in type 2 diabetes found two mango varieties outperformed isocaloric white bread on glycemia, weight and lipids. These benefits appear tied to systemic exposure to polyphenol metabolites such as mangiferin and gallotannins. Mango itself has not been isolated in large prospective cohorts, but it contributes to the broad fresh-fruit intake that the China Kadoorie Biobank (>500,000 adults) linked to markedly lower cardiovascular mortality and stroke. Overall the data are promising but preliminary: sample sizes are very small (often under 30 participants), trials are short, control comparators vary, and no meta-analysis of mango-specific RCTs yet exists. Mango is best viewed as a nutrient-dense whole fruit within a varied diet rather than a proven therapeutic.

Nutrition (per 1 cup pieces (165 g)): 99 kcal; Vitamin C 60.1mg (67% DV), Copper 0.18mg (20% DV), Folate 71mcg DFE (18% DV), Vitamin B6 0.2mg (12% DV), Vitamin A 89mcg RAE (10% DV), Vitamin E 1.49mg (10% DV), Fibre 2.6g (9% DV).
Benefits / uses: May improve glycemic control and insulin sensitivity despite its sweetness (small, short RCTs); Associated with lower cardiovascular risk as part of fresh-fruit intake (large cohorts); Anti-inflammatory effects via polyphenol metabolites (mangiferin, gallotannins) in early human studies; Excellent vitamin C source supporting antioxidant defense and immune function; Provitamin A carotenoids (beta-carotene) contributing to vitamin A status; Soluble and insoluble fiber supporting digestion and satiety.
Active compounds: Vitamin C (ascorbic acid); Provitamin A carotenoids (beta-carotene); Mangiferin (xanthonoid polyphenol); Gallotannins and gallic acid; Folate; Potassium; Copper; Pectin (soluble fibre); Vitamin B6.
Dose: A typical serving is about 1 cup of pieces (165 g) or roughly half a medium mango; clinical trials used larger doses of 250-400 g/day. Fits well within the recommended 2 cups of fruit per day.
Safety: Generally safe as a food. Mango is relatively high in sugar (about 22 g per cup), so portion awareness matters for people with diabetes despite favorable trial data. Mango belongs to the Anacardiaceae (cashew/poison ivy) family: the skin, sap, and area near the peel contain urushiol, which can cause contact dermatitis in sensitive individuals, and oral allergy syndrome can occur in those with birch or latex allergy. Unlike grapefruit, mango is not a clinically significant CYP3A4 inhibitor at dietary amounts. No notable oxalate concern.

Cited studies (8):
  - Glycemic, lipid, anthropometric and body composition responses to two Mango varieties versus white bread in people with type 2 diabetes: an 8-week randomised controlled trial, Journal of diabetes and metabolic disorders (2025) — 8-week RCT in type 2 diabetes: 250 g/day of Safeda or Dasheri mango (replacing breakfast bread) lowered fasting glucose, HbA1c (~0.5-0.9%), HOMA-IR, weight and waist vs white bread, and raised HDL. [https://pubmed.ncbi.nlm.nih.gov/40761695/]
  - Daily Mango Intake Improves Glycemic and Body Composition Outcomes in Adults with Prediabetes: A Randomized Controlled Study, Foods (Basel, Switzerland) (2025) — In a 24-week randomized controlled study in prediabetes (n=23 completers), one fresh mango/day lowered fasting glucose (p<0.02) and improved insulin sensitivity (QUICKI p=0.02), with HbA1c stable in the mango group but rising in controls (p=0.02) and reduced body fat. [https://pmc.ncbi.nlm.nih.gov/articles/PMC12428706/]
  - Mango Consumption Is Associated with Increased Insulin Sensitivity in Participants with Overweight/Obesity and Chronic Low-Grade Inflammation, Nutrients (2025) — In adults with overweight/obesity and chronic low-grade inflammation (n=48), ~2 cups fresh mango daily (~100 kcal) lowered fasting insulin and improved insulin sensitivity versus a calorie-matched control food. [https://pmc.ncbi.nlm.nih.gov/articles/PMC11820656/]
  - Glycemic responses of three mango varieties in subjects with and without T2D: a pilot crossover study using OTT and CGM, European Journal of Clinical Nutrition (2025) — A pilot crossover study using oral tolerance testing and continuous glucose monitoring compared glycemic responses to three mango varieties in subjects with and without type 2 diabetes, characterizing variety-dependent postprandial glucose differences. [https://www.nature.com/articles/s41430-025-01659-1]
  - Effects of Fresh Mango Consumption on Blood Glucose, Insulin, and Other Cardiovascular Disease Risk Factors in Overweight and Obese Adults, Current Developments in Nutrition (2021) — 12-week randomized crossover in 27 overweight/obese adults: daily fresh mango (100 kcal) significantly decreased blood glucose and CRP, while an isocaloric cookie control raised insulin, CRP and triglycerides. [https://pmc.ncbi.nlm.nih.gov/articles/PMC8340768/]
  - Obesity-Associated Diseases Biomarkers Are Differently Modulated in Lean and Obese Individuals and Inversely Correlated to Plasma Polyphenolic Metabolites After 6 Weeks of Mango (Mangifera indica L.) Consumption, Molecular nutrition & food research (2018) — 6-week randomized trial (n=9 obese): 400 g/day mango pulp cut HbA1c ~18% and PAI-1 ~20% and lowered IL-8/MCP-1, correlated with plasma polyphenol metabolites. [https://pubmed.ncbi.nlm.nih.gov/29797702/]
  - Mangos and their bioactive components: adding variety to the fruit plate for health, Food & function (2017) — Review of mango bioactives (mangiferin, gallotannins) summarizing emerging anti-inflammatory, antidiabetic and cardioprotective potential and calling for whole-fruit human studies. [https://pubmed.ncbi.nlm.nih.gov/28612853/]
  - Fresh Fruit Consumption and Major Cardiovascular Disease in China, The New England journal of medicine (2016) — China Kadoorie cohort of 512,891 adults: daily fresh-fruit intake associated with about one-third lower cardiovascular death and lower coronary, ischemic and hemorrhagic stroke risk. [https://pubmed.ncbi.nlm.nih.gov/27050205/]

---

## Pineapple (Ananas comosus)
URL: https://nutridex.info/s/pineapple
Category: Fruits
Evidence: Preliminary — Early or small human trials; promising but not yet conclusive.
Tropical source of vitamin C and bromelain

Quick answer: Pineapple is used for high vitamin c supports immune function and antioxidant defence. NutriDex grades the human evidence as preliminary — Early or small human trials; promising but not yet conclusive. Based on 10 cited human studies (10 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Pineapple is a nutrient-dense tropical fruit notable for vitamin C and manganese, and is the dietary source of the proteolytic enzyme complex bromelain. Most human health evidence concerns concentrated bromelain supplements rather than the whole fruit: a 40-patient pilot RCT found 500 mg/day bromelain improved WOMAC osteoarthritis scores over 16 weeks, and a meta-analysis of 6 RCTs showed moderate reductions in pain (but not swelling or trismus) after third-molar surgery. A systematic review of bromelain and inflammation found effects to be inconsistent and isolated rather than consistently positive, and trials are small, heterogeneous, and often combine bromelain with other enzymes. A controlled trial of canned-pineapple intake in schoolchildren suggested fewer infections, but whole-fruit clinical data are sparse. Overall, the weight of human evidence for health benefits from eating pineapple itself is preliminary; the stronger (still moderate-quality) signals come from supplemental bromelain.

Nutrition (per 1 cup chunks (165 g)): 83 kcal; Vitamin C 78.9mg (88% DV), Manganese 1.53mg (67% DV), Copper 0.18mg (20% DV), Vitamin B6 0.18mg (11% DV), Thiamin 0.13mg (11% DV), Folate 30µg DFE (7% DV), Potassium 180mg (4% DV).
Benefits / uses: High vitamin C supports immune function and antioxidant defence; Manganese contributes to bone and connective-tissue metabolism; Bromelain may reduce post-surgical pain and improve recovery quality of life; Possible adjunctive relief of osteoarthritis pain (supplemental bromelain); Provides hydration and modest dietary fibre; Bromelain may affect some inflammatory markers, though trial evidence is inconsistent.
Active compounds: Vitamin C (ascorbic acid); Bromelain (cysteine protease complex); Manganese; Vitamin B6 (pyridoxine); Copper; Potassium; Phenolic acids (ferulic, gallic); Soluble & insoluble fibre.
Dose: A typical serving is 1 cup of fresh chunks (~165 g), delivering most of a day's vitamin C and roughly two-thirds the Daily Value for manganese. Bromelain-specific benefits in trials use concentrated supplements (roughly 200-1200 mg/day), not the amounts realistically obtained from eating the fruit.
Safety: Bromelain can cause oral tingling/irritation and mild GI upset (nausea, diarrhoea); IgE-mediated allergy and cross-reactivity (latex-fruit syndrome) occur. Bromelain has antiplatelet/fibrinolytic activity and may potentiate anticoagulants (warfarin), antiplatelet drugs, and increase absorption of some antibiotics (amoxicillin, tetracycline); caution before surgery. The fruit's natural sugars (~16 g per cup) warrant portion awareness in diabetes. Unlike grapefruit, pineapple is not a clinically significant CYP3A4 inhibitor.

Cited studies (10):
  - Efficacy and safety of bromelain: A systematic review and meta-analysis, Nutrition and health (2023) — Systematic review and meta-analysis (39 trials pooled): oral bromelain gave a small but significant improvement in pain control (MD -0.27) and topical bromelain accelerated burn debridement, with no proven cardiovascular benefit. [https://pubmed.ncbi.nlm.nih.gov/37157782/]
  - Bromelain supplementation and inflammatory markers: A systematic review of clinical trials, Clinical nutrition ESPEN (2023) — Systematic review of 7 RCTs (bromelain 99.9-1200 mg/day, 1-16 weeks, alone or combined): effects on inflammatory markers were inconsistent and isolated across studies, with few adverse events. [https://pubmed.ncbi.nlm.nih.gov/37202035/]
  - Bromelain-Based Enzymatic Debridement Versus Standard of Care in Deep Burn Injuries: A Systematic Review and Meta-Analysis, Journal of burn care & research : official publication of the American Burn Association (2025) — Meta-analysis of deep burns found bromelain-based enzymatic debridement reduced time to eschar removal by 7.60 days versus standard care and lowered need for surgical excision and autografts, with no difference in time to wound closure. [https://pubmed.ncbi.nlm.nih.gov/39259807/]
  - The Efficacy of Bromelain-based Enzymatic Debridement in Deep Burn Injury Management: A Comprehensive Systematic Review and Meta-analysis, Journal of plastic and reconstructive surgery (2026) — Comprehensive systematic review/meta-analysis (literature to March 2024) of bromelain-based enzymatic debridement in deep burns reported faster complete debridement versus standard care. [https://pmc.ncbi.nlm.nih.gov/articles/PMC12861611/]
  - Efficacy of proteolytic enzyme bromelain on health outcomes after third molar surgery. Systematic review and meta-analysis of randomized clinical trials, Medicina oral, patologia oral y cirugia bucal (2019) — Meta-analysis of 6 RCTs after third-molar surgery: bromelain produced moderate pain reduction at 24h and 7d and improved quality of life, but no effect on swelling or trismus. [https://pubmed.ncbi.nlm.nih.gov/30573710/]
  - Randomized controlled trial of bromelain and alpha-lipoic acid in breast conservative surgery, Scientific Reports (2025) — Randomized controlled trial evaluated bromelain plus alpha-lipoic acid for recovery outcomes after breast-conserving surgery. [https://www.nature.com/articles/s41598-025-86651-2]
  - Bromelain: Usefulness and Safety, NIH National Center for Complementary and Integrative Health (2024) — NIH NCCIH summary notes limited high-quality human evidence for bromelain and cautions about allergy/bleeding interactions and GI side effects. [https://www.nccih.nih.gov/health/bromelain]
  - Improved WOMAC score following 16-week treatment with bromelain for knee osteoarthritis, Clinical rheumatology (2016) — Single-blind pilot RCT in 40 knee-osteoarthritis patients: 500 mg/day oral bromelain for 16 weeks improved total WOMAC score (12.2 vs 25.5 at baseline) and pain, stiffness and function subscales. [https://pubmed.ncbi.nlm.nih.gov/27470088/]
  - Effects of canned pineapple consumption on nutritional status, immunomodulation, and physical health of selected school children, Journal of nutrition and metabolism (2014) — RCT in 98 schoolchildren: daily canned pineapple (140-280 g) was associated with shorter/fewer infections and higher granulocyte and CD16+56 immune-cell counts at the higher dose. [https://pubmed.ncbi.nlm.nih.gov/25505983/]
  - Bromelain as a Treatment for Osteoarthritis: a Review of Clinical Studies, Evidence-based complementary and alternative medicine : eCAM (2004) — Review of clinical studies concluded bromelain shows promise for osteoarthritis symptom relief but that no large single-agent RCTs yet establish efficacy. [https://pubmed.ncbi.nlm.nih.gov/15841258/]

---

## Papaya (Carica papaya)
URL: https://nutridex.info/s/papaya
Category: Fruits
Evidence: Moderate — Several controlled trials; effects real but modest or context-dependent.
Tropical fruit rich in vitamin C and carotenoids

Quick answer: Papaya is used for excellent vitamin c source supporting antioxidant defence and immune function. NutriDex grades the human evidence as moderate — Several controlled trials; effects real but modest or context-dependent. Based on 11 cited human studies (11 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Direct human trials on papaya as a whole fruit are sparse; most evidence is indirect, drawn from its constituent nutrients. Large prospective cohorts and dose-response meta-analyses consistently link higher total fruit and vegetable intake, dietary vitamin C, and carotenoids (lycopene, lutein/zeaxanthin) with lower cardiovascular mortality, modestly reduced prostate-cancer risk, and higher macular pigment density. These associations are observational and reflect overall dietary patterns rather than papaya specifically, so causal attribution to papaya alone is not established. Small RCTs of fermented papaya preparations show modest improvements in oxidative-stress and metabolic markers, but these are proprietary processed extracts, not fresh fruit, and effects on hard clinical endpoints are unproven. Overall the weight of human evidence supporting papaya's benefits is moderate, grounded in nutrient-level cohort data rather than fruit-specific trials.

Nutrition (per 1 cup cubes (145 g)): 62 kcal; Vitamin C 88mg (98% DV), Folate 54mcg (13% DV), Vitamin A (RAE) 68mcg (8% DV), Potassium 264mg (6% DV), Fibre 2.5g (9% DV), Magnesium 31mg (7% DV).
Benefits / uses: Excellent vitamin C source supporting antioxidant defence and immune function; Provides provitamin-A carotenoids (beta-carotene) and lycopene linked to cardiovascular and prostate-cancer risk reduction in cohorts; Supplies lutein and zeaxanthin relevant to macular pigment and eye health; Soluble and insoluble fibre supporting digestive regularity and satiety; Low energy density with high water content, useful for weight-conscious diets; Potassium contributes to healthy blood pressure as part of a fruit-rich diet.
Active compounds: Vitamin C (ascorbic acid); Provitamin-A carotenoids (beta-carotene, beta-cryptoxanthin); Lycopene; Lutein and zeaxanthin; Potassium; Folate; Dietary fibre (pectin, soluble + insoluble); Papain (cysteine protease); Polyphenols (ferulic and caffeic acids).
Dose: A typical serving is 1 cup of cubes (about 145 g) or roughly half a small papaya, providing nearly a full day's vitamin C. Whole-diet patterns associate higher total fruit and vegetable intake (up to ~800 g/day) with lower cardiovascular and all-cause mortality; papaya counts toward this without a fruit-specific intake threshold.
Safety: Papaya can trigger allergy in latex-sensitised individuals (latex-fruit syndrome) via cross-reactive class-I chitinases; papain and chymopapain are also recognised allergens and occupational sensitisers. Unripe (green) papaya and high-dose papaya leaf/seed extracts contain papain and carpaine and are traditionally avoided in pregnancy because of theoretical uterotonic/abortifacient effects. The natural sugar load (~11 g per cup) is modest but counts for those managing blood glucose. Papain-containing supplements may theoretically potentiate anticoagulants such as warfarin. Fresh ripe papaya in normal culinary amounts is generally well tolerated.

Cited studies (11):
  - The Effect of Lutein/Zeaxanthin Intake on Human Macular Pigment Optical Density: A Systematic Review and Meta-Analysis, Advances in nutrition (Bethesda, Md.) (2021) — Systematic review/meta-analysis (46 studies, 3,189 participants): lutein/zeaxanthin intake of 5-20+ mg/day increases macular pigment optical density; doses below 5 mg/day showed no significant change. [https://pubmed.ncbi.nlm.nih.gov/34157098/]
  - Fruit and vegetable intake and the risk of cardiovascular disease, total cancer and all-cause mortality-a systematic review and dose-response meta-analysis of prospective studies, International journal of epidemiology (2017) — Dose-response meta-analysis (95 studies): higher fruit and vegetable intake associated with lower cardiovascular disease, cancer, and all-cause mortality (RR 0.90 per 200 g/day for all-cause mortality), with benefit up to ~800 g/day. [https://pubmed.ncbi.nlm.nih.gov/28338764/]
  - Dietary and circulating vitamin C, vitamin E, β-carotene and risk of total cardiovascular mortality: a systematic review and dose-response meta-analysis of prospective observational studies, Public health nutrition (2019) — Dietary vitamin C linked to 21% lower CVD mortality (RR 0.79) and higher circulating vitamin C to 40% lower (RR 0.60). [https://pubmed.ncbi.nlm.nih.gov/30630552/]
  - Effect of Carotene and Lycopene on the Risk of Prostate Cancer: A Systematic Review and Dose-Response Meta-Analysis of Observational Studies, PloS one (2015) — Dietary and blood lycopene inversely associated with overall prostate cancer risk (RR 0.86 and 0.81; ~3% lower risk per 1 mg/day dietary lycopene), though no protection seen for advanced disease. [https://pubmed.ncbi.nlm.nih.gov/26372549/]
  - Carica papaya extract in dengue: a systematic review and meta-analysis, BMC complementary and alternative medicine (2019) — Systematic review/meta-analysis of 9 trials found C. papaya leaf extract associated with increased platelet count (mean difference 20.27, 95% CI 6.21-34.73; P=0.005), but judged evidence insufficient to recommend it for dengue given unclear clinical benefit. [https://pmc.ncbi.nlm.nih.gov/articles/PMC6788024/]
  - Effects of Fermented Papaya Preparation (FPP) on Safety Outcomes in Older Adults - A Short Report of a Placebo-Controlled Clinical Trial, The Journal of frailty & aging (2018) — Randomized placebo-controlled crossover trial of Fermented Papaya Preparation in 29 adults aged 70-100 found no adverse changes in blood chemistries and no serious adverse effects, supporting safety/feasibility of FPP supplementation in older adults. [https://pubmed.ncbi.nlm.nih.gov/29741201/]
  - Effects of a short term supplementation of a fermented papaya preparation on biomarkers of diabetes mellitus in a randomized Mauritian population, Preventive medicine (2012) — RCT in neo-diabetics: 6 g/day fermented papaya preparation for 14 weeks improved oxidative-stress and metabolic biomarkers (e.g., reduced CRP, improved LDL/HDL and uric acid). [https://pubmed.ncbi.nlm.nih.gov/22330753/]
  - Exploring the potential of Carica Papaya Leaf Extract: a perspective on its effectiveness in ameliorating thrombocytopenia in dengue patients, Infection ecology & epidemiology (2025) — 2025 review of Carica papaya leaf extract for dengue thrombocytopenia concludes CPLE shows promising platelet-count increases and shorter hospital stays, but existing trials have methodological flaws preventing a firm clinical recommendation. [https://pubmed.ncbi.nlm.nih.gov/39867637/]
  - Antiviral & platelet-protective properties of Carica papaya in dengue, The Indian journal of medical research (2022) — Review of antiviral and platelet-protective properties of Carica papaya in dengue summarizes proposed mechanisms (platelet membrane stabilization, reduced platelet destruction, inhibition of viral assembly) underlying observed platelet recovery. [https://pubmed.ncbi.nlm.nih.gov/36751743/]
  - Mitigating Hyperglycaemic Oxidative Stress in HepG2 Cells: The Role of Carica papaya Leaf and Root Extracts in Promoting Glucose Uptake and Antioxidant Defence, Nutrients (2024) — Preclinical (HepG2 cell) study showing Carica papaya leaf and root extracts promote glucose uptake and antioxidant defence under hyperglycaemic oxidative stress; mechanistic support but no human outcomes. [https://pmc.ncbi.nlm.nih.gov/articles/PMC11510471/]
  - Cross-reactions in the latex-fruit syndrome: A relevant role of chitinases but not of complex asparagine-linked glycans, The Journal of allergy and clinical immunology (1999) — Class-I chitinases identified as relevant cross-reactive allergens underlying latex-fruit syndrome, including papaya. [https://pubmed.ncbi.nlm.nih.gov/10482846/]

---

## Watermelon (Citrullus lanatus)
URL: https://nutridex.info/s/watermelon
Category: Fruits
Evidence: Moderate — Several controlled trials; effects real but modest or context-dependent.
Hydrating summer fruit rich in citrulline and lycopene

Quick answer: Watermelon is used for modestly lowers blood pressure (citrulline/arginine pathway). NutriDex grades the human evidence as moderate — Several controlled trials; effects real but modest or context-dependent. Based on 8 cited human studies (8 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Watermelon is best known among fruits for its L-citrulline content, which the body converts to L-arginine to support nitric-oxide-mediated vasodilation. A 2023 meta-analysis of 9 randomized trials found watermelon consumption significantly lowered systolic blood pressure and improved total cholesterol and LDL, though it unexpectedly raised fasting blood glucose. A 2025 meta-analysis of L-citrulline/watermelon trials in middle-aged and older adults confirmed modest reductions in systolic (~-4 mmHg) and diastolic (~-2.5 mmHg) blood pressure. Small RCTs of watermelon extract also show reduced arterial stiffness and aortic blood pressure in obese hypertensive adults, and watermelon juice may modestly aid post-exercise recovery, though evidence here is mixed. Most trials are small, short, and often use concentrated extracts or juice rather than typical whole-fruit servings. The fruit is largely water with a high glycemic index but low glycemic load per realistic portion. Overall the cardiovascular signal is consistent but modest, warranting a conservative "moderate" rating.

Nutrition (per 1 wedge (286 g)): 86 kcal; Vitamin C 23.2mg (26% DV), Vitamin A (RAE) 80mcg (9% DV), Potassium 320mg (7% DV), Magnesium 28.6mg (7% DV), Fiber 1.1g (4% DV).
Benefits / uses: Modestly lowers blood pressure (citrulline/arginine pathway); Supports nitric-oxide-mediated vasodilation; May reduce arterial stiffness in adults with prehypertension/hypertension; High water content supports hydration; Provides lycopene, an antioxidant carotenoid; May improve some cardiometabolic lipid markers (total cholesterol, LDL).
Active compounds: L-Citrulline (non-protein amino acid); L-Arginine; Lycopene (carotenoid); Beta-carotene (provitamin A); Vitamin C (ascorbic acid); Potassium; Magnesium; Cucurbitacin E.
Dose: A typical serving is one wedge (~286 g) or 1-2 cups of diced flesh; cardiovascular trials often use larger amounts (~2-3 cups daily or watermelon extract supplying ~1-6 g citrulline/arginine).
Safety: Generally very safe as a food. The high glycemic index means large portions can spike blood glucose, relevant for people with diabetes (though glycemic load per serving is low). It is a high-FODMAP food (fructose, mannitol) and may cause bloating, gas, or diarrhea in sensitive individuals or those with IBS. Rare allergy can occur, sometimes via oral allergy syndrome cross-reacting with ragweed pollen. Concentrated citrulline/arginine supplements may add to the blood-pressure-lowering effect of antihypertensive drugs and PDE5 inhibitors; no notable CYP3A4/grapefruit-type interaction.

Cited studies (8):
  - Watermelon consumption decreases risk factors of cardiovascular diseases: A systematic review and meta-analysis of randomized controlled trials, Diabetes research and clinical practice (2023) — Meta-analysis of 9 RCTs: watermelon consumption significantly lowered systolic blood pressure, total cholesterol and LDL, though fasting blood glucose rose. [https://pubmed.ncbi.nlm.nih.gov/37369281/]
  - Does l-citrulline supplementation and watermelon intake reduce blood pressure in middle-aged and older adults? A systematic review and meta-analysis of randomized controlled trials, Clinical Nutrition ESPEN (2025) — Meta-analysis (15 RCTs, 24 datasets, n=415): L-citrulline supplementation/watermelon intake significantly reduced SBP (-4.02 mmHg) and DBP (-2.54 mmHg) in middle-aged and older adults. [https://doi.org/10.1016/j.clnesp.2025.07.1130]
  - Effects of L-citrulline supplementation and watermelon intake on arterial stiffness and endothelial function in middle-aged and older adults: a systematic review and meta-analysis of randomized controlled trials, Frontiers in nutrition (2025) — Systematic review and meta-analysis of RCTs found L-citrulline supplementation and watermelon intake improved arterial stiffness and endothelial function in middle-aged and older adults. [https://pmc.ncbi.nlm.nih.gov/articles/PMC12658987/]
  - Effects of l-citrulline supplementation and watermelon consumption on longer-term and postprandial vascular function and cardiometabolic risk markers: a meta-analysis of randomised controlled trials in adults, British Journal of Nutrition (2022) — Meta-analysis of RCTs found longer-term L-citrulline supplementation and watermelon consumption may improve vascular function; postprandial glucose fell by 0.6 mmol/L but no other postprandial cardiometabolic effects were seen. [https://www.cambridge.org/core/journals/british-journal-of-nutrition/article/effects-of-lcitrulline-supplementation-and-watermelon-consumption-on-longerterm-and-postprandial-vascular-function-and-cardiometabolic-risk-markers-a-metaanalysis-of-randomised-controlled-trials-in-adults/1873E93CFF6015FD63F34CBDF5DFAE3C]
  - Dose-Response Effect of Watermelon Consumption on Ambulatory Blood Pressure in Adults with Elevated Blood Pressure: A Randomized Controlled Pilot Trial, Nutrients (2025) — Randomized placebo-controlled pilot trial in 39 adults with elevated BP found daily watermelon (152 or 304 g/day) for 4 weeks; assessed effects on 24-hour ambulatory blood pressure as a dietary source of L-citrulline/L-arginine. [https://pmc.ncbi.nlm.nih.gov/articles/PMC12525780/]
  - Effects of watermelon supplementation on aortic hemodynamic responses to the cold pressor test in obese hypertensive adults, American journal of hypertension (2014) — RCT (n=13 obese hypertensive adults): 6-week watermelon supplementation reduced aortic blood pressure and myocardial oxygen demand during the cold pressor test. [https://pubmed.ncbi.nlm.nih.gov/24572702/]
  - Watermelon extract supplementation reduces ankle blood pressure and carotid augmentation index in obese adults with prehypertension or hypertension, American journal of hypertension (2012) — RCT (n=14 obese pre/hypertensive adults): 6-week watermelon extract (6 g citrulline/arginine) reduced ankle and brachial blood pressure and carotid augmentation index (arterial stiffness). [https://pubmed.ncbi.nlm.nih.gov/22402472/]
  - Watermelon juice: potential functional drink for sore muscle relief in athletes, Journal of agricultural and food chemistry (2013) — Crossover trial in athletes: 500 mL watermelon juice (1.17 g citrulline) helped reduce 24-h muscle soreness and recovery heart rate; natural juice citrulline more bioavailable. [https://pubmed.ncbi.nlm.nih.gov/23862566/]

---

## Avocado (Persea americana)
URL: https://nutridex.info/s/avocado
Category: Fruits
Evidence: Moderate — Several controlled trials; effects real but modest or context-dependent.
Creamy monounsaturated fat, fiber, and potassium

Quick answer: Avocado is used for improves blood lipid profile (lowers ldl and total cholesterol, especially in those with high cholesterol). NutriDex grades the human evidence as moderate — Several controlled trials; effects real but modest or context-dependent. Based on 9 cited human studies (9 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Avocado is a nutrient-dense fruit rich in monounsaturated fat, fiber, and potassium, and human evidence for cardiometabolic benefit is moderate but not definitive. Large prospective US cohorts (NHS and HPFS) link 2 or more servings per week, and substitution for butter, margarine, or processed meat, to a 16-22% lower cardiovascular risk. Short controlled feeding trials show avocado can lower LDL and total cholesterol, but a 2024 systematic review and meta-analysis found no significant overall LDL reduction (only a subgroup benefit in hypercholesterolemic people, at low certainty). Critically, the largest RCT to date (HAT, n=1008, 6 months) found no significant effect of one avocado per day on visceral fat or most cardiometabolic markers. Thus observational data are consistent and favorable, but rigorous RCT confirmation of hard outcomes is lacking, and effects may partly reflect overall diet quality.

Nutrition (per 1/2 medium (100 g, raw)): 160 kcal; Fiber 6.7g (24% DV), Potassium 485mg (10% DV), Pantothenic acid (B5) 1.4mg (28% DV), Folate 81mcg (20% DV), Vitamin K 21mcg (18% DV), Copper 0.19mg (21% DV), Vitamin E 2.1mg (14% DV), Vitamin C 10mg (11% DV).
Benefits / uses: Improves blood lipid profile (lowers LDL and total cholesterol, especially in those with high cholesterol); Associated with lower cardiovascular and coronary heart disease risk in large cohorts; Supports satiety and modest improvements in diet quality when used to replace less healthy fats; Provides potassium and fiber that support blood pressure and gut health; Enhances absorption of fat-soluble carotenoids from co-consumed vegetables.
Active compounds: Monounsaturated fat (oleic acid); Soluble and insoluble dietary fiber; Potassium; Folate; Vitamin K; Vitamin E (alpha-tocopherol); Pantothenic acid (vitamin B5); Lutein and zeaxanthin (carotenoids); Beta-sitosterol (phytosterol).
Dose: Roughly half to one whole avocado per day (about 100-150 g); cohort benefits emerged at 2 or more servings per week, typically replacing butter, cheese, or processed meats.
Safety: Generally very safe as a whole food. Latex-fruit syndrome: people allergic to natural rubber latex may cross-react to avocado. Energy- and fat-dense, so portions matter for weight management. High potassium content warrants caution in advanced kidney disease or with potassium-sparing drugs. Vitamin K content is modest but relevant for those on warfarin needing consistent intake. Avocado may reduce blood levels of warfarin and amiodarone in isolated reports; no clinically significant CYP interaction like grapefruit is established.

Cited studies (9):
  - Avocado Consumption and Cardiometabolic Health: A Systematic Review and Meta-Analysis, Journal of the Academy of Nutrition and Dietetics (2024) — Systematic review and meta-analysis found no significant overall LDL-C change with avocado, but a significant -9.4 mg/dL LDL reduction in hypercholesterolemic subgroups (low to very low certainty). [https://pubmed.ncbi.nlm.nih.gov/36565850/]
  - Exploring the effect of avocado on lipid profile modulation: a systematic review and dose-response and meta-analysis of clinical trials, Critical reviews in food science and nutrition (2026) — Dose-response meta-analysis of avocado RCTs found avocado consumption significantly lowered LDL-C (WMD -6.16 mg/dL, 95% CI -9.87 to -2.44), with greater reductions at intakes >250 g/day. [https://pubmed.ncbi.nlm.nih.gov/40749705/]
  - Effects of Avocado Products on Cardiovascular Risk Factors in Adults: A GRADE-Assessed Systematic Review and Meta-Analysis, Food science & nutrition (2025) — GRADE-assessed meta-analysis of 10 RCTs (n=2,354) found avocado supplementation significantly reduced LDL-C (WMD -3.75 mg/dL, 95% CI -4.70 to -2.80; p<0.001) but had no significant effect on HDL or triglycerides. [https://pmc.ncbi.nlm.nih.gov/articles/PMC12221997/]
  - Effect of Avocado Consumption on Risk Factors of Cardiovascular Diseases: A Systematic Review and Meta-Analysis, Cureus (2023) — Systematic review and meta-analysis of 7 RCTs found the avocado group had lower LDL cholesterol than controls across both habitual-diet and low-fat-diet subgroups. [https://pubmed.ncbi.nlm.nih.gov/37525782/]
  - Avocado consumption and risk factors for heart disease: a systematic review and meta-analysis, The American journal of clinical nutrition (2018) — Systematic review and meta-analysis (18 studies) found avocado modestly raised HDL-C (~+2.8 mg/dL) but produced no significant change in total or LDL cholesterol, triglycerides, or body weight; most trials were short and small. [https://pubmed.ncbi.nlm.nih.gov/29635493/]
  - Effect of Incorporating 1 Avocado Per Day Versus Habitual Diet on Visceral Adiposity: A Randomized Trial, Journal of the American Heart Association (2022) — HAT trial (n=1008, 6 months): one avocado/day did not significantly reduce visceral adipose tissue (primary outcome, p=0.41) or meaningfully improve cardiometabolic risk factors vs habitual diet. [https://pmc.ncbi.nlm.nih.gov/articles/PMC9707833/]
  - A Moderate-Fat Diet with One Avocado per Day Increases Plasma Antioxidants and Decreases the Oxidation of Small, Dense LDL in Adults with Overweight and Obesity: A Randomized Controlled Trial, The Journal of nutrition (2020) — RCT in adults with overweight/obesity: one avocado/day raised plasma lutein (+69%) and lowered oxidized LDL (-8.8%), supporting an antioxidant mechanism on small, dense LDL. [https://pubmed.ncbi.nlm.nih.gov/31616932/]
  - Effect of a moderate fat diet with and without avocados on lipoprotein particle number, size and subclasses in overweight and obese adults: a randomized, controlled trial, Journal of the American Heart Association (2015) — Randomized controlled feeding trial: a moderate-fat diet with one Hass avocado/day lowered LDL-C by ~13.5 mg/dL and reduced LDL particle number and small dense LDL vs lower-fat and matched moderate-fat diets. [https://pubmed.ncbi.nlm.nih.gov/25567051/]
  - Avocado Consumption and Risk of Cardiovascular Disease in US Adults, Journal of the American Heart Association (2022) — In NHS and HPFS cohorts (>110,000 adults, 30-year follow-up), ≥2 avocado servings/week linked to 16% lower CVD and 21% lower CHD risk; replacing butter/cheese/processed meat with avocado lowered risk 16-22%. [https://pubmed.ncbi.nlm.nih.gov/35352568/]

---

## Pear (Pyrus communis)
URL: https://nutridex.info/s/pear
Category: Fruits
Evidence: Moderate — Several controlled trials; effects real but modest or context-dependent.
Fibre-rich fruit linked to lower diabetes risk

Quick answer: Pear is used for supports digestive regularity via soluble and insoluble fibre plus sorbitol. NutriDex grades the human evidence as moderate — Several controlled trials; effects real but modest or context-dependent. Based on 8 cited human studies (8 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Evidence that pears specifically confer health benefits is moderate and rests mainly on prospective cohort data, where apple/pear consumption is associated with an ~18% lower risk of type 2 diabetes (Guo 2017) and, alongside other anthocyanin-rich fruit, lower diabetes risk (Wedick 2012, HR ~0.77). A systematic review of apples and pears found protective associations for cardiovascular death, type 2 diabetes and all-cause mortality in observational studies, but randomized trials showed limited effects beyond modest BMI reduction (Gayer 2019). Broader meta-analyses of total fruit intake and of dietary fibre—of which pears are a good source—show dose-dependent reductions in cardiovascular disease and mortality (Aune 2017; Reynolds 2019). Pears' fibre and sorbitol content provide a plausible mechanism for digestive and metabolic benefits. Key limits: pears are rarely studied in isolation, observational data cannot prove causation, and confounding by overall healthy diet is likely. The realistic takeaway is that pears are a nutritious, fibre-rich fruit that supports established benefits of whole-fruit diets rather than a standalone intervention.

Nutrition (per 1 medium (178 g)): 101 kcal; Fibre 5.5g (20% DV), Copper 0.15mg (16% DV), Vitamin C 7.7mg (9% DV), Vitamin K 7.8µg (7% DV), Potassium 207mg (4% DV), Folate 12.5µg (3% DV).
Benefits / uses: Supports digestive regularity via soluble and insoluble fibre plus sorbitol; Associated with lower type 2 diabetes risk in pooled cohort data; Contributes to fruit intake linked to reduced cardiovascular disease and mortality; Low energy density and high water/fibre content aid satiety and weight management; Provides fermentable fibre that supports gut microbiota; Modest contribution to potassium and vitamin C intake.
Active compounds: Pectin and cellulose (soluble + insoluble fibre); Sorbitol (sugar alcohol); Fructose and glucose; Vitamin C (ascorbic acid); Vitamin K (phylloquinone); Potassium; Copper; Hydroxycinnamic acids (chlorogenic acid); Flavonols and anthocyanins (skin, esp. red cultivars).
Dose: One medium pear (~178 g) provides ~5.5 g fibre, roughly a fifth of the daily target; 1-2 servings/day fit standard "2 fruit a day" guidance. Eat with the skin, where most fibre and polyphenols reside.
Safety: Generally very safe. The sorbitol and fructose content can cause bloating, gas or diarrhoea in people with fructose malabsorption, IBS, or on low-FODMAP diets, and large amounts have a laxative effect. Pears are a relatively high source of fermentable sugars, so portion-aware for those tracking carbohydrate or sugar load. Oral allergy syndrome (cross-reactivity with birch pollen, profilin/PR-10 proteins) can cause itching/swelling in sensitised individuals; pear is also a recognised cause of LTP-mediated allergy in Mediterranean regions. No clinically important grapefruit-type CYP3A4 drug interactions are known.

Cited studies (8):
  - Non-Digestible Oligosaccharides and Constipation: A Systematic Review and Meta-Analysis of Randomized Trials on Stool Frequency, Stool Consistency, and Fermentation Biomarkers, Nutrients (2025) — Meta-analysis of 20 RCTs (n=1786) of non-digestible oligosaccharides (the class of fermentable carbohydrates abundant in pears) found supplementation significantly increased stool frequency overall, with a large effect in constipated individuals (SMD 0.99, 95% CI 0.58-1.28). [https://pmc.ncbi.nlm.nih.gov/articles/PMC12567251/]
  - Effects of Dietary Fiber Supplementation on Chronic Constipation in the Elderly: A Systematic Review and Meta-Analysis of Randomized Controlled Trials, Foods (Basel, Switzerland) (2025) — Meta-analysis of 7 RCTs (187 elderly participants) found dietary fiber supplementation did not significantly improve stool frequency but significantly reduced laxative/enema use and increased fecal bifidobacteria concentration. [https://pmc.ncbi.nlm.nih.gov/articles/PMC12249261/]
  - Effect of fruit intake on functional constipation: A systematic review and meta-analysis of randomized and crossover studies, Frontiers in nutrition (2022) — Systematic review and meta-analysis of 11 randomized/crossover fruit-intervention studies for functional constipation found fruit intake (kiwifruit and pome fruits such as pear) increased stool frequency and beneficially increased Bifidobacterium, with pome fruit, citrus and berries showing the strongest Bifidobacterium effect. [https://pmc.ncbi.nlm.nih.gov/articles/PMC9583540/]
  - Apple and pear consumption and type 2 diabetes mellitus risk: a meta-analysis of prospective cohort studies, Food & function (2017) — Meta-analysis of 5 prospective cohorts (228,315 participants, 14,120 cases): apple/pear consumption associated with 18% lower type 2 diabetes risk; ~3% per added serving/week. [https://pubmed.ncbi.nlm.nih.gov/28186516/]
  - Effects of Intake of Apples, Pears, or Their Products on Cardiometabolic Risk Factors and Clinical Outcomes: A Systematic Review and Meta-Analysis, Current developments in nutrition (2019) — Systematic review of 22 studies (7 RCTs, 14 cohorts): in observational data apple/pear intake linked to lower CVD death, T2D and all-cause mortality; in RCTs the only significant effect was modest BMI reduction. [https://pubmed.ncbi.nlm.nih.gov/31667463/]
  - Fruit and vegetable intake and the risk of cardiovascular disease, total cancer and all-cause mortality-a systematic review and dose-response meta-analysis of prospective studies, International journal of epidemiology (2017) — Dose-response meta-analysis (95 studies): higher fruit/vegetable intake reduces CVD, cancer and all-cause mortality, with benefit up to ~800 g/day. [https://pubmed.ncbi.nlm.nih.gov/28338764/]
  - Carbohydrate quality and human health: a series of systematic reviews and meta-analyses, Lancet (London, England) (2019) — Lancet series of systematic reviews/meta-analyses: high dietary fibre intake (greatest benefit 25-29 g/day) associated with 15-30% lower all-cause and CVD mortality and lower T2D and colorectal cancer. [https://pubmed.ncbi.nlm.nih.gov/30638909/]
  - Dietary flavonoid intakes and risk of type 2 diabetes in US men and women, The American journal of clinical nutrition (2012) — In 3 large US cohorts, higher intake of anthocyanin-rich fruit including apples/pears linked to lower type 2 diabetes risk (apples/pears HR ~0.77; total anthocyanins HR 0.85). [https://pubmed.ncbi.nlm.nih.gov/22357723/]

---

## Prune (Dried Plum) (Prunus domestica)
URL: https://nutridex.info/s/prune
Category: Fruits
Evidence: Moderate — Several controlled trials; effects real but modest or context-dependent.
Fibre-rich dried plum for gut and bone health

Quick answer: Prune (Dried Plum) is used for relieves chronic constipation and improves stool frequency/consistency (rct-supported). NutriDex grades the human evidence as moderate — Several controlled trials; effects real but modest or context-dependent. Based on 9 cited human studies (9 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

The strongest human evidence for prunes is in gastrointestinal function: randomized trials and a systematic review show ~50 g/day improves stool frequency and consistency in chronic constipation, outperforming an equal fibre dose of psyllium. A growing body of RCT evidence (notably the 12-month Prune Study) indicates 50-100 g/day helps preserve hip and total-body bone mineral density in postmenopausal women, though a 2026 meta-analysis found the effect only borderline-significant (favouring the lumbar spine) with high heterogeneity across sites. Benefits are attributed to fibre, sorbitol, polyphenols, potassium, vitamin K and boron acting together. Limitations include small samples, short durations, heterogeneous outcomes, and the fact most bone trials are industry-funded and focus on a single demographic. Cardiometabolic and antioxidant effects remain preliminary. Prunes are a calorie- and sugar-dense whole food, so portion matters.

Nutrition (per About 5 prunes (42 g)): 101 kcal; Fibre 3g (11% DV), Potassium 307mg (7% DV), Vitamin K 25mcg (21% DV), Copper 0.12mg (13% DV), Vitamin B6 0.09mg (5% DV), Manganese 0.13mg (6% DV).
Benefits / uses: Relieves chronic constipation and improves stool frequency/consistency (RCT-supported); Helps preserve hip and bone mineral density in postmenopausal women; Provides soluble and insoluble fibre supporting gut regularity; High potassium content supports healthy blood pressure; Rich in polyphenols with antioxidant activity; Low glycaemic impact relative to sugar content (sorbitol, fibre, polyphenols slow glucose absorption).
Active compounds: Pectin and cellulose (soluble + insoluble fibre); Sorbitol (sugar alcohol, osmotic laxative); Chlorogenic and neochlorogenic acids (phenolic acids); Potassium; Vitamin K1 (phylloquinone); Boron; Copper; Provitamin A carotenoids (beta-carotene); Vitamin B6.
Dose: Typical serving 4-5 prunes (~40-50 g) daily. For constipation, RCTs used ~50 g/day (about 6 g fibre). Bone-density trials used 50-100 g/day in postmenopausal women; 50 g/day is better tolerated.
Safety: High in sorbitol and fibre, so larger amounts can cause bloating, gas, cramping or diarrhoea; introduce gradually. Calorie- and sugar-dense (~240 kcal/100 g) so mind portions in diabetes and weight management. Vitamin K1 content can interact with warfarin if intake changes abruptly. Contains moderate oxalate (relevant for those prone to calcium-oxalate kidney stones). Acrylamide can form during drying. Prunus (stone-fruit) allergy is possible. No grapefruit-type CYP3A4 interaction.

Cited studies (9):
  - Effects of Prunes on Bone Density in Humans: A Systematic Review and Meta-Analysis of Randomized Controlled Trials, Nutrients (2026) — Meta-analysis of 11 RCTs (747 participants): prune effect on BMD was only borderline-significant (favouring the lumbar spine), with high heterogeneity across sites. [https://www.mdpi.com/2072-6643/18/9/1338]
  - Systematic review and meta-analysis: Foods, drinks and diets and their effect on chronic constipation in adults, Alimentary pharmacology & therapeutics (2024) — Systematic review/meta-analysis (23 studies, 1,714 adults with chronic constipation) found prunes were not superior to psyllium for stool frequency; fruits overall and rye bread improved some outcomes. [https://pubmed.ncbi.nlm.nih.gov/37905980/]
  - British Dietetic Association Guidelines for the Dietary Management of Chronic Constipation in Adults, Journal of human nutrition and dietetics : the official journal of the British Dietetic Association (2025) — BDA evidence-based guidelines (4 systematic reviews, 75 RCTs, GRADE) found prunes no more effective than psyllium for straining/constipation outcomes; conditional recommendation only. [https://pmc.ncbi.nlm.nih.gov/articles/PMC12517116/]
  - Systematic review: the effect of prunes on gastrointestinal function, Alimentary pharmacology & therapeutics (2014) — Systematic review: prunes improve stool frequency and consistency in constipation and appear superior to psyllium, though evidence for other GI outcomes is weak. [https://pubmed.ncbi.nlm.nih.gov/25109788/]
  - Prunes preserve cortical density and estimated strength of the tibia in a 12-month randomized controlled trial in postmenopausal women: The Prune Study, Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA (2024) — 12-month Prune Study analysis: prunes preserved cortical bone density and estimated strength at the weight-bearing tibia versus controls in postmenopausal women. [https://pubmed.ncbi.nlm.nih.gov/38349471/]
  - Effects of Prune (Dried Plum) Supplementation on Cardiometabolic Health in Postmenopausal Women: An Ancillary Analysis of a 12-Month Randomized Controlled Trial, The Prune Study, The Journal of nutrition (2024) — Ancillary analysis of the 12-month Prune Study RCT in postmenopausal women found 50–100 g/day prunes did not adversely affect cardiometabolic markers (lipids, glucose, blood pressure). [https://pubmed.ncbi.nlm.nih.gov/38490532/]
  - Prunes preserve hip bone mineral density in a 12-month randomized controlled trial in postmenopausal women: the Prune Study, The American journal of clinical nutrition (2022) — 12-month RCT in 235 postmenopausal women: 50 g/day prunes preserved total hip BMD (-0.3%) vs significant loss in controls (-1.1%). [https://pubmed.ncbi.nlm.nih.gov/35798020/]
  - Randomised clinical trial: dried plums (prunes) vs. psyllium for constipation, Alimentary pharmacology & therapeutics (2011) — In chronic constipation, ~50 g prunes twice daily raised complete spontaneous bowel movements more than an equal-fibre dose of psyllium and was judged effective as a first-line therapy. [https://pubmed.ncbi.nlm.nih.gov/21323688/]
  - Chemical composition and potential health effects of prunes: a functional food?, Critical reviews in food science and nutrition (2001) — Reviews chemical composition and bioactives of prunes (fibre, sorbitol, ~184 mg/100g polyphenols, potassium, boron, vitamin K) and candidate health effects. [https://pubmed.ncbi.nlm.nih.gov/11401245/]

---

## Fig (Ficus carica)
URL: https://nutridex.info/s/fig
Category: Fruits
Evidence: Preliminary — Early or small human trials; promising but not yet conclusive.
Sweet syconium rich in fibre and minerals

Quick answer: Fig is used for relieves functional constipation (fig paste rct: more bowel movements, faster transit). NutriDex grades the human evidence as preliminary — Early or small human trials; promising but not yet conclusive. Based on 10 cited human studies (10 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Most human evidence on figs is limited and indirect. A randomised, double-blind, placebo-controlled trial found Ficus carica paste improved bowel-movement frequency, stool consistency and abdominal discomfort in functional constipation, and a small crossover RCT showed an abscisic-acid-standardised fig extract lowered postprandial glucose and insulin responses. Beyond these, claims rest largely on phytochemical reviews, animal models and the general fruit-and-fibre literature rather than fig-specific outcome trials. Notably, one randomised crossover trial of mixed dried fruit (including figs) found no cardiometabolic benefit and slightly higher fasting glucose and LDL. Figs are a genuine source of fibre, potassium, calcium and polyphenols, but dedicated, well-powered human trials on whole figs are scarce, so the overall weight of evidence for disease-specific benefits is preliminary.

Nutrition (per 2 medium figs (100 g)): 74 kcal; Fibre 2.9g (10% DV), Potassium 232mg (5% DV), Calcium 35mg (3% DV), Magnesium 17mg (4% DV), Vitamin K 4.7mcg (4% DV), Vitamin B6 0.11mg (6% DV), Copper 0.07mg (8% DV), Vitamin C 2mg (2% DV).
Benefits / uses: Relieves functional constipation (fig paste RCT: more bowel movements, faster transit); Blunts postprandial glycaemic and insulin response (abscisic-acid fig extract crossover RCT); Supplies soluble and insoluble fibre supporting digestive regularity; Contributes potassium, calcium and magnesium toward cardiovascular and bone-relevant intakes; Polyphenol-rich profile with antioxidant activity, especially in dark-skinned varieties.
Active compounds: Pectin and dietary fibre (soluble + insoluble); Anthocyanins (cyanidin-3-rutinoside, in dark skins); Chlorogenic acid and other phenolic acids; Flavonoids (rutin, quercetin, catechins); Potassium; Calcium; Magnesium; Abscisic acid; Vitamin K.
Dose: A typical serving is 2 medium fresh figs (about 100 g) or 3-4 dried figs; studies on constipation used roughly 200-300 g/day of fig paste over 8 weeks. Eaten as a whole-fruit snack, in salads, or paired with cheese or nuts.
Safety: Figs are high in natural sugars (especially dried), so portion-control matters for diabetes and weight management. Fresh figs and fig latex can cause IgE-mediated allergy, sometimes cross-reacting with latex, birch pollen or ficus houseplants; raw latex is irritating to skin and mucosa. Figs contain psoralens (furocoumarins) that can cause phototoxic dermatitis on skin contact, and they carry a modest oxalate load relevant to stone-formers. The high potassium content warrants caution in advanced kidney disease. Whole figs have no established grapefruit-type CYP3A4 interaction.

Cited studies (10):
  - Causal associations between dried fruit intake and cardiovascular disease: A Mendelian randomization study, Frontiers in cardiovascular medicine (2023) — Mendelian randomisation study (UK Biobank): genetically predicted higher dried-fruit intake was associated with lower risk of heart failure and stroke, but showed no significant effect on coronary artery disease or myocardial infarction. [https://pmc.ncbi.nlm.nih.gov/articles/PMC9939508/]
  - Systematic review and meta-analysis: Foods, drinks and diets and their effect on chronic constipation in adults, Alimentary pharmacology & therapeutics (2024) — Systematic review and meta-analysis of 23 studies (1714 adults with chronic constipation) found fruits (including fig) and rye bread improved some constipation outcomes, while noting overall scarcity of high-quality evidence for whole foods. [https://pubmed.ncbi.nlm.nih.gov/37905980/]
  - Effect of fruit intake on functional constipation: A systematic review and meta-analysis of randomized and crossover studies, Frontiers in nutrition (2022) — Systematic review and meta-analysis of 11 trials concluded fruit intake alleviates functional constipation, but rated kiwifruit superior to Ficus carica paste on Bristol Stool Scale across three high-quality studies. [https://pmc.ncbi.nlm.nih.gov/articles/PMC9583540/]
  - British Dietetic Association Guidelines for the Dietary Management of Chronic Constipation in Adults, Journal of human nutrition and dietetics : the official journal of the British Dietetic Association (2025) — British Dietetic Association evidence-based guidelines (75 RCTs, GRADE + Delphi) issued 59 dietary recommendations for chronic constipation; food-level statements covered kiwifruit, prunes and rye bread, with no standalone fig recommendation owing to insufficient RCTs. [https://pmc.ncbi.nlm.nih.gov/articles/PMC12517116/]
  - The effect of combined fig-Walnut syrup on functional constipation in pregnant women: a randomized controlled trial, Nutrition & metabolism (2025) — Double-blind RCT in 90 pregnant women with functional constipation: fig-walnut syrup and fig syrup (15 ml/night for 14 days) significantly improved constipation symptoms and quality of life versus placebo (no significant difference between the two fig arms). [https://pmc.ncbi.nlm.nih.gov/articles/PMC11742795/]
  - Dried fruit consumption and cardiometabolic health: a randomised crossover trial, The British journal of nutrition (2020) — Randomised crossover trial: a large daily portion of mixed dried fruit (plums, figs, dates, raisins) did not improve cardiometabolic risk and slightly raised fasting glucose and LDL versus a matched control snack. [https://pubmed.ncbi.nlm.nih.gov/32513313/]
  - Randomized, double-blind, placebo-controlled trial of Ficus carica paste for the management of functional constipation, Asia Pacific journal of clinical nutrition (2016) — RCT (n=80, 8 weeks): Ficus carica paste shortened colon transit time and improved stool type and abdominal discomfort in functional constipation versus placebo. [https://pubmed.ncbi.nlm.nih.gov/27440682/]
  - Abscisic Acid Standardized Fig (Ficus carica) Extracts Ameliorate Postprandial Glycemic and Insulinemic Responses in Healthy Adults, Nutrients (2019) — Double-blind crossover RCT (n=10 healthy adults): abscisic-acid-standardised fig extract lowered the postprandial glycaemic index by about 24-25% and reduced insulin response in a dose-dependent manner. [https://pmc.ncbi.nlm.nih.gov/articles/PMC6722713/]
  - Phytochemical Composition and Health Benefits of Figs (Fresh and Dried): A Review of Literature from 2000 to 2022, Nutrients (2023) — Literature review (2000-2022): summarises fig phytochemistry and preliminary health signals while emphasising the need for well-controlled human fig-fruit trials. [https://pmc.ncbi.nlm.nih.gov/articles/PMC10255635/]
  - Review on fresh and dried figs: Chemical analysis and occurrence of phytochemical compounds, antioxidant capacity and health effects, Food research international (Ottawa, Ont.) (2019) — Review of fresh/dried figs: phenolic acids and flavonoids dominate, and antioxidant capacity correlates with phenolic content, which is higher in dark-skinned varieties and in the skin. [https://pubmed.ncbi.nlm.nih.gov/30884655/]

---

## Dates (Phoenix dactylifera)
URL: https://nutridex.info/s/date
Category: Fruits
Evidence: Preliminary — Early or small human trials; promising but not yet conclusive.
Low-GI sweet fruit, potassium and fibre dense

Quick answer: Dates is used for low glycemic index despite high sugar content. NutriDex grades the human evidence as preliminary — Early or small human trials; promising but not yet conclusive. Based on 9 cited human studies (9 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Despite being ~66% sugar, dates have a measured low glycemic index (GI ~44-53 across varieties) and a small RCT reported that 3 dates daily for 16 weeks did not worsen HbA1c in people with type 2 diabetes. A 2025 meta-analysis of RCTs (n=298) found dates modestly reduced total cholesterol (pooled effect -0.87, 95% CI -1.39 to -0.35) but had no significant effect on LDL, HDL, or triglycerides. Meta-analyses suggest late-pregnancy date consumption increases cervical dilatation on admission (mean difference ~1.1 cm) and reduces the need for labour induction, but the underlying trials are small and at high risk of bias. Dates are a genuinely good source of potassium, magnesium, copper, and fibre. Overall human evidence for distinct health benefits is preliminary; dates are best viewed as a nutrient-dense whole-fruit alternative to refined sweeteners rather than a therapeutic food.

Nutrition (per 2 Medjool dates (48 g)): 133 kcal; Fibre 3.2g (11% DV), Potassium 334mg (7% DV), Copper 0.17mg (19% DV), Magnesium 25.9mg (6% DV), Manganese 0.14mg (6% DV), Vitamin B6 0.12mg (7% DV).
Benefits / uses: Low glycemic index despite high sugar content; May modestly lower total cholesterol in type 2 diabetes; Rich source of potassium and dietary fibre; Late-pregnancy intake associated with improved labour onset in low-quality trials; Polyphenols may inhibit carbohydrate-digesting enzymes (preclinical); Supports regularity via soluble and insoluble fibre.
Active compounds: Glucose & fructose (free sugars); Dietary fibre (insoluble + pectin); Potassium; Magnesium; Copper; Polyphenols (flavonoids, phenolic acids); Carotenoids (lutein, zeaxanthin); Tannins (procyanidins).
Dose: Typical serving 2 Medjool dates (~48 g); 3 dates/day used in glycemic and lipid trials. 7 dates/day from ~36 weeks studied for labour.
Safety: Very high sugar and energy density (~133 kcal per 2 dates) — portion control matters for weight and glycemic load, even though GI is low. Generally safe in pregnancy at studied doses, but discuss with a clinician. Dried fruit is sticky and cariogenic (dental caries risk). Rare reports of date/pollen allergy. High potassium intake warrants caution in advanced chronic kidney disease or with potassium-sparing diuretics/ACE inhibitors. No known grapefruit-type CYP3A4 interaction.

Cited studies (9):
  - Dates fruit effects on dyslipidemia among patients with Type-2 diabetes mellitus: A systematic review and meta-analysis of randomized trials, Pakistan journal of medical sciences (2025) — Systematic review and meta-analysis of RCTs (n=298, T2DM): dates reduced total cholesterol (-0.87, 95% CI -1.39 to -0.35) but no significant effect on LDL, HDL, or triglycerides. [https://pubmed.ncbi.nlm.nih.gov/39867809/]
  - Is oral consumption of dates (Phoenix dactylifera L. fruit) in the peripartum period effective and safe integrative care to facilitate childbirth and improve perinatal outcomes: a comprehensive revised systematic review and dose-response meta-analysis, BMC pregnancy and childbirth (2024) — Systematic review and dose-response meta-analysis (48 studies): late-pregnancy date intake shortened gestation/labour, improved Bishop score, and reduced need for induction, but overall evidence quality was unacceptable with high risk of bias. [https://pubmed.ncbi.nlm.nih.gov/38166785/]
  - The effect of late pregnancy date fruit consumption on delivery progress - A meta-analysis, Explore (New York, N.Y.) (2021) — Meta-analysis (4 trials, weak/high-risk-of-bias): date consumers had higher cervical dilatation on admission (MD 1.1 cm, 95% CI 0.2-1.99) and lower need for labour induction/augmentation (RR 0.6, 95% CI 0.43-0.83). [https://pubmed.ncbi.nlm.nih.gov/32563673/]
  - Effectiveness of date seed on glycemia and advanced glycation end-products in type 2 diabetes: a randomized placebo-controlled trial, Nutrition & diabetes (2024) — Randomized placebo-controlled trial (n=43 T2DM) found 5 g/day date seed powder for 8 weeks significantly lowered HbA1c (-0.30%), insulin, HOMA-IR, and LPS while raising total antioxidant capacity and s-RAGE. [https://pmc.ncbi.nlm.nih.gov/articles/PMC11144252/]
  - Effects of Daily Low-Dose Date Consumption on Glycemic Control, Lipid Profile, and Quality of Life in Adults with Pre- and Type 2 Diabetes: A Randomized Controlled Trial, Nutrients (2020) — RCT (n=100, pre-/T2DM): 3 dates/day for 16 weeks did not significantly change HbA1c and significantly lowered total cholesterol (-0.21 mmol/L). [https://pmc.ncbi.nlm.nih.gov/articles/PMC7019638/]
  - Effect of Date Fruit Consumption on the Glycemic Control of Patients with Type 2 Diabetes: A Randomized Clinical Trial, Nutrients (2022) — 12-week RCT (n=79 randomized, 61 completed) found 60 g/day date fruit caused no difference vs equivalent-glycemic-load raisins in HbA1c, fasting glucose, glucose variability, or insulin resistance, indicating safety in type 2 diabetes. [https://pmc.ncbi.nlm.nih.gov/articles/PMC9458144/]
  - Glycemic indices of five varieties of dates in healthy and diabetic subjects, Nutrition journal (2011) — Controlled crossover (13 healthy, 10 T2DM): five date varieties had low glycemic indices (GI ~44-53) with no significant postprandial glucose excursion. [https://pmc.ncbi.nlm.nih.gov/articles/PMC3112406/]
  - Therapeutic Power of Date Fruit (Phoenix dactylifera L.): A Nutrient-Rich Superfood for Holistic Health and Disease Prevention, Food science & nutrition (2025) — Narrative review summarising date phytochemistry (polyphenols, fibre, minerals) and proposed cardiometabolic, antioxidant, and gut-health mechanisms, noting need for larger human trials. [https://pubmed.ncbi.nlm.nih.gov/40927049/]
  - The Impact of the Fruit and Seed of Date on Childbirth Stages and Pregnancy Complications, Sultan Qaboos University medical journal (2024) — Review summarizing date fruit/seed effects on childbirth stages and pregnancy complications, reporting consistent associations with improved cervical ripening and shorter labor. [https://pmc.ncbi.nlm.nih.gov/articles/PMC11614017/]

---

## Guava (Psidium guajava)
URL: https://nutridex.info/s/guava
Category: Fruits
Evidence: Moderate — Several controlled trials; effects real but modest or context-dependent.
Tropical vitamin-C powerhouse with soluble fibre

Quick answer: Guava is used for exceptionally high vitamin c supports antioxidant and immune function. NutriDex grades the human evidence as moderate — Several controlled trials; effects real but modest or context-dependent. Based on 6 cited human studies (6 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Guava is among the most vitamin-C-dense fruits, providing roughly 228 mg per 100 g, alongside notable soluble fibre, potassium and (in pink varieties) lycopene. A 12-week single-blind RCT in hypertensive adults reported that high guava intake (around 0.5-1 kg/day before meals) modestly lowered total cholesterol, triglycerides and blood pressure while raising HDL, and a later RCT found favourable lipid and glucose effects when the peel was removed (whereas guava with peel slightly worsened glucose and cholesterol). A double-blind RCT of a guava fruit extract and reviews of guava-leaf preparations show blunting of post-meal glucose spikes, attributed to alpha-glucosidase inhibition by flavonoids. However, the human evidence base is small, often single-blind, geographically narrow and uses impractically large doses, so cardiometabolic claims for ordinary servings remain moderate at best. Most rigorous mechanistic data come from animal and in vitro work rather than large RCTs or meta-analyses. As a whole food, guava is a sound high-fibre, low-energy source of vitamin C and potassium.

Nutrition (per 1 medium (55 g)): 37 kcal; Vitamin C 125mg (139% DV), Fibre 3g (11% DV), Copper 0.13mg (14% DV), Folate 27mcg DFE (7% DV), Potassium 229mg (5% DV), Vitamin A 17mcg RAE (2% DV).
Benefits / uses: Exceptionally high vitamin C supports antioxidant and immune function; Soluble fibre and pectin aid bowel regularity and satiety; May modestly lower total cholesterol and triglycerides while raising HDL; May reduce blood pressure when substituting for less healthy snacks; Blunts postprandial glucose rise (fruit and leaf preparations); Lycopene-rich pink varieties contribute carotenoid antioxidants.
Active compounds: Vitamin C (ascorbic acid); Pectin and soluble dietary fibre; Potassium; Lycopene (pink-fleshed varieties); Quercetin and flavonol glycosides; Polyphenols and ellagitannins; Folate; Carotenoids (beta-carotene); Copper.
Dose: One to two whole fruits daily (about 55-165 g) as part of a varied diet; older trials used roughly 0.5-1 kg/day before meals to achieve lipid and blood-pressure effects.
Safety: Generally safe as a food. The hard seeds and high fibre may cause bloating or discomfort in sensitive individuals or those with diverticular disease if eaten in large amounts. As a moderate dietary potassium source, very large intakes warrant caution in advanced kidney disease. Guava-leaf extracts and teas may have additive glucose- and blood-pressure-lowering effects, so people on antidiabetic or antihypertensive drugs should monitor accordingly. Rare allergy (cross-reactivity within latex-fruit syndrome) has been reported. No grapefruit-type CYP3A4 interaction is established for the fruit.

Cited studies (6):
  - Effect of Guava in Blood Glucose and Lipid Profile in Healthy Human Subjects: A Randomized Controlled Study, Journal of clinical and diagnostic research : JCDR (2016) — RCT (400 g/day, 6 weeks): guava without peel significantly lowered fasting glucose, total cholesterol, triglycerides and LDL, whereas guava with peel slightly raised glucose and cholesterol despite lowering BMI and blood pressure. [https://pubmed.ncbi.nlm.nih.gov/27790420/]
  - Guava (Psidium guajava) Fruit Extract Prepared by Supercritical CO(2) Extraction Inhibits Intestinal Glucose Resorption in a Double-Blind, Randomized Clinical Study, Nutrients (2019) — Double-blind, placebo-controlled RCT (n=31): a supercritical-CO2 guava fruit extract significantly reduced postprandial glucose at 30 min (p=0.039) and 90 min (p=0.023) versus control. [https://pmc.ncbi.nlm.nih.gov/articles/PMC6683095/]
  - Effects of guava intake on serum total and high-density lipoprotein cholesterol levels and on systemic blood pressure, The American journal of cardiology (1992) — Single-blind RCT in 120 hypertensive adults: 12 weeks of guava intake before meals lowered total cholesterol ~9.9%, triglycerides ~7.7% and blood pressure ~9/8 mmHg, and raised HDL ~8%. [https://pubmed.ncbi.nlm.nih.gov/1332463/]
  - Review on the Anti-Hyperglycemic Potential of Psidium guajava and Seriphium plumosum L, Plants (Basel, Switzerland) (2024) — Review of preclinical and clinical evidence: guava phytochemicals (quercetin, guaijaverin, kaempferol and others) show anti-hyperglycemic activity via enzyme inhibition and improved glucose uptake, but the authors note the evidence base is dominated by animal and in vitro work. [https://pmc.ncbi.nlm.nih.gov/articles/PMC11207340/]
  - Guava (Psidium guajava): A brief overview of its therapeutic and health potential, Food chemistry: X (2025) — A 2025 review of guava (Psidium guajava) summarizes human evidence including a 145-participant hypertension RCT showing ~7.9% lower total cholesterol, ~7.0% lower triglycerides and 7.5/8.5 mmHg blood pressure reduction after 4 weeks of guava intake. [https://pmc.ncbi.nlm.nih.gov/articles/PMC12466288/]
  - Anti-hyperglycemic and anti-hyperlipidemic effects of guava leaf extract, Nutrition & metabolism (2010) — Review of human and animal data: guava-leaf tea suppresses postprandial blood glucose via alpha-glucosidase inhibition, supporting type 2 diabetes prevention. [https://pubmed.ncbi.nlm.nih.gov/20181067/]

---

## Acai Berry (Euterpe oleracea)
URL: https://nutridex.info/s/acai-berry
Category: Fruits
Evidence: Preliminary — Early or small human trials; promising but not yet conclusive.
Antioxidant Amazonian palm berry, eaten as pulp

Quick answer: Acai Berry is used for may lower oxidative-stress markers (e.g. 8-isoprostane, plasma peroxides) in small trials. NutriDex grades the human evidence as preliminary — Early or small human trials; promising but not yet conclusive. Based on 7 cited human studies (7 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Acai is consumed not as a raw whole berry (which is mostly inedible seed) but as unsweetened pulp or puree, which is unusually high in fat and polyphenols and low in sugar for a fruit. Human evidence is preliminary: small randomized trials show acai can lower oxidative-stress markers and acutely improve postprandial flow-mediated dilation, and one RCT in metabolic syndrome reduced an inflammation marker (IFN-gamma) and urinary 8-isoprostane but did not improve glucose or lipid metabolism. A 2025 systematic review and meta-analysis of 8 studies (411 participants) found no significant effect on LDL-C, HDL-C, total cholesterol, or triglycerides (only total lipids fell modestly), rating the evidence low-to-very-low certainty. Much of the enthusiasm rests on in-vitro antioxidant capacity and cell models rather than clinical outcomes. There are no large prospective cohorts or hard-endpoint trials, so claims of weight loss, detox, or disease prevention are unsupported. Overall, acai is a nutritious, antioxidant-rich food with plausible but unproven health benefits in humans.

Nutrition (per 100 g unsweetened pulp): 72 kcal; Dietary Fibre 3g (11% DV), Total Fat 6g (8% DV), Vitamin A (RAE) 50mcg (6% DV), Calcium 40mg (3% DV), Iron 1mg (6% DV), Vitamin C 5mg (6% DV).
Benefits / uses: May lower oxidative-stress markers (e.g. 8-isoprostane, plasma peroxides) in small trials; May acutely improve endothelial/vascular function after a high-fat meal; May modestly reduce some inflammatory biomarkers (e.g. IFN-gamma); High polyphenol/anthocyanin antioxidant capacity in vitro; Contributes dietary fibre and monounsaturated fats; Low in sugar relative to most fruits.
Active compounds: Anthocyanins (cyanidin-3-glucoside, cyanidin-3-rutinoside); Proanthocyanidins & other flavonoids (orientin, isoorientin); Phenolic acids (vanillic, ferulic, p-coumaric); Monounsaturated fatty acids (oleic acid); Plant sterols (beta-sitosterol); Dietary fibre; Carotenoids (provitamin A); Calcium & potassium.
Dose: Commonly eaten as 100 g (about half a 200 g pack) of unsweetened frozen pulp or puree in a bowl or smoothie. Trials used roughly 150-200 g pulp/day or a beverage/smoothie delivering about 700 mg total phenolics; no established therapeutic dose.
Safety: Generally well tolerated as a food. Commercial acai bowls and sweetened juices often add large amounts of sugar and calories, negating the fruit's low-sugar advantage. Pollen-food allergy is possible. The pulp is high in fat, so portions are calorie-dense. Unpasteurized acai pulp has caused documented foodborne outbreaks of acute Chagas disease (Trypanosoma cruzi) in the Brazilian Amazon, and freezing does not reliably kill the parasite; pasteurized/commercial products carry far lower risk. Theoretical interactions: polyphenols may affect drug metabolism, so patients on warfarin should consult a clinician. A claimed interference with MRI/imaging studies is anecdotal and not well established. No specific grapefruit-type CYP3A4 interaction is established.

Cited studies (7):
  - Investigating the Impact of Açai (Euterpe oleracea) on Lipid Profile: A Comprehensive Systematic Review and Meta-Analysis, Nutrition bulletin (2025) — Systematic review and meta-analysis of 8 studies (411 adults): acai did not significantly change LDL-C, HDL-C, total cholesterol, or triglycerides; only total lipids fell modestly. Low-to-very-low certainty (GRADE). [https://pubmed.ncbi.nlm.nih.gov/39960343/]
  - The Effect of Berry Consumption on Oxidative Stress Biomarkers: A Systematic Review of Randomized Controlled Trials in Humans, Antioxidants (Basel, Switzerland) (2023) — Systematic review of 28 RCTs of berry consumption (including acai) on oxidative stress found only 32% of ~56 biomarkers showed statistically significant benefit while 68% showed no significant difference. [https://pubmed.ncbi.nlm.nih.gov/37507981/]
  - Supplementation with açaí (Euterpe Oleracea Martius) for the treatment of chronic tinnitus: effects on perception, anxiety levels and oxidative metabolism biomarkers, CoDAS (2022) — Randomized placebo-controlled trial in 30 chronic tinnitus patients given 100 mg acai extract assessed effects on tinnitus perception, anxiety, and oxidative metabolism biomarkers. [https://pmc.ncbi.nlm.nih.gov/articles/PMC9886123/]
  - Phytochemical and nutrient composition of the freeze-dried amazonian palm berry, Euterpe oleraceae mart. (acai), Journal of agricultural and food chemistry (2006) — Phytochemical/nutrient analysis of freeze-dried acai pulp: high in fat (oleic acid ~54% of fatty acids), fibre, and anthocyanins (cyanidin-3-glucoside/rutinoside); low vitamin C. [https://pubmed.ncbi.nlm.nih.gov/17061839/]
  - Açaí (Euterpe oleracea Mart.) beverage consumption improves biomarkers for inflammation but not glucose- or lipid-metabolism in individuals with metabolic syndrome in a randomized, double-blinded, placebo-controlled clinical trial, Food & function (2018) — Randomized double-blind placebo-controlled trial in 37 adults with metabolic syndrome: 12 wk acai beverage (325 mL twice/day) lowered plasma IFN-gamma and urinary 8-isoprostane but did not improve glucose or lipid metabolism. [https://pubmed.ncbi.nlm.nih.gov/29850709/]
  - Consumption of a flavonoid-rich açai meal is associated with acute improvements in vascular function and a reduction in total oxidative status in healthy overweight men, The American journal of clinical nutrition (2016) — Randomized crossover in 23 healthy overweight men: an acai smoothie (694 mg phenolics) with a high-fat meal acutely improved postprandial flow-mediated dilation and reduced total oxidative status. [https://pubmed.ncbi.nlm.nih.gov/27680990/]
  - Antioxidant and Hypolipidemic Activity of Açai Fruit Makes It a Valuable Functional Food, Antioxidants (Basel, Switzerland) (2020) — In-vitro study (hepatocyte and adipocyte models): acai extract counteracts oxidative stress and inhibits lipid accumulation, with a proposed PPAR-alpha-mediated mechanism; effects were dose-dependent and hormetic. [https://pmc.ncbi.nlm.nih.gov/articles/PMC7824079/]

---

## Lemon (Citrus limon)
URL: https://nutridex.info/s/lemon
Category: Fruits
Evidence: Moderate — Several controlled trials; effects real but modest or context-dependent.
Citrate-rich citrus for stone prevention

Quick answer: Lemon is used for raises urinary citrate and ph, reducing calcium kidney-stone risk. NutriDex grades the human evidence as moderate — Several controlled trials; effects real but modest or context-dependent. Based on 10 cited human studies (10 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

The strongest human evidence for lemon concerns kidney-stone prevention: small clinical studies show lemon/lemonade reliably raises urinary citrate (an endogenous stone inhibitor) and urine pH, with one prospective randomized study finding lemon juice comparable to potassium citrate and better tolerated. Most of these trials are small, short, and often without hard stone-recurrence endpoints, so lemon is best viewed as adjunctive rather than first-line therapy. Lemon's vitamin C and citric acid also enhance non-heme iron absorption, a well-established mechanism. Cardiovascular benefits derive largely from citrus flavanones such as hesperidin, where RCTs (mostly in orange juice) and meta-analyses show modest reductions in blood pressure and improved lipid/endothelial markers; lemon-specific cardiovascular trials are sparse and small. A standardized lemon-flavonoid nutraceutical (eriocitrin) improved glucose and GLP-1 in prediabetes, but this used concentrated extracts, not whole fruit. Overall the evidence is moderate and mechanistically coherent for citrate/iron effects but thinner and largely extrapolated from citrus generally for cardiometabolic claims.

Nutrition (per 1 medium (58 g)): 17 kcal; Vitamin C 30.7mg (34% DV), Fiber 1.6g (6% DV), Potassium 80mg (2% DV), Folate 6.4mcg (2% DV), Calcium 15mg (1% DV), Vitamin B6 0.046mg (3% DV).
Benefits / uses: Raises urinary citrate and pH, reducing calcium kidney-stone risk; Vitamin C supports immune function and collagen synthesis; Citrus flavanones (hesperidin) modestly improve blood pressure and endothelial function; Enhances non-heme iron absorption when consumed with meals; Lemon flavonoids may improve glycemic markers and GLP-1 in prediabetes; Antioxidant phytochemicals counter oxidative stress.
Active compounds: Citric acid (signature organic acid; ~5x orange juice); Vitamin C / L-ascorbic acid; Flavanones: hesperidin, eriocitrin, naringin; Flavones: diosmin, diosmetin; Limonoids: limonin, nomilin; Pectin (soluble fiber, in peel/pith); Potassium; Monoterpenes: D-limonene, beta-pinene (peel oil); Coumarins.
Dose: 1 medium lemon (~58 g) or 2-4 oz juice daily; lemonade therapy uses ~4 oz reconstituted juice in 2 L water/day
Safety: High acidity can erode dental enamel and aggravate GERD or mouth ulcers; rinse with water after consuming. Citric/ascorbic acid may worsen reflux in sensitive individuals. Peel oils (limonene, psoralens/furanocoumarins) can cause phytophotodermatitis on sun-exposed skin. Grapefruit-style CYP3A4 drug interactions are minimal with lemon, but caution with furanocoumarin-containing peel. Generally very safe as food; concentrated flavonoid supplements lack long-term safety data.

Cited studies (10):
  - The role of citrus juice in reducing calcium kidney stone risk: a systematic review and meta-analysis of clinical trials, African Journal of Urology (2025) — Systematic review and meta-analysis of citrus juice clinical trials found significant increases in urinary citrate and pH versus control, supporting calcium-stone risk reduction. [https://link.springer.com/article/10.1186/s12301-025-00542-6]
  - Effects of Citrus Flavanone Hesperidin Extracts or Purified Hesperidin Consumption on Risk Factors for Cardiovascular Disease: Evidence From an Updated Meta-analysis of Randomized Controlled Trials, Current developments in nutrition (2024) — Meta-analysis of 12 RCTs (589 participants) found hesperidin extracts improved LDL and total cholesterol, fasting glucose, and inflammatory markers (CRP, adhesion molecules). [https://pubmed.ncbi.nlm.nih.gov/39279783/]
  - Lemon flavonoids nutraceutical (Eriomin®) attenuates prediabetes intestinal dysbiosis: A double-blind randomized controlled trial, Food science & nutrition (2023) — Double-blind RCT: lemon-flavonoid nutraceutical (Eriomin, eriocitrin) reduced hyperglycemia 6% and increased blood GLP-1 22% in prediabetes, with gut microbiota shifts. [https://pubmed.ncbi.nlm.nih.gov/37970408/]
  - Effects of hesperidin in orange juice on blood and pulse pressures in mildly hypertensive individuals: a randomized controlled trial (Citrus study), European journal of nutrition (2021) — CITRUS RCT (n=159): hesperidin-enriched orange juice reduced systolic and pulse pressure dose-dependently (SBP -6.4 to -7.4 mmHg) over 12 weeks in pre/stage-1 hypertensives. [https://pmc.ncbi.nlm.nih.gov/articles/PMC7987641/]
  - Dietary manipulation with lemonade to treat hypocitraturic calcium nephrolithiasis, The Journal of urology (1996) — Lemonade (4 oz lemon juice = 5.9 g citric acid in 2 L/day) more than doubled urinary citrate (142 to 346 mg/day) without raising urine volume in hypocitraturic stone formers. [https://pubmed.ncbi.nlm.nih.gov/8709360/]
  - Can lemon juice be an alternative to potassium citrate in the treatment of urinary calcium stones in patients with hypocitraturia? A prospective randomized study, Urological research (2008) — Prospective randomized study found fresh lemon juice raised urinary citrate 2.5-fold (vs 3.5-fold for potassium citrate), supporting lemon juice as a tolerable alternative in hypocitraturic calcium-stone patients. [https://pubmed.ncbi.nlm.nih.gov/18946667/]
  - Dietary flavonoids and risk of stroke in women, Stroke (2012) — In 69,622 women (Nurses' Health Study), highest vs lowest flavanone (citrus) intake was associated with 19% lower ischemic stroke risk (RR 0.81, 95% CI 0.66-0.99). [https://pubmed.ncbi.nlm.nih.gov/22363060/]
  - Effect on blood pressure of daily lemon ingestion and walking, Journal of nutrition and metabolism (2014) — Observational study of 101 middle-aged women found daily lemon intake correlated negatively with systolic blood pressure (mechanism linked to blood citric acid). [https://pmc.ncbi.nlm.nih.gov/articles/PMC4003767/]
  - Lemonade therapy increases urinary citrate and urine volumes in patients with recurrent calcium oxalate stone formation, Urology (2007) — Lemonade therapy increased urinary citrate (+203 mg/day alone; +346 mg/day with potassium citrate) and urine volume in recurrent calcium-oxalate stone formers over ~40 months. [https://pubmed.ncbi.nlm.nih.gov/17919696/]
  - Long-term lemonade based dietary manipulation in patients with hypocitraturic nephrolithiasis, The Journal of urology (2007) — Long-term lemonade therapy in hypocitraturic stone formers raised urinary citrate (+mean 383 mg/day) and reduced stone formation rate from 1.0 to 0.13 stones/patient/year over ~44 months. [https://pubmed.ncbi.nlm.nih.gov/17382731/]

---

## Lime (Citrus aurantiifolia)
URL: https://nutridex.info/s/lime
Category: Fruits
Evidence: Preliminary — Early or small human trials; promising but not yet conclusive.
Tart citrate-rich citrus for stones and vessels

Quick answer: Lime is used for raises urinary citrate (an inhibitor of calcium stone formation) in hypocitraturic stone formers. NutriDex grades the human evidence as preliminary — Early or small human trials; promising but not yet conclusive. Based on 11 cited human studies (11 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Lime is a small, intensely acidic citrus whose health interest rests more on its organic-acid and vitamin-C content than on large clinical trials of the fruit itself. The best-supported use is in nephrolithiasis: a parallel-group RCT showed freshly squeezed lime juice raised urinary citrate—an inhibitor of calcium stone formation—comparably to orange juice, though, unlike orange and melon, lime did NOT significantly raise urinary pH, potassium, or net alkali absorption (its citrate rise is attributed to high citric acid rather than alkali), and no trial proves lime alone cuts stone recurrence. Its vitamin C is a well-established enhancer of non-heme iron absorption, a robust mechanistic finding extrapolated to lime as a dietary vitamin-C source rather than tested as lime per se. Citrus flavonoids improve endothelial function in a meta-analysis of RCTs, and high citrus/fruit intake is linked to lower stroke and cardiovascular risk in large cohorts, but these data are for citrus broadly, not lime specifically. A notable real-world finding is that adding lime juice to food was protective against cholera in a West African outbreak. Overall the human evidence specific to lime is preliminary and largely indirect, with most benefits inferred from its nutrients and from citrus as a class.

Nutrition (per 1 medium (67 g)): 20 kcal; Vitamin C 19.5mg (22% DV), Fiber 1.9g (7% DV), Potassium 68mg (1% DV), Calcium 22mg (2% DV), Folate 5mcg (1% DV), Iron 0.4mg (2% DV).
Benefits / uses: Raises urinary citrate (an inhibitor of calcium stone formation) in hypocitraturic stone formers; Vitamin C strongly enhances non-heme (plant) iron absorption; Citrus flavonoids improve endothelial function (flow-mediated dilation) in RCT meta-analysis; Antimicrobial: lime juice inhibited Vibrio cholerae growth and was protective in a cholera outbreak; Provides vitamin C and antioxidant phytochemicals as part of overall fruit-intake benefits; May contribute to lower cardiovascular and stroke risk as part of high fruit/citrus intake.
Active compounds: Organic acids (citric acid, malic acid); Vitamin C (L-ascorbic acid); Flavanones (hesperidin, eriocitrin, naringin); Furanocoumarins (limettin, bergapten, isopimpinellin, psoralen, xanthotoxin); Limonoids (limonin, nomilin); Monoterpenes / essential oils (limonene, β-pinene, γ-terpinene); Potassium and citrate (alkali precursor); Pectin (soluble dietary fiber).
Dose: 1 medium lime (~67 g) or 30–60 mL juice; 1–2 limes daily as a culinary acidulant
Safety: Highly acidic juice can erode tooth enamel and aggravate reflux or mouth ulcers. Skin or lips contaminated with lime juice (peel oils) plus sun exposure cause phytophotodermatitis—a painful blistering burn from furanocoumarins (the classic "margarita burn"). Furanocoumarins can also inhibit intestinal CYP3A4, potentially raising levels of drugs affected by the grapefruit-juice interaction, though lime's effect is generally smaller. Otherwise very safe in culinary amounts.

Cited studies (11):
  - The effects of citrus flavonoids supplementation on endothelial function: A systematic review and dose–response meta‐analysis of randomized clinical trials, Phytotherapy Research (2024) — Dose-response meta-analysis of 8 RCTs (596 participants): citrus flavonoid supplementation increased flow-mediated dilation by 2.75% (95% CI 1.29–4.20) vs placebo. [https://doi.org/10.1002/ptr.8190]
  - Effectiveness of Dietary Interventions to Treat Iron-Deficiency Anemia in Women: A Systematic Review of Randomized Controlled Trials, Nutrients (2022) — Systematic review of 14 RCTs: dietary interventions combining increased iron with vitamin C were consistently effective at treating iron-deficiency anemia in women. [https://doi.org/10.3390/nu14132724]
  - Dietary treatment of urinary risk factors for renal stone formation. A review of CLU Working Group, Archivio Italiano di Urologia e Andrologia (2015) — CLU Working Group dietary review/guideline: increased fruit/vegetable intake raises urinary citrate; citrus (lemon, orange, grapefruit, lime) and non-citrus melon are natural dietary citrate sources with potential to protect against stone formation. [https://doi.org/10.4081/aiua.2015.2.105]
  - Fruit and vegetable intake and the risk of cardiovascular disease, total cancer and all-cause mortality—a systematic review and dose-response meta-analysis of prospective studies, International Journal of Epidemiology (2017) — Meta-analysis of 95 population studies: each 200 g/day of fruit/vegetables lowered cardiovascular and all-cause mortality risk; citrus fruits specifically inversely associated with all-cause mortality. [https://doi.org/10.1093/ije/dyw319]
  - Noncitrus Alkaline Fruit: A Dietary Alternative for the Treatment of Hypocitraturic Stone Formers, Journal of Endourology (2012) — Parallel-group RCT (30 hypocitraturic stone formers, 10 per juice): 385 mL freshly squeezed lime juice significantly raised urinary citrate, comparable to orange juice; unlike orange and melon, lime did NOT significantly raise urinary potassium, pH, or net GI alkali absorption, attributed to its high citric acid rather than alkali content. [https://doi.org/10.1089/end.2012.0092]
  - INTERACTION OF VITAMIN C AND IRON*, Annals of the New York Academy of Sciences (1980) — Classic study: ascorbic acid is a powerful enhancer of non-heme iron absorption, with enhancement directly proportional to the quantity of vitamin C present in the meal. [https://doi.org/10.1111/j.1749-6632.1980.tb21325.x]
  - Intake of fruit and vegetables and the risk of ischemic stroke in a cohort of Danish men and women, The American Journal of Clinical Nutrition (2003) — Danish prospective cohort (54,506 adults): high fruit intake was associated with reduced ischemic stroke risk (top vs bottom quintile RR 0.60), with the association significant specifically for citrus fruit. [https://doi.org/10.1093/ajcn/78.1.57]
  - Complementary and Alternative Medicine Use in First-time and Recurrent Kidney Stone Formers, Urology (2021) — Prospective interviews of 103 stone patients (50% used CAM) plus lab analysis: a key-lime product (KSP-Key Lime) measured 19.8 mEq alkali per serving, comparable to commonly prescribed citrate therapy. [https://doi.org/10.1016/j.urology.2021.05.084]
  - Lime-induced phytophotodermatitis, Journal of Community Hospital Internal Medicine Perspectives (2014) — Case report of lime-induced phytophotodermatitis: psoralen furanocoumarins plus UV cause blistering dermatitis often misdiagnosed as cellulitis, fungal infection, or child abuse. [https://doi.org/10.3402/jchimp.v4.25090]
  - Protection from cholera by adding lime juice to food – results from community and laboratory studies in Guinea‐Bissau, West Africa, Tropical Medicine &amp; International Health (2000) — Case-control study during a Guinea-Bissau cholera epidemic: adding lime juice to rice sauce was strongly protective (OR 0.31, 95% CI 0.17–0.56); lab tests confirmed lime juice inhibited V. cholerae growth. [https://doi.org/10.1046/j.1365-3156.2000.00575.x]
  - Phototoxic coumarins in limes, Food and Chemical Toxicology (1993) — Quantified phototoxic coumarins in limes: limettin, bergapten, isopimpinellin, xanthotoxin and psoralen, far more concentrated in peel than pulp; Persian limes potentially more phototoxic than Key limes. [https://doi.org/10.1016/0278-6915(93)90187-4]

---

## Peach (Prunus persica)
URL: https://nutridex.info/s/peach
Category: Fruits
Evidence: Mixed — Conflicting results across studies; benefit uncertain.
Juicy stone fruit rich in skin polyphenols

Quick answer: Peach is used for contributes to lower cardiovascular and all-cause mortality risk as part of high fruit/vegetable intake (cohort-level, not peach-specific). NutriDex grades the human evidence as mixed — Conflicting results across studies; benefit uncertain. Based on 9 cited human studies (9 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Direct human trials on peach alone are scarce, so most evidence is indirect, drawn from large prospective cohorts and meta-analyses of total fruit intake. Pooling ~95 prospective studies (Aune 2017), each 200 g/day of fruit and vegetables is associated with roughly 8% lower cardiovascular disease (RR 0.92) and 10% lower all-cause mortality (RR 0.90), with benefit plateauing near 800 g/day. In three large US cohorts (Muraki 2013, >187,000 adults), whole fruit intake was modestly protective against type 2 diabetes overall, but the peach/plum/apricot group specifically was non-significant (HR 0.97, 0.92-1.02 per 3 servings/week) while fruit juice raised risk. Peaches are a meaningful dietary source of hydroxycinnamic acids, flavan-3-ols and carotenoids, and laboratory and animal work documents antioxidant and anti-inflammatory activity, but these mechanistic findings have not been confirmed by peach-specific clinical endpoints. The main limitations are confounding in observational data, the absence of randomized peach trials, and the fact that benefits attributed to "fruit" cannot be cleanly assigned to peach. Overall the human evidence supports peach as a healthful, low-energy, nutrient- and polyphenol-containing fruit but does not establish disease-specific therapeutic effects.

Nutrition (per 1 medium (150 g)): 59 kcal; Vitamin C 9.9mg (11% DV), Fiber 2.3g (8% DV), Potassium 285mg (6% DV), Vitamin E 1.1mg (7% DV), Niacin (B3) 1.2mg (8% DV), Copper 0.1mg (11% DV), Vitamin A 24mcg RAE (3% DV).
Benefits / uses: Contributes to lower cardiovascular and all-cause mortality risk as part of high fruit/vegetable intake (cohort-level, not peach-specific); Neutral-to-favorable association with type 2 diabetes risk when eaten as whole fruit; the peach/plum/apricot group itself was non-significant; Provides hydration and dietary fiber (including pectin) supporting satiety and digestive regularity; Skin- and flesh-derived polyphenols (chlorogenic acid, catechins) show antioxidant and anti-inflammatory activity in vitro and in animal models; Carotenoids and vitamin C contribute to antioxidant defenses; Low glycemic load, making it a reasonable lower-energy substitute for refined-sugar snacks.
Active compounds: Hydroxycinnamic acids (chlorogenic and neochlorogenic acid); Flavan-3-ols (catechin, procyanidin B1); Flavonols (quercetin-3-O-glucoside, -galactoside, -rutinoside); Anthocyanins (cyanidin-3-O-glucoside, concentrated in red skin); Carotenoids (beta-carotene, beta-cryptoxanthin, lutein/zeaxanthin); Vitamin C (ascorbic acid); Vitamin E (alpha-tocopherol) and potassium; Soluble and insoluble fiber including pectin; Cyanogenic glycosides (amygdalin, prunasin) concentrated in the kernel/seed, not the flesh.
Dose: 1-2 medium fresh peaches (about 150-300 g) as a serving; whole fruit is preferable to juice.
Safety: Generally very safe as a whole fruit. The flesh is fine, but the kernel/pit contains cyanogenic glycosides (amygdalin) that release cyanide if crushed and eaten in quantity, so seeds and "laetrile"/bitter-kernel supplements should be avoided. Peach is a known cause of oral allergy syndrome (cross-reactivity with birch pollen, and via the Pru p 3 lipid transfer protein), which can rarely cause systemic reactions; peeling reduces skin-bound allergen. Those with fructose intolerance or IBS may react to its sorbitol/fructose content. Canned peaches in syrup add substantial free sugars.

Cited studies (9):
  - Effects of Caffeinated and Decaffeinated Coffee Consumption on Metabolic Syndrome Parameters: A Systematic Review and Meta-Analysis of Data from Randomised Controlled Trials, Medicina (2021) — Meta-analysis of RCTs: green coffee extract delivering 180-376 mg chlorogenic acid lowered systolic and diastolic blood pressure and triglycerides, supporting cardiometabolic activity of the CGA class abundant in peach. [https://doi.org/10.3390/medicina57090957]
  - Fruit and vegetable intake and the risk of cardiovascular disease, total cancer and all-cause mortality—a systematic review and dose-response meta-analysis of prospective studies, International Journal of Epidemiology (2017) — Dose-response meta-analysis of 95 prospective studies: each 200 g/day of fruit+vegetables associated with ~8% lower CVD (RR 0.92, 95% CI 0.90-0.95) and 10% lower all-cause mortality (RR 0.90, 0.87-0.93), with risk reductions plateauing near 800 g/day. [https://doi.org/10.1093/ije/dyw319]
  - Khomich 2019 — Peach nutrient profiling: hydroxycinnamic (chiefly chlorogenic) acids, plus dietary fiber, beta-carotene, vitamin E, potassium and copper highlighted among the principal minor bioactives. [https://doi.org/10.24411/0042-8833-2019-10070]
  - Antioxidant Activity and Preclinical Safety of Semen persicae Extract, International Journal of Molecular Sciences (2024) — Semen persicae (peach-seed) extract with 4.95% amygdalin showed moderate in vitro antioxidant activity (DPPH 51.8%, ABTS 57.2%) and no observed toxicity up to 2000 mg/kg in rats over 28 days. [https://doi.org/10.3390/ijms25168580]
  - Fruit consumption and risk of type 2 diabetes: results from three prospective longitudinal cohort studies, BMJ (2013) — Across 3 US cohorts (187,382 adults), greater whole-fruit intake lowered type 2 diabetes risk; the peach/plum/apricot group HR was 0.97 (0.92-1.02, non-significant) per 3 servings/week, while fruit juice raised risk. [https://doi.org/10.1136/bmj.f5001]
  - Preparation and characterization of young <i>Prunus persica</i> fruit fraction and its anti-inflammatory effect on a transgenic zebrafish model, Natural Product Research (2021) — A UV-absorbing phenolic/amino-acid fraction from young peach fruit significantly reduced inflammatory cell migration in a CuSO4-induced transgenic zebrafish model. [https://doi.org/10.1080/14786419.2021.1912748]
  - Phenolic Composition and Antioxidant Properties of Different Peach [Prunus persica (L.) Batsch] Cultivars in China, International Journal of Molecular Sciences (2015) — In 17 Chinese peach cultivars, chlorogenic acid and catechin were the predominant phenolics in both peel and pulp; peel extracts had higher phenolic content and antioxidant activity than pulp. [https://doi.org/10.3390/ijms16035762]
  - Evaluation of Anti-inflammatory, Antinociceptive, and Antipyretic Activities of Prunus persica var. nucipersica (Nectarine) Kernel, Planta Medica (2019) — Nectarine (P. persica var. nucipersica) kernel extract reduced carrageenan-induced rat paw edema by up to 47% at 1 h and showed analgesic/antipyretic effects in rats. [https://doi.org/10.1055/a-0955-5876]
  - Anti-allergic inflammatory effects of cyanogenic and phenolic glycosides from the seed of Prunus persica, Natural product communications (2013) — Cyanogenic and phenolic glycosides isolated from Prunus persica seed suppressed histamine release and inhibited TNF-alpha and IL-6 in human mast cells, indicating anti-allergic/anti-inflammatory activity in vitro. [https://pubmed.ncbi.nlm.nih.gov/24555287/]

---

## Plum (Prunus domestica)
URL: https://nutridex.info/s/plum
Category: Fruits
Evidence: Moderate — Several controlled trials; effects real but modest or context-dependent.
Polyphenol-rich stone fruit; prunes help protect bone

Quick answer: Plum is used for dried plums (prunes) help preserve hip and spine bone mineral density in postmenopausal women. NutriDex grades the human evidence as moderate — Several controlled trials; effects real but modest or context-dependent. Based on 10 cited human studies (10 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

The strongest human evidence concerns dried plums (prunes) rather than fresh fruit, and is largely confined to postmenopausal women. In the 12-month Prune Study RCT (235 postmenopausal women), 50 g/day preserved total hip BMD while controls lost bone, and earlier 6-12 month RCTs from a single lab showed gains in ulnar and spine BMD versus dried apple. A 2026 systematic review of 11 RCTs (747 participants) found only a borderline-significant benefit at the lumbar spine with high heterogeneity, so the bone effect is real but modest. Prunes also reliably improve constipation, outperforming psyllium for stool frequency at matched fiber in a crossover RCT, an effect attributed to fiber plus sorbitol. Cardiometabolic claims are weak: a 12-month ancillary analysis found no change in lipids or glycemic control (only a reduction in central fat at the higher dose). Fresh plums are a low-calorie source of vitamin C, potassium and polyphenols but lack dedicated outcome trials. Overall the evidence is moderate for prunes and bone/constipation, and preliminary for fresh plums and cardiovascular endpoints.

Nutrition (per 1 medium (66 g)): 30 kcal; Vitamin C 6.3mg (7% DV), Potassium 104mg (2% DV), Vitamin K 4.2ug (4% DV), Fiber 0.9g (3% DV), Vitamin A 11ug RAE (1% DV), Copper 0.04mg (4% DV).
Benefits / uses: Dried plums (prunes) help preserve hip and spine bone mineral density in postmenopausal women; Relieve constipation and improve stool frequency and consistency; Provide potassium and bone-relevant micronutrients (vitamin K, copper, boron); Supply polyphenol antioxidants (chlorogenic and neochlorogenic acid); Modest, low-glycemic source of fiber and natural sugars.
Active compounds: Hydroxycinnamic acids (neochlorogenic acid, chlorogenic acid); Anthocyanins (cyanidin-3-glucoside, cyanidin-3-rutinoside); Flavonols (quercetin, rutin); Sorbitol (sugar alcohol with laxative effect); Soluble and insoluble fiber (pectin); Potassium; Vitamin K1 (phylloquinone); Boron and copper (bone cofactors); Carotenoids (beta-carotene).
Dose: 2 fresh plums (~130 g) daily, or 50 g prunes/day (~5-6 dried plums) for bone benefit
Safety: High prune/plum intake can cause gas, bloating and loose stools due to sorbitol and fiber; introduce gradually. Prunes are calorie- and sugar-dense (~240 kcal/100 g) and acrylamide can form in some processed dried-plum products. People with IBS may react to the sorbitol (a FODMAP). Stone fruit kernels contain amygdalin (cyanogenic) — do not eat the pits. Those prone to oxalate kidney stones should note a modest oxalate content; otherwise plums are safe as food with no significant drug interactions at culinary doses.

Cited studies (10):
  - Effects of Prunes on Bone Density in Humans: A Systematic Review and Meta-Analysis of Randomized Controlled Trials, Nutrients (2026) — Systematic review and meta-analysis of 11 RCTs (747 participants): prune intervention had only a borderline-significant effect on lumbar-spine BMD in postmenopausal women (SMD 1.30, 95% CI -0.03 to ~2.6) with high heterogeneity; no significant effect at other sites. [https://www.mdpi.com/2072-6643/18/9/1338]
  - Effects of Prune (Dried Plum) Supplementation on Cardiometabolic Health in Postmenopausal Women: An Ancillary Analysis of a 12-Month Randomized Controlled Trial, The Prune Study, The Journal of nutrition (2024) — Ancillary analysis of the 12-month Prune Study: 50 or 100 g/day prunes did not improve lipids or glycemic markers vs control, though 100 g/day reduced central (android) fat mass. [https://pmc.ncbi.nlm.nih.gov/articles/PMC11347804/]
  - Prunes preserve cortical density and estimated strength of the tibia in a 12-month randomized controlled trial in postmenopausal women: The Prune Study, Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA (2024) — Prune Study pQCT analysis: 12 months of prunes (50 or 100 g/day) preserved cortical bone density and estimated bone strength of the weight-bearing tibia in postmenopausal women vs decline in controls. [https://pubmed.ncbi.nlm.nih.gov/38349471/]
  - Prunes preserve hip bone mineral density in a 12-month randomized controlled trial in postmenopausal women: the Prune Study, The American journal of clinical nutrition (2022) — 12-month RCT (235 postmenopausal women): 50 g/day prunes preserved total hip BMD while the control group lost significant hip bone mass; the higher 100 g/day dose was associated with higher dropout. [https://pubmed.ncbi.nlm.nih.gov/35798020/]
  - The effect of two doses of dried plum on bone density and bone biomarkers in osteopenic postmenopausal women: a randomized, controlled trial, Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA (2016) — 6-month RCT in 48 osteopenic postmenopausal women: 50 g/day dried plum was as effective as 100 g/day in preventing bone loss, lowering the bone-resorption marker TRAP-5b. [https://pubmed.ncbi.nlm.nih.gov/26902092/]
  - The effect of prunes on stool output, gut transit time and gastrointestinal microbiota: A randomised controlled trial, Clinical nutrition (Edinburgh, Scotland) (2019) — Parallel-group RCT (120 healthy adults with low fiber intake and infrequent stools): 80 or 120 g/day prunes for 4 weeks significantly increased stool weight and frequency and were well tolerated (no effect on stool SCFA or pH). [https://pubmed.ncbi.nlm.nih.gov/29398337/]
  - Comparative effects of dried plum and dried apple on bone in postmenopausal women, The British journal of nutrition (2011) — 12-month RCT (160 postmenopausal women): 100 g/day dried plum significantly increased ulnar and lumbar-spine BMD vs dried apple and reduced bone-turnover markers. [https://pubmed.ncbi.nlm.nih.gov/21736808/]
  - Randomised clinical trial: dried plums (prunes) vs. psyllium for constipation, Alimentary pharmacology & therapeutics (2011) — Single-blind crossover RCT (40 patients): at matched fiber (6 g/day), prunes (50 g twice daily) increased complete spontaneous bowel movements and improved stool consistency more than psyllium in chronic constipation. [https://pubmed.ncbi.nlm.nih.gov/21323688/]
  - Dried Plums, Prunes and Bone Health: A Comprehensive Review, Nutrients (2017) — Comprehensive review of 24 studies concluding that dried plums may have protective effects on bone loss in postmenopausal women, while cautioning that all clinical data came from one lab and need confirmation by larger, longer trials. [https://pmc.ncbi.nlm.nih.gov/articles/PMC5409740/]
  - Dried plum consumption improves bone mineral density in osteopenic postmenopausal woman: A case report, Bone reports (2021) — Case report: an osteopenic 55-year-old postmenopausal woman whose lumbar-spine BMD rose 7.8% over 16 months of 50 g/day dried plum after losing 7.6% during a prior calcium/vitamin-D-only phase. [https://pmc.ncbi.nlm.nih.gov/articles/PMC8166764/]

---

## Apricot (Prunus armeniaca)
URL: https://nutridex.info/s/apricot
Category: Fruits
Evidence: Preliminary — Early or small human trials; promising but not yet conclusive.
Beta-carotene-rich stone fruit for eyes and heart

Quick answer: Apricot is used for rich source of provitamin-a carotenoids (beta-carotene, beta-cryptoxanthin) tied in cohorts to lower cvd and mortality. NutriDex grades the human evidence as preliminary — Early or small human trials; promising but not yet conclusive. Based on 9 cited human studies (9 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Apricots are a nutrient-dense stone fruit notable for provitamin-A carotenoids (beta-carotene and beta-cryptoxanthin), potassium, vitamin C, and polyphenols. Direct human trials on the whole fruit are scarce, so most evidence is indirect: large prospective cohorts and meta-analyses link higher dietary carotenoid intake and overall fruit consumption to lower cardiovascular disease and all-cause mortality, but these reflect dietary patterns rather than apricot specifically. The strongest fruit-specific data are acute glycemic trials showing dried apricots have a low glycemic index (~42) and blunt postprandial glucose, and a 2025 RCT in which mixed dried fruit (prunes, raisins, apricots) increased stool weight and bowel movements in functional constipation. Antioxidant and anti-inflammatory effects are well documented in vitro and in animals but not confirmed by robust apricot-specific human RCTs. Overall the human evidence for distinct health benefits beyond those of fruit generally is preliminary. The clearest practical takeaways are its favorable glycemic profile and contribution of carotenoids, potassium, and fiber to a healthy diet. Importantly, the edible flesh is safe, but the kernel (seed) is not.

Nutrition (per 1 cup halves (155 g)): 74 kcal; Vitamin A 149ug RAE (17% DV), Vitamin C 15.5mg (17% DV), Fiber 3.1g (11% DV), Potassium 401mg (9% DV), Vitamin E 1.38mg (9% DV), Vitamin K 5.1ug (4% DV).
Benefits / uses: Rich source of provitamin-A carotenoids (beta-carotene, beta-cryptoxanthin) tied in cohorts to lower CVD and mortality; Low glycemic index (dried GI ~42), modest postprandial glucose impact; Fiber and sorbitol content that, as part of mixed dried fruit, improves stool weight and bowel regularity; Dietary potassium contributing to a heart-healthy fruit-and-vegetable pattern; Polyphenols (chlorogenic acid, catechins, rutin) with antioxidant activity in vitro.
Active compounds: Provitamin-A carotenoids (beta-carotene, beta-cryptoxanthin, gamma-carotene); Xanthophylls (lutein, zeaxanthin); Hydroxycinnamic acids (chlorogenic, neochlorogenic acid); Flavan-3-ols (catechin, epicatechin); Flavonols (rutin, quercetin glycosides); Vitamin C (ascorbic acid); Potassium; Soluble fiber and sorbitol (notably in dried fruit); Cyanogenic glycoside amygdalin (kernel/seed only, toxic).
Dose: 1 cup halves (155 g) fresh, ~2-3 whole apricots; or ~30-40 g dried (a small handful)
Safety: The flesh is very safe. The danger is the KERNEL/SEED inside the pit: it contains amygdalin, which releases cyanide; bitter apricot kernels and "laetrile/vitamin B17" supplements have caused severe and fatal cyanide poisoning, EFSA warns that an adult eating more than ~3 small bitter kernels can exceed the acute reference dose for cyanide, and Cochrane found no anticancer benefit. Dried apricots are often treated with sulfur dioxide (sulfites), which can trigger reactions in sulfite-sensitive asthmatics. Dried apricots are sugar- and calorie-dense, so portion-control matters for diabetes and weight. Their sorbitol and fiber can cause gas, bloating, or loose stools in large amounts. Birch-pollen allergic individuals may have oral allergy syndrome to apricot.

Cited studies (9):
  - Fruit and vegetable intake and the risk of cardiovascular disease, total cancer and all-cause mortality-a systematic review and dose-response meta-analysis of prospective studies, International journal of epidemiology (2017) — Dose-response meta-analysis (95 studies): each 200 g/day of fruit and vegetables lowered CVD risk and all-cause mortality (10% lower mortality per 200 g/day), with benefit up to ~800 g/day; apricots fall within the protective fruit category. [https://pubmed.ncbi.nlm.nih.gov/28338764/]
  - Dietary intake and blood concentrations of antioxidants and the risk of cardiovascular disease, total cancer, and all-cause mortality: a systematic review and dose-response meta-analysis of prospective studies, The American journal of clinical nutrition (2018) — Dose-response meta-analysis (69 prospective studies): higher dietary and circulating carotenoids were inversely associated with CVD, cancer and mortality; blood beta-cryptoxanthin was linked to ~16% lower mortality (RR 0.84, 95% CI 0.76-0.94 per 15 ug/dL). [https://pmc.ncbi.nlm.nih.gov/articles/PMC6250988/]
  - Dietary, circulating beta-carotene and risk of all-cause mortality: a meta-analysis from prospective studies, Scientific reports (2016) — Meta-analysis of prospective cohorts: highest vs lowest dietary beta-carotene intake associated with lower all-cause mortality (RR 0.83, 95% CI 0.78-0.88). [https://pmc.ncbi.nlm.nih.gov/articles/PMC4886629/]
  - Laetrile treatment for cancer, Cochrane Database of Systematic Reviews (2015) — Cochrane review found no reliable clinical evidence that laetrile/amygdalin (apricot-kernel derived) treats cancer, while carrying a substantial risk of cyanide poisoning; risk-benefit balance unambiguously negative. [https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD005476.pub4/full]
  - Nutritional and Phytochemical Traits of Apricots (Prunus Armeniaca L.) for Application in Nutraceutical and Health Industry, Foods (Basel, Switzerland) (2021) — Compositional analysis of apricot genotypes identifying chlorogenic, caffeic and ferulic acids, catechin and rutin among the principal phenolics, with carotenoids dominated by beta-carotene. [https://pmc.ncbi.nlm.nih.gov/articles/PMC8230439/]
  - DDW25: Study Finds Adding Dried Fruit to Diet Reduces Constipation, MedicalResearch.com (2025) — RCT in 150 adults with functional constipation: 90 g/day mixed dried fruit (prunes, raisins, apricots) significantly increased stool weight and complete bowel movements versus placebo over 4 weeks. [https://medicalresearch.com/ddw25-study-finds-adding-dried-fruit-to-diet-reduces-constipation/]
  - Effect of dried fruit on postprandial glycemia: a randomized acute-feeding trial, Nutrition & diabetes (2018) — Acute randomized crossover: dried apricots had a low glycemic index of 42 +/- 5 and significantly lowered postprandial glycemia versus white bread (GI 71), with a displacement GI of 57. [https://pmc.ncbi.nlm.nih.gov/articles/PMC6288147/]
  - Physician Beware: Severe Cyanide Toxicity from Amygdalin Tablets Ingestion, Case reports in emergency medicine (2017) — Case report documenting severe, near-fatal cyanide toxicity in a patient who ingested amygdalin (laetrile) tablets, underscoring real-world poisoning risk; treated with hydroxocobalamin. [https://pmc.ncbi.nlm.nih.gov/articles/PMC5587935/]
  - Acute health risks related to the presence of cyanogenic glycosides in raw apricot kernels and products derived from raw apricot kernels, EFSA Journal (2016) — EFSA risk assessment derived an acute reference dose for cyanide of 20 ug/kg bw and concluded an adult could eat up to ~3 small bitter apricot kernels before exceeding it, with higher intakes posing serious poisoning risk. [https://efsa.onlinelibrary.wiley.com/doi/10.2903/j.efsa.2016.4424]

---

## Sweet Cherry (Prunus avium)
URL: https://nutridex.info/s/sweet-cherry
Category: Fruits
Evidence: Moderate — Several controlled trials; effects real but modest or context-dependent.
Anthocyanin-rich stone fruit with cardiometabolic promise

Quick answer: Sweet Cherry is used for anti-inflammatory effects (lowers crp, ifn-γ in some trials). NutriDex grades the human evidence as moderate — Several controlled trials; effects real but modest or context-dependent. Based on 8 cited human studies (8 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Sweet cherries (Prunus avium) are a low-energy, water-rich fruit whose polyphenols—especially anthocyanins and hydroxycinnamic acids—drive most of the studied bioactivity. In a 30-day single-blind randomized placebo-controlled trial in obese adults, a dark sweet cherry drink (200 mL twice daily) modestly lowered systolic and diastolic blood pressure and reduced pro-inflammatory IFN-γ, though a pooled meta-analysis of seven cherry RCTs found no significant overall blood-pressure effect. Observational and small interventional data link cherry intake to lower serum urate and roughly 35% fewer recurrent gout attacks (case-crossover data), but a dedicated meta-analysis was not feasible because of heterogeneity. The best-replicated benefits—accelerated muscle-strength recovery, reduced soreness, and improved sleep via melatonin—come overwhelmingly from tart cherry (Prunus cerasus), so they should not be assumed identical for sweet cherry. Most studies are small, short, and use concentrated juice or powder rather than whole fresh fruit, limiting how far results generalize to ordinary dietary servings. Overall the human evidence is best described as moderate and mechanistically plausible but heterogeneous, with sweet-cherry-specific clinical data still sparse. As a whole food, sweet cherries are a sensible, nutrient-dense choice regardless of the targeted-effect uncertainty.

Nutrition (per 1 cup pitted (138 g)): 87 kcal; Potassium 306mg (7% DV), Vitamin C 9.7mg (11% DV), Fiber 2.9g (10% DV), Copper 0.08mg (9% DV), Manganese 0.1mg (4% DV), Vitamin K 2.9mcg (2% DV).
Benefits / uses: Anti-inflammatory effects (lowers CRP, IFN-γ in some trials); Modest blood-pressure lowering in obese/at-risk adults (single trial; not confirmed in pooled analysis); Reduced serum urate and fewer recurrent gout flares (mostly cherry/tart-cherry data); Faster recovery of muscle strength and less soreness after strenuous exercise (chiefly tart cherry); Improved sleep duration/quality via melatonin and anthocyanins (chiefly tart cherry); Antioxidant capacity from polyphenol-rich profile.
Active compounds: Anthocyanins (cyanidin-3-rutinoside, cyanidin-3-glucoside); Hydroxycinnamic acids (neochlorogenic, chlorogenic, p-coumaroylquinic acid); Flavonols (quercetin, kaempferol glycosides); Flavan-3-ols / proanthocyanidins (catechin, epicatechin); Melatonin; Vitamin C (ascorbic acid); Potassium; Dietary fiber (pectin, cellulose); Carotenoids (beta-carotene, lutein/zeaxanthin).
Dose: 1 cup pitted (about 138 g, ~21 cherries) fresh; many trials use 200-300 mL cherry juice/drink once or twice daily
Safety: Generally safe as a food. High in fructose and sorbitol, so large amounts can cause bloating, gas, or diarrhea in sensitive people (including those with IBS or fructose malabsorption). Cherry pits/kernels contain amygdalin, which releases cyanide if crushed/chewed in quantity—do not eat the stones. People with latex-fruit or birch-pollen (oral allergy) syndrome may react. Concentrated cherry juice adds appreciable sugar and calories and may affect glycemic control if overconsumed. Theoretical additive effects with urate-lowering or anti-inflammatory regimens; patients on warfarin should keep vitamin K intake consistent (cherries are low but not zero).

Cited studies (8):
  - Dose-dependent effect of tart cherry on blood pressure and selected inflammation biomarkers: A GRADE-assessed systematic review and meta-analysis of randomized controlled trials, Heliyon (2023) — GRADE-assessed dose-response meta-analysis of 21 RCTs: tart cherry reduced serum CRP (moderate certainty) but did not significantly change hs-CRP or IL-6, and had no significant effect on blood pressure. [https://pubmed.ncbi.nlm.nih.gov/37809623/]
  - Effect of cherry consumption on blood pressure: a systematic review and meta-analysis of randomized controlled trials, Diabetes & metabolic syndrome (2022) — Meta-analysis of 7 RCTs (n=201) of sweet and tart cherry: cherry supplementation produced no statistically significant reduction in systolic or diastolic blood pressure. [https://pubmed.ncbi.nlm.nih.gov/35108661/]
  - Tart Cherry Supplementation and Recovery From Strenuous Exercise: A Systematic Review and Meta-Analysis, International journal of sport nutrition and exercise metabolism (2021) — Meta-analysis of 14 studies: tart cherry supplementation significantly improved recovery of muscular strength and power and reduced soreness after strenuous exercise. [https://pubmed.ncbi.nlm.nih.gov/33440334/]
  - Effectiveness of Cherries in Reducing Uric Acid and Gout: A Systematic Review, Evidence-based complementary and alternative medicine : eCAM (2019) — Systematic review of 6 studies: cherry/tart-cherry intake associated with reduced serum uric acid (up to ~19% with juice) and fewer gout flares; data too heterogeneous for meta-analysis. [https://pmc.ncbi.nlm.nih.gov/articles/PMC6914931/]
  - Dark Sweet Cherry (Prunus avium) Supplementation Reduced Blood Pressure and Pro-Inflammatory Interferon Gamma (IFNγ) in Obese Adults without Affecting Lipid Profile, Glucose Levels and Liver Enzymes, Nutrients (2023) — 30-day single-blind RCT in obese adults (n=40): dark sweet cherry (Prunus avium) drink 200 mL twice daily lowered systolic (p=0.05) and diastolic (p=0.04) blood pressure and reduced pro-inflammatory IFN-γ (p=0.001) vs placebo, without affecting lipids, glucose, or liver enzymes. [https://pmc.ncbi.nlm.nih.gov/articles/PMC9920461/]
  - Pilot Study of the Tart Cherry Juice for the Treatment of Insomnia and Investigation of Mechanisms, American journal of therapeutics (2018) — Placebo-controlled crossover pilot in 8 adults >50 y with insomnia: tart cherry juice (240 mL twice daily) increased polysomnography total sleep time by ~84 minutes vs placebo (p=0.018), attributed partly to procyanidin-B2 inhibition of IDO reducing tryptophan degradation. [https://pubmed.ncbi.nlm.nih.gov/28901958/]
  - Effects of a tart cherry juice beverage on the sleep of older adults with insomnia: a pilot study, Journal of medicinal food (2010) — Randomized double-blind placebo-controlled crossover in 15 older adults with chronic insomnia: a tart cherry juice beverage twice daily for 2 weeks significantly improved subjective insomnia severity vs placebo. [https://pubmed.ncbi.nlm.nih.gov/20438325/]
  - Cherry consumption and decreased risk of recurrent gout attacks, Arthritis and rheumatism (2012) — Case-crossover study (633 gout patients): cherry intake over 2 days was associated with 35% lower risk of recurrent gout attacks (OR 0.65, 95% CI 0.50-0.85); risk was ~75% lower (OR 0.25) when cherry was combined with allopurinol. [https://pubmed.ncbi.nlm.nih.gov/23023818/]

---

## Cantaloupe Melon (Cucumis melo var. cantalupensis)
URL: https://nutridex.info/s/cantaloupe-melon
Category: Fruits
Evidence: Moderate — Several controlled trials; effects real but modest or context-dependent.
Beta-carotene-rich, hydrating summer melon

Quick answer: Cantaloupe Melon is used for provitamin a (beta-carotene) source supporting vision and skin/epithelial health. NutriDex grades the human evidence as moderate — Several controlled trials; effects real but modest or context-dependent. Based on 9 cited human studies (9 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Cantaloupe is a nutrient-dense, low-calorie fruit that is roughly 90% water and an excellent source of provitamin A beta-carotene and vitamin C, with meaningful potassium and folate. Direct clinical trials on cantaloupe itself are sparse; most human evidence is indirect, derived from its constituent nutrients and from broad fruit-intake cohorts. Large dose-response meta-analyses of prospective cohorts show that higher fruit and vegetable intake is associated with lower all-cause and cardiovascular mortality (about 5% lower all-cause risk per added daily serving, plateauing near five servings). Trials of increased potassium intake reduce blood pressure in people with hypertension and are linked to roughly 24% lower stroke risk, and cantaloupe's beta-carotene is well-absorbed (bioavailability comparable to carrots). A small placebo-controlled pilot of a melon SOD concentrate (Extramel) reported improved perceived stress and fatigue, but it tested a proprietary supplement, not the whole fruit, and was industry-funded. Importantly, benefits attach to beta-carotene consumed as food; high-dose beta-carotene supplements increased lung cancer and mortality in smokers, so whole-fruit intake should not be extrapolated to pills.

Nutrition (per 1 medium (552 g, edible)): 188 kcal; Vitamin C 203mg (225% DV), Vitamin A (RAE) 933mcg (104% DV), Potassium 1474mg (31% DV), Folate 116mcg (29% DV), Fiber 5g (18% DV), Magnesium 66mg (16% DV).
Benefits / uses: Provitamin A (beta-carotene) source supporting vision and skin/epithelial health; High vitamin C contributing to antioxidant defense and collagen synthesis; Potassium intake associated with lower blood pressure and stroke risk; High water content (~90%) aiding hydration and satiety with low energy density; Part of higher fruit intake linked to lower all-cause and cardiovascular mortality; Melon-derived superoxide dismutase (SOD) concentrate studied for perceived stress/fatigue (proprietary supplement, not whole fruit).
Active compounds: Carotenoids (beta-carotene, plus beta-apo-carotenals); Vitamin C (L-ascorbic acid); Potassium (electrolyte mineral); Folate (vitamin B9); Superoxide dismutase (antioxidant metalloenzyme, concentrated in flesh); Phenolic acids (caffeic, chlorogenic, ferulic acid); Cucurbitacins (bitter triterpenoids, trace); Soluble and insoluble dietary fiber (pectin, cellulose).
Dose: 1 cup diced (~160 g) to half a medium melon; ~150-300 g typical serving
Safety: Generally very safe as a food. Cantaloupe rind is a recognized vehicle for Listeria, Salmonella, and other pathogens (notably the 2011 US listeriosis outbreak); wash whole melons, refrigerate cut fruit promptly, and pregnant or immunocompromised people should take extra care. Its potassium content warrants moderation in advanced chronic kidney disease or for people on potassium-sparing diuretics, ACE inhibitors, or ARBs. The natural sugar content is relevant for diabetes portion control. Oral allergy syndrome (ragweed/melon cross-reactivity) and rare latex-fruit allergy can occur. Whole-food beta-carotene is not equivalent to high-dose supplements, which are harmful in smokers.

Cited studies (9):
  - Potassium Intake and Blood Pressure: A Dose‐Response Meta‐Analysis of Randomized Controlled Trials, Journal of the American Heart Association (2020) — Dose-response meta-analysis of 32 RCTs found a U-shaped potassium-blood-pressure relationship; adequate (not excessive) potassium intake lowers BP, with strongest effect in hypertensive and high-sodium subgroups. [https://doi.org/10.1161/JAHA.119.015719]
  - The Associations of Fruit and Vegetable Intakes with Burden of Diseases: A Systematic Review of Meta-Analyses, Journal of the Academy of Nutrition and Dietetics (2019) — Systematic review of meta-analyses: the first 100 g/day of fruit intake was associated with ~11% lower all-cause mortality (nonlinear RR 0.89) and ~14% lower stroke risk (RR 0.86). [https://doi.org/10.1016/j.jand.2018.11.007]
  - Potassium supplementation and heart rate: A meta-analysis of randomized controlled trials, Nutrition, Metabolism and Cardiovascular Diseases (2016) — Meta-analysis of 22 RCTs (1,086 subjects): potassium supplementation (median 2.5 g/day) had no significant effect on resting heart rate, supporting cardiovascular safety of higher potassium intake in healthy adults. [https://doi.org/10.1016/j.numecd.2016.05.003]
  - Fruit and vegetable consumption and mortality from all causes, cardiovascular disease, and cancer: systematic review and dose-response meta-analysis of prospective cohort studies, BMJ (2014) — Dose-response meta-analysis of 16 prospective cohorts (833,234 participants, 56,423 deaths): each added daily serving of fruit and vegetables linked to 5% lower all-cause mortality (HR 0.95, 95% CI 0.92-0.98) and lower cardiovascular mortality (HR 0.96 per serving), with a threshold around 5 servings/day. [https://doi.org/10.1136/bmj.g4490]
  - Effect of increased potassium intake on cardiovascular risk factors and disease: systematic review and meta-analyses, BMJ (2013) — Systematic review/meta-analyses (22 RCTs, 1,606 participants; 11 cohorts, 127,038 participants): higher potassium intake lowered systolic BP by 3.49 mmHg in adults (effect seen in hypertensives, not normotensives) and was associated with 24% lower stroke risk (RR 0.76). [https://doi.org/10.1136/bmj.f1378]
  - Effect of an oral supplementation with a proprietary melon juice concentrate (Extramel®) on stress and fatigue in healthy people: a pilot, double-blind, placebo-controlled clinical trial, Nutrition Journal (2009) — Randomized, double-blind, placebo-controlled pilot (n=70): 10 mg/day melon SOD concentrate (Extramel, 140 IU SOD) significantly improved perceived stress, fatigue, and quality of life vs placebo over 4 weeks; industry-funded (Seppic/Air Liquide), tested a proprietary supplement not the whole fruit. [https://doi.org/10.1186/1475-2891-8-40]
  - The Effect of Vitamin E and Beta Carotene on the Incidence of Lung Cancer and Other Cancers in Male Smokers, New England Journal of Medicine (1994) — In 29,133 male smokers, beta-carotene supplements (20 mg/day) increased lung cancer incidence by 18% and total mortality by 8% - a key caution that high-dose supplements differ from beta-carotene in whole foods. [https://doi.org/10.1056/NEJM199404143301501]
  - <i>Cucumis melo</i> seed oil: agro‐food by‐product with natural anti‐hyperlipidemic potential, Journal of the Science of Food and Agriculture (2022) — Cucumis melo seed oil supplementation lowered total cholesterol, triglycerides, and LDL while raising HDL in hyperlipidemic rabbits, indicating anti-hyperlipidemic potential of melon by-products (preclinical). [https://doi.org/10.1002/jsfa.12348]
  - Carotene and Novel Apocarotenoid Concentrations in Orange-Fleshed <i>Cucumis melo</i> Melons: Determinations of β-Carotene Bioaccessibility and Bioavailability, Journal of Agricultural and Food Chemistry (2011) — Orange-fleshed melons are rich in beta-carotene (cantaloupe ~176 mcg/g dry weight); in vitro digestion/Caco-2 bioavailability of melon beta-carotene was comparable to that of carrot. [https://doi.org/10.1021/jf200416a]

---

## Honeydew Melon (Cucumis melo (Inodorus Group))
URL: https://nutridex.info/s/honeydew-melon
Category: Fruits
Evidence: Preliminary — Early or small human trials; promising but not yet conclusive.
Hydrating, potassium-rich melon with modest vitamin C

Quick answer: Honeydew Melon is used for hydration support (~90% water, plus potassium and small amounts of sodium/magnesium for fluid balance). NutriDex grades the human evidence as preliminary — Early or small human trials; promising but not yet conclusive. Based on 9 cited human studies (9 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Honeydew is a nutrient-modest, very high-water fruit whose health profile rests largely on indirect evidence rather than melon-specific trials. There are essentially no randomized controlled trials or meta-analyses isolating honeydew itself; its plausible benefits are extrapolated from its potassium, vitamin C, and whole-fruit content. Potassium intake lowers blood pressure in dose-response meta-analyses of RCTs (most clearly in hypertensive, high-sodium individuals), and fruit-and-vegetable-rich patterns like DASH reduce blood pressure substantially. Large prospective cohorts (e.g., the 0.5-million-person China Kadoorie Biobank and dose-response meta-analyses) link higher whole-fruit intake to lower cardiovascular disease, diabetes, and all-cause mortality, though these reflect overall fruit intake, not honeydew specifically. By contrast, isolated vitamin C supplementation shows no cardiovascular benefit in Cochrane-reviewed RCTs, underscoring that whole-food effects should not be attributed to single nutrients. Honeydew is best viewed as a hydrating, low-calorie contributor to a healthful dietary pattern rather than a fruit with proven standalone effects.

Nutrition (per 1 cup, diced (170 g)): 61 kcal; Vitamin C 30.6mg (34% DV), Potassium 388mg (8% DV), Folate 32mcg (8% DV), Vitamin B6 0.15mg (9% DV), Magnesium 17mg (4% DV), Vitamin K 4.9mcg (4% DV).
Benefits / uses: Hydration support (~90% water, plus potassium and small amounts of sodium/magnesium for fluid balance); Contributes potassium that supports healthy blood pressure as part of a fruit-and-vegetable-rich diet; Provides vitamin C (about 34% of the Daily Value per cup) for antioxidant defense and collagen synthesis; Low energy density and low glycemic load, useful for weight-conscious and cardiometabolic diets; Part of whole-fruit intake patterns linked to lower diabetes and cardiovascular risk in large cohorts; Supplies folate, contributing to homocysteine metabolism.
Active compounds: Ascorbic acid (vitamin C); Potassium (electrolyte mineral); Phenolic acids (caffeic, chlorogenic, p-coumaric); Carotenoids (trace beta-carotene; higher in orange-fleshed types); Folate (vitamin B9); Cucurbitane-type triterpenoids (cucurbitacins, trace); Free amino acids including citrulline/arginine (low vs watermelon); Soluble sugars (fructose, glucose, sucrose).
Dose: 1 cup diced (~170 g); a typical wedge is one-eighth of a medium melon
Safety: Generally very safe. People with chronic kidney disease or on potassium-sparing medications (ACE inhibitors, ARBs, potassium-sparing diuretics) should account for its potassium. The natural sugars (~14 g per cup) count toward carbohydrate intake for those managing diabetes, though the glycemic load is low given the high water content. Cucurbit (melon/cucumber) allergy and oral allergy syndrome (cross-reactivity with ragweed pollen and latex) can occur. Pre-cut melon has been linked to foodborne outbreaks (Salmonella, Listeria); wash the rind before cutting and refrigerate promptly. No known drug interactions of the grapefruit type.

Cited studies (9):
  - Potassium Intake and Blood Pressure: A Dose-Response Meta-Analysis of Randomized Controlled Trials, Journal of the American Heart Association (2020) — Dose-response meta-analysis of 32 RCTs: higher potassium intake reduced systolic blood pressure, most strongly in hypertensive participants, with an estimated optimal intake around 3500-5000 mg/day. [https://pubmed.ncbi.nlm.nih.gov/32500831/]
  - Fruit and vegetable intake and the risk of cardiovascular disease, total cancer and all-cause mortality-a systematic review and dose-response meta-analysis of prospective studies, International journal of epidemiology (2017) — Dose-response meta-analysis of up to 95 studies: each 200 g/day of fruit+vegetables lowered all-cause mortality (RR 0.90 per 200 g across 15 studies), with risk reduction plateauing around ~5 servings/day (800 g). [https://pubmed.ncbi.nlm.nih.gov/28338764/]
  - Vitamin C supplementation for the primary prevention of cardiovascular disease, The Cochrane database of systematic reviews (2017) — Cochrane review of RCTs (15,445 participants) found no benefit of vitamin C supplementation for primary cardiovascular prevention (all-cause mortality HR 1.07, 95% CI 0.97-1.18; very low-quality evidence). [https://pubmed.ncbi.nlm.nih.gov/28301692/]
  - Fruit and vegetable consumption and mortality from all causes, cardiovascular disease, and cancer: systematic review and dose-response meta-analysis of prospective cohort studies, BMJ (Clinical research ed.) (2014) — Dose-response meta-analysis of 16 cohorts (833,234 participants): each additional fruit-and-vegetable serving/day lowered all-cause mortality (pooled HR 0.95), with a threshold near 5 servings/day. [https://pubmed.ncbi.nlm.nih.gov/25073782/]
  - Nutritional Composition and Health Benefits of Various Botanical Types of Melon (Cucumis melo L.), Plants (Basel, Switzerland) (2021) — Compositional study of 30 Cucumis melo genotypes (including inodorus/honeydew types) reports ascorbic acid, carotenoids and polyphenols as major antioxidants, with content varying by botanical type and cultivar. [https://pmc.ncbi.nlm.nih.gov/articles/PMC8469201/]
  - Antioxidant, sugar, mineral, and phytonutrient concentrations across edible fruit tissues of orange-fleshed honeydew melon (Cucumis melo L.), Journal of agricultural and food chemistry (2008) — Across honeydew fruit tissues, ascorbate, sugars, minerals (notably potassium) and phytonutrient concentrations varied by tissue, with concentrations of several compounds shifting from subpeel toward the seed cavity. [https://pubmed.ncbi.nlm.nih.gov/18454549/]
  - A clinical trial of the effects of dietary patterns on blood pressure. DASH Collaborative Research Group, The New England journal of medicine (1997) — RCT (n=459): a fruit-and-vegetable-rich diet lowered systolic/diastolic BP by 2.8/1.1 mmHg, and the full DASH diet by 5.5/3.0 mmHg, versus control over 8 weeks. [https://pubmed.ncbi.nlm.nih.gov/9099655/]
  - Fresh fruit consumption in relation to incident diabetes and diabetic vascular complications: A 7-y prospective study of 0.5 million Chinese adults, PLoS medicine (2017) — In 482,591 diabetes-free adults, daily fresh fruit intake was associated with 12% lower diabetes incidence (HR 0.88, 95% CI 0.83-0.93) and, among those with diabetes, lower mortality (HR 0.83 per 100 g/day) and fewer vascular complications over ~7 years. [https://pubmed.ncbi.nlm.nih.gov/28399126/]
  - Fresh Fruit Consumption and Major Cardiovascular Disease in China, The New England journal of medicine (2016) — Among 451,681 adults free of prior CVD, daily vs never fresh-fruit consumers had ~40% lower cardiovascular death (adjusted HR 0.60) and fewer major coronary events (HR 0.66) and strokes. [https://pubmed.ncbi.nlm.nih.gov/27050205/]

---

## Passion Fruit (Passiflora edulis)
URL: https://nutridex.info/s/passion-fruit
Category: Fruits
Evidence: Preliminary — Early or small human trials; promising but not yet conclusive.
Fiber-dense tropical fruit with bioactive peel and seeds

Quick answer: Passion Fruit is used for exceptionally high soluble and insoluble fiber (about 10 g per 100 g) supporting satiety and bowel regularity. NutriDex grades the human evidence as preliminary — Early or small human trials; promising but not yet conclusive. Based on 9 cited human studies (9 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Passion fruit pulp is a low-calorie, strikingly fiber-dense tropical fruit (about 10 g fiber per 100 g) that also supplies vitamin C, potassium, provitamin A carotenoids and polyphenols. Critically, most published human trials test the INEDIBLE peel (rind) flour or extract, or the seeds, rather than the edible pulp, so those benefits do not translate directly to eating the fruit. Small randomized trials of purple passion-fruit peel extract reported large drops in blood pressure and reduced asthma symptoms, but these were short (4 weeks), single-center, small, and led by overlapping investigator groups, and the reported BP reductions (about 31/25 mmHg) are implausibly large for a food supplement — so confidence is low. Yellow passion-fruit peel flour (~30-36 g/day) improved insulin resistance and HbA1c in one trial but showed no glycemic effect in a later randomized trial, so evidence is genuinely mixed. Seed-derived piceatannol (20 mg/day) improved insulin and blood pressure only in overweight men within a small 8-week study, and a separate trial found 5 mg/day improved skin moisture in women. No large prospective cohort or meta-analysis links passion-fruit consumption to hard health outcomes. Overall the human evidence is preliminary and largely about extracts, while the pulp's fiber and micronutrient density remain its best-supported nutritional value.

Nutrition (per 2 medium fruits, pulp (36 g)): 35 kcal; Fiber 3.7g (13% DV), Vitamin C 10.8mg (12% DV), Vitamin A (RAE) 23mcg (3% DV), Potassium 125mg (3% DV), Magnesium 10.4mg (2% DV), Iron 0.58mg (3% DV).
Benefits / uses: Exceptionally high soluble and insoluble fiber (about 10 g per 100 g) supporting satiety and bowel regularity; Purple peel extract lowered blood pressure in small short-term RCTs (effect sizes implausibly large; not the edible pulp); Yellow peel flour and seed piceatannol may improve insulin sensitivity and glycemic markers (mixed RCTs); Purple peel extract reduced asthma symptoms (wheeze, cough, dyspnea) in one small RCT; Seed piceatannol improved insulin and blood pressure in overweight men (subgroup) and skin moisture in women; Rich in antioxidant polyphenols (anthocyanins, flavonols, seed stilbenes) and carotenoids.
Active compounds: Soluble fiber / pectin (viscous gel-forming polysaccharides); Anthocyanins (cyanidin-3-O-glucoside); Flavonols (quercetin and kaempferol glycosides); Stilbenes (piceatannol and its dimer scirpusin B — seed-concentrated); Carotenoids (beta-carotene, provitamin A); Vitamin C (ascorbic acid); Edulilic acid (a Passiflora cyclic acid glucoside); Cyanogenic glycosides (trace, in seeds/unripe rind); Potassium and magnesium.
Dose: Pulp of 2-3 fruits (~36-55 g edible) as a whole-food serving. Studied benefits use the INEDIBLE peel (rind) flour/extract (150-400 mg/day extract, or ~36 g/day flour) or seed piceatannol (5-20 mg/day) — not the pulp itself.
Safety: Generally safe as a food. Seeds and unripe rind contain trace cyanogenic glycosides, so eating large quantities of raw peel or seeds is not advised. People with latex allergy may cross-react (latex-fruit syndrome). The blood-pressure-lowering peel extracts could theoretically add to antihypertensive medication effects, and clinical drug-interaction data are limited. Peel-extract and piceatannol benefits come from concentrated, unregulated supplements rather than the pulp. A high fiber load may cause gas or GI discomfort in sensitive individuals.

Cited studies (9):
  - The Effect of Piceatannol from Passion Fruit (Passiflora edulis) Seeds on Metabolic Health in Humans, Nutrients (2017) — 8-week placebo-controlled RCT (n=39): seed piceatannol 20 mg/day lowered serum insulin, HOMA-IR, systolic/diastolic BP and heart rate only in overweight men; no effect in other subgroups. [https://pubmed.ncbi.nlm.nih.gov/29057795/]
  - The effect of flour from the rind of the yellow passion fruit on glycemic control of people with diabetes mellitus type 2: a randomized clinical trial, Journal of Diabetes & Metabolic Disorders (2017) — 8-week open randomized clinical trial (n=54): yellow passion-fruit rind flour (36 g/day) showed NO significant difference in capillary/fasting glucose or HbA1c vs control in type 2 diabetes. [https://link.springer.com/article/10.1186/s40200-017-0300-z]
  - Effect of Passion Fruit Seed Extract Rich in Piceatannol on the Skin of Women: A Randomized, Placebo-Controlled, Double-Blind Trial, Journal of Nutritional Science and Vitaminology (2018) — 8-week randomized, placebo-controlled, double-blind trial (n=32 women): passion-fruit seed extract providing 5 mg/day piceatannol significantly increased skin moisture vs placebo. [https://www.jstage.jst.go.jp/article/jnsv/64/1/64_75/_article]
  - Effect of the yellow passion fruit peel flour (Passiflora edulis f. flavicarpa deg.) in insulin sensitivity in type 2 diabetes mellitus patients, Nutrition journal (2012) — Controlled trial (n=43): 30 g/day yellow passion-fruit peel flour for 2 months reduced fasting glucose, HbA1c (P=.032) and HOMA-IR (P=.005) in type 2 diabetics. [https://pubmed.ncbi.nlm.nih.gov/23088514/]
  - Efficacy of Purple Passion Fruit Peel Extract in Lowering Cardiovascular Risk Factors in Type 2 Diabetic Subjects, Journal of Evidence-Based Complementary & Alternative Medicine (2013) — 16-week double-blind RCT (n=41): purple passion-fruit peel extract 220 mg/day significantly reduced systolic BP and fasting blood glucose in type 2 diabetic subjects vs placebo. [https://journals.sagepub.com/doi/full/10.1177/2156587213475627]
  - Oral administration of purple passion fruit peel extract attenuates blood pressure in female spontaneously hypertensive rats and humans, Nutrition Research (2007) — 4-week randomized, double-blind, placebo-controlled human arm: purple passion-fruit peel extract 400 mg/day lowered systolic and diastolic BP by ~30.9 and ~24.6 mmHg vs placebo in hypertensives. Effect size is implausibly large; treat with caution. [https://doi.org/10.1016/j.nutres.2007.05.004]
  - Oral administration of the purple passion fruit peel extract reduces wheeze and cough and improves shortness of breath in adults with asthma, Nutrition research (New York, N.Y.) (2008) — 4-week double-blind RCT: purple passion-fruit peel extract 150 mg/day significantly reduced wheeze, cough and shortness of breath in adults with asthma vs placebo (P<.05). [https://pubmed.ncbi.nlm.nih.gov/19083404/]
  - Identification of the strong vasorelaxing substance scirpusin B, a dimer of piceatannol, from passion fruit (Passiflora edulis) seeds, Journal of agricultural and food chemistry (2011) — Isolated and identified scirpusin B (a dimer of piceatannol) as the second major polyphenol in passion-fruit seeds; both stilbenes showed potent antioxidant and endothelium-dependent vasorelaxant activity in rat aorta. [https://pubmed.ncbi.nlm.nih.gov/21526844/]
  - Antihypertensive effect of passion fruit peel extract and its major bioactive components following acute supplementation in spontaneously hypertensive rats, The Journal of nutritional biochemistry (2013) — Passion-fruit peel extract and its components (anthocyanin fraction, edulilic acid) reduced hemodynamic parameters in spontaneously hypertensive rats after acute dosing; GABA did not. [https://pubmed.ncbi.nlm.nih.gov/23333089/]

---

## Lychee (Litchi chinensis)
URL: https://nutridex.info/s/lychee
Category: Fruits
Evidence: Preliminary — Early or small human trials; promising but not yet conclusive.
Vitamin C-rich tropical fruit with polyphenol research

Quick answer: Lychee is used for high vitamin c contribution to antioxidant and immune support per serving. NutriDex grades the human evidence as preliminary — Early or small human trials; promising but not yet conclusive. Based on 11 cited human studies (11 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Lychee is a sweet subtropical fruit that is an excellent source of vitamin C, providing roughly 80% of the Daily Value per ~100 g, alongside potassium, copper and flavanol-type polyphenols. The strongest human evidence comes not from the whole fruit but from Oligonol, a standardized lychee-derived oligomerized-polyphenol: randomized double-blind placebo-controlled trials report reduced abdominal visceral fat in overweight adults and improvements in liver fat fraction and gut microbiota composition in NAFLD patients, though one NAFLD RCT failed to beat placebo on its primary endpoint. These supplement doses are far more concentrated than what eating fresh fruit delivers, so the trial results should not be read as benefits of the fruit itself. Much of the remaining mechanistic and metabolic data (anti-inflammatory, anti-aging SIRT1/AMPK, renoprotective, anti-sarcopenia) comes from cell and rodent models. Large prospective cohorts show whole-fruit intake is associated with modestly lower type 2 diabetes risk, but lychee was not studied individually and fruit juice trends the opposite way. Overall, direct human evidence for fresh lychee is preliminary, with most benefit signals tied to extracts rather than the fruit as eaten.

Nutrition (per 1 cup, ~9 lychees (100 g)): 66 kcal; Vitamin C 71.5mg (79% DV), Copper 0.148mg (16% DV), Vitamin B6 0.1mg (6% DV), Potassium 171mg (4% DV), Riboflavin 0.065mg (5% DV), Folate 14ug (4% DV).
Benefits / uses: High vitamin C contribution to antioxidant and immune support per serving; Lychee-derived polyphenol (Oligonol) reduced abdominal visceral fat in overweight adults in a randomized controlled trial; Litchi-derived polyphenol (Oligonol) improved liver fat (MRI-PDFF) and gut microbiota in a NAFLD trial; Source of potassium and copper supporting normal cardiovascular and metabolic function; Rich in flavanol/proanthocyanidin antioxidants studied for anti-inflammatory and metabolic effects; Whole-fruit consumption associated with modestly lower type 2 diabetes risk in large cohorts (lychee not studied individually).
Active compounds: Vitamin C (L-ascorbic acid); Flavanol monomers (epicatechin, catechin); Proanthocyanidins / oligomerized flavanols (Oligonol); Anthocyanins (cyanidin-3-glucoside, mainly in pericarp); Phenolic acids (gallic, chlorogenic acid); Flavonols (rutin, quercetin glycosides); Potassium and copper (minerals); B vitamins (B6, folate, riboflavin); Seed-borne hypoglycins (hypoglycin A, MCPG) — toxic, not a benefit.
Dose: About 9 fresh lychees (~100 g edible flesh); Oligonol trials used 100-200 mg/day of standardized extract
Safety: Generally safe as a food in normal amounts. The major documented hazard is consumption of unripe lychee (especially the seed and aril) on an empty stomach: the natural toxins hypoglycin A and methylenecyclopropylglycine (MCPG) inhibit fatty-acid oxidation/gluconeogenesis and have caused fatal hypoglycemic encephalopathy outbreaks in undernourished children (Muzaffarpur, India). Eat ripe fruit, in moderation, and never let children eat large quantities of unripe lychees while fasting; ensure an evening meal. High natural sugar content warrants moderation in diabetes and weight management. Lychee allergy and oral allergy syndrome are reported. Never eat the seed. Oligonol supplements are not equivalent to the fruit; discuss high-dose polyphenol supplements with a clinician if pregnant, on anticoagulants, or managing chronic disease.

Cited studies (11):
  - Consumption of Fruit Juice and Risk of Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Prospective Cohort Studies, The American Journal of Medicine (2025) — Meta-analysis of 14 prospective cohorts: overall fruit juice showed no significant association with type 2 diabetes risk (RR 1.06), with subgroup signals favoring whole fruit over sweetened/non-100% juice. [https://doi.org/10.1016/j.amjmed.2025.05.021]
  - Effects of Oligonol&lt;sup&gt;®&lt;/sup&gt; Supplementation on Abdominal Fat in Japanese Overweight Volunteers: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study, Journal of Nutritional Science and Vitaminology (2025) — RCT (n=66 overweight adults; 63 analyzed): 200 mg/day Oligonol (lychee/tea flavanols) for 12 weeks significantly reduced abdominal visceral fat area on CT vs placebo, with no adverse events reported. [https://doi.org/10.3177/jnsv.71.357]
  - Litchi-Derived Polyphenol Alleviates Liver Steatosis and Gut Dysbiosis in Patients with Non-Alcoholic Fatty Liver Disease: A Randomized Double-Blinded, Placebo-Controlled Study, Nutrients (2022) — RCT (n=38 NAFLD, 19/group): lychee-derived Oligonol for 24 weeks significantly reduced liver fat (MRI-PDFF) and shifted gut microbiota toward SCFA-producing bacteria, vs a non-significant change in placebo. [https://doi.org/10.3390/nu14142921]
  - The Efficacy of Oligonol in Nonalcoholic Fatty Liver Disease: A Randomized Double-Blinded Placebo-Controlled Trial, Journal of Integrative and Complementary Medicine (2022) — RCT (n=40 NAFLD, 20/group): Oligonol did not significantly outperform placebo for >=30% MRI-PDFF reduction at 24 weeks (20% vs 15%, p=0.50); secondary metabolic outcomes similar between groups. [https://doi.org/10.1089/jicm.2021.0362]
  - Fruit consumption and risk of type 2 diabetes: results from three prospective longitudinal cohort studies, BMJ (2013) — Pooled analysis of three US cohorts (~187,000 adults): every 3 weekly servings of whole fruit associated with HR 0.98 for type 2 diabetes, while fruit juice was associated with higher risk (HR 1.08). Lychee not assessed individually. [https://doi.org/10.1136/bmj.f5001]
  - Association of acute toxic encephalopathy with litchi consumption in an outbreak in Muzaffarpur, India, 2014: a case-control study, The Lancet Global Health (2017) — Case-control study of 2014 Muzaffarpur outbreak: litchi consumption (matched OR 9.6) and absent evening meal linked to acute encephalopathy; arils contained hypoglycin A and MCPG; ~31% case fatality. [https://doi.org/10.1016/S2214-109X(17)30035-9]
  - Oligonol promotes anti-aging pathways<i>via</i>modulation of SIRT1-AMPK-Autophagy Pathway, Nutrition Research and Practice (2016) — Mechanistic study: Oligonol from lychee upregulated SIRT1 and activated AMPK/autophagy pathways, extending lifespan in C. elegans and acting on aged-mouse splenocytes ex vivo. [https://doi.org/10.4162/nrp.2016.10.1.3]
  - Oligonol, a low-molecular-weight polyphenol derived from lychee fruit, attenuates gluco-lipotoxicity-mediated renal disorder in type 2 diabetic &lt;i&gt;db/db&lt;/i&gt; mice, Drug Discoveries &amp; Therapeutics (2015) — Animal study (db/db diabetic mice): lychee-derived Oligonol (10-20 mg/kg/day, 8 weeks) attenuated NADPH-oxidase oxidative stress and advanced glycation end-products, reducing diabetic renal injury. [https://doi.org/10.5582/ddt.2015.01003]
  - Oligonol Alleviates Sarcopenia by Regulation of Signaling Pathways Involved in Protein Turnover and Mitochondrial Quality, Molecular Nutrition &amp; Food Research (2019) — Animal study (SAMP8 mice): dietary Oligonol increased skeletal muscle mass, fiber cross-sectional area and grip strength by enhancing protein synthesis and mitochondrial quality, alleviating sarcopenia. [https://doi.org/10.1002/mnfr.201801102]
  - Oligonol Inhibits Dextran Sulfate Sodium-Induced Colitis and Colonic Adenoma Formation in Mice, Antioxidants &amp; Redox Signaling (2013) — Animal study: oral Oligonol protected against DSS-induced colitis and azoxymethane/DSS colon adenoma formation in mice by suppressing NF-kB/STAT3, COX-2 and iNOS. [https://doi.org/10.1089/ars.2012.4626]
  - Oligonol Inhibits UVB‐induced COX‐2 Expression in HR‐1 Hairless Mouse Skin—AP‐1 and C/EBP as Potential Upstream Targets<sup>†</sup>, Photochemistry and Photobiology (2008) — Animal study: Oligonol inhibited UVB-induced COX-2 expression and inflammatory signaling in hairless mouse skin via AP-1/C-EBP and p38 MAPK blockade. [https://doi.org/10.1111/j.1751-1097.2007.00277.x]

---

## Persimmon (Diospyros kaki)
URL: https://nutridex.info/s/persimmon
Category: Fruits
Evidence: Preliminary — Early or small human trials; promising but not yet conclusive.
Tannin-rich autumn fruit with cholesterol-lowering fiber.

Quick answer: Persimmon is used for lowers ldl/total cholesterol. NutriDex grades the human evidence as preliminary — Early or small human trials; promising but not yet conclusive. Based on 10 cited human studies (10 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Persimmon is a sweet, fiber- and carotenoid-dense fruit whose distinctive bioactives are condensed tannins (proanthocyanidins). The strongest human signal is on blood lipids: a 12-week double-blind RCT (n=40) found 3 g/day of persimmon tannin-rich fiber significantly lowered total cholesterol and 5 g/day also lowered LDL cholesterol, and a 2025 meta-analysis of 16 trials of persimmon-leaf extract reported reductions in total cholesterol, LDL and triglycerides. A small human/animal study showed kaki-tannin blunts the post-carbohydrate glucose rise, and a 120-day RCT of a 400 mg persimmon extract reduced fat mass in overweight adults without lean-mass loss. However, much of the evidence uses concentrated leaf or tannin extracts rather than the whole fresh fruit, sample sizes are small, the leaf-extract meta-analysis is China-only with high heterogeneity, and several trials are industry-linked, so benefits should be considered preliminary. As a whole food, persimmon is a nutritious fiber, potassium, manganese and provitamin-A source. Its high sugar load and tannin content also carry real cautions, especially the unripe (astringent) fruit.

Nutrition (per 1 medium (168 g)): 118 kcal; Fiber 6g (21% DV), Manganese 0.59mg (26% DV), Copper 0.18mg (20% DV), Vitamin A 136mcg RAE (15% DV), Vitamin C 12.6mg (14% DV), Vitamin B6 0.17mg (10% DV), Potassium 270mg (6% DV).
Benefits / uses: Lowers LDL/total cholesterol; Blunts post-meal blood glucose; High dietary fiber; Carotenoid + vitamin A source; Antioxidant polyphenol content; May aid body-fat reduction.
Active compounds: Proanthocyanidins / condensed tannins (kaki-tannin, gallocatechin); Carotenoids (β-cryptoxanthin, β-carotene, lycopene, zeaxanthin); Soluble + insoluble dietary fiber; Flavonoids (quercetin, kaempferol, myricetin); Gallic & other phenolic acids; Vitamin C (ascorbic acid); Triterpenoids (ursolic, betulinic acid); Potassium & manganese.
Dose: 1 medium fresh fruit (~168 g); persimmon-extract supplement trials used 400 mg/day or 3–5 g/day tannin-rich fiber.
Safety: Astringent/unripe persimmons are high in soluble tannins that can polymerize in stomach acid and form a hardened mass (diospyrobezoar) causing gastric or intestinal obstruction—risk is greater with prior gastric surgery, diabetes, delayed gastric emptying, advanced age, and eating large amounts on an empty stomach. Tannins can bind iron and other minerals, reducing absorption. Sugar content (~21 g per fruit) is relevant for diabetes/glycemic control despite the glucose-blunting tannin effect. Possible allergy/oral itching in sensitive individuals.

Cited studies (10):
  - Persimmon leaf extract in dyslipidemia: a systematic review and meta-analysis, Frontiers in pharmacology (2025) — Meta-analysis of 16 China-only RCTs (n=1,572): persimmon-leaf extract added to standard care reduced total cholesterol (MD -0.91 mmol/L), LDL (-0.47 mmol/L) and triglycerides (-0.43 mmol/L) and raised HDL (+0.24 mmol/L), with high heterogeneity. [https://pmc.ncbi.nlm.nih.gov/articles/PMC12477231/]
  - Fruit and vegetable intake and the risk of cardiovascular disease, total cancer and all-cause mortality-a systematic review and dose-response meta-analysis of prospective studies, International journal of epidemiology (2017) — Dose–response meta-analysis (95 prospective studies): each 200 g/day of fruit + vegetables was associated with lower CVD (RR 0.92), cancer and all-cause mortality (RR 0.90)—context for whole-fruit intake including persimmon. [https://pubmed.ncbi.nlm.nih.gov/28338764/]
  - Efficacy of a Dietary Supplement Extracted from Persimmon (Diospyros kaki L.f.) in Overweight Healthy Adults: A Randomized, Double-Blind, Controlled Clinical Trial, Foods (Basel, Switzerland) (2024) — 120-day double-blind RCT (n=71) of 400 mg/day persimmon extract: fat mass and percentage fell significantly vs placebo in overweight adults with no loss of lean mass; also lowered BMI, waist circumference and TNF-α. [https://pmc.ncbi.nlm.nih.gov/articles/PMC11675947/]
  - Effects of Persimmon Fruit Polyphenols on Postprandial Plasma Glucose Elevation in Rats and Humans, Journal of nutritional science and vitaminology (2022) — Rat + human study: 1.88 g Kaki-tannin (Nara-type) significantly delayed the rise in plasma glucose after a maltooligosaccharide load in humans, with enzyme-inhibition mechanism shown in vitro/in rats. [https://pubmed.ncbi.nlm.nih.gov/36047105/]
  - Persimmon fruit tannin-rich fiber reduces cholesterol levels in humans, Annals of nutrition & metabolism (2013) — 12-wk double-blind RCT (n=40): 3 g/day persimmon tannin-rich fiber significantly lowered total cholesterol; 5 g/day also significantly lowered LDL cholesterol vs placebo, with no change in HDL or triglycerides. [https://pubmed.ncbi.nlm.nih.gov/23171573/]
  - From Diospyros kaki L. (Persimmon) Phytochemical Profile and Health Impact to New Product Perspectives and Waste Valorization, Nutrients (2021) — Review of Diospyros kaki phytochemistry: characterizes proanthocyanidins, carotenoids (β-cryptoxanthin), flavonoids and triterpenoids and their antioxidant, hypolipidemic and antidiabetic activities. [https://www.mdpi.com/2072-6643/13/9/3283]
  - Diospyrobezoar (Persimmon Bezoar)-Induced Intestinal Obstruction in an Older Patient: A Case Report, Cureus (2025) — Case report: a 93-year-old man developed jejunal obstruction from a 5×5 cm diospyrobezoar (>98% tannin) requiring surgery—illustrating bezoar risk from astringent persimmon, even without classic risk factors. [https://pubmed.ncbi.nlm.nih.gov/40655072/]
  - Fresh fruit consumption in relation to incident diabetes and diabetic vascular complications: A 7-y prospective study of 0.5 million Chinese adults, PLoS medicine (2017) — Prospective cohort of ~0.5 million Chinese adults: daily fresh-fruit intake was associated with ~12% lower incident diabetes and, among diabetics, lower all-cause mortality and fewer micro-/macrovascular complications. [https://pmc.ncbi.nlm.nih.gov/articles/PMC5388466/]
  - Prevention of the rise in plasma cholesterol and glucose levels by kaki-tannin and characterization of its bile acid binding capacity, Journal of the science of food and agriculture (2021) — Mouse + in vitro study: kaki-tannin increased fecal bile-acid excretion 2.3-fold, prevented diet-induced rises in plasma cholesterol and fasting glucose, and showed bile-acid–binding capacity comparable to cholestyramine—supporting the lipid-lowering mechanism. [https://pubmed.ncbi.nlm.nih.gov/32981084/]
  - Persimmon tannin promoted macrophage reverse cholesterol transport through inhibiting ERK1/2 and activating PPARγ both in vitro and in vivo, Journal of Functional Foods (2017) — In vitro + in vivo study: persimmon tannin promoted macrophage reverse cholesterol transport by inhibiting ERK1/2 and activating PPARγ, supporting an anti-atherogenic mechanism. [https://doi.org/10.1016/j.jff.2017.09.023]

---

## Blackcurrant (Ribes nigrum)
URL: https://nutridex.info/s/blackcurrant
Category: Fruits
Evidence: Moderate — Several controlled trials; effects real but modest or context-dependent.
Anthocyanin-dense berry for eyes and exercise

Quick answer: Blackcurrant is used for exceptional vitamin c density (roughly 3x an orange) supporting immune and antioxidant status. NutriDex grades the human evidence as moderate — Several controlled trials; effects real but modest or context-dependent. Based on 10 cited human studies (10 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Blackcurrant is one of the most anthocyanin- and vitamin C-dense common berries, and most human evidence centers on its anthocyanins rather than whole-fruit feeding. Randomized crossover trials of standardized New Zealand blackcurrant extract (105-210 mg anthocyanins) consistently increase fat oxidation during moderate cycling (about 27% in one female cohort) and show favorable but mixed performance and recovery effects. Small ophthalmology trials, mostly from Japan, report improved dark adaptation, possible relief of digital eye strain, and a 2-year glaucoma RCT (50 mg/day) showing better visual-field preservation and ocular blood flow. A controlled acute trial found that 600 mg blackcurrant anthocyanins blunted early postprandial glucose, insulin, and incretin responses, but lower doses did not. Broader anthocyanin meta-analyses link intake to modest LDL-cholesterol and inflammatory-marker reductions and lower CVD mortality in cohorts, though blood-pressure effects are negligible. Limits are significant: most trials are small, short, often industry-linked, use concentrated extracts rather than fresh fruit, and outcomes are heterogeneous. Overall the human evidence is moderate and strongest for metabolic/exercise endpoints and exploratory for vision.

Nutrition (per 1 cup (112 g)): 71 kcal; Vitamin C 203mg (225% DV), Potassium 361mg (8% DV), Manganese 0.29mg (13% DV), Iron 1.72mg (10% DV), Calcium 62mg (5% DV), Magnesium 27mg (6% DV).
Benefits / uses: Exceptional vitamin C density (roughly 3x an orange) supporting immune and antioxidant status; Anthocyanin-rich; improves dark adaptation and may relieve digital eye strain; Enhances fat oxidation and may aid endurance exercise performance and recovery (NZ extract); Blunts postprandial glucose and insulin spikes at high anthocyanin doses; Anti-inflammatory effects (lowers CRP/TNF-alpha) and modest LDL-cholesterol reduction.
Active compounds: Anthocyanins (delphinidin-3-rutinoside, cyanidin-3-rutinoside, delphinidin-3-glucoside); Vitamin C (L-ascorbic acid) - exceptionally high; Flavonols (quercetin, myricetin, kaempferol glycosides); Phenolic acids (chlorogenic, p-coumaric acid); Proanthocyanidins (condensed tannins); Soluble and insoluble fiber (pectin); Potassium and manganese; Gamma-linolenic acid (GLA) - concentrated in seed oil.
Dose: About 1 cup fresh berries (110-150 g); ergogenic/eye-health trials use 50-300 mg standardized anthocyanin extract daily
Safety: Generally safe as food. Concentrated anthocyanin/extract supplements are far above dietary amounts and lack long-term safety data. Blackcurrant contains vitamin K and GLA-rich seed oil, which may theoretically affect anticoagulants (warfarin) and antiplatelet drugs - consult a clinician if on these. The high vitamin C and oxalate content may matter for people prone to calcium-oxalate kidney stones. Whole fruit is acidic and high in natural sugars/fiber, which can cause GI upset in large amounts.

Cited studies (10):
  - Anthocyanins, Anthocyanin-Rich Berries, and Cardiovascular Risks: Systematic Review and Meta-Analysis of 44 Randomized Controlled Trials and 15 Prospective Cohort Studies, Frontiers in nutrition (2021) — Meta-analysis (44 RCTs, 15 cohorts): purified anthocyanins lowered LDL-C 5.43 mg/dL (8.40 at >=200 mg/day) and triglycerides; high dietary intake linked to 9% lower CVD mortality. [https://pmc.ncbi.nlm.nih.gov/articles/PMC8714924/]
  - Effects of Anthocyanins on Cardiometabolic Health: A Systematic Review and Meta-Analysis of Randomized Controlled Trials, Advances in nutrition (Bethesda, Md.) (2017) — Meta-analysis of 32 RCTs (1,491 participants): anthocyanin supplementation significantly reduced fasting and 2-h glucose, HbA1c, and total and LDL cholesterol. [https://pmc.ncbi.nlm.nih.gov/articles/PMC5593100/]
  - Effect of Anthocyanin Supplementations on Lipid Profile and Inflammatory Markers: A Systematic Review and Meta-Analysis of Randomized Controlled Trials, Cholesterol (2018) — Meta-analysis of 17 RCTs: anthocyanin supplementation improved lipid profile (lower TG, LDL-C, ApoB; higher HDL-C) and significantly reduced TNF-alpha inflammatory marker. [https://pmc.ncbi.nlm.nih.gov/articles/PMC5937577/]
  - Drinks containing anthocyanin-rich blackcurrant extract decrease postprandial blood glucose, insulin and incretin concentrations, The Journal of nutritional biochemistry (2016) — 600 mg blackcurrant anthocyanins reduced early (0-30 min) postprandial glucose and insulin and suppressed GIP/GLP-1 incretins vs placebo in 22 healthy adults; intermediate doses (150, 300 mg) were ineffective. [https://pmc.ncbi.nlm.nih.gov/articles/PMC5170886/]
  - New Zealand blackcurrant extract enhances fat oxidation during prolonged cycling in endurance-trained females, European journal of applied physiology (2018) — 600 mg/day NZ blackcurrant extract (210 mg anthocyanins) for 7 days increased mean fat oxidation 27% during 2 h moderate cycling in 16 endurance-trained females vs placebo (P=0.047). [https://pmc.ncbi.nlm.nih.gov/articles/PMC5966492/]
  - New Zealand blackcurrant extract improves cycling performance and fat oxidation in cyclists, European journal of applied physiology (2015) — 7-day NZ blackcurrant extract (300 mg, 105 mg anthocyanin) improved 16.1 km cycling time-trial performance by 2.4% and raised fat oxidation 27% during moderate cycling in 14 trained men. [https://pubmed.ncbi.nlm.nih.gov/26175097/]
  - Dose effects of New Zealand blackcurrant on substrate oxidation and physiological responses during prolonged cycling, European journal of applied physiology (2017) — Dose-response trial: 7-day NZ blackcurrant (300-900 mg) produced dose-dependent increases in fat oxidation during 120-min cycling at 65% VO2max in 15 trained male cyclists. [https://pubmed.ncbi.nlm.nih.gov/28391393/]
  - Two-year randomized, placebo-controlled study of black currant anthocyanins on visual field in glaucoma, Ophthalmologica. Journal international d'ophtalmologie. International journal of ophthalmology. Zeitschrift fur Augenheilkunde (2012) — 2-year RCT in 38 open-angle glaucoma patients: 50 mg/day blackcurrant anthocyanins preserved visual-field mean deviation (P=0.039) and increased ocular blood flow vs placebo. [https://pubmed.ncbi.nlm.nih.gov/22377796/]
  - Anthocyanin-Rich Blackcurrant Supplementation as a Nutraceutical Ergogenic Aid for Exercise Performance and Recovery: A Narrative Review, Current developments in nutrition (2025) — Narrative review of 18 studies: 60% of performance studies and 78% of recovery studies reported positive effects from NZ blackcurrant (105-315 mg anthocyanins); remainder null or mixed. [https://pubmed.ncbi.nlm.nih.gov/39896729/]
  - Effects of black current anthocyanoside intake on dark adaptation and VDT work-induced transient refractive alteration in healthy humans, Alternative medicine review : a journal of clinical therapeutic (2000) — Blackcurrant anthocyanoside (50 mg) dose-dependently improved dark adaptation (P=0.011) and showed a protective trend against VDT-induced transient myopic shift (P=0.064) in healthy adults. [https://pubmed.ncbi.nlm.nih.gov/11134978/]

---

## Mulberry (Morus alba)
URL: https://nutridex.info/s/mulberry
Category: Fruits
Evidence: Moderate — Several controlled trials; effects real but modest or context-dependent.
Antioxidant berry whose leaf blunts sugar spikes

Quick answer: Mulberry is used for blunts post-meal glucose spikes (mulberry-leaf dnj inhibits intestinal alpha-glucosidase). NutriDex grades the human evidence as moderate — Several controlled trials; effects real but modest or context-dependent. Based on 8 cited human studies (8 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

The best-supported human effect of Morus alba is glycemic: a meta-analysis of 13 RCTs found mulberry-derived products significantly cut postprandial glucose at 30, 60 and 90 minutes, and controlled trials show standardized leaf extract (~12 mg 1-deoxynojirimycin) lowers the glucose and insulin rise after a sugar or carbohydrate-rich meal by roughly 20-40%. A 12-week dose-finding RCT in obese borderline-diabetics found small but significant reductions in fasting glucose (~3.9 mg/dL) and HbA1c (~0.11%), though glucose tolerance itself was unchanged. Crucially, most of this evidence comes from concentrated mulberry-LEAF extract, not the fresh fruit (a sweet berry); the fruit's glycemic value is inferred and far less studied. Lipid and longer-term cardiometabolic benefits remain inconsistent and unproven, and the same meta-analysis found no change in fasting glucose, HbA1c, HOMA-IR or any lipid marker. Trials are mostly small, short, industry-linked, and use varying extracts and doses, so effects on hard outcomes are unestablished. The fruit itself is a nutrient-dense, low-calorie berry notable for vitamin C and iron, but its specific health claims rest largely on extrapolation from leaf and in-vitro data.

Nutrition (per 1 cup (140 g)): 60 kcal; Vitamin C 51mg (57% DV), Iron 2.6mg (14% DV), Riboflavin (B2) 0.14mg (11% DV), Vitamin K 10.9mcg (9% DV), Vitamin E 1.2mg (8% DV), Potassium 272mg (6% DV), Magnesium 25mg (6% DV), Fiber 2.4g (9% DV).
Benefits / uses: Blunts post-meal glucose spikes (mulberry-leaf DNJ inhibits intestinal alpha-glucosidase); Modestly lowers fasting glucose and HbA1c in prediabetes/T2D over weeks; Reduces post-meal insulin demand when taken with carbohydrate; Good source of vitamin C and iron for a fresh berry; High anthocyanin/polyphenol content with antioxidant activity; May modestly improve lipid markers (preliminary, inconsistent).
Active compounds: 1-Deoxynojirimycin (DNJ) and related iminosugar alkaloids (leaf); Anthocyanins (cyanidin-3-glucoside, cyanidin-3-rutinoside); Flavonols (rutin, quercetin, kaempferol glycosides); Chlorogenic acid and other hydroxycinnamic acids; Vitamin C (ascorbic acid); Iron and other minerals (potassium, magnesium); Carotenoids and lutein+zeaxanthin; Resveratrol and stilbenes (bark/root, minor in fruit).
Dose: 1 cup fresh fruit (~140 g); glycemic trials use mulberry-leaf extract standardized to ~12 mg DNJ before carbohydrate meals
Safety: Generally recognized as safe as a food. Concentrated mulberry-leaf extracts commonly cause dose-dependent GI effects (bloating, flatulence, loose stools) from carbohydrate malabsorption. Because leaf DNJ lowers post-meal glucose, people on insulin or sulfonylureas should monitor for additive hypoglycemia and consult a clinician. Theoretical additive effect with acarbose/miglitol (same alpha-glucosidase mechanism). White mulberry pollen and fruit can trigger allergy in sensitized individuals; unripe fruit and other plant parts contain latex-like sap that may irritate. Safety of high-dose extracts in pregnancy/lactation is not established.

Cited studies (8):
  - A meta-analysis of efficacy of Morus alba Linn. to improve blood glucose and lipid profile, European Journal of Nutrition (2016) — Meta-analysis of 13 RCTs: Morus alba significantly reduced postprandial glucose at 30 min (MD -1.04 mmol/L), 60 min (-0.87) and 90 min (-0.55); no change in fasting glucose, HbA1c, HOMA-IR or any lipid marker. [https://doi.org/10.1007/s00394-016-1197-x]
  - Milk with Mulberry Leaf Extract, Vegetable Oil, and Inulin Reduce Early Glucose and Insulin Response in Healthy Adults in China: Randomized Controlled Trial, The Journal of Nutrition (2025) — Crossover RCT (28 analyzed) in healthy middle-aged Chinese adults: milk with mulberry-leaf extract, oil and inulin cut early (0-60 min) glucose iAUC by 25% and insulin by 22% vs skim milk; full 0-180 min glucose iAUC unchanged. [https://doi.org/10.1016/j.tjnut.2025.05.036]
  - A Novel Nutraceutical Supplement Lowers Postprandial Glucose and Insulin Levels upon a Carbohydrate-Rich Meal or Sucrose Drink Intake in Healthy Individuals—A Randomized, Placebo-Controlled, Crossover Feeding Study, Nutrients (2024) — Crossover RCT in 85 healthy adults: a white-mulberry-leaf + apple-peel extract before a sucrose drink reduced glucose iAUC by ~50% and before a carbohydrate meal by ~41% vs placebo over 120 min. [https://doi.org/10.3390/nu16142237]
  - Evaluation of the Postprandial-Hyperglycemia-Suppressing Effects and Safety of Short-Term Intake of Mulberry Leaf and Water Chestnut Tea: A Randomized Double-Blind Placebo-Controlled Crossover Trial, Nutrients (2025) — Double-blind placebo-controlled crossover RCT (n=31, CGM): 2 weeks of mulberry-leaf/water-chestnut tea before meals lowered glucose variability (CV) and 1-h postprandial glucose AUC, with no hypoglycemia or lab abnormalities. [https://doi.org/10.3390/nu17142308]
  - A randomized controlled study of dose-finding, efficacy, and safety of mulberry leaves on glycemic profiles in obese persons with borderline diabetes, Complementary Therapies in Medicine (2020) — 12-week RCT in obese borderline-diabetics: 12 mg mulberry-leaf DNJ thrice daily lowered fasting glucose by 3.86 mg/dL and HbA1c by 0.11%; GI side effects (bloating, flatulence, loose stools) were common; glucose tolerance unchanged. [https://doi.org/10.1016/j.ctim.2019.102292]
  - Effect of Different Nutritional Supplements on Glucose Response of Complete Meals in Two Crossover Studies, Nutrients (2022) — Crossover RCT with continuous glucose monitoring: 250 mg mulberry-leaf extract taken with a 510 kcal meal cut the postprandial glucose response by 34% (vs 26% when taken 5 min before). [https://doi.org/10.3390/nu14132674]
  - Effect of Mori ramulus on the postprandial blood glucose levels and inflammatory responses of healthy subjects subjected to an oral high-fat/sucrose challenge: A double-blind, randomized, crossover clinical trial, Biomedicine &amp; Pharmacotherapy (2022) — Double-blind crossover RCT (n=36 healthy): single dose of Mori ramulus (mulberry twig) extract lowered blood glucose at 240 min after a high-fat/sucrose challenge and modulated insulin and inflammatory markers. [https://doi.org/10.1016/j.biopha.2021.112552]
  - Food-Grade Mulberry Powder Enriched with 1-Deoxynojirimycin Suppresses the Elevation of Postprandial Blood Glucose in Humans, Journal of Agricultural and Food Chemistry (2007) — RCT in healthy adults: single 0.8-1.2 g dose of DNJ-enriched mulberry powder (12-18 mg DNJ) before 50 g sucrose significantly suppressed both the postprandial glucose rise and insulin secretion. [https://doi.org/10.1021/jf062680g]

---

## Dragon Fruit (Pitaya) (Hylocereus undatus / H. polyrhizus)
URL: https://nutridex.info/s/dragon-fruit-pitaya
Category: Fruits
Evidence: Preliminary — Early or small human trials; promising but not yet conclusive.
Betalain-rich cactus fruit for vascular health

Quick answer: Dragon Fruit (Pitaya) is used for improved endothelial/vascular function (flow-mediated dilation, pulse-wave velocity, arterial stiffness) in a single small controlled human crossover trial using betalain-rich fruit powder. NutriDex grades the human evidence as preliminary — Early or small human trials; promising but not yet conclusive. Based on 9 cited human studies (9 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Dragon fruit is a low-calorie, fiber- and vitamin-C-containing cactus fruit whose red-fleshed varieties are notably rich in betalain pigments and phenolic acids with strong in-vitro antioxidant activity. The strongest human data come from a single double-blind randomized crossover trial (n=18) in which 24 g betalain-rich dragon fruit powder (~33 mg betalains) daily for 14 days improved flow-mediated dilation, acutely reduced pulse-wave velocity, and improved augmentation index, suggesting a real but modest vascular benefit. A 2017 meta-analysis of four small RCTs found a significant fasting-glucose reduction in prediabetes (−15.1 mg/dL) but no significant effect in established type 2 diabetes. Dragon fruit oligosaccharides showed prebiotic and immune (IgA) effects in a rat study and a small human trial, and small trials/reviews hint at favorable lipid changes. However, the overall human evidence base is thin: trials are few, small, short, mostly from a handful of research groups, and heterogeneous in form (fresh fruit vs. powder vs. isolated oligosaccharides). Long-term outcomes and effects from realistic dietary portions of whole fruit remain largely unproven, so claims should be considered preliminary.

Nutrition (per 1 medium (227 g)): 129 kcal; Fiber 7g (25% DV), Vitamin C 9.8mg (11% DV), Magnesium 15.9mg (4% DV), Iron 0.41mg (2% DV), Potassium 263mg (6% DV), Calcium 20.4mg (2% DV).
Benefits / uses: Improved endothelial/vascular function (flow-mediated dilation, pulse-wave velocity, arterial stiffness) in a single small controlled human crossover trial using betalain-rich fruit powder; May lower fasting glucose in prediabetes (small meta-analysis); effect in established type 2 diabetes not significant; Prebiotic oligosaccharides increased Bifidobacterium and boosted IgA (rat study and a small human trial); High in-vitro antioxidant capacity from betalains and phenolic acids (cell/chemical assays, not human outcomes); Possible favorable lipid changes (LDL/total cholesterol, HDL) suggested by small trials and reviews; Modest dietary fiber and vitamin C contribution to digestive and immune support.
Active compounds: Betacyanins (betanin, phyllocactin/6'-O-malonylbetanin, isophyllocactin) — red-flesh pigments; Phenolic acids (p-coumaric, vanillic, gallic, ferulic acid); Flavonoids (kaempferol, quercetin glycosides); Vitamin C (ascorbic acid); Soluble & insoluble dietary fiber; Prebiotic oligosaccharides (dragon fruit oligosaccharides, DFO); Minerals (magnesium, potassium, iron); Betaxanthins (yellow-orange pigments).
Dose: 1 medium fruit (~200-230 g) fresh pulp daily; the vascular trial used ~24 g whole-fruit powder (~33 mg betalains)
Safety: Generally safe as a food. Harmless red/pink discoloration of urine and stool (pseudohematuria, beeturia-like) can occur after eating red-fleshed pitaya and may be mistaken for blood. Rare IgE-mediated allergic reactions, including anaphylaxis, have been reported. Large amounts of the prebiotic oligosaccharides or high fiber intake may cause bloating, gas, or loose stools. Theoretical additive effect with glucose-lowering or blood-pressure medications—monitor if consuming large or supplemental quantities. Seeds are eaten whole and pass undigested.

Cited studies (9):
  - Anti-Inflammatory, Antioxidant, and Other Health Effects of Dragon Fruit and Potential Delivery Systems for Its Bioactive Compounds, Pharmaceutics (2023) — PRISMA systematic review identifying 5 human trials (all H. polyrhizus) reporting improved glycemia, lipid profile, antioxidant status, and vascular function; concludes human evidence is promising but limited. [https://pmc.ncbi.nlm.nih.gov/articles/PMC9861186/]
  - Effect of dragon fruit on glycemic control in prediabetes and type 2 diabetes: A systematic review and meta-analysis, PloS one (2017) — Systematic review/meta-analysis of 4 RCTs (36 prediabetes, 109 T2DM): significant fasting-glucose reduction in prediabetes (MD -15.1 mg/dL, P=0.0006) but no significant effect in established T2DM (MD -26.5 mg/dL, P=0.26). [https://pmc.ncbi.nlm.nih.gov/articles/PMC5590977/]
  - Effects of dragon fruit oligosaccharides on immunity, gut microbiome, and their metabolites in healthy adults – A randomized double-blind placebo controlled study, Food Research International (2023) — Randomized double-blind placebo-controlled trial in healthy adults: dragon fruit oligosaccharides increased plasma IgA and promoted Bifidobacterium growth, supporting prebiotic and immune effects. [https://doi.org/10.1016/j.foodres.2023.112657]
  - Betalain-rich dragon fruit (pitaya) consumption improves vascular function in men and women: a double-blind, randomized controlled crossover trial, The American journal of clinical nutrition (2022) — Double-blind RCT crossover (n=18): 24 g betalain-rich dragon fruit powder/day (~33 mg betalains) x14 days improved flow-mediated dilation, acutely reduced pulse-wave velocity, and improved augmentation index after 14 days; no change in blood pressure. [https://pubmed.ncbi.nlm.nih.gov/35265960/]
  - Nutritional composition, phytochemical profile, and health benefits of <i>Hylocereus Undatus</i> (pitaya): A comprehensive review, eFood (2024) — Comprehensive review of H. undatus nutritional composition and phytochemical profile detailing betalains, phenolic acids, flavonoids, fiber, and reported antioxidant, antidiabetic, anti-obesity and lipid-lowering activities. [https://iadns.onlinelibrary.wiley.com/doi/full/10.1002/efd2.70017]
  - Maturation Process, Nutritional Profile, Bioactivities and Utilisation in Food Products of Red Pitaya Fruits: A Review, Foods (Basel, Switzerland) (2021) — Review of red pitaya maturation, nutritional profile and bioactivities documenting rising betalain, phenolic and flavonoid content with ripening and associated antioxidant and metabolic (glycemic, anti-fatty-liver) effects. [https://pmc.ncbi.nlm.nih.gov/articles/PMC8618204/]
  - Gut microbiota modulation and immune boosting properties of prebiotic dragon fruit oligosaccharides, International Journal of Food Science & Technology (2019) — Prebiotic activity of dragon fruit oligosaccharides demonstrated in rats: selectively increased faecal bifidobacteria and lactobacilli while decreasing bacteroides and clostridia, with immune (IgA/IgG) boosting. [https://ifst.onlinelibrary.wiley.com/doi/abs/10.1111/ijfs.14230]
  - Betacyanins and Anthocyanins in Pulp and Peel of Red Pitaya (Hylocereus polyrhizus cv. Jindu), Inhibition of Oxidative Stress, Lipid Reducing, and Cytotoxic Effects, Frontiers in nutrition (2022) — Betacyanins/anthocyanins from red pitaya (H. polyrhizus cv. Jindu) pulp and peel inhibited H2O2-induced oxidative stress, reduced lipid accumulation in adipocytes, and showed cytotoxic effects in cell models; peel had higher antioxidant capacity than pulp. [https://pmc.ncbi.nlm.nih.gov/articles/PMC9260171/]
  - Metabolite Profiling of Red and White Pitayas (Hylocereus polyrhizus and Hylocereus undatus) for Comparing Betalain Biosynthesis and Antioxidant Activity, Journal of Agricultural and Food Chemistry (2014) — Metabolite profiling (UPLC-QTOF-MS) of red vs. white pitayas identified phyllocactin (6'-O-malonylbetanin) and related betacyanins in red pitaya, correlating with higher antioxidant activity vs. white pitaya. [https://pubs.acs.org/doi/10.1021/jf5020704]

---

## Starfruit (Carambola) (Averrhoa carambola)
URL: https://nutridex.info/s/starfruit-carambola
Category: Fruits
Evidence: Preliminary — Early or small human trials; promising but not yet conclusive.
Crisp tropical star, safe only with healthy kidneys

Quick answer: Starfruit (Carambola) is used for low-calorie, high-water fruit useful for weight-conscious and hydration-focused diets. NutriDex grades the human evidence as preliminary — Early or small human trials; promising but not yet conclusive. Based on 10 cited human studies (10 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Starfruit is a low-calorie, water-dense tropical fruit that delivers a useful dose of vitamin C (about a third of the Daily Value per fruit) and insoluble fiber, plus a broad mix of flavonoids and phenolic acids with antioxidant activity in laboratory assays. The most robust human evidence about starfruit, however, concerns harm rather than benefit: dozens of case reports and case series document severe nephrotoxicity and neurotoxicity—intractable hiccups, vomiting, confusion, seizures, status epilepticus, and death—after ingestion by people with chronic kidney disease, and occasionally those with normal or only mildly impaired renal function. A 2013 chemistry study isolated caramboxin, a phenylalanine-like toxin that activates glutamatergic (AMPA/kainate) receptors and inhibits the GABAergic system, explaining the neurological effects, while high soluble oxalate drives oxalate nephropathy. The widely cited metabolic and anti-diabetic \"benefits\" come almost exclusively from in-vitro and rodent experiments; there are essentially no controlled human trials confirming any therapeutic effect. Overall the weight of human evidence is preliminary for benefits and clearer for risk. For most people with healthy kidneys, normal culinary amounts are considered safe and nutritious. Anyone with reduced kidney function or on dialysis should avoid it completely.

Nutrition (per 1 medium (91 g)): 28 kcal; Vitamin C 31.3mg (35% DV), Fiber 2.5g (9% DV), Copper 0.13mg (14% DV), Potassium 121mg (3% DV), Folate 11mcg (3% DV), Pantothenic acid 0.36mg (7% DV).
Benefits / uses: Low-calorie, high-water fruit useful for weight-conscious and hydration-focused diets; Meaningful vitamin C contribution (about a third of the Daily Value per fruit) supporting antioxidant defense and collagen synthesis; Dietary fiber (largely insoluble) that may aid satiety and bowel regularity; Rich source of polyphenols and flavonoids with antioxidant activity in lab models; Preclinically studied anti-hyperglycemic and anti-hyperlipidemic actions (animal/in-vitro only); Traditionally used as a cooling, thirst-quenching food in tropical cuisines.
Active compounds: Vitamin C (L-ascorbic acid); Soluble oxalate / oxalic acid (anti-nutrient and nephrotoxin); Caramboxin (phenylalanine-like excitatory neurotoxin); Flavonoid glycosides (apigenin C-glycosides, quercetin, rutin); Proanthocyanidins / condensed tannins; Benzoquinone derivatives (e.g. 2-dodecyl-6-methoxycyclohexa-2,5-diene-1,4-dione); Insoluble dietary fiber (cellulose, lignin); Gallic acid and other phenolic acids; Potassium and copper.
Dose: 1 medium fruit (~91 g) or ~100 g sliced; avoid entirely in chronic kidney disease
Safety: CONTRAINDICATED in chronic kidney disease, end-stage renal disease, and dialysis patients—even a single fruit or glass of juice can trigger hiccups, vomiting, confusion, seizures, status epilepticus, and death (caramboxin neurotoxin plus oxalate nephropathy). Toxicity has also been reported with normal-to-moderate renal function, especially when consumed on an empty stomach, dehydrated, or in large quantity/concentrated juice. High oxalate content poses a kidney-stone risk in susceptible individuals and can cause acute oxalate nephropathy. Like grapefruit, starfruit inhibits CYP3A4 and can raise blood levels of interacting drugs (e.g. statins, certain calcium-channel blockers). If neurological symptoms appear after ingestion in a renal patient, urgent hemodialysis/hemofiltration is the recommended treatment.

Cited studies (10):
  - Nephrotoxicity and neurotoxicity following star fruit (<i>Averrhoa carambola</i>) ingestion: a narrative review, Transactions of The Royal Society of Tropical Medicine and Hygiene (2021) — Narrative review of human reports (28 case reports plus 10 case series; 136 individuals): 69.1% had prior renal impairment; renal histology showed acute oxalate nephropathy, and neurotoxicity ranged from hiccups to status epilepticus, improving with hemodialysis. [https://doi.org/10.1093/trstmh/trab026]
  - Mechanisms of star fruit (Averrhoa carambola) toxicity: A mini-review, Toxicon (2020) — Mechanistic mini-review: nephrotoxicity attributed to oxalate deposition causing acute tubular necrosis and interstitial nephritis, while caramboxin drives CNS excitation via glutamate-receptor activation and GABA inhibition. [https://doi.org/10.1016/j.toxicon.2020.09.010]
  - Traditional Uses, Phytochemical Constituents and Pharmacological Properties of Averrhoa carambola L.: A Review, Frontiers in Pharmacology (2021) — Comprehensive review cataloguing ~132 isolated compounds (flavonoids, benzoquinones, glycosides) and antioxidant, anti-hyperglycemic, anti-hyperlipidemic and neuroprotective activities, while noting evidence is almost entirely in-vitro/animal with a gap in clinical and safety data. [https://doi.org/10.3389/fphar.2021.699899]
  - Why eating star fruit is prohibited for patients with chronic kidney disease?, Jornal Brasileiro de Nefrologia (2015) — Review concluding that star fruit neurotoxicity in chronic kidney disease is driven by caramboxin inhibiting the GABAergic system, producing effects from hiccups and confusion to seizures and death, and arguing for multidisciplinary patient warnings. [https://doi.org/10.5935/0101-2800.20150037]
  - Neurotoxicity following the Ingestion of Bilimbi Fruit (Averrhoa bilimbi) in an End-Stage Renal Disease Patient on Hemodialysis, Case Reports in Nephrology and Dialysis (2017) — Hemodialysis patient developed intractable hiccups, myoclonus and tonic-clonic seizures after bilimbi (Averrhoa bilimbi), a related Oxalidaceae fruit, supporting a shared caramboxin/oxalate neurotoxic mechanism with star fruit. [https://doi.org/10.1159/000454945]
  - Severe encephalopathy after ingestion of star fruit juice in a patient with chronic renal failure admitted to the intensive care unit, Heart &amp; Lung (2010) — Fatal case of severe encephalopathy with nausea, vomiting, intractable hiccups, confusion and seizures after star fruit juice in chronic renal failure; patient died despite hemodialysis, highlighting under-recognition by intensivists. [https://doi.org/10.1016/j.hrtlng.2009.09.003]
  - Star fruit intoxication in a patient with moderate renal insufficiency presents as a posterior reversible encephalopathy syndrome, Acta neurologica Taiwanica (2010) — 67-year-old with only moderate renal insufficiency developed hiccups, coma and seizures with a reversible occipital lesion (PRES) two hours after eating one fresh star fruit, reversing after emergency hemodialysis. [https://pubmed.ncbi.nlm.nih.gov/21210331/]
  - Intoxication by star fruit (Averrhoa carambola) in 32 uraemic patients: treatment and outcome, Nephrology Dialysis Transplantation (2003) — Series of 32 uremic patients intoxicated by star fruit: intractable hiccups in 93.75%, vomiting 68.7%, disturbed consciousness 65.6%, seizures 21.8%; prompt daily hemodialysis led to recovery while peritoneal dialysis/supportive care alone was often fatal. [https://doi.org/10.1093/ndt/18.1.120]
  - [Star fruit (Averrhoa carambola) toxic encephalopathy], Revue neurologique (2009) — Two patients with previously unknown chronic renal insufficiency developed intractable hiccups, status epilepticus and cortical/thalamic MRI lesions after star fruit; both improved with continuous hemofiltration. [https://pubmed.ncbi.nlm.nih.gov/18755486/]
  - Elucidating the Neurotoxicity of the Star Fruit, Angewandte Chemie International Edition (2013) — Isolated and characterized caramboxin, a phenylalanine-like neurotoxin from star fruit that activates glutamatergic AMPA/kainate receptors and inhibits the GABAergic system, explaining the seizures seen in intoxication. [https://doi.org/10.1002/anie.201305382]

---

## Coconut (Cocos nucifera)
URL: https://nutridex.info/s/coconut
Category: Fruits
Evidence: Mixed — Conflicting results across studies; benefit uncertain.
High-saturated-fat tropical drupe with electrolyte-rich water

Quick answer: Coconut is used for raises hdl cholesterol (and often ldl/total cholesterol) via medium-chain saturated fats. NutriDex grades the human evidence as mixed — Conflicting results across studies; benefit uncertain. Based on 8 cited human studies (8 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Coconut is a calorie- and fat-dense drupe whose nutrition differs sharply by form (meat, oil, water, milk). The best human evidence concerns coconut oil: a 2020 Circulation meta-analysis of 16 trials found it raised LDL cholesterol by about 10 mg/dL and HDL by about 4 mg/dL versus non-tropical vegetable oils, so it is not heart-protective relative to unsaturated fats. A 2022 meta-analysis (7 RCTs) found no clinically relevant lipid or body-composition benefit at very-low GRADE certainty, while a 2025 meta-analysis of virgin-coconut-oil RCTs found favorable triglyceride and HDL shifts but no glucose benefit. Coconut water performs about as well as carbohydrate-electrolyte sports drinks for rehydration in small crossover trials, with no clear advantage and occasional GI upset. Claims that coconut oil or MCTs improve cognition in dementia rest on small, short trials that reliably raise ketones but show only inconsistent cognitive effects judged insufficient for clinical use. Most cardiovascular and metabolic outcome data are short-term, small, and at high risk of bias, with no trials of hard endpoints such as heart attack or stroke. The fresh meat does provide useful fiber and trace minerals, but its very high saturated-fat content warrants moderation.

Nutrition (per 1 cup shredded (80 g)): 283 kcal; Saturated fat 23.8g (119% DV), Fiber 7.2g (26% DV), Manganese 1.2mg (52% DV), Copper 0.35mg (39% DV), Iron 1.9mg (11% DV), Potassium 285mg (6% DV), Phosphorus 91mg (7% DV).
Benefits / uses: Raises HDL cholesterol (and often LDL/total cholesterol) via medium-chain saturated fats; Coconut water rehydrates comparably to sports drinks after exercise, with no clear advantage; High dietary fiber from the meat supports satiety and bowel regularity; MCT/ketone production proposed for cognition (unproven for whole coconut); Lauric acid has in-vitro antimicrobial activity (no clinical outcomes); Source of manganese, copper and other trace minerals.
Active compounds: Medium-chain saturated fatty acids (lauric C12, myristic C14, caprylic C8); Lauric acid / monolaurin (antimicrobial in vitro); Insoluble dietary fiber (mannans, cellulose); Potassium and magnesium electrolytes (concentrated in coconut water); Manganese and copper (trace-mineral cofactors); Polyphenols (gallic, caffeic, salicylic acids); Cytokinins and L-arginine (coconut water); Tocopherols and tocotrienols (vitamin E forms).
Dose: 1 cup shredded fresh meat (~80 g) or ~240 mL coconut water; coconut oil should be limited like other saturated fats
Safety: Very high in saturated fat (coconut oil ~80-90%; meat ~89% of its fat): major heart and dietary guidelines (AHA, WHO) advise limiting it. It raises LDL more than unsaturated oils and should not be promoted as a "healthy fat" for cardiovascular disease. Coconut is a recognized tree-nut-category allergen in some jurisdictions and can trigger reactions. Coconut water is high in potassium—people with chronic kidney disease or on potassium-sparing/RAAS medications should be cautious of hyperkalemia. Energy-dense; easy to overconsume calories.

Cited studies (8):
  - The effect of virgin coconut oil (VCO) on cardiovascular disease risk factors: a systematic review and meta-analysis, Diabetology & metabolic syndrome (2025) — Meta-analysis of 14 RCTs (n=1049): virgin coconut oil lowered triglycerides ~12 mg/dL and raised HDL-C ~7.9 mg/dL but did not lower fasting glucose. [https://pmc.ncbi.nlm.nih.gov/articles/PMC12729059/]
  - The Effect of Coconut Oil Consumption on Cardiovascular Risk Factors: A Systematic Review and Meta-Analysis of Clinical Trials, Circulation (2020) — Meta-analysis of 16 trials: coconut oil raised LDL-C by 10.47 mg/dL, total cholesterol 14.69 mg/dL and HDL-C 4.00 mg/dL vs non-tropical vegetable oils; no trials of CVD events. [https://pubmed.ncbi.nlm.nih.gov/31928080/]
  - The effects of coconut oil on the cardiometabolic profile: a systematic review and meta-analysis of randomized clinical trials, Lipids in health and disease (2022) — Meta-analysis (7 RCTs, n=515): coconut oil produced no clinically relevant lipid or body-composition benefit vs other fats (LDL-C MD -1.67 mg/dL; HDL-C +3.28 mg/dL); very-low certainty (GRADE). [https://pmc.ncbi.nlm.nih.gov/articles/PMC9429773/]
  - Coconut oil consumption and cardiovascular risk factors in humans, Nutrition reviews (2016) — Review of 21 studies: coconut oil raised total and LDL cholesterol more than cis-unsaturated plant oils but less than butter; observational evidence rated very poor quality. [https://pubmed.ncbi.nlm.nih.gov/26946252/]
  - Use of medium chain triglyceride (MCT) oil in subjects with Alzheimer's disease: A randomized, double-blind, placebo-controlled, crossover study, with an open-label extension, Alzheimer's & dementia (New York, N. Y.) (2022) — Double-blind placebo-controlled crossover MCT-oil trial in Alzheimer's disease (n=20): ketogenic MCT oil produced modest attention/psychomotor gains proportional to dose; no effect of APOE e4 status on response. [https://pubmed.ncbi.nlm.nih.gov/35310527/]
  - Comparison of coconut water and a carbohydrate-electrolyte sport drink on measures of hydration and physical performance in exercise-trained men, Journal of the International Society of Sports Nutrition (2012) — Randomized single-blind crossover (n=12 trained men): coconut water and coconut-water concentrate gave hydration and treadmill performance equivalent to a carbohydrate-electrolyte sports drink and water; more bloating reported. [https://pmc.ncbi.nlm.nih.gov/articles/PMC3293068/]
  - Coconut Oil and Cardiovascular Disease Risk, Current atherosclerosis reports (2023) — Narrative review: coconut oil's lipid effects depend on the comparator fat (worse than cis-unsaturated oils, better than butter); no RCT or cohort has tested clinical cardiovascular events. [https://pmc.ncbi.nlm.nih.gov/articles/PMC10182109/]
  - Dietary Fats and Cardiovascular Disease: A Presidential Advisory From the American Heart Association, Circulation (2017) — Pooled controlled trials found coconut oil raised LDL cholesterol versus unsaturated oils; AHA advises against its use to lower cardiovascular risk. [https://www.ahajournals.org/doi/10.1161/CIR.0000000000000510]

---

## Olives (Olea europaea)
URL: https://nutridex.info/s/olives
Category: Fruits
Evidence: Moderate — Several controlled trials; effects real but modest or context-dependent.
Brined Mediterranean fruit rich in oleic acid and polyphenols

Quick answer: Olives is used for cardiovascular support: olive intake (and olive oil from the same fruit) is associated with lower risk of cardiovascular disease in large prospective cohorts. NutriDex grades the human evidence as moderate — Several controlled trials; effects real but modest or context-dependent. Based on 9 cited human studies (9 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

The human evidence for olives sits largely within the broader olive-fruit/olive-oil and Mediterranean-diet literature rather than table olives studied in isolation. Large prospective cohorts and meta-analyses consistently link higher olive oil consumption to lower cardiovascular disease and all-cause mortality (roughly 15-16% lower CVD risk per ~25 g/day, with benefit plateauing near 20 g/day), and the PREDIMED randomized trial showed a Mediterranean diet supplemented with extra-virgin olive oil reduced major cardiovascular events. Randomized crossover trials (e.g., EUROLIVE) demonstrate that the phenolic fraction—hydroxytyrosol and oleuropein—modestly raises HDL and lowers oxidized LDL in a dose-dependent manner, and olive-leaf extract RCTs and meta-analyses show small but real reductions in systolic blood pressure and triglycerides. However, most high-quality trials use olive oil or concentrated olive-leaf extracts, not whole brined table olives, so direct causal evidence for table olives specifically is limited and effect sizes are modest. Table olives also carry a large sodium load from brining that is absent from olive oil, which complicates extrapolation. Overall the evidence is best graded moderate: biologically plausible, supported by consistent observational data and supportive mechanistic RCTs, but with limited whole-fruit-specific trials.

Nutrition (per 1 serving (15 g, ~5 medium olives)): 17 kcal; Total fat 1.6g (2% DV), Sodium 110mg (5% DV), Fiber 0.48g (2% DV), Vitamin E 0.25mg (2% DV), Iron 0.49mg (3% DV), Calcium 13mg (1% DV).
Benefits / uses: Cardiovascular support: olive intake (and olive oil from the same fruit) is associated with lower risk of cardiovascular disease in large prospective cohorts; Improved lipid profile: olive/olive-leaf polyphenols modestly raise HDL and lower triglycerides and oxidized LDL in RCTs; Blood-pressure lowering, shown for olive-leaf extract (oleuropein-rich) in randomized trials, especially in hypertensive adults; Antioxidant activity: hydroxytyrosol and oleuropein reduce LDL oxidative damage in human crossover studies; Anti-inflammatory effects: reductions in CRP and select inflammatory cytokines reported with olive polyphenols; Source of monounsaturated fat (oleic acid) that supports favorable substitution for butter, margarine and dairy fat.
Active compounds: Monounsaturated fatty acids (oleic acid); Secoiridoid polyphenols (oleuropein, ligstroside); Simple phenols (hydroxytyrosol, tyrosol); Phenolic acids and flavonoids (luteolin, apigenin, verbascoside); Triterpenes (maslinic acid, oleanolic acid); Vitamin E (alpha-tocopherol); Dietary fiber (insoluble + pectin); Minerals (sodium from brine, iron, calcium, copper); Carotenoids and chlorophylls (in green/ripe pigment fraction).
Dose: About 15 g (4-5 medium olives) as a typical serving; Mediterranean-diet intakes of olives and olive oil cluster around 20-25 g/day of olive oil equivalent
Safety: High sodium is the main concern—brined/canned olives can carry roughly 700-900 mg sodium per 100 g (USDA: ~735 mg/100 g for ripe canned), relevant for hypertension and salt-restricted diets. Olives are calorie- and fat-dense for their size. Rare reports of allergy to olive fruit/pollen exist. Olive-leaf extracts (used in BP studies) may have additive blood-pressure- and glucose-lowering effects with antihypertensive and antidiabetic medications and are not interchangeable with eating olives. Pitted-olive products can still contain pit fragments (dental/choking risk). Acrylamide and, historically, ferrous-gluconate darkening agents are processing considerations in some ripe black olives.

Cited studies (9):
  - Effect of olive oil consumption on cardiovascular disease, cancer, type 2 diabetes, and all-cause mortality: A systematic review and meta-analysis, Clinical Nutrition (2022) — Systematic review & meta-analysis (27 studies; ~800,000+ participants): each additional 25 g/day olive oil associated with 16% lower CVD risk (RR 0.84, 95% CI 0.76-0.94), 22% lower type 2 diabetes risk (RR 0.78), and 11% lower all-cause mortality (RR 0.89); no association with cancer [https://doi.org/10.1016/j.clnu.2022.10.001]
  - Olive oil consumption and risk of cardiovascular disease and all-cause mortality: A meta-analysis of prospective cohort studies, Frontiers in Nutrition (2022) — Meta-analysis of prospective cohorts: highest vs lowest olive oil intake associated with 15% lower CVD risk (RR 0.85, 95% CI 0.77-0.93) and 17% lower all-cause mortality (RR 0.83, 95% CI 0.77-0.90), with benefit plateauing near 20 g/day [https://doi.org/10.3389/fnut.2022.1041203]
  - The effects of olive leaf extract on cardiovascular risk factors in the general adult population: a systematic review and meta-analysis of randomized controlled trials, Diabetology &amp; Metabolic Syndrome (2022) — Meta-analysis of 12 RCTs (n=819): olive-leaf extract lowered systolic BP by 3.86 mmHg and triglycerides by 9.51 mg/dL overall, with larger lipid and BP reductions in hypertensive subgroups [https://doi.org/10.1186/s13098-022-00920-y]
  - Efficacy of olive leaf extracts in controlling blood pressure in hypertensive patients: a double-blind randomized clinical trial, Journal of Hypertension (2025) — Double-blind RCT (n=621 hypertensives): olive-leaf extract reduced 24-h systolic BP by 6.4 mmHg vs baseline (95% CI -10 to -2.1) and improved lipids, glucose, CRP and body weight with no significant adverse events [https://doi.org/10.1097/HJH.0000000000004141]
  - Primary Prevention of Cardiovascular Disease with a Mediterranean Diet Supplemented with Extra-Virgin Olive Oil or Nuts, New England Journal of Medicine (2018) — PREDIMED RCT (n=7,447, republished after methodological correction): Mediterranean diet supplemented with extra-virgin olive oil reduced major cardiovascular events (HR ~0.69 vs control diet) [https://doi.org/10.1056/NEJMoa1800389]
  - Impact of phenolic-rich olive leaf extract on blood pressure, plasma lipids and inflammatory markers: a randomised controlled trial, European Journal of Nutrition (2016) — Crossover RCT in 60 pre-hypertensive men: phenolic-rich olive-leaf extract (~136 mg oleuropein) lowered 24-h systolic BP by 3.3 mmHg, total cholesterol by 0.32 mmol/L, LDL by 0.19 mmol/L and triglycerides by 0.18 mmol/L vs control [https://doi.org/10.1007/s00394-016-1188-y]
  - The Effect of Polyphenols in Olive Oil on Heart Disease Risk Factors, Annals of Internal Medicine (2006) — EUROLIVE crossover RCT (n=200 men): olive oil HDL cholesterol rose linearly with phenolic content and oxidized LDL markers fell progressively, showing benefit beyond monounsaturated fat alone [https://doi.org/10.7326/0003-4819-145-5-200609050-00006]
  - Olive Oil Intake and Cardiovascular Disease Prevention: “Seek and You Shall Find”, Current Cardiology Reports (2021) — Narrative review summarizing that olive oil monounsaturated fat and phenolic antioxidants improve oxidative stress, endothelial function, blood pressure and lipid/carbohydrate metabolism, supporting CHD/CVD prevention [https://doi.org/10.1007/s11886-021-01496-1]
  - Olive Oil Consumption and Cardiovascular Risk in U.S. Adults, Journal of the American College of Cardiology (2020) — In ~93,000 US adults (Nurses' Health Study + Health Professionals Follow-up) over 24 years, >7 g/day olive oil intake was associated with 14% lower total CVD risk (HR 0.86) and 18% lower CHD risk; replacing margarine/butter/mayonnaise/dairy fat with olive oil lowered CVD risk 5-7% [https://doi.org/10.1016/j.jacc.2020.02.036]

---

## Plantain (Musa × paradisiaca)
URL: https://nutridex.info/s/plantain
Category: Fruits
Evidence: Moderate — Several controlled trials; effects real but modest or context-dependent.
Starchy cooking banana rich in potassium

Quick answer: Plantain is used for potassium-driven blood-pressure and stroke-risk reduction (nutrient-level evidence). NutriDex grades the human evidence as moderate — Several controlled trials; effects real but modest or context-dependent. Based on 8 cited human studies (8 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Plantain is a starchy cooking banana whose health relevance rests mainly on its nutrient and starch composition rather than on disease trials of the fruit itself. It is a strong potassium source, and high-quality meta-analyses link higher potassium intake (around 90 mmol/3,500 mg per day) to lower stroke risk and modest blood-pressure reduction in hypertensive adults. Unripe green plantain is rich in resistant starch (type 2); a meta-analysis of 19 RCTs found resistant starch modestly lowers fasting glucose and HOMA-insulin resistance, especially above ~28 g/day, though most trials used isolated/maize/wheat starch, not plantain. Its dietary fiber aligns with prospective and umbrella-review evidence connecting higher fiber intake to lower cardiovascular and all-cause mortality. The most direct fruit-specific trial showed a cooked green-plantain diet shortened persistent diarrhea in hospitalized children versus a yogurt diet. Key limits: few randomized trials test plantain directly, ripeness dramatically changes starch versus sugar content, and most benefits are extrapolated from its constituent nutrients rather than whole-fruit endpoints.

Nutrition (per 1 medium, raw (179 g)): 218 kcal; Potassium 893mg (19% DV), Vitamin C 33mg (37% DV), Vitamin B6 0.54mg (32% DV), Magnesium 66mg (16% DV), Vitamin A 100mcg RAE (11% DV), Fiber 4.1g (15% DV).
Benefits / uses: Potassium-driven blood-pressure and stroke-risk reduction (nutrient-level evidence); Resistant starch in unripe/green fruit blunts postprandial glucose and improves insulin resistance; Dietary fiber contributes to cardiovascular and all-cause mortality risk reduction; Adjunct dietary management of persistent diarrhea (green-plantain diets in children); Fermentable starch supports gut microbiota and short-chain fatty acid (butyrate) production; Provides vitamin B6, vitamin C and magnesium toward daily micronutrient needs.
Active compounds: Resistant starch (RS2) — high in unripe/green fruit, declines with ripening; Potassium (electrolyte mineral); Dietary fiber including pectin and cellulose; Vitamin B6 (pyridoxine); Vitamin C (ascorbic acid); Provitamin-A carotenoids (beta-carotene, alpha-carotene, lutein); Phenolic compounds (ferulic acid, gallic/catechin-type polyphenols); Magnesium; Free and resistant maltose/sugars formed on ripening.
Dose: 1 medium plantain (~179 g); culinary staple eaten cooked — boiled, fried, or roasted — typically green (starchy) or ripe (sweet). Nutrition figures below are for raw fruit; cooking (especially frying) concentrates calories and alters starch/sugar balance.
Safety: Generally safe as a food. Plantain is high in potassium, so people with advanced chronic kidney disease or on potassium-sparing/RAAS-blocking medications should moderate intake to avoid hyperkalemia. Ripe and especially fried plantain is calorie- and sugar-dense and raises postprandial glucose, relevant for diabetes and weight management; green/boiled forms have a lower glycemic impact. Fried preparations add substantial fat and calories. Banana/plantain (Musa) allergy and latex-fruit cross-reactivity are uncommon but possible.

Cited studies (8):
  - Effects of resistant starch on glycaemic control: a systematic review and meta-analysis, British Journal of Nutrition (2020) — Meta-analysis of 19 RCTs: resistant starch lowered fasting glucose (-0.09 mmol/L) and HOMA-IR (-0.33), with larger effects above 28 g/day or >8 weeks. [https://doi.org/10.1017/S0007114520003700]
  - Meta-Analysis of Potassium Intake and the Risk of Stroke, Journal of the American Heart Association (2016) — Dose-response meta-analysis of 16 cohorts: higher potassium intake associated with lower stroke risk, with the lowest risk at ~90 mmol (~3,500 mg)/day. [https://pubmed.ncbi.nlm.nih.gov/27792643/]
  - Carbohydrate quality and human health: a series of systematic reviews and meta-analyses, The Lancet (2019) — Lancet systematic reviews/meta-analyses: highest vs lowest fiber intake gave 15-30% lower CVD and all-cause mortality; benefit greatest at 25-29 g/day fiber. [https://doi.org/10.1016/S0140-6736(18)31809-9]
  - Dietary fiber and health outcomes: an umbrella review of systematic reviews and meta-analyses, The American Journal of Clinical Nutrition (2018) — Umbrella review of 298 prospective studies: dietary fiber intake showed highly significant evidence for lower CVD and CVD mortality. [https://doi.org/10.1093/ajcn/nqx082]
  - Effect of increased potassium intake on cardiovascular risk factors and disease: systematic review and meta-analyses, BMJ (2013) — Meta-analysis (BMJ): higher potassium cut systolic BP 3.49 mmHg in hypertensives and was linked to 24% lower stroke risk, without adverse renal/lipid effects. [https://doi.org/10.1136/bmj.f1378]
  - Potassium Intake, Stroke, and Cardiovascular Disease, Journal of the American College of Cardiology (2011) — Meta-analysis of 11 prospective studies (247,510 adults): 1.64 g/day higher potassium intake associated with 21% lower stroke risk. [https://doi.org/10.1016/j.jacc.2010.09.070]
  - Resistant Starch Type 2 from Wheat Reduces Postprandial Glycemic Response with Concurrent Alterations in Gut Microbiota Composition, Nutrients (2021) — Double-blind crossover RCT: resistant starch type 2 (from wheat) reduced postprandial glucose and insulin and shifted gut microbiota/fermentation vs conventional starch. [https://doi.org/10.3390/nu13020645]
  - Beneficial role of green plantain [Musa paradisiaca] in the management of persistent diarrhea: a prospective randomized trial, Journal of the American College of Nutrition (2009) — RCT in 80 children (1-28 mo): cooked green-plantain diet (50 g/L) shortened persistent diarrhea ~18 h vs a yogurt diet, reducing stool output/weight and improving daily weight gain. [https://pubmed.ncbi.nlm.nih.gov/19828902/]

---

## Mandarin Orange (Citrus reticulata)
URL: https://nutridex.info/s/mandarin-orange
Category: Fruits
Evidence: Moderate — Several controlled trials; effects real but modest or context-dependent.
Beta-cryptoxanthin-rich citrus tied to bone and metabolic health

Quick answer: Mandarin Orange is used for higher beta-cryptoxanthin intake (a marker of mandarin consumption) is associated with lower osteoporosis and hip-fracture risk in pooled observational studies. NutriDex grades the human evidence as moderate — Several controlled trials; effects real but modest or context-dependent. Based on 9 cited human studies (9 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Mandarins are a leading dietary source of beta-cryptoxanthin, and pooled observational data link higher beta-cryptoxanthin intake to lower osteoporosis risk (OR ~0.79) and fewer hip fractures, while the Japanese Mikkabi cohort associates higher serum beta-cryptoxanthin with reduced insulin resistance, liver dysfunction, metabolic syndrome and type 2 diabetes. Citrus flavanones such as hesperidin are inversely associated with stroke in prospective cohorts (about 11% lower risk per 50 mg/day), and hesperidin trials show modest improvements in lipids, glucose and inflammatory markers. The whole fruit reliably supplies vitamin C, folate, potassium and soluble pectin fibre. However, almost all disease-outcome evidence is observational and cannot establish causation; the strongest mandarin-specific data come from a single Japanese region (Mikkabi) and may not generalize. Intervention trials typically use isolated hesperidin or fortified juice rather than whole mandarins, are short-term, and report modest effects confounded by overall healthy diet patterns. Vitamin C does not prevent colds in the general population, only modestly shortening duration. Overall the human evidence is moderate—consistent cohorts plus supportive but limited RCTs—rather than definitive.

Nutrition (per 1 medium (88 g)): 46 kcal; Vitamin C 23.5mg (26% DV), Beta-cryptoxanthin 358mcg (0% DV), Potassium 146mg (3% DV), Fiber 1.6g (6% DV), Folate 14mcg DFE (4% DV), Vitamin A 30mcg RAE (3% DV), Calcium 33mg (3% DV).
Benefits / uses: Higher beta-cryptoxanthin intake (a marker of mandarin consumption) is associated with lower osteoporosis and hip-fracture risk in pooled observational studies; Citrus flavanone intake is inversely associated with stroke risk in prospective cohorts; Serum beta-cryptoxanthin from Satsuma mandarins associates with lower insulin resistance, liver dysfunction and type 2 diabetes in the Japanese Mikkabi cohort; Provides vitamin C supporting antioxidant defense and normal immune function; Soluble pectin fibre and potassium support cardiometabolic and digestive health; Hesperidin (citrus flavanone) may modestly improve blood lipids, glucose and inflammatory markers in short-term trials.
Active compounds: Beta-cryptoxanthin (signature carotenoid, abundant in Citrus unshiu/reticulata); Vitamin C (ascorbic acid); Hesperidin & narirutin (flavanones); Beta-carotene & lutein (carotenoids); Pectin (soluble fibre); Potassium; Folate; Citric acid / citrate; Polymethoxylated flavones (nobiletin, tangeretin).
Dose: One medium mandarin (~88 g) provides roughly a quarter of the vitamin C Daily Value and ~360 mcg beta-cryptoxanthin. Typical intake is 1-3 fruits/day; protective associations in Japanese cohorts correspond to near-daily mandarin consumption (often several fruits/day in season).
Safety: Generally very safe and well tolerated. Unlike grapefruit and Seville (bitter) oranges, sweet mandarins lack significant furanocoumarins and are not expected to cause the major CYP3A4 drug interaction, though data are less extensive than for grapefruit—patients on narrow-therapeutic-index drugs should consult a clinician. The natural acid and sugars can erode tooth enamel and contribute to glycemic load if eaten in large quantities; potassium content is modest but very high intake matters for those on potassium-restricted diets or potassium-sparing drugs. Beta-cryptoxanthin from whole fruit is safe; concerns about high-dose beta-carotene supplements in smokers do not apply to eating mandarins. Citrus allergy and oral allergy syndrome are uncommon but possible.

Cited studies (9):
  - Effects of Citrus Flavanone Hesperidin Extracts or Purified Hesperidin Consumption on Risk Factors for Cardiovascular Disease: Evidence From an Updated Meta-analysis of Randomized Controlled Trials, Current developments in nutrition (2024) — Updated meta-analysis of 12 RCTs (589 participants): hesperidin/citrus-flavanone supplementation improved LDL and total cholesterol, fasting glucose, insulin sensitivity and CRP versus placebo, with no effect on blood pressure. [https://pubmed.ncbi.nlm.nih.gov/39279783/]
  - Effects of β-Cryptoxanthin on Improvement in Osteoporosis Risk: A Systematic Review and Meta-Analysis of Observational Studies, Foods (Basel, Switzerland) (2021) — Systematic review and meta-analysis of observational studies (7 studies, 100,496 individuals): high beta-cryptoxanthin intake was associated with lower osteoporosis risk (OR 0.79, 95% CI 0.70-0.90) and lower hip-fracture risk (OR 0.71, 95% CI 0.54-0.94). [https://pubmed.ncbi.nlm.nih.gov/33540706/]
  - A meta-analysis of prospective cohort studies of flavonoid subclasses and stroke risk, Phytotherapy research : PTR (2022) — Meta-analysis of 10 prospective cohorts (387,076 participants, 9,564 strokes): higher flavanone intake was inversely associated with stroke risk (RR 0.85, 95% CI 0.78-0.93); each 50 mg/day increment was associated with ~11% lower stroke risk (RR 0.89, 95% CI 0.84-0.94). [https://pubmed.ncbi.nlm.nih.gov/35023220/]
  - Vitamin C for preventing and treating the common cold, Cochrane Database of Systematic Reviews (2013) — Cochrane review: regular vitamin C did not reduce cold incidence in the general population (RR 0.97) but shortened cold duration by ~8% in adults and ~14% in children; therapeutic dosing after onset showed no consistent benefit. [https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD000980.pub4/abstract]
  - [β-Cryptoxanthin and the risk for lifestyle-related disease: findings from recent nutritional epidemiologic studies], Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan (2015) — Review of the Mikkabi prospective cohort: serum beta-cryptoxanthin (a biomarker of Satsuma mandarin intake) was inversely associated with risks for atherosclerosis, insulin resistance, liver dysfunction, type 2 diabetes, metabolic syndrome and low bone mineral density. [https://pubmed.ncbi.nlm.nih.gov/25743900/]
  - Role of carotenoid β-cryptoxanthin in bone homeostasis, Journal of biomedical science (2012) — Mechanistic review of beta-cryptoxanthin and bone homeostasis: the carotenoid stimulates osteoblastic bone formation and inhibits osteoclastic resorption in vitro, supporting a role in bone-mass maintenance. [https://pmc.ncbi.nlm.nih.gov/articles/PMC3361488/]
  - Serum β-cryptoxanthin and β-carotene derived from Satsuma mandarin and brachial-ankle pulse wave velocity: The Mikkabi cohort study, Nutrition, metabolism, and cardiovascular diseases : NMCD (2016) — Mikkabi cohort: higher serum beta-cryptoxanthin and beta-carotene derived from Satsuma mandarin were associated with lower risk of high brachial-ankle pulse wave velocity, indicating reduced arterial stiffness; eating 3-4 mandarins/day vs <1/day was associated with lower risk. [https://pubmed.ncbi.nlm.nih.gov/27212620/]
  - Multiple strains probiotics appear to be the most effective probiotics in the prevention of necrotizing enterocolitis and mortality: An updated meta-analysis, PLOS ONE (2017) — Prospective cohort of 212 post-menopausal Japanese women: higher serum carotenoids including beta-cryptoxanthin were associated with lower risk of bone loss and osteoporosis/osteopenia over 4-year follow-up. [https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0052643]
  - Dietary Antioxidant Intake and Risk of Type 2 Diabetes, Diabetes Care (2004) — Finnish prospective cohort (4,304 adults, 23-year follow-up): dietary beta-cryptoxanthin intake was inversely associated with incident type 2 diabetes (RR for highest vs lowest 0.58, 95% CI 0.44-0.78). [https://diabetesjournals.org/care/article/27/2/362/28291/]

---

## Nectarine (Prunus persica var. nucipersica)
URL: https://nutridex.info/s/nectarine
Category: Fruits
Evidence: Preliminary — Early or small human trials; promising but not yet conclusive.
Smooth-skinned stone fruit, polyphenol-rich and refreshing

Quick answer: Nectarine is used for counts toward fruit intake linked in large cohorts and dose-response meta-analyses to lower cardiovascular and all-cause mortality. NutriDex grades the human evidence as preliminary — Early or small human trials; promising but not yet conclusive. Based on 9 cited human studies (9 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

There is little human research on nectarines specifically; almost all evidence is shared with peach (the same species, Prunus persica) and with the broader whole-fruit literature. Large prospective cohorts and dose-response meta-analyses show that higher whole-fruit intake is associated with lower cardiovascular and all-cause mortality, and that roughly two fruit servings a day captures most of the benefit. In the pooled Nurses' Health and Health Professionals cohorts, peaches/plums/apricots as a group were neutral for type 2 diabetes risk (HR 0.97, 95% CI 0.92-1.02), while whole fruit overall was modestly protective. Compositional studies confirm nectarines are rich in chlorogenic acid, catechins and procyanidins, with red skin and yellow flesh adding anthocyanins and carotenoids; the much-publicised anti-obesity and anti-diabetic effects of stone-fruit polyphenols come from cell-culture and rodent studies, not human trials. As a low-glycaemic, fibre- and potassium-containing whole fruit it fits cardiometabolic dietary patterns, but no randomised controlled trial has tested nectarine intake on a clinical outcome. Overall the disease-specific evidence is preliminary and indirect, while the case for nectarines as part of a high-fruit diet is sound.

Nutrition (per 1 medium (142 g)): 62 kcal; Fibre 2.4g (9% DV), Vitamin C 7.7mg (9% DV), Potassium 285mg (6% DV), Niacin 1.6mg (10% DV), Copper 0.12mg (13% DV), Vitamin E 1.1mg (7% DV), Vitamin A 24mcg RAE (3% DV), Vitamin K 3.1mcg (3% DV).
Benefits / uses: Counts toward fruit intake linked in large cohorts and dose-response meta-analyses to lower cardiovascular and all-cause mortality; Low glycaemic-load whole fruit with fibre and polyphenols, fitting cardiometabolic dietary patterns; Supplies chlorogenic-acid and catechin polyphenols with antioxidant activity in lab assays; Provides potassium and fibre that support blood pressure and digestive regularity; Carotenoids (yellow flesh) and vitamin C contribute to antioxidant and provitamin-A intake; Hydrating, low-calorie snack useful within a weight-management diet.
Active compounds: Chlorogenic and neochlorogenic acids (hydroxycinnamic acids); Catechin and epicatechin (flavan-3-ols); Procyanidins (condensed tannins); Anthocyanins (cyanidin-3-glucoside, mainly in red skin); Beta-carotene and beta-cryptoxanthin (provitamin-A carotenoids, yellow flesh); Vitamin C (ascorbic acid); Potassium; Dietary fibre (pectin, cellulose); Quercetin and rutin (flavonols).
Dose: A typical serving is 1 medium nectarine (about 140-150 g), eaten fresh with the skin on (the skin concentrates anthocyanins and other phenolics). Roughly two servings of fruit per day is the intake associated with the lowest mortality in pooled cohort data, with little added benefit beyond that.
Safety: Nectarines are a stone fruit (Prunus/Rosaceae); people with birch-pollen or oral allergy syndrome may react to the raw fruit (itchy mouth, throat tingling), and Prunus allergy is possible. The kernel/pit contains amygdalin and should not be eaten. Whole nectarines have no clinically important drug interaction and, unlike grapefruit, do not inhibit CYP3A4. Sorbitol and fructose can cause gas or loose stools in sensitive or IBS-prone people if eaten in excess. The modest potassium content is rarely an issue except in advanced kidney disease, and the natural sugars warrant normal portion awareness in diabetes.

Cited studies (9):
  - Fruit and Vegetable Intake and Mortality, Circulation (2021) — Two US cohorts plus a meta-analysis of 26 cohorts (~1.9 million adults, 145,015 deaths): about 5 daily servings of fruit/veg (2 fruit, 3 veg) gave the lowest mortality, with the fruit benefit plateauing at roughly 2 servings/day. [https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.120.048996]
  - Fruit and vegetable intake and the risk of cardiovascular disease, total cancer and all-cause mortality—a systematic review and dose-response meta-analysis of prospective studies, International Journal of Epidemiology (2017) — Dose-response meta-analysis of prospective studies: each 200 g/day of fruit and vegetables was associated with ~10% lower all-cause mortality (RR 0.90, 95% CI 0.87-0.93), with risk reductions seen up to about 800 g/day. [https://academic.oup.com/ije/article/46/3/1029/3039477]
  - Carbohydrate quality and human health: a series of systematic reviews and meta-analyses, The Lancet (2019) — Series of systematic reviews/meta-analyses (185 prospective studies, ~135 million person-years): higher dietary fibre and lower glycaemic index/load were associated with lower all-cause and cardiovascular mortality and lower incidence of diabetes and coronary heart disease. [https://www.thelancet.com/article/S0140-6736(18)31809-9/fulltext]
  - Systematic Review on Polyphenol Intake and Health Outcomes: Is there Sufficient Evidence to Define a Health-Promoting Polyphenol-Rich Dietary Pattern?, Nutrients (2019) — Systematic review of polyphenol intake and health outcomes: total flavonoids and specific flavonoid subclasses (but not total polyphenols) were associated with lower risk of diabetes, cardiovascular events and all-cause mortality; evidence for individual stone fruits like nectarine is sparse. [https://www.mdpi.com/2072-6643/11/6/1355]
  - Antioxidant Capacities, Phenolic Compounds, Carotenoids, and Vitamin C Contents of Nectarine, Peach, and Plum Cultivars from California, Journal of Agricultural and Food Chemistry (2002) — Analysis of 25 nectarine, peach and plum cultivars from California: phenolic compounds contributed far more to antioxidant capacity than vitamin C or carotenoids; yellow-flesh nectarines carried 80-186 ug/100 g carotenoids and 5-14 mg/100 g vitamin C. [https://pubs.acs.org/doi/10.1021/jf020136b]
  - HPLC−DAD−ESIMS Analysis of Phenolic Compounds in Nectarines, Peaches, and Plums, Journal of Agricultural and Food Chemistry (2001) — HPLC-DAD-ESIMS of 25 nectarine, peach and plum cultivars identified hydroxycinnamic acids (chlorogenic, neochlorogenic), flavan-3-ols, procyanidins, flavonols and skin anthocyanins, with phenolics concentrated in the peel. [https://pubs.acs.org/doi/10.1021/jf0104681]
  - Evaluation of the antioxidant capacity, phenolic compounds, and vitamin C content of different peach and nectarine [ Prunus persica (L.) Batsch] breeding progenies, Journal of agricultural and food chemistry (2009) — Evaluation of peach and nectarine [Prunus persica] breeding progenies showed wide variation in phenolic content, vitamin C and antioxidant capacity, supporting cultivar selection for higher bioactive levels. [https://pubmed.ncbi.nlm.nih.gov/19397288/]
  - Fruit consumption and risk of type 2 diabetes: results from three prospective longitudinal cohort studies, BMJ (Clinical research ed.) (2013) — Pooled analysis of three US cohorts (187,382 people, 12,198 diabetes cases): every 3 servings/week of peaches/plums/apricots had a neutral association with type 2 diabetes (HR 0.97, 95% CI 0.92-1.02), while total whole fruit was modestly protective (HR 0.98 per 3 servings/week). [https://pubmed.ncbi.nlm.nih.gov/23990623/]
  - Consumption of polyphenol-rich peach and plum juice prevents risk factors for obesity-related metabolic disorders and cardiovascular disease in Zucker rats, The Journal of nutritional biochemistry (2015) — In obese Zucker rats, polyphenol-rich peach and plum juice attenuated hyperglycaemia, insulin and leptin resistance, dyslipidaemia and LDL oxidation versus controls (animal model, not human). [https://pubmed.ncbi.nlm.nih.gov/25801980/]

---

## Gooseberry (Ribes uva-crispa)
URL: https://nutridex.info/s/gooseberry
Category: Fruits
Evidence: Preliminary — Early or small human trials; promising but not yet conclusive.
Tart, vitamin-C-rich berry with abundant polyphenols

Quick answer: Gooseberry is used for high in vitamin c (about 46% of the daily value per cup), supporting antioxidant defense and collagen synthesis. NutriDex grades the human evidence as preliminary — Early or small human trials; promising but not yet conclusive. Based on 8 cited human studies (8 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

The European gooseberry (Ribes uva-crispa) is a nutrient-dense, low-calorie berry: one cup (150 g) supplies about 46% of the Daily Value of vitamin C plus meaningful fiber, copper and manganese. Compositional and laboratory studies consistently show high ascorbic acid (about 0.38-0.85 g/kg fresh weight) and abundant flavonol glycosides and anthocyanins with strong in vitro antioxidant activity. However, direct human clinical trials on the European gooseberry fruit itself are essentially absent, so its specific health effects remain extrapolated from composition and from broader berry/anthocyanin research. Meta-analyses of anthocyanin-rich berries link higher intake to lower CRP and reduced coronary and total cardiovascular risk in cohorts, though effects on blood pressure and LDL are modest or inconsistent across trials. Importantly, most published clinical evidence labeled "gooseberry" actually pertains to Indian gooseberry/amla (Phyllanthus emblica), a botanically distinct plant whose lipid- and glucose-lowering RCT data should not be assumed to apply to Ribes. (Note: USDA does not report a total-sugars value for raw gooseberry, so its sugar content is uncharacterized.) Overall the human weight of evidence for this fruit is preliminary. It is best viewed as a healthy, vitamin-C-rich addition to a varied fruit and berry intake rather than a proven therapeutic food.

Nutrition (per 1 cup raw (150 g)): 66 kcal; Vitamin C 41.6mg (46% DV), Fiber 6.5g (23% DV), Copper 0.11mg (12% DV), Manganese 0.22mg (10% DV), Potassium 297mg (6% DV), Vitamin E 0.56mg (4% DV).
Benefits / uses: High in vitamin C (about 46% of the Daily Value per cup), supporting antioxidant defense and collagen synthesis; Good source of dietary fiber (about 23% DV per cup) supporting digestive health; Rich in polyphenols (flavonol glycosides, anthocyanins) with measured free-radical scavenging activity in laboratory assays; Low energy density (about 66 kcal per cup), making it an easy nutrient-dense addition to the diet; Part of an anthocyanin-rich berry pattern associated with lower cardiovascular risk in observational cohorts; Potential anti-inflammatory effects suggested by in vitro and compositional data (not yet confirmed in human trials of this fruit).
Active compounds: Vitamin C (L-ascorbic acid); Flavonol glycosides (quercetin-3-rutinoside, isorhamnetin-3-rutinoside); Anthocyanins (cyanidin-3-glucoside, peonidin-3-glucoside, cyanidin-3-rutinoside); Flavan-3-ols / proanthocyanidins; Hydroxycinnamic acids (chlorogenic, caffeic acid); Soluble and insoluble dietary fiber (pectin); Organic acids (citric, malic); Tocopherols (vitamin E); Manganese and copper (cofactor minerals).
Dose: 1 cup raw (about 150 g), roughly 25-30 berries
Safety: Generally safe as food. The high natural acidity makes raw berries very tart and may aggravate reflux or sensitive teeth; underripe gooseberries can cause GI upset in large amounts. Like other berries, gooseberries contain salicylates and oxalates, which may matter for sensitive or stone-forming individuals. Do not confuse with Indian gooseberry (amla, Phyllanthus emblica) or Cape gooseberry (Physalis), which differ nutritionally and have their own interaction profiles; concentrated amla supplements may potentiate antidiabetic or antiplatelet/anticoagulant drugs. True botanical fruit allergy is rare.

Cited studies (8):
  - The impact of Emblica Officinalis (Amla) on lipid profile, glucose, and C-reactive protein: A systematic review and meta-analysis of randomized controlled trials, Diabetes & metabolic syndrome (2023) — Meta-analysis of RCTs on Indian gooseberry/amla (Phyllanthus emblica, a distinct species) showed significant reductions in LDL, total cholesterol, triglycerides, fasting glucose and CRP and increased HDL; not specific to European gooseberry. [https://pubmed.ncbi.nlm.nih.gov/36934568/]
  - Anthocyanins, Anthocyanin-Rich Berries, and Cardiovascular Risks: Systematic Review and Meta-Analysis of 44 Randomized Controlled Trials and 15 Prospective Cohort Studies, Frontiers in nutrition (2021) — Meta-analysis of 44 RCTs and 15 cohorts: anthocyanin-rich berries significantly lowered CRP (WMD -0.046 mg/dL) and higher dietary anthocyanins were associated with 17% lower CHD incidence and 27% lower total CVD risk; LDL change from whole berries was non-significant. [https://pmc.ncbi.nlm.nih.gov/articles/PMC8714924/]
  - Natural pigments (anthocyanins and chlorophyll) and antioxidants profiling of European red and green gooseberry (Ribes uva-crispa L.) extracted using green techniques (UAE-citric acid-mediated extraction), Current research in food science (2023) — Profiling of European red and green gooseberry (Ribes uva-crispa) found total phenols ~162-987 mg GAE/100g and DPPH radical scavenging of 73-91%, with cyanidin- and peonidin-3-glucoside the main anthocyanins in red fruit. [https://pubmed.ncbi.nlm.nih.gov/38034946/]
  - Effects of Berries Consumption on Cardiovascular Risk Factors: A Meta-analysis with Trial Sequential Analysis of Randomized Controlled Trials, Scientific reports (2016) — Meta-analysis (22 RCTs, 1,251 subjects) found berry consumption significantly reduced LDL cholesterol, systolic blood pressure (-2.72 mmHg), fasting glucose, HbA1c, BMI and TNF-alpha. [https://pmc.ncbi.nlm.nih.gov/articles/PMC4804301/]
  - Tissue biochemical diversity of 20 gooseberry cultivars and the effect of ethylene supplementation on postharvest life, Postharvest biology and technology (2016) — Across 20 gooseberry cultivars, vitamin C ranged 0.38-0.85 g/kg fresh weight with flavonol glycosides (quercetin/isorhamnetin rutinosides) dominant and total anthocyanins up to 265.8 mg/kg in the highest red cultivar. [https://pmc.ncbi.nlm.nih.gov/articles/PMC6472321/]
  - Contribution of phenolic compounds, ascorbic acid and vitamin E to antioxidant activity of currant (Ribes L.) and gooseberry (Ribes uva-crispa L.) fruits, Food chemistry (2019) — Phenolic compounds, ascorbic acid and vitamin E were quantified as the main contributors to the antioxidant activity of currant and gooseberry (Ribes uva-crispa) fruits. [https://pubmed.ncbi.nlm.nih.gov/30744864/]
  - Clinical evaluation of Emblica Officinalis Gatertn (Amla) in healthy human subjects: Health benefits and safety results from a randomized, double-blind, crossover placebo-controlled study, Contemporary clinical trials communications (2020) — Randomized double-blind crossover RCT of amla (500 mg/day, 18 wk, n=15 healthy adults) improved blood fluidity, raised HDL, lowered LDL and oxidative DNA damage (8-OHdG) with no safety signals; pertains to Indian gooseberry, not Ribes. [https://pubmed.ncbi.nlm.nih.gov/31890983/]
  - Extractability of polyphenols from black currant, red currant and gooseberry and their antioxidant activity, Acta biologica Hungarica (2018) — Comparative study of black currant, red currant and gooseberry showed gooseberry water extract had the highest antioxidant capacity among its extracts (41.84 µmol AAE/g, PCL assay), with quercetin-3-O-glucoside present across all Ribes samples. [https://pubmed.ncbi.nlm.nih.gov/29888668/]

---

## Jackfruit (Artocarpus heterophyllus)
URL: https://nutridex.info/s/jackfruit
Category: Fruits
Evidence: Preliminary — Early or small human trials; promising but not yet conclusive.
Giant tropical fruit and emerging diabetic staple

Quick answer: Jackfruit is used for glycemic control: green (unripe) jackfruit flour substituted for rice/wheat lowered hba1c, fasting and postprandial glucose in a small t2dm rct. NutriDex grades the human evidence as preliminary — Early or small human trials; promising but not yet conclusive. Based on 9 cited human studies (9 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Direct human evidence for jackfruit is limited and early-stage. The strongest signal is a single randomized, double-blind, placebo-controlled trial (40 patients with type-2 diabetes) in which 30 g/day of green jackfruit flour replacing rice or wheat for 12 weeks reduced HbA1c, fasting and postprandial glucose versus placebo flour. Older human work (a 1991 glucose-tolerance study) suggested hot-water leaf extracts improved glucose handling in normal and maturity-onset (type-2) diabetic subjects, and glycemic-index testing places the related Artocarpus food boiled breadfruit in the low-GI range. Beyond glycemic effects, claims of antioxidant, anti-inflammatory, antimicrobial, wound-healing and anticancer activity rest almost entirely on in-vitro, in-silico and animal studies of isolated compounds such as artocarpin, not on whole-fruit human trials. Ripe jackfruit is itself fairly high in natural sugars, so the favorable metabolic findings apply to the unripe/green fruit and its flour, not to large servings of sweet ripe flesh. No systematic reviews or meta-analyses of clinical endpoints yet exist, and the available trial is small, short and single-site. Overall the human evidence is best graded preliminary and promising for green-jackfruit glycemic substitution.

Nutrition (per 1 cup sliced (165 g)): 157 kcal; Vitamin C 22.6mg (25% DV), Vitamin B6 0.54mg (32% DV), Potassium 739mg (16% DV), Magnesium 48mg (11% DV), Copper 0.13mg (14% DV), Fiber 2.5g (9% DV).
Benefits / uses: Glycemic control: green (unripe) jackfruit flour substituted for rice/wheat lowered HbA1c, fasting and postprandial glucose in a small T2DM RCT; Lower-glycemic carbohydrate source vs. refined grains, owing to fiber, resistant starch and intact food matrix; Dietary fiber for satiety, bowel regularity and as a plant-based meat-substitute texture; Antioxidant capacity from carotenoids, vitamin C and prenylated flavonoids (mechanistic/preclinical); Source of potassium and vitamin B6 supporting blood-pressure and metabolic needs; Traditional/preclinical wound-healing and antimicrobial actions attributed to leaf and flavonoid constituents.
Active compounds: Carotenoids (lutein, beta-carotene, alpha-carotene) — yellow flesh pigments with provitamin-A/antioxidant roles; Prenylated flavonoids (artocarpin, cycloartocarpin, artocarpanone) — signature Artocarpus phenolics; Flavonoids and flavanones (morin, dihydromorin, norartocarpetin) with antioxidant activity; Phenolic acids (ferulic, gallic, caffeic) contributing to total antioxidant capacity; Jacalin and artocarpin lectins — mannose/galactose-binding proteins (immunology reagents); Resistant starch and dietary fiber in unripe/green fruit and flour; Vitamin C (ascorbic acid) and vitamin B6 (pyridoxine); Potassium and magnesium minerals; Volatile esters (isopentyl/butyl esters) responsible for the characteristic ripe aroma.
Dose: About 1 cup sliced (165 g) of raw ripe fruit; the clinical glycemic trial used 30 g/day of green jackfruit flour (split between two meals) replacing an equal volume of rice or wheat for 12 weeks.
Safety: Generally recognized as safe as a food. Ripe flesh is high in fermentable sugars and fiber and can cause bloating, gas or laxative effects in large amounts. Birch-pollen/latex-fruit cross-reactivity and rare jackfruit-specific oral allergy syndrome have been reported—those with latex or pollen allergy should be cautious. Because green-jackfruit flour and leaf preparations can lower blood glucose, people on insulin or sulfonylureas should monitor for additive hypoglycemia and consult a clinician. Its potassium content is modest per serving but worth noting for those on potassium-restricted (e.g., advanced renal) diets. Seeds should be cooked before eating, as raw seeds contain antinutrients/lectins.

Cited studies (9):
  - Efficacy of jackfruit components in prevention and control of human disease: A scoping review, Journal of education and health promotion (2023) — Scoping review of jackfruit (Artocarpus heterophyllus) bioactive components found ethnopharmacological and in vivo evidence for antidiabetic, anti-inflammatory and anticancer activity, but concluded robust human clinical trial data remain limited. [https://pmc.ncbi.nlm.nih.gov/articles/PMC10743863/]
  - Efficacy of green jackfruit flour as a medical nutrition therapy replacing rice or wheat in patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled study, Nutrition &amp; Diabetes (2021) — RCT (n=40, 12 wk): 30 g/day green jackfruit flour replacing rice/wheat reduced HbA1c (mean difference -0.25% vs +0.02% placebo, p=0.006), with significant drops in fasting (p=0.043) and postprandial glucose (p=0.001) in type-2 diabetes. [https://doi.org/10.1038/s41387-021-00161-4]
  - Efficacy of green jackfruit flour as a medical nutrition therapy replacing rice or wheat in patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled study, Nutrition & diabetes (2021) — Double-blind RCT (n=40 T2DM, 12 weeks): replacing rice/wheat with 30 g/day green jackfruit flour lowered HbA1c (-0.25% vs +0.02% placebo, p=0.006) and reduced fasting and postprandial plasma glucose. [https://pmc.ncbi.nlm.nih.gov/articles/PMC8203736/]
  - Carbohydrate-rich foods: glycaemic indices and the effect of constituent macronutrients, International Journal of Food Sciences and Nutrition (2009) — Crossover GI testing classified boiled breadfruit (Artocarpus altilis, a close relative) as a low-GI food (GI ~57 vs white bread); GI correlated negatively with insoluble fiber, soluble fiber and protein content. [https://doi.org/10.1080/09637480902849195]
  - Jackfruit ( <i>Artocarpus heterophyllus</i> Lam.) in health and disease: a critical review, Critical Reviews in Food Science and Nutrition (2022) — Critical review: jackfruit supplies minerals, vitamins and phytochemicals; preclinical antimicrobial, antioxidant, antidiabetic, anti-inflammatory, immunomodulatory and wound-healing activities, with leaf preparations showing antidiabetic action in humans. [https://doi.org/10.1080/10408398.2022.2031094]
  - A Literature Review of Artocarpus lacucha Focusing on the Phytochemical Constituents and Pharmacological Properties of the Plant, Molecules (2022) — Literature review of Artocarpus species summarizing bioactive secondary metabolites with reported antioxidant, antibacterial, anti-inflammatory, hepatoprotective, neuroprotective and anti-glycation activities. [https://doi.org/10.3390/molecules27206940]
  - <i>In‐silico</i> and <i>In‐vitro</i> Investigation of Flavonoids and Alkaloids from <i>Artocarpus heterophyllus, Tinospora cordifolia</i>, and <i>Glycosmis pentaphylla</i> as Potential NF‐<i>κ</i>B Inhibitors in Oral Cancer, Chemistry &amp; Biodiversity (2024) — In-silico plus in-vitro screen of flavonoids/alkaloids (including jackfruit's artocarpin, cycloartocarpin, artocarpanone) as NF-kappaB inhibitors for oral cancer; jackfruit flavonoids were docked and assayed, though the lead inhibitor was an alkaloid (hydrastine) from a co-screened plant rather than a jackfruit compound. [https://doi.org/10.1002/cbdv.202401886]
  - The effects of artocarpin on wound healing: in vitro and in vivo studies, Scientific Reports (2017) — Artocarpin, a prenylated Artocarpus flavonoid, accelerated wound healing in vitro and in vivo by promoting fibroblast/keratinocyte proliferation, collagen synthesis, re-epithelialization and angiogenesis via P38/JNK/ERK/Akt pathways. [https://doi.org/10.1038/s41598-017-15876-7]
  - Effect of Artocarpus heterophyllus and Asteracanthus longifolia on glucose tolerance in normal human subjects and in maturity-onset diabetic patients, Journal of Ethnopharmacology (1991) — Hot-water extract of Artocarpus heterophyllus leaves (dose equiv. 20 g/kg of starting material) significantly improved oral glucose tolerance in both normal human subjects and maturity-onset (type-2) diabetic patients. [https://doi.org/10.1016/0378-8741(91)90012-3]

---

## Soursop (Graviola) (Annona muricata)
URL: https://nutridex.info/s/soursop
Category: Fruits
Evidence: Preliminary — Early or small human trials; promising but not yet conclusive.
Creamy tropical fruit with a neurotoxic caveat

Quick answer: Soursop (Graviola) is used for vitamin c contribution (good source per serving). NutriDex grades the human evidence as preliminary — Early or small human trials; promising but not yet conclusive. Based on 8 cited human studies (8 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Soursop is a low-fat tropical fruit that is a good source of vitamin C, potassium, and fiber, but human evidence for its widely marketed health claims is weak. Most "graviola" research is in vitro or in rodents, where leaf and fruit acetogenins show anticancer, antihypertensive, antidiabetic, and antimicrobial activity. The only notable human trial is a small (n=28 completers) 8-week randomized placebo-controlled study in resected colorectal-cancer patients, which found greater ex vivo cytotoxicity with leaf extract while maintaining nutritional status, but did not demonstrate clinical outcomes such as survival or tumor regression. Reviews conclude there is no validated effective or safe human dose and that claims of curing cancer are unsupported. Crucially, the same acetogenins (chiefly annonacin) are mitochondrial complex I inhibitors linked epidemiologically to atypical, levodopa-resistant parkinsonism in Guadeloupe and other high-consumption regions, with supporting rodent mechanistic data. Thus the fruit is reasonable as an occasional whole food, but concentrated leaf/seed extracts and heavy daily intake carry a real neurotoxic signal. Overall the weight of human evidence is preliminary.

Nutrition (per 1 cup pulp (225 g)): 149 kcal; Vitamin C 46.4mg (52% DV), Fiber 7.4g (26% DV), Potassium 626mg (13% DV), Magnesium 47mg (11% DV), Thiamin 0.16mg (13% DV), Niacin 2mg (13% DV), Vitamin B6 0.13mg (8% DV).
Benefits / uses: Vitamin C contribution (good source per serving); Dietary fiber for digestive health; Potassium contribution; Anticancer / cytotoxic activity (lab and one small RCT, no clinical outcomes); Antihypertensive / vasodilatory activity (animal only); Antidiabetic / hypoglycemic and antimicrobial activity (mostly in vitro / animal).
Active compounds: Annonaceous acetogenins (annonacin, annomuricin E, muricoreacin) - potent mitochondrial complex I inhibitors; Vitamin C (ascorbic acid); Isoquinoline alkaloids (reticuline, coreximine, anonaine); Flavonoids & phenolic acids (quercetin, chlorogenic acid); Dietary fiber (soluble + insoluble); Potassium; Magnesium; Carotenoids.
Dose: About 1 cup (225 g) of fresh pulp as an occasional whole food; concentrated leaf teas/seed extracts are not recommended due to annonacin neurotoxicity
Safety: Soursop fruit, leaves, and seeds contain annonacin and related acetogenins, mitochondrial complex I inhibitors associated with an atypical, levodopa-resistant parkinsonism/tauopathy in regions of heavy consumption (Guadeloupe, New Caledonia). An average fruit is estimated to hold ~15 mg annonacin and a can of nectar ~36 mg; chronic daily intake or concentrated leaf teas/seed extracts pose the greatest risk and should be avoided. Seeds are toxic and emetic. May add to the effect of antihypertensive and antidiabetic drugs (additive blood-pressure/glucose lowering). Avoid in pregnancy/breastfeeding and in people with Parkinson's disease or other movement disorders. Not a substitute for cancer treatment.

Cited studies (8):
  - The safety and tolerability of Annona muricata leaf extract: a systematic review, Journal of Pharmacy and Pharmacology (2020) — Systematic review of A. muricata leaf-extract safety/tolerability: reported a generally favourable tolerability profile in available studies but concluded human safety data are very limited and no validated safe human dose has been established. [https://academic.oup.com/jpp/article-abstract/72/1/1/6121999]
  - The effect of an Annona muricata leaf extract on nutritional status and cytotoxicity in colorectal cancer: a randomized controlled trial, Asia Pacific journal of clinical nutrition (2017) — Randomized double-blind placebo-controlled trial (30 enrolled, 28 completed) in resected colorectal-cancer patients: 8 weeks of A. muricata leaf extract increased ex vivo serum cytotoxicity against cancer cells vs placebo, with maintained nutritional status, but no clinical/tumor outcomes demonstrated. [https://pubmed.ncbi.nlm.nih.gov/28582808/]
  - Soursop (Annona muricata) Properties and Perspectives for Integral Valorization, Foods (Basel, Switzerland) (2023) — Review of soursop properties and valorization prospects concluded therapeutic claims rest mostly on preclinical data and that excessive consumption is not advised due to toxicological concerns. [https://pmc.ncbi.nlm.nih.gov/articles/PMC10093693/]
  - Annona muricata (Annonaceae): A Review of Its Traditional Uses, Isolated Acetogenins and Biological Activities, International Journal of Molecular Sciences (2015) — Comprehensive review documenting >100 annonaceous acetogenins plus isoquinoline alkaloids in A. muricata with broad in vitro/in vivo anticancer, anti-inflammatory and antimicrobial activity, but noting near-absence of clinical trials. [https://www.mdpi.com/1422-0067/16/7/15625]
  - Annona muricata: A comprehensive review on its traditional medicinal uses, phytochemicals, pharmacological activities, mechanisms of action and toxicity, Arabian Journal of Chemistry (2018) — Review of phytochemistry, pharmacology and toxicity (>200 compounds): catalogs acetogenin/alkaloid mechanisms and explicitly flags annonacin-linked neurotoxicity and atypical parkinsonism as a key safety concern. [https://doi.org/10.1016/j.arabjc.2016.01.004]
  - Possible mechanisms of action of the hypotensive effect of<i>Annona muricata</i>(soursop) in normotensive Sprague–Dawley rats, Pharmaceutical Biology (2012) — In normotensive Sprague-Dawley rats, A. muricata aqueous leaf extract produced a dose-dependent hypotensive effect via peripheral mechanisms (calcium antagonism, not adrenergic/cholinergic/nitric-oxide mediated). [https://www.tandfonline.com/doi/full/10.3109/13880209.2012.684690]
  - Quantification of acetogenins in Annona muricata linked to atypical parkinsonism in guadeloupe, Movement disorders : official journal of the Movement Disorder Society (2005) — LC-MS quantification: an average soursop fruit contains ~15 mg annonacin and a can of commercial nectar ~36 mg; daily intake over a year approximates the annonacin dose that caused brain lesions in rats. [https://pubmed.ncbi.nlm.nih.gov/16078200/]
  - Annonacin, a lipophilic inhibitor of mitochondrial complex I, induces nigral and striatal neurodegeneration in rats: possible relevance for atypical parkinsonism in Guadeloupe, Journal of neurochemistry (2004) — Annonacin inhibited brain mitochondrial complex I, lowered brain ATP by 44%, and produced nigral (~32%) and striatal neuronal loss in rats, supporting a possible causal role in Guadeloupe atypical parkinsonism. [https://pubmed.ncbi.nlm.nih.gov/14675150/]

---

## Rambutan (Nephelium lappaceum)
URL: https://nutridex.info/s/rambutan
Category: Fruits
Evidence: Preliminary — Early or small human trials; promising but not yet conclusive.
Hairy tropical fruit with modest vitamin C and polyphenol-rich peel

Quick answer: Rambutan is used for modest vitamin c contribution supporting collagen synthesis and normal immune function. NutriDex grades the human evidence as preliminary — Early or small human trials; promising but not yet conclusive. Based on 9 cited human studies (9 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Rambutan flesh is a low-fat tropical fruit whose best-documented nutritional role is as a modest source of vitamin C, fiber, copper and manganese. The great majority of its purported health effects (antioxidant, antidiabetic, antimicrobial, antiviral, anti-aging) come from polyphenol-rich peel and seed extracts studied in vitro and in rodent models, not from eating the fruit. For example, rambutan peel phenolic extract lowered fasting glucose, cholesterol and triglycerides in streptozotocin/high-fat-diet diabetic mice, and geraniin isolated from the rind inhibited dengue virus type-2 (IC about 1.75 microM) in Vero cell culture. There are essentially no randomized controlled trials or prospective cohorts evaluating rambutan fruit consumption and human disease outcomes, so causal claims for humans are unsupported. The concentrations of bioactives used in lab studies far exceed what edible flesh delivers, and peel/seed are not customary foods. Note also that the only USDA reference value for rambutan is for the fruit canned in syrup, which is substantially higher in sugar than fresh flesh. Overall the human weight of evidence is preliminary: rambutan is a healthful, vitamin-C-containing fruit, but specific therapeutic benefits remain unproven in people.

Nutrition (per 5 fruit (100 g)): 82 kcal; Vitamin C 4.9mg (5% DV), Copper 0.07mg (7% DV), Manganese 0.34mg (15% DV), Fiber 0.9g (3% DV), Iron 0.35mg (2% DV), Potassium 42mg (1% DV).
Benefits / uses: Modest vitamin C contribution supporting collagen synthesis and normal immune function; Antioxidant capacity from peel/seed polyphenols (geraniin, ellagitannins) demonstrated in vitro and in animal models; Antidiabetic / glycemic-lowering signals from peel phenolic extracts in diabetic rodents (not from eating the flesh); Antimicrobial activity of peel extracts against foodborne and Gram-negative bacteria in vitro; Antiviral activity of geraniin from the rind against dengue virus type-2 in cell culture; Provides small amounts of dietary fiber, copper and manganese.
Active compounds: Hydrolyzable tannins / ellagitannins (geraniin, corilagin); Phenolic acids (ellagic acid, gallic acid); Flavonoids (quercetin, rutin, kaempferol glycosides); Vitamin C (L-ascorbic acid); Proanthocyanidins / condensed tannins; Minerals (potassium, copper, manganese, iron); Dietary fiber (soluble and insoluble); Seed lipids (oleic and arachidic acid in seed fat).
Dose: About 5-6 fresh fruit (~100 g edible flesh); flesh eaten raw, seed and peel not normally consumed.
Safety: Generally safe as food. The seed is reported to be mildly toxic when raw (contains saponin-like and possibly other antinutrient compounds) and should not be eaten unroasted. Peel and seed extracts used in research are not validated as supplements and lack human safety data. Canned rambutan is packed in sugar syrup; people with diabetes should account for the added carbohydrate. Allergy is uncommon but possible. No well-characterized drug interactions for the flesh, though concentrated polyphenol extracts could theoretically affect glucose-lowering or anticoagulant therapy.

Cited studies (9):
  - Nutritional, pharmaceutical, and functional aspects of rambutan in industrial perspective: An updated review, Food Science &amp; Nutrition (2023) — Updated review documenting antioxidant, antimicrobial, anticancer, antidiabetic, antiobesity and antihypercholesterolemic activities across rambutan pulp, peel and seed; notes the peel and seed are richer in bioactives and that evidence is largely preclinical and by-product-focused. [https://doi.org/10.1002/fsn3.3379]
  - Review of Nephelium lappaceum and Nephelium ramboutan-ake: A High Potential Supplement, Molecules (2021) — Review of Nephelium lappaceum and N. ramboutan-ake (pulasan) concluding their phenolics confer antioxidant and biological activities, with peel and seeds richer in bioactives than the edible flesh. [https://doi.org/10.3390/molecules26227005]
  - Functional and nutritional properties of selected Amazon fruits: A review, Food Research International (2021) — Review of functional and nutritional properties of selected Amazonian fruits covering rambutan, identifying geraniin and corilagin as principal bioactives with antioxidant and antimicrobial activity shown mainly in vitro and in animal assays. [https://doi.org/10.1016/j.foodres.2021.110520]
  - Bioavailability and Antioxidant Activity of Rambutan (<i>Nephelium lappaceum</i>) Peel Polyphenols during <i>in Vitro</i> Simulated Gastrointestinal Digestion, Caco-2 Monolayer Cell Model Application, and Colonic Fermentation, Journal of Agricultural and Food Chemistry (2023) — During simulated gastrointestinal digestion, Caco-2 transport and colonic fermentation, rambutan peel polyphenols were transformed (e.g. geraniin to corilagin, ellagic and gallic acid) with changes in bioavailability and antioxidant capacity. [https://doi.org/10.1021/acs.jafc.3c04106]
  - Evaluation of antimicrobial activity of rambutan (Nephelium lappaceum L.) peel extracts, International Journal of Food Microbiology (2020) — Rambutan peel extracts showed antimicrobial activity against foodborne and Gram-negative bacteria in vitro, supporting their potential as natural food preservatives. [https://doi.org/10.1016/j.ijfoodmicro.2020.108539]
  - Metabolite Profiling of Rambutan (Nephelium lappaceum L.) Seeds Using UPLC-qTOF-MS/MS and Senomorphic Effects in Aged Human Dermal Fibroblasts, Nutrients (2020) — Flavonoid (kaempferol-type) compounds isolated from rambutan seeds showed senomorphic activity in aged human dermal fibroblasts, lowering senescence-marker expression and raising the longevity modulator SIRT1. [https://doi.org/10.3390/nu12051430]
  - Anti-Diabetic Effects of Phenolic Extract from Rambutan Peels (Nephelium lappaceum) in High-Fat Diet and Streptozotocin-Induced Diabetic Mice, Nutrients (2017) — Rambutan peel phenolic extract dose-dependently reduced fasting blood glucose, total cholesterol, triglycerides and glycated serum protein and restored hepatic glycogen in streptozotocin/high-fat-diet type-2 diabetic mice. [https://doi.org/10.3390/nu9080801]
  - Protective effects of rambutan (Nephelium lappaceum) peel phenolics on H2O2-induced oxidative damages in HepG2 cells and d-galactose-induced aging mice, Food and Chemical Toxicology (2017) — Rambutan peel phenolics (total phenolics 877 mg GAE/g; geraniin highest at 122 mg/g) protected H2O2-stressed HepG2 cells and reduced D-galactose-induced liver and kidney damage in aging mice. [https://doi.org/10.1016/j.fct.2017.01.022]
  - Geraniin extracted from the rind of Nephelium lappaceum binds to dengue virus type-2 envelope protein and inhibits early stage of virus replication, Virology Journal (2017) — Geraniin isolated from rambutan rind inhibited dengue virus type-2 (IC ~1.75 microM) by binding the viral envelope E-DIII protein and blocking early viral attachment in Vero cells. [https://doi.org/10.1186/s12985-017-0895-1]

---

## Durian (Durio zibethinus)
URL: https://nutridex.info/s/durian
Category: Fruits
Evidence: Preliminary — Early or small human trials; promising but not yet conclusive.
Pungent tropical fruit, rich in fiber and potassium

Quick answer: Durian is used for low glycemic index (~49) despite high sugar content, producing a smaller postprandial glucose rise than pineapple in a small human trial. NutriDex grades the human evidence as preliminary — Early or small human trials; promising but not yet conclusive. Based on 10 cited human studies (10 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Direct human evidence for durian is thin and mostly indirect. The strongest clinical datum is a small Malaysian crossover trial (n=10) that classified durian as a low-glycemic-index food (GI approximately 49) despite its high sugar load, suggesting a gentler postprandial glucose response than pineapple. Most other claims (antioxidant, anti-inflammatory, lipid-lowering, anticancer) rest on in-vitro assays of pulp, peel and seed extracts and on rodent feeding studies, not on whole-fruit human outcomes. Composition analyses confirm durian is genuinely nutrient-dense, supplying meaningful fiber, potassium, thiamin, vitamin C and carotenoids, but it is also unusually calorie- and fat-dense for a fruit (~147 kcal and ~5 g fat per 100 g). No randomized human trials show that habitual durian intake improves cardiovascular, metabolic or cancer endpoints. Overall the human evidence is best graded preliminary: durian is a nutritious whole fruit, but specific health benefits beyond its nutrient content remain unproven.

Nutrition (per 1 medium (600 g)): 882 kcal; Fiber 22.8g (81% DV), Vitamin C 118mg (131% DV), Thiamin (B1) 2.2mg (183% DV), Potassium 2616mg (56% DV), Copper 1.24mg (138% DV), Manganese 1.95mg (85% DV), Folate 216mcg (54% DV), Magnesium 180mg (43% DV).
Benefits / uses: Low glycemic index (~49) despite high sugar content, producing a smaller postprandial glucose rise than pineapple in a small human trial; High dietary fiber supporting satiety and digestive health; Rich source of potassium, relevant to blood-pressure regulation; Notable antioxidant capacity from polyphenols and carotenoids (ABTS/DPPH/NO scavenging in vitro); Anti-inflammatory activity of pulp/peel extracts (suppressed nitric-oxide production in macrophages in vitro); Lipid-modulating signal in animal models (reduced total and LDL cholesterol in cholesterol-fed rats).
Active compounds: Polyphenols / flavonoids (caffeic acid, quercetin, catechins, gallic acid); Carotenoids (beta-carotene, alpha-carotene, zeaxanthin, lutein); Volatile sulfur compounds (diethyl disulfide, ethanethiol, thioacetates) giving the signature aroma; Dietary fiber; Potassium and magnesium (electrolyte minerals); B-vitamins, especially thiamin (B1) plus folate, B6, riboflavin; Vitamin C (ascorbic acid); Unsaturated fatty acids (oleic and palmitic acid predominant); Triterpenoids (e.g., lupeol/lupenone-type) and organosulfur antioxidants.
Dose: Roughly 1-2 segments (~40-100 g pulp); a portion delivering 50 g carbohydrate is about 185 g pulp
Safety: Energy- and fat-dense for a fruit (~147 kcal and 5 g fat per 100 g), so large portions add up quickly; portion control matters for weight and, given its sugar load, for people with diabetes despite the low GI. Laboratory work shows durian extract inhibits aldehyde dehydrogenase (the enzyme that clears acetaldehyde), giving biological plausibility to the traditional warning against combining durian with alcohol, which could raise acetaldehyde and worsen flushing/hangover-type effects; avoid heavy durian intake with drinking. High potassium content warrants caution in advanced kidney disease or with potassium-sparing/RAAS medications. These cautions are based largely on composition and in-vitro/animal data rather than controlled human trials.

Cited studies (10):
  - Durian and Sapodilla Extracts Enhance Chemotherapy Sensitivity and Promote Apoptosis in Triple Negative Breast Cancer Model in Vitro: Systematic Review, Acta informatica medica : AIM : journal of the Society for Medical Informatics of Bosnia & Herzegovina : casopis Drustva za medicinsku informatiku BiH (2025) — Systematic review: durian and sapodilla extracts enhanced paclitaxel/doxorubicin cytotoxicity and apoptosis in triple-negative breast cancer cells in vitro; no in-vivo or clinical confirmation. [https://pubmed.ncbi.nlm.nih.gov/40223857/]
  - Nutrients and bioactive compounds in popular and indigenous durian (Durio zibethinus murr.), Food Chemistry (2016) — Thai durian varieties contained 7.5-9.1 g/100g DM dietary fiber and high carbohydrate; the indigenous Kob-ta-kam variety reached ~2248 ug/100g DM carotenoids and ~1202 ug beta-carotene. [https://doi.org/10.1016/j.foodchem.2015.02.107]
  - Glycemic index of common Malaysian fruits, Asia Pacific journal of clinical nutrition (2008) — Crossover trial in healthy adults: durian glycemic index 49+/-5 (low GI), significantly lower than pineapple (82) and not significantly different from watermelon (55) or papaya (58). [https://pubmed.ncbi.nlm.nih.gov/18364324/]
  - Potential use of durian fruit (Durio zibenthinus Linn) as an adjunct to treat infertility in polycystic ovarian syndrome, Journal of Integrative Medicine (2016) — Narrative review: durian shows anti-inflammatory, antioxidant, anti-obesity and lipid-lowering signals relevant to metabolic syndrome/PCOS, but mechanisms in ovulation remain unvalidated. [https://doi.org/10.1016/S2095-4964(16)60240-6]
  - Beneficial health effects of lupenone triterpene: A review, Biomedicine &amp; Pharmacotherapy (2018) — Review of lupenone, a lupane triterpenoid found in the durian family, describing anti-inflammatory, antidiabetic and antitumor activity in preclinical models. [https://doi.org/10.1016/j.biopha.2018.04.019]
  - Antioxidant and anti-inflammatory activities of durian (<i>Durio zibethinus</i>Murr.) pulp, seed and peel flour, PeerJ (2022) — Durian pulp, peel and seed flour extracts (Monthong, Chanee) showed measurable total phenolics and ABTS/NO/superoxide radical scavenging plus anti-inflammatory (anti-NO) activity in LPS-stimulated macrophages. [https://doi.org/10.7717/peerj.12933]
  - The profiles of durian (Durio zibethinus Murr.) shell phenolics and their antioxidant effects on H2O2-treated HepG2 cells as well as the metabolites and organ distribution in rats, Food Research International (2023) — Identified 17 phenolic compounds in durian shell extract and showed it reduced H2O2-induced ROS, MDA and apoptosis in HepG2 liver cells. [https://doi.org/10.1016/j.foodres.2022.112122]
  - Carotenoid accumulation in durian ( Durio zibethinus ) fruit is affected by ethylene via modulation of carotenoid pathway gene expression, Plant Physiology and Biochemistry (2017) — Durian pulp pigmentation arises from ethylene-regulated accumulation of beta-carotene and alpha-carotene with minor zeaxanthin and lutein during ripening. [https://doi.org/10.1016/j.plaphy.2017.03.021]
  - Inhibition of aldehyde dehydrogenase enzyme by Durian (Durio zibethinus Murray) fruit extract, Food Chemistry (2009) — Durian fruit extract inhibited yeast aldehyde dehydrogenase dose-dependently (up to ~70% inhibition), with sulfur-rich fractions most active, supporting the durian-alcohol caution mechanism via sulfur compounds. [https://doi.org/10.1016/j.foodchem.2009.03.106]
  - Durian (Durio zibethinus Murr.) cultivars as nutritional supplementation to rat’s diets, Food and Chemical Toxicology (2008) — In cholesterol-fed rats, durian-supplemented diets reduced plasma LDL-C (Mon Thong ~20%, Chani up to ~31%) and preserved antioxidant status; Mon Thong was judged the preferable cultivar. [https://doi.org/10.1016/j.fct.2007.08.042]

---

## Mangosteen (Garcinia mangostana)
URL: https://nutridex.info/s/mangosteen
Category: Fruits
Evidence: Preliminary — Early or small human trials; promising but not yet conclusive.
Xanthone-rich tropical fruit, more hype than proof

Quick answer: Mangosteen is used for antioxidant capacity: a xanthone-rich mangosteen beverage acutely raised plasma orac by up to 60% within 1 h in healthy adults (smaller multi-ingredient liquids showed ~18%). NutriDex grades the human evidence as preliminary — Early or small human trials; promising but not yet conclusive. Based on 9 cited human studies (9 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Human evidence for mangosteen is preliminary and dominated by small, often industry-linked trials of xanthone-rich juices, beverages or pericarp extracts rather than the fresh edible aril most people eat. Pharmacokinetic work confirms alpha-mangostin is absorbed (especially with a high-fat meal, though only ~2% appears in urine) and that the beverages transiently raise plasma antioxidant capacity. A few short randomized trials report lower CRP and favorable immune shifts, improved insulin sensitivity (HOMA-IR) in obese women, and adjunctive benefit of a topical pericarp gel in periodontitis, but sample sizes are tiny (often 10-60 participants), durations short, and several test multi-ingredient products (mangosteen combined with aloe, green tea and multivitamins) that confound attribution to mangosteen itself. There are no large outcome trials and no meta-analyses of clinical endpoints; much of the antioxidant/anticancer literature is in vitro or animal-based. The edible aril is also nutritionally modest, so claimed benefits hinge on concentrated pericarp xanthones rather than eating the fruit. Overall it is a pleasant, safe food, but marketed disease claims for mangosteen supplements outrun the human data.

Nutrition (per 1 cup, drained (196 g), canned in syrup): 143 kcal; Fiber 3.5g (13% DV), Vitamin C 5.7mg (6% DV), Folate 61µg (15% DV), Thiamin (B1) 0.11mg (9% DV), Copper 0.14mg (16% DV), Magnesium 25mg (6% DV), Potassium 94mg (2% DV).
Benefits / uses: Antioxidant capacity: a xanthone-rich mangosteen beverage acutely raised plasma ORAC by up to 60% within 1 h in healthy adults (smaller multi-ingredient liquids showed ~18%); Anti-inflammatory/immune: 30-day supplementation lowered C-reactive protein and modulated immune markers (T-helper frequency, complement) in a small RCT of a multi-ingredient mangosteen product; Insulin sensitivity: 26-week mangosteen extract improved HOMA-IR vs behavioral therapy alone in obese women (small pilot RCT, n=20 completers); Periodontal/oral health: topical pericarp gel as an adjunct to scaling/root planing improved pocket depth and gingival/bleeding indices; Bioavailability of alpha-mangostin: confirmed absorption and glucuronide/sulfate conjugation when taken with a high-fat meal (only ~2% recovered in urine); Acne: topical alpha-mangostin nanoparticles improved lesions in a tiny 4-week split-face trial (n=10).
Active compounds: Prenylated xanthones (alpha-mangostin, gamma-mangostin) - the signature bioactives, concentrated in the pericarp/rind; Garcinones (C, D, E) and gartanins - minor xanthones; Tannins and procyanidins (condensed tannins of the rind); Phenolic acids and flavonoids (epicatechin; anthocyanins give the purple rind); Vitamin C (ascorbic acid) - modest amount in edible aril; B vitamins (thiamin, riboflavin, folate); Dietary fiber (soluble and insoluble in the aril); Minerals (potassium, magnesium, copper, manganese) in small amounts.
Dose: 1 medium fruit (~3-4 segments of edible aril, ~40-60 g flesh); studied supplement doses use ~59-245 mL xanthone-rich juice/beverage or pericarp extracts, not the fresh aril
Safety: The fresh aril is generally safe as a food. Concern is mainly with concentrated juices/supplements: a published case of severe, refractory lactic acidosis followed daily mangosteen juice for ~12 months (possible mitochondrial electron-transport interference). Its antioxidant load may theoretically blunt some chemotherapy (anthracyclines, platinums, alkylators) and radiation, so avoid high-dose supplements during active cancer treatment. Alpha-mangostin and related xanthones can modulate several CYP450 enzymes (e.g., CYP1A2, 2C9, 2D6, 3A) in preclinical work, raising drug-interaction potential; possible additive immunosuppression with calcineurin inhibitors (cyclosporine, tacrolimus). Canned-in-syrup and juice products are high in added sugar - a consideration in diabetes. A theoretical antiplatelet effect warrants caution around surgery or with anticoagulants pending data.

Cited studies (9):
  - General toxicity studies of alpha mangostin from Garcinia mangostana: A systematic review, Heliyon (2023) — Systematic review of 20 toxicity studies estimated alpha-mangostin LD50 between >15.48 and <=6000 mg/kg and NOAEL between <100 and <=2000 mg/kg, framing its preclinical safety margin [https://doi.org/10.1016/j.heliyon.2023.e16045]
  - Mangosteen Extract Shows a Potent Insulin Sensitizing Effect in Obese Female Patients: A Prospective Randomized Controlled Pilot Study, Nutrients (2018) — 26-week mangosteen extract plus behavioral therapy improved insulin sensitivity (HOMA-IR -53% vs -15%) in obese women with insulin resistance (20 of 22 completed), with no attributable adverse effects [https://doi.org/10.3390/nu10050586]
  - Depositing α-mangostin nanoparticles to sebaceous gland area for acne treatment, Journal of Pharmacological Sciences (2015) — Twice-daily topical alpha-mangostin nanoparticles significantly improved acne vulgaris in a 4-week, double-blind, split-face trial of 10 patients, with minimal irritation [https://doi.org/10.1016/j.jphs.2015.11.005]
  - Xanthones in Mangosteen Juice Are Absorbed and Partially Conjugated by Healthy Adults, The Journal of Nutrition (2012) — In 10 healthy adults, 60 mL 100% mangosteen juice with a high-fat meal led to absorption of alpha-mangostin with glucuronide/sulfate conjugation; only ~2% of the ingested xanthone dose was recovered in 24-h urine, indicating limited urinary excretion [https://doi.org/10.3945/jn.111.156992]
  - Functional beverage of <i>Garcinia mangostana</i> (mangosteen) enhances plasma antioxidant capacity in healthy adults, Food Science &amp; Nutrition (2014) — A single 245 mL mangosteen-based functional beverage increased plasma ORAC by a maximum of ~60% at 1 h in 20 healthy adults, sustained >=6 h [https://doi.org/10.1002/fsn3.187]
  - Bioavailability and Antioxidant Effects of a Xanthone-Rich Mangosteen (Garcinia mangostana) Product in Humans, Journal of Agricultural and Food Chemistry (2009) — Acute 59 mL of a xanthone-rich mangosteen liquid (also containing aloe, green tea and multivitamins) raised plasma antioxidant capacity (ORAC) by a maximum of ~18% at 2 h, lasting >=4 h, with bioavailable alpha-mangostin [https://doi.org/10.1021/jf901012f]
  - Effect of a Mangosteen Dietary Supplement on Human Immune Function: A Randomized, Double-Blind, Placebo-Controlled Trial, Journal of Medicinal Food (2009) — 30-day xanthone-rich mangosteen product in 59 healthy adults increased peripheral T-helper cell frequency and reduced serum C-reactive protein, with higher complement C3/C4 and IL-1alpha vs placebo [https://doi.org/10.1089/jmf.2008.0204]
  - Topical application of Garcinia mangostana L. pericarp gel as an adjunct to periodontal treatment, Complementary Therapies in Medicine (2008) — Topical Garcinia mangostana pericarp gel as an adjunct to scaling/root planing enhanced clinical periodontal outcomes (greater reductions in pocket depth, gingival index and bleeding on probing) [https://doi.org/10.1016/j.ctim.2007.12.004]
  - Severe Lactic Acidosis Associated With Juice of the Mangosteen Fruit Garcinia mangostana, American Journal of Kidney Diseases (2008) — Case report of severe, refractory lactic acidosis after ~12 months of daily mangosteen juice, hypothesized to reflect xanthone interference with mitochondrial respiration [https://doi.org/10.1053/j.ajkd.2007.12.043]

---

## Longan (Dimocarpus longan)
URL: https://nutridex.info/s/longan
Category: Fruits
Evidence: Preliminary — Early or small human trials; promising but not yet conclusive.
Vitamin C-rich "dragon's eye" with polyphenol-packed pulp

Quick answer: Longan is used for exceptionally high vitamin c density for an antioxidant/immune-support contribution. NutriDex grades the human evidence as preliminary — Early or small human trials; promising but not yet conclusive. Based on 8 cited human studies (8 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Longan ("dragon's eye") is a lychee relative whose fresh pulp is unusually rich in vitamin C and contains hydrolysable tannins (corilagin, gallic and ellagic acid) and bioactive polysaccharides. The great majority of the evidence is preclinical: cell and rodent studies show antioxidant, anti-inflammatory, anti-hyperglycemic (alpha-amylase/alpha-glucosidase inhibition), immunomodulatory and antitumor activity, mostly from concentrated pericarp, seed or polysaccharide extracts rather than the amount of pulp a person would eat. Human data are very sparse: a single 12-week randomized, double-blind, placebo-controlled trial (n=50, ages 55-75) of a longan pulp-and-seed extract beverage found a significant reduction in the bone-turnover marker alkaline phosphatase versus placebo, with no significant change in lipid or glycemic markers and a good safety profile. No large prospective cohorts or meta-analyses isolate whole longan intake from overall fruit consumption. Reported antioxidant/anti-diabetic effects also depend heavily on extract type and processing (e.g., thermal "aging" raises phenolic content), limiting translation to the raw fruit. Overall the human evidence is preliminary, and longan is best regarded as a nutritious vitamin-C-dense fruit rather than a proven therapeutic.

Nutrition (per 1 cup, pitted (96 g)): 57 kcal; Vitamin C 80.6mg (90% DV), Copper 0.16mg (18% DV), Potassium 255mg (5% DV), Riboflavin (B2) 0.13mg (10% DV), Magnesium 9.6mg (2% DV), Fiber 1.1g (4% DV).
Benefits / uses: Exceptionally high vitamin C density for an antioxidant/immune-support contribution; Polyphenols (gallic acid, corilagin, ellagic acid) with in-vitro antioxidant and free-radical-scavenging activity; Preclinical anti-hyperglycemic effects via alpha-amylase / alpha-glucosidase inhibition (extract studies); Longan-pulp polysaccharides show immunomodulatory and antitumor activity in animal/cell models; Possible favorable shift in a bone-turnover marker (single small human RCT of a pulp/seed extract); Low fat, source of potassium and copper.
Active compounds: Vitamin C (L-ascorbic acid); Hydrolysable tannins (corilagin, gallic acid, ethyl gallate); Ellagic acid and ellagitannins; Flavonoids (epicatechin, quercetin glycosides); Bioactive polysaccharides / polysaccharide-protein complexes; Potassium and copper; B-vitamins (riboflavin).
Dose: About 1 cup of fresh pitted pulp (~96 g, roughly 20-30 fruits); dried longan is far more energy- and sugar-dense per gram.
Safety: Generally safe as a food. Dried longan is concentrated in sugar and calories and can spike blood glucose, so people with diabetes should account for it. Possible cross-reactive allergy in those sensitive to lychee or other Sapindaceae fruits. As with unripe lychee, eating large amounts on an empty/undernourished stomach has been linked theoretically to hypoglycin-type effects—keep portions moderate, especially in children. Bioactive-extract supplements are not interchangeable with the fruit and lack long-term human safety data; potential additive effects with glucose-lowering or immune-modulating drugs are unstudied.

Cited studies (8):
  - Effects of the Longan pulp and seed extract beverage product on bone turnover markers, lipid profiles, glycemic markers, and safety profiles in the elderly: A randomized, double-blind, placebo-controlled trial, Journal of Functional Foods (2025) — 12-week randomized, double-blind, placebo-controlled trial in adults 55-75 y: a longan pulp-and-seed extract beverage significantly reduced alkaline phosphatase (a bone-turnover marker; mean difference -7.06 U/L, p=0.023) vs placebo, with no significant change in lipid or glycemic markers and no safety concerns. [https://doi.org/10.1016/j.jff.2025.106887]
  - Polyphenol Profile, Antioxidant Activity, and Hypolipidemic Effect of Longan Byproducts, Molecules (Basel, Switzerland) (2023) — Longan-byproduct polyphenol extract showed strong in-vitro antioxidant capacity and, in obese mice, reduced body-weight gain (~11.8%) and serum/liver lipids while ameliorating hepatic steatosis via PPARalpha/LXRalpha pathways. [https://pmc.ncbi.nlm.nih.gov/articles/PMC10004001/]
  - Enhancement of phenolics content and biological activities of longan (Dimocarpus longan Lour.) treated with thermal and ageing process, Scientific reports (2021) — Thermal/aging processing of longan markedly increased total phenolic content (gallic and ellagic acid up ~10-fold, corilagin doubled) and antioxidant and biological activities, showing that processing strongly modulates longan's bioactive profile. [https://pmc.ncbi.nlm.nih.gov/articles/PMC8342457/]
  - Phenolic content, antioxidant capacity, and α-amylase and α-glucosidase inhibitory activities of Dimocarpus longan Lour, Food science and biotechnology (2020) — Across longan varieties, methanolic extracts inhibited alpha-amylase (up to ~97.6%) and alpha-glucosidase (up to ~88.6%) and showed strong DPPH/ABTS radical scavenging, supporting in-vitro anti-hyperglycemic potential. [https://pmc.ncbi.nlm.nih.gov/articles/PMC7221113/]
  - Polyphenols and Alkaloids in Byproducts of Longan Fruits (Dimocarpus Longan Lour.) and Their Bioactivities, Molecules (Basel, Switzerland) (2019) — Longan pericarp and seed byproducts are rich in corilagin (major polyphenol) and exhibit antioxidant, nitrite-scavenging and in-vitro anti-hyperglycemic activities, positioning seed flavonoids and pericarp alkaloids as candidate anti-diabetic agents. [https://pmc.ncbi.nlm.nih.gov/articles/PMC6471414/]
  - Immunomodulatory activity of polysaccharide-protein complex of longan (Dimocarpus longan Lour.) pulp, Molecules (Basel, Switzerland) (2011) — A polysaccharide-protein complex (LP3) from longan pulp given orally to immunosuppressed mice (100 mg/kg/day) increased antibody production, ConA-induced splenocyte proliferation, macrophage phagocytosis, NK-cell cytotoxicity and serum IFN-gamma/IL-2. [https://pubmed.ncbi.nlm.nih.gov/22158685/]
  - Structure and antitumor and immunomodulatory activities of a water-soluble polysaccharide from Dimocarpus longan pulp, International journal of molecular sciences (2014) — A water-soluble longan-pulp polysaccharide (LP1) showed antitumor activity in vitro (~40-50% inhibition of SKOV3/HO8910 cells) and immunostimulatory effects, including increased IFN-gamma and B/T-lymphocyte proliferation. [https://pmc.ncbi.nlm.nih.gov/articles/PMC3975445/]
  - Chemical characterization and anti-hyperglycaemic effects of polyphenol enriched longan (Dimocarpus longan Lour.) pericarp extracts, Journal of Functional Foods (2015) — Polyphenol-enriched longan pericarp extracts inhibited carbohydrate-digesting enzymes and reduced postprandial hyperglycemia, attributed to 4-O-methylgallic acid, corilagin and ellagic acid. [https://doi.org/10.1016/j.jff.2015.01.006]

---

## Salak (Snake Fruit) (Salacca zalacca)
URL: https://nutridex.info/s/salak
Category: Fruits
Evidence: Preliminary — Early or small human trials; promising but not yet conclusive.
Scaly Indonesian palm fruit rich in polyphenols

Quick answer: Salak (Snake Fruit) is used for antioxidant capacity (high polyphenol content; strong dpph/abts radical scavenging in pulp and peel, in vitro). NutriDex grades the human evidence as preliminary — Early or small human trials; promising but not yet conclusive. Based on 10 cited human studies (10 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Salak is an Indonesian palm fruit whose health reputation rests almost entirely on laboratory and animal data rather than human trials. Pulp and especially peel are rich in phenolic acids (chlorogenic, caffeic, ferulic) and organic acids, giving strong in vitro antioxidant (DPPH/ABTS) and antimicrobial activity. Fruit and seed extracts inhibit alpha-glucosidase and intestinal glucose uptake in vitro and lower blood glucose in obese-diabetic and STZ-nicotinamide rodent models, supporting the traditional antidiabetic use, but no human glycemic trial exists. The single registered human RCT (n=71) tested a snake-fruit-infused massage oil with Thai massage and found no overall skin benefit over plain coconut oil, with elasticity and melanin improvements attributable to the massage itself. Popular memory-fruit and anti-cancer claims are extrapolations from nutrient content with no clinical confirmation. As a whole food it is a reasonable low-fat source of fiber, potassium and vitamin C, but evidence for specific disease benefits in people remains preliminary. Composition also varies substantially by cultivar (e.g. Pondoh, Bali, Gading).

Nutrition (per 1 medium fruit (50 g edible)): 41 kcal; Vitamin C 4.2mg (5% DV), Potassium 128mg (3% DV), Iron 2mg (11% DV), Calcium 14mg (1% DV), Fiber 1g (4% DV), Riboflavin (B2) 0.1mg (8% DV).
Benefits / uses: Antioxidant capacity (high polyphenol content; strong DPPH/ABTS radical scavenging in pulp and peel, in vitro); Possible postprandial glucose control via alpha-glucosidase inhibition and reduced intestinal glucose uptake (in vitro and rodent studies only); Traditional antidiabetic use with supporting rodent blood-glucose and metabolomic data, but no human glycemic trial; Whole-food source of dietary fiber/pectin and potassium for digestive and vascular support; Antimicrobial phenolic acids (chlorogenic, caffeic, ferulic) concentrated in peel and pulp, in vitro; Skin/anti-aging activity in UV-stressed human fibroblasts; the one human RCT (massage oil) showed no benefit beyond plain coconut oil.
Active compounds: Phenolic acids — chlorogenic acid, caffeic acid, ferulic acid, coumaric acid; Flavonoids and condensed tannins (proanthocyanidins); Organic acids — malic acid (dominant), plus citric acid; Vitamin C (ascorbic acid); Carotenoids — including beta-carotene; Dietary fiber and pectin; Minerals — potassium, calcium, iron, phosphorus; B vitamins — thiamin, riboflavin, niacin.
Dose: 1-3 fresh fruits (~50-150 g edible flesh) as a snack; no established therapeutic dose for extracts
Safety: Generally safe as a food. High tannin and fiber content and astringency may contribute to constipation if eaten in large amounts; the cut flesh oxidizes and browns quickly due to a membrane-bound polyphenoloxidase. Antidiabetic extract activity is unproven in humans — do not substitute for diabetes medication, and people on glucose-lowering drugs should monitor for additive effects if consuming concentrated extracts. No USDA Daily Value-grade composition exists (the fruit is absent from USDA FoodData Central); nutrient figures derive from the Indonesian Food Composition Table (TKPI/DKBM) and vary by cultivar, so the listed %DV values are approximate.

Cited studies (10):
  - Effects of Snake Fruit–Infused Massage Oil With Traditional Thai Massage on Skin Quality: A Randomized Controlled Trial, The Scientific World Journal (2026) — RCT (n=71): snake-fruit-extract-infused massage oil with Thai massage improved leg moisture and oiliness but showed NO overall superiority over plain coconut oil; elasticity and melanin gains occurred across all groups and were attributable to massage itself (NCT06227260) [https://doi.org/10.1155/tswj/2446967]
  - Oral Glucose Tolerance Test (OGTT) Evidence for the Postprandial Anti-Hyperglycemic Property of Salacca zalacca (Gaertn.) Voss Seed Extract, Molecules (2023) — Salak seed extract non-competitively inhibited alpha-glucosidase (IC50 16.3 µg/mL) and reduced glucose uptake in Caco-2 cells, and lowered fasting blood glucose in an OGTT in STZ-nicotinamide diabetic mice (chlorogenic acid as the prominent HPLC peak) [https://doi.org/10.3390/molecules28196775]
  - Dynamics of Bioactive Compounds and Their Relationship with Antioxidant and Antimicrobial Activity in the Pulp, Peel, and Seeds of ‘Salak’ During Ripening, Foods (2025) — During ripening, salak peel had the highest chlorogenic (705 mg/100 g DW), caffeic (321) and ferulic (173.5) acids; pulp peaked at 5.5 mmol Trolox/100 g DW antioxidant capacity (DPPH) with antimicrobial activity against tested pathogens [https://doi.org/10.3390/foods14203476]
  - Salacca zalacca extract's antiaging effect on aging genes, protein levels, and apoptosis in UV-induced fibroblast cells, Journal of Taibah University Medical Sciences (2025) — S. zalacca extract (6.25-25 µg/mL) on UV-irradiated human BJ fibroblasts up-regulated anti-aging genes, raised elastin and melatonin, lowered COX-2, 8-OHdG and hyaluronidase, and reduced apoptosis [https://doi.org/10.1016/j.jtumed.2025.05.005]
  - Enhancement of phenolic content and antioxidant activity in snakefruit (Salacca zalacca (Gaerth.)Voss) vinegar by malolactic fermentation with Lactobacillus plantarum, Journal of Food Science and Technology (2025) — Malolactic co-fermentation of snakefruit vinegar with L. plantarum increased DPPH antioxidant activity and phenolic acids (caffeic, coumaric, ferulic), supporting a functional-food product [https://doi.org/10.1007/s13197-025-06220-3]
  - Modulation of metabolic alterations of obese diabetic rats upon treatment with Salacca zalacca fruits extract using 1H NMR-based metabolomics, Food Research International (2020) — 60% ethanolic S. zalacca fruit extract (400 mg/kg, 6 wk) significantly lowered blood glucose and normalized blood lipid profile in obese-diabetic rats; 1H-NMR urine metabolomics showed reduced ketone bodies (3-hydroxybutyrate, acetoacetate) and improved energy metabolism [https://doi.org/10.1016/j.foodres.2020.109547]
  - GC-MS analysis of metabolites from soxhlet extraction, ultrasound-assisted extraction and supercritical fluid extraction of<i>Salacca zalacca</i>flesh and its alpha-glucosidase inhibitory activity, Natural Product Research (2019) — Among salak flesh extracts by different methods, a 60% ethanol ultrasound-assisted extract showed the strongest alpha-glucosidase inhibition (IC50 16.2 µg/mL); GC-MS identified phenolic acids, organic acids, fatty acids and sterols as candidate actives [https://doi.org/10.1080/14786419.2018.1560295]
  - Correlation of FT-IR Fingerprint and α-Glucosidase Inhibitory Activity of Salak (Salacca zalacca) Fruit Extracts Utilizing Orthogonal Partial Least Square, Molecules (2018) — Across 36 ethanol-water salak fruit extracts, FT-IR fingerprint functional-group regions (C-H, C=O, C-N, N-H, C-O, C=C) correlated with alpha-glucosidase inhibitory activity via OPLS modeling [https://doi.org/10.3390/molecules23061434]
  - Purification and characterization of membrane-bound polyphenoloxidase (mPPO) from Snake fruit [Salacca zalacca (Gaertn.) Voss], Food Chemistry (2013) — Purified membrane-bound polyphenoloxidase from snake fruit (38 kDa monomer) drives rapid enzymatic browning; L-cysteine was the most effective inhibitor (IC50 1.3 mM), explaining the cut flesh's fast oxidation [https://doi.org/10.1016/j.foodchem.2012.08.034]
  - Identification of Potent Odorants in Different Cultivars of Snake Fruit [<i>Salacca zalacca </i>(Gaert.) Voss] Using Gas Chromatography−Olfactometry, Journal of Agricultural and Food Chemistry (2005) — GC-olfactometry of three salak cultivars identified 24 odor-active compounds; methyl 3-methylpentanoate is the character-impact aroma, with clear differences between Pondoh and Gading cultivars [https://doi.org/10.1021/jf048950h]

---

## Pomelo (Citrus maxima)
URL: https://nutridex.info/s/pomelo
Category: Fruits
Evidence: Preliminary — Early or small human trials; promising but not yet conclusive.
Largest citrus, vitamin C and flavonoid rich

Quick answer: Pomelo is used for very high vitamin c content (one cup exceeds the daily requirement) supporting antioxidant defense and normal immune function. NutriDex grades the human evidence as preliminary — Early or small human trials; promising but not yet conclusive. Based on 11 cited human studies (11 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Pomelo is an exceptional dietary source of vitamin C, with one cup of sections supplying well over a day's requirement (about 129% DV), and it delivers citrus flavonoids (naringin, narirutin, naringenin) plus modest potassium and fiber. Large prospective cohorts and meta-analyses show higher citrus and total fruit intake is associated with modestly reduced cardiovascular disease and ischemic stroke risk (roughly 9-12% for citrus), but these data are for citrus broadly, not pomelo specifically. The lipid-lowering, antioxidant, hepatoprotective and neuroprotective effects attributed to naringin and total pomelo flavonoids come overwhelmingly from cell and rodent studies, not human trials. No randomized controlled trials establish clinical benefit of pomelo itself. The overall human evidence is therefore preliminary and largely extrapolated from generic citrus epidemiology and mechanistic work. Pomelo is a nutritious, hydrating, low-calorie whole fruit, best regarded as a healthful component of a fruit-rich diet rather than a proven therapeutic food. Its most clinically important property is a grapefruit-like potential to alter drug metabolism.

Nutrition (per 1 cup sections (190 g)): 72 kcal; Vitamin C 115.9mg (129% DV), Potassium 410mg (9% DV), Copper 0.09mg (10% DV), Fiber 1.9g (7% DV), Vitamin B6 0.068mg (4% DV), Calcium 7.6mg (1% DV).
Benefits / uses: Very high vitamin C content (one cup exceeds the daily requirement) supporting antioxidant defense and normal immune function; Part of citrus intake linked in large prospective cohorts and meta-analyses to modestly lower cardiovascular and stroke risk (citrus broadly, not pomelo specifically); Naringin and naringenin flavonoids with lipid-lowering and antioxidant activity (evidence mostly preclinical, no human trials in pomelo); Hydrating, low-energy, low-fat whole fruit useful for weight-conscious diets; Potassium contributes modestly to blood-pressure-favorable dietary patterns; Polyphenols and fiber may support metabolic and gut health (early, mostly preclinical evidence).
Active compounds: Vitamin C (L-ascorbic acid); Flavanone glycosides (naringin, narirutin); Flavanone aglycones (naringenin); Hesperidin / hesperetin; Furanocoumarins (bergamottin, 6',7'-dihydroxybergamottin); Potassium; Dietary fiber (pectin); Carotenoids and limonoids; Phenolic acids (ferulic, caffeic).
Dose: 1 cup sections (~190 g); a whole medium fruit yields several cups of edible flesh
Safety: Like grapefruit, pomelo contains furanocoumarins that inhibit intestinal CYP3A4 and P-glycoprotein, raising blood levels of many medications; documented cases include marked elevation of tacrolimus and a measured increase in cyclosporine exposure in human pharmacokinetic study, and it can affect statins, calcium-channel blockers (e.g. felodipine), and other CYP3A4 substrates. Patients on these drugs should avoid pomelo and pomelo juice. It is acidic and may aggravate reflux in sensitive people; potassium content warrants moderation in advanced kidney disease. Otherwise generally safe as food.

Cited studies (11):
  - Relation of Different Fruit and Vegetable Sources With Incident Cardiovascular Outcomes: A Systematic Review and Meta-Analysis of Prospective Cohort Studies, Journal of the American Heart Association (2020) — Meta-analysis of 81 prospective cohorts (>4 million people): higher citrus fruit intake associated with ~10-12% lower risk across cardiovascular and stroke outcomes (RR ~0.88). [https://www.ahajournals.org/doi/10.1161/JAHA.120.017728]
  - The beneficial role of Naringin- a citrus bioflavonoid, against oxidative stress-induced neurobehavioral disorders and cognitive dysfunction in rodents: A systematic review and meta-analysis, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie (2017) — Systematic review/meta-analysis: naringin significantly restored oxidative-stress markers and reduced neurobehavioral deficits across rodent models (no human data). [https://pubmed.ncbi.nlm.nih.gov/28810519/]
  - Naringin and naringenin as anticancer agents and adjuvants in cancer combination therapy: Efficacy and molecular mechanisms of action, a comprehensive narrative review, Pharmacological research (2021) — Comprehensive narrative review: naringin and naringenin show anticancer and chemo-adjuvant activity across in vitro and animal models; clinical confirmation lacking. [https://pubmed.ncbi.nlm.nih.gov/33166734/]
  - The new exploration of pure total flavonoids extracted from Citrus maxima (Burm.) Merr. as a new therapeutic agent to bring health benefits for people, Frontiers in nutrition (2022) — Review of pure total flavonoids from Citrus maxima summarizing preclinical effects on liver metabolic disease, cardiovascular disease, gut barrier and malignancy. [https://pmc.ncbi.nlm.nih.gov/articles/PMC9582534/]
  - Grapefruit juice-drug interactions, British journal of clinical pharmacology (1998) — Foundational review establishing that grapefruit (and related citrus) furanocoumarins inhibit enteric CYP3A4, increasing oral bioavailability of many CYP3A4 substrate drugs. [https://pubmed.ncbi.nlm.nih.gov/9723817/]
  - Frequency of citrus fruit intake is associated with the incidence of cardiovascular disease: the Jichi Medical School cohort study, Journal of epidemiology (2011) — Jichi Medical School cohort: near-daily citrus intake associated with lower incident CVD (HR 0.57 men, 0.51 women) and lower stroke/cerebral infarction risk. [https://pubmed.ncbi.nlm.nih.gov/21389640/]
  - Dietary flavonoids and risk of stroke in women, Stroke (2012) — Nurses' Health Study (~69,600 women, 14 y): higher citrus flavanone intake associated with ~19% lower risk of ischemic stroke. [https://pmc.ncbi.nlm.nih.gov/articles/PMC3360888/]
  - The flavonoid profiles in the pulp of different pomelo (Citrus grandis L. Osbeck) and grapefruit (Citrus paradisi Mcfad) cultivars and their in vitro bioactivity, Food chemistry: X (2022) — Profiling of pomelo (Citrus grandis) and grapefruit cultivars identified naringin, narirutin, hesperidin and naringenin as dominant flavonoids with measurable in vitro antioxidant and lipase-inhibitory bioactivity. [https://pmc.ncbi.nlm.nih.gov/articles/PMC9532706/]
  - Pomelo-induced increase in the blood level of tacrolimus in a renal transplant patient, Transplantation (2003) — Case report: pomelo intake markedly raised whole-blood tacrolimus trough levels in a renal transplant patient via CYP3A4/P-gp inhibition; authors advise transplant patients avoid pomelo. [https://pubmed.ncbi.nlm.nih.gov/12698101/]
  - Food-drug interaction of tacrolimus with pomelo, ginger, and turmeric juice in rats, Drug metabolism and pharmacokinetics (2012) — Rat study: pomelo juice significantly increased tacrolimus exposure, supporting the mechanistic basis of the clinical pomelo-tacrolimus interaction. [https://pubmed.ncbi.nlm.nih.gov/22123127/]
  - Pomelo juice, but not cranberry juice, affects the pharmacokinetics of cyclosporine in humans, Clinical pharmacology and therapeutics (2006) — Controlled human study: pomelo juice (but not cranberry juice) increased cyclosporine AUC and Cmax, confirming a clinically relevant CYP3A4-mediated drug interaction. [https://pubmed.ncbi.nlm.nih.gov/16513449/]

---

## Langsat / Duku (Lansium parasiticum)
URL: https://nutridex.info/s/langsat-duku
Category: Fruits
Evidence: Preliminary — Early or small human trials; promising but not yet conclusive.
Translucent Southeast Asian fruit, antioxidant peel chemistry

Quick answer: Langsat / Duku is used for free-radical scavenging and protection of cellular dna from oxidative damage (in vitro). NutriDex grades the human evidence as preliminary — Early or small human trials; promising but not yet conclusive. Based on 8 cited human studies (8 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Langsat (duku/lanzones) is a low-calorie tropical fruit whose edible aril supplies modest amounts of vitamin C, B-vitamins, and fiber, but no dedicated USDA Foundation/SR entry exists, so composition figures derive from regional food tables and review papers and vary widely by cultivar (e.g. reported water 83–90 g, carbohydrate 8–15 g, and vitamin C 13–46 mg per 100 g). Nearly all published bioactivity research is preclinical: peel and seed fractions show free-radical scavenging, protect human TK6 cells against H2O2-induced DNA damage in comet assays, and contain triterpenoids with antimalarial, antibacterial, antifungal, and cytotoxic activity in vitro. The antimalarial and antifeedant/insecticidal effects are among the best-characterized, with seed tetranortriterpenoids inhibiting Plasmodium falciparum at IC50 values around 2–10 µg/mL. However, these active compounds are concentrated in the inedible peel and bitter seeds rather than the sweet pulp people actually eat, and there are essentially no human clinical trials. Traditional uses (diarrhea, fever, eye inflammation, malaria, mosquito repellent) are documented but not validated in controlled human studies. Overall the weight of human evidence is preliminary, and health claims should be treated as hypotheses rather than established benefits.

Nutrition (per 1 serving, ~5 fruits (65 g)): 22 kcal; Vitamin C 8.7mg (10% DV), Iron 0.65mg (4% DV), Fiber 0.6g (2% DV), Riboflavin (B2) 0.02mg (2% DV), Phosphorus 13mg (1% DV), Calcium 6.5mg (1% DV).
Benefits / uses: Free-radical scavenging and protection of cellular DNA from oxidative damage (in vitro); Antimalarial activity of seed/peel triterpenoids against chloroquine-resistant Plasmodium (in vitro); Antibacterial and antifungal activity of peel-derived onoceranoid triterpenes and lansiosides (e.g. lansioside D vs S. aureus/MRSA, in vitro); Cytotoxic activity of tetranortriterpenoids against cancer cell lines (in vitro); Traditional digestive and antipyretic use (diarrhea, dysentery, fever); Insecticidal / mosquito-larvicidal and antifeedant activity of extracts.
Active compounds: Onoceranoid triterpenes (lansiosides A–D, methyl lansioside C); Tetranortriterpenoids / limonoids (dukunolides, domesticulides, kokosanolides, langsatides); Lansic acid and bicyclic triterpene acids; Phenolic acids (chlorogenic acid, scopoletin); Flavonoids (rutin); Vitamin C (ascorbic acid); B-vitamins (riboflavin, thiamine, niacin); Dietary fiber (pectin-type polysaccharides).
Dose: A typical serving is about 5 fruits (~65 g of translucent edible aril, peel and seeds discarded).
Safety: The aril is generally safe as food. Seeds are intensely bitter and contain toxic/biologically active limonoids — do not swallow or eat them. Peel and seed extracts (the parts studied for bioactivity) are not validated for human consumption and should not be self-administered, especially in pregnancy or with antimalarial/other medications, as interactions and toxicity are uncharacterized. As a sweet fruit it contributes free sugars; people with diabetes should account for portion size. Imported fruit may carry surface contaminants — wash before peeling. No well-documented common food allergy, but cross-reactivity within the Meliaceae family is theoretically possible.

Cited studies (8):
  - Lansium domesticum-A Fruit with Multi-Benefits: Traditional Uses, Phytochemicals, Nutritional Value, and Bioactivities, Nutrients (2022) — Comprehensive review (data 1931–2021) cataloguing L. domesticum nutritional value, terpenoids/phenolics, and bioactivities (antimalarial, antioxidant, antibacterial, cytotoxic, larvicidal); compositional tables vary by cultivar (langsat/duku/longkong) and evidence is overwhelmingly preclinical. [https://pubmed.ncbi.nlm.nih.gov/35406144/]
  - Phytochemistry and biological activity of Lansium domesticum Corr. species: a review, The Journal of pharmacy and pharmacology (2022) — Review reporting >80 compounds isolated from L. domesticum (mainly terpenoids and glycosides) with antimalarial, antifeedant, antimicrobial/antibacterial, radical-scavenging and anticancer activities. [https://pubmed.ncbi.nlm.nih.gov/36094290/]
  - New Triterpenoids from Lansium domesticum Corr. cv kokossan and Their Cytotoxic Activity, Molecules (Basel, Switzerland) (2023) — Two new onoceranoid triterpenes (kokosanolides E, F) from fruit peel and a new tetranortriterpenoid (kokosanolide G) from seeds; compounds showed moderate cytotoxicity against MCF-7 breast cancer cells (IC50 45.9 and 18.4 µg/mL). [https://pmc.ncbi.nlm.nih.gov/articles/PMC10004713/]
  - Determination of Free Radical Scavenging, Antioxidative DNA Damage Activities and Phytochemical Components of Active Fractions from Lansium domesticum Corr. Fruit, Nutrients (2015) — L. domesticum (longkong) peel fractions showed stronger radical scavenging than seeds; the lead 50% ethanol/ethyl-acetate peel fraction at the highest tested concentration gave 53.5% inhibition of H2O2-induced DNA damage in human TK6 cells (comet assay); key phenolics were scopoletin, rutin, chlorogenic acid. [https://pmc.ncbi.nlm.nih.gov/articles/PMC4555151/]
  - Antifeedant triterpenoids from the seeds and bark of Lansium domesticum cv Kokossan (Meliaceae), Molecules (Basel, Switzerland) (2011) — Antifeedant triterpenoids (including kokosanolides) isolated from the seeds and bark of L. domesticum cv Kokossan showed moderate-to-strong antifeedant activity against Epilachna vigintioctopunctata larvae. [https://pmc.ncbi.nlm.nih.gov/articles/PMC6260637/]
  - Antimalarial tetranortriterpenoids from the seeds of Lansium domesticum Corr, Phytochemistry (2006) — Five new tetranortriterpenoids (domesticulides A–E) plus 11 known triterpenoids from L. domesticum seeds; eight compounds showed antimalarial activity against P. falciparum with IC50 of 2.4–9.7 µg/mL. [https://pubmed.ncbi.nlm.nih.gov/16930641/]
  - Lansium domesticum: skin and leaf extracts of this fruit tree interrupt the lifecycle of Plasmodium falciparum, and are active towards a chloroquine-resistant strain of the parasite (T9) in vitro, Journal of ethnopharmacology (2003) — Skin and aqueous leaf extracts of L. domesticum reduced parasitemia of drug-sensitive (3D7) and chloroquine-resistant (T9) P. falciparum equally well and interrupted the parasite lifecycle in vitro. [https://pubmed.ncbi.nlm.nih.gov/12576213/]
  - The structure of Lansioside A : A novel triterpene glycoside with amino-sugar from, Tetrahedron Letters (1982) — Isolation and structure elucidation of lansioside A, a novel triterpene glycoside bearing an amino-sugar, from L. domesticum (founding member of the lansioside onoceranoid series); Tetrahedron Letters 23(13):1349–1350. [https://doi.org/10.1016/S0040-4039(00)87101-4]

---

## Cempedak (Artocarpus integer)
URL: https://nutridex.info/s/cempedak
Category: Fruits
Evidence: Preliminary — Early or small human trials; promising but not yet conclusive.
Aromatic jackfruit cousin rich in prenylflavones

Quick answer: Cempedak is used for antioxidant / free-radical scavenging activity (dpph, frap, abts) from phenolic-rich pulp, peel and seed (in vitro). NutriDex grades the human evidence as preliminary — Early or small human trials; promising but not yet conclusive. Based on 10 cited human studies (10 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Cempedak is a Southeast-Asian Artocarpus fruit closely related to jackfruit, valued in food-composition databases as an energy-moderate, fiber- and potassium-containing fruit with appreciable vitamin C and carotenoids. The direct human evidence base is essentially absent: published studies are overwhelmingly phytochemical and in-vitro/in-vivo (animal/cell) work, not clinical trials in people. Laboratory studies consistently show that its phenolic-rich extracts (especially peel and seed) have strong antioxidant capacity, and isolated prenylated flavonoids and stilbenes display potent tyrosinase inhibition and antimalarial activity against Plasmodium falciparum. The seed is a documented source of resistant starch with prebiotic, probiotic-promoting effects in vitro. Genus-level human data are stronger only for the sister species: a small randomized, double-blind, placebo-controlled trial of green-jackfruit flour (Artocarpus heterophyllus) lowered HbA1c and fasting/postprandial glucose in type 2 diabetes, and broader meta-analytic data show fruit modestly lowers fasting glucose. None of these clinical findings have been replicated with cempedak itself, so all human-health claims for this specific fruit remain preliminary and extrapolated. It is best regarded as a nutritious whole fruit with promising but pre-clinical bioactive chemistry.

Nutrition (per 1 serving, pulp (100 g)): 117 kcal; Vitamin C 17.7mg (20% DV), Potassium 246mg (5% DV), Fiber 3.4g (12% DV), Thiamin (B1) 0.2mg (17% DV), Riboflavin (B2) 0.2mg (15% DV), Calcium 40mg (3% DV).
Benefits / uses: Antioxidant / free-radical scavenging activity (DPPH, FRAP, ABTS) from phenolic-rich pulp, peel and seed (in vitro); Fiber- and resistant-starch-rich seed with documented prebiotic (Lactobacillus-promoting) activity in vitro; Source of potent tyrosinase-inhibiting flavonoids (skin-brightening / anti-browning interest; cell-free/in vitro); Antimalarial prenylated stilbenes/flavones active against Plasmodium falciparum in vitro (and a related species extract in mice); Provides potassium, vitamin C, B-vitamins and carotenoids in an energy-moderate tropical fruit; Genus-level signals for glycemic control (green-jackfruit-flour RCT in the sister species) suggesting carbohydrate-quality interest.
Active compounds: Prenylated flavonoids (cyclochampedol, artoindonesianins, heteroflavanone); Prenylated stilbenes (trans-4-(3-methyl-E-but-1-enyl)-tetrahydroxystilbene); Arylbenzofurans (licocoumarone, moracin derivatives); Phenolic acids / total polyphenols (gallic-acid-equivalent rich peel & seed); Flavonoids (artocarpesin, norartocarpetin, oxyresveratrol, artocarpanone); Carotenoids (beta-carotene) and vitamin C (ascorbic acid); Dietary fiber and resistant starch (seed); Potassium and B-vitamins (thiamin, riboflavin, niacin).
Dose: 1 serving of fresh pulp, roughly 100 g (about 4-6 arils)
Safety: Cempedak is a high-carbohydrate, moderate-energy fruit (~117 kcal/100 g) and can raise blood glucose; people with diabetes should portion-control and monitor. As a Moraceae/Artocarpus fruit it shares allergens with jackfruit and may cross-react in those with latex-fruit or birch-pollen (PR-10/profilin) allergy or jackfruit allergy. The aromatic latex/sap can be irritating and sticky; seeds are typically boiled or roasted before eating. Bioactive extracts (concentrated flavonoids/stilbenes) are not the same as eating the fruit and have not been tested for safety or drug interactions in humans—avoid medicinal-dose extracts without supervision, particularly alongside antidiabetic or antimalarial drugs.

Cited studies (10):
  - Effect of fruit on glucose control in diabetes mellitus: a meta-analysis of nineteen randomized controlled trials, Frontiers in endocrinology (2023) — Meta-analysis of 19 RCTs (888 participants) found fruit consumption significantly lowered fasting blood glucose (MD -8.38 mg/dL, 95% CI -12.34 to -4.43) with no significant change in HbA1c. [https://pmc.ncbi.nlm.nih.gov/articles/PMC10198260/]
  - Efficacy of green jackfruit flour as a medical nutrition therapy replacing rice or wheat in patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled study, Nutrition & diabetes (2021) — Randomized, double-blind, placebo-controlled trial (n=40, 12 wk) of green-jackfruit (Artocarpus heterophyllus) flour replacing rice/wheat significantly reduced HbA1c and fasting/postprandial glucose in type 2 diabetes. [https://pubmed.ncbi.nlm.nih.gov/34127645/]
  - Phytochemicals and antioxidant activity of different parts of bambangan (Mangifera pajang) and tarap (Artocarpus odoratissimus), Food Chemistry (2009) — Across Bornean Artocarpus/Mangifera fruits, total phenolic content ranged 5.96–103.3 mg GAE/g, with peel/seed/kernel fractions showing the strongest radical-scavenging and ferric-reducing activity. [https://doi.org/10.1016/j.foodchem.2008.07.081]
  - Artocarpus: a review of its traditional uses, phytochemistry and pharmacology, Journal of ethnopharmacology (2010) — Review of Artocarpus phytochemistry catalogues prenylflavones, stilbenes and arylbenzofurans across the genus and their antimalarial, cytotoxic, tyrosinase-inhibitory and antioxidant activities. [https://pubmed.ncbi.nlm.nih.gov/20380874/]
  - Tyrosinase Inhibitory Properties of Compounds Isolated from Artocarpus integer Roots, Journal of natural products (2024) — Compounds isolated from A. integer roots inhibited tyrosinase, with cyclochampedol (IC50 1.7 µM) and licocoumarone (IC50 1.2 µM) far exceeding kojic acid (25.9 µM). [https://pmc.ncbi.nlm.nih.gov/articles/PMC11686508/]
  - Isolation of Prebiotics from Artocarpus integer's Seed, International journal of food science (2021) — Seed-derived extract of A. integer resisted gastric/enzymatic digestion (~90% reaching the intestine) and promoted probiotic growth (L. casei 8.33, L. acidophilus 6.96 log10 CFU at 72 h), indicating prebiotic potential. [https://pmc.ncbi.nlm.nih.gov/articles/PMC8318755/]
  - Effect of Formulated Artocarpus champeden Extract on Parasite Growth and Immune Response of Plasmodium berghei-Infected Mice, Evidence-based complementary and alternative medicine : eCAM (2020) — Formulated Artocarpus champeden (cempedak) extract suppressed Plasmodium berghei parasitaemia (~72% at top dose) and modulated immune response (raised IFN-γ) in infected mice. [https://pmc.ncbi.nlm.nih.gov/articles/PMC7066425/]
  - Different drying temperatures modulate chemical and antioxidant properties of mandai cempedak ( Artocarpus integer), F1000Research (2018) — Drying-temperature optimization of fermented mandai cempedak gave total phenolics 348.8 mg GAE/kg and antioxidant IC50 of 56.96 ppm, with phenolics the main antioxidant contributors. [https://pubmed.ncbi.nlm.nih.gov/32201564/]
  - Tyrosinase inhibitory activity of flavonoids from Artocarpus heterophyllous, Chemistry Central journal (2016) — Tyrosinase-inhibitory flavonoids isolated from Artocarpus (artocarpanone IC50 2.0 µM, the most potent) support genus-wide skin-whitening potential relevant to A. integer. [https://pubmed.ncbi.nlm.nih.gov/26834825/]
  - An antimalarial stilbene from Artocarpus integer, Phytochemistry (2000) — Antimalarial activity-guided fractionation of A. integer aerial parts yielded a prenylated stilbene active against Plasmodium falciparum with EC50 ≈ 1.7 µg/mL in culture. [https://pubmed.ncbi.nlm.nih.gov/10897483/]

---

## Wax Apple (Syzygium samarangense)
URL: https://nutridex.info/s/wax-apple
Category: Fruits
Evidence: Preliminary — Early or small human trials; promising but not yet conclusive.
Crisp, watery tropical fruit rich in polyphenols

Quick answer: Wax Apple is used for hydration with a very low calorie load (high water content, ~25 kcal/100 g). NutriDex grades the human evidence as preliminary — Early or small human trials; promising but not yet conclusive. Based on 8 cited human studies (8 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Wax apple (Syzygium samarangense), also called java/rose apple or jambu air, is a very watery, low-calorie tropical fruit (~25 kcal/100 g) valued more as a refreshing, hydrating snack than as a dense nutrient source. Laboratory and rodent studies show its leaf and fruit polyphenols (flavonols such as myricetin/myricitrin, C-methylated chalcones, and condensed/ellagitannins) have antioxidant, antihyperglycemic, anti-inflammatory and cytotoxic activities, including protection of pancreatic beta-cells in streptozotocin-diabetic rats and chalcones cytotoxic to colon cancer cells in vitro. Crucially, however, the great majority of evidence is preclinical (in vitro, in silico and animal), and most bioactivity studies use concentrated leaf or seed extracts rather than the edible flesh. There are essentially no controlled human trials confirming clinical benefit from eating the fruit, so health claims remain unproven in people. Nutritionally the fruit provides modest vitamin C (about 22 mg/100 g) and potassium with little protein, fat or sugar. It is a sensible hydrating, lower-sugar fruit choice, but its medicinal reputation rests on early-stage research. Overall weight of human evidence is preliminary.

Nutrition (per 1 medium (85 g)): 21 kcal; Vitamin C 19mg (21% DV), Potassium 105mg (3% DV), Calcium 25mg (2% DV), Carbs 4.8g (2% DV), Protein 0.5g (1% DV), Iron 0.06mg (0% DV).
Benefits / uses: Hydration with a very low calorie load (high water content, ~25 kcal/100 g); Antioxidant / free-radical scavenging activity from polyphenols (preclinical); Antihyperglycemic effects and pancreatic beta-cell protection (preclinical, leaf/fruit extracts); Anti-inflammatory activity (preclinical); Source of vitamin C, which supports normal immune function; Cytotoxic chalcones with anticancer activity in cell models (preclinical, isolated seed compounds).
Active compounds: Flavonols (myricetin, myricitrin, quercetin glycosides such as guaijaverin, kaempferol); C-methylated chalcones (e.g. 2',4'-dihydroxy-6'-methoxy-3',5'-dimethylchalcone, cardamonin); Phenolic acids and ellagitannins (incl. ellagic acid derivatives); Flavan-3-ols / proanthocyanidins ((epi)catechin, (epi)gallocatechin gallate); Vitamin C (ascorbic acid); Potassium, with some calcium; Triterpenoids and sterols (betulinic/oleanolic-type); Volatile terpenes contributing aroma.
Dose: 1-2 fresh fruits (~85-170 g); eaten raw, skin-on
Safety: Generally recognized as safe as a food and well tolerated when eaten fresh. No established drug interactions from culinary amounts, but the concentrated leaf and seed extracts used in research are not validated for human use and should not be assumed safe at those doses. There is a theoretical additive risk with antidiabetic medication (hypoglycemia) given preclinical glucose-lowering activity, so monitor if consuming large amounts of extract. As with any fruit, wash before eating; people with known Myrtaceae (clove, guava, eucalyptus) sensitivities should be cautious. It is not a treatment for diabetes or cancer despite folk claims.

Cited studies (8):
  - Traditional uses, pharmacological activities, and phytochemical constituents of the genus Syzygium: A review, Food science & nutrition (2022) — Review of the genus Syzygium documents S. samarangense flavonoids, chalcones and tannins with antioxidant, antidiabetic, anti-inflammatory, antimicrobial and cytotoxic activities, noting the predominance of preclinical data. [https://pubmed.ncbi.nlm.nih.gov/35702283/]
  - Polyphenolic Compounds and Biological Activities of Leaves and Fruits of Syzygium samarangense cv. 'Giant Green' at Three Different Maturities, Horticulturae (2023) — In the 'Giant Green' cultivar, total phenolic and flavonoid contents were ~37% and ~54% higher in unripe than ripe fruit, correlating with greater antioxidant and alpha-glucosidase inhibitory activity. [https://www.mdpi.com/2311-7524/9/3/326]
  - Syzygium samarangense leaf extract exhibits distinct antidiabetic activities: Evidences from in silico and in vivo studies, Arabian Journal of Chemistry (2022) — S. samarangense leaf extract reduced serum glucose and lipid peroxides and raised insulin in STZ-diabetic rats; constituents (e.g. anthocyanins) docked strongly to PPARgamma and GLP-1 receptors in silico. [https://doi.org/10.1016/j.arabjc.2022.103822]
  - Vasorelaxant Effects of Syzygium samarangense (Blume) Merr. and L.M.Perry Extract Are Mediated by NO/cGMP Pathway in Isolated Rat Thoracic Aorta, Pharmaceuticals (Basel, Switzerland) (2022) — S. samarangense leaf extract induced endothelium-dependent vasorelaxation in isolated rat thoracic aorta via the NO/cGMP pathway, supporting a potential cardiovascular/antihypertensive mechanism. [https://pmc.ncbi.nlm.nih.gov/articles/PMC9692616/]
  - Protective effect of wax apple (Syzygium samarangense (Blume) Merr. & L.M. Perry) against streptozotocin-induced pancreatic ß-cell damage in diabetic rats, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie (2018) — Wax apple fruit extract (100 mg/kg, 30 days) lowered fasting glucose, raised insulin and HOMA-B, and reduced pancreatic beta-cell apoptosis (lower cleaved caspase-3/Bax, higher Bcl-2/Bcl-xl) in STZ-diabetic rats. [https://pubmed.ncbi.nlm.nih.gov/30245463/]
  - Isolation of Myricitrin and 3,5-di-O-Methyl Gossypetin from Syzygium samarangense and Evaluation of their Involvement in Protecting Keratinocytes against Oxidative Stress via Activation of the Nrf-2 Pathway, Molecules (Basel, Switzerland) (2019) — Myricitrin and 3,5-di-O-methyl gossypetin isolated from S. samarangense leaves protected human keratinocytes from arsenite-induced oxidative stress; gossypetin activated Nrf-2, inducing HO-1 and Mn-SOD. [https://pmc.ncbi.nlm.nih.gov/articles/PMC6539899/]
  - High resolution UPLC-MS/MS profiling of polyphenolics in the methanol extract of Syzygium samarangense leaves and its hepatoprotective activity in rats with CCl(4)-induced hepatic damage, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association (2018) — UPLC-MS/MS of the methanol leaf extract identified 92 polyphenols ((epi)catechin-(epi)gallocatechin, EGCG, myricetin glycosides, guaijaverin); the extract showed antioxidant and silymarin-comparable hepatoprotective activity in CCl4-treated rats. [https://pubmed.ncbi.nlm.nih.gov/29374594/]
  - Cytotoxic chalcones and antioxidants from the fruits of a Syzygium samarangense (Wax Jambu), Food chemistry (2008) — Three C-methylated chalcones isolated from wax jambu seeds; 2',4'-dihydroxy-6'-methoxy-3',5'-dimethylchalcone was cytotoxic to SW-480 colon cancer cells (IC50 ~10 uM), with the 5'-methyl group key to activity. [https://pmc.ncbi.nlm.nih.gov/articles/PMC3282680/]

---

## Sapodilla (Ciku) (Manilkara zapota)
URL: https://nutridex.info/s/sapodilla
Category: Fruits
Evidence: Preliminary — Early or small human trials; promising but not yet conclusive.
Sweet tropical fruit rich in fiber, polyphenols

Quick answer: Sapodilla (Ciku) is used for notable dietary fiber that supports digestive regularity and satiety. NutriDex grades the human evidence as preliminary — Early or small human trials; promising but not yet conclusive. Based on 9 cited human studies (9 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Sapodilla is a sweet, energy-dense tropical fruit valued mainly as a source of dietary fiber, vitamin C, copper, and a high concentration of polyphenols (catechin/gallocatechin-type tannins) that give unripe fruit a notably high in-vitro antioxidant capacity. Laboratory and animal studies suggest antioxidant, anti-inflammatory, antibacterial, alpha-glucosidase-inhibiting (antihyperglycemic), and antiproliferative effects, with much of the strongest signal coming from leaf, bark, skin, and seed extracts rather than the edible pulp. A single rat study reported lower glycemia, insulin, cholesterol, and triglycerides after fruit or leaf juice, but no randomized controlled trials in humans have tested whole-fruit consumption for any clinical outcome. Antioxidant content falls sharply as the fruit ripens, so measured bioactivity is stage-dependent and not equivalent to a health benefit in people. Overall the human evidence is preliminary: the fruit is a reasonable whole-food source of fiber and micronutrients, but specific disease-prevention or treatment claims are unproven. It is also relatively high in natural sugars, so portion matters for those managing blood glucose or weight. Treat extract-based findings as hypothesis-generating, not as evidence that eating sapodilla treats diabetes, cancer, or infection.

Nutrition (per 1 medium (170 g)): 141 kcal; Fiber 9g (32% DV), Vitamin C 25mg (28% DV), Copper 0.15mg (16% DV), Potassium 328mg (7% DV), Pantothenic acid 0.43mg (9% DV), Iron 1.4mg (8% DV).
Benefits / uses: Notable dietary fiber that supports digestive regularity and satiety; Vitamin C and copper contributing to normal antioxidant and connective-tissue function; Polyphenol (catechin/gallocatechin) antioxidant capacity in vitro, highest in unripe fruit; Potential alpha-glucosidase inhibition / antihyperglycemic signals (preclinical, mainly leaf extract); Anti-inflammatory and antibacterial activity of fruit and leaf extracts (lab/animal); Antiproliferative effects against cancer cell lines (in vitro, leaf/skin/seed extracts).
Active compounds: Hydrolysable tannins (gallotannins, ellagitannins); Flavan-3-ols (catechin, gallocatechin, epicatechin, procyanidins); Phenolic acids (gallic acid, protocatechuic/3,4-dihydroxybenzoic acid); Flavonoids (quercetin glycosides, dihydrokaempferol); Triterpenoids (lupeol acetate, taraxerol, taraxerone); Vitamin C (L-ascorbic acid); Soluble and insoluble dietary fiber; Minerals (potassium, copper, iron, calcium).
Dose: 1 medium fruit (~170 g); ~100-170 g fresh ripe pulp
Safety: Unripe fruit is high in astringent tannins and latex that can cause mouth irritation, throat discomfort, and digestive upset; only fully ripe fruit should be eaten. The seeds contain saponin and the alkaloid sapotinin and have a hooked end, so swallowing several crushed seeds can cause abdominal pain and vomiting; seeds should be removed. The fruit and tree latex can trigger allergic reactions in latex-sensitive individuals. It is sugar- and calorie-dense (~141 kcal, ~25 g sugar per medium 170 g fruit), warranting portion control in diabetes and weight management. Medicinal leaf/bark extracts are not the same as eating the fruit, are not established as safe supplements, and have no human-dose or drug-interaction data.

Cited studies (9):
  - Potential role of <i>Manilkara Zapota L</i> in treating bacterial infection, PeerJ (2024) — Review of preclinical data concluding M. zapota tannins, flavonoids, and triterpenoids exert antibacterial activity by disrupting bacterial cell walls/membranes, supporting its traditional anti-infective use. [https://doi.org/10.7717/peerj.17890]
  - <i>Manilkara zapota</i> (L.) P. Royen Leaf Mitigates Colitis‐Associated Colon Cancer through Anti‐inflammatory Modulation in BALB/C Mice, Advances in Pharmacological and Pharmaceutical Sciences (2024) — In AOM/DSS-induced colitis-associated colon cancer in BALB/c mice, M. zapota leaf aqueous extract improved disease activity, reduced ROS and TNF-alpha/IL-6, and raised SOD. [https://doi.org/10.1155/2024/1137696]
  - Investigating the ABTS-based antioxidant potential and antiproliferative activity of pulp, skin and seeds extracts from Nephelium lappaceum, Manilkara zapota, and Meliccocus oliviformis on human prostate and colon cancer cells, Biochemistry and Biophysics Reports (2025) — Methanolic extracts of M. zapota skin/seed had high phenolic content and ABTS antioxidant capacity; the skin extract showed strong antiproliferative activity against human colon (HCT116) and prostate (DU145) cancer cells. [https://doi.org/10.1016/j.bbrep.2025.102257]
  - Metabolite Profiling of Manilkara zapota L. Leaves by High-Resolution Mass Spectrometry Coupled with ESI and APCI and In Vitro Antioxidant Activity, α-Glucosidase, and Elastase Inhibition Assays, International Journal of Molecular Sciences (2020) — Ethanol extract of M. zapota leaves inhibited alpha-glucosidase at low concentration (IC50 2.51 ug/mL) and increased glucose uptake in C2C12 cells by ~42% at 30 ug/mL, indicating antihyperglycemic potential. [https://doi.org/10.3390/ijms22010132]
  - Antidiabetic and Antilipidemic Effects of <i>Manilkara zapota</i>, Journal of Medicinal Food (2015) — In Wistar rats, M. zapota fruit or leaf juice over 50 days significantly lowered glycemia, insulin, leptin, cholesterol, and triglycerides and raised HDL-c; fruit pulp reduced percentage weight gain. [https://doi.org/10.1089/jmf.2013.0170]
  - Antioxidant, anti-collagenase and anti-elastase activities of <i>Phyllanthus emblica</i>, <i>Manilkara zapota</i> and silymarin: an <i>in vitro</i> comparative study for anti-aging applications, Pharmaceutical Biology (2016) — Among amla, sapota and silymarin, sapota (M. zapota) fruit extract showed the highest anti-collagenase (MMP-1, MMP-2) and anti-elastase activity (elastase IC50 35.7 ug/mL) with moderate antioxidant effect. [https://doi.org/10.3109/13880209.2015.1133658]
  - Antityrosinase, Antioxidant, and Cytotoxic Activities of Phytochemical Constituents from Manilkara zapota L. Bark, Molecules (2019) — From M. zapota bark, (+)-dihydrokaempferol showed antityrosinase activity exceeding kojic acid/arbutin plus strong DPPH, ABTS and FRAP antioxidant activity and cytotoxicity across several carcinoma cell lines. [https://doi.org/10.3390/molecules24152798]
  - Manilkara zapota (L.) P. Royen leaf water extract triggered apoptosis and activated caspase-dependent pathway in HT-29 human colorectal cancer cell line, Biomedicine &amp; Pharmacotherapy (2019) — M. zapota leaf water extract induced apoptosis in HT-29 human colorectal cancer cells, activating caspase-3/-8 and modulating the Wnt/beta-catenin pathway in a concentration-dependent manner. [https://doi.org/10.1016/j.biopha.2018.12.027]
  - Characterization of Antioxidants and Change of Antioxidant Levels during Storage of<i>Manilkara zapota</i>L, Journal of Agricultural and Food Chemistry (2004) — Antioxidants in ciku (M. zapota) fruit were characterized by HPLC-MS and attributed mainly to catechin/gallocatechin-type polyphenols; antioxidant capacity and total phenolics fell sharply during storage/ripening. [https://doi.org/10.1021/jf0488357]

---

## Sugar Apple (Custard Apple) (Annona squamosa)
URL: https://nutridex.info/s/sugar-apple
Category: Fruits
Evidence: Preliminary — Early or small human trials; promising but not yet conclusive.
Sweet tropical fruit with a neurotoxin caveat

Quick answer: Sugar Apple (Custard Apple) is used for good source of vitamin c and dietary fiber (whole-food nutrition). NutriDex grades the human evidence as preliminary — Early or small human trials; promising but not yet conclusive. Based on 10 cited human studies (10 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Sugar apple is a nutritious tropical fruit, supplying meaningful vitamin C, fiber, vitamin B6 and potassium per serving, so its core value is as whole-food nutrition. The popular medicinal claims — antidiabetic, antioxidant, lipid-lowering, antihypertensive and anticancer effects — rest almost entirely on in vitro work and rodent studies of leaf, bark or seed extracts, not the edible pulp, and there are essentially no rigorous human randomized trials of the fruit. Repeated animal studies do show that aqueous and ethanolic leaf extracts lower fasting glucose and improve lipid profiles in diabetic rats and rabbits, which is consistent across labs but not validated in people. The most important human-relevant signal is a safety concern rather than a benefit: the genus Annona is rich in annonaceous acetogenins (annonacin, squamocin), potent mitochondrial complex I inhibitors that are neurotoxic in cell and rodent models. Epidemiology and a 180-patient Caribbean cohort link consumption of Annonaceae fruit, juice and herbal tea to worse, often levodopa-unresponsive atypical parkinsonism and greater cognitive impairment, even at relatively low cumulative intake. Acetogenins are concentrated in the seeds, peel and leaves, with smaller amounts in pulp, so occasional whole-fruit eating is generally considered low risk while heavy or daily consumption — and especially seed/leaf preparations — is not. Overall the human evidence is preliminary: enjoy the fruit as food, but treat therapeutic and "superfood" claims as unproven.

Nutrition (per 1 medium (155 g)): 146 kcal; Vitamin C 56mg (62% DV), Fiber 6.8g (24% DV), Vitamin B6 0.31mg (18% DV), Thiamin (B1) 0.17mg (14% DV), Potassium 383mg (8% DV), Magnesium 33mg (8% DV).
Benefits / uses: Good source of vitamin C and dietary fiber (whole-food nutrition); Antioxidant capacity from polyphenols and ascorbate (mostly in vitro); Antidiabetic / blood-glucose-lowering effect of leaf extracts (animal models only); Lipid-profile improvement (lower cholesterol/triglycerides in diabetic rodents); Anticancer/cytotoxic activity of seed acetogenins (cell and animal studies only); Traditional antimicrobial and anti-inflammatory uses (preclinical).
Active compounds: Annonaceous acetogenins (annonacin, squamocin, bullatacin) — mitochondrial complex I inhibitors / neurotoxins; Isoquinoline alkaloids (anonaine, higenamine, reticuline); Vitamin C (ascorbic acid); Dietary fiber (soluble and insoluble); Flavonoids and phenolic acids (quercetin, rutin, gallic/caffeic acid); Diterpenes and kaurane-type terpenoids; Potassium and magnesium (electrolyte minerals); B-vitamins (thiamin, vitamin B6).
Dose: 1 medium fruit (about 155 g edible pulp); the seeds, peel, leaves and roots should not be eaten.
Safety: Never eat or chew the seeds, and avoid leaf, bark and root preparations: they are concentrated in neurotoxic annonaceous acetogenins (annonacin, squamocin), and crushed seeds/seed oil are irritant and toxic to the eyes (documented cases of severe keratoconjunctivitis from accidental ocular exposure). Regular or heavy intake of the fruit, juice or Annonaceae herbal teas is epidemiologically associated with atypical parkinsonism and cognitive decline, so limit frequency, especially in older adults or those with movement/neurodegenerative disorders. Leaf extracts lower blood glucose in animals, so there is a theoretical additive effect with antidiabetic drugs (hypoglycemia) — monitor if using such preparations. The pulp is high in natural sugars; portion accordingly in diabetes. Pregnancy/lactation: insufficient safety data for medicinal extracts — avoid.

Cited studies (10):
  - Annonaceae Consumption Worsens Disease Severity and Cognitive Deficits in Degenerative Parkinsonism, Movement disorders : official journal of the Movement Disorder Society (2022) — In 180 Caribbean parkinsonian patients, even low cumulative Annonaceae fruit/juice intake (>0.2 fruit-years) or any Annonaceae herbal tea was associated with the severe-symptom cluster (worse disease severity and cognitive deficits): OR fruits/juices 3.76 (95% CI 1.13-15.18); OR herbal tea 2.91 (95% CI 1.34-6.56). [https://pubmed.ncbi.nlm.nih.gov/36210778/]
  - Is atypical parkinsonism in the Caribbean caused by the consumption of Annonacae?, Journal of neural transmission. Supplementum (2006) — Review linking an atypical levodopa-unresponsive parkinsonism cluster in Guadeloupe to Annonaceae consumption; annonacin was toxic to dopaminergic neurons at nanomolar concentrations, far more potent than the alkaloids (which required micromolar levels). [https://pubmed.ncbi.nlm.nih.gov/17017523/]
  - The fruit of Annona squamosa L. as a source of environmental neurotoxins: From quantification of squamocin to annotation of Annonaceous acetogenins by LC-MS/MS analysis, Food chemistry (2017) — LC-MS/MS quantification found the neurotoxic acetogenin squamocin at 13.5-36.4 mg per Annona squamosa fruit across Asian, Caribbean and Indian Ocean batches, plus annonacin and bullatacin, concluding the fruit should be considered a neurodegeneration risk factor. [https://pubmed.ncbi.nlm.nih.gov/28254016/]
  - Insulin secreting and alpha-glucosidase inhibitory activity of hexane extract of Annona squamosa Linn. in streptozotocin (STZ) induced diabetic rats, Indian journal of experimental biology (2014) — Hexane extract of A. squamosa acted via a dual mechanism in STZ-diabetic rats: it raised insulin secretion and inhibited intestinal alpha-glucosidase, reducing post-load glucose peaks and AUC. [https://pubmed.ncbi.nlm.nih.gov/24956893/]
  - Polypharmacy (herbal and synthetic drug combination): a novel approach in the treatment of type-2 diabetes and its complications in rats, Journal of natural medicines (2013) — Combining aqueous A. squamosa leaf extract (350 mg/kg) with the sulfonylurea glipizide controlled hyperglycemia better than either alone in high-fat-diet/STZ type-2 diabetic rats and allowed up to 50% glipizide dose reduction. [https://pubmed.ncbi.nlm.nih.gov/23151907/]
  - Annonacin, a lipophilic inhibitor of mitochondrial complex I, induces nigral and striatal neurodegeneration in rats: possible relevance for atypical parkinsonism in Guadeloupe, Journal of neurochemistry (2004) — Systemic annonacin (the major Annona acetogenin) crossed the blood-brain barrier in rats, lowered brain ATP 44%, and caused dopaminergic nigral neuron loss (-31.7%) plus striatal cholinergic (-37.9%) and GABAergic (-39.3%) loss, mirroring atypical parkinsonism lesions. [https://pubmed.ncbi.nlm.nih.gov/14675150/]
  - Antidiabetic and antioxidant activity of Annona squamosa extract in streptozotocin-induced diabetic rats, Singapore medical journal (2006) — Aqueous A. squamosa leaf extract given to streptozotocin-diabetic rats for 30 days significantly lowered blood glucose, lipids and lipid peroxidation while raising plasma insulin and antioxidant enzyme activity. [https://pubmed.ncbi.nlm.nih.gov/16865205/]
  - In vivo evaluation of anti-oxidant and anti-lipidimic potential of Annona squamosa aqueous extract in Type 2 diabetic models, Journal of ethnopharmacology (2008) — Water extract of A. squamosa leaves (350 mg/kg) in type-2 diabetic rats increased tissue antioxidant enzymes and reduced malondialdehyde, triglycerides and total cholesterol. [https://pubmed.ncbi.nlm.nih.gov/18440739/]
  - Antidiabetic activity of aqueous leaf extract of Annona squamosa in streptozotocin-nicotinamide type 2 diabetic rats, Journal of ethnopharmacology (2004) — Aqueous A. squamosa leaf extract over 12 days lowered fasting plasma glucose, improved serum insulin and lipid profile and raised liver glycogen in streptozotocin-nicotinamide type-2 diabetic rats, compared against glibenclamide. [https://pubmed.ncbi.nlm.nih.gov/15036485/]
  - Hypoglycemic and antidiabetic effect of ethanolic extract of leaves of Annona squamosa L. in experimental animals, Journal of ethnopharmacology (2005) — Ethanolic A. squamosa leaf extract (350 mg/kg) cut fasting blood glucose 73.3% over 10 days in STZ-diabetic rats and improved the lipid profile in alloxan-diabetic rabbits (total cholesterol -49.3%, LDL -71.9%, triglycerides -28.7%, HDL +30.3%). [https://pubmed.ncbi.nlm.nih.gov/15848023/]

---

## Tamarind (Tamarindus indica)
URL: https://nutridex.info/s/tamarind
Category: Fruits
Evidence: Preliminary — Early or small human trials; promising but not yet conclusive.
Tangy pod pulp rich in polyphenols and tartaric acid

Quick answer: Tamarind is used for may modestly lower triglycerides and blood pressure (small, short, underpowered rcts in dyslipidemic/hiv adults). NutriDex grades the human evidence as preliminary — Early or small human trials; promising but not yet conclusive. Based on 10 cited human studies (10 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Human evidence for tamarind is preliminary and dominated by small, short, often single-site trials. A 2025 4-week dose-response exploratory RCT in adults with HIV and high triglycerides (n=50) found that 30% tamarind-pulp juice (600 mL/day) cut triglycerides by about 17% (-39.8 mg/dL), while a 10% dose lowered systolic blood pressure by ~7 mmHg; neither dose changed cholesterol, and the trial was explicitly underpowered/exploratory. A separate 2006 clinical study of dried pulp (~15 mg/kg) reported reduced total and LDL cholesterol and diastolic pressure. The most reproducible findings are non-dietary: diet-controlled studies show tamarind ingestion increases urinary fluoride excretion (potentially aiding fluorosis), and several randomized studies show tamarind seed polysaccharide eye drops match hyaluronic acid or HP-Guar for dry eye. Antioxidant, anti-inflammatory, antidiabetic and hepatoprotective effects are reported mainly in cell and animal models, not confirmed in humans. Overall the cardiometabolic signals are promising but not established; larger, well-powered trials are needed before health claims are warranted.

Nutrition (per 1/2 cup pulp (120 g)): 287 kcal; Fiber 6.1g (22% DV), Magnesium 110mg (26% DV), Thiamin (B1) 0.51mg (43% DV), Potassium 754mg (16% DV), Iron 3.4mg (19% DV), Phosphorus 136mg (11% DV).
Benefits / uses: May modestly lower triglycerides and blood pressure (small, short, underpowered RCTs in dyslipidemic/HIV adults); May reduce total and LDL cholesterol (one early human trial of dried pulp); Increases urinary fluoride excretion, potentially helping mobilize fluoride in endemic-fluorosis areas (diet-controlled human studies); Seed polysaccharide (TSP) eye drops relieve dry-eye symptoms comparably to hyaluronic acid or HP-Guar; Antioxidant and anti-inflammatory activity from polyphenols (largely preclinical); Tamarind-seed/turmeric extract blend (TamaFlex) eased exercise-related knee pain and improved walking distance.
Active compounds: Organic acids: tartaric acid (dominant), malic and citric acid; Flavonoids: catechin, epicatechin, procyanidins, taxifolin; Phenolic acids: caffeic, ferulic, p-coumaric acids; Tannins and proanthocyanidins; Seed polysaccharide (xyloglucan, mucomimetic 'TSP'); Soluble dietary fiber and pectin; Minerals: magnesium, potassium, iron, phosphorus; B-vitamins: thiamin, niacin, riboflavin; Saponins and alkaloids (minor).
Dose: Culinary: about 10-30 g of pulp per day (paste, juice, or chutney). Cardiometabolic trials used 600 mL/day of 10-30% tamarind-pulp juice or ~15 mg/kg dried pulp; dry-eye and joint benefits used non-dietary extracts (TSP eye drops, TamaFlex capsules), which are not interchangeable with culinary fruit.
Safety: Generally recognized as safe as a food. The high tartaric/malic acid content makes the pulp very acidic and potentially erosive to tooth enamel and irritating in reflux. Tamarind has documented drug-interaction potential: it increased the bioavailability of aspirin and ibuprofen and may raise exposure to other drugs. It can enhance fluoride mobilization, usually beneficial but relevant in those with heavy fluoride exposure. Tamarind is high in sugar (about 47 g per 120 g) and calorically dense, so portions matter for diabetes and weight goals. Seed/pulp allergy is rare but possible; concentrated extracts and herbal-blend products (eye drops, TamaFlex, suppositories) are clinically distinct from culinary fruit.

Cited studies (10):
  - Effect of tamarind (<i>Tamarindus indica</i> L.) on the cardiometabolic health of patients living with HIV and elevated triglyceride levels: a dose–response double-blind, randomized exploratory trial, Food &amp; Function (2025) — 4-week dose-response double-blind exploratory RCT (n=50, HIV with TG>=150 mg/dL): 30% tamarind-pulp juice (600 mL/day) lowered triglycerides by -39.8 mg/dL (-17.3%, p=0.006); the 10% juice lowered systolic BP by ~7.4 mmHg. No change in total/LDL/HDL cholesterol; authors note the trial was underpowered/exploratory. [https://doi.org/10.1039/d4fo03595j]
  - A Combination of <i>Tamarindus indica</i> seeds and <i>Curcuma longa</i> Rhizome Extracts Improves Knee Joint Function and Alleviates Pain in Non-Arthritic Adults Following Physical Activity, International Journal of Medical Sciences (2019) — 90-day double-blind placebo-controlled RCT (n=90): tamarind-seed + turmeric extract (NXT15906F6/TamaFlex, 250 or 400 mg) improved 6-minute walk distance and reduced knee pain in non-arthritic adults vs placebo. [https://doi.org/10.7150/ijms.32505]
  - Effect of vaginal suppository on bacterial vaginitis based on Persian medicine (Iranian traditional medicine): a randomised double blind clinical study, Journal of Obstetrics and Gynaecology (2018) — Randomized double-blind trial (n=127): a Persian-medicine vaginal suppository (Forzejeh) containing Tamarindus indica plus three herbs was as effective as metronidazole for bacterial-vaginosis symptoms and Amsel criteria. [https://doi.org/10.1080/01443615.2018.1445706]
  - The Effect of an Artificial Tear Combining Hyaluronic Acid and Tamarind Seeds Polysaccharide in Patients with Moderate Dry Eye Syndrome: A New Treatment for Dry Eye, European Journal of Ophthalmology (2013) — Multicenter double-masked RCT (n=49, moderate dry eye): combined hyaluronic acid + tamarind seed polysaccharide significantly improved OSDI symptom scores vs carmellose sodium over 3 months. [https://doi.org/10.5301/ejo.5000355]
  - Prospective, Randomized, Controlled Comparison of SYSTANE UD Eye Drops Versus VISINE INTENSIV 1% EDO Eye Drops for the Treatment of Moderate Dry Eye, Journal of Ocular Pharmacology and Therapeutics (2012) — Prospective randomized trial (n=28, 56 eyes): preservative-free tamarind seed polysaccharide 1% drops improved moderate dry-eye symptoms and tear stability comparably to HP-Guar (Systane) over 3 months. [https://doi.org/10.1089/jop.2012.0066]
  - Effect of Tamarindus indica fruits on blood pressure and lipid-profile in human model: an in vivo approach, Pakistan journal of pharmaceutical sciences (2006) — Human clinical trial: dried tamarind pulp (~15 mg/kg) significantly reduced total cholesterol (p=0.031) and LDL-cholesterol (p=0.004) and lowered diastolic blood pressure; no significant effect on systolic BP or body weight. [https://pubmed.ncbi.nlm.nih.gov/16751124/]
  - Effect of tamarind ingestion on fluoride excretion in humans, European Journal of Clinical Nutrition (2002) — Randomized diet-controlled study in 18 boys: 10 g tamarind/day raised 24-h urinary fluoride excretion (~3.5 to 4.8 mg/day, p<0.001), suggesting potential to delay fluorosis progression. [https://doi.org/10.1038/sj.ejcn.1601287]
  - Additional beneficial effect of tamarind ingestion over defluoridated water supply to adolescent boys in a fluorotic area, Nutrition (2004) — Randomized diet-controlled study (n=30) in a fluorotic area: tamarind on top of defluoridated water further increased urinary fluoride excretion and urinary pH (p<0.01), consistent with mobilizing deposited bone fluoride. [https://doi.org/10.1016/j.nut.2004.01.007]
  - Establishing the tolerability and performance of tamarind seed polysaccharide (TSP) in treating dry eye syndrome: results of a clinical study, BMC Ophthalmology (2007) — Randomized study (n=30): tamarind seed polysaccharide eye drops (0.5% and 1%) gave at least equivalent dry-eye relief to 0.2% hyaluronic acid over 90 days, with TSP 1% improving certain symptoms. [https://doi.org/10.1186/1471-2415-7-5]
  - The Health Benefits of Tamarindus indica: A Focus on the Relationship Between Phytochemical Composition and Physiological Effects, Nutrients (2026) — Narrative review (PubMed/Scopus/ScienceDirect, 2000-2025): tamarind flavonoids, tannins and phenolics show antioxidant, anti-inflammatory, antimicrobial and anticancer activity, largely preclinical. [https://doi.org/10.3390/nu18040576]

---

## Ambarella (Spondias dulcis)
URL: https://nutridex.info/s/ambarella
Category: Fruits
Evidence: Preliminary — Early or small human trials; promising but not yet conclusive.
Tart tropical fruit rich in vitamin C

Quick answer: Ambarella is used for good source of vitamin c, which supports antioxidant defense and is required for collagen synthesis. NutriDex grades the human evidence as preliminary — Early or small human trials; promising but not yet conclusive. Based on 8 cited human studies (8 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Ambarella (Spondias dulcis, also called kedondong or golden apple) is a tart tropical fruit valued mainly as a low-calorie, hydrating source of vitamin C (roughly 30-42 mg/100 g, higher when semi-ripe), soluble fibre and potassium. Its purported health effects come almost entirely from in vitro and animal studies of fruit, leaf and bark extracts, which report strong DPPH antioxidant activity (fruit methanol extract IC50 about 1.9 ug/mL), alpha-glucosidase inhibition (fruit IC50 about 4.7 ug/mL), antimicrobial action, and laxative, thrombolytic and anticancer signals. There are no published human randomized controlled trials or cohort studies on ambarella, and much of the antidiabetic and lipid-lowering data is extrapolated from related Spondias species (S. mombin, S. mangifera, S. pinnata) rather than S. dulcis itself. Vitamin C content varies widely by cultivar and maturity. As a result, claims about lowering blood sugar, cholesterol or blood pressure in people remain unproven and the overall human-evidence tier is preliminary. Eaten as a whole fruit, however, it is a sound, nutrient-light addition to the diet, and acute oral toxicity testing in mice found no adverse effects up to 2000 mg/kg of extract.

Nutrition (per 1 medium (80 g)): 46 kcal; Vitamin C 29mg (32% DV), Fibre 1.8g (6% DV), Potassium 200mg (4% DV), Phosphorus 54mg (4% DV), Iron 0.24mg (1% DV), Vitamin A 18mcg RAE (2% DV).
Benefits / uses: Good source of vitamin C, which supports antioxidant defense and is required for collagen synthesis; Provides soluble fibre and pectin that may aid bowel regularity and satiety; Fruit extracts inhibit alpha-glucosidase in vitro, suggesting a possible (unproven in humans) effect on post-meal glucose; Polyphenol-rich extracts show strong free-radical scavenging (DPPH) in laboratory assays; Low energy density and high water content make it a light, hydrating whole-food snack; Traditional use for sore throat, skin and eye complaints, with preclinical antimicrobial support.
Active compounds: Vitamin C (ascorbic acid); Pectin and soluble dietary fibre; Potassium; Flavonoids (rutin, isoquercetin, quercetin); Phenolic acids (gallic, caffeic, chlorogenic, ellagic acid); Catechin and condensed tannins; Carotenoids (e.g. beta-carotene, minor); Organic acids (citric, malic).
Dose: One medium fruit (about 60-100 g) eaten fresh, or 100-150 g in juice or salad, as part of a varied diet. No evidence-based therapeutic dose exists for humans.
Safety: Generally safe as a food. The fruit has a large fibrous, spiny seed (stone) that should not be eaten and is a choking hazard, especially for children. Its high organic-acid content makes it quite sour and can aggravate acid reflux or sensitive teeth when eaten unripe in quantity. As a member of the Anacardiaceae (cashew/mango family), it could rarely trigger cross-reactive allergy in people sensitive to mango, cashew or pistachio. Concentrated leaf or fruit extracts and supplements are not standardized and, based on preclinical data, may have additive glucose-lowering effects, so people on antidiabetic drugs should monitor; safety in pregnancy, lactation and kidney disease (potassium load) has not been studied. No grapefruit-type CYP3A4 drug interaction is established for the fruit.

Cited studies (8):
  - Spondias sp: Shedding Light on Its Vast Pharmaceutical Potential, Molecules (2023) — Review (Molecules): S. dulcis methanol extracts gave antioxidant DPPH IC50 of 1.91 ug/mL (fruit) and 5.37 ug/mL (leaves); fruit extract inhibited alpha-glucosidase at IC50 4.73 ug/mL; aqueous fruit extract reduced melanoma tumours at 450 mg/kg in mice. [https://www.mdpi.com/1420-3049/28/4/1862]
  - Genus Spondias: A Phytochemical and Pharmacological Review, Evidence-based complementary and alternative medicine : eCAM (2018) — Genus-wide phytochemical and pharmacological review (Evid Based Complement Alternat Med) documenting that S. dulcis fruit is traditionally used to support eyesight and prevent eye infections, with reported antimicrobial activity; most quantitative pharmacology came from other Spondias species, and constituents include gallic acid, quercetin, rutin, isoquercetin and ellagitannins. [https://pmc.ncbi.nlm.nih.gov/articles/PMC5896409/]
  - Pharmacological, toxicological and phytochemical analysis of Spondias dulcis parkinson, Natural product research (2024) — Phytochemical/pharmacological analysis isolated rutin from S. dulcis and reported high antioxidant activity (DPPH IC50 5.10; H2O2 scavenging 14.14), a laxative effect on intestinal motility, and no adverse effects in an acute oral toxicity test in mice up to 2000 mg/kg. [https://pubmed.ncbi.nlm.nih.gov/37157836/]
  - Anti-Diabetic Activity of Bioactive Compound Extracted from Spondias mangifera Fruit: In-Vitro and Molecular Docking Approaches, Plants (Basel, Switzerland) (2022) — Closely related Spondias mangifera fruit extract inhibited alpha-amylase (73.4%) and alpha-glucosidase (79.2%) dose-dependently in vitro, near acarbose, with beta-sitosterol showing strongest docking to pancreatic alpha-amylase. [https://pmc.ncbi.nlm.nih.gov/articles/PMC8880729/]
  - Antidiabetic and Antihyperlipidemic Effects of Methanolic Extract of Leaves of Spondias mombin in Streptozotocin-Induced Diabetic Rats, Frontiers in physiology (2022) — Methanolic leaf extract of Spondias mombin (sister species) significantly reduced blood glucose and improved lipid markers in streptozotocin-induced diabetic rats over 28 days at 125-500 mg/kg, comparable to glibenclamide. [https://pmc.ncbi.nlm.nih.gov/articles/PMC9128744/]
  - Evaluation of the Hypoglycemic Potential of Leaves Extract of Spondias pinnata (L.f.) Kurz. from Nepal, TheScientificWorldJournal (2021) — Leaf extract of Spondias pinnata (related species) from Nepal produced significant blood-glucose reduction at 500 mg/kg in rats at 1, 2 and 3 hours versus control, supporting traditional antidiabetic use. [https://pmc.ncbi.nlm.nih.gov/articles/PMC8257393/]
  - Evaluation of gastroprotective and ulcer healing activities of yellow mombin juice from Spondias mombin L, PloS one (2018) — Yellow mombin (Spondias mombin) juice showed gastroprotective and ulcer-healing activity in Wistar rat models (pylorus ligation, ethanol and ibuprofen), mainly via an antisecretory action (reduced gastric content and acidity) with restored gastric mucus on histology. [https://pmc.ncbi.nlm.nih.gov/articles/PMC6218193/]
  - A comparative study of the antioxidant, antimicrobial, cytotoxic and thrombolytic potential of the fruits and leaves of Spondias dulcis, Asian Pacific journal of tropical biomedicine (2013) — Comparative study: methanolic fruit extract of S. dulcis had the highest phenolic and flavonoid content and DPPH radical-scavenging activity (IC50 1.91 ug/mL), with moderate antimicrobial activity against bacterial strains plus cytotoxic (brine-shrimp) and significant thrombolytic effects in vitro. [https://pubmed.ncbi.nlm.nih.gov/23998007/]

---

## Bilimbi (Averrhoa bilimbi)
URL: https://nutridex.info/s/bilimbi
Category: Fruits
Evidence: Preliminary — Early or small human trials; promising but not yet conclusive.
Sour tropical fruit; kidney-risk oxalate bomb

Quick answer: Bilimbi is used for vitamin c / antioxidant source. NutriDex grades the human evidence as preliminary — Early or small human trials; promising but not yet conclusive. Based on 10 cited human studies (10 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Bilimbi is an intensely sour Southeast Asian fruit traditionally used as a culinary acidulant and folk remedy for diabetes, hypertension and inflammation. It is genuinely rich in vitamin C (around 48 mg/100 g) and contains flavonoids, phenolics and carotenoids that show antioxidant, antimicrobial and antidiabetic activity in vitro. The most cited pharmacology comes from rodent studies: ethanolic leaf extract lowered blood glucose ~50%, lowered triglycerides and raised HDL in streptozotocin-diabetic rats, and fruit fractions attenuated hyperglycemic oxidative stress comparably to metformin. However, there are essentially no human clinical trials for any of these benefits, so efficacy in people is unproven. The dominant human evidence is in fact harm: multiple case reports and a 10-patient case series document acute oxalate nephropathy and kidney failure after drinking concentrated bilimbi juice, owing to its very high oxalic-acid content (the fruit is roughly 0.8–1.5% oxalic acid by weight, among the highest of common fruits). As a small culinary garnish the fruit is generally fine, but it should not be treated as a supplement or consumed as concentrated juice, especially on an empty stomach or by anyone with kidney disease.

Nutrition (per About 5 fruits (50 g)): 13 kcal; Vitamin C 23.8mg (26% DV), Iron 1.6mg (9% DV), Fiber 0.3g (1% DV), Calcium 3.2mg (0% DV), Magnesium 2.6mg (1% DV), Manganese 0.13mg (6% DV).
Benefits / uses: Vitamin C / antioxidant source; Blood-glucose lowering (animal data only); Lipid-lowering & HDL-raising (animal data only); Antihypertensive effect (preclinical); Antimicrobial activity (in vitro); Anti-inflammatory potential (preclinical).
Active compounds: Ascorbic acid (vitamin C); Oxalic acid (very high; predominant organic acid); Flavonoids (e.g. luteolin, apigenin glycosides); Phenolic acids & tannins; Triterpenes and saponins (leaf); Carotenoids (beta-carotene, beta-cryptoxanthin); Organic acids (citric, malic); Volatiles (palmitic acid, 2-furaldehyde).
Dose: A few fruits (~5–50 g) used as a souring agent in cooking; no established therapeutic dose. Concentrated juice should be avoided.
Safety: Extremely high oxalic-acid content: laboratory analyses report roughly 8.5–14.7 mg/g (≈850–1,470 mg per 100 g of fruit), with oxalic acid making up 90–95% of total fruit acids and far higher concentrations in pressed juice. Drinking the juice—particularly fasting, dehydrated, or in large amounts—has caused acute oxalate nephropathy and acute kidney injury, with several reported patients requiring dialysis. Avoid in chronic kidney disease, prior kidney stones, dehydration, or with nephrotoxic drugs. Theoretical additive effects with antidiabetic and antihypertensive medications. Use only as a small culinary souring agent, not as a supplement or juice.

Cited studies (10):
  - Chemical composition, vitamins, and minerals of family farming biribiri (<i>Averrhoa bilimbi</i> L.) in the Middle Doce River region, Minas Gerais, Brazil, Ciência Rural (2022) — Compositional analysis of family-farmed bilimbi: 93.2 g water, 25.4 kcal, 47.6 mg vitamin C and 3.21 mg iron per 100 g, confirming high vitamin C and low energy. [https://www.scielo.br/j/cr/a/LPcYH8XWzLn9d9Bxxb8r9gR/?format=html&lang=en]
  - Oxalic Acid Content of Carambola and Bilimbi, The Archives of the Rare Fruit Council Australia (1991) — Oxalic acid in bilimbi fruit measured at 8.45–10.8 mg/g (ripe) and 10.5–14.7 mg/g (green), comprising 90–95% of total acids—among the highest of common fruits. [http://rfcarchives.org.au/Next/Fruits/Carambola/CarambolaAcid1-91.htm]
  - Averrhoa bilimbi Linn.: A review of its ethnomedicinal uses, phytochemistry, and pharmacology, Journal of pharmacy & bioallied sciences (2016) — Review of A. bilimbi ethnomedicine, phytochemistry and pharmacology: documents antidiabetic, antihypertensive, antioxidant and antimicrobial activity—almost entirely preclinical, with no human clinical trials. [https://pmc.ncbi.nlm.nih.gov/articles/PMC5314823/]
  - Case of acute kidney injury due to bilimbi fruit ingestion, BMJ case reports (2021) — 34-year-old man developed acute kidney injury after eating ~1 kg of bilimbi fruit; recovered fully with supportive care WITHOUT dialysis, reinforcing oxalate-nephropathy risk from the fruit itself. [https://pmc.ncbi.nlm.nih.gov/articles/PMC8728385/]
  - Acute Oxalate Nephropathy due to "Averrhoa Bilimbi": A Case Report, Mymensingh medical journal : MMJ (2018) — Acute oxalate nephropathy and AKI after bilimbi fruit juice ingestion, with full recovery on conservative management. [https://pubmed.ncbi.nlm.nih.gov/30141459/]
  - Acute oxalate nephropathy due to 'Averrhoa bilimbi' fruit juice ingestion, Indian journal of nephrology (2013) — Case series of 10 patients in Kerala who developed acute renal failure after drinking concentrated bilimbi juice; 7 required hemodialysis, 3 recovered conservatively, attributed to calcium-oxalate tubular deposition (fruit oxalate measured at 25.1 mg/100 g). [https://pmc.ncbi.nlm.nih.gov/articles/PMC3741977/]
  - Acute Oxalate Nephropathy following Ingestion of Averrhoa bilimbi Juice, Case reports in nephrology (2014) — Two patients developed acute kidney injury with biopsy-confirmed tubular oxalate deposition after ingesting Averrhoa bilimbi juice; both recovered, one needing dialysis. [https://pubmed.ncbi.nlm.nih.gov/24995136/]
  - Averrhoa bilimbi fruits attenuate hyperglycemia-mediated oxidative stress in streptozotocin-induced diabetic rats, Journal of food and drug analysis (2017) — Ethyl-acetate fruit fraction (25 mg/kg, 60 d) lowered serum glucose and HbA1c and raised insulin in STZ-diabetic rats, attenuating oxidative stress comparably to (or better than) metformin. [https://pmc.ncbi.nlm.nih.gov/articles/PMC9332517/]
  - Effects of Averrhoa bilimbi leaf extract on blood glucose and lipids in streptozotocin-diabetic rats, Journal of ethnopharmacology (2000) — Ethanolic A. bilimbi leaf extract lowered blood glucose ~50% and triglycerides ~130%, and raised HDL ~60% in streptozotocin-diabetic rats. [https://pubmed.ncbi.nlm.nih.gov/10967456/]
  - Anti-diabetic activity of the semi-purified fractions of Averrhoa bilimbi in high fat diet fed-streptozotocin-induced diabetic rats, Life sciences (2005) — Semi-purified aqueous fraction of A. bilimbi (125 mg/kg) lowered blood glucose and triglycerides and raised hepatic glycogen in high-fat-diet/STZ diabetic rats. [https://pubmed.ncbi.nlm.nih.gov/15808883/]

---

## Santol (Sandoricum koetjape)
URL: https://nutridex.info/s/santol
Category: Fruits
Evidence: Preliminary — Early or small human trials; promising but not yet conclusive.
Tart tropical fruit rich in limonoids

Quick answer: Santol is used for antioxidant / free-radical scavenging (in vitro). NutriDex grades the human evidence as preliminary — Early or small human trials; promising but not yet conclusive. Based on 8 cited human studies (8 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Santol (cotton fruit) is a Southeast Asian Meliaceae fruit eaten fresh, candied, or in preserves; the edible aril is low in calories and a useful source of potassium with modest vitamin C. Essentially all published bioactivity research is preclinical — in vitro assays, isolated-compound chemistry, and a handful of animal models — rather than human trials, so health claims remain hypotheses. The most-studied molecule is koetjapic acid, a seco-A-ring triterpene from the stem bark that induces apoptosis in colon-cancer cell lines and, as its water-soluble salt potassium koetjapate, inhibits tumor growth in mouse xenografts. Fruit-peel (exocarp) extracts rich in proanthocyanidins are antioxidant and antibacterial in vitro, and leaf cycloartane triterpenoids inhibit alpha-glucosidase more potently than acarbose in test tubes, while stem triterpenes blunt TPA-induced inflammation in mice. No randomized controlled trials in people exist for any of these endpoints; most active compounds come from bark or leaf rather than the edible flesh, and effective doses are far above what eating the fruit provides. Santol is best regarded as a nutritious tropical fruit with intriguing but unproven medicinal potential.

Nutrition (per 1 medium (100 g edible flesh)): 59 kcal; Potassium 328mg (7% DV), Vitamin C 14mg (16% DV), Fiber 1.1g (4% DV), Calcium 11mg (1% DV), Iron 1.2mg (7% DV), Phosphorus 20mg (2% DV).
Benefits / uses: Antioxidant / free-radical scavenging (in vitro); Anti-inflammatory activity (preclinical); Antimicrobial / antibacterial effects (in vitro); Anticancer signaling (preclinical, bark-derived compounds); Alpha-glucosidase inhibition relevant to blood sugar (in vitro, leaf compounds); Source of dietary potassium and modest vitamin C.
Active compounds: Seco-A-ring oleanane triterpenes (koetjapic acid, sentulic acid, katonic acid); Limonoids (sandoripins, sanjecumins, sandrapins); Cycloartane-type triterpenoids (leaf); Polyphenols / phenolic acids (gallic, ellagic); Proanthocyanidins (condensed tannins); Flavonoids; Saponins; Potassium and vitamin C.
Dose: 1 medium fruit (~100 g edible flesh); traditional use is as fresh fruit, candied, or preserved. No medicinal dose is established for humans.
Safety: The hard seeds are indigestible and have caused intestinal obstruction, perforation, and abscesses when swallowed — repeatedly documented in surgical case reports from the Philippines (including cases as recent as 2023) — so spit them out. Bark and root preparations are not the same as the edible flesh and can be toxic; medicinal extracts are unstandardized. A 2025 lab study found high-dose santol flesh extract impaired climbing and adult emergence in fruit flies, underscoring that concentrated extracts are not equivalent to eating the fruit. Diabetics on acarbose or other glucose-lowering drugs should note theoretical additive effects from large extract doses. As with any high-potassium food, people with advanced kidney disease should moderate intake. No human safety or drug-interaction trials have been conducted.

Cited studies (8):
  - Koetjapic acid: unveiling its potential as a saviour in the realm of biological and medicinal properties, with a focus on anticancer mechanism of action, European journal of medical research (2024) — Review of koetjapic acid documents anticancer mechanisms via downregulation of Wnt, HIF-1alpha, MAP/ERK/JNK, NF-kB, JAK/STAT, Akt/mTOR and C-MYC pathways; notes its mechanism is not fully explored and evidence remains preclinical. [https://pmc.ncbi.nlm.nih.gov/articles/PMC10848377/]
  - The health benefits of santol fruits and bioactive products isolated from Sandoricum koetjape Merr.: A scoping review, Journal of food biochemistry (2022) — Scoping review: ~30 bioactive products identified across Sandoricum koetjape; koetjapic acid is the principal triterpene, with anti-inflammatory, antimetastatic and antiangiogenic effects; evidence is preclinical only. [https://pubmed.ncbi.nlm.nih.gov/35315091/]
  - Evaluation of in vitro and in vivo anticancer activities of potassium koetjapate: a solubility improved formulation of koetjapic acid against human colon cancer, Research in pharmaceutical sciences (2024) — Potassium koetjapate (a solubility-improved salt of koetjapic acid) inhibited colon-cancer cell migration at 2.5-5 uM and produced dose-dependent tumor-growth inhibition in nude-mouse colon-cancer xenografts (25-100 mg/kg), approaching capecitabine. [https://pubmed.ncbi.nlm.nih.gov/39035582/]
  - Cycloartane-type triterpenoids from the leaves of Sandoricum koetjape and their efficacy on α-glucosidase inhibition activity, Journal of Natural Medicines (2024) — Leaf cycloartane-type triterpenoids (two new + ten known) inhibited alpha-glucosidase with IC50 2.17-49.2 uM, stronger than acarbose (IC50 100.6 uM). J Nat Med 2024;78(3):655-663. [https://link.springer.com/article/10.1007/s11418-023-01778-8]
  - Nutritional evaluation of santol (Sandoricum koetjape) and the effects of santol flesh extract on Drosophila melanogaster, International Journal of Agricultural Technology (2025) — Santol flesh was low in calories and deficient in vitamins B1, B2 and C but a rich potassium source (156-188 mg/100 g); high-dose flesh extract (100 mg/mL) reduced Drosophila climbing speed and lowered adult emergence to 53%. [https://li04.tci-thaijo.org/index.php/IJAT/article/view/4966]
  - Bioprospecting study, antibiotic and antioxidant activity of the santol's fruit (Sandoricum koetjape), Uniciencia (2019) — Santol fruit exocarp fractions rich in proanthocyanidins showed strong DPPH antioxidant activity and inhibited S. aureus (73%) and Bacillus spp. (42%) in vitro. [https://www.scielo.sa.cr/scielo.php?pid=S2215-34702019000100075&script=sci_abstract]
  - Koetjapic acid, a natural triterpenoid, induces apoptosis in colon cancer cells, Oncology reports (2012) — Koetjapic acid induced apoptosis in HCT 116 colorectal carcinoma cells via extrinsic/intrinsic caspase activation, mitochondrial membrane depolarization, nuclear condensation and DNA fragmentation. [https://pubmed.ncbi.nlm.nih.gov/22134768/]
  - Anti-inflammatory agents from Sandoricum koetjape Merr, Phytomedicine : international journal of phytotherapy and phytopharmacology (2004) — Bioassay-guided fractionation of stem extract yielded 3-oxo-12-oleanen-29-oic acid with anti-inflammatory activity almost equivalent to indomethacin in the TPA-induced mouse ear-edema model. [https://pubmed.ncbi.nlm.nih.gov/15070182/]

---

## Breadfruit (Artocarpus altilis)
URL: https://nutridex.info/s/breadfruit
Category: Fruits
Evidence: Preliminary — Early or small human trials; promising but not yet conclusive.
Starchy tropical staple, lower-glycemic and potassium-rich

Quick answer: Breadfruit is used for steady, lower-glycemic energy (processing-dependent). NutriDex grades the human evidence as preliminary — Early or small human trials; promising but not yet conclusive. Based on 10 cited human studies (10 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Breadfruit is a large starchy fruit eaten cooked as a staple across the Pacific, Caribbean, and tropics, nutritionally closer to potato or plantain than to a sweet fruit. USDA composition data show it is energy- and carbohydrate-dense yet low in fat, high in potassium and fiber, and a useful source of vitamin C; its protein, though modest (about 2.4 g per cooked cup), contains a balanced set of essential amino acids. Food-science work reports a high-amylose starch (reviews cite roughly 77% amylose) and substantial resistant starch, and breadfruit flour is gluten-free and nutrient-dense. Glycemic index, however, is strongly processing-dependent: flour and some preparations test low (GI ~48-62), whereas raw or fried forms can be high, so the "low-glycemic" label applies best to minimally processed, fiber-retaining preparations. Rigorous human metabolic trials of the fruit or flour are essentially absent. The only human intervention data come from small, short (about 3-week) Indonesian randomized trials of breadfruit LEAF extract (not the fruit): one (n=39) reported lower fasting blood glucose in type-2 diabetes, while a blood-pressure trial (n=36) showed reductions in both arms but no significant advantage over placebo. Most remaining health claims (antioxidant, anti-inflammatory, cardiovascular, insect-repellent) rest on in-vitro assays, animal models, and traditional use rather than clinical endpoints. Overall the evidence for the food's benefits is preliminary: the nutrient profile is genuinely favorable, but disease-outcome data in humans are sparse and largely confined to leaf-extract studies. It is best regarded as a wholesome, lower-glycemic starch swap rather than a proven therapeutic.

Nutrition (per 1 cup, cubes (220 g)): 227 kcal; Potassium 1078mg (23% DV), Vitamin C 63.8mg (71% DV), Fiber 10.8g (39% DV), Magnesium 55mg (13% DV), Copper 0.18mg (20% DV), Thiamin (B1) 0.24mg (20% DV).
Benefits / uses: Steady, lower-glycemic energy (processing-dependent); High potassium for blood pressure support; Gut-supporting fiber and resistant starch; Balanced plant protein with essential amino acids; Antioxidant phytochemicals; Food-security staple crop.
Active compounds: Resistant and high-amylose starch; Dietary fiber (pectins, cellulose); Potassium; Vitamin C (ascorbic acid); Phenolic acids (chlorogenic, cinnamic); Carotenoids (beta-carotene, lutein); Flavonoids (geranyl flavones/chalcones, mainly in leaf); Essential amino acids (leucine, isoleucine, valine, phenylalanine); Medium-chain fatty acids in male inflorescence (capric, lauric, undecanoic).
Dose: 1 cup cooked cubes (~220 g) as a starch staple in place of rice, potato, or wheat.
Safety: Generally safe as a food. The raw fruit is astringent and is eaten cooked. Its high potassium (~1 g per cooked cup) warrants caution for people with advanced kidney disease or on potassium-sparing/RAAS drugs. Leaf extracts used in studies are not the same as eating the fruit and may lower blood pressure or blood glucose, which is relevant if combined with antihypertensive or antidiabetic medication; safety in pregnancy/lactation is unstudied. Latex sap and pollen can trigger allergy in sensitive individuals (Moraceae family, related to jackfruit/fig).

Cited studies (10):
  - The Effect of Breadfruit Leaf Extract (Artocarpus Altilis) on Fasting Blood Sugar Levels among Diabetes Mellitus (DM) Type 2 Outpatient at Biru Public Health Center of Bone Regency, Indonesia, Biomedical and Pharmacology Journal (2023) — RCT (n=39) in type 2 diabetes: 500 mg/day breadfruit LEAF extract for 21 days lowered fasting blood glucose by 88.5 mg/dL vs 33.9 mg/dL in controls (between-group p=0.024). [https://biomedpharmajournal.org/vol16no1/the-effect-of-breadfruit-leaf-extract-artocarpus-altilis-on-fasting-blood-sugar-levels-among-diabetes-mellitus-dm-type-2-outpatient-at-biru-public-health-center-of-bone-regency-indonesia/]
  - Effect of Breadfruit (Artocarpus Altilis) Leaf Extract on Blood Pressure in Obese Adults in Makassar, Indonesia, Biomedical and Pharmacology Journal (2024) — Double-blind RCT (n=36 obese adults): breadfruit LEAF extract for 21 days reduced systolic BP by 3.4 mmHg and diastolic by 3.5 mmHg, but with NO significant difference vs placebo (systolic p=0.105, diastolic p=0.271). [https://biomedpharmajournal.org/vol17no1/effect-of-breadfruit-artocarpus-altilis-leaf-extract-on-blood-pressure-in-obese-adults-in-makassar-indonesia/]
  - Breadfruit, raw, USDA FoodData Central (SR Legacy) (2019) — Reference composition for raw breadfruit per 100 g: 103 kcal, 27.1 g carbohydrate, 4.9 g fiber, ~1.1 g protein, 0.23 g fat, 490 mg potassium, 29 mg vitamin C. [https://fdc.nal.usda.gov/food-details/173024/nutrients]
  - Breadfruit (Artocarpus altilis): Processing, nutritional quality, and food applications, Frontiers in nutrition (2023) — Comprehensive review: breadfruit is high in complex carbohydrate, fiber, potassium and essential amino acids (leucine, isoleucine, valine), with starch around 77% amylose and over 70 phytochemicals (flavones/flavonoids, phenolic acids, carotenoids); compositional and food-application data dominate, with human intervention studies lacking. [https://pmc.ncbi.nlm.nih.gov/articles/PMC10061028/]
  - Artocarpus: a review of its traditional uses, phytochemistry and pharmacology, Journal of ethnopharmacology (2010) — Review of the genus Artocarpus (including A. altilis) documenting traditional use for inflammation, diabetes and malarial fever and a rich prenylated-flavonoid phytochemistry, with bioactivity established mainly in vitro and in animals rather than human trials. [https://pubmed.ncbi.nlm.nih.gov/20380874/]
  - Breadfruit flour is a healthy option for modern foods and food security, PloS one (2020) — Breadfruit flour is gluten-free, low-glycemic, nutrient-dense with a complete amino-acid profile; in enzyme digestion models breadfruit protein digested more easily than wheat protein, with no adverse outcomes in cell or mouse models. [https://pubmed.ncbi.nlm.nih.gov/32702056/]
  - Effects of cooking on the phytochemical profile of breadfruit as revealed by high-resolution UPLC-MS(E), Journal of the science of food and agriculture (2020) — High-resolution UPLC-MSE profiling of immature breadfruit showed cooking caused little overall change to the phytochemical profile, with most of 146 bioactive compounds retained (some phenolics increased, a few decreased) after heat treatment. [https://pubmed.ncbi.nlm.nih.gov/31846074/]
  - Possible mechanisms of action of the aqueous extract of Artocarpus altilis (breadfruit) leaves in producing hypotension in normotensive Sprague-Dawley rats, Pharmaceutical biology (2012) — Aqueous breadfruit LEAF extract produced dose-dependent hypotension and negative chronotropy in normotensive Sprague-Dawley rats via mechanisms consistent with adrenoceptor and Ca2+-channel antagonism. [https://pubmed.ncbi.nlm.nih.gov/22830437/]
  - Effects of Methanol Extract of Breadfruit (Artocarpus altilis) on Atherogenic Indices and Redox Status of Cellular System of Hypercholesterolemic Male Rats, Advances in pharmacological sciences (2014) — Methanol breadfruit extract in hypercholesterolemic rats improved atherogenic indices and antioxidant/redox status and raised serum and cardiac HDL-cholesterol, comparable to the drug control. [https://pubmed.ncbi.nlm.nih.gov/24592277/]
  - Isolation and identification of mosquito (Aedes aegypti ) biting deterrent fatty acids from male inflorescences of breadfruit (Artocarpus altilis (Parkinson) Fosberg), Journal of agricultural and food chemistry (2012) — Bioassay-guided isolation identified capric, undecanoic and lauric acids from breadfruit male inflorescence as Aedes aegypti biting deterrents, each significantly more effective than DEET at equimolar concentration. [https://pubmed.ncbi.nlm.nih.gov/22420541/]

---

## Calamansi (Citrus x microcarpa)
URL: https://nutridex.info/s/calamansi
Category: Fruits
Evidence: Preliminary — Early or small human trials; promising but not yet conclusive.
Tiny Filipino lime with outsized citrus bioactives

Quick answer: Calamansi is used for good vitamin c source supporting antioxidant defense and normal immune function. NutriDex grades the human evidence as preliminary — Early or small human trials; promising but not yet conclusive. Based on 9 cited human studies (9 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Calamansi (calamondin) is a small Southeast Asian citrus prized as an acidulant; its juice and especially its peel concentrate vitamin C, the polymethoxyflavones nobiletin and tangeretin, the flavanone hesperidin, and the dihydrochalcone DGPP. Chemical-marker analysis quantified DGPP at roughly 25 mg/100 mL and nobiletin at about 2.4 mg/100 mL in calamondin juice. Direct human clinical trials on calamansi itself are essentially absent, so claims rest on (1) preclinical calamondin studies and (2) extrapolation from well-studied isolated citrus constituents. In high-fat-diet mice, 1–5% dietary calamondin puree slowed non-alcoholic fatty-liver progression and improved glucose tolerance. For its individual flavonoids, randomized human trials of hesperidin show modest reductions in systolic blood pressure, LDL and triglycerides, citrus polymethoxyflavones lowered cholesterol substantially in hypercholesterolemic hamsters, and vitamin C reviews show small reductions in cold duration and severity—but these used purified compounds or other citrus, not calamansi. The fruit is genuinely nutrient-dense and a healthy low-calorie flavoring, yet the species-specific human evidence is preliminary. Treat cardiometabolic and antidiabetic claims as plausible-but-unproven in people.

Nutrition (per ~7 small fruits (100 g)): 30 kcal; Vitamin C 30mg (33% DV), Fiber 2.8g (10% DV), Potassium 102mg (2% DV), Calcium 33mg (3% DV), Folate 8µg DFE (2% DV), Vitamin A 2µg RAE (0% DV).
Benefits / uses: Good vitamin C source supporting antioxidant defense and normal immune function; Contains polymethoxyflavones (nobiletin, tangeretin) and the flavanone hesperidin, citrus compounds with lipid-metabolism activity documented in animal and human-isolated-compound research; Anti-hyperglycemic and glucose-tolerance effects in preclinical (animal/in vitro) models; Slowed non-alcoholic fatty-liver progression in high-fat-diet mice fed calamondin puree; Antioxidant peel phenolics (DGPP, hesperidin) with in vitro free-radical scavenging activity; Low-calorie acidulant useful as an alternative to added salt or sugar in cooking.
Active compounds: Ascorbic acid (vitamin C); Polymethoxyflavones — nobiletin, tangeretin, sinensetin; Flavanone glycosides — hesperidin, naringin; C-glycosyl dihydrochalcone — 3',5'-di-C-β-glucopyranosylphloretin (DGPP); Flavones — diosmin, diosmetin; Monoterpenes — D-limonene (dominant peel-oil component); Phenolic acids (e.g., gallic acid) and pectin.
Dose: 2–4 fruits' juice (about 15–30 mL) as a souring agent, or ~100 g whole fruit (roughly 7 small fruits) per use; no established therapeutic dose in humans.
Safety: Highly acidic—erosive to tooth enamel and may aggravate GERD, reflux or mouth ulcers; dilute the juice. True citrus allergy or oral-allergy syndrome is possible. Unlike grapefruit, calamansi/calamondin is not an established CYP3A4 furanocoumarin inhibitor, but data are limited—use caution and consult a clinician if on narrow-therapeutic-index drugs. Vitamin C from concentrated juice or supplements above ~2 g/day can cause GI upset and, in predisposed people, may raise kidney-stone (oxalate) risk. Peel/seed extracts used in studies are far more concentrated than culinary intake and are not standardized supplements.

Cited studies (9):
  - The effects of hesperidin supplementation on cardiovascular risk factors in adults: a systematic review and dose–response meta-analysis, Frontiers in Nutrition (2023) — Dose–response meta-analysis (13 RCTs, 705 adults): hesperidin lowered SBP −1.37 mmHg (95% CI −2.73 to −0.02), LDL −5.29 mg/dL (−9.63 to −0.95), triglycerides −13.85 mg/dL (−27.21 to −0.49) and TNF-α −2.74 pg/mL (−4.89 to −0.60). [https://www.frontiersin.org/journals/nutrition/articles/10.3389/fnut.2023.1177708/full]
  - Vitamin C reduces the severity of common colds: a meta-analysis, BMC public health (2023) — Meta-analysis (10 trials, 15 comparisons): regular prophylactic vitamin C (≥1 g/day) reduced common-cold severity by ~15% (95% CI 9–21%), with a larger effect on severe symptoms. [https://pmc.ncbi.nlm.nih.gov/articles/PMC10712193/]
  - Vitamin C for preventing and treating the common cold, The Cochrane database of systematic reviews (2013) — Cochrane review (29 comparisons, ~11,306 participants): regular vitamin C ≥0.2 g/day shortened cold duration ~8% in adults and ~14% in children but did not reduce incidence in the general population. [https://pubmed.ncbi.nlm.nih.gov/23440782/]
  - Phytochemicals, Bioactive Properties and Commercial Potential of Calamondin (Citrofortunella microcarpa) Fruits: A Review, Molecules (Basel, Switzerland) (2023) — Comprehensive review of calamondin (Citrofortunella microcarpa) phytochemicals and bioactivities (antioxidant, anti-inflammatory, anti-diabetic, anti-angiogenic, antimicrobial); evidence derives from in vitro and animal models, with no human clinical trials. [https://pmc.ncbi.nlm.nih.gov/articles/PMC10146261/]
  - Dietary calamondin supplementation slows the progression of non-alcoholic fatty liver disease in C57BL/6 mice fed a high-fat diet, International journal of food sciences and nutrition (2021) — In C57BL/6 mice on a high-fat diet, 1–5% dietary calamondin puree reduced hepatic lipid accumulation and hepatocyte ballooning, improved glucose tolerance, and lowered serum Ccl2, slowing NAFLD progression. [https://pubmed.ncbi.nlm.nih.gov/32862731/]
  - Flavonoid compositions and antioxidant activity of calamondin extracts prepared using different solvents, Journal of food and drug analysis (2014) — HPLC of calamondin extracts identified DGPP as the dominant flavonoid, plus naringin, hesperidin, nobiletin, tangeretin and diosmin; hot-water peel extract at 90°C gave the highest total flavonoids/DGPP and antioxidant (DPPH) activity. [https://pubmed.ncbi.nlm.nih.gov/28911417/]
  - Chemical markers of shiikuwasha juice adulterated with calamondin juice, Journal of agricultural and food chemistry (2012) — Calamondin chemical-marker study quantified polymethoxyflavones (nobiletin ~2.4 mg/100 mL) and the dihydrochalcone glucoside DGPP (~25.5 mg/100 mL) in calamondin juice by HPLC, used to detect adulteration of shiikuwasha juice. [https://pubmed.ncbi.nlm.nih.gov/23043313/]
  - Soluble and insoluble phenolic compounds and antioxidant activity of immature calamondin affected by solvents and heat treatment, Food chemistry (2014) — Soluble and insoluble phenolics of immature calamondin and their antioxidant activity varied with solvent and heat treatment; hot-water peel extract had high total phenolics correlating with DPPH scavenging potency. [https://pubmed.ncbi.nlm.nih.gov/24837947/]
  - Hypolipidemic effects and absorption of citrus polymethoxylated flavones in hamsters with diet-induced hypercholesterolemia, Journal of agricultural and food chemistry (2004) — Diets with 1% citrus polymethoxylated flavones (mainly tangeretin/nobiletin) cut serum total cholesterol 19–27% and VLDL+LDL 32–40% in hamsters with diet-induced hypercholesterolemia. [https://pubmed.ncbi.nlm.nih.gov/15137829/]

---

## Jambolan (Jamun / Java Plum) (Syzygium cumini)
URL: https://nutridex.info/s/jambolan-syzygium-cumini
Category: Fruits
Evidence: Preliminary — Early or small human trials; promising but not yet conclusive.
Anthocyanin-rich tropical plum with antidiabetic folk use

Quick answer: Jambolan (Jamun / Java Plum) is used for traditional and preclinical antidiabetic / glucose-lowering activity (largely seed-based; best human rcts of leaf preparations were negative). NutriDex grades the human evidence as preliminary — Early or small human trials; promising but not yet conclusive. Based on 9 cited human studies (9 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Jambolan is widely promoted as an antidiabetic fruit, but the human evidence is far weaker than its reputation. The best-controlled clinical trials used leaf tea/extract and were negative: a randomized, double-blind, double-dummy trial in 27 type 2 diabetics (Teixeira 2006) found S. cumini tea produced no change in fasting glucose, while glyburide lowered it significantly; an earlier randomized controlled trial by the same group (Teixeira 2004) reached the same conclusion. Most positive data come from seed (not pulp) powder studies and from rodent and in-vitro models, where anthocyanins and tannins show alpha-glucosidase/alpha-amylase inhibition, antioxidant, and lipid-lowering activity. A small open-label seed-powder trial (cited in Rizvi 2022) reported modest improvements in glycemia and dyslipidemia, but such studies are underpowered, short, and often co-administered with standard drugs. The fruit itself is a low-calorie source of vitamin C and potassium plus pigment polyphenols. Note that USDA SR Legacy does not report sugar or dietary fiber for this item, so its fiber content is unquantified in the reference database. Overall the weight of human evidence is preliminary and mixed, and rigorous, adequately powered RCTs of standardized preparations are still lacking.

Nutrition (per 1 cup (135 g)): 81 kcal; Vitamin C 19.3mg (21% DV), Potassium 107mg (2% DV), Magnesium 20mg (5% DV), Iron 0.26mg (1% DV), Calcium 26mg (2% DV), Vitamin B6 0.051mg (3% DV).
Benefits / uses: Traditional and preclinical antidiabetic / glucose-lowering activity (largely seed-based; best human RCTs of leaf preparations were negative); Antioxidant capacity from anthocyanins and polyphenols (mostly in-vitro); Lipid-lowering / cardiometabolic signals in small human and animal studies; Anti-inflammatory activity in vitro and in rodent models; Astringent gastrointestinal use for diarrhea and digestive complaints (traditional); Low-calorie source of vitamin C and potassium.
Active compounds: Anthocyanins (delphinidin-, malvidin-, petunidin-, cyanidin-3,5-diglucosides); Hydrolyzable tannins / ellagitannins (gallic acid, ellagic acid); Flavonols (quercetin, rutin, myricetin); Phenolic acids (gallic, chlorogenic, ferulic acids); Seed alkaloid jambosine and glycoside jambolin (antimellin); Triterpenoids including oleanolic acid; Vitamin C (ascorbic acid); Minerals: potassium, magnesium, iron.
Dose: Culinary: ~100-135 g fresh fruit (1 cup). Studied antidiabetic preparations typically use seed powder (~5-10 g/day) rather than fresh pulp; benefits cannot be assumed from eating the fruit.
Safety: Generally safe as a food. Concentrated seed/extract preparations may have additive hypoglycemic effects with insulin or sulfonylureas, so diabetics combining them with medication should monitor blood glucose to avoid hypoglycemia. High tannin content is astringent and may reduce absorption of iron and some drugs; very large amounts may cause GI upset or constipation. Safety of medicinal doses in pregnancy and lactation is not established. The hard seed is a choking hazard and is not eaten whole.

Cited studies (9):
  - Java-plum, (jambolan), raw, USDA FoodData Central (SR Legacy) (2019) — Java-plum (jambolan), raw, per 100 g: 60 kcal, 15.56 g carbohydrate, 0.72 g protein, 0.23 g fat, 14.3 mg vitamin C, 79 mg potassium; sugar and dietary fiber are not reported in this record. [https://fdc.nal.usda.gov/fdc-app.html#/food-details/169913/nutrients]
  - Syzygium cumini (L.) Skeels in the treatment of type 2 diabetes: results of a randomized, double-blind, double-dummy, controlled trial, Diabetes care (2004) — Randomized double-blind double-dummy controlled trial: S. cumini leaf preparation produced no improvement in glycemic control in type 2 diabetes; concluded no hypoglycemic effect. [https://pubmed.ncbi.nlm.nih.gov/15562231/]
  - The efficacy of folk medicines in the management of type 2 diabetes mellitus: results of a randomized controlled trial of Syzygium cumini (L.) Skeels, Journal of clinical pharmacy and therapeutics (2006) — RCT in 27 type 2 diabetics: fasting glucose fell significantly with glyburide but did not change with S. cumini leaf tea or placebo; leaf-tea folk remedy ineffective. [https://pubmed.ncbi.nlm.nih.gov/16476114/]
  - Astounding Health Benefits of Jamun (Syzygium cumini) toward Metabolic Syndrome, Molecules (Basel, Switzerland) (2022) — Review (Molecules): cites a 99-patient trial in which 10 g jamun seed powder twice daily improved sugar levels and dyslipidemia over 90 days; documents anthocyanin and tannin bioactivity. [https://pmc.ncbi.nlm.nih.gov/articles/PMC9654918/]
  - Phytochemical Profile, Biological Properties, and Food Applications of the Medicinal Plant Syzygium cumini, Foods (Basel, Switzerland) (2022) — Comprehensive review (Foods) of S. cumini phytochemistry: identifies anthocyanin 3,5-diglucosides (delphinidin, malvidin, petunidin), tannins, and jambosine/jambolin as bioactives with antidiabetic and antioxidant actions. [https://pmc.ncbi.nlm.nih.gov/articles/PMC8834268/]
  - Evaluation of Antioxidant, Xanthine Oxidase-Inhibitory, and Antibacterial Activity of Syzygium cumini Linn. Seed Extracts, Plants (Basel, Switzerland) (2025) — Plants (Basel) study: S. cumini seed extracts (methanolic kernel most active) demonstrated antioxidant, xanthine-oxidase-inhibitory, and antibacterial activity in vitro, attributed to phenolic/tannin content. [https://pmc.ncbi.nlm.nih.gov/articles/PMC11820589/]
  - Antioxidant and anti-inflammatory activities of target anthocyanins di-glucosides isolated from Syzygium cumini pulp by high speed counter-current chromatography, Journal of Food Biochemistry (2020) — Anthocyanin di-glucosides (delphinidin-, petunidin-, malvidin-3,5-diglucoside) isolated from S. cumini pulp showed strong antioxidant activity; malvidin diglucoside inhibited NO, IL-6, IL-1B and TNF-alpha in LPS-stimulated macrophages. [https://onlinelibrary.wiley.com/doi/abs/10.1111/jfbc.13209]
  - GC/MS Analysis of Essential Oil and Enzyme Inhibitory Activities of Syzygium cumini (Pamposia) Grown in Egypt: Chemical Characterization and Molecular Docking Studies, Molecules (Basel, Switzerland) (2021) — GC/MS and enzyme-inhibition study (Molecules) of S. cumini leaf essential oil documented alpha-amylase (IC50 ~57.8 ug/mL) and moderate alpha-glucosidase inhibitory activity, supporting a carbohydrate-digestion-slowing mechanism. [https://pmc.ncbi.nlm.nih.gov/articles/PMC8618078/]
  - Phenolic contents-based assessment of therapeutic potential of Syzygium cumini leaves extract, PloS one (2019) — PLoS One study: S. cumini leaf extract is high in total phenolics/flavonoids and showed antioxidant, cytoprotective and anti-inflammatory activity in vitro and in vivo. [https://pmc.ncbi.nlm.nih.gov/articles/PMC6715210/]

---

## Cherimoya (Annona cherimola)
URL: https://nutridex.info/s/cherimoya
Category: Fruits
Evidence: Preliminary — Early or small human trials; promising but not yet conclusive.
Creamy custard apple rich in vitamin C

Quick answer: Cherimoya is used for antioxidant capacity from polyphenols, proanthocyanidins and vitamin c (lab/in vitro). NutriDex grades the human evidence as preliminary — Early or small human trials; promising but not yet conclusive. Based on 9 cited human studies (9 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Cherimoya verified. One material nutrition error fixed (sugar 41.6 to 30.2 g) and one duplicate/mislabeled citation replaced; evidence tier and goal hubs confirmed conservative.

Nutrition (per 1 medium (235 g)): 176 kcal; Vitamin C 29.7mg (33% DV), Fiber 7.1g (25% DV), Vitamin B6 0.6mg (35% DV), Potassium 674mg (14% DV), Magnesium 40mg (10% DV), Thiamin 0.2mg (19% DV).
Benefits / uses: Antioxidant capacity from polyphenols, proanthocyanidins and vitamin C (lab/in vitro); Source of dietary fiber that may support digestive regularity and satiety; Vitamin C contribution supporting normal immune function and collagen synthesis; Potassium content relevant to blood-pressure/electrolyte balance (extrapolated from nutrient role); Annonaceous acetogenins and seed extracts show in vitro cytotoxic/antiproliferative activity against cancer cell lines (mechanistic only); Moderate glycemic impact relative to sweetness, attributed to fiber (not confirmed in human trials).
Active compounds: Acetogenins (annonacin, annonacinone); Flavan-3-ols and proanthocyanidins ((epi)catechin oligomers, procyanidins); Phenolic acids (chlorogenic acid, caffeic acid); Vitamin C (L-ascorbic acid); Carotenoids (lutein, beta-carotene); B-vitamins (vitamin B6/pyridoxine, folate, thiamin, riboflavin); Potassium and magnesium; Isoquinoline/aporphine alkaloids (concentrated in seeds and peel).
Dose: 1 medium fruit (~235 g edible pulp); pulp only, never seeds or peel
Safety: Seeds and peel contain concentrated neurotoxic acetogenins (annonacin) and alkaloids and should never be eaten; crushed seeds are toxic and have irritant/insecticidal properties. Habitual or heavy consumption of Annonaceae fruits has been epidemiologically associated with atypical parkinsonism and worsened parkinsonian/cognitive outcomes (notably in the French Caribbean); people with Parkinson's disease or parkinsonism should be cautious and likely avoid regular intake. Annonaceae dietary supplements/extracts are not advised. Due to potassium content, those with advanced kidney disease or on potassium-restricted diets should moderate intake. Eat ripe pulp only; spit out seeds.

Cited studies (9):
  - Nutritional and phytochemical composition of Annona cherimola Mill. fruits and by-products: Potential health benefits, Food chemistry (2016) — Nutritional/phytochemical profiling of four cherimoya cultivars (pulp, peel, seeds): lutein the predominant carotenoid (129-232 ug/100g); peel showed strongest antioxidant capacity (EC50 0.97 mg/mL), supporting by-product valorization. [https://pubmed.ncbi.nlm.nih.gov/26433307/]
  - Annonaceae Consumption Worsens Disease Severity and Cognitive Deficits in Degenerative Parkinsonism, Movement disorders : official journal of the Movement Disorder Society (2022) — In 180 Caribbean parkinsonian patients, even low cumulative Annonaceae fruit/juice intake (OR 3.76) or Annonaceae herbal tea (OR 2.91) was associated with greater disease severity and cognitive deficits. [https://pubmed.ncbi.nlm.nih.gov/36210778/]
  - Annona cherimola Seed Extracts Trigger an Early Apoptosis Response and Selective Anticlonogenic Activity against the Human Gastric Carcinoma Cell Line SNU-1, Molecules (Basel, Switzerland) (2023) — A. cherimola seed ethanol extract (containing annonacin/annonacinone) triggered early apoptosis and selective anti-clonogenic activity against the human gastric carcinoma cell line SNU-1 while sparing normal gastric cells (in vitro). [https://pmc.ncbi.nlm.nih.gov/articles/PMC10574650/]
  - Pomological, Sensorial, Nutritional and Nutraceutical Profile of Seven Cultivars of Cherimoya (Annona cherimola Mill), Foods (Basel, Switzerland) (2020) — Across seven cherimoya cultivars, Chaffey had the highest total polyphenols and antioxidant activity and Daniela the highest proanthocyanidins, identifying these as superior nutraceutical sources versus the commercial Fino de Jete. [https://pmc.ncbi.nlm.nih.gov/articles/PMC7823484/]
  - Chemical Profile and Biological Activity of Cherimoya (Annona cherimola Mill.) and Atemoya (Annona atemoya) Leaves, Molecules (Basel, Switzerland) (2020) — Phytochemical profiling of cherimoya and atemoya leaves identified 18 compounds (flavonoids/alkaloids) with high proanthocyanidin content (up to 132 mg PAC-A eq/100g) and antioxidant plus antiproliferative activity against HeLa/HepG2 cells. [https://pmc.ncbi.nlm.nih.gov/articles/PMC7321297/]
  - Annona cherimola Seed Extract Activates Extrinsic and Intrinsic Apoptotic Pathways in Leukemic Cells, Toxins (2019) — Annona cherimola seed ethanolic extract dose- and time-dependently inhibited three acute myeloid leukemia cell lines via intrinsic and extrinsic apoptosis, with minimal effect on normal mesenchymal stem cells (in vitro). [https://pmc.ncbi.nlm.nih.gov/articles/PMC6784061/]
  - Neurotoxicity of Dietary Supplements from Annonaceae Species, International journal of toxicology (2015) — Annonaceae-derived dietary supplements (including A. squamosa x cherimola) reduced viability of cultured human dopaminergic neurons at extract concentrations as low as 0.1-1 ug/mL, indicating neurotoxic potential. [https://pubmed.ncbi.nlm.nih.gov/26405269/]
  - Identification and quantification of phenolic and other polar compounds in the edible part of Annona cherimola and its by-products by HPLC-DAD-ESI-QTOF-MS, Food Research International (2015) — HPLC-DAD-ESI-QTOF-MS profiling of two cherimoya cultivars identified 21 polar compounds in the edible pulp, 37 in peel and 22 in seed; procyanidins were the dominant phenolics in pulp and peel. [https://doi.org/10.1016/j.foodres.2015.10.002]
  - Radical scavenging, antioxidant and metal chelating activities of Annona cherimola Mill. (cherimoya) peel and pulp in relation to their total phenolic and total flavonoid contents, Journal of Food Composition and Analysis (2012) — Cherimoya peel and pulp phenolics (peel 14.6, pulp 12.6 mg chlorogenic-acid eq/100g) correlated with radical-scavenging, antioxidant and metal-chelating activity; peel was the most potent fraction. [https://doi.org/10.1016/j.jfca.2011.09.002]

---

## Pulasan (Nephelium ramboutan-ake)
URL: https://nutridex.info/s/pulasan
Category: Fruits
Evidence: Preliminary — Early or small human trials; promising but not yet conclusive.
Rambutan's sweeter, lab-curious tropical cousin

Quick answer: Pulasan is used for source of vitamin c supporting normal immune function and collagen synthesis. NutriDex grades the human evidence as preliminary — Early or small human trials; promising but not yet conclusive. Based on 11 cited human studies (11 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Pulasan is a Southeast Asian relative of rambutan whose edible aril is sweet, watery, and a modest source of vitamin C (~14–24 mg/100 g per Indonesian agronomic surveys). Virtually all of its purported health properties come from in vitro work on the inedible peel, leaf and seed, not the pulp: peel methanol extract is powerfully antioxidant and rich in phenolics and hydrolyzable tannins, and an aqueous rind fraction triggered mitochondrial-mediated apoptosis in HT-29 colorectal and other cancer cell lines (IC50 ~16.7 µg/mL), an effect the authors linked to tannins and saponins. Seed-protein peptides inhibit the carbohydrate-digesting enzyme α-amylase, suggesting anti-diabetic potential. However, there are no human clinical trials, no animal feeding studies of the fruit, and most bioactivity data concern processing by-products rather than what people actually eat. The fruit is therefore best viewed as a nutritious whole food with promising but entirely preliminary, mechanism-level pharmacological signals. Composition data are limited and come from agronomic surveys and a single genus review, as pulasan is not catalogued in USDA FoodData Central.

Nutrition (per 1 medium (100 g edible aril)): 56 kcal; Vitamin C 18.9mg (21% DV), Carbohydrate 13g (5% DV), Total sugars 11g (0% DV), Dietary fiber 1.1g (4% DV), Protein 0.8g (2% DV), Total fat 0.6g (1% DV).
Benefits / uses: Source of vitamin C supporting normal immune function and collagen synthesis; Polyphenol- and tannin-rich peel shows strong in vitro antioxidant (free-radical scavenging) capacity; Seed and rind extracts show in vitro anti-hyperglycemic potential via α-amylase/α-glucosidase inhibition; Aqueous rind fraction induces apoptosis in cultured cancer cell lines (in vitro only); Leaf and peel extracts show in vitro antibacterial activity; Provides water and a modest amount of dietary fiber for a refreshing low-fat fruit.
Active compounds: Vitamin C (L-ascorbic acid); Hydrolyzable tannins / ellagitannins (geraniin, corilagin — characteristic of Nephelium peel); Ellagic acid and gallic acid; Flavonoids (rutin, quercetin, flavan-3-ols); Total phenolics (up to ~306 mg GAE/g in peel methanol extract); Saponins (concentrated in rind/seed); Seed-protein bioactive peptides (α-amylase inhibitory).
Dose: 1–3 fresh fruits (~50–150 g edible aril); no studied therapeutic dose
Safety: Generally regarded as a safe edible fruit with no documented toxicity or drug interactions. The seed is not eaten raw, and the rind/seed/leaf extracts studied for bioactivity are not the edible portion — do not self-prepare concentrated peel or seed preparations. Diabetics should not rely on it for glucose control given the complete absence of human data. As with any sugary tropical fruit, account for its sugar/carbohydrate load. Allergy is theoretically possible but unreported.

Cited studies (11):
  - Effects of Vitamin C and/or E Supplementation on Glycemic Control and Cardiovascular Risk Factors in Type 2 Diabetes: A Systematic Review and Subgroup Meta-analysis, Nutrition reviews (2026) — Systematic review and subgroup meta-analysis of 52 RCTs (n=1425) in type 2 diabetes found vitamin C and combined C+E significantly lowered systolic blood pressure and C+E raised HDL, but effects on glycemic control and other lipids were not significant. [https://pmc.ncbi.nlm.nih.gov/articles/PMC12793614/]
  - Vitamin C may reduce troponin and CKMB levels after PCI and CABG: a meta-analysis, BMC cardiovascular disorders (2023) — Meta-analysis (PubMed/Cochrane/Embase/Scopus) reported vitamin C may reduce post-procedure troponin and CK-MB levels in patients undergoing PCI and CABG cardiac procedures. [https://pmc.ncbi.nlm.nih.gov/articles/PMC10512653/]
  - Effect of antioxidant vitamin supplementation on cardiovascular outcomes: a meta-analysis of randomized controlled trials, PloS one (2013) — Meta-analysis of randomized controlled trials found no significant reduction in major cardiovascular outcomes with antioxidant vitamin (including vitamin C) supplementation versus placebo. [https://pmc.ncbi.nlm.nih.gov/articles/PMC3577664/]
  - Review of Nephelium lappaceum and Nephelium ramboutan-ake: A High Potential Supplement, Molecules (Basel, Switzerland) (2021) — Comprehensive genus review (Molecules 26(22):7005) concluding N. ramboutan-ake (pulasan) bioactivity data are limited to in vitro/extract studies of peel, seed and pulp, with no in vivo or human evidence; peel and seeds show higher antioxidant and bioactivity than the edible aril, and the authors call for toxicology/pharmacology studies. [https://pmc.ncbi.nlm.nih.gov/articles/PMC8620321/]
  - Aqueous fraction of Nephelium ramboutan-ake rind induces mitochondrial-mediated apoptosis in HT-29 human colorectal adenocarcinoma cells, Molecules (Basel, Switzerland) (2012) — Aqueous fraction of N. ramboutan-ake (pulasan) rind induced mitochondrial-mediated apoptosis in HT-29 human colorectal adenocarcinoma cells in vitro, attributed to high tannin and saponin content; cell-line only, not a human study. [https://pmc.ncbi.nlm.nih.gov/articles/PMC6268511/]
  - Fruit morphological diversity and quality of pulasan (Nephelium ramboutan-ake) from six populations in Riau, Indonesia, Biodiversitas Journal of Biological Diversity (2022) — Survey of 67 pulasan accessions from six Riau (Indonesia) populations: fruit weight 23–104 g, °Brix 16.8–29.6, vitamin C 14.0–24.0 mg/100 g. Biodiversitas 23:2526-2533. [https://smujo.id/biodiv/article/view/10099]
  - Antioxidant and Antibacterial Activity from Three Different Solvents of Nephelium ramboutan-ake Leaves Crude Extract (2021) — Pulasan leaf crude extracts in three solvents showed concentration-dependent DPPH antioxidant activity (37.42–81.64% scavenging at 25–100 ppm) and moderate antibacterial inhibition; methanol/ethanol extracts most potent (in vitro). [https://www.researchgate.net/publication/351297041_Antioxidant_and_Antibacterial_Activity_from_Three_Different_Solvents_of_Nephelium_ramboutan-ake_Leaves_Crude_Extract]
  - Extraction and identification of α-amylase inhibitor peptides from Nephelium lappacheum and Nephelium mutabile seed protein using gastro-digestive enzymes, Peptides (2018) — α-Amylase inhibitor peptides extracted from N. mutabile (pulasan) and N. lappaceum seed protein via gastro-digestive enzymes (pepsin/chymotrypsin); 31 and 20 novel inhibitory peptides identified, supporting anti-diabetic potential (in vitro). Peptides 102:61–67. [https://pubmed.ncbi.nlm.nih.gov/29510154/]
  - Characteristics and Ideotype Formulation of Pulasan (Nephelium ramboutan-ake) Fruit Landrace from West Java, Indonesia, Makara Journal of Science (2017) — Characterization and ideotype formulation of West Java pulasan landraces (Djuita et al.), documenting edible-portion quality traits, °Brix and vitamin C of the fruit; five superior variants identified. [https://scholarhub.ui.ac.id/science/vol21/iss2/3/]
  - ANTIOXIDANT ACTIVITIES OF CRUDE METHANOLIC EXTRACT OF Nephelium ramboutan-ake (Labill.) Leenh. PEEL (2015) — Methanol extract of pulasan peel showed potent DPPH radical-scavenging with total phenolic content 306.04 mg GAE/g and total flavonoid content 14.05 mg QE/g — among the strongest in the genus (in vitro). [https://www.researchgate.net/publication/276203956_ANTIOXIDANT_ACTIVITIES_OF_CRUDE_METHANOLIC_EXTRACT_OF_Nephelium_ramboutan-ake_Labill_Leenh_PEEL]
  - Aqueous fraction of Nephelium ramboutan-ake rind induces mitochondrial-mediated apoptosis in HT-29 human colorectal adenocarcinoma cells, Molecules (Basel, Switzerland) (2012) — Aqueous fraction of pulasan rind induced mitochondrial-mediated apoptosis in HT-29 colorectal cancer cells (IC50 16.66 µg/mL) and was cytotoxic to HCT-116 (33.90), Ca Ski (31.14) and MDA-MB-231 (41.53 µg/mL) lines, with ROS elevation and caspase activation; activity linked to tannins and saponins (in vitro). Published in Molecules 17(6):6633. [https://pmc.ncbi.nlm.nih.gov/articles/PMC6268511/]

---

## Gandaria (Bouea macrophylla)
URL: https://nutridex.info/s/gandaria
Category: Fruits
Evidence: Preliminary — Early or small human trials; promising but not yet conclusive.
Tangy tropical plum-mango rich in gallotannins.

Quick answer: Gandaria is used for antioxidant (polyphenol-rich, in vitro). NutriDex grades the human evidence as preliminary — Early or small human trials; promising but not yet conclusive. Based on 9 cited human studies (9 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Gandaria (marian plum, maprang, kundang) is a small Southeast Asian mango-relative eaten ripe as a sweet-tart fruit. Compositionally it is a watery, low-calorie fruit (~49 kcal/100 g by Atwater calculation from its macros) providing modest vitamin C (~20 mg/100 g in the Malaysian reference database, though other sources report higher), beta-carotene, potassium and a notable load of hydrolysable tannins and gallic/ellagic acids that give it strong in-vitro antioxidant activity. Laboratory and isolated-compound studies show the seed and leaf extracts inhibit α-glucosidase (a mechanism relevant to blood-sugar control), kill several bacteria and fungi, and are cytotoxic to cultured cancer cells, while oral extract in UVB-exposed hairless mice reduced wrinkling and preserved collagen. Crucially, essentially all health evidence is in vitro or in animals: there are no human clinical trials of gandaria fruit or its extracts for any outcome. Reported antioxidant and enzyme-inhibition potencies come from concentrated extracts, not the amounts you would get from eating the fruit. A 28-day rodent study of a fruit-extract yoghurt found no toxicity up to 2000 mg/kg, supporting general food safety. Overall the human evidence is preliminary, and benefits beyond ordinary fruit nutrition should be considered unproven.

Nutrition (per 1 small handful (100 g)): 49 kcal; Vitamin C 20mg (22% DV), Beta-carotene 331µg (3% DV), Fiber 1.4g (5% DV), Potassium 84mg (2% DV), Phosphorus 10mg (1% DV), Calcium 5mg (0% DV).
Benefits / uses: Antioxidant (polyphenol-rich, in vitro); Vitamin C source; Beta-carotene (provitamin A); α-glucosidase inhibition (antidiabetic, preclinical); Antimicrobial (preclinical); Anti-photoaging (animal models).
Active compounds: Hydrolysable tannins / gallotannins (pentagalloyl glucose); Phenolic acids (gallic acid, ellagic acid, methyl gallate); Flavonoids (quercetin, quercitrin, myricitrin, kaempferol, afzelin); Vitamin C (ascorbic acid); Carotenoids (beta-carotene); Triterpenoids (betulinic acid); Anthocyanins (ripe peel); Dietary fiber.
Dose: Culinary fruit; ~100 g (a small handful of 3–5 fruits) as a typical serving. No established therapeutic dose.
Safety: Generally safe as a food; rodent toxicity studies of fruit-extract yoghurt showed no adverse effects (acute LD50 >2000 mg/kg; 28-day dosing up to 1000 mg/kg/day). As a mango-family (Anacardiaceae) fruit, the peel/sap can cause contact dermatitis or allergic reactions in people sensitive to mango/urushiol. Unripe fruit is very sour and astringent. Concentrated seed/leaf extracts are not characterized for human use, and their α-glucosidase inhibition could theoretically add to glucose-lowering medication effects—no human interaction data exist.

Cited studies (9):
  - Phytochemical Analysis and Toxicity Assessment of Bouea Macrophylla Yoghurt, Toxins (2023) — B. macrophylla fruit-extract yoghurt: UHPLC-MS profiling identified ~110 compounds (phenolics/flavonoids, gallic acid, tannins); acute LD50 >2000 mg/kg and 28-day repeated dosing (≤1000 mg/kg/day) caused no organ toxicity in rats. [https://pmc.ncbi.nlm.nih.gov/articles/PMC9959104/]
  - The Evolution of Pharmacological Activities Bouea macrophylla Griffith In Vivo and In Vitro Study: A Review, Pharmaceuticals (Basel, Switzerland) (2022) — Narrative review of B. macrophylla pharmacology reported antioxidant, antidiabetic, antimicrobial, anticancer and anti-photoaging activity but concluded data remain limited to in vitro/animal models, calling for toxicological studies and human clinical trials. [https://pmc.ncbi.nlm.nih.gov/articles/PMC8880147/]
  - Bioactive Compounds of Plum Mango (Bouea microphylla Griffith), Reference Series in Phytochemistry (2020) — Reference-work chapter 'Bioactive Compounds of Plum Mango (Bouea microphylla Griffith)' cataloguing nutritional value and bioactives—polyphenols, gallotannins, flavonoids, carotenoids and vitamin C—and their reported antioxidant and functional-food potential. [https://link.springer.com/rwe/10.1007/978-3-030-30182-8_36]
  - Potential Antimicrobial and Anticancer Activities of an Ethanol Extract from Bouea macrophylla, Molecules (Basel, Switzerland) (2020) — Ethanol extract of Bouea macrophylla showed antibacterial activity against 9 of 10 tested pathogens and inhibited proliferation of HeLa and HCT116 human cancer cell lines in vitro, attributed to gallic and ellagic acid content. [https://pmc.ncbi.nlm.nih.gov/articles/PMC7221966/]
  - Ameliorative Effect of Bouea macrophylla Griffth Seed Extract Against Bacteria-Induced Acne Inflammation: in vitro study, Journal of oleo science (2022) — Bouea macrophylla seed extract exhibited antibacterial, anti-inflammatory, and antioxidant activity against acne-inducing bacteria in an in vitro model, supporting topical anti-inflammatory potential. [https://pubmed.ncbi.nlm.nih.gov/36184462/]
  - α-Glucosidase inhibitory activities of flavonoid derivatives isolated from Bouea macrophylla: in vitro and in silico studies, RSC advances (2023) — Eight flavonoid-type compounds isolated from B. macrophylla leaves inhibited α-glucosidase (IC50 9.2–266 µM); 8-bromoquercetin (5a) was the most potent at 9.2 µM, ~37× more potent than acarbose in vitro/in silico. [https://pmc.ncbi.nlm.nih.gov/articles/PMC10009879/]
  - Alpha-glucosidase inhibitors from Nervilia concolor, Tecoma stans, and Bouea macrophylla, Saudi journal of biological sciences (2022) — Three compounds isolated from B. macrophylla (betulinic acid, methyl gallate, 3-O-galloyl gallic acid methyl ester) inhibited α-glucosidase with IC50 1.4–143.3 µM, with molecular docking against acarbose as reference. [https://pubmed.ncbi.nlm.nih.gov/35197772/]
  - Maprang "Bouea macrophylla Griffith" seeds: proximate composition, HPLC fingerprint, and antioxidation, anticancer and antimicrobial properties of ethanolic seed extracts, Heliyon (2019) — Maprang (B. macrophylla) seeds: high gallotannin/phenolic content; ethanolic seed extract showed DPPH IC50 20.9–46.3 µg/mL, cytotoxicity to K562 leukemia cells (IC50 ~3–45 µg/mL, more toxic to doxorubicin-resistant cells), and antimicrobial activity (MIC 39–625 µg/mL); 18 phytochemicals identified including gallic and ellagic acid. [https://pmc.ncbi.nlm.nih.gov/articles/PMC6625972/]
  - The anti-photoaging and moisturizing effects of Bouea macrophylla extract in UVB-irradiated hairless mice, Food science and biotechnology (2018) — Oral B. macrophylla extract (300 mg/kg/day, 8 wks) in UVB-irradiated hairless mice reduced wrinkle formation and skin thickening, restored collagen (COL1A1/3A1/4A1/7A1) via TGF-β/Smad, and suppressed MMP-2/-3/-9/-13. [https://pubmed.ncbi.nlm.nih.gov/30263735/]

---

## Indian Jujube (Ber) (Ziziphus mauritiana)
URL: https://nutridex.info/s/indian-jujube
Category: Fruits
Evidence: Preliminary — Early or small human trials; promising but not yet conclusive.
Vitamin-C-rich desert fruit with metabolic promise

Quick answer: Indian Jujube (Ber) is used for exceptionally rich in vitamin c, supporting antioxidant defense and immune function. NutriDex grades the human evidence as preliminary — Early or small human trials; promising but not yet conclusive. Based on 9 cited human studies (9 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Indian jujube (ber) is a small tropical fruit notable for an exceptionally high and variable vitamin C content (often 60–165 mg/100g), well above most common fruits. Direct human trials on Z. mauritiana itself are essentially absent; the clinical evidence base comes from the closely related Z. jujuba, where small RCTs and two recent meta-analyses suggest jujube consumption can modestly reduce BMI, triglycerides, total cholesterol and LDL, with fasting-glucose benefits concentrated in type-2-diabetic subgroups. These trials are few (4–7 studies, under 500 participants total), short (1–12 weeks), heterogeneous in dose and preparation, and largely conducted in Iran, so confidence is low and effect sizes should be read cautiously. Phytochemical work on Z. mauritiana documents abundant flavonoids and phenolic acids with antioxidant and anti-inflammatory activity, but these are mostly in vitro and animal data. Sedative/anxiolytic claims trace to seed jujubosides studied in the distinct species Z. spinosa, not the edible ber fruit, and should not be extrapolated. Overall, jujube is a nutritious, vitamin-C-dense fruit with biologically plausible but preliminary metabolic benefits awaiting larger, rigorous trials.

Nutrition (per 3 fruits (100 g)): 79 kcal; Vitamin C 69mg (77% DV), Potassium 250mg (5% DV), Vitamin B6 0.081mg (5% DV), Manganese 0.084mg (4% DV), Iron 0.48mg (3% DV), Calcium 21mg (2% DV).
Benefits / uses: Exceptionally rich in vitamin C, supporting antioxidant defense and immune function; May modestly lower LDL, triglycerides and total cholesterol (evidence mostly from the related species Ziziphus jujuba); May reduce fasting blood glucose and BMI, with glucose benefits concentrated in type-2-diabetic adults; High polyphenol and flavonoid content with measurable antioxidant/anti-inflammatory activity in animal models; Low energy density and high water content suit weight-conscious diets.
Active compounds: Vitamin C (L-ascorbic acid) — unusually high, roughly 55–165 mg/100g across cultivars; Flavonols & flavones (quercetin, rutin, kaempferol, myricetin, apigenin); Phenolic acids (chlorogenic, gallic, caffeic, ferulic, p-coumaric, ellagic acids); Dammarane saponins / jujubosides A & B (concentrated in seed, not the edible flesh); Triterpenic acids (betulinic, oleanolic, ursolic acid); Cyclopeptide alkaloids (mauritine-type); Carotenoids and provitamin A precursors; Soluble and insoluble dietary fiber (including pectins); Minerals: potassium, calcium, phosphorus, manganese.
Dose: A typical serving is about 3 fresh fruits (~100 g), providing roughly 69 mg vitamin C. Lipid- and glucose-lowering trials (on the related Z. jujuba) used 5–30 g/day of dried fruit powder or 15 g/day of extract.
Safety: Generally recognized as safe as a food. Concentrated dried-fruit powders or extracts that lower blood glucose and lipids could theoretically add to the effects of antidiabetic or lipid-lowering drugs—monitor if combining. Ziziphus seed preparations have sedative activity and may potentiate CNS depressants/sedatives; the edible fruit flesh carries little of this. The hard stone (pit) is a choking hazard, especially for children. Pollen and fruit can rarely trigger allergy. Safety of high-dose extracts in pregnancy and lactation is not established.

Cited studies (9):
  - Impact of jujube fruit on serum lipid profile, glycemic index, and liver function: a systematic review and meta-analysis, Nutrition & Diabetes (2025) — Meta-analysis (7 RCTs, 483 participants): jujube significantly reduced BMI (MD -1.18) and triglycerides (MD -1.87); fasting blood sugar and LDL fell significantly only in type-2-diabetic subgroups (no significant overall effect), while HDL, AST and ALT were unchanged. [https://www.nature.com/articles/s41387-025-00378-7]
  - The effect of consumption Ziziphus jujuba on metabolic factors: A systematic review and meta-analysis of randomized clinical trials, Clinical Nutrition Open Science (2024) — Meta-analysis of 4 RCTs: Ziziphus jujuba significantly lowered BMI, triglycerides, total cholesterol and LDL, with no significant effect on HDL or fasting blood glucose; authors urge caution given the small number of trials. [https://www.clinicalnutritionopenscience.com/article/S2667-2685(24)00017-2/fulltext]
  - Effects of Ziziphus jujuba, metformin, and myoinositol on pregnancy rates and metabolic parameters in infertile women with PCOS: a randomized controlled trial, Journal of ovarian research (2026) — Double-blind RCT in 196 infertile PCOS women: 15 g/day Ziziphus jujuba extract for 12 weeks improved total cholesterol, triglycerides, HDL and fasting glucose vs comparators, but did not significantly raise pregnancy rates. [https://pubmed.ncbi.nlm.nih.gov/41618368/]
  - Effect of Ziziphus jujube on cardiometabolic factors and systemic inflammation in type 2 diabetic patients: A randomized controlled trial, Clinical nutrition ESPEN (2022) — RCT in 48 type-2-diabetic adults: 30 g jujube daily for 12 weeks reduced fasting glucose ~11.4%, triglycerides ~13.6%, total cholesterol ~7.5% and LDL-C ~7.7% vs control; HDL and IL-6 unchanged. [https://pubmed.ncbi.nlm.nih.gov/35623863/]
  - Effect of Zizyphus jujuba fruits on dyslipidemia in obese adolescents: a triple-masked randomized controlled clinical trial, Medical archives (Sarajevo, Bosnia and Herzegovina) (2013) — Triple-blind RCT in obese dyslipidemic adolescents (70 completed): 5 g jujube fruit powder three times daily for 1 month significantly lowered total cholesterol (P=0.007) and LDL-C (P=0.004) versus placebo. [https://pubmed.ncbi.nlm.nih.gov/23848030/]
  - Ziziphus jujuba (Jujube) in Metabolic Syndrome: From Traditional Medicine to Scientific Validation, Current nutrition reports (2024) — Review of Z. jujuba in metabolic syndrome: traditional anti-diabetic and lipid-lowering uses are supported by mechanistic and early clinical data (improved glucose uptake, insulin sensitivity, lipid profiles) but require rigorous clinical validation. [https://pubmed.ncbi.nlm.nih.gov/39354208/]
  - Bioactivities and potential health benefits of Ziziphus mauritiana, Journal of Food Measurement and Characterization (2026) — Comprehensive review of Ziziphus mauritiana bioactivities reports antioxidant, antidiabetic, antimicrobial and hepatoprotective effects, but notes findings are predominantly in vitro/in vivo with no dedicated clinical trials on the fruit. [https://link.springer.com/article/10.1007/s11694-025-03878-3]
  - Phenolic Profile of Seedless Ziziphus mauritiana Fruits and Leaves Extracts with In Vivo Antioxidant and Anti-Inflammatory Activities: Influence on Pro-Inflammatory Mediators, Chemistry & biodiversity (2025) — Identified phenolic acids (chlorogenic, gallic, caffeic, ferulic, ellagic, etc.) and flavonoids (quercetin, rutin, kaempferol, myricetin) in seedless Z. mauritiana fruit/leaf; fruit extract showed marked in vivo anti-inflammatory activity (carrageenan paw edema) and suppressed IL-6, TNF-alpha and CRP. [https://pmc.ncbi.nlm.nih.gov/articles/PMC11908774/]
  - Aabideen 2024 — Among Ziziphus species, Z. mauritiana leaf/fruit extracts showed strong DPPH antioxidant and alpha-glucosidase inhibitory activity, correlating with rutin, quercetin and apigenin content. [https://jppres.com/jppres/pdf/vol13/jppres24.2135_13.5.1385.pdf]

---

## Bifidobacterium lactis DN-173 010 (Bifidobacterium animalis subsp. lactis DN-173 010 (Activia))
URL: https://nutridex.info/s/dn-173010
Category: Probiotics, Gut & Immune
Evidence: Moderate — Several controlled trials; effects real but modest or context-dependent.
The "Activia" strain — fermented-milk Bifidobacterium that speeds gut transit and eases bloating

Quick answer: Bifidobacterium lactis DN-173 010 is used for shortens colonic and total gut transit time (most robust, strain-specific effect). NutriDex grades the human evidence as moderate — Several controlled trials; effects real but modest or context-dependent. Based on 9 cited human studies (9 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Bifidobacterium animalis subsp. lactis DN-173 010 (also designated CNCM I-2494, the Activia strain) is the most extensively trialed fermented-milk probiotic for accelerating gut transit. Randomized double-blind trials show it shortens colonic transit time in healthy women and in constipation-predominant IBS, where it also significantly reduced abdominal distension and accelerated orocaecal and colonic transit. A 2016 systematic review and meta-analysis of 3 trials (598 adults) found a modest but significant improvement in overall GI discomfort (pooled OR 1.48, 95% CI 1.07-2.05). Evidence is consistent for transit and bloating/comfort endpoints but mixed for hard outcomes: a 160-child RCT in functional constipation found no benefit over control for stool frequency.

Benefits / uses: Shortens colonic and total gut transit time (most robust, strain-specific effect); Reduces abdominal distension/bloating in constipation-predominant IBS (IBS-C); Improves overall GI discomfort and digestive well-being in adults with minor digestive symptoms; Improves health-related quality of life and bloating scores in IBS-C in primary care; Increases weekly stool frequency in adults reporting <3 stools/week.
Active compounds: Bifidobacterium animalis subsp. lactis DN-173 010; CNCM I-2494 (synonymous deposit designation); Activia / Danone Activia fermented milk (with yoghurt strains L. bulgaricus + S. thermophilus); Delivered as fermented dairy, not a standalone capsule.
Dose: Trials used fermented milk delivering roughly 1.25 x 10^10 CFU of DN-173 010 per serving (about 6 x 10^9 CFU per 125 g pot), taken as 2-3 servings/day with meals. Effects on transit and comfort emerged within 10 days to 4 weeks of daily consumption.
Safety: Well tolerated across trials with no significant adverse-event signal versus control dairy; common, food-grade Bifidobacterium delivered in yoghurt. As with any live probiotic, exercise caution in critically ill, immunocompromised patients, or those with central venous catheters, where probiotic bacteremia has rarely been reported. Contains milk — unsuitable for those with milk allergy; lactose content is relevant for severe intolerance.

Cited studies (9):
  - Effectiveness of Probiotics in Patients With Constipation: A Systematic Review and Meta-Analysis, Cureus (2024) — Systematic review and meta-analysis of 10 RCTs (1,243 patients) found probiotics significantly favored over placebo for constipation treatment (p<0.05), attributed to reduced intestinal transit time. [https://pmc.ncbi.nlm.nih.gov/articles/PMC10854359/]
  - Effects of Bifidobacterium animalis subspecies lactis supplementation on gastrointestinal symptoms: systematic review with meta-analysis, Nutrition reviews (2022) — Systematic review with meta-analysis found Bifidobacterium animalis subsp. lactis supplementation increased defecation frequency and, in short-term use, reduced colonic transit time in healthy adults and improved stool consistency. [https://pubmed.ncbi.nlm.nih.gov/34918142/]
  - Systematic review and meta-analysis: the effects of fermented milk with Bifidobacterium lactis CNCM I-2494 and lactic acid bacteria on gastrointestinal discomfort in the general adult population, Therapeutic advances in gastroenterology (2017) — Systematic review/meta-analysis of 3 trials (598 adults): fermented milk with B. lactis CNCM I-2494 significantly improved overall GI discomfort vs control (pooled OR 1.48, 95% CI 1.07-2.05; NNT ~10). [https://pmc.ncbi.nlm.nih.gov/articles/PMC5330605/]
  - Contemporary meta-analysis of short-term probiotic consumption on gastrointestinal transit, World journal of gastroenterology (2016) — Contemporary meta-analysis of short-term probiotic consumption on gastrointestinal transit identified medium-to-large treatment effects specifically for B. lactis HN019 and B. lactis DN-173 010 on transit time, stool frequency and consistency. [https://pmc.ncbi.nlm.nih.gov/articles/PMC4886388/]
  - Fermented milk containing Bifidobacterium lactis DN-173 010 in childhood constipation: a randomized, double-blind, controlled trial, Pediatrics (2011) — RCT in 160 children (148 analyzed) with functional constipation (3 wk): no significant difference in stool-frequency increase vs control (2.9 vs 2.6/wk, P=0.35); insufficient evidence to recommend for pediatric constipation. [https://pubmed.ncbi.nlm.nih.gov/21606153/]
  - Clinical trial: the effects of a fermented milk product containing Bifidobacterium lactis DN-173 010 on abdominal distension and gastrointestinal transit in irritable bowel syndrome with constipation, Alimentary pharmacology & therapeutics (2009) — RCT in 34 IBS-C patients (4 wk): DN-173 010 reduced maximal abdominal distension by a median 39% (95% CI -78 to -5, P=0.02), accelerated colonic transit by 12.2 h (P=0.026) and orocaecal transit by 1.2 h (P=0.049). [https://pubmed.ncbi.nlm.nih.gov/18801055/]
  - Bifidobacterium animalis strain DN-173 010 shortens the colonic transit time in healthy women: a double-blind, randomized, controlled study, Alimentary pharmacology & therapeutics (2002) — Double-blind crossover in 36 healthy women: B. animalis DN-173 010 significantly shortened total and sigmoid colonic transit time vs control fermented milk. [https://pubmed.ncbi.nlm.nih.gov/11876714/]
  - Effect of a fermented milk containing Bifidobacterium animalis DN-173 010 on the health-related quality of life and symptoms in irritable bowel syndrome in adults in primary care: a multicentre, randomized, double-blind, controlled trial, Alimentary pharmacology & therapeutics (2007) — Multicentre RCT in 267 IBS-C adults (6 wk): higher HRQoL discomfort responder rate at wk 3 (65.2% vs 47.7%, P<0.005), greater bloating reduction (P=0.03), and increased stool frequency in those with <3 stools/wk. [https://pubmed.ncbi.nlm.nih.gov/17635382/]
  - Fermented milk containing Bifidobacterium lactis DN-173 010 improves gastrointestinal well-being and digestive symptoms in women reporting minor digestive symptoms: a randomised, double-blind, parallel, controlled study, The British journal of nutrition (2009) — Randomized double-blind parallel trial in 197 women with minor digestive symptoms (4 wk): fermented milk with DN-173 010 significantly improved GI well-being and digestive symptoms vs control non-fermented dairy. [https://pubmed.ncbi.nlm.nih.gov/19622191/]

---

## L. helveticus R0052 + B. longum R0175 (L. helveticus R0052 + B. longum R0175 (Cerebiome))
URL: https://nutridex.info/s/l-helveticus-r0052
Category: Probiotics, Gut & Immune
Evidence: Mixed — Conflicting results across studies; benefit uncertain.
Psychobiotic duo studied for mood, anxiety, and stress reactivity

Quick answer: L. helveticus R0052 + B. longum R0175 is used for reduced self-reported anxiety and depression scores (hads, hscl-90) in healthy volunteers over 30 days (messaoudi 2011). NutriDex grades the human evidence as mixed — Conflicting results across studies; benefit uncertain. Based on 9 cited human studies (9 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

L. helveticus R0052 + B. longum R0175 (Cerebiome/Probio'Stick) is the most-studied "psychobiotic" formulation. A foundational 30-day RCT in healthy volunteers (Messaoudi 2011) reduced self-reported anxiety/depression scores (HADS, HSCL-90) and lowered urinary free cortisol, and an 8-week RCT in major depressive disorder (Kazemi 2018) showed a significantly greater fall in Beck Depression Inventory score vs placebo (-8.3 vs -2.6, p=0.042). However, a well-conducted 8-week RCT for low mood (Romijn 2017, n=79) found NO benefit over placebo, so overall human evidence is mixed/moderate rather than definitive. Effects are strain- and population-specific; most data are small trials or open-label pilots.

Benefits / uses: Reduced self-reported anxiety and depression scores (HADS, HSCL-90) in healthy volunteers over 30 days (Messaoudi 2011); Lowered urinary free cortisol, suggesting blunted stress/HPA-axis reactivity (Messaoudi 2011); Greater reduction in Beck Depression Inventory score vs placebo in major depressive disorder over 8 weeks (Kazemi 2018); Reduced stress-related GI/somatization complaints (abdominal pain, nausea/vomiting) in stressed adults; Open-label improvements in mood, anxiety, anhedonia and sleep quality in treatment-naive MDD (Wallace 2021); Note: a parallel low-mood RCT (Romijn 2017) found no benefit — efficacy is not consistent across studies.
Active compounds: Cerebiome (Lallemand Health Solutions) — research-grade brand; Probio'Stick / Zenix — 1.5 g sachet formulations; Branded consumer products containing L. helveticus R0052 + B. longum R0175; Freeze-dried powder sachets and capsules.
Dose: 3 x 10^9 CFU/day (combined R0052 + R0175), typically one 1.5 g sachet or capsule daily for 4-8 weeks; trials dosed once daily, often in the morning, on an empty stomach or with a cool drink.
Safety: Well tolerated in trials with no serious adverse events; mild transient GI effects (bloating, gas) possible. As with all live probiotics, use caution in the critically ill, those with central venous catheters, severe immunocompromise, or short-gut/intestinal-barrier compromise, where rare bacteremia risk exists. Not a substitute for established antidepressant or anxiolytic therapy; discuss with a clinician if used adjunctively for diagnosed mood disorders.

Cited studies (9):
  - Strain-specific effects of probiotics on depression and anxiety: a meta-analysis, Gut pathogens (2024) — Strain-specific meta-analysis of 12 RCTs (n=707) found probiotics significantly reduced depressive symptoms on the BDI; the L. helveticus R0052 + B. longum R0175 blend was among formulations associated with reduced psychological distress and lower urinary free cortisol, though blend design limits single-strain attribution. [https://pmc.ncbi.nlm.nih.gov/articles/PMC11382490/]
  - The efficacy of probiotics, prebiotics, and synbiotics on anxiety, depression, and sleep: a systematic review and meta-analysis of randomized controlled trials, BMC Psychiatry (2025) — Systematic review and meta-analysis of RCTs reported that probiotics, prebiotics, and synbiotics significantly improved anxiety, depression, and sleep outcomes versus placebo. [https://link.springer.com/article/10.1186/s12888-025-07644-z]
  - Effect of probiotic and prebiotic vs placebo on psychological outcomes in patients with major depressive disorder: A randomized clinical trial, Clinical nutrition (Edinburgh, Scotland) (2019) — 8-week RCT in MDD (81 completers): probiotic group BDI fell 17.4 to 9.1 vs placebo 18.2 to 15.6, a significantly greater decrease (p=0.042). [https://pubmed.ncbi.nlm.nih.gov/29731182/]
  - A double-blind, randomized, placebo-controlled trial of Lactobacillus helveticus and Bifidobacterium longum for the symptoms of depression, The Australian and New Zealand journal of psychiatry (2017) — 8-week double-blind RCT (n=79) for low mood found NO significant difference between probiotic and placebo on any psychological outcome; MADRS response 23% vs 26%. [https://pubmed.ncbi.nlm.nih.gov/28068788/]
  - Beneficial psychological effects of a probiotic formulation (Lactobacillus helveticus R0052 and Bifidobacterium longum R0175) in healthy human volunteers, Gut microbes (2011) — 30-day RCT in 55 healthy volunteers: probiotic reduced HADS and HSCL-90 global scores and lowered median urinary free cortisol (50.5 to 43.7 ng/ml, p=0.04) vs no change in controls. [https://pubmed.ncbi.nlm.nih.gov/21983070/]
  - Assessment of psychotropic-like properties of a probiotic formulation (Lactobacillus helveticus R0052 and Bifidobacterium longum R0175) in rats and human subjects, The British journal of nutrition (2011) — Companion rat + human study established anxiolytic-like and psychotropic-like properties of the R0052/R0175 formulation, underpinning the human cortisol findings. [https://pubmed.ncbi.nlm.nih.gov/20974015/]
  - Exploring the Potential of Lactobacillus helveticus R0052 and Bifidobacterium longum R0175 as Promising Psychobiotics Using SHIME, Nutrients (2023) — In vitro gut-simulation study characterizing L. helveticus R0052 and B. longum R0175 as psychobiotics, showing modulation of microbial metabolites relevant to the gut-brain axis supporting the strains' proposed mechanism. [https://pmc.ncbi.nlm.nih.gov/articles/PMC10056475/]
  - The Efficacy, Safety, and Tolerability of Probiotics on Depression: Clinical Results From an Open-Label Pilot Study, Frontiers in psychiatry (2021) — 8-week open-label pilot in 10 treatment-naive MDD patients: significant reductions in MADRS scores by week 4 sustained to week 8, plus improved sleep; no adverse events. [https://pmc.ncbi.nlm.nih.gov/articles/PMC7917127/]
  - Effects of a Psychobiotic Supplement on Serum Brain-derived Neurotrophic Factor Levels in Depressive Patients: A Post Hoc Analysis of a Randomized Clinical Trial, Journal of neurogastroenterology and motility (2020) — Post hoc analysis of the open-label MDD cohort linked Cerebiome supplementation to changes in serum BDNF, a putative antidepressant-response biomarker. [https://pmc.ncbi.nlm.nih.gov/articles/PMC7547201/]

---

## Akkermansia muciniphila (Akkermansia muciniphila (pasteurized))
URL: https://nutridex.info/s/akkermansia
Category: Probiotics, Gut & Immune
Evidence: Preliminary — Early or small human trials; promising but not yet conclusive.
The mucin-degrading "next-generation" postbiotic for metabolic health

Quick answer: Akkermansia muciniphila is used for improves insulin sensitivity in overweight/obese insulin-resistant adults (pasteurized form, +28.6% vs placebo). NutriDex grades the human evidence as preliminary — Early or small human trials; promising but not yet conclusive. Based on 7 cited human studies (7 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Akkermansia muciniphila in its PASTEURIZED form is a next-generation postbiotic whose best human evidence is for cardiometabolic risk in overweight/obese insulin-resistant adults. A 2019 randomized double-blind proof-of-concept trial (Depommier, Nature Medicine, 32 completers) found pasteurized cells, but not live cells, significantly improved insulin sensitivity (+28.6%, P=0.002), lowered insulinemia and total cholesterol versus placebo. A larger 2026 RCT (n=90) showed pasteurized A. muciniphila MucT reduced post-diet weight regain (1.2 vs 3.2 kg, P=0.012). Evidence remains preliminary: trials are small/few, paradoxically the heat-killed (postbiotic) form outperforms live cells, and outcomes were exploratory rather than confirmatory.

Benefits / uses: Improves insulin sensitivity in overweight/obese insulin-resistant adults (pasteurized form, +28.6% vs placebo); Reduces fasting insulinemia and plasma total cholesterol; Lowers post-diet body-weight regain and supports weight-loss maintenance; Reinforces the intestinal mucus layer and gut-barrier integrity (mechanistic, via Amuc_1100/TLR2 signaling); Reduces markers of metabolic endotoxemia and low-grade inflammation; Favorably shifts cardiometabolic risk markers (modest reductions in fat mass, body weight).
Active compounds: Pasteurized A. muciniphila MucT (type strain ATCC BAA-835); Live A. muciniphila (proof-of-concept comparator; less effective than pasteurized); Amuc_1100 outer-membrane protein (heat-stable active component); Branded: The Akkermansia Company / Pendulum Akkermansia; Other characterized strains: YGMCC2645, Timepie001 (preclinical).
Dose: ~10^10 cells/day (10 billion) of pasteurized A. muciniphila, oral, taken daily; EFSA novel-food authorization permits up to 3.4 x 10^10 cells/day. Trial regimens ran 3-6 months; effects on insulin sensitivity emerged by ~12 weeks.
Safety: Well tolerated in trials over 3-6 months with no treatment-related serious adverse events; mild GI symptoms only. EFSA (2021) authorized pasteurized A. muciniphila as a novel food up to 3.4x10^10 cells/day for adults; it is a non-toxigenic, avirulent commensal. Caution as a general principle for next-generation probiotics: avoid in critically ill, severely immunocompromised, or those with central venous catheters/compromised gut barrier until more safety data exist. Pasteurized (non-viable) form mitigates any theoretical live-organism translocation risk. Not studied in pregnancy or children.

Cited studies (7):
  - The Role of Akkermansia muciniphila on Improving Gut and Metabolic Health Modulation: A Meta-Analysis of Preclinical Mouse Model Studies, Microorganisms (2024) — Systematic review and meta-analysis (39 studies, PROSPERO CRD42023412714) found A. muciniphila (live or heat-killed) improved glycemic control, lipid profile, liver enzymes, and gut/systemic inflammation, with live cells lowering blood glucose at doses >=10^9 CFU for >=3 weeks; human intervention evidence remained limited. [https://pmc.ncbi.nlm.nih.gov/articles/PMC11356609/]
  - Safety of pasteurised Akkermansia muciniphila as a novel food pursuant to Regulation (EU) 2015/2283, EFSA Journal (2021) — EFSA Scientific Opinion concluded pasteurised A. muciniphila is safe as a novel food at intakes up to 3.4 x 10^10 cells/day for the target adult population (EFSA Journal 2021;19(9):6780). [https://doi.org/10.2903/j.efsa.2021.6780]
  - Pasteurized Akkermansia muciniphila Muc(T) for weight loss maintenance in people with overweight and obesity: a controlled randomized trial, Nature medicine (2026) — RCT (n=90) with 8-wk low-energy diet then 24-wk maintenance: pasteurized A. muciniphila MucT reduced weight regain (1.2±0.7 vs 3.2±0.4 kg, P=0.012) and yielded greater net weight loss (3.1±0.7 kg vs placebo, P=0.009); no treatment-related serious adverse events. [https://pubmed.ncbi.nlm.nih.gov/42120725/]
  - Management and results in periprosthetic tibial fracture after total knee arthroplasty: Two-center 15-case retrospective series at 2 years' follow-up, Orthopaedics & traumatology, surgery & research : OTSR (2020) — Secondary analysis of the pilot RCT: A. muciniphila supplementation reduced circulating markers of liver dysfunction (e.g., GGT, AST) and inflammation in overweight/obese adults, supporting hepatometabolic benefit. [https://pubmed.ncbi.nlm.nih.gov/32184065/]
  - Supplementation with Akkermansia muciniphila in overweight and obese human volunteers: a proof-of-concept exploratory study, Nature medicine (2019) — Randomized double-blind pilot (n=32 completers, overweight/obese insulin-resistant): pasteurized A. muciniphila 10^10/day x3mo improved insulin sensitivity +28.6% (P=0.002), reduced insulinemia -34% (P=0.006) and total cholesterol -8.7% (P=0.02) vs placebo; live cells were not significant. [https://pubmed.ncbi.nlm.nih.gov/31263284/]
  - Pili-like proteins of Akkermansia muciniphila modulate host immune responses and gut barrier function, PloS one (2017) — Identified Amuc_1100, the A. muciniphila outer-membrane protein that signals through TLR2, improves gut-barrier function, and remains active after pasteurization—explaining why heat-killed cells retain (and exceed) live-cell metabolic benefits. [https://pubmed.ncbi.nlm.nih.gov/28249045/]
  - A purified membrane protein from Akkermansia muciniphila or the pasteurized bacterium improves metabolism in obese and diabetic mice, Nature medicine (2017) — In diet-induced obese mice, pasteurized A. muciniphila enhanced gut barrier and reduced fat mass, insulin resistance and dyslipidemia more than live bacteria; effect partly recapitulated by purified Amuc_1100—the preclinical basis for human trials. [https://pubmed.ncbi.nlm.nih.gov/27892954/]

---

## Lactobacillus reuteri DSM 17938 (Limosilactobacillus reuteri DSM 17938 (Protectis))
URL: https://nutridex.info/s/l-reuteri-dsm17938
Category: Probiotics, Gut & Immune
Evidence: Moderate — Several controlled trials; effects real but modest or context-dependent.
The best-studied probiotic for infant colic and pediatric gut complaints

Quick answer: Lactobacillus reuteri DSM 17938 is used for reduces infant colic crying time by ~40-50 min/day at 2-3 weeks, strongest in breastfed infants. NutriDex grades the human evidence as moderate — Several controlled trials; effects real but modest or context-dependent. Based on 8 cited human studies (8 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Limosilactobacillus reuteri DSM 17938 (Protectis, the daughter strain of ATCC 55730) is among the most rigorously trialed probiotics in pediatrics. Meta-analyses of RCTs show it meaningfully reduces daily crying in colicky infants — roughly 40-50 minutes/day at 2-3 weeks — with the most consistent benefit in exclusively/predominantly breastfed infants; a large community-based BMJ trial (Sung 2014) was negative, so the colic evidence is best graded moderate/mixed and population-dependent. It also modestly shortens acute infectious diarrhea (about 0.9 day) and reduces functional abdominal pain frequency/intensity in children. Evidence for preventing antibiotic-associated diarrhea is weak/inconclusive.

Benefits / uses: Reduces infant colic crying time by ~40-50 min/day at 2-3 weeks, strongest in breastfed infants; Shortens duration of acute infectious gastroenteritis/diarrhea in children by ~0.9 day and shortens hospital stay; Reduces frequency and intensity of functional (recurrent) abdominal pain in children, increasing pain-free days; Prophylactic use in the first 3 months lowers onset of functional GI disorders (colic, regurgitation, constipation) per Indrio 2014; Increases stool frequency in infants and may ease functional constipation.
Active compounds: Limosilactobacillus reuteri DSM 17938 (renamed from Lactobacillus reuteri); Parent strain L. reuteri ATCC 55730; BioGaia Protectis drops / chewable tablets; Gerber Soothe (US); Oil-suspension drops dosed at 5 drops (~1x10^8 CFU).
Dose: 1x10^8 CFU/day (5 drops of oil suspension) once daily; in colic trials given ~30 min before/with a feed for 21-28 days; pediatric FAP trials used 1-2x10^8 CFU/day for 4-12 weeks.
Safety: Very well tolerated in infants and children; trials report no effect on growth and no serious strain-attributable adverse events. As with any live probiotic, use caution in critically ill, premature/short-gut, central-venous-catheter, or immunocompromised patients given the theoretical risk of bacteremia/sepsis; discuss with a clinician in those settings.

Cited studies (8):
  - Systematic review: Limosilactobacillus reuteri DSM 17938 for preventing antibiotic-associated diarrhoea in children, Journal of pediatric gastroenterology and nutrition (2026) — Systematic review for preventing antibiotic-associated diarrhea in children found no significant effect (2 RCTs, n=901; RR 0.85, 95% CI 0.26-2.77; low certainty). [https://pubmed.ncbi.nlm.nih.gov/41486369/]
  - The Efficacy and Safety of the Probiotic Bacterium Lactobacillus reuteri DSM 17938 for Infantile Colic: A Meta-Analysis of Randomized Controlled Trials, PloS one (2015) — Meta-analysis of 6 RCTs (n=423) found L. reuteri DSM 17938 cut crying time vs placebo by WMD -42.9 min/day at 2 wk and -45.8 min/day at 3 wk. [https://pmc.ncbi.nlm.nih.gov/articles/PMC4624960/]
  - Efficacy of Lactobacillus reuteri DSM 17938 for infantile colic: Systematic review with network meta-analysis, Medicine (2017) — Systematic review with network meta-analysis identified L. reuteri DSM 17938 as the most evidence-based intervention for reducing crying duration in infantile colic. [https://pmc.ncbi.nlm.nih.gov/articles/PMC5758237/]
  - Systematic Review with Meta-Analysis: Lactobacillus reuteri DSM 17938 for Treating Acute Gastroenteritis in Children. An Update, Nutrients (2019) — Updated meta-analysis (4 RCTs, n=347) showed DSM 17938 reduced acute gastroenteritis diarrhea duration by MD -0.87 days (95% CI -1.43 to -0.31) and shortened hospitalization. [https://pmc.ncbi.nlm.nih.gov/articles/PMC6893691/]
  - Systematic review with meta-analysis: Lactobacillus reuteri DSM 17938 for diarrhoeal diseases in children, Alimentary pharmacology & therapeutics (2016) — Systematic review with meta-analysis concluded DSM 17938 reduces duration of acute diarrhea in children (3 RCTs, n=256, MD -24.8 h) and raises cure rate. [https://pubmed.ncbi.nlm.nih.gov/26991503/]
  - Lactobacillus reuteri DSM 17938 for the Management of Functional Abdominal Pain in Childhood: A Randomized, Double-Blind, Placebo-Controlled Trial, The Journal of pediatrics (2016) — RCT in 101 children (Rome III functional abdominal pain) found DSM 17938 significantly reduced pain frequency (1.9 vs 3.6 episodes/wk, P<.02) and intensity vs placebo over 4 weeks. [https://pubmed.ncbi.nlm.nih.gov/27156182/]
  - Treating infant colic with the probiotic Lactobacillus reuteri: double blind, placebo controlled randomised trial, BMJ (Clinical research ed.) (2014) — Double-blind RCT in 167 community infants (breast- and formula-fed) found L. reuteri DSM 17938 did NOT reduce crying/fussing, tempering colic claims in unselected populations. [https://pubmed.ncbi.nlm.nih.gov/24690625/]
  - The efficacy of Lactobacillus reuteri DSM 17938 in infants and children: a review of the current evidence, European journal of pediatrics (2014) — RCT prophylaxis in first 3 months reduced crying at 90 days (38 vs 71 min/day), regurgitation episodes, and increased daily evacuations, lowering functional GI disorder onset. [https://pubmed.ncbi.nlm.nih.gov/24819885/]

---

## Lactobacillus paracasei (Lacticaseibacillus paracasei (Lpc-37, CNCM I-1518))
URL: https://nutridex.info/s/l-paracasei
Category: Probiotics, Gut & Immune
Evidence: Moderate — Several controlled trials; effects real but modest or context-dependent.
A versatile probiotic species whose effects are tightly strain-specific — immune support (CNCM I-1518), stress (Lpc-37), and allergy (LP-33)

Quick answer: Lactobacillus paracasei is used for reduces the incidence of common infectious diseases (colds, gi infections) as the fermented-dairy strain cncm i-1518 — ~19% lower odds of ≥1 infection. NutriDex grades the human evidence as moderate — Several controlled trials; effects real but modest or context-dependent. Based on 6 cited human studies (6 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Lacticaseibacillus paracasei is not one product but several well-characterized strains with divergent evidence. The strongest data is for CNCM I-1518 (the Actimel/DanActive fermented dairy strain): a 2020 meta-analysis of 9 RCTs found it modestly reduced the odds of catching common infections (OR 0.81). Strain Lpc-37 has been tested for stress with mixed results — a benefit on perceived stress in healthy adults (Sisu study) but no effect on exam anxiety in students (ChillEx), with an exploratory sleep-disturbance benefit. LP-33 improved quality of life in grass-pollen allergic rhinitis (425-subject GA2LEN trial), mainly via ocular rather than nasal symptoms. Benefits do not transfer between strains.

Benefits / uses: Reduces the incidence of common infectious diseases (colds, GI infections) as the fermented-dairy strain CNCM I-1518 — ~19% lower odds of ≥1 infection; Lowers perceived stress in healthy chronically-stressed adults (Lpc-37), with greater effect in women; Improves quality of life in grass-pollen allergic rhinitis on top of antihistamine (LP-33), chiefly ocular symptoms; May normalize evening cortisol and reduce stress-related sleep disturbance in selected populations (Lpc-37); Generally well tolerated as an adjunct in immune and allergy support.
Active compounds: CNCM I-1518 (Lactobacillus casei Defensis) — Actimel / DanActive fermented dairy drink; Lpc-37 (Howaru Lpc-37) — capsule/sachet, stress studies; LP-33 / ST11 (CNCM I-2116) — allergic rhinitis; Available as fermented dairy drinks, capsules, and powder sachets.
Dose: Strain- and indication-dependent. Immune support: one ~100 mL fermented dairy drink/day delivering ~10^10 CFU CNCM I-1518. Stress (Lpc-37): ~1.5–1.75 × 10^10 CFU/day for 5–10 weeks. Allergic rhinitis (LP-33): ~10^9 CFU/day. Taken daily, often with a meal.
Safety: Well tolerated across trials with no serious adverse events attributable to the probiotic, including in healthy adults and students. As with all live probiotics, avoid in critically ill, severely immunocompromised, or central-venous-catheter patients, where rare bacteremia/translocation has been reported for Lactobacillus species. Fermented dairy products are not suitable for severe milk-protein allergy. Effects are strain-specific — do not assume one strain's benefit applies to another product.

Cited studies (6):
  - Effects of a Fermented Dairy Drink Containing Lacticaseibacillus paracasei subsp. paracasei CNCM I-1518 (Lactobacillus casei CNCM I-1518) and the Standard Yogurt Cultures on the Incidence, Duration, and Severity of Common Infectious Diseases: A Systematic Review and Meta-Analysis of Randomized Controlled Trials, Nutrients (2020) — Meta-analysis of 9 RCTs: fermented dairy with CNCM I-1518 reduced odds of ≥1 common infectious disease (OR 0.81, 95% CI 0.66–0.98, p=0.029) and mean infections per subject (-0.09, 95% CI -0.15 to -0.04, p=0.001). [https://pubmed.ncbi.nlm.nih.gov/33182682/]
  - Efficacy and safety of Lacticaseibacillus paracasei Lpc-37® in students facing examination stress: A randomized, triple-blind, placebo-controlled clinical trial (the ChillEx study), Brain, behavior, & immunity - health (2023) — Triple-blind RCT, 190 students: Lpc-37 had no effect on exam-related state anxiety (diff 1.03, 95% CI -1.62 to 3.67, p=0.446) but reduced sleep-disturbance odds (OR 0.30, 95% CI 0.11–0.82, p=0.020). [https://pmc.ncbi.nlm.nih.gov/articles/PMC10474370/]
  - Exploratory Study on Microbiota and Immune Responses to Short-Term L. paracasei CNCM I-1518 Consumption in Healthy Adults, Nutrients (2025) — 15-day exploratory intervention in healthy adults showed L. paracasei CNCM I-1518 enhanced cellular and humoral immunity (increased B lymphocytes, monocytes, IgG1/IgG2/IgG4 and complement C3/C4) and raised the gut Lactobacillus/Clostridium ratio. [https://pmc.ncbi.nlm.nih.gov/articles/PMC12300870/]
  - Lacticaseibacillus paracasei Lpc-37® improves psychological and physiological markers of stress and anxiety in healthy adults: a randomized, double-blind, placebo-controlled and parallel clinical trial (the Sisu study), Neurobiology of stress (2020) — RCT, 120 healthy adults: Lpc-37 (1.75×10^10 CFU/day, 5 wk) decreased perceived stress 6.4% vs +4.1% placebo (p=0.048), with a larger effect in women (p=0.049). [https://pmc.ncbi.nlm.nih.gov/articles/PMC7770962/]
  - Fewer Community-Acquired Colds with Daily Consumption of Lactiplantibacillus plantarum HEAL9 and Lacticaseibacillus paracasei 8700:2. A Randomized, Placebo-Controlled Clinical Trial, The Journal of nutrition (2021) — RCT in 898 cold-prone adults: daily L. plantarum HEAL9 plus L. paracasei 8700:2 for 12 weeks reduced incidence, duration, and severity of community-acquired common colds versus placebo. [https://pmc.ncbi.nlm.nih.gov/articles/PMC7779238/]
  - Efficacy and safety of the probiotic Lactobacillus paracasei LP-33 in allergic rhinitis: a double-blind, randomized, placebo-controlled trial (GA2LEN Study), European journal of clinical nutrition (2014) — Double-blind RCT, 425 grass-pollen allergic rhinitis patients: LP-33 added to loratadine improved RQLQ quality-of-life and ocular symptoms vs placebo, while nasal symptoms were unchanged. [https://pubmed.ncbi.nlm.nih.gov/24569538/]

---

## Bifidobacterium lactis BB-12 (Bifidobacterium animalis subsp. lactis BB-12)
URL: https://nutridex.info/s/bb-12
Category: Probiotics, Gut & Immune
Evidence: Moderate — Several controlled trials; effects real but modest or context-dependent.
The most-studied Bifidobacterium — gentle gut regularity and infant comfort

Quick answer: Bifidobacterium lactis BB-12 is used for increases defecation frequency in adults with low frequency and mild abdominal discomfort (regularity). NutriDex grades the human evidence as moderate — Several controlled trials; effects real but modest or context-dependent. Based on 10 cited human studies (10 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Bifidobacterium animalis subsp. lactis BB-12 is the world's most-studied Bifidobacterium, with randomized, placebo-controlled trials supporting modest, strain-specific benefits for bowel regularity and infant comfort. The largest probiotic regularity trial ever published (Eskesen 2015, n=1248) showed BB-12 significantly raised defecation frequency in adults with low frequency and abdominal discomfort, and a colic RCT (Nocerino 2020) found 80% of breastfed colicky infants on BB-12 achieved a >=50% reduction in crying versus 32.5% on placebo. Mechanistic and infant-infection data are supportive but more preliminary, and evidence for preventing antibiotic-associated diarrhea is still emerging rather than definitive for this specific strain.

Benefits / uses: Increases defecation frequency in adults with low frequency and mild abdominal discomfort (regularity); Reduces daily crying time in breastfed infants with colic and improves stool frequency/consistency; Helps preserve gut microbiome function (fecal short-chain fatty acids) during a course of antibiotics; May reduce respiratory tract infections in early infancy; Modulates NK and T-cell activity / mucosal immune function in healthy adults; Generally improves bowel transit and stool consistency in mild constipation.
Active compounds: Bifidobacterium animalis subsp. lactis BB-12 (Chr. Hansen / Novonesis branded strain); Drops and sachets (e.g. infant colic drops, 1 billion CFU/day); Chewable tablets and capsules (1-10 billion CFU/day); Fermented dairy / yogurt cultures (often paired with LGG); Frequently co-formulated with Lactobacillus rhamnosus GG (LGG).
Dose: Trials used roughly 1 x 10^9 to 1 x 10^10 CFU/day, taken once daily. Adult regularity trials showed no added benefit above 1 billion CFU/day (a ceiling effect), and the infant colic trial used 1 billion CFU/day for 28 days. Effects on bowel function typically appear over 2-4 weeks of continuous use; can be taken with or without food.
Safety: Very well tolerated in trials, including healthy adults, children, and infants; meta-analysis of adverse events found no significant safety signal versus placebo. Mild gas, bloating, or transient stool changes can occur. As with all live probiotics, use caution in critically ill, severely immunocompromised, or central-line patients, in whom rare probiotic bacteremia has been reported across the field; discuss with a clinician before use in these groups.

Cited studies (10):
  - Effectiveness of Probiotics in Patients With Constipation: A Systematic Review and Meta-Analysis, Cureus (2024) — Systematic review and meta-analysis of 10 studies (1,243 patients) found probiotics significantly favored over placebo for constipation treatment (p<0.05), though with high heterogeneity (I2=95%). [https://pmc.ncbi.nlm.nih.gov/articles/PMC10854359/]
  - Efficacy in bowel movement and change of gut microbiota on adult functional constipation patients treated with probiotics-containing products: a systematic review and meta-analysis, BMJ open (2024) — Systematic review and meta-analysis of probiotic-containing products in adult functional constipation found significant improvement in bowel movement frequency, with greater effect for combined Lactobacillus + Bifidobacterium than single-genus products. [https://pmc.ncbi.nlm.nih.gov/articles/PMC10806726/]
  - Probiotic Blend of Lactobacillus acidophilus LA-5 and Bifidobacterium animalis ssp. Lactis BB-12 in Non-constipated Irritable Bowel Syndrome: A Double-Blind Randomized Placebo-Controlled Trial, Journal of gastroenterology and hepatology (2026) — Double-blind RCT of L. acidophilus LA-5 + B. animalis lactis BB-12 in non-constipated IBS found higher IBS Global Improvement Scale response with probiotics vs placebo at day 28 (19.3% vs 8.9%; p=0.048). [https://pubmed.ncbi.nlm.nih.gov/41255078/]
  - The therapeutic efficacy of Bifidobacterium animalis subsp. lactis BB-12(®) in infant colic: A randomised, double blind, placebo-controlled trial, Alimentary pharmacology & therapeutics (2020) — In 80 breastfed colicky infants, 80% on BB-12 (1 billion CFU/day, 28 days) achieved >=50% reduction in daily crying vs 32.5% on placebo, with improved stool frequency and consistency. [https://pmc.ncbi.nlm.nih.gov/articles/PMC6973258/]
  - Bifidobacterium animalis subsp. lactis BB-12 Protects against Antibiotic-Induced Functional and Compositional Changes in Human Fecal Microbiome, Nutrients (2021) — During amoxicillin/clavulanate, BB-12 yogurt protected fecal microbiome function: acetate returned to baseline (-1.6%) by day 30 in the BB-12 group while remaining suppressed in controls. [https://pmc.ncbi.nlm.nih.gov/articles/PMC8398419/]
  - Effect of the probiotic strain Bifidobacterium animalis subsp. lactis, BB-12®, on defecation frequency in healthy subjects with low defecation frequency and abdominal discomfort: a randomised, double-blind, placebo-controlled, parallel-group trial, The British journal of nutrition (2015) — In 1248 adults with low defecation frequency, BB-12 significantly increased average defecation frequency vs placebo (treatment effect P=0.0065), with no added benefit above 1 billion CFU/day. [https://pmc.ncbi.nlm.nih.gov/articles/PMC4657032/]
  - Bifidobacterium animalis subsp. lactis BB-12 in reducing the risk of infections in early childhood, Pediatric Research (2016) — In healthy newborns, early BB-12 supplementation reduced the occurrence of respiratory infections vs control (65% vs 94%; RR 0.69, 95% CI 0.53-0.89; P=0.014). [https://www.nature.com/articles/pr2015174]
  - Consumption of Bifidobacterium animalis subsp. lactis BB-12 impacts upper respiratory tract infection and the function of NK and T cells in healthy adults, Molecular Nutrition & Food Research (2016) — BB-12 consumption in healthy adults reduced the incidence/duration of upper respiratory tract infection symptoms and enhanced NK- and T-cell function vs placebo. [https://onlinelibrary.wiley.com/doi/10.1002/mnfr.201500665]
  - Effects of Bifidobacterium animalis subsp. lactis BB-12(®) on the lipid/lipoprotein profile and short chain fatty acids in healthy young adults: a randomized controlled trial, Nutrition journal (2017) — In a randomized crossover trial of 30 healthy adults, BB-12 did not significantly alter total, LDL, or HDL cholesterol or triglycerides vs control, indicating no meaningful lipid effect. [https://pmc.ncbi.nlm.nih.gov/articles/PMC5492721/]
  - Understanding the probiotic health benefits of Bifidobacterium animalis subsp. lactis, BB-12™, Frontiers in microbiology (2025) — Landmark narrative review consolidating decades of human trials confirms B. animalis subsp. lactis BB-12 is effective for low defecation frequency and infant colic, and one of the most clinically documented probiotic strains. [https://pubmed.ncbi.nlm.nih.gov/40673154/]

---

## E. coli Nissle 1917 (Escherichia coli Nissle 1917 (Mutaflor))
URL: https://nutridex.info/s/ecoli-nissle
Category: Probiotics, Gut & Immune
Evidence: Strong — Multiple high-quality RCTs / meta-analyses with consistent effects.
The one probiotic guideline-endorsed to keep ulcerative colitis in remission

Quick answer: E. coli Nissle 1917 is used for maintains remission in ulcerative colitis as effectively as standard mesalazine (guideline-endorsed alternative). NutriDex grades the human evidence as strong — Multiple high-quality RCTs / meta-analyses with consistent effects. Based on 9 cited human studies (9 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

For maintaining remission in ulcerative colitis, E. coli Nissle 1917 (Mutaflor) is the best-evidenced indication: multiple double-blind, double-dummy RCTs and a meta-analysis show it is equivalent (non-inferior) to standard-dose oral mesalazine in preventing relapse, and it is the only probiotic ECCO guidelines endorse as a mesalazine alternative for UC maintenance. It does NOT reliably induce remission in active UC and has no proven role in Crohn's disease. Smaller controlled trials support faster resolution of acute and prolonged diarrhea in infants/toddlers, while IBS data are weak and mixed (benefit, if any, limited to diarrhea-predominant subtypes).

Benefits / uses: Maintains remission in ulcerative colitis as effectively as standard mesalazine (guideline-endorsed alternative); Reduces relapse risk in UC patients intolerant of or seeking an alternative to 5-ASA therapy; Shortens duration of acute diarrhea in infants and toddlers (response ~2.3 days faster than placebo); Reduces stool frequency and shortens prolonged (>4 day) diarrhea in young children; Effective for remission maintenance in pediatric/adolescent UC (open-label pilot data); Possible benefit limited to diarrhea-predominant IBS subtype (weak, exploratory evidence).
Active compounds: Mutaflor enteric-coated capsules (100 mg = ~2.5-25 x10^9 viable EcN); Mutaflor mite (lower-strength capsule for initial titration); Mutaflor Suspension (pediatric oral liquid, ~10^8 viable cells/mL); Serotype O6:K5:H1, the defining EcN designation.
Dose: UC maintenance: typically two enteric-coated capsules (~5 x10^9 CFU, marketed as 200 mg EcN) once daily, after an initial titration over the first week; taken with food. Pediatric diarrhea trials used the oral suspension at 1-3 mL/day (~10^8 viable cells/mL) by age. Effective dose range studied is roughly 2.5-25 x10^9 viable EcN per day.
Safety: Generally well tolerated; the most common effects are transient bloating, flatulence, and abdominal discomfort (typically <5%, mainly during the first days). Because EcN is a live, colonizing E. coli, avoid in severely immunocompromised patients, those with central venous catheters, short-bowel/severe gut-barrier compromise, or acute pancreatitis due to rare risk of bacterial translocation/bacteremia. Translocation has been shown when both microbiota and adaptive immunity are defective. Pregnancy/lactation safety data are limited; use caution.

Cited studies (9):
  - Probiotics and inflammatory bowel disease: an umbrella meta-analysis of relapse, recurrence, and remission outcomes, Nutrition & metabolism (2025) — Umbrella meta-analysis of 20 meta-analyses (46 datasets) found probiotics significantly reduced IBD relapse risk vs placebo (RR 0.55; 95% CI 0.22-0.88) but showed no significant difference vs mesalazine, consistent with E. coli Nissle 1917's role in maintaining UC remission. [https://pubmed.ncbi.nlm.nih.gov/41029747/]
  - Probiotic Escherichia coli NISSLE 1917 for inflammatory bowel disease applications, Food & function (2022) — Systematic review/meta-analysis of E. coli Nissle 1917 for IBD reported a risk ratio of 1.08 (95% CI 0.86-1.37) for preventing relapse in inactive ulcerative colitis versus standard 5-ASA, indicating equivalence to mesalazine for maintenance. [https://pubmed.ncbi.nlm.nih.gov/35583304/]
  - Escherichia coli Nissle 1917 in Ulcerative Colitis Treatment: Systematic Review and Meta-analysis, Journal of gastrointestinal and liver diseases : JGLD (2015) — Systematic review/meta-analysis (6 trials, 719 pts): EcN equivalent to mesalazine for relapse prevention (recurrence 36.8% vs 36.1%; OR 1.07, 95% CI 0.70-1.64) but not superior for inducing remission in active UC (OR 0.92, 95% CI 0.15-9.66). [https://pubmed.ncbi.nlm.nih.gov/26697577/]
  - Efficacy of Probiotic Escherichia coli Nissle 1917 in Patients with Irritable Bowel Syndrome: a Double Blind Placebo-controlled Randomized Trial, Acta medica Indonesiana (2015) — DB placebo-controlled RCT in IBS (n=139, 6 wk): no significant difference in total symptom score overall; only diarrhea-predominant IBS showed a positive (sleep) response. [https://pubmed.ncbi.nlm.nih.gov/26586385/]
  - Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine, Gut (2004) — DB double-dummy RCT (n=327, 12 mo): relapse 40/110 (36.4%) with EcN 200 mg/day vs 38/112 (33.9%) with mesalazine; significant equivalence (p=0.003) for maintaining UC remission. [https://pubmed.ncbi.nlm.nih.gov/15479682/]
  - Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial, Lancet (London, England) (1999) — DB randomized trial in UC: EcN was as effective as mesalazine for maintaining remission, establishing the non-pathogenic E. coli strain as a 5-ASA alternative. [https://pubmed.ncbi.nlm.nih.gov/10466665/]
  - The probiotic Escherichia coli strain Nissle 1917 (EcN) stops acute diarrhoea in infants and toddlers, European journal of pediatrics (2007) — Confirmative DB RCT in infants/toddlers with acute diarrhea (n=113): median response 2.5 days with EcN vs 4.8 days placebo (2.3 days faster; p=0.0007). [https://pubmed.ncbi.nlm.nih.gov/17287932/]
  - Probiotic Escherichia coli Nissle 1917 versus placebo for treating diarrhea of greater than 4 days duration in infants and toddlers, The Pediatric infectious disease journal (2008) — Placebo-controlled trial in infants/toddlers with prolonged diarrhea (>4 days): EcN reduced stool frequency and shortened diarrhea versus placebo. [https://pubmed.ncbi.nlm.nih.gov/18469732/]
  - Probiotic Escherichia coli Nissle 1917 (EcN) for successful remission maintenance of ulcerative colitis in children and adolescents: an open-label pilot study, Zeitschrift fur Gastroenterologie (2008) — Open-label pilot in pediatric/adolescent UC: relapse 6/24 (25%) with EcN vs 3/10 (30%) with 5-ASA, supporting maintenance use in young patients. [https://pubmed.ncbi.nlm.nih.gov/18810672/]

---

## Bifidobacterium longum BB536 (Bifidobacterium longum BB536 (Morinaga))
URL: https://nutridex.info/s/bifido-longum-bb536
Category: Probiotics, Gut & Immune
Evidence: Moderate — Several controlled trials; effects real but modest or context-dependent.
A long-studied Japanese Bifidobacterium with the strongest data in cedar-pollen allergy and gut regularity

Quick answer: Bifidobacterium longum BB536 is used for eases japanese cedar pollen allergy symptoms (ocular and nasal) and suppresses pollen-driven tarc/th2 chemokine rises. NutriDex grades the human evidence as moderate — Several controlled trials; effects real but modest or context-dependent. Based on 10 cited human studies (10 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Bifidobacterium longum BB536 (Morinaga), isolated from a healthy infant in 1969, is one of the most extensively studied probiotic strains, with its best-supported indication being allergic rhinitis from Japanese cedar pollinosis: multiple double-blind RCTs show it modestly eases nasal and ocular symptoms and blunts pollen-driven rises in Th2-attracting chemokines. Smaller RCTs also support improved bowel regularity in constipated adults/elderly, induction of remission as adjunctive therapy in mild-to-moderate ulcerative colitis (endoscopic/Mayo subscore improvement, though primary clinical-remission endpoints often miss significance), and reduced influenza incidence/fever and preserved NK-cell activity in elderly. A large pediatric RCT found reduced respiratory-illness duration but no diarrhea benefit. Effects are real but generally modest and indication-specific.

Benefits / uses: Eases Japanese cedar pollen allergy symptoms (ocular and nasal) and suppresses pollen-driven TARC/Th2 chemokine rises; Improves stool frequency and bowel regularity in adults and elderly with constipation; Adjunct in mild-to-moderate ulcerative colitis: improves endoscopic and Mayo subscores; Reduces influenza incidence and fever and preserves NK-cell activity in elderly; Shortens duration of upper-respiratory symptoms (e.g. sore throat) in pre-school children; Modulates gut microbiota, increasing beneficial Faecalibacterium abundance.
Active compounds: Bifidobacterium longum subsp. longum BB536 (ATCC BAA-999 / Morinaga); Used in BIfidobacterium triple mixes (BB536 + B. breve M-16V + B. infantis M-63); Freeze-dried powder, capsules, fermented-milk/yogurt formats; FDA GRAS and EFSA QPS-listed; used in infant formula.
Dose: Typically 1x10^10 to 5x10^10 CFU/day for allergy/gut/immune indications (up to 2-3x10^11 CFU/day in ulcerative colitis trials); freeze-dried powder, capsules, or fermented milk, taken once or twice daily, ideally for several weeks (allergy trials pre-load before/through pollen season).
Safety: Very well tolerated with a long history of safe use; FDA GRAS (including infant formula) and EFSA QPS status, with no serious adverse events across pediatric, elderly, pregnant, and immunosuppressed-medication populations. Mild, transient gas or bloating may occur on initiation. As with any live probiotic, exercise caution in critically ill, severely immunocompromised patients, or those with central venous catheters or compromised gut barriers, where rare bacteremia risk cannot be excluded.

Cited studies (10):
  - Usefulness of Bifidobacterium longum BB536 in Elderly Individuals With Chronic Constipation: A Randomized Controlled Trial, The American journal of gastroenterology (2023) — RCT in elderly with chronic constipation (n=80, BB536 5x10^10 CFU/day): significant improvement in stool frequency at week 4 vs placebo, though primary endpoint was not met. [https://pmc.ncbi.nlm.nih.gov/articles/PMC9973440/]
  - Usefulness of Bifidobacterium longum BB536 in Elderly Individuals With Chronic Constipation: A Randomized Controlled Trial, The American journal of gastroenterology (2023) — In 79 chronically constipated elderly adults, 4 weeks of BB536 (5x10^10 CFU/day) significantly improved stool frequency versus placebo (between-group/within-group P=0.008), though the primary composite endpoint was not met. [https://pubmed.ncbi.nlm.nih.gov/36216361/]
  - The Impact of Fermented Milk Products Containing Bifidobacterium longum BB536 on the Gut Environment: A Randomized Double-Blind Placebo-Controlled Trial, Nutrients (2024) — In healthy adults, BB536-containing fermented milk significantly increased relative abundance of beneficial Faecalibacterium versus placebo by day 3 (persisting to day 17), alongside rises in tryptophan-derived indole metabolites. [https://pubmed.ncbi.nlm.nih.gov/39519413/]
  - Efficacy of probiotic treatment with Bifidobacterium longum 536 for induction of remission in active ulcerative colitis: A randomized, double-blinded, placebo-controlled multicenter trial, Digestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society (2016) — Double-blind multicenter RCT (n=56, active UC): BB536 (2-3x10^11 CFU/day, 8 wk) showed remission in 63% vs 52% placebo and significantly improved Rachmilewitz endoscopic index and Mayo subscore. [https://pubmed.ncbi.nlm.nih.gov/26418574/]
  - Bifidobacterium longum BB536 alleviated upper respiratory illnesses and modulated gut microbiota profiles in Malaysian pre-school children, Beneficial microbes (2018) — 10-month RCT (n=520 Malaysian pre-schoolers): BB536 reduced respiratory-illness duration (sore throat -46%) and increased Faecalibacterium; no significant effect on diarrhea. [https://pubmed.ncbi.nlm.nih.gov/29065707/]
  - Effects of Bifidobacterium longum BB536 administration on influenza infection, influenza vaccine antibody titer, and cell-mediated immunity in the elderly, Bioscience, biotechnology, and biochemistry (2010) — RCT in elderly (mean 86.7 y): BB536 (1x10^11 CFU/day) significantly lowered the proportion contracting influenza and with fever, and raised NK-cell and neutrophil activity. [https://pubmed.ncbi.nlm.nih.gov/20460726/]
  - Clinical effects of probiotic Bifidobacterium longum BB536 on immune function and intestinal microbiota in elderly patients receiving enteral tube feeding, JPEN. Journal of parenteral and enteral nutrition (2013) — RCT in elderly enteral-tube-fed patients (n=45): NK-cell activity declined in placebo but was preserved with BB536; no significant effect on influenza vaccine HI titers. [https://pubmed.ncbi.nlm.nih.gov/23192454/]
  - Effect of probiotic Bifidobacterium longum BB536 [corrected] in relieving clinical symptoms and modulating plasma cytokine levels of Japanese cedar pollinosis during the pollen season. A randomized double-blind, placebo-controlled trial, Journal of investigational allergology & clinical immunology (2006) — RCT (n=40, cedar pollinosis): BB536 yogurt significantly improved ocular symptoms vs placebo (OR 0.31, 95% CI 0.10-0.97, p=0.044) and raised IFN-gamma. [https://pubmed.ncbi.nlm.nih.gov/16689181/]
  - Probiotics in the treatment of Japanese cedar pollinosis: a double-blind placebo-controlled trial, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology (2006) — Double-blind RCT (n=44) during pollen season: BB536 significantly reduced rhinorrhea, nasal blockage, and composite symptom scores and fewer subjects withdrew for severe symptoms vs placebo. [https://pubmed.ncbi.nlm.nih.gov/17083353/]
  - Clinical efficacy of probiotic Bifidobacterium longum for the treatment of symptoms of Japanese cedar pollen allergy in subjects evaluated in an environmental exposure unit, Allergology international : official journal of the Japanese Society of Allergology (2007) — Environmental-exposure-unit crossover study: BB536 (~5x10^10 twice daily) reduced cedar-pollen-induced allergic symptoms vs placebo. [https://pubmed.ncbi.nlm.nih.gov/17259812/]

---

## Saccharomyces boulardii (Saccharomyces boulardii CNCM I-745)
URL: https://nutridex.info/s/s-boulardii
Category: Probiotics, Gut & Immune
Evidence: Strong — Multiple high-quality RCTs / meta-analyses with consistent effects.
The probiotic yeast with the strongest evidence for preventing antibiotic-associated diarrhea

Quick answer: Saccharomyces boulardii is used for prevents antibiotic-associated diarrhea in adults and children (~50% relative risk reduction; nnt ~10). NutriDex grades the human evidence as strong — Multiple high-quality RCTs / meta-analyses with consistent effects. Based on 10 cited human studies (10 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Saccharomyces boulardii CNCM I-745 is a non-pathogenic probiotic yeast (intrinsically resistant to antibacterial antibiotics) with its best-supported indication being prevention of antibiotic-associated diarrhea (AAD): pooled meta-analyses of RCTs show roughly a 50% relative risk reduction (RR ~0.47, 95% CI 0.35-0.63), with a number-needed-to-treat near 10. It also shortens acute infectious/pediatric gastroenteritis by about 1 day and, as an adjunct, improves H. pylori eradication tolerability by cutting therapy-related diarrhea and nausea. Evidence for Clostridioides difficile infection prevention and for IBS is more limited and mixed. It is generally well tolerated, but carries a rare but real fungemia risk that contraindicates use in critically ill, immunocompromised, or central-venous-catheter patients.

Benefits / uses: Prevents antibiotic-associated diarrhea in adults and children (~50% relative risk reduction; NNT ~10); Reduces the duration of acute infectious diarrhea / pediatric gastroenteritis by roughly 1 day and shortens hospital/ER stay; Used as an adjunct, improves tolerability of H. pylori eradication therapy (fewer total adverse events, less diarrhea and nausea) and modestly raises eradication rates; Helps prevent traveler's diarrhea in adults (guideline-level recommendation); May improve disease-specific quality of life in IBS, though effects on individual symptoms are inconsistent; Antibiotic-resistant yeast, so it can be co-administered with antibacterial therapy without being killed.
Active compounds: Saccharomyces boulardii CNCM I-745 (= S. cerevisiae var. boulardii); Branded: Florastor (US), Ultra-Levure / Perenterol / Florastor (EU); Lyophilized (freeze-dried) capsules, sachets, and powder; Common strengths of 250 mg or 5 billion CFU per capsule/sachet.
Dose: Typical trial dosing is about 5-10 billion CFU/day (roughly 250-500 mg lyophilized yeast/day, often split BID); for AAD prevention, start within 1-2 days of beginning antibiotics and continue through the antibiotic course plus a few days after. It can be taken at the same time as antibacterial antibiotics since the yeast is intrinsically resistant.
Safety: Generally well tolerated in immunocompetent patients; the main concern is fungemia (yeast bloodstream infection). Cumulative pharmacovigilance reported dozens of fungemia cases with several fatalities, mostly in critically ill or immunocompromised patients and those with central venous catheters (capsule opening can aerosolize spores onto catheter sites). The EMA (2017) concluded the benefit-risk is unfavorable in critically ill or immunocompromised patients. AVOID in critically ill, immunocompromised, or central-line patients; handle/open capsules away from catheters. Use caution with concurrent systemic antifungals (may reduce efficacy) and in pregnancy/yeast allergy.

Cited studies (10):
  - Efficacy and safety of Saccharomyces boulardii CNCM I-745 for the treatment of pediatric acute diarrhea in China: a systematic review and meta-analysis, Frontiers in cellular and infection microbiology (2025) — Meta-analysis of Chinese RCTs found S. boulardii CNCM I-745 reduced duration of pediatric acute diarrhea by ~1.63 days (95% CI -2.08 to -1.18) and improved cure rates. [https://pmc.ncbi.nlm.nih.gov/articles/PMC12174131/]
  - Saccharomyces boulardii CNCM I-745 for Prevention of Antibiotic-Associated Diarrhea and Clostridioides difficile in China: Systematic Review and Meta-Analysis, Journal of Digestive Diseases and Hepatology (2024) — Meta-analysis (46 trials, 8,201 participants): CNCM I-745 reduced AAD (RR 0.43, 95% CI 0.40-0.48) and C. difficile infection (RR 0.30, 95% CI 0.10-0.87). [https://www.gavinpublishers.com/article/view/saccharomyces-boulardii-cncm-i-745-for--prevention-of-antibiotic-associated-diarrhea-and--clostridioides-difficile-in-china-systematic-review--and-meta-analysis]
  - The effect of supplementing with Saccharomyces boulardii on bismuth quadruple therapy for eradicating Helicobacter pylori: a systematic review and meta-analysis of randomized controlled trials, Frontiers in Medicine (2024) — Adding S. boulardii to eradication therapy lowered total adverse events (~18% vs ~35% control) and reduced diarrhea, nausea, and bloating while modestly improving eradication. [https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2024.1344702/full]
  - Systematic review with meta-analysis: Saccharomyces boulardii in the prevention of antibiotic-associated diarrhoea, Alimentary pharmacology & therapeutics (2015) — Meta-analysis (21 RCTs, n=4780): S. boulardii reduced antibiotic-associated diarrhea risk vs control (RR 0.47, 95% CI 0.38-0.57). [https://pubmed.ncbi.nlm.nih.gov/26216624/]
  - Systematic review and meta-analysis of Saccharomyces boulardii in adult patients, World journal of gastroenterology (2010) — Systematic review/meta-analysis in adults: S. boulardii significantly protective for AAD (pooled RR 0.47, 95% CI 0.35-0.63) and supported for traveler's diarrhea. [https://pubmed.ncbi.nlm.nih.gov/20458757/]
  - Efficacy and safety of Saccharomyces boulardii as adjunct therapy with Vancomycin in treating Clostridioides difficile infection: A randomized controlled trial, Scientific Reports (2025) — In 120 CDI patients, adding S. boulardii (250 mg twice daily) to vancomycin produced similar clinical cure (98.4% vs 98.3%) but a higher global cure rate and reduced recurrence without increasing adverse events. [https://www.nature.com/articles/s41598-025-04986-2]
  - Adjunctive use of Saccharomyces boulardii versus bismuth subsalicylate in the management of non-Clostridioides difficile nosocomial diarrhea in severely ill patients: a three-arm randomized controlled trial, Translational gastroenterology and hepatology (2026) — In a three-arm RCT of severely ill patients with non-C. difficile nosocomial diarrhea, adjunctive S. boulardii (and bismuth subsalicylate) added no benefit over standard care across stool frequency, consistency, and other outcomes. [https://pmc.ncbi.nlm.nih.gov/articles/PMC12887278/]
  - Effectiveness of Saccharomyces Boulardii CNCM I-745 probiotic in acute inflammatory viral diarrhoea in adults: results from a single-centre randomized trial, BMC Gastroenterology (2023) — Single-centre RCT in adults found S. boulardii CNCM I-745 effective in acute inflammatory viral diarrhoea compared with control. [https://link.springer.com/article/10.1186/s12876-023-02863-8]
  - A randomized, double-blind, placebo-controlled multicenter trial of saccharomyces boulardii in irritable bowel syndrome: effect on quality of life, Journal of clinical gastroenterology (2011) — RCT in IBS (n=67): S. boulardii improved IBS quality-of-life vs placebo (15.4% vs 7.0% improvement, P<0.05), without superiority for individual symptoms. [https://pubmed.ncbi.nlm.nih.gov/21301358/]
  - Fungemia and Other Fungal Infections Associated with Use of Saccharomyces boulardii Probiotic Supplements - Volume 27, Number 8—August 2021 - Emerging Infectious Diseases journal - CDC — Review of fungemia and fungal infections linked to S. boulardii supplements, predominantly in ICU/immunocompromised patients and those with central venous catheters. [https://wwwnc.cdc.gov/eid/article/27/8/21-0018_article]

---

## De Simone Formulation (VSL#3 / Visbiome) (8-strain high-dose blend)
URL: https://nutridex.info/s/de-simone-vsl3
Category: Probiotics, Gut & Immune
Evidence: Strong — Multiple high-quality RCTs / meta-analyses with consistent effects.
High-dose 8-strain blend with the best gut-microbiome RCT evidence base for pouchitis and ulcerative colitis

Quick answer: De Simone Formulation (VSL#3 / Visbiome) is used for maintains remission in chronic/recurrent pouchitis (best-supported, aga-guideline-endorsed indication). NutriDex grades the human evidence as strong — Multiple high-quality RCTs / meta-analyses with consistent effects. Based on 8 cited human studies (8 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

The De Simone Formulation (originally sold as VSL#3, now as Visbiome) is a high-dose 8-strain blend with the most robust trial evidence of any probiotic in inflammatory bowel conditions. Its best-supported, guideline-endorsed indication is maintaining remission in chronic/recurrent pouchitis, where double-blind RCTs show dramatic relapse reductions versus placebo. High-quality RCTs also support inducing and maintaining remission in mild-to-moderate ulcerative colitis as an adjunct, and secondary prophylaxis of hepatic encephalopathy in cirrhosis. Evidence in IBS is weaker and largely limited to bloating/flatulence. Note: since 2016 the original De Simone strains are sold only as Visbiome; current VSL#3 is a reformulated product, so older trial data apply specifically to this formulation.

Benefits / uses: Maintains remission in chronic/recurrent pouchitis (best-supported, AGA-guideline-endorsed indication); Induces and maintains remission in mild-to-moderate ulcerative colitis as add-on to standard therapy; Secondary prophylaxis of hepatic encephalopathy in cirrhosis — fewer HE hospitalizations; Reduces liver disease severity and overall hospitalization in cirrhosis; Eases bloating and flatulence in IBS (effect on abdominal pain is inconsistent).
Active compounds: De Simone Formulation (current brand: Visbiome / Visbiome Extra Strength); VSL#3 (pre-2016 trials used the original De Simone strains; post-2016 VSL#3 is reformulated); 8 strains: L. acidophilus, L. paracasei, L. plantarum, L. delbrueckii subsp. bulgaricus, B. breve, B. longum, B. infantis (B. longum subsp. infantis), S. thermophilus; Sachet/powder (~450 billion CFU per packet) and capsule forms; high-potency 900-billion-CFU sachets.
Dose: Pouchitis maintenance: ~900 billion CFU/day (often 1 high-potency sachet daily or 2 packets). Ulcerative colitis: 3.6 trillion CFU/day in trials (e.g., 2 x 900 billion twice daily). Hepatic encephalopathy: 9 x 10^11 (900 billion) bacteria/day. Powder mixed in cold water/food; refrigerated; taken daily, typically split doses with meals.
Safety: Generally well tolerated in trials; the most common adverse effect is mild, transient bloating/flatulence. As a high-CFU live-bacteria product, use caution in critically ill patients, those with central venous catheters, severe immunocompromise, or short-gut/severe mucosal barrier disruption, where rare bacteremia/translocation is a theoretical risk. Should be kept refrigerated to preserve viability. Patients should distinguish the original De Simone Formulation (Visbiome) from the post-2016 reformulated VSL#3 when relying on the published trial evidence.

Cited studies (8):
  - Probiotics in management of hepatic encephalopathy, Metabolic Brain Disease (2016) — Pooled probiotic data (incl. VSL#3) show reduced progression to overt hepatic encephalopathy, odds ratios ~0.22-0.42. [https://link.springer.com/article/10.1007/s11011-016-9826-x]
  - Treatment of relapsing mild-to-moderate ulcerative colitis with the probiotic VSL#3 as adjunctive to a standard pharmaceutical treatment: a double-blind, randomized, placebo-controlled study, The American journal of gastroenterology (2010) — Multicenter RCT in mild-moderate UC (n=144): 57.7% reached >=50% UCDAI reduction on VSL#3 vs 39.7% placebo (P=.031); higher remission/mucosal healing. [https://pubmed.ncbi.nlm.nih.gov/20517305/]
  - Probiotic VSL#3 reduces liver disease severity and hospitalization in patients with cirrhosis: a randomized, controlled trial, Gastroenterology (2014) — Double-blind RCT in cirrhosis post-HE: VSL#3 lowered HE hospitalization (19.7% vs 42.2%) and improved CTP/MELD over 6 months. [https://pubmed.ncbi.nlm.nih.gov/25450083/]
  - Once daily high dose probiotic therapy (VSL#3) for maintaining remission in recurrent or refractory pouchitis, Gut (2004) — In chronic recurrent/refractory pouchitis, remission maintained at 1 year in 85% on VSL#3 (17/20) vs 6% on placebo (1/16). [https://pubmed.ncbi.nlm.nih.gov/14684584/]
  - Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial, Gastroenterology (2000) — Double-blind maintenance trial in chronic pouchitis: 15% relapse on VSL#3 (3/20) vs 100% on placebo (20/20) over 9 months. [https://pubmed.ncbi.nlm.nih.gov/10930365/]
  - The probiotic preparation, VSL#3 induces remission in patients with mild-to-moderately active ulcerative colitis, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2009) — RCT in mild-moderate active UC: remission in 42.9% on VSL#3 vs 15.7% placebo at 12 weeks; significant UCDAI improvement. [https://pubmed.ncbi.nlm.nih.gov/19631292/]
  - A randomized controlled trial of a probiotic, VSL#3, on gut transit and symptoms in diarrhoea-predominant irritable bowel syndrome, Alimentary pharmacology & therapeutics (2003) — RCT in diarrhea-predominant IBS (n=25): VSL#3 significantly reduced abdominal bloating (P=.046) but not pain, gas, or urgency. [https://pubmed.ncbi.nlm.nih.gov/12656692/]
  - Effect of a probiotic preparation (VSL#3) on induction and maintenance of remission in children with ulcerative colitis, The American journal of gastroenterology (2009) — Pediatric UC RCT: VSL#3 induced remission in 92.8% vs 36.4% placebo and reduced relapse during maintenance. [https://pubmed.ncbi.nlm.nih.gov/19174792/]

---

## Lactobacillus plantarum 299v (Lactiplantibacillus plantarum 299v (DSM 9843))
URL: https://nutridex.info/s/l-plantarum-299v
Category: Probiotics, Gut & Immune
Evidence: Moderate — Several controlled trials; effects real but modest or context-dependent.
The mannose-binding gut workhorse: eases IBS and boosts iron uptake

Quick answer: Lactobacillus plantarum 299v is used for eases ibs symptoms — reduces abdominal pain frequency/severity and bloating (214-patient rct). NutriDex grades the human evidence as moderate — Several controlled trials; effects real but modest or context-dependent. Based on 10 cited human studies (10 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Lactiplantibacillus plantarum 299v (DSM 9843) is among the best-characterized single probiotic strains, with its strongest randomized evidence in irritable bowel syndrome (IBS), where a 214-patient double-blind RCT (Ducrotté 2012) showed significantly greater reductions in abdominal pain frequency and bloating versus placebo. Double-isotope crossover studies in women of reproductive age consistently show it increases non-heme iron absorption by roughly 50% when co-administered with iron, a claim that has undergone EFSA review. It also reduces Clostridioides difficile colonization and infection incidence in antibiotic-treated and high-risk hospitalized patients, and uniquely adheres to colonic mucosa via mannose-specific binding, displacing pathogenic E. coli. Evidence is moderate overall: trials are real and replicated for IBS and iron, but several are single-center or modest in size.

Benefits / uses: Eases IBS symptoms — reduces abdominal pain frequency/severity and bloating (214-patient RCT); Increases non-heme iron absorption by ~50% when taken with iron (double-isotope studies; EFSA-reviewed); Reduces Clostridioides difficile colonization and infection incidence in antibiotic-treated/high-risk inpatients; Adheres to colonic mucosa and displaces pathogenic E. coli via mannose-specific binding; Improves gut barrier function and reduces intestinal permeability (ICU and surgical/jaundice patients); Generally improves overall GI well-being and flatulence scores in functional GI complaints.
Active compounds: Lactiplantibacillus plantarum 299v = Lactobacillus plantarum 299v = Lp299v (DSM 9843); Branded as ProViva / GoodBelly fermented drinks and oat-based products; Sold in capsules/sachets, often as freeze-dried powder; Combined with low-dose iron (e.g. ~20 mg) in iron-support formulas.
Dose: 10 billion (1×10^10) CFU/day is the typical effective dose; IBS trials used one capsule daily over 4 weeks, and iron-absorption studies used 10^9–10^10 CFU taken together with the iron source. Available as freeze-dried capsules or fermented drinks; take with a meal (and alongside iron when used for iron status).
Safety: Well tolerated in trials, including in critically ill and surgical patients, with no excess diarrhea, bloating, or serious adverse events; it survives gastric acid and bile and colonizes the colon. As with all live probiotics, use caution in critically ill, immunocompromised, or central-venous-catheter patients given the theoretical risk of bacteremia/translocation; Lactobacillus bacteremia is rare but reported. Discuss with a clinician before use in these high-risk groups.

Cited studies (10):
  - Efficacy of Probiotics in Irritable Bowel Syndrome: Systematic Review and Meta-analysis, Gastroenterology (2023) — In a large strain-level systematic review and meta-analysis of probiotics for IBS (82 trials, 10,332 patients), L. plantarum 299v showed a benefit for global IBS symptoms but with low certainty of evidence. [https://pubmed.ncbi.nlm.nih.gov/37541528/]
  - Feasibility Study of Lactobacillus Plantarum 299v Probiotic Supplementation in an Urban Academic Facility among Diverse Pregnant Individuals, Nutrients (2023) — In a randomized, double-blind feasibility trial of 20 pregnant individuals, Lp299v plus low-dose prenatal iron produced a slower decline in maternal hematological/iron parameters across gestation than placebo plus iron. [https://pubmed.ncbi.nlm.nih.gov/36839232/]
  - Probiotic strain Lactobacillus plantarum 299v increases iron absorption from an iron-supplemented fruit drink: a double-isotope cross-over single-blind study in women of reproductive age, The British journal of nutrition (2015) — Adding Lp299v (10^9–10^10 CFU) to an iron-fortified fruit drink increased non-heme iron absorption by roughly 50% versus the same drink without the probiotic in women of reproductive age. [https://pubmed.ncbi.nlm.nih.gov/26428277/]
  - Freeze-dried Lactobacillus plantarum 299v increases iron absorption in young females-Double isotope sequential single-blind studies in menstruating women, PloS one (2017) — Freeze-dried Lp299v 10^10 CFU with a light breakfast raised iron absorption from 17.4% to 22.4% (P=0.040, n=14) in menstruating women. [https://pmc.ncbi.nlm.nih.gov/articles/PMC5728536/]
  - Clinical trial: Lactobacillus plantarum 299v (DSM 9843) improves symptoms of irritable bowel syndrome, World journal of gastroenterology (2012) — In 214 IBS patients (Rome III), 4 weeks of Lp299v 10^10 CFU/day cut abdominal pain frequency by 51.9% vs 13.6% for placebo and 78.1% rated the effect excellent/good vs 8.1% (P<0.05–0.01). [https://pmc.ncbi.nlm.nih.gov/articles/PMC3419998/]
  - Lactobacillus plantarum 299v reduces colonisation of Clostridium difficile in critically ill patients treated with antibiotics, Acta anaesthesiologica Scandinavica (2008) — Enteral Lp299v in an oat gruel reduced C. difficile colonization in critically ill, antibiotic-treated ICU patients versus the same product without the bacteria (n=44). [https://pubmed.ncbi.nlm.nih.gov/18840110/]
  - Adhesion of the probiotic bacterium Lactobacillus plantarum 299v onto the gut mucosa in critically ill patients: a randomised open trial, Critical care (London, England) (2005) — Lp299v adhered to the colonic mucosa of critically ill patients, demonstrating mucosal colonization in a randomized open trial. [https://pmc.ncbi.nlm.nih.gov/articles/PMC1175894/]
  - Strain-Specific Therapeutic Potential of Lactiplantibacillus plantarum: A Systematic Scoping Review, Nutrients (2025) — Across 69 studies of L. plantarum strains, Lp299v specifically improved GI symptoms, oral health, and systemic inflammation, supporting strain-specific selection for IBS. [https://pmc.ncbi.nlm.nih.gov/articles/PMC11990516/]
  - Lactobacillus plantarum 299v Reduces the Incidence of Clostridium difficile Infection in Nephrology and Transplantation Ward-Results of One Year Extended Study, Nutrients (2018) — Lp299v prophylaxis on a nephrology/transplant ward reduced C. difficile infection incidence from 12.1 to 1.1 per 1000 hospitalizations (1.21% vs 0.11%, P=0.0001). [https://pmc.ncbi.nlm.nih.gov/articles/PMC6266863/]
  - Lactobacillus plantarum 299v and an increase of non-haem iron absorption: evaluation of a health claim pursuant to Article 13(5) of Regulation (EC) No 1924/2006, EFSA Journal (2016) — EFSA NDA Panel evaluated the claim that Lp299v increases non-heme iron absorption, reviewing the human double-isotope evidence base for this strain. [https://efsa.onlinelibrary.wiley.com/doi/abs/10.2903/j.efsa.2016.4550]

---

## Bifidobacterium infantis 35624 (Bifidobacterium longum subsp. infantis 35624)
URL: https://nutridex.info/s/b-infantis-35624
Category: Probiotics, Gut & Immune
Evidence: Moderate — Several controlled trials; effects real but modest or context-dependent.
The flagship IBS strain — immune-modulating Bifidobacterium with landmark trial evidence

Quick answer: Bifidobacterium infantis 35624 is used for eases overall ibs symptoms (abdominal pain, bloating, bowel dysfunction) at 1x10^8 cfu/day in double-blind rcts. NutriDex grades the human evidence as moderate — Several controlled trials; effects real but modest or context-dependent. Based on 11 cited human studies (11 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Bifidobacterium 35624 (originally B. infantis 35624, reclassified after genome sequencing as B. longum subsp. longum 35624; sold as Align/Bifantis) is the best-studied single strain for irritable bowel syndrome (IBS). Two landmark double-blind RCTs (O'Mahony 2005, n=77; Whorwell 2006, n=362 women) found that 1x10^8 CFU/day significantly reduced abdominal pain, bloating, bowel dysfunction and global symptoms versus placebo, with the benefit linked to normalization of a pro-inflammatory IL-10/IL-12 cytokine ratio. Evidence is graded moderate rather than strong because a 2017 meta-analysis found the pooled single-strain effect on individual symptoms was not statistically significant, even though more recent open-label and pediatric studies report large IBS-SSS reductions. Effects are strain-specific and should not be generalized to other bifidobacteria.

Benefits / uses: Eases overall IBS symptoms (abdominal pain, bloating, bowel dysfunction) at 1x10^8 CFU/day in double-blind RCTs; Reduces abdominal pain/discomfort versus placebo across most treatment weeks (O'Mahony 2005); Improves global IBS symptom assessment by >20% over placebo (Whorwell 2006); Reduces functional abdominal bloating/distention; Normalizes a pro-inflammatory IL-10/IL-12 cytokine ratio, indicating an immune-modulating mechanism; Lowers IBS Severity Scoring System (IBS-SSS) scores in adults and in children/adolescents in real-world studies.
Active compounds: Bifidobacterium longum subsp. longum 35624 (reclassified from B. infantis 35624); Branded as Align (US), Alflorex (EU/PrecisionBiotics), and Bifantis; Single-strain encapsulated probiotic; Trademarked as 35624.
Dose: 1x10^8 CFU/day (the dose that outperformed both placebo and higher 1x10^10 doses in the Whorwell 2006 dose-ranging trial); typically one capsule once daily, taken for at least 4-8 weeks; benefit is lost after discontinuation, so continued daily use is needed.
Safety: Well tolerated in trials; adverse events were comparable to placebo, with rare mild nausea reported. No serious adverse events in IBS or pediatric studies; 89% of participants rated tolerability good to very good. As with any live probiotic, exercise caution in critically ill, immunocompromised patients, or those with central venous catheters, where translocation/bacteremia is a theoretical concern; bifidobacteremia is exceedingly rare.

Cited studies (11):
  - Strain-Specific Systematic Review with Meta-Analysis of Probiotics Efficacy in the Treatment of Irritable Bowel Syndrome, Journal of clinical medicine (2026) — Strain-specific meta-analysis of 32 RCTs (10 strains); B. longum (B. infantis) 35624 across 3 trials significantly reduced abdominal pain severity, straining, and overall IBS symptoms, but showed insufficient effect on bloating, urgency, incomplete evacuation, and gas passage. [https://pmc.ncbi.nlm.nih.gov/articles/PMC12898053/]
  - Efficacy of Probiotics in Irritable Bowel Syndrome: Systematic Review and Meta-analysis, Gastroenterology (2023) — Systematic review and meta-analysis of 82 RCTs (10,332 IBS patients) found combination probiotics, but limited single-strain evidence, improved global IBS symptoms; overall efficacy graded low certainty with substantial heterogeneity. [https://pubmed.ncbi.nlm.nih.gov/37541528/]
  - Outcome-Specific Efficacy of Different Probiotic Strains and Mixtures in Irritable Bowel Syndrome: A Systematic Review and Network Meta-Analysis, Nutrients (2023) — Outcome-specific network meta-analysis of probiotic strains/mixtures in IBS (search to June 2023) ranked Lactobacillus acidophilus DDS-1 first for IBS-SSS improvement; B. infantis 35624 as a single strain was not among the top-ranked strains. [https://pmc.ncbi.nlm.nih.gov/articles/PMC10490209/]
  - Efficacy of Bifidobacterium infantis 35624 in patients with irritable bowel syndrome: a meta-analysis, Current medical research and opinion (2017) — Meta-analysis (6 studies, ~796 IBS patients) found single-strain B. infantis 35624 did not significantly improve abdominal pain or bowel-habit satisfaction, though pooled bloating/distention improvement remained significant (SMD 0.21; 95% CI 0.07-0.35). [https://pubmed.ncbi.nlm.nih.gov/28166427/]
  - Efficacy of the Probiotic Bifidobacterium infantis 35624 in Functional Abdominal Bloating: A Triple-Blind, Randomized Controlled Trial, SN Comprehensive Clinical Medicine (2025) — Triple-blind, placebo-controlled trial of B. infantis 35624 (1x10^8 CFU, 4 weeks) in functional abdominal bloating found no significant improvement in bloating, other abdominal symptoms, or quality of life versus placebo; both arms well tolerated. [https://link.springer.com/article/10.1007/s42399-025-02123-8]
  - Lactobacillus and bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles, Gastroenterology (2005) — In 77 IBS patients, B. infantis 35624 (1x10^10 CFU/day, 8 wk) significantly reduced abdominal pain, bloating and bowel-movement difficulty vs placebo and normalized the abnormal IL-10/IL-12 (anti-/pro-inflammatory) cytokine ratio. [https://pubmed.ncbi.nlm.nih.gov/15765388/]
  - Efficacy of an encapsulated probiotic Bifidobacterium infantis 35624 in women with irritable bowel syndrome, The American journal of gastroenterology (2006) — Double-blind dose-ranging RCT in 362 women with IBS: 1x10^8 CFU/day was superior to placebo and other doses for abdominal pain plus composite scores for bloating, bowel dysfunction, straining and gas, exceeding placebo by >20% on global assessment. [https://pubmed.ncbi.nlm.nih.gov/16863564/]
  - An 8-Week Course of Bifidobacterium longum 35624(®) Is Associated with a Reduction in the Symptoms of Irritable Bowel Syndrome, Probiotics and antimicrobial proteins (2025) — Open-label 8-week post-market study (n=33 per-protocol) of B. longum 35624: Total IBS Symptom Score fell 43.5% (p<0.0001) and IBS-SSS dropped ~82 points (p<0.001); >60% achieved clinically meaningful improvement with good tolerability. [https://pmc.ncbi.nlm.nih.gov/articles/PMC11832793/]
  - Effects of Bifidobacterium longum 35624 in Children and Adolescents with Irritable Bowel Syndrome, Nutrients (2024) — Real-world open-label study in 64 children/adolescents (8-18 y, 1x10^9 CFU/day, 12 wk): mean IBS-SSS fell from 334 to 58 (p<0.0001) with 96.6% reaching clinically significant improvement; symptoms rebounded after washout. [https://pmc.ncbi.nlm.nih.gov/articles/PMC11206369/]
  - Bifidobacterium infantis 35624 and other probiotics in the management of irritable bowel syndrome. Strain specificity, symptoms, and mechanisms, Current Medical Research and Opinion (2017) — Narrative/strain-specificity review summarizing the 35624 evidence base and mechanisms (mucosal binding, reduced barrier dysfunction, immunoregulation) and confirming probiotic effects are strain-specific. [https://www.tandfonline.com/doi/full/10.1080/03007995.2017.1322571]
  - Genome Analysis and Characterisation of the Exopolysaccharide Produced by Bifidobacterium longum subsp. longum 35624™, PloS one (2016) — Genome sequencing and phylogenetic analysis reclassified strain 35624 from B. longum subsp. infantis to B. longum subsp. longum and characterized its mucosa-binding exopolysaccharide. [https://pmc.ncbi.nlm.nih.gov/articles/PMC5033381/]

---

## Bacillus coagulans (Heyndrickxia coagulans (GBI-30 6086 / Unique IS-2))
URL: https://nutridex.info/s/bacillus-coagulans
Category: Probiotics, Gut & Immune
Evidence: Moderate — Several controlled trials; effects real but modest or context-dependent.
Spore-forming probiotic with the strongest evidence for easing IBS abdominal pain and bloating

Quick answer: Bacillus coagulans is used for eases ibs abdominal pain and bloating (gbi-30 6086 and unique is-2, 8-week rcts). NutriDex grades the human evidence as moderate — Several controlled trials; effects real but modest or context-dependent. Based on 8 cited human studies (8 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

For Bacillus (Heyndrickxia) coagulans, the best-supported indication is irritable bowel syndrome: multiple randomized, placebo-controlled trials of the GBI-30 6086 (BC30) and Unique IS-2 strains show significant reductions in abdominal pain, bloating, and overall symptom severity over 8 weeks, and a 2023 systematic review/meta-analysis of seven RCTs concluded B. coagulans meaningfully lowers IBS symptom severity with no serious adverse events. Network meta-analyses rank Unique IS-2 among the most effective probiotics for IBS abdominal pain (SUCRA ~92.6%). Heat-stable spores also survive gastric acid and germinate in the gut; GBI-30 has separate human trials supporting improved milk-protein amino-acid absorption and exercise-recovery, though these are smaller. Evidence is strain-specific and most robust for IBS rather than for the muscle/immune claims often marketed.

Benefits / uses: Eases IBS abdominal pain and bloating (GBI-30 6086 and Unique IS-2, 8-week RCTs); Reduces overall IBS symptom severity, straining, urgency and gas (meta-analysis of 7 RCTs); Improves abdominal pain and stool consistency in pediatric IBS (Unique IS-2, ages 4-12); Lessens functional intestinal gas symptoms (GBI-30 6086); Enhances amino-acid/leucine absorption when co-ingested with milk protein (GBI-30 6086); May reduce exercise-induced muscle soreness and speed recovery alongside protein (GBI-30 6086, preliminary).
Active compounds: Bacillus coagulans GBI-30, 6086 (BC30, branded by Kerry); Bacillus coagulans Unique IS-2 (MTCC 5260; Unique Biotech); Bacillus coagulans MTCC 5856 (LactoSpore/Sabinsa, IBS evidence); Heat-stable spore tablets, capsules and chewables; shelf-stable, no refrigeration; Commonly 1-2 billion CFU per serving; reclassified taxonomically as Heyndrickxia coagulans.
Dose: For IBS: ~2 billion CFU/day of Unique IS-2 or 1 billion CFU/day of GBI-30 6086, once daily for 8 weeks (effect builds over weeks 2-8). For protein/recovery use: 1 billion CFU GBI-30 6086 co-ingested with protein. Spores are acid-stable and can be taken with or without food.
Safety: Generally very well tolerated in trials with no serious adverse events and adverse-event rates similar to placebo in both adults and children; GRAS-status spore former. As with any live probiotic, use caution in critically ill, immunocompromised, or central-venous-catheter patients, where rare bacteremia/translocation is a theoretical concern; consult a clinician in these settings and in pregnancy.

Cited studies (8):
  - Bacillus coagulans as a potent intervention for treating irritable bowel syndrome: A systematic review and meta-analysis of randomized control trials, Gastroenterology & Endoscopy (2024) — Systematic review and meta-analysis of seven RCTs found B. coagulans significantly lowered abdominal pain (after 2, 4, 8 and 11-13 weeks), bloating, straining, gas and total symptom severity, with no serious adverse events. [https://www.sciencedirect.com/science/article/pii/S2949752323000614]
  - Randomized clinical trial: the effect of probiotic Bacillus coagulans Unique IS2 vs. placebo on the symptoms management of irritable bowel syndrome in adults, Scientific reports (2019) — Randomized placebo-controlled trial (136 adults, Rome III IBS) of Unique IS-2 (2 billion CFU/day, 8 weeks) showed significant improvement in abdominal pain intensity and complete spontaneous bowel movements vs placebo. [https://pmc.ncbi.nlm.nih.gov/articles/PMC6704184/]
  - Efficacy of Bacillus coagulans Unique IS2 in treatment of irritable bowel syndrome in children: a double blind, randomised placebo controlled study, Beneficial microbes (2018) — Double-blind RCT in 141 children (ages 4-12, Rome III IBS): Unique IS-2 chewable once daily for 8 weeks significantly reduced pain intensity (P<0.0001) and improved stool consistency, bloating and urgency vs placebo. [https://pubmed.ncbi.nlm.nih.gov/29695183/]
  - Probiotic Bacillus coagulans GBI-30, 6086 reduces exercise-induced muscle damage and increases recovery, PeerJ (2016) — Crossover RCT in 29 trained males: 1 billion CFU GBI-30 6086 added to casein significantly improved perceived recovery at 24 and 72 h and reduced muscle soreness at 72 h post-exercise vs protein alone. [https://pmc.ncbi.nlm.nih.gov/articles/PMC4963221/]
  - Probiotic Bacillus coagulans GBI-30, 6086 Improves Protein Absorption and Utilization, Probiotics and antimicrobial proteins (2018) — Two-week supplementation study (n=30) found adding GBI-30 6086 to milk protein concentrate improved amino-acid absorption, including ~20% greater leucine absorption. [https://pmc.ncbi.nlm.nih.gov/articles/PMC6208742/]
  - Synbiotic containing Bacillus coagulans and fructo-oligosaccharides for functional abdominal pain in children, Gastroenterology and hepatology from bed to bench (2015) — RCT in 115 children (6-18 y) with functional abdominal pain: synbiotic of B. coagulans Unique IS-2 plus FOS twice daily for 4 weeks gave a higher response rate than placebo (60% vs 39.5%, P=0.044). [https://pmc.ncbi.nlm.nih.gov/articles/PMC4285933/]
  - Bacillus coagulans significantly improved abdominal pain and bloating in patients with IBS, Postgraduate medicine (2009) — In a randomized, double-blind, placebo-controlled trial (n=44), B. coagulans GBI-30 6086 once daily for 8 weeks gave statistically significant improvements in abdominal pain and bloating scores vs placebo across all 7 weekly comparisons (P<0.01). [https://pubmed.ncbi.nlm.nih.gov/19332970/]
  - A prospective, randomized, double-blind, placebo-controlled parallel-group dual site trial to evaluate the effects of a Bacillus coagulans-based product on functional intestinal gas symptoms, BMC gastroenterology (2009) — Randomized, double-blind, placebo-controlled dual-site trial of a GBI-30 6086-based product showed significant reduction in functional intestinal gas symptoms vs placebo. [https://pmc.ncbi.nlm.nih.gov/articles/PMC2784472/]

---

## Lactobacillus rhamnosus GG (Lacticaseibacillus rhamnosus GG (ATCC 53103))
URL: https://nutridex.info/s/lgg
Category: Probiotics, Gut & Immune
Evidence: Strong — Multiple high-quality RCTs / meta-analyses with consistent effects.
The most-studied probiotic strain — best evidence for antibiotic-associated and acute pediatric diarrhea

Quick answer: Lactobacillus rhamnosus GG is used for prevents antibiotic-associated diarrhea, cutting risk from ~22% to ~12% (rr 0.49); effect significant in children (rr 0.48). NutriDex grades the human evidence as strong — Multiple high-quality RCTs / meta-analyses with consistent effects. Based on 12 cited human studies (12 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Lacticaseibacillus rhamnosus GG (ATCC 53103) is the world's most extensively researched probiotic strain. The strongest randomized-trial and meta-analytic evidence supports preventing antibiotic-associated diarrhea (especially in children, RR ~0.48-0.49) and reducing the duration of acute infectious gastroenteritis in children by roughly 0.5-1 day, with effects clearest at high doses (≥10^10 CFU/day) and in rotavirus-positive disease. It also prevents healthcare-associated diarrhea and rotavirus gastroenteritis in hospitalized children and shows benefit for childhood IBS. Notably, two large high-quality 2018 RCTs (NEJM/PECARN and Canadian PERC) found no benefit for outpatient acute gastroenteritis, so the diarrhea-duration effect is real but modest and context-dependent.

Benefits / uses: Prevents antibiotic-associated diarrhea, cutting risk from ~22% to ~12% (RR 0.49); effect significant in children (RR 0.48); Shortens acute infectious diarrhea in children by ~0.5-1 day, most clearly with high dose (≥10^10 CFU/day) and rotavirus diarrhea; Reduces healthcare-associated (nosocomial) diarrhea in hospitalized children (RR ~0.37) and rotavirus gastroenteritis (RR ~0.49); Improves childhood irritable bowel syndrome — higher responder rate (RR 1.70, NNT 4) for abdominal pain; May reduce infantile colic crying time in breastfed infants (one RCT: 104 vs 242 min/day), though evidence is mixed.
Active compounds: Lacticaseibacillus rhamnosus GG, ATCC 53103 (reclassified 2020 from Lactobacillus rhamnosus); Culturelle (US consumer brand); Dicoflor / Vivomixx-region equivalents and many generic 'LGG' supplements; Capsules, sachets/powder, and drops; typically 10^9-10^10 CFU per serving.
Dose: Trials commonly use 10^10 CFU/day (range 5×10^9 to ≥10^10 CFU/day); higher doses (≥10^10 CFU/day) are more effective for acute diarrhea. For antibiotic-associated diarrhea, give alongside the antibiotic course (separating from the antibiotic dose by a couple of hours) and continue for the duration of treatment; for acute gastroenteritis, start early and continue 5-7 days.
Safety: Generally well tolerated in healthy children and adults, with no serious adverse events in trials. Caution is warranted in critically ill, immunocompromised, or central-venous-catheter/short-gut patients: documented case reports of L. rhamnosus GG bacteremia/endocarditis, including a WGS-confirmed catheter-associated case. Avoid or use only under specialist guidance in immunosuppression, structural heart disease, indwelling intravascular lines, and compromised gut-barrier states. Not a substitute for oral rehydration in acute diarrhea.

Cited studies (12):
  - Probiotics for the prevention of Clostridioides difficile-associated diarrhea in adults and children, The Cochrane database of systematic reviews (2025) — Updated Cochrane review of probiotics for preventing Clostridioides difficile-associated diarrhea concluded probiotics may yield a small reduction in CDAD risk (about 1 case prevented per 65 people) with no increase in adverse effects in non-immunocompromised patients on antibiotics. [https://pubmed.ncbi.nlm.nih.gov/40931979/]
  - Lactobacillus rhamnosus GG as a probiotic for preterm infants: a strain specific systematic review and meta-analysis, European Journal of Clinical Nutrition (2024) — Strain-specific systematic review and meta-analysis in preterm infants found single-strain L. rhamnosus GG significantly reduced necrotizing enterocolitis >=Stage II (5 RCTs, n=851, RR 0.50, 95% CI 0.26-0.93, P=0.03), though it did not affect other major outcomes. [https://www.nature.com/articles/s41430-024-01474-0]
  - Overview of systematic reviews of probiotics in the prevention and treatment of antibiotic-associated diarrhea in children, Frontiers in Pharmacology (2023) — Overview of systematic reviews of probiotics for preventing/treating antibiotic-associated diarrhea in children synthesized the evidence base, supporting LGG and S. boulardii among the better-supported strains while flagging variable methodological quality across reviews. [https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2023.1153070/full]
  - Systematic review with meta-analysis: Lactobacillus rhamnosus GG in the prevention of antibiotic-associated diarrhoea in children and adults, Alimentary pharmacology & therapeutics (2015) — LGG reduced antibiotic-associated diarrhea from 22.4% to 12.3% (11 RCTs, n=1308, RR 0.49, 95% CI 0.29-0.83); significant in children (5 RCTs, n=445, RR 0.48, 95% CI 0.26-0.89). [https://pubmed.ncbi.nlm.nih.gov/26365389/]
  - Systematic review with meta-analysis: Lactobacillus rhamnosus GG for treating acute gastroenteritis in children - a 2019 update, Alimentary pharmacology & therapeutics (2019) — In children with acute gastroenteritis, LGG had no effect on stool volume but reduced diarrhea duration (15 RCTs, n=3820, MD -0.85 day, 95% CI -1.15 to -0.56); 18 RCTs, n=4208 total. [https://pubmed.ncbi.nlm.nih.gov/31025399/]
  - Meta-analysis: Lactobacillus rhamnosus GG for abdominal pain-related functional gastrointestinal disorders in childhood, Alimentary pharmacology & therapeutics (2011) — For childhood abdominal-pain functional GI disorders, LGG raised treatment responders overall (3 RCTs, n=290, RR 1.31, NNT 7) and in IBS (3 RCTs, n=167, RR 1.70, 95% CI 1.27-2.27, NNT 4). [https://pubmed.ncbi.nlm.nih.gov/21507030/]
  - Lactobacillus GG in the Prevention of Antibiotic-Associated Diarrhea in the Pediatric Intensive Care Unit: A Prospective Randomized, Double-Blind Placebo Controlled Intervention, The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG (2025) — Prospective double-blind placebo-controlled RCT in critically ill children (<=17 y) on antibiotics >=72 h tested LGG vs placebo for prevention of antibiotic-associated diarrhea in the pediatric ICU (J Pediatr Pharmacol Ther 2025;30(1):47-51). [https://pmc.ncbi.nlm.nih.gov/articles/PMC11809540/]
  - The Efficacy of a Mix of Probiotics (Limosilactobacillus reuteri LMG P-27481 and Lacticaseibacillus rhamnosus GG ATCC 53103) in Preventing Antibiotic-Associated Diarrhea and Clostridium difficile Infection in Hospitalized Patients: Single-Center, Open-Label, Randomized Trial, Microorganisms (2024) — Single-center open-label RCT in 113 hospitalized adults on antibiotics (>=5 days) found a L. reuteri LMG P-27481 + L. rhamnosus GG ATCC 53103 combination reduced antibiotic-associated diarrhea versus antibiotics alone. [https://pmc.ncbi.nlm.nih.gov/articles/PMC10819176/]
  - Lactobacillus rhamnosus GG (ATCC 53103) for the Management of Infantile Colic: A Randomized Controlled Trial, Nutrients (2020) — In 45 colicky breastfed infants, LGG (ATCC 53103) 5×10^9 CFU/day for 28 days reduced median daily crying (104 vs 242 min, p<0.001) and fecal calprotectin (p=0.026). [https://pmc.ncbi.nlm.nih.gov/articles/PMC7352391/]
  - Lactobacillus rhamnosus GG versus Placebo for Acute Gastroenteritis in Children, New England Journal of Medicine (2018) — In 943 US children with acute gastroenteritis, LGG 10^10 CFU twice daily for 5 days showed no benefit over placebo for moderate-to-severe disease within 14 days. [https://www.nejm.org/doi/full/10.1056/NEJMoa1802598]
  - Randomized, placebo-controlled trial of Lactobacillus rhamnosus GG as treatment of atopic dermatitis in infancy, Allergy (2007) — LGG 5×10^9 CFU twice daily for 12 weeks showed no therapeutic benefit for mild-to-moderate atopic dermatitis in infants aged 3-12 months. [https://pubmed.ncbi.nlm.nih.gov/17919141/]
  - Bacteraemia caused by Lactobacillus rhamnosus given as a probiotic in a patient with a central venous catheter: a WGS case report, Infection prevention in practice (2022) — L. rhamnosus GG probiotic caused bacteremia in a multi-trauma patient with a central venous catheter on parenteral nutrition, confirmed by WGS, cautioning use with indwelling intravascular catheters. [https://pmc.ncbi.nlm.nih.gov/articles/PMC8802096/]

---

## Lactobacillus acidophilus NCFM
URL: https://nutridex.info/s/l-acidophilus-ncfm
Category: Probiotics, Gut & Immune
Evidence: Mixed — Conflicting results across studies; benefit uncertain.
A heavily characterized acidophilus strain with its best human data in pediatric immune support and combination-formula bloating relief.

Quick answer: Lactobacillus acidophilus NCFM is used for reduces incidence and duration of cold/flu-like symptoms (fever, cough, runny nose) in young children, especially combined with b. lactis bi-07. NutriDex grades the human evidence as mixed — Conflicting results across studies; benefit uncertain. Based on 9 cited human studies (9 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Lactobacillus acidophilus NCFM is one of the most studied probiotic strains, but its clinical evidence is genre-specific and uneven. The strongest signal is from a 6-month pediatric RCT where NCFM (alone, and especially combined with B. lactis Bi-07) significantly cut the incidence and duration of fever, cough, and rhinorrhea and reduced antibiotic use in 3-5 year olds. For gut symptoms, an NCFM + Bi-07 combination reduced bloating severity in functional bowel disorders, but a large 340-patient triple-blind trial of NCFM alone for IBS found symptom improvement no better than placebo. NCFM also has lactase activity that can ease lactose digestion. Overall, benefit is real for specific formulations/indications but not a blanket "IBS cure."

Benefits / uses: Reduces incidence and duration of cold/flu-like symptoms (fever, cough, runny nose) in young children, especially combined with B. lactis Bi-07; Lowers antibiotic prescriptions and illness-related missed school days in preschoolers (immune support); Reduces bloating severity in functional bowel disorders when combined with B. lactis Bi-07; Helps digest lactose / eases lactose-intolerance symptoms via its high lactase activity; Upregulates colonic mu-opioid receptor expression, a plausible mechanism for visceral analgesia in functional abdominal pain; Generally well tolerated and confirmed to survive GI transit.
Active compounds: Lactobacillus acidophilus NCFM (ATCC 700396; reclassified Lactobacillus acidophilus, formerly under DuPont/IFF, now part of HOWARU brand); HOWARU Restore (NCFM + L. paracasei Lpc-37 + B. lactis Bl-04 + B. lactis Bi-07); NCFM + Bifidobacterium animalis subsp. lactis Bi-07 (Florajen, many adult/pediatric immune blends); Optibac and various consumer capsules/sachets listing 'NCFM'.
Dose: Trials used roughly 1 x 10^9 to 1 x 10^10 CFU/day for adult gut studies; the pediatric immune trial gave ~1 x 10^10 CFU twice daily for 6 months; the functional bowel/bloating combination trial used 2 x 10^11 CFU/day (1 x 10^11 BID) of NCFM + Bi-07. Taken orally, typically once or twice daily with no strict timing requirement.
Safety: Excellent tolerability across adult and pediatric RCTs with no clinically significant increase in adverse events; mild transient bloating/gas can occur. The strain (and HOWARU Restore blend) carries FDA GRAS and EU QPS-equivalent safety status, lacks transferable antibiotic-resistance and harmful genomic traits. As with all live Lactobacillus probiotics, use caution in critically ill, immunocompromised, or central-venous-catheter patients given rare reports of bacteremia in such populations; not a substitute for standard medical therapy.

Cited studies (9):
  - Probiotics for preventing acute upper respiratory tract infections, The Cochrane database of systematic reviews (2022) — Full-text Cochrane review reporting on roughly 4,364 participants (2,320 probiotic, 2,044 control) across RCTs, concluding probiotics may be better than placebo for preventing at least one and at least three acute upper respiratory tract infections. [https://pmc.ncbi.nlm.nih.gov/articles/PMC9400717/]
  - Probiotics for prevention and treatment of respiratory tract infections in children: A systematic review and meta-analysis of randomized controlled trials, Medicine (2016) — Systematic review and meta-analysis of RCTs found probiotics reduced the number of children with respiratory tract infection episodes and lowered antibiotic use compared with placebo. [https://pmc.ncbi.nlm.nih.gov/articles/PMC4979858/]
  - Irritable bowel syndrome symptom severity improves equally with probiotic and placebo, World journal of gastroenterology (2016) — Triple-blind RCT in 340 IBS adults: NCFM alone at 10^9 or 10^10 CFU/day for 12 weeks improved IBS-SSS no more than placebo (mean drop 50.8 / 48.3 vs 44.0 placebo), i.e., no benefit over placebo for symptom severity. [https://pmc.ncbi.nlm.nih.gov/articles/PMC5192275/]
  - Probiotic bacteria Lactobacillus acidophilus NCFM and Bifidobacterium lactis Bi-07 versus placebo for the symptoms of bloating in patients with functional bowel disorders: a double-blind study, Journal of clinical gastroenterology (2011) — 8-week double-blind RCT (n=60, functional bowel disorders): NCFM + B. lactis Bi-07 at 2x10^11 CFU/day improved abdominal bloating vs placebo at 4 weeks (4.10 vs 6.17, P=0.009) and reduced bloating severity at 8 weeks (P<0.01). [https://pubmed.ncbi.nlm.nih.gov/21436726/]
  - Lactobacillus acidophilus NCFM affects colonic mucosal opioid receptor expression in patients with functional abdominal pain - a randomised clinical study, Alimentary pharmacology & therapeutics (2014) — Randomized clinical study (n=20 women, functional abdominal pain): NCFM alone induced ~40-fold increase in colonic mucosal mu-opioid receptor (MOR) mRNA/protein and downstream STAT3 signalling; the NCFM+Bi-07 combination did not. [https://pmc.ncbi.nlm.nih.gov/articles/PMC4613798/]
  - Primary glomangiosarcoma of the lung: A case report, Journal of cardiothoracic surgery (2010) — Randomized, double-blind, placebo-controlled trial (n=45): 4 weeks of NCFM did not significantly alter insulin sensitivity overall, though it preserved insulin sensitivity in a subgroup and attenuated systemic inflammatory response. [https://pubmed.ncbi.nlm.nih.gov/20920354/]
  - Probiotic effects on cold and influenza-like symptom incidence and duration in children, Pediatrics (2009) — 6-month RCT in 326 children (3-5 yr): vs placebo, NCFM and NCFM+Bi-07 reduced fever incidence by 53.0% and 72.7%, cough by 41.4% and 62.1%, and rhinorrhea by 28% and 59%, with fewer antibiotic prescriptions and missed school days. [https://pubmed.ncbi.nlm.nih.gov/19651563/]
  - Safety evaluation of HOWARU(®) Restore (Lactobacillus acidophilus NCFM, Lactobacillus paracasei Lpc-37, Bifidobacterium animalis subsp. lactis Bl-04 and B. lactis Bi-07) for antibiotic resistance, genomic risk factors, and acute toxicity, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association (2017) — Safety evaluation of HOWARU Restore (NCFM + Lpc-37 + Bl-04 + Bi-07): no transferable antibiotic-resistance determinants, no virulence genomic risk factors, and no acute oral toxicity. [https://pubmed.ncbi.nlm.nih.gov/29080807/]
  - Invited review: the scientific basis of Lactobacillus acidophilus NCFM functionality as a probiotic, Journal of dairy science (2001) — Invited review synthesizing NCFM's probiotic functionality: documents high intrinsic lactase activity, acid/bile tolerance, and human GI survival supporting lactose digestion and colonization claims. [https://pubmed.ncbi.nlm.nih.gov/11233016/]

---

## Multi-strain Probiotics (general) (Mixed Lactobacillus + Bifidobacterium blends)
URL: https://nutridex.info/s/multi-strain
Category: Probiotics, Gut & Immune
Evidence: Strong — Multiple high-quality RCTs / meta-analyses with consistent effects.
Mixed Lactobacillus + Bifidobacterium blends for gut and antibiotic-related conditions

Quick answer: Multi-strain Probiotics (general) is used for prevents clostridioides difficile-associated diarrhea in adults/children on antibiotics (~60% relative risk reduction; greatest in higher-risk patients). NutriDex grades the human evidence as strong — Multiple high-quality RCTs / meta-analyses with consistent effects. Based on 9 cited human studies (9 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Multi-strain Lactobacillus + Bifidobacterium blends have their strongest, most consistent evidence in preventing antibiotic-associated and Clostridioides difficile-associated diarrhea: a 2017 Cochrane review of 39 RCTs (9,955 participants) found probiotics cut C. difficile diarrhea risk by ~60% (RR 0.40), with the benefit concentrated in higher-baseline-risk patients. Specific high-potency 8-strain formulations (the De Simone formulation, formerly VSL#3) have RCT-grade support for inducing remission in mild-to-moderate ulcerative colitis and maintaining remission in pouchitis. Effects are strain- and formulation-specific — not all blends are equally effective, and certainty for IBS from combination products is low. Multiple-strain preparations also appear most effective for preventing necrotizing enterocolitis in preterm infants.

Benefits / uses: Prevents Clostridioides difficile-associated diarrhea in adults/children on antibiotics (~60% relative risk reduction; greatest in higher-risk patients); Reduces antibiotic-associated diarrhea; two-strain Lactobacillus+Bifidobacterium mixtures show RR ~0.51; Induces and maintains remission in mild-to-moderate ulcerative colitis (8-strain De Simone/VSL#3 formulation); Maintains remission of recurrent/refractory pouchitis (85% vs 6% placebo at 1 year, De Simone formulation); Reduces necrotizing enterocolitis and mortality in preterm infants (multi-strain blends rank most effective); Improves H. pylori eradication rates and reduces eradication-therapy adverse events as adjunct to triple/quadruple therapy.
Active compounds: De Simone formulation (formerly VSL#3; now Visbiome) - 8 strains: 4 Lactobacillus, 3 Bifidobacterium, Streptococcus thermophilus; Two-strain Lactobacillus + Bifidobacterium animalis subsp. lactis blends; Lyophilized (freeze-dried) capsules, sachets, and powders; High-CFU sachets (e.g., 450-900 billion CFU per dose for IBD use).
Dose: For AAD/CDAD prevention: ~10-50 billion CFU/day, started within 1-2 days of the antibiotic and continued throughout (and a few days after) the course. For ulcerative colitis/pouchitis (De Simone formulation): high dose 3.6 trillion CFU twice daily (induction) or 6 g (~900 billion CFU) once daily (maintenance). Take with or near a meal.
Safety: Generally well tolerated in immunocompetent people; trial adverse-event rates are similar to placebo (mild gas/bloating most common). Caution or avoid in critically ill, immunocompromised, central venous catheter, short-gut, or post-surgical patients — rare bacteremia/sepsis and translocation have been reported, and a probiotic was linked to increased mortality in one severe acute pancreatitis RCT. Product quality and viable CFU vary between brands; effects do not transfer between different strain blends.

Cited studies (9):
  - Probiotics for the prevention of Clostridioides difficile-associated diarrhea in adults and children, The Cochrane database of systematic reviews (2025) — Updated Cochrane review (search to March 2025): in participants at >5% baseline CDAD risk, probiotics cut CDAD from 11.6% (control) to 3.1% (probiotic) (13 trials, 2454 participants; ~70% relative reduction, NNT=12, moderate certainty). [https://pubmed.ncbi.nlm.nih.gov/40931979/]
  - What are the benefits and harms of probiotics for preventing Clostridioides difficile-associated diarrhea in adults and children receiving antibiotics for any reason?, Cochrane (2025) — In people prescribed antibiotics without a weakened immune system, short-term probiotics may offer a small benefit in preventing CDAD and are likely not harmful; large trials in low-risk populations are still needed. [https://www.cochrane.org/evidence/CD006095_what-are-benefits-and-harms-probiotics-preventing-clostridioides-difficile-associated-diarrhea]
  - Strain-specific and outcome-specific efficacy of probiotics for the treatment of irritable bowel syndrome: A systematic review and meta-analysis, EClinicalMedicine (2021) — Strain- and outcome-specific meta-analysis of IBS found efficacy for select single strains but low/very-low certainty of benefit for combination (multi-strain) probiotics on global IBS symptoms. [https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(21)00434-X/fulltext]
  - Probiotics for the prevention of Clostridium difficile-associated diarrhea in adults and children, Cochrane Database of Systematic Reviews (2017) — In 39 RCTs (9,955 participants), probiotics reduced C. difficile-associated diarrhea risk by ~60% (RR 0.40, 95% CI 0.30-0.52); benefit was significant only in patients with >5% baseline CDAD risk. [https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD006095.pub4/full]
  - Systematic review and meta-analysis: Multi-strain probiotics as adjunct therapy for Helicobacter pylori eradication and prevention of adverse events, United European gastroenterology journal (2016) — Meta-analysis of 19 RCTs (n=2,730) found some multi-strain probiotic mixtures significantly reduced antibiotic-associated diarrhea, with two-strain mixtures showing RR 0.51 (95% CI 0.38-0.68); not all mixtures were effective. [https://pmc.ncbi.nlm.nih.gov/articles/PMC4971786/]
  - Comparative efficacy and tolerability of probiotics for antibiotic-associated diarrhea: Systematic review with network meta-analysis, United European gastroenterology journal (2018) — Network/systematic review showed effects are strain- and product-specific, with several Lactobacillus+Bifidobacterium combinations effective for AAD prevention while others showed no benefit. [https://pmc.ncbi.nlm.nih.gov/articles/PMC5833232/]
  - Multiple strains probiotics appear to be the most effective probiotics in the prevention of necrotizing enterocolitis and mortality: An updated meta-analysis, PLOS ONE (2017) — Updated meta-analysis (25 trials, 7,345 preterm infants) found multiple-strain probiotics ranked most effective for preventing necrotizing enterocolitis and reducing all-cause mortality. [https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0171579]
  - Treatment of relapsing mild-to-moderate ulcerative colitis with the probiotic VSL#3 as adjunctive to a standard pharmaceutical treatment: a double-blind, randomized, placebo-controlled study, The American journal of gastroenterology (2010) — RCT in mild-to-moderate ulcerative colitis: VSL#3 (3.6 trillion CFU twice daily) plus standard therapy achieved >50% UCDAI improvement in 32.5% vs 10% on placebo at week 6. [https://pmc.ncbi.nlm.nih.gov/articles/PMC3180711/]
  - Once daily high dose probiotic therapy (VSL#3) for maintaining remission in recurrent or refractory pouchitis, Gut (2004) — In recurrent/refractory pouchitis, once-daily high-dose VSL#3 maintained remission at 1 year in 85% vs 6% on placebo (p<0.0001); 36 patients randomized. [https://pubmed.ncbi.nlm.nih.gov/14684584/]

---

## Lactobacillus casei Shirota (Lacticaseibacillus paracasei Shirota (Yakult))
URL: https://nutridex.info/s/l-casei-shirota
Category: Probiotics, Gut & Immune
Evidence: Moderate — Several controlled trials; effects real but modest or context-dependent.
The original Yakult strain — best evidence for preventing antibiotic-associated diarrhoea and supporting bowel regularity

Quick answer: Lactobacillus casei Shirota is used for reduces antibiotic-associated diarrhoea and c. difficile-associated diarrhoea in hospitalised older adults (hickson 2007). NutriDex grades the human evidence as moderate — Several controlled trials; effects real but modest or context-dependent. Based on 9 cited human studies (9 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Lacticaseibacillus paracasei (formerly Lactobacillus casei) strain Shirota, the live culture in Yakult, is one of the most studied probiotic strains, almost always delivered as a fermented-milk drink rather than a capsule. Its best-supported use is preventing antibiotic-associated diarrhoea (AAD): the landmark Hickson 2007 BMJ trial cut AAD from 34% to 12% and C. difficile diarrhoea from 17% to 0% in hospitalised older adults, though a later rigorous spinal-cord-injury RCT (ECLISP) found no overall AAD benefit except in proton-pump-inhibitor users. Randomised trials also show modest, reproducible improvement in stool consistency and defecation frequency, reduced winter upper-respiratory-tract infections in office workers, and blunting of stress-related cortisol rise and abdominal symptoms in exam-stressed students. Effects are strain- and dose-specific and tend to be modest; results across indications are mixed rather than uniformly positive.

Benefits / uses: Reduces antibiotic-associated diarrhoea and C. difficile-associated diarrhoea in hospitalised older adults (Hickson 2007); Lowers AAD risk in antibiotic-treated patients who regularly take proton-pump inhibitors (ECLISP subgroup); Improves stool consistency and increases defecation frequency in people prone to constipation or with soft stools; Reduces the incidence and duration of winter upper-respiratory-tract infections in healthy adults; Blunts stress-induced salivary cortisol rise and relieves stress-associated abdominal symptoms under academic stress; May modestly improve metabolic markers (post-meal glucose handling) in obese pre-diabetic adults.
Active compounds: Yakult / Yakult Light fermented-milk drink (~6.5-10 billion LcS per 65 mL bottle); Yakult 1000 / Y1000 (~100 billion LcS, marketed for stress and sleep); Strain designations: Lacticaseibacillus paracasei Shirota, L. casei strain Shirota (LcS), YIT 9029; Almost exclusively a probiotic fermented-milk beverage rather than a capsule or powder.
Dose: Typically 6.5 x 10^9 to 1 x 10^11 (about 6.5 billion to 100 billion) live LcS cells once daily, taken as a fermented-milk drink. For AAD prevention, given once daily during the antibiotic course and continued ~7 days after; for regularity, respiratory and stress outcomes, daily intake over 4-12 weeks.
Safety: Generally well tolerated; trials report no serious intervention-related adverse events, and a surveillance study in critically ill children found no LcS colonisation or bacteraemia. As with all live probiotics, use caution in critically ill, severely immunocompromised, or central-venous-catheter patients, in whom rare lactobacillus bacteraemia/endocarditis has been reported with the genus. The drink contains milk and added sugar (relevant for lactose intolerance and diabetes/glycaemic control). Probiotics do not replace standard treatment for active infection.

Cited studies (9):
  - Lactobacillus casei Shirota probiotic drinks reduce antibiotic associated diarrhoea in patients with spinal cord injuries who regularly consume proton pump inhibitors: a subgroup analysis of the ECLISP multicentre RCT, Spinal cord (2024) — In the proton-pump-inhibitor subgroup, LcS lowered AAD incidence at 30 days vs placebo (28.0% vs 53.3%; p=0.01), suggesting benefit restricted to regular PPI users. [https://pubmed.ncbi.nlm.nih.gov/38519563/]
  - A study into the effect of Lactobacillus casei Shirota in preventing antibiotic associated diarrhoea including Clostridioides difficile infection in patients with spinal cord injuries: a multicentre randomised, double-blind, placebo-controlled trial, EClinicalMedicine (2021) — Multicentre double-blind RCT in spinal-cord-injury patients found a single-strain LcS drink did NOT prevent AAD overall, with no significant difference in AAD incidence vs placebo. [https://pmc.ncbi.nlm.nih.gov/articles/PMC8435694/]
  - Daily intake of fermented milk with Lactobacillus casei strain Shirota reduces the incidence and duration of upper respiratory tract infections in healthy middle-aged office workers, European journal of nutrition (2017) — In healthy middle-aged office workers, daily LcS-fermented milk over winter significantly reduced the incidence of upper-respiratory-tract infections (22.4% vs 53.2%; p=0.002) and shortened their duration. [https://pmc.ncbi.nlm.nih.gov/articles/PMC5290054/]
  - Fermented Milk Containing Lactobacillus casei Strain Shirota Preserves the Diversity of the Gut Microbiota and Relieves Abdominal Dysfunction in Healthy Medical Students Exposed to Academic Stress, Applied and environmental microbiology (2016) — In medical students under exam stress (n=24 per arm), 8 weeks of LcS-fermented milk preserved gut-microbiota diversity and significantly suppressed stress-induced abdominal dysfunction vs placebo. [https://pubmed.ncbi.nlm.nih.gov/27208120/]
  - Probiotic Lactobacillus casei strain Shirota relieves stress-associated symptoms by modulating the gut-brain interaction in human and animal models, Neurogastroenterology & Motility (2016) — Pooled human RCT data showed LcS suppressed the pre-examination rise in salivary cortisol and reduced physical (abdominal/cold) symptoms, modulating the gut-brain axis. [https://onlinelibrary.wiley.com/doi/10.1111/nmo.12804]
  - Effect of Lactobacillus casei strain Shirota-fermented milk on metabolic abnormalities in obese prediabetic Japanese men: a randomised, double-blind, placebo-controlled trial, Bioscience of microbiota, food and health (2018) — In obese pre-diabetic Japanese men, a randomised double-blind placebo-controlled trial of LcS-fermented milk assessed effects on metabolic abnormalities, showing modest changes in glucose/metabolic markers. [https://pubmed.ncbi.nlm.nih.gov/29387517/]
  - Effects of a probiotic fermented milk beverage containing Lactobacillus casei strain Shirota on defecation frequency, intestinal microbiota, and the intestinal environment of healthy individuals with soft stools, Journal of bioscience and bioengineering (2010) — In healthy adults with soft stools, 4 weeks of LcS-fermented milk significantly hardened stool consistency vs placebo and normalised defecation frequency, with effects strongest in those tending toward constipation. [https://pubmed.ncbi.nlm.nih.gov/20580604/]
  - Use of probiotic Lactobacillus preparation to prevent diarrhoea associated with antibiotics: randomised double blind placebo controlled trial, BMJ (Clinical research ed.) (2007) — In 135 hospitalised older patients on antibiotics, LcS drink reduced antibiotic-associated diarrhoea from 34% to 12% (absolute risk reduction 22%; 95% CI 7-37%) and C. difficile diarrhoea from 17% to 0%. [https://pubmed.ncbi.nlm.nih.gov/17604300/]
  - Clinical safety of Lactobacillus casei shirota as a probiotic in critically ill children, Journal of pediatric gastroenterology and nutrition (2006) — Bacteriologic surveillance in critically ill children found no LcS colonisation or bacteraemia and good tolerability, supporting the strain's safety profile. [https://pubmed.ncbi.nlm.nih.gov/16456410/]

---

## Bacillus subtilis (Bacillus subtilis (DE111 / R0179))
URL: https://nutridex.info/s/bacillus-subtilis
Category: Probiotics, Gut & Immune
Evidence: Preliminary — Early or small human trials; promising but not yet conclusive.
Shelf-stable spore-forming probiotic with promising but still-preliminary human GI and immune data

Quick answer: Bacillus subtilis is used for reduces days of vomiting and hard stools / occasional gi discomfort in young children (de111, 1 billion cfu/day). NutriDex grades the human evidence as preliminary — Early or small human trials; promising but not yet conclusive. Based on 8 cited human studies (8 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Bacillus subtilis is a spore-forming probiotic whose acid-resistant spores survive gastric transit; both DE111 and R0179 designations have been shown in human RCTs to reach and germinate in the small intestine and to be well tolerated. The strongest data are for digestive comfort: in a 2021 RCT of 102 daycare children, DE111 (1 billion CFU/day x 8 weeks) reduced days of vomiting and hard stools versus placebo. In healthy adults, a 2021 pilot RCT (n=44) found DE111 enhanced regulatory T-cell responses but left most GI symptom and inflammation markers largely unchanged, and a 2015 R0179 dose-ranging trial (n=81) confirmed tolerability and GI survival without persistent microbiota shifts. Overall the human evidence is positive but small and pilot-grade — no large meta-analyses yet exist for these specific strains.

Benefits / uses: Reduces days of vomiting and hard stools / occasional GI discomfort in young children (DE111, 1 billion CFU/day); Eases occasional constipation and diarrhea / improves daily bowel-movement profile in healthy adults; Enhances regulatory immune responses (increased CD25+/FoxP3+ Tregs after LPS challenge) in healthy adults (DE111); Survives gastric transit and germinates in the small intestine (spore-based delivery; DE111, R0179); May improve body-fat percentage when combined with resistance training in female athletes (DE111, 5 billion CFU/day); May attenuate circulating pro-inflammatory TNF-alpha in trained athletes (DE111).
Active compounds: DE111 (Deerland, branded spore strain; 1-5 billion CFU); R0179 (Lallemand/Rosell dose-ranging strain); BS50, DG101 (other studied B. subtilis strains); Acid-resistant spore capsules, gummies, and shelf-stable powders (no refrigeration needed).
Dose: Typically 1 billion CFU/day (DE111) for GI/pediatric use, up to 5 billion CFU/day in athlete trials; R0179 well tolerated from 0.1 to 10 billion CFU/day. Taken once daily as a shelf-stable spore capsule, with or without food, over 4-8 weeks in trials.
Safety: Well tolerated across all human trials, including children 2-6 years and adults up to 10 billion CFU/day; reported adverse events (mild flatulence, transient constipation/diarrhea) were non-severe and similar to placebo. As with any live probiotic, use caution in critically ill, severely immunocompromised, or central-venous-catheter patients given theoretical bacteremia risk. Spores are cleared from the gut shortly after dosing stops and do not durably colonize.

Cited studies (8):
  - Effect of Daily Bacillus subtilis DE111 Intake on Gastrointestinal Health and Respiratory Infections in Children Attending Day-care: A Randomised, Parallel, Double-blind, Placebo-controlled Study, Journal of Probiotics & Health (2020) — RCT in 102 daycare children (1 billion CFU/day x 8 wk): fewer days of vomiting (2 vs 14) and hard stools (0 vs 15) vs placebo, supporting GI health. [https://www.longdom.org/open-access/effect-of-daily-bacillus-subtilis-de111-intake-on-gastrointestinalhealth-and-respiratory-infections-in-children-attending-daycare--59503.html]
  - Examining the Gastrointestinal and Immunomodulatory Effects of the Novel Probiotic Bacillus subtilis DE111, International journal of molecular sciences (2021) — Parallel RCT (n=44, 1 billion CFU/day x 4 wk): DE111 increased regulatory CD25+/FoxP3+ Tregs after LPS stimulation; GI symptoms and inflammation markers largely unchanged. [https://pmc.ncbi.nlm.nih.gov/articles/PMC7957723/]
  - Effects of Probiotic (Bacillus subtilis) Supplementation During Offseason Resistance Training in Female Division I Athletes, Journal of Strength and Conditioning Research (2020) — RCT in 23 female Division I athletes (5 billion CFU/day x 10 wk): greater body-fat reduction with DE111 (-2.05%) vs placebo (-0.2%), p=0.015; no performance change. [https://journals.lww.com/nsca-jscr/abstract/2020/11000/effects_of_probiotic__bacillus_subtilis_.20.aspx]
  - Presence and Germination of the Probiotic Bacillus subtilis DE111(®) in the Human Small Intestinal Tract: A Randomized, Crossover, Double-Blind, and Placebo-Controlled Study, Frontiers in microbiology (2021) — Randomized crossover DB placebo-controlled ileostomy study (n=11) confirming DE111 spores are present and germinate in the human small intestine. [https://pmc.ncbi.nlm.nih.gov/articles/PMC8366289/]
  - The Effect of Bacillus subtilis DE111 on the Daily Bowel Movement Profile for People with Occasional Gastrointestinal Irregularity, Journal of Probiotics & Health — Randomized DB placebo-controlled trial; DE111 improved daily bowel-movement profile and reduced occasional GI discomfort in healthy adults. [https://www.longdom.org/open-access/the-effect-of-embacillus-subtilisem-de111-on-the-daily-bowel-movement-profile-for-people-with-occasional-gastrointestina-36720.html]
  - Evaluation of Bacillus subtilis R0179 on gastrointestinal viability and general wellness: a randomised, double-blind, placebo-controlled trial in healthy adults, Beneficial microbes (2015) — Dose-ranging RCT (n=81, 0.1-10 billion CFU/day x 4 wk): R0179 survived GI transit and was well tolerated at all doses without persistent microbiota changes. [https://pubmed.ncbi.nlm.nih.gov/25062611/]
  - Effects of Probiotic (Bacillus subtilis DE111) Supplementation on Immune Function, Hormonal Status, and Physical Performance in Division I Baseball Players, Sports (Basel, Switzerland) (2018) — RCT in 25 male Division I baseball players (1 billion CFU/day x 12 wk): no change in body composition or performance, but attenuated circulating TNF-alpha. [https://pmc.ncbi.nlm.nih.gov/articles/PMC6162611/]
  - Spore-Based Probiotic Bacillus subtilis: Current Applications in Humans and Future Perspectives, Fermentation (2024) — Review of human applications of spore-based B. subtilis probiotics summarizing GI-symptom and microbiota effects across strains (DE111, BS50, DG101, R0179). [https://www.mdpi.com/2311-5637/10/2/78]

---

## romaine-lettuce
URL: https://nutridex.info/s/romaine-lettuce
Category: Vegetables
Evidence: Moderate — Several controlled trials; effects real but modest or context-dependent.
A crisp, ultra-low-calorie leafy green delivering outsized vitamin K, vitamin A, folate, and the eye-protective carotenoids lutein and zeaxanthin.

Quick answer: romaine-lettuce is used for supports blood-pressure regulation via dietary nitrate. NutriDex grades the human evidence as moderate — Several controlled trials; effects real but modest or context-dependent. Based on 8 cited human studies (8 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Romaine is a nutrient-dense, water-rich leafy green: a single shredded cup is roughly 8 kcal yet supplies meaningful vitamin K, provitamin-A carotenoids, and folate. As one of the higher-nitrate leafy greens, it shares the bioactive profile (dietary nitrate, lutein/zeaxanthin, vitamin K, folate) tied in human studies to lower cardiovascular risk, slower cognitive decline, and reduced progression of age-related macular degeneration. The strongest randomized evidence is indirect, coming from inorganic-nitrate and lutein/zeaxanthin trials rather than romaine itself; whole-diet leafy-green data are observational but consistent.

Nutrition (per 1 cup shredded, raw (47 g)): 8 kcal; Vitamin C 1.9mg (2% DV), Fiber 1g (4% DV), Potassium 116mg (2% DV), Folate 64µg (16% DV), Vitamin A 205µg (23% DV), Vitamin K 48µg (40% DV), Vitamin B6 0.035mg (2% DV), Manganese 0.073mg (3% DV).
Benefits / uses: Supports blood-pressure regulation via dietary nitrate; Rich in eye-protective lutein and zeaxanthin; Linked to slower age-related cognitive decline; Very low calorie, high water and folate; Associated with lower cardiovascular disease risk.
Active compounds: dietary nitrate; lutein; zeaxanthin; beta-carotene; vitamin K1 (phylloquinone); folate; kaempferol.
Dose: Standard serving: 1 cup shredded, raw (47 g). Eat whole (with skin where edible); favour whole fruit over juice.
Safety: High in vitamin K (about 48 ug per cup), which can interfere with warfarin and similar anticoagulants — keep intake consistent if on these drugs. Leafy greens including romaine have been recurrent sources of E. coli and Listeria outbreaks, so wash thoroughly and observe recalls. Oxalate content is low to moderate. Otherwise very well tolerated.

Cited studies (8):
  - The effect of green leafy and cruciferous vegetable intake on the incidence of cardiovascular disease: A meta-analysis, JRSM cardiovascular disease (2016) — Higher green leafy and cruciferous vegetable intake was associated with a 15.8% lower incidence of cardiovascular disease (RR 0.842, 95% CI 0.753-0.941). [https://pmc.ncbi.nlm.nih.gov/articles/PMC4973479/]
  - Inorganic nitrate and beetroot juice supplementation reduces blood pressure in adults: a systematic review and meta-analysis, The Journal of nutrition (2013) — Across 16 crossover trials (n=254), inorganic nitrate/beetroot supplementation reduced systolic BP by -4.4 mm Hg (95% CI -5.9 to -2.8; P<0.001), with a dose-response relationship. [https://pubmed.ncbi.nlm.nih.gov/23596162/]
  - Fruit and vegetable intake and risk of type 2 diabetes mellitus: meta-analysis of prospective cohort studies, BMJ open (2014) — Pooling 10 articles (24,013 cases; 434,342 participants), each 0.2 serving/day increase in green leafy vegetables was associated with a lower type 2 diabetes risk (RR 0.87, 95% CI 0.81-0.93). [https://pmc.ncbi.nlm.nih.gov/articles/PMC4225228/]
  - A randomized clinical trial of the effects of leafy green vegetables and inorganic nitrate on blood pressure, The American journal of clinical nutrition (2020) — In 243 adults aged 50-70 with elevated SBP, 5 weeks of leafy-green vegetables or matched inorganic nitrate pills (300 mg/d) did not significantly lower 24-h ambulatory systolic blood pressure versus low-nitrate control. [https://pmc.ncbi.nlm.nih.gov/articles/PMC7338722/]
  - Long-term Outcomes of Adding Lutein/Zeaxanthin and ω-3 Fatty Acids to the AREDS Supplements on Age-Related Macular Degeneration Progression: AREDS2 Report 28, JAMA ophthalmology (2022) — Over 10 years in AREDS2 (n=4203), lutein/zeaxanthin versus no lutein/zeaxanthin reduced progression to late age-related macular degeneration (HR 0.91, 95% CI 0.84-0.99; P=0.02). [https://pubmed.ncbi.nlm.nih.gov/35653117/]
  - Increasing Nitrate-Rich Vegetable Intake Lowers Ambulatory Blood Pressure in (pre)Hypertensive Middle-Aged and Older Adults: A 12-Wk Randomized Controlled Trial, The Journal of nutrition (2021) — A 12-week increase in nitrate-rich vegetable intake lowered ambulatory systolic blood pressure in (pre)hypertensive middle-aged and older adults compared with control. [https://pubmed.ncbi.nlm.nih.gov/34236392/]
  - Association of dietary nitrate with atherosclerotic vascular disease mortality: a prospective cohort study of older adult women, The American journal of clinical nutrition (2017) — In 1226 older women over 15 years, women in the highest tertile of vegetable-derived nitrate intake had lower atherosclerotic vascular disease mortality (HR 0.53, 95% CI 0.33-0.86) versus the lowest. [https://pubmed.ncbi.nlm.nih.gov/28566306/]
  - Nutrients and bioactives in green leafy vegetables and cognitive decline, Neurology (2018) — In 960 older adults over ~4.7 years, the highest green-leafy-vegetable quintile (~1.3 servings/d) showed slower cognitive decline (beta=0.05 standardized units/y; P=0.0001), equivalent to being ~11 years younger. [https://www.neurology.org/doi/10.1212/WNL.0000000000004815]

---

## brussels-sprouts
URL: https://nutridex.info/s/brussels-sprouts
Category: Vegetables
Evidence: Moderate — Several controlled trials; effects real but modest or context-dependent.
A vitamin K and C powerhouse delivering glucosinolate-derived sulforaphane.

Quick answer: brussels-sprouts is used for linked to lower cardiovascular disease risk. NutriDex grades the human evidence as moderate — Several controlled trials; effects real but modest or context-dependent. Based on 11 cited human studies (11 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Brussels sprouts are a glucosinolate-rich cruciferous vegetable; one raw cup supplies well over a day's vitamin K and most of a day's vitamin C for under 40 kcal. The strongest human evidence is observational: large prospective cohorts and meta-analyses link higher cruciferous-vegetable intake to lower cardiovascular disease, all-cause mortality, and colorectal cancer risk. Randomized trials of the signature bioactive (sulforaphane from cruciferous sprouts) show modest improvements in glycemic and postprandial measures, though effect sizes are small.

Nutrition (per 1 cup, raw (88 g)): 38 kcal; Vitamin C 74.8mg (83% DV), Fiber 3.3g (12% DV), Potassium 342mg (7% DV), Folate 54µg (14% DV), Vitamin A 33µg (4% DV), Vitamin K 156µg (130% DV), Vitamin B6 0.19mg (11% DV), Manganese 0.3mg (13% DV).
Benefits / uses: Linked to lower cardiovascular disease risk; Associated with reduced all-cause mortality; Inversely associated with colorectal cancer; Modest postprandial glycemic benefit; Exceptional vitamin K and vitamin C source.
Active compounds: sulforaphane; glucosinolates (glucobrassicin, sinigrin); indole-3-carbinol; kaempferol; vitamin C; vitamin K1 (phylloquinone).
Dose: Standard serving: 1 cup, raw (88 g). Eat whole (with skin where edible); favour whole fruit over juice.
Safety: Very high in vitamin K1 (~156 µg per raw cup), which can antagonize warfarin — patients on vitamin K antagonists should keep intake consistent. Raw cruciferous vegetables contain goitrogens that may affect thyroid function in iodine-deficient individuals at high intakes. As a fermentable-fiber (FODMAP) food, large servings can cause bloating/gas in sensitive people. Glucosinolate intake has been linked to higher type 2 diabetes risk in some cohorts, so claims should stay measured.

Cited studies (11):
  - Unveiling the Effects of Cruciferous Vegetable Intake on Different Cancers: A Systematic Review and Dose-Response Meta-analysis, Nutrition reviews (2025) — Systematic review and dose-response meta-analysis: higher cruciferous vegetable intake was associated with lower overall cancer risk (pooled OR 0.77; RR 0.96), with optimal protective intakes of ~3-7.4 servings/week depending on cancer site. [https://pubmed.ncbi.nlm.nih.gov/39348271/]
  - Effect of cruciferous vegetable intake on cancer: An umbrella review of meta-analysis, Journal of food science (2024) — Umbrella review of 22 meta-analyses (175 independent cancer studies) found cruciferous vegetable intake associated with reduced risk across multiple cancers, while flagging heterogeneity and inconsistency in prior evidence. [https://pubmed.ncbi.nlm.nih.gov/39138635/]
  - The effect of green leafy and cruciferous vegetable intake on the incidence of cardiovascular disease: A meta-analysis, JRSM cardiovascular disease (2016) — Meta-analysis of 8 cohort/case-control studies (>540,000 participants, 26,173 CVD cases): highest vs lowest green leafy/cruciferous vegetable intake gave pooled RR 0.842 (95% CI 0.753–0.941) for cardiovascular disease incidence (~15.8% lower). [https://pmc.ncbi.nlm.nih.gov/articles/PMC4973479/]
  - Fruit and vegetable intake and the risk of cardiovascular disease, total cancer and all-cause mortality—a systematic review and dose-response meta-analysis of prospective studies, International Journal of Epidemiology (2017) — Systematic review and dose-response meta-analysis of prospective studies: cruciferous vegetables among the vegetable subtypes most strongly inversely associated with cardiovascular disease, total cancer, and all-cause mortality. [https://academic.oup.com/ije/article/46/3/1029/3039477]
  - Cruciferous vegetables intake and the risk of colorectal cancer: a meta-analysis of observational studies, Annals of oncology : official journal of the European Society for Medical Oncology (2013) — Meta-analysis of 35 observational studies: high vs low cruciferous vegetable intake associated with ~18% lower colorectal cancer risk (pooled RR 0.82, 95% CI 0.75–0.90). [https://pubmed.ncbi.nlm.nih.gov/23211939/]
  - Effect of broccoli sprout extract and baseline gut microbiota on fasting blood glucose in prediabetes: a randomized, placebo-controlled trial, Nature microbiology (2025) — Randomized double-blind placebo-controlled trial in prediabetes (n=89): broccoli sprout extract (150 µmol sulforaphane/day, 12 weeks) lowered fasting blood glucose by 0.2 mmol/L vs placebo (95% CI −0.44 to −0.01; P=0.04); larger 0.4 mmol/L effect in a metabolic subgroup. [https://pmc.ncbi.nlm.nih.gov/articles/PMC11879859/]
  - Cruciferous vegetables improve glycaemic control compared to root/squash vegetables in a randomized, controlled, crossover trial: The VEgetableS for vaScular hEaLth (VESSEL) study, Diabetes, obesity & metabolism (2025) — Randomized controlled crossover trial (VESSEL, n=18): 300 g/day cruciferous vs root/squash vegetables for 2 weeks reduced 2-hour postprandial glucose by 0.14 mmol/L (95% CI −0.24 to −0.04; P=0.005) and glycemic variability by 2.0% (95% CI −2.8 to −1.1). [https://pubmed.ncbi.nlm.nih.gov/40375391/]
  - Cruciferous vegetables lower blood pressure in adults with mildly elevated blood pressure in a randomized, controlled, crossover trial: the VEgetableS for vaScular hEaLth (VESSEL) study, BMC Medicine (2024) — Randomized controlled crossover trial in adults with mildly elevated BP (n=18): ~300 g/day cruciferous vs root/squash vegetables for 2 weeks reduced 24-hour brachial systolic blood pressure by 2.5 mmHg (95% CI -4.2 to -0.8; P=0.005). [https://link.springer.com/article/10.1186/s12916-024-03577-8]
  - Cruciferous vegetable intake is inversely associated with extensive abdominal aortic calcification in elderly women: a cross-sectional study, The British journal of nutrition (2021) — Cross-sectional study of 684 older women (mean age 74.9; cruciferous group incl. cabbage, Brussels sprouts, cauliflower, broccoli): higher cruciferous vegetable intake was associated with lower odds of extensive abdominal aortic calcification (AAC24 score >=6). [https://pmc.ncbi.nlm.nih.gov/articles/PMC7844610/]
  - Dietary glucosinolates and risk of type 2 diabetes in 3 prospective cohort studies, The American journal of clinical nutrition (2018) — Pooled analysis of 3 large US prospective cohorts: higher cruciferous vegetable and glucosinolate intake showed only borderline associations with type 2 diabetes, with some signals toward higher risk at high glucosinolate intake — tempering glycemic claims. [https://pmc.ncbi.nlm.nih.gov/articles/PMC6669329/]
  - Cruciferous vegetable consumption is associated with a reduced risk of total and cardiovascular disease mortality, The American journal of clinical nutrition (2011) — Pooled prospective analysis of the Shanghai Women's and Men's Health Studies (134,796 adults): highest vs lowest cruciferous vegetable intake associated with lower all-cause mortality (men HR 0.86, 95% CI 0.80–0.93; women HR 0.89, 95% CI 0.81–0.98), driven largely by CVD mortality. [https://pubmed.ncbi.nlm.nih.gov/21593509/]

---

## pumpkin
URL: https://nutridex.info/s/pumpkin
Category: Vegetables
Evidence: Moderate — Several controlled trials; effects real but modest or context-dependent.
A low-calorie, beta-carotene powerhouse whose seeds are the best-studied part for prostate and urinary health.

Quick answer: pumpkin is used for very high provitamin-a / carotenoid content. NutriDex grades the human evidence as moderate — Several controlled trials; effects real but modest or context-dependent. Based on 11 cited human studies (11 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Pumpkin flesh is very low in calories yet exceptionally rich in provitamin-A carotenoids (beta-carotene, alpha-carotene, lutein/zeaxanthin), delivering well over a day's vitamin A in a single cup. The strongest human evidence centers on pumpkin seed oil/extract: randomized and controlled trials show modest improvements in lower-urinary-tract symptoms of benign prostatic hyperplasia, and small RCTs suggest favorable effects on HDL cholesterol, blood pressure, and androgenetic-alopecia hair growth. Glycemic and broader cardiometabolic benefits of the flesh remain inconsistent and based largely on small or controlled (non-randomized) trials.

Nutrition (per 1 cup mashed, cooked (boiled, drained) (245 g)): 49 kcal; Vitamin C 11.5mg (13% DV), Fiber 2.7g (10% DV), Potassium 564mg (12% DV), Folate 22µg (6% DV), Vitamin A 706µg (78% DV), Vitamin K 2µg (2% DV), Vitamin B6 0.1mg (6% DV), Manganese 0.22mg (10% DV).
Benefits / uses: Very high provitamin-A / carotenoid content; Low energy density, high water content; Pumpkin-seed extracts may ease prostate/urinary symptoms; Seed oil linked to higher HDL and lower blood pressure; Source of potassium and lutein/zeaxanthin.
Active compounds: beta-carotene; alpha-carotene; lutein; zeaxanthin; phytosterols (delta-7-sterols); tocopherols; cucurbitin.
Dose: Standard serving: 1 cup mashed, cooked (boiled, drained) (245 g). Eat whole (with skin where edible); favour whole fruit over juice.
Safety: Generally very safe as a food. Pumpkin seed oil is a concentrated supplement; doses used in trials (about 360 mg twice daily to 2 g/day) far exceed culinary intake. Seed allergy is possible. As with other vitamin-A-rich foods, the carotenoids in flesh are non-toxic, but very high intake of orange vegetables can cause harmless carotenemia (yellow-orange skin).

Cited studies (11):
  - Effects of Pumpkin (Cucurbita spp.) on Glycemic and Type 2 Diabetes–Related Metabolic Biomarkers: A Systematic Review of Controlled Clinical Trials, Nutrition Reviews (2026) — Systematic review of controlled clinical trials concluded that pumpkin's effects on glycemic control and type-2-diabetes biomarkers remain inconsistent, with low-quality and mixed results. [https://academic.oup.com/nutritionreviews/advance-article-abstract/doi/10.1093/nutrit/nuag027/8586671]
  - Beneficial effects of pumpkin seed soft extract on lower urinary tract symptoms and quality of life in men with benign prostatic hyperplasia: a meta-analysis of two randomized, placebo-controlled trials over 12 months, Clinical Phytoscience (2022) — Pooled analysis of two 12-month placebo-controlled RCTs found pumpkin seed soft extract significantly reduced IPSS for lower-urinary-tract symptoms in BPH versus placebo, with improved quality of life. [https://link.springer.com/article/10.1186/s40816-022-00345-0]
  - Pumpkin seed oil (Cucurbita pepo) versus tamsulosin for benign prostatic hyperplasia symptom relief: a single-blind randomized clinical trial, BMC urology (2021) — Single-blind RCT comparing pumpkin seed oil (Cucurbita pepo, 360 mg twice daily) to tamsulosin for benign prostatic hyperplasia found both reduced International Prostate Symptom Score over 3 months, with pumpkin seed oil offering symptom relief without tamsulosin's side-effect profile. [https://pmc.ncbi.nlm.nih.gov/articles/PMC8527717/]
  - Effects of pumpkin seed in men with lower urinary tract symptoms due to benign prostatic hyperplasia in the one-year, randomized, placebo-controlled GRANU study, Urologia internationalis (2015) — One-year randomized placebo-controlled trial in 1,431 men with BPH/LUTS: pumpkin seed reduced IPSS more than placebo (-6.8 vs -5.2 points), a significant but clinically modest difference. [https://pubmed.ncbi.nlm.nih.gov/25196580/]
  - Effects of an Oil-Free Hydroethanolic Pumpkin Seed Extract on Symptom Frequency and Severity in Men with Benign Prostatic Hyperplasia: A Pilot Study in Humans, Journal of medicinal food (2019) — In 60 men with BPH, 12 weeks of an oil-free hydroethanolic pumpkin seed extract reduced IPSS by 30.1% and lowered post-void residual urine volume (83.7 to 63.1 mL). [https://pmc.ncbi.nlm.nih.gov/articles/PMC6590724/]
  - The effects of pumpkin seed oil supplementation on arterial hemodynamics, stiffness and cardiac autonomic function in postmenopausal women, Complementary therapies in clinical practice (2019) — Randomized trial of pumpkin seed oil supplementation in postmenopausal women reported favorable effects on arterial hemodynamics and cardiac autonomic function versus control. [https://pubmed.ncbi.nlm.nih.gov/31445363/]
  - Clinical study of effectiveness and safety of CELcomplex(®) containing Cucurbita Pepo Seed extract and Flax and Casuarina on stress urinary incontinence in women, Journal of traditional and complementary medicine (2019) — Clinical study of a Cucurbita pepo seed extract plus flax and Casuarina (CELcomplex) reported improved effectiveness and safety for stress urinary incontinence in women. [https://pmc.ncbi.nlm.nih.gov/articles/PMC6435946/]
  - Effect of pumpkin seed oil on hair growth in men with androgenetic alopecia: a randomized, double-blind, placebo-controlled trial, Evidence-based complementary and alternative medicine : eCAM (2014) — Randomized, double-blind, placebo-controlled trial in 76 men with androgenetic alopecia: 400 mg/day pumpkin seed oil for 24 weeks increased mean hair count by ~40% versus ~10% with placebo. [https://pmc.ncbi.nlm.nih.gov/articles/PMC4017725/]
  - Improvement in HDL cholesterol in postmenopausal women supplemented with pumpkin seed oil: pilot study, Climacteric (2011) — In 35 postmenopausal women, 12 weeks of 2 g/day pumpkin seed oil significantly raised HDL cholesterol (0.92 to 1.07 mmol/L) and lowered diastolic blood pressure versus wheat-germ-oil control. [https://www.tandfonline.com/doi/abs/10.3109/13697137.2011.563882]
  - Extract from Cucurbita pepo improves BPH symptoms without affecting sexual function: a 24-month noninterventional study, World journal of urology (2022) — 24-month noninterventional study of a Cucurbita pepo seed extract in men reported improvement in BPH lower urinary tract symptoms without adverse effects on sexual function. [https://pmc.ncbi.nlm.nih.gov/articles/PMC9236993/]
  - Cucurbita pepo-Rhus aromatica-Humulus lupulus Combination Reduces Overactive Bladder Symptoms in Women - A Noninterventional Study, Planta medica (2019) — 12-week noninterventional study of a Cucurbita pepo-Rhus aromatica-Humulus lupulus combination in women with overactive bladder showed significant reductions in daytime and nighttime urination frequency after treatment. [https://pubmed.ncbi.nlm.nih.gov/31261419/]

---

## bell-pepper
URL: https://nutridex.info/s/bell-pepper
Category: Vegetables
Evidence: Moderate — Several controlled trials; effects real but modest or context-dependent.
A vitamin-C powerhouse — one red pepper delivers nearly double a full day's vitamin C for just 31 calories.

Quick answer: bell-pepper is used for exceptional vitamin c density (~170% rda per pepper). NutriDex grades the human evidence as moderate — Several controlled trials; effects real but modest or context-dependent. Based on 8 cited human studies (8 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Red bell pepper is among the most vitamin-C-dense common vegetables, with a single medium pepper supplying roughly 150 mg (about 170% of the adult RDA) plus provitamin-A carotenoids, vitamin B6 and folate. The strongest human evidence relates to its signature nutrient, vitamin C: pooled randomized trials show modest blood-pressure lowering, and large prospective cohorts link higher dietary and circulating vitamin C to lower cardiovascular and stroke mortality. Evidence specific to the Capsicum genus (chili/capsaicin trials) is more preliminary and heterogeneous, and bell peppers themselves are sweet and non-pungent, so most of the rigorous data is for the vitamin and carotenoid content rather than capsaicin.

Nutrition (per 1 medium red bell pepper, raw (119 g)): 31 kcal; Vitamin C 152mg (169% DV), Fiber 2.5g (9% DV), Potassium 251mg (5% DV), Folate 55µg (14% DV), Vitamin A 187µg (21% DV), Vitamin K 5.8µg (5% DV), Vitamin B6 0.35mg (21% DV), Manganese 0.13mg (6% DV).
Benefits / uses: Exceptional vitamin C density (~170% RDA per pepper); Modest blood-pressure lowering via vitamin C; Associated with lower stroke and cardiovascular mortality; Provitamin-A carotenoids for eye and skin health; Very low calorie, high water and fiber.
Active compounds: vitamin C (ascorbic acid); capsanthin; beta-carotene; lutein; zeaxanthin; quercetin; luteolin.
Dose: Standard serving: 1 medium red bell pepper, raw (119 g). Eat whole (with skin where edible); favour whole fruit over juice.
Safety: Generally very safe and well tolerated. Bell peppers are nightshades (Solanaceae) and contain trace solanine-type alkaloids, but at negligible levels; some people report digestive discomfort or report nightshade sensitivity. Raw peppers are a moderate source of fructose and can trigger symptoms in people with FODMAP sensitivity or IBS. Birch-pollen-allergic individuals may experience oral allergy syndrome. Vitamin K content is low, so no meaningful warfarin interaction.

Cited studies (8):
  - Effects of dietary pulse consumption on body weight: a systematic review and meta-analysis of randomized controlled trials, The American Journal of Clinical Nutrition (2016) — Pooled RCTs (median 500 mg/d, ~8 wk) found vitamin C supplementation reduced systolic BP by -3.84 mmHg (95% CI -5.29 to -2.38) and diastolic BP by -1.48 mmHg (95% CI -2.86 to -0.10). [https://ajcn.nutrition.org/article/S0002-9165(23)02774-0/fulltext]
  - The effect of red pepper/capsaicin on cardiovascular risk factors: a systematic review, meta-analysis, and GRADE assessment, Nutrition, metabolism, and cardiovascular diseases : NMCD (2026) — Systematic review with GRADE of RCTs found red pepper/capsaicin produced only modest, statistically unstable reductions in total cholesterol and diastolic BP that became non-significant on sensitivity analysis (low certainty). [https://pubmed.ncbi.nlm.nih.gov/41856833/]
  - Meta-analysis evaluating the impact of chili-pepper intake on all-cause and cardiovascular mortality: A systematic review, Annals of medicine and surgery (2012) (2021) — Pooled prospective cohorts found higher chili-pepper (Capsicum) intake associated with lower all-cause mortality (HR ~0.75) and cardiovascular mortality, supporting Capsicum-genus cardiometabolic signals. [https://pmc.ncbi.nlm.nih.gov/articles/PMC8463741/]
  - Dietary and circulating vitamin C, vitamin E, β-carotene and risk of total cardiovascular mortality: a systematic review and dose-response meta-analysis of prospective observational studies, Public health nutrition (2019) — Dose-response meta-analysis of 18 cohorts (320,548 participants) linked highest vs lowest vitamin C intake to 21% lower cardiovascular mortality (RR 0.79, 95% CI 0.68-0.89); circulating vitamin C RR 0.60 (95% CI 0.42-0.78). [https://pubmed.ncbi.nlm.nih.gov/30630552/]
  - Dietary and circulating vitamin C, vitamin E, β-carotene and risk of total cardiovascular mortality: a systematic review and dose-response meta-analysis of prospective observational studies, Public health nutrition (2019) — Updated meta-analysis confirming inverse dose-response between dietary/circulating vitamin C and total cardiovascular mortality, with apparent threshold near ~200 mg/day intake. [https://pubmed.ncbi.nlm.nih.gov/30630552/]
  - Vitamin C Intake, Circulating Vitamin C and Risk of Stroke: A Meta-Analysis of Prospective Studies, Journal of the American Heart Association (2013) — Across 217,454 participants, high vs low dietary vitamin C was associated with lower stroke risk (RR 0.81, 95% CI 0.74-0.90); circulating vitamin C RR 0.62 (95% CI 0.49-0.79). [https://www.ahajournals.org/doi/10.1161/jaha.113.000329]
  - Effect of oral vitamin C supplementation on serum uric acid: a meta-analysis of randomized controlled trials, Arthritis care & research (2011) — Meta-analysis of 13 RCTs (556 participants, median 500 mg/d for 30 d) found vitamin C supplementation significantly lowered serum uric acid by -0.35 mg/dL (95% CI -0.66 to -0.04). [https://pmc.ncbi.nlm.nih.gov/articles/PMC3169708/]
  - Vitamin C for preventing and treating the common cold, Cochrane Database of Systematic Reviews (2013) — Regular vitamin C did not prevent colds in the general population but shortened cold duration by 8% in adults and 14% in children; halved cold risk in people under extreme physical stress. [https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD000980.pub4/full]

---

## cucumber
URL: https://nutridex.info/s/cucumber
Category: Vegetables
Evidence: Preliminary — Early or small human trials; promising but not yet conclusive.
Mostly water and crunch — a near-zero-calorie hydrator with modest potassium and vitamin K.

Quick answer: cucumber is used for very low energy density aids satiety and weight control. NutriDex grades the human evidence as preliminary — Early or small human trials; promising but not yet conclusive. Based on 10 cited human studies (10 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Cucumber is roughly 95% water and one of the lowest-energy-density foods in the diet, which is its main evidence-based virtue: it adds volume, hydration and crunch for almost no calories. Direct human trials are small — a few RCTs of concentrated cucumber seed extract or juice report improved lipids and glycemic markers, but doses far exceed culinary intake and the studies are underpowered. The strongest applicable evidence is indirect: large dose-response meta-analyses show higher overall vegetable intake is associated with lower cardiovascular disease and all-cause mortality.

Nutrition (per 1 cup sliced, raw with peel (104 g)): 16 kcal; Vitamin C 2.9mg (3% DV), Fiber 0.5g (2% DV), Potassium 153mg (3% DV), Folate 7µg (2% DV), Vitamin A 4µg (0% DV), Vitamin K 17µg (14% DV), Vitamin B6 0.04mg (2% DV), Manganese 0.08mg (3% DV).
Benefits / uses: Very low energy density aids satiety and weight control; High water content supports hydration; Modest potassium and vitamin K; Concentrated extracts may improve lipids (small RCTs); Adds vegetable volume linked to lower CVD risk.
Active compounds: cucurbitacins; fisetin; cucumegastigmanes; lutein; vitexin/orientin flavonoids.
Dose: Standard serving: 1 cup sliced, raw with peel (104 g). Eat whole (with skin where edible); favour whole fruit over juice.
Safety: Generally very safe and well tolerated. Provides vitamin K (~17 ug/cup), relevant for patients on warfarin who should keep intake consistent. Cucurbitacins can make some varieties bitter and, rarely, cause GI upset. Mild oral-allergy/cross-reactivity (ragweed/melon) is possible in sensitized individuals.

Cited studies (10):
  - Efficacy and Safety of Topical Application of Plant-Based Products on Skin Aging in Healthy Individuals: A Systematic Review and Meta-Analysis of Randomized Controlled Trials, Journal of cosmetic dermatology (2025) — Systematic review and meta-analysis of RCTs of topical plant-based products (incl. cucumber) found significant improvement in skin hydration and elasticity and reduced melanin/erythema, but no significant effect on transepidermal water loss. [https://pmc.ncbi.nlm.nih.gov/articles/PMC11845950/]
  - Effects of oral intake fruit or fruit extract on skin aging in healthy adults: a systematic review and Meta-analysis of randomized controlled trials, Frontiers in nutrition (2023) — Systematic review and meta-analysis of RCTs found oral intake of fruit or fruit extracts improved skin elasticity and hydration parameters in healthy adults. [https://pmc.ncbi.nlm.nih.gov/articles/PMC10436291/]
  - Fruit and vegetable intake and the risk of cardiovascular disease, total cancer and all-cause mortality—a systematic review and dose-response meta-analysis of prospective studies, International Journal of Epidemiology (2017) — Dose-response meta-analysis of 95 cohort studies: each 200 g/day increase in fruit and vegetable intake was associated with 8% lower CVD (RR 0.92) and 10% lower all-cause mortality (RR 0.90), with benefit up to ~800 g/day. [https://doi.org/10.1093/ije/dyw319]
  - Fruit and vegetable consumption and risk of cardiovascular disease: A meta-analysis of prospective cohort studies, Critical reviews in food science and nutrition (2017) — Meta-analysis of prospective cohorts (38 studies, 1,498,909 participants): highest vs lowest vegetable intake was associated with 13% lower cardiovascular disease risk (RR 0.87, 95% CI 0.83-0.91). [https://pubmed.ncbi.nlm.nih.gov/26114864/]
  - Fruit and vegetable consumption and mortality from all causes, cardiovascular disease, and cancer: systematic review and dose-response meta-analysis of prospective cohort studies, BMJ (Clinical research ed.) (2014) — BMJ dose-response meta-analysis (16 cohorts, 833,234 participants): each additional daily serving of vegetables was associated with a 5% lower all-cause mortality (RR 0.95, 95% CI 0.92-0.99), plateauing near five servings/day. [https://pubmed.ncbi.nlm.nih.gov/25073782/]
  - Separate and Combined Effects of Resistance Training and Cucumber (Cucumis sativus) Juice Consumption on the Diabetic Indicators and Lipid Profile in Women with Type 2 Diabetes, Journal of Kermanshah University of Medical Sciences (2023) — In a randomized trial of women with type 2 diabetes (n=40), cucumber juice consumption significantly reduced fasting blood sugar, HbA1c, triglycerides, total cholesterol and LDL and raised HDL (P<0.05), with greater effect combined with resistance training. [https://doi.org/10.5812/jkums-137856]
  - Effectiveness of Cucumis sativus L. Supplementation on Mild to Moderate Joint Pain: A Randomized, Double-Blind, Placebo-Controlled Study, Cureus (2025) — Double-blind RCT in 80 adults with mild-moderate joint pain: 60 days of standardized Cucumis sativus extract (Q-actin, 20 mg/d, >1% idoBR1) improved WOMAC, Brief Pain Inventory and Pain Disability Index versus placebo (e.g. WOMAC +31.8% vs placebo -14.3%). [https://pubmed.ncbi.nlm.nih.gov/41040766/]
  - Effectiveness of Cucumis sativus L. Supplementation on Mood, Anxiety, and Sleep Quality: A Randomized Double-Blind Placebo-Controlled Study, Health science reports (2025) — CONSORT-compliant double-blind RCT (n=80, mean age 50): 60 days of Cucumis sativus L. extract (20 mg/d) produced greater improvements than placebo in fatigue, mood, sleep quality, perceived stress, anxiety, and health-related quality of life. [https://pmc.ncbi.nlm.nih.gov/articles/PMC12239509/]
  - Evaluation of the Effects of Cucumis sativus Seed Extract on Serum Lipids in Adult Hyperlipidemic Patients: A Randomized Double-Blind Placebo-Controlled Clinical Trial, Journal of food science (2017) — In a 6-week double-blind RCT (n=47), 500 mg/day cucumber (Cucumis sativus) seed extract significantly lowered total cholesterol (P=0.016), LDL-C (P<0.001) and triglycerides (P<0.001) and raised HDL-C (P=0.012) vs placebo. [https://pubmed.ncbi.nlm.nih.gov/27886382/]
  - Potential of cucurbitacin as an anticancer drug, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie (2023) — Review of cucurbitacins (triterpenoids abundant in Cucurbitaceae including cucumber): preclinical and mechanistic data show pro-apoptotic, anti-proliferative and JAK/STAT-inhibiting anticancer activity, with no confirmatory human trials to date. [https://pubmed.ncbi.nlm.nih.gov/37862969/]

---

## cabbage
URL: https://nutridex.info/s/cabbage
Category: Vegetables
Evidence: Moderate — Several controlled trials; effects real but modest or context-dependent.
A humble cruciferous staple with glucosinolate-driven cardiovascular and cancer-protective signals.

Quick answer: cabbage is used for modest blood-pressure lowering (cruciferous rct). NutriDex grades the human evidence as moderate — Several controlled trials; effects real but modest or context-dependent. Based on 13 cited human studies (13 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Cabbage is a low-calorie cruciferous vegetable that delivers vitamin C, vitamin K, and folate alongside glucosinolates that break down into bioactive isothiocyanates. Human evidence is strongest at the cruciferous-vegetable class level: a controlled crossover RCT showed daily cruciferous intake modestly lowers blood pressure, and large meta-analyses link higher cruciferous consumption with lower cardiovascular disease incidence and reduced colorectal and gastric cancer risk. Diabetes evidence is mixed and not yet convincing.

Nutrition (per 1 cup chopped, raw (89 g)): 22 kcal; Vitamin C 32.6mg (36% DV), Fiber 2.2g (8% DV), Potassium 151mg (3% DV), Folate 38µg (10% DV), Vitamin A 4µg (0% DV), Vitamin K 67.6µg (56% DV), Vitamin B6 0.11mg (6% DV), Manganese 0.14mg (6% DV).
Benefits / uses: Modest blood-pressure lowering (cruciferous RCT); Lower cardiovascular disease incidence in cohorts; Reduced colorectal and gastric cancer risk; Very low energy, good fiber and vitamin C; Excellent source of vitamin K and folate.
Active compounds: glucosinolates (sinigrin, glucobrassicin); sulforaphane; indole-3-carbinol; isothiocyanates; vitamin C; vitamin K1; anthocyanins (red cabbage).
Dose: Standard serving: 1 cup chopped, raw (89 g). Eat whole (with skin where edible); favour whole fruit over juice.
Safety: Raw cruciferous vegetables contain goitrogens that may affect thyroid function at very high intakes, mainly with iodine deficiency. High vitamin K content can interfere with warfarin dosing—keep intake consistent. Cabbage is a high-FODMAP food (raffinose/fructans) that can cause gas and bloating in sensitive or IBS individuals.

Cited studies (13):
  - Effect of cruciferous vegetable intake on cancer: An umbrella review of meta-analysis, Journal of food science (2024) — Umbrella review of 22 meta-analyses (175 cancer studies) found cruciferous vegetable intake associated with reduced cancer risk (pooled OR 0.77; RR 0.96), with signals across lung, gastric, prostate, breast, endometrial, ovarian cancer and renal cell carcinoma. [https://pubmed.ncbi.nlm.nih.gov/39138635/]
  - Unveiling the Effects of Cruciferous Vegetable Intake on Different Cancers: A Systematic Review and Dose-Response Meta-analysis, Nutrition reviews (2025) — Systematic review and dose-response meta-analysis (Nutrition Reviews) identified protective cruciferous vegetable intake thresholds, e.g. ~5.41 servings/week for colorectal and lung cancer and ~3 servings/week for prostate cancer. [https://pubmed.ncbi.nlm.nih.gov/39348271/]
  - The Intake of Cruciferous Vegetables and the Risk of Ovarian Cancer: A Systematic Review and Dose-Response Meta-Analysis, Gynecologic and obstetric investigation (2024) — Dose-response meta-analysis (7 cohort + 7 case-control studies; 7,269 cases) found highest vs lowest cruciferous vegetable intake associated with a combined relative risk of 0.90 (95%CI 0.84-0.96) for ovarian cancer. [https://pubmed.ncbi.nlm.nih.gov/38479372/]
  - Cruciferous vegetables intake and risk of colon cancer: a dose–response meta-analysis, BMC Gastroenterology (2025) — Updated dose-response meta-analysis (BMC Gastroenterology 2025) found higher cruciferous vegetable intake inversely associated with colon cancer risk. [https://link.springer.com/article/10.1186/s12876-025-04163-9]
  - The effect of green leafy and cruciferous vegetable intake on the incidence of cardiovascular disease: A meta-analysis, JRSM cardiovascular disease (2016) — Meta-analysis of 8 cohorts: higher green-leafy/cruciferous vegetable intake associated with 15.8% lower CVD incidence (RR 0.842, 95% CI 0.753-0.941). [https://pmc.ncbi.nlm.nih.gov/articles/PMC4973479/]
  - Green leafy and cruciferous vegetable consumption and risk of type 2 diabetes: results from the Singapore Chinese Health Study and meta-analysis, The British journal of nutrition (2018) — Singapore Chinese Health Study plus meta-analysis (11 cohorts, ~754,000 participants): high cruciferous intake associated with ~13% lower type 2 diabetes risk, though heterogeneity was high. [https://pubmed.ncbi.nlm.nih.gov/29457582/]
  - Cruciferous vegetables intake and the risk of colorectal cancer: a meta-analysis of observational studies, Annals of oncology : official journal of the European Society for Medical Oncology (2013) — Meta-analysis of 35 studies: highest vs lowest cruciferous intake associated with reduced colorectal cancer risk (RR 0.82, 95% CI 0.75-0.90). [https://pubmed.ncbi.nlm.nih.gov/23211939/]
  - Cruciferous vegetable consumption and gastric cancer risk: a meta-analysis of epidemiological studies, Cancer science (2013) — Meta-analysis of epidemiological studies: high cruciferous vegetable consumption inversely associated with gastric cancer risk (RR 0.81, 95% CI 0.75-0.88). [https://pubmed.ncbi.nlm.nih.gov/23679348/]
  - Cruciferous vegetables lower blood pressure in adults with mildly elevated blood pressure in a randomized, controlled, crossover trial: the VEgetableS for vaScular hEaLth (VESSEL) study, BMC medicine (2024) — Crossover RCT (n=17): 300 g/day cruciferous vegetables for 2 weeks lowered 24-h systolic BP by 2.5 mmHg (95% CI -4.1 to -0.9) vs root/squash vegetables. [https://pmc.ncbi.nlm.nih.gov/articles/PMC11367748/]
  - Cruciferous vegetables lower blood pressure in adults with mildly elevated blood pressure in a randomized, controlled, crossover trial: the VEgetableS for vaScular hEaLth (VESSEL) study, BMC medicine (2024) — In a randomized controlled crossover trial of 18 adults with mildly elevated BP, ~300 g/day cruciferous vegetables (including cabbage) for 2 weeks lowered 24-h brachial systolic BP by 2.5 mmHg (95%CI -4.2, -0.9; P=0.002) vs root/squash vegetables. [https://pmc.ncbi.nlm.nih.gov/articles/PMC11367748/]
  - Cruciferous vegetables lower blood pressure in adults with mildly elevated blood pressure in a randomized, controlled, crossover trial: the VEgetableS for vaScular hEaLth (VESSEL) study, BMC Medicine (2024) — Cruciferous vegetable intervention also significantly reduced serum triglycerides by 0.2 mmol/L (95%CI -0.4, -0.0; P=0.047) vs control in adults with mildly elevated blood pressure. [https://link.springer.com/article/10.1186/s12916-024-03577-8]
  - Cruciferous and Total Vegetable Intakes Are Inversely Associated With Subclinical Atherosclerosis in Older Adult Women, Journal of the American Heart Association (2018) — Cross-sectional cohort of older women (n=684): each 10 g/day higher cruciferous vegetable intake associated with 0.8% lower carotid plaque/subclinical atherosclerosis burden. [https://www.ahajournals.org/doi/10.1161/jaha.117.008391]
  - Cruciferous vegetable consumption is associated with a reduced risk of total and cardiovascular disease mortality, The American journal of clinical nutrition (2011) — Prospective cohorts of Chinese women and men: higher cruciferous vegetable intake associated with lower total and cardiovascular disease mortality. [https://pmc.ncbi.nlm.nih.gov/articles/PMC3127519/]

---

## green-peas
URL: https://nutridex.info/s/green-peas
Category: Vegetables
Evidence: Strong — Multiple high-quality RCTs / meta-analyses with consistent effects.
A protein-and-fibre-dense pulse with solid RCT evidence for lower cholesterol and steadier blood sugar.

Quick answer: green-peas is used for pulse-rich diets lower ldl cholesterol by ~5% vs control (rct meta-analysis). NutriDex grades the human evidence as strong — Multiple high-quality RCTs / meta-analyses with consistent effects. Based on 8 cited human studies (8 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Green peas are a starchy legume (pulse) whose human evidence is among the stronger in the vegetable world because peas fall within the broader pulse literature studied in dozens of randomized trials. Pooled RCTs show that pulse-rich diets at about one serving (~130 g) per day modestly lower LDL cholesterol and improve fasting glucose, HbA1c and insulin resistance, with the largest glycemic benefit in people with type 2 diabetes. Meta-analyses also link pulses to small but significant body-weight reduction even without intentional calorie restriction, driven by their high fibre and protein and low glycemic index. Large prospective cohorts on legumes and hard cardiovascular/diabetes endpoints are less consistent (suggestive of null), so the strongest, most causal signal is on intermediate cardiometabolic markers rather than disease events.

Nutrition (per 1 cup, boiled (160 g)): 134 kcal; Vitamin C 22.7mg (25% DV), Fiber 8.8g (31% DV), Potassium 434mg (9% DV), Folate 101µg (25% DV), Vitamin A 64µg (7% DV), Vitamin K 41.4µg (35% DV), Vitamin B6 0.35mg (21% DV), Manganese 0.84mg (37% DV).
Benefits / uses: Pulse-rich diets lower LDL cholesterol by ~5% vs control (RCT meta-analysis); Improve fasting glucose, HbA1c and insulin resistance, especially in type 2 diabetes; Modest weight reduction even without calorie restriction; High plant protein (~8.6 g/cup) and fibre (~8.8 g/cup) promote satiety; Rich in folate, vitamin K, vitamin C and manganese.
Active compounds: Soluble and insoluble dietary fibre; Resistant starch; Plant protein (globulins, albumins); Folate; Vitamin K1 (phylloquinone); Lutein and zeaxanthin (carotenoids); Polyphenols (flavonols, phenolic acids); Saponins.
Dose: Standard serving: 1 cup, boiled (160 g). Eat whole (with skin where edible); favour whole fruit over juice.
Safety: Generally very safe and recommended within heart-healthy and diabetes diets. As a legume, peas are high in fermentable carbohydrates (FODMAPs, including galacto-oligosaccharides) and can cause gas or bloating, particularly in IBS or with large portions. They are a meaningful source of vitamin K (~41 ug/cup), so people on warfarin should keep intake consistent rather than avoid it. Peas are purine-containing and count toward carbohydrate intake for those managing blood glucose. Legume allergy is uncommon but possible.

Cited studies (8):
  - Legume consumption in adults and risk of cardiovascular disease and type 2 diabetes: a systematic review and meta-analysis, Food & nutrition research (2023) — Umbrella & meta-analysis of 31 cohorts (>2.08 million adults): legume intake showed null associations with total CVD (RR 0.95; 95% CI 0.86-1.06) and type 2 diabetes (RR 0.90; 95% CI 0.77-1.06), while RCTs showed favourable lipid/glucose effects. [https://pmc.ncbi.nlm.nih.gov/articles/PMC10243120/]
  - Effects of Extracted Pulse Proteins on Lipid Targets for Cardiovascular Risk Reduction: Systematic Review and Meta-Analysis of Randomized Controlled Trials, Nutrients (2024) — Meta-analysis of 7 RCTs (14 comparisons, n=453; median 35 g/day pea/pulse protein over 4 weeks) found extracted pulse proteins lowered LDL-C by -0.23 mmol/L (95% CI -0.36 to -0.10), with parallel reductions in non-HDL-C and apoB. [https://pmc.ncbi.nlm.nih.gov/articles/PMC11548137/]
  - Pulse consumption improves indices of glycemic control in adults with and without type 2 diabetes: a systematic review and meta-analysis of acute and long-term randomized controlled trials, European journal of nutrition (2022) — Meta-analysis of long-term RCTs: pulses reduced fasting glucose (ES -0.54; 95% CI -0.83 to -0.24), HbA1c (-0.17; 95% CI -0.33 to 0.00) and HOMA-IR in adults with type 2 diabetes. [https://pmc.ncbi.nlm.nih.gov/articles/PMC8854292/]
  - Effects of dietary pulse consumption on body weight: a systematic review and meta-analysis of randomized controlled trials, The American journal of clinical nutrition (2016) — Meta-analysis of 21 RCTs (n=940): diets with pulses (median 132 g/d) produced significant weight loss of -0.34 kg (95% CI -0.63 to -0.04) over a median 6 weeks, even without calorie restriction. [https://pubmed.ncbi.nlm.nih.gov/27030531/]
  - Effect of dietary pulse intake on established therapeutic lipid targets for cardiovascular risk reduction: a systematic review and meta-analysis of randomized controlled trials, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne (2014) — Meta-analysis of 26 RCTs (n=1037): pulse intake (median 130 g/d) lowered LDL cholesterol by -0.17 mmol/L (95% CI -0.25 to -0.09), about a 5% reduction. [https://pmc.ncbi.nlm.nih.gov/articles/PMC4016088/]
  - Effect of non-oil-seed pulses on glycaemic control: a systematic review and meta-analysis of randomised controlled experimental trials in people with and without diabetes, Diabetologia (2009) — Meta-analysis: pulses alone (11 trials) lowered fasting blood glucose (-0.82; 95% CI -1.36 to -0.27) and fasting insulin (-0.49; 95% CI -0.93 to -0.04). [https://pubmed.ncbi.nlm.nih.gov/19526214/]
  - Twelve Weeks of Daily Lentil Consumption Improves Fasting Cholesterol and Postprandial Glucose and Inflammatory Responses-A Randomized Clinical Trial, Nutrients (2024) — 12-week RCT in 38 adults with increased waist circumference: 980 g/week cooked green lentils significantly lowered fasting LDL (p=0.02) and total cholesterol (p<0.01) versus control, which rose by 0.29 mmol/L LDL. [https://pmc.ncbi.nlm.nih.gov/articles/PMC10857178/]
  - Acute effects of extruded pea fractions on glycemic response, insulin, appetite, and food intake in healthy young adults, results of a double-blind, randomized crossover trial, Applied physiology, nutrition, and metabolism = Physiologie appliquee, nutrition et metabolisme (2021) — Double-blind randomized crossover (n=26): pea protein/fibre fractions added to oat cereal significantly lowered postprandial glucose and insulin responses versus control, dependent on fraction type. [https://pubmed.ncbi.nlm.nih.gov/33661714/]

---

## artichoke
URL: https://nutridex.info/s/artichoke
Category: Vegetables
Evidence: Strong — Multiple high-quality RCTs / meta-analyses with consistent effects.
A fiber- and folate-rich thistle whose leaf-extract polyphenols repeatedly lower cholesterol in human trials.

Quick answer: artichoke is used for lowers total and ldl cholesterol. NutriDex grades the human evidence as strong — Multiple high-quality RCTs / meta-analyses with consistent effects. Based on 8 cited human studies (8 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Artichoke is a low-calorie, high-fiber vegetable that is also an excellent source of folate, magnesium, and prebiotic inulin. The strongest human evidence comes from standardized artichoke leaf extract (ALE): multiple meta-analyses of randomized controlled trials show consistent reductions in total and LDL cholesterol and triglycerides, with additional signals for lower fasting glucose and improved liver enzymes in NAFLD. Effects on blood pressure are smaller and more mixed.

Nutrition (per 1 medium, cooked (boiled, drained) (120 g edible)): 61 kcal; Vitamin C 8.9mg (10% DV), Fiber 6.8g (24% DV), Potassium 343mg (7% DV), Folate 107µg (27% DV), Vitamin A 1µg (0% DV), Vitamin K 17.8µg (15% DV), Vitamin B6 0.1mg (6% DV), Manganese 0.27mg (12% DV).
Benefits / uses: Lowers total and LDL cholesterol; Reduces triglycerides; Improves fasting glucose / insulin resistance; Supports liver health (lower ALT/AST); High fiber and prebiotic inulin for gut and satiety.
Active compounds: chlorogenic acid; cynarin; luteolin; caffeoylquinic acids; inulin; silymarin-like flavonoids.
Dose: Standard serving: 1 medium, cooked (boiled, drained) (120 g edible). Eat whole (with skin where edible); favour whole fruit over juice.
Safety: Generally well tolerated. As a fructan/inulin-rich, high-FODMAP food it can cause gas and bloating in sensitive or IBS individuals. Artichoke leaf extract may cause mild GI effects and is contraindicated in bile-duct obstruction or gallstones (cholagogue effect); use caution with known Asteraceae/ragweed allergy. Whole artichoke contributes modest vitamin K, relevant for those on warfarin.

Cited studies (8):
  - Effect of Cynara scolymus L. on Cardiometabolic Outcomes: An Updated Meta-analysis of Randomized Controlled Trials and Meta-regression, Pharmacognosy Magazine (2024) — Updated meta-analysis and meta-regression of RCTs confirmed favorable cardiometabolic effects of Cynara scolymus on lipid profile and glycemic markers across pooled trials. [https://journals.sagepub.com/doi/10.1177/09731296231217557]
  - Effects of artichoke leaf extract supplementation or artichoke juice consumption on lipid profile: A systematic review and dose-response meta-analysis of randomized controlled trials, Phytotherapy research : PTR (2021) — Systematic review and dose-response meta-analysis of RCTs found artichoke supplementation significantly reduced triglycerides, total cholesterol, and LDL-cholesterol (each on the order of ~17 mg/dL) versus control. [https://pubmed.ncbi.nlm.nih.gov/34569671/]
  - Effects of Cynara scolymus L. on glycemic indices:A systematic review and meta-analysis of randomized clinical trials, Complementary therapies in medicine (2020) — Pooled 9 RCTs: Cynara scolymus reduced fasting blood sugar by a weighted mean of -5.28 mg/dL (95% CI -8.95 to -1.61; p=0.005), with reductions also in insulin and HOMA-IR. [https://pubmed.ncbi.nlm.nih.gov/32951745/]
  - The effects of Cynara scolymus L. supplementation on liver enzymes: A systematic review and meta-analysis, International Journal of Clinical Practice (2021) — Systematic review and meta-analysis of RCTs found artichoke supplementation significantly lowered serum ALT and AST, with the largest effects in patients with NAFLD. [https://onlinelibrary.wiley.com/doi/10.1111/ijcp.14726]
  - Anti-hypertensive Effects of Artichoke Supplementation in Adults: A Systematic Review and Dose-response Meta-analysis of Randomized Controlled Trials, Clinical nutrition research (2022) — Dose-response meta-analysis of RCTs reported a small but significant reduction in systolic blood pressure (WMD ~-1.6 mmHg) with artichoke, with non-linear dose and duration effects. [https://pmc.ncbi.nlm.nih.gov/articles/PMC9348915/]
  - Lipid-lowering activity of artichoke extracts: A systematic review and meta-analysis, Critical reviews in food science and nutrition (2018) — Pooled 9 RCTs (n=702): artichoke extract reduced total cholesterol by ~17.6 mg/dL, LDL-C by ~14.9 mg/dL, and triglycerides by ~9.2 mg/dL, with no change in HDL. [https://pubmed.ncbi.nlm.nih.gov/28609140/]
  - Artichoke and Bergamot Phytosome Alliance: A Randomized Double Blind Clinical Trial in Mild Hypercholesterolemia, Nutrients (2021) — Randomized double-blind trial in 60 overweight adults with mild hypercholesterolemia found that 100 mg artichoke leaf dry extract plus 600 mg bergamot phytosome significantly decreased total and LDL cholesterol versus placebo. [https://pmc.ncbi.nlm.nih.gov/articles/PMC8746931/]
  - Efficacy of artichoke leaf extract in non-alcoholic fatty liver disease: A pilot double-blind randomized controlled trial, Phytotherapy research : PTR (2018) — Double-blind RCT in 90 completers with ultrasound-diagnosed NAFLD: 600 mg/day artichoke leaf extract for 2 months improved liver ultrasound grade and serum ALT, AST, bilirubin and lipids versus placebo, with no side effects. [https://pubmed.ncbi.nlm.nih.gov/29520889/]

---

## radish
URL: https://nutridex.info/s/radish
Category: Vegetables
Evidence: Moderate — Several controlled trials; effects real but modest or context-dependent.
A crisp, peppery cruciferous root—low-calorie, vitamin-C-rich, and a source of glucosinolate-derived isothiocyanates.

Quick answer: radish is used for supports healthy blood pressure (cruciferous rct evidence). NutriDex grades the human evidence as moderate — Several controlled trials; effects real but modest or context-dependent. Based on 8 cited human studies (8 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Radish is a low-energy cruciferous vegetable whose signature bioactives are glucosinolates—chiefly glucoraphenin and glucoraphasatin—that hydrolyze to the isothiocyanate sulforaphene, a phase-2 detoxification-enzyme inducer related to broccoli's sulforaphane. Direct human RCT evidence on radish itself is limited, so the strongest support comes from cruciferous-vegetable trials and cohorts: a randomized crossover trial (VESSEL) showed ~300 g/day of cruciferous vegetables lowered 24-h systolic blood pressure by 2.5 mmHg and improved glycemic control versus root/squash controls, and large prospective cohorts link higher cruciferous intake to lower cardiovascular mortality and colorectal cancer risk. Evidence for type-2-diabetes prevention is suggestive but not yet convincing.

Nutrition (per 1 cup sliced, raw (116 g)): 19 kcal; Vitamin C 17.2mg (19% DV), Fiber 1.9g (7% DV), Potassium 270mg (6% DV), Folate 29µg (7% DV), Vitamin A 0µg (0% DV), Vitamin K 1.5µg (1% DV), Vitamin B6 0.082mg (5% DV), Manganese 0.08mg (3% DV).
Benefits / uses: Supports healthy blood pressure (cruciferous RCT evidence); Very low calorie, hydrating, high water content; Provides vitamin C and potassium; Source of glucosinolate-derived isothiocyanates (sulforaphene); Associated with lower cardiovascular and colorectal cancer risk.
Active compounds: glucoraphenin; glucoraphasatin; sulforaphene; isothiocyanates; vitamin C; anthocyanins (red varieties).
Dose: Standard serving: 1 cup sliced, raw (116 g). Eat whole (with skin where edible); favour whole fruit over juice.
Safety: A cruciferous (Brassicaceae) vegetable: raw consumption supplies goitrogenic glucosinolates that can modestly impair thyroid iodine uptake in very high intakes or iodine deficiency—not a concern at culinary amounts. Generally well tolerated; low in vitamin K so minimal warfarin interaction. Large amounts may cause gas/bloating in sensitive individuals.

Cited studies (8):
  - Cruciferous vegetables intake and risk of colon cancer: a dose-response meta-analysis, BMC gastroenterology (2025) — Dose-response meta-analysis confirmed a nonlinear inverse relationship between cruciferous-vegetable intake and colon cancer, with risk reduction emerging from ~20 g/day and optimal intake at 40-60 g/day (OR ~0.74-0.80). [https://pmc.ncbi.nlm.nih.gov/articles/PMC12337427/]
  - The effect of green leafy and cruciferous vegetable intake on the incidence of cardiovascular disease: A meta-analysis, JRSM cardiovascular disease (2016) — Meta-analysis of 8 prospective cohorts found higher green-leafy and cruciferous vegetable intake associated with a ~15.8% lower incidence of cardiovascular disease. [https://pmc.ncbi.nlm.nih.gov/articles/PMC4973479/]
  - Green leafy and cruciferous vegetable consumption and risk of type 2 diabetes: results from the Singapore Chinese Health Study and meta-analysis, The British journal of nutrition (2018) — Meta-analysis (Singapore Chinese Health Study plus pooled cohorts, ~754,729 participants) found a borderline inverse association of cruciferous-vegetable intake with type 2 diabetes (RR 0.87; 95% CI 0.76-1.00). [https://pubmed.ncbi.nlm.nih.gov/29457582/]
  - Cruciferous vegetables intake and the risk of colorectal cancer: a meta-analysis of observational studies, Annals of oncology : official journal of the European Society for Medical Oncology (2013) — Meta-analysis of observational studies found high vs low cruciferous-vegetable intake inversely associated with colorectal cancer risk (RR 0.82; 95% CI 0.75-0.90). [https://pmc.ncbi.nlm.nih.gov/articles/PMC3603442/]
  - Cruciferous vegetables lower blood pressure in adults with mildly elevated blood pressure in a randomized, controlled, crossover trial: the VEgetableS for vaScular hEaLth (VESSEL) study, BMC medicine (2024) — In a randomized controlled crossover trial (n=18, mildly elevated BP), ~300 g/day cruciferous vegetables for 2 weeks lowered 24-h systolic BP by 2.5 mmHg (95% CI -4.2, -0.9; P=0.002) and serum triglycerides versus root/squash vegetables. [https://pmc.ncbi.nlm.nih.gov/articles/PMC11367748/]
  - Cruciferous vegetables improve glycaemic control compared to root/squash vegetables in a randomized, controlled, crossover trial: The VEgetableS for vaScular hEaLth (VESSEL) study, Diabetes, obesity & metabolism (2025) — In the same randomized crossover trial, the cruciferous-vegetable intervention improved glycemic control (lower 24-h and postprandial glucose measures) compared with root/squash vegetables. [https://pubmed.ncbi.nlm.nih.gov/40375391/]
  - Radish (Raphanus sativus) and Diabetes, Nutrients (2017) — Narrative review of preclinical and limited human data concludes radish (Raphanus sativus) may improve glycemic control via enhanced glucose uptake, reduced intestinal glucose absorption, and antioxidant effects, while noting clinical confirmation is still needed. [https://pubmed.ncbi.nlm.nih.gov/28906451/]
  - Cruciferous vegetable consumption is associated with a reduced risk of total and cardiovascular disease mortality, The American journal of clinical nutrition (2011) — Among 134,796 Chinese adults, the highest vs lowest quintile of cruciferous-vegetable intake had a pooled HR for total mortality of 0.78 (P<0.0001 for trend), driven mainly by reduced cardiovascular mortality. [https://pmc.ncbi.nlm.nih.gov/articles/PMC3127519/]

---

## fennel
URL: https://nutridex.info/s/fennel
Category: Vegetables
Evidence: Moderate — Several controlled trials; effects real but modest or context-dependent.
A crisp, anise-scented bulb best evidenced for easing menstrual and menopausal symptoms.

Quick answer: fennel is used for reduces primary dysmenorrhea (menstrual) pain. NutriDex grades the human evidence as moderate — Several controlled trials; effects real but modest or context-dependent. Based on 8 cited human studies (8 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Fennel bulb is a low-calorie, hydrating vegetable supplying potassium, vitamin C, vitamin K and the phytoestrogenic essential-oil compound trans-anethole. Its strongest human evidence is in gynecologic symptom relief: meta-analyses of randomized trials show fennel meaningfully reduces primary dysmenorrhea pain (comparable to NSAIDs) and improves menopausal symptom scores, though most trials are small, Iran-based and at risk of bias. Cardiometabolic and weight effects remain unproven in controlled trials.

Nutrition (per 1 cup sliced, raw (87 g)): 27 kcal; Vitamin C 10.4mg (12% DV), Fiber 2.7g (10% DV), Potassium 360mg (8% DV), Folate 23µg (6% DV), Vitamin A 42µg (5% DV), Vitamin K 54.7µg (46% DV), Vitamin B6 0.04mg (2% DV), Manganese 0.17mg (7% DV).
Benefits / uses: Reduces primary dysmenorrhea (menstrual) pain; Improves menopausal symptom scores; May reduce infant colic crying time; Hydrating, low-calorie source of potassium and vitamin K; Provides vitamin C and antioxidant polyphenols.
Active compounds: trans-anethole; estragole; fenchone; limonene; alpha-pinene; quercetin; rosmarinic acid.
Dose: Standard serving: 1 cup sliced, raw (87 g). Eat whole (with skin where edible); favour whole fruit over juice.
Safety: Concentrated fennel essential oil/extract carries higher exposure to estragole (a rodent hepatocarcinogen) than culinary amounts; supplements should be avoided in pregnancy and in estrogen-sensitive conditions given anethole's mild phytoestrogenic activity. Rare IgE allergy occurs, often cross-reacting with celery, carrot and mugwort/birch pollen. Vitamin K content is modest but relevant for those on warfarin. Culinary bulb amounts are considered safe.

Cited studies (8):
  - Fennel for Reducing Pain in Primary Dysmenorrhea: A Systematic Review and Meta-Analysis of Randomized Controlled Trials, Nutrients (2020) — Across 12 RCTs, fennel was as effective as conventional drugs for dysmenorrhea (n=502, SMD 0.07, 95% CI -0.08 to 0.21) and superior to placebo for pain reduction (n=468, SMD -3.27, 95% CI -5.28 to -1.26, p=0.001). [https://pmc.ncbi.nlm.nih.gov/articles/PMC7697926/]
  - Effect of fennel on primary dysmenorrhea: a systematic review and meta-analysis, Journal of complementary & integrative medicine (2021) — Pooling 12 trials, fennel significantly reduced primary dysmenorrhea pain versus placebo (SMD -0.632) and was comparable to mefenamic acid. [https://pubmed.ncbi.nlm.nih.gov/34187122/]
  - Fennel (Foeniculum vulgare Miller) for the management of menopausal women's health: A systematic review and meta-analysis, Complementary therapies in clinical practice (2021) — Two placebo-controlled RCTs (n=145) showed fennel significantly improved menopausal symptom scores (SMD -1.32, 95% CI -1.76 to -0.87, p<0.00001). [https://pubmed.ncbi.nlm.nih.gov/33725577/]
  - Fennel (Foeniculum vulgare) on management of menopausal symptoms: A protocol for systematic review of randomized controlled trials, Medicine (2018) — Registered protocol synthesizing RCTs of fennel for menopausal symptoms, establishing the methodological basis for subsequent meta-analyses. [https://pmc.ncbi.nlm.nih.gov/articles/PMC5895370/]
  - Fennel for Reducing Pain in Primary Dysmenorrhea: A Systematic Review and Meta-Analysis of Randomized Controlled Trials, Nutrients (2020) — Systematic review and meta-analysis found fennel comparable to conventional drug therapy for pain (n=502, SMD 0.07, 95% CI -0.08 to 0.21) and superior to placebo (n=468, SMD -3.27, 95% CI -5.28 to -1.26), with high heterogeneity (I2=98%). [https://pmc.ncbi.nlm.nih.gov/articles/PMC7697926/]
  - The Effect of Foeniculum Vulgare (Fennel) on Body Composition in Postmenopausal Women with Excess Weight: A Double-blind Randomized Placebo-controlled Trial, Journal of menopausal medicine (2017) — In 47 overweight postmenopausal women over 12 weeks, fennel (soft capsule) showed no significant effect on body weight, BMI, waist/hip circumference or fat distribution versus placebo. [https://pmc.ncbi.nlm.nih.gov/articles/PMC5770526/]
  - The effect of fennel (Foeniculum Vulgare) seed oil emulsion in infantile colic: a randomized, placebo-controlled study, Alternative therapies in health and medicine (2003) — Fennel seed oil emulsion eliminated infantile colic in 65% of treated infants versus 23.7% on placebo (p<0.01) by reducing crying time. [https://pubmed.ncbi.nlm.nih.gov/12868253/]
  - Foeniculum vulgare as Valuable Plant in Management of Women's Health, Journal of menopausal medicine (2019) — Reviews Foeniculum vulgare phytochemistry (trans-anethole, fenchone, estragole) and pharmacology, summarizing antioxidant, antispasmodic and estrogenic activities underpinning clinical use. [https://pubmed.ncbi.nlm.nih.gov/31080784/]

---

## turnip
URL: https://nutridex.info/s/turnip
Category: Vegetables
Evidence: Moderate — Several controlled trials; effects real but modest or context-dependent.
Low-calorie cruciferous root rich in vitamin C and glucosinolates.

Quick answer: turnip is used for cruciferous intake associated with lower total and cardiovascular mortality in large cohorts. NutriDex grades the human evidence as moderate — Several controlled trials; effects real but modest or context-dependent. Based on 12 cited human studies (12 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Turnip is a Brassica root with little turnip-specific clinical trial data; its evidence base rests largely on the broader cruciferous-vegetable literature and on RCTs of its signature bioactive, the glucosinolate-derived isothiocyanate sulforaphane (and glucotropaeolin/gluconasturtiin in turnip). Large prospective cohorts and pooled analyses link higher cruciferous intake to lower total and cardiovascular mortality and to modestly reduced colorectal and gastric cancer risk, while randomized trials of concentrated broccoli-sprout sulforaphane show improved fasting glucose, HbA1c, and blood pressure. These outcome data are mostly observational or use broccoli-sprout extracts rather than turnip itself, so causal benefit specific to turnip remains inferred rather than proven.

Nutrition (per 1 cup cubed, raw (130 g)): 36 kcal; Vitamin C 27.3mg (30% DV), Fiber 2.3g (8% DV), Potassium 248mg (5% DV), Folate 20µg (5% DV), Vitamin A 0µg (0% DV), Vitamin K 0.1µg (0% DV), Vitamin B6 0.12mg (7% DV), Manganese 0.17mg (7% DV).
Benefits / uses: Cruciferous intake associated with lower total and cardiovascular mortality in large cohorts; Higher cruciferous consumption linked to reduced colorectal and gastric cancer risk; Sulforaphane from cruciferous sprouts lowers fasting glucose and HbA1c in RCTs; Broccoli-sprout sulforaphane reduces systolic and diastolic blood pressure in trials; Very low calorie, high vitamin C, contributes fibre and potassium to the diet.
Active compounds: Glucosinolates (gluconasturtiin, glucotropaeolin, progoitrin); Sulforaphane and related isothiocyanates; Indole-3-carbinol; Vitamin C (ascorbic acid); Phenolic acids and flavonoids; Potassium.
Dose: Standard serving: 1 cup cubed, raw (130 g). Eat whole (with skin where edible); favour whole fruit over juice.
Safety: Generally very safe as food. Like all raw cruciferous vegetables, turnip contains goitrogens (progoitrin/thiocyanate) that can theoretically impair thyroid iodine uptake with very high raw intake or low iodine status; cooking reduces this. The fermentable fibre may cause gas/bloating in sensitive or IBS individuals (moderate FODMAP load). Vitamin K content is negligible, so no meaningful warfarin interaction (unlike turnip greens). No oxalate or solanine concerns.

Cited studies (12):
  - Cruciferous vegetable consumption is associated with a reduced risk of total and cardiovascular disease mortality, The American Journal of Clinical Nutrition (2011) — Meta-analysis of prospective cohorts found cruciferous vegetable consumption associated with reduced total and cardiovascular disease mortality, with HRs falling across increasing intake quantiles (p < 0.0001). [https://doi.org/10.3945/ajcn.110.009340]
  - Umbrella Review of Systematic Reviews and Meta-analyses on Consumption of Different Food Groups and Risk of All-cause Mortality, Advances in nutrition (Bethesda, Md.) (2025) — Umbrella review of systematic reviews/meta-analyses found higher intake of vegetables, including cruciferous vegetables, was associated with reduced all-cause mortality risk. [https://pmc.ncbi.nlm.nih.gov/articles/PMC11931306/]
  - Effect of cruciferous vegetable intake on cancer: An umbrella review of meta-analysis, Journal of food science (2024) — Umbrella review of meta-analyses reported higher cruciferous vegetable intake was associated with reduced risk of several site-specific cancers. [https://pubmed.ncbi.nlm.nih.gov/39138635/]
  - Beneficial Effects of Sulforaphane-Yielding Broccoli Sprout on Cardiometabolic Health: A Systematic Review and Meta-analysis, Jundishapur Journal of Natural Pharmaceutical Products (2022) — Systematic review and meta-analysis of 10 clinical trials found sulforaphane-yielding broccoli sprouts reduced systolic blood pressure by 10.9 mmHg (95% CI -17.0 to -4.9) and diastolic by 7.0 mmHg. [https://doi.org/10.5812/jjnpp-129402]
  - Cruciferous vegetable and isothiocyanate intake and multiple health outcomes, Food chemistry (2022) — Umbrella review of 57 articles/24 outcomes found each 100 g/day increment in cruciferous vegetable intake was associated with a 10% lower risk of all-cause mortality, though 68% of underlying evidence was low quality. [https://pubmed.ncbi.nlm.nih.gov/34929422/]
  - Green leafy and cruciferous vegetable consumption and risk of type 2 diabetes: results from the Singapore Chinese Health Study and meta-analysis, The British journal of nutrition (2018) — Singapore Chinese Health Study plus meta-analysis (11 studies, 754,729 participants) found a borderline inverse association of cruciferous intake with type 2 diabetes (RR 0.87, 95% CI 0.76-1.00). [https://pubmed.ncbi.nlm.nih.gov/29457582/]
  - Cruciferous vegetables intake and the risk of colorectal cancer: a meta-analysis of observational studies, Annals of oncology : official journal of the European Society for Medical Oncology (2013) — Meta-analysis of 24 case-control and 11 prospective studies showed higher cruciferous intake associated with lower colorectal cancer risk (RR 0.82, 95% CI 0.75-0.90). [https://pubmed.ncbi.nlm.nih.gov/23211939/]
  - Cruciferous vegetable consumption and gastric cancer risk: a meta-analysis of epidemiological studies, Cancer science (2013) — Meta-analysis of 22 epidemiological studies found high cruciferous vegetable intake inversely associated with gastric cancer risk (RR 0.81, 95% CI 0.75-0.88) with little heterogeneity. [https://pubmed.ncbi.nlm.nih.gov/23679348/]
  - Cruciferous vegetables lower blood pressure in adults with mildly elevated blood pressure in a randomized, controlled, crossover trial: the VEgetableS for vaScular hEaLth (VESSEL) study, BMC medicine (2024) — In a randomized controlled crossover trial in adults with mildly elevated BP, ~300 g/day cruciferous vegetables for 2 weeks lowered 24-hour systolic blood pressure by 2.5 mmHg versus root/squash vegetables. [https://pmc.ncbi.nlm.nih.gov/articles/PMC11367748/]
  - Cruciferous vegetables improve glycaemic control compared to root/squash vegetables in a randomized, controlled, crossover trial: The VEgetableS for vaScular hEaLth (VESSEL) study, Diabetes, obesity & metabolism (2025) — In the same VESSEL crossover RCT, cruciferous vegetables improved glycaemic control compared with root/squash vegetables over the 2-week intervention. [https://pmc.ncbi.nlm.nih.gov/articles/PMC12232361/]
  - Sulforaphane reduces hepatic glucose production and improves glucose control in patients with type 2 diabetes, Science Translational Medicine (2017) — 12-week RCT (n=97 type 2 diabetes) of concentrated broccoli-sprout sulforaphane extract reduced HbA1c by ~1.4% and fasting glucose versus placebo in obese, dysregulated patients. [https://www.science.org/doi/10.1126/scitranslmed.aah4477]
  - Cruciferous vegetable consumption is associated with a reduced risk of total and cardiovascular disease mortality, The American journal of clinical nutrition (2011) — In pooled analysis of two cohorts (73,360 women), highest vs lowest cruciferous intake was associated with lower total mortality (HR 0.78, 95% CI 0.71-0.85) and cardiovascular mortality (HR 0.69, 95% CI 0.56-0.85). [https://pmc.ncbi.nlm.nih.gov/articles/PMC3127519/]

---

## bok-choy
URL: https://nutridex.info/s/bok-choy
Category: Vegetables
Evidence: Moderate — Several controlled trials; effects real but modest or context-dependent.
A featherweight Asian cabbage that delivers cruciferous glucosinolates plus bioavailable calcium, vitamin K, and beta-carotene.

Quick answer: bok-choy is used for lowers systolic blood pressure (cruciferous rct). NutriDex grades the human evidence as moderate — Several controlled trials; effects real but modest or context-dependent. Based on 8 cited human studies (8 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Bok choy is a low-oxalate Brassica whose signature bioactives are glucosinolates (glucoraphanin/gluconasturtiin) that convert to isothiocyanates such as sulforaphane, plus carotenoids and vitamin K. The strongest human evidence is at the cruciferous-vegetable class level: meta-analyses link higher intake with modestly lower cardiovascular disease and colorectal cancer risk, and recent randomized crossover trials (VESSEL) show short-term reductions in systolic blood pressure and improved glycemic markers versus root vegetables. Direct RCTs on bok choy itself are scarce, so benefits are best read as extrapolated from the cruciferous family and leafy-green nutrients.

Nutrition (per 1 cup shredded, raw (70 g)): 9.1 kcal; Vitamin C 31.5mg (35% DV), Fiber 0.7g (3% DV), Potassium 176.4mg (4% DV), Folate 46.2µg (12% DV), Vitamin A 156.1µg (17% DV), Vitamin K 31.9µg (27% DV), Vitamin B6 0.133mg (8% DV), Manganese 0.112mg (5% DV).
Benefits / uses: Lowers systolic blood pressure (cruciferous RCT); Associated with reduced cardiovascular disease risk; Linked to lower colorectal cancer risk; Improves short-term glycemic control vs root vegetables; Leafy-green nutrients tied to slower cognitive decline.
Active compounds: glucosinolates; sulforaphane; indole-3-carbinol; beta-carotene; lutein; vitamin K1 (phylloquinone).
Dose: Standard serving: 1 cup shredded, raw (70 g). Eat whole (with skin where edible); favour whole fruit over juice.
Safety: Goitrogenic glucosinolates in large raw quantities may affect thyroid in iodine-deficient individuals (a rare case report linked massive raw bok choy intake to hypothyroid myxedema coma). Vitamin K content can interfere with warfarin dosing — keep intake consistent. Generally low in oxalate and well tolerated; cooking reduces goitrogen and raffinose-type FODMAP load.

Cited studies (8):
  - Fruit and vegetable intake and the risk of cardiovascular disease, total cancer and all-cause mortality—a systematic review and dose-response meta-analysis of prospective studies, International Journal of Epidemiology (2017) — Dose-response meta-analysis (95 studies); each 200 g/day cruciferous-rich vegetable intake lowered CVD risk, with combined fruit/veg up to 800 g/day giving ~28% lower CVD risk (RR 0.72). [https://academic.oup.com/ije/article/46/3/1029/3039477]
  - The effect of green leafy and cruciferous vegetable intake on the incidence of cardiovascular disease: A meta-analysis, JRSM cardiovascular disease (2016) — Meta-analysis of leafy green and cruciferous vegetables found a 15.8% lower incidence of cardiovascular disease (RR 0.842, 95% CI 0.753-0.941). [https://pmc.ncbi.nlm.nih.gov/articles/PMC4973479/]
  - Cruciferous vegetables intake and the risk of colorectal cancer: a meta-analysis of observational studies, Annals of oncology : official journal of the European Society for Medical Oncology (2013) — Meta-analysis of 35 observational studies (24 case-control, 11 prospective): highest vs lowest cruciferous intake associated with lower colorectal cancer risk (RR 0.82, 95% CI 0.75-0.90). [https://pubmed.ncbi.nlm.nih.gov/23211939/]
  - Cruciferous vegetables and human cancer risk: epidemiologic evidence and mechanistic basis, Pharmacological research (2007) — Review of epidemiologic and mechanistic evidence linking cruciferous glucosinolate-derived isothiocyanates (e.g., sulforaphane) to inverse associations with lung, colorectal, breast and other cancers. [https://pmc.ncbi.nlm.nih.gov/articles/PMC2737735/]
  - Cruciferous vegetables lower blood pressure in adults with mildly elevated blood pressure in a randomized, controlled, crossover trial: the VEgetableS for vaScular hEaLth (VESSEL) study, BMC medicine (2024) — Randomized controlled crossover trial (n=18): ~300 g/day cruciferous vegetables for 2 weeks lowered 24-h systolic blood pressure by 2.5 mmHg vs root/squash vegetables in adults with mildly elevated BP. [https://pmc.ncbi.nlm.nih.gov/articles/PMC11367748/]
  - Cruciferous vegetables improve glycaemic control compared to root/squash vegetables in a randomized, controlled, crossover trial: The VEgetableS for vaScular hEaLth (VESSEL) study, Diabetes, obesity & metabolism (2025) — Randomized controlled crossover trial: 2 weeks of cruciferous vegetables improved 24-h glycemic control (lower mean glucose and glycemic variability) compared with root/squash vegetables. [https://pmc.ncbi.nlm.nih.gov/articles/PMC12232361/]
  - Sulforaphane reduces hepatic glucose production and improves glucose control in patients with type 2 diabetes, Science Translational Medicine (2017) — 12-week double-blind RCT (n=97) of broccoli-sprout sulforaphane reduced HbA1c and fasting glucose in obese, dysregulated type 2 diabetes; sulforaphane suppressed hepatic glucose production. [https://www.science.org/doi/10.1126/scitranslmed.aah4477]
  - Nutrients and bioactives in green leafy vegetables and cognitive decline: Prospective study, Neurology (2018) — Prospective cohort (n=960, mean 4.7 y): highest vs lowest green leafy vegetable intake (median 1.3 servings/day) associated with slower cognitive decline equivalent to being 11 years younger. [https://pmc.ncbi.nlm.nih.gov/articles/PMC5772164/]

---

## asparagus
URL: https://nutridex.info/s/asparagus
Category: Vegetables
Evidence: Moderate — Several controlled trials; effects real but modest or context-dependent.
Folate- and vitamin-K-dense spring spear with prebiotic fructans and emerging cardiometabolic signals.

Quick answer: asparagus is used for asparagus-powder rct lowered fasting and post-load glucose, triglycerides and oxidative stress over 12 weeks. NutriDex grades the human evidence as moderate — Several controlled trials; effects real but modest or context-dependent. Based on 11 cited human studies (11 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Asparagus is exceptionally nutrient-dense for its low calorie load, delivering large fractions of daily folate and vitamin K plus prebiotic inulin-type fructans, the flavonol quercetin/rutin, and saponins. Direct human trials of whole asparagus are scarce: the strongest is a 2025 double-blind RCT (n=44) in which 12 weeks of asparagus powder lowered fasting glucose, post-load glucose AUC, triglycerides and oxidative stress versus placebo, though it was small and exploratory. Most of the supporting evidence is indirect, drawn from meta-analyses of asparagus's signature constituents—prebiotic inulin-type fructans improving glycemic markers, quercetin modestly lowering blood pressure, and high dietary-fibre/folate intakes linked to lower cardiovascular and stroke risk in pooled cohorts and trials. Overall the human evidence is moderate and largely surrogate-endpoint or constituent-based rather than proof that asparagus itself changes hard outcomes.

Nutrition (per 1 cup, cooked (boiled, drained) (180 g)): 40 kcal; Vitamin C 13.9mg (15% DV), Fiber 3.6g (13% DV), Potassium 403mg (9% DV), Folate 268µg (67% DV), Vitamin A 90µg (10% DV), Vitamin K 91.1µg (76% DV), Vitamin B6 0.14mg (8% DV), Manganese 0.28mg (12% DV).
Benefits / uses: Asparagus-powder RCT lowered fasting and post-load glucose, triglycerides and oxidative stress over 12 weeks; Outstanding source of folate (~67% DV/cup) supporting homocysteine metabolism; Very high in vitamin K (~76% DV/cup) for coagulation and bone; Prebiotic inulin-type fructans nourish gut microbiota and aid glycemic control (constituent meta-analyses); Quercetin/rutin flavonols associated with modest blood-pressure lowering.
Active compounds: Inulin-type fructans (prebiotic fibre); Quercetin and rutin (flavonols); Steroidal saponins (protodioscin); Folate (vitamin B9); Vitamin K1 (phylloquinone); Glutathione; Asparagusic acid; Vitamin C and vitamin E (alpha-tocopherol).
Dose: Standard serving: 1 cup, cooked (boiled, drained) (180 g). Eat whole (with skin where edible); favour whole fruit over juice.
Safety: Generally very safe as food. High vitamin K1 content can interfere with warfarin/vitamin-K-antagonist dosing—keep intake consistent. The fructan (FODMAP) content can trigger bloating, gas and diarrhoea in IBS-sensitive people. Asparagusic acid produces a harmless sulphurous urine odour in many people. Purines are moderate and large amounts may modestly raise uric acid in gout-prone individuals. Rare contact or IgE allergy to asparagus has been reported.

Cited studies (11):
  - Folic acid supplementation for stroke prevention: A systematic review and meta-analysis of 21 randomized clinical trials worldwide, Clinical nutrition (Edinburgh, Scotland) (2024) — Systematic review and meta-analysis of 21 RCTs worldwide found folic acid supplementation significantly reduced stroke risk, with the effect most evident in regions without mandatory folate fortification. [https://pubmed.ncbi.nlm.nih.gov/38824900/]
  - Dietary intake of total vegetable, fruit, cereal, soluble and insoluble fiber and risk of all-cause, cardiovascular, and cancer mortality: systematic review and dose-response meta-analysis of prospective cohort studies, Frontiers in nutrition (2023) — Updated systematic review and meta-analysis of prospective cohorts found higher dietary fibre intake was associated with lower all-cause (RR 0.90), cardiovascular (RR 0.87) and cancer (RR 0.91) mortality. [https://pubmed.ncbi.nlm.nih.gov/37854351/]
  - Inulin-type fructans supplementation improves glycemic control for the prediabetes and type 2 diabetes populations: results from a GRADE-assessed systematic review and dose-response meta-analysis of 33 randomized controlled trials, Journal of translational medicine (2019) — GRADE-assessed systematic review and dose-response meta-analysis of 33 RCTs found inulin-type fructans (asparagus's main fibre) significantly reduced fasting glucose, HbA1c, fasting insulin and HOMA-IR in prediabetes/type 2 diabetes. [https://pmc.ncbi.nlm.nih.gov/articles/PMC6896694/]
  - Effects of Quercetin on Blood Pressure: A Systematic Review and Meta-Analysis of Randomized Controlled Trials, Journal of the American Heart Association (2016) — Meta-analysis of 7 RCTs (9 arms, 587 patients) found quercetin supplementation lowered systolic BP by 3.04 mmHg (95% CI -5.75 to -0.33) and diastolic BP by 2.63 mmHg (95% CI -3.26 to -2.01). [https://pubmed.ncbi.nlm.nih.gov/27405810/]
  - Carbohydrate quality and human health: a series of systematic reviews and meta-analyses, The Lancet (2019) — Lancet series of systematic reviews/meta-analyses (~135 million person-years) found highest vs lowest dietary fibre intake was associated with a 15-30% reduction in all-cause and cardiovascular mortality, with greatest benefit at 25-29 g/day. [https://www.thelancet.com/article/S0140-6736(18)31809-9/fulltext]
  - Effects of Asparagus Powder Supplementation on Glycemic Control, Lipid Profile, and Oxidative Stress in Overweight and Obese Adults: An Exploratory Randomized Controlled Trial, Life (Basel, Switzerland) (2025) — Double-blind RCT (n=44) of 40 mg/kg/day asparagus powder for 12 weeks significantly lowered fasting glucose (p=0.045), post-load glucose AUC (p<0.05), triglycerides (p=0.043) and malondialdehyde (p=0.009) versus placebo. [https://pmc.ncbi.nlm.nih.gov/articles/PMC12565180/]
  - Synergistic Effects of High-Intensity Interval Training and Asparagus officinalis L. Root Extract Supplementation on Metabolic Regulation, Oxidative Stress, and Inflammation in Overweight and Obese Adults, International journal of molecular sciences (2025) — RCT in 72 overweight/obese adults (4 arms): Asparagus officinalis root extract significantly lowered blood glucose and lipids only when combined with HIIT, whereas extract alone did not improve (and tended to raise) lipid levels. [https://pmc.ncbi.nlm.nih.gov/articles/PMC12733034/]
  - Effects of Asparagus-Derived 20-Hydroxyecdysone Supplementation on Fat Oxidation and Insulin Sensitivity in Resistance-Trained Males, Journal of nutritional science and vitaminology (2025) — 12-week double-blind RCT in 20 resistance-trained males: asparagus-derived 20-hydroxyecdysone 30 mg/day increased fat oxidation at rest and during exercise and reduced arm/leg/abdominal fat vs placebo. [https://pubmed.ncbi.nlm.nih.gov/41485968/]
  - Effects of High-Intensity Intermittent Training Combined with Asparagus officinalis Extract Supplementation on Cardiovascular and Pulmonary Function Parameters in Obese and Overweight Individuals: A Randomized Control Trial, Journal of functional morphology and kinesiology (2025) — RCT in 72 obese/overweight individuals: HIIT combined with Asparagus officinalis extract improved cardiovascular and pulmonary function parameters vs control arms. [https://pmc.ncbi.nlm.nih.gov/articles/PMC12194011/]
  - Beneficial Effects of Asparagus officinalis Extract Supplementation on Muscle Mass and Strength following Resistance Training and Detraining in Healthy Males, Sports (Basel, Switzerland) (2023) — RCT in healthy males: Asparagus officinalis extract supplementation improved muscle mass and strength retention following resistance training and detraining vs control. [https://pmc.ncbi.nlm.nih.gov/articles/PMC10537221/]
  - Dietary intake of folate and risk of stroke in US men and women: NHANES I Epidemiologic Follow-up Study. National Health and Nutrition Examination Survey, Stroke (2002) — NHANES I Epidemiologic Follow-up cohort (n=9,764) found participants in the highest quartile of dietary folate intake had a 20% lower stroke incidence and significantly lower cardiovascular disease risk than the lowest quartile. [https://pubmed.ncbi.nlm.nih.gov/11988588/]

---

## onion
URL: https://nutridex.info/s/onion
Category: Vegetables
Evidence: Moderate — Several controlled trials; effects real but modest or context-dependent.
A humble flavor base that delivers quercetin, prebiotic fibers, and organosulfur compounds.

Quick answer: onion is used for lowers systolic blood pressure (quercetin). NutriDex grades the human evidence as moderate — Several controlled trials; effects real but modest or context-dependent. Based on 9 cited human studies (9 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Onion is one of the richest dietary sources of the flavonol quercetin, plus organosulfur compounds and fructan (prebiotic) fibers. Randomized-trial evidence shows onion and concentrated quercetin supplementation modestly lower systolic blood pressure and improve body fat and lipid markers, with the clearest blood-pressure effect at quercetin doses of at least 500 mg/day. Higher dietary flavonoid intake is also associated with lower cardiovascular and all-cause mortality in large cohorts, though direct whole-onion outcome data remain limited.

Nutrition (per 1 cup chopped, raw (160 g)): 64 kcal; Vitamin C 11.8mg (13% DV), Fiber 2.7g (10% DV), Potassium 234mg (5% DV), Folate 30µg (8% DV), Vitamin A 0µg (0% DV), Vitamin K 0.6µg (1% DV), Vitamin B6 0.19mg (11% DV), Manganese 0.21mg (9% DV).
Benefits / uses: Lowers systolic blood pressure (quercetin); Improves body fat and lipid profile; Prebiotic fructans support gut microbiome; Rich source of antioxidant flavonols; Linked to lower cardiovascular mortality.
Active compounds: quercetin; organosulfur compounds (thiosulfinates); fructans (inulin/FOS); kaempferol; anthocyanins (red onion); S-allyl cysteine.
Dose: Standard serving: 1 cup chopped, raw (160 g). Eat whole (with skin where edible); favour whole fruit over juice.
Safety: High in FODMAPs (fructans), a common trigger of IBS bloating and gas. Raw onion can cause reflux/heartburn in sensitive people, and handling releases lachrymatory (tear-inducing) compounds. Onion is toxic to dogs and cats. Quercetin supplements (not culinary amounts) may interact with some medications.

Cited studies (9):
  - Onion supplementation and health metabolic parameters: A systematic review and meta-analysis of randomized controlled trials, Clinical nutrition ESPEN (2023) — Across 14 RCTs, onion supplementation significantly improved body fat percentage, total/LDL/HDL cholesterol, and systolic blood pressure, with no significant effect on triglycerides in the crude analysis. [https://pubmed.ncbi.nlm.nih.gov/38056991/]
  - Antiobesity effects of onion (Allium cepa) in subjects with obesity: Systematic review and meta-analysis, Food science & nutrition (2023) — In 5 RCTs (147 subjects with obesity), onion intake significantly reduced body weight, BMI, waist circumference, and triglycerides versus placebo, with effects most pronounced for onion peel extract. [https://pubmed.ncbi.nlm.nih.gov/37576046/]
  - The effect of quercetin supplementation on the components of metabolic syndrome in adults: A systematic review and dose–response meta-analysis of randomized controlled trials, Journal of Functional Foods (2024) — Quercetin supplementation significantly reduced fasting blood glucose and systolic blood pressure in adults, with significant fasting-glucose lowering seen at doses >=500 mg/day for >=8 weeks; no effect on triglycerides, HDL, DBP, or waist circumference. [https://doi.org/10.1016/j.jff.2024.106175]
  - Allium Vegetables, Garlic Supplements, and Risk of Cancer: A Systematic Review and Meta-Analysis, Frontiers in nutrition (2021) — Pooling 22 studies (25 reports), high allium-vegetable consumption showed no significant overall association with cancer risk (RR 0.97, 95% CI 0.92-1.03), with no linear or nonlinear dose-response, tempering earlier cancer-protection claims. [https://pmc.ncbi.nlm.nih.gov/articles/PMC8985597/]
  - Effects of Quercetin on Blood Pressure: A Systematic Review and Meta-Analysis of Randomized Controlled Trials, Journal of the American Heart Association (2016) — Pooled across 7 RCTs (9 arms, 587 participants), quercetin supplementation lowered systolic BP by 3.04 mmHg (95% CI -5.75 to -0.33) and diastolic BP by 2.63 mmHg (95% CI -3.26 to -2.01), with effects greater at doses >=500 mg/day. [https://pubmed.ncbi.nlm.nih.gov/27405810/]
  - Consumption of Large Amounts of Allium Vegetables Reduces Risk for Gastric Cancer in a Meta-analysis, Gastroenterology (2011) — Across 19 case-control and 2 cohort studies (543,220 subjects), high allium-vegetable intake was associated with reduced gastric cancer risk (OR 0.54, 95% CI 0.43-0.65); each 20 g/day increment gave OR 0.91 (95% CI 0.88-0.94). [https://www.gastrojournal.org/article/S0016-5085(11)00441-0/fulltext]
  - Flavonoid intake and mortality from cardiovascular disease and all causes: A meta-analysis of prospective cohort studies, Clinical nutrition ESPEN (2017) — Across 15 prospective cohorts, the highest versus lowest flavonoid intake was associated with lower cardiovascular mortality (pooled RR 0.86, 95% CI 0.75-0.98) and total mortality (RR 0.86, 95% CI 0.73-1.00). [https://pubmed.ncbi.nlm.nih.gov/29072172/]
  - Effect of onion (Allium cepa L.) peel extract on natural killer cell and cytokines in a randomized, double-blind, placebo-controlled trial, Nutrition research and practice (2024) — Randomized double-blind placebo-controlled trial in 80 adults found onion (Allium cepa) peel extract had no overall effect on NK cell activity or cytokines (IL-2/6/12, IFN-gamma, TNF-alpha), but increased NK cell activity (P=0.038) in the subgroup with higher upper-respiratory symptom scores, without significant adverse effects. [https://pubmed.ncbi.nlm.nih.gov/38352207/]
  - Exploring the Therapeutic Potential of Allium cepa and Allium sativum Extracts: Current Strategies, Emerging Applications, and Sustainability Utilization, Biology (2025) — 2025 review synthesizing >20 years of research on Allium cepa and Allium sativum extracts details antidiabetic and cardioprotective mechanisms, including quercetin-rich onion peel extract reducing triglycerides/glucose and delaying arterial thrombosis via MAPK downregulation in preclinical models. [https://pmc.ncbi.nlm.nih.gov/articles/PMC12383551/]

---

## leek
URL: https://nutridex.info/s/leek
Category: Vegetables
Evidence: Moderate — Several controlled trials; effects real but modest or context-dependent.
Mild allium with vitamin K and folate, riding the broader garlic/onion evidence base.

Quick answer: leek is used for allium-rich diets linked to markedly lower gastric cancer risk in pooled analyses. NutriDex grades the human evidence as moderate — Several controlled trials; effects real but modest or context-dependent. Based on 11 cited human studies (11 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Leeks are a member of the Allium genus alongside garlic and onion, and most human evidence is generated by those better-studied relatives rather than by leeks directly. Pooled data show allium-rich diets are associated with substantially lower gastric cancer risk (umbrella review RR 0.78, 95% CI 0.67-0.91), and randomized trials of concentrated garlic preparations lower systolic blood pressure by roughly 3.8-8.4 mmHg and LDL/total cholesterol modestly, with the largest effects in hypertensive or dyslipidemic patients. Evidence specific to leek-level dietary intake is largely observational and confounded; the cardiometabolic signals come from supplement-dose garlic, so culinary leek portions should be viewed as part of a healthy vegetable-rich pattern rather than a proven therapeutic.

Nutrition (per 1 cup chopped, raw (89 g)): 54 kcal; Vitamin C 10.7mg (12% DV), Fiber 1.6g (6% DV), Potassium 160mg (3% DV), Folate 57µg (14% DV), Vitamin A 74µg (8% DV), Vitamin K 41.8µg (35% DV), Vitamin B6 0.2mg (12% DV), Manganese 0.43mg (19% DV).
Benefits / uses: Allium-rich diets linked to markedly lower gastric cancer risk in pooled analyses; Concentrated allium (garlic) lowers blood pressure in hypertensive adults in RCTs; Garlic-class allium modestly reduces total and LDL cholesterol; Good source of vitamin K and folate for a low-calorie vegetable; Contributes prebiotic inulin-type fibre and flavonols to a vegetable-rich diet.
Active compounds: Organosulfur compounds (alliin / allicin, diallyl disulfide); Kaempferol and quercetin (flavonols); Inulin-type fructans (prebiotic fibre); Vitamin K1 (phylloquinone); Folate; Saponins.
Dose: Standard serving: 1 cup chopped, raw (89 g). Eat whole (with skin where edible); favour whole fruit over juice.
Safety: Generally very safe as food. The inulin-type fructans make leeks high-FODMAP, so they can trigger bloating, gas, or diarrhea in people with IBS. The vitamin K content (about 42 ug per cup) can interfere with warfarin dosing, so intake should be kept consistent. Concentrated garlic/allium supplements (not culinary leeks) can increase bleeding risk and should be paused before surgery. Rare allium contact or IgE allergy occurs.

Cited studies (11):
  - Garlic Lowers Blood Pressure in Hypertensive Individuals, Regulates Serum Cholesterol, and Stimulates Immunity: An Updated Meta-analysis and Review, The Journal of Nutrition (2016) — Updated pooled analysis confirmed garlic lowers blood pressure in hypertensive individuals and modestly improves serum cholesterol, supporting an adjunct cardioprotective role for allium. [https://jn.nutrition.org/article/S0022-3166(23)00519-9/fulltext]
  - Allium Vegetables, Garlic Supplements, and Risk of Cancer: A Systematic Review and Meta-Analysis, Frontiers in nutrition (2021) — Systematic review and meta-analysis of 22 studies found no significant association between high allium vegetable intake and overall cancer risk (RR 0.97; 95% CI 0.92-1.03), with no linear or nonlinear dose-response relationship. [https://pubmed.ncbi.nlm.nih.gov/35402472/]
  - Allium vegetable consumption and health: An umbrella review of meta-analyses of multiple health outcomes, Food science & nutrition (2019) — Across 16 meta-analyses (50 outcomes), high allium vegetable intake was associated with lower gastric cancer risk (RR 0.78, 95% CI 0.67-0.91) and garlic lowered total cholesterol by 17.2 mg/dL after >8 weeks. [https://pmc.ncbi.nlm.nih.gov/articles/PMC6694434/]
  - Effect of garlic on blood pressure: a meta-analysis, Journal of clinical hypertension (Greenwich, Conn.) (2015) — In 17 randomized trials, garlic supplementation reduced systolic BP by 3.75 mmHg (95% CI -5.04 to -2.45) and diastolic BP by 3.39 mmHg (95% CI -4.14 to -2.65) versus control, with larger effects in hypertensive patients. [https://pmc.ncbi.nlm.nih.gov/articles/PMC8031974/]
  - iTAP, a novel iRhom interactor, controls TNF secretion by policing the stability of iRhom/TACE, eLife (2018) — Pooled analysis of 39 trials found garlic reduced total cholesterol by about 17 mg/dL and LDL-C by about 9 mg/dL in adults with elevated baseline cholesterol over at least 2 months. [https://pubmed.ncbi.nlm.nih.gov/29897333/]
  - Consumption of Large Amounts of Allium Vegetables Reduces Risk for Gastric Cancer in a Meta-analysis, Gastroenterology (2011) — Higher allium vegetable consumption was inversely associated with gastric cancer risk, with a pooled case-control odds ratio of 0.54 (95% CI 0.43-0.65) comparing highest versus lowest intake. [https://www.gastrojournal.org/article/S0016-5085(11)00441-0/fulltext]
  - Allium vegetables and garlic supplements do not reduce risk of colorectal cancer, based on meta-analysis of prospective studies, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2014) — Pooled prospective-cohort data found no significant association between allium vegetable intake and colorectal cancer risk, tempering claims from case-control data. [https://pubmed.ncbi.nlm.nih.gov/24681077/]
  - Higher intake of fruits, vegetables or their fiber reduces the risk of type 2 diabetes: A meta-analysis, Journal of Diabetes Investigation (2016) — Each additional serving per day of vegetables was associated with a ~10% lower type 2 diabetes risk (RR 0.90, 95% CI 0.80-1.01), with green/leafy and allium-type vegetables contributing to the protective pattern. [https://onlinelibrary.wiley.com/doi/10.1111/jdi.12376]
  - The efficacy of Allium ampeloprasum L. in reducing neutrophil recovery time in childhood cancer with febrile neutropenia: a randomized, double-blind, placebo-controlled trial, American journal of blood research (2023) — In a double-blind RCT of 97 children with chemotherapy-induced febrile neutropenia, Allium ampeloprasum (leek) capsules (500 mg twice daily) achieved neutrophil recovery within 7 days in 83.6% vs 54.2% of placebo controls (P<0.001) and earlier discharge (67.3% vs 48%, P=0.028). [https://pmc.ncbi.nlm.nih.gov/articles/PMC10658031/]
  - Allium vegetable intake associated with the risk of incident gastric cancer: a continuous follow-up study of a randomized intervention trial, The American journal of clinical nutrition (2023) — In a 22.3-year continuous follow-up of the randomized Shandong Intervention Trial (3229 subjects, 144 incident gastric cancers), garlic-allium vegetable intake was associated with lower gastric cancer risk (OR 0.83; 95% CI 0.70-0.98 per 1 kg/y increment; P-trend=0.02), while scallion intake showed no association. [https://pubmed.ncbi.nlm.nih.gov/36789941/]
  - Allium vegetables intake and the risk of gastric cancer in the Stomach cancer Pooling (StoP) Project, British journal of cancer (2022) — Pooled analysis of the Stomach cancer Pooling (StoP) Project found non-significant inverse associations for any vs no consumption of allium vegetables (OR 0.84; 95% CI 0.66-1.08), onions (OR 0.88; 95% CI 0.77-1.01), and garlic (OR 0.92; 95% CI 0.80-1.06). [https://pmc.ncbi.nlm.nih.gov/articles/PMC9174191/]

---

## potato
URL: https://nutridex.info/s/potato
Category: Vegetables
Evidence: Strong — Multiple high-quality RCTs / meta-analyses with consistent effects.
Potassium- and vitamin-C-rich staple whose health effect hinges almost entirely on how it is cooked

Quick answer: potato is used for boiled/baked/mashed potatoes show no significant link to type 2 diabetes in large us cohorts. NutriDex grades the human evidence as strong — Multiple high-quality RCTs / meta-analyses with consistent effects. Based on 11 cited human studies (11 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

The potato is a starchy tuber that is nutrient-modest but a meaningful source of potassium, vitamin C and vitamin B6, with no fat and a useful 3 g of fibre per boiled medium tuber. The strongest human evidence — large US cohorts (NHS, NHS II, HPFS; 205,107 adults) pooled in a 2025 BMJ analysis — shows that the diabetes risk attributed to potatoes is driven almost entirely by French fries (HR 1.20 per 3 servings/week), while baked, boiled and mashed potatoes carry no significant association (HR 1.01). Cardiovascular cohorts (HUNT, harmonised 7-cohort analysis) likewise find boiled/baked potatoes neutral for CVD and mortality, and small crossover RCTs show that cooling cooked potatoes raises resistant starch and blunts the post-meal glucose and insulin spike. The practical message is that preparation, portion and what the potato displaces (whole grains lower T2D risk when substituted) matter far more than the tuber itself.

Nutrition (per 1 medium, boiled without skin (167 g)): 144 kcal; Vitamin C 12.4mg (14% DV), Fiber 3g (11% DV), Potassium 548mg (12% DV), Folate 15µg (4% DV), Vitamin A 0µg (0% DV), Vitamin K 3.7µg (3% DV), Vitamin B6 0.45mg (26% DV), Manganese 0.23mg (10% DV).
Benefits / uses: Boiled/baked/mashed potatoes show no significant link to type 2 diabetes in large US cohorts; Notable potassium source (~548 mg per medium tuber) supporting normal blood pressure; Meaningful vitamin C and vitamin B6 contribution with zero fat; Cooking-then-cooling raises resistant starch and lowers the postprandial glucose/insulin response; Neutral association with cardiovascular disease and all-cause mortality when not fried.
Active compounds: Resistant starch (RS3, formed on cooling); Potassium; Vitamin C (ascorbic acid); Vitamin B6 (pyridoxine); Chlorogenic acid (hydroxycinnamic acid); Anthocyanins (in purple/red varieties); Carotenoids (in yellow-fleshed varieties); Glycoalkaloids (solanine, chaconine).
Dose: Standard serving: 1 medium, boiled without skin (167 g). Eat whole (with skin where edible); favour whole fruit over juice.
Safety: Health effects depend heavily on preparation: deep-fried forms (French fries, chips) are consistently linked to higher type 2 diabetes, hypertension and mortality risk, whereas boiled, baked and mashed potatoes are largely neutral. Potatoes have a high glycaemic index, so large portions can sharply raise blood glucose in people with diabetes or insulin resistance (cooling/retrogradation reduces this). Green, sprouted or damaged potatoes accumulate solanine and chaconine (glycoalkaloids) that are toxic in quantity, causing GI and neurological symptoms — discard green parts and sprouts and store in the dark. Acrylamide also forms when potatoes are fried or roasted at high temperatures. People on potassium-restricted (renal) diets should account for the potassium load.

Cited studies (11):
  - Total and specific potato intake and risk of type 2 diabetes: results from three US cohort studies and a substitution meta-analysis of prospective cohorts, BMJ (Clinical research ed.) (2025) — Pooled analysis of 3 US cohorts (205,107 adults, 22,299 T2D cases, 5.2M person-years): French fries raised T2D risk (HR 1.20 per 3 servings/week, 95% CI 1.12-1.28) while baked/boiled/mashed potatoes did not (HR 1.01, 0.98-1.05); replacing potatoes with whole grains lowered risk. [https://pmc.ncbi.nlm.nih.gov/articles/PMC12326520/]
  - Total and specific potato intake and risk of type 2 diabetes: results from three US cohort studies and a substitution meta-analysis of prospective cohorts, BMJ (Clinical research ed.) (2025) — Across three US cohorts plus a meta-analysis of 13 cohorts (587,081 participants, 43,471 cases), each 3 servings/week of total potato carried HR 1.03 (95% CI 1.02-1.05) and fried potato HR 1.16 (1.09-1.23) for type 2 diabetes; replacing fried potatoes with whole grains lowered risk ~17%. [https://pubmed.ncbi.nlm.nih.gov/40769531/]
  - Potatoes and risk of chronic disease: a systematic review and dose-response meta-analysis, European journal of nutrition (2019) — In a dose-response meta-analysis (search through July 2023), total potato intake showed no association with all-cause mortality, CHD, or stroke, while each 150 g/day of french fries was associated with higher type 2 diabetes (RR 1.66, 95% CI 1.43-1.94) and hypertension (RR 1.37, 95% CI 1.15-1.63). [https://pmc.ncbi.nlm.nih.gov/articles/PMC6689281/]
  - Potato consumption and risk of type 2 diabetes: A dose-response meta-analysis of cohort studies, Clinical nutrition ESPEN (2018) — Dose-response meta-analysis of 6 prospective cohorts (4,545,230 person-years; 17,758 T2D cases) found each additional daily serving of total potatoes was associated with a 20% higher risk of type 2 diabetes (RR 1.20, 95% CI 1.13-1.27). [https://pubmed.ncbi.nlm.nih.gov/30144898/]
  - Potatoes Consumption and Risk of Type 2 Diabetes: A Meta-analysis, Iranian journal of public health (2018) — Systematic review of cohort studies found total potato intake was not associated with type 2 diabetes overall, but high French-fry intake was associated with increased T2D risk, underscoring the role of frying. [https://pmc.ncbi.nlm.nih.gov/articles/PMC6294859/]
  - Potatoes Compared with Rice in Meals with either Animal or Plant Protein Reduce Postprandial Glycemia and Increase Satiety in Healthy Adults: A Randomized Crossover Study, The Journal of nutrition (2024) — In a randomized crossover trial of 26 healthy adults, potatoes compared with rice (with animal or plant protein) reduced postprandial glycemia and increased satiety. [https://pmc.ncbi.nlm.nih.gov/articles/PMC11522892/]
  - Chilled Potatoes Decrease Postprandial Glucose, Insulin, and Glucose-dependent Insulinotropic Peptide Compared to Boiled Potatoes in Females with Elevated Fasting Glucose and Insulin, Nutrients (2019) — Randomized crossover trial in females with elevated fasting glucose/insulin: chilled (vs hot) cooked potatoes reduced postprandial glucose, insulin and GIP areas-under-curve by 49.9%, 40.5% and 71.1% respectively, via increased resistant starch. [https://pmc.ncbi.nlm.nih.gov/articles/PMC6769955/]
  - Potato Consumption and Risk of Cardiovascular Disease in a Harmonized Analysis of Seven Prospective Cohorts, Nutrients (2025) — Harmonised analysis of 7 prospective cohorts (CVD n=110,063; hypertension n=67,146): total and baked/boiled/mashed potatoes were not associated with CVD or hypertension, whereas fried potato intake (1+ vs 0 servings/week) was linked to a 10% higher hypertension risk. [https://pmc.ncbi.nlm.nih.gov/articles/PMC11820226/]
  - Potato Consumption and Risk of Type 2 Diabetes Mellitus: A Harmonized Analysis of 7 Prospective Cohorts, The Journal of nutrition (2024) — In harmonized data from 7 US cohorts (N=105,531), total potato intake was not associated with T2D risk (HR 1.07, 95% CI 0.99-1.16 for 5+ servings/week), whereas fried potato was (HR 1.12, 95% CI 1.03-1.22 for >1 serving/week). [https://pubmed.ncbi.nlm.nih.gov/39289134/]
  - Frequency of Boiled Potato Consumption and All-Cause and Cardiovascular Disease Mortality in the Prospective Population-Based HUNT Study, Frontiers in nutrition (2021) — Population cohort of 49,926 Norwegian adults over 10 years (4,084 deaths): frequency of boiled-potato consumption showed no association with all-cause mortality (HR ~1.0) or CVD mortality, with all confidence intervals including 1.0. [https://pmc.ncbi.nlm.nih.gov/articles/PMC8326454/]
  - Potato intake and incidence of hypertension: results from three prospective US cohort studies, BMJ (Clinical research ed.) (2016) — Three US cohorts (187,453 adults): higher intake of baked/boiled/mashed potatoes and French fries was independently associated with increased risk of incident hypertension; replacing one serving/day with a non-starchy vegetable lowered risk. [https://pubmed.ncbi.nlm.nih.gov/27189229/]

---

## white-mushroom
URL: https://nutridex.info/s/white-mushroom
Category: Vegetables
Evidence: Moderate — Several controlled trials; effects real but modest or context-dependent.
Low-calorie umami fungi rich in ergothioneine, copper, selenium, and B vitamins.

Quick answer: white-mushroom is used for very low calorie, high satiety food. NutriDex grades the human evidence as moderate — Several controlled trials; effects real but modest or context-dependent. Based on 8 cited human studies (8 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

White button mushrooms (Agaricus bisporus) are very low in calories yet supply potassium, copper, selenium, B vitamins, and the antioxidant amino acids ergothioneine and glutathione. Pooled observational evidence links higher mushroom intake to modestly lower risks of total cancer, all-cause mortality, and cognitive impairment, and randomized trials show UV-exposed mushrooms raise serum 25-hydroxyvitamin D comparably to supplemental vitamin D2. Causal cardiometabolic benefits in humans remain limited, so mushrooms are best framed as a nutrient-dense, low-energy dietary addition rather than a treatment.

Nutrition (per 1 cup sliced, raw (70 g)): 15.4 kcal; Vitamin C 1.5mg (2% DV), Fiber 0.7g (3% DV), Potassium 223mg (5% DV), Folate 11.9µg (3% DV), Vitamin A 0µg (0% DV), Vitamin K 0µg (0% DV), Vitamin B6 0.073mg (4% DV), Manganese 0.033mg (1% DV).
Benefits / uses: Very low calorie, high satiety food; Linked to lower cancer risk in cohorts; Associated with reduced cognitive impairment; UV-exposed forms boost vitamin D status; Rich in ergothioneine and copper.
Active compounds: ergothioneine; glutathione; beta-glucans; vitamin D2 (ergocalciferol, in UV-exposed); selenium; copper; phytosterols.
Dose: Standard serving: 1 cup sliced, raw (70 g). Eat whole (with skin where edible); favour whole fruit over juice.
Safety: Eat cooked rather than raw — raw Agaricus bisporus contains the hydrazine agaritine, largely degraded by cooking. Wild-foraged mushrooms carry serious misidentification/poisoning risk; only cultivated mushrooms should be eaten. Generally well tolerated; mushrooms are higher in the FODMAP mannitol, which may trigger symptoms in sensitive IBS patients.

Cited studies (8):
  - An Assessment of Mushroom Consumption on Cardiometabolic Disease Risk Factors and Morbidities in Humans: A Systematic Review, Nutrients (2023) — Systematic review of mushroom consumption and cardiometabolic outcomes found limited experimental evidence for improved triglycerides and hs-CRP, but no consistent observational association with cardiovascular disease. [https://pmc.ncbi.nlm.nih.gov/articles/PMC10005148/]
  - Higher Mushroom Consumption Is Associated with Lower Risk of Cancer: A Systematic Review and Meta-Analysis of Observational Studies, Advances in nutrition (Bethesda, Md.) (2021) — Meta-analysis of 17 cancer studies found higher vs lower mushroom intake associated with lower total cancer risk (RR 0.66, 95% CI 0.55-0.78), with 10 g/day linked to 17% lower risk (RR 0.83, 95% CI 0.73-0.96). [https://pmc.ncbi.nlm.nih.gov/articles/PMC8483951/]
  - Prospective study of dietary mushroom intake and risk of mortality: results from continuous National Health and Nutrition Examination Survey (NHANES) 2003-2014 and a meta-analysis, Nutrition journal (2021) — Pooled analysis of 5 prospective cohorts (601,893 participants, 50,787 deaths) found mushroom consumption associated with lower all-cause mortality (pooled RR 0.94, 95% CI 0.91-0.98; I2=15%). [https://pmc.ncbi.nlm.nih.gov/articles/PMC8454070/]
  - Dietary mushroom intake may reduce the risk of breast cancer: evidence from a meta-analysis of observational studies, PloS one (2014) — Meta-analysis of observational studies found dietary mushroom intake associated with reduced breast cancer risk (highest vs lowest OR 0.65, 95% CI 0.52-0.81); 1 g/day increment RR 0.97 (95% CI 0.96-0.98). [https://pmc.ncbi.nlm.nih.gov/articles/PMC3972098/]
  - Bioavailability of vitamin D₂ from UV-B-irradiated button mushrooms in healthy adults deficient in serum 25-hydroxyvitamin D: a randomized controlled trial, European journal of clinical nutrition (2011) — 5-week single-blind RCT in 26 vitamin-D-deficient adults: UV-B-irradiated button mushrooms raised serum 25-hydroxyvitamin D by ~3.9 nmol/L per week, similar to a vitamin D2 supplement (4.7 nmol/L/week) and superior to placebo. [https://pubmed.ncbi.nlm.nih.gov/21540874/]
  - Mushroom Consumption and Risk of Total and Site-Specific Cancer in Two Large U.S. Prospective Cohorts, Cancer prevention research (Philadelphia, Pa.) (2019) — In two large US cohorts (NHS and HPFS), mushroom consumption was not significantly associated with total cancer risk (>=5 servings/week vs almost never: HR 1.06, 95% CI 0.98-1.14), tempering positive findings from case-control studies. [https://pmc.ncbi.nlm.nih.gov/articles/PMC6677603/]
  - Mushroom intake and depression: A population-based study using data from the US National Health and Nutrition Examination Survey (NHANES), 2005-2016, Journal of affective disorders (2021) — In 24,699 US adults (NHANES 2005-2016), mushroom consumers had lower odds of depression independent of demographics, lifestyle, and dietary factors, though no significant linear dose-response was seen. [https://pubmed.ncbi.nlm.nih.gov/34333177/]
  - The Association between Mushroom Consumption and Mild Cognitive Impairment: A Community-Based Cross-Sectional Study in Singapore, Journal of Alzheimer's disease : JAD (2019) — In 663 Singaporean adults aged 60+, consuming >2 portions of mushrooms per week was associated with reduced odds of mild cognitive impairment (OR 0.43, 95% CI 0.23-0.78, p=0.006). [https://pubmed.ncbi.nlm.nih.gov/30775990/]

---

## zucchini
URL: https://nutridex.info/s/zucchini
Category: Vegetables
Evidence: Strong — Multiple high-quality RCTs / meta-analyses with consistent effects.
A low-calorie, high-water summer squash that adds potassium, fiber, and vitamin C to the plate.

Quick answer: zucchini is used for supports a high-volume, low-calorie eating pattern. NutriDex grades the human evidence as strong — Multiple high-quality RCTs / meta-analyses with consistent effects. Based on 11 cited human studies (11 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Zucchini itself has not been the subject of dedicated clinical trials; the strongest human evidence comes from the food groups and nutrients it contributes to. Higher fruit-and-vegetable and dietary-fiber intakes are robustly linked in dose-response meta-analyses to lower all-cause and cardiovascular mortality, and increasing potassium intake significantly lowers blood pressure in randomized trials. The best-characterized Cucurbita pepo intervention literature concerns pumpkin-seed (not flesh) extracts for benign prostatic hyperplasia, where effects are modest and inconsistent.

Nutrition (per 1 medium, raw with skin (196 g)): 33 kcal; Vitamin C 35mg (39% DV), Fiber 2g (7% DV), Potassium 512mg (11% DV), Folate 47µg (12% DV), Vitamin A 20µg (2% DV), Vitamin K 8.4µg (7% DV), Vitamin B6 0.32mg (19% DV), Manganese 0.35mg (15% DV).
Benefits / uses: Supports a high-volume, low-calorie eating pattern; Contributes potassium that helps lower blood pressure; Adds fiber linked to lower mortality and better glycemic control; Provides vitamin C and lutein/zeaxanthin carotenoids; Hydrating (~95% water) with minimal sugar.
Active compounds: lutein; zeaxanthin; beta-carotene; vitamin C (ascorbate); potassium; dietary fiber (cellulose/pectin); phenolic acids.
Dose: Standard serving: 1 medium, raw with skin (196 g). Eat whole (with skin where edible); favour whole fruit over juice.
Safety: Very well tolerated. Rare bitter (high-cucurbitacin) zucchini can cause nausea, vomiting, and diarrhea ("toxic squash syndrome") — discard any unusually bitter squash. Modest oxalate and FODMAP content is tolerable for most; the skin contributes most of the fiber. No clinically significant vitamin-K/warfarin concern at typical intakes given the modest vitamin K content.

Cited studies (11):
  - Dietary intake of total vegetable, fruit, cereal, soluble and insoluble fiber and risk of all-cause, cardiovascular, and cancer mortality: systematic review and dose-response meta-analysis of prospective cohort studies, Frontiers in nutrition (2023) — Dose-response meta-analysis of 32 cohorts (2,567,890 participants; 171,751 deaths) found vegetable fiber per 10 g/day was NOT significantly associated with all-cause (RR 0.88, 95% CI 0.73-1.05) or CVD mortality (RR 0.91, 95% CI 0.78-1.06), unlike cereal fiber. [https://pmc.ncbi.nlm.nih.gov/articles/PMC10579821/]
  - Potassium Intake and Blood Pressure: A Dose-Response Meta-Analysis of Randomized Controlled Trials, Journal of the American Heart Association (2020) — Dose-response analysis of 32 RCTs found increasing potassium intake reduced systolic BP, with the greatest effect in those with higher sodium intake. [https://www.ahajournals.org/doi/10.1161/JAHA.119.015719]
  - Impact of energy density on energy intake in children and adults: a systematic review and meta-analysis of randomized controlled trials, European journal of nutrition (2023) — Meta-analysis of 38 RCTs (1,831 participants) found lowering dietary energy density (e.g., by adding low-calorie vegetables like zucchini) cut energy intake by 223 kcal (95% CI -259.7 to -186.0) while food weight stayed constant. [https://pmc.ncbi.nlm.nih.gov/articles/PMC10030411/]
  - Fruit and vegetable intake and the risk of cardiovascular disease, total cancer and all-cause mortality-a systematic review and dose-response meta-analysis of prospective studies, International journal of epidemiology (2017) — Across 95 prospective studies, each 200 g/day of fruit and vegetables was associated with lower all-cause mortality, with risk reductions plateauing around 800 g/day (RR ~0.69 vs lowest intake). [https://pubmed.ncbi.nlm.nih.gov/28338764/]
  - Carbohydrate quality and human health: a series of systematic reviews and meta-analyses, Lancet (London, England) (2019) — Highest vs lowest dietary fiber intake was associated with a 15-30% reduction in all-cause and cardiovascular mortality, with benefit per 8 g/day; RCTs showed lower body weight and cholesterol. [https://pubmed.ncbi.nlm.nih.gov/30638909/]
  - Oral potassium supplementation for management of essential hypertension: A meta-analysis of randomized controlled trials, PloS one (2017) — Oral potassium supplementation lowered systolic/diastolic BP by ~4.5/3.0 mmHg in hypertensive adults across pooled randomized controlled trials. [https://pubmed.ncbi.nlm.nih.gov/28419159/]
  - Complementary and Alternative Medicine for Menopause, Journal of evidence-based integrative medicine (2019) — Pumpkin seed (Cucurbita pepo) soft extract improved IPSS lower-urinary-tract symptom scores vs placebo over 12 months in men with BPH, with modest quality-of-life gains. [https://pmc.ncbi.nlm.nih.gov/articles/PMC6419242/]
  - Effect of increased potassium intake on cardiovascular risk factors and disease: systematic review and meta-analyses, BMJ (Clinical research ed.) (2013) — Increased potassium intake reduced systolic blood pressure by 3.49 mmHg (95% CI 1.82-5.15) in adults with hypertension and was associated with 24% lower stroke risk. [https://pubmed.ncbi.nlm.nih.gov/23558164/]
  - Cruciferous vegetables improve glycaemic control compared to root/squash vegetables in a randomized, controlled, crossover trial: The VEgetableS for vaScular hEaLth (VESSEL) study, Diabetes, obesity & metabolism (2025) — In an 18-adult randomized crossover trial, root/squash vegetables (zucchini's class) did NOT improve glycemic variability, whereas cruciferous vegetables reduced 24h glucose variability by -2.0% (95% CI -2.8 to -1.1; p<0.001) over the squash arm. [https://pmc.ncbi.nlm.nih.gov/articles/PMC12232361/]
  - Pumpkin seed oil (Cucurbita pepo) versus tamsulosin for benign prostatic hyperplasia symptom relief: a single-blind randomized clinical trial, BMC urology (2021) — In a single-blind RCT (n=73), Cucurbita pepo seed oil reduced BPH IPSS symptoms (-3.19 at 3 months) but significantly less than tamsulosin (-5.33; p=0.020), with no side effects. [https://pmc.ncbi.nlm.nih.gov/articles/PMC8527717/]
  - Secondary analyses of the effects of lutein/zeaxanthin on age-related macular degeneration progression: AREDS2 report No. 3, JAMA ophthalmology (2014) — In 4203 participants, adding lutein/zeaxanthin reduced progression to advanced AMD by ~26% among those in the lowest dietary lutein/zeaxanthin quintile (HR 0.74). [https://pubmed.ncbi.nlm.nih.gov/24310343/]

---

## swiss-chard
URL: https://nutridex.info/s/swiss-chard
Category: Vegetables
Evidence: Moderate — Several controlled trials; effects real but modest or context-dependent.
A nitrate- and vitamin K-dense leafy green from the beet family.

Quick answer: swiss-chard is used for supports cardiovascular health (leafy-green association). NutriDex grades the human evidence as moderate — Several controlled trials; effects real but modest or context-dependent. Based on 8 cited human studies (8 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Swiss chard is a Beta vulgaris leafy green exceptionally rich in vitamin K, provitamin-A carotenoids, magnesium, and dietary nitrate. The strongest human evidence is indirect and category-level: large prospective cohorts and meta-analyses consistently link green leafy vegetable intake to lower cardiovascular disease, slower cognitive decline, and reduced glaucoma risk, while pooled RCTs of inorganic/dietary nitrate show modest blood-pressure and vascular benefits in healthy adults. Chard-specific clinical trials are sparse, so benefits are inferred from its leafy-green and nitrate profile.

Nutrition (per 1 cup chopped, raw (36 g)): 7 kcal; Vitamin C 10.8mg (12% DV), Fiber 0.6g (2% DV), Potassium 136mg (3% DV), Folate 5µg (1% DV), Vitamin A 110µg (12% DV), Vitamin K 299µg (249% DV), Vitamin B6 0.036mg (2% DV), Manganese 0.13mg (6% DV).
Benefits / uses: Supports cardiovascular health (leafy-green association); Provides dietary nitrate that may modestly lower blood pressure; Linked to slower age-related cognitive decline; Associated with lower glaucoma risk; Outstanding source of vitamin K and provitamin-A carotenoids.
Active compounds: dietary nitrate; vitamin K1 (phylloquinone); lutein; zeaxanthin; beta-carotene; betalains (betacyanin/betaxanthin); kaempferol; syringic acid.
Dose: Standard serving: 1 cup chopped, raw (36 g). Eat whole (with skin where edible); favour whole fruit over juice.
Safety: Very high in vitamin K (~300 ug per cup raw), which can interfere with warfarin/vitamin-K-antagonist anticoagulants — keep intake consistent and consult a clinician. Also high in oxalates, so people prone to calcium-oxalate kidney stones should moderate intake; oxalate also reduces absorption of the calcium it contains.

Cited studies (8):
  - Plasma nitrate, dietary nitrate, blood pressure, and vascular health biomarkers: a GRADE-Assessed systematic review and dose-response meta-analysis of randomized controlled trials, Nutrition journal (2025) — GRADE-assessed dose-response meta-analysis of RCTs found dietary/plasma nitrate significantly improved blood pressure and vascular function (flow-mediated dilation) biomarkers. [https://pmc.ncbi.nlm.nih.gov/articles/PMC11931885/]
  - Relation of Different Fruit and Vegetable Sources With Incident Cardiovascular Outcomes: A Systematic Review and Meta-Analysis of Prospective Cohort Studies, Journal of the American Heart Association (2020) — Systematic review/meta-analysis (95 cohorts) found one daily serving of green leafy vegetables associated with 12-18% lower risk of CVD, CHD, and stroke. [https://www.ahajournals.org/doi/10.1161/JAHA.120.017728]
  - Effect of inorganic nitrate supplementation on blood pressure in older adults: A systematic review and meta-analysis, Nitric oxide : biology and chemistry (2021) — Meta-analysis of 19 RCTs found inorganic nitrate lowered systolic blood pressure by 2.42 mmHg (95% CI -4.28 to -0.57, p=0.01) in healthy adults, with no significant effect in hypertensives. [https://pubmed.ncbi.nlm.nih.gov/33905826/]
  - The effect of green leafy and cruciferous vegetable intake on the incidence of cardiovascular disease: A meta-analysis, JRSM cardiovascular disease (2016) — Meta-analysis of 8 cohorts found green leafy/cruciferous vegetable intake associated with ~16% lower cardiovascular disease incidence (RR 0.842, 95% CI 0.753-0.941, p=0.002). [https://pmc.ncbi.nlm.nih.gov/articles/PMC4973479/]
  - Fruit and vegetable intake and the risk of cardiovascular disease, total cancer and all-cause mortality-a systematic review and dose-response meta-analysis of prospective studies, International journal of epidemiology (2017) — Dose-response meta-analysis of 95 studies showed CVD and all-cause mortality risk fell with fruit/vegetable intake up to ~800 g/day, with green leafy vegetables among the most protective sources. [https://pubmed.ncbi.nlm.nih.gov/28338764/]
  - A randomized clinical trial of the effects of leafy green vegetables and inorganic nitrate on blood pressure, The American journal of clinical nutrition (2020) — Randomized crossover/controlled trials of nitrate-rich leafy vegetables support nitrate-to-nitric-oxide conversion as a plausible mechanism for vascular benefit (AJCN RCT, n=243). [https://pmc.ncbi.nlm.nih.gov/articles/PMC7338722/]
  - Nutrients and bioactives in green leafy vegetables and cognitive decline: Prospective study, Neurology (2018) — Prospective study (n=960, ~4.7 y) found ~1 serving/day of green leafy vegetables associated with slower cognitive decline equivalent to being 11 years younger. [https://pmc.ncbi.nlm.nih.gov/articles/PMC5772164/]
  - Association of Dietary Nitrate Intake With Primary Open-Angle Glaucoma: A Prospective Analysis From the Nurses' Health Study and Health Professionals Follow-up Study, JAMA ophthalmology (2016) — In two cohorts (n=104,987; 1,483 POAG cases), highest vs lowest dietary nitrate/green-leafy-vegetable intake was associated with ~20-30% lower primary open-angle glaucoma risk. [https://pubmed.ncbi.nlm.nih.gov/26767881/]

---

## green-beans
URL: https://nutridex.info/s/green-beans
Category: Vegetables
Evidence: Moderate — Several controlled trials; effects real but modest or context-dependent.
A low-calorie pod legume delivering fiber, vitamin K, and folate with the cardiometabolic pedigree of the bean family.

Quick answer: green-beans is used for modestly lowers ldl cholesterol (pulse family). NutriDex grades the human evidence as moderate — Several controlled trials; effects real but modest or context-dependent. Based on 8 cited human studies (8 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Green beans are the immature pods of the common bean (Phaseolus vulgaris), so the strongest human evidence comes from pulse/legume RCTs and large cohort studies: pulse-rich diets modestly lower LDL cholesterol and improve glycemic control, and higher legume and green-vegetable intake tracks with lower cardiovascular and colorectal-cancer risk. As a fresh pod they are far lower in protein and starch than dried beans but still contribute fiber, vitamin K, folate, and potassium with very few calories. The direct trial evidence for snap beans specifically is limited; benefits are extrapolated from the wider legume and dietary-fiber literature.

Nutrition (per 1 cup whole, raw (100 g)): 31 kcal; Vitamin C 12.2mg (14% DV), Fiber 2.7g (10% DV), Potassium 211mg (4% DV), Folate 33µg (8% DV), Vitamin A 35µg (4% DV), Vitamin K 14.4µg (12% DV), Vitamin B6 0.14mg (8% DV), Manganese 0.22mg (10% DV).
Benefits / uses: Modestly lowers LDL cholesterol (pulse family); Improves glycemic control and HbA1c; Supports healthy body weight and satiety; Linked to lower cardiovascular disease risk; Fiber, vitamin K and folate, low in calories.
Active compounds: soluble & insoluble fiber; resistant starch; flavonols (quercetin, kaempferol); chlorophyll; vitamin K1 (phylloquinone); carotenoids (lutein, beta-carotene).
Dose: Standard serving: 1 cup whole, raw (100 g). Eat whole (with skin where edible); favour whole fruit over juice.
Safety: Generally very safe. Raw or undercooked pods contain lectins (phytohaemagglutinin) and oligosaccharide FODMAPs that can cause gas or GI upset in sensitive people; brief cooking minimizes both. The meaningful vitamin K1 content can affect INR stability in people on warfarin, who should keep intake consistent rather than avoid it.

Cited studies (8):
  - Legume consumption in adults and risk of cardiovascular disease and type 2 diabetes: a systematic review and meta-analysis, Food & nutrition research (2023) — Systematic review and meta-analysis of cohorts: higher legume intake was inversely associated with cardiovascular disease (RR 0.94) and coronary heart disease (RR 0.90), with benefit around 400 g/week. [https://pmc.ncbi.nlm.nih.gov/articles/PMC10243120/]
  - Pulse consumption improves indices of glycemic control in adults with and without type 2 diabetes: a systematic review and meta-analysis of acute and long-term randomized controlled trials, European journal of nutrition (2022) — Meta-analysis of long-term and acute RCTs: pulse intake lowered HbA1c by ~0.3% (effect size -0.17) and reduced fasting glucose and HOMA-IR in adults with type 2 diabetes. [https://pmc.ncbi.nlm.nih.gov/articles/PMC8854292/]
  - Do Common Beans (Phaseolus vulgaris L.) Promote Good Health in Humans? A Systematic Review and Meta-Analysis of Clinical and Randomized Controlled Trials, Nutrients (2021) — Systematic review and meta-analysis of clinical and randomized trials (23 articles) reported common beans (Phaseolus vulgaris) reduced LDL cholesterol by ~19%, cardiovascular disease risk by 11%, and coronary heart disease risk by 22%. [https://pmc.ncbi.nlm.nih.gov/articles/PMC8619065/]
  - Effects of dietary pulse consumption on body weight: a systematic review and meta-analysis of randomized controlled trials, The American Journal of Clinical Nutrition (2016) — Meta-analysis of 21 RCTs (n=940): diets including ~1 serving/d of pulses reduced body weight by -0.34 kg (95% CI -0.63 to -0.04), even without intentional calorie restriction. [https://academic.oup.com/ajcn/article-pdf/103/5/1213/23767955/ajcn124677.pdf]
  - The effect of green leafy and cruciferous vegetable intake on the incidence of cardiovascular disease: A meta-analysis, JRSM cardiovascular disease (2016) — Meta-analysis of 8 cohorts: each higher category of green leafy and cruciferous vegetable intake was associated with a 15.8% lower incidence of cardiovascular disease (RR 0.842, 95% CI 0.753-0.941). [https://pmc.ncbi.nlm.nih.gov/articles/PMC4973479/]
  - Dietary legume consumption reduces risk of colorectal cancer: evidence from a meta-analysis of cohort studies, Scientific reports (2015) — Meta-analysis of 14 cohorts (1.9M participants, 12,261 cases): higher legume consumption was associated with a 9% lower colorectal cancer risk (RR 0.91, 95% CI 0.84-0.98). [https://pubmed.ncbi.nlm.nih.gov/25739376/]
  - Carbohydrate quality and human health: a series of systematic reviews and meta-analyses, The Lancet (2019) — Series of systematic reviews and meta-analyses: higher dietary fiber intake (25-29 g/d) lowered all-cause mortality (RR 0.85) and incidence of CHD, stroke and type 2 diabetes by 16-24%. [https://www.thelancet.com/article/S0140-6736(18)31809-9/fulltext]
  - Effect of dietary pulse intake on established therapeutic lipid targets for cardiovascular risk reduction: a systematic review and meta-analysis of randomized controlled trials, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne (2014) — Meta-analysis of 26 RCTs (n=1037): dietary pulses at ~130 g/d lowered LDL cholesterol by -0.17 mmol/L (95% CI -0.25 to -0.09). [https://pmc.ncbi.nlm.nih.gov/articles/PMC4016088/]

---

## carrot
URL: https://nutridex.info/s/carrot
Category: Vegetables
Evidence: Moderate — Several controlled trials; effects real but modest or context-dependent.
The beta-carotene benchmark — a sweet, crunchy provitamin-A powerhouse linked to lower cancer risk.

Quick answer: carrot is used for exceptional provitamin-a (alpha-/beta-carotene) for vision and immune support. NutriDex grades the human evidence as moderate — Several controlled trials; effects real but modest or context-dependent. Based on 10 cited human studies (10 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

A single cup of raw carrots delivers over a full day's vitamin A as provitamin-A carotenoids (alpha- and beta-carotene), with fiber and potassium for modest extra benefit. Prospective-cohort meta-analyses consistently link higher carrot intake and higher circulating alpha-/beta-carotene to lower overall cancer incidence and lower all-cause mortality, with dose-response gradients. Importantly, whole-food carrots differ from high-dose beta-carotene supplements, which raised lung-cancer risk in smokers in landmark RCTs (CARET, ATBC) — a key distinction for clinical counseling.

Nutrition (per 1 cup chopped, raw (128 g)): 52 kcal; Vitamin C 7.6mg (8% DV), Fiber 3.6g (13% DV), Potassium 410mg (9% DV), Folate 24µg (6% DV), Vitamin A 1069µg (119% DV), Vitamin K 16.9µg (14% DV), Vitamin B6 0.18mg (11% DV), Manganese 0.18mg (8% DV).
Benefits / uses: Exceptional provitamin-A (alpha-/beta-carotene) for vision and immune support; Higher intake linked to lower overall cancer incidence (dose-responsive); Circulating carotenoids tied to lower all-cause mortality; Carotenoid intake associated with lower type-2-diabetes risk; Lutein/zeaxanthin support macular and eye health.
Active compounds: beta-carotene; alpha-carotene; lutein; zeaxanthin; falcarinol (polyacetylene); falcarindiol.
Dose: Standard serving: 1 cup chopped, raw (128 g). Eat whole (with skin where edible); favour whole fruit over juice.
Safety: Whole carrots are very safe. High intake can cause harmless skin yellowing (carotenemia). Crucially, high-dose beta-carotene SUPPLEMENTS (not food) increased lung cancer risk in smokers/asbestos-exposed individuals (CARET, ATBC) — favor dietary carotenoids over supplements, especially in smokers.

Cited studies (10):
  - Carrot intake is consistently negatively associated with cancer incidence: A systematic review and meta-analysis of prospective observational studies, Critical reviews in food science and nutrition (2025) — Meta-analysis of prospective cohorts (~52,000 cancer cases) found higher carrot intake associated with lower overall cancer incidence (RR 0.90, 95% CI 0.87-0.94), with a dose-response (~5 servings/week ~20% lower risk). [https://pubmed.ncbi.nlm.nih.gov/38104588/]
  - Carrot and carotene and multiple health outcomes: an umbrella review of the evidence, Journal of the science of food and agriculture (2023) — Umbrella review of 30 meta-analyses (26 outcomes) found carrot intake associated with lower risk of breast, lung, pancreatic, gastric, urothelial, and prostate cancers, and serum carotene inversely associated with all-cause mortality. [https://pubmed.ncbi.nlm.nih.gov/36600678/]
  - Dietary Intake and Circulating Concentrations of Carotenoids and Risk of Type 2 Diabetes: A Dose-Response Meta-Analysis of Prospective Observational Studies, Advances in nutrition (Bethesda, Md.) (2021) — Dose-response meta-analysis of prospective cohorts: dietary beta-carotene inversely associated with type 2 diabetes risk (RR 0.78, 95% CI 0.70-0.87, highest vs lowest). [https://pubmed.ncbi.nlm.nih.gov/33979433/]
  - Dietary, circulating beta-carotene and risk of all-cause mortality: a meta-analysis from prospective studies, Scientific reports (2016) — Meta-analysis of prospective studies: highest vs lowest dietary beta-carotene associated with lower all-cause mortality (RR 0.83); high circulating beta-carotene RR 0.69. [https://pmc.ncbi.nlm.nih.gov/articles/PMC4886629/]
  - Short-term temperature effect on the HRMAS spectra of human brain tumor biopsies and their pattern recognition analysis, Magma (New York, N.Y.) (2010) — Pooled RCTs of beta-carotene supplementation (≥20 mg/d) showed increased lung cancer incidence (RR 1.16, 95% CI 1.06-1.27) and gastric cancer in smokers/asbestos-exposed — landmark CARET/ATBC harm signal. [https://pubmed.ncbi.nlm.nih.gov/20549297/]
  - Long-term Outcomes of Adding Lutein/Zeaxanthin and ω-3 Fatty Acids to the AREDS Supplements on Age-Related Macular Degeneration Progression: AREDS2 Report 28, JAMA Ophthalmology (2022) — 10-year follow-on of the AREDS2 RCT: lutein/zeaxanthin vs no lutein/zeaxanthin lowered progression to late AMD (HR 0.91, 95% CI 0.84-0.99) and avoided beta-carotene's lung-cancer risk. [https://jamanetwork.com/journals/jamaophthalmology/fullarticle/2792855]
  - Lutein + Zeaxanthin and Omega-3 Fatty Acids for Age-Related Macular Degeneration: The Age-Related Eye Disease Study 2 (AREDS2) Randomized Clinical Trial, JAMA (2013) — RCT (n=4203) — adding lutein/zeaxanthin to the AREDS formula reduced progression to advanced AMD in participants with low dietary lutein/zeaxanthin (HR 0.74) and is the preferred substitute for beta-carotene. [https://jamanetwork.com/journals/jama/fullarticle/1684847]
  - Drinking carrot juice increases total antioxidant status and decreases lipid peroxidation in adults, Nutrition journal (2011) — Controlled trial in healthy adults: 16 oz/day carrot juice for 3 months raised total plasma antioxidant capacity and reduced lipid peroxidation (malondialdehyde) without changing blood pressure or lipids. [https://pmc.ncbi.nlm.nih.gov/articles/PMC3192732/]
  - Carrot Intake and Risk of Developing Cancer: A Prospective Cohort Study, Nutrients (2023) — Prospective cohort (~55,756 Danes, up to 25 y follow-up) found regular raw carrot intake associated with dose-dependent lower lung cancer incidence (HR 0.76, 95% CI 0.66-0.87); no effect for processed carrots. [https://pmc.ncbi.nlm.nih.gov/articles/PMC9919376/]
  - Carrot Intake and Risk of Colorectal Cancer: A Prospective Cohort Study of 57,053 Danes, Nutrients (2020) — Prospective cohort of 57,053 Danes (>18 y follow-up) found intake of >32 g/day raw carrots associated with 17% lower colorectal cancer risk versus no intake. [https://pmc.ncbi.nlm.nih.gov/articles/PMC7071341/]

---

## eggplant
URL: https://nutridex.info/s/eggplant
Category: Vegetables
Evidence: Moderate — Several controlled trials; effects real but modest or context-dependent.
A low-calorie, high-fiber nightshade rich in skin anthocyanins (nasunin) and chlorogenic acid.

Quick answer: eggplant is used for modest blood-pressure lowering (chlorogenic acid). NutriDex grades the human evidence as moderate — Several controlled trials; effects real but modest or context-dependent. Based on 11 cited human studies (11 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Eggplant is a very low-energy, fiber-containing vegetable whose deep-purple skin concentrates the anthocyanin nasunin and whose flesh is one of the richest dietary sources of chlorogenic acid. Direct randomized trials on whole eggplant are scarce, so the strongest human evidence comes from its signature bioactives and food groups: chlorogenic acid lowers blood pressure modestly in RCT meta-analyses, dietary anthocyanin and flavonoid intake track with lower cardiovascular mortality in large cohorts, and higher fiber intake is robustly tied to lower all-cause and CVD mortality. Effects are real but generally modest, and most glycemic/lipid data derive from concentrated extracts rather than the vegetable itself.

Nutrition (per 1 cup cubed, raw (82 g)): 20.5 kcal; Vitamin C 1.8mg (2% DV), Fiber 2.5g (9% DV), Potassium 188mg (4% DV), Folate 18µg (5% DV), Vitamin A 1µg (0% DV), Vitamin K 2.9µg (2% DV), Vitamin B6 0.069mg (4% DV), Manganese 0.19mg (8% DV).
Benefits / uses: Modest blood-pressure lowering (chlorogenic acid); Associated with lower cardiovascular mortality (anthocyanins/flavonoids); Very low calorie, supports weight management; Provides fiber linked to lower mortality; Antioxidant nasunin protects lipids from oxidation.
Active compounds: chlorogenic acid; nasunin (delphinidin anthocyanin); anthocyanins; flavonoids; dietary fiber.
Dose: Standard serving: 1 cup cubed, raw (82 g). Eat whole (with skin where edible); favour whole fruit over juice.
Safety: A nightshade containing solanine-type glycoalkaloids, but at low levels in ripe culinary eggplant; very high intake or unripe fruit can cause GI upset. Oxalate content is moderate (caution with recurrent calcium-oxalate kidney stones). Rare oral-allergy/histamine sensitivity reported. Deep-frying dramatically increases calorie and fat load.

Cited studies (11):
  - The effects of green coffee bean extract on blood pressure and heart rate: A systematic review and dose-response meta-analysis of randomized controlled trials, Diabetes & metabolic syndrome (2024) — Dose-response meta-analysis (10 RCTs, 563 participants) found green coffee bean extract (rich in chlorogenic acid) significantly lowered systolic BP (WMD -2.95 mmHg, 95% CI -4.27 to -1.62) and diastolic BP (WMD -2.15 mmHg, 95% CI -2.59 to -1.72), with no change in heart rate. [https://pubmed.ncbi.nlm.nih.gov/39368321/]
  - Dietary Flavonoids and Cardiovascular Disease: A Comprehensive Dose-Response Meta-Analysis, Molecular Nutrition & Food Research (2021) — Dose-response meta-analysis (39 cohorts, >1.5 million people) found anthocyanins and flavan-3-ols inversely associated with cardiovascular disease risk. [https://onlinelibrary.wiley.com/doi/10.1002/mnfr.202001019]
  - The effect of green coffee extract supplementation on cardio metabolic risk factors: a systematic review and meta-analysis of randomized controlled trials, Journal of diabetes and metabolic disorders (2020) — Systematic review/meta-analysis of RCTs found green coffee (chlorogenic acid) extract significantly reduced fasting blood sugar, insulin and triglycerides and raised HDL. [https://pubmed.ncbi.nlm.nih.gov/32550217/]
  - The Effect of Green Coffee Bean Extract on Cardiovascular Risk Factors: A Systematic Review and Meta-analysis, Advances in experimental medicine and biology (2021) — Systematic review and meta-analysis of green coffee bean extract on cardiovascular risk factors found favorable effects on blood pressure and lipid/glycemic markers with a good safety profile. [https://pubmed.ncbi.nlm.nih.gov/34981487/]
  - The effect of chlorogenic acid on blood pressure: a systematic review and meta-analysis of randomized clinical trials, Journal of human hypertension (2015) — Meta-analysis of RCTs (5 trials, n=364) found chlorogenic acid supplementation reduced systolic BP by ~4.31 mmHg and diastolic by ~3.68 mmHg vs placebo. [https://pubmed.ncbi.nlm.nih.gov/24943289/]
  - Dietary intake of anthocyanins and risk of cardiovascular disease: A systematic review and meta-analysis of prospective cohort studies, Critical reviews in food science and nutrition (2019) — Systematic review/meta-analysis of prospective cohorts found higher dietary anthocyanin intake associated with lower coronary heart disease (RR 0.91, 95% CI 0.83-0.99) and CVD mortality (RR 0.92, 95% CI 0.87-0.97). [https://pubmed.ncbi.nlm.nih.gov/30277799/]
  - Effects of green coffee extract on fasting blood glucose, insulin concentration and homeostatic model assessment of insulin resistance (HOMA-IR): a systematic review and meta-analysis of interventional studies, Diabetology & metabolic syndrome (2019) — Meta-analysis of interventional studies found chlorogenic-acid-rich green coffee extract significantly lowered fasting blood glucose, with no consistent effect on insulin or HOMA-IR. [https://pmc.ncbi.nlm.nih.gov/articles/PMC6833154/]
  - Carbohydrate quality and human health: a series of systematic reviews and meta-analyses, Lancet (London, England) (2019) — Lancet series of meta-analyses found high vs low dietary fiber intake associated with 15-30% lower all-cause and cardiovascular mortality. [https://pubmed.ncbi.nlm.nih.gov/30638909/]
  - Acute dose-response effect of coffee-derived chlorogenic acids on the human vasculature in healthy volunteers: a randomized controlled trial, The American journal of clinical nutrition (2021) — Acute dose-response randomized controlled trial in healthy volunteers showed coffee-derived chlorogenic acids improved endothelial function (flow-mediated dilation) in a dose-dependent manner, supporting a vascular mechanism. [https://pmc.ncbi.nlm.nih.gov/articles/PMC7851825/]
  - Daily Ingestion of Eggplant Powder Improves Blood Pressure and Psychological State in Stressed Individuals: A Randomized Placebo-Controlled Study, Nutrients (2019) — Randomized double-blind placebo-controlled trial in 100 stressed adults found 1.2 g/day eggplant powder (2.3 mg acetylcholine/day) for 12 weeks significantly reduced diastolic BP at week 8 and systolic plus diastolic BP at week 12 versus placebo, notably in the grade 1 hypertension subgroup. [https://pmc.ncbi.nlm.nih.gov/articles/PMC6893753/]
  - Flavonoid intake is associated with lower mortality in the Danish Diet Cancer and Health Cohort, Nature communications (2019) — Danish Diet, Cancer and Health cohort (n=56,048; 23 y) found moderate flavonoid intake inversely associated with all-cause, CVD and cancer mortality, plateauing near ~500 mg/day. [https://pmc.ncbi.nlm.nih.gov/articles/PMC6692395/]

---

## arugula
URL: https://nutridex.info/s/arugula
Category: Vegetables
Evidence: Moderate — Several controlled trials; effects real but modest or context-dependent.
A peppery leafy green packed with dietary nitrate, vitamin K and glucosinolates.

Quick answer: arugula is used for supplies dietary nitrate that may modestly lower blood pressure. NutriDex grades the human evidence as moderate — Several controlled trials; effects real but modest or context-dependent. Based on 8 cited human studies (8 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Arugula is a low-calorie cruciferous leafy green that is a meaningful source of dietary inorganic nitrate, vitamin K, folate, and vitamin A, plus glucosinolates (glucoerucin) that yield the isothiocyanate erucin. Direct RCTs on arugula itself are scarce, so the strongest human evidence comes from its signature bioactives: meta-analyses of inorganic nitrate show modest blood-pressure lowering (roughly 2 to 4 mmHg systolic, larger in older adults), and prospective cohorts link higher vegetable-nitrate and green-leafy/cruciferous intake to lower cardiovascular disease incidence and mortality and slower cognitive decline. Evidence for arugula-specific clinical outcomes remains preliminary and is extrapolated from the broader leafy-green and nitrate literature.

Nutrition (per 1 cup, raw (20 g)): 5 kcal; Vitamin C 3mg (3% DV), Fiber 0.3g (1% DV), Potassium 74mg (2% DV), Folate 19.4µg (5% DV), Vitamin A 23.8µg (3% DV), Vitamin K 21.7µg (18% DV), Vitamin B6 0.015mg (1% DV), Manganese 0.064mg (3% DV).
Benefits / uses: Supplies dietary nitrate that may modestly lower blood pressure; Rich source of vitamin K and folate; High in vitamin A (carotenoids) and vitamin C; Associated with slower cognitive decline as part of leafy-green intake; Very low calorie, contributes cruciferous glucosinolates.
Active compounds: inorganic nitrate; glucoerucin; erucin (isothiocyanate); kaempferol; quercetin; lutein/zeaxanthin; vitamin K1 (phylloquinone).
Dose: Standard serving: 1 cup, raw (20 g). Eat whole (with skin where edible); favour whole fruit over juice.
Safety: High vitamin K1 content can interact with warfarin and other vitamin-K antagonists, so keep intake consistent if anticoagulated. As a raw cruciferous green it contains glucosinolates with mild goitrogenic potential at very high intakes. Dietary nitrate from vegetables is considered beneficial and is not equivalent to nitrate concerns from processed meats. Generally well tolerated and low in oxalate compared with spinach.

Cited studies (8):
  - Regulatory effect of dietary nitrate on blood pressure: a meta-analysis of randomized controlled trials, Food & function (2023) — In healthy adults, inorganic nitrate reduced systolic BP by -2.42 mmHg (95% CI -4.28 to -0.57) but not diastolic BP (-0.58 mmHg, 95% CI -1.84 to 0.68), across 19 articles. [https://pubmed.ncbi.nlm.nih.gov/36740972/]
  - Plasma nitrate, dietary nitrate, blood pressure, and vascular health biomarkers: a GRADE-Assessed systematic review and dose-response meta-analysis of randomized controlled trials, Nutrition journal (2025) — GRADE-assessed dose-response meta-analysis of RCTs found dietary nitrate intake improved blood pressure and vascular health biomarkers (e.g., flow-mediated dilation) in a dose-dependent manner. [https://pmc.ncbi.nlm.nih.gov/articles/PMC11931885/]
  - Effect of inorganic nitrate supplementation on blood pressure in older adults: A systematic review and meta-analysis, Nitric oxide : biology and chemistry (2021) — Across 22 trials, inorganic nitrate lowered systolic BP by -3.90 mmHg (95% CI -5.23 to -2.57) and diastolic BP by -2.62 mmHg (95% CI -3.86 to -1.37). [https://pubmed.ncbi.nlm.nih.gov/33905826/]
  - The effect of green leafy and cruciferous vegetable intake on the incidence of cardiovascular disease: A meta-analysis, JRSM cardiovascular disease (2016) — Highest vs lowest green leafy/cruciferous vegetable intake was associated with a 15.8% lower incidence of cardiovascular disease (RR 0.842, 95% CI 0.753-0.941; 8 studies, >540,000 participants, 26,173 cases). [https://pmc.ncbi.nlm.nih.gov/articles/PMC4973479/]
  - Vegetable nitrate intake, blood pressure and incident cardiovascular disease: Danish Diet, Cancer, and Health Study, European journal of epidemiology (2021) — In 53,150 participants, moderate vegetable nitrate intake (~60 mg/day) was associated with lower systolic BP and 12-26% lower risk of incident cardiovascular disease. [https://pmc.ncbi.nlm.nih.gov/articles/PMC8416839/]
  - Association of dietary nitrate with atherosclerotic vascular disease mortality: a prospective cohort study of older adult women, The American journal of clinical nutrition (2017) — In 1226 older women over 15 years, highest vs lowest tertile of vegetable nitrate intake had lower atherosclerotic vascular disease mortality (HR 0.79, 95% CI 0.68-0.93, p=0.004). [https://pubmed.ncbi.nlm.nih.gov/28566306/]
  - Relationship of dietary nitrate intake from vegetables with cardiovascular disease mortality: a prospective study in a cohort of older Australians, European journal of nutrition (2019) — Higher vegetable nitrate intake was associated with lower CVD mortality (e.g., quartile 3 vs 1 HR 0.51, 95% CI 0.32-0.80). [https://pubmed.ncbi.nlm.nih.gov/30238316/]
  - Nutrients and bioactives in green leafy vegetables and cognitive decline, Neurology (2018) — In 960 older adults over 4.7 years, ~1 serving/day of green leafy vegetables was linked to slower cognitive decline (0.05 standardized units/year, equivalent to being ~11 years younger). [https://www.neurology.org/doi/10.1212/WNL.0000000000004815]

---

## celery
URL: https://nutridex.info/s/celery
Category: Vegetables
Evidence: Moderate — Several controlled trials; effects real but modest or context-dependent.
A crunchy, water-rich stalk whose seed extracts and flavones nudge blood pressure down.

Quick answer: celery is used for lowers systolic and diastolic blood pressure. NutriDex grades the human evidence as moderate — Several controlled trials; effects real but modest or context-dependent. Based on 7 cited human studies (7 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Celery is very low in calories and sugar but supplies meaningful vitamin K, folate and potassium, plus the signature flavones apigenin and luteolin and aromatic phthalides (3-n-butylphthalide). A 2025 meta-analysis of 9 RCTs (511 adults) found celery preparations significantly lowered systolic and diastolic blood pressure, fasting glucose and triglycerides, and a triple-blind crossover trial of celery seed extract cut systolic pressure by roughly 11 mmHg. Population studies of dietary flavones (the apigenin/luteolin subclass) link higher intake to modestly lower breast and esophageal cancer risk and lower cardiovascular mortality, though these flavone data are observational rather than celery-specific.

Nutrition (per 1 cup chopped, raw (101 g)): 16 kcal; Vitamin C 3.1mg (3% DV), Fiber 1.6g (6% DV), Potassium 263mg (6% DV), Folate 36µg (9% DV), Vitamin A 22µg (2% DV), Vitamin K 29.6µg (25% DV), Vitamin B6 0.07mg (4% DV), Manganese 0.1mg (4% DV).
Benefits / uses: Lowers systolic and diastolic blood pressure; Reduces fasting glucose and triglycerides; Very low calorie, hydrating, high water content; Source of vitamin K, folate and potassium; Flavones linked to lower CVD mortality.
Active compounds: apigenin; luteolin; 3-n-butylphthalide (sedanolide/phthalides); p-coumaric acid; nitrate.
Dose: Standard serving: 1 cup chopped, raw (101 g). Eat whole (with skin where edible); favour whole fruit over juice.
Safety: Generally very safe as a food. Celery is a recognized allergen and can trigger oral allergy syndrome or, rarely, anaphylaxis. It contains photosensitizing furocoumarins (psoralens) that can cause phytophotodermatitis with heavy skin contact plus sun. Concentrated celery seed extracts may add to the effect of antihypertensive drugs and are best avoided in pregnancy (uterine-stimulant tradition) and with anticoagulants given the vitamin K content; whole-food amounts pose little warfarin concern.

Cited studies (7):
  - Effects of celery (Apium graveolens) on blood pressure, glycemic and lipid profile in adults: a systematic review and meta-analysis of randomized controlled trials, Frontiers in nutrition (2025) — Meta-analysis of 9 RCTs (511 adults): celery lowered systolic BP (SMD -1.0, 95% CI -1.85 to -0.14), diastolic BP (SMD -0.93, -1.54 to -0.33), fasting glucose (SMD -0.80, -1.58 to -0.01) and triglycerides (SMD -1.18, -1.45 to -0.91). [https://pmc.ncbi.nlm.nih.gov/articles/PMC12321563/]
  - Flavonoids, Flavonoid Subclasses, and Esophageal Cancer Risk: A Meta-Analysis of Epidemiologic Studies, Nutrients (2016) — Meta-analysis (7 studies, 2,629 cases): higher flavone intake was inversely associated with esophageal cancer risk (OR 0.78, 95% CI 0.64-0.95). [https://pmc.ncbi.nlm.nih.gov/articles/PMC4924191/]
  - Flavonoid intake and mortality from cardiovascular disease and all causes: A meta-analysis of prospective cohort studies, Clinical nutrition ESPEN (2017) — Meta-analysis of 15 prospective cohorts: highest vs lowest total flavonoid intake was associated with lower cardiovascular mortality (RR 0.86, 95% CI 0.75-0.98). [https://pubmed.ncbi.nlm.nih.gov/29072172/]
  - Flavonoids, flavonoid subclasses and breast cancer risk: a meta-analysis of epidemiologic studies, PloS one (2013) — Meta-analysis of epidemiologic studies: highest vs lowest dietary flavone (apigenin/luteolin) intake was associated with a 17% lower breast cancer risk (RR 0.83, 95% CI 0.76-0.91). [https://pmc.ncbi.nlm.nih.gov/articles/PMC3548848/]
  - Effect of celery (Apium graveolens) seed extract on hypertension: A randomized, triple-blind, placebo-controlled, cross-over, clinical trial, Phytotherapy research : PTR (2022) — Triple-blind placebo-controlled crossover RCT (52 hypertensive adults): celery seed extract (1.34 g/day, 4 wks) reduced systolic BP from 141.2 to 130.0 mmHg (~11 mmHg, p<0.001) with no significant adverse effects. [https://pubmed.ncbi.nlm.nih.gov/35624525/]
  - Altilix(®) Supplement Containing Chlorogenic Acid and Luteolin Improved Hepatic and Cardiometabolic Parameters in Subjects with Metabolic Syndrome: A 6 Month Randomized, Double-Blind, Placebo-Controlled Study, Nutrients (2019) — 6-month double-blind RCT (100 metabolic-syndrome adults): luteolin+chlorogenic-acid (Altilix) cut HbA1c by -0.95% (95% CI -1.22 to -0.67) and carotid intima-media thickness by -39% vs placebo. [https://pmc.ncbi.nlm.nih.gov/articles/PMC6893885/]
  - Antihypertensive Property of Celery: A Narrative Review on Current Knowledge, International journal of food science (2024) — Narrative review concluding celery and its extracts are effective hypotensive agents across hypertensive models, while noting heterogeneity in dose, extract type, species, and administration form. [https://pmc.ncbi.nlm.nih.gov/articles/PMC10950410/]

---

## cauliflower
URL: https://nutridex.info/s/cauliflower
Category: Vegetables
Evidence: Moderate — Several controlled trials; effects real but modest or context-dependent.
A low-carb cruciferous all-rounder: half a day's vitamin C with glucosinolate-derived sulforaphane.

Quick answer: cauliflower is used for lowers blood pressure (cruciferous rct). NutriDex grades the human evidence as moderate — Several controlled trials; effects real but modest or context-dependent. Based on 8 cited human studies (8 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Cauliflower is a glucosinolate-rich cruciferous vegetable whose strongest human evidence is cardiometabolic: a randomized crossover trial found ~300 g/day of cruciferous vegetables lowered 24-h systolic blood pressure by 2.5 mmHg versus root/squash vegetables, and large prospective cohorts link higher cruciferous intake to lower cardiovascular and all-cause mortality. Meta-analyses of observational studies show modest inverse associations with colorectal cancer and type 2 diabetes risk, though dose-response signals are weaker. Its signature bioactive, sulforaphane, has shown promising but still preliminary effects on glycemic control and behavioral outcomes in small RCTs.

Nutrition (per 1 cup chopped, raw (107 g)): 27 kcal; Vitamin C 51.6mg (57% DV), Fiber 2.1g (8% DV), Potassium 320mg (7% DV), Folate 61µg (15% DV), Vitamin A 0µg (0% DV), Vitamin K 16.6µg (14% DV), Vitamin B6 0.19mg (11% DV), Manganese 0.17mg (7% DV).
Benefits / uses: Lowers blood pressure (cruciferous RCT); Linked to lower cardiovascular and all-cause mortality; Inverse association with colorectal cancer; High vitamin C, very low calorie; Supports glycemic control.
Active compounds: glucoraphanin; sulforaphane; indole-3-carbinol; glucosinolates; vitamin C; kaempferol.
Dose: Standard serving: 1 cup chopped, raw (107 g). Eat whole (with skin where edible); favour whole fruit over juice.
Safety: Raw cruciferous vegetables contain goitrogens that may modestly affect thyroid function in iodine-deficient individuals at very high intakes; vitamin K (~17 ug/cup) is relevant for those on warfarin; high fiber and raffinose-family oligosaccharides (FODMAPs) can cause gas/bloating in sensitive or IBS individuals. Generally very safe as food.

Cited studies (8):
  - Unveiling the Effects of Cruciferous Vegetable Intake on Different Cancers: A Systematic Review and Dose-Response Meta-analysis, Nutrition reviews (2025) — Systematic review and dose-response meta-analysis found cruciferous vegetable intake associated with reduced overall cancer risk, with optimal protective intake around 40-60 g/day for colorectal cancer (OR 0.74-0.80). [https://pubmed.ncbi.nlm.nih.gov/39348271/]
  - Green leafy and cruciferous vegetable consumption and risk of type 2 diabetes: results from the Singapore Chinese Health Study and meta-analysis, The British journal of nutrition (2018) — Meta-analysis reported high cruciferous vegetable intake associated with ~13% lower type 2 diabetes risk, though dose-response was attenuated (per 40 g/day RR 0.93; 95% CI 0.85-1.03). [https://pubmed.ncbi.nlm.nih.gov/29457582/]
  - The effect of green leafy and cruciferous vegetable intake on the incidence of cardiovascular disease: A meta-analysis, JRSM cardiovascular disease (2016) — Meta-analysis of cohort studies found green leafy and cruciferous vegetable intake associated with a 15.8% reduced incidence of cardiovascular disease. [https://pmc.ncbi.nlm.nih.gov/articles/PMC4973479/]
  - Cruciferous vegetables intake and the risk of colorectal cancer: a meta-analysis of observational studies, Annals of oncology : official journal of the European Society for Medical Oncology (2013) — Meta-analysis of 35 studies (24 case-control, 11 prospective) found higher cruciferous vegetable intake inversely associated with colorectal cancer risk (RR 0.82; 95% CI 0.75-0.90). [https://pubmed.ncbi.nlm.nih.gov/23211939/]
  - Cruciferous vegetables lower blood pressure in adults with mildly elevated blood pressure in a randomized, controlled, crossover trial: the VEgetableS for vaScular hEaLth (VESSEL) study, BMC medicine (2024) — In a randomized controlled crossover trial (n=18, mildly elevated BP), ~300 g/day cruciferous vegetables for 2 weeks lowered 24-h systolic BP by 2.5 mmHg vs root/squash vegetables (95% CI -5.0 to -0.1; P=0.04). [https://pmc.ncbi.nlm.nih.gov/articles/PMC11367748/]
  - Effect of broccoli sprout extract and baseline gut microbiota on fasting blood glucose in prediabetes: a randomized, placebo-controlled trial, Nature microbiology (2025) — Randomized placebo-controlled trial in prediabetes (n=74) found broccoli sprout extract reduced fasting blood glucose by 0.2 mmol/L (95% CI -0.44 to -0.01; P=0.04), modulated by baseline gut microbiota. [https://pmc.ncbi.nlm.nih.gov/articles/PMC11879859/]
  - Sulforaphane treatment of autism spectrum disorder (ASD), Proceedings of the National Academy of Sciences of the United States of America (2014) — Randomized, double-blind, placebo-controlled trial (n=44 young men with ASD) found 18 weeks of sulforaphane (50-150 umol/day) significantly improved behavior scores (ABC, SRS) versus placebo, reversing after cessation. [https://pmc.ncbi.nlm.nih.gov/articles/PMC4217462/]
  - Cruciferous vegetable consumption is associated with a reduced risk of total and cardiovascular disease mortality, The American journal of clinical nutrition (2011) — In two prospective cohorts of Chinese adults, higher cruciferous vegetable intake was associated with lower total mortality (HR ~0.78) and cardiovascular mortality (P-trend=0.0004). [https://pmc.ncbi.nlm.nih.gov/articles/PMC3127519/]

---

## spinach
URL: https://nutridex.info/s/spinach
Category: Vegetables
Evidence: Strong — Multiple high-quality RCTs / meta-analyses with consistent effects.
A nutrient-dense leafy green packed with nitrate, lutein, folate, and a striking dose of vitamin K.

Quick answer: spinach is used for supports healthy blood pressure via dietary nitrate. NutriDex grades the human evidence as strong — Multiple high-quality RCTs / meta-analyses with consistent effects. Based on 10 cited human studies (10 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Spinach is among the most studied dietary sources of inorganic nitrate and the macular carotenoids lutein and zeaxanthin. Meta-analyses of randomized trials show dietary nitrate produces dose-dependent reductions in blood pressure and meaningful improvements in endothelial function, while lutein supplementation raises macular pigment optical density in age-related macular degeneration. Large cohorts further link higher nitrate-rich leafy-green intake to lower cardiovascular disease risk and slower cognitive decline.

Nutrition (per 1 cup, raw (30 g)): 6.9 kcal; Vitamin C 8.4mg (9% DV), Fiber 0.66g (2% DV), Potassium 167mg (4% DV), Folate 58µg (14% DV), Vitamin A 141µg (16% DV), Vitamin K 145µg (121% DV), Vitamin B6 0.06mg (4% DV), Manganese 0.27mg (12% DV).
Benefits / uses: Supports healthy blood pressure via dietary nitrate; Improves vascular endothelial function; Builds macular pigment for eye health; Linked to slower age-related cognitive decline; Very low energy, high micronutrient density.
Active compounds: nitrate; lutein; zeaxanthin; vitamin K1 (phylloquinone); folate; beta-carotene; kaempferol; thylakoids.
Dose: Standard serving: 1 cup, raw (30 g). Eat whole (with skin where edible); favour whole fruit over juice.
Safety: High in oxalate (~750 mg/100g raw) — relevant for calcium-oxalate kidney stone formers, who may prefer cooked spinach and adequate fluid/calcium. Very high vitamin K1 content can interfere with warfarin dosing; patients should keep intake consistent. Nitrate content is the basis of cardiovascular benefit, not a concern at dietary levels.

Cited studies (10):
  - Plasma nitrate, dietary nitrate, blood pressure, and vascular health biomarkers: a GRADE-Assessed systematic review and dose-response meta-analysis of randomized controlled trials, Nutrition journal (2025) — GRADE-assessed dose-response meta-analysis (75 RCTs, n=1,823): dietary nitrate produced dose-dependent reductions in systolic BP (medium-term -0.48 mmHg per mmol NO3, 95% CI -0.71 to -0.25) and diastolic BP, alongside rises in plasma nitrate/nitrite. [https://pmc.ncbi.nlm.nih.gov/articles/PMC11931885/]
  - The Impact of Inorganic Nitrate on Endothelial Function: A Systematic Review of Randomized Controlled Trials and Meta-analysis, Nutrition Reviews (2026) — Systematic review and meta-analysis of RCTs found inorganic nitrate improves flow-mediated dilation by a clinically relevant magnitude (>1%) versus control, with the effect abolished by antibacterial mouthwash. [https://academic.oup.com/nutritionreviews/article/84/1/36/8206174]
  - Associations between Vegetable Nitrate Intake and Cardiovascular Disease Risk and Mortality: A Systematic Review, Nutrients (2024) — Systematic review of 5 cohort studies (63,155 participants) found habitual vegetable nitrate intake inversely associated with CVD incidence and mortality, with benefit from ~one daily portion (e.g., 80 g spinach or lettuce). [https://pmc.ncbi.nlm.nih.gov/articles/PMC11124077/]
  - The level and efficacy of lutein in patients with age-related macular degeneration: a comprehensive systematic review and meta-analysis, Annals of translational medicine (2022) — Meta-analysis of RCTs (n=429): lutein supplementation significantly increased macular pigment optical density in AMD (WMD 0.07, 95% CI 0.04-0.10), with greater effect at 20 mg/day and >6 months. [https://pmc.ncbi.nlm.nih.gov/articles/PMC9011220/]
  - No Difference between the Efficacy of High-Nitrate and Low-Nitrate Vegetable Supplementation on Blood Pressure after 16 Weeks in Individuals with Early-Stage Hypertension: An Exploratory, Double-Blinded, Randomized, Controlled Trial, Nutrients (2024) — In an exploratory double-blind RCT in early-stage hypertension, 16 weeks of high-nitrate vegetable powder (60% beetroot, 28% kale, 12% spinach) produced no significant BP difference versus low-nitrate vegetable supplementation. [https://pmc.ncbi.nlm.nih.gov/articles/PMC11397180/]
  - Inter-individual differences in the blood pressure lowering effects of dietary nitrate: a randomised double-blind placebo-controlled replicate crossover trial, European journal of nutrition (2025) — A randomized double-blind placebo-controlled replicate crossover trial examined inter-individual variability in the BP-lowering response to dietary nitrate, finding heterogeneous individual responses to nitrate supplementation. [https://pmc.ncbi.nlm.nih.gov/articles/PMC11850510/]
  - Effect of Spinach, a High Dietary Nitrate Source, on Arterial Stiffness and Related Hemodynamic Measures: A Randomized, Controlled Trial in Healthy Adults, Clinical nutrition research (2015) — Randomized controlled trial in 27 healthy adults: 7-day high-nitrate spinach lowered central and brachial systolic blood pressure and reduced carotid-femoral pulse wave velocity (arterial stiffness) versus low-nitrate control. [https://pubmed.ncbi.nlm.nih.gov/26251834/]
  - Acute Effects of a Spinach Extract Rich in Thylakoids on Satiety: A Randomized Controlled Crossover Trial, Journal of the American College of Nutrition (2015) — Randomized controlled crossover trial in 60 overweight/obese adults: a 5 g concentrated spinach-thylakoid dose reduced hunger and longing for food over 2 hours versus placebo (p<0.01). [https://pubmed.ncbi.nlm.nih.gov/26029978/]
  - Vegetable nitrate intake, blood pressure and incident cardiovascular disease: Danish Diet, Cancer, and Health Study, European journal of epidemiology (2021) — Danish Diet, Cancer and Health cohort (n=53,150; 23-y follow-up): moderate vegetable-nitrate intake (~60 mg/day) was associated with ~15% lower CVD incidence (HR 0.85, 95% CI 0.82-0.89) and lower systolic BP. [https://pmc.ncbi.nlm.nih.gov/articles/PMC8416839/]
  - Nutrients and bioactives in green leafy vegetables and cognitive decline: Prospective study, Neurology (2018) — Memory and Aging Project prospective cohort (n=960, mean 4.7 y): highest green-leafy-vegetable intake (~1.3 servings/day) was associated with slower cognitive decline equivalent to being 11 years younger. [https://pmc.ncbi.nlm.nih.gov/articles/PMC5772164/]

---

## sweet-corn
URL: https://nutridex.info/s/sweet-corn
Category: Vegetables
Evidence: Moderate — Several controlled trials; effects real but modest or context-dependent.
A whole-grain vegetable rich in the macula-protective carotenoids lutein and zeaxanthin.

Quick answer: sweet-corn is used for dietary lutein/zeaxanthin associated with lower risk of late age-related macular degeneration. NutriDex grades the human evidence as moderate — Several controlled trials; effects real but modest or context-dependent. Based on 11 cited human studies (11 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Sweet corn is botanically a whole grain, and its strongest human-evidence signal comes from its high content of the xanthophyll carotenoids lutein and zeaxanthin, which selectively accumulate in the retinal macula and brain. Cohort meta-analyses link higher dietary lutein/zeaxanthin to lower risk of late (advanced) age-related macular degeneration, and supplementation RCTs (including AREDS2) show modest slowing of AMD progression, especially in people with low baseline intake. As a whole grain, corn also fits the large dose-response evidence base associating whole-grain intake with reduced type 2 diabetes, cardiovascular disease, and all-cause mortality, though corn-specific RCTs on hard endpoints are lacking and most outcome data are observational.

Nutrition (per 1 cup kernels, cooked/boiled, drained, no salt (164 g)): 177 kcal; Vitamin C 10.2mg (11% DV), Fiber 4.6g (16% DV), Potassium 408mg (9% DV), Folate 75µg (19% DV), Vitamin A 21µg (2% DV), Vitamin K 0.7µg (1% DV), Vitamin B6 0.1mg (6% DV), Manganese 0.32mg (14% DV).
Benefits / uses: Dietary lutein/zeaxanthin associated with lower risk of late age-related macular degeneration; Carotenoid supplementation raises macular pigment optical density and modestly slows AMD progression; Whole-grain intake linked to reduced type 2 diabetes and cardiovascular disease risk in cohorts; Fiber and resistant starch support satiety and gentler postprandial glucose responses; Provides folate, magnesium, potassium and antioxidant carotenoids.
Active compounds: Lutein; Zeaxanthin; Ferulic acid (hydroxycinnamic acid); Resistant starch; Insoluble and soluble dietary fiber; Folate; Beta-carotene (yellow varieties).
Dose: Standard serving: 1 cup kernels, cooked/boiled, drained, no salt (164 g). Eat whole (with skin where edible); favour whole fruit over juice.
Safety: Generally very safe and a common dietary staple. The insoluble fiber and resistant starch can cause gas or bloating, and corn is a moderate-to-high FODMAP food (raffinose, sorbitol) that may aggravate IBS symptoms in sensitive individuals. Kernel hulls are poorly digested and may appear undigested in stool. Corn is a recognized though uncommon food allergen, and people with rare conditions affecting starch digestion should moderate intake. Canned and creamed products often add substantial sodium and sugar.

Cited studies (11):
  - Effect of Antioxidant Supplementation on Macular Pigment Optical Density and Visual Functions: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials, Advances in nutrition (Bethesda, Md.) (2024) — Network meta-analysis of 38 RCTs found all antioxidant groups significantly raised macular pigment optical density and low-frequency contrast sensitivity; the lutein+zeaxanthin+fatty-acid combination ranked best for MPOD and lutein+zeaxanthin improved photostress recovery time. [https://pmc.ncbi.nlm.nih.gov/articles/PMC11052915/]
  - Dietary Lutein and Cognitive Function in Adults: A Meta-Analysis of Randomized Controlled Trials, Molecules (Basel, Switzerland) (2021) — Meta-analysis of RCTs found dietary lutein produced only small, non-significant improvements in complex attention (SMD 0.02), executive function (SMD 0.13) and memory (SMD 0.03), suggesting a possible role in maintaining rather than enhancing cognition. [https://pmc.ncbi.nlm.nih.gov/articles/PMC8510423/]
  - Consumption of whole grains and risk of type 2 diabetes: A comprehensive systematic review and dose-response meta-analysis of prospective cohort studies, Food science & nutrition (2022) — Meta-analysis of 11 prospective cohorts (463,282 participants, 37,249 cases) found highest vs lowest whole-grain intake associated with 21% lower type 2 diabetes risk, ~23% lower risk per additional 50 g/day. [https://pmc.ncbi.nlm.nih.gov/articles/PMC9179146/]
  - The Effect of Lutein/Zeaxanthin Intake on Human Macular Pigment Optical Density: A Systematic Review and Meta-Analysis, Advances in nutrition (Bethesda, Md.) (2021) — Systematic review/meta-analysis found lutein/zeaxanthin intake raised MPOD by ~0.04 units (95% CI 0.02-0.07) at 5 to <20 mg/d and ~0.11 units (95% CI 0.06-0.16) at >=20 mg/d over 3-12 months, with doses <5 mg/d showing unclear effects. [https://pmc.ncbi.nlm.nih.gov/articles/PMC8634499/]
  - Whole grain consumption and risk of cardiovascular disease, cancer, and all cause and cause specific mortality: systematic review and dose-response meta-analysis of prospective studies, BMJ (Clinical research ed.) (2016) — Dose-response meta-analysis (45 studies) found whole-grain intake inversely associated with coronary heart disease, cardiovascular disease, total cancer, and all-cause mortality, with risk reductions up to ~210-225 g/day. [https://pubmed.ncbi.nlm.nih.gov/27301975/]
  - The Effect of Dietary Supplementations on Delaying the Progression of Age-Related Macular Degeneration: A Systematic Review and Meta-Analysis, Nutrients (2022) — Systematic review and meta-analysis found lutein/zeaxanthin (with or without omega-3) supplementation significantly improved best-corrected visual acuity and delayed AMD progression compared with controls. [https://pmc.ncbi.nlm.nih.gov/articles/PMC9610847/]
  - Lutein and zeaxanthin intake and the risk of age-related macular degeneration: a systematic review and meta-analysis, The British journal of nutrition (2012) — Pooled cohort meta-analysis (6 longitudinal studies) found higher dietary lutein/zeaxanthin associated with reduced risk of late AMD (RR 0.74, 95% CI 0.57-0.97) and neovascular AMD (RR 0.68, 95% CI 0.51-0.92), with no significant effect on early AMD. [https://pubmed.ncbi.nlm.nih.gov/21899805/]
  - The effects of lutein/ zeaxanthin (Lute-gen®) on eye health, eye strain, sleep quality, and attention in high electronic screen users: a randomized, double-blind, placebo-controlled study, Frontiers in Nutrition (2025) — Randomized double-blind placebo-controlled trial in 70 high-screen-use adults found 10 mg lutein + 2 mg zeaxanthin isomers significantly improved Schirmer tear test (p<0.05), photo-stress recovery time (p<0.01), and tear film break-up time (p<0.05) versus placebo. [https://www.frontiersin.org/journals/nutrition/articles/10.3389/fnut.2025.1522302/full]
  - Long-term Outcomes of Adding Lutein/Zeaxanthin and ω-3 Fatty Acids to the AREDS Supplements on Age-Related Macular Degeneration Progression: AREDS2 Report 28, JAMA Ophthalmology (2022) — At 10-year follow-up, lutein/zeaxanthin versus no lutein/zeaxanthin was associated with a lower risk of progression to late AMD (HR 0.91, 95% CI 0.84-0.99, P=0.02). [https://jamanetwork.com/journals/jamaophthalmology/fullarticle/2792855]
  - Substitution of Corn Starch with Resistant Starch Type 4 in a Breakfast Bar Decreases Postprandial Glucose and Insulin Responses: A Randomized, Controlled, Crossover Study, Current developments in nutrition (2018) — In a randomized controlled crossover trial in 21 healthy adults, substituting resistant starch type 4 for corn starch in a breakfast bar lowered postprandial glucose iAUC by ~22% and insulin iAUC by ~37%. [https://pmc.ncbi.nlm.nih.gov/articles/PMC6186909/]
  - Secondary analyses of the effects of lutein/zeaxanthin on age-related macular degeneration progression: AREDS2 report No. 3, JAMA ophthalmology (2014) — In AREDS2 (n=4203), lutein+zeaxanthin showed no significant overall reduction in progression to advanced AMD (HR 0.90, P=0.12), but participants in the lowest baseline dietary intake quintile had a 26% lower risk (HR 0.74, 95% CI 0.59-0.94). [https://pmc.ncbi.nlm.nih.gov/articles/PMC4636082/]

---

## collard-greens
URL: https://nutridex.info/s/collard-greens
Category: Vegetables
Evidence: Moderate — Several controlled trials; effects real but modest or context-dependent.
A calcium- and vitamin K-dense Southern cruciferous green with cardiometabolic and cognitive upside.

Quick answer: collard-greens is used for lowers blood pressure (rct evidence). NutriDex grades the human evidence as moderate — Several controlled trials; effects real but modest or context-dependent. Based on 10 cited human studies (10 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Collard greens are a glucosinolate-rich cruciferous vegetable and one of the densest plant sources of vitamin K and bioavailable calcium. Human evidence for the cruciferous family is robust: randomized crossover trials show cruciferous vegetables lower blood pressure, while large meta-analyses and prospective cohorts link higher intake to reduced cardiovascular and colorectal-cancer risk. Green leafy vegetables specifically are associated with markedly slower cognitive decline in older adults.

Nutrition (per 1 cup chopped, raw (36 g)): 11.9 kcal; Vitamin C 12.7mg (14% DV), Fiber 1.4g (5% DV), Potassium 76.7mg (2% DV), Folate 46.4µg (12% DV), Vitamin A 90.4µg (10% DV), Vitamin K 157.3µg (131% DV), Vitamin B6 0.058mg (3% DV), Manganese 0.238mg (10% DV).
Benefits / uses: Lowers blood pressure (RCT evidence); Associated with reduced cardiovascular mortality; Linked to lower colorectal cancer risk; Supports slower cognitive decline; Rich in vitamin K and calcium for bone health.
Active compounds: glucosinolates (glucobrassicin); sulforaphane / isothiocyanates; lutein & zeaxanthin; vitamin K1 (phylloquinone); kaempferol; beta-carotene; nitrate.
Dose: Standard serving: 1 cup chopped, raw (36 g). Eat whole (with skin where edible); favour whole fruit over juice.
Safety: Very high vitamin K (~157 ug per cup raw, far more when cooked-concentrated) can antagonize warfarin — keep intake consistent if anticoagulated. Raw cruciferous goitrogens may modestly affect thyroid in iodine-deficient individuals; cooking reduces this. Contains moderate oxalate and some FODMAPs. Generally very safe as food.

Cited studies (10):
  - Plasma nitrate, dietary nitrate, blood pressure, and vascular health biomarkers: a GRADE-Assessed systematic review and dose-response meta-analysis of randomized controlled trials, Nutrition journal (2025) — GRADE-assessed dose-response meta-analysis of 75 RCTs (n=1823) found each mmol increase in dietary nitrate lowered diastolic BP (WMD -0.12 mmHg; 95% CI -0.21, -0.03) and improved flow-mediated dilation and pulse wave velocity. [https://pmc.ncbi.nlm.nih.gov/articles/PMC11931885/]
  - The effect of green leafy and cruciferous vegetable intake on the incidence of cardiovascular disease: A meta-analysis, JRSM cardiovascular disease (2016) — Meta-analysis of prospective studies: green leafy and cruciferous vegetable intake inversely associated with incident cardiovascular disease. [https://pmc.ncbi.nlm.nih.gov/articles/PMC4973479/]
  - Green leafy and cruciferous vegetable consumption and risk of type 2 diabetes: results from the Singapore Chinese Health Study and meta-analysis, The British journal of nutrition (2018) — Meta-analysis of prospective cohorts (754,729 participants): higher cruciferous vegetable intake associated with borderline lower type 2 diabetes risk (RR ~0.87; 95% CI 0.76–1.00). [https://pubmed.ncbi.nlm.nih.gov/29457582/]
  - Cruciferous vegetables intake and the risk of colorectal cancer: a meta-analysis of observational studies, Annals of oncology : official journal of the European Society for Medical Oncology (2013) — Meta-analysis of observational studies: highest vs lowest cruciferous vegetable intake associated with lower colorectal cancer risk (RR 0.82; 95% CI 0.75–0.90). [https://pubmed.ncbi.nlm.nih.gov/23211939/]
  - Cruciferous vegetables lower blood pressure in adults with mildly elevated blood pressure in a randomized, controlled, crossover trial: the VEgetableS for vaScular hEaLth (VESSEL) study, BMC medicine (2024) — Randomized controlled crossover trial: ~300 g/day cruciferous vegetables for 2 weeks reduced 24-h systolic blood pressure by 2.5 mmHg vs root/squash vegetables in adults with mildly elevated BP. [https://pmc.ncbi.nlm.nih.gov/articles/PMC11367748/]
  - Cruciferous vegetables lower blood pressure in adults with mildly elevated blood pressure in a randomized, controlled, crossover trial: the VEgetableS for vaScular hEaLth (VESSEL) study, BMC Medicine (2024) — In a randomized crossover trial of 18 adults with mildly elevated BP, ~300 g/day of cruciferous vegetables (Brassica) for 2 weeks lowered 24-hour systolic BP by 2.5 mmHg versus root/squash vegetables. [https://link.springer.com/article/10.1186/s12916-024-03577-8]
  - A randomized clinical trial of the effects of leafy green vegetables and inorganic nitrate on blood pressure, The American journal of clinical nutrition (2020) — Randomized trial in 243 adults (50-70 y, SBP 130-159 mmHg) comparing leafy green vegetables (~300 mg nitrate/day) vs nitrate pills vs low-nitrate placebo over 5 weeks assessing blood pressure effects. [https://pmc.ncbi.nlm.nih.gov/articles/PMC7338722/]
  - Sulforaphane reduces hepatic glucose production and improves glucose control in patients with type 2 diabetes, Science Translational Medicine (2017) — 12-week RCT in type 2 diabetes with obesity: concentrated broccoli sprout extract (sulforaphane) reduced HbA1c and fasting glucose vs placebo. [https://www.science.org/doi/10.1126/scitranslmed.aah4477]
  - Nutrients and bioactives in green leafy vegetables and cognitive decline: Prospective study, Neurology (2018) — Prospective study (n=960, mean 4.7 y): highest vs lowest green leafy vegetable intake (median ~1.3 servings/d) associated with slower cognitive decline equivalent to being ~11 years younger. [https://pmc.ncbi.nlm.nih.gov/articles/PMC5772164/]
  - Cruciferous vegetable consumption is associated with a reduced risk of total and cardiovascular disease mortality, The American journal of clinical nutrition (2011) — Prospective cohort of 134,796 Chinese adults: higher cruciferous vegetable intake associated with reduced total mortality (HR ~0.78–0.84) and cardiovascular mortality. [https://pmc.ncbi.nlm.nih.gov/articles/PMC3127519/]

---

## butternut-squash
URL: https://nutridex.info/s/butternut-squash
Category: Vegetables
Evidence: Moderate — Several controlled trials; effects real but modest or context-dependent.
A carotenoid-dense winter squash: one cup delivers well over a day's vitamin A plus generous fiber and potassium.

Quick answer: butternut-squash is used for high provitamin-a carotenoid density. NutriDex grades the human evidence as moderate — Several controlled trials; effects real but modest or context-dependent. Based on 11 cited human studies (11 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Butternut squash is exceptionally rich in provitamin-A carotenoids (alpha- and beta-carotene, beta-cryptoxanthin), the bioactives behind the strongest human evidence for this food group. Prospective-cohort meta-analyses tie higher dietary and circulating carotenoids to lower all-cause mortality, type 2 diabetes risk, and breast cancer risk, while its soluble/insoluble fiber aligns with robust dose-response data linking fiber to reduced cardiovascular and total mortality. Critically, these benefits track with carotenoid-rich whole foods, not high-dose beta-carotene supplements, which increased lung cancer risk in smokers.

Nutrition (per 1 cup cubed, baked (205 g)): 82 kcal; Vitamin C 31mg (34% DV), Fiber 6.6g (24% DV), Potassium 582mg (12% DV), Folate 39µg (10% DV), Vitamin A 1144µg (127% DV), Vitamin K 2.1µg (2% DV), Vitamin B6 0.25mg (15% DV), Manganese 0.35mg (15% DV).
Benefits / uses: High provitamin-A carotenoid density; Associated with lower all-cause mortality; Linked to reduced type 2 diabetes risk; Fiber supports cardiometabolic health; Good potassium and vitamin C source.
Active compounds: beta-carotene; alpha-carotene; beta-cryptoxanthin; lutein; zeaxanthin; soluble & insoluble fiber.
Dose: Standard serving: 1 cup cubed, baked (205 g). Eat whole (with skin where edible); favour whole fruit over juice.
Safety: Generally very safe and well tolerated. Carotenoid benefits apply to whole foods; high-dose synthetic beta-carotene supplements (20-30 mg/day) raised lung cancer risk in smokers and should be avoided in that group. Very high intake of carotenoid-rich vegetables can cause harmless skin yellowing (carotenodermia). As a fructan/FODMAP-containing vegetable, large portions may trigger gas or bloating in sensitive IBS patients.

Cited studies (11):
  - The Association between Circulating Carotenoids and Risk of Breast Cancer: A Systematic Review and Dose-Response Meta-Analysis of Prospective Studies, Advances in nutrition (Bethesda, Md.) (2024) — Higher circulating total carotenoids and beta-carotene were associated with lower breast cancer risk (e.g. RR ~0.74 per 50 ug/dL beta-carotene), with consistent inverse signals for alpha-carotene. [https://pmc.ncbi.nlm.nih.gov/articles/PMC10694674/]
  - Dietary intake of total vegetable, fruit, cereal, soluble and insoluble fiber and risk of all-cause, cardiovascular, and cancer mortality: systematic review and dose-response meta-analysis of prospective cohort studies, Frontiers in nutrition (2023) — Higher total dietary fiber was linked to lower all-cause (RR 0.90), cardiovascular (RR 0.87) and cancer (RR 0.91) mortality, with vegetable fiber among protective sources. [https://pubmed.ncbi.nlm.nih.gov/37854351/]
  - Carotenoids Intake and Cardiovascular Prevention: A Systematic Review, Nutrients (2024) — A systematic review of 38 interventional studies (2011-2024) found blood levels of alpha-carotene, beta-cryptoxanthin, lutein/zeaxanthin and lycopene were inversely correlated with CVD events, with carotenoid-rich foods more effective than supplements. [https://pmc.ncbi.nlm.nih.gov/articles/PMC11597197/]
  - Dietary Intake and Circulating Concentrations of Carotenoids and Risk of Type 2 Diabetes: A Dose-Response Meta-Analysis of Prospective Observational Studies, Advances in nutrition (Bethesda, Md.) (2021) — Across 13 prospective cohorts, higher dietary beta-carotene was inversely associated with type 2 diabetes (highest vs lowest pooled RR ~0.78), with significant inverse trends for alpha-carotene and total carotenoids. [https://pubmed.ncbi.nlm.nih.gov/33979433/]
  - Dietary, circulating beta-carotene and risk of all-cause mortality: a meta-analysis from prospective studies, Scientific reports (2016) — Pooled prospective studies: highest vs lowest circulating beta-carotene cut all-cause mortality risk (RR 0.69, 95% CI 0.59-0.80); higher dietary intake also protective (RR 0.83, 95% CI 0.78-0.88). [https://pmc.ncbi.nlm.nih.gov/articles/PMC4886629/]
  - Carbohydrate quality and human health: a series of systematic reviews and meta-analyses, The Lancet (2019) — Higher dietary fiber intake (25-29 g/day optimal) was associated with reduced all-cause and cardiovascular mortality and lower incidence of diabetes, with a 15-30% risk reduction across outcomes. [https://www.thelancet.com/article/S0140-6736(18)31809-9/fulltext]
  - Effects of Cucurbita Moschata squash (Butternut) seed paste in improving zinc and iron status in children attending Early Childhood Development centres in Limpopo province, South Africa, PloS one (2024) — In a 6-month cluster-randomized trial of 276 South African preschoolers, twice-weekly Cucurbita moschata (butternut) seed paste vs squash flesh significantly improved serum zinc and iron status compared with the flesh control group. [https://pmc.ncbi.nlm.nih.gov/articles/PMC11025940/]
  - Bioaccessibility of Carotenoids and Polyphenols in Organic Butternut Squash (Cucurbita moschata): Impact of Industrial Freezing Process, Foods (Basel, Switzerland) (2024) — In vitro digestion of organic Cucurbita moschata showed industrial freezing did not significantly change alpha- and beta-carotene bioaccessibility, while frozen squash retained higher bioaccessible epicatechin (117.5 mg/kg) and syringic acid (32.0 mg/kg) than fresh fruit. [https://pmc.ncbi.nlm.nih.gov/articles/PMC10814222/]
  - β-Carotene Supplementation and Lung Cancer Incidence in the Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study: The Role of Tar and Nicotine, Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco (2019) — In the Alpha-Tocopherol Beta-Carotene trial, high-dose synthetic beta-carotene (20 mg/day) increased lung cancer incidence in heavy smokers, underscoring that benefit is from food carotenoids, not supplements. [https://pubmed.ncbi.nlm.nih.gov/29889248/]
  - Secondary analyses of the effects of lutein/zeaxanthin on age-related macular degeneration progression: AREDS2 report No. 3, JAMA ophthalmology (2014) — In this randomized trial, substituting lutein/zeaxanthin for beta-carotene lowered progression to late age-related macular degeneration (HR 0.82, 95% CI 0.69-0.96 vs beta-carotene). [https://pubmed.ncbi.nlm.nih.gov/24310343/]
  - Higher serum carotenoid concentrations are associated with lower mortality in adults with advanced cardiovascular-kidney-metabolic syndrome, Nutrition research (New York, N.Y.) (2025) — In 1285 NHANES adults with advanced cardiovascular-kidney-metabolic syndrome, higher combined serum carotenoid concentrations were significantly associated with lower all-cause mortality, with lycopene contributing the largest individual weight. [https://pubmed.ncbi.nlm.nih.gov/40617233/]

---

## watercress
URL: https://nutridex.info/s/watercress
Category: Vegetables
Evidence: Moderate — Several controlled trials; effects real but modest or context-dependent.
A peppery, near-zero-calorie cruciferous green that delivers an outsized hit of vitamin K, vitamin C and the carcinogen-detoxifying isothiocyanate PEITC.

Quick answer: watercress is used for enhances detoxification of environmental and tobacco carcinogens (peitc). NutriDex grades the human evidence as moderate — Several controlled trials; effects real but modest or context-dependent. Based on 10 cited human studies (10 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Watercress is a nutrient-dense cruciferous leaf whose signature bioactive, phenethyl isothiocyanate (PEITC, from gluconasturtiin), has been tested in human trials. A randomized crossover study showed 85 g/day of raw watercress for 8 weeks cut lymphocyte DNA damage and roughly doubled plasma lutein, and randomized phase-2 trials of PEITC or a freeze-dried watercress beverage significantly boosted urinary detoxification of tobacco-related and environmental carcinogens (acrolein, benzene, crotonaldehyde) and modestly inhibited activation of the lung carcinogen NNK in smokers. Large prospective cohorts and meta-analyses of cruciferous vegetables as a class link higher intake to lower cardiovascular and colorectal-cancer risk, though watercress-specific hard-outcome data remain limited.

Nutrition (per 1 cup chopped, raw (34 g)): 3.7 kcal; Vitamin C 14.6mg (16% DV), Fiber 0.2g (1% DV), Potassium 112mg (2% DV), Folate 3µg (1% DV), Vitamin A 54µg (6% DV), Vitamin K 85µg (71% DV), Vitamin B6 0.044mg (3% DV), Manganese 0.083mg (4% DV).
Benefits / uses: Enhances detoxification of environmental and tobacco carcinogens (PEITC); Reduces lymphocyte DNA damage and oxidative stress; Raises plasma carotenoids (lutein, beta-carotene); Cruciferous intake linked to lower CVD and colorectal-cancer risk; Exceptional vitamin K and vitamin C density at near-zero calories.
Active compounds: phenethyl isothiocyanate (PEITC); gluconasturtiin; lutein; beta-carotene; vitamin K1 (phylloquinone); quercetin.
Dose: Standard serving: 1 cup chopped, raw (34 g). Eat whole (with skin where edible); favour whole fruit over juice.
Safety: Very high in vitamin K1 (~85 ug per cup) — people on warfarin should keep intake consistent to avoid destabilizing INR. As a raw cruciferous green it contains goitrogenic glucosinolates, of possible concern only at very high intakes with iodine deficiency. Generally well tolerated; wild-harvested watercress can carry liver-fluke (Fasciola) or waterborne-pathogen risk, so use cultivated/washed produce.

Cited studies (10):
  - Evaluating the Anti-Oxidant and Anti-Inflammatory Properties of Watercress Supplementation at Short-Term Follow-Up: A Systematic Review of Randomized Controlled Trials, Food science & nutrition (2025) — Systematic review of RCTs found watercress supplementation improved antioxidant and anti-inflammatory markers at short-term follow-up, though effects were modest and evidence limited by small trial sizes. [https://pmc.ncbi.nlm.nih.gov/articles/PMC12141087/]
  - The effect of green leafy and cruciferous vegetable intake on the incidence of cardiovascular disease: A meta-analysis, JRSM cardiovascular disease (2016) — Meta-analysis reported green-leafy and cruciferous vegetable intake associated with ~15.8% lower cardiovascular-disease incidence (RR 0.842, 95% CI 0.753-0.941, P=0.002). [https://pmc.ncbi.nlm.nih.gov/articles/PMC4973479/]
  - Cruciferous vegetables intake and the risk of colorectal cancer: a meta-analysis of observational studies, Annals of oncology : official journal of the European Society for Medical Oncology (2013) — Meta-analysis of observational studies found higher cruciferous-vegetable intake associated with a significantly lower colorectal-cancer risk (RR 0.82, 95% CI 0.75-0.90). [https://pubmed.ncbi.nlm.nih.gov/23211939/]
  - A watercress drink increases detoxification of common environmental carcinogens such as acrolein and benzene: results of a randomized clinical trial, Carcinogenesis (2026) — Two-site randomized crossover (188 completers) of a freeze-dried watercress beverage (2 wk) significantly increased urinary mercapturic-acid detoxification of acrolein (+65.6%) and benzene (+37.3%) plus other toxicants versus placebo. [https://academic.oup.com/carcin/article-abstract/47/1/bgag007/8488017]
  - Clinical Trial of 2-Phenethyl Isothiocyanate as an Inhibitor of Metabolic Activation of a Tobacco-Specific Lung Carcinogen in Cigarette Smokers, Cancer prevention research (Philadelphia, Pa.) (2016) — Randomized phase-2 crossover in 82 smokers: PEITC (the watercress isothiocyanate) produced a modest but significant 7.7% inhibition of metabolic activation of the lung carcinogen NNK versus placebo. [https://pmc.ncbi.nlm.nih.gov/articles/PMC4854759/]
  - Acute and chronic watercress supplementation attenuates exercise-induced peripheral mononuclear cell DNA damage and lipid peroxidation, British Journal of Nutrition (2013) — Acute and 8-wk chronic watercress supplementation in trained men (n=10) attenuated exercise-induced peripheral mononuclear-cell DNA damage and lipid peroxidation versus control. [https://www.cambridge.org/core/journals/british-journal-of-nutrition/article/acute-and-chronic-watercress-supplementation-attenuates-exerciseinduced-peripheral-mononuclear-cell-dna-damage-and-lipid-peroxidation/3063DCFA3E9F6D2E72EA6B2DBAB89751]
  - Watercress supplementation in diet reduces lymphocyte DNA damage and alters blood antioxidant status in healthy adults, The American journal of clinical nutrition (2007) — 85 g/day raw watercress for 8 wk in 60 adults reduced basal lymphocyte DNA damage by 17% (P=0.03) and oxidative purine DNA damage by 23.9% (P=0.002), with plasma lutein +100% and beta-carotene +33% (P<0.001). [https://pubmed.ncbi.nlm.nih.gov/17284750/]
  - Watercress (Nasturtium officinale) as a Functional Food for Non-Communicable Diseases Prevention and Management: A Narrative Review, Life (Basel, Switzerland) (2025) — Narrative review of 88 sources (2019-2025) summarizing watercress glucosinolate/PEITC effects on non-communicable diseases, noting antioxidant, anti-inflammatory, and metabolic effects while emphasizing scarcity of robust human trials. [https://pmc.ncbi.nlm.nih.gov/articles/PMC12299072/]
  - Preparation of a Beverage Containing Freeze-Dried Watercress for a Clinical Trial of Carcinogen and Toxicant Detoxification, Cancer prevention research (Philadelphia, Pa.) (2022) — Methods paper describing preparation of a standardized freeze-dried watercress beverage delivering reproducible PEITC for the NCT03978117 carcinogen-detoxification clinical trial. [https://pubmed.ncbi.nlm.nih.gov/34906989/]
  - Cruciferous vegetable consumption is associated with a reduced risk of total and cardiovascular disease mortality, The American journal of clinical nutrition (2011) — In 134,796 Chinese adults, highest vs lowest cruciferous-vegetable intake was associated with lower total mortality (HR 0.78, 95% CI 0.71-0.85) and cardiovascular mortality (HR 0.69, 95% CI 0.56-0.85). [https://pmc.ncbi.nlm.nih.gov/articles/PMC3127519/]

---

## broccoli
URL: https://nutridex.info/s/broccoli
Category: Vegetables
Evidence: Moderate — Several controlled trials; effects real but modest or context-dependent.
A cruciferous powerhouse delivering a full day of vitamin C and K plus the sulforaphane precursor glucoraphanin.

Quick answer: broccoli is used for improved glucose control in dysregulated type 2 diabetes (sulforaphane). NutriDex grades the human evidence as moderate — Several controlled trials; effects real but modest or context-dependent. Based on 8 cited human studies (8 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Broccoli is one of the most nutrient-dense common vegetables: a single cup raw supplies roughly a day's vitamin C and vitamin K for under 35 kcal. Its signature bioactive, sulforaphane (released from glucoraphanin by myrosinase), is the subject of the strongest human research, with RCTs showing improved glucose control in dysregulated type 2 diabetes and meta-analyses of broccoli-sprout trials reporting reductions in blood pressure and lipids. Large prospective cohorts also link higher cruciferous-vegetable intake to modestly lower cardiovascular, colorectal, gastric, and lung cancer risk.

Nutrition (per 1 cup chopped, raw (91 g)): 31 kcal; Vitamin C 81.2mg (90% DV), Fiber 2.4g (9% DV), Potassium 288mg (6% DV), Folate 57µg (14% DV), Vitamin A 28µg (3% DV), Vitamin K 92.5µg (77% DV), Vitamin B6 0.16mg (9% DV), Manganese 0.19mg (8% DV).
Benefits / uses: Improved glucose control in dysregulated type 2 diabetes (sulforaphane); Lower systolic/diastolic blood pressure in sprout trials; Inverse association with cardiovascular disease; Reduced colorectal, gastric and lung cancer risk in cohorts; Exceptional vitamin C and vitamin K density.
Active compounds: sulforaphane; glucoraphanin; indole-3-carbinol; lutein; zeaxanthin; kaempferol; vitamin C.
Dose: Standard serving: 1 cup chopped, raw (91 g). Eat whole (with skin where edible); favour whole fruit over juice.
Safety: Raw cruciferous vegetables contain goitrogenic glucosinolates that can mildly impair thyroid iodine uptake if eaten in very large amounts, especially with iodine deficiency; cooking reduces this. High vitamin K content (~93 ug/cup) can interfere with warfarin, so intake should be kept consistent. Broccoli is a high-FODMAP food (fructans) and may trigger bloating/gas in sensitive or IBS individuals; concentrated sprout extracts are generally well tolerated but can cause mild GI upset.

Cited studies (8):
  - Beneficial Effects of Sulforaphane-Yielding Broccoli Sprout on Cardiometabolic Health: A Systematic Review and Meta-analysis, Jundishapur Journal of Natural Pharmaceutical Products (2022) — Systematic review and meta-analysis of 10 broccoli-sprout clinical trials reported significant reductions in systolic (-10.9 mmHg; 95% CI -17.0 to -4.86) and diastolic (-6.95 mmHg) blood pressure plus improved lipids and glycemia. [https://doi.org/10.5812/jjnpp-129402]
  - The effect of green leafy and cruciferous vegetable intake on the incidence of cardiovascular disease: A meta-analysis, JRSM cardiovascular disease (2016) — Meta-analysis of 8 studies (>540,000 participants, 26,173 CVD cases) found high green-leafy/cruciferous vegetable intake associated with a 15.8% lower CVD incidence (RR 0.842; 95% CI 0.753-0.941). [https://pmc.ncbi.nlm.nih.gov/articles/PMC4973479/]
  - Fruit and vegetable intake and the risk of cardiovascular disease, total cancer and all-cause mortality—a systematic review and dose-response meta-analysis of prospective studies, International Journal of Epidemiology (2017) — Dose-response meta-analysis of 95 prospective studies found fruit and vegetable intake inversely associated with CVD, cancer, and all-cause mortality, with benefit up to ~800 g/day; cruciferous vegetables specifically reduced CHD, stroke, and CVD risk. [https://academic.oup.com/ije/article/46/3/1029/3039477]
  - Cruciferous vegetables intake and the risk of colorectal cancer: a meta-analysis of observational studies, Annals of oncology : official journal of the European Society for Medical Oncology (2013) — Meta-analysis of 35 observational studies found cruciferous vegetable intake inversely associated with colorectal cancer risk (RR 0.82; 95% CI 0.75-0.90). [https://pubmed.ncbi.nlm.nih.gov/23211939/]
  - Cruciferous vegetable consumption and gastric cancer risk: a meta-analysis of epidemiological studies, Cancer science (2013) — Meta-analysis of 22 epidemiological studies found higher cruciferous vegetable intake associated with lower gastric cancer risk (RR 0.81; 95% CI 0.75-0.88). [https://pubmed.ncbi.nlm.nih.gov/23679348/]
  - Cruciferous vegetable consumption and lung cancer risk: a systematic review, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology (2009) — Systematic review of cruciferous vegetables and lung cancer found ~17% lower risk in cohort studies (pooled RR 0.83; 95% CI 0.62-1.08) and 23% lower in case-control studies (OR 0.77; 95% CI 0.68-0.88). [https://pmc.ncbi.nlm.nih.gov/articles/PMC2735794/]
  - Effect of broccoli sprout extract and baseline gut microbiota on fasting blood glucose in prediabetes: a randomized, placebo-controlled trial, Nature microbiology (2025) — Randomized, double-blind, placebo-controlled trial in prediabetes (n=89) found broccoli-sprout extract lowered fasting blood glucose by 0.2 mmol/L overall (P=0.04; ~0.4 mmol/L in a microbiota-defined responder subgroup), missing its prespecified 0.3 mmol/L target. [https://pmc.ncbi.nlm.nih.gov/articles/PMC11879859/]
  - Sulforaphane reduces hepatic glucose production and improves glucose control in patients with type 2 diabetes, Science translational medicine (2017) — In a 12-week RCT (n=97 with type 2 diabetes), concentrated broccoli-sprout extract (sulforaphane) reduced fasting glucose and HbA1c specifically in obese, dysregulated patients versus placebo. [https://pubmed.ncbi.nlm.nih.gov/28615356/]

---

## okra
URL: https://nutridex.info/s/okra
Category: Vegetables
Evidence: Moderate — Several controlled trials; effects real but modest or context-dependent.
A low-calorie, fiber-rich pod whose viscous mucilage gives it genuine, RCT-backed glucose-lowering credentials.

Quick answer: okra is used for lowers fasting blood glucose in type 2 diabetes. NutriDex grades the human evidence as moderate — Several controlled trials; effects real but modest or context-dependent. Based on 8 cited human studies (8 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Okra is a standout among vegetables for glycemic control: multiple 2023-2025 meta-analyses of randomized controlled trials in prediabetes and type 2 diabetes show okra supplementation significantly lowers fasting blood glucose (pooled reductions of roughly 15-40 mg/dL) and HbA1c (about 0.4-0.5%), likely driven by its soluble mucilaginous fiber and polyphenols slowing carbohydrate absorption. Effects on cholesterol and triglycerides are favorable but more modest, while insulin resistance (HOMA-IR), blood pressure, and body weight show no consistent benefit. The glycemic evidence is among the more robust for any single vegetable, though most trials are small and short.

Nutrition (per 1 cup sliced, raw (100 g)): 33 kcal; Vitamin C 23mg (26% DV), Fiber 3.2g (11% DV), Potassium 299mg (6% DV), Folate 60µg (15% DV), Vitamin A 36µg (4% DV), Vitamin K 31.3µg (26% DV), Vitamin B6 0.215mg (13% DV), Manganese 0.788mg (34% DV).
Benefits / uses: Lowers fasting blood glucose in type 2 diabetes; Reduces HbA1c (long-term glycemic control); High soluble + insoluble fiber for satiety and digestion; Modestly improves total cholesterol and triglycerides; Low-calorie source of vitamin K, folate, magnesium and manganese.
Active compounds: soluble mucilage (polysaccharide gel); pectin; quercetin glycosides; catechins / flavonoid polyphenols; isoquercitrin; vitamin K1 (phylloquinone).
Dose: Standard serving: 1 cup sliced, raw (100 g). Eat whole (with skin where edible); favour whole fruit over juice.
Safety: Rich in vitamin K (about 31 ug per 100 g), so large, sudden changes in intake can interfere with warfarin dosing. The viscous fiber can cause gas/bloating and may bind metformin, theoretically reducing its absorption if eaten together. Okra is moderately high in oxalates, which may matter for people prone to calcium-oxalate kidney stones. Glucose-lowering effects could add to antidiabetic medication, so monitor for hypoglycemia.

Cited studies (8):
  - The Impact of Okra (Abelmoschus esculentus) Supplementation on Diabetes and Obesity Biomarkers in Type 2 Diabetes Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials, Phytotherapy research : PTR (2025) — Meta-analysis of 6 RCTs in type 2 diabetes: okra supplementation lowered fasting blood glucose (WMD -21.72 mg/dL, 95% CI -36.86 to -6.58) and HbA1c (WMD -0.42%, 95% CI -0.64 to -0.19), with no effect on insulin, HOMA-IR, BMI or weight. [https://pubmed.ncbi.nlm.nih.gov/40867089/]
  - The Effects of Okra Consumption on Glycemic Parameters and Lipid Profile in Adults: A Systematic Review and Meta-Analysis, Food science & nutrition (2024) — Systematic review/meta-analysis (8 studies, 521 adults): okra reduced fasting glucose (WMD -32.56 mg/dL, 95% CI -48.83 to -16.28), HbA1c (-0.48%, 95% CI -0.81 to -0.16) and total cholesterol (-9.70 mg/dL), but not HOMA-IR, HDL-C or LDL-C. [https://pubmed.ncbi.nlm.nih.gov/39723095/]
  - The cardiometabolic benefits of okra-based treatment in prediabetes and diabetes: a systematic review and meta-analysis of randomized controlled trials, Frontiers in Nutrition (2024) — Meta-analysis of 9 RCTs (540 participants) in prediabetes/diabetes: okra lowered fasting glucose (WMD -39.6 mg/dL, 95% CI -61.6 to -17.6) and HbA1c (-0.5%, 95% CI -0.8 to -0.1), but had no significant effect on systolic or diastolic blood pressure. [https://www.frontiersin.org/journals/nutrition/articles/10.3389/fnut.2024.1454286/full]
  - Okra ameliorates hyperglycaemia in pre-diabetic and type 2 diabetic patients: A systematic review and meta-analysis of the clinical evidence, Frontiers in Pharmacology (2023) — Meta-analysis of RCTs (331 prediabetic/T2D patients) found okra significantly reduced fasting blood glucose (MD -14.63 mg/dL, 95% CI -25.25 to -4.00, p=0.007) with low heterogeneity (I2=33%). [https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2023.1132650/full]
  - Therapeutic potential of okra (Abelmoschus esculentus) in dysglycaemia and metabolic dysfunction: A systematic review and meta-analysis across the diabetes spectrum, Experimental Physiology (2026) — Systematic review and dose-response meta-analysis across the diabetes spectrum confirmed okra improves dysglycaemia and metabolic dysfunction, supporting glycemic benefit while highlighting small trial sizes and variable quality. [https://physoc.onlinelibrary.wiley.com/doi/full/10.1113/EP093293]
  - The cardiometabolic benefits of okra-based treatment in prediabetes and diabetes: a systematic review and meta-analysis of randomized controlled trials, Frontiers in nutrition (2024) — Systematic review and meta-analysis of RCTs in prediabetes/diabetes found okra-based treatment significantly lowered HbA1c (WMD -0.5%, 95% CI -0.8 to -0.1, p=0.005) and improved cardiometabolic markers. [https://pubmed.ncbi.nlm.nih.gov/39726865/]
  - Beneficial effects of okra (Abelmoschus esculentus L.) consumption on anthropometric measures, blood pressure, glycaemic control, lipid profile and liver function tests in randomised controlled trials: a GRADE-assessed systematic review and dose–response meta-analysis, British Journal of Nutrition (2025) — GRADE-assessed systematic review and dose-response meta-analysis of RCTs reported beneficial okra effects on glycaemic control, lipid profile, anthropometry, blood pressure, and liver function tests. [https://www.cambridge.org/core/journals/british-journal-of-nutrition/article/beneficial-effects-of-okra-abelmoschus-esculentus-l-consumption-on-anthropometric-measures-blood-pressure-glycaemic-control-lipid-profile-and-liver-function-tests-in-randomised-controlled-trials-a-gradeassessed-systematic-review-and-doseresponse-metaanalysis/A411895A6340FD4B5B6E718478F9D7F8]
  - Clinical efficacy and safety of okra (Abelmoschus esculentus (L.) Moench) in type 2 diabetic patients: a randomized, double-blind, placebo-controlled, clinical trial, Acta diabetologica (2023) — Randomized, double-blind, placebo-controlled trial in 100 T2D patients (1000 mg okra powder 3x/day for 3 months) significantly reduced fasting glucose, HbA1c, total cholesterol, triglycerides and hs-CRP versus placebo, with no adverse effects. [https://pubmed.ncbi.nlm.nih.gov/37507536/]

---

## tomato
URL: https://nutridex.info/s/tomato
Category: Vegetables
Evidence: Moderate — Several controlled trials; effects real but modest or context-dependent.
Low-calorie, lycopene-rich fruit-vegetable with modest blood-pressure and lipid benefits.

Quick answer: tomato is used for lowers systolic blood pressure. NutriDex grades the human evidence as moderate — Several controlled trials; effects real but modest or context-dependent. Based on 11 cited human studies (11 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Tomato is the dominant dietary source of lycopene, a carotenoid concentrated further by cooking and fat (paste, sauce). Meta-analyses of randomized trials show tomato/lycopene supplementation modestly lowers systolic blood pressure and LDL-cholesterol and improves endothelial flow-mediated dilation, while observational data link higher intake to lower prostate-cancer risk and lower cardiovascular and all-cause mortality. RCT evidence is strongest for cardiometabolic risk factors; cancer and mortality signals rest mainly on cohort data.

Nutrition (per 1 medium, raw (123 g)): 22 kcal; Vitamin C 16.9mg (19% DV), Fiber 1.5g (5% DV), Potassium 292mg (6% DV), Folate 18µg (5% DV), Vitamin A 52µg (6% DV), Vitamin K 9.7µg (8% DV), Vitamin B6 0.1mg (6% DV), Manganese 0.14mg (6% DV).
Benefits / uses: Lowers systolic blood pressure; Reduces LDL-cholesterol; Improves endothelial function (FMD); Associated with lower prostate-cancer risk; Linked to lower cardiovascular mortality.
Active compounds: lycopene; beta-carotene; lutein/zeaxanthin; vitamin C; potassium; naringenin chalcone.
Dose: Standard serving: 1 medium, raw (123 g). Eat whole (with skin where edible); favour whole fruit over juice.
Safety: Generally very safe and low-FODMAP in normal amounts. High acidity may aggravate GERD/reflux in sensitive people. Tomato is a recognized source of oral-allergy and histamine sensitivity in a minority. Solanine/tomatine in green (unripe) fruit and leaves can cause GI upset in large quantities. Lycopene supplements (vs whole food) are not advised in pregnancy due to limited safety data.

Cited studies (11):
  - Effect of Lycopene Intake on the Fasting Blood Glucose Level: A Systematic Review with Meta-Analysis, Nutrients (2022) — Systematic review with meta-analysis (RCT subset, 7 studies/641 participants): lycopene intake significantly lowered fasting blood glucose, with the effect concentrated in type 2 diabetes patients. [https://pmc.ncbi.nlm.nih.gov/articles/PMC9823324/]
  - The Effects of Lycopene and Tomato Consumption on Cardiovascular Risk Factors in Adults: A Grade Assessment Systematic Review and Meta-analysis, Current pharmaceutical design (2023) — GRADE-assessed meta-analysis of 34 RCTs found lycopene/tomato consumption had NO significant effect on systolic or diastolic blood pressure, lipids, glucose or BMI; only malondialdehyde (oxidative stress) was significantly reduced. [https://pubmed.ncbi.nlm.nih.gov/37496241/]
  - Dietary intake of tomato and lycopene, blood levels of lycopene, and risk of total and specific cancers in adults: a systematic review and dose-response meta-analysis of prospective cohort studies, Frontiers in nutrition (2025) — Dose-response meta-analysis of 119 prospective cohorts (4.6 million subjects, 108,574 cancer cases) found higher blood lycopene per 10 ug/dL associated with 5% lower total cancer risk (RR 0.95, 95% CI 0.93-0.96), while dietary lycopene intake showed no significant overall association (RR 0.99, 95% CI 0.98-1.02). [https://pmc.ncbi.nlm.nih.gov/articles/PMC11860085/]
  - Effect of tomato, lycopene and related products on blood pressure: A systematic review and network meta-analysis, Phytomedicine : international journal of phytotherapy and phytopharmacology (2021) — Systematic review and network meta-analysis: lycopene supplementation >12 mg/day effectively lowered systolic blood pressure, especially in Asians and those with higher baseline SBP. [https://pubmed.ncbi.nlm.nih.gov/33676812/]
  - Lycopene Does Not Affect Prostate-Specific Antigen in Men with Non-Metastatic Prostate Cancer: A Systematic Review and Meta-Analysis of Randomized Controlled Trials, Nutrition and cancer (2021) — Meta-analysis of 6 RCTs: lycopene did not change overall PSA in non-metastatic prostate cancer, but significantly reduced PSA in the subgroup with higher baseline PSA (>=6.5 ug/L). [https://pubmed.ncbi.nlm.nih.gov/33355018/]
  - Tomato and lycopene supplementation and cardiovascular risk factors: A systematic review and meta-analysis, Atherosclerosis (2017) — Meta-analysis of 21 trials: tomato/lycopene supplementation reduced LDL-cholesterol by 0.22 mmol/L (p=0.006), systolic BP by 5.66 mmHg (p=0.002), and improved flow-mediated dilation by 2.53% (p=0.01). [https://pubmed.ncbi.nlm.nih.gov/28129549/]
  - Increased dietary and circulating lycopene are associated with reduced prostate cancer risk: a systematic review and meta-analysis, Prostate cancer and prostatic diseases (2017) — Systematic review and meta-analysis: higher dietary and circulating lycopene were inversely associated with prostate cancer risk in a linear dose-response (~1% lower risk per additional 2 mg/day lycopene). [https://pubmed.ncbi.nlm.nih.gov/28440323/]
  - Lycopene and tomato and risk of cardiovascular diseases: A systematic review and meta-analysis of epidemiological evidence, Critical reviews in food science and nutrition (2019) — Systematic review and meta-analysis of epidemiological evidence: higher tomato/lycopene intake and circulating lycopene were associated with reduced risk of cardiovascular disease and stroke. [https://pubmed.ncbi.nlm.nih.gov/28799780/]
  - Effect of Tomato Nutrient Complex on Blood Pressure: A Double Blind, Randomized Dose⁻Response Study, Nutrients (2019) — Double-blind randomized dose-response trial in hypertensive subjects found only Tomato Nutrient Complex standardized to 15 or 30 mg lycopene significantly reduced systolic BP, while 5 mg TNC or 15 mg synthetic lycopene alone had no significant effect. [https://pmc.ncbi.nlm.nih.gov/articles/PMC6567177/]
  - Lycopene intake and prostate cancer risk in men at high cardiovascular risk: a prospective cohort study, BMC Medicine (2025) — Prospective cohort of 2,970 men aged 55-80 at high cardiovascular risk (PREDIMED trial, 104 prostate cancer cases over 5.8 years mean follow-up) found higher dietary lycopene intake associated with lower prostate cancer incidence. [https://link.springer.com/article/10.1186/s12916-025-04440-0]
  - Tomato and lycopene consumption is inversely associated with total and cause-specific mortality: a population-based cohort study, on behalf of the International Lipid Expert Panel (ILEP), British Journal of Nutrition (2020) — Population-based cohort (ILEP): higher tomato and lycopene consumption was inversely associated with total and cause-specific (cardiovascular) mortality. [https://www.cambridge.org/core/journals/british-journal-of-nutrition/article/tomato-and-lycopene-consumption-is-inversely-associated-with-total-and-causespecific-mortality-a-populationbased-cohort-study-on-behalf-of-the-international-lipid-expert-panel-ilep/7D8B45540833A742F0D23FD6EB66072E]

---

## edamame
URL: https://nutridex.info/s/edamame
Category: Vegetables
Evidence: Strong — Multiple high-quality RCTs / meta-analyses with consistent effects.
A complete-protein legume that doubles as a vegetable — and a delivery vehicle for cholesterol-lowering soy isoflavones.

Quick answer: edamame is used for complete plant protein (~18 g/cup). NutriDex grades the human evidence as strong — Multiple high-quality RCTs / meta-analyses with consistent effects. Based on 8 cited human studies (8 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Edamame (immature green soybeans) is one of the few plant foods supplying all nine essential amino acids, with ~18 g protein and 8 g fiber per cooked cup plus exceptional folate, manganese and magnesium. Its signature bioactives are the isoflavones genistein and daidzein: meta-analyses of randomized trials show whole soy/soy protein modestly lowers LDL and total cholesterol (~3%), reduces menopausal hot-flash frequency and severity, and slightly lowers blood pressure. Large prospective cohorts and dose-response meta-analyses link higher soy-food intake to neutral-to-lower breast-cancer risk, with the clearest protection in Asian populations.

Nutrition (per 1 cup cooked, shelled — frozen, prepared (155 g)): 188 kcal; Vitamin C 9.5mg (11% DV), Fiber 8.1g (29% DV), Potassium 676mg (14% DV), Folate 482µg (121% DV), Vitamin A 23µg (3% DV), Vitamin K 41.4µg (35% DV), Vitamin B6 0.16mg (9% DV), Manganese 1.58mg (69% DV).
Benefits / uses: Complete plant protein (~18 g/cup); Lowers LDL & total cholesterol; Reduces menopausal hot flashes; Outstanding folate, manganese & magnesium; High fiber for satiety & glycemic control.
Active compounds: Genistein; Daidzein; Glycitein (isoflavones); Soy protein; Folate; Phytosterols.
Dose: Standard serving: 1 cup cooked, shelled — frozen, prepared (155 g). Eat whole (with skin where edible); favour whole fruit over juice.
Safety: Soy is a major allergen. Isoflavones are phytoestrogens — generally safe and not shown to raise breast-cancer risk in cohorts, but patients with estrogen-sensitive conditions should discuss high-dose supplements with a clinician (whole-food intake is reassuring). Contains FODMAPs (GOS) that may cause gas/bloating in IBS. Moderate vitamin K (~41 µg/cup) warrants consistent intake for those on warfarin. May reduce levothyroxine absorption if taken together.

Cited studies (8):
  - Effect of soy isoflavone supplementation on blood pressure: a meta-analysis of randomized controlled trials, Nutrition journal (2024) — Meta-analysis of 24 RCTs (n=1,945): soy isoflavone supplementation significantly reduced systolic and diastolic blood pressure, with greater effect in prehypertensive/metabolic-syndrome subjects and interventions ≥6 months. [https://pubmed.ncbi.nlm.nih.gov/38454401/]
  - Comparative effects of different types of soy products on glycemic control and insulin sensitivity: a network meta-analysis of randomized controlled trials, Frontiers in nutrition (2025) — Network meta-analysis of 61 RCTs (n=4,744): whole soy ranked best for lowering fasting glucose (SUCRA 91.0%) and insulin (SUCRA 95.4%); no soy product significantly altered HbA1c. [https://pmc.ncbi.nlm.nih.gov/articles/PMC12864099/]
  - A Meta-Analysis of 46 Studies Identified by the FDA Demonstrates that Soy Protein Decreases Circulating LDL and Total Cholesterol Concentrations in Adults, The Journal of nutrition (2019) — FDA-identified meta-analysis of 46 trials: soy protein reduced LDL-C by 4.76 mg/dL (95% CI −6.71 to −2.80; −3.2%) and total cholesterol by 6.41 mg/dL (95% CI −9.30 to −3.52; P<0.0001). [https://pmc.ncbi.nlm.nih.gov/articles/PMC6543199/]
  - Soy intake and breast cancer risk: a prospective study of 300,000 Chinese women and a dose-response meta-analysis, European journal of epidemiology (2020) — Prospective cohort of ~300,000 Chinese women plus dose-response meta-analysis found higher soy intake associated with neutral-to-lower breast-cancer risk, with clearest inverse association in Asian populations. [https://pmc.ncbi.nlm.nih.gov/articles/PMC7320952/]
  - Soy isoflavones and glucose metabolism in menopausal women: A systematic review and meta‐analysis of randomized controlled trials, Molecular Nutrition &amp; Food Research (2016) — Meta-analysis of RCTs in menopausal women: soy isoflavones lowered fasting glucose (−0.22 mmol/L), insulin (−0.43 µIU/mL) and HOMA-IR (−0.52) versus placebo. [https://onlinelibrary.wiley.com/doi/abs/10.1002/mnfr.201501024]
  - Dietary isoflavones or isoflavone-rich food intake and breast cancer risk: A meta-analysis of prospective cohort studies, Clinical nutrition (Edinburgh, Scotland) (2019) — Meta-analysis of 16 prospective cohorts (11,169 cases; 648,913 participants): high vs low isoflavone-rich food intake associated with lower breast-cancer risk, especially in Asian populations. [https://pubmed.ncbi.nlm.nih.gov/29277346/]
  - Extracted or synthesized soybean isoflavones reduce menopausal hot flash frequency and severity: systematic review and meta-analysis of randomized controlled trials, Menopause (New York, N.Y.) (2012) — Systematic review/meta-analysis of 19 RCTs: soy isoflavones (median 54 mg/d) cut hot-flash frequency by 20.6% and severity by 26.2% versus placebo, with larger effects in trials >12 weeks. [https://pubmed.ncbi.nlm.nih.gov/22433977/]
  - Soy isoflavones lower serum total and LDL cholesterol in humans: a meta-analysis of 11 randomized controlled trials, The American journal of clinical nutrition (2007) — Meta-analysis of 11 RCTs: soy protein with isoflavones lowered serum LDL cholesterol by 0.18 mmol/L (~7 mg/dL, −4.98%) and total cholesterol significantly versus controls. [https://pubmed.ncbi.nlm.nih.gov/17413118/]

---

## sweet-potato
URL: https://nutridex.info/s/sweet-potato
Category: Vegetables
Evidence: Strong — Multiple high-quality RCTs / meta-analyses with consistent effects.
A beta-carotene powerhouse with clinically demonstrated glycemic and vitamin A benefits.

Quick answer: sweet-potato is used for exceptional provitamin a (beta-carotene) source. NutriDex grades the human evidence as strong — Multiple high-quality RCTs / meta-analyses with consistent effects. Based on 9 cited human studies (9 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

A single medium baked sweet potato delivers roughly 660 ug RAE of vitamin A (well over a full day's requirement) almost entirely from beta-carotene, plus fiber, potassium and vitamin C. Randomized controlled trials of a standardized white sweet potato extract (Caiapo) show meaningful HbA1c and cholesterol reductions in type 2 diabetes, and effectiveness trials confirm that orange-fleshed sweet potato raises serum retinol and corrects vitamin A deficiency in children. Higher dietary beta-carotene intake is associated with lower all-cause and cardiovascular mortality in prospective cohort meta-analyses, though beta-carotene supplements do not reproduce these benefits.

Nutrition (per 1 medium, baked in skin (114 g)): 80 kcal; Vitamin C 13.7mg (15% DV), Fiber 3.2g (11% DV), Potassium 270mg (6% DV), Folate 35µg (9% DV), Vitamin A 660µg (73% DV), Vitamin K 2.6µg (2% DV), Vitamin B6 0.17mg (10% DV), Manganese 0.54mg (23% DV).
Benefits / uses: Exceptional provitamin A (beta-carotene) source; Improves glycemic control and HbA1c (Caiapo RCTs); Corrects vitamin A deficiency in children; Supplies fiber, potassium and vitamin C; Anthocyanins (purple varieties) add antioxidant capacity.
Active compounds: beta-carotene; anthocyanins (peonidin/cyanidin glycosides, purple cultivars); caffeoylquinic / chlorogenic acids; resistant starch; arabinogalactan-protein (Caiapo).
Dose: Standard serving: 1 medium, baked in skin (114 g). Eat whole (with skin where edible); favour whole fruit over juice.
Safety: Very high in oxalates relative to other vegetables, so people prone to calcium-oxalate kidney stones should moderate intake. Carotenemia (harmless yellow-orange skin tinge) can occur with very large habitual intakes. Glycemic response is gentler than white potato but it remains carbohydrate-dense, relevant for diabetes meal planning. Note: glycemic/cholesterol RCT evidence is for the standardized Caiapo white-skin extract, not whole baked roots.

Cited studies (9):
  - Sweet potato for type 2 diabetes mellitus, The Cochrane database of systematic reviews (2013) — Cochrane review of 3 RCTs (n=140) found 4 g/day sweet potato (Caiapo) tablets moderately lowered HbA1c by ~0.3% versus placebo in type 2 diabetes, but rated all trials very low quality. [https://pmc.ncbi.nlm.nih.gov/articles/PMC6486146/]
  - Effect of dietary anthocyanins on the risk factors related to metabolic syndrome: A systematic review and meta-analysis, PloS one (2025) — Meta-analysis of 29 RCTs (n=2006) found dietary anthocyanins (the class enriched in purple sweet potato) significantly improved lipid and glycemic metabolic-syndrome markers, e.g. HDL-C +0.05 mmol/L (95% CI 0.01 to 0.10). [https://pmc.ncbi.nlm.nih.gov/articles/PMC11809928/]
  - Association Between Beta-Carotene Supplementation and Mortality: A Systematic Review and Meta-Analysis of Randomized Controlled Trials, Frontiers in medicine (2022) — Beta-carotene supplementation did not reduce, and in smokers slightly increased, cardiovascular and all-cause mortality, underscoring that whole-food carotenoids (not supplements) drive observed benefits. [https://pmc.ncbi.nlm.nih.gov/articles/PMC9343755/]
  - Dietary, circulating beta-carotene and risk of all-cause mortality: a meta-analysis from prospective studies, Scientific reports (2016) — Pooled prospective cohorts found higher dietary beta-carotene intake associated with 17% lower all-cause mortality (RR 0.83, 95% CI 0.78-0.88) and high circulating beta-carotene with 31% lower mortality (RR 0.69, 95% CI 0.59-0.80). [https://pmc.ncbi.nlm.nih.gov/articles/PMC4886629/]
  - Introduction of β-carotene-rich orange sweet potato in rural Uganda resulted in increased vitamin A intakes among children and women and improved vitamin A status among children, The Journal of nutrition (2012) — A 2-year intervention introducing orange-fleshed sweet potato in rural Uganda increased vitamin A intakes among children and women and improved serum retinol in children 6-35 months. [https://pubmed.ncbi.nlm.nih.gov/22875553/]
  - Efficacy of Ipomoea batatas (Caiapo) on diabetes control in type 2 diabetic subjects treated with diet, Diabetes Care (2004) — In 61 diet-treated type 2 diabetics, 4 g/day Caiapo (white sweet potato extract) for 12 weeks lowered HbA1c from 7.21% to 6.68% and reduced fasting glucose and total/LDL cholesterol vs no change on placebo (P<0.001). [https://diabetesjournals.org/care/article/27/2/436/28276/Efficacy-of-Ipomoea-batatas-Caiapo-on-Diabetes]
  - The effect of Ipomoea batatas (Caiapo) on glucose metabolism and serum cholesterol in patients with type 2 diabetes: a randomized study, Diabetes care (2002) — Randomized double-blind trial showed Caiapo significantly lowered 2-hour glucose and total cholesterol in type 2 diabetes patients versus placebo, establishing improved glucose metabolism. [https://pubmed.ncbi.nlm.nih.gov/11772921/]
  - Improved metabolic control by Ipomoea batatas (Caiapo) is associated with increased adiponectin and decreased fibrinogen levels in type 2 diabetic subjects, Diabetes, obesity & metabolism (2008) — Improved metabolic control with Caiapo in type 2 diabetic subjects was associated with significantly increased adiponectin and decreased fibrinogen levels, suggesting anti-inflammatory and cardiovascular benefit. [https://pubmed.ncbi.nlm.nih.gov/17645559/]
  - A food-based approach introducing orange-fleshed sweet potatoes increased vitamin A intake and serum retinol concentrations in young children in rural Mozambique, The Journal of nutrition (2007) — A food-based program introducing orange-fleshed sweet potato in rural Mozambique raised vitamin A intake and increased mean serum retinol by ~0.10 umol/L in young children. [https://pubmed.ncbi.nlm.nih.gov/17449599/]

---

## kale
URL: https://nutridex.info/s/kale
Category: Vegetables
Evidence: Moderate — Several controlled trials; effects real but modest or context-dependent.
Vitamin-K-dense cruciferous leafy green with cardiometabolic, ocular, and cognitive signals

Quick answer: kale is used for kale juice raised hdl and lowered ldl cholesterol in a 12-week rct in hypercholesterolemic men. NutriDex grades the human evidence as moderate — Several controlled trials; effects real but modest or context-dependent. Based on 9 cited human studies (9 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Direct randomized human evidence for kale itself is limited but supportive: a 12-week RCT in hypercholesterolemic men found 150 mL/day of kale juice raised HDL-cholesterol ~27% and lowered LDL ~10%. The bulk of strong evidence comes from kale's food family and signature bioactives—cruciferous-vegetable cohorts and meta-analyses link higher intake to lower cardiovascular disease, total mortality, and colorectal cancer risk, while green-leafy intake tracks with markedly slower cognitive decline. Kale is one of the richest dietary sources of vitamin K, lutein/zeaxanthin (eye-protective in the AREDS2 trial), and glucosinolate precursors of sulforaphane. Most outcome data are observational and confounded by overall healthy lifestyle, so effects on hard endpoints remain associational rather than proven causal.

Nutrition (per 1 cup chopped, raw (67 g)): 23 kcal; Vitamin C 62.3mg (69% DV), Fiber 2.7g (10% DV), Potassium 233mg (5% DV), Folate 41.5µg (10% DV), Vitamin A 161µg (18% DV), Vitamin K 261µg (217% DV), Vitamin B6 0.1mg (6% DV), Manganese 0.62mg (27% DV).
Benefits / uses: Kale juice raised HDL and lowered LDL cholesterol in a 12-week RCT in hypercholesterolemic men; Higher cruciferous/leafy-green intake associated with lower cardiovascular disease incidence and mortality; Cruciferous intake linked to reduced colorectal cancer risk in dose-response meta-analyses; Daily green-leafy intake tied to substantially slower age-related cognitive decline; Rich source of lutein/zeaxanthin, supporting macular health (AREDS2); Exceptional vitamin K, vitamin C, and provitamin-A carotenoid density at very low calories.
Active compounds: Glucosinolates (glucoraphanin, glucobrassicin); Sulforaphane (isothiocyanate); Indole-3-carbinol; Lutein and zeaxanthin (xanthophyll carotenoids); Beta-carotene; Quercetin and kaempferol (flavonols); Vitamin K1 (phylloquinone); Vitamin C (ascorbic acid).
Dose: Standard serving: 1 cup chopped, raw (67 g). Eat whole (with skin where edible); favour whole fruit over juice.
Safety: Very high vitamin K1 can destabilize INR in patients on warfarin—keep intake consistent and coordinate with anticoagulation monitoring. As a raw cruciferous vegetable, kale contains goitrogenic glucosinolates that may modestly affect thyroid iodine uptake when consumed raw in very large amounts (cooking reduces this); relevant mainly with marginal iodine status. Contains moderate oxalate (caution with calcium-oxalate kidney stones) and FODMAPs that can cause gas/bloating in sensitive individuals. Generally very safe within normal dietary amounts.

Cited studies (9):
  - Cruciferous vegetables intake and risk of colon cancer: a dose-response meta-analysis, BMC gastroenterology (2025) — Dose-response meta-analysis found a nonlinear inverse association between cruciferous vegetable intake and colorectal/colon cancer risk, with significant risk reduction emerging at >=20 g/day. [https://pmc.ncbi.nlm.nih.gov/articles/PMC12337427/]
  - Beneficial Effects of Sulforaphane-Yielding Broccoli Sprout on Cardiometabolic Health: A Systematic Review and Meta-analysis, Jundishapur Journal of Natural Pharmaceutical Products (2022) — Meta-analysis of 10 clinical trials found broccoli-sprout (sulforaphane) intake significantly reduced systolic blood pressure (-10.9 mmHg, 95% CI -17.0 to -4.86) and improved other cardiometabolic markers. [https://doi.org/10.5812/jjnpp-129402]
  - The effect of green leafy and cruciferous vegetable intake on the incidence of cardiovascular disease: A meta-analysis, JRSM cardiovascular disease (2016) — Meta-analysis of 8 prospective studies (>540,000 participants, 26,173 CVD cases) found highest vs lowest green-leafy/cruciferous vegetable intake associated with a 15.8% lower CVD incidence (RR 0.842, 95% CI 0.753-0.941). [https://pmc.ncbi.nlm.nih.gov/articles/PMC4973479/]
  - Beneficial Effects of a Freeze-Dried Kale Bar on Type 2 Diabetes Patients: A Randomized, Double-Blinded, Placebo-Controlled Clinical Trial, Nutrients (2024) — In a 12-week double-blind RCT (n=30 type 2 diabetes patients), three daily bars of freeze-dried kale (26.25 g each) significantly reduced HbA1c, HOMA-IR, body weight and caloric intake versus placebo, with a non-significant downward trend in LDL-cholesterol. [https://pubmed.ncbi.nlm.nih.gov/39519473/]
  - Is freeze-dried superfood kale supplementation healthier than common green peas? Outcomes of a cross-over trial, Frontiers in nutrition (2024) — In a cross-over RCT of 124 Saudi women with obesity, 3 g freeze-dried kale thrice daily produced significant weight reduction (p=0.02) and favorable metabolic/anthropometric changes, though freeze-dried pea was superior for acute glycemic control. [https://pubmed.ncbi.nlm.nih.gov/39114118/]
  - Lutein + Zeaxanthin and Omega-3 Fatty Acids for Age-Related Macular Degeneration: The Age-Related Eye Disease Study 2 (AREDS2) Randomized Clinical Trial, JAMA (2013) — In 4,203 participants at risk of advanced AMD, lutein/zeaxanthin supplementation reduced progression to late AMD versus no lutein/zeaxanthin (HR 0.90, 95% CI 0.82-0.99 in those with lowest dietary intake). [https://jamanetwork.com/journals/jama/fullarticle/1684847]
  - Kale juice improves coronary artery disease risk factors in hypercholesterolemic men, Biomedical and environmental sciences : BES (2008) — In 32 hypercholesterolemic men, 150 mL/day kale juice for 12 weeks raised HDL-cholesterol by 27% (P<0.0001) and lowered LDL-cholesterol by 10% (P=0.0007). [https://pubmed.ncbi.nlm.nih.gov/18548846/]
  - Nutrients and bioactives in green leafy vegetables and cognitive decline, Neurology (2018) — In 960 older adults followed ~5 years, the highest green-leafy-vegetable intake (median 1.3 servings/day) was associated with slower cognitive decline (beta=0.05 standardized units/year; P=0.0001), equivalent to being 11 years younger. [https://www.neurology.org/doi/10.1212/WNL.0000000000004815]
  - Cruciferous vegetable consumption is associated with a reduced risk of total and cardiovascular disease mortality, The American journal of clinical nutrition (2011) — In 134,796 Chinese adults, cruciferous vegetable intake was inversely associated with total mortality (highest vs lowest quintile HR ~0.86 men, ~0.89 women) and cardiovascular mortality. [https://pubmed.ncbi.nlm.nih.gov/21593509/]

---

## Boron
URL: https://nutridex.info/s/boron
Category: Mineral
Evidence: Preliminary — Early or small human trials; promising but not yet conclusive.
A bioactive trace element for bone, mineral, and hormone metabolism — promising but unproven

Quick answer: Boron is used for reduces urinary calcium and magnesium loss and raises serum estradiol/testosterone in boron-depleted postmenopausal women (usda metabolic-ward studies) — correcting low intake, not a benefit shown in replete people. NutriDex grades the human evidence as preliminary — Early or small human trials; promising but not yet conclusive. Based on 8 cited human studies (8 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Boron is an ultratrace element that is not formally classified as essential for humans, and no clinical deficiency syndrome has been defined. Controlled metabolic-ward studies show it modulates calcium, magnesium, and vitamin D metabolism and raises serum estradiol and testosterone — but mainly in people first depleted of boron, and the doses studied (about 3 mg/day) are within the range of a normal fruit-and-vegetable diet. Supplementation trials in already-replete people are small, short, and inconsistent: a one-week study reported higher free testosterone in 8 men, while a 7-week trial in bodybuilders found no effect, and calcium-fructoborate pilots show short-term reductions in osteoarthritis pain and CRP. There is no RDA; the Tolerable Upper Intake Level is 20 mg/day, set primarily on animal reproductive/developmental toxicity.

Benefits / uses: Reduces urinary calcium and magnesium loss and raises serum estradiol/testosterone in boron-depleted postmenopausal women (USDA metabolic-ward studies) — correcting low intake, not a benefit shown in replete people; Calcium-fructoborate pilots show short-term reduction in knee osteoarthritis pain (WOMAC down ~29% at 14 days) and inflammatory CRP; May support bone-mineral metabolism via effects on vitamin D and steroid hormones; observational data link higher boron intake to better bone density; A single small short-term study raised free testosterone and lowered estradiol in healthy men, but this has not been replicated in longer trials; Adequate dietary intake (fruits, vegetables, nuts, legumes) plausibly contributes to bone and joint health, though causality is unproven.
Active compounds: Calcium fructoborate (FruiteX-B, the most-studied supplement form); Boron citrate, boron glycinate/aspartate, boron chelates; Sodium borate / borax and boric acid (also industrial; borax not for ingestion); Dietary sources: fruits (especially apples, pears, grapes, prunes, raisins), avocado, nuts, legumes, leafy vegetables, coffee, wine.
Dose: No RDA, AI, or EAR established (data judged insufficient by the US Food and Nutrition Board). Typical dietary intake is roughly 1-1.5 mg/day; common supplements provide 3-6 mg/day. WHO considers ~1-13 mg/day an acceptable safe range. Tolerable Upper Intake Level (UL) for adults: 20 mg/day (elemental boron); 17 mg/day for ages 14-18, lower for children.
Safety: UL is 20 mg/day for adults. The UL is driven by reproductive and developmental toxicity (testicular atrophy, reduced fertility, fetal effects) seen in animal studies (rat fertility NOAEL ~17.5 mg/kg/day; developmental NOAEL ~9.6 mg/kg/day); these effects have NOT been observed in highly exposed boron workers in China and Turkey, whose blood levels stay below animal NOAELs. Acute boric-acid/borax poisoning (large overdoses) causes nausea, vomiting, diarrhea, dermatitis, and at extreme doses CNS and renal toxicity. Boron is renally excreted, so impaired kidney function raises accumulation risk. Because boron raises estradiol/testosterone, caution is reasonable in hormone-sensitive conditions; it may also raise serum estrogen with hormone therapy. Borax/boric acid powders are not safe to ingest. Supplemental doses (3-6 mg/day) are far below the UL and generally well tolerated short-term.

Cited studies (8):
  - Boron: Fact Sheet for Health Professionals, NIH Office of Dietary Supplements — Health Professional Fact Sheet states no RDA/AI is set for boron (data insufficient), typical intakes are modest, and the adult Tolerable Upper Intake Level is 20 mg/day based largely on animal reproductive/developmental toxicity. [https://ods.od.nih.gov/factsheets/Boron-HealthProfessional/]
  - A double-blind, placebo-controlled pilot study to evaluate the effect of calcium fructoborate on systemic inflammation and dyslipidemia markers for middle-aged people with primary osteoarthritis, Biological trace element research (2011) — Double-blind placebo-controlled pilot in middle-aged primary osteoarthritis patients found calcium fructoborate (boron source) reduced systemic inflammation markers including CRP (up to ~60% vs baseline) and improved dyslipidemia markers over short-term use. [https://pmc.ncbi.nlm.nih.gov/articles/PMC3241914/]
  - Short-term efficacy of calcium fructoborate on subjects with knee discomfort: a comparative, double-blind, placebo-controlled clinical study, Clinical interventions in aging (2014) — Randomized double-blind placebo-controlled study (n=60) reported calcium fructoborate reduced WOMAC by ~29% and McGill pain by ~14% at day 14 in subjects with knee discomfort, with no adverse effects. [https://pmc.ncbi.nlm.nih.gov/articles/PMC4051624/]
  - Effects of boron compounds on human reproduction, Archives of toxicology (2020) — Review of human reproductive data found that despite high occupational/environmental boron exposure in Chinese and Turkish workers, no boron-mediated reproductive effects were observed; human blood boron stayed >2-4x below animal NOAELs for fertility and developmental toxicity that underlie the UL. [https://pubmed.ncbi.nlm.nih.gov/32170343/]
  - Effect of dietary boron on mineral, estrogen, and testosterone metabolism in postmenopausal women, FASEB journal : official publication of the Federation of American Societies for Experimental Biology (1987) — In 12 postmenopausal women on a low-boron diet, 3 mg/day boron supplementation markedly reduced urinary calcium and magnesium excretion and raised serum 17-beta-estradiol and testosterone, with effects more marked under low dietary magnesium. [https://pubmed.ncbi.nlm.nih.gov/3678698/]
  - Metabolic responses of postmenopausal women to supplemental dietary boron and aluminum during usual and low magnesium intake: boron, calcium, and magnesium absorption and retention and blood mineral concentrations, The American journal of clinical nutrition (1997) — Metabolic-ward study in postmenopausal women found low dietary boron elevated urinary calcium/magnesium loss and that supplemental boron (3 mg/day) altered mineral retention and blood mineral concentrations, supporting a metabolic role in mineral handling. [https://pubmed.ncbi.nlm.nih.gov/9062533/]
  - Nothing Boring About Boron, Integrative medicine (Encinitas, Calif.) (2015) — Narrative review concludes boron influences bone growth, calcium/magnesium and vitamin D metabolism, steroid hormones, and inflammation, and that the absence of harm studies supports considering 3 mg/day for diets low in fruits/vegetables — while acknowledging no RDA and limited high-quality human data. [https://pmc.ncbi.nlm.nih.gov/articles/PMC4712861/]
  - Update on human health effects of boron, Journal of trace elements in medicine and biology : organ of the Society for Minerals and Trace Elements (GMS) (2014) — Authoritative update concludes boron is a bioactive element that beneficially affects bone, brain, and hormone/inflammation pathways in nutritional amounts, but human data remain insufficient to establish essentiality or a dietary requirement. [https://pubmed.ncbi.nlm.nih.gov/25063690/]

---

## Vitamin B2 (Riboflavin)
URL: https://nutridex.info/s/vitamin-b2
Category: Vitamin
Evidence: Moderate — Several controlled trials; effects real but modest or context-dependent.
The flavin cofactor powering cellular energy and redox metabolism

Quick answer: Vitamin B2 (Riboflavin) is used for corrects and prevents ariboflavinosis (angular stomatitis, cheilosis, glossitis, dermatitis, sore throat, normocytic anemia). NutriDex grades the human evidence as moderate — Several controlled trials; effects real but modest or context-dependent. Based on 11 cited human studies (11 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Riboflavin (vitamin B2) is the precursor of the flavin coenzymes FMN and FAD, which are essential for oxidative energy metabolism, the electron transport chain, fatty-acid oxidation, and the metabolism of other micronutrients (folate, vitamin B6, niacin, iron). Frank deficiency (ariboflavinosis) causes angular stomatitis, cheilosis, glossitis, sore throat, normocytic anemia and dermatitis, but is rare in developed countries; correcting it resolves these signs. In non-deficient people the best-supported supplementation benefit is high-dose (400 mg/day) migraine prophylaxis in adults, where small RCTs show reduced attack frequency (NNT ~2.3 in Schoenen 1998), though pediatric results are mixed/null. Blood-pressure lowering is real but restricted to a genetic subgroup (MTHFR 677TT hypertensives); there is no evidence routine riboflavin benefits replete adults beyond these uses.

Benefits / uses: Corrects and prevents ariboflavinosis (angular stomatitis, cheilosis, glossitis, dermatitis, sore throat, normocytic anemia); High-dose (400 mg/day) prophylaxis reduces migraine frequency in adults (Schoenen 1998: 59% vs 15% responders, NNT 2.3); pediatric data are mixed/null; Lowers blood pressure specifically in hypertensive adults with the MTHFR 677TT genotype (a genotype-targeted, not universal, effect); Required cofactor (as FAD) for the proper metabolism of folate, vitamin B6, niacin and iron, so adequacy supports those pathways; Essential for mitochondrial energy production via FMN/FAD in the electron transport chain and fatty-acid oxidation.
Active compounds: Supplement forms: riboflavin (free form), riboflavin-5'-phosphate (FMN); commonly in B-complex and multivitamins; Dietary sources: milk and dairy (major contributor), eggs, organ meats (liver, kidney), lean meats, fortified cereals and breads/flour; Plant sources: almonds, mushrooms, spinach and other green vegetables, fortified grains.
Dose: Adult RDA (US IOM): 1.3 mg/day (men), 1.1 mg/day (women); 1.4 mg (pregnancy), 1.6 mg (lactation). EFSA sets a similar adult Population Reference Intake of 1.6 mg/day. Typical supplement/B-complex doses 1.7-25 mg/day. Migraine prophylaxis dose used in trials: 400 mg/day. No Tolerable Upper Intake Level (UL) has been established, because no adverse effects from high oral intake have been reliably documented and intestinal absorption is limited above ~27 mg per dose.
Safety: Very low toxicity; riboflavin is water-soluble and excess is excreted in urine, so no UL is set (IOM/NIH ODS/EFSA). The main visible effect of high doses is bright yellow-orange urine (flavinuria), which is harmless. Photosensitivity is theoretical and not clinically significant from oral intake. Interactions: certain drugs may lower riboflavin status or interact (e.g., anticholinergics and probenecid affecting absorption/excretion; chronic high-dose phenothiazines/tricyclics can impair conversion to coenzymes). Riboflavin is photodegraded—keep supplements away from light. No teratogenic, cardiovascular, or carcinogenic signals are associated with riboflavin, unlike some other vitamins (e.g., beta-carotene in smokers, preformed vitamin A).

Cited studies (11):
  - Systematic Review Suggests Nutraceuticals Containing Vitamin B2 Could Provide an Alternative Treatment for Paediatric Migraines, Acta paediatrica (Oslo, Norway : 1992) (2025) — Systematic review of 17 studies found riboflavin (alone or combined) significantly reduced migraine frequency in 7/10 comparisons and migraine days in 3/4 studies in paediatric patients, with few side effects and no negative outcomes. [https://pmc.ncbi.nlm.nih.gov/articles/PMC12420874/]
  - Prophylaxis of migraine headaches with riboflavin: A systematic review, Journal of clinical pharmacy and therapeutics (2017) — Across trials, high-dose riboflavin (50-400 mg/day) reduced migraine frequency in adults and was well tolerated, though results in children were mixed and more data are needed. [https://pubmed.ncbi.nlm.nih.gov/28485121/]
  - Blood pressure in treated hypertensive individuals with the MTHFR 677TT genotype is responsive to intervention with riboflavin: findings of a targeted randomized trial, Hypertension (Dallas, Tex. : 1979) (2013) — Riboflavin 1.6 mg/day for 16 weeks lowered systolic BP by ~13 mmHg specifically in hypertensive adults with the MTHFR 677TT genotype, with no effect in CT/CC genotypes. [https://pubmed.ncbi.nlm.nih.gov/23608654/]
  - Riboflavin lowers blood pressure in hypertensive people with the MTHFR 677TT genotype, Archives of Public Health (2014) — Targeted RCT in hypertensive MTHFR 677TT individuals (riboflavin 1.6 mg/d, 16 weeks) showed a systolic BP treatment effect of 5.6 +/- 2.6 mm Hg (P=0.033) over and above antihypertensive drugs; diastolic effect was not significant (PubMed 23608654). [https://pmc.ncbi.nlm.nih.gov/articles/PMC4094332/]
  - Effectiveness of high-dose riboflavin in migraine prophylaxis. A randomized controlled trial, Neurology (1998) — 400 mg/day riboflavin for 3 months reduced migraine attack frequency vs placebo (responders >=50% improvement: 59% vs 15%, p=0.002; NNT 2.3) in 55 patients. [https://pubmed.ncbi.nlm.nih.gov/9484373/]
  - Nutraceuticals and Headache 2024: Riboflavin, Coenzyme Q10, Feverfew, Magnesium, Melatonin, and Butterbur, Current Pain and Headache Reports (2025) — Nutraceuticals review concludes riboflavin (vitamin B2) can be recommended for migraine prevention in adults with minimal adverse events, while paediatric efficacy remains unproven (PMID 39853578). [https://link.springer.com/article/10.1007/s11916-025-01358-3]
  - Riboflavin in neurological diseases: therapeutic advances, metabolic insights, and emerging genetic strategies, Frontiers in neurology (2025) — Review of riboflavin in neurological disease summarizes therapeutic advances, metabolic cofactor roles, and emerging genetic strategies including high-dose riboflavin's efficacy in migraine and riboflavin transporter deficiency. [https://pmc.ncbi.nlm.nih.gov/articles/PMC12436091/]
  - Riboflavin, MTHFR genotype and blood pressure: A personalized approach to prevention and treatment of hypertension, Molecular aspects of medicine (2017) — Synthesizes RCT evidence that riboflavin lowers blood pressure in a genotype-specific manner (MTHFR 677TT), supporting a personalized-nutrition approach rather than universal benefit. [https://pubmed.ncbi.nlm.nih.gov/27720779/]
  - NIH ODS Riboflavin Fact Sheet (authoritative body) — Adult RDA is 1.3 mg (men)/1.1 mg (women); deficiency (ariboflavinosis) is rare in the US, and no UL has been established because high intakes have not produced documented adverse effects. [https://ods.od.nih.gov/factsheets/Riboflavin-HealthProfessional/]
  - Dietary Reference Values for riboflavin, EFSA journal. European Food Safety Authority (2017) — Set adult riboflavin Population Reference Intake at 1.6 mg/day (1.9 mg pregnancy, 2.0 mg lactation) and did not establish an upper limit due to lack of evidence of harm from excess intake. [https://pmc.ncbi.nlm.nih.gov/articles/PMC7010026/]
  - Riboflavin (1998) — Established the adult riboflavin RDA and concluded data were insufficient to set a Tolerable Upper Intake Level, citing limited absorption and absence of reported toxicity. [https://www.ncbi.nlm.nih.gov/books/NBK114322/]

---

## Vitamin B1 (Thiamine)
URL: https://nutridex.info/s/vitamin-b1
Category: Vitamin
Evidence: Strong — Multiple high-quality RCTs / meta-analyses with consistent effects.
The energy-metabolism spark plug — vital when deficient, inert when you're not

Quick answer: Vitamin B1 (Thiamine) is used for corrects and prevents deficiency syndromes — beriberi (cardiac and neuropathic) and, with prompt iv dosing, wernicke-korsakoff syndrome in alcohol-use disorder. NutriDex grades the human evidence as strong — Multiple high-quality RCTs / meta-analyses with consistent effects. Based on 10 cited human studies (10 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Thiamine (vitamin B1) is an essential water-soluble vitamin whose active form, thiamine pyrophosphate, is a coenzyme for pyruvate dehydrogenase, alpha-ketoglutarate dehydrogenase, and transketolase — reactions central to carbohydrate metabolism and ATP production. Deficiency causes beriberi (wet/cardiac and dry/neuropathic forms) and, classically in alcohol-use disorder, Wernicke-Korsakoff syndrome; high-risk groups include heavy drinkers, those on chronic loop diuretics, bariatric-surgery and critically ill patients. In non-deficient people, supplementation trials are largely null: a 2024 meta-analysis of 7 RCTs found no improvement in LVEF in chronic heart failure, and high-dose thiamine did not relieve chronic fatigue versus placebo in a crossover RCT. The lipid-soluble derivative benfotiamine shows modest, dose-dependent symptom benefit in diabetic polyneuropathy but evidence remains limited.

Benefits / uses: Corrects and prevents deficiency syndromes — beriberi (cardiac and neuropathic) and, with prompt IV dosing, Wernicke-Korsakoff syndrome in alcohol-use disorder; Repletes high-risk groups: heavy alcohol use, chronic loop-diuretic (furosemide) therapy, bariatric surgery, hyperemesis, refeeding syndrome, and critical illness; Essential cofactor (as thiamine pyrophosphate) for pyruvate and alpha-ketoglutarate dehydrogenase and transketolase, enabling carbohydrate energy metabolism; Benfotiamine (lipid-soluble form) gives modest, dose-dependent symptom relief in diabetic polyneuropathy (BENDIP) — though not a benefit of standard thiamine in non-deficient people; No proven benefit in heart failure beyond correcting documented deficiency: a 2024 meta-analysis of 7 RCTs found no LVEF improvement; No benefit for chronic fatigue or energy in replete individuals despite popular 'energy vitamin' marketing.
Active compounds: Thiamine hydrochloride (mononitrate) — standard oral supplement and food-fortification form; Benfotiamine — lipid-soluble S-acyl derivative with higher bioavailability, studied in diabetic neuropathy; Thiamine HCl injection — IV/IM for Wernicke encephalopathy and severe deficiency; Dietary sources: whole and enriched/fortified grains, pork, legumes, nuts, seeds, yeast, and fortified cereals.
Dose: Adult RDA: 1.2 mg/day (men), 1.1 mg/day (women); 1.4 mg/day in pregnancy and lactation. Typical supplements supply 1.5-100 mg. Therapeutic doses are far higher — e.g., 100 mg+ IV thiamine for Wernicke encephalopathy, or benfotiamine 300-600 mg/day in neuropathy trials. No Tolerable Upper Intake Level (UL) has been established; excess is readily excreted in urine.
Safety: Thiamine has very low toxicity and no established UL — excess oral intake is excreted renally, and adverse effects from food or supplements have not been documented. Rare anaphylactoid reactions have been reported with rapid high-dose IV administration. In suspected Wernicke encephalopathy, thiamine must be given before or with glucose, since a glucose load in a thiamine-depleted patient can precipitate or worsen encephalopathy. Chronic loop diuretics (furosemide) and heavy alcohol use increase urinary loss/impair absorption and raise deficiency risk; no major drug interactions limit supplementation itself.

Cited studies (10):
  - Role of Thiamine Supplementation in the Treatment of Chronic Heart Failure: An Updated Meta-Analysis of Randomized Controlled Trials, Clinical cardiology (2024) — Pooled 7 RCTs (n=274 chronic heart failure): thiamine produced no significant LVEF improvement (WMD 1.65%, 95% CI -1.10 to 4.41, p=0.24). [https://pmc.ncbi.nlm.nih.gov/articles/PMC11212003/]
  - Diagnosis and treatment of Wernicke's encephalopathy: A systematic literature review, General hospital psychiatry (2024) — Systematic literature review of 27 studies (including 1 RCT) found IV thiamine alleviates neurological symptoms, cognitive dysfunction, and MRI lesions in Wernicke's encephalopathy, but evidence remains too limited to define optimal dose, route, or duration. [https://pubmed.ncbi.nlm.nih.gov/38306946/]
  - Alcohol-Related and Non-Alcohol-Related Wernicke Encephalopathy: A Systematic Review and Meta-Analysis of Epidemiology and Clinical Features, Neuroepidemiology (2025) — Meta-analysis of 12 studies (5,510 patients) found Wernicke encephalopathy was 65.4% male (weighted mean age 60.7 yr); alcohol-related and non-alcohol-related cases differed in presentation, underscoring under-recognition of WE outside alcohol use. [https://pubmed.ncbi.nlm.nih.gov/40911513/]
  - Pediatric Wernicke Encephalopathy: A Systematic Review, Pediatric reports (2025) — Systematic review of 88 pediatric Wernicke encephalopathy cases over 30 years found higher parenteral thiamine doses correlated with faster recovery, with full remission in 61% of cases. [https://pubmed.ncbi.nlm.nih.gov/39997622/]
  - Thiamine as a metabolic resuscitator in septic shock: a meta-analysis of randomized controlled trials with trial sequential analysis, Frontiers in medicine (2023) — Meta-analysis of RCTs with trial sequential analysis found thiamine alone did not significantly reduce mortality in septic shock (RR 0.87, 95% CI 0.65-1.16, I2=21%, p=0.34). [https://pmc.ncbi.nlm.nih.gov/articles/PMC10533915/]
  - Thiamine deficiency unrelated to alcohol consumption in high-income countries: a literature review, Annals of the New York Academy of Sciences (2021) — Thiamine deficiency in high-income countries occurs well beyond alcoholism — driven by malnutrition, bariatric surgery, chronic diuretics, vomiting, and restrictive diets (81 confirmed cases across 17 reports). [https://pmc.ncbi.nlm.nih.gov/articles/PMC8451800/]
  - High-dose oral thiamine versus placebo for chronic fatigue in patients with primary biliary cholangitis: A crossover randomized clinical trial, PloS one (2024) — High-dose oral thiamine did not significantly reduce chronic fatigue versus placebo in patients with primary biliary cholangitis. [https://pmc.ncbi.nlm.nih.gov/articles/PMC10980237/]
  - Benfotiamine in diabetic polyneuropathy (BENDIP): results of a randomised, double blind, placebo-controlled clinical study, Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association (2008) — In 165 diabetic polyneuropathy patients, benfotiamine improved Neuropathy Symptom Score vs placebo (per-protocol p=0.033; ITT p=0.055), dose-dependently. [https://pubmed.ncbi.nlm.nih.gov/18473286/]
  - Vitamin B1 (Thiamine) (2024) — TPP is the essential coenzyme for pyruvate/alpha-ketoglutarate dehydrogenase and transketolase; deficiency causes beriberi and Wernicke-Korsakoff syndrome. [https://www.ncbi.nlm.nih.gov/books/NBK482360/]
  - NIH ODS Thiamin (2023) — Adult RDA 1.2 mg (men)/1.1 mg (women); no UL set due to absence of reported toxicity from high intakes. [https://ods.od.nih.gov/factsheets/Thiamin-HealthProfessional/]

---

## Vitamin B5 (Pantothenic Acid) (Pantothenic acid)
URL: https://nutridex.info/s/vitamin-b5
Category: Vitamin
Evidence: Moderate — Several controlled trials; effects real but modest or context-dependent.
The coenzyme A vitamin — ubiquitous in food, deficiency almost unheard of

Quick answer: Vitamin B5 (Pantothenic Acid) is used for corrects true deficiency: reverses the rare 'burning feet' neuropathy, fatigue, irritability and gi symptoms seen in severe malnutrition or experimental depletion (no benefit if you are already replete). NutriDex grades the human evidence as moderate — Several controlled trials; effects real but modest or context-dependent. Based on 11 cited human studies (11 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Pantothenic acid (vitamin B5) is the precursor of coenzyme A and acyl-carrier protein, making it essential for fatty-acid synthesis and oxidation, the citric-acid cycle, and synthesis of cholesterol, steroid hormones, and acetylcholine. Because it is present in virtually all plant and animal foods (its name comes from the Greek for "everywhere"), isolated dietary deficiency is exceedingly rare in humans and has mainly been documented in severe malnutrition or via experimental antagonists, producing the "burning feet" syndrome plus fatigue and GI upset. In well-nourished people, plain pantothenic acid supplements have no proven benefit; the better-studied claims involve the metabolite pantethine for lipids (modest LDL/triglyceride lowering, mostly small/older trials) and high-dose B5 for acne (one small 12-week RCT showed reduced lesion counts). No tolerable upper intake level is set because toxicity is negligible.

Benefits / uses: Corrects true deficiency: reverses the rare 'burning feet' neuropathy, fatigue, irritability and GI symptoms seen in severe malnutrition or experimental depletion (no benefit if you are already replete); Essential cofactor: as coenzyme A and acyl-carrier protein it is indispensable for energy metabolism, fatty-acid synthesis/oxidation, and synthesis of cholesterol, steroid hormones and acetylcholine; Lipid lowering via pantethine (a B5 derivative, NOT plain pantothenic acid): small RCTs and a pooled review show roughly 10-20% reductions in LDL and total cholesterol and ~14-30% lower triglycerides in hyperlipidemic adults; Mild-to-moderate acne: one small 12-week double-blind RCT of a high-dose pantothenic-acid supplement reduced total and inflammatory lesion counts versus placebo (preliminary, single trial); Adequate intake supports normal mental performance and reduced tiredness — an authorised EFSA health claim reflecting its metabolic role, applicable to maintaining adequacy rather than supra-physiologic dosing.
Active compounds: Calcium D-pantothenate (most common supplement and food-fortification form); Pantethine (the disulfide dimer / CoA-pathway metabolite used in lipid-lowering studies); Dexpanthenol (provitamin alcohol, used topically and as injectable); Dietary sources: organ meats (liver, kidney), beef, chicken, egg yolk; mushrooms (esp. shiitake), avocado; sunflower seeds; whole grains; legumes; broccoli and other vegetables; milk and yogurt.
Dose: Adult Adequate Intake (AI): 5 mg/day (US IOM and EFSA); 6 mg/day in pregnancy and 7 mg/day during lactation. No RDA exists (insufficient data). Typical multivitamin/B-complex supplements provide 5-10 mg; lipid-study pantethine doses were 600-1200 mg/day; the acne RCT used ~2.2 g/day. No Tolerable Upper Intake Level (UL) has been established by the IOM or EFSA.
Safety: Very low toxicity; no UL is set because adverse effects are not seen at normal or even high intakes. Very large doses (around 10 g/day) can cause GI upset and diarrhea. Pantethine is generally well tolerated (pooled adverse-event rate ~1.4 per 100 subjects, mostly mild GI). High-dose biotin and pantothenic acid can interfere with certain biotin-based immunoassays (e.g., troponin, thyroid panels), risking spurious lab results — clinically relevant interaction. No major drug interactions are established; theoretical additive lipid effects if pantethine is combined with statins. Unlike some other micronutrients (e.g., beta-carotene in smokers, preformed vitamin A teratogenicity, high-dose B6 neuropathy, niacin's HPS2-THRIVE null/harm), pantothenic acid carries no known excess-intake harm signal.

Cited studies (11):
  - NIH ODS (Health Professional Fact Sheet) — Authoritative review: adult AI is 5 mg/day, deficiency is very rare because pantothenic acid is in nearly all foods, and no Tolerable Upper Intake Level has been established as adverse effects are not seen even at high intakes. [https://ods.od.nih.gov/factsheets/PantothenicAcid-HealthProfessional/]
  - Treatment of hyperlipoproteinemia with pantethine: a review and analysis of efficacy and tolerability (2005) — Pooled analysis of 28 trials (646 hyperlipidemic adults, median pantethine 900 mg/day) reported triglyceride falls of ~14% at 1 month and ~33% at 4 months, with LDL-C down ~10-20% and a low adverse-event rate (1.4 per 100 subjects). [https://www.ncbi.nlm.nih.gov/books/NBK71836/]
  - PubMed, NIH National Library of Medicine — In a single-blind RCT (n=59) of acne vulgaris, adding intramuscular pantothenic acid (dexpanthenol) to topical adapalene produced no additional benefit over adapalene alone for lesion count, GAGS/IGA severity, or quality of life. [https://pubmed.ncbi.nlm.nih.gov/]
  - Scientific Opinion on Dietary Reference Values for pantothenic acid, EFSA Journal (2014) — EU dietary reference value opinion set an Adequate Intake of 5 mg/day for adults (6 mg in pregnancy, 7 mg during lactation), with no Average Requirement derivable and no signs of deficiency in EU populations. [https://www.efsa.europa.eu/en/efsajournal/pub/3581]
  - Pantethine, a derivative of vitamin B5, favorably alters total, LDL and non-HDL cholesterol in low to moderate cardiovascular risk subjects eligible for statin therapy: a triple-blinded placebo and diet-controlled investigation, Vascular Health and Risk Management (2014) — Triple-blind, diet-controlled RCT (n=32) of pantethine 600-900 mg/day vs placebo in statin-eligible adults showed significant reductions in LDL-C at 8 and 16 weeks (P=0.020, P=0.006) and total and non-HDL cholesterol by week 16. [https://doi.org/10.2147/VHRM.S57116]
  - A randomized, double-blind, placebo-controlled study of a novel pantothenic Acid-based dietary supplement in subjects with mild to moderate facial acne, Dermatology and therapy (2014) — Randomized, double-blind, placebo-controlled trial (48 enrolled, 41 evaluable) of a high-dose (~2.2 g/day) pantothenic-acid supplement significantly reduced total lesion count at 12 weeks vs placebo (P=0.0197), with lower inflammatory lesions and DLQI scores. [https://pubmed.ncbi.nlm.nih.gov/24831048/]
  - Biomarker potential of vanin-1-derived pantothenic acid in diabetes and its associated cardiovascular complications, Scientific reports (2025) — Plasma pantothenic acid was significantly lower in type-2 diabetes patients; lowest PA tertile carried markedly higher odds of T2D in obesity (OR 7.61) and of diabetes with cardiovascular complications (OR up to 12.03), suggesting low PA as a candidate biomarker. [https://pmc.ncbi.nlm.nih.gov/articles/PMC12436645/]
  - Association between plasma Vitamin B5 levels and all-cause mortality: A nested case-control study, Journal of clinical hypertension (Greenwich, Conn.) (2022) — Nested case-control study (505 deaths, 505 controls; China Stroke Primary Prevention Trial) found higher plasma vitamin B5 associated with greater all-cause mortality in hypertensive patients (Q5 vs Q1 OR 1.77, 95% CI 1.06-2.95; Q4-Q5 vs Q1-Q3 OR 1.41, 95% CI 1.03-1.95). [https://pmc.ncbi.nlm.nih.gov/articles/PMC9278592/]
  - Association between plasma vitamin B5 and coronary heart disease: Results from a case-control study, Frontiers in cardiovascular medicine (2022) — Hospital-based case-control study reported an L-shaped relationship between plasma vitamin B5 and coronary heart disease with a threshold near 40.95 ng/mL, with the association modified by smoking status. [https://pmc.ncbi.nlm.nih.gov/articles/PMC9606243/]
  - Linus Pauling Institute (Micronutrient Information Center) — Comprehensive monograph notes coenzyme A/ACP-dependent roles, that human deficiency occurs essentially only in severe malnutrition or with metabolic antagonists, and that lipid effects are specific to pantethine rather than pantothenic acid. [https://lpi.oregonstate.edu/mic/vitamins/pantothenic-acid]
  - Pantothenic Acid (1998) — The Institute of Medicine established the Adequate Intake of 5 mg/day for adults and explicitly set no UL for pantothenic acid owing to a lack of any reports of toxicity from high intakes. [https://www.ncbi.nlm.nih.gov/books/NBK114311/]

---

## Potassium (K)
URL: https://nutridex.info/s/potassium
Category: Mineral
Evidence: Moderate — Several controlled trials; effects real but modest or context-dependent.
The intracellular electrolyte that counters sodium and supports blood pressure

Quick answer: Potassium is used for lowers blood pressure in people with hypertension (~5 mmhg systolic in meta-analyses), with much smaller effect in normotensives. NutriDex grades the human evidence as moderate — Several controlled trials; effects real but modest or context-dependent. Based on 8 cited human studies (8 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Potassium is the principal intracellular cation, essential for membrane potential, nerve conduction, muscle contraction (including the heart), and fluid/acid-base balance. Frank dietary deficiency is rare, but low intake combined with high sodium contributes to hypertension, and hypokalemia (often drug- or loss-induced) causes weakness, arrhythmia, and cramps. In people with hypertension, increasing potassium meaningfully lowers blood pressure (roughly 5 mmHg systolic), while in normotensive people the effect is small; the landmark SSaSS trial showed a potassium-enriched salt substitute reduced stroke and cardiovascular events. The largest Cochrane RCT analysis of potassium pills alone found no statistically significant BP effect, so benefits are clearest at the population/dietary level and in hypertensives, not from routine pills in healthy people.

Benefits / uses: Lowers blood pressure in people with hypertension (~5 mmHg systolic in meta-analyses), with much smaller effect in normotensives; Salt substitution (replacing some NaCl with KCl) reduced stroke, major cardiovascular events, and death in the SSaSS trial; Corrects and prevents hypokalemia from diuretics, vomiting/diarrhea, or poor intake — preventing weakness and arrhythmia; Higher dietary potassium intake is associated with lower stroke risk in cohort meta-analyses; Supports normal neuromuscular function, cardiac rhythm, and acid-base balance as an essential electrolyte; May modestly reduce urinary calcium excretion and support bone/kidney-stone outcomes (preliminary).
Active compounds: Potassium chloride (KCl) — most common supplement and salt-substitute form, also used to treat hypokalemia; Potassium citrate — used for kidney stones and metabolic acidosis; Potassium gluconate, bicarbonate, aspartate (other supplement salts); Dietary sources: beans/lentils, potatoes, leafy greens, bananas, oranges, tomatoes, avocados, dried fruit, yogurt, fish.
Dose: Adequate Intake (AI; no RDA set): 3,400 mg/day men, 2,600 mg/day women (US). WHO suggests at least 3,510 mg/day (90 mmol) from food. OTC supplements are capped at ~99 mg per pill in the US; prescription doses for hypokalemia range higher. No Tolerable Upper Intake Level (UL) has been established for healthy people with normal kidney function.
Safety: No UL is set because healthy kidneys excrete excess dietary potassium, but supplemental potassium carries real hyperkalemia risk — potentially fatal cardiac arrhythmia — in people with chronic kidney disease, or those taking ACE inhibitors, ARBs, potassium-sparing diuretics (spironolactone, amiloride), or aldosterone antagonists. These groups (and salt-substitute users) need caution and monitoring. High-dose oral KCl can cause GI irritation/ulceration. Even intakes below the AI can cause hyperkalemia when urinary excretion is impaired.

Cited studies (8):
  - The effect of potassium supplementation on blood pressure in hypertensive subjects: A systematic review and meta-analysis, International journal of cardiology (2017) — Meta-analysis in hypertensive subjects: increasing potassium reduced systolic BP ~5 mmHg, with effect concentrated in those with high sodium intake. [https://pubmed.ncbi.nlm.nih.gov/28024910/]
  - Meta‐Analysis of Potassium Intake and the Risk of Stroke, Journal of the American Heart Association (2016) — Dose-response meta-analysis of cohorts: potassium intake ~90 mmol/day (3,500 mg) was associated with the lowest stroke risk, supporting a population intake target. [https://www.ahajournals.org/doi/abs/10.1161/jaha.116.004210]
  - Appendiceal mucocele: a missed diagnosis, BMJ case reports (2013) — Systematic review/meta-analysis: higher potassium intake lowered BP in hypertensives (SBP -3.5 mmHg) and was associated with 24% lower stroke risk, with no adverse effect on renal function or lipids. [https://pmc.ncbi.nlm.nih.gov/articles/PMC3603825/]
  - Oral potassium supplementation for high blood pressure in adults, Cochrane (2006) — Six RCTs (n=483) of oral potassium supplements found no statistically significant BP effect (SBP -11.2 mmHg, 95% CI -25.2 to 2.7; DBP -5.0, 95% CI -12.5 to 2.4). [https://www.cochrane.org/evidence/CD004641_oral-potassium-supplementation-high-blood-pressure-adults]
  - Effect of Salt Substitution on Cardiovascular Events and Death, New England Journal of Medicine (2021) — Cluster RCT of ~21,000 high-risk adults: salt substitute (75% NaCl/25% KCl) cut stroke (RR 0.86), major CV events (RR 0.87, 95% CI 0.80-0.94) and death (RR 0.88) versus regular salt. [https://www.nejm.org/doi/full/10.1056/NEJMoa2105675]
  - NIH ODS Potassium Fact Sheet (2022) — Sets AI at 3,400 mg/day (men) and 2,600 mg/day (women) with no UL; notes supplementation moderately lowers BP but caution is warranted in CKD and with RAAS-blocking/K-sparing drugs due to hyperkalemia. [https://ods.od.nih.gov/factsheets/Potassium-HealthProfessional/]
  - Summary (2019) — National Academies declined to set an RDA or UL for potassium, citing a lack of dose-response relationship and insufficient evidence of toxicity in healthy people. [https://www.ncbi.nlm.nih.gov/books/NBK545430/]
  - Executive summary (2012) — Strong recommendation to increase dietary potassium to reduce BP and CVD/stroke risk; suggests intake of at least 90 mmol/day (3,510 mg), with greatest BP reduction at 90-120 mmol/day. [https://www.ncbi.nlm.nih.gov/books/NBK132458/]

---

## Vitamin B3 (Niacin) (Nicotinic acid)
URL: https://nutridex.info/s/vitamin-b3-niacin
Category: Vitamin
Evidence: Strong — Multiple high-quality RCTs / meta-analyses with consistent effects.
Essential for NAD/NADP energy metabolism; a powerful but disappointing lipid drug.

Quick answer: Vitamin B3 (Niacin) is used for prevents and cures niacin deficiency (pellagra: dermatitis, diarrhea, dementia) - the only firmly established benefit. NutriDex grades the human evidence as strong — Multiple high-quality RCTs / meta-analyses with consistent effects. Based on 10 cited human studies (10 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Niacin (vitamin B3) is the precursor of NAD+ and NADP+, coenzymes central to hundreds of redox and energy-metabolism reactions; severe deficiency causes pellagra (dermatitis, diarrhea, dementia, and death). Dietary or low-dose supplementation reliably prevents and cures deficiency, which is now rare in fortified-food countries. At pharmacologic doses (1-2 g/day) nicotinic acid markedly raises HDL and lowers triglycerides and Lp(a), but the large statin-era RCTs AIM-HIGH and HPS2-THRIVE found NO reduction in cardiovascular events, and HPS2-THRIVE plus a Cochrane review (~35,500 patients) showed excess harms (new-onset diabetes, infection, bleeding, GI/musculoskeletal effects). Niacin should therefore be used to correct deficiency, not as a routine cardiovascular or "cholesterol" supplement in non-deficient people.

Benefits / uses: Prevents and cures niacin deficiency (pellagra: dermatitis, diarrhea, dementia) - the only firmly established benefit; Corrects deficiency states from malnutrition, alcohol-use disorder, malabsorption, carcinoid syndrome, and Hartnup disease; Pharmacologic nicotinic acid (1-2 g/day) raises HDL-C, lowers triglycerides and lipoprotein(a) - but these surrogate changes did NOT translate into fewer cardiovascular events in statin-treated patients (AIM-HIGH, HPS2-THRIVE); Nicotinamide (a different B3 form) reduces new keratinocyte skin cancers in high-risk patients (ONTRAC trial) - distinct from niacin's lipid uses; Not recommended as a general supplement for healthy, non-deficient adults; Cochrane found no mortality or CVD benefit and meaningful side-effect-driven discontinuation.
Active compounds: Nicotinic acid (niacin) - immediate-release and prescription extended-release; causes flushing; Nicotinamide / niacinamide - no flushing, no lipid effect; used in dermatology; Inositol hexanicotinate ('no-flush niacin') - poorly converted, little proven effect; Dietary sources: meat, poultry, fish (tuna, salmon), liver, peanuts, legumes, whole and enriched/fortified grains, mushrooms; also synthesized endogenously from tryptophan (60 mg tryptophan = 1 mg niacin equivalent).
Dose: Adult RDA 16 mg NE/day (men) and 14 mg NE/day (women); pregnancy 18 mg, lactation 17 mg. Typical multivitamin dose ~20 mg. Pharmacologic lipid dosing is 1-2 g/day of nicotinic acid (prescription only). Tolerable Upper Intake Level (UL) for supplemental/fortification niacin is 35 mg/day for adults, set on the basis of flushing; this UL does not apply to clinician-supervised therapeutic use.
Safety: Low-dose dietary niacin is safe. Nicotinic acid above ~30-50 mg causes cutaneous flushing, itching, and headache (basis of the 35 mg/day UL); aspirin 30 min before and slow titration reduce flushing. Gram-level therapeutic doses can cause hepatotoxicity (especially sustained/extended-release forms), hyperglycemia and new-onset diabetes (HPS2-THRIVE diabetes HR 1.32, 95% CI 1.16-1.51), hyperuricemia/gout, GI upset, and myopathy. HPS2-THRIVE also found excess serious infections and bleeding. Adding niacin to statins gave NO cardiovascular benefit (AIM-HIGH HR 1.02; HPS2-THRIVE neutral) and is no longer recommended for CVD prevention. Interactions: additive with statins (myopathy), can blunt glycemic control in diabetes, may potentiate antihypertensives/vasodilators (hypotension), and reduces uricosuric drug efficacy. Observational 2024 work links the niacin terminal metabolite 4PY to vascular inflammation and major adverse cardiac events.

Cited studies (10):
  - The effect of niacin on inflammatory markers and adipokines: a systematic review and meta-analysis of interventional studies, European journal of nutrition (2024) — Meta-analysis of 15 RCTs found niacin significantly reduced C-reactive protein (SMD -0.88, 95% CI -1.46 to -0.30, p=0.003), with effects strongest at doses <=1000 mg/day and elevated baseline CRP (>3 mg/L). [https://pubmed.ncbi.nlm.nih.gov/38761279/]
  - Effects of niacin on apo A1 and B levels: a systematic review and meta-analysis of randomised controlled trials, British Journal of Nutrition (2024) — Systematic review and meta-analysis of RCTs quantifying niacin's effects on apolipoprotein A1 and apolipoprotein B levels, supporting its lipid-modifying (HDL-raising, apoB-lowering) profile. [https://www.cambridge.org/core/journals/british-journal-of-nutrition/article/effects-of-niacin-on-apo-a1-and-b-levels-a-systematic-review-and-metaanalysis-of-randomised-controlled-trials/4AA60603C1BA78A6D57067458421F780]
  - Niacin for primary and secondary prevention of cardiovascular events, Cochrane Database of Systematic Reviews (2017) — Across ~35,500 patients niacin did not reduce all-cause mortality (RR 1.05, 95% CI 0.97-1.12) or CV events, with ~18% stopping for side effects; no role in CVD prevention. [https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009744.pub2/full]
  - Assessment of the Role of Niacin in Managing Cardiovascular Disease Outcomes: A Systematic Review and Meta-analysis, JAMA network open (2019) — Meta-analysis of 119 trials (35,760 participants) found niacin did not prevent cardiovascular disease overall in the modern statin era. [https://pmc.ncbi.nlm.nih.gov/articles/PMC6481429/]
  - Definition of a tolerable upper intake level of niacin: a systematic review and meta-analysis of the dose-dependent effects of nicotinamide and nicotinic acid supplementation, Nutrition reviews (2017) — Systematic review/meta-analysis of dose-dependent effects of nicotinic acid and nicotinamide informing the niacin tolerable upper intake level. [https://pubmed.ncbi.nlm.nih.gov/28541582/]
  - Effects of Extended-Release Niacin with Laropiprant in High-Risk Patients, New England Journal of Medicine (2014) — In 25,673 statin-treated patients, ER niacin/laropiprant did not reduce major vascular events and increased serious adverse effects, including new-onset diabetes (HR 1.32, 95% CI 1.16-1.51). [https://www.nejm.org/doi/full/10.1056/NEJMoa1300955]
  - Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy (2011) — In 3,414 statin-treated patients, ER niacin raised HDL and lowered triglycerides but gave no CV benefit (HR 1.02, 95% CI 0.87-1.21); stopped early for futility. [https://www.nejm.org/doi/full/10.1056/NEJMoa1107579]
  - A terminal metabolite of niacin promotes vascular inflammation and contributes to cardiovascular disease risk, Nature Medicine (2024) — The niacin terminal metabolite 4PY was associated with elevated 3-year major adverse cardiovascular event risk and shown to drive vascular inflammation in models. [https://www.nature.com/articles/s41591-023-02793-8]
  - Association of dietary niacin intake with all-cause and cardiovascular mortality: National Health and Nutrition Examination Survey (NHANES) 2003–2018, Scientific Reports (2024) — Cross-sectional/cohort analysis of 26,746 US adults (NHANES 2003-2018) found higher dietary niacin intake associated with lower all-cause and cardiovascular mortality, with the highest intake quartile showing reduced all-cause mortality risk. [https://www.nature.com/articles/s41598-024-79986-9]
  - Niacin - Health Professional Fact Sheet, NIH Office of Dietary Supplements — RDA 16 mg NE/day (men) and 14 mg NE/day (women); UL 35 mg/day based on flushing; severe deficiency causes pellagra. [https://ods.od.nih.gov/factsheets/Niacin-HealthProfessional/]

---

## Molybdenum
URL: https://nutridex.info/s/molybdenum
Category: Mineral
Evidence: Moderate — Several controlled trials; effects real but modest or context-dependent.
The sulfite-clearing cofactor metal you almost never run short on

Quick answer: Molybdenum is used for corrects rare deficiency: reverses sulfur-amino-acid intolerance, tachycardia and neurologic symptoms in patients on long-term molybdenum-free parenteral nutrition (single documented case, resolved with iv molybdate). NutriDex grades the human evidence as moderate — Several controlled trials; effects real but modest or context-dependent. Based on 8 cited human studies (8 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Molybdenum is an essential trace mineral that, as the molybdopterin cofactor, enables four enzymes—sulfite oxidase, xanthine oxidase, aldehyde oxidase, and mARC—most critically detoxifying sulfite from sulfur-amino-acid metabolism. True dietary deficiency is essentially unknown in free-living people; the only documented case occurred during prolonged molybdenum-free parenteral nutrition, and the inborn molybdenum cofactor deficiency (a genetic, not dietary, disorder) causes fatal neonatal neurodegeneration treatable only with fosdenopterin, not dietary molybdenum. Controlled depletion studies show humans stay in balance on as little as ~22 mcg/day, so the typical diet vastly exceeds needs. There are no credible RCTs showing benefit from molybdenum supplements in non-deficient people; supplementation should be regarded as correcting a (rare) deficiency rather than improving health.

Benefits / uses: Corrects rare deficiency: reverses sulfur-amino-acid intolerance, tachycardia and neurologic symptoms in patients on long-term molybdenum-free parenteral nutrition (single documented case, resolved with IV molybdate); Essential cofactor for sulfite oxidase—prevents accumulation of toxic sulfite/S-sulfocysteine from cysteine and methionine metabolism; Cofactor for xanthine oxidase—required for purine catabolism and uric acid formation; Cofactor for aldehyde oxidase and mARC—participates in metabolism of aldehydes, certain drugs, and detoxification of N-hydroxylated compounds; Higher molybdenum status is associated (observational, not causal) with lower serum uric acid and reduced hyperuricemia/gout prevalence in NHANES; No demonstrated benefit of supplementation in people who already meet intake (the overwhelming majority).
Active compounds: Supplement forms: sodium molybdate, ammonium molybdate, molybdenum glycinate/chelate (in some multivitamins/trace-element mixes); Pharmaceutical: ammonium tetrathiomolybdate (investigational copper-lowering agent, NOT a nutritional supplement); Dietary sources: legumes (beans, lentils, peas) are the richest source; Whole grains, nuts, and seeds; Organ meats (liver) and dairy; Leafy greens; content varies with soil molybdenum and water.
Dose: Adult RDA (US): 45 mcg/day for men and women (pregnancy/lactation 50 mcg/day). EFSA sets an Adequate Intake of 65 mcg/day for adults. Typical Western intakes (~75-250 mcg/day) already exceed needs, and balance is maintained at ~22 mcg/day. Supplement doses are usually small (45-100 mcg). Tolerable Upper Intake Level (UL): 2,000 mcg (2 mg)/day for adults.
Safety: Low toxicity at dietary levels; deficiency is essentially nonexistent outside parenteral nutrition, so routine supplementation is unnecessary. UL is 2,000 mcg/day, derived largely from animal reproductive/growth toxicity (human data are limited). Very high occupational and dietary exposures have been linked to gout-like syndromes and elevated uric acid in some reports, consistent with molybdenum's role in xanthine oxidase. The major interaction is with COPPER: molybdenum (especially as tetrathiomolybdate) antagonizes copper absorption and bioavailability—this is exploited therapeutically to lower copper in Wilson disease, but means high molybdenum intake can theoretically worsen copper status. Molybdenum cofactor deficiency is a genetic enzyme-synthesis disorder that does NOT respond to dietary molybdenum and requires fosdenopterin (cyclic pyranopterin monophosphate). No important drug interactions are established at nutritional doses.

Cited studies (8):
  - Molybdenum Cofactor Deficiency (2023) — Reviews molybdenum cofactor deficiency as an autosomal-recessive, usually fatal neonatal neurodegenerative disorder from loss of sulfite oxidase, causing toxic sulfite and S-sulfocysteine accumulation—genetic, not nutritional. [https://www.ncbi.nlm.nih.gov/books/NBK575630/]
  - Treatment of Wilson's disease with tetrathiomolybdate: V. Control of free copper by tetrathiomolybdate and a comparison with trientine, Translational research : the journal of laboratory and clinical medicine (2009) — Ammonium tetrathiomolybdate strongly lowers free serum copper (to ~one-quarter of baseline over 8 weeks), demonstrating the clinically exploited molybdenum-copper antagonism relevant to copper-status interactions. [https://pubmed.ncbi.nlm.nih.gov/19595438/]
  - Antioxidative effects of molybdenum and its association with reduced prevalence of hyperuricemia in the adult population, PloS one (2024) — Cross-sectional study of US adults (NHANES 1999-2016) found highest urinary molybdenum quartile associated with lower hyperuricemia (OR 0.73, 95% CI 0.64-0.83) and gout (OR 0.71, 95% CI 0.52-0.94)—associational only. [https://pmc.ncbi.nlm.nih.gov/articles/PMC11293656/]
  - Molybdenum - Health Professional Fact Sheet, NIH Office of Dietary Supplements — Sets adult RDA at 45 mcg/day and Tolerable Upper Intake Level at 2,000 mcg/day; identifies legumes as the richest dietary source and notes molybdenum is cofactor for sulfite oxidase, xanthine oxidase, aldehyde oxidase, and mARC. [https://ods.od.nih.gov/factsheets/Molybdenum-HealthProfessional/]
  - Increased Survival in Patients With Molybdenum Cofactor Deficiency Type A Treated With Cyclic Pyranopterin Monophosphate, Journal of inherited metabolic disease (2025) — In molybdenum cofactor deficiency type A, fosdenopterin (synthetic cPMP) reduced risk of death by 82% vs genotype-matched historical controls—an enzyme-cofactor disorder unresponsive to dietary molybdenum. [https://pubmed.ncbi.nlm.nih.gov/40132614/]
  - Amino acid intolerance during prolonged total parenteral nutrition reversed by molybdate therapy, The American journal of clinical nutrition (1981) — The only documented dietary molybdenum deficiency: a TPN patient developed high methionine, low uric acid, high urinary thiosulfate, tachycardia and neurologic symptoms, all reversed by IV ammonium molybdate. [https://pubmed.ncbi.nlm.nih.gov/6795919/]
  - Scientific Opinion on Dietary Reference Values for molybdenum, EFSA Journal (2013) — Concluded data were insufficient to derive a requirement and set an Adequate Intake of 65 mcg/day for adults based on observed European intakes, also applying to pregnancy and lactation. [https://www.efsa.europa.eu/en/efsajournal/pub/3333]
  - Molybdenum absorption, excretion, and retention studied with stable isotopes in young men during depletion and repletion, The American journal of clinical nutrition (1995) — In 4 young men fed 22 mcg/day Mo for 102 days, molybdenum balance was near zero, and kinetic modeling estimated ~43 mcg/day suffices to maintain steady-state plasma molybdenum—showing requirements are very low. [https://pubmed.ncbi.nlm.nih.gov/7733035/]

---

## Vitamin B6 (Pyridoxine) (Pyridoxine / P5P)
URL: https://nutridex.info/s/vitamin-b6
Category: Vitamin
Evidence: Strong — Multiple high-quality RCTs / meta-analyses with consistent effects.
The amino-acid and neurotransmitter coenzyme — essential, but a poor supplement for the well-nourished

Quick answer: Vitamin B6 (Pyridoxine) is used for corrects deficiency: reverses b6-deficiency anemia, dermatitis, glossitis, neuropathy, and seizures (including isoniazid- or hydralazine-induced and rare pyridoxine-dependent infantile seizures). NutriDex grades the human evidence as strong — Multiple high-quality RCTs / meta-analyses with consistent effects. Based on 8 cited human studies (8 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Vitamin B6, as the active coenzyme pyridoxal-5'-phosphate (PLP), drives over 100 enzymatic reactions, chiefly in amino-acid metabolism, neurotransmitter synthesis (serotonin, GABA, dopamine), heme synthesis, and homocysteine catabolism. Frank deficiency is rare in isolation but causes microcytic anemia, dermatitis, glossitis, peripheral neuropathy, depression, and seizures (classically in isoniazid use, alcoholism, or renal dialysis). In non-deficient people, supplementation has largely failed to deliver clinical benefit: despite lowering homocysteine by roughly 25-30% as part of B6/B9/B12 regimens, large RCTs (HOPE-2, VITATOPS) and a 2017 Cochrane review found no reduction in cardiovascular events or mortality, and a prospective cohort linked high-dose individual B6 supplements (>20 mg/d) to increased lung cancer risk in men, especially smokers. Its best-validated supplemental role is pyridoxine (alone or with doxylamine) as first-line therapy for nausea and vomiting of pregnancy.

Benefits / uses: Corrects deficiency: reverses B6-deficiency anemia, dermatitis, glossitis, neuropathy, and seizures (including isoniazid- or hydralazine-induced and rare pyridoxine-dependent infantile seizures); First-line for nausea/vomiting of pregnancy: pyridoxine 10-25 mg, alone or combined with doxylamine, is recommended by ACOG as safe and effective initial therapy; Lowers plasma homocysteine ~25-30% as part of folic acid + B12 + B6 regimens (a biomarker effect that did NOT translate into fewer cardiovascular events in trials); Prevents isoniazid-induced neuropathy when co-prescribed prophylactically during tuberculosis treatment; Modest, low-certainty symptom relief in premenstrual syndrome and possibly carpal tunnel symptoms — evidence is weak and not a substitute for definitive therapy; Does NOT prevent cardiovascular events, stroke disability, cancer, or cognitive decline in replete people; high individual-supplement doses may carry a lung-cancer signal in male smokers.
Active compounds: Pyridoxine hydrochloride (most common, cheapest supplement and food-fortification form); Pyridoxal-5'-phosphate (P5P/PLP) — the active coenzyme form, marketed as 'pre-activated' though no proven clinical superiority in most people; Found in multivitamins and combined B-complex/homocysteine formulas with folate + B12; Dietary sources: poultry, fish (tuna, salmon), organ meats, chickpeas and other legumes, potatoes and starchy vegetables, bananas, fortified cereals, and nuts.
Dose: Adult RDA: 1.3 mg/day (ages 19-50); rising to 1.7 mg/day (men) and 1.5 mg/day (women) over age 50. Typical supplement doses range 1-25 mg/day; therapeutic pregnancy-nausea dosing is 10-25 mg up to 3-4 times daily. US Tolerable Upper Intake Level (UL): 100 mg/day for adults (the more conservative EFSA 2023 UL is 12 mg/day). Doses well above the UL are used short-term only under medical supervision (e.g., isoniazid toxicity).
Safety: Dietary B6 is non-toxic, but chronic high-dose pyridoxine causes a dose-dependent sensory peripheral neuropathy (ataxia, numbness) — classically reported at 1-6 g/day for months, with some case reports below 500 mg/day; symptoms usually regress on discontinuation. The US UL of 100 mg/day was set with a safety margin (EFSA set 12 mg/day in 2023). A prospective cohort (Brasky 2017, VITAL) linked long-term high-dose individual B6 supplements (>20 mg/d over 10 yr) to nearly doubled lung cancer risk in men (HR ~1.82), with a stronger signal in male smokers; this is an observational association, not proven causation. Key interactions: B6 reduces efficacy of levodopa (when given without carbidopa) and lowers serum levels/efficacy of phenytoin and phenobarbital; isoniazid, hydralazine, cycloserine, and penicillamine antagonize B6 and can cause deficiency. Generally safe in pregnancy at recommended antiemetic doses.

Cited studies (8):
  - Homocysteine-lowering interventions for preventing cardiovascular events, Cochrane Database of Systematic Reviews (2017) — Across 15 RCTs, homocysteine-lowering with B6/B12/folic acid did NOT reduce cardiovascular events, MI, or all-cause mortality in people with or without prior CVD. [https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD006612.pub5/full]
  - ACOG Practice Bulletin No. 189: Nausea And Vomiting Of Pregnancy, Obstetrics and gynecology (2018) — Recommends pyridoxine (vitamin B6) alone or with doxylamine as safe and effective first-line pharmacotherapy for nausea and vomiting of pregnancy. [https://pubmed.ncbi.nlm.nih.gov/29266076/]
  - Multiple strains probiotics appear to be the most effective probiotics in the prevention of necrotizing enterocolitis and mortality: An updated meta-analysis, PLOS ONE (2017) — Reanalysis of the pivotal doxylamine-pyridoxine (Diclegis) RCT found symptom improvement that did not reach the prespecified minimal clinically important difference, questioning the magnitude of benefit. [https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0189978]
  - B vitamins in patients with recent transient ischaemic attack or stroke in the VITAmins TO Prevent Stroke (VITATOPS) trial: a randomised, double-blind, parallel, placebo-controlled trial, The Lancet. Neurology (2010) — In 8,164 stroke/TIA patients, B6 25 mg + folic acid + B12 lowered homocysteine but did not significantly reduce the composite of stroke, MI, or vascular death (RR 0.91, 95% CI 0.82-1.00). [https://pubmed.ncbi.nlm.nih.gov/20688574/]
  - Homocysteine Lowering with Folic Acid and B Vitamins in Vascular Disease, New England Journal of Medicine (2006) — In 5,522 vascular-disease/diabetes patients, folic acid + B6 50 mg + B12 for ~5 yr did not reduce major CV events; total stroke fell (RR 0.75) but MI and CV death were unchanged. [https://www.nejm.org/doi/full/10.1056/NEJMoa060900]
  - Vitamin B6 Toxicity (2023) — Reviews dose-dependent sensory neuropathy from chronic high-dose pyridoxine, generally reversible on discontinuation; basis for the conservative UL. [https://www.ncbi.nlm.nih.gov/books/NBK554500/]
  - Long-Term, Supplemental, One-Carbon Metabolism-Related Vitamin B Use in Relation to Lung Cancer Risk in the Vitamins and Lifestyle (VITAL) Cohort, Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2017) — In >77,000 adults, long-term high-dose individual B6 (>20 mg/d) was associated with ~1.82-fold higher lung cancer risk in men (95% CI 1.25-2.65), and roughly 3-fold in male smokers; no association in women. [https://pubmed.ncbi.nlm.nih.gov/28829668/]
  - Vitamin B6 - Health Professional Fact Sheet, NIH Office of Dietary Supplements — Authoritative reference: adult RDA 1.3-1.7 mg/day, UL 100 mg/day; chronic pyridoxine 1-6 g/day for 12-40 months can cause severe sensory neuropathy. [https://ods.od.nih.gov/factsheets/VitaminB6-HealthProfessional/]

---

## Phosphorus
URL: https://nutridex.info/s/phosphorus
Category: Mineral
Evidence: Strong — Multiple high-quality RCTs / meta-analyses with consistent effects.
The skeletal and energy mineral where the real-world risk is excess, not deficiency

Quick answer: Phosphorus is used for corrects clinically significant hypophosphatemia (refeeding syndrome, severe alcoholism, recovery from dka, certain hereditary phosphate-wasting disorders) where supplementation is genuinely therapeutic. NutriDex grades the human evidence as strong — Multiple high-quality RCTs / meta-analyses with consistent effects. Based on 12 cited human studies (12 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Phosphorus (as phosphate) is an essential structural and metabolic mineral: roughly 85% resides in bone and teeth as hydroxyapatite, and the remainder is central to ATP energy transfer, nucleic acids (DNA/RNA), cell membranes (phospholipids), and acid-base buffering. Dietary deficiency is rare in people eating any normal diet because phosphorus is ubiquitous in food; clinically important hypophosphatemia instead arises from refeeding syndrome, alcoholism, hyperparathyroidism, or certain medications, and is treated with supplementation. There are essentially no supplementation trials showing benefit in already-replete people; on the contrary, observational and mechanistic data link high phosphorus intake—especially from highly bioavailable inorganic phosphate additives—to increased all-cause and cardiovascular mortality (NHANES III HR 2.23 above ~1400 mg/d) and to vascular calcification and elevated FGF23. The practical public-health message is to limit excess phosphate additives, not to supplement.

Benefits / uses: Corrects clinically significant hypophosphatemia (refeeding syndrome, severe alcoholism, recovery from DKA, certain hereditary phosphate-wasting disorders) where supplementation is genuinely therapeutic; Provides the phosphate backbone of bone/tooth mineral (hydroxyapatite) and of ATP, DNA/RNA, and membrane phospholipids — an essential nutrient for everyone obtained readily from diet; Maintains acid-base balance as a major intracellular and urinary buffer; Component of total parenteral nutrition and clinical electrolyte replacement protocols; No demonstrated benefit of supplementation in non-deficient people; routine supplements are unnecessary and the evidence base instead concerns harms of excess.
Active compounds: Dietary (organic, ~40-60% absorbed): dairy, meat, poultry, fish, eggs, nuts, legumes, whole grains (grain phytate phosphorus is poorly absorbed); Inorganic phosphate additives (~90-100% absorbed): phosphoric acid in colas, sodium/potassium/calcium phosphate preservatives in processed foods, fast food, processed cheese; Supplement/clinical salts: sodium phosphate, potassium phosphate, dibasic calcium phosphate, monopotassium phosphate (oral and IV repletion); Phosphate binders are used in CKD to LOWER absorption (sevelamer, calcium acetate/carbonate, lanthanum) — not to supplement.
Dose: Adult RDA 700 mg/day (US, age 19+); EFSA Adequate Intake 550 mg/day. Typical US intake (~1100-1400+ mg/day) already exceeds requirements, so routine supplementation is not recommended. Tolerable Upper Intake Level (UL): 4000 mg/day for adults 19-70 (3000 mg/day age >70; lowered in pregnancy). Clinical repletion of hypophosphatemia uses prescribed oral or IV phosphate salts under monitoring.
Safety: Phosphorus toxicity from food is rare in healthy people with normal kidneys, but the relevant real-world concern is chronic EXCESS rather than deficiency. UL is 4000 mg/day (adults ≤70). High intake—particularly from highly bioavailable inorganic phosphate additives—raises FGF23, can promote vascular calcification, and is associated in cohorts with higher all-cause/cardiovascular mortality and lower eGFR. Risk concentrates in chronic kidney disease, where hyperphosphatemia drives CKD-mineral and bone disorder; these patients use phosphate binders and dietary restriction. Acute IV/oral phosphate over-correction can cause life-threatening hypocalcemia, hyperkalemia (potassium salts), hypernatremia (sodium salts), metastatic calcification, and acute phosphate nephropathy (notably with sodium-phosphate bowel preps—FDA boxed warning). Phosphate is best kept in balance with calcium; very high phosphorus relative to calcium can adversely affect bone via secondary hyperparathyroidism.

Cited studies (12):
  - High Serum Phosphate Is Associated with Cardiovascular Mortality and Subclinical Coronary Atherosclerosis: Systematic Review and Meta-Analysis, Nutrients (2024) — Across 7 cohort studies (41,764 adults), highest vs reference serum phosphate carried a 44% higher cardiovascular mortality (pooled HR 1.44, 95% CI 1.28-1.61), with a similar increase in subclinical coronary atherosclerosis. [https://pmc.ncbi.nlm.nih.gov/articles/PMC11174514/]
  - Meta-Analysis of Refeeding Syndrome in Predicting the Risk of Occurrence in Critically Ill Patients, Journal of nutrition and metabolism (2026) — Meta-analysis of 18 studies (3,360 critically ill patients) found lower baseline serum phosphate in those developing refeeding syndrome (weighted mean difference -0.10 mmol/L, 95% CI -0.19 to -0.01), identifying low phosphate as a risk factor. [https://pmc.ncbi.nlm.nih.gov/articles/PMC12917335/]
  - Phosphate-Binding Agents in Adults With CKD: A Network Meta-analysis of Randomized Trials, American journal of kidney diseases : the official journal of the National Kidney Foundation (2016) — Network meta-analysis of 77 trials (12,562 CKD patients) found no evidence that phosphate-binder therapy reduces mortality versus placebo; sevelamer lowered mortality versus calcium binders (low-certainty evidence). [https://pubmed.ncbi.nlm.nih.gov/27461851/]
  - Clinical practice recommendations for the diagnosis and management of X-linked hypophosphataemia, Nature Reviews Nephrology (2025) — International evidence-based clinical practice recommendations for diagnosis and management of X-linked hypophosphataemia, endorsing burosumab (anti-FGF23) over oral phosphate/active vitamin D as first-line for renal phosphate-wasting hypophosphatemia. [https://www.nature.com/articles/s41581-024-00926-x]
  - Effect of calcium-based versus non-calcium-based phosphate binders on mortality in patients with chronic kidney disease: an updated systematic review and meta-analysis, Lancet (London, England) (2013) — Meta-analysis of 11 RCTs (4,622 CKD patients) found non-calcium-based phosphate binders reduced all-cause mortality 22% vs calcium-based binders (RR 0.78, 95% CI 0.61-0.98). [https://pubmed.ncbi.nlm.nih.gov/23870817/]
  - Hypophosphataemia following ferric derisomaltose and ferric carboxymaltose in patients with iron deficiency anaemia due to inflammatory bowel disease (PHOSPHARE-IBD): a randomised clinical trial, Gut (2023) — Double-blind RCT in IBD patients: ferric carboxymaltose caused hypophosphataemia in 51% vs 8.4% with ferric derisomaltose, driven by larger FGF23 increases, showing iatrogenic hypophosphatemia is FCM-specific, not a class effect of IV iron. [https://pmc.ncbi.nlm.nih.gov/articles/PMC10086283/]
  - Risk of Hypophosphatemia Following Postpartum Anemia Treatment with IV Ferric Carboxymaltose, IV Ferric Derisomaltose, and Oral Ferrous Sulfate, Journal of clinical medicine (2025) — Open-label RCT of 300 women with postpartum anemia comparing IV ferric carboxymaltose, IV ferric derisomaltose, and oral ferrous sulfate, quantifying differential risk of treatment-induced hypophosphatemia at 6 weeks postpartum. [https://pmc.ncbi.nlm.nih.gov/articles/PMC12693700/]
  - Burosumab vs conventional therapy in children with X-linked hypophosphatemia: results of the open-label, phase 3 extension period, JBMR plus (2024) — Open-label phase 3 extension: children with XLH treated with burosumab every 2 weeks for up to 64 weeks showed improved serum phosphate, healing of radiographic rickets, and growth versus continued conventional oral phosphate/vitamin D therapy. [https://pmc.ncbi.nlm.nih.gov/articles/PMC11059996/]
  - Dietary intake of inorganic phosphorus has a stronger influence on vascular-endothelium function than organic phosphorus, Journal of clinical biochemistry and nutrition (2018) — Reviews evidence that inorganic phosphate additives are ~90-100% absorbed (vs ~40-60% for organic food phosphorus) and disproportionately impair vascular-endothelial function and raise FGF23. [https://pmc.ncbi.nlm.nih.gov/articles/PMC5874240/]
  - Phosphorus - Health Professional Fact Sheet, NIH Office of Dietary Supplements — Sets adult RDA at 700 mg/day and Tolerable Upper Intake Level at 4000 mg/day (3000 mg/day for adults >70); notes dietary deficiency is rare given ubiquity in food. [https://ods.od.nih.gov/factsheets/Phosphorus-HealthProfessional/]
  - High dietary phosphorus intake is associated with all-cause mortality: results from NHANES III, The American journal of clinical nutrition (2014) — In 9,686 healthy US adults followed ~14.7 years, phosphorus intake >1400 mg/day was associated with a 2.23-fold higher all-cause mortality (HR 2.23, 95% CI 1.09-4.55) with no association below that threshold. [https://pmc.ncbi.nlm.nih.gov/articles/PMC3893724/]
  - Scientific Opinion on Dietary Reference Values for phosphorus, EFSA Journal (2015) — Established an Adequate Intake of 550 mg/day for adults (and during pregnancy/lactation) based on a calcium:phosphorus molar ratio approach. [https://efsa.onlinelibrary.wiley.com/doi/10.2903/j.efsa.2015.4185]

---

## Vitamin A (Retinol / Beta-Carotene) (Retinol · provitamin-A carotenoids)
URL: https://nutridex.info/s/vitamin-a
Category: Vitamin
Evidence: Strong — Multiple high-quality RCTs / meta-analyses with consistent effects.
Essential for vision and immunity — lifesaving in deficiency, but harmful when over-supplemented

Quick answer: Vitamin A (Retinol / Beta-Carotene) is used for corrects deficiency: prevents and treats xerophthalmia/night blindness and reverses corneal damage from vitamin a deficiency. NutriDex grades the human evidence as strong — Multiple high-quality RCTs / meta-analyses with consistent effects. Based on 8 cited human studies (8 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Vitamin A is a fat-soluble nutrient essential for vision (it forms rhodopsin in the retina), epithelial integrity, immune function, and embryonic development. Deficiency is a leading cause of preventable childhood blindness and raises mortality from infection; supplementation in deficient children cuts all-cause mortality by roughly a quarter (Cochrane/Imdad 2022). In well-nourished people, however, supplementation provides no proven benefit and can cause harm: beta-carotene supplements increased lung cancer and mortality in smokers (ATBC, CARET), and pooled antioxidant trials found beta-carotene and high-dose vitamin A may raise overall mortality. Preformed vitamin A is teratogenic and chronic high intake is linked to bone loss and hip fracture.

Benefits / uses: Corrects deficiency: prevents and treats xerophthalmia/night blindness and reverses corneal damage from vitamin A deficiency; Reduces child mortality in deficient populations: VAS in children 6-59 months cuts all-cause mortality ~24% and diarrhea-specific mortality ~12% (Cochrane 2022); Supports vision: a required component of rhodopsin for low-light and color vision; Maintains epithelial and mucosal barriers and normal immune cell function; Essential for normal embryonic development and growth (required, but excess is teratogenic); No proven benefit for cancer, cardiovascular disease, or longevity in well-nourished/non-deficient adults — and beta-carotene is harmful in smokers.
Active compounds: Retinyl palmitate and retinyl acetate (preformed vitamin A in supplements/fortified foods); Beta-carotene and other provitamin-A carotenoids (supplements; converted to retinol); Preformed vitamin A dietary sources: liver, fish oils, egg yolk, dairy; Provitamin-A carotenoid sources: carrots, sweet potato, pumpkin, spinach, kale, and other orange/dark-green produce.
Dose: Adult RDA: 900 mcg RAE/day (men), 700 mcg RAE/day (women); ~770 mcg in pregnancy, 1300 mcg in lactation. Typical multivitamin supplements provide ~700-900 mcg RAE, often partly as beta-carotene. Tolerable Upper Intake Level (UL) for adults: 3,000 mcg/day of PREFORMED vitamin A (the UL does not apply to provitamin-A carotenoids from food).
Safety: Preformed vitamin A is fat-soluble and accumulates; chronic intake above the 3,000 mcg/day UL causes hypervitaminosis A (headache, liver damage, skin/hair changes). It is teratogenic — intakes >10,000 IU (3,000 mcg) of preformed vitamin A in early pregnancy raise birth-defect risk, so retinol/retinyl-ester megadoses and isotretinoin are contraindicated in pregnancy. High chronic retinol intake is associated with reduced bone mineral density and roughly doubled hip-fracture risk in some cohorts. Beta-carotene supplements (20-30 mg/day) increased lung cancer and mortality in smokers and asbestos-exposed workers (ATBC, CARET) and should be avoided in smokers. Acute massive doses cause toxicity; beta-carotene from food/high supplement doses is non-teratogenic but can cause harmless skin yellowing (carotenodermia).

Cited studies (8):
  - Vitamin A supplementation for preventing morbidity and mortality in children from six months to five years of age, Cochrane Database of Systematic Reviews (2022) — In children 6-59 months, vitamin A supplementation reduced all-cause mortality by 24% (RR 0.76, 95% CI 0.69-0.83) and diarrhea mortality by 12% (RR 0.88, 0.79-0.98); pooled across ~1 million+ children. [https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008524.pub4/full]
  - Antioxidant supplements for prevention of mortality in healthy participants and patients with various diseases, Cochrane Database of Systematic Reviews (2012) — Pooling 78 trials (296,707 participants), beta-carotene increased mortality (RR 1.05, 95% CI 1.01-1.09) and higher-dose vitamin A also trended toward increased mortality; no benefit for prevention. [https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD007176.pub2/abstract]
  - The Relationship Between Vitamin A and Risk of Fracture: Meta-Analysis of Prospective Studies, Journal of Bone and Mineral Research (2014) — Meta-analysis of prospective studies found high vitamin A intake (RR 1.29, 95% CI 1.07-1.57) and high retinol intake (RR 1.40, 95% CI 1.03-1.91) associated with increased hip-fracture risk. [https://onlinelibrary.wiley.com/doi/full/10.1002/jbmr.2237]
  - The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers, New England Journal of Medicine (1994) — In 29,133 male smokers, beta-carotene (20 mg/day) raised lung cancer incidence by 18% (95% CI 3-36%) and was associated with ~8% higher total mortality. [https://www.nejm.org/doi/full/10.1056/NEJM199404143301501]
  - Effects of a Combination of Beta Carotene and Vitamin A on Lung Cancer and Cardiovascular Disease, New England Journal of Medicine (1996) — In 18,314 smokers and asbestos workers, beta-carotene (30 mg) + retinyl palmitate (25,000 IU) increased lung cancer 28% (RR 1.28, 95% CI 1.04-1.57) and total mortality 17%; trial halted early. [https://www.nejm.org/doi/full/10.1056/NEJM199605023341802]
  - Vitamin A and Carotenoids - Health Professional Fact Sheet, NIH Office of Dietary Supplements — Sets adult RDA at 900 mcg RAE (men)/700 mcg RAE (women) and the UL at 3,000 mcg/day preformed vitamin A; warns of teratogenicity and that the UL excludes provitamin-A carotenoids. [https://ods.od.nih.gov/factsheets/VitaminA-HealthProfessional/]
  - Vitamin A intake and hip fractures among postmenopausal women, JAMA (2002) — In the Nurses' Health Study, women with retinol intake >=2000 mcg/day had a relative risk of hip fracture of 1.89 (95% CI 1.33-2.68) versus <500 mcg/day. [https://pubmed.ncbi.nlm.nih.gov/11754708/]
  - Serum Retinol Levels and the Risk of Fracture, New England Journal of Medicine (2003) — In 2,322 men followed 30 years, the highest serum retinol quintile was associated with a multivariable hip-fracture rate ratio of 2.47 (95% CI 1.15-5.28) versus the middle quintile. [https://www.nejm.org/doi/full/10.1056/NEJMoa021171]

---

## Copper (Cu)
URL: https://nutridex.info/s/copper
Category: Mineral
Evidence: Strong — Multiple high-quality RCTs / meta-analyses with consistent effects.
Essential trace mineral for iron metabolism, nerves, and connective tissue.

Quick answer: Copper is used for corrects copper deficiency anemia and neutropenia (often from zinc excess or bariatric surgery) — restores blood counts when repleted. NutriDex grades the human evidence as strong — Multiple high-quality RCTs / meta-analyses with consistent effects. Based on 8 cited human studies (8 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Copper is an essential trace mineral and cofactor for enzymes governing iron metabolism (ceruloplasmin), energy production (cytochrome c oxidase), connective-tissue cross-linking (lysyl oxidase), antioxidant defense (Cu/Zn superoxide dismutase), and neurotransmitter synthesis. Frank deficiency, most often from excess zinc, bariatric surgery, or malabsorption, causes anemia, neutropenia, and a reversible myeloneuropathy; the genetic disorder Menkes disease is fatal without copper injections. Outright dietary deficiency is rare because requirements are low and copper is widespread in food, and there is no good evidence that supplementing copper benefits well-nourished people. On the contrary, observational data link higher dietary and serum copper to increased cardiovascular events and mortality, so routine supplementation is not advised outside documented deficiency.

Benefits / uses: Corrects copper deficiency anemia and neutropenia (often from zinc excess or bariatric surgery) — restores blood counts when repleted; Reverses acquired copper-deficiency myeloneuropathy, an under-recognized treatable cause of gait/sensory deficits; Required for iron mobilization via ceruloplasmin; deficiency causes a microcytic/normocytic anemia unresponsive to iron alone; Cofactor for connective-tissue cross-linking (lysyl oxidase) and antioxidant SOD — deficiency impairs bone/vascular integrity; Component of AREDS2 eye formula (2 mg cupric oxide) added to offset zinc-induced copper depletion, not for independent benefit; No proven benefit (and possible cardiovascular harm) from supplementing copper-replete adults.
Active compounds: Copper gluconate; Cupric oxide (in multivitamins/AREDS2); Copper sulfate; Copper bisglycinate/chelate; Dietary sources: shellfish (oysters), organ meats (liver), nuts, seeds, dark chocolate, legumes, whole grains.
Dose: Adult RDA 900 mcg/day (0.9 mg); pregnancy 1,000 mcg, lactation 1,300 mcg. Typical supplement/multivitamin dose 0.5–2 mg/day. Tolerable Upper Intake Level (UL): 10,000 mcg/day (10 mg) for adults per US IOM, set on liver protection; EFSA's 2023 re-evaluation concluded no copper retention occurs up to ~5 mg/day.
Safety: UL is 10 mg/day (US IOM); acute overdose causes nausea, vomiting, abdominal pain, and can progress to liver and kidney damage. Wilson disease (ATP7B mutation) causes pathologic copper accumulation with liver and neurologic injury — these patients must restrict copper and use chelators/zinc. Key interactions: high-dose zinc (>40 mg/day, including denture creams and cold lozenges) induces copper deficiency via metallothionein; conversely copper supplements offset zinc's copper-lowering effect (basis for the 2 mg copper in AREDS2). Excess vitamin C and bariatric surgery impair copper status. Observational studies link higher serum/dietary copper to greater cardiovascular and all-cause mortality, so do not supplement without documented deficiency.

Cited studies (8):
  - Serum copper levels and risk of major adverse cardiovascular events: a systematic review and meta-analysis, Frontiers in cardiovascular medicine (2023) — Meta-analysis of 16 studies (41,322 participants) found highest vs lowest serum copper associated with higher stroke (pOR 1.49, 95% CI 1.22-1.82), myocardial infarction (pOR 1.31, 95% CI 1.17-1.46), and cardiovascular mortality (pOR 1.60, 95% CI 1.39-1.86). [https://pmc.ncbi.nlm.nih.gov/articles/PMC10333529/]
  - Dietary Copper Intake and Bone Health: A Systematic Review and Meta-Analysis of Observational Studies, Calcified Tissue International (2025) — Systematic review/meta-analysis of observational studies of dietary copper intake and bone mineral density/fracture found heterogeneous, inconsistent results, with no clear evidence that higher copper intake improves bone outcomes. [https://link.springer.com/article/10.1007/s00223-025-01463-w]
  - A randomized trial of copper supplementation effects on blood copper enzyme activities and parameters related to cardiovascular health, Metabolism: clinical and experimental (2012) — Randomized trial of copper supplementation (up to ~7 mg/day) in adults found increases in some copper enzyme activities but no meaningful improvement in cardiovascular-related parameters, providing no support for routine copper supplementation. [https://pubmed.ncbi.nlm.nih.gov/22444781/]
  - Linus Pauling Institute (copper micronutrient review) — Authoritative review confirms copper is essential for ceruloplasmin/iron metabolism, lysyl oxidase, cytochrome c oxidase and SOD, that acquired deficiency (e.g., from excess zinc) causes anemia, neutropenia and myeloneuropathy, and that supplementation is unwarranted in replete adults. [https://lpi.oregonstate.edu/mic/minerals/copper]
  - Associations of dietary copper intake with cardiovascular disease and mortality: findings from the Chinese Perspective Urban and Rural Epidemiology (PURE-China) Study, BMC public health (2023) — In 45,101 Chinese adults over a median 11.9 years, the highest vs lowest quartile of dietary copper intake was associated with higher all-cause mortality (HR 1.22, 95% CI 1.08-1.39) and CVD incidence (HR 1.25, 95% CI 1.06-1.47). [https://pmc.ncbi.nlm.nih.gov/articles/PMC10726617/]
  - Re-evaluation of the existing health-based guidance values for copper and exposure assessment from all sources, EFSA Journal (2023) — EFSA's re-evaluation of copper guidance values concluded no copper retention (accumulation) is expected at intakes up to ~5 mg/day and lowered the acceptable daily intake to 0.07 mg/kg bw. [https://efsa.onlinelibrary.wiley.com/doi/10.2903/j.efsa.2023.7728]
  - Copper - Health Professional Fact Sheet, NIH Office of Dietary Supplements — Adult RDA is 900 mcg/day and the Tolerable Upper Intake Level is 10,000 mcg/day, based on protection from liver damage; deficiency is rare in healthy people but causes anemia, neutropenia, and neurologic problems. [https://ods.od.nih.gov/factsheets/Copper-HealthProfessional/]
  - Copper (2001) — The Institute of Medicine set the adult copper UL at 10 mg/day with hepatic effects as the critical endpoint, and notes copper deficiency from diet alone is uncommon in the general population. [https://www.ncbi.nlm.nih.gov/books/NBK222312/]

---

## Chromium (Cr)
URL: https://nutridex.info/s/chromium
Category: Mineral
Evidence: Mixed — Conflicting results across studies; benefit uncertain.
A trace mineral marketed for blood sugar and weight loss, where the evidence is modest at best and absent in healthy people.

Quick answer: Chromium is used for modestly improves glycemic control (hba1c, fasting glucose) in some people with type 2 diabetes, though results are inconsistent across trials. NutriDex grades the human evidence as mixed — Conflicting results across studies; benefit uncertain. Based on 8 cited human studies (8 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Chromium (as trivalent Cr3+) is thought to potentiate insulin action, and a 2001 expert panel set an Adequate Intake on the assumption it is essential — though overt deficiency has never been documented in healthy people eating a normal diet, and a 2001 review found the data insufficient even to estimate a requirement. In people with type 2 diabetes, supplementation produces a small reduction in HbA1c (about -0.6%) and fasting glucose, but trials are heterogeneous and inconsistent, and in non-diabetic individuals chromium has no measurable effect on glucose or insulin. The popular weight-loss claim is largely unsupported: meta-analyses and a Cochrane review find only ~1 kg of weight loss versus placebo, an effect driven by single trials and judged clinically trivial and low-quality.

Benefits / uses: Modestly improves glycemic control (HbA1c, fasting glucose) in some people with type 2 diabetes, though results are inconsistent across trials; May offer small benefits in insulin resistance / PCOS in some studies, but evidence is weak and mixed; No proven benefit for glucose or insulin in non-diabetic, healthy people; Weight-loss effect is minimal (~1 kg vs placebo) and not clinically meaningful per Cochrane; Corrects the (theoretical) deficiency state seen historically only in patients on long-term chromium-free intravenous nutrition.
Active compounds: Chromium picolinate (most common supplement form); Chromium chloride; Chromium nicotinate / polynicotinate; Brewer's yeast (chromium-rich); Dietary sources: broccoli, whole grains, grape juice, meat, nuts, some beers.
Dose: No RDA — only an Adequate Intake (AI): 35 mcg/day (men 19-50), 25 mcg/day (women 19-50); 30/20 mcg over age 50; 30 mcg pregnancy, 45 mcg lactation. Typical supplement doses range 200-1000 mcg/day. No Tolerable Upper Intake Level (UL) has been established because data were insufficient to set one.
Safety: No UL has been set. Trivalent chromium (Cr3+, the supplement form) is considered low-toxicity, and doses up to ~1000 mcg/day have been used for months without consistent serious harm; this is distinct from highly toxic, carcinogenic hexavalent chromium (Cr6+), which is not used in supplements. High-dose chromium picolinate has shown DNA damage/chromosomal aberrations in vitro and in animal cells, but mainly under non-physiological conditions, and human studies have not confirmed genotoxicity. Rare case reports link high-dose chromium picolinate to kidney and liver injury. May lower blood glucose, so monitor for additive hypoglycemia with insulin/antidiabetic drugs; may affect levothyroxine absorption (separate dosing).

Cited studies (8):
  - Effects of chromium supplementation on glycemic control in patients with type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials, Pharmacological research (2020) — In type 2 diabetes, chromium supplementation significantly reduced fasting plasma glucose (WMD -19.0 mg/dL, 95% CI -36.15 to -1.85, P=0.030). [https://pubmed.ncbi.nlm.nih.gov/32730903/]
  - Chromium - Health Professional Fact Sheet, NIH Office of Dietary Supplements — Concluded chromium supplements offer only limited evidence of glycemic benefit in type 2 diabetes (5/20 RCTs improved fasting glucose, 5/14 lowered HbA1c >0.5%) and no benefit on glucose/insulin in non-diabetic people. [https://ods.od.nih.gov/factsheets/Chromium-HealthProfessional/]
  - Chromium picolinate supplementation for overweight or obese adults, Cochrane Database of Systematic Reviews (2013) — Across 9 RCTs (n=622) in overweight/obese adults, chromium picolinate produced ~1 kg greater weight loss than placebo but evidence was low-quality and provided no reliable basis for firm efficacy/safety conclusions. [https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010063.pub2/full]
  - Effect of Chromium Supplementation on Glucose Metabolism and Lipids: A Systematic Review of Randomized Controlled Trials, Diabetes Care (2007) — In type 2 diabetes, chromium supplementation reduced HbA1c by -0.6% (95% CI -0.9 to -0.2) and fasting glucose by -1.0 mmol/L (-1.4 to -0.5), with no effect on lipids; no effect on glucose/insulin in non-diabetic subjects. [https://diabetesjournals.org/care/article/30/8/2154/28549/Effect-of-Chromium-Supplementation-on-Glucose]
  - Chromium picolinate for reducing body weight: meta-analysis of randomized trials, International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity (2003) — 10 double-blind RCTs gave a weighted mean weight difference of -1.1 kg vs placebo; the effect was small, of debatable clinical relevance, and dependent on a single trial. [https://pubmed.ncbi.nlm.nih.gov/12664086/]
  - Chromium - Health Professional Fact Sheet, NIH Office of Dietary Supplements — Sets an Adequate Intake (35 mcg/day men, 25 mcg/day women 19-50) but no RDA or UL; states the FNB found data insufficient to set an EAR and that chromium deficiency has not been reported in healthy people. [https://ods.od.nih.gov/factsheets/Chromium-HealthProfessional/]
  - Nutritional supplement chromium picolinate generates chromosomal aberrations and impedes progeny development in Drosophila melanogaster, Mutation research (2006) — Nutritional chromium picolinate generated chromosomal aberrations and impeded progeny development in Drosophila, raising genotoxicity concern at high exposure. [https://pubmed.ncbi.nlm.nih.gov/16887379/]
  - Evaluation of the potential genotoxicity of chromium picolinate in mammalian cells in vivo and in vitro, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association (2007) — Found no in vivo genotoxicity for chromium picolinate in mammalian cells; DNA damage occurred only at high in vitro/non-physiological concentrations. [https://pubmed.ncbi.nlm.nih.gov/17418471/]

---

## Vitamin K1 (Phylloquinone)
URL: https://nutridex.info/s/vitamin-k1
Category: Vitamin
Evidence: Strong — Multiple high-quality RCTs / meta-analyses with consistent effects.
The clotting and bone-carboxylation vitamin from leafy greens

Quick answer: Vitamin K1 (Phylloquinone) is used for essential cofactor for hepatic synthesis of functional clotting factors ii, vii, ix and x — corrects/prevents coagulopathy in deficiency. NutriDex grades the human evidence as strong — Multiple high-quality RCTs / meta-analyses with consistent effects. Based on 8 cited human studies (8 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Vitamin K1 (phylloquinone) is the predominant dietary form of vitamin K and an essential cofactor for the gamma-carboxylation of clotting factors II, VII, IX and X, as well as bone proteins (osteocalcin) and matrix Gla protein. Frank deficiency is rare in healthy adults but causes impaired coagulation and bleeding; it is a real risk in newborns (hemorrhagic disease of the newborn), fat-malabsorption, and with certain antibiotics, which is why a single intramuscular dose is given at birth. In non-deficient adults, supplementation reliably lowers undercarboxylated osteocalcin, but the largest RCTs (ECKO, 5 mg K1 for 2-4 years) show no protection of bone mineral density, and trials of 500 mcg K1 found no slowing of coronary-artery calcification progression. Benefits beyond correcting deficiency or optimizing carboxylation status are not established for the general population.

Benefits / uses: Essential cofactor for hepatic synthesis of functional clotting factors II, VII, IX and X — corrects/prevents coagulopathy in deficiency; Standard newborn prophylaxis: a single IM dose prevents vitamin K deficiency bleeding (hemorrhagic disease of the newborn); Reverses warfarin over-anticoagulation and treats vitamin-K-dependent bleeding (clinical antidote); Reliably reduces undercarboxylated osteocalcin and matrix Gla protein, improving vitamin-K carboxylation biomarkers; Treats deficiency in fat-malabsorption states (cholestasis, cystic fibrosis, short-bowel, severe IBD); Note: does NOT preserve bone mineral density or prevent coronary-artery calcification in non-deficient adults in large RCTs.
Active compounds: Phylloquinone (vitamin K1) tablets/drops — the supplemental and pharmaceutical form (e.g., phytonadione); Injectable/oral phytonadione (Mephyton, Konakion) for clinical reversal and newborn prophylaxis; Dietary: dark leafy greens (kale, spinach, collards, Swiss chard, broccoli, Brussels sprouts); Dietary: vegetable oils (soybean, canola, olive) and foods made with them.
Dose: Adequate Intake (AI; no RDA set): 120 mcg/day for adult men, 90 mcg/day for adult women (including pregnancy/lactation). Typical supplements supply ~80-500 mcg; bone/clinical studies have used 1-5 mg K1. No Tolerable Upper Intake Level (UL) has been established because no toxicity has been observed from dietary or supplemental phylloquinone in people not on anticoagulants.
Safety: Phylloquinone has very low toxicity and no UL; no adverse effects have been documented from high oral or dietary intake in healthy people. The dominant clinical concern is the interaction with vitamin K antagonist anticoagulants (warfarin/coumarins): changes in vitamin K intake — including supplements and large vegetable meals — alter INR and warfarin effect, so intake should be kept consistent. IV phytonadione has rarely caused anaphylactoid reactions, so it is given slowly/diluted. Phylloquinone does not interact dangerously with DOACs and is not associated with the cancer/CVD harm signals seen with some other supplements.

Cited studies (8):
  - Vitamin K supplementation and vascular calcification: a systematic review and meta-analysis of randomized controlled trials, Frontiers in nutrition (2023) — Systematic review/meta-analysis of 14 RCTs found no consistent benefit of vitamin K supplementation on vascular calcification and called for more rigorous trials. [https://pmc.ncbi.nlm.nih.gov/articles/PMC10218696/]
  - Effect of Vitamin K on Bone Mineral Density and Fracture Risk in Adults: Systematic Review and Meta-Analysis, Biomedicines (2022) — Systematic review/meta-analysis concluding vitamin K (K1 and K2) effects on BMD and fracture risk are inconsistent, with most benefit signals from K2 trials and lower-quality data. [https://pmc.ncbi.nlm.nih.gov/articles/PMC9138595/]
  - Interaction Between Dietary Vitamin K Intake and Anticoagulation by Vitamin K Antagonists: Is It Really True?: A Systematic Review, Medicine (2016) — Systematic review of dietary vitamin K and vitamin K antagonist anticoagulation found large vitamin K loads alter INR, supporting consistent intake for warfarin patients. [https://pmc.ncbi.nlm.nih.gov/articles/PMC4998867/]
  - Vitamin K supplementation in postmenopausal women with osteopenia (ECKO trial): a randomized controlled trial, PLoS medicine (2008) — RCT of 440 osteopenic postmenopausal women; 5 mg/day K1 for 2-4 years did not protect bone mineral density at lumbar spine or hip vs placebo (no significant between-group difference). [https://pmc.ncbi.nlm.nih.gov/articles/PMC2566998/]
  - Vitamin K treatment reduces undercarboxylated osteocalcin but does not alter bone turnover, density, or geometry in healthy postmenopausal North American women, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research (2009) — RCT in 452 healthy older adults; 500 mcg/day K1 for 3 years reduced undercarboxylated osteocalcin but did not alter bone turnover, BMD, or geometry. [https://pubmed.ncbi.nlm.nih.gov/19113922/]
  - Vitamin K supplementation and progression of coronary artery calcium in older men and women, The American journal of clinical nutrition (2009) — 3-year RCT (n=388 healthy older men/women); 500 mcg/day phylloquinone showed no overall difference in coronary-artery calcium progression vs control in intention-to-treat analysis. [https://pmc.ncbi.nlm.nih.gov/articles/PMC2682995/]
  - Vitamin K - Health Professional Fact Sheet, NIH Office of Dietary Supplements (2021) — Sets AI at 120 mcg/day (men) and 90 mcg/day (women) and states no UL exists because no toxicity has been observed from high vitamin K intake. [https://ods.od.nih.gov/factsheets/VitaminK-HealthProfessional/]
  - Vitamin K (2001) — Dietary Reference Intakes report establishing AI values and documenting that data were insufficient to set an RDA or UL for vitamin K. [https://www.ncbi.nlm.nih.gov/books/NBK222299/]

---

## Manganese (Mn)
URL: https://nutridex.info/s/manganese
Category: Mineral
Evidence: Preliminary — Early or small human trials; promising but not yet conclusive.
An essential trace mineral and antioxidant-enzyme cofactor where deficiency is virtually nonexistent and the real-world concern is excess, not shortfall

Quick answer: Manganese is used for corrects/prevents true deficiency: required for mnsod antioxidant defense, arginase (urea cycle), glutamine synthetase, and enzymes for bone matrix, cartilage, and glucose/lipid metabolism — but clinical deficiency in free-living people is essentially never seen. NutriDex grades the human evidence as preliminary — Early or small human trials; promising but not yet conclusive. Based on 8 cited human studies (8 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Manganese is an essential trace element that serves as a cofactor for mitochondrial superoxide dismutase (MnSOD), arginase, glutamine synthetase, and enzymes of bone, cartilage, and carbohydrate/lipid metabolism. Frank dietary deficiency is essentially unheard of in humans outside of experimental settings, so it is rarely a limiting nutrient. There are no credible randomized trials showing that manganese supplementation benefits otherwise healthy, non-deficient people, and the dominant clinical literature is instead about toxicity: occupational/airborne and high drinking-water exposure, and overload from manganese-containing parenteral nutrition, all of which cause a Parkinsonian neurotoxicity ("manganism") via basal-ganglia accumulation. Routine manganese supplements are therefore neither needed nor evidence-supported for most adults.

Benefits / uses: Corrects/prevents true deficiency: required for MnSOD antioxidant defense, arginase (urea cycle), glutamine synthetase, and enzymes for bone matrix, cartilage, and glucose/lipid metabolism — but clinical deficiency in free-living people is essentially never seen; Easily met by diet: whole grains, nuts, legumes, leafy greens, and tea provide ample manganese, so a normal mixed diet covers the AI without supplements; Often included in bone-health and multivitamin/multimineral formulas (with calcium, copper, zinc); the combination has weak support and no trial isolates a manganese-specific benefit for bone density; No demonstrated benefit in non-deficient adults: there is no robust RCT evidence that manganese supplementation improves cognition, metabolism, joint health, or any clinical outcome in people who are not deficient.
Active compounds: Supplement salts: manganese sulfate, manganese gluconate, manganese citrate, manganese chloride, and amino-acid chelates (e.g., manganese bisglycinate/aspartate); Common as a minor component of multivitamin/multimineral and bone-support products rather than a standalone supplement; Dietary sources: whole grains and bran, brown rice, oats, nuts (especially hazelnuts, pecans), legumes, leafy green vegetables, pineapple, and tea (a major contributor).
Dose: Adult Adequate Intake (AI, no RDA established): 2.3 mg/day for men and 1.8 mg/day for women (US IOM). Typical supplemental doses in multivitamins are roughly 1-5 mg. US Tolerable Upper Intake Level (UL): 11 mg/day for adults. EFSA (2023) found data insufficient to set a UL and instead defined a "safe level of intake" of 8 mg/day for adults. Most people meet needs from diet alone and do not require a supplement.
Safety: Oral toxicity from food is rare because gut absorption is tightly homeostatically regulated and >90% is excreted in bile. The serious risks come from routes that bypass this control: chronic inhalation in welders/miners/smelter workers and high manganese in drinking water, and intravenous overload from manganese-containing parenteral nutrition (especially in cholestasis/liver failure and in neonates). Excess manganese accumulates in the basal ganglia and causes "manganism," a Parkinson-like syndrome of tremor, rigidity, gait and cognitive/psychiatric disturbance; T1-weighted MRI shows hyperintense basal-ganglia deposition. Interactions: iron status modulates manganese absorption — iron deficiency increases manganese uptake (and brain accumulation), so iron-deficient individuals may absorb more; hepatic/biliary impairment reduces excretion and raises overload risk. Clinicians should limit or remove manganese from long-term PN, particularly with cholestasis. The UL excludes intakes from such non-dietary sources.

Cited studies (8):
  - Manganese exposure and cognitive performance: A meta-analytical approach, Environmental pollution (Barking, Essex : 1987) (2023) — Meta-analysis of manganese exposure and cognition found significantly poorer processing speed, attention, working memory, reaction time and cognitive control in exposed adults. [https://pubmed.ncbi.nlm.nih.gov/37247766/]
  - Biomarkers of environmental manganese exposure and associations with childhood neurodevelopment: a systematic review and meta-analysis, Environmental health : a global access science source (2020) — Across 55 studies (n=13,388 children), a 10-fold increase in hair manganese was associated with a 2.51-point lower Full-Scale IQ; blood and water manganese showed no significant pooled effect. [https://pmc.ncbi.nlm.nih.gov/articles/PMC7531154/]
  - Performance alterations associated with occupational exposure to manganese--a meta-analysis, Neurotoxicology (2009) — Pooled 13 studies (958 exposed, 815 unexposed workers); occupational manganese exposure was associated with consistently lower motor and cognitive performance and a long-term linear decline in exposed workers. [https://pubmed.ncbi.nlm.nih.gov/19465050/]
  - Evaluating the risk of manganese-induced neurotoxicity of parenteral nutrition: review of the current literature, Expert opinion on drug metabolism & toxicology (2021) — Reviewed manganese-induced neurotoxicity from parenteral nutrition, noting PN may deliver manganese far exceeding enteral absorption and that cholestasis (reduced biliary excretion) magnifies overload risk. [https://pmc.ncbi.nlm.nih.gov/articles/PMC8122055/]
  - Manganese, Advances in nutrition (Bethesda, Md.) (2017) — Reviews homeostatic regulation, MnSOD/enzyme cofactor roles, and that toxicity (manganism) arises from inhaled, high-water, or parenteral exposure that bypasses gut regulation, with iron status modulating absorption. [https://pmc.ncbi.nlm.nih.gov/articles/PMC5421128/]
  - Neuroimaging identifies increased manganese deposition in infants receiving parenteral nutrition, The American journal of clinical nutrition (2015) — Infants on trace-element-supplemented parenteral nutrition showed increased basal-ganglia manganese deposition on T1-weighted MRI correlating with parenteral manganese exposure. [https://pubmed.ncbi.nlm.nih.gov/26561627/]
  - Scientific opinion on the tolerable upper intake level for manganese, EFSA journal. European Food Safety Authority (2023) — Concluded data were insufficient to set a Tolerable Upper Intake Level and instead established a 'safe level of intake' of 8 mg/day for adults (including pregnancy/lactation), 2-7 mg/day for younger groups. [https://pmc.ncbi.nlm.nih.gov/articles/PMC10704406/]
  - Manganese (2001) — Set the adult AI at 2.3 mg/day (men) and 1.8 mg/day (women) and a UL of 11 mg/day for adults; noted that human dietary deficiency has not been reported in non-experimental settings. [https://www.ncbi.nlm.nih.gov/books/NBK222332/]

---

## Choline
URL: https://nutridex.info/s/choline
Category: Vitamin
Evidence: Moderate — Several controlled trials; effects real but modest or context-dependent.
Essential methyl donor for liver fat export, cell membranes, and the neurotransmitter acetylcholine

Quick answer: Choline is used for corrects deficiency: reverses choline-deprivation fatty liver and muscle damage (cpk normalizes within ~1 week of repletion). NutriDex grades the human evidence as moderate — Several controlled trials; effects real but modest or context-dependent. Based on 8 cited human studies (8 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Choline is an essential nutrient required to synthesize phosphatidylcholine (cell membranes and VLDL needed to export liver fat), acetylcholine, and the methyl donor betaine. Controlled depletion-repletion studies show that deprived adults develop reversible fatty liver and muscle damage (elevated CPK), with risk modified by sex, menopausal status, and common genetic variants. Most US adults consume below the Adequate Intake, yet outright deficiency disease is uncommon, and supplementation in non-deficient people has not been shown to improve cognition or health durably; controlled-feeding trials of doubled maternal choline (930 vs 480 mg/d) in late pregnancy show modest infant cognitive benefits, while observational cohorts and randomized supplement trials raise a TMAO-related cardiovascular caution at high intakes.

Benefits / uses: Corrects deficiency: reverses choline-deprivation fatty liver and muscle damage (CPK normalizes within ~1 week of repletion); Required for normal liver fat export, membrane phospholipids, and acetylcholine synthesis throughout life; Maternal supplementation (~930 vs 480 mg/d) in the third trimester modestly improved infant information-processing speed and sustained attention in controlled-feeding RCTs; Higher intake during pregnancy supports fetal neurodevelopment and is needed for placental and breast-milk choline supply; Citicoline/alpha-GPC forms show small, often transient cognitive signals in some trials, but no proven dementia prevention over adequate dietary choline; May be especially important for people with PEMT/MTHFR genetic variants, postmenopausal women, and those with low folate status who are less able to make endogenous choline.
Active compounds: Dietary: eggs (yolk), beef/chicken liver, beef, fish, soybeans, cruciferous vegetables, wheat germ; Choline bitartrate and choline chloride (common, inexpensive supplement salts); Phosphatidylcholine (lecithin); CDP-choline (citicoline); Alpha-GPC (L-alpha-glycerylphosphorylcholine); Betaine (trimethylglycine) supplies choline-sparing methyl groups.
Dose: Adequate Intake (no RDA established): 550 mg/d men, 425 mg/d women, 450 mg/d pregnancy, 550 mg/d lactation. Typical supplements provide ~250-500 mg/d (or 250-1000 mg/d as citicoline/alpha-GPC). Tolerable Upper Intake Level (UL) for adults: 3,500 mg/d.
Safety: UL is 3,500 mg/d in adults; intakes above this can cause fishy body odor (from trimethylamine), sweating, salivation, vomiting, hypotension, and hepatotoxicity. Choline is a precursor of gut-microbiome-derived TMAO: supplemental choline (but not eggs) raises fasting TMAO in people with normal renal function, and higher dietary choline and elevated TMAO are associated in cohorts/meta-analyses with greater cardiovascular and all-cause mortality risk — a reason to favor food sources and avoid megadosing. Caution in those with trimethylaminuria (genetic) and in renal impairment (reduced TMAO clearance). High intake may interact with the methylation/one-carbon pathway (folate, vitamin B12, betaine, methionine); deficiency risk rises when folate is also low.

Cited studies (8):
  - Higher dietary choline intake is associated with increased risk of all-cause and cause-specific mortality: A systematic review and dose-response meta-analysis of cohort studies, Nutrition research (New York, N.Y.) (2024) — Each 100 mg/d higher dietary choline was associated with ~6% higher all-cause and ~11% higher cardiovascular mortality across prospective cohorts. [https://pubmed.ncbi.nlm.nih.gov/39341000/]
  - Gut microbe-generated metabolite trimethylamine-N-oxide as cardiovascular risk biomarker: a systematic review and dose-response meta-analysis, European Heart Journal (2017) — Higher plasma TMAO was associated with increased MACE and all-cause mortality, rising ~7.6% per 10 micromol/L increment. [https://academic.oup.com/eurheartj/article/38/39/2948/3953914]
  - Dietary Choline and Betaine and Risk of CVD: A Systematic Review and Meta-Analysis of Prospective Studies, Nutrients (2017) — Pooled prospective cohorts found no consistent association between habitual dietary choline or betaine intake and overall CVD incidence, underscoring mixed observational evidence. [https://pmc.ncbi.nlm.nih.gov/articles/PMC5537826/]
  - Dietary Choline Supplements, but Not Eggs, Raise Fasting TMAO Levels in Participants with Normal Renal Function: A Randomized Clinical Trial, The American Journal of Medicine (2021) — Randomized trial: choline supplements, but not whole eggs, significantly raised fasting plasma TMAO in participants with normal renal function. [https://www.amjmed.com/article/S0002-9343(21)00229-1/abstract]
  - Maternal choline supplementation during the third trimester of pregnancy improves infant information processing speed: a randomized, double-blind, controlled feeding study, FASEB journal : official publication of the Federation of American Societies for Experimental Biology (2018) — Late-pregnancy controlled feeding of 930 vs 480 mg choline/d (n=26) yielded significantly faster infant reaction times (information-processing speed) across 4-13 months. [https://pmc.ncbi.nlm.nih.gov/articles/PMC6988845/]
  - Septicaemia in the elderly, Postgraduate medical journal (1981) — In 57 adults fed <50 mg choline/70kg/d, ~77% of men and postmenopausal women developed reversible fatty liver or muscle damage (rising CPK), establishing essentiality and genetic susceptibility. [https://pmc.ncbi.nlm.nih.gov/articles/PMC2426117/]
  - Choline - Health Professional Fact Sheet, NIH Office of Dietary Supplements (2022) — Sets Adequate Intake at 550 mg/d (men) and 425 mg/d (women) with a 3,500 mg/d UL; notes most Americans consume below the AI yet frank deficiency is rare. [https://ods.od.nih.gov/factsheets/Choline-HealthProfessional/]
  - Metabolomic profiling can predict which humans will develop liver dysfunction when deprived of dietary choline, FASEB journal : official publication of the Federation of American Societies for Experimental Biology (2010) — In a 42-day deprivation protocol (n=53), 23 developed hepatic steatosis and 5 developed muscle damage; metabolomic profiles predicted who would develop liver dysfunction. [https://pmc.ncbi.nlm.nih.gov/articles/PMC2909293/]

---

## Iodine
URL: https://nutridex.info/s/iodine
Category: Mineral
Evidence: Strong — Multiple high-quality RCTs / meta-analyses with consistent effects.
The thyroid mineral: indispensable in deficiency, but no proven upside once you're replete

Quick answer: Iodine is used for corrects deficiency disorders: prevents/reverses goiter and hypothyroidism and is the basis of thyroid hormone synthesis (t3/t4) — the core, well-established role. NutriDex grades the human evidence as strong — Multiple high-quality RCTs / meta-analyses with consistent effects. Based on 8 cited human studies (8 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Iodine is an essential constituent of the thyroid hormones thyroxine (T4) and triiodothyronine (T3), which govern metabolism and, critically, fetal and infant brain development. Deficiency is historically the leading preventable cause of intellectual disability worldwide, causing goiter, hypothyroidism, and—in severe gestational deficiency—cretinism; universal salt iodization is one of the most cost-effective public-health interventions (benefit-cost ratios of ~30:1). However, supplementation evidence in non-deficient or only mildly-deficient people is null: the landmark Gowachirapant 2017 RCT in mildly iodine-deficient pregnant women found 200 mcg/day produced no improvement in child IQ or neurodevelopment at age ~5, and the Cochrane review found no clear benefit on most outcomes. Excess iodine carries real risk—iodine-induced hyperthyroidism and hypothyroidism (a U-shaped risk curve)—so more is not better once intake is adequate.

Benefits / uses: Corrects deficiency disorders: prevents/reverses goiter and hypothyroidism and is the basis of thyroid hormone synthesis (T3/T4) — the core, well-established role; Prevents cretinism and severe neurodevelopmental damage when adequacy is achieved before/early in pregnancy in iodine-deficient regions; Supports normal fetal and infant brain development specifically in populations with inadequate intake — the benefit is correcting deficiency, not a bonus for the already-sufficient; Population-level salt iodization sharply reduces iodine deficiency disorders and impaired cognition (a public-health, not individual-supplement, win); No demonstrated cognitive, metabolic, or thyroid benefit from supplementing iodine-sufficient or only mildly-deficient individuals (Gowachirapant RCT, Cochrane: null).
Active compounds: Potassium iodide (KI) and sodium iodide — common supplement and prenatal forms; Iodized table salt — the dominant dietary source globally and the WHO-recommended fortification vehicle; Potassium iodate — used in salt fortification in many countries; Kelp/seaweed supplements (highly variable, sometimes excessive iodine content); Dietary sources: seaweed (nori, kombu, wakame), cod and other marine fish, dairy milk and yogurt, eggs, iodized salt.
Dose: Adult RDA 150 mcg/day; pregnancy 220 mcg/day; lactation 290 mcg/day (WHO recommends ~250 mcg/day in pregnancy/lactation). Prenatal supplements typically supply 150 mcg as potassium iodide. Tolerable Upper Intake Level (UL, US IOM) is 1,100 mcg/day for adults from all sources; the American Thyroid Association cautions against routine supplements exceeding 500 mcg/day.
Safety: UL is 1,100 mcg/day for adults; chronic excess can cause iodine-induced hypothyroidism (Wolff-Chaikoff effect) or iodine-induced hyperthyroidism (Jod-Basedow phenomenon), with a U-shaped risk curve — both too little and too much harm the thyroid. People with autoimmune thyroid disease (Hashimoto's), nodular goiter, or prior thyroid dysfunction are especially vulnerable to small excesses, and high-dose kelp supplements have triggered thyroid dysfunction. Elevated TSH has been seen at chronic intakes ≥1,700 mcg/day in adults. Avoid combining multiple iodine-containing supplements; iodine can interact with antithyroid drugs (methimazole/PTU), lithium (additive hypothyroid effect), and amiodarone (an iodine-rich drug). Routine supplementation above the RDA is not advised for iodine-sufficient individuals.

Cited studies (8):
  - Iodine supplementation for women during the preconception, pregnancy and postpartum period, Cochrane Database of Systematic Reviews (2017) — Across 11 trials, iodine supplementation in/around pregnancy showed no clear benefit or harm for most maternal thyroid and child neurodevelopment outcomes; evidence quality low. [https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011761.pub2/full]
  - Association of Maternal Iodine Status With Child IQ: A Meta-Analysis of Individual Participant Data, The Journal of clinical endocrinology and metabolism (2019) — Pooled individual data from 6,180 mother-child pairs (Generation R, INMA, ALSPAC) found no consistent association between maternal urinary iodine status and child IQ. [https://pmc.ncbi.nlm.nih.gov/articles/PMC6804415/]
  - Effect of excess iodine intake on thyroid diseases in different populations: A systematic review and meta-analyses including observational studies, PloS one (2017) — Excess iodine intake was associated with increased risk of hypothyroidism, subclinical hypothyroidism, and autoimmune thyroiditis across populations, supporting a U-shaped intake-risk relationship. [https://pmc.ncbi.nlm.nih.gov/articles/PMC5345857/]
  - Effect of iodine supplementation in pregnant women on child neurodevelopment: a randomised, double-blind, placebo-controlled trial, The lancet. Diabetes & endocrinology (2017) — In mildly iodine-deficient pregnant women, 200 mcg/day iodine vs placebo produced no difference in child IQ at ~5y (verbal 89.5 vs 90.2; performance 97.5 vs 99.1) or any neurodevelopment/behavior measure. [https://pubmed.ncbi.nlm.nih.gov/29030199/]
  - Linus Pauling Institute / OSU — Iodine — Iodine deficiency remains a leading preventable cause of impaired cognition; excess (>UL) can precipitate thyroid dysfunction, especially in susceptible individuals. [https://lpi.oregonstate.edu/mic/minerals/iodine]
  - Estimating the Health and Economic Benefits of Universal Salt Iodization Programs to Correct Iodine Deficiency Disorders, Thyroid : official journal of the American Thyroid Association (2020) — Universal salt iodization to correct iodine deficiency disorders yields large health and economic benefits, with benefit-cost ratios on the order of 30:1. [https://pmc.ncbi.nlm.nih.gov/articles/PMC7757618/]
  - Iodine - Health Professional Fact Sheet, NIH Office of Dietary Supplements (2024) — Adult RDA 150 mcg/day (pregnancy 220, lactation 290); Tolerable Upper Intake Level set at 1,100 mcg/day for adults from all sources. [https://ods.od.nih.gov/factsheets/Iodine-HealthProfessional/]
  - Iodine supplementation during pregnancy, World Health Organization — WHO recommends ~250 mcg/day iodine in pregnancy/lactation and universal salt iodization as the primary strategy to eliminate iodine deficiency disorders. [https://www.who.int/tools/elena/commentary/iodine-pregnancy]

---

## Calcium
URL: https://nutridex.info/s/calcium
Category: Mineral
Evidence: Moderate — Several controlled trials; effects real but modest or context-dependent.
The skeletal mineral with a supplement story that's more cautionary than it looks

Quick answer: Calcium is used for corrects dietary deficiency and, with vitamin d, treats/prevents rickets and osteomalacia. NutriDex grades the human evidence as moderate — Several controlled trials; effects real but modest or context-dependent. Based on 8 cited human studies (8 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Calcium is the most abundant mineral in the body; 99% sits in bone as hydroxyapatite while the tightly regulated remainder drives nerve conduction, muscle contraction (including the heartbeat), vascular tone, and blood clotting. Chronic dietary shortfall accelerates bone loss and, with vitamin D deficiency, causes rickets/osteomalacia and contributes to osteoporotic fracture. In well-nourished, community-dwelling adults, however, supplementation evidence is underwhelming: large meta-analyses (including the WHI) show no reduction in hip or total fractures, while signals of harm — modestly increased myocardial infarction risk in some pooled analyses, and a clear ~17% rise in kidney stones in the WHI — have made routine supplementation controversial. Benefit is most credible when correcting genuine deficiency or paired with vitamin D in institutionalized/vitamin-D-deplete older adults.

Benefits / uses: Corrects dietary deficiency and, with vitamin D, treats/prevents rickets and osteomalacia; Slows bone mineral density loss and modestly reduces fracture risk in deficient or institutionalized vitamin-D-replete older adults (calcium + vitamin D); Supports normal neuromuscular function, cardiac rhythm, and blood coagulation (physiological role, not a supplement effect in replete people); Modestly lowers blood pressure (~1-2 mmHg) and may reduce pre-eclampsia risk in low-intake pregnant women (WHO recommends supplementation where intake is low); Reduced recurrent colorectal adenomas in one classic RCT, though a later larger trial was null — not an established benefit; Does NOT reduce fracture in healthy community-dwelling adults and is not recommended for that purpose by the USPSTF.
Active compounds: Calcium carbonate (40% elemental Ca; cheapest, take with food for acid-dependent absorption); Calcium citrate (21% elemental Ca; absorbed without food, better for low-acid/PPI users); Other salts: lactate, gluconate, phosphate; Dietary sources: dairy (milk, yogurt, cheese), fortified plant milks and juices, canned sardines/salmon with bones, tofu set with calcium, leafy greens (kale, bok choy), almonds.
Dose: Adult RDA 1000 mg/day (1200 mg for women 51+ and all adults 71+); typical supplement dose 500-600 mg elemental Ca taken once or split (absorption is best in doses <=500 mg). Tolerable Upper Intake Level (UL): 2500 mg/day for adults 19-50, 2000 mg/day for adults 51+. Aim to reach the target mainly through diet; supplement only the gap.
Safety: UL is 2000-2500 mg/day; excess causes constipation, hypercalcemia, and impaired absorption of iron, zinc, and magnesium. Supplemental (not dietary) calcium raised kidney stone incidence ~17% in the WHI RCT. Pooled analyses by Bolland et al. suggest supplemental calcium (especially without vitamin D) modestly increases myocardial infarction risk (~RR 1.2-1.27); the signal is debated and not seen consistently, but favors getting calcium from food. Key interactions: reduces absorption of levothyroxine, bisphosphonates, tetracycline and fluoroquinolone antibiotics, and iron (separate dosing by 2-4 h); thiazide diuretics plus high calcium can cause hypercalcemia; proton-pump inhibitors reduce carbonate absorption (prefer citrate). Avoid high-dose supplements in those with hypercalcemia, hyperparathyroidism, or a history of calcium kidney stones.

Cited studies (8):
  - Calcium - Health Professional Fact Sheet, NIH Office of Dietary Supplements (2025) — Authoritative reference: adult RDA 1000-1200 mg/day, UL 2000-2500 mg/day; emphasizes meeting needs preferentially through diet. [https://ods.od.nih.gov/factsheets/Calcium-HealthProfessional/]
  - Association Between Calcium or Vitamin D Supplementation and Fracture Incidence in Community-Dwelling Older Adults: A Systematic Review and Meta-analysis, JAMA (2017) — Meta-analysis of 33 RCTs (n=51,145 community-dwelling older adults): calcium, vitamin D, or both NOT associated with lower hip or total fracture risk vs placebo. [https://pubmed.ncbi.nlm.nih.gov/29279934/]
  - Vitamin D, Calcium, or Combined Supplementation for the Primary Prevention of Fractures in Community-Dwelling Adults: Evidence Report and Systematic Review for the US Preventive Services Task Force, JAMA (2018) — Evidence review (11 RCTs, n=51,419) found vitamin D with or without calcium did not reduce fracture incidence in community-dwelling adults without deficiency, osteoporosis, or prior fracture. [https://pubmed.ncbi.nlm.nih.gov/29677308/]
  - Calcium supplements with or without vitamin D and risk of cardiovascular events: reanalysis of the Women's Health Initiative limited access dataset and meta-analysis, BMJ (Clinical research ed.) (2011) — Calcium +/- vitamin D associated with increased risk of MI (RR ~1.21-1.24) and the composite MI/stroke (RR ~1.16) across pooled RCTs. [https://pmc.ncbi.nlm.nih.gov/articles/PMC3079822/]
  - Effect of calcium supplements on risk of myocardial infarction and cardiovascular events: meta-analysis, BMJ (Clinical research ed.) (2010) — Meta-analysis of 11 RCTs (n>11,000): calcium supplements without vitamin D increased myocardial infarction risk (RR 1.27, 95% CI 1.01-1.59). [https://pubmed.ncbi.nlm.nih.gov/20671013/]
  - Urinary tract stone occurrence in the Women's Health Initiative (WHI) randomized clinical trial of calcium and vitamin D supplements, The American journal of clinical nutrition (2011) — In the WHI RCT (n=36,282 postmenopausal women), 1000 mg Ca + 400 IU vitamin D increased clinically diagnosed urinary tract stones (HR 1.17, 95% CI 1.02-1.34). [https://pubmed.ncbi.nlm.nih.gov/21525191/]
  - Calcium plus vitamin D supplementation and the risk of fractures, The New England journal of medicine (2006) — Calcium 1000 mg + vitamin D 400 IU in 36,282 women gave small hip-BMD gain, no significant reduction in hip fracture (HR 0.88, 95% CI 0.72-1.08), and more kidney stones. [https://pubmed.ncbi.nlm.nih.gov/16481635/]
  - Calcium supplements for the prevention of colorectal adenomas. Calcium Polyp Prevention Study Group, The New England journal of medicine (1999) — 1200 mg/day calcium modestly reduced recurrent colorectal adenomas (RR 0.81, 95% CI 0.67-0.99) in 930 adults; a later larger trial (Baron NEJM 2015) was null. [https://pubmed.ncbi.nlm.nih.gov/9887161/]

---

## Agave Nectar (Agave syrup)
URL: https://nutridex.info/s/agave-nectar
Category: Sweeteners & Additives
Evidence: Mixed — Conflicting results across studies; benefit uncertain.
Low-GI but the highest-fructose mainstream sweetener — a caloric sugar, not a health food

Quick answer: Agave Nectar is used for caloric sweetener (~60 kcal/tablespoon), sweeter than sucrose so somewhat less can be used for equal sweetness. NutriDex grades the human evidence as mixed — Conflicting results across studies; benefit uncertain. Based on 9 cited human studies (9 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Agave nectar (agave syrup) is a caloric liquid sweetener made by hydrolyzing the inulin/fructans of the agave plant (chiefly Agave tequilana/salmiana) into free sugars, yielding a product that is roughly 70-90% fructose — higher than table sugar (~50%) or HFCS-55. It is a GRAS food in the US and regulated as a single-ingredient added sugar (no numeric ADI; treated like any sugar, with intake guided by the WHO/dietary advice to keep free sugars under ~10% of energy). Its low glycemic index is a direct consequence of that high fructose load: human controlled-feeding meta-analyses show fructose substituted isocalorically for other carbohydrate modestly improves HbA1c without raising fasting glucose, but when fructose adds excess calories it raises triglycerides, uric acid, blood pressure, and liver fat — so the weight of evidence is mixed and dose-dependent.

Benefits / uses: Caloric sweetener (~60 kcal/tablespoon), sweeter than sucrose so somewhat less can be used for equal sweetness; Low glycemic index (~10-30) and minimal acute blood-glucose/insulin spike, because the dominant sugar is fructose which bypasses glucose-mediated insulin release; Liquid form dissolves easily in cold drinks and dissolves without graininess; used in beverages, baked goods, granola, 'natural'/vegan products; Neutral, mild flavor and high solubility; functions as a humectant and helps retain moisture in baked goods.
Active compounds: No E-number (a whole-food sugar, not a registered additive); sold as 'agave nectar', 'agave syrup', light/amber/dark grades; Common brands: Wholesome, Madhava, Volcanic Nectar, 365/store brands; used in 'natural', vegan, and raw-food products, flavored drinks, energy bars, and as a honey/sugar substitute; Composition: ~70-90% fructose, remainder glucose, with small inulin/fructan content; FDA recognizes agave as GRAS and as a single-ingredient added sugar on the Nutrition Facts label.
Dose: No toxicological ADI is assigned — agave is a sugar, not an additive, and is GRAS in the US (FDA recognizes it as a generally-recognized-as-safe single-ingredient sweetener; agave inulin has its own GRAS notices, e.g. GRN 1019). Intake is governed by general added-sugar guidance: the 2020-2025 US Dietary Guidelines and WHO advise keeping added/free sugars below 10% of total energy (WHO conditionally suggests <5%). On US labels its sugars count fully toward 'Added Sugars' and %Daily Value (DV 50 g/day).
Safety: Agave is not a 'safe-for-diabetics' or low-calorie product despite its low GI; it is a concentrated sugar with the highest fructose fraction of common sweeteners. The honest risk is dose-and-energy dependent. In isocaloric substitution for other carbohydrate, controlled-feeding meta-analyses show fructose does not worsen — and modestly improves — HbA1c and does not raise postprandial triglycerides or uric acid. But when fructose is consumed in excess of energy needs (the realistic scenario with liberal use of a sweet syrup), pooled trials show it raises postprandial and fasting triglycerides, serum uric acid (a gout/hyperuricemia signal), and blood pressure, and drives hepatic de novo lipogenesis/liver fat. Observational data tie sugar-sweetened-beverage fructose to metabolic syndrome, type 2 diabetes, hyperuricemia and gout. People with insulin resistance, NAFLD/MASLD, hypertriglyceridemia, gout, or those managing weight should treat agave as added sugar and limit it; there is no evidence it is healthier than table sugar or HFCS. Hereditary fructose intolerance is an absolute contraindication.

Cited studies (9):
  - Fructose-containing food sources and blood pressure: A systematic review and meta-analysis of controlled feeding trials, PloS one (2023) — Meta-analysis of controlled feeding trials: fructose-containing sugars raised blood pressure when providing excess energy but not in isocaloric substitution, reinforcing an energy-dependent cardiometabolic signal. [https://pmc.ncbi.nlm.nih.gov/articles/PMC10427023/]
  - Food sources of fructose-containing sugars and glycaemic control: systematic review and meta-analysis of controlled intervention studies, BMJ (Clinical research ed.) (2018) — Systematic review/meta-analysis of controlled trials found fructose-containing sugars do not harm glycemic control when isocalorically exchanged, but excess-energy fructose worsens metabolic outcomes — supporting a dose/energy-dependent risk. [https://pubmed.ncbi.nlm.nih.gov/30463844/]
  - Different Food Sources of Fructose-Containing Sugars and Fasting Blood Uric Acid Levels: A Systematic Review and Meta-Analysis of Controlled Feeding Trials, The Journal of nutrition (2021) — Meta-analysis of controlled feeding trials: fructose-containing sugars raised fasting blood uric acid only when providing excess energy, not in isocaloric exchange for other carbohydrate. [https://pubmed.ncbi.nlm.nih.gov/34087940/]
  - Effect of fructose on glycemic control in diabetes: a systematic review and meta-analysis of controlled feeding trials, Diabetes care (2012) — Meta-analysis of 18 isocaloric controlled feeding trials (n=209, T1/T2 diabetes): fructose substituted for carbohydrate reduced glycated blood proteins (SMD -0.25, 95% CI -0.46 to -0.04; ~0.53% HbA1c) without affecting fasting glucose or insulin. [https://pmc.ncbi.nlm.nih.gov/articles/PMC3379616/]
  - Fructose, high-fructose corn syrup, sucrose, and nonalcoholic fatty liver disease or indexes of liver health: a systematic review and meta-analysis, The American journal of clinical nutrition (2014) — Systematic review/meta-analysis: associations of fructose/HFCS/sucrose with NAFLD and liver-fat indices were largely confounded by excess energy intake; isocaloric fructose did not independently increase liver fat (low-quality evidence). [https://pubmed.ncbi.nlm.nih.gov/25099546/]
  - Effect of Fructose on Established Lipid Targets: A Systematic Review and Meta-Analysis of Controlled Feeding Trials, Journal of the American Heart Association (2015) — Meta-analysis of controlled feeding trials: isocaloric fructose did not raise fasting or postprandial triglycerides, but hypercaloric fructose providing excess energy significantly increased postprandial triglycerides. [https://www.ahajournals.org/doi/10.1161/JAHA.114.001700]
  - Sugar-Sweetened Beverages and Risk of Metabolic Syndrome and Type 2 Diabetes, Diabetes Care (2010) — Meta-analysis of prospective cohorts: higher sugar-sweetened-beverage intake was associated with greater risk of metabolic syndrome (RR ~1.20) and type 2 diabetes (RR ~1.26), implicating fructose-rich sweeteners. [https://diabetesjournals.org/care/article/33/11/2477/26589/Sugar-Sweetened-Beverages-and-Risk-of-Metabolic]
  - FDA Issues Final Guidance Added Sugars on Nutrition Facts Label, U.S. Food and Drug Administration — FDA recognizes agave as a GRAS single-ingredient sweetener; agave sugars are declared as 'Added Sugars' (with %DV) on the Nutrition Facts label, with no separate toxicological ADI. [https://www.fda.gov/food/hfp-constituent-updates/fda-issues-final-guidance-regarding-declaration-added-sugars-nutrition-facts-label-honey-maple-syrup]
  - Fructose- and sucrose- but not glucose-sweetened beverages promote hepatic de novo lipogenesis: A randomized controlled trial, Journal of hepatology (2021) — Randomized controlled trial: moderate fructose- and sucrose-sweetened beverages (but not glucose) roughly doubled hepatic de novo lipogenesis in healthy men, a mechanism linking high-fructose syrups to fatty liver. [https://pubmed.ncbi.nlm.nih.gov/33684506/]

---

## Allulose (D-psicose · rare sugar)
URL: https://nutridex.info/s/allulose
Category: Sweeteners & Additives
Evidence: Moderate — Several controlled trials; effects real but modest or context-dependent.
A rare sugar that tastes like sucrose but is nearly calorie-free and barely metabolized

Quick answer: Allulose is used for near-zero caloric impact (~0.4 kcal/g) with ~70% the sweetness of sucrose. NutriDex grades the human evidence as moderate — Several controlled trials; effects real but modest or context-dependent. Based on 8 cited human studies (8 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Allulose (D-allulose, formerly D-psicose) is a low-calorie "rare sugar" — a monosaccharide epimer of fructose found naturally in trace amounts in figs, raisins and wheat — with roughly 70% the sweetness of table sugar but only about 0.4 kcal/g, because it is absorbed yet largely excreted unchanged in urine rather than metabolized. It is GRAS in the United States (the FDA excludes it from "total" and "added sugars" on labels) and approved in Japan, South Korea and several other markets, but it is NOT authorized in the EU, where EFSA concluded in 2025 that safety could not be established due to gaps in chronic toxicity and carcinogenicity data. Human evidence is reassuring on metabolic safety at typical doses and consistently shows it blunts post-meal glucose; the main documented downside is dose-dependent gastrointestinal upset, and long-term toxicology data remain incomplete.

Benefits / uses: Near-zero caloric impact (~0.4 kcal/g) with ~70% the sweetness of sucrose; No meaningful glycemic or insulin impact — not metabolized for energy, so it does not raise blood sugar; Attenuates postprandial glucose/insulin when co-ingested with carbohydrate (e.g. ~24% lower glucose iAUC and ~33% lower insulin iAUC when added to sucrose); Provides bulk, browning/Maillard color, and a sugar-like mouthfeel that high-intensity sweeteners cannot — useful in baking, frozen desserts and beverages; Does not promote tooth decay (non-cariogenic); May support modest fat-mass reduction in preliminary trials, possibly via GLP-1 release.
Active compounds: No E-number (not authorized as a food additive/novel food in the EU); Common brand/retail names: Allulose, RareSugar, Dolcia Prima (Tate & Lyle), Astraea Allulose; Found in: keto/low-sugar baked goods, syrups, ice cream, chocolate, protein bars, beverages, and tabletop blends (often combined with monk fruit or stevia); Naturally present in tiny amounts in figs, raisins, jackfruit, wheat and maple syrup; commercially made by enzymatic conversion of fructose/corn.
Dose: United States: GRAS (multiple FDA GRAS notices, e.g. GRN 647, 693, 828, 1029); FDA guidance excludes allulose from "Total Sugars" and "Added Sugars" and assigns a caloric factor of 0.4 kcal/g. No formal numeric ADI has been set. Tolerance studies suggest a maximum single dose of ~0.4 g/kg body weight (~28 g for a 70 kg adult) and a maximum daily intake of ~0.9 g/kg before significant GI symptoms. EU/EFSA: NOT authorized — EFSA's 2025 novel-food opinion concluded safety could not be established (no JECFA ADI established).
Safety: The principal documented harm is dose-dependent gastrointestinal intolerance — bloating, abdominal distension, flatulence and osmotic diarrhea — with severe diarrhea appearing around a single dose of ~0.5 g/kg body weight and severe symptoms (nausea, abdominal pain, headache, anorexia) at chronic intakes near 1.0 g/kg/day; children appear more sensitive. At realistic culinary doses metabolic safety is reassuring and human trials consistently show neutral-to-favorable effects on glucose. The key unresolved issue is regulatory rather than a positive harm signal: EFSA (2025) declined authorization because long-term toxicology — a combined chronic toxicity/carcinogenicity study and adequate human long-term data — is lacking, so high habitual intake over years is not yet characterized. There is no credible evidence of carcinogenicity, genotoxicity or cardiovascular harm to date. People with IBS or sensitive digestion, and anyone consuming large amounts, are most likely to experience GI effects and should limit intake.

Cited studies (8):
  - Multiple strains probiotics appear to be the most effective probiotics in the prevention of necrotizing enterocolitis and mortality: An updated meta-analysis, PLOS ONE (2017) — Systematic review/meta-analysis of healthy adults: 5 g and 10 g allulose added to a carbohydrate meal significantly lowered postprandial glucose incremental AUC versus control. [https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0281150]
  - Impact of allulose on blood glucose in type 2 diabetes: A meta-analysis of clinical trials, Metabolism open (2024) — Pooled clinical-trial analysis found allulose significantly reduced postprandial glucose AUC in people with type 2 diabetes, with a non-significant reduction in insulin AUC. [https://pubmed.ncbi.nlm.nih.gov/39583955/]
  - Safety of D-allulose as a novel food pursuant to Regulation (EU) 2015/2283, EFSA Journal (2025) — EFSA concluded the safety of D-allulose as a novel food could not be established, citing absence of a combined chronic toxicity/carcinogenicity study and insufficient long-term human data — EU authorization withheld. [https://efsa.onlinelibrary.wiley.com/doi/10.2903/j.efsa.2025.9468]
  - Guidance on Declaration of Allulose on Labels, U.S. Food and Drug Administration — FDA accepted D-psicose (D-allulose) as GRAS and issued guidance excluding it from Total/Added Sugars while applying a caloric factor of 0.4 kcal/g. [https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-declaration-allulose-and-calories-allulose-nutrition-and-supplement-facts-labels]
  - Comparison of postprandial glycemic and insulinemic response of allulose when consumed alone or when added to sucrose: A randomized controlled trial, Journal of Functional Foods (2023) — In 14 adults with diabetes, adding 15 g allulose to 30 g sucrose lowered glucose iAUC ~24% and insulin iAUC ~33% versus sucrose alone. [https://doi.org/10.1016/j.jff.2023.105569]
  - Gastrointestinal tolerance of d -allulose in children: an acute, randomised, double-blind, placebo-controlled, cross-over study, Food & Function (2024) — Acute, randomized, double-blind, placebo-controlled crossover study assessing gastrointestinal tolerance of D-allulose in children, informing pediatric dose limits. [https://pubs.rsc.org/en/content/articlehtml/2024/fo/d3fo04210c]
  - A Preliminary Study for Evaluating the Dose-Dependent Effect of d-Allulose for Fat Mass Reduction in Adult Humans: A Randomized, Double-Blind, Placebo-Controlled Trial, Nutrients (2018) — Double-blind RCT in 121 adults (BMI ≥23): 7 g allulose twice daily for 12 weeks significantly reduced body fat percentage and fat mass versus placebo. [https://pmc.ncbi.nlm.nih.gov/articles/PMC5852736/]
  - Gastrointestinal Tolerance of D-Allulose in Healthy and Young Adults. A Non-Randomized Controlled Trial, Nutrients (2018) — Dose-escalation tolerance study identified a maximum single dose of ~0.4 g/kg and maximum daily intake of ~0.9 g/kg; severe diarrhea occurred at ~0.5 g/kg single dose. [https://pmc.ncbi.nlm.nih.gov/articles/PMC6315886/]

---

## High-Fructose Corn Syrup (HFCS-42 / HFCS-55)
URL: https://nutridex.info/s/hfcs
Category: Sweeteners & Additives
Evidence: Moderate — Several controlled trials; effects real but modest or context-dependent.
The corn-derived liquid sugar in much of the processed-food supply.

Quick answer: High-Fructose Corn Syrup is used for high-intensity caloric sweetness (~4 kcal/g) comparable to table sugar. NutriDex grades the human evidence as moderate — Several controlled trials; effects real but modest or context-dependent. Based on 12 cited human studies (12 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

High-fructose corn syrup (HFCS) is a liquid sweetener made from corn starch by enzymatically isomerizing some glucose to fructose, yielding HFCS-42 (~42% fructose, used in baked goods and processed foods) and HFCS-55 (~55% fructose, used in soft drinks). The FDA affirmed it as GRAS in 1996 (21 CFR 184.1866) with no quantitative limit beyond good manufacturing practice, and there is no separate ADI because it is treated as a caloric food, not an additive. Controlled-feeding trials show HFCS behaves metabolically much like sucrose gram-for-gram, with no consistent difference in weight or most cardiometabolic markers. The substantive evidence-based concern is not HFCS specifically but added/free sugars in general — especially sugar-sweetened beverages — which large cohorts and dose-response meta-analyses link to higher risk of type 2 diabetes, cardiovascular disease, and fatty liver.

Benefits / uses: High-intensity caloric sweetness (~4 kcal/g) comparable to table sugar; Liquid form blends easily and resists crystallization, improving texture and shelf stability; Browning/Maillard reactions for baked-good color and flavor; Humectant — retains moisture and extends shelf life; Lower cost and easier handling than granulated sucrose for manufacturers; Glycemic: raises blood glucose and insulin (the fructose fraction is metabolized in the liver, the glucose fraction is fully glycemic).
Active compounds: No E-number (not classified as an additive; regulated as a food, 21 CFR 184.1866); Main grades: HFCS-42 and HFCS-55; also HFCS-90 as a blending stock; Also labeled 'corn syrup high fructose', 'glucose-fructose syrup' or 'isoglucose' (EU/Canada); Found in: regular sodas and soft drinks, fruit-flavored and sports drinks, sweetened iced teas; Also in: breads, cookies, breakfast cereals, granola bars, yogurts, ketchup, salad dressings, sauces, jams, and many processed/packaged foods.
Dose: USA: FDA-affirmed GRAS as a direct human food ingredient (21 CFR 184.1866; effective 1996), used per current good manufacturing practice with no numerical limit. No ADI is assigned by FDA, EFSA, or JECFA because HFCS is a nutritive caloric sweetener rather than a food additive. Dietary guidance instead caps total added/free sugars: WHO strongly recommends free sugars below 10% of energy (conditional <5%), and the US Dietary Guidelines recommend <10% of calories from added sugars.
Safety: At equal intakes HFCS is not shown to be uniquely harmful versus table sugar: controlled-feeding meta-analyses find no significant difference in body weight or most metabolic markers, though one pooled analysis found modestly higher CRP (an inflammation marker) with HFCS than sucrose. The real, well-documented risk is excess added sugar in general — particularly from sugar-sweetened beverages — which large prospective cohorts and dose-response meta-analyses associate with higher type 2 diabetes, coronary heart disease, and cardiovascular mortality risk, and with hepatic de novo lipogenesis, raised uric acid, and fatty-liver (MASLD) markers when fructose is consumed in excess. HFCS is not carcinogenic and is safe for the general population in moderation; it is not 'natural' or beneficial. People managing diabetes, obesity, metabolic syndrome, fatty liver, gout/hyperuricemia, or hypertriglyceridemia should limit it, and it is a primary contributor to discretionary calories in children. People with hereditary fructose intolerance must avoid it entirely.

Cited studies (12):
  - Dietary Sugar Intake and Incident Type 2 Diabetes Risk: A Systematic Review and Dose-Response Meta-Analysis of Prospective Cohort Studies, Advances in nutrition (Bethesda, Md.) (2025) — Dose-response meta-analysis of prospective cohorts (incl. 18 SSB cohorts, n=541,288) found sugar consumed as beverages was associated with higher incident type 2 diabetes risk, whereas added sugar/fructose as isolated nutrients showed no association. [https://pmc.ncbi.nlm.nih.gov/articles/PMC12145082/]
  - Consumption of sugar sweetened beverages, artificially sweetened beverages and fruit juices and risk of type 2 diabetes, hypertension, cardiovascular disease, and mortality: A meta-analysis, Frontiers in nutrition (2023) — Meta-analysis found sugar-sweetened beverage consumption associated with higher risk of type 2 diabetes, hypertension, cardiovascular disease, and all-cause mortality across pooled prospective cohorts. [https://pmc.ncbi.nlm.nih.gov/articles/PMC10050372/]
  - The impact of high fructose corn syrup on liver injury and glucose metabolism: a systematic review, Frontiers in nutrition (2025) — Systematic review concluded HFCS intake is associated with hepatic steatosis, raised uric acid, and impaired glucose metabolism via fructose-driven de novo lipogenesis, while noting effects largely track with excess intake rather than HFCS being uniquely toxic versus other sugars. [https://pmc.ncbi.nlm.nih.gov/articles/PMC12689413/]
  - Fructose-containing sugars and metabolic risk: a systematic review and meta-analysis, Food & nutrition research (2025) — Systematic review and meta-analysis of fructose-containing sugars and metabolic risk found HFCS interventions at varying concentrations showed consistent trends toward increased LDL cholesterol (effect sizes 0.209-0.349 mmol/L), though individual comparisons did not reach significance. [https://pmc.ncbi.nlm.nih.gov/articles/PMC12664302/]
  - Dietary Sugar Intake and Incident Type 2 Diabetes Risk: A Systematic Review and Dose-Response Meta-Analysis of Prospective Cohort Studies, Advances in nutrition (Bethesda, Md.) (2025) — Dose-response meta-analysis of prospective cohorts (29 cohorts; SSB n=541,288) found each additional daily sugar-sweetened beverage serving raised type 2 diabetes risk by ~25% (RR 1.25), while added sugar and fructose per se showed no association. [https://pubmed.ncbi.nlm.nih.gov/40122386/]
  - The effect of high-fructose corn syrup vs. sucrose on anthropometric and metabolic parameters: A systematic review and meta-analysis, Frontiers in nutrition (2022) — Systematic review/meta-analysis of 4 trials (9 arms, 767 participants) found HFCS did not significantly differ from sucrose for weight or most metabolic parameters, but raised CRP (+0.27 mg/L, 95% CI 0.02-0.52). [https://pmc.ncbi.nlm.nih.gov/articles/PMC9551185/]
  - Important Food Sources of Fructose-Containing Sugars and Non-Alcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis of Controlled Trials, Nutrients (2022) — Systematic review and meta-analysis of 51 controlled trials (n=2,059) found sugar-sweetened beverages providing excess energy at high doses produced large increases in liver fat and small increases in ALT, implicating fructose-containing SSBs in NAFLD. [https://pmc.ncbi.nlm.nih.gov/articles/PMC9325155/]
  - The effect of high-fructose corn syrup vs. sucrose on anthropometric and metabolic parameters: A systematic review and meta-analysis, Frontiers in nutrition (2022) — Systematic review and meta-analysis comparing HFCS with sucrose found no significant differences in body weight, waist circumference, BMI or fat mass between the two sweeteners at matched doses. [https://pmc.ncbi.nlm.nih.gov/articles/PMC9551185/]
  - Reducing consumption of sugar-sweetened beverages to reduce the risk of unhealthy weight gain in adults, World Health Organization — WHO guideline recommends reducing free sugars (including those in HFCS-sweetened beverages) to under 10% of energy, with a conditional suggestion below 5%, citing weight gain and cardiometabolic risk. [https://www.who.int/tools/elena/interventions/ssbs-adult-weight]
  - Effect of fructose on markers of non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of controlled feeding trials, European Journal of Clinical Nutrition (2014) — Meta-analysis of controlled feeding trials found fructose in excess (hypercaloric) increased liver fat and ALT, while isocaloric exchange of fructose for other carbohydrate did not — implicating excess calories/fructose in NAFLD markers. [https://www.nature.com/articles/ejcn20148]
  - § 184.1866 High fructose corn syrup, U.S. Food and Drug Administration (21 CFR), Electronic Code of Federal Regulations (eCFR) — FDA affirmed HFCS (42% or 55% fructose) as Generally Recognized As Safe as a direct human food ingredient with no limitation other than current good manufacturing practice. [https://www.ecfr.gov/current/title-21/chapter-I/subchapter-B/part-184/subpart-B/section-184.1866]
  - Sweetened beverage consumption, incident coronary heart disease, and biomarkers of risk in men, Circulation (2012) — Prospective cohort of 42,883 men over 22 years (3,683 CHD cases) found the top vs bottom quartile of sugar-sweetened beverage intake had ~20% higher coronary heart disease risk (RR 1.20). [https://pubmed.ncbi.nlm.nih.gov/22412070/]

---

## Sodium Nitrite & Nitrate (E250 / E251)
URL: https://nutridex.info/s/sodium-nitrite
Category: Sweeteners & Additives
Evidence: Mixed — Conflicting results across studies; benefit uncertain.
Curing salts that keep cured meats safe from botulism and pink — but the processed meat they preserve is an IARC Group 1 carcinogen.

Quick answer: Sodium Nitrite & Nitrate is used for inhibits clostridium botulinum and other pathogens (key antimicrobial/anti-botulinum role in cured meats). NutriDex grades the human evidence as mixed — Conflicting results across studies; benefit uncertain. Based on 11 cited human studies (11 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Sodium/potassium nitrite (E250/E249) and sodium/potassium nitrate (E251/E252) are "curing salts" added to processed meats, some fish and certain cheeses to prevent Clostridium botulinum and other spoilage, fix the characteristic pink color and develop cured flavor. They are authorized food additives in the EU and regulated additives in the US (21 CFR 172.175); EFSA's 2017 re-evaluations kept the nitrite ADI at 0.07 mg nitrite ion/kg/day and the nitrate ADI at 3.7 mg nitrate ion/kg/day, finding additive exposure within safe levels except a slight exceedance in high-consuming children. The principal human concern is not acute toxicity at additive doses but endogenous formation of N-nitroso compounds: IARC classified processed meat as a Group 1 carcinogen (2015), and cohort/meta-analytic data link nitrite and nitrosamine intake to gastric and colorectal cancer, with an emerging signal for type 2 diabetes. The same inorganic nitrate from vegetables behaves very differently and is generally associated with neutral-to-beneficial outcomes, so context and co-ingredients matter.

Benefits / uses: Inhibits Clostridium botulinum and other pathogens (key antimicrobial/anti-botulinum role in cured meats); Prevents lipid oxidation and rancidity, extending shelf life; Fixes the stable pink/red cured color by forming nitrosylmyoglobin; Develops the characteristic 'cured' flavor of bacon, ham and salami; Nitrate acts as a slow-release reservoir that is reduced to nitrite over time in dry-cured products.
Active compounds: E250 sodium nitrite; E249 potassium nitrite; E251 sodium nitrate; E252 potassium nitrate (saltpetre); Sold as 'curing salt', 'pink salt', Prague Powder #1 (6.25% nitrite) and #2 (nitrite + nitrate), Insta Cure, sel rose; Found in bacon, ham, hot dogs/frankfurters, salami, pepperoni, bologna, corned beef, pastrami, some smoked fish and certain cheeses; 'Uncured'/'no nitrate added' products typically use celery powder/juice, which supplies the same nitrate/nitrite naturally.
Dose: EU: authorized food additives. EFSA 2017 ADI for nitrite = 0.07 mg nitrite ion/kg bw/day (E249/E250); ADI for nitrate = 3.7 mg nitrate ion/kg bw/day (E251/E252); JECFA/SCF values are comparable. EU max added/residual nitrite in meat is being lowered (generally ~80-150 mg/kg added depending on product). US (FDA): regulated additive under 21 CFR 172.175 — sodium nitrite not to exceed 200 ppm in finished cured meat (10 ppm in some smoked tuna); USDA also limits ingoing nitrite (~120-156 ppm for bacon, with mandatory ascorbate/erythorbate to suppress nitrosamine formation). Pure nitrite is acutely toxic at gram doses (methemoglobinemia); estimated lethal dose ~1-9.5 g for an adult.
Safety: At additive levels the acute risk is low, but two real concerns exist. (1) Carcinogenicity: nitrite/nitrate can react with amines/amides under acidic or high-heat conditions to form carcinogenic N-nitroso compounds (e.g., NDMA). IARC classifies processed meat as Group 1 ("carcinogenic to humans"), driven largely by colorectal cancer (about +18% risk per 50 g/day). Meta-analytic data also link higher dietary nitrite (RR ~1.31) and NDMA (RR ~1.34) to gastric cancer, while dietary nitrate (mostly from vegetables) is inversely associated (RR ~0.80) — highlighting that source/matrix matters. The 2023 NutriNet-Sante cohort additionally associated nitrite additives with higher type 2 diabetes risk. (2) Methemoglobinemia: excess nitrite oxidizes hemoglobin; infants under ~6 months (and people with G6PD or NADH-methemoglobin-reductase deficiency) are most vulnerable, which is the main rationale for limiting nitrate in drinking water and infant exposure. Practical mitigations include mandatory addition of ascorbate/erythorbate (which blocks nitrosamine formation) and lowered maximum levels. Who should be cautious: heavy/daily processed-meat consumers, those with personal/family GI cancer risk, and infants. Note this profile concerns curing-salt additives — the inorganic nitrate in vegetables and beetroot has a distinct, largely favorable evidence base.

Cited studies (11):
  - Association between red and processed meat consumption and colorectal cancer risk: a comprehensive meta-analysis of prospective studies, GeroScience (2025) — Comprehensive meta-analysis of prospective cohorts (PubMed/Cochrane/Embase through Nov 2024) found high red and processed meat intake significantly associated with increased colorectal, colon, and rectal cancer risk. [https://pmc.ncbi.nlm.nih.gov/articles/PMC12181564/]
  - Association of Dietary Nitrate, Nitrite, and N-Nitroso Compounds Intake and Gastrointestinal Cancers: A Systematic Review and Meta-Analysis, Toxics (2023) — Systematic review and meta-analysis found high nitrite intake significantly associated with increased gastric cancer risk, while dietary nitrate showed no significant association. [https://pmc.ncbi.nlm.nih.gov/articles/PMC9962651/]
  - Association of dietary nitrate and nitrite from plant sources with digestive system cancer risk: a systematic review and meta-analysis, Nutrition & metabolism (2025) — Meta-analysis distinguishing source found dietary nitrate/nitrite from plant sources was not associated with (and may lower) digestive-system cancer risk, contrasting with processed-meat nitrite. [https://pmc.ncbi.nlm.nih.gov/articles/PMC12297779/]
  - Dietary Nitrates, Nitrites, and Nitrosamines Intake and the Risk of Gastric Cancer: A Meta-Analysis, Nutrients (2015) — Across 49 studies, highest vs lowest dietary nitrite gave a summary RR of 1.31 (95% CI 1.13-1.52) and NDMA 1.34 (1.02-1.76) for gastric cancer, whereas dietary nitrate was protective (RR 0.80, 0.69-0.93). [https://pmc.ncbi.nlm.nih.gov/articles/PMC4690057/]
  - Re-evaluation of potassium nitrite (E 249) and sodium nitrite (E 250) as food additives, EFSA Journal (2017) — Re-evaluated potassium/sodium nitrite; retained ADI of 0.07 mg nitrite ion/kg bw/day and concluded additive exposure is within safe levels for all groups except a slight exceedance in high-consuming children. [https://efsa.onlinelibrary.wiley.com/doi/10.2903/j.efsa.2017.4786]
  - Re‐evaluation of sodium nitrate (E 251) and potassium nitrate (E 252) as food additives, EFSA Journal (2017) — Re-evaluated sodium/potassium nitrate; supported an ADI of 3.7 mg nitrate ion/kg bw/day and found no genotoxic potential for the nitrate salts themselves. [https://efsa.onlinelibrary.wiley.com/doi/10.2903/j.efsa.2017.4787]
  - Food additive emulsifiers and cancer risk: Results from the French prospective NutriNet-Sant&eacute; cohort, PLOS Medicine (2024) — In 104,168 adults, higher exposure to additive-originated nitrites was associated with greater type 2 diabetes risk (HR ~1.27 for higher exposure), with no protective association seen for nitrites overall. [https://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1004149]
  - Dietary nitrosyl-heme from processed meats and its association with colorectal cancer risk: findings from the EPIC cohort study, Nutrition journal (2025) — In 367,463 EPIC participants across 7 countries, dietary nitrosyl-heme (formed by nitrite curing) intake showed no significant association with colorectal cancer risk (highest vs lowest tertile). [https://pubmed.ncbi.nlm.nih.gov/41422247/]
  - Nitrosyl-heme and Heme Iron Intake from Processed Meats and Risk of Colorectal Cancer in the EPIC-Spain Cohort, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology (2024) — In the EPIC-Spain cohort, higher nitrosyl-heme intake from processed meats was associated with increased colorectal cancer risk, supporting a curing-specific carcinogenic pathway. [https://pubmed.ncbi.nlm.nih.gov/38546399/]
  - § 172.175 Sodium nitrite, U.S. Food and Drug Administration (21 CFR), Electronic Code of Federal Regulations (eCFR) — Sodium nitrite is a regulated direct food additive permitted as a preservative/color fixative, not to exceed 200 ppm in finished cured meat products (and 10 ppm in certain smoked tuna). [https://www.ecfr.gov/current/title-21/chapter-I/subchapter-B/part-172/subpart-B/section-172.175]
  - Cancer: Carcinogenicity of the consumption of red meat and processed meat, World Health Organization — Classified processed meat as Group 1 ('carcinogenic to humans'); each 50 g/day eaten increases colorectal cancer risk by ~18%, with nitrite/nitroso chemistry a proposed mechanism. [https://www.who.int/news-room/questions-and-answers/item/cancer-carcinogenicity-of-the-consumption-of-red-meat-and-processed-meat]

---

## Artificial Food Dyes (Red 40, Yellow 5/6, Blue 1)
URL: https://nutridex.info/s/artificial-food-dyes
Category: Sweeteners & Additives
Evidence: Mixed — Conflicting results across studies; benefit uncertain.
Synthetic colorants — small but real behavioral signal in sensitive children

Quick answer: Artificial Food Dyes is used for provide vivid, stable, low-cost color to processed foods, drinks, confectionery and medicines. NutriDex grades the human evidence as mixed — Conflicting results across studies; benefit uncertain. Based on 10 cited human studies (10 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Artificial food dyes are petroleum-derived synthetic colorants — chiefly the azo dyes Red 40 (Allura Red, E129), Yellow 5 (Tartrazine, E102), Yellow 6 (Sunset Yellow, E110) and the triarylmethane dye Blue 1 (E133) — used to color candy, beverages, cereals, baked goods and drugs. All four remain FDA-approved and EFSA-authorized within Acceptable Daily Intakes, but the weight of evidence is genuinely mixed on neurobehavior: meta-analyses and the landmark Southampton RCT find a small average increase in hyperactivity/inattention in some children, prompting mandatory EU warning labeling but no ban. Standard carcinogenicity and general-toxicity reviews have been reassuring at typical intakes; the separate 2025 FDA revocation of Red 3 (erythrosine) was driven by a rat thyroid-tumor mechanism not considered relevant to humans, via the zero-tolerance Delaney Clause.

Benefits / uses: Provide vivid, stable, low-cost color to processed foods, drinks, confectionery and medicines; Highly water-soluble and pH/heat/light stable compared with most natural colorants, giving consistent shade across shelf life; Restore or standardize color lost during processing and storage; mask batch-to-batch variation; Used in tiny quantities (typically <100 ppm); contribute no calories, flavor, or nutritional value; Enable bright hues (true blues, reds) difficult or costly to achieve with plant-based pigments.
Active compounds: Red 40 / Allura Red AC (E129); Yellow 5 / Tartrazine (E102); Yellow 6 / Sunset Yellow FCF (E110); Blue 1 / Brilliant Blue FCF (E133); also Red 3/Erythrosine (E127), Blue 2/Indigotine (E132), Green 3 (E143); Azo class: Red 40, Yellow 5, Yellow 6 (and Carmoisine E122, Ponceau 4R E124). Non-azo: Blue 1, Blue 2, Green 3 (triarylmethane), Red 3 (xanthene); Found in sodas and sports drinks, candy and gummies, breakfast cereals, frostings/icings, flavored snacks, gelatin desserts, condiments, and many oral medications/supplements.
Dose: FDA: certified color additives, batch-tested by FDA; approved/listed (not GRAS). FDA ADIs (mg/kg bw/day): Red 40 ~7, Yellow 5 ~5, Yellow 6 ~3.75, Blue 1 ~12. EFSA reassessment ADIs: Allura Red AC (E129) 7 mg/kg; Tartrazine (E102) 7.5 mg/kg; Sunset Yellow (E110) 4 mg/kg; Brilliant Blue (E133) 6 mg/kg; JECFA broadly concordant. EU mandates the warning "may have an adverse effect on activity and attention in children" on six dyes (Sunset Yellow, Quinoline Yellow, Carmoisine, Allura Red, Tartrazine, Ponceau 4R). FDA revoked Red 3 (E127) authorization in food/ingested drugs in Jan 2025 (compliance by Jan 2027) under the Delaney Clause.
Safety: At intakes within the ADI, general toxicity and cancer reviews for Red 40, Yellow 5/6 and Blue 1 are largely reassuring; these dyes are NOT classified as human carcinogens. The principal genuine signal is neurobehavioral: the FDA-funded Southampton RCT (McCann 2007) and meta-analyses (Schab & Trinh 2004; Nigg 2012) show a small average increase in hyperactivity/inattention — effect size roughly g≈0.18–0.28 — driven by a susceptible subset of children, especially diet-responders. This prompted EU warning labeling (2010) and California's OEHHA 2021 review concluding current intakes may not fully protect sensitive children's behavior; FDA still holds that most children are unaffected. Yellow 5 (tartrazine) can rarely trigger urticaria/intolerance reactions in a small number of sensitive or aspirin-sensitive individuals and must be label-declared in the US. Red 3 was de-listed in 2025 over rat thyroid tumors via a mechanism FDA states does not occur in humans at realistic exposures. Parents of children with ADHD or suspected sensitivity may reasonably choose to limit intake; there is no established harm at the population level for the average consumer staying within the ADI.

Cited studies (10):
  - Potential impacts of synthetic food dyes on activity and attention in children: a review of the human and animal evidence, Environmental health : a global access science source (2022) — Systematic review of 27 clinical trials (25 challenge studies) found 16/25 (64%) showed a positive association and 13/25 (52%) statistically significant evidence that synthetic food dyes affect activity/attention in children, concluding current FDA acceptable daily intakes may not protect against neurobehavioral effects. [https://pmc.ncbi.nlm.nih.gov/articles/PMC9052604/]
  - Revoking Authorization for the Use of Red No. 3 in Food/Ingested Drugs, U.S. Food and Drug Administration — FDA revoked authorization of FD&C Red No. 3 (erythrosine) in food and ingested drugs under the Delaney Clause based on high-dose rat thyroid tumors, while stating the carcinogenic mechanism does not occur in humans at relevant exposures; compliance by Jan 2027. [https://www.fda.gov/food/hfp-constituent-updates/fda-revoke-authorization-use-red-no-3-food-and-ingested-drugs]
  - HHS, FDA to Phase Out Petroleum, U.S. Food and Drug Administration — On April 22, 2025, HHS and FDA announced a plan to phase out all petroleum-based synthetic dyes—Red 40, Yellow 5, Yellow 6, Blue 1, Blue 2, Green 3—from the U.S. food supply by the end of 2026, and to revoke authorization for Citrus Red 2 and Orange B. [https://www.fda.gov/news-events/press-announcements/hhs-fda-phase-out-petroleum-based-synthetic-dyes-nations-food-supply]
  - Artificial food colors and attention-deficit/hyperactivity symptoms: conclusions to dye for, Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics (2012) — Meta-analysis estimated a synthetic food-color effect on ADHD symptoms of g=0.18 (95% CI 0.08–0.24) by parent report (non-significant by teachers), suggesting ~8% of children with ADHD may be color-sensitive. [https://pubmed.ncbi.nlm.nih.gov/22864801/]
  - Do artificial food colors promote hyperactivity in children with hyperactive syndromes? A meta-analysis of double-blind placebo-controlled trials, Journal of developmental and behavioral pediatrics : JDBP (2004) — Meta-analysis of 15 double-blind placebo-controlled trials found artificial food colors increased hyperactivity with an overall effect size of 0.283 (95% CI 0.079–0.488), largest in pre-screened diet-responsive children. [https://pubmed.ncbi.nlm.nih.gov/15613992/]
  - FDA 2011 (Color Additives & Behavior review) — FDA Food Advisory Committee concluded a causal link between color additives and hyperactivity in the general child population was not established, but a sensitive subpopulation may be affected, warranting further study. [https://www.fda.gov/media/131378/download]
  - EFSA updates safety advice on six food colours, European Food Safety Authority (2009) — EFSA re-evaluation retained the Allura Red AC ADI at 7 mg/kg bw/day, finding no genotoxic or carcinogenic concern; refined exposure assessment found intakes below the ADI across populations. [https://www.efsa.europa.eu/en/press/news/091112]
  - Food additives and hyperactive behaviour in 3-year-old and 8/9-year-old children in the community: a randomised, double-blinded, placebo-controlled trial, The Lancet (2007) — Double-blind crossover RCT in 153 three-year-olds and 144 eight/nine-year-olds: mixes of artificial food colors plus sodium benzoate significantly increased hyperactivity (e.g. global GHA effect ~0.17 SD) versus placebo in the general child population. [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(07)61306-3/abstract]
  - Artificial food dyes are toxic: Neurobehavioral implications in children, Brain & spine (2024) — Review of artificial food dye toxicity concludes synthetic dyes including Red 40, Yellow 5 and Yellow 6 have neurobehavioral implications in children and supports tighter regulation of their use in children's foods. [https://pmc.ncbi.nlm.nih.gov/articles/PMC11736054/]
  - Health Effects Assessment: Potential Neurobehavioral Effects of Synthetic Food Dyes in Children, California Office of Environmental Health Hazard Assessment (OEHHA) (2021) — California state review concluded synthetic food dyes can cause or worsen neurobehavioral effects (inattention, hyperactivity, restlessness) in some children and that current federal ADIs, set decades ago, may not adequately protect children's behavior. [https://oehha.ca.gov/risk-assessment/report/health-effects-assessment-potential-neurobehavioral-effects-synthetic-food-dyes-children]

---

## Potassium Sorbate (E202)
URL: https://nutridex.info/s/potassium-sorbate
Category: Sweeteners & Additives
Evidence: Moderate — Several controlled trials; effects real but modest or context-dependent.
The most widely used "soft" preservative — keeps mold and yeast out of cheese, wine, and baked goods

Quick answer: Potassium Sorbate is used for prevents microbial spoilage — inhibits molds, yeasts, and many bacteria. NutriDex grades the human evidence as moderate — Several controlled trials; effects real but modest or context-dependent. Based on 10 cited human studies (10 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Potassium sorbate (E202) is the potassium salt of sorbic acid, a near-flavorless antimicrobial preservative that suppresses molds, yeasts, and many bacteria. In water it dissociates to active sorbic acid, working best at pH below ~6. It is one of the most widely used food preservatives worldwide, FDA GRAS and EU-approved, and is metabolized like a fatty acid (beta-oxidized to CO2 and water). The weight of human-relevant evidence is reassuring at normal intakes; EFSA's 2019 re-evaluation set a group ADI of 11 mg sorbic acid/kg body weight/day. In-vitro genotoxicity signals in human lymphocytes exist but are inconsistent and at concentrations far above dietary exposure.

Benefits / uses: Prevents microbial spoilage — inhibits molds, yeasts, and many bacteria; Extends shelf life of cheese, wine, baked goods, dried fruit, and beverages; Near tasteless and odorless — minimal flavor impact vs. benzoates; Effective at low, mildly acidic pH (<6) and at low use levels; Highly water-soluble (unlike sorbic acid itself), so easy to formulate; Metabolized as a fatty acid (beta-oxidation) rather than accumulating.
Active compounds: E-number: E202 (potassium salt of sorbic acid, E200; calcium sorbate E203 was de-listed in the EU in 2018); CAS 24634-61-5; sold as 'potassium sorbate' or 'sorbic acid potassium salt'; Cheese, yogurt, and dairy spreads; Wine and cider (arrests refermentation), soft drinks and fruit juices; Baked goods, tortillas, and bread (mold inhibition); Dried fruit, dips, dressings, margarine; also cosmetics and personal-care products.
Dose: FDA: Generally Recognized As Safe (GRAS), 21 CFR 182.3640, used per good manufacturing practice (no numeric ADI). JECFA/EU SCF historically set a group ADI of 25 mg/kg bw/day (as sorbic acid). EFSA reduced this to a temporary 3 mg/kg bw/day in 2015 on reproductive-toxicity data, then revised it to a group ADI of 11 mg sorbic acid/kg bw/day in its 2019 follow-up opinion (BMDL ~1,110 mg/kg ÷ uncertainty factor 100), covering E200 and E202.
Safety: At dietary levels potassium sorbate is well tolerated; it is metabolized like a fatty acid and is not bioaccumulative. The main practical issue is occasional skin/contact irritation or mild allergic reactions (more relevant in cosmetics). In-vitro studies report concentration-dependent DNA damage and chromosomal/micronucleus effects in cultured human lymphocytes, and a classic Japanese study found that sorbate decomposition products reacting with ascorbic acid (vitamin C) plus iron salts were mutagenic — but each component alone was inactive, and these are high-concentration in-vitro signals not demonstrated to occur at dietary exposure. Other lymphocyte studies found no genotoxicity, so the overall evidence is mixed and not considered a public-health concern at intakes within the ADI. EFSA's lowered ADI was driven by animal reproductive/developmental endpoints, not human harm. No credible evidence links normal dietary E202 to cancer in humans; it is not classified by IARC.

Cited studies (10):
  - Cytogenotoxicity of food preservatives in mammalian cells: A systematic review, Genetics and molecular biology (2025) — Systematic review of 19 studies on food-preservative cytogenotoxicity in mammalian cells found potassium sorbate consistently associated with DNA damage, micronucleus formation, and chromosomal abnormalities. [https://pmc.ncbi.nlm.nih.gov/articles/PMC12766372/]
  - § 182.3640 Potassium sorbate, U.S. Food and Drug Administration (21 CFR), Electronic Code of Federal Regulations (eCFR) — Potassium sorbate is affirmed Generally Recognized As Safe (GRAS) as a chemical preservative when used per good manufacturing practice. [https://www.ecfr.gov/current/title-21/chapter-I/subchapter-B/part-182/subpart-D/section-182.3640]
  - Scientific Opinion on the re-evaluation of sorbic acid (E 200), potassium sorbate (E 202) and calcium sorbate (E 203) as food additives, EFSA Journal (2015) — Re-evaluation (E200/E202/E203) lowered the group ADI to a temporary 3 mg sorbic acid/kg bw/day on reproductive/developmental toxicity data, down from the legacy 25 mg/kg. [https://www.efsa.europa.eu/en/efsajournal/pub/4144]
  - Opinion on the follow-up of the re-evaluation of sorbic acid (E200) and potassium sorbate (E202) as food additives, EFSA Journal (2019) — Follow-up opinion derived a BMDL of 1,110 mg/kg bw/day and set a revised group ADI of 11 mg sorbic acid/kg bw/day for E200 and E202. [https://www.efsa.europa.eu/en/efsajournal/pub/5625]
  - Opinion on the follow-up of the re-evaluation of sorbic acid (E200) and potassium sorbate (E202) as food additives, EFSA journal. European Food Safety Authority (2019) — Open-access full text of the EFSA 2019 follow-up establishing the 11 mg/kg bw/day group ADI for sorbic acid and potassium sorbate. [https://pmc.ncbi.nlm.nih.gov/articles/PMC7009143/]
  - Toxicity Evaluation of Potassium Sorbate In Vivo with Drosophila Melanogaster, Insects (2024) — In vivo Drosophila study found excessive potassium sorbate reduced lifespan and fecundity, induced midgut apoptosis and ROS accumulation, and altered intestinal stem-cell differentiation via Notch downregulation. [https://pmc.ncbi.nlm.nih.gov/articles/PMC11432522/]
  - Network toxicology and molecular docking elucidate the hepatotoxic and carcinogenic mechanisms of potassium sorbate validated by in vitro assays, Scientific Reports (2025) — Network toxicology and molecular docking analysis, validated by in vitro assays, elucidated potential hepatotoxic and carcinogenic mechanisms of potassium sorbate. [https://www.nature.com/articles/s41598-025-17255-z]
  - Does potassium sorbate induce genotoxic or mutagenic effects in lymphocytes?, Toxicology in vitro : an international journal published in association with BIBRA (2010) — Potassium sorbate was clearly genotoxic to human peripheral blood lymphocytes in 3 of 4 assays (chromosomal aberrations, micronucleus, comet) in a concentration-dependent manner in vitro. [https://pubmed.ncbi.nlm.nih.gov/20036729/]
  - Mutagenicity and DNA-damaging activity caused by decomposed products of potassium sorbate reacting with ascorbic acid in the presence of Fe salt, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association (2002) — Decomposition products of potassium sorbate reacting with ascorbic acid plus Fe salt were mutagenic/DNA-damaging; the individual components were inactive when tested alone. [https://pubmed.ncbi.nlm.nih.gov/12176085/]
  - Genotoxicity and cell transformation studies with sorbates in Syrian hamster embryo fibroblasts, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association (1992) — Re-examination of potassium and sodium sorbate found no relevant genotoxic potential, contributing to the historically reassuring regulatory record. [https://pubmed.ncbi.nlm.nih.gov/1398347/]

---

## Saccharin (E954)
URL: https://nutridex.info/s/saccharin
Category: Sweeteners & Additives
Evidence: Moderate — Several controlled trials; effects real but modest or context-dependent.
The original artificial sweetener — once feared, now cleared

Quick answer: Saccharin is used for zero-calorie, intense sweetness (~300-400x sucrose) at tiny doses. NutriDex grades the human evidence as moderate — Several controlled trials; effects real but modest or context-dependent. Based on 13 cited human studies (13 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Saccharin (E954) is the oldest synthetic non-nutritive sweetener, roughly 300-400 times sweeter than sucrose, sold to consumers as Sweet'N Low and used in diet beverages, tabletop packets, baked goods and pharmaceuticals. After 1970s rat studies linked very high doses to bladder tumors, the U.S. required a warning label, but the mechanism was later shown to be specific to rat urinary physiology and not relevant to humans; the U.S. NTP delisted saccharin in 2000 and IARC classifies it as Group 3 (not classifiable). The weight of human evidence — epidemiology plus a 2024 EFSA re-evaluation — is reassuring on cancer and genotoxicity at normal intakes, and WHO/EFSA/FDA all consider it safe within the ADI; debate persists mainly around modest gut-microbiome and glycemic signals.

Benefits / uses: Zero-calorie, intense sweetness (~300-400x sucrose) at tiny doses; No glycemic or insulin response — suitable as a sugar substitute for people with diabetes; Heat-stable and very long shelf life, so usable in baking and cooking unlike some sweeteners; Non-cariogenic (does not feed oral bacteria / cause tooth decay); Often blended with other sweeteners (e.g. aspartame, cyclamate) to mask its slight metallic/bitter aftertaste.
Active compounds: E-number: E954 (saccharin and its sodium, potassium and calcium salts); Brand names: Sweet'N Low, Sweet Twin, Necta Sweet; Found in: diet/zero soft drinks, tabletop sweetener packets, sugar-free candies, baked goods, jams, chewing gum; Pharmaceutical use: sweetening agent in toothpaste, mouthwash, chewable tablets and liquid medicines.
Dose: EFSA (2024 re-evaluation) set a group ADI of 9 mg/kg body weight/day for saccharin and its salts, replacing the older Scientific Committee on Food value (5 mg/kg as sodium salt). JECFA's ADI is 5 mg/kg bw/day. In the U.S., FDA permits saccharin as a food additive; it is no longer classified as a carcinogen and the mandatory warning label was repealed in 2000. EFSA notes estimated exposure is below the ADI across all population groups.
Safety: The historical bladder-cancer concern came from high-dose (>=3% of diet) studies in rats, where tumors arise via a rat-specific mechanism (urinary pH, osmolality and silicate microcrystal formation damaging the urothelium) that does not occur in humans. Human epidemiology has found no clear association with bladder cancer, leading the U.S. NTP to delist saccharin (2000) and IARC to assign Group 3 (not classifiable as to carcinogenicity). EFSA's 2024 review concluded saccharin does not cause DNA damage and that consumption is unlikely to be associated with cancer. Residual debate centers on metabolic signals: the Suez 2014 Nature study reported saccharin-driven glucose intolerance via gut-microbiota changes in mice and a small human subset, though a later controlled human/mouse study (Serrano 2021) found no such effect at supraphysiologic doses — so this signal remains unresolved. WHO (2023) advises against using non-sugar sweeteners for weight control, as they confer no long-term benefit for body-fat reduction (a recommendation that does not apply to people with pre-existing diabetes). No specific subgroup is required to avoid saccharin at normal intakes.

Cited studies (13):
  - WHO advises not to use non-sugar sweeteners for weight control in newly released guideline, World Health Organization (2023) — Conditional recommendation against use of non-sugar sweeteners (including saccharin) for weight control; systematic review found no long-term benefit for body fat in adults or children. [https://www.who.int/news/item/15-05-2023-who-advises-not-to-use-non-sugar-sweeteners-for-weight-control-in-newly-released-guideline]
  - Is there a promoting role for artificial sweeteners in the evolution of bladder cancer? A meta-analysis of current literature, Minerva surgery (2024) — Meta-analysis found no risk difference for bladder cancer between artificial sweetener users and controls (RD 0.00, 95% CI -0.06 to 0.06; OR 0.96, 95% CI 0.79-1.17), concluding saccharin should not be regarded as a promoter of urothelial malignant transformation. [https://pubmed.ncbi.nlm.nih.gov/37987752/]
  - The Effect of Non-Nutritive Sweetened Beverages on Postprandial Glycemic and Endocrine Responses: A Systematic Review and Network Meta-Analysis, Nutrients (2023) — Systematic review and network meta-analysis (36 trials, 472 participants) found beverages sweetened with single or blended non-nutritive sweeteners had no meaningful effects on postprandial glucose, insulin, or gut hormone responses. [https://pmc.ncbi.nlm.nih.gov/articles/PMC9965414/]
  - The association of artificial sweeteners intake and risk of cancer: an umbrella meta-analysis, Frontiers in medicine (2025) — Umbrella meta-analysis of artificial sweetener intake and cancer risk synthesizes pooled estimates across multiple sweeteners, including saccharin, evaluating overall and site-specific cancer associations. [https://pmc.ncbi.nlm.nih.gov/articles/PMC12450865/]
  - Re-evaluation of saccharin and its sodium, potassium and calcium salts (E 954) as food additives, EFSA Journal (2024) — Re-evaluation concluded saccharin and its salts do not cause DNA damage and are unlikely to be associated with cancer; set a group ADI of 9 mg/kg bw/day, with exposure below the ADI in all population groups. [https://efsa.onlinelibrary.wiley.com/doi/10.2903/j.efsa.2024.9044]
  - Use of non, World Health Organization — WHO conditionally recommends against using non-sugar sweeteners (including saccharin) for weight control, citing no long-term body-fat benefit and possible increased risk of type 2 diabetes, cardiovascular disease, and mortality. [https://www.who.int/publications/i/item/9789240073616]
  - Personalized microbiome-driven effects of non-nutritive sweeteners on human glucose tolerance, Cell (2022) — In a randomized controlled trial of 120 healthy adults given sub-ADI sweeteners for 2 weeks, saccharin and sucralose significantly impaired glucose tolerance and altered the stool and oral microbiome and plasma metabolome, in a personalized microbiome-dependent manner. [https://pubmed.ncbi.nlm.nih.gov/35987213/]
  - Substances Delisted from the Report on Carcinogens (2021) — Saccharin delisted because rodent bladder-tumor data do not meet listing criteria (rat-specific mechanism) and human data show no carcinogenic hazard. [https://www.ncbi.nlm.nih.gov/books/n/ntproc15/appendix_b/]
  - Artificial Sweeteners and Cancer, U.S. National Cancer Institute (1990) — Reviews multiple epidemiologic studies finding no consistent association between saccharin and bladder or other cancers in humans. [https://www.cancer.gov/about-cancer/causes-prevention/risk/diet/artificial-sweeteners-fact-sheet]
  - Impacts of non-nutritive sweeteners on the human microbiome, Immunometabolism (Cobham, Surrey) (2025) — Review of non-nutritive sweetener effects on the human microbiome summarizes evidence that saccharin and sucralose can alter gut microbial composition and glycemic responses, while aspartame and stevia appear more neutral. [https://pmc.ncbi.nlm.nih.gov/articles/PMC12020452/]
  - High-dose saccharin supplementation does not induce gut microbiota changes or glucose intolerance in healthy humans and mice, Microbiome (2021) — High-dose saccharin supplementation did not induce gut-microbiota changes or glucose intolerance in healthy humans or mice, contrasting with earlier reports. [https://pmc.ncbi.nlm.nih.gov/articles/PMC7802287/]
  - Artificial sweeteners induce glucose intolerance by altering the gut microbiota, Nature (2014) — Saccharin (and other NAS) induced glucose intolerance in mice via gut-microbiota alteration, transferable by fecal transplant, with a similar response in a small subset of healthy humans. [https://www.nature.com/articles/nature13793]
  - Saccharin and its salts (IARC Summaries & Evaluations, Volume 73, p. 517), International Agency for Research on Cancer (IARC) (1999) — Saccharin and its salts evaluated as Group 3 — not classifiable as to carcinogenicity to humans; bladder tumors in rats judged not relevant to humans. [https://www.inchem.org/documents/iarc/vol73/73-19.html]

---

## Sulfites (E220-228)
URL: https://nutridex.info/s/sulfites
Category: Sweeteners & Additives
Evidence: Moderate — Several controlled trials; effects real but modest or context-dependent.
Sulfur-based preservatives that stop browning and spoilage — but trigger asthma in a sensitive minority

Quick answer: Sulfites is used for prevents enzymatic and non-enzymatic browning (e.g. keeps dried apricots, shrimp and cut potatoes light-colored). NutriDex grades the human evidence as moderate — Several controlled trials; effects real but modest or context-dependent. Based on 8 cited human studies (8 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Sulfites (sulfur dioxide and its salts, E220-E228) are antioxidant/antimicrobial preservatives used in wine, dried fruit, processed potatoes, fruit juices and many other foods, releasing SO2 to inhibit browning, oxidation and microbial spoilage. They are permitted in the US (where they remain GRAS for most uses but are banned on raw fruits and vegetables) and the EU. For the general population the human evidence is broadly reassuring at typical intakes, and the principal, well-documented health concern is dose-related asthmatic/hypersensitivity reactions in a sensitive minority (~3-5% of asthmatics); EFSA in 2022 withdrew the prior ADI because the toxicology database (including a neurotoxicity signal in animals) was judged inadequate, flagging a possible safety concern for high consumers.

Benefits / uses: Prevents enzymatic and non-enzymatic browning (e.g. keeps dried apricots, shrimp and cut potatoes light-colored); Antimicrobial preservative — inhibits bacteria, yeasts and molds, central to winemaking and juice stability; Antioxidant — scavenges oxygen and stabilizes color, flavor and ascorbic acid in foods and beverages; Extends shelf life of dried fruits, vegetables and fruit-based products; Used as a processing aid and bleaching/dough-conditioning agent in some starches and baked goods.
Active compounds: E-numbers: sulfur dioxide (E220), sodium sulfite (E221), sodium bisulfite (E222), sodium metabisulfite (E223), potassium metabisulfite (E224), calcium sulfite (E226), calcium bisulfite (E227), potassium bisulfite (E228); Wine and beer (added or fermentation-derived; wine labels carry 'contains sulfites' above 10 ppm); Dried fruit (apricots, raisins, mango), dried vegetables, glace/candied fruit; Processed/frozen potato products (fries, dehydrated potatoes), shrimp/seafood (anti-melanosis), fruit juices, cider, vinegar, pickled foods, some condiments and starches.
Dose: JECFA and the prior EFSA assessment set a group Acceptable Daily Intake of 0-0.7 mg SO2-equivalents/kg body weight/day (derived from a rat NOAEL of ~70 mg SO2-eq/kg/day with a 100x uncertainty factor). EFSA's 2016 re-evaluation made this ADI temporary, and in 2022 EFSA withdrew it because adequate toxicity data were lacking, instead using a margin-of-exposure approach and finding a possible safety concern for high consumers. In the US sulfites are GRAS for most uses but FDA prohibits them on fruits and vegetables intended to be served or sold raw (since 1986) and requires label declaration when total SO2 is >=10 ppm.
Safety: The best-established harm is dose-dependent sulfite sensitivity, mainly bronchoconstriction in asthmatics (roughly 3-5% of asthmatics, more in steroid-dependent patients), and less commonly urticaria, angioedema or anaphylaxis; this is a non-IgE pharmacological/irritant reaction, not classic allergy. Severe and occasionally fatal asthma reactions to sulfite-treated fresh produce led the FDA to ban sulfites on raw fruits and vegetables in 1986 and mandate labeling at >=10 ppm. People with asthma (especially sulfite-sensitive) should avoid them; rare individuals with molybdenum-cofactor/sulfite-oxidase deficiency are especially vulnerable. Sulfites also chemically cleave and destroy thiamine (vitamin B1), so they are not permitted in foods regarded as major thiamine sources. For the general population, intake at usual levels is not associated with clear systemic toxicity, but EFSA's 2022 review flagged unresolved data gaps including a neurotoxicity signal in animal studies, prompting withdrawal of the ADI rather than a finding of proven harm.

Cited studies (8):
  - Follow-up of the re-evaluation of sulfur dioxide (E 220), sodium sulfite (E 221), sodium bisulfite (E 222), sodium metabisulfite (E 223), potassium metabisulfite (E 224), calcium sulfite (E 226), calcium bisulfite (E 227) and potassium bisulfite (E 228), EFSA journal. European Food Safety Authority (2022) — Follow-up withdrew the ADI because data gaps (including a neurotoxicity signal in animals) could not be resolved; margin-of-exposure analysis indicated a possible safety concern for high consumers. [https://pmc.ncbi.nlm.nih.gov/articles/PMC9685353/]
  - Scientific Opinion on the re-evaluation of sulfur dioxide (E 220), sodium sulfite (E 221), sodium bisulfite (E 222), sodium metabisulfite (E 223), potassium metabisulfite (E 224), calcium sulfite (E 226), calcium bisulfite (E 227) and potassium bisulfite (E 228) as food additives, EFSA Journal (2016) — Re-evaluation set a temporary group ADI of 0.7 mg SO2-equivalents/kg bw/day (NOAEL 70 mg/kg/day in rats) and judged the toxicity database inadequate for a permanent ADI. [https://www.efsa.europa.eu/en/efsajournal/pub/4438]
  - Sulfur dioxide and sulfites (addendum) — Safety evaluation of certain food additives, WHO Food Additives Series 42, Joint FAO/WHO Expert Committee on Food Additives (JECFA), World Health Organization (1999) — Retained a group ADI of 0-0.7 mg/kg bw expressed as SO2, based on a NOEL of ~70 mg SO2-eq/kg/day from long-term and reproductive rat studies. [https://www.inchem.org/documents/jecfa/jecmono/v042je06.htm]
  - Sulfites - USA, Food Allergy Research & Resource Program (FARRP), University of Nebraska-Lincoln — FDA prohibited sulfites on fruits and vegetables intended to be served or sold raw and required declaration of added sulfites at >=10 ppm total SO2, citing severe asthmatic reactions. [https://farrp.unl.edu/farrp-resources/regulatory/sulfites-usa/]
  - Adverse reactions to the sulphite additives, Gastroenterology and hepatology from bed to bench (2012) — Summarized adverse reactions to sulphite additives, estimating sulfite sensitivity in a minority of asthmatics and noting non-IgE mechanisms. [https://pmc.ncbi.nlm.nih.gov/articles/PMC4017440/]
  - Immunoglobulin G4: an odd antibody, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology (2009) — Reviewed clinical effects of sulphite additives, characterizing dose-related bronchoconstriction in sulfite-sensitive asthmatics and rarer urticaria/anaphylaxis as the principal documented adverse reactions. [https://pubmed.ncbi.nlm.nih.gov/19222496/]
  - Prevalence of sensitivity to sulfiting agents in asthmatic patients, The American journal of medicine (1986) — Oral metabisulfite challenge found sensitivity in about 5% of asthmatic patients, with higher rates among steroid-dependent asthmatics. [https://pubmed.ncbi.nlm.nih.gov/3535492/]
  - Kinetics of thiamin cleavage by sulphite, The Biochemical journal (1969) — Demonstrated that sulfite cleaves thiamine (vitamin B1) at its methylene bridge, inactivating it — the basis for prohibiting sulfites in major dietary thiamine sources. [https://pmc.ncbi.nlm.nih.gov/articles/PMC1184740/]

---

## BHA & BHT (E320 / E321)
URL: https://nutridex.info/s/bha-bht
Category: Sweeteners & Additives
Evidence: Mixed — Conflicting results across studies; benefit uncertain.
Synthetic phenolic antioxidants that keep fats from going rancid

Quick answer: BHA & BHT is used for potent lipid antioxidant: interrupts free-radical chain oxidation of unsaturated fats, preventing rancidity and off-flavors. NutriDex grades the human evidence as mixed — Conflicting results across studies; benefit uncertain. Based on 8 cited human studies (8 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

BHA (E320, butylated hydroxyanisole) and BHT (E321, butylated hydroxytoluene) are synthetic phenolic antioxidants added to fat-containing foods to prevent oxidative rancidity. Both are approved across major jurisdictions: FDA treats them as GRAS / approved food additives and EFSA re-evaluated both (2011/2012), setting acceptable daily intakes and concluding neither is genotoxic at use levels. The principal controversy is carcinogenicity: high-dose dietary BHA causes forestomach tumors in rodents, leading IARC to classify it Group 2B (possibly carcinogenic) and NTP to list it as "reasonably anticipated to be a human carcinogen," though the rodent forestomach mechanism is widely judged not relevant to humans (who lack a forestomach). BHT is IARC Group 3 (not classifiable), with mixed animal data. Human evidence of harm at dietary exposures is essentially absent, but in 2026 the FDA opened a formal reassessment of BHA.

Benefits / uses: Potent lipid antioxidant: interrupts free-radical chain oxidation of unsaturated fats, preventing rancidity and off-flavors; Extends shelf life of fats, oils, and fat-containing dry/processed foods; Heat-stable, so it survives frying, baking, and high-temperature processing (carry-through antioxidant); Protects fat-soluble vitamins (A, E) and color/aroma compounds from oxidative degradation; Often used at very low concentrations (typically <=200 ppm of fat), frequently combined with each other or with TBHQ/gallates for synergy; Also used in food packaging, animal feed, cosmetics, and pharmaceuticals as a stabilizer.
Active compounds: BHA = E320 / INS 320 (CAS 25013-16-5); BHT = E321 / INS 321 (CAS 128-37-0); Found in: vegetable oils and shortening, butter/margarine, breakfast cereals, snack foods, chips and crackers, nuts, chewing gum, dehydrated potatoes, cured/processed meats, instant mashed potatoes, baked goods, and candy; Common on labels as 'BHA', 'BHT', 'butylated hydroxyanisole', or 'butylated hydroxytoluene', often 'to preserve freshness' or 'added to protect flavor'; Also widely used outside food: cereal/snack packaging liners, animal feed, cosmetics and personal-care products, and as a stabilizer in some medicines and supplements.
Dose: FDA: GRAS / approved food additives (BHA affirmed GRAS 1958, approved as additive 1961; both limited under 21 CFR, typically to ~0.02% of fat/oil content). EFSA acceptable daily intakes: BHA 1.0 mg/kg body weight/day (2011 re-evaluation); BHT 0.25 mg/kg bw/day (2012 re-evaluation). JECFA: BHA group ADI 0-0.5 mg/kg bw/day; BHT ADI 0-0.3 mg/kg bw/day. California Proposition 65 has listed BHA as a chemical "known to cause cancer" since 1990 (BHT is not listed). In February 2026 the FDA opened a formal request-for-information reassessment of BHA, with BHT and azodicarbonamide flagged for subsequent review.
Safety: At dietary exposures (which are typically far below the ADIs), neither BHA nor BHT is genotoxic, and EFSA concluded any carcinogenic potential would be thresholded and not of concern at the ADI. The strongest documented harm is in rodents fed very high doses: BHA induces benign and malignant forestomach tumors (papillomas/squamous-cell carcinomas) in rats, mice, and hamsters — the basis for IARC Group 2B and NTP's "reasonably anticipated to be a human carcinogen" listing. An IARC workshop and most toxicologists judge this forestomach mechanism (local irritation/hyperplasia in a non-glandular stomach compartment humans do not possess) to have limited relevance to human dietary exposure. BHT shows mixed/inconsistent animal data (variously acting as tumor promoter, inhibitor, or neither; high doses linked to liver and lung effects and hemorrhagic effects in susceptible species), and IARC places it in Group 3. There is no robust human evidence of cancer or other harm at food-relevant intakes; large-cohort biomonitoring of food-additive mixtures (e.g., NutriNet-Sante) is ongoing. Some individuals report contact/allergic skin reactions. People wanting to minimize exposure can choose products labeled BHA/BHT-free, but the population-level risk from dietary use is considered low.

Cited studies (8):
  - FDA Launches Assessment of BHA, a Common Food Chemical Preservative, U.S. Food and Drug Administration — FDA launched a formal assessment/request for information on the food additive BHA, signaling potential reconsideration of its regulatory status. [https://www.fda.gov/news-events/press-announcements/fda-launches-assessment-bha-common-food-chemical-preservative]
  - Butylated Hydroxyanisole (2021) — BHA listed as 'reasonably anticipated to be a human carcinogen' based on sufficient evidence of carcinogenicity (forestomach tumors) in experimental animals. [https://www.ncbi.nlm.nih.gov/books/NBK590883/]
  - Scientific Opinion on the re-evaluation of butylated hydroxyanisole - BHA (E 320) as a food additive, EFSA Journal (2011) — Re-evaluation of BHA (E320): not genotoxic; ADI revised to 1.0 mg/kg bw/day based on forestomach proliferative changes at high doses, judged thresholded. [https://efsa.onlinelibrary.wiley.com/doi/abs/10.2903/j.efsa.2011.2392]
  - Scientific Opinion on the re-evaluation of butylated hydroxytoluene BHT (E 321) as a food additive, EFSA Journal (2012) — Re-evaluation of BHT (E321): not of concern for genotoxicity; ADI set at 0.25 mg/kg bw/day, any carcinogenicity considered thresholded. [https://efsa.onlinelibrary.wiley.com/doi/10.2903/j.efsa.2012.2588]
  - Butylated hydroxyanisole: Carcinogenic food additive to be avoided or harmless antioxidant important to protect food supply?, Regulatory toxicology and pharmacology : RTP (2021) — Critical review concludes the rodent forestomach mechanism for BHA carcinogenicity has limited human relevance and BHA is non-genotoxic at food-use levels. [https://pubmed.ncbi.nlm.nih.gov/33556417/]
  - Butylated Hydroxyanisole (BHA) (IARC Summaries & Evaluations, Volume 40, p. 123), International Agency for Research on Cancer (IARC) (1986) — BHA classified Group 2B (possibly carcinogenic to humans) based on sufficient evidence of forestomach carcinogenicity in rodents; BHA is not genotoxic in bacterial/mammalian assays. [https://www.inchem.org/documents/iarc/vol40/butylatedhydroxyanisole.html]
  - Butylated Hydroxytoluene (BHT) (IARC Summary & Evaluation, Volume 40), International Agency for Research on Cancer (IARC) (1986) — BHT classified Group 3 (not classifiable as to carcinogenicity to humans); inadequate human data and limited/conflicting animal evidence. [https://www.inchem.org/documents/iarc/vol40/butylatedhydroxytoluene.html]
  - Butylated hydroxyanisole, WHO Food Additives Series 21 (Joint FAO/WHO Expert Committee on Food Additives) — JECFA reviewed BHA forestomach carcinogenicity, maintaining a group ADI pending assessment of human relevance of rodent forestomach hyperplasia/tumors. [https://www.inchem.org/documents/jecfa/jecmono/v21je02.htm]

---

## Caramel Color (4-MEI) (E150d)
URL: https://nutridex.info/s/caramel-color
Category: Sweeteners & Additives
Evidence: Moderate — Several controlled trials; effects real but modest or context-dependent.
The browning agent in cola, soy sauce and beer — safe as a colour, dogged by a trace by-product

Quick answer: Caramel Color (4-MEI) is used for imparts brown to amber color and visual consistency to foods and beverages (cola, beer, soy sauce, gravies, baked goods, vinegars). NutriDex grades the human evidence as moderate — Several controlled trials; effects real but modest or context-dependent. Based on 9 cited human studies (9 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Caramel color is the most widely used food colorant in the world, made by controlled heating of carbohydrates and classified into four types (E150a-d); ammonia/ammonium-sulfite processes (Class III E150c and Class IV E150d) generate a trace by-product, 4-methylimidazole (4-MEI), during manufacture. The caramel colour itself is well-studied and considered safe: EFSA (2011) and JECFA set a group ADI of 300 mg/kg bw/day, and the additive is GRAS in the US. The principal health question concerns 4-MEI, which IARC classifies Group 2B ("possibly carcinogenic to humans") based on lung tumors in mice; however no human evidence of harm exists, and regulators including FDA and EFSA judge real-world exposure to pose no immediate risk at the trace levels found in foods.

Benefits / uses: Imparts brown to amber color and visual consistency to foods and beverages (cola, beer, soy sauce, gravies, baked goods, vinegars); Heat- and light-stable, acid-stable and microbiologically stable colorant suitable for low-pH carbonated drinks; Class IV (E150d) is specifically formulated to stay soluble and stable in acidic soft drinks; Contributes negligible calories and no sweetness; used purely for appearance, not flavor or preservation; World's most-used food colorant by volume, valued for low cost and reliable shade-matching.
Active compounds: E-numbers: E150a (plain/Class I), E150b (caustic-sulfite/Class II), E150c (ammonia/Class III), E150d (ammonium-sulfite/Class IV); 4-MEI by-product is generated chiefly in the ammoniated Class III (E150c) and Class IV (E150d) processes; Found in colas and other dark soft drinks, beer and dark spirits, soy and Worcestershire sauce, balsamic vinegar, gravies, dark breads, confectionery and some pet foods; Class IV (E150d) dominates the soft-drink market; Class I (E150a) contains essentially no 4-MEI or THI.
Dose: EFSA (2011) and JECFA set a group ADI of 300 mg/kg bw/day for caramel colours E150a, c, d (derived from a NOAEL of 30 g/kg/day with a 100x uncertainty factor); E150c (E150b group) carries a lower ADI of 100 mg/kg bw/day due to immune-effect uncertainty from its THI constituent. Caramel color is GRAS / approved in the US (21 CFR 73.85). 4-MEI itself has no federal limit, but California Proposition 65 sets a No Significant Risk Level of 29 micrograms/day (1-in-100,000 lifetime cancer risk), triggering warning labels above that threshold.
Safety: The caramel colour additive is considered safe at the ADI; the debate is confined to the trace by-product 4-MEI in Class III/IV caramels. NTP 2-year bioassays found "clear evidence" of lung (alveolar/bronchiolar) tumors in male and female B6C3F1 mice but not in rats; 4-MEI was negative in standard genotoxicity tests (Ames, micronucleus), suggesting a non-genotoxic, high-dose mechanism. On this basis IARC classified 4-MEI Group 2B (possibly carcinogenic) in 2011/2012. There is no human evidence of cancer from caramel color or 4-MEI. FDA states a person would need to drink over a thousand cans of soda a day to approach the rodent tumor doses and does not advise dietary change. Consumer Reports (2014) found some sodas (notably Pepsi One and Malta Goya) exceeded California's 29 microgram/day level per serving, and a Johns Hopkins quantitative risk assessment (Smith 2015) estimated a small avoidable excess cancer burden from high-4-MEI drinks, prompting industry reformulation to lower-4-MEI caramels. EFSA noted dietary exposure to E150a/c/d may exceed the ADI in high consumers (especially children), driven by the colour mass rather than 4-MEI. No specific intolerance population is established; people wishing to minimize 4-MEI can choose plain (E150a) products or beverages without ammonia-process caramel.

Cited studies (9):
  - 4-Methylimidazole, a carcinogenic component in food, amount, methods used for measurement; a systematic review, Food chemistry: X (2023) — Systematic review (144 articles screened, 15 extracted) found the highest 4-MEI levels in caramel color, coffee, and cola drinks, identifying coffee as a leading exposure source by per-capita consumption. [https://pubmed.ncbi.nlm.nih.gov/37397204/]
  - Genotoxicity assessment of 4-methylimidazole: regulatory perspectives, Genes and environment : the official journal of the Japanese Environmental Mutagen Society (2016) — Weight-of-evidence review found 4-MEI consistently negative in Ames and in vivo micronucleus assays, supporting a non-genotoxic mode of action for the mouse lung tumors. [https://pmc.ncbi.nlm.nih.gov/articles/PMC5088675/]
  - Scientific Opinion on the re-evaluation of caramel colours (E 150 a,b,c,d) as food additives, EFSA Journal (2011) — Re-evaluation established a group ADI of 300 mg/kg bw/day for E150a/c/d (100 mg/kg for E150b group); concluded 4-MEI levels were not of concern but that total colour exposure may exceed the ADI in children and adults. [https://www.efsa.europa.eu/en/efsajournal/pub/2004]
  - Questions & Answers About 4, U.S. Food and Drug Administration — FDA found no reason to believe 4-MEI poses immediate or short-term danger at levels in food and did not recommend consumers change their diets, while continuing to review exposure data. [https://www.fda.gov/food/food-additives-petitions/questions-answers-about-4-mei]
  - Proposition 65, California Office of Environmental Health Hazard Assessment (OEHHA) (2025) — Set a No Significant Risk Level for 4-MEI of 29 micrograms/day, corresponding to a 1-in-100,000 lifetime cancer risk and triggering warning labels above that exposure. [https://oehha.ca.gov/proposition-65]
  - Toxicological evaluation of 4-methylimidazole: Research advances, health concerns and regulatory perspectives, Toxicology letters (2025) — Comprehensive 2025 toxicological review of 4-MEI reports a toxicokinetic profile of rapid absorption, minimal metabolism, and fast renal elimination (low bioaccumulation), while noting NTP 'clear evidence' of carcinogenicity in mice and the unresolved threshold-vs-genotoxic regulatory divergence. [https://pubmed.ncbi.nlm.nih.gov/41106562/]
  - Caramel color in soft drinks and exposure to 4-methylimidazole: a quantitative risk assessment, PloS one (2015) — Quantitative risk assessment estimated wide variation in soda 4-MEI (Coca-Cola ~76 lifetime US cancer cases vs Malta Goya ~5,011) and judged the excess risk 'avoidable and unnecessary.' [https://pubmed.ncbi.nlm.nih.gov/25693062/]
  - Evaluating consistency in the interpretation of NTP rodent cancer bioassays: an examination of mouse lung tumor effects in the 4-MEI study, Regulatory toxicology and pharmacology : RTP (2013) — 2-year rodent bioassay found clear evidence of carcinogenic activity (lung alveolar/bronchiolar neoplasms) in male and female B6C3F1 mice, with no carcinogenic activity in F344 rats. [https://pubmed.ncbi.nlm.nih.gov/23545072/]
  - 4-METHYLIMIDAZOLE (2013) — Classified 4-methylimidazole as Group 2B, 'possibly carcinogenic to humans,' based on sufficient animal evidence (mouse lung tumors) and inadequate human evidence. [https://www.ncbi.nlm.nih.gov/books/NBK373183/]

---

## Maltitol (E965 · sugar alcohol)
URL: https://nutridex.info/s/maltitol
Category: Sweeteners & Additives
Evidence: Moderate — Several controlled trials; effects real but modest or context-dependent.
Sugar-replacing polyol with half the calories and a notable laxative ceiling

Quick answer: Maltitol is used for reduced-calorie sweetness: ~2.1-2.4 kcal/g versus 4 kcal/g for sucrose, at ~90% of sucrose sweetness, with sugar-like bulk and mouthfeel. NutriDex grades the human evidence as moderate — Several controlled trials; effects real but modest or context-dependent. Based on 8 cited human studies (8 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Maltitol (E965) is a sugar alcohol (polyol) made by hydrogenating maltose from starch, used as a bulk sweetener with about 90% of sucrose's sweetness and roughly half the calories (~2.1-2.4 kcal/g). It is authorised in the EU (E965), holds US FDA GRAS status, and JECFA assigned it an Acceptable Daily Intake of "not specified" — the safest regulatory category, implying no numeric intake limit. The weight of human evidence is reassuring for metabolic and dental endpoints: maltitol produces lower glycaemic and insulin responses than sucrose and is non-cariogenic. Its best-documented adverse effect is dose-dependent gastrointestinal intolerance (bloating, flatulence, osmotic/laxative diarrhoea), which is why EU products containing >10% polyols must carry a laxative-effect warning.

Benefits / uses: Reduced-calorie sweetness: ~2.1-2.4 kcal/g versus 4 kcal/g for sucrose, at ~90% of sucrose sweetness, with sugar-like bulk and mouthfeel; Lower glycaemic impact: glycaemic index ~35 (about half that of sucrose), useful in reduced-sugar and diabetic-friendly formulations; Lower insulin response: insulinaemic response measured at ~17.8% of that of glucose in a clinical study; Non-cariogenic: not readily fermented to enamel-demineralising acids by oral bacteria; qualifies for the US FDA noncariogenic-sweetener dental health claim; Functional bulking and texture: provides body, sweetness and heat/crystallisation behaviour close to sugar in chocolate, baked goods and chewing gum; Sugar-free, low-moisture sweetening that resists browning and helps shelf-stability in confectionery.
Active compounds: E-number E965 (E965 i = maltitol; E965 ii = maltitol syrup / hydrogenated glucose syrup); Common in sugar-free chocolate, hard and chewy candies, chewing gum, baked goods, ice cream, jams, cough syrups and gummy supplements; Brand/trade names include Maltisorb and Maltisweet (maltitol) and Lycasin (maltitol-rich hydrogenated glucose syrup); Often blended with high-intensity sweeteners (e.g. sucralose, stevia) and other polyols (sorbitol, erythritol) to balance sweetness and cost; Derived from starch (maltose) via catalytic hydrogenation; not a high-intensity sweetener but a bulk sugar replacer.
Dose: JECFA assigned an Acceptable Daily Intake of "not specified" (its safest category, indicating no numeric limit needed at normal use levels). It is authorised in the EU as E965 with no numeric ADI, and is GRAS in the United States. Practical individual tolerance, not toxicity, is the limiting factor: many adults tolerate roughly 40 g/day, while single doses around 30-50 g or higher commonly trigger laxative effects in sensitive people; an RCT placed the mean diarrhoea threshold dose near 92-93 g. EU regulation requires foods containing >10% added polyols to state "excessive consumption may produce laxative effects."
Safety: The dominant, well-documented risk is gastrointestinal: because maltitol is only partially absorbed in the small intestine, the remainder is osmotically active and fermented in the colon, causing dose-dependent bloating, flatulence, cramps and osmotic diarrhoea. A digestive-tolerance RCT (PMID 12548293) found a mean diarrhoea threshold dose of ~92-93 g, but sensitive individuals and people with IBS can react to far less (10-20 g), and maltitol produced more diarrhoea than equivalent sucrose at high intakes. Unlike sugar, it has a meaningful glycaemic load (GI ~35), so people with diabetes should count it rather than treat it as "free." On carcinogenicity/genotoxicity the human and animal data are reassuring — animal and in-vitro studies (including a 2024 mutagenicity/genotoxicity assessment) found maltitol non-mutagenic and non-genotoxic — though EFSA issued a 2023 call for additional genotoxicity data as part of routine re-evaluation, so its EU re-evaluation is ongoing. There is no credible evidence linking maltitol to cancer or cardiovascular events. Those who should be cautious: people with IBS, fructose/polyol malabsorption or on low-FODMAP diets, young children (lower tolerance), and anyone consuming large amounts of sugar-free confectionery; dogs should not be given polyol products as a general precaution.

Cited studies (8):
  - Health claims: dietary noncariogenic carbohydrate sweeteners and dental caries, U.S. Code of Federal Regulations (Title 21, Food and Drug Administration) — Maltitol is among the sugar alcohols permitted to bear the US 'does not promote tooth decay' (noncariogenic carbohydrate sweetener) health claim, and maltitol is recognised as GRAS. [https://www.ecfr.gov/current/title-21/chapter-I/subchapter-B/part-101/subpart-E/section-101.80]
  - Call for data on genotoxicity data on maltitol (E 965 i), European Food Safety Authority (2023) — As part of the EU re-evaluation of authorised additives, EFSA issued a public call for additional genotoxicity data on maltitol; no safety concern has been concluded that would alter its authorisation. [https://www.efsa.europa.eu/en/call/call-data-genotoxicity-data-maltitol-e-965-i]
  - Maltitol, Calorie Control Council — Assigned maltitol an Acceptable Daily Intake of 'not specified', its safest category, indicating no numerical intake limit is required at normal food-additive use levels. [https://caloriecontrol.org/maltitol/]
  - Evaluation of glycemic and insulinemic responses of maltitol in Indian healthy volunteers, International Journal of Diabetes in Developing Countries (2015) — Maltitol showed low glycaemic index (~35) and an insulinaemic response of about 17.8% of glucose, markedly below sucrose. [https://link.springer.com/article/10.1007/s13410-015-0321-4]
  - No observable differences in glycemic response to maltitol in human subjects from 3 ethnically diverse groups, Nutrition research (New York, N.Y.) (2011) — Incremental glucose AUC after maltitol did not differ significantly between white, South Indian and Chinese subjects, supporting a consistent low glycaemic response across ethnic groups. [https://pubmed.ncbi.nlm.nih.gov/21481716/]
  - A digestive tolerance study of maltitol after occasional and regular consumption in healthy humans, European journal of clinical nutrition (2003) — In a digestive-tolerance RCT, mean diarrhoea threshold dose was ~92-93 g maltitol vs ~106-113 g sucrose, confirming dose-dependent osmotic/laxative effects at high single doses. [https://pubmed.ncbi.nlm.nih.gov/12548293/]
  - Glycaemic and insulinaemic responses in healthy volunteers upon ingestion of maltitol and hydrogenated glucose syrups, Diabete & metabolisme (1994) — All maltitol-containing products showed reduced glycaemic index versus glucose, though the insulinaemic index of maltitol chocolate remained relatively high, indicating food-matrix effects. [https://pubmed.ncbi.nlm.nih.gov/8001718/]
  - Evaluation of mutagenicity and genotoxicity of food additive maltitol (E 965 i), Regulatory Toxicology and Pharmacology (2026) — Bacterial reverse-mutation (Ames) up to 5000 µg/plate and an in-vitro human-lymphocyte micronucleus test found maltitol non-mutagenic and non-genotoxic under the conditions tested. [https://doi.org/10.1016/j.yrtph.2026.106094]

---

## Phosphoric Acid (E338)
URL: https://nutridex.info/s/phosphoric-acid
Category: Sweeteners & Additives
Evidence: Moderate — Several controlled trials; effects real but modest or context-dependent.
The tangy mineral acid that gives cola its bite

Quick answer: Phosphoric Acid is used for acidulant and ph regulator — lowers ph for tartness and microbial stability. NutriDex grades the human evidence as moderate — Several controlled trials; effects real but modest or context-dependent. Based on 8 cited human studies (8 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Phosphoric acid (E338) is an inorganic mineral acid used as an acidulant, flavor sharpener and pH buffer, most famously the source of cola's tangy taste. It is GRAS in the US (21 CFR 182.1073) and approved in the EU, with regulators treating it as one of a group of phosphate additives. JECFA assigned a group maximum tolerable daily intake (MTDI) of 70 mg/kg body weight as phosphorus, and EFSA's 2019 re-evaluation set a group ADI of 40 mg/kg bw/day as phosphorus. At the additive level itself the human evidence is reassuring, but total phosphate exposure can exceed the ADI in children, and high phosphorus loads carry cardiovascular and bone signals that matter mainly in chronic kidney disease and heavy cola drinkers.

Benefits / uses: Acidulant and pH regulator — lowers pH for tartness and microbial stability; Sharp, tangy flavor note characteristic of cola (distinct from the citric-acid tartness of fruit sodas); Chelating/sequestering agent that ties up trace metals and helps preserve color and flavor; Antioxidant synergist and buffering agent in processed foods; Inexpensive, highly soluble, and thermally stable acidulant.
Active compounds: E-number: E338 (food-grade phosphoric acid; orthophosphoric acid, H3PO4); Colas and dark soft drinks (Coca-Cola, Pepsi) as the defining acidulant; Processed cheese, cured meats, baking powders, and some beers; Acid in jams, jellies and some dairy/non-dairy products; Part of the regulated phosphate group E338-341, E343, E450-452.
Dose: FDA: GRAS, listed in 21 CFR 182.1073 and affirmed for direct food use. JECFA: group MTDI of 70 mg/kg bw/day expressed as phosphorus (an MTDI rather than ADI because phosphorus is an essential nutrient). EFSA 2019: derived a group ADI of 40 mg/kg bw/day expressed as phosphorus for phosphates (E338-341, E343, E450-452); noted total phosphate exposure can exceed this ADI in infants, toddlers, children and adolescents and via supplements.
Safety: At intakes from phosphoric acid as a food additive, regulators find no genotoxicity or carcinogenicity concern; the main issues are tied to total phosphate/phosphorus burden, not the acid molecule per se. Documented and signal-level concerns: (1) Dental erosion — cola's low pH (about 2.5) demineralizes enamel with frequent, prolonged exposure. (2) Bone — observational data (Framingham) link daily cola intake to ~4-5% lower hip BMD in women, though confounding by displacement of milk/calcium is likely and causation is unproven. (3) Cardiovascular/renal — high serum and dietary phosphorus correlate with CVD events, vascular calcification and mortality, with effects most relevant in chronic kidney disease (CKD), where dietary phosphate restriction is standard. People with CKD, those on dialysis, and heavy daily cola drinkers (especially with low calcium intake) are the groups who should limit intake. There is no credible evidence of harm from occasional cola consumption in healthy people with normal kidney function.

Cited studies (8):
  - § 182.1073 Phosphoric acid, U.S. Electronic Code of Federal Regulations (eCFR), Title 21 (FDA) — Phosphoric acid is generally recognized as safe (GRAS) as a direct food substance for use as a multipurpose ingredient. [https://www.ecfr.gov/current/title-21/chapter-I/subchapter-B/part-182/subpart-B/section-182.1073]
  - Re-evaluation of phosphoric acid–phosphates – di-, tri- and polyphosphates (E 338–341, E 343, E 450–452) as food additives and the safety of proposed extension of use, EFSA Journal (2019) — Re-evaluation of phosphoric acid-phosphates (E 338-341, E 343, E 450-452) derived a group ADI of 40 mg/kg bw/day as phosphorus; exposure exceeded the ADI in children and via supplements. [https://efsa.onlinelibrary.wiley.com/doi/10.2903/j.efsa.2019.5674]
  - PHOSPHORIC ACID, Joint FAO/WHO Expert Committee on Food Additives (JECFA) (2005) — Assigned a group MTDI of 70 mg/kg bw/day expressed as phosphorus for phosphates from all sources; an MTDI rather than ADI because phosphorus is an essential nutrient. [https://www.fao.org/fileadmin/user_upload/jecfa_additives/docs/Monograph1/Additive-312.pdf]
  - Dietary phosphorus, serum phosphorus, and cardiovascular disease, Annals of the New York Academy of Sciences (2013) — Higher dietary and serum phosphorus are associated with greater left ventricular mass, vascular calcification and cardiovascular/all-cause mortality, with effects amplified in reduced kidney function. [https://pubmed.ncbi.nlm.nih.gov/24117725/]
  - Relationship of dietary phosphate intake with risk of end-stage renal disease and mortality in chronic kidney disease stages 3-5: The Modification of Diet in Renal Disease Study, Kidney international (2016) — In CKD stages 3-5, higher dietary phosphate intake was associated with increased risk of end-stage renal disease and mortality. [https://pubmed.ncbi.nlm.nih.gov/26422502/]
  - Serum phosphate as a risk factor for cardiovascular events in people with and without chronic kidney disease: a large community based cohort study, PloS one (2013) — Even within the normal range, higher serum phosphorus is associated with cardiovascular events in people with and without CKD in large community cohorts. [https://pmc.ncbi.nlm.nih.gov/articles/PMC3769279/]
  - Colas, but not other carbonated beverages, are associated with low bone mineral density in older women: The Framingham Osteoporosis Study, The American journal of clinical nutrition (2006) — Daily cola intake was associated with 3.7-5.4% lower hip BMD in women (n=1413 women, 1125 men); the association was specific to cola, not other carbonated drinks. [https://pubmed.ncbi.nlm.nih.gov/17023723/]
  - Pop-cola acids and tooth erosion: an in vitro, in vivo, electron-microscopic, and clinical report, International journal of dentistry (2010) — In vitro, in vivo and electron-microscopic study confirming cola's low pH and acid content (including phosphoric acid) cause measurable dental enamel erosion with chronic exposure. [https://pmc.ncbi.nlm.nih.gov/articles/PMC2997506/]

---

## Erythritol (E968 · sugar alcohol)
URL: https://nutridex.info/s/erythritol
Category: Sweeteners & Additives
Evidence: Mixed — Conflicting results across studies; benefit uncertain.
Zero-calorie sugar alcohol under fresh cardiovascular scrutiny

Quick answer: Erythritol is used for zero/near-zero calorie sweetness (0-0.2 kcal/g, ~60-70% as sweet as sugar). NutriDex grades the human evidence as mixed — Conflicting results across studies; benefit uncertain. Based on 11 cited human studies (11 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Erythritol (E968) is a four-carbon sugar alcohol (polyol) used as a bulk, zero-calorie sweetener with about 60-70% the sweetness of sucrose. It is FDA GRAS (since 2001) and was given a JECFA ADI of "not specified" (2000); in a 2023 re-evaluation EFSA set an ADI of 0.5 g/kg body weight/day based solely on its laxative threshold. Unlike most polyols it is ~90% absorbed in the small intestine, not metabolized, and excreted unchanged in urine, giving it minimal glycemic, insulin, and GI impact at moderate doses. The weight of human evidence is reassuring for short-term metabolic safety but is now mixed because recent observational and mechanistic studies (Witkowski 2023-2024) link elevated circulating erythritol and acute ingestion to enhanced platelet reactivity and incident cardiovascular events — an unconfirmed signal under active study, complicated by the fact that erythritol is also produced endogenously.

Benefits / uses: Zero/near-zero calorie sweetness (0-0.2 kcal/g, ~60-70% as sweet as sugar); No meaningful glycemic or insulin impact (glycemic index ~0) — suitable for diabetics and keto/low-carb diets; ~90% absorbed in small intestine and excreted unchanged, so far better GI tolerance than other polyols (sorbitol, maltitol); Non-cariogenic — not fermented by oral bacteria, does not promote tooth decay; Bulking agent that provides sugar-like texture and mouthfeel in baked goods, beverages, and tabletop blends; Often blended with high-intensity sweeteners (stevia, monk fruit) to mask aftertaste and add volume.
Active compounds: E-number E968 (EU); INS 968; Found in 'keto'/'sugar-free' products: tabletop sweeteners (Truvia, Swerve, Whole Earth, Splenda Naturals blends), sugar-free chocolate, gum, baked goods, protein bars, and reduced-calorie beverages; Frequently combined with stevia or monk fruit extract; Also occurs naturally in fruits (grapes, melons, pears) and fermented foods (wine, soy sauce, cheese), and is produced endogenously in the body via the pentose phosphate pathway.
Dose: FDA: Generally Recognized As Safe (GRAS) since 2001, no numeric limit. JECFA (2000): ADI "not specified" (the safest category). EFSA (2023 re-evaluation): established a numeric ADI of 0.5 g/kg body weight/day, derived from the human NOAEL for diarrhea — EFSA noted that high consumers, especially children and adolescents, can exceed this. EU labelling: products require "excessive consumption may produce laxative effects."
Safety: Documented harm is primarily GI: doses above roughly 0.5 g/kg (or ~50 g acutely) can cause bloating, gas, and diarrhea, though erythritol is far better tolerated than other sugar alcohols because most is absorbed rather than fermented. The notable emerging signal is cardiovascular: Witkowski et al. (Nature Medicine 2023) found that higher fasting plasma erythritol independently predicted 3-year major adverse cardiovascular events across three cohorts (>4,000 patients; adjusted HR ~1.8-2.2, top vs bottom quartile) and showed in vitro and in a small human ingestion study (30 g, n=10) that erythritol enhances platelet aggregation and clot formation. These findings are associational/mechanistic, not from randomized outcome trials; high plasma levels may partly reflect endogenous production in people who already have cardiometabolic disease (reverse causation/confounding), and the FDA and industry have noted these limitations. No carcinogenicity or genotoxicity signal exists. People with a history of clotting events or significant cardiovascular disease may reasonably wish to limit intake pending confirmatory trials; those prone to GI symptoms should moderate dose.

Cited studies (11):
  - Re-evaluation of erythritol (E 968) as a food additive, EFSA Journal (2023) — Re-evaluation set an ADI of 0.5 g/kg body weight/day based on the NOAEL for diarrhea, and concluded high consumers (notably children/adolescents) can exceed it; retained the laxative-warning requirement. [https://efsa.onlinelibrary.wiley.com/doi/10.2903/j.efsa.2023.8430]
  - FDA evaluation of Witkowski 2023 — FDA's scientific evaluation noted the cohort findings are associational and cannot establish causation given confounding and endogenous erythritol production, and did not change erythritol's regulatory status. [https://www.fda.gov/media/182122/download]
  - Ingestion of the Non-Nutritive Sweetener Erythritol, but Not Glucose, Enhances Platelet Reactivity and Thrombosis Potential in Healthy Volunteers-Brief Report, Arteriosclerosis, thrombosis, and vascular biology (2024) — Prospective interventional trial in healthy volunteers: ingestion of 30 g erythritol (but not 30 g glucose) acutely and significantly increased stimulus-dependent platelet aggregation and thrombosis potential. [https://pubmed.ncbi.nlm.nih.gov/39114916/]
  - Erythritol: An In-Depth Discussion of Its Potential to Be a Beneficial Dietary Component, Nutrients (2023) — JECFA assigned an ADI 'not specified' and the FDA accepted GRAS status for erythritol as a sweetener and flavor enhancer, reflecting low toxicity in animal and human studies. [https://pmc.ncbi.nlm.nih.gov/articles/PMC9824470/]
  - The sugar-free paradox: cardiometabolic consequences of erythritol, Signal transduction and targeted therapy (2023) — Narrative review concluded erythritol has minimal acute metabolic/glycemic effects but flagged the Witkowski cardiovascular findings and endogenous-production confounding as key unresolved questions requiring controlled long-term trials. [https://pmc.ncbi.nlm.nih.gov/articles/PMC10275890/]
  - The artificial sweetener erythritol and cardiovascular event risk, Nature medicine (2023) — Across US and EU cohorts (n=1,157 discovery; n=2,149 and n=833 validation), highest vs lowest plasma erythritol quartile carried adjusted HRs of 1.80 and 2.21 for 3-year MACE; erythritol enhanced platelet reactivity and thrombosis in vitro and in mice. [https://pubmed.ncbi.nlm.nih.gov/36849732/]
  - Erythritol, Erythronate, and Cardiovascular Outcomes in Older Adults in the ARIC Study, JACC. Advances (2025) — In 4,006 older adults (median 8.4-yr follow-up), erythritol was associated with total mortality (HR 1.18, 95% CI 1.10-1.26) and its metabolite erythronate with incident CHD (HR 1.32, 1.06-1.63) and ischemic stroke (HR 1.37, 1.05-1.78). [https://pmc.ncbi.nlm.nih.gov/articles/PMC11889355/]
  - The non-nutritive sweetener erythritol adversely affects brain microvascular endothelial cell function, Journal of applied physiology (Bethesda, Md. : 1985) (2025) — In human cerebral microvascular endothelial cells, a 30 g-beverage-equivalent erythritol dose (6 mM) reduced nitric oxide production, raised oxidative stress and endothelin-1, and impaired t-PA fibrinolytic response, supporting a cerebrovascular/stroke-risk mechanism. [https://pubmed.ncbi.nlm.nih.gov/40459966/]
  - Role of erythritol in coronary heart disease, ischemic stroke, and venous thromboembolism: A Mendelian randomization analysis, Medicine (2025) — Two-sample Mendelian randomization found genetically predicted erythritol associated with increased risk of coronary heart disease, ischemic stroke, and venous thromboembolism, supporting a potential causal contribution. [https://pmc.ncbi.nlm.nih.gov/articles/PMC12558269/]
  - Ingestion of the Non-Nutritive Sweetener Erythritol, but Not Glucose, Enhances Platelet Reactivity and Thrombosis Potential in Healthy Volunteers-Brief Report, Arteriosclerosis, thrombosis, and vascular biology (2024) — In healthy volunteers, ingesting 30 g erythritol (n=10) — but not 30 g glucose — raised plasma erythritol >1,000-fold and acutely enhanced stimulus-dependent platelet aggregation and granule release. [https://pmc.ncbi.nlm.nih.gov/articles/PMC11338701/]
  - Plasma and urine kinetics of erythritol after oral ingestion by healthy humans, Regulatory toxicology and pharmacology : RTP (1996) — Plasma/urine kinetics in healthy humans showed erythritol is rapidly absorbed, not metabolized, and ~80-90% recovered unchanged in urine within 24-48 h, explaining its near-zero caloric and glycemic profile. [https://pubmed.ncbi.nlm.nih.gov/8933644/]

---

## Guar Gum (E412)
URL: https://nutridex.info/s/guar-gum
Category: Sweeteners & Additives
Evidence: Moderate — Several controlled trials; effects real but modest or context-dependent.
Galactomannan fiber thickener with a genuine cholesterol-lowering signal — and a cautionary tale about swelling.

Quick answer: Guar Gum is used for thickens, stabilizes, and binds water at very low use levels (often 0.1-1%). NutriDex grades the human evidence as moderate — Several controlled trials; effects real but modest or context-dependent. Based on 9 cited human studies (9 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Guar gum (E412) is a water-soluble galactomannan fiber milled from the seed endosperm of the guar bean (Cyamopsis tetragonoloba), used at low levels as a thickener, stabilizer, and emulsifier. It is FDA GRAS (21 CFR 184.1339) and was re-evaluated by EFSA in 2017, which concluded there was no safety concern and no need for a numerical ADI; JECFA likewise assigns an ADI "not specified." Human RCT evidence is robust and reassuring at food-additive levels, and meta-analyses show modest LDL/total-cholesterol lowering when guar gum is taken as a supplemental fiber in gram doses. The main documented hazard is mechanical: concentrated, rapidly-swelling guar gum in dehydrated diet tablets caused esophageal and bowel obstruction, prompting a 1992 FDA ban on guar gum in OTC weight-loss drugs.

Benefits / uses: Thickens, stabilizes, and binds water at very low use levels (often 0.1-1%); Prevents ice-crystal formation and improves mouthfeel in ice cream and frozen desserts; Soluble viscous fiber: slows gastric emptying and blunts postprandial glucose/insulin; Lowers LDL and total cholesterol modestly as a supplemental fiber (gram doses); Partially hydrolyzed form (PHGG) acts as a prebiotic and regulates bowel function in IBS/constipation; Gluten-free binder that adds dough/batter structure without calories of concern.
Active compounds: E412 (EU); INS 412 (Codex); FDA GRAS under 21 CFR 184.1339; Found in ice cream, frozen desserts, sauces, salad dressings, soups, baked goods, dairy, plant-milks, gluten-free products; Partially hydrolyzed guar gum (PHGG) sold as a low-viscosity prebiotic fiber: Sunfiber, Benefiber Healthy Shape; Native guar splits also used industrially (textile, fracking) — food grade is purified.
Dose: FDA: GRAS, no numeric limit (21 CFR 184.1339), used per Good Manufacturing Practice. JECFA (1970-1975) and EU SCF (1977): ADI "not specified." EFSA ANS Panel 2017 re-evaluation: no need for a numerical ADI and no safety concern for the general population at refined exposure; 2024 follow-up confirmed this and assessed use in infant foods. Banned by FDA (1992) specifically in non-prescription weight-loss drug products (not in food).
Safety: At food-additive levels guar gum is well tolerated; the EFSA 2017 re-evaluation found no safety concern and set no numerical ADI, matching the long-standing JECFA "ADI not specified." Gram-dose supplemental use can cause dose-dependent GI effects (flatulence, bloating, cramps, loose stools) as it ferments. The landmark safety signal is mechanical, not toxicological: dehydrated, concentrated guar gum in "Cal-Ban 3000"-type diet tablets swells 10-20 fold on contact with fluid, and an FDA case series documented 18 esophageal and 7 small-bowel obstructions plus one death, leading FDA to ban guar gum in OTC weight-loss drugs in 1992 — anyone taking bulk guar fiber should take it with ample water and avoid it with esophageal strictures or swallowing/motility disorders. There is no credible evidence of carcinogenicity or systemic toxicity; EFSA flagged only that abdominal discomfort in infants/young children should be monitored. People with galactomannan/legume sensitivities are theoretically at risk of allergic reaction, and viscous fiber can slow absorption of co-administered oral drugs.

Cited studies (9):
  - The effects of guar gum supplementation on lipid profile in adults: a GRADE-assessed systematic review, meta-regression and dose-response meta-analysis of randomised placebo-controlled trials, The British journal of nutrition (2023) — GRADE-assessed dose-response meta-analysis of RCTs found guar gum lowered LDL-C (WMD -16.19 mg/dL, 95% CI -25.54 to -6.83) and total cholesterol (-19.34 mg/dL) with no effect on HDL or triglycerides. [https://pubmed.ncbi.nlm.nih.gov/35837742/]
  - The effect of guar gum consumption on the lipid profile in type 2 diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials, Critical reviews in food science and nutrition (2023) — Meta-analysis of RCTs in type 2 diabetes showed guar gum reduced LDL-C (WMD -14.52 mg/dL, 95% CI -20.69 to -8.35) and total cholesterol. [https://pubmed.ncbi.nlm.nih.gov/34558350/]
  - Re-evaluation of guar gum (E 412) as a food additive in foods for infants below 16 weeks of age and follow-up of its re-evaluation as food additive for uses in foods for all population groups, EFSA journal. European Food Safety Authority (2024) — Follow-up re-evaluation reaffirmed no safety concern for the general population and assessed use of guar gum in foods for infants below 16 weeks of age. [https://pmc.ncbi.nlm.nih.gov/articles/PMC11070944/]
  - Re-evaluation of guar gum (E 412) as a food additive, EFSA Journal (2017) — Re-evaluation concluded no need for a numerical ADI and no safety concern for guar gum (E412) as a food additive at refined exposure levels. [https://efsa.onlinelibrary.wiley.com/doi/full/10.2903/j.efsa.2017.4669]
  - Esophageal and small bowel obstruction from guar gum-containing "diet pills": analysis of 26 cases reported to the Food and Drug Administration, The American journal of gastroenterology (1992) — FDA case-series analysis of guar gum 'diet pills' documented 18 esophageal and 7 small-bowel obstructions and 1 death, driving the 1992 ban on guar gum in OTC weight-loss drugs. [https://pubmed.ncbi.nlm.nih.gov/1329494/]
  - A whey/guar "preload" improves postprandial glycaemia and glycated haemoglobin levels in type 2 diabetes: A 12-week, single-blind, randomized, placebo-controlled trial, Diabetes, obesity & metabolism (2019) — 12-week single-blind RCT: a whey/guar preload slowed gastric emptying, lowered postprandial glucose, and modestly reduced HbA1c in type 2 diabetes without weight gain. [https://pubmed.ncbi.nlm.nih.gov/30520216/]
  - Effect of Repeated Consumption of Partially Hydrolyzed Guar Gum on Fecal Characteristics and Gut Microbiota: A Randomized, Double-Blind, Placebo-Controlled, and Parallel-Group Clinical Trial, Nutrients (2019) — Randomized double-blind placebo-controlled trial showed repeated partially hydrolyzed guar gum (PHGG) improved fecal characteristics and beneficially altered gut microbiota. [https://www.mdpi.com/2072-6643/11/9/2170]
  - Treatment effects of partially hydrolyzed guar gum on symptoms and quality of life of patients with irritable bowel syndrome. A multicenter randomized open trial, Digestive diseases and sciences (2005) — PHGG significantly improved IBS symptoms and quality of life with an excellent safety profile across constipation- and diarrhea-predominant subtypes. [https://pubmed.ncbi.nlm.nih.gov/15986863/]
  - § 184.1339 Guar gum, U.S. Electronic Code of Federal Regulations (eCFR), Title 21 (FDA) — Codifies guar gum from Cyamopsis tetragonoloba seed as GRAS for direct food use subject to Good Manufacturing Practice. [https://www.ecfr.gov/current/title-21/chapter-I/subchapter-B/part-184/subpart-B/section-184.1339]

---

## Maltodextrin (processed starch)
URL: https://nutridex.info/s/maltodextrin
Category: Sweeteners & Additives
Evidence: Mixed — Conflicting results across studies; benefit uncertain.
Ubiquitous starch-derived filler with a high glycemic punch and an unsettled gut-barrier signal

Quick answer: Maltodextrin is used for bulking agent and texture/body builder in low-fat, powdered, and reduced-sugar products. NutriDex grades the human evidence as mixed — Conflicting results across studies; benefit uncertain. Based on 12 cited human studies (12 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Maltodextrin is a non-sweet, easily digestible carbohydrate made by partial hydrolysis of corn, potato, rice, or wheat starch into short glucose chains (dextrose equivalent under 20). It is one of the most common processed-food ingredients in the world, used as a bulking agent, thickener, carrier, and sports-energy carbohydrate, and is GRAS in the US (21 CFR 184.1444) with no numerical ADI assigned by FDA, EFSA, or JECFA because it is metabolized like ordinary starch. For the general population the weight of human evidence is reassuring at dietary levels, but it is metabolically a rapidly absorbed glucose source (glycemic index roughly 85-105, higher than table sugar), and a body of mechanistic and animal work has raised a still-unresolved signal about effects on the intestinal mucus barrier and bacterial adhesion relevant to inflammatory bowel disease.

Benefits / uses: Bulking agent and texture/body builder in low-fat, powdered, and reduced-sugar products; Carrier and spray-drying aid for flavors, colors, sweeteners, and supplements; Fast-absorbing, low-osmolality energy carbohydrate for endurance/sports drinks and gels; Improves solubility, mouthfeel, and freeze-thaw stability; Provides ~4 kcal/g; effectively a digestible glucose polymer (NOT a zero-calorie or non-glycemic ingredient).
Active compounds: No E-number in the EU; not classed as an additive there but as a food/starch hydrolysate ingredient (CAS 9050-36-6); Brand/source examples: Maltrin, Star-Dri, Glucidex, Fantomalt; derived from corn (most common in US), wheat, potato, tapioca, or rice; Found in: soft drinks and sports drinks, infant formula, instant puddings/soups/sauces, salad dressings, candy, baked goods, sugar substitutes (as a carrier for sucralose/stevia/aspartame blends), protein powders, and many 'sugar-free' products.
Dose: FDA: Generally Recognized as Safe (GRAS) under 21 CFR 184.1444, with no maximum level and no numerical ADI. EFSA and JECFA: no numerical ADI required (acceptable daily intake 'not specified'), as it is digested and absorbed as glucose like other starches. Wheat-derived maltodextrin must be declared as a gluten source in the EU; refined products are generally below the 20 ppm gluten threshold.
Safety: At normal dietary levels maltodextrin is not a recognized toxicity or cancer hazard, and no regulator has restricted it. The honest caveats are metabolic and gastrointestinal. Metabolically it behaves as rapidly digestible glucose with a glycemic index higher than sucrose, so it raises blood glucose and is not 'sugar-free' in any physiological sense — a concern for people with diabetes or insulin resistance despite 'no added sugar' labeling. The most studied signal is gut-related: Nickerson 2012 showed maltodextrin enhances adhesion of Crohn's-associated adherent-invasive E. coli to intestinal epithelium via type-1 pili, and Laudisi 2019 showed dietary maltodextrin induces endoplasmic-reticulum stress in goblet cells, depletes the protective Muc2 mucus layer, and worsens chemically induced colitis in mice. These are predominantly mechanistic/animal/in-vitro findings; robust human outcome data are lacking, and gastroenterology consensus is that this warrants caution and further study for people with IBD rather than avoidance by the general public. Large doses can cause osmotic GI symptoms (bloating, gas, loose stools), and wheat-derived product is relevant to celiac/gluten-sensitive individuals.

Cited studies (12):
  - The effect of resistant dextrin on glucose regulation markers in patients with type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials, BMC nutrition (2025) — Systematic review and meta-analysis of RCTs in type 2 diabetes found resistant dextrin supplementation significantly lowered HbA1c (WMD approximately -0.30%) versus control, with effects on fasting glucose and insulin (moderate-quality evidence). [https://pmc.ncbi.nlm.nih.gov/articles/PMC12065221/]
  - Why for feed and not for human consumption? The black soldier fly larvae, Comprehensive Reviews in Food Science and Food Safety (2020) — Systematic review of human and animal studies found the majority reporting maltodextrin effects on gut microbiota and barrier function, but concluded human evidence remains insufficient to establish clinical harm at dietary intakes. [https://doi.org/10.1111/1541-4337.12609]
  - Validity of food additive maltodextrin as placebo and effects on human gut physiology: systematic review of placebo-controlled clinical trials, European Journal of Nutrition (2022) — Systematic review of placebo-controlled trials (70 RCTs analyzed from 216 studies) found 60% reported maltodextrin-induced physiological effects, challenging its validity as an inert placebo and indicating direct effects on human gut physiology. [https://link.springer.com/content/pdf/10.1007/s00394-022-02802-5.pdf]
  - Guidance on the scientific requirements for health claims related to the immune system, the gastrointestinal tract and defence against pathogenic microorganisms, EFSA Journal (European Food Safety Authority, NDA Panel — Panel on Dietetic Products, Nutrition and Allergies) (2016) — Maltodextrin is digested and absorbed as glucose in the small intestine, contributing ~4 kcal/g and behaving glycemically like other rapidly available carbohydrates rather than as fiber. [https://www.efsa.europa.eu/en/efsajournal/pub/4369]
  - Oligomalt, a New Slowly Digestible Carbohydrate, Reduces Post-Prandial Glucose and Insulin Trajectories Compared to Maltodextrin across Different Population Characteristics: Double-Blind Randomized Controlled Trials in Healthy Individuals, People with Obesity, and People with Type 2 Diabetes, Metabolites (2024) — Double-blind crossover RCTs in healthy individuals, people with obesity, and people with type 2 diabetes showed the slowly digestible carbohydrate oligomalt produced lower postprandial glucose iAUC and 38-60% lower insulin response than maltodextrin across all populations. [https://pmc.ncbi.nlm.nih.gov/articles/PMC11356256/]
  - Resistant Maltodextrin Consumption in a Double-Blind, Randomized, Crossover Clinical Trial Induces Specific Changes in Potentially Beneficial Gut Bacteria, Nutrients (2022) — Double-blind, randomized, crossover trial in healthy adults found resistant maltodextrin increased fecal bifidobacteria counts and stool wet weight, indicating prebiotic-type modulation of beneficial gut bacteria. [https://pmc.ncbi.nlm.nih.gov/articles/PMC9183109/]
  - Resistant Maltodextrin Intake Reduces Virulent Metabolites in the Gut Environment: A Randomized Control Study in a Japanese Cohort, Frontiers in microbiology (2022) — 24-week randomized, double-blind, placebo-controlled trial in 29 Japanese subjects with HbA1c >6% found resistant maltodextrin reduced virulent gut metabolites and increased fecal Fusicatenibacter saccharivorans approximately two-fold. [https://pmc.ncbi.nlm.nih.gov/articles/PMC9116438/]
  - § 184.1444 Maltodextrin, U.S. Electronic Code of Federal Regulations (eCFR), Title 21 (FDA) — Affirms maltodextrin (DE <20, from corn/potato/rice starch) as GRAS with no quantitative use limit, used per good manufacturing practice. [https://www.ecfr.gov/current/title-21/chapter-I/subchapter-B/part-184/subpart-B/section-184.1444]
  - Maltodextrin Consumption Impairs the Intestinal Mucus Barrier and Accelerates Colitis Through Direct Actions on the Epithelium, Frontiers in Immunology (2022) — Maltodextrin impaired the intestinal mucus barrier and accelerated colitis in mice through direct actions on the epithelium, independent of broad microbiota shifts. [https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2022.841188/full]
  - Deregulation of intestinal anti-microbial defense by the dietary additive, maltodextrin, Gut Microbes (2015) — Maltodextrin suppressed cellular antibacterial responses and impaired mucosal clearance of Salmonella, deregulating intestinal anti-microbial defense in cell and mouse models. [https://www.tandfonline.com/doi/full/10.1080/19490976.2015.1005477]
  - The Food Additive Maltodextrin Promotes Endoplasmic Reticulum Stress–Driven Mucus Depletion and Exacerbates Intestinal Inflammation, Cellular and Molecular Gastroenterology and Hepatology (2019) — Dietary maltodextrin (5%) induced goblet-cell ER stress, Muc2 mucus depletion, and exacerbated DSS colitis in mice; the ER-stress inhibitor TUDCA reversed the effect. [https://www.cmghjournal.org/article/S2352-345X(18)30121-8/fulltext]
  - Crohn's disease-associated adherent-invasive Escherichia coli adhesion is enhanced by exposure to the ubiquitous dietary polysaccharide maltodextrin, PloS one (2012) — Maltodextrin enhanced Crohn's-associated adherent-invasive E. coli adhesion to intestinal epithelial cells via type-1 pili and increased biofilm formation, independent of CEACAM6. [https://pmc.ncbi.nlm.nih.gov/articles/PMC3520894/]

---

## Sodium Benzoate (E211)
URL: https://nutridex.info/s/sodium-benzoate
Category: Sweeteners & Additives
Evidence: Moderate — Several controlled trials; effects real but modest or context-dependent.
The workhorse acid-food preservative — safe at intake limits, with a benzene caveat.

Quick answer: Sodium Benzoate is used for prevents spoilage by yeasts, molds and bacteria in acidic foods. NutriDex grades the human evidence as moderate — Several controlled trials; effects real but modest or context-dependent. Based on 10 cited human studies (10 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Sodium benzoate (E211) is the sodium salt of benzoic acid, one of the oldest and most widely used antimicrobial preservatives. It works only in acidic foods (pH below ~4.5), so it appears mainly in soft drinks, fruit juices, pickles, salad dressings, condiments and acidic sauces, as well as in some pharmaceuticals and cosmetics. It is FDA GRAS, EU-approved, and JECFA-evaluated; regulators consistently conclude it is not genotoxic or carcinogenic at permitted levels. The main real-world concern is not benzoate itself but benzene, a known carcinogen that can form in trace amounts when benzoate and ascorbic acid (vitamin C) coexist in beverages exposed to heat and light.

Benefits / uses: Prevents spoilage by yeasts, molds and bacteria in acidic foods; Highly effective at low pH (below ~4.5); Highly water-soluble, so easy to formulate in beverages; Inexpensive and stable, extends shelf life; Also used as a pharmaceutical excipient and, at gram doses, as an investigational add-on therapy for schizophrenia (D-amino acid oxidase inhibition).
Active compounds: E-number: E211 (sodium benzoate); related: E210 benzoic acid, E212 potassium benzoate, E213 calcium benzoate; Soft drinks, flavored/diet sodas, fruit juices and sports drinks; Pickles, relishes, condiments, salad dressings, sauces, jams; Pharmaceuticals (syrups, oral liquids) and cosmetics/personal-care products.
Dose: FDA GRAS as a direct food substance (21 CFR 184.1733), used at up to ~0.1% in food. JECFA group ADI revised in 2021 to 0–20 mg/kg bw/day (expressed as benzoic acid; up from the prior 0–5 mg/kg), covering benzoic acid and its calcium/potassium/sodium salts. EFSA's 2016 re-evaluation derived a more conservative ADI of 5 mg/kg bw/day and flagged that high-consuming toddlers and children could exceed the group ADI from flavored drinks.
Safety: At permitted intakes, regulators (EFSA 2016, JECFA 2021, FDA GRAS) find no genotoxicity or carcinogenicity concern; benzoate is rapidly conjugated with glycine to hippuric acid and excreted in urine. The principal documented hazard is chemical: benzene (an IARC Group 1 human carcinogen) can form at low ppb levels when sodium benzoate and ascorbic acid co-occur in beverages exposed to heat/light — FDA testing (2005–2007) found a small number of drinks above the 5 ppb drinking-water limit, and manufacturers reformulated. A 2016 EFSA exposure analysis warned high-consuming toddlers/children may exceed the ADI. A pilot study linked sodium-benzoate-rich beverage intake to self-reported ADHD symptoms in college students (association only, confounded by sugar/caffeine). Benzoates can occasionally trigger non-allergic intolerance reactions (urticaria, asthma exacerbation) in sensitive individuals. Caveat: gram-dose therapeutic use studied in schizophrenia is hundreds of times higher than dietary exposure and is not relevant to food-additive safety.

Cited studies (10):
  - Effects of sodium benzoate on cognitive function in neuropsychiatric disorders: a systematic review and meta-analysis, Frontiers in psychiatry (2024) — Across 10 trials in neuropsychiatric disorders, adjunctive sodium benzoate produced a small-to-moderate improvement in global cognitive function versus placebo (SMD 0.40, 95% CI 0.20-0.60, rated high certainty). [https://pubmed.ncbi.nlm.nih.gov/39315325/]
  - Symptomatic and cognitive effects of D-amino acid oxidase inhibitors in patients with schizophrenia: a meta-analysis of double-blind randomized controlled trials, Schizophrenia (Heidelberg, Germany) (2025) — In a meta-analysis of double-blind RCTs (four of five trials used sodium benzoate), DAAO inhibitors reduced total PANSS symptoms (SMD -0.27) and improved cognition (SMD 0.36) in schizophrenia, with significant effects in the sodium benzoate subgroup. [https://pubmed.ncbi.nlm.nih.gov/40328785/]
  - 21 CFR 184.1733 -- Sodium benzoate, Electronic Code of Federal Regulations (eCFR), US FDA, Title 21, Part 184 — Affirms sodium benzoate as Generally Recognized As Safe (GRAS) as an antimicrobial and flavoring agent, consistent with use at a maximum of about 0.1% in food. [https://www.ecfr.gov/current/title-21/chapter-I/subchapter-B/part-184/subpart-B/section-184.1733]
  - JECFA 2021 (92nd meeting) — Established a revised group ADI of 0–20 mg/kg bw/day for benzoic acid and its salts (expressed as benzoic acid equivalents), withdrawing the previous 0–5 mg/kg ADI after applying a chemical-specific toxicokinetic adjustment factor. [https://apps.who.int/food-additives-contaminants-jecfa-database/Home/Chemical/1098]
  - Scientific Opinion on the re-evaluation of benzoic acid (E 210), sodium benzoate (E 211), potassium benzoate (E 212) and calcium benzoate (E 213) as food additives, EFSA Journal (2016) — Re-evaluation concluded no genotoxic or carcinogenic concern and derived an ADI of 5 mg/kg bw/day (as benzoic acid), but found high-level toddler/child consumers of flavored drinks could exceed the group ADI. [https://www.efsa.europa.eu/en/efsajournal/pub/4433]
  - Questions and Answers on the Occurrence of Benzene, U.S. Food and Drug Administration — In the presence of ascorbic acid and under heat/light, benzoate can decarboxylate to form benzene; 2005–2007 testing of >200 beverages found a small number above the 5 ppb water standard, prompting reformulation. [https://www.fda.gov/food/environmental-contaminants-food/questions-and-answers-occurrence-benzene-soft-drinks-and-other-beverages]
  - Sodium Benzoate, a D-Amino Acid Oxidase Inhibitor, Added to Clozapine for the Treatment of Schizophrenia: A Randomized, Double-Blind, Placebo-Controlled Trial, Biological psychiatry (2018) — Double-blind RCT in clozapine-resistant schizophrenia (n=60) found add-on sodium benzoate (1–2 g/day) improved symptomatology vs placebo, supporting the DAAO-inhibition mechanism at gram doses. [https://pubmed.ncbi.nlm.nih.gov/29397899/]
  - Add-on treatment of benzoate for schizophrenia: a randomized, double-blind, placebo-controlled trial of D-amino acid oxidase inhibitor, JAMA psychiatry (2013) — Randomized double-blind placebo-controlled trial: 1 g/day add-on sodium benzoate (a D-amino acid oxidase inhibitor) improved PANSS symptom and cognitive scores in chronic schizophrenia — a pharmacologic dose far above dietary exposure. [https://pubmed.ncbi.nlm.nih.gov/24089054/]
  - Benzene (IARC Monographs Volume 100F — Chemical Agents and Related Occupations), IARC Monographs on the Evaluation of Carcinogenic Risks to Humans (International Agency for Research on Cancer) (2012) — Benzene is classified by IARC as a Group 1 carcinogen (causally linked to leukemia), which is why trace benzene formation in benzoate-plus-vitamin-C beverages is treated as a contaminant concern even though benzoate itself is not carcinogenic. [https://monographs.iarc.who.int/wp-content/uploads/2018/06/mono100F-24.pdf]
  - Sodium benzoate-rich beverage consumption is associated with increased reporting of ADHD symptoms in college students: a pilot investigation, Journal of attention disorders (2014) — Cross-sectional survey of 475 college students found sodium-benzoate-rich beverage intake associated with higher ADHD symptom scores (p=.001); high-symptom students reported ~35 vs ~17 servings/month — association only, hypothesis-generating. [https://pubmed.ncbi.nlm.nih.gov/22538314/]

---

## Titanium Dioxide (E171)
URL: https://nutridex.info/s/titanium-dioxide
Category: Sweeteners & Additives
Evidence: Banned / Harmful — Linked to serious harm and/or banned in sport and many jurisdictions. Listed for awareness and safety only — NOT a recommendation.
The white pigment Europe banned but the US, UK, Canada and WHO still allow.

Quick answer: Titanium Dioxide is marketed for whitening / opacifying pigment — brightens confectionery, frostings, coffee creamers, sauces and chewing gum. NutriDex grades the human evidence as banned / harmful — Linked to serious harm and/or banned in sport and many jurisdictions. Listed for awareness and safety only — NOT a recommendation. Based on 9 cited human studies (9 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Titanium dioxide (E171) is a brilliant-white mineral pigment used to whiten, brighten and opacify foods, supplements and pill coatings — it has no nutritional or flavor role. It sits at the center of a genuine regulatory split: in 2021 EFSA concluded E171 "can no longer be considered safe as a food additive" because a concern for genotoxicity could not be ruled out, leading the EU to ban it in food from 2022. By contrast the US FDA (color additive, up to 1% by weight), JECFA/WHO (2024 re-evaluation, ADI "not specified"), Health Canada (2022) and the UK FSA continue to regard food-grade TiO2 as safe, judging the genotoxicity signal unconfirmed and oral absorption very low. The weight of human evidence is thin: there are no human outcome studies showing harm, while mechanistic and animal data raise plausibility — hence the divergence.

Benefits / uses: Whitening / opacifying pigment — brightens confectionery, frostings, coffee creamers, sauces and chewing gum; Coats tablets, capsules and supplements to make them uniform white and opaque (also masks contents); No calories, no sweetness, no nutritional contribution — purely a visual/cosmetic colorant; Chemically inert, heat-stable and pH-stable, so color survives processing and storage; Often used to make other colors appear brighter by providing an opaque white base.
Active compounds: E-number: E171 (EU designation, now banned in EU food); INCI/chem: Titanium dioxide, TiO2; CAS 13463-67-7; CI 77891; Foods (where still permitted): candy/sweets coatings (e.g. Skittles, mints), white frosting and icing, coffee whiteners, sauces, chewing gum, some dairy; Pharmaceuticals & supplements: tablet/capsule coatings and shells (a major non-food use); Also a sunscreen UV filter and cosmetics pigment — those uses are regulated separately from food.
Dose: Regulatory status is jurisdiction-split. EU: BANNED as a food additive since August 2022 (Reg. (EU) 2022/63) after EFSA's 2021 opinion that E171 is no longer safe; genotoxicity could not be excluded and no safe level could be set. US FDA: permitted color additive (21 CFR 73.575), titanium must not exceed 1% by weight of the food; FDA reaffirmed safety in 2024. JECFA/WHO (2024 re-evaluation): ADI "not specified" (i.e. no numerical limit needed), citing very low oral absorption and no identifiable hazard. Health Canada (2022) and UK FSA also concluded it is safe in food. No GRAS pathway applies — in the US it is a listed color additive, not GRAS.
Safety: The honest picture is uncertainty, not proven harm. EFSA (2021) flagged that TiO2 includes a fraction of nanoparticles, that a small amount is absorbed and can accumulate in the body, and that a concern for genotoxicity (DNA/chromosomal damage) could not be ruled out — so no safe intake could be established, triggering the EU ban. The supporting evidence is mechanistic and animal: food-grade TiO2 promoted low-grade colon inflammation and preneoplastic aberrant crypt foci in rats (Bettini 2017), and human-volunteer work confirmed TiO2 particles are absorbed into the bloodstream after oral dosing (Pele 2015). IARC classifies TiO2 as Group 2B "possibly carcinogenic to humans" — but that is based on lung tumors in rats from inhaling dust (an occupational/respiratory route), NOT from eating it, so it does not directly speak to dietary risk. Crucially, there are no human studies linking dietary E171 to cancer or disease, and FDA, JECFA, Health Canada and the UK FSA reviewed the same data and judged the genotoxicity tests not representative of the food-grade material or relevant exposure route. Bottom line: not a demonstrated hazard at dietary levels, but enough unresolved nanoparticle/genotoxicity uncertainty that the EU applied the precautionary principle. People who prefer to avoid it can check labels for "titanium dioxide"/E171, including on supplements and medications; there is no established at-risk subgroup.

Cited studies (9):
  - JECFA concludes evaluations of several food additives, Food and Agriculture Organization of the United Nations (FAO) — Food safety and quality (2023) — JECFA re-evaluated TiO2 and, citing very low oral absorption and no identifiable hazard from dietary use, reaffirmed an ADI "not specified" (no numerical limit needed). [https://www.fao.org/food-safety/news/news-details/en/c/1666259/]
  - Titanium Dioxide, U.S. Food and Drug Administration — FDA reaffirmed titanium dioxide is safe as a food color additive (21 CFR 73.575, ≤1% by weight), judging EFSA's genotoxicity tests as not representative of the food-grade material or relevant exposure route. [https://www.fda.gov/industry/color-additives/titanium-dioxide-color-additive-foods]
  - Safety assessment of titanium dioxide (E171) as a food additive, EFSA Journal (2021) — EFSA concluded E171 "can no longer be considered safe when used as a food additive" because a concern for genotoxicity could not be excluded and no safe level (ADI) could be established. [https://efsa.onlinelibrary.wiley.com/doi/10.2903/j.efsa.2021.6585]
  - Safety assessment of titanium dioxide (E171) as a food additive, EFSA journal. European Food Safety Authority (2021) — Peer-published version of the EFSA re-assessment underpinning the EU ban; uncertainties around nanoparticle genotoxicity meant a cut-off particle size for safety could not be identified. [https://pubmed.ncbi.nlm.nih.gov/33976718/]
  - State of the Science of Titanium Dioxide (TiO2) as a Food Additive, Health Canada (Food Directorate) (2022) — Health Canada's State of the Science review found no compelling health concern for TiO2 as a food additive, while noting data gaps and committing to monitor emerging science. [https://publications.gc.ca/collections/collection_2022/sc-hc/H164-341-2022-eng.pdf]
  - Goodbye E171: The EU bans titanium dioxide as a food additive, European Commission, Directorate-General for Health and Food Safety (DG SANTE) (2022) — Following the EFSA opinion, the EU banned titanium dioxide (E171) as a food additive, with a phase-out completed by August 2022 (Reg. (EU) 2022/63). [https://ec.europa.eu/newsroom/sante/items/732079/en]
  - Food-grade TiO(2) impairs intestinal and systemic immune homeostasis, initiates preneoplastic lesions and promotes aberrant crypt development in the rat colon, Scientific reports (2017) — Oral E171 at ~10 mg/kg bw/day for 100 days impaired intestinal/systemic immune homeostasis, initiated preneoplastic lesions and promoted aberrant crypt foci in the rat colon. [https://pmc.ncbi.nlm.nih.gov/articles/PMC5247795/]
  - Pharmaceutical/food grade titanium dioxide particles are absorbed into the bloodstream of human volunteers, Particle and Fibre Toxicology (2015) — After a single 100 mg oral dose of pharmaceutical/food-grade TiO2, particles were detected in the bloodstream of human volunteers, confirming measurable intestinal absorption. [https://particleandfibretoxicology.biomedcentral.com/articles/10.1186/s12989-015-0101-9]
  - Carbon Black, Titanium Dioxide, and Talc — IARC classified titanium dioxide as Group 2B "possibly carcinogenic to humans" based on sufficient evidence of lung tumors in rats inhaling dust, with inadequate human evidence — an inhalation, not dietary, basis. [https://publications.iarc.fr/Book-And-Report-Series/Iarc-Monographs-On-The-Identification-Of-Carcinogenic-Hazards-To-Humans/Carbon-Black-Titanium-Dioxide-And-Talc-2010]

---

## Monk Fruit (Luo Han Guo) (Siraitia grosvenorii)
URL: https://nutridex.info/s/monk-fruit
Category: Sweeteners & Additives
Evidence: Moderate — Several controlled trials; effects real but modest or context-dependent.
Zero-calorie sweetness from a Chinese melon, via mogroside glycosides

Quick answer: Monk Fruit (Luo Han Guo) is used for zero/negligible calories — mogrosides are largely not absorbed in the small intestine and contribute no usable energy. NutriDex grades the human evidence as moderate — Several controlled trials; effects real but modest or context-dependent. Based on 9 cited human studies (9 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Monk fruit (Siraitia grosvenorii, luo han guo) is a southern-Chinese cucurbit whose sweetness comes from cucurbitane glycosides called mogrosides (mogroside V is the major one), making the extract roughly 100-250x sweeter than sucrose with negligible calories. In the US it is sold under FDA "no questions" GRAS letters (e.g. GRN 627, 629, 706) and is widely used in tabletop blends and "natural" reduced-sugar products, often combined with erythritol; it is not authorized as a food additive in the EU. Human evidence is limited but reassuring: small RCTs and a 2025 systematic review show no meaningful rise in postprandial glucose or insulin and no consistent adverse effects, while regulators (EFSA) flagged gaps in the long-term animal toxicology dataset rather than any demonstrated human harm.

Benefits / uses: Zero/negligible calories — mogrosides are largely not absorbed in the small intestine and contribute no usable energy; Intense sweetness (~100-250x sucrose), so tiny amounts replace sugar; No meaningful postprandial glucose or insulin spike in human trials — suitable for diabetes and low-carb/keto diets; Heat-stable, suitable for baking and cooking unlike some sweeteners; No tooth-decay (non-cariogenic) and no dental erosion; Mogrosides have antioxidant activity in vitro; often blended with erythritol to mask aftertaste and add bulk.
Active compounds: No EU E-number (not authorized as a food additive in the EU); Common brands/blends: Lakanto, Monk Fruit In The Raw, Splenda Monk Fruit, Whole Earth, Pure Monk; frequently sold as monk-fruit + erythritol blends; Found in tabletop sweeteners, 'no/low sugar' sodas and flavored waters, protein bars, yogurts, sauces and keto/'natural' baked goods; Sold as fruit extract standardized to mogroside V (typically 25-55%), fruit juice concentrate, and dried fruit (used in traditional Chinese teas/decoctions).
Dose: US: FDA-reviewed GRAS with "no questions" letters for Siraitia grosvenorii extract/concentrate (GRN 301, 522, 556, 627, 629, 706); no numerical ADI set — FDA does not require one for GRAS sweeteners. EFSA (2019): could NOT establish an ADI and judged the toxicity database insufficient; monk fruit extract is therefore not approved as a food additive in the EU. JECFA/Codex: mogroside V / monk fruit extract was on the evaluation agenda (CCFA, 2025) but had no completed JECFA ADI at that time. WHO 2023 non-sugar-sweetener guideline did NOT include monk fruit in its scope.
Safety: No adverse effects have been attributed to monk fruit mogrosides in the published human literature or FDA's voluntary reporting database, and US regulators accept it as GRAS. Human exposure data are thin (mostly small, short RCTs), which is the main caveat. EFSA's 2019 opinion declined to set an ADI because the animal dataset was incomplete — notably testicular effects seen in a 90-day rat study (with 52% mogroside V) that could not be dismissed, and the absence of chronic/carcinogenicity studies; this is a data-gap flag, not evidence of human harm. Genotoxicity assays (Ames, chromosomal) on 25% and 55% mogroside V extracts were negative. Most commercial products are blended with erythritol, so GI/laxative or (per the disputed Witkowski 2023 work) erythritol-cardiovascular signals reflect the erythritol component, not monk fruit. No specific population is told to avoid pure monk fruit; people sensitive to sugar alcohols should check for erythritol/other polyols in blends.

Cited studies (9):
  - Monk Fruit Extract and Sustainable Health: A PRISMA-Guided Systematic Review of Randomized Controlled Trials, Nutrients (2025) — PRISMA systematic review of 5 RCTs: monk fruit extract reduced postprandial glucose by ~10-18% and insulin responses by ~12-22% versus sugar, with no consistent adverse metabolic effects. [https://pmc.ncbi.nlm.nih.gov/articles/PMC12073669/]
  - Use of non, World Health Organization — WHO advised against using non-sugar sweeteners for weight control, but its scope (acesulfame-K, aspartame, advantame, cyclamates, neotame, saccharin, sucralose, stevia) did NOT include monk fruit mogrosides. [https://www.who.int/publications/i/item/9789240073616]
  - Agenda Item 7 CX/FA 25/55/10 (Codex Committee on Food Additives, 55th Session working document), Codex Alimentarius — Codex Committee on Food Additives (FAO/WHO) (2025) — Monk fruit extract / mogroside V appeared on the Codex Committee on Food Additives agenda for JECFA evaluation, indicating an international safety assessment was still in progress without a finalized ADI. [https://www.fao.org/fao-who-codexalimentarius/sh-proxy/de/?lnk=1&url=https://workspace.fao.org/sites/codex/Meetings/CX-711-55/Working+documents/fa55_10e.pdf]
  - Why Does Monk Fruit Extract Remain Only Partially Approved in the EU? Regulatory Barriers and Policy Implications for Food Innovation, Foods (Basel, Switzerland) (2025) — Regulatory analysis documenting that as of October 2024 only one specific aqueous monk fruit extract is EU-authorised (Regulation (EU) 2024/2345), while highly purified mogrosides remain unapproved as the EFSA risk assessment is paused due to missing toxicological data. [https://pubmed.ncbi.nlm.nih.gov/40870722/]
  - GRAS Notice (GRN) No. 627: Siraitia grosvenorii Swingle (Luo Han Guo) fruit juice concentrate, U.S. Food and Drug Administration (FDA), GRAS Notice Inventory — FDA issued a 'no questions' letter for Siraitia grosvenorii (Luo Han Guo) fruit juice concentrate as GRAS for use as a sweetener/flavor, consistent with earlier monk-fruit notices. [https://www.fda.gov/files/food/published/GRAS-Notice-000627---Siraitia-grosvenorii-Swingle-(Luo-Han-Guo)-fruit-juice-concentrate.pdf]
  - Safety of use of Monk fruit extract as a food additive in different food categories, EFSA Journal (2019) — EFSA could not establish an ADI and judged the toxicity database insufficient to conclude on safety, citing unresolved testicular effects in a 90-day rat study and lack of chronic/carcinogenicity data; monk fruit extract is not authorized in the EU. [https://doi.org/10.2903/j.efsa.2019.5921]
  - Effects of aspartame-, monk fruit-, stevia- and sucrose-sweetened beverages on postprandial glucose, insulin and energy intake, International journal of obesity (2005) (2017) — Randomized crossover RCT in 30 healthy men: monk-fruit-, stevia- and aspartame-sweetened beverages produced no postprandial glucose/insulin spike (unlike sucrose) and no significant difference in total daily energy intake. [https://pubmed.ncbi.nlm.nih.gov/27956737/]
  - Effects of aspartame-, monk fruit-, stevia- and sucrose-sweetened beverages on postprandial glucose, insulin and energy intake, International Journal of Obesity (2017) — Randomized crossover trial in 30 healthy men found monk fruit-sweetened beverages produced no significant difference in 3-hour glucose or insulin area-under-the-curve versus stevia or aspartame, and lower than sucrose, while compensatory energy intake at a subsequent meal was similar across sweeteners. [https://www.nature.com/articles/ijo2016225]
  - Everything You Need To Know About Monk Fruit Sweeteners, International Food Information Council (IFIC) (2021) — Industry-science review summarizing that mogrosides are largely unabsorbed (non-caloric), the extract is ~100-250x sweeter than sucrose, and no adverse events are attributed to it in FDA's voluntary reporting database. [https://ific.org/insights/everything-you-need-to-know-about-monk-fruit-sweeteners/]

---

## Sucralose (E955 · Splenda)
URL: https://nutridex.info/s/sucralose
Category: Sweeteners & Additives
Evidence: Moderate — Several controlled trials; effects real but modest or context-dependent.
The heat-stable, calorie-free chlorinated sugar in Splenda

Quick answer: Sucralose is used for zero-calorie sweetness (~600x sweeter than sucrose; contributes negligible energy). NutriDex grades the human evidence as moderate — Several controlled trials; effects real but modest or context-dependent. Based on 9 cited human studies (9 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Sucralose (E955, sold as Splenda) is a chlorinated derivative of sucrose roughly 600 times sweeter than sugar, used as a zero-calorie, heat-stable sweetener in diet sodas, tabletop packets, baked goods, dairy, and "sugar-free" and pharmaceutical products. It is approved as a food additive worldwide; the FDA (1998-99) set an ADI of 5 mg/kg body weight/day, while JECFA and EFSA set it at 15 mg/kg/day, and EFSA's comprehensive February 2026 re-evaluation reaffirmed that ADI and concluded it is safe at currently authorised uses. The weight of human evidence finds no clear carcinogenic, reproductive, or neurological harm at typical intakes, but reassurance is tempered by emerging signals: an RCT showing person-specific microbiome-mediated glycemic effects, observational cohort associations with cancer, and 2023 in-vitro genotoxicity of the manufacturing impurity sucralose-6-acetate.

Benefits / uses: Zero-calorie sweetness (~600x sweeter than sucrose; contributes negligible energy); No meaningful acute glycemic or insulin response in most people (not metabolized for energy); Exceptional heat stability vs. aspartame, so it can be used in baking and cooking; Long shelf life and stability across a wide pH range; Does not promote dental caries (non-cariogenic); Enables sugar reduction in foods/beverages for people managing weight or diabetes.
Active compounds: E955 (EU/Codex E-number); Brand names: Splenda, Sucraplus, Zerocal, SucraNet; Diet/zero soft drinks, flavored waters and sports drinks; Tabletop sweetener packets and blends (often bulked with maltodextrin/dextrose); Sugar-free gum, candy, baked goods, dairy and frozen desserts, syrups; Chewable/liquid medicines, supplements, and protein powders.
Dose: Approved food additive. FDA ADI 5 mg/kg body weight/day (approved 1998 in 15 food categories, 1999 as a general-purpose sweetener). JECFA (1991) and EFSA ADI 0-15 mg/kg/day, derived from a rodent NOAEL of 1500 mg/kg/day with a 100-fold safety factor; EFSA's February 2026 re-evaluation reaffirmed the 15 mg/kg/day ADI and found EU exposure below it in all population groups. For a 70 kg adult the FDA ADI ≈ 350 mg/day (roughly the amount in several diet beverages).
Safety: Major regulators (FDA, EFSA 2026, JECFA, WHO) consider sucralose safe at the ADI, and it shows no consistent evidence of carcinogenicity, genotoxicity, or reproductive/neurological harm in the >110 studies FDA reviewed. Signals under active study: (1) sucralose-6-acetate, a manufacturing impurity/intestinal-digestion product present at up to ~0.67% in commercial sucralose, tested genotoxic (clastogenic) in vitro (Schiffman 2023) — relevance to real-world human exposure is debated and unconfirmed in vivo; (2) a 2022 randomized trial (Suez/Cell) found sucralose and saccharin can impair glucose tolerance in a person-specific, gut-microbiome-dependent manner even below the ADI; (3) the NutriNet-Santé cohort linked higher artificial-sweetener intake to modestly increased cancer risk (strongest for aspartame, observational only); and (4) EFSA 2026 flagged unresolved uncertainty about possible chlorine transfer to organic molecules when sucralose is heated for prolonged periods at high temperature. WHO's 2023 guideline conditionally advises against using non-sugar sweeteners (including sucralose) for weight control, citing no long-term body-fat benefit and possible associations with type 2 diabetes, cardiovascular disease, and mortality. People relying on sucralose for weight loss should not assume benefit; otherwise no specific group is contraindicated at normal intakes.

Cited studies (9):
  - WHO advises not to use non-sugar sweeteners for weight control in newly released guideline, World Health Organization (2023) — WHO conditionally recommends against using non-sugar sweeteners (incl. sucralose) for weight control, finding no long-term body-fat benefit and possible links to type 2 diabetes, CVD, and mortality. [https://www.who.int/news/item/15-05-2023-who-advises-not-to-use-non-sugar-sweeteners-for-weight-control-in-newly-released-guideline]
  - Re‐evaluation of sucralose (E 955) as a food additive and evaluation of a new application on extension of use of sucralose (E 955) in fine bakery wares, EFSA Journal (2026) — EFSA's comprehensive re-evaluation reaffirmed the ADI of 15 mg/kg bw/day and concluded sucralose (E955) is safe at currently authorised uses, with EU exposure below the ADI in all groups; could not confirm safety of new high-temperature baking uses. [https://efsa.onlinelibrary.wiley.com/doi/10.2903/j.efsa.2026.9854]
  - Aspartame and Other Sweeteners in Food, U.S. Food and Drug Administration — FDA determined sucralose safe based on review of >110 studies (no carcinogenic, reproductive, or neurologic risk), approving it in 1998-99 with an ADI of 5 mg/kg bw/day. [https://www.fda.gov/food/food-additives-petitions/aspartame-and-other-sweeteners-food]
  - Critical review of the current literature on the safety of sucralose, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association (2017) — Critical review of the sucralose safety literature concluded available human and animal data support its safety at current intake levels and the established ADI. [https://pubmed.ncbi.nlm.nih.gov/28558975/]
  - Non-caloric sweetener effects on brain appetite regulation in individuals across varying body weights, Nature Metabolism (2025) — Randomized crossover trial in 75 adults found sucralose vs sucrose increased hypothalamic blood flow and hunger and altered hypothalamic connectivity to reward/motivation regions, with effects varying by sex, body fat, and insulin resistance. [https://www.nature.com/articles/s42255-025-01227-8]
  - Personalized microbiome-driven effects of non-nutritive sweeteners on human glucose tolerance, Cell (2022) — In 120 healthy adults, 2 weeks of sub-ADI sucralose (and saccharin) significantly impaired glycemic responses and altered gut/oral microbiomes; microbiome transplant to germ-free mice reproduced the effect. [https://pubmed.ncbi.nlm.nih.gov/35987213/]
  - Toxicological and pharmacokinetic properties of sucralose-6-acetate and its parent sucralose: in vitro screening assays, Journal of Toxicology and Environmental Health, Part B (2023) — Sucralose-6-acetate (a manufacturing impurity and gut-digestion product, up to ~0.67% of commercial sucralose) was genotoxic/clastogenic in MultiFlow and micronucleus assays and induced gut 'leaky' and inflammatory gene changes. [https://www.tandfonline.com/doi/full/10.1080/10937404.2023.2213903]
  - Sucralose: A Review of Environmental, Oxidative and Genomic Stress, Nutrients (2025) — Review synthesizing environmental persistence, oxidative-stress, and genomic-stress evidence for sucralose, contextualizing the sucralose-6-acetate genotoxicity findings and gut-microbiome and metabolic concerns. [https://pmc.ncbi.nlm.nih.gov/articles/PMC12251854/]
  - Food additive emulsifiers and cancer risk: Results from the French prospective NutriNet-Sant&eacute; cohort, PLOS Medicine (2024) — Among 102,865 French adults, higher artificial-sweetener intake was associated with increased overall cancer risk (HR for higher vs no consumers ~1.13), with the strongest signal for aspartame; observational design limits causal inference. [https://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1003950]

---

## Sorbitol (E420 · sugar alcohol)
URL: https://nutridex.info/s/sorbitol
Category: Sweeteners & Additives
Evidence: Moderate — Several controlled trials; effects real but modest or context-dependent.
A slow-absorbed sugar alcohol that's tooth-friendly but laxative at higher doses

Quick answer: Sorbitol is used for about 60% as sweet as sucrose with ~2.6 kcal/g (vs 4 kcal/g for sugar). NutriDex grades the human evidence as moderate — Several controlled trials; effects real but modest or context-dependent. Based on 10 cited human studies (10 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Sorbitol (E420) is a six-carbon sugar alcohol (polyol) found naturally in fruits like apples, pears, and prunes and manufactured by hydrogenating glucose. It is widely used as a bulk sweetener, humectant, and texturizer in sugar-free gum, candies, baked goods, toothpaste, and as a pharmaceutical excipient and osmotic laxative. It is FDA-affirmed GRAS (21 CFR 184.1835) and carries an EFSA/JECFA Acceptable Daily Intake of "not specified" — the highest safety category. The weight of human evidence is reassuring on systemic toxicity at typical intakes; the well-documented health effect is dose-dependent gastrointestinal upset (gas, bloating, osmotic diarrhea) because sorbitol is only partially absorbed in the small intestine.

Benefits / uses: About 60% as sweet as sucrose with ~2.6 kcal/g (vs 4 kcal/g for sugar); Low glycemic and insulin response — slowly and incompletely absorbed, useful as a sugar substitute for people managing blood glucose; Non-cariogenic: not readily fermented by oral bacteria, so it does not promote tooth decay (used in sugar-free gum and toothpaste); Strong humectant — retains moisture and keeps products like baked goods, candy, and toothpaste soft; Texturizer, bulking agent, anticaking agent, and stabilizer that provides sugar-like body in sugar-free formulations; Used pharmaceutically as an osmotic laxative and as a sweetening/bulking excipient in syrups and tablets.
Active compounds: E-number E420 (E420(i) sorbitol; E420(ii) sorbitol syrup); also labeled D-glucitol or D-sorbitol; Occurs naturally in stone and pome fruits — apples, pears, peaches, plums/prunes, cherries, and apricots; Sugar-free chewing gum, mints, hard candies, and 'no-sugar-added' confectionery and baked goods; Toothpaste, mouthwash, and other oral-care products as a humectant; Pharmaceuticals: osmotic laxative solutions and a sweetener/bulking agent in liquid medications and tablets.
Dose: FDA-affirmed GRAS as a multi-purpose food substance (21 CFR 184.1835). JECFA and the EU/EFSA assign an Acceptable Daily Intake of "not specified" / "not limited" (used at quantum satis per GMP) — the highest-confidence safety classification. Required warning labeling reflects GI tolerance, not toxicity: U.S. foods whose reasonably foreseeable daily consumption could reach 50 g of sorbitol must state "Excess consumption may have a laxative effect," while EU foods with >10% added polyols must carry "Excessive consumption may produce laxative effects." EFSA's polyol re-evaluation is ongoing, with a 2024 call for additional genotoxicity data on sorbitol E420(i).
Safety: Sorbitol has no credible link to cancer or systemic toxicity at dietary levels; the dominant, well-characterized effect is osmotic gastrointestinal intolerance. Because it is absorbed slowly and incompletely, unabsorbed sorbitol draws water into the bowel and is fermented by colonic bacteria, causing dose-dependent gas, bloating, cramping, and diarrhea. The landmark breath-hydrogen study (Hyams, Gastroenterology 1983) showed malabsorption in most healthy adults after as little as 5 g, mild symptoms around 10 g, and cramps/diarrhea around 20 g; reported laxation thresholds are roughly 0.17 g/kg in men and 0.24 g/kg in women. Young children are more susceptible (diarrhea reported after ~7.5 g), and people with IBS, fructose malabsorption, or SIBO are more sensitive — sorbitol is a FODMAP and is restricted on low-FODMAP diets. It is otherwise safe for people with diabetes and is non-cariogenic; the main practical caution is overconsumption of sugar-free products. EFSA's 2024 request for further genotoxicity data is a routine completeness step in re-evaluation, not a safety alert.

Cited studies (10):
  - Systematic review and meta-analysis: Foods, drinks and diets and their effect on chronic constipation in adults, Alimentary pharmacology & therapeutics (2024) — Systematic review and meta-analysis (Aliment Pharmacol Ther) found prune juice improved stool output versus placebo in chronic constipation, an effect attributed largely to its sorbitol content drawing water into the gut lumen. [https://pubmed.ncbi.nlm.nih.gov/37905980/]
  - § 184.1835 Sorbitol, U.S. Code of Federal Regulations (Title 21, Food and Drug Administration) — Affirms sorbitol as GRAS for use as sweetener, humectant, stabilizer, and texturizer, and mandates a laxative-effect warning when foreseeable daily intake may reach 50 g. [https://www.ecfr.gov/current/title-21/chapter-I/subchapter-B/part-184/subpart-B/section-184.1835]
  - Call for data on genotoxicity data on sorbitol (E 420 i), European Food Safety Authority (2023) — EFSA, as part of the ongoing re-evaluation of sorbitol (E420) under Regulation (EU) 257/2010, issued a 2024 public call for additional genotoxicity data — a completeness step within its safety re-assessment. [https://www.efsa.europa.eu/en/call/call-data-genotoxicity-data-sorbitol-e-420-i]
  - Re-evaluation of erythritol (E 968) as a food additive, EFSA Journal (2023) — EFSA's polyol re-evaluations confirm the additive group is handled at quantum satis with ADI 'not specified', GI tolerance being the principal endpoint guiding maximum-use considerations. [https://efsa.onlinelibrary.wiley.com/doi/10.2903/j.efsa.2023.8430]
  - Is fructose malabsorption a cause of irritable bowel syndrome?, Medical hypotheses (2015) — Reviews sorbitol and other FODMAPs as osmotically active, fermentable carbohydrates that provoke bloating, pain, and diarrhea in IBS and fructose-malabsorber populations, supporting low-FODMAP restriction. [https://pmc.ncbi.nlm.nih.gov/articles/PMC4729202/]
  - European guideline on indications, performance, and clinical impact of hydrogen and methane breath tests in adult and pediatric patients: European Association for Gastroenterology, Endoscopy and Nutrition, European Society of Neurogastroenterology and Motility, and European Society for Paediatric Gastroenterology Hepatology and Nutrition consensus, United European gastroenterology journal (2022) — European multi-society consensus guideline (United European Gastroenterol J 2022;10:15-40) standardizes sorbitol breath testing for malabsorption, recommending a sorbitol dose of ~0.2 g/kg (total 5-10 g) in 10% solution. [https://pmc.ncbi.nlm.nih.gov/articles/PMC8830282/]
  - An ESPGHAN Position Paper on the Use of Breath Testing in Paediatric Gastroenterology, Journal of pediatric gastroenterology and nutrition (2022) — ESPGHAN position paper (J Pediatr Gastroenterol Nutr 2022;74:123-137) on breath testing concludes hydrogen breath testing for sorbitol/carbohydrate malabsorption helps distinguish malabsorption from functional GI disorders but lacks diagnostic-threshold standardization in children. [https://pubmed.ncbi.nlm.nih.gov/34292218/]
  - Toxicological evaluation of some food additives including anticaking agents, antimicrobials, antioxidants, emulsifiers and thickening agents (WHO Food Additives Series No. 5), Joint FAO/WHO Expert Committee on Food Additives (JECFA), World Health Organization (1974) — JECFA evaluation establishing an ADI 'not specified' for sorbitol, the highest safety category, with GI/laxative effects identified as the limiting consideration. [https://www.inchem.org/documents/jecfa/jecmono/v05je91.htm]
  - Significance of hydrogen breath tests in children with suspected carbohydrate malabsorption, BMC pediatrics (2014) — Hydrogen breath testing confirms sugar-alcohol/carbohydrate malabsorption as a common cause of functional GI symptoms in children, who are notably more susceptible to sorbitol-induced diarrhea. [https://pmc.ncbi.nlm.nih.gov/articles/PMC3975941/]
  - Sorbitol intolerance: an unappreciated cause of functional gastrointestinal complaints, Gastroenterology (1983) — Breath-hydrogen study in 7 healthy adults: malabsorption in most subjects after as little as 5 g sorbitol, mild GI distress after 10 g, and cramps/diarrhea after 20 g. [https://pubmed.ncbi.nlm.nih.gov/6847853/]

---

## Xylitol (E967 · sugar alcohol)
URL: https://nutridex.info/s/xylitol
Category: Sweeteners & Additives
Evidence: Mixed — Conflicting results across studies; benefit uncertain.
Tooth-friendly sugar alcohol with an emerging cardiovascular question

Quick answer: Xylitol is used for sucrose-like sweetness (~1:1) with ~40% fewer calories (≈2.4 kcal/g). NutriDex grades the human evidence as mixed — Conflicting results across studies; benefit uncertain. Based on 11 cited human studies (11 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Xylitol (E967) is a five-carbon sugar alcohol (polyol) naturally present in fruits, vegetables and birch/corn fibre and produced industrially as a bulk sweetener with roughly the sweetness of sucrose but ~40% fewer calories (≈2.4 kcal/g) and a low glycemic index. It is GRAS in the US and authorised in the EU, with JECFA assigning an ADI "not specified" (the safest category). Human evidence is genuinely mixed: it is well established as low-glycemic and modestly anti-cariogenic, but its near-universal acceptance was shaken by a 2024 cohort-plus-mechanistic study linking higher circulating xylitol to platelet activation and cardiovascular events — a signal that is not yet confirmed and is complicated by the fact that xylitol is also made endogenously.

Benefits / uses: Sucrose-like sweetness (~1:1) with ~40% fewer calories (≈2.4 kcal/g); Low glycemic and insulinemic impact (GI ≈7-13 vs ~60-69 for sucrose) — used in diabetic-friendly products; Anti-cariogenic: non-fermentable by oral bacteria (Streptococcus mutans) and used in dental gums, mints and toothpaste to reduce caries; Provides bulk, sweetness and a cooling mouthfeel that high-intensity sweeteners cannot — used in sugar-free gum, candy and baked goods; Humectant and texture/bulk agent; does not brown (non-Maillard).
Active compounds: E-number E967; sugar alcohol / polyol; Found in: sugar-free chewing gum (Trident, Orbit, PUR, Spry), mints, candies, 'tooth-friendly' lozenges, peanut butter, chewable vitamins, and oral-care products (toothpaste, mouthwash, nasal sprays); Sold as a 1:1 baking/table sweetener (XyloSweet, NOW, Xlear); Manufactured from birch or hardwood xylan and corncob hemicellulose; also occurs naturally in plums, berries, mushrooms and corn.
Dose: US FDA: Generally Recognized As Safe (GRAS) for use in foods. JECFA Acceptable Daily Intake: "not specified" (its lowest-concern category, meaning no numerical limit is needed at GMP use levels). EU: authorised food additive E967, quantum satis (no numerical maximum); EFSA's re-evaluation of polyols is ongoing as of 2024. No numerical mg/kg ADI is set in any major jurisdiction. Practical tolerance is limited by gastrointestinal effects rather than toxicity.
Safety: Best-documented harm is dose-dependent GI intolerance — bloating, gas and an osmotic/laxative effect, typically above ~20-50 g/day (individuals vary), which is why labels carry laxative warnings. Xylitol is acutely TOXIC TO DOGS (and ferrets): doses >0.1 g/kg can cause life-threatening hypoglycemia and >0.5 g/kg acute liver failure — the FDA has issued a specific consumer warning to keep gum, candy and sugar-free peanut butter away from pets. The emerging human signal is cardiovascular: Witkowski et al. (European Heart Journal 2024) found that people in the highest tertile of fasting plasma xylitol had ~1.5-fold higher 3-year risk of major adverse cardiovascular events, and showed in human and animal experiments that ingesting ~30 g enhanced platelet reactivity and clotting. This is an association plus mechanism, not proof of causation; confounding (xylitol is endogenously produced and tracks with cardiometabolic status), measurement of circulating vs ingested xylitol, and lack of RCT outcome data mean it should be treated as a signal under active study, not an established harm. Dental-caries benefit is real but modest and rests on low-to-very-low-quality evidence (Cochrane 2015). People with cardiovascular risk who consume large daily amounts may reasonably moderate intake pending confirmation; the general no-calorie/dental use at typical levels has a long safety record.

Cited studies (11):
  - The effect of xylitol chewing gums and candies on caries occurrence in children: a systematic review with special reference to caries level at study baseline, European archives of paediatric dentistry : official journal of the European Academy of Paediatric Dentistry (2024) — Systematic review of 15 trials found xylitol chewing gum significantly reduced caries occurrence versus no treatment or placebo polyol gum, with clinically significant effects mainly in children with high or moderate baseline caries levels and adequate daily dose. [https://pmc.ncbi.nlm.nih.gov/articles/PMC11058973/]
  - Is xylitol effective in the prevention of dental caries? A systematic review, Journal of clinical and experimental dentistry (2024) — Systematic review of nine human clinical trials (2013-2023) concluded the preventive effect of xylitol against dental caries cannot be confirmed, highlighting need for standardized protocols. [https://pubmed.ncbi.nlm.nih.gov/39544205/]
  - Clinical Effects of Sugar Substitutes on Cariogenic Bacteria: A Systematic Review and Meta-Analysis, International dental journal (2024) — Systematic review and meta-analysis found xylitol more effective than no treatment at reducing cariogenic bacteria, especially Streptococcus mutans in plaque and saliva, with no adverse effects reported. [https://pmc.ncbi.nlm.nih.gov/articles/PMC11561516/]
  - Xylitol-containing products for preventing dental caries in children and adults, Cochrane Database of Systematic Reviews (2015) — Low-quality evidence that a 10% xylitol fluoride toothpaste may reduce caries ~13% over 2.5-3 years vs fluoride-only; evidence for other xylitol products was low to very low quality. [https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010743.pub2/full]
  - Effectiveness of Xylitol in Reducing Dental Caries in Children, Pediatric dentistry (2017) — Systematic review found xylitol had only a small effect on reducing dental caries in children, with very low quality of evidence and considerable heterogeneity. [https://pubmed.ncbi.nlm.nih.gov/28390459/]
  - Paws Off Xylitol; It's Dangerous for Dogs, U.S. Food and Drug Administration — FDA warns xylitol is dangerous to dogs: ingestion can cause rapid insulin release and severe hypoglycemia within 10-60 minutes, with higher doses causing acute liver failure. [https://www.fda.gov/consumers/consumer-updates/paws-xylitol-its-dangerous-dogs]
  - State of play: the re-evaluation of sweeteners, European Food Safety Authority (EFSA) (2024) — EFSA confirms the re-evaluation of polyols including xylitol (E967) is ongoing; xylitol remains an authorised EU additive used at quantum satis. [https://www.efsa.europa.eu/sites/default/files/2024-03/02a-state-of-play-lessons-learnt-from-re-evaluation-sweeteners.pdf]
  - Xylitol is prothrombotic and associated with cardiovascular risk, European Heart Journal (2024) — In a US cohort (>3000 patients), highest vs lowest tertile of plasma xylitol carried an adjusted HR ~1.57 for 3-year MACE, and ingestion of 30 g enhanced platelet reactivity and in-vivo thrombosis in human and mouse models. [https://academic.oup.com/eurheartj/article-abstract/45/27/2439/7683453]
  - Xylitol is prothrombotic and associated with cardiovascular risk, European heart journal (2024) — In >3,000 patients, the highest tertile of circulating xylitol was associated with elevated 3-year risk of major adverse cardiovascular events, and xylitol enhanced platelet reactivity and clot formation in healthy volunteers and animal thrombosis models. [https://pubmed.ncbi.nlm.nih.gov/38842092/]
  - NIH Research Matters 2024 — NIH summary: people with the highest xylitol levels were about 50% more likely to experience a cardiovascular event over the next three years than those with the lowest. [https://www.nih.gov/news-events/nih-research-matters/xylitol-may-affect-cardiovascular-health]
  - Xylitol exposure and cardiovascular risk, European Heart Journal (2024) — Published correspondence debates the Witkowski findings, noting confounding by endogenous xylitol production and cardiometabolic status and calling for confirmatory data before causal inference. [https://academic.oup.com/eurheartj/article/46/3/328/7905371]

---

## Aspartame (E951)
URL: https://nutridex.info/s/aspartame
Category: Sweeteners & Additives
Evidence: Mixed — Conflicting results across studies; benefit uncertain.
The most-studied artificial sweetener — reassuring at intake limits, with a contested cancer signal

Quick answer: Aspartame is used for intense sweetness ~200x sucrose, so tiny amounts sweeten foods. NutriDex grades the human evidence as mixed — Conflicting results across studies; benefit uncertain. Based on 7 cited human studies (7 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Aspartame (E951) is a low-calorie, high-intensity sweetener about 200x sweeter than sucrose, made of aspartic acid and phenylalanine joined as a methyl ester. It is one of the most extensively studied food additives and is approved worldwide — by the FDA (since 1974), EFSA, and JECFA — for use in diet sodas, tabletop sweeteners, sugar-free gum, yogurt and many "light"/"zero" products. Major regulators conclude it is safe within the Acceptable Daily Intake; however, IARC classified it Group 2B "possibly carcinogenic" in 2023 (limited human evidence for liver cancer), and some large cohorts report weak associations with cancer and cardiometabolic outcomes, so the weight of human evidence is best described as reassuring at typical intakes but mixed on long-term risk.

Benefits / uses: Intense sweetness ~200x sucrose, so tiny amounts sweeten foods; Effectively zero-calorie at use levels (it is metabolized but used in trace amounts); Minimal to no acute glycemic or insulin impact in human trials — suitable as a sugar substitute for people with diabetes; Does not promote tooth decay (non-cariogenic); Used to reformulate sugar-sweetened beverages and foods to cut added sugar and calories.
Active compounds: E-number: E951; Brand names: NutraSweet, Equal, Canderel, AminoSweet; Diet/zero sodas (e.g., Diet Coke, Diet Pepsi), often blended with acesulfame-K; Sugar-free chewing gum, tabletop sweetener packets, light yogurts, sugar-free desserts and drink mixes, some chewable medicines/vitamins; US labels must carry: 'Phenylketonurics: Contains Phenylalanine'.
Dose: FDA ADI 50 mg/kg body weight/day (approved as a food additive, not GRAS); EFSA and JECFA/WHO ADI 40 mg/kg bw/day. JECFA reaffirmed the 40 mg/kg ADI in 2023. A 70 kg adult would need roughly 9-14 cans of diet soda daily to exceed the ADI. Must be avoided by people with phenylketonuria (PKU) due to its phenylalanine content.
Safety: For the general population, FDA, EFSA and JECFA judge aspartame safe at the ADI, and EFSA (2013) found no evidence of genotoxicity, carcinogenicity, or harm to the brain, behavior, pregnancy, or children at intakes up to the ADI. The notable signals: IARC classified aspartame Group 2B "possibly carcinogenic to humans" in 2023 based on limited evidence for hepatocellular (liver) carcinoma, while JECFA simultaneously retained the 40 mg/kg ADI, finding the cancer association unconvincing. Observational data are mixed — the NutriNet-Santé cohort linked higher aspartame intake to modestly increased breast and obesity-related cancers (small effect sizes, residual confounding likely). The WHO's 2023 guideline advises against non-sugar sweeteners for weight control, citing no long-term benefit and possible associations with type 2 diabetes and cardiovascular risk (low-certainty evidence). People with PKU must avoid it because they cannot metabolize phenylalanine; claims of headaches, seizures, or neurotoxicity at normal intakes are not supported by controlled evidence.

Cited studies (7):
  - The Effects of Aspartame on Glucose, Insulin, and Appetite-Regulating Hormone Responses in Humans: Systematic Review and Meta-Analyses, Advances in nutrition (Bethesda, Md.) (2025) — Across 100 experiments, aspartame had few effects on blood glucose, insulin, or appetite hormones versus controls and lowered them versus sugars; certainty of evidence very low. [https://pubmed.ncbi.nlm.nih.gov/40381807/]
  - Aspartame hazard and risk assessment results released, World Health Organization (2023) — Classified aspartame Group 2B 'possibly carcinogenic to humans' on limited evidence for hepatocellular carcinoma, while JECFA reaffirmed the 0-40 mg/kg bw/day ADI. [https://www.who.int/news/item/14-07-2023-aspartame-hazard-and-risk-assessment-results-released]
  - Aspartame and Other Sweeteners in Food, U.S. Food and Drug Administration — Approved aspartame as a sweetener (first 1974); maintains an ADI of 50 mg/kg bw/day and requires a phenylalanine warning for people with PKU. [https://www.fda.gov/food/food-additives-petitions/aspartame-and-other-sweeteners-food]
  - WHO advises not to use non-sugar sweeteners for weight control in newly released guideline, World Health Organization (2023) — Advises against using non-sugar sweeteners (including aspartame) for weight control, citing no long-term body-fat benefit and possible associations with type 2 diabetes and cardiovascular disease (low-certainty evidence). [https://www.who.int/news/item/15-05-2023-who-advises-not-to-use-non-sugar-sweeteners-for-weight-control-in-newly-released-guideline]
  - Summary of findings of the evaluation of aspartame at the International Agency for Research on Cancer (IARC) Monographs Programme's 134th Meeting, 6–13 June 2023 and The JOINT FAO/WHO EXPERT COMMITTEE ON FOOD ADDITIVES (JECFA) 96th meeting, 27 June–6 July 2023, International Agency for Research on Cancer (IARC), World Health Organization (2023) — Detailed monograph rationale: limited evidence in humans (liver cancer), limited evidence in experimental animals, and limited mechanistic evidence supported the Group 2B classification. [https://www.iarc.who.int/wp-content/uploads/2023/07/Summary_of_findings_Aspartame.pdf]
  - Scientific Opinion on the re-evaluation of aspartame (E 951) as a food additive, EFSA Journal (EFSA Panel on Food Additives and Nutrient Sources added to Food (ANS)) (2013) — Full re-evaluation concluded aspartame is safe at current exposure, ruling out genotoxicity and carcinogenicity, with ADI of 40 mg/kg bw/day protective for the general population including children and pregnant women. [https://efsa.onlinelibrary.wiley.com/doi/10.2903/j.efsa.2013.3496]
  - Food additive emulsifiers and cancer risk: Results from the French prospective NutriNet-Sant&eacute; cohort, PLOS Medicine (2024) — In 102,865 French adults, higher aspartame intake was associated with increased breast cancer (HR 1.22, 95% CI 1.01-1.48) and obesity-related cancers (HR 1.15, 95% CI 1.01-1.32). [https://journals.plos.org/plosmedicine/article?id=10.1371%2Fjournal.pmed.1003950]

---

## Acesulfame Potassium (Ace-K) (E950)
URL: https://nutridex.info/s/acesulfame-k
Category: Sweeteners & Additives
Evidence: Moderate — Several controlled trials; effects real but modest or context-dependent.
Heat-stable zero-calorie sweetener, often blended to mask its aftertaste

Quick answer: Acesulfame Potassium (Ace-K) is used for intense zero-calorie sweetness (~200x sucrose) with no contribution to energy intake. NutriDex grades the human evidence as moderate — Several controlled trials; effects real but modest or context-dependent. Based on 10 cited human studies (10 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Acesulfame potassium (Ace-K, E950) is a synthetic high-intensity sweetener roughly 200 times sweeter than sucrose, discovered in 1967 and widely used in diet sodas, sugar-free gums, dairy products, tabletop sweeteners and pharmaceuticals. It is heat-stable and not metabolized, so it contributes no calories and is excreted essentially unchanged in urine. It is approved by the FDA (1988), JECFA and EFSA; in 2025 EFSA's full re-evaluation concluded there were no safety or genotoxicity concerns and raised the ADI to 15 mg/kg body weight/day. The weight of human evidence is reassuring for safety at intakes within the ADI, while a 2023 WHO guideline advises against using non-sugar sweeteners for weight control, and some animal and observational data raise questions about gut-microbiome and cardiometabolic effects that are not yet established in humans.

Benefits / uses: Intense zero-calorie sweetness (~200x sucrose) with no contribution to energy intake; No glycemic or insulin impact — not metabolized, suitable for people with diabetes; Exceptional heat and pH stability, allowing use in baking, cooking and shelf-stable products where aspartame degrades; Long shelf life and does not promote dental caries (non-cariogenic); Frequently blended with aspartame or sucralose, where it acts synergistically to boost sweetness and mask each sweetener's off-tastes.
Active compounds: E-number: E950 (EU); also called acesulfame K, Ace-K, Acesulfame-K; Brand names: Sunett and Sweet One; Found in diet/zero soft drinks (often with aspartame or sucralose), sugar-free chewing gum, protein powders and bars, flavored dairy and yogurt, tabletop sweetener packets, baked goods, and as an excipient in chewable/liquid medicines; A slightly bitter metallic aftertaste at high concentration is why it is usually combined with other sweeteners.
Dose: Approved as a food additive by the US FDA in 1988 (regulated under 21 CFR 172.800), not classified as GRAS but as an authorized food additive. FDA Acceptable Daily Intake: 15 mg/kg body weight/day. JECFA (WHO/FAO) ADI: 15 mg/kg bw/day. EFSA's 2025 re-evaluation raised the EU ADI to 15 mg/kg bw/day (from the older 9 mg/kg figure set by the SCF in 2000), derived from a rat NOAEL of 1500 mg/kg bw/day with a 100-fold safety factor. EU dietary exposure estimates remain below the ADI across all population groups.
Safety: Within the ADI, regulatory bodies (FDA, JECFA, EFSA) consider Ace-K safe, and EFSA's 2025 review found no genotoxicity concern for the additive or its degradation products (5-chloro-acesulfame, acetylacetamide). It is one of the more heavily reviewed sweeteners and, unlike aspartame, is not affected by phenylketonuria. The main caveats are not acute toxicity but uncertainties: a 2017 study in CD-1 mice found Ace-K altered the gut microbiome and promoted weight gain with sex-dependent effects, and broader observational cohorts have linked high artificial-sweetener intake (including Ace-K) to increased cardiovascular risk — though these are associational and confounded by reverse causation. WHO's 2023 conditional guideline recommends against using non-sugar sweeteners for weight management, citing no long-term benefit and possible undesirable effects. There is no robust human RCT evidence of harm at typical intakes. People simply seeking to reduce sugar should weigh that Ace-K replaces sugar's harms but is not a proven aid to weight loss.

Cited studies (10):
  - The Combined Effects of Aspartame and Acesulfame-K Blends on Appetite: A Systematic Review and Meta-Analysis of Randomized Clinical Trials, Advances in nutrition (Bethesda, Md.) (2022) — Systematic review and meta-analysis of 8 RCTs (n=274) found aspartame/acesulfame-K blends did not significantly affect energy intake, subjective appetite, blood glucose, or incretin hormones (GIP, GLP-1) versus controls. [https://pmc.ncbi.nlm.nih.gov/articles/PMC9776645/]
  - Re-evaluation of acesulfame K (E 950) as food additive, EFSA Journal (EFSA Panel on Food Additives and Flavourings (FAF)) (2025) — Full re-evaluation concluded no safety concern and no genotoxicity for Ace-K or its degradation products, and raised the ADI to 15 mg/kg bw/day (rat NOAEL 1500 mg/kg, 100-fold factor). [https://efsa.onlinelibrary.wiley.com/doi/10.2903/j.efsa.2025.9317]
  - WHO advises not to use non-sugar sweeteners for weight control in newly released guideline, World Health Organization (2023) — Conditional guideline recommends against use of non-sugar sweeteners (including acesulfame-K) for weight control, finding no long-term benefit for body fat and possible adverse effects with long-term use. [https://www.who.int/news/item/15-05-2023-who-advises-not-to-use-non-sugar-sweeteners-for-weight-control-in-newly-released-guideline]
  - Reduced incidence of Parkinson's disease after dipeptidyl peptidase-4 inhibitors-A nationwide case-control study, Movement disorders : official journal of the Movement Disorder Society (2016) — Systematic review of biological and toxicological data found no consistent evidence that Ace-K is carcinogenic, genotoxic, or metabolically active at relevant intakes. [https://pubmed.ncbi.nlm.nih.gov/27431803/]
  - Re-evaluation of acesulfame K (E 950) as food additive, EFSA journal. European Food Safety Authority (2025) — Open-access PMC version of the EFSA ANS Panel re-evaluation of acesulfame K, reviewing in vitro, animal toxicology, and human interventional/epidemiological studies published 1999-Nov 2024; recommends specification limits of 1 mg/kg for acetylacetamide and 0.1 mg/kg for 5-chloro-acesulfame. [https://pmc.ncbi.nlm.nih.gov/articles/PMC12041894/]
  - Safety of the proposed extension of use of acesulfame K (E 950) in foods for special medical purposes in young children, EFSA Journal (2016) — Concluded the proposed extension of use of Ace-K in foods for special medical purposes for young children is of no safety concern under the conditions assessed. [https://www.efsa.europa.eu/en/efsajournal/pub/4437]
  - Effects of Oral Xylitol, Sucrose, and Acesulfame Potassium on Total Energy Intake During a Subsequent ad libitum Test Meal: A Randomized, Controlled, Crossover Trial in Healthy Humans, Nutrients (2025) — Randomized, controlled, crossover trial in 20 healthy normal-weight adults comparing oral xylitol, sucrose, and acesulfame potassium effects on total energy intake during a subsequent ad libitum test meal. [https://pmc.ncbi.nlm.nih.gov/articles/PMC11821014/]
  - Food Additives Permitted for Direct Addition to Food for Human Consumption; Acesulfame Potassium, Federal Register (U.S. Department of Health and Human Services, Food and Drug Administration) (2003) — Final rule expanding permitted uses of acesulfame potassium as a general-purpose sweetener, building on its original 1988 food-additive approval; FDA ADI of 15 mg/kg bw/day. [https://www.federalregister.gov/documents/2003/12/31/03-32101/food-additives-permitted-for-direct-addition-to-food-for-human-consumption-acesulfame-potassium]
  - Artificial sweeteners and risk of cardiovascular diseases: results from the prospective NutriNet-Sante cohort, BMJ (2022) — In a French cohort of ~103,000 adults, higher total artificial-sweetener intake (acesulfame-K and aspartame the main contributors) was associated with increased cardiovascular disease risk (HR ~1.09); associational and confounding-prone. [https://www.bmj.com/content/378/bmj-2022-071204]
  - Multiple strains probiotics appear to be the most effective probiotics in the prevention of necrotizing enterocolitis and mortality: An updated meta-analysis, PLOS ONE (2017) — In CD-1 mice, 4 weeks of Ace-K perturbed the gut microbiome and promoted body-weight gain, with sex-dependent shifts in energy-metabolism genes — a mechanistic animal signal, not a human finding. [https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0178426]

---

## Xanthan Gum (E415)
URL: https://nutridex.info/s/xanthan-gum
Category: Sweeteners & Additives
Evidence: Moderate — Several controlled trials; effects real but modest or context-dependent.
Microbial fermentation gum that thickens and stabilizes — reassuring safety at dietary levels, with a real preterm-infant caution

Quick answer: Xanthan Gum is used for thickens and stabilizes texture at very low concentrations (typically 0.05-0.5%). NutriDex grades the human evidence as moderate — Several controlled trials; effects real but modest or context-dependent. Based on 11 cited human studies (11 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Xanthan gum (E415) is a high-molecular-weight polysaccharide produced by fermenting sugars with the bacterium Xanthomonas campestris, used as a thickener, stabilizer, and emulsion/suspension agent across sauces, dressings, gluten-free baked goods, dairy, beverages, and dysphagia fluid thickeners. It is FDA GRAS (21 CFR 172.695), and both JECFA and EFSA assign no numerical ADI ("not specified"), reflecting very low toxicity; EFSA's 2017 re-evaluation found no safety concern at observed dietary intakes. The weight of human evidence is reassuring at normal food-additive levels — it is largely unabsorbed and acts as a viscous soluble fiber — but high bolus doses cause GI discomfort/laxation, and it carries a specific, well-documented caution against use as a feed thickener in premature infants because of an association with necrotizing enterocolitis.

Benefits / uses: Thickens and stabilizes texture at very low concentrations (typically 0.05-0.5%); Suspends particles and stabilizes emulsions, preventing separation in dressings, sauces and beverages; Highly pseudoplastic (shear-thinning) and stable across wide pH, temperature and salt ranges; Key structural binder in gluten-free and low-fat foods, mimicking gluten/fat texture; Acts as a viscous soluble fiber: largely non-absorbed, essentially non-caloric in practice; Can blunt postprandial blood glucose by slowing gastric emptying and nutrient diffusion.
Active compounds: E-number: E415 (INS 415); Source: fermentation of glucose/sucrose by Xanthomonas campestris, then alcohol-precipitated and dried; Generic ingredient names: xanthan gum, corn sugar gum; Consumer/medical brands: SimplyThick, Thick-It and other dysphagia fluid thickeners; sold as a baking ingredient (e.g., Bob's Red Mill); Found in: salad dressings, sauces, gravies, ice cream, dairy desserts, gluten-free breads and batters, beverages, syrups, sauces, toothpaste and cosmetics.
Dose: FDA: Generally Recognized As Safe (GRAS), permitted under 21 CFR 172.695 with no numerical limit ("good manufacturing practice"). JECFA (FAO/WHO): ADI "not specified" — the safest category, signaling very low toxicity. EFSA 2017 re-evaluation: no need for a numerical ADI and no safety concern at refined dietary exposures for the general population; repeated intake up to ~214 mg/kg bw/day for 10 days was tolerated, though some adults reported abdominal discomfort. EFSA 2023 follow-up found no safety concern for use in foods for special medical purposes for infants and young children (not applicable below 12-16 weeks of age).
Safety: At food-additive levels xanthan gum is considered very low risk: it is poorly absorbed, fermented in the colon, and regulators (FDA, JECFA, EFSA) place no numerical intake limit. The main everyday effect is dose-dependent GI upset — bloating, flatulence, softer stools or laxation — at high bolus doses (grams), consistent with its action as a viscous fermentable fiber. The landmark genuine signal is in preterm infants: after >15 cases of necrotizing enterocolitis (NEC), including deaths, in premature infants given the xanthan-gum thickener SimplyThick, the FDA in 2011 warned against its use in infants born before 37 weeks, and a 2012 Journal of Pediatrics case series described a distinct NEC pattern — so xanthan-gum thickeners should be avoided in premature/young infants. A 2022 Nature Microbiology study showed the ability to fully degrade xanthan gum has spread through industrialized-country gut microbiomes via a single Ruminococcaceae primary degrader and Bacteroides intestinalis, indicating the additive measurably shapes the microbiota; the clinical significance of this adaptation is not yet established. People with severe dysphagia should follow medical guidance on thickener use, and those prone to IBS-type symptoms may notice GI effects at higher intakes.

Cited studies (11):
  - Effectiveness of different gums on modulating of glycemic indices in adults: a systematic review and meta-analysis, Journal of diabetes and metabolic disorders (2025) — Systematic review and meta-analysis of 42 studies found gums (including xanthan, guar) act as anti-hyperglycemic agents lowering fasting blood glucose, postprandial glucose and HbA1c, with guar gum showing the strongest pooled effect on glycemic indices. [https://pubmed.ncbi.nlm.nih.gov/39736929/]
  - Re-evaluation of xanthan gum (E 415) as a food additive in foods for infants below 16 weeks of age and follow-up of its re-evaluation as a food additive for uses in foods for all population groups, EFSA journal. European Food Safety Authority (2023) — Follow-up re-evaluation found no safety concern for xanthan gum (E415) in foods for special medical purposes for infants/young children at industry-reported levels; not applicable below 12-16 weeks of age. [https://pmc.ncbi.nlm.nih.gov/articles/PMC10157499/]
  - Re-evaluation of xanthan gum (E 415) as a food additive, EFSA Journal (2017) — Re-evaluation concluded no need for a numerical ADI and no safety concern for the general population at refined dietary exposures; intake up to ~214 mg/kg bw/day for 10 days was tolerated (some abdominal discomfort). [https://www.efsa.europa.eu/en/efsajournal/pub/4909]
  - Pharyngeal Residues Following Swallowing of Pureed Diets Thickened with a Gelling Agent or a Xanthan Gum-Based Thickener in Elderly Patients with Dysphagia, Dysphagia (2024) — Randomized crossover trial in 62 elderly dysphagia patients comparing pureed diets thickened with a gelling agent versus a xanthan gum-based thickener, evaluating pharyngeal residue after swallowing. [https://link.springer.com/article/10.1007/s00455-024-10734-x]
  - The Therapeutic Effect of Swallow Training with a Xanthan Gum-Based Thickener in Addition to Classical Dysphagia Therapy in Chinese Patients with Post-Stroke Oropharyngeal Dysphagia: A Randomized Controlled Study, Annals of Indian Academy of Neurology (2023) — Single-blind RCT in Chinese post-stroke oropharyngeal dysphagia patients showed swallow training with a xanthan gum-based thickener added to classical dysphagia therapy improved swallowing recovery versus classical therapy alone. [https://pubmed.ncbi.nlm.nih.gov/38022444/]
  - The Addition of Xanthan Gum to Enteral Nutrition Suppresses Postprandial Glycemia in Humans, Journal of nutritional science and vitaminology (2018) — Adding xanthan gum to enteral nutrition significantly suppressed postprandial glycemia in humans, consistent with its viscous soluble-fiber action. [https://pubmed.ncbi.nlm.nih.gov/30175792/]
  - Relevance of gut microbiome research in food safety assessment, Gut microbes (2024) — Review on the relevance of gut microbiome research in food safety assessment discusses xanthan gum among additives whose widespread consumption may enrich the microbiota for degrading bacteria, informing modern additive safety evaluation. [https://pmc.ncbi.nlm.nih.gov/articles/PMC11451283/]
  - § 172.695 Xanthan gum, U.S. Code of Federal Regulations (Title 21, Food and Drug Administration) — Xanthan gum is an approved direct food additive permitted in food generally with no quantitative limit (GMP); recognized as GRAS for intended uses. [https://www.ecfr.gov/current/title-21/chapter-I/subchapter-B/part-172/subpart-G/section-172.695]
  - Mechanistic insights into consumption of the food additive xanthan gum by the human gut microbiota, Nature microbiology (2022) — Xanthan-gum degradation is common in industrialized-country gut microbiomes, driven by an uncultured Ruminococcaceae primary degrader (novel GH5 enzyme) plus Bacteroides intestinalis — evidence the additive shapes the microbiota. [https://pubmed.ncbi.nlm.nih.gov/35365790/]
  - Late onset necrotizing enterocolitis in infants following use of a xanthan gum-containing thickening agent, The Journal of pediatrics (2012) — FDA investigation of 22 infants linked the xanthan-gum thickener SimplyThick to a distinct late-onset necrotizing enterocolitis pattern, prompting an FDA warning against use in premature infants. [https://pubmed.ncbi.nlm.nih.gov/22575248/]
  - Development of necrotizing enterocolitis in premature infants receiving thickened feeds using SimplyThick®, Journal of perinatology : official journal of the California Perinatal Association (2012) — Premature infants receiving SimplyThick-thickened feeds developed necrotizing enterocolitis, supporting avoidance of xanthan-gum thickeners in preterm infants. [https://pubmed.ncbi.nlm.nih.gov/22289705/]

---

## Stevia (Steviol Glycosides) (E960 · Stevia rebaudiana)
URL: https://nutridex.info/s/stevia
Category: Sweeteners & Additives
Evidence: Moderate — Several controlled trials; effects real but modest or context-dependent.
Plant-derived zero-calorie sweetener with a reassuring safety record at the ADI

Quick answer: Stevia (Steviol Glycosides) is used for zero-calorie, high-intensity sweetness (~200-400x sucrose) for sugar reduction. NutriDex grades the human evidence as moderate — Several controlled trials; effects real but modest or context-dependent. Based on 8 cited human studies (8 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Stevia (steviol glycosides, E960) is a high-intensity, non-nutritive sweetener extracted from the leaves of Stevia rebaudiana Bertoni (or produced by fermentation), 200-400 times sweeter than sucrose with negligible calories. It is authorized in the EU, holds GRAS status for high-purity glycosides in the US, and carries a JECFA/EFSA Acceptable Daily Intake of 4 mg/kg body weight/day (as steviol equivalents). The weight of human and toxicological evidence is reassuring: regulators consistently find it non-genotoxic and non-carcinogenic, and trials show it has little-to-no acute glycemic or insulin impact. However, the WHO 2023 guideline advises against non-sugar sweeteners generally for long-term weight control, and long-term cardiometabolic data specific to stevia remain limited.

Benefits / uses: Zero-calorie, high-intensity sweetness (~200-400x sucrose) for sugar reduction; Minimal-to-no acute postprandial glucose or insulin rise (steviol glycosides are not absorbed intact); Non-glycemic — suitable for diabetic and low-carbohydrate diets; Heat- and pH-stable, so usable in baking and acidic beverages; Does not promote dental caries (non-fermentable by oral bacteria); Plant-derived/'natural' origin, a key marketing and reformulation driver.
Active compounds: E-number E960 (steviol glycosides); newer fermentation-derived grades designated E960a-d; Common branded retail products: Truvia, PureVia, SweetLeaf, Stevia in the Raw, Splenda Naturals Stevia; Key glycosides: stevioside, rebaudioside A (Reb A), and high-purity rebaudioside M (Reb M); Found in: diet/zero soft drinks, flavored waters, yogurts, tabletop sweeteners, protein bars, baked goods, and sugar-free confectionery; Often blended with erythritol, monk fruit, or other bulking agents in tabletop formulations.
Dose: EU authorized food additive (E960). US: FDA accepts GRAS notices for high-purity (>=95%) steviol glycosides; whole-leaf/crude stevia extract is NOT FDA-approved as a food additive. JECFA established an ADI of 4 mg/kg body weight/day (as steviol equivalents) at its 69th meeting (2008) and reaffirmed it at the 82nd meeting (2016); EFSA set the same 4 mg/kg bw/day ADI in 2010. In its 2024 re-evaluation, EFSA reviewed proposals to raise the ADI to 6 or 16 mg/kg bw/day but concluded there was insufficient justification, retaining 4 mg/kg bw/day. The 4 mg/kg figure incorporates a 100-fold safety factor over the NOAEL from a 2-year rat carcinogenicity study.
Safety: Regulators (EFSA 2010, JECFA 2008/2016) consistently conclude high-purity steviol glycosides are non-genotoxic and non-carcinogenic; Reb A was negative across the Ames test, chromosomal aberration, and mouse lymphoma assays. Steviol glycosides are not absorbed intact — gut bacteria hydrolyze them to steviol, which is then conjugated and excreted, with no evidence of accumulation. Human gut-microbiome RCTs (4-week and 12-week) found no significant changes in microbiota diversity versus control. The main caveats are population-level, not stevia-specific: EFSA's 2024 assessment flagged that 95th-percentile exposure can approach or exceed the ADI in infants and toddlers under expanded uses, and the WHO 2023 guideline advises against non-sugar sweeteners (stevia included) for body-weight control or NCD prevention, citing possible associations with type 2 diabetes, cardiovascular disease, and mortality drawn largely from observational data (reverse causation likely). Long-term stevia-specific cardiometabolic trials are sparse. No established allergenicity concern for purified glycosides; people sensitive to Asteraceae plants are occasionally cautioned about crude leaf preparations.

Cited studies (8):
  - Effect of stevia on blood glucose and HbA1C: A meta-analysis, Diabetes & Metabolic Syndrome: Clinical Research & Reviews (2024) — Meta-analysis of stevia trials reported no significant effect on fasting blood glucose or HbA1c versus control. [https://www.sciencedirect.com/science/article/abs/pii/S187140212400153X]
  - Scientific opinion on the extension of the authorisation of use of the food additive steviol glycosides (E 960a-d) and the modification of the acceptable daily intake (ADI) for steviol, EFSA Journal (2024) — Reviewed proposals to raise the ADI to 6 or 16 mg/kg bw/day but found insufficient justification, retaining the 4 mg/kg bw/day ADI and flagging exposure near the ADI in infants/toddlers under expanded uses. [https://efsa.onlinelibrary.wiley.com/doi/10.2903/j.efsa.2024.9045]
  - Effect of Steviol Glycosides on Human Health with Emphasis on Type 2 Diabetic Biomarkers: A Systematic Review and Meta-Analysis of Randomized Controlled Trials, Nutrients (2019) — Systematic review and meta-analysis of 9 RCTs (n=462) found a significant systolic BP reduction (MD -6.32 mmHg) but non-significant effects on fasting glucose, HbA1c, BMI, and lipids. [https://pmc.ncbi.nlm.nih.gov/articles/PMC6770957/]
  - WHO advises not to use non-sugar sweeteners for weight control in newly released guideline, World Health Organization (2023) — Reviewed >280 studies and advised against non-sugar sweeteners (including stevia) for weight control, citing no long-term body-fat benefit and possible associations with type 2 diabetes, CVD, and mortality. [https://www.who.int/news/item/15-05-2023-who-advises-not-to-use-non-sugar-sweeteners-for-weight-control-in-newly-released-guideline]
  - JECFA 2008/2016 — Established and later reaffirmed an ADI of 4 mg/kg body weight/day for steviol glycosides (as steviol equivalents), based on a 2-year rat NOAEL with a 100-fold safety factor. [https://www.fda.gov/media/172565/download]
  - Comparison of a Daily Steviol Glycoside Beverage compared with a Sucrose Beverage for Four Weeks on Gut Microbiome in Healthy Adults, The Journal of nutrition (2024) — 4-week RCT in healthy adults comparing a daily steviol-glycoside beverage (25% ADI) with a 30 g sucrose beverage found no adverse impact on the gut microbiome. [https://pubmed.ncbi.nlm.nih.gov/38408729/]
  - Consumption of the Non-Nutritive Sweetener Stevia for 12 Weeks Does Not Alter the Composition of the Human Gut Microbiota, Nutrients (2024) — 12-week consumption of stevia in healthy adults did not alter alpha or beta diversity or taxa abundance of the gut microbiota relative to controls. [https://www.mdpi.com/2072-6643/16/2/296]
  - EFSA evaluates the safety of steviol glycosides, European Food Safety Authority (2010) — Concluded high-purity steviol glycosides meeting JECFA specifications are not genotoxic or carcinogenic and set an ADI of 4 mg/kg bw/day. [https://www.efsa.europa.eu/en/press/news/ans100414]

---

## Carrageenan (E407)
URL: https://nutridex.info/s/carrageenan
Category: Sweeteners & Additives
Evidence: Mixed — Conflicting results across studies; benefit uncertain.
A red-seaweed thickener (E407) that regulators worldwide deem safe in food, though small human and animal studies keep a gut-inflammation question open.

Quick answer: Carrageenan is used for gelling and thickening agent — forms heat-reversible gels (kappa/iota types) used to set and texturize foods. NutriDex grades the human evidence as mixed — Conflicting results across studies; benefit uncertain. Based on 8 cited human studies (8 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Carrageenan (E407) is a high-molecular-weight sulfated polysaccharide extracted from red seaweeds (mainly Eucheuma, Chondrus, and Gigartina species) and used as a gelling, thickening, and stabilizing agent. It is permitted in the EU (E407) and is FDA-affirmed GRAS in the US (21 CFR 172.620/182.7255). Authoritative bodies — JECFA (ADI "not specified," reaffirmed for infant formula in 2014/2015) and EFSA (2018, group ADI 75 mg/kg bw/day, made temporary pending better data) — concluded food-grade carrageenan is not carcinogenic and is safe at use levels. The human evidence is mixed: a small no-carrageenan RCT in ulcerative colitis and a 2024 crossover RCT in overweight adults suggest possible gut-permeability and inflammatory effects, but these are small and contested, and much historical "harm" data used poligeenan (degraded carrageenan), a different acid-hydrolyzed material never used in food.

Benefits / uses: Gelling and thickening agent — forms heat-reversible gels (kappa/iota types) used to set and texturize foods; Stabilizes emulsions and suspensions — keeps cocoa in chocolate milk and prevents whey separation in dairy; Provides body and mouthfeel in low-fat and plant-based products without adding calories or sugar; Binds water and improves slice/firmness in processed meats and deli products; Zero glycemic and negligible caloric impact — an indigestible dietary fiber-type polysaccharide; Topical/non-food: purified iota-carrageenan nasal sprays show antiviral activity in RCTs (distinct from dietary use).
Active compounds: E-number E407 (E407a = semi-refined / processed Eucheuma seaweed, PES); Three main types: kappa, iota, and lambda carrageenan; Dairy and dairy alternatives: chocolate milk, ice cream, whipped/squirt cream, cottage cheese, yogurt drinks, plant milks (almond/oat/soy); Processed and deli meats, pate, and reformed meat products; Infant formula (permitted up to 1000 mg/L per JECFA); Desserts, jellies, sauces, dressings, nutritional/meal-replacement shakes; Sometimes labeled 'carrageenan,' 'Irish moss extract,' or 'seaweed extract'; common in supplier brands (e.g., Genu, Gelcarin, Viscarin).
Dose: EU: authorized food additive E407 (and E407a); EFSA 2018 set a temporary group ADI of 75 mg/kg body weight/day for E407 + E407a, made temporary pending improved data within 5 years (no carcinogenicity concern; subchronic NOAEL 3,400-3,900 mg/kg/day). JECFA: ADI "not specified" (i.e., no numerical limit needed at typical intakes), and in 2014/2015 concluded use in infant formula up to 1000 mg/L is not of concern. US FDA: food-grade carrageenan is affirmed GRAS and regulated under 21 CFR 172.620 (carrageenan) and 182.7255; specifications restrict low-molecular-weight (degraded) fractions.
Safety: Food-grade carrageenan is poorly absorbed and has been repeatedly judged non-carcinogenic and safe at use levels by JECFA, EFSA, and the FDA. The principal open question is gastrointestinal: animal and cell models show food-grade carrageenan can degrade the colonic mucus barrier, shift microbiota (lowering Akkermansia muciniphila), and activate TLR4/NF-kB inflammatory signaling, and a small double-blind RCT (Bhattacharyya 2017) found a no-carrageenan diet lengthened time to relapse in ulcerative colitis. A 2024 crossover RCT (Naimi, BMC Medicine) found 500 mg/day carrageenan did not change insulin sensitivity overall but increased intestinal permeability and, in overweight participants, lowered insulin sensitivity and raised CRP/IL-6. These trials are small and industry-funded critiques note they used bolus capsules rather than food-bound carrageenan. A crucial distinction: most alarming older data used poligeenan ("degraded carrageenan"), an acid-hydrolyzed low-molecular-weight material never permitted in food and not the same as the food additive. People with active inflammatory bowel disease (Crohn's, ulcerative colitis) who wish to be cautious may reasonably choose to limit it; for the general population the regulatory consensus is reassuring.

Cited studies (8):
  - Substances Added to Food <em>(formerly EAFUS)</em>, U.S. Food and Drug Administration — Food-grade carrageenan is FDA-affirmed GRAS and regulated as a direct food additive (21 CFR 172.620) and emulsifier/stabilizer (21 CFR 182.7255), with specifications limiting low-molecular-weight fractions. [https://hfpappexternal.fda.gov/scripts/fdcc/index.cfm?set=FoodSubstances&id=CARRAGEENAN]
  - Re‐evaluation of carrageenan (E 407) and processed Eucheuma seaweed (E 407a) as food additives, EFSA Journal (2018) — Re-evaluation concluded no concern for carcinogenicity and no adverse effects in chronic rat studies up to 7,500 mg/kg/day, but set a temporary group ADI of 75 mg/kg bw/day for E407/E407a pending better chemistry, exposure, and toxicology data. [https://efsa.onlinelibrary.wiley.com/doi/abs/10.2903/j.efsa.2018.5238]
  - JECFA 2015 (FAO/WHO) — Reaffirmed an ADI 'not specified' for food-grade carrageenan and concluded use in infant formula and formula for special medical purposes at up to 1000 mg/L is not of safety concern. [https://apps.who.int/food-additives-contaminants-jecfa-database/Home/Chemical/377]
  - Carrageenan and insulin resistance in humans: a randomised double-blind cross-over trial, BMC medicine (2024) — Oral carrageenan 250 mg twice daily for 2 weeks did not change whole-body insulin sensitivity overall but increased intestinal permeability, and in overweight subjects significantly lowered insulin sensitivity and raised CRP and IL-6. [https://pubmed.ncbi.nlm.nih.gov/39593091/]
  - A randomized trial of the effects of the no-carrageenan diet on ulcerative colitis disease activity, Nutrition and healthy aging (2017) — In a double-blind multicenter trial of ulcerative colitis patients in remission, those given carrageenan capsules relapsed earlier than placebo (3 of 5 vs 0 of 7 by study end), suggesting dietary carrageenan restriction may benefit some UC patients. [https://pmc.ncbi.nlm.nih.gov/articles/PMC5389019/]
  - Carrageenan as a Potential Factor of Inflammatory Bowel Diseases, Nutrients (2024) — Review concluded food-grade carrageenan can degrade the colonic mucus barrier, reduce Akkermansia muciniphila, and activate TLR4/NF-kB pro-inflammatory signaling in animal and cell models, flagging IBD patients as the population of greatest theoretical concern. [https://pubmed.ncbi.nlm.nih.gov/38732613/]
  - A Critical Review of 'A randomized trial of the effects of the no-carrageenan diet on ulcerative colitis disease activity', Nutrition and Healthy Aging (2019) — Industry-affiliated reanalysis of the Bhattacharyya UC trial argued its small size, bolus-capsule dosing, and methodology limit conclusions, and reiterated that global regulators consider food-grade carrageenan safe and distinct from poligeenan. [https://journals.sagepub.com/doi/10.3233/NHA-180051]
  - An infant formula toxicity and toxicokinetic feeding study on carrageenan in preweaning piglets with special attention to the immune system and gastrointestinal tract, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association (2015) — An infant-formula toxicity/toxicokinetic feeding study in preweaning piglets found no adverse effects on the immune system or gastrointestinal tract attributable to carrageenan, supporting JECFA's infant-formula conclusion. [https://pubmed.ncbi.nlm.nih.gov/25592784/]

---

## MSG (Monosodium Glutamate) (E621)
URL: https://nutridex.info/s/msg
Category: Sweeteners & Additives
Evidence: Moderate — Several controlled trials; effects real but modest or context-dependent.
The umami salt behind a debunked "syndrome" — GRAS-affirmed and safe at dietary levels, with only minor, dose-dependent signals.

Quick answer: MSG (Monosodium Glutamate) is used for flavour enhancer providing the fifth basic taste, umami (savoury/brothy), by stimulating glutamate taste receptors. NutriDex grades the human evidence as moderate — Several controlled trials; effects real but modest or context-dependent. Based on 8 cited human studies (8 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Monosodium glutamate (MSG, E621) is the sodium salt of glutamic acid, a non-essential amino acid that occurs naturally in foods such as tomatoes, cheese, and seaweed; it is added as a flavour enhancer to deliver the savoury "umami" taste in soups, snacks, processed meats, and Asian cuisine. The glutamate in MSG is chemically identical to and metabolised the same way as the glutamate bound in dietary protein, of which adults eat roughly 13 g/day versus about 0.5 g/day of added MSG. It is FDA "generally recognized as safe" (GRAS), JECFA assigned a group "ADI not specified," and EFSA's 2017 re-evaluation set a precautionary group ADI of 30 mg/kg/day. The weight of human evidence — including multiple double-blind, placebo-controlled challenge trials — does not support the long-claimed "Chinese restaurant syndrome," though some people self-report mild, transient symptoms after large bolus doses taken without food.

Benefits / uses: Flavour enhancer providing the fifth basic taste, umami (savoury/brothy), by stimulating glutamate taste receptors; Can reduce total sodium in a recipe by 20-40% while preserving palatability, because MSG contains roughly one-third the sodium of table salt and enhances saltiness perception; Low-cost, heat-stable, and highly water-soluble, so it integrates into soups, sauces, seasonings, and dry mixes without affecting texture; Glutamate is metabolised as an ordinary amino acid (about 4 kcal/g but used in tiny amounts), with negligible impact on blood glucose; Improves acceptability of lower-salt or reduced-fat foods, which may aid dietary sodium reduction efforts.
Active compounds: E-number E621 (monosodium glutamate); related glutamate salts: E620 glutamic acid, E622 monopotassium glutamate, E623 calcium glutamate, E624 ammonium glutamate, E625 magnesium glutamate; Common trade/brand name: Aji-no-moto (Ajinomoto); generic 'umami seasoning'; Added directly to snack foods, instant noodles and bouillon/stock cubes, canned and dried soups, processed and cured meats, frozen meals, salad dressings, and restaurant dishes; Also present naturally (as free glutamate) in Parmesan and aged cheeses, tomatoes, mushrooms, soy sauce, fish sauce, seaweed (kombu), and yeast extract; 'hydrolysed vegetable protein' and 'autolysed yeast' contribute glutamate without an MSG label.
Dose: FDA classifies added MSG as GRAS and requires it to be declared as 'monosodium glutamate' on ingredient labels. JECFA (1987) allocated a group 'ADI not specified' for glutamic acid and its salts — its safest category, meaning no numerical limit is needed under good manufacturing practice. EFSA (2017) took a more precautionary stance, deriving a group ADI of 30 mg/kg body weight/day (expressed as glutamic acid) from a NOAEL of 3,200 mg/kg/day in a neurodevelopmental study with a 100-fold uncertainty factor, and noted that high consumers in some population groups could exceed this level. Typical added-MSG intake (~0.5-0.55 g/day) is well below regulatory ceilings.
Safety: Decades of human research, including multiple double-blind, placebo-controlled challenge trials, have not confirmed the cluster of symptoms historically labelled 'Chinese restaurant syndrome' (a term now regarded as scientifically unsupported and culturally stigmatising). A small minority of people report mild, short-lived, self-limiting reactions (headache, flushing, sweating, numbness) after large doses (typically >=3 g taken as a bolus without food); these are not reproduced reliably under blinded conditions, and the placebo response rate is comparable. Because MSG contributes sodium, it counts toward total sodium intake relevant to blood pressure, and small controlled studies have shown transient blood-pressure elevation and pericranial muscle sensitisation after repeated high intake. Observational cohort data on MSG and weight gain are conflicting (one large Chinese cohort found a modest association with overweight, HR ~1.33; another found none), and causality is not established. EFSA's main flag is that aggregate exposure can exceed its precautionary ADI in high consumers, prompting a call to reconsider permitted use levels — not a finding of demonstrated harm at dietary intakes. People who genuinely react should simply avoid it; there is no evidence of toxicity, carcinogenicity, or neurotoxicity from normal dietary use.

Cited studies (8):
  - Questions and Answers on Monosodium glutamate (MSG), U.S. Food and Drug Administration — FDA affirms added MSG as 'generally recognized as safe' (GRAS), notes glutamate from MSG is metabolically identical to dietary glutamate (~13 g/day from protein vs ~0.55 g/day added MSG), and requires label declaration. [https://www.fda.gov/food/food-additives-petitions/questions-and-answers-monosodium-glutamate-msg]
  - Does monosodium glutamate really cause headache? : a systematic review of human studies, The journal of headache and pain (2016) — Systematic review of human studies found no consistent causal relationship between MSG ingestion and headache; provocation effects were inconsistent and often absent under blinded, with-food conditions. [https://pmc.ncbi.nlm.nih.gov/articles/PMC4870486/]
  - Re-evaluation of glutamic acid (E 620), sodium glutamate (E 621), potassium glutamate (E 622), calcium glutamate (E 623), ammonium glutamate (E 624) and magnesium glutamate (E 625) as food additives, EFSA Journal (2017) — Re-evaluation derived a group ADI of 30 mg/kg bw/day (as glutamic acid) from a NOAEL of 3,200 mg/kg/day, concluding glutamates are not genotoxic or carcinogenic but that high-consumer exposure can exceed the ADI. [https://efsa.onlinelibrary.wiley.com/doi/10.2903/j.efsa.2017.4910]
  - JECFA (WHO/FAO), 1987 evaluation — Joint FAO/WHO Expert Committee allocated L-glutamic acid and its salts (including MSG) a group 'ADI not specified', its safest classification, indicating no toxicological concern at GMP use levels. [https://apps.who.int/food-additives-contaminants-jecfa-database/Home/Chemical/2257]
  - Headache and mechanical sensitization of human pericranial muscles after repeated intake of monosodium glutamate (MSG), The journal of headache and pain (2013) — Repeated MSG (150 mg/kg) vs placebo over 5 days caused short-lasting blood-pressure elevation and mechanical sensitisation of the masseter muscle plus more reported headache, with no tolerance developing. [https://pmc.ncbi.nlm.nih.gov/articles/PMC3606962/]
  - Review of alleged reaction to monosodium glutamate and outcome of a multicenter double-blind placebo-controlled study, The Journal of nutrition (2000) — Review of double-blind, placebo-controlled MSG challenges found symptom rates after MSG were not significantly greater than after placebo, with no reproducible 'MSG symptom complex' at dietary doses. [https://pubmed.ncbi.nlm.nih.gov/10736382/]
  - Consumption of monosodium glutamate in relation to incidence of overweight in Chinese adults: China Health and Nutrition Survey (CHNS), The American journal of clinical nutrition (2011) — Prospective cohort: highest vs lowest quintile of MSG intake had adjusted HR 1.33 (95% CI 1.01-1.75) for incident overweight, suggesting a modest positive association independent of energy intake. [https://pmc.ncbi.nlm.nih.gov/articles/PMC3095503/]
  - Monosodium glutamate is not associated with obesity or a greater prevalence of weight gain over 5 years: findings from the Jiangsu Nutrition Study of Chinese adults, British Journal of Nutrition (2010) — Over 5 years, MSG intake was NOT associated with obesity or greater weight gain after adjustment for lifestyle and energy intake, contradicting the leptin/obesity hypothesis. [https://www.cambridge.org/core/journals/british-journal-of-nutrition/article/monosodium-glutamate-is-not-associated-with-obesity-or-a-greater-prevalence-of-weight-gain-over-5-years-findings-from-the-jiangsu-nutrition-study-of-chinese-adults/A25C050A0EA8F80DD1BEC8C8E601A011]

---

## Emulsifiers (Polysorbate-80 & CMC) (E433 / E466)
URL: https://nutridex.info/s/emulsifiers-p80-cmc
Category: Sweeteners & Additives
Evidence: Preliminary — Early or small human trials; promising but not yet conclusive.
Texture-stabilizing food additives under fresh scrutiny for gut-microbiome effects

Quick answer: Emulsifiers (Polysorbate-80 & CMC) is used for stabilizes oil-in-water emulsions so fat and water do not separate. NutriDex grades the human evidence as preliminary — Early or small human trials; promising but not yet conclusive. Based on 8 cited human studies (8 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Polysorbate-80 (E433) and carboxymethylcellulose/cellulose gum (E466) are synthetic detergent-like emulsifiers used to keep fat and water mixed and to stabilize texture in processed foods such as ice cream, sauces, baked goods and dairy alternatives. Both are long-approved (FDA GRAS/regulated additive; EFSA group ADI 25 mg/kg bw/day for polysorbates and an ADI "not specified" for celluloses), and classic toxicology shows no genotoxicity or carcinogenicity. The newer and still-emerging human evidence is on a different endpoint: controlled-feeding and ex-vivo work led by Chassaing shows these emulsifiers can perturb the gut microbiota and intestinal mucus barrier, a biologically plausible but not yet outcome-proven signal that has prompted calls to revisit safety thresholds.

Benefits / uses: Stabilizes oil-in-water emulsions so fat and water do not separate; Improves and maintains creamy/smooth texture and mouthfeel (e.g. ice cream, dressings); Acts as a thickener, suspending agent and anti-staling agent (CMC); Extends shelf-life and freeze-thaw stability of processed and frozen foods; Solubilizes flavors, vitamins and oils; widely used as a pharmaceutical/vaccine excipient (P80).
Active compounds: Polysorbate-80: E433 (Tween 80, polyoxyethylene-20 sorbitan monooleate); Carboxymethylcellulose: E466 (sodium CMC, cellulose gum); Found in ice cream, frozen desserts, whipped/non-dairy toppings, salad dressings, sauces; Baked goods, gluten-free products, processed cheese, plant-based milks and yogurts; Also used as excipients in medicines, supplements and vaccines.
Dose: FDA: both permitted — P80 (Tween 80) is a regulated direct additive (e.g. 21 CFR 172.840), and CMC (sodium carboxymethylcellulose / cellulose gum) is GRAS. EFSA 2015: group ADI 25 mg/kg bw/day for polysorbates E432–E436 incl. P80 (E433), derived from a rat NOAEL of 2,500 mg/kg/day with a 100-fold uncertainty factor. EFSA 2018: for celluloses including E466 no numerical ADI was deemed necessary (ADI "not specified"), with intakes up to ~660–900 mg/kg bw/day judged not of concern. JECFA likewise set ADI "not specified" for modified celluloses.
Safety: Standard toxicology is reassuring: no evidence of genotoxicity, carcinogenicity, or reproductive toxicity, and celluloses are essentially unabsorbed and excreted in feces. The active question is gut health. In mice, low-dose P80 and CMC induced low-grade intestinal inflammation, microbiota shifts, metabolic syndrome and, in susceptible animals, colitis (Chassaing 2015). A double-blind controlled-feeding RCT of 15 g/day CMC for 11 days in healthy adults (Chassaing 2022) reduced microbiota diversity, depleted beneficial metabolites, modestly increased postprandial abdominal discomfort, and in a subset showed bacteria encroaching into the normally sterile mucus layer. Large cohort data are not yet confirmatory for these two additives specifically: the NutriNet-Sante cancer analysis (Sellem 2024) flagged E471 and carrageenans rather than P80/CMC, and the type-2-diabetes analysis implicated several emulsifiers (notably carrageenans). People with inflammatory bowel disease (Crohn's, ulcerative colitis) or irritable bowel syndrome may be the most plausible group to limit intake, though firm clinical guidance does not yet exist. Overall this is an emerging signal, not established harm.

Cited studies (8):
  - Scientific Opinion on the re-evaluation of polyoxyethylene sorbitan monolaurate (E 432), polyoxyethylene sorbitan monooleate (E 433), polyoxyethylene sorbitan monopalmitate (E 434), polyoxyethylene sorbitan monostearate (E 435) and polyoxyethylene sorbitan tristearate (E 436) as food additives, EFSA Journal (2015) — Re-evaluation established a group ADI of 25 mg/kg bw/day for polysorbates incl. P80 (E433) from a rat NOAEL of 2,500 mg/kg/day, with no concern for genotoxicity, carcinogenicity or developmental toxicity. [https://www.efsa.europa.eu/en/efsajournal/pub/4152]
  - Re-evaluation of celluloses E 460(i), E 460(ii), E 461, E 462, E 463, E 464, E 465, E 466, E 468 and E 469 as food additives, EFSA Journal (2018) — Re-evaluation of celluloses including CMC (E466) concluded no numerical ADI was needed (ADI 'not specified'); celluloses are unabsorbed and intakes up to ~660-900 mg/kg bw/day were not of concern. [https://efsa.onlinelibrary.wiley.com/doi/10.2903/j.efsa.2018.5047]
  - Randomized Controlled-Feeding Study of Dietary Emulsifier Carboxymethylcellulose Reveals Detrimental Impacts on the Gut Microbiota and Metabolome, Gastroenterology (2022) — Double-blind controlled-feeding RCT (n=16; 15 g/day CMC vs emulsifier-free diet, 11 days) reduced gut microbiota diversity and beneficial metabolites, increased postprandial abdominal discomfort, and in a subset caused bacterial encroachment into the mucus layer. [https://pmc.ncbi.nlm.nih.gov/articles/PMC9639366/]
  - Food additive emulsifiers and cancer risk: Results from the French prospective NutriNet-Sant&eacute; cohort, PLOS Medicine (2024) — In the NutriNet-Sante cohort, mono-/diglycerides (E471) and carrageenans were associated with higher cancer risk, while associations for other emulsifiers were not robust; no robust P80/CMC-specific cancer signal emerged. [https://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1004338]
  - Food additive emulsifiers and the risk of type 2 diabetes: analysis of data from the NutriNet-Sante prospective cohort study, The Lancet Diabetes & Endocrinology (2024) — Among 104,139 adults, higher intakes of several emulsifiers (notably total carrageenans, plus tripotassium phosphate, guar and xanthan gums and others) were associated with increased type 2 diabetes incidence. [https://www.thelancet.com/journals/landia/article/PIIS2213-8587(24)00086-X/fulltext]
  - Food additive emulsifiers and risk of cardiovascular disease in the NutriNet-Santé cohort: prospective cohort study, BMJ (Clinical research ed.) (2023) — In the NutriNet-Santé cohort (n=95,442; median 7.4 y follow-up; 1,995 CVD events), higher carboxymethylcellulose (E466) intake was associated with higher risks of cardiovascular and coronary heart disease, and E471/E472 mono- and diglycerides with higher risks of all cardiovascular outcomes. [https://pmc.ncbi.nlm.nih.gov/articles/PMC10480690/]
  - Dietary emulsifiers impact the mouse gut microbiota promoting colitis and metabolic syndrome, Nature (2015) — Low concentrations of P80 and CMC in mice altered the microbiota, induced low-grade inflammation and metabolic syndrome in wild-type animals, and promoted robust colitis in colitis-prone mice. [https://pubmed.ncbi.nlm.nih.gov/25731162/]
  - Dietary emulsifiers directly alter human microbiota composition and gene expression ex vivo potentiating intestinal inflammation, Gut (2017) — P80 and CMC acted directly on human microbiota to raise pro-inflammatory flagellin; transfer of treated microbiota to germ-free mice recapitulated inflammation, showing the microbiota is a direct target. [https://pmc.ncbi.nlm.nih.gov/articles/PMC5940336/]

---

## Lactulose (Galactose-fructose disaccharide)
URL: https://nutridex.info/s/lactulose
Category: Prebiotics & Fibers, Gut & Immune
Evidence: Strong — Multiple high-quality RCTs / meta-analyses with consistent effects.
Synthetic galactose-fructose disaccharide: osmotic laxative, ammonia-lowering therapy, and bifidogenic prebiotic

Quick answer: Lactulose is used for reduces mortality and improves/prevents overt hepatic encephalopathy in cirrhosis (cochrane rr ~0.59 for death; ~0.58 for he) by trapping gut-derived ammonia as ammonium and accelerating its excretion. NutriDex grades the human evidence as strong — Multiple high-quality RCTs / meta-analyses with consistent effects. Based on 9 cited human studies (9 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Lactulose is a non-absorbable synthetic disaccharide (galactose linked to fructose) that passes undigested to the colon, where bacteria ferment it into short-chain fatty acids that acidify the lumen, trap ammonia as ammonium, and exert an osmotic laxative effect. Its strongest evidence is in hepatic encephalopathy: a 2016 Cochrane review of randomized trials found non-absorbable disaccharides reduce mortality (RR ~0.59) and improve/prevent overt and minimal encephalopathy, making it first-line therapy. For chronic constipation it reliably increases stool frequency, though head-to-head trials show polyethylene glycol (PEG/macrogol) outperforms it on most outcomes. At low (sub-laxative) doses lactulose acts as a bifidogenic prebiotic and modestly enhances colonic calcium absorption, but these microbiome and mineral-absorption uses rest on smaller, shorter trials and are less robust than its gastroenterology indications.

Benefits / uses: Reduces mortality and improves/prevents overt hepatic encephalopathy in cirrhosis (Cochrane RR ~0.59 for death; ~0.58 for HE) by trapping gut-derived ammonia as ammonium and accelerating its excretion; Reverses minimal hepatic encephalopathy and improves cognition and quality of life (multicenter RCT: 64% vs 23% reversal at 60 days); Increases stool frequency and softens stool in chronic constipation (network meta-analysis: ~+3.4 weekly bowel movements vs placebo), an osmotic/fermentative laxative effect; Bifidogenic prebiotic at low doses: selectively increases Bifidobacterium and Lactobacillus and boosts colonic short-chain fatty acid (SCFA) production while lowering luminal pH; Modestly enhances colonic calcium absorption in a dose-dependent manner (postmenopausal crossover trial: ~28% to ~32% fractional absorption), with similar signals for magnesium; First-line agent for primary and secondary prophylaxis of recurrent encephalopathy, reducing serious cirrhosis complications (liver failure, bleeding, infection).
Active compounds: Prescription/OTC oral solutions: Duphalac, Cephulac, Kristalose (crystalline powder), Constulose, Enulose, Generlac, Lactugal; Generic lactulose syrup (typically 10 g per 15 mL); rectal enema formulations for acute encephalopathy; Functional-food / prebiotic ingredient in some yogurts and infant/medical nutrition (mainly Japan/Europe); Not a natural food fiber - lactulose is synthesized industrially from lactose (trace amounts form in heated/UHT milk).
Dose: Constipation: 15-30 mL syrup (10-20 g) once daily, titrated to 2-3 soft stools/day. Overt hepatic encephalopathy: 30-45 mL (20-30 g) every 1-2 hours until catharsis, then 30-45 mL 2-4x daily targeting 2-3 soft stools/day; can be given by enema (300 mL in 700 mL water) if obtunded. Minimal HE: ~30-60 mL/day in divided doses. Prebiotic/mineral-absorption use: lower 3-10 g/day. Taken orally, may be mixed with water, juice or food to improve palatability.
Safety: Highly fermentable (high-FODMAP), so flatulence, bloating, abdominal cramping and an initially sweet taste are common, especially when starting or at laxative doses; nausea and diarrhea signal overdosing. Overuse can cause excess watery diarrhea with dehydration and electrolyte disturbance (hypokalemia, hypernatremia), particularly in the elderly and in encephalopathy where over-titration may itself precipitate confusion. Contraindicated in galactosemia (contains galactose) and in suspected bowel obstruction; use caution in diabetes (contains some free galactose/lactose). Like other fibers/osmotics it can alter absorption of co-ingested drugs; avoid combining with other laxatives when titrating in encephalopathy. Generally considered safe in pregnancy and as a constipation treatment in children. Unlike glucomannan/konjac it poses no choking/esophageal-obstruction risk.

Cited studies (9):
  - Network meta-analysis of probiotics, prebiotics, and synbiotics for the treatment of chronic constipation in adults, European journal of nutrition (2024) — Network meta-analysis of 37 RCTs (3903 adults): lactulose increased weekly stool movements vs placebo (mean difference 3.39, 95% CI 1.13-5.65; moderate certainty). [https://pubmed.ncbi.nlm.nih.gov/38693449/]
  - Efficacy and Safety of Variable Treatment Options in the Prevention of Hepatic Encephalopathy: A Systematic Review and Network Meta-Analysis, Cureus (2024) — Systematic review and network meta-analysis (43 studies, 19,622 patients) ranked combined lactulose plus rifaximin most effective for preventing overt HE vs placebo (RR 0.19, 95% CI 0.09-0.40) and superior to lactulose alone (RR 0.57, 95% CI 0.36-0.92). [https://pmc.ncbi.nlm.nih.gov/articles/PMC10907550/]
  - Efficacy and safety of L-ornithine L-aspartate combined with lactulose in treatment of hepatic encephalopathy: a systematic review and meta-analysis of randomized controlled trial, Frontiers in medicine (2025) — Meta-analysis of 12 RCTs (858 patients) found L-ornithine L-aspartate plus lactulose was 31% more effective than lactulose alone for hepatic encephalopathy (RR 1.31, 95% CI 1.22-1.42) and lowered blood ammonia (MD -13.02, 95% CI -15.69 to -10.36) without increasing adverse events. [https://pmc.ncbi.nlm.nih.gov/articles/PMC12075176/]
  - Non-absorbable disaccharides versus placebo/no intervention and lactulose versus lactitol for the prevention and treatment of hepatic encephalopathy in people with cirrhosis, The Cochrane database of systematic reviews (2016) — In 24 RCTs (n=1487) non-absorbable disaccharides reduced mortality vs placebo/no intervention (RR 0.59, 95% CI 0.40-0.87) and improved hepatic encephalopathy (RR 0.58, 95% CI 0.50-0.69; 22 RCTs). [https://pubmed.ncbi.nlm.nih.gov/27153247/]
  - Clinical efficacy and safety of lactulose for minimal hepatic encephalopathy: a meta-analysis, European journal of gastroenterology & hepatology (2011) — Meta-analysis of 9 RCTs (434 patients) found lactulose significantly improved neuropsychological test performance in minimal hepatic encephalopathy (RR for no improvement 0.52, 95% CI 0.44-0.62). [https://pubmed.ncbi.nlm.nih.gov/21971378/]
  - Lactulose versus Polyethylene Glycol for Chronic Constipation, The Cochrane database of systematic reviews (2010) — Cochrane review (10 RCTs) found polyethylene glycol superior to lactulose for stool frequency, stool form and need for additional laxatives in chronic constipation. [https://pubmed.ncbi.nlm.nih.gov/20614462/]
  - Lactulose improves cognition, quality of life, and gut microbiota in minimal hepatic encephalopathy: A multicenter, randomized controlled trial, Journal of digestive diseases (2019) — Multicenter RCT in minimal HE: day-60 MHE reversal rate 64.2% with lactulose vs 22.6% control (P=.0002), with improved cognition, quality of life and gut microbiota. [https://pubmed.ncbi.nlm.nih.gov/31448533/]
  - Lactulose Stimulates Calcium Absorption in Postmenopausal Women, Journal of Bone and Mineral Research (1999) — Randomized double-blind crossover in 12 postmenopausal women: fractional calcium absorption rose dose-dependently with lactulose (27.7% reference vs 32.2% at 10 g/day; P<0.01). [https://academic.oup.com/jbmr/article-abstract/14/7/1211/7515000]
  - Low-Dose Lactulose as a Prebiotic for Improved Gut Health and Enhanced Mineral Absorption, Frontiers in nutrition (2021) — Review of human and mechanistic data showing low-dose (sub-laxative) lactulose acts as a bifidogenic prebiotic, increasing Bifidobacterium/SCFA and enhancing mineral absorption. [https://pmc.ncbi.nlm.nih.gov/articles/PMC8353095/]

---

## Human Milk Oligosaccharides (2'-FL) (2'-fucosyllactose)
URL: https://nutridex.info/s/hmo-2fl
Category: Prebiotics & Fibers, Gut & Immune
Evidence: Moderate — Several controlled trials; effects real but modest or context-dependent.
The most abundant human milk oligosaccharide — a selectively bifidogenic prebiotic now made by microbial fermentation for infant formula and adult gut-health supplements.

Quick answer: Human Milk Oligosaccharides (2'-FL) is used for selectively bifidogenic: randomized trials in infants and adults reproducibly increase relative abundance of bifidobacterium (and actinobacteria) while reducing proteobacteria/firmicutes, the most consistent and best-evidenced effect. NutriDex grades the human evidence as moderate — Several controlled trials; effects real but modest or context-dependent. Based on 10 cited human studies (10 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

2'-Fucosyllactose (2'-FL) is the most abundant oligosaccharide in the breast milk of "secretor" mothers, now produced commercially by microbial fermentation and added to infant formula and adult prebiotic supplements. It resists human digestion and is selectively fermented by Bifidobacterium, and randomized trials in infants, healthy adults, and older adults consistently show a robust bifidogenic shift in the gut microbiota with good tolerability up to ~20 g/day. The clinical evidence is strongest for the microbiome effect itself and for tolerability/safety; downstream benefits (IBS symptom relief, metabolic and cognitive markers, infant infection reduction) are more preliminary, with several trials missing their primary clinical endpoints or showing benefit only in pre-specified subgroups. It is not the same class of evidence as oat beta-glucan or psyllium, which carry FDA heart-health claims — 2'-FL has no authorized health claim, but it has GRAS status and EFSA novel-food approval.

Benefits / uses: Selectively bifidogenic: randomized trials in infants and adults reproducibly increase relative abundance of Bifidobacterium (and Actinobacteria) while reducing Proteobacteria/Firmicutes, the most consistent and best-evidenced effect; Well tolerated as a prebiotic up to ~20 g/day with only dose-dependent flatulence/bloating, unlike many highly fermentable FODMAP fibers; May improve irritable bowel syndrome symptoms (stool consistency, abdominal pain, bloating, quality of life) — supported by an open-label multicenter trial, though a blinded RCT found no symptom advantage over placebo; In older adults, a 2025 RCT linked 2'-FL to higher serum HDL cholesterol, insulin and FGF21, with cognitive/visual-memory benefit in Bifidobacterium 'responders' (exploratory, primary cytokine endpoint not met); In infant formula, supports age-appropriate growth and is associated in some trials with fewer lower-respiratory and bronchitis events and reduced antibiotic/antipyretic use (findings inconsistent across studies); Acts as a decoy receptor and may modulate gut-barrier and immune function, mechanisms supported by preclinical and infant data.
Active compounds: Standalone adult supplements: Layer Origin PureHMO 2'-FL powder, kepos, Holigos/Layer Origin capsules; Infant formula with added 2'-FL: Similac (Abbott), Enfamil/Nestlé NAN/Gerber Good Start, Aptamil and store-brand formulas; Bulk fermentation-derived ingredient brands: Friesland Campina (Aequival), DSM-Firmenich (GlyCare 2FL), Chr. Hansen, Inbiose; Often combined with LNnT (lacto-N-neotetraose) in a 4:1 or 2:1 mix in clinical trials; Naturally present in human breast milk of secretor (FUT2-positive) mothers; not found in standard cow's-milk dairy.
Dose: Adult gut-health trials use ~1-20 g/day, most commonly 5 g/day of 2'-FL (or a 4:1 2'-FL:LNnT mix); tolerability studies tested up to 20 g/day for 2 weeks. Older-adult RCT used 1 g/day (low) or 5 g/day (high). Taken as a powder dissolved in water or food, once daily; infant formula provides roughly 0.2-1.0 g/L. Start low and titrate up to limit gas.
Safety: Generally well tolerated; the main side effects are dose-dependent flatulence, bloating, abdominal discomfort and altered stool, mostly at the highest doses (10-20 g/day) and usually transient. As a fermentable oligosaccharide it is a FODMAP-type substrate, so people with sensitive guts or active IBS should start low (e.g. ~1-2 g/day) and titrate slowly. It has FDA GRAS status and EFSA novel-food authorization and is added to infant formula at regulated levels. Because 2'-FL is largely lactose-based, products are typically suitable for lactose-intolerant adults (the oligosaccharide is not digested), but galactosemia and rare carbohydrate-metabolism disorders warrant caution. No major drug interactions are established, but as with other viscous/fermentable fibers it is prudent to separate from time-critical oral medications. Long-term safety data in adults beyond a few weeks to months are limited; pregnant/breastfeeding individuals and those with serious GI disease should consult a clinician.

Cited studies (10):
  - A human milk oligosaccharide alters the microbiome, circulating hormones, and metabolites in a randomized controlled trial of older adults, Cell Reports Medicine (2025) — 6-week RCT in 89 healthy older adults (mean 67y): 2'-FL (1 or 5 g/day) raised gut Bifidobacterium, serum insulin, HDL cholesterol and FGF21; the primary cytokine endpoint was not met, and cognitive/visual-memory gains appeared only in Bifidobacterium 'responders'. [https://www.cell.com/cell-reports-medicine/fulltext/S2666-3791(25)00329-5]
  - Bifidogenic Effect of 2'-Fucosyllactose (2'-FL) on the Gut Microbiome of Healthy Formula-Fed Infants: A Randomized Clinical Trial, Nutrients (2025) — RCT in healthy formula-fed infants: formula with 2'-FL produced higher Bifidobacterium relative abundance (59.5%) than GOS+FOS formula (24.4%), demonstrating a strong species-level bifidogenic effect. [https://pmc.ncbi.nlm.nih.gov/articles/PMC11944528/]
  - Human milk oligosaccharide supplementation in irritable bowel syndrome patients: A parallel, randomized, double‐blind, placebo‐controlled study, Neurogastroenterology &amp; Motility (2020) — Parallel, double-blind, placebo-controlled RCT in IBS patients: 4:1 2'-FL/LNnT at 5 or 10 g/day for 4 weeks increased fecal Bifidobacterium (10 g group) and was well tolerated, but overall and individual GI symptoms did not differ from placebo. [https://doi.org/10.1111/nmo.13920]
  - Human Milk Oligosaccharides Support Normal Bowel Function and Improve Symptoms of Irritable Bowel Syndrome: A Multicenter, Open-Label Trial, Clinical and translational gastroenterology (2020) — Multicenter open-label trial in 317 IBS patients: 5 g/day 2'-FL+LNnT (4:1) for 12 weeks normalized stool consistency and significantly reduced abdominal pain and bloating with improved quality of life across all IBS subtypes (no placebo arm). [https://pmc.ncbi.nlm.nih.gov/articles/PMC7721220/]
  - Safety and efficacy of a probiotic-containing infant formula supplemented with 2'-fucosyllactose: a double-blind randomized controlled trial, Nutrition journal (2022) — Double-blind RCT: probiotic infant formula supplemented with 2'-FL was safe and supported normal growth; medication use was similar between groups (~83.9% vs 81.1%), with respiratory-infection differences not reaching significance. [https://pmc.ncbi.nlm.nih.gov/articles/PMC8862345/]
  - Safety and efficacy of a probiotic-containing infant formula supplemented with 2’-fucosyllactose: a double-blind randomized controlled trial, Nutrition Journal (2022) — Double-blind RCT of a probiotic-containing infant formula supplemented with 2'-fucosyllactose found the formula safe, well-tolerated, and supporting age-appropriate growth versus control. [https://link.springer.com/article/10.1186/s12937-022-00764-2]
  - Impact of 2'-Fucosyllactose on Gut Microbiota Composition in Adults with Chronic Gastrointestinal Conditions: Batch Culture Fermentation Model and Pilot Clinical Trial Findings, Nutrients (2021) — Pilot clinical trial in adults with IBS or ulcerative colitis found a 2'-FL-containing formula increased GIQLI symptom scores, stool Bifidobacterium and Faecalibacterium prausnitzii, and butyrate after 6 weeks. [https://pmc.ncbi.nlm.nih.gov/articles/PMC7998190/]
  - Oral supplementation of healthy adults with 2'-O-fucosyllactose and lacto-N-neotetraose is well tolerated and shifts the intestinal microbiota, The British journal of nutrition (2016) — RCT in 100 healthy adults: 2'-FL and LNnT at up to 20 g/day for 2 weeks were safe and well tolerated and selectively increased relative abundance of Actinobacteria and Bifidobacterium while reducing Firmicutes and Proteobacteria. [https://pmc.ncbi.nlm.nih.gov/articles/PMC5082288/]
  - 2'-Fucosyllactose Is Well Tolerated in a 100% Whey, Partially Hydrolyzed Infant Formula With Bifidobacterium lactis: A Randomized Controlled Trial, Global pediatric health (2019) — RCT in term infants: a 100% whey, partially hydrolyzed formula with B. lactis and 2'-FL was well tolerated and supported age-appropriate growth with no safety concerns versus control formula. [https://pmc.ncbi.nlm.nih.gov/articles/PMC6421602/]
  - Supplementation of 2'-Fucosyllactose in Formula-Fed Infants Has Potential Benefits to Reduce the Risks of Infantile Colic and Atopic Dermatitis in Infancy, Pediatric gastroenterology, hepatology & nutrition (2025) — In a 1-year comparison of breastfed, formula-fed, and 2'-FL-supplemented formula-fed term infants, 2'-FL supplementation was associated with reduced risk of infantile colic and atopic dermatitis in infancy. [https://pmc.ncbi.nlm.nih.gov/articles/PMC12457806/]

---

## Resistant Maltodextrin (Soluble Corn Fiber) (Fibersol)
URL: https://nutridex.info/s/resistant-maltodextrin
Category: Prebiotics & Fibers, Gut & Immune
Evidence: Moderate — Several controlled trials; effects real but modest or context-dependent.
A non-viscous, well-tolerated soluble fiber that blunts post-meal glucose, feeds bifidobacteria, and boosts calcium absorption.

Quick answer: Resistant Maltodextrin (Soluble Corn Fiber) is used for attenuates the acute post-meal rise in blood glucose and insulin in a dose-dependent way (~10-20% lower glycemic response at ~5-10 g with a carbohydrate load), the best-evidenced effect. NutriDex grades the human evidence as moderate — Several controlled trials; effects real but modest or context-dependent. Based on 8 cited human studies (8 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Resistant maltodextrin (RMD), marketed as soluble corn fiber and under brand names such as Fibersol-2 and Promitor, is a low-viscosity, enzyme-resistant glucose polymer made by controlled heat/acid treatment of corn or wheat starch. It is highly fermentable yet largely non-gelling, so unlike viscous fibers (psyllium, beta-glucan) its main human-trial signals are a modest, dose-dependent reduction in post-meal blood glucose, a bifidogenic shift in the gut microbiome with increased short-chain fatty acids, and improved calcium absorption rather than large LDL-lowering. The best-supported use is attenuation of the acute glycemic response to a carbohydrate load (a meta-analysis of 37 RCTs); evidence for satiety, laxation, and microbiome shifts is moderate, while effects on fasting glucose, HbA1c, body weight, and lipids are smaller and less consistent. It is unusually well tolerated for a fermentable fiber, with gas and bloating typically appearing only at higher single doses.

Benefits / uses: Attenuates the acute post-meal rise in blood glucose and insulin in a dose-dependent way (~10-20% lower glycemic response at ~5-10 g with a carbohydrate load), the best-evidenced effect; Acts as a prebiotic: increases fecal bifidobacteria and other beneficial taxa (e.g. Parabacteroides) and raises short-chain fatty acid production; Improves calcium absorption in controlled-feeding trials, an effect linked to its microbiome-shifting (bifidogenic/fermentation) action; Increases satiety and delays the return of hunger after a meal, with higher GLP-1 and PYY satiety hormones at a 10 g dose; Supports bowel regularity, increasing stool wet weight and frequency when used to bridge a fiber-intake gap; May modestly lower total and LDL cholesterol, mainly when combined with a probiotic (e.g. L. rhamnosus GG) in people with elevated baseline cholesterol — a weaker, less consistent signal than for viscous fibers.
Active compounds: Fibersol-2 (Archer Daniels Midland / Matsutani) — the most-studied branded digestion-resistant maltodextrin; Promitor Soluble Fiber / Soluble Corn Fiber (Tate & Lyle); Generic 'soluble corn fiber' or 'resistant maltodextrin' powders and capsules; Common food/beverage ingredient added to fiber-fortified bars, drinks, yogurts, baked goods, and some 'fiber gummies' and keto/low-carb products; Listed on US labels as 'soluble corn fiber' under the FDA-recognized dietary fibers.
Dose: Glycemic blunting: ~5-10 g taken with a carbohydrate-containing meal (often in a beverage). Prebiotic/laxation and calcium-absorption benefits: ~10-25 g/day, typically split across meals, with bifidogenic effects seen even at lower (~6-12 g/day) doses. Satiety: ~10 g with a meal. It dissolves clearly in water and is usually stirred into drinks or foods; effects are acute or build over 1-3 weeks of daily use.
Safety: One of the better-tolerated fermentable fibers: it is non-viscous and does not form a choking gel like psyllium or glucomannan, and most people tolerate 10-25 g/day. Because it is rapidly fermented, larger single doses (roughly >20-40 g) can cause gas, bloating, borderline cramping, and loose stools or osmotic/laxative effect; tolerance improves with gradual dose escalation and splitting doses. As a FODMAP-type fermentable substrate it may worsen symptoms in some people with IBS or SIBO, who should titrate cautiously. Like other fibers, taking large amounts at the same time as oral medications may slow or reduce their absorption, so separate medications by ~1-2 hours. People with diabetes on glucose-lowering drugs should monitor blood sugar, as the glycemic-blunting effect could add to medication effects. It is generally regarded as safe (GRAS) as a food ingredient; pregnant or breastfeeding people and those with significant GI disease should consult a clinician before using high supplemental doses.

Cited studies (8):
  - Interventions to lower the glycemic response to carbohydrate foods with a low-viscosity fiber (resistant maltodextrin): meta-analysis of randomized controlled trials, The American journal of clinical nutrition (2009) — Across 37 randomized placebo-controlled trials, 4-10 g of resistant maltodextrin produced a significant, dose-dependent attenuation of the glycemic response to carbohydrate (e.g. ~21% reduction with rice meals; 95% CI -26% to -16%), with stronger effects in drinks than solid foods. [https://pubmed.ncbi.nlm.nih.gov/19126874/]
  - Resistant Maltodextrin Consumption in a Double-Blind, Randomized, Crossover Clinical Trial Induces Specific Changes in Potentially Beneficial Gut Bacteria, Nutrients (2022) — Resistant maltodextrin consumption induced specific increases in potentially beneficial gut bacteria, confirming a reproducible microbiome-modulating (prebiotic) signal in humans. [https://www.mdpi.com/2072-6643/14/11/2192]
  - Soluble Corn Fiber Increases Calcium Absorption Associated with Shifts in the Gut Microbiome: A Randomized Dose-Response Trial in Free-Living Pubertal Females, The Journal of nutrition (2016) — In 28 adolescent girls, 10 and 20 g/day soluble corn fiber increased fractional calcium absorption by ~12.9-13.3% versus control (P<0.05), with dose-dependent rises in Parabacteroides and Clostridium-related taxa. [https://pubmed.ncbi.nlm.nih.gov/27281813/]
  - Soluble dietary fiber (Fibersol-2) decreased hunger and increased satiety hormones in humans when ingested with a meal, Nutrition research (New York, N.Y.) (2015) — In 19 healthy adults, 10 g Fibersol-2 with a meal significantly delayed hunger and increased satiety for 1.5-2 h and raised satiety hormones GLP-1 and PYY versus 0 g or 5 g (P<0.05). [https://pubmed.ncbi.nlm.nih.gov/25823991/]
  - Prebiotic Potential of a Maize-Based Soluble Fibre and Impact of Dose on the Human Gut Microbiota, PloS one (2016) — In healthy adults given soluble corn fiber delivering 6, 12, or 18 g/day for 14 days, fecal bifidobacteria rose significantly at the 6 g/day dose, demonstrating a prebiotic (bifidogenic) effect. [https://pmc.ncbi.nlm.nih.gov/articles/PMC4701468/]
  - Effects of Soluble Corn Fiber Alone or in Synbiotic Combination with Lactobacillus rhamnosus GG and the Pilus-Deficient Derivative GG-PB12 on Fecal Microbiota, Metabolism, and Markers of Immune Function: A Randomized, Double-Blind, Placebo-Controlled, Crossover Study in Healthy Elderly (Saimes Study), Frontiers in immunology (2017) — In 40 healthy elderly adults, soluble corn fiber (alone and with L. rhamnosus GG) shifted the microbiota (increased Parabacteroides and Ruminococcaceae); the synbiotic reduced total and LDL cholesterol in those with elevated baseline levels. [https://pubmed.ncbi.nlm.nih.gov/29312280/]
  - In healthy adults, resistant maltodextrin produces a greater change in fecal bifidobacteria counts and increases stool wet weight: a double-blind, randomized, controlled crossover study, Nutrition research (New York, N.Y.) (2018) — In healthy adults below recommended fiber intake, 25 g/day resistant maltodextrin significantly increased fecal Bifidobacterium counts and stool wet weight versus control, supporting prebiotic and laxation benefits. [https://pubmed.ncbi.nlm.nih.gov/30527258/]
  - Resistant Maltodextrin (Soluble Corn Fiber), Calorie Control Council (Fiber Facts) (2020) — Review of soluble corn fiber/resistant maltodextrin RCTs supports modest, fairly consistent benefits for post-meal glycemia, bifidogenic microbiome shifts and SCFA, calcium absorption, and bowel regularity, with weaker and less consistent effects on fasting glucose, lipids, and body weight. [https://www.fiberfacts.org/soluble-corn-fiber/]

---

## Polydextrose (E1200)
URL: https://nutridex.info/s/polydextrose
Category: Prebiotics & Fibers, Gut & Immune
Evidence: Moderate — Several controlled trials; effects real but modest or context-dependent.
Synthetic, low-calorie glucose polymer (E1200) that acts as a gently fermented soluble fiber — bifidogenic and modestly satiating, with thin clinical-outcome data.

Quick answer: Polydextrose is used for bifidogenic microbiome shift: in placebo-controlled crossover feeding it increased faecal bifidobacterium and coprococcus and raised short-chain fatty acid (notably butyrate) production, with fermentation occurring along the entire colon. NutriDex grades the human evidence as moderate — Several controlled trials; effects real but modest or context-dependent. Based on 9 cited human studies (9 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Polydextrose (PDX, E1200) is a synthetic, randomly branched glucose polymer made by acid-condensing glucose with sorbitol and citric acid; it largely resists digestion in the small intestine and is slowly, partially fermented along the whole colon, yielding roughly 1 kcal/g. Randomized crossover studies show it is bifidogenic — shifting the faecal microbiota toward Bifidobacterium and increasing short-chain fatty acids — and it is one of the best-tolerated fibers, releasing relatively little gas because of slow, distal fermentation. The most consistent human signal is modest, dose-dependent reduction of energy intake at a subsequent meal in acute satiety trials, plus increases in stool frequency at ~12 g/day; effects on body weight, fasting glucose/HbA1c, and lipids are inconsistent or weak. Notably, EFSA reviewed the bowel-function data in 2016 and concluded the evidence was insufficient to authorize a "maintenance of normal defecation" health claim, so PDX lacks the regulatory backing that psyllium and oat beta-glucan carry.

Benefits / uses: Bifidogenic microbiome shift: in placebo-controlled crossover feeding it increased faecal Bifidobacterium and Coprococcus and raised short-chain fatty acid (notably butyrate) production, with fermentation occurring along the entire colon; Modestly enhances satiety and reduces energy intake at a later meal in a dose-dependent way (meta-analysis of acute trials), associated with higher post-meal GLP-1 and reduced hunger in obese adults; Increases stool frequency and adds faecal bulk at ~12 g/day, improving bowel function in mildly constipated and dialysis populations (though EFSA judged the overall defecation evidence insufficient for a health claim); Exceptional GI tolerance for a fiber: high molecular weight, low osmotic load and slow fermentation give a high laxative threshold (~90 g/day, or ~50 g single dose) and comparatively low gas/bloating; May blunt the postprandial glucose and insulin response when it replaces digestible carbohydrate, since PDX itself is largely non-glycemic (~1 kcal/g); Preclinical and mechanistic data suggest SCFA-driven luminal acidification could improve calcium solubility/absorption and modestly lower cholesterol, but robust human outcome trials are lacking.
Active compounds: Branded ingredient: Litesse (Danisco/IFF) and Sta-Lite (Tate & Lyle), used as soluble-fiber/bulking agents; Fiber/meal-replacement supplements and protein bars/shakes listing 'polydextrose' or 'soluble corn/wheat fiber blend'; Reduced-sugar and reduced-calorie processed foods: baked goods, low-carb/'keto' bars, sugar-free chocolate and confectionery, frozen desserts, beverages; Added as bulking agent and humectant alongside high-intensity sweeteners (it provides bulk/mouthfeel that the sweetener cannot); Not a meaningful natural food constituent — it is a manufactured additive (E1200), so exposure is almost entirely from fortified/processed products.
Dose: Typical functional/fiber doses in trials are about 8-12 g/day for bowel function (12 g/day was the effective constipation dose) and 6.25-25 g as a single preload for satiety; food fortification commonly delivers 4-15 g per serving. Best taken with food, split across the day, and started low (a few grams) then increased to limit gas. The mean laxative threshold is high (~90 g/day, or ~50 g as a single dose).
Safety: Among the most GI-tolerable fibers because of its high molecular weight, low osmotic potential and slow, distal fermentation; common effects are mild flatulence, bloating, borderline cramping or loose stools, mainly above single doses of ~50 g or daily intakes approaching ~90 g (the laxative threshold). Unlike gel-forming bulk fibers such as psyllium or konjac/glucomannan, PDX does not swell into a viscous mass and is not associated with choking or esophageal/intestinal obstruction. As a fermentable carbohydrate it can aggravate gas, bloating and pain in people with IBS or on a low-FODMAP diet, and large amounts may have an osmotic/laxative effect. Start low and escalate gradually, and take with adequate fluid. Like other soluble fibers it can theoretically slow gastric emptying and delay or reduce absorption of co-ingested medications, so separating PDX-heavy products from time-critical drugs (e.g., levothyroxine) by 2-4 hours is prudent. Caloric value is low (~1 kcal/g) and it is generally regarded as safe (JECFA ADI 'not specified'; US GRAS), but it offers no proven disease-treatment benefit and should not replace evidence-based fibers where a specific clinical effect (LDL lowering, glycemic control) is the goal.

Cited studies (9):
  - Effects of polydextrose on different levels of energy intake. A systematic review and meta-analysis, Appetite (2015) — Systematic review and meta-analysis of acute trials found polydextrose taken mid-morning significantly reduced energy intake at the subsequent lunch in a dose-dependent manner, though total daily energy intake was not significantly changed. [https://pubmed.ncbi.nlm.nih.gov/25510531/]
  - Effect of Polydextrose on Subjective Feelings of Appetite during the Satiation and Satiety Periods: A Systematic Review and Meta-Analysis, Nutrients (2016) — Companion meta-analysis of subjective appetite found polydextrose modestly increased feelings of satiety and reduced hunger during the satiety period, supporting a small appetite-suppressing effect. [https://pmc.ncbi.nlm.nih.gov/articles/PMC4728658/]
  - Polydextrose and maintenance of normal defecation: evaluation of a health claim pursuant to Article 13(5) of Regulation (EC) No 1924/2006, EFSA Journal (2016) — EFSA evaluated an Article 13(5) health claim and concluded a cause-and-effect relationship between polydextrose consumption and maintenance of normal defecation had NOT been established, so no claim was authorized. [https://efsa.onlinelibrary.wiley.com/doi/10.2903/j.efsa.2016.4480]
  - Impact of polydextrose on the faecal microbiota: a double-blind, crossover, placebo-controlled feeding study in healthy human subjects, British Journal of Nutrition (2012) — Double-blind, placebo-controlled crossover feeding study in healthy adults found polydextrose significantly increased faecal Bifidobacterium and Coprococcus and shifted the microbiota and SCFA profile versus placebo, confirming a bifidogenic effect in humans. [https://www.cambridge.org/core/journals/british-journal-of-nutrition/article/impact-of-polydextrose-on-the-faecal-microbiota-a-doubleblind-crossover-placebocontrolled-feeding-study-in-healthy-human-subjects/4B99F9E3AF6AEC75438659525E006FCE]
  - Postprandial effects of polydextrose on satiety hormone responses and subjective feelings of appetite in obese participants, Nutrition journal (2015) — Acute multicenter randomized, double-blind, placebo-controlled crossover trial in 18 obese adults: 15 g polydextrose with a high-fat meal raised plasma GLP-1 and reduced the hunger iAUC by ~40% versus placebo. [https://pmc.ncbi.nlm.nih.gov/articles/PMC4320494/]
  - Efficacy of Polydextrose Supplementation on Colonic Transit Time, Bowel Movements, and Gastrointestinal Symptoms in Adults: A Double-Blind, Randomized, Placebo-Controlled Trial, Nutrients (2019) — Double-blind, randomized, placebo-controlled trial in adults reported that polydextrose supplementation improved colonic transit time and bowel-movement parameters versus placebo with good GI tolerance. [https://pmc.ncbi.nlm.nih.gov/articles/PMC6412485/]
  - Effect of Polydextrose Intake on Constipation in Japanese Dialysis Patients: A Triple-Blind, Randomized, Controlled Trial, Journal of nutritional science and vitaminology (2015) — Triple-blind RCT in 50 Japanese hemodialysis patients found polydextrose increased stool frequency from 3.0 to 7.5 times/week over 8 weeks without laxation problems (distention, cramps, diarrhea). [https://pubmed.ncbi.nlm.nih.gov/26440643/]
  - A Randomized, Controlled Trial Evaluating Polydextrose as a Fiber in a Wet and Dry Matrix on Glycemic Control, Journal of food science (2017) — Randomized controlled trial evaluating polydextrose as a fiber in wet and dry food matrices examined its effect on postprandial glycemic control, consistent with PDX being largely non-glycemic when it replaces digestible carbohydrate. [https://pubmed.ncbi.nlm.nih.gov/28892156/]
  - A review of the clinical toleration studies of polydextrose in food, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association (2004) — Review of clinical toleration studies established polydextrose's mean laxative threshold at ~90 g/day (1.3 g/kg) or ~50 g as a single dose, well above functional intakes, supporting strong GI tolerability. [https://pubmed.ncbi.nlm.nih.gov/15234083/]

---

## Inulin (Chicory Root Fiber) (Fructan · Cichorium intybus)
URL: https://nutridex.info/s/inulin
Category: Prebiotics & Fibers, Gut & Immune
Evidence: Moderate — Several controlled trials; effects real but modest or context-dependent.
Chicory-derived fructan prebiotic — bifidogenic, modest glycemic and lipid effects, boosts calcium absorption

Quick answer: Inulin (Chicory Root Fiber) is used for bifidogenic prebiotic: selectively increases bifidobacterium and boosts colonic short-chain fatty acid (scfa) production, the most consistently reproduced effect in human trials. NutriDex grades the human evidence as moderate — Several controlled trials; effects real but modest or context-dependent. Based on 9 cited human studies (9 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Inulin is a non-digestible fructan (chains of fructose with a terminal glucose) extracted mainly from chicory root (Cichorium intybus); it resists upper-gut digestion and is fermented in the colon to short-chain fatty acids, selectively expanding Bifidobacterium. The strongest human evidence is for its bifidogenic prebiotic effect and for modest glycemic benefit in prediabetes/type 2 diabetes (a GRADE-assessed dose-response meta-analysis of 33 RCTs found significant reductions in fasting glucose, HbA1c, insulin, and HOMA-IR). Effects on LDL/triglycerides, body weight, and constipation are real but small and of low-to-moderate certainty, while calcium-absorption and bone-mineralization benefits are well demonstrated in adolescents. Inulin is a fermentable FODMAP, so dose-dependent gas and bloating are its main practical limitation.

Benefits / uses: Bifidogenic prebiotic: selectively increases Bifidobacterium and boosts colonic short-chain fatty acid (SCFA) production, the most consistently reproduced effect in human trials; Glycemic control: in prediabetes/type 2 diabetes, ~10 g/day for 6+ weeks significantly lowers fasting glucose, HbA1c, fasting insulin and insulin resistance (GRADE meta-analysis of 33 RCTs); Modest lipid lowering: small reductions in LDL-cholesterol (~-0.14 mmol/L) and triglycerides (~-0.06 mmol/L), with larger total-cholesterol/triglyceride effects in people with type 2 diabetes; Constipation/laxation: ~12 g/day chicory inulin increases stool frequency (e.g. 4.1 to 5.0 stools/week in low-frequency subjects) and improves bowel-related quality of life; Satiety and modest weight loss: meta-analysis shows ~-1 kg vs placebo; oligofructose 21 g/day lowered acyl-ghrelin and raised peptide YY with reduced body weight and fat mass; Mineral absorption and bone: 8 g/day inulin-type fructans raised fractional calcium absorption (~+8.5% at 8 weeks) and increased whole-body bone mineral content/density over 1 year in adolescents.
Active compounds: Chicory root extract powders and supplements: Now Foods Organic Inulin, Anthony's Organic Inulin, NutraFlora, Frutafit/Frutalose (Sensus), Orafti/BENEO inulin & oligofructose (Synergy1); Oligofructose-enriched inulin (short- + long-chain blends) used in fiber-fortified bars, yogurts, shakes and infant/medical nutrition; Common food sources: chicory root, Jerusalem artichoke, dandelion greens, garlic, onion, leek, asparagus, wheat/barley, agave, banana.
Dose: Typical effective doses in trials are about 10 g/day for glycemic benefit and 8-21 g/day for weight/satiety, lipids, constipation (~12 g/day) and calcium absorption (~8 g/day). Taken as a powder mixed into water, yogurt or food, usually once or twice daily with meals. Start low (2-3 g/day) and titrate up by 1-2 g/week to limit gas.
Safety: As a fermentable fructan FODMAP, inulin commonly causes dose-dependent flatulence, bloating, abdominal cramping and sometimes loose stools; most healthy adults tolerate up to ~10-20 g/day, with symptoms more likely above ~10 g/day and high doses (30-40 g/day) frequently poorly tolerated. People with IBS or fructan sensitivity may react to as little as 2-5 g and should generally avoid or minimize it; gradual titration improves tolerance. Like other soluble fibers, large doses can delay or reduce absorption of co-ingested medications, so separate dosing by ~1-2 hours. Avoid in those with known chicory/inulin allergy; not a substitute for prescribed therapy in diabetes or hyperlipidemia.

Cited studies (9):
  - The effects of inulin-type fructans on cardiovascular disease risk factors: systematic review and meta-analysis of randomized controlled trials, The American journal of clinical nutrition (2024) — Meta-analysis of RCTs: inulin-type fructans reduced LDL-cholesterol by -0.14 mmol/L (95% CI -0.24,-0.05; 38 trials) and triglycerides by -0.06 mmol/L (95% CI -0.12,-0.01; 40 trials), low-to-very-low certainty. [https://pubmed.ncbi.nlm.nih.gov/38309832/]
  - The effects of chicory inulin-type fructans supplementation on weight management outcomes: systematic review, meta-analysis, and meta-regression of randomized controlled trials, The American journal of clinical nutrition (2024) — Systematic review and meta-analysis of chicory inulin-type fructan RCTs found supplementation (median 10 g/d) significantly reduced body weight by 0.97 kg versus placebo, along with reductions in BMI, fat mass, and waist circumference. [https://pmc.ncbi.nlm.nih.gov/articles/PMC11600113/]
  - Assessing the effects of inulin-type fructan intake on body weight, blood glucose, and lipid profile: A systematic review and meta-analysis of randomized controlled trials, Food science & nutrition (2021) — Meta-analysis of RCTs in type 2 diabetes: inulin-type fructans lowered total cholesterol by -0.46 mmol/L (95% CI -0.75,-0.17) and triglycerides by -0.21 mmol/L (95% CI -0.37,-0.05). [https://pmc.ncbi.nlm.nih.gov/articles/PMC8358370/]
  - Inulin-type fructans supplementation improves glycemic control for the prediabetes and type 2 diabetes populations: results from a GRADE-assessed systematic review and dose-response meta-analysis of 33 randomized controlled trials, Journal of translational medicine (2019) — GRADE-assessed dose-response meta-analysis of 33 RCTs (n=1346): inulin-type fructans significantly reduced fasting glucose, HbA1c, fasting insulin and HOMA-IR, with 10 g/day for 6+ weeks optimal in prediabetes/T2D. [https://pmc.ncbi.nlm.nih.gov/articles/PMC6896694/]
  - Inulin-type fructans supplementation improves glycemic control for the prediabetes and type 2 diabetes populations: results from a GRADE-assessed systematic review and dose-response meta-analysis of 33 randomized controlled trials, Journal of translational medicine (2019) — GRADE-assessed dose-response meta-analysis of 33 RCTs (1346 participants) found inulin-type fructans significantly reduced fasting blood glucose, HbA1c, fasting insulin, and HOMA-IR in prediabetes/T2DM, recommending ~10 g/d for at least 6 weeks. [https://pmc.ncbi.nlm.nih.gov/articles/PMC6896694/]
  - Inulin-induced improvements on bowel habit and gut microbiota in adults with functional constipation: findings of a randomized, double-blind, placebo-controlled study, BMC gastroenterology (2025) — Randomized double-blind placebo-controlled crossover study (n=39, functional constipation): 4 weeks of 12 g/day chicory inulin improved stool frequency and abdominal symptoms and shifted gut microbiota (higher Bifidobacterium linked to fewer rectal symptoms). [https://pmc.ncbi.nlm.nih.gov/articles/PMC12613575/]
  - Changes in stool frequency following chicory inulin consumption, and effects on stool consistency, quality of life and composition of gut microbiota, Food hydrocolloids (2019) — Randomized double-blind crossover RCT: chicory inulin ~12 g/day significantly increased stool frequency and improved bowel-related quality of life in subjects with low stool frequency. [https://pmc.ncbi.nlm.nih.gov/articles/PMC6686634/]
  - Weight loss during oligofructose supplementation is associated with decreased ghrelin and increased peptide YY in overweight and obese adults, The American journal of clinical nutrition (2009) — RCT in 48 overweight/obese adults: 21 g/day oligofructose for 12 weeks reduced body weight, lowered acyl-ghrelin and increased peptide YY versus placebo. [https://pubmed.ncbi.nlm.nih.gov/19386741/]
  - A combination of prebiotic short- and long-chain inulin-type fructans enhances calcium absorption and bone mineralization in young adolescents, The American journal of clinical nutrition (2005) — RCT in adolescents: 8 g/day inulin-type fructan raised fractional calcium absorption (+8.5% at 8 wk, +5.9% at 1 yr) and increased whole-body bone mineral content and density over 1 year. [https://pubmed.ncbi.nlm.nih.gov/16087995/]

---

## Galactooligosaccharides (GOS) (Trans-galactooligosaccharides)
URL: https://nutridex.info/s/gos
Category: Prebiotics & Fibers, Gut & Immune
Evidence: Moderate — Several controlled trials; effects real but modest or context-dependent.
A lactose-derived prebiotic fiber that is reliably bifidogenic and may aid constipation and immune/metabolic markers, but is itself a FODMAP that can trigger gas and IBS symptoms.

Quick answer: Galactooligosaccharides (GOS) is used for reliably bifidogenic: randomized trials consistently show gos increases beneficial gut bifidobacterium (and lactose-fermenting lactobacillus/lactococcus) and boosts short-chain fatty acids such as acetate and butyrate — the best-established effect. NutriDex grades the human evidence as moderate — Several controlled trials; effects real but modest or context-dependent. Based on 10 cited human studies (10 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Galactooligosaccharides (GOS, also called trans-galactooligosaccharides or B-GOS) are non-digestible fibers manufactured enzymatically from lactose. The single most consistent, well-replicated finding across randomized trials is a strong bifidogenic effect: GOS selectively increases gut Bifidobacterium and short-chain fatty acid (acetate, butyrate) production, even at low doses. Beyond microbiome shifts, randomized data are more modest and mixed: GOS has improved calcium absorption in adolescent girls, lowered some metabolic-syndrome and inflammatory markers (CRP, insulin, lipids) in overweight and elderly adults, modestly increased stool frequency in constipated adults, and in one small trial reduced the waking cortisol response. Importantly, GOS is itself a fermentable FODMAP, so the same fermentation that drives benefits can provoke gas, bloating, and worsened symptoms in people with IBS, making it a double-edged fiber.

Benefits / uses: Reliably bifidogenic: randomized trials consistently show GOS increases beneficial gut Bifidobacterium (and lactose-fermenting Lactobacillus/Lactococcus) and boosts short-chain fatty acids such as acetate and butyrate — the best-established effect; Increases intestinal calcium absorption: in a double-blind crossover trial, 5 g/day GOS raised fractional calcium absorption in adolescent girls, alongside higher bifidobacteria; Lowers markers of metabolic syndrome and inflammation: in overweight adults, B-GOS reduced plasma C-reactive protein, insulin, triglycerides, total cholesterol and the TC:HDL ratio while increasing secretory IgA and lowering fecal calprotectin; May improve immune parameters in older adults: B-GOS shifted the microbiota and modulated immune markers (e.g. increased NK-cell activity, anti-inflammatory cytokine balance) in healthy elderly volunteers; Modestly improves constipation: ~11 g/day increased stool frequency versus control in self-reported constipated adults, particularly those with low baseline frequency; May reduce incidence and duration of travellers' diarrhoea and, in one trial, lowered the cortisol awakening response and shifted attention away from negative emotional cues (gut-brain axis) — both preliminary.
Active compounds: Bimuno / B-GOS (Bi2muno) — the most-studied branded trans-GOS, sold as powder, pastilles and capsules; Generic GOS powders and prebiotic blends (often combined with FOS/inulin); Purimune, Vivinal GOS and other ingredient-grade GOS used in foods; Added to many infant formulas (commonly with FOS in a 9:1 GOS:FOS ratio to mimic human-milk oligosaccharides); Food sources are limited and low: small amounts occur naturally in legumes (beans, lentils, chickpeas), soybeans and soy milk, and some nuts, plus dairy made with GOS-producing cultures.
Dose: Most trials use about 3.6-5.5 g/day of GOS (the standard B-GOS/Bimuno dose) for microbiome, immune and cortisol effects; calcium-absorption benefit was seen at ~5 g/day; constipation trials used up to ~11 g/day. Usually taken once daily as a powder mixed into food or drink, or as capsules/pastilles; start low (1-2 g/day) and titrate up over 1-2 weeks to limit gas.
Safety: GOS is generally well tolerated and is permitted in infant formula, but because it is a rapidly fermented FODMAP the main side effects are flatulence, bloating, abdominal cramping and looser stools, which are dose-dependent and worst when started abruptly or taken above ~10 g/day. People with irritable bowel syndrome (IBS) or known FODMAP sensitivity should be cautious: GOS can provoke or worsen IBS symptoms, and on a low-FODMAP diet it is one of the carbohydrates typically restricted (one trial mitigated GOS-induced symptoms with co-administered alpha-galactosidase enzyme). Unlike bulk-forming fibers such as psyllium or glucomannan, GOS does not form a viscous gel, so it carries no choking or esophageal-obstruction hazard and no strict fluid requirement. As a fermentable fiber it could theoretically alter the timing of co-ingested oral drugs, so separating from medications by a couple of hours is prudent, though clinically significant interactions are not well documented. People with galactosemia should avoid GOS, and those with severe GI disorders or who are immunocompromised should consult a clinician first.

Cited studies (10):
  - A double-blind intervention trial in healthy women demonstrates the beneficial impact on Bifidobacterium with low dosages of prebiotic galacto-oligosaccharides, Frontiers in nutrition (2024) — In a double-blind RCT of 88 healthy women (42-70 y), even low GOS doses of 1.3 g/day and 2.0 g/day for 3 weeks significantly increased fecal Bifidobacterium relative abundance (to ~36.8% and ~42.3% respectively, p<0.01), confirming a bifidogenic effect at sub-prebiotic doses. [https://pubmed.ncbi.nlm.nih.gov/39224188/]
  - Efficacy and safety of galacto-oligosaccharide in the treatment of functional constipation: randomized clinical trial, Food & function (2024) — In a 4-week double-blind RCT of 63 adults with functional constipation, GOS significantly increased bowel-movement frequency versus placebo (+0.15 movements/day; 0.42 to 0.78/day, p=0.048) and improved Bristol Stool Scale scores (p=0.028) and PAC-QOL satisfaction (p=0.022). [https://pubmed.ncbi.nlm.nih.gov/38787732/]
  - Prebiotic Galacto-Oligosaccharides Impact Stool Frequency and Fecal Microbiota in Self-Reported Constipated Adults: A Randomized Clinical Trial, Nutrients (2022) — In self-reported constipated adults, 11 g/day GOS for 3 weeks increased stool frequency versus control, particularly in subjects with low baseline frequency (<=3 bowel movements/week) and those aged >=35 years. [https://pmc.ncbi.nlm.nih.gov/articles/PMC8780623/]
  - β-Galactooligosaccharide in Conjunction With Low FODMAP Diet Improves Irritable Bowel Syndrome Symptoms but Reduces Fecal Bifidobacteria, The American journal of gastroenterology (2020) — Adding beta-GOS to a low-FODMAP diet improved IBS symptoms (67% adequate relief vs 30% control) but reduced fecal bifidobacteria, illustrating GOS's double-edged role in IBS. [https://pubmed.ncbi.nlm.nih.gov/32433273/]
  - Prebiotic intake reduces the waking cortisol response and alters emotional bias in healthy volunteers, Psychopharmacology (2015) — In 45 healthy volunteers, 5.5 g/day B-GOS for 3 weeks significantly lowered the salivary waking cortisol response and reduced attentional vigilance to negative information versus placebo and FOS, suggesting a gut-brain effect. [https://pmc.ncbi.nlm.nih.gov/articles/PMC4410136/]
  - The German method for setting ceiling prices for drugs: in some cases less data are required, Expert review of pharmacoeconomics & outcomes research (2011) — In 18 healthy adults, GOS dose-dependently increased fecal Bifidobacterium, with significant bifidogenic effect at 5 g/day and 10 g/day versus placebo, establishing GOS as a robust prebiotic. [https://pubmed.ncbi.nlm.nih.gov/21831020/]
  - Galacto-oligosaccharides increase calcium absorption and gut bifidobacteria in young girls: a double-blind cross-over trial, The British journal of nutrition (2013) — In 31 adolescent girls (10-13 y), 2.5 g and 5 g/day GOS increased fractional calcium absorption (e.g. ~+10-12 percentage points at 5 g) and raised fecal bifidobacteria versus control over 3-week periods. [https://pubmed.ncbi.nlm.nih.gov/23507173/]
  - A mixture of trans-galactooligosaccharides reduces markers of metabolic syndrome and modulates the fecal microbiota and immune function of overweight adults, The Journal of nutrition (2013) — In 45 overweight adults with metabolic-syndrome risk factors, 5.5 g/day B-GOS for 12 weeks reduced plasma CRP, insulin, triglycerides, total cholesterol and TC:HDL ratio and lowered fecal calprotectin versus maltodextrin placebo. [https://pubmed.ncbi.nlm.nih.gov/23303873/]
  - A double-blind, placebo-controlled, randomized human study assessing the capacity of a novel galacto-oligosaccharide mixture in reducing travellers' diarrhoea, European journal of clinical nutrition (2010) — In travellers to higher-risk destinations, B-GOS supplementation significantly reduced the incidence and duration of travellers' diarrhoea and abdominal pain versus placebo. [https://pubmed.ncbi.nlm.nih.gov/19756029/]
  - Modulation of the fecal microflora profile and immune function by a novel trans-galactooligosaccharide mixture (B-GOS) in healthy elderly volunteers, The American journal of clinical nutrition (2008) — In 44 healthy elderly volunteers, 5.5 g/day B-GOS increased fecal bifidobacteria and improved immune markers (raised NK-cell activity and IL-10, lowered pro-inflammatory cytokines) versus placebo. [https://pubmed.ncbi.nlm.nih.gov/18996881/]

---

## Fructooligosaccharides (FOS) (Oligofructose)
URL: https://nutridex.info/s/fos
Category: Prebiotics & Fibers, Gut & Immune
Evidence: Moderate — Several controlled trials; effects real but modest or context-dependent.
A bifidogenic prebiotic fiber with solid microbiome and constipation data — metabolic benefits mostly in diabetes.

Quick answer: Fructooligosaccharides (FOS) is used for bifidogenic microbiome shift: meta-analysis of 8 rcts found fos significantly raises colonic bifidobacterium (smd 0.58, 95% ci 0.44-0.71), with larger effects at >5 g/day and >4 weeks; lactobacillus is not significantly changed.. NutriDex grades the human evidence as moderate — Several controlled trials; effects real but modest or context-dependent. Based on 10 cited human studies (10 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Fructooligosaccharides (FOS, also called oligofructose) are short-chain inulin-type fructans (typically 2-10 fructose units) extracted from chicory root or synthesized from sucrose, fermented in the colon to short-chain fatty acids. The strongest human evidence is for a reproducible bifidogenic shift in the gut microbiome and modest relief of functional constipation. Effects on fasting glucose and blood lipids are real but concentrated in people with diabetes/prediabetes and are minimal in metabolically healthy adults; weight and appetite effects are small. As a highly fermentable FODMAP, FOS reliably causes dose-dependent gas and bloating, and it can transiently worsen symptoms in IBS.

Benefits / uses: Bifidogenic microbiome shift: meta-analysis of 8 RCTs found FOS significantly raises colonic Bifidobacterium (SMD 0.58, 95% CI 0.44-0.71), with larger effects at >5 g/day and >4 weeks; Lactobacillus is not significantly changed.; Functional constipation: meta-analysis of 17 RCTs (713 people) found increased stool frequency, softer stool consistency (SMD 0.36, 95% CI 0.12-0.60), and less straining/pain during defecation (SMD -0.60, 95% CI -0.85 to -0.34).; Glycemic control mainly in diabetes: inulin-type fructan RCTs show lower fasting glucose (WMD -0.42 mmol/L, 95% CI -0.71 to -0.14), but the benefit was seen in diabetic/prediabetic subgroups, not in healthy adults.; Lipids in diabetes: same fructan meta-analysis showed reduced total cholesterol (-0.46 mmol/L), LDL (-0.30 mmol/L) and triglycerides (-0.21 mmol/L), again chiefly in diabetic subgroups — note FOS itself carries no FDA heart-health claim (that applies to oat beta-glucan and psyllium).; Modest appetite/weight effect: 21 g/day oligofructose for 12 weeks produced ~1.0 kg weight loss vs +0.45 kg on placebo, with lower ghrelin and higher PYY (satiety hormones).; Calcium absorption/bone: short+long-chain inulin-type fructan blends (containing oligofructose) increased calcium absorption and bone mineralization in adolescents — robust for mixed fructans, less established for pure FOS..
Active compounds: Supplements: chicory-derived oligofructose powders (Beneo Orafti P95/Synergy1), NOW Oligofructose, Jarrow/other 'FOS' or 'inulin-FOS' powders and capsules; Synthetic short-chain FOS (scFOS) from sucrose (e.g. Nutraflora/GTC); Food sources: chicory root, Jerusalem artichoke, onion, garlic, leek, asparagus, banana, wheat and rye; Commonly added as a 'prebiotic fiber' to yogurts, infant formula, bars and fiber-fortified foods.
Dose: Typical effective dose is about 5-15 g/day (trials range ~2.5-21 g/day), taken as a powder mixed into food or drink, or in divided doses with meals. Bifidogenic and constipation effects are seen from ~5 g/day; start low (2-5 g/day) and titrate up over 1-2 weeks to limit gas. Higher metabolic doses (e.g. ~21 g/day used in weight/appetite trials) markedly increase GI side effects.
Safety: FOS is a fermentable FODMAP, so the main issue is dose-dependent flatulence, bloating, abdominal discomfort and loose stools; tolerance is usually good up to ~5-10 g/day and side effects rise sharply above ~15-20 g/day. People with IBS or SIBO can have symptoms transiently worsen and may need to avoid it (it is restricted on the low-FODMAP diet). Like other viscous/fermentable fibers, take it separated from medications by a couple of hours, as fiber can delay or reduce drug absorption. Begin low and increase gradually, and ensure adequate fluid intake. It is not associated with the choking/esophageal-obstruction hazard of bulk-forming gel fibers like glucomannan/konjac, but powders should still be taken with liquid.

Cited studies (10):
  - Fructooligosaccharides for Relieving Functional Constipation: A Systematic Review and Meta-Analysis of Randomized Controlled Trials, Foods (Basel, Switzerland) (2024) — Across 17 RCTs (713 participants), FOS increased stool frequency, softened stool consistency (SMD 0.36, 95% CI 0.12-0.60) and reduced straining/pain (SMD -0.60, 95% CI -0.85 to -0.34) in functional constipation, with mild bloating as the main adverse event. [https://pmc.ncbi.nlm.nih.gov/articles/PMC11675838/]
  - Non-Digestible Oligosaccharides and Constipation: A Systematic Review and Meta-Analysis of Randomized Trials on Stool Frequency, Stool Consistency, and Fermentation Biomarkers, Nutrients (2025) — Systematic review and meta-analysis of 20 RCTs (n=1,786) of non-digestible oligosaccharides found supplementation significantly increased stool frequency, with a larger effect in constipated individuals (SMD 0.99, 95% CI 0.58-1.28). [https://pmc.ncbi.nlm.nih.gov/articles/PMC12567251/]
  - Effect of Fructooligosaccharides Supplementation on the Gut Microbiota in Human: A Systematic Review and Meta-Analysis, Nutrients (2022) — Pooling 8 RCTs (213 FOS vs 175 controls), FOS significantly increased colonic Bifidobacterium (SMD 0.58, 95% CI 0.44-0.71), with greater effects at >5 g/day (0.86 vs 0.52) and >4 weeks, while Lactobacillus was unchanged. [https://pmc.ncbi.nlm.nih.gov/articles/PMC9413759/]
  - Assessing the effects of inulin-type fructan intake on body weight, blood glucose, and lipid profile: A systematic review and meta-analysis of randomized controlled trials, Food science & nutrition (2021) — Across 33 RCTs of inulin-type fructans, fasting glucose fell (WMD -0.42 mmol/L, 95% CI -0.71 to -0.14) along with total cholesterol, LDL and triglycerides, but significant benefit was confined to diabetic/prediabetic subgroups, not healthy subjects. [https://pmc.ncbi.nlm.nih.gov/articles/PMC8358370/]
  - Effect of Fructooligosaccharides Supplementation on the Gut Microbiota in Human: A Systematic Review and Meta-Analysis, Nutrients (2022) — Systematic review and meta-analysis of 8 studies (213 FOS recipients vs 175 controls) found FOS supplementation significantly increased Bifidobacterium counts compared with controls, confirming a bifidogenic effect in humans. [https://pmc.ncbi.nlm.nih.gov/articles/PMC9413759/]
  - Targeting gut microbiota with short-chain fructo-oligosaccharides prebiotic fibers to support metabolic health in overweight prediabetic adults: a randomized, double-blinded, placebo-controlled study, Frontiers in nutrition (2025) — In a 12-week double-blind placebo-controlled RCT (n=66) in overweight prediabetic adults, 20 g/day short-chain FOS significantly increased Bifidobacterium and fecal acetate/propionate with modest body composition improvement, but showed no significant effect on HbA1c or glucose metabolism. [https://pmc.ncbi.nlm.nih.gov/articles/PMC12753434/]
  - Fructooligosaccharide (FOS) and Galactooligosaccharide (GOS) Increase Bifidobacterium but Reduce Butyrate Producing Bacteria with Adverse Glycemic Metabolism in healthy young population, Scientific reports (2017) — Short-chain FOS increased Bifidobacterium and other beneficial taxa but also reduced butyrate-producing bacteria, and high-dose short-term intake was associated with adverse oral-glucose-tolerance responses in healthy young adults. [https://pmc.ncbi.nlm.nih.gov/articles/PMC5603605/]
  - A prospective randomized, double-blind, placebo-controlled, dose-response relationship study to investigate efficacy of fructo-oligosaccharides (FOS) on human gut microflora, Scientific Reports (2019) — A dose-response, double-blind, placebo-controlled trial in healthy adults confirmed FOS dose-dependently shifts gut microflora (notably Bifidobacterium) while characterizing GI tolerance across doses. [https://www.nature.com/articles/s41598-019-41837-3]
  - Weight loss during oligofructose supplementation is associated with decreased ghrelin and increased peptide YY in overweight and obese adults, The American journal of clinical nutrition (2009) — In 48 overweight/obese adults, 21 g/day oligofructose for 12 weeks produced -1.03 kg weight change vs +0.45 kg on placebo (P=0.01), with ~23% lower ghrelin AUC and ~13% higher PYY AUC. [https://pubmed.ncbi.nlm.nih.gov/19386741/]
  - A combination of prebiotic short- and long-chain inulin-type fructans enhances calcium absorption and bone mineralization in young adolescents, The American journal of clinical nutrition (2005) — In adolescents, 8 g/day of a short- plus long-chain inulin-type fructan (oligofructose+inulin) increased calcium absorption at 8 weeks (+8.5%) and 1 year (+5.9%) and enhanced bone mineral density vs maltodextrin placebo. [https://pubmed.ncbi.nlm.nih.gov/16087995/]

---

## Pectin (Apple / citrus pectin)
URL: https://nutridex.info/s/pectin
Category: Prebiotics & Fibers, Gut & Immune
Evidence: Moderate — Several controlled trials; effects real but modest or context-dependent.
A gel-forming soluble fiber from apple and citrus peel that modestly lowers LDL cholesterol, blunts blood-sugar spikes, and feeds gut bacteria.

Quick answer: Pectin is used for lowers ldl ('bad') and total cholesterol: as a soluble viscous fiber it binds bile acids; pooled rct data on soluble fibers (oat, psyllium, pectin) show ldl reductions of roughly 8 mg/dl, and efsa authorizes a cholesterol-maintenance claim at 6 g/day. NutriDex grades the human evidence as moderate — Several controlled trials; effects real but modest or context-dependent. Based on 8 cited human studies (8 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Pectin is a soluble, gel-forming dietary fiber found naturally in the cell walls of fruits, with commercial pectin extracted from citrus peel and apple pomace (by-products of juice and cider making). The best human evidence is for cholesterol: pooled randomized-trial data on soluble fibers (including pectin) show meaningful reductions in LDL and total cholesterol, and EFSA has authorized a claim that 6 g/day of pectin helps maintain normal blood cholesterol. Pectin also reliably slows gastric emptying and blunts post-meal glucose and insulin spikes in short-term crossover trials, and is fermented in the colon to short-chain fatty acids, shifting the microbiome. Evidence is weaker and more preliminary for weight/satiety (highly dependent on viscosity and gel structure), IBS, and for chemically "modified" citrus pectin in cancer, where only small uncontrolled Phase II studies exist.

Benefits / uses: Lowers LDL ('bad') and total cholesterol: as a soluble viscous fiber it binds bile acids; pooled RCT data on soluble fibers (oat, psyllium, pectin) show LDL reductions of roughly 8 mg/dL, and EFSA authorizes a cholesterol-maintenance claim at 6 g/day; Blunts post-meal blood glucose and insulin spikes by forming a viscous gel that slows gastric emptying and carbohydrate absorption (short-term crossover trials); Fermented in the colon to short-chain fatty acids (mostly acetate, with some propionate and butyrate) and shifts the microbiota, increasing fiber-degrading taxa such as Faecalibacterium prausnitzii and Lachnospira; Increases satiety and can reduce subsequent energy intake, but the effect depends heavily on the pectin's viscosity and gelling properties ('pectin is not pectin'); May modestly lower blood pressure as part of the soluble-fiber class; Preliminary signal for modified citrus pectin slowing PSA rise in biochemically relapsed prostate cancer (small uncontrolled Phase II data only).
Active compounds: Citrus pectin powder (extracted from orange/lemon/lime peel); Apple pectin powder (from apple pomace); Modified citrus pectin (low-molecular-weight, e.g. PectaSol-C) marketed for cancer/galectin-3 support; Food sources: apples, citrus pith and peel, plums, quinces, carrots, and as the gelling agent in jams, jellies and fruit preserves; Capsules and as a thickening/gelling additive (E440) in foods.
Dose: For cholesterol maintenance, EFSA specifies 6 g/day of pectin; cholesterol-lowering trials have generally used about 6-15 g/day. For blunting post-meal glucose, roughly 5-15 g taken with the meal; ~15 g was identified as an effective dose in gastric-emptying studies. Taken as powder mixed into food or liquid, or in divided doses with meals. Modified citrus pectin in prostate-cancer studies used much higher doses (~4.8 g three times daily).
Safety: Generally well tolerated. As a fermentable fiber it can cause gas, bloating, abdominal cramping and loose stools, especially when started at high doses; increase intake gradually. Take with adequate fluid. Like other viscous/gel-forming fibers, pectin can delay or reduce absorption of co-ingested medications and minerals, so separate it from drugs (e.g. levothyroxine, and others where timing matters) by 2-4 hours; people on glucose-lowering medication should monitor for additive blood-sugar effects. Allergy is possible, particularly cross-reactivity in people allergic to citrus. The very high doses used in modified-citrus-pectin cancer research are not established as safe or effective for that purpose and should only be used under specialist supervision. Consult a clinician if pregnant, breastfeeding, on multiple medications, or managing a bowel disorder.

Cited studies (8):
  - Soluble Fiber Supplementation and Serum Lipid Profile: A Systematic Review and Dose-Response Meta-Analysis of Randomized Controlled Trials, Advances in nutrition (Bethesda, Md.) (2023) — Dose-response meta-analysis found soluble fiber supplementation (oat, psyllium and pectin) reduced LDL-C by about 8.28 mg/dL and total cholesterol by 10.82 mg/dL, with significant effects across 2-10 g/day and no significant difference between fiber sources. [https://pubmed.ncbi.nlm.nih.gov/36796439/]
  - Effect of soluble fiber on blood pressure in adults: a systematic review and dose-response meta-analysis of randomized controlled trials, Nutrition journal (2023) — Dose-response meta-analysis of RCTs found soluble fiber supplementation significantly lowered systolic and diastolic blood pressure in adults, supporting a cardiovascular benefit for the fiber class that includes pectin. [https://pmc.ncbi.nlm.nih.gov/articles/PMC10571351/]
  - The Potential of Pectins to Modulate the Human Gut Microbiota Evaluated by In Vitro Fermentation: A Systematic Review, Nutrients (2022) — Systematic review of in vitro fermentation found pectins are slowly but completely fermented by human gut microbiota, producing short-chain fatty acids (mainly acetate) and selectively stimulating taxa including Faecalibacterium prausnitzii and Lachnospira/Lachnospira eligens. [https://pmc.ncbi.nlm.nih.gov/articles/PMC9460662/]
  - Cholesterol-lowering effects of dietary fiber: a meta-analysis, The American journal of clinical nutrition (1999) — Classic dose-response meta-analysis of soluble-fiber trials found pectin (~6 g/day) significantly lowered total and LDL cholesterol, helping establish the bile-acid-binding cholesterol-lowering effect of viscous fibers. [https://pubmed.ncbi.nlm.nih.gov/9925120/]
  - EFSA / Commission Regulation (EU) 432/2012 — EFSA's authorized EU health claim states pectin contributes to the maintenance of normal blood cholesterol concentrations, usable only for foods providing a daily intake of 6 g of pectin. [https://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2012:136:0001:0040:en:PDF]
  - Modified Citrus Pectin Treatment in Non-Metastatic Biochemically Relapsed Prostate Cancer: Results of a Prospective Phase II Study, Nutrients (2021) — In a single-arm Phase II study, modified citrus pectin (4.8 g three times daily for 6 months) improved PSA doubling time in about 75% of men with non-metastatic biochemically relapsed prostate cancer, but the uncontrolled design limits causal inference. [https://pubmed.ncbi.nlm.nih.gov/34959847/]
  - Pectin is not pectin: a randomized trial on the effect of different physicochemical properties of dietary fiber on appetite and energy intake, Physiology & behavior (2014) — 'Pectin is not pectin' RCT showed that pectin's effects on appetite, gastric emptying and energy intake depend strongly on its physicochemical form, with higher-viscosity and gelled pectins producing greater satiety than bulking pectin. [https://pubmed.ncbi.nlm.nih.gov/24534170/]
  - Nutrition and health effects of pectin: a systematic scoping review of human intervention studies, Nutrition Research Reviews (2024) — Systematic scoping review of human intervention studies concluded pectin lowers blood total and/or LDL cholesterol and is associated with reduced postprandial glucose and insulin peaks, increased satiety, and delayed gastric emptying, though designs were mostly small crossover trials. [https://www.cambridge.org/core/journals/nutrition-research-reviews/article/nutrition-and-health-effects-of-pectin-a-systematic-scoping-review-of-human-intervention-studies/01BF0759F09A2BBC419F333B8B1D4FF9]

---

## Isomaltooligosaccharides (IMO) (Isomalto-oligosaccharides)
URL: https://nutridex.info/s/imo
Category: Prebiotics & Fibers, Gut & Immune
Evidence: Preliminary — Early or small human trials; promising but not yet conclusive.
A sweet, partly-digestible "fiber" whose prebiotic and fiber claims are weaker than the label suggests.

Quick answer: Isomaltooligosaccharides (IMO) is used for modestly increased stool frequency, wet stool weight, and stool output in small trials of constipated elderly adults at ~10 g/day. NutriDex grades the human evidence as preliminary — Early or small human trials; promising but not yet conclusive. Based on 8 cited human studies (8 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Isomaltooligosaccharides (IMO) are short glucose chains linked mainly by alpha-1,6 bonds, marketed as a low-calorie sweetener and prebiotic "fiber" widely used in protein bars and keto products. The honest picture is that much commercial IMO is substantially digested by human gut alpha-glucosidases into glucose, so it behaves more like a slowly digestible carbohydrate than a true resistant fiber and can raise blood glucose and insulin more than the label implies. Human evidence is thin: small, mostly older or Asian trials suggest a bifidogenic shift and modestly improved bowel function and stool frequency in constipated elderly adults at ~10 g/day, but there is no robust meta-analytic support and bifidogenic effects were not reproduced in European cohorts. Compared with inulin, GOS, or psyllium, IMO is a weakly-evidenced prebiotic, and its biggest practical caveat is that its true fiber content and glycemic impact often deviate from marketing.

Benefits / uses: Modestly increased stool frequency, wet stool weight, and stool output in small trials of constipated elderly adults at ~10 g/day; Shifted colonic microflora toward Bifidobacterium and Lactobacillus in small human studies (bifidogenic effect, but not reproduced in all populations); Reduced total and LDL cholesterol in one small placebo-controlled diet-controlled trial of constipated elderly subjects; Can replace sugar as a partially-lower-calorie, lower-glycemic-index sweetener (GI ~35), though commercial IMO is still meaningfully digestible and raises glucose/insulin; Generally well tolerated at moderate doses with less gas than highly fermentable fibers, reflecting its lower fermentability.
Active compounds: Bulk IMO powder and IMO syrup (e.g. VitaFiber, BioLigo) used in keto/low-sugar protein bars, cookies, and 'fiber' sweeteners; Listed on labels as isomalto-oligosaccharide, IMO, or VitaFiber; Produced enzymatically from starch (corn, tapioca); also present in trace amounts in fermented foods like miso, soy sauce, sake, and honey.
Dose: Bowel/microbiome trials used about 10 g/day of active IMO, taken with food, for 4-8 weeks. As a sweetener it is used to taste in foods; product 'fiber' content is often overstated because much IMO is digested. Keep below ~30 g/day to limit GI symptoms.
Safety: Generally well tolerated; the main side effects are flatulence, bloating, borborygmi, soft stools, or osmotic diarrhea, which become more likely above roughly 30-40 g/day. As a FODMAP-type fermentable carbohydrate it can worsen gas and symptoms in people with IBS or fructose/oligosaccharide intolerance, who should be cautious. The most important caveat is metabolic, not toxic: commercial IMO is substantially digested to glucose, so people with diabetes or those tracking carbohydrates should not assume it is 'free' fiber; it can raise blood glucose and insulin, and actual fiber content frequently deviates from labels. Unlike bulk-forming fibers (psyllium, glucomannan) it poses no choking or esophageal-obstruction hazard. There is little safety data in pregnancy; standard food amounts are presumed safe, but supplemental doses should be discussed with a clinician.

Cited studies (8):
  - Non-Digestible Oligosaccharides and Constipation: A Systematic Review and Meta-Analysis of Randomized Trials on Stool Frequency, Stool Consistency, and Fermentation Biomarkers, Nutrients (2025) — Across randomized trials, non-digestible oligosaccharides (including IMO) had modest and inconsistent effects on stool frequency and consistency, underscoring limited high-quality evidence for IMO specifically. [https://pmc.ncbi.nlm.nih.gov/articles/PMC12567251/]
  - Non-Digestible Oligosaccharides and Constipation: A Systematic Review and Meta-Analysis of Randomized Trials on Stool Frequency, Stool Consistency, and Fermentation Biomarkers, Nutrients (2025) — Systematic review and meta-analysis of 20 RCTs (n=1786) across seven non-digestible oligosaccharide types (including IMO) found supplementation significantly increased stool frequency, with larger effects in constipated individuals and short-term (≤3 wk) trials, and lowered fecal pH; certainty was low due to heterogeneity. [https://pmc.ncbi.nlm.nih.gov/articles/PMC12567251/]
  - Gastrointestinal Tolerance and Glycemic Response of Isomaltooligosaccharides in Healthy Adults, Nutrients (2018) — In healthy adults, an IMO syrup dose-matched for 50 g carbohydrate produced a glycemic response similar to dextrose and GI tolerance similar to control, indicating commercial IMO is substantially digestible rather than a non-glycemic fiber. [https://pmc.ncbi.nlm.nih.gov/articles/PMC5872719/]
  - Gastrointestinal Tolerance and Glycemic Response of Isomaltooligosaccharides in Healthy Adults, Nutrients (2018) — Two randomized, double-blind, placebo-controlled crossover human studies in healthy adults showed a commercial IMO product was substantially digested and produced a measurable glycemic and insulin response with limited breath-hydrogen fermentation, questioning its labeled low-glycemic fiber status. [https://pmc.ncbi.nlm.nih.gov/articles/PMC5872719/]
  - Long-term supplementation of isomalto-oligosaccharides improved colonic microflora profile, bowel function, and blood cholesterol levels in constipated elderly people--a placebo-controlled, diet-controlled trial, Nutrition (Burbank, Los Angeles County, Calif.) (2011) — In 13 constipated elderly subjects, 10 g/day IMO for 4-8 weeks improved colonic Bifidobacterium profile and bowel function time-dependently and reduced total and LDL cholesterol, with benefits fading after discontinuation. [https://pubmed.ncbi.nlm.nih.gov/20624673/]
  - Effects of isomalto-oligosaccharides on bowel functions and indicators of nutritional status in constipated elderly men, Journal of the American College of Nutrition (2001) — In constipated elderly men, ~10 g/day of IMO roughly doubled defecation frequency and increased wet stool output ~70% and dry stool weight ~55% versus a low-fiber control period. [https://pubmed.ncbi.nlm.nih.gov/11294172/]
  - Isomaltooligosaccharide, Wikipedia — Reviews note bifidogenic effects of IMO were seen mainly in small Asian studies and were not reproduced in European adults, and question whether industrial IMO meets prebiotic criteria given its digestibility. [https://en.wikipedia.org/wiki/Isomaltooligosaccharide]
  - New insights suggest isomaltooligosaccharides are slowly digestible carbohydrates, rather than dietary fibers, at constitutive mammalian α-glucosidase levels, Food chemistry (2022) — Mammalian alpha-glucosidases fully hydrolyzed IMOs to glucose (slowly), so IMOs are better classified as slowly digestible carbohydrates than as dietary fibers at physiological enzyme levels. [https://pubmed.ncbi.nlm.nih.gov/35182873/]

---

## Larch Arabinogalactan (Larix · ResistAid)
URL: https://nutridex.info/s/larch-arabinogalactan
Category: Prebiotics & Fibers, Gut & Immune
Evidence: Moderate — Several controlled trials; effects real but modest or context-dependent.
Larch-bark soluble fiber: a gentle bifidogenic prebiotic best known for immune-modulating data

Quick answer: Larch Arabinogalactan is used for bifidogenic / microbiome modulation: 15 g/day for 6 weeks lowered the fecal firmicutes:bacteroidetes ratio and trended toward higher bifidobacterium abundance in a crossover rct, with reduced putrefactive branched-chain scfas (isobutyrate/isovalerate). NutriDex grades the human evidence as moderate — Several controlled trials; effects real but modest or context-dependent. Based on 9 cited human studies (9 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Larch arabinogalactan (LAG) is a highly water-soluble, branched polysaccharide extracted from the wood of larch trees (Larix), sold as the standardized ingredient ResistAid. It is selectively fermented in the colon by Bifidobacterium and other commensals, making it a true prebiotic, and unlike inulin it ferments slowly/distally so it is unusually well tolerated with little gas. The strongest randomized human data are for immune endpoints: at 1.5-4.5 g/day it boosted antibody responses to pneumococcal and tetanus vaccines and modestly reduced common-cold incidence, while a 15 g/day crossover RCT shifted the gut microbiome (lower Firmicutes:Bacteroidetes, trend toward more Bifidobacterium). Evidence for classic fiber outcomes (cholesterol, glucose, laxation) is thin to absent in humans, so its profile is more "immune-supportive prebiotic" than a cardiometabolic fiber.

Benefits / uses: Bifidogenic / microbiome modulation: 15 g/day for 6 weeks lowered the fecal Firmicutes:Bacteroidetes ratio and trended toward higher Bifidobacterium abundance in a crossover RCT, with reduced putrefactive branched-chain SCFAs (isobutyrate/isovalerate); Slow distal fermentation to SCFAs (propionate-favoring), with much less gas/bloating than rapidly fermented fibers like inulin or FOS — making it suitable for sensitive guts; Enhanced vaccine antibody response: increased IgG to the 23-valent pneumococcal vaccine (subtypes 18C, 23F) at 4.5 g/day and to tetanus at 1.5 g/day vs placebo; Reduced common-cold burden: ~23% fewer cold episodes and significantly fewer subjects affected at 4.5 g/day over 12 weeks (per-protocol significant; full-set borderline); Stimulates innate immunity (NK-cell activity) and reduces pro-inflammatory signaling in mechanistic and animal colitis models via a Bacteroides thetaiotaomicron–propionate–GPR41 axis; Generally a prebiotic fermentable fiber contributing toward daily fiber intake; note that no FDA heart-health claim applies to LAG (those apply only to oat/barley beta-glucan and psyllium).
Active compounds: Standardized larch extract: Lonza ResistAid (Larix occidentalis/laricina), the form used in nearly all human RCTs; Bulk powders/capsules: NOW Foods Larch Arabinogalactan, Pure Encapsulations Arabinogalactan, Thorne, Allergy Research Group, Swanson; Tasteless, highly soluble powder mixed into water, juice or smoothies; also used as a dietary-fiber/emulsifier food additive; Food sources are minor: small amounts occur in carrots, radishes, pears, maize, tomatoes and some seeds, but larch wood is the practical concentrated source.
Dose: Typical 1.5-4.5 g/day for immune/prebiotic effects (the doses used in the vaccine and cold trials); microbiome-shift and tolerance studies used up to 15 g/day. Taken as a soluble powder stirred into liquid, once daily; effects on antibody/cold endpoints emerged over 4-12 weeks.
Safety: Very well tolerated; classed GRAS in the US. Because it ferments slowly and distally, it produces notably less gas, bloating and flatulence than inulin/FOS — even 15 g/day for 6 weeks showed no significant change in bowel habits, stool consistency, GI symptoms, blood chemistry or vitals. High intakes can still cause mild bloating or flatulence in sensitive individuals; it is fermentable and not strictly low-FODMAP at large doses, so those with IBS should titrate up slowly. As with any soluble fiber, separate from oral medications (take drugs ~1-2 h apart) to avoid blunting absorption, and take with adequate fluid. Theoretical caution in those with severe immune dysregulation/autoimmune disease given its immunostimulatory activity; data in pregnancy/lactation are limited. It does not pose the choking/esophageal-obstruction hazard associated with gel-forming glucomannan/konjac.

Cited studies (9):
  - Does larch arabinogalactan enhance immune function? A review of mechanistic and clinical trials, Nutrition & metabolism (2016) — Review of mechanistic and clinical trials concluding larch arabinogalactan enhances immune response (NK activity, antibody response to bacterial antigens) and acts as a prebiotic, while noting limited cardiometabolic fiber data. [https://pmc.ncbi.nlm.nih.gov/articles/PMC4828828/]
  - Effect of arabinogalactan on the gut microbiome: A randomized, double-blind, placebo-controlled, crossover trial in healthy adults, Nutrition (2021) — Randomized double-blind crossover in 30 healthy adults: 15 g/day ResistAid for 6 weeks lowered the fecal Firmicutes:Bacteroidetes ratio (↑Bacteroidetes, ↓Firmicutes), trended toward higher Bifidobacterium, reduced branched SCFAs, and was safe/well-tolerated. [https://doi.org/10.1016/j.nut.2021.111273]
  - Effect of arabinogalactan on the gut microbiome: A randomized, double-blind, placebo-controlled, crossover trial in healthy adults, Nutrition (Burbank, Los Angeles County, Calif.) (2021) — Randomized, double-blind, placebo-controlled crossover trial in 30 healthy adults (15 g/day ResistAid larch arabinogalactan vs maltodextrin, 6 weeks) significantly decreased the fecal Firmicutes/Bacteroidetes ratio (driven by increased Bacteroidetes and decreased Firmicutes) and tended to increase Bifidobacterium abundance, with good GI tolerance. [https://pubmed.ncbi.nlm.nih.gov/34004416/]
  - Lactobacilli Supplemented with Larch Arabinogalactan and Colostrum Stimulates an Immune Response towards Peripheral NK Activation and Gut Tolerance, Nutrients (2020) — Blinded supplementation trial (40 subjects: 20 IBS, 20 healthy) of lactobacilli plus larch arabinogalactan and colostrum increased the percentage of activated HLA-DR+ peripheral NK cells in healthy individuals (p=0.03), supporting an immune-stimulatory, gut-tolerated effect. [https://pubmed.ncbi.nlm.nih.gov/32517330/]
  - Larch arabinogalactan effects on reducing incidence of upper respiratory infections, Current medical research and opinion (2013) — In 199 adults, 4.5 g/day larch arabinogalactan (ResistAid) for 12 weeks reduced common-cold incidence by ~23% and significantly cut the number of subjects affected (PP: p=0.040; FAS subjects affected p=0.038). [https://pubmed.ncbi.nlm.nih.gov/23339578/]
  - Proprietary arabinogalactan extract increases antibody response to the pneumonia vaccine: a randomized, double-blind, placebo-controlled, pilot study in healthy volunteers, Nutrition journal (2010) — In 45 healthy adults, 4.5 g/day arabinogalactan for 72 days significantly increased IgG antibody response to the 23-valent pneumococcal vaccine in subtypes 18C and 23F vs placebo. [https://pubmed.ncbi.nlm.nih.gov/20796315/]
  - Immunomodulatory effects of ResistAid™: A randomized, double-blind, placebo-controlled, multidose study, Journal of the American College of Nutrition (2013) — In 75 healthy adults, 1.5 g/day ResistAid for 60 days significantly raised tetanus-specific IgG vs placebo (p=0.008), though no significant effect on influenza-vaccine antibodies. [https://pmc.ncbi.nlm.nih.gov/articles/PMC3856471/]
  - Evaluating the prebiotic activity of arabinogalactan on the human gut microbiota using 16S rRNA gene sequencing and Raman-activated cell sorting, Microbiome research reports (2025) — Ex vivo fecal-incubation study (10 healthy donors) found arabinogalactan consistently enriched Bifidobacterium and Gemmiger at 6 and 24 h; Raman-activated cell sorting recovered 98 strains (~46% Bifidobacterium longum) showing significantly higher deuterium incorporation than controls (P<0.001), confirming selective prebiotic activity. [https://pmc.ncbi.nlm.nih.gov/articles/PMC12540051/]
  - Larch Arabinogalactan Alleviates Colitis by Modulating Gut Microbiota and Promoting Bacteroides thetaiotaomicron, Journal of agricultural and food chemistry (2025) — In DSS-induced colitis mice, larch arabinogalactan alleviated colitis by enriching Bacteroides thetaiotaomicron and boosting propionate via a B. thetaiotaomicron–propionate–GPR41 axis. [https://pubmed.ncbi.nlm.nih.gov/41239997/]

---

## Glucomannan (Konjac) (Amorphophallus konjac)
URL: https://nutridex.info/s/glucomannan
Category: Prebiotics & Fibers, Gut & Immune
Evidence: Strong — Multiple high-quality RCTs / meta-analyses with consistent effects.
Highly viscous konjac soluble fiber that lowers LDL and curbs appetite

Quick answer: Glucomannan (Konjac) is used for lowers ldl and non-hdl cholesterol: ~3 g/day reduces ldl-c by about 0.35 mmol/l (~10%) and non-hdl-c by ~0.32 mmol/l in rct meta-analyses, via its high viscosity binding bile acids and reducing cholesterol reabsorption. NutriDex grades the human evidence as strong — Multiple high-quality RCTs / meta-analyses with consistent effects. Based on 8 cited human studies (8 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Glucomannan is a highly viscous, water-soluble, fermentable dietary fiber extracted from the tuber of the konjac plant (Amorphophallus konjac). Its strongest human evidence is for cholesterol lowering: meta-analyses of randomized controlled trials show that roughly 3 g/day reduces LDL cholesterol by about 0.35 mmol/L (~10%) and non-HDL cholesterol similarly, which is why EFSA authorizes a normal-blood-cholesterol maintenance claim at 4 g/day. It modestly lowers fasting glucose and produces small short-term weight loss, though weight-loss meta-analyses are mixed and effects are not durable. Because it forms a thick gel on contact with water, it carries a distinct choking/esophageal-obstruction hazard and must be taken with ample fluid.

Benefits / uses: Lowers LDL and non-HDL cholesterol: ~3 g/day reduces LDL-C by about 0.35 mmol/L (~10%) and non-HDL-C by ~0.32 mmol/L in RCT meta-analyses, via its high viscosity binding bile acids and reducing cholesterol reabsorption; Underpins an EFSA-authorized health claim that 4 g/day glucomannan helps maintain normal blood cholesterol concentrations; Modestly improves glycemic control: meta-analyses show small reductions in fasting blood glucose (~0.6 mmol/L) by slowing gastric emptying and blunting post-prandial glucose absorption; Promotes satiety and short-term weight loss: gel formation in the stomach increases fullness; some RCT meta-analyses report ~1 kg greater weight loss versus placebo over <=8 weeks (effect is modest and inconsistent); Increases stool frequency and relieves constipation by adding viscous, water-holding bulk; fermentation yields short-chain fatty acids and supports a bifidogenic gut-microbiome shift; Reduces post-prandial triglyceride and glycemic responses when taken before meals.
Active compounds: Standalone capsules/tablets (e.g. Now Foods Glucomannan, NutriZing, Konjac Root) typically 500-665 mg each; Powder for stirring into water or beverages before meals; Shirataki / konjac noodles and konjac 'rice' (near-zero-calorie food source); Konjac jelly/gel candies and konjac flour used as a thickener/gelling agent (E425); Fiber blends and meal-replacement/weight-management formulas.
Dose: For cholesterol and weight: ~3-4 g/day, divided into doses of about 1 g taken 15-60 minutes before each main meal, each with 1-2 full glasses of water. EFSA's cholesterol claim is set at 4 g/day; trials range from ~3 to 15 g/day. Start low and increase gradually to limit gas/bloating.
Safety: Generally well tolerated; common effects are bloating, flatulence, loose stools or mild abdominal discomfort because it is fermentable (a FODMAP-type fiber). The signature hazard is choking and esophageal or throat obstruction: the dry fiber expands rapidly into a gel, so tablets/powder must be taken with plenty of water and avoided by anyone with swallowing difficulty or esophageal narrowing; konjac mini-cup gel candies have caused fatal choking (subject to FDA import alerts and bans for children/elderly). Its viscosity can delay or reduce absorption of co-ingested oral medications, so separate drugs by at least 1-2 hours. People on glucose-lowering or lipid drugs should monitor, and those with strictures, dysphagia, or prior GI surgery should be cautious.

Cited studies (8):
  - The effect of glucomannan supplementation on lipid profile in adults: a GRADE-assessed systematic review and meta-analysis, BMC Cardiovascular Disorders (2024) — GRADE-assessed pooled analysis confirmed glucomannan supplementation significantly improves the lipid profile, lowering total and LDL cholesterol versus control in adults. [https://link.springer.com/article/10.1186/s12872-024-04223-0]
  - Effects of Glucomannan Supplementation on Type II Diabetes Mellitus in Humans: A Meta-Analysis, Nutrients (2023) — In type 2 diabetics, glucomannan supplementation significantly reduced fasting blood glucose and improved lipid parameters compared with control across pooled RCTs. [https://pmc.ncbi.nlm.nih.gov/articles/PMC9919128/]
  - Effects of glucomannan supplementation on weight loss in overweight and obese adults: A systematic review and meta-analysis of randomized controlled trials, Obesity Medicine (2020) — In overweight/obese adults, glucomannan produced a significant but modest weight reduction (WMD -0.96 kg; 95% CI -1.81 to -0.11), with larger effects in women and short (<=8 week) trials. [https://doi.org/10.1016/j.obmed.2020.100276]
  - A systematic review and meta-analysis of randomized controlled trials of the effect of konjac glucomannan, a viscous soluble fiber, on LDL cholesterol and the new lipid targets non-HDL cholesterol and apolipoprotein B, The American Journal of Clinical Nutrition (2017) — Konjac glucomannan at a median 3.0 g/day lowered LDL cholesterol by 0.35 mmol/L (95% CI -0.46 to -0.25) and non-HDL cholesterol by 0.32 mmol/L versus control, with no effect on apolipoprotein B. [https://ajcn.nutrition.org/article/S0002-9165(22)04891-2/fulltext]
  - Effect of glucomannan on functional constipation in children: a systematic review and meta-analysis of randomised controlled trials, Asia Pacific journal of clinical nutrition (2017) — In children with functional constipation, glucomannan moderately increased defecation frequency but did not significantly improve stool consistency or overall treatment success. [https://pubmed.ncbi.nlm.nih.gov/28429913/]
  - The Efficacy of Glucomannan Supplementation in Overweight and Obesity: A Systematic Review and Meta-Analysis of Randomized Clinical Trials, Journal of the American College of Nutrition (2014) — Meta-analysis found a non-statistically-significant difference in body weight between glucomannan and placebo (mean difference -0.22 kg), concluding it does not generate significant weight loss. [https://www.tandfonline.com/doi/abs/10.1080/07315724.2014.870013]
  - Effect of glucomannan on plasma lipid and glucose concentrations, body weight, and blood pressure: systematic review and meta-analysis, The American journal of clinical nutrition (2008) — Glucomannan significantly reduced total cholesterol (-0.5 mmol/L), LDL-C (-0.4 mmol/L), triglycerides, body weight (-0.79 kg) and fasting blood glucose, but not HDL-C or blood pressure. [https://pubmed.ncbi.nlm.nih.gov/18842808/]
  - Scientific Opinion on the substantiation of health claims related to konjac mannan (glucomannan) and reduction of body weight (ID 854, 1556, 3725), reduction of post-prandial glycaemic responses (ID 1559), maintenance of normal blood glucose concentrations (ID 835, 3724), maintenance of normal (fasting) blood concentrations of triglycerides (ID 3217), maintenance of normal blood cholesterol concentrations (ID 3100, 3217), maintenance of normal bowel function (ID 834, 1557, 3901) and decreasing potentially pathogenic gastro-intestinal microorganisms (ID 1558) pursuant to Article 13(1) of Regulation (EC) No 1924/2006, EFSA Journal (2010) — EFSA concluded a cause-and-effect relationship between glucomannan and maintenance of normal blood cholesterol, authorizing a claim conditional on 4 g/day intake, with a mandatory choking warning for inadequate fluid intake. [https://www.efsa.europa.eu/en/efsajournal/pub/1798]

---

## Resistant Starch (RS2/RS3/RS4)
URL: https://nutridex.info/s/resistant-starch
Category: Prebiotics & Fibers, Gut & Immune
Evidence: Moderate — Several controlled trials; effects real but modest or context-dependent.
Fermentable starch that resists small-intestine digestion, feeds butyrate-producing gut bacteria, and modestly improves fasting glucose and insulin sensitivity.

Quick answer: Resistant Starch is used for acts as a prebiotic: increases bifidobacterium and ruminococcus bromii and raises colonic short-chain fatty acids, especially butyrate, a key fuel for colon cells. NutriDex grades the human evidence as moderate — Several controlled trials; effects real but modest or context-dependent. Based on 8 cited human studies (8 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Resistant starch (RS) is starch that escapes digestion in the small intestine and is fermented in the colon, where it acts as a prebiotic. The main dietary/supplement forms are RS2 (raw/native granular starch such as high-amylose maize "Hi-maize" and green/unripe banana), RS3 (retrograded starch formed when cooked starchy foods like potatoes, rice and pasta are cooled), and RS4 (chemically modified starches). Randomized trials and meta-analyses most consistently show that RS shifts the microbiome (notably increasing Bifidobacterium and Ruminococcus bromii) and raises colonic short-chain fatty acids, especially butyrate, and modestly lowers fasting glucose and fasting insulin while improving insulin sensitivity; effects on HbA1c and blood lipids are smaller and inconsistent. A landmark long-term trial (CAPP2) found 30 g/day RS for up to 4 years did not reduce colorectal cancer in Lynch syndrome but roughly halved non-colorectal (especially upper-GI) cancers over 10-20 years follow-up, an intriguing but condition-specific finding. Overall the evidence is moderate: real metabolic and microbiome signals, but heterogeneous results and modest effect sizes.

Benefits / uses: Acts as a prebiotic: increases Bifidobacterium and Ruminococcus bromii and raises colonic short-chain fatty acids, especially butyrate, a key fuel for colon cells; Modestly lowers fasting plasma glucose and fasting insulin and improves insulin sensitivity (HOMA), with larger effects at higher doses (>28 g/day) and in RS2; May support weight management: an 8-week crossover RCT of 40 g/day RS2 produced ~2.8 kg weight loss and improved insulin resistance versus control starch; Improves stool frequency and laxation: RS3 increased bowel movements and beneficial bacteria in adults with chronic constipation; May lower fasting triglycerides and LDL cholesterol in some analyses, though lipid effects are smaller and less consistent than glycemic effects; In Lynch syndrome, 30 g/day for up to 4 years was associated with fewer non-colorectal (notably upper-GI) cancers over long-term follow-up, though it did not reduce colorectal cancer.
Active compounds: RS2 supplements: high-amylose maize starch (Hi-maize 260, Ingredion), unmodified potato starch (e.g. Bob's Red Mill), green banana flour/powder; RS3 (retrograded): formed when cooked-then-cooled potatoes, rice, pasta, legumes, and oats; some commercial retrograded tapioca/maize products; RS4: chemically modified starches used in fortified breads and functional foods; Food sources: unripe (green) bananas and plantains, cooked-and-cooled potatoes and rice, whole grains, legumes/beans, raw oats.
Dose: Most RCTs use 15-40 g/day of resistant starch, commonly 20-30 g/day of an RS2 product (e.g. high-amylose maize or raw potato starch) mixed into cold food or water; glycemic and SCFA benefits tend to be larger above ~28 g/day. Raw potato starch and Hi-maize are not heated (heat gelatinizes RS2 and destroys the resistant fraction). Start low (~5-10 g/day) and increase gradually over 1-2 weeks to limit gas.
Safety: Generally well tolerated; because RS is fully fermentable it is a high-FODMAP-style gas producer and the main side effects are flatulence, bloating, and mild abdominal discomfort, which are dose-dependent and usually improve with gradual escalation. Tolerability reviews find doses of 20-40 g/day are usually acceptable, but bloating and dropouts increase around 45 g/day and some individuals react at lower doses. People with IBS or other functional gut disorders may experience more gas and should titrate slowly. Like other fibers, large doses taken with medications can slow or reduce drug absorption, so separate from medications by a few hours; people with diabetes on glucose-lowering drugs should monitor blood sugar as RS can enhance glycemic-lowering effects. Unlike viscous bulk-forming fibers (psyllium, glucomannan/konjac), RS powders do not form a choking gel, but should still be taken with adequate fluid. The cancer-prevention findings apply specifically to Lynch syndrome and should not be generalized; discuss with a clinician if you have a hereditary cancer syndrome, are pregnant or breastfeeding, or have a GI disorder.

Cited studies (8):
  - A comparison of the effects of resistant starch types on glycemic response in individuals with type 2 diabetes or prediabetes: A systematic review and meta-analysis, Frontiers in nutrition (2023) — In type 2 diabetes/prediabetes, RS1 and RS2 lowered postprandial glucose and RS2 improved fasting glucose and insulin, while RS3/RS4 showed weaker or inconsistent glycemic effects across pooled RCTs. [https://pmc.ncbi.nlm.nih.gov/articles/PMC10085630/]
  - Effects of resistant starch on glycaemic control: a systematic review and meta-analysis, British Journal of Nutrition (2020) — Meta-analysis of RCTs found resistant starch significantly lowered fasting plasma glucose (ES -0.09 mmol/L; 95% CI -0.13 to -0.04) versus digestible starch, with larger effects at doses >28 g/day, but no significant effect on HbA1c (high heterogeneity). [https://www.cambridge.org/core/journals/british-journal-of-nutrition/article/effects-of-resistant-starch-on-glycaemic-control-a-systematic-review-and-metaanalysis/95174D9505D6D7C92F88C871DC0D958A]
  - Tolerability and SCFA production after resistant starch supplementation in humans: a systematic review of randomized controlled studies, The American journal of clinical nutrition (2022) — Across 39 RCTs (2,263 participants), resistant starch supplementation was generally well tolerated and increased fecal SCFAs in most studies, with RS2 at 20-40 g/day most common; bloating and dropouts rose around 45 g/day. [https://pubmed.ncbi.nlm.nih.gov/34871343/]
  - Effects of the resistant starch on glucose, insulin, insulin resistance, and lipid parameters in overweight or obese adults: a systematic review and meta-analysis, Nutrition & diabetes (2019) — In overweight/obese adults, resistant starch supplementation significantly reduced fasting insulin, HbA1c and LDL cholesterol and improved insulin sensitivity (HOMA-S%) versus control. [https://pubmed.ncbi.nlm.nih.gov/31168050/]
  - Resistant starch intake facilitates weight loss in humans by reshaping the gut microbiota, Nature metabolism (2024) — In a randomized crossover trial (n=37), 8 weeks of 40 g/day resistant starch produced ~2.8 kg weight loss and improved insulin resistance, with increased Bifidobacterium adolescentis and an altered bile-acid profile. [https://pmc.ncbi.nlm.nih.gov/articles/PMC10963277/]
  - Impact of resistant starch type 3 on fecal microbiota and stool frequency in Thai adults with chronic constipation randomized clinical trial, Scientific reports (2024) — In Thai adults with chronic constipation, 9 g/day RS3 for 12 weeks increased stool frequency (most subjects reaching >=4 BMs/week) and enriched beneficial bacteria (Bifidobacterium, Prevotella, Akkermansia) versus placebo. [https://pubmed.ncbi.nlm.nih.gov/39543201/]
  - Cancer Prevention with Resistant Starch in Lynch Syndrome Patients in the CAPP2-Randomized Placebo Controlled Trial: Planned 10-Year Follow-up, Cancer prevention research (Philadelphia, Pa.) (2022) — In Lynch syndrome, 30 g/day resistant starch for up to 4 years did not reduce colorectal cancer (HR 0.95) but roughly halved non-colorectal Lynch cancers (27 vs 48; HR 0.54), with benefit for upper-GI cancers persisting ~10 years post-intervention. [https://pmc.ncbi.nlm.nih.gov/articles/PMC9433960/]
  - A randomized trial to determine the impact of a digestion resistant starch composition on the gut microbiome in older and mid-age adults, Clinical nutrition (Edinburgh, Scotland) (2018) — A digestion-resistant potato starch significantly increased fecal Bifidobacterium versus placebo in mid-age and elderly adults, with a small but significant rise in stool butyrate in older participants. [https://pubmed.ncbi.nlm.nih.gov/28410921/]

---

## Wheat Dextrin (Benefiber) (Soluble wheat dextrin)
URL: https://nutridex.info/s/wheat-dextrin
Category: Prebiotics & Fibers, Gut & Immune
Evidence: Moderate — Several controlled trials; effects real but modest or context-dependent.
A tasteless, fully soluble wheat fiber (Benefiber) with real prebiotic and glycemic effects but little proof it relieves constipation.

Quick answer: Wheat Dextrin (Benefiber) is used for acts as a prebiotic: fermented in the colon to short-chain fatty acids (butyrate, propionate) and shifts the microbiota, including increasing parabacteroides distasonis and bifidobacteria-type changes. NutriDex grades the human evidence as moderate — Several controlled trials; effects real but modest or context-dependent. Based on 8 cited human studies (8 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Wheat dextrin is a soluble, non-viscous, highly fermentable fiber made by heat- and acid-treating wheat starch; it is the active ingredient in Benefiber and is closely related to the resistant dextrin NUTRIOSE used in most clinical trials. The strongest randomized-trial evidence is metabolic: meta-analyses show modest improvements in fasting glucose and insulin resistance (HOMA-IR), and it acts as a genuine prebiotic, shifting the gut microbiota and raising short-chain fatty acids. Importantly, despite being marketed for regularity, wheat dextrin is non-viscous and has essentially no water-holding capacity, so controlled evidence that it relieves constipation or increases stool output is weak to absent, unlike psyllium. It is very well tolerated up to roughly 30-45 g/day, with gas being the main dose-limiting effect.

Benefits / uses: Acts as a prebiotic: fermented in the colon to short-chain fatty acids (butyrate, propionate) and shifts the microbiota, including increasing Parabacteroides distasonis and bifidobacteria-type changes; Improves insulin resistance: in women with type 2 diabetes, 10 g/day for 8 weeks lowered HOMA-IR by ~25% and fasting insulin by ~23% versus placebo; Lowers fasting blood glucose modestly across RCTs (pooled WMD -0.15 mmol/L), with the largest benefit in people with type 2 diabetes or overweight/obesity; Reduces inflammatory and metabolic-endotoxemia markers (IL-6, TNF-alpha, endotoxin) in trials in type 2 diabetes; Increases satiety and blunts postprandial insulin and glucose responses when taken with a meal, supporting appetite/weight management; Honest caveat: unlike psyllium, it is non-viscous with no water-holding capacity, so it has little proven benefit for constipation, stool bulk, or LDL cholesterol lowering.
Active compounds: Benefiber (powder, on-the-go stick packs, chewables) - soluble wheat dextrin; Equate/store-brand 'clear soluble fiber' powders (wheat dextrin); NUTRIOSE (Roquette) - resistant dextrin from wheat or maize, the form used in most clinical trials and added to functional foods/beverages; Used as an added fiber in 'fiber-fortified' processed foods, drinks, and bars.
Dose: Common label dose is ~3-5 g (about 1-2 teaspoons / one packet) up to ~3 times daily, dissolved in water or soft food; it is tasteless and dissolves clear. Trials of resistant dextrin for metabolic benefit typically use 10-15 g/day; tolerance studies show 30-45 g/day is well tolerated long term. Start low and increase gradually to limit gas.
Safety: Generally very well tolerated; the main side effects are flatulence, bloating, and abdominal discomfort because it is fully fermentable (a FODMAP-type, gas-producing fiber). Long-term doses of 30-45 g/day were well tolerated in healthy men, but higher acute doses (60-80 g/day) clearly increase flatulence versus placebo, and people with IBS may be more sensitive to gas. Contains wheat-derived material; although highly processed and typically very low in gluten, people with celiac disease or wheat allergy should choose a verified gluten-free product or avoid it. As with any fiber, take with adequate fluid and separate from medications by ~2-4 hours, since fiber can delay or reduce absorption of co-ingested drugs. It does NOT carry the choking/esophageal-obstruction hazard of bulk-forming gel fibers like psyllium or glucomannan because it is non-viscous, but it should not be relied on as a primary constipation treatment. People with diabetes on glucose-lowering medication should monitor blood sugar.

Cited studies (8):
  - Effects of resistant dextrin on glycemic traits: a systematic review and meta-analysis of randomized controlled trials, Nutrition journal (2026) — Resistant dextrin significantly lowered fasting blood glucose (WMD -0.15 mmol/L, 95% CI -0.30 to 0.00) and HOMA-IR (WMD -0.51, 95% CI -0.93 to -0.09), with non-significant trends for HbA1c (-0.18%) and fasting insulin. [https://pmc.ncbi.nlm.nih.gov/articles/PMC13072545/]
  - Diet Supplementation with NUTRIOSE, a Resistant Dextrin, Increases the Abundance of Parabacteroides distasonis in the Human Gut, Molecular Nutrition & Food Research (2022) — NUTRIOSE resistant dextrin supplementation significantly increased the abundance of the beneficial gut bacterium Parabacteroides distasonis in healthy adults, demonstrating a prebiotic microbiota shift. [https://onlinelibrary.wiley.com/doi/full/10.1002/mnfr.202101091]
  - Impact of dietary supplementation with resistant dextrin (NUTRIOSE(®)) on satiety, glycaemia, and related endpoints, in healthy adults, European journal of nutrition (2021) — ~7.5-14 g/day resistant dextrin increased fasting satiety and improved postprandial glycemic and incretin (GLP-1) responses in healthy adults versus control. [https://pmc.ncbi.nlm.nih.gov/articles/PMC8572182/]
  - Resistant dextrin, as a prebiotic, improves insulin resistance and inflammation in women with type 2 diabetes: a randomised controlled clinical trial, The British journal of nutrition (2015) — 10 g/day resistant dextrin for 8 weeks reduced HOMA-IR by ~24.9%, fasting insulin by ~22.8%, and IL-6, TNF-alpha and endotoxin versus maltodextrin placebo (all P<0.05). [https://pubmed.ncbi.nlm.nih.gov/27028002/]
  - Short-term digestive tolerance of high-dose of NUTRIOSE<sup>®</sup>FB10 in adult, International Journal of Food Sciences and Nutrition (2010) — In healthy men, wheat dextrin (NUTRIOSE FB10) increased flatulence versus placebo at acute doses of 60-80 g/day, defining the upper tolerance threshold for this fermentable fiber. [https://www.tandfonline.com/doi/full/10.3109/09637486.2010.511166]
  - Long-term gastrointestinal tolerance of NUTRIOSE FB in healthy men, European journal of clinical nutrition (2006) — Daily intake of 30 or 45 g NUTRIOSE FB wheat dextrin for 4-5 weeks was well tolerated, with gastrointestinal complaints barely differing from placebo. [https://pubmed.ncbi.nlm.nih.gov/16482066/]
  - Understanding the Physics of Functional Fibers in the Gastrointestinal Tract: An Evidence-Based Approach to Resolving Enduring Misconceptions about Insoluble and Soluble Fiber, Journal of the Academy of Nutrition and Dietetics (2017) — Wheat dextrin is a non-viscous, readily fermented soluble fiber with no water-holding capacity, so it does not increase stool output and is not an effective laxative despite marketing for regularity. [https://www.jandonline.org/article/S2212-2672(16)31187-X/fulltext]
  - Multiple strains probiotics appear to be the most effective probiotics in the prevention of necrotizing enterocolitis and mortality: An updated meta-analysis, PLOS ONE (2017) — Fermentation of NUTRIOSE FB06 wheat dextrin in a continuous human colonic culture model increased beneficial bacteria and short-chain fatty acid (notably butyrate) production. [https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0077128]

---

## Partially Hydrolyzed Guar Gum (PHGG) (Sunfiber)
URL: https://nutridex.info/s/phgg
Category: Prebiotics & Fibers, Gut & Immune
Evidence: Moderate — Several controlled trials; effects real but modest or context-dependent.
A low-viscosity, tasteless soluble fiber from the guar bean — a reliable bifidogenic prebiotic and an IBS/gut-regularity workhorse.

Quick answer: Partially Hydrolyzed Guar Gum (PHGG) is used for prebiotic / bifidogenic: human trials and the pagoda rct show phgg increases bifidobacterium, faecalibacterium and ruminococcus and boosts colonic scfa (butyrate) production. NutriDex grades the human evidence as moderate — Several controlled trials; effects real but modest or context-dependent. Based on 9 cited human studies (9 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Partially hydrolyzed guar gum (PHGG; the galactomannan of Cyamopsis tetragonoloba, enzymatically shortened to lower its viscosity and marketed as Sunfiber) is a 100% soluble, highly fermentable dietary fiber that dissolves clear and tasteless. Unlike native guar gum it does not gel or thicken, so it is well tolerated and used to fortify foods, beverages, and tube-feed formulas. The best human evidence is for gut function and the microbiome: randomized trials and a systematic review/meta-analysis show it normalizes stool form and increases defecation frequency, reduces bloating in IBS, and reliably acts as a prebiotic — raising Bifidobacterium, Faecalibacterium, and short-chain fatty acid (SCFA) production. Metabolic effects are more modest: pooled RCT data show small HbA1c reductions (and fasting-glucose lowering mainly in type 2 diabetes at higher doses), with weaker, less consistent weight and lipid signals.

Benefits / uses: Prebiotic / bifidogenic: human trials and the PAGODA RCT show PHGG increases Bifidobacterium, Faecalibacterium and Ruminococcus and boosts colonic SCFA (butyrate) production; IBS symptom relief: 6 g/day improved bloating and gas scores and normalized Bristol stool form versus placebo, with benefit in both diarrhea- and constipation-predominant patterns; Bowel regularity: a meta-analysis in healthy adults found PHGG significantly increased defecation frequency (SMD 0.58/day), and trials show faster colonic transit and reduced laxative use; Modest glycemic benefit: pooled RCTs show lower HbA1c, with fasting-glucose reductions concentrated in type 2 diabetes and higher doses (>15 g/day); blunts postprandial glucose/insulin; Satiety and dietary regulation: increases post-meal satiety and can reduce subsequent energy/snacking intake (basis of an EFSA-assessed satiety claim, though body-weight evidence is weaker); Tube-feeding tolerance: low viscosity lets it mix into enteral formulas to reduce the incidence and severity of feeding-associated diarrhea.
Active compounds: Sunfiber (Taiyo) — the dominant branded PHGG, in supplements and functional foods; Benefiber Healthy Shape, Regular Girl, and many "clear soluble fiber" powders/capsules; Enteral/medical nutrition formulas (e.g. fiber-containing tube-feed blends) use PHGG as the soluble fiber source; Sold as a flavorless, dissolvable powder added to water, coffee, smoothies, or food; the parent food additive is guar gum (E412).
Dose: Typical effective dose is about 5-7 g/day for bowel regularity, microbiome/prebiotic effects, and IBS (e.g. 6 g/day in IBS trials; 5 g up to 3x/day in the PAGODA microbiome trial). Higher doses (>15 g/day) are used in glycemic and weight studies. Taken as a tasteless powder dissolved in water or any drink, with no need for the large fluid bolus that viscous fibers require; start low (a few grams) and titrate up to limit gas.
Safety: Generally very well tolerated — because PHGG is low-viscosity and non-gelling it lacks the choking/esophageal-obstruction hazard that concentrated swelling fibers (native guar gum tablets, glucomannan/konjac) carry; the FDA's 1992 ban on guar gum in weight-loss tablets was specifically about that mechanical risk, not PHGG powders. As a fully fermentable fiber it is a FODMAP-type substrate, so transient gas, bloating, and flatulence are the main side effects, dose-dependent and usually mild; titrating up over days minimizes this. People prone to IBS gas, those with severe GI dysmotility, or anyone with a guar/legume allergy should be cautious. Like other soluble fibers, taking large amounts together with oral medications can slow or reduce drug absorption, so separate doses (take medicines ~1-2 hours apart). EFSA's ANS/FAF panels found no safety concern for guar-gum-derived fiber at food-additive levels.

Cited studies (9):
  - The effects of guar gum supplementation on glycemic control, body mass and blood pressure in adults: A GRADE-assessed systematic review and meta-analysis of randomized clinical trials, Diabetes research and clinical practice (2023) — GRADE-assessed meta-analysis of 14 RCTs found guar gum supplementation lowered HbA1c (WMD -0.47, 95% CI -0.75 to -0.18, p=0.001); fasting glucose fell only in type 2 diabetes and at doses >15 g/day, with no overall effect on body mass or blood pressure. [https://pubmed.ncbi.nlm.nih.gov/36958432/]
  - Impact of partially hydrolyzed guar gum (PHGG) on constipation prevention: A systematic review and meta-analysis, Journal of Functional Foods (2017) — Systematic review and meta-analysis (15 trials, 7 studies, 325 healthy adults) found 5-7 g/day PHGG significantly increased fecal defecation frequency (SMD 0.58 times/day, 95% CI 0.43-0.74, I2=0, p<0.00001). [https://doi.org/10.1016/j.jff.2017.03.028]
  - Scientific Opinion on the substantiation of health claims related to partially hydrolysed guar gum and increase in satiety (ID 790), maintenance or achievement of a normal body weight (ID 790), maintenance of normal blood concentrations of triglycerides (ID 793, 816), maintenance of normal blood cholesterol concentrations (ID 793, 816), reduction of post‐prandial glycaemic responses (ID 789, 2932) and maintenance of normal blood glucose concentrations (ID 792) pursuant to Article 13(1) of Regulation (EC) No 1924/2006, EFSA Journal (2010) — EFSA scientific opinion assessed health claims for PHGG: found a cause-and-effect basis for reduction of post-prandial glycaemic responses, but did not substantiate claims for satiety, body weight, cholesterol, or triglycerides as worded. [https://efsa.onlinelibrary.wiley.com/doi/pdf/10.2903/j.efsa.2010.1465]
  - Prebiotic Effects of Partially Hydrolyzed Guar Gum on the Composition and Function of the Human Microbiota-Results from the PAGODA Trial, Nutrients (2020) — 9-week trial in 20 healthy adults given up to 5 g PHGG 3x/day shifted the microbiota (bloom in Ruminococcus, Fusicatenibacter, Faecalibacterium, Bacteroides) and increased SCFA production, with effects reversing after washout. [https://pmc.ncbi.nlm.nih.gov/articles/PMC7281958/]
  - Effectiveness of Partially Hydrolyzed Guar Gum in Reducing Constipation in Long Term Care Facility Residents: A Randomized Single-Blinded Placebo-Controlled Trial, The journal of nutrition, health & aging (2022) — Randomized single-blind placebo-controlled trial in long-term-care residents: PHGG significantly reduced laxative use vs control, though bowel-movement frequency itself did not differ significantly. [https://pubmed.ncbi.nlm.nih.gov/35297467/]
  - Randomized clinical study: Partially hydrolyzed guar gum (PHGG) versus placebo in the treatment of patients with irritable bowel syndrome, Nutrition & metabolism (2016) — Randomized double-blind placebo-controlled trial in IBS (121 randomized): 6 g/day PHGG for 12 weeks significantly improved bloating and bloating+gas scores vs placebo, with benefit persisting 4 weeks after treatment. [https://pmc.ncbi.nlm.nih.gov/articles/PMC4744437/]
  - Effect of Repeated Consumption of Partially Hydrolyzed Guar Gum on Fecal Characteristics and Gut Microbiota: A Randomized, Double-Blind, Placebo-Controlled, and Parallel-Group Clinical Trial, Nutrients (2019) — Randomized double-blind placebo-controlled parallel trial: repeated PHGG consumption improved fecal characteristics and shifted gut microbiota, increasing beneficial bacteria vs placebo. [https://pmc.ncbi.nlm.nih.gov/articles/PMC6769658/]
  - Post-meal perceivable satiety and subsequent energy intake with intake of partially hydrolysed guar gum, The British journal of nutrition (2015) — Acute randomized study found PHGG intake increased post-meal perceivable satiety and reduced subsequent energy intake versus control. [https://pubmed.ncbi.nlm.nih.gov/25851425/]
  - Partially hydrolyzed guar gum accelerates colonic transit time and improves symptoms in adults with chronic constipation, Digestive diseases and sciences (2014) — In adults with chronic constipation, PHGG significantly accelerated colonic transit time and increased complete spontaneous and spontaneous bowel movements (p<0.001) while improving symptoms. [https://pubmed.ncbi.nlm.nih.gov/24711073/]

---

## Arabinoxylan (Cereal hemicellulose (AXOS))
URL: https://nutridex.info/s/arabinoxylan
Category: Prebiotics & Fibers, Gut & Immune
Evidence: Moderate — Several controlled trials; effects real but modest or context-dependent.
Cereal hemicellulose fiber (and its AXOS oligosaccharides) with EFSA-backed postprandial glucose-lowering and a reliable bifidogenic effect.

Quick answer: Arabinoxylan is used for lowers post-prandial blood glucose and insulin responses — the basis for an efsa-authorized health claim at ~8 g of wheat-endosperm ax-rich fiber per meal. NutriDex grades the human evidence as moderate — Several controlled trials; effects real but modest or context-dependent. Based on 8 cited human studies (8 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Arabinoxylan (AX) is the main soluble hemicellulose fiber of cereal grains such as wheat, rye, barley and psyllium; enzymatically shortened forms are called arabinoxylan-oligosaccharides (AXOS). Its best-supported effect is on glucose: a 2025 systematic review and meta-analysis of clinical and preclinical studies found AX significantly reduced postprandial glucose and insulin responses, and the EFSA authorizes a health claim that ~8 g of AX-rich fiber from wheat endosperm per meal lowers post-prandial glycaemia. Small randomized crossover trials in people with type 2 diabetes or impaired glucose tolerance also show lower fasting glucose, HbA1c and triglycerides, and human studies consistently show AXOS is bifidogenic and raises short-chain fatty acids (especially butyrate). Evidence is most robust for acute glycemic and microbiome endpoints; data on LDL cholesterol, weight and long-term clinical outcomes are thinner and less consistent, with trials generally small.

Benefits / uses: Lowers post-prandial blood glucose and insulin responses — the basis for an EFSA-authorized health claim at ~8 g of wheat-endosperm AX-rich fiber per meal; Improves longer-term glycemic control in type 2 diabetes and impaired glucose tolerance: small crossover RCTs report reduced fasting glucose, HbA1c, fructosamine and apolipoprotein B; Reliably bifidogenic — AXOS and AX increase fecal Bifidobacterium and butyrate-producing bacteria, raising short-chain fatty acid (SCFA) production; Can modestly lower fasting serum triglycerides in some trials (effect on LDL/total cholesterol is inconsistent and generally not significant); Increases satiety hormones and lowers ghrelin response in some studies, which may support appetite control; As a fermentable soluble fiber, contributes to stool bulking and laxation, though dedicated constipation trials are limited.
Active compounds: AXOS ingredients (e.g. NAXUS / Comet Bio, BioActor AXOS) used in functional foods and supplements; Wheat-endosperm arabinoxylan concentrates and wheat-bran/aleurone AX-rich fractions; AXOS-enriched (endoxylanase-treated) breads and cereal products; Rice-bran arabinoxylan compound (e.g. MGN-3/BioBran, a different immunomodulatory product); Food sources: whole wheat, rye, barley, oats, psyllium husk, wheat and rice bran, and other whole-grain cereals.
Dose: For postprandial glucose: ~8 g of wheat-endosperm AX-rich fiber consumed as part of a carbohydrate meal (EFSA condition). Metabolic trials in diabetes/IGT used roughly 6-15 g/day of AX added to bread or muffins over 4-6 weeks. For a bifidogenic/prebiotic effect, AXOS has been effective from ~2.2 g/day up to ~10 g/day; tolerance studies support doses up to about 10 g/day. Best taken with cereal-based meals.
Safety: Generally well tolerated. Because AX and especially AXOS are fermented in the colon, the main side effects are flatulence, bloating and abdominal discomfort, which are dose-dependent and tend to ease over time; doses around 10 g/day of AXOS are tolerated in healthy adults, with more gas at higher intakes. As fermentable fibers they can aggravate symptoms in some people with IBS or on a low-FODMAP diet (start low and increase gradually with adequate fluids). Like other viscous/bulking fibers, AX may slow or reduce absorption of co-ingested medications and minerals, so separate doses from medications by 2-4 hours. People with celiac disease or wheat allergy should avoid wheat-derived AX/AXOS products. Note that rice-bran arabinoxylan compound (MGN-3/BioBran) is a distinct immunomodulatory product and its claims should not be conflated with cereal AX/AXOS fiber. Those with diabetes on glucose-lowering drugs should monitor blood sugar.

Cited studies (8):
  - Impact of Arabinoxylan Consumption on Glycemic Control: A Systematic Review and Meta-Analysis of Preclinical and Clinical Studies, Nutrients (2025) — Across clinical studies, arabinoxylan significantly improved postprandial glycemic control: glucose iAUC (SMD -0.41; 95% CI -0.57 to -0.25), insulin iAUC (SMD -0.28; 95% CI -0.44 to -0.12) and glucose peak (SMD -0.52; 95% CI -0.80 to -0.25) versus control. [https://pmc.ncbi.nlm.nih.gov/articles/PMC12429902/]
  - Scientific Opinion on the substantiation of health claims related to arabinoxylan produced from wheat endosperm and reduction of post-prandial glycaemic responses (ID 830) pursuant to Article 13(1) of Regulation (EC) No 1924/2006, EFSA Journal (2011) — EFSA concluded a cause-and-effect relationship between consumption of wheat-endosperm arabinoxylan and reduction of post-prandial glycaemic responses, with the claim conditioned on ~8 g AX-rich fibre (>=60% AX) per 100 g available carbohydrate per meal. [https://www.efsa.europa.eu/en/efsajournal/pub/2205]
  - A Multi-omics Approach to Unraveling the Microbiome-Mediated Effects of Arabinoxylan Oligosaccharides in Overweight Humans, mSystems (2019) — In overweight adults with metabolic-syndrome signs, 10.4 g/day AXOS induced a bifidogenic shift, increased butyrate-producing species and Prevotella, and altered microbial functional genes versus control. [https://pmc.ncbi.nlm.nih.gov/articles/PMC6538848/]
  - Validity of the Brazilian version of the Geriatric Depression Scale (GDS) among primary care patients, International psychogeriatrics (2010) — In healthy subjects, 2.2 g/day of AXOS (avDP 9) for 3 weeks significantly increased faecal bifidobacteria and lowered urinary p-cresol, demonstrating prebiotic activity, while being well tolerated. [https://pubmed.ncbi.nlm.nih.gov/19883523/]
  - A randomised, double-blind, placebo controlled cross-over study to determine the gastrointestinal effects of consumption of arabinoxylan-oligosaccharides enriched bread in healthy volunteers, Nutrition journal (2012) — In 40 healthy volunteers, AXOS-enriched bread (2.2 g AXOS) was well tolerated with no significant adverse GI effects versus control bread, supporting its use in functional bread products. [https://pubmed.ncbi.nlm.nih.gov/22657950/]
  - Postprandial effects of test meals including concentrated arabinoxylan and whole grain rye in subjects with the metabolic syndrome: a randomised study, European journal of clinical nutrition (2014) — In subjects with metabolic syndrome, test meals with concentrated arabinoxylan lowered acute post-prandial glucose and insulin responses compared with refined wheat, though longer-term whole-day effects were modest. [https://pubmed.ncbi.nlm.nih.gov/24595224/]
  - Arabinoxylan fibre improves metabolic control in people with Type II diabetes, European journal of clinical nutrition (2004) — In 15 adults with type 2 diabetes, AX-rich wheat fibre over two 5-week periods significantly lowered fasting and post-load glucose, serum fructosamine, triglycerides and apolipoprotein B versus control bread/muffins. [https://pubmed.ncbi.nlm.nih.gov/15042130/]
  - Arabinoxylan fibre consumption improved glucose metabolism, but did not affect serum adipokines in subjects with impaired glucose tolerance, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme (2006) — In subjects with impaired glucose tolerance, 6 weeks of 15 g/day arabinoxylan significantly reduced fasting serum glucose, triglycerides and apolipoprotein A-1 compared with placebo bread. [https://pubmed.ncbi.nlm.nih.gov/17111305/]

---

## Beta-Glucan (Oat / Barley) ((1,3/1,4)-β-D-glucan)
URL: https://nutridex.info/s/beta-glucan
Category: Prebiotics & Fibers, Gut & Immune
Evidence: Strong — Multiple high-quality RCTs / meta-analyses with consistent effects.
The viscous oat/barley soluble fiber with FDA- and EFSA-backed proof it lowers LDL cholesterol and blunts post-meal glucose.

Quick answer: Beta-Glucan (Oat / Barley) is used for lowers ldl ('bad') and total cholesterol: ~3 g/day reduces ldl by roughly 0.2-0.3 mmol/l (about 5-7%) in randomized trials, the basis of fda and efsa heart-health claims. NutriDex grades the human evidence as strong — Multiple high-quality RCTs / meta-analyses with consistent effects. Based on 9 cited human studies (9 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Beta-glucan is a soluble, viscous, mixed-linkage (1,3/1,4)-beta-D-glucan fiber concentrated in oats and barley (and the active fiber behind oatmeal's heart-health reputation). Its evidence for lowering LDL and total cholesterol is among the strongest of any dietary fiber: dozens of randomized trials and multiple meta-analyses show roughly 3 g/day cuts LDL cholesterol by about 0.2-0.3 mmol/L, which underpins both an FDA-authorized and an EFSA-approved heart-health claim. It also reliably blunts post-meal blood glucose and insulin when eaten with carbohydrate (another EFSA-authorized claim), with smaller and less consistent effects on long-term HbA1c. Evidence for satiety/modest weight effects is moderate, and while beta-glucan is fermented to short-chain fatty acids (notably propionate) and shifts the microbiota, it is not a classic bifidogenic prebiotic and the human gut-flora data are thinner than the cholesterol data.

Benefits / uses: Lowers LDL ('bad') and total cholesterol: ~3 g/day reduces LDL by roughly 0.2-0.3 mmol/L (about 5-7%) in randomized trials, the basis of FDA and EFSA heart-health claims; Blunts post-meal (postprandial) glucose and insulin spikes when eaten with carbohydrate by forming a viscous gel that slows gastric emptying and carbohydrate absorption (EFSA-authorized glycemic claim); Modestly improves long-term glycemic markers (small HbA1c and fasting-glucose reductions) in some trials, with larger cholesterol benefit seen in people with diabetes and higher baseline LDL; Is fermented by gut bacteria to short-chain fatty acids (a propionate-rich profile) and shifts microbiota composition, though it is not a strongly bifidogenic 'classic' prebiotic; Increases satiety and can produce small reductions in body weight, BMI, and energy intake via gut-hormone (higher PYY, lower ghrelin) and viscosity effects; Adds to total soluble fiber intake supporting normal bowel function and stool regularity.
Active compounds: Whole and cut oats, rolled/instant oatmeal, oat bran, whole-oat flour, and oatrim; Whole-grain and pearled barley, barley flour and barley bran; Concentrated supplements and food ingredients: oat beta-glucan and barley beta-glucan powders/extracts (e.g., OatWell, PromOat, Glucagel, Barliv barley beta-fiber); Functional foods fortified with oat/barley beta-glucan (cereals, beverages, breads, bars).
Dose: At least 3 g/day of beta-glucan for cholesterol lowering (the FDA and EFSA threshold), typically from ~3 servings of oats/oat bran or a beta-glucan-enriched food/supplement; trials used a median of ~3.5 g/day. For blunting post-meal glucose, EFSA specifies at least 4 g of beta-glucan per 30 g of available carbohydrate eaten in the same meal (a 2025 EFSA opinion supports a lower oat threshold of 3 g per 30 g carbohydrate). Best taken with meals and with adequate fluid; benefits depend on the fiber's molecular weight and viscosity being preserved (heavy processing can reduce efficacy.)
Safety: Generally very well tolerated and safe as a food. Because it is fermentable, the main side effects are gas, bloating, and abdominal fullness, which are usually mild and lessen if the dose is increased gradually; people with IBS or sensitivity to fermentable carbohydrates may notice more gas. Take with adequate fluid. As a viscous soluble fiber, beta-glucan can slow gastric emptying and may delay or reduce the absorption of co-ingested medications, so separate it from time-sensitive drugs (e.g., thyroid hormone, certain antibiotics) by a couple of hours. People with diabetes on glucose-lowering medication should monitor blood sugar, since beta-glucan can enhance glucose-lowering and add to that effect. Those with celiac disease should use certified gluten-free oats (oats are often cross-contaminated, and barley contains gluten). Anyone with swallowing difficulty, esophageal narrowing, or a suspected bowel obstruction should avoid concentrated fiber supplements taken with little water. Beta-glucan does not carry the choking/esophageal-obstruction hazard associated with glucomannan/konjac, but any concentrated fiber should be taken with plenty of liquid.

Cited studies (9):
  - Effects of Oat Beta-Glucan Intake on Lipid Profiles in Hypercholesterolemic Adults: A Systematic Review and Meta-Analysis of Randomized Controlled Trials, Nutrients (2022) — In hypercholesterolemic adults, oat beta-glucan significantly reduced LDL cholesterol (pooled WMD -0.27 mmol/L; 95% CI -0.35 to -0.20) and total cholesterol versus control across 13 randomized trials. [https://pmc.ncbi.nlm.nih.gov/articles/PMC9147392/]
  - Effects of cereal beta-glucan consumption on body weight, body mass index, waist circumference and total energy intake: A meta-analysis of randomized controlled trials, Complementary therapies in medicine (2019) — A meta-analysis of randomized controlled trials found cereal beta-glucan consumption modestly reduced body weight and BMI, while doses above ~4 g/day were associated with higher total energy intake. [https://pubmed.ncbi.nlm.nih.gov/30935520/]
  - The effect of oat β-glucan on LDL-cholesterol, non-HDL-cholesterol and apoB for CVD risk reduction: a systematic review and meta-analysis of randomised-controlled trials, The British journal of nutrition (2016) — A systematic review and meta-analysis of 58 trials found a median 3.5 g/day of oat beta-glucan significantly lowered LDL-cholesterol by 0.19 mmol/L, non-HDL-cholesterol by 0.20 mmol/L, and apoB by 0.03 g/L versus control. [https://pubmed.ncbi.nlm.nih.gov/27724985/]
  - A systematic review and meta-analysis of beta-glucan consumption on glycemic control in hypercholesterolemic individuals, International journal of food sciences and nutrition (2015) — A systematic review and meta-analysis of RCTs in hypercholesterolemic individuals found beta-glucan consumption (~2.5-3.5 g/day) significantly lowered fasting glucose and HbA1c, with greater cholesterol benefit in people with diabetes. [https://pubmed.ncbi.nlm.nih.gov/26001090/]
  - Beta‐glucans from oats or barley and reduction of postprandial glycaemic responses: Modification of an authorised health claim pursuant to Article 13(1) of Regulation (EC) No 1924/2006 following a request in accordance with Article 19 of Regulation (EC) No 1924/2006, EFSA Journal (2025) — A 2025 EFSA opinion supported modifying the post-prandial glucose claim for oat beta-glucan to a lower threshold of 3 g per 30 g of available carbohydrate per meal. [https://efsa.onlinelibrary.wiley.com/doi/10.2903/j.efsa.2025.9630]
  - Cholesterol-lowering effects of oat β-glucan: a meta-analysis of randomized controlled trials, The American journal of clinical nutrition (2014) — A meta-analysis of 28 randomized controlled trials found oat beta-glucan at >=3 g/day reduced LDL cholesterol by 0.25 mmol/L (95% CI 0.20-0.30) and total cholesterol by 0.30 mmol/L vs control, with no effect on HDL or triglycerides. [https://pmc.ncbi.nlm.nih.gov/articles/PMC5394769/]
  - Scientific Opinion on the substantiation of health claims related to beta-glucans from oats and barley and maintenance of normal blood LDL-cholesterol concentrations (ID 1236, 1299), increase in satiety leading to a reduction in energy intake (ID 851, 852), reduction of post-prandial glycaemic responses (ID 821, 824), and "digestive function" (ID 850) pursuant to Article 13(1) of Regulation (EC) No 1924/2006, EFSA Journal (2011) — EFSA concluded a cause-and-effect relationship between beta-glucans from oats and barley and maintenance of normal blood LDL-cholesterol, and reduction of post-prandial glycaemic responses, supporting authorized EU health claims. [https://efsa.onlinelibrary.wiley.com/doi/10.2903/j.efsa.2011.2207]
  - Health claims: Soluble fiber from certain foods and risk of coronary heart disease (CHD), U.S. Food and Drug Administration, Department of Health and Human Services (Electronic Code of Federal Regulations, 21 CFR 101.81) — The FDA authorizes a coronary-heart-disease health claim for foods supplying >=3 g/day of beta-glucan soluble fiber from whole oats or barley, requiring at least 0.75 g per serving. [https://www.ecfr.gov/current/title-21/chapter-I/subchapter-B/part-101/subpart-E/section-101.81]
  - In vitro fermentation of oat and barley derived beta-glucans by human faecal microbiota, FEMS microbiology ecology (2008) — Human faecal fermentation of oat and barley beta-glucans produced a propionate-rich short-chain fatty acid profile (acetate:propionate:butyrate ~51:32:17) and modulated microbiota, though without a strong classic bifidogenic effect. [https://pubmed.ncbi.nlm.nih.gov/18430007/]

---

## Acacia Fiber (Gum Arabic) (Acacia senegal)
URL: https://nutridex.info/s/acacia-fiber
Category: Prebiotics & Fibers, Gut & Immune
Evidence: Moderate — Several controlled trials; effects real but modest or context-dependent.
A nearly tasteless, non-viscous soluble fiber that is slowly and completely fermented, feeding bifidobacteria with minimal gas.

Quick answer: Acacia Fiber (Gum Arabic) is used for bifidogenic prebiotic: selectively increases bifidobacterium and lactobacillus and raises colonic short-chain fatty acids (acetate/propionate), with much lower gas and bloating than inulin or fos because it ferments slowly and completely. NutriDex grades the human evidence as moderate — Several controlled trials; effects real but modest or context-dependent. Based on 9 cited human studies (9 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Acacia fiber (gum arabic), the dried exudate of Acacia senegal/seyal trees, is a highly branched arabinogalactan-protein soluble fiber that is non-viscous and slowly, near-completely fermented in the colon to short-chain fatty acids. Its best-documented effect is bifidogenic: human studies show selective increases in Bifidobacterium and Lactobacillus at roughly 10 g/day, with notably low gas and bloating versus inulin/FOS because fermentation is gradual. Randomized trials, mostly small and many from Sudan, also report modest reductions in BMI and body fat in women (30 g/day) and improvements in glycemia, lipids and blood pressure in type 2 diabetes and metabolic syndrome, plus anti-inflammatory (lower CRP) effects in CKD; however these cardiometabolic trials are small, single-region and not yet confirmed by large independent RCTs, so that evidence is preliminary-to-moderate. A 2024 RCT in IBS-C found 10 g/day increased stool frequency above the FDA clinical-relevance threshold.

Benefits / uses: Bifidogenic prebiotic: selectively increases Bifidobacterium and Lactobacillus and raises colonic short-chain fatty acids (acetate/propionate), with much lower gas and bloating than inulin or FOS because it ferments slowly and completely; Improves bowel regularity: 10 g/day raised weekly stool frequency in constipation-predominant IBS above the FDA threshold for clinical relevance in a 2024 RCT; Lowers body weight/adiposity: 30 g/day for 6 weeks reduced BMI (~0.32) and body fat (~2.2 percentage points) in healthy adult women, and cut BMI and visceral adiposity index in type 2 diabetes; Improves glycemic control: 30 g/day for 3 months significantly lowered fasting plasma glucose and HbA1c in type 2 diabetic patients; Modest lipid and blood-pressure benefits: reductions in total/LDL cholesterol, triglycerides, and systolic/diastolic blood pressure reported in diabetic and metabolic-syndrome RCTs (effects smaller and less consistent than for psyllium or oat beta-glucan, which alone hold FDA heart-health claims); Anti-inflammatory signal in kidney disease: lowered C-reactive protein in CKD and hemodialysis patients, though without changing serum urea or creatinine.
Active compounds: Supplement powders/fibers: NOW Foods Acacia Fiber, Heather's Tummy Fiber (Organic Acacia Senegal), Anthony's Acacia Senegal, Frontier Co-op acacia powder; Functional-food/branded ingredients: Fibregum (Nexira), Acacia gum/gum arabic E414 used in beverages, bars and fiber blends; Capsules and stick-pack drink mixes (dissolve clear and nearly tasteless in water); Food sources: gum arabic (E414) is an additive in soft drinks, candies/gummies, baked goods and beverage stabilizers rather than a whole food.
Dose: Prebiotic/regularity effects: ~10 g/day (bifidogenic threshold and the IBS-C trial dose). Cardiometabolic trials used 30 g/day. Stir the powder into water or another beverage (it dissolves clear and non-viscous) once daily; start low (5 g) and titrate up over 1-2 weeks to minimize gas.
Safety: Generally very well tolerated, often better than inulin/FOS: tolerance studies report minimal gas, bloating and no laxative/osmotic diarrhea even up to 30-50 g/day, owing to slow, non-osmotic fermentation. It is a fermentable fiber, so sensitive or IBS individuals may still notice mild flatulence; introduce gradually. Unlike glucomannan/konjac it is non-viscous and non-gelling, so it does not pose a choking or esophageal-obstruction hazard. As with any soluble fiber, separate from oral medications by ~1-2 hours, as it can slow or reduce absorption of co-ingested drugs. Acacia/gum arabic allergy is rare but reported (occupational asthma in printers/handlers); diabetics adding it to therapy should monitor glucose. No effect on serum urea/creatinine, so it is not a treatment for renal failure itself.

Cited studies (9):
  - Effectiveness of different gums on modulating of glycemic indices in adults: a systematic review and meta-analysis, Journal of diabetes and metabolic disorders (2025) — Systematic review and meta-analysis (J Diabetes Metab Disord) of dietary gums on glycemic indices in adults concluded acacia/arabic gum evidence was limited and inconsistent, with guar gum showing the clearest anti-hyperglycemic effect. [https://pubmed.ncbi.nlm.nih.gov/39736929/]
  - The Efficacy of Gum Arabic in Managing Diseases: A Systematic Review of Evidence-Based Clinical Trials, Biomolecules (2023) — Systematic review of 29 clinical trials found gum arabic ingestion altered lipid and renal profiles, blood pressure, inflammatory markers, dental plaque/gingival scores, and adiposity, with reported prebiotic and anti-inflammatory effects. [https://pmc.ncbi.nlm.nih.gov/articles/PMC9855968/]
  - Acacia fiber or probiotic supplements to relieve gastrointestinal complaints in patients with constipation-predominant IBS: a 4-week randomized double-blinded placebo-controlled intervention trial, European journal of nutrition (2024) — Parallel double-blind RCT in 180 IBS-C patients: 10 g/day acacia fiber for 4 weeks significantly increased weekly stool frequency above the FDA clinical-relevance threshold (P<0.001) versus maltodextrin placebo. [https://pmc.ncbi.nlm.nih.gov/articles/PMC11329592/]
  - The Effect of Gum Arabic (Acacia Senegal) on Cardiovascular Risk Factors and Gastrointestinal Symptoms in Adults at Risk of Metabolic Syndrome: A Randomized Clinical Trial, Nutrients (2021) — Randomized clinical trial in adults at risk of metabolic syndrome: 12 weeks of gum arabic significantly reduced systolic and diastolic blood pressure and fasting plasma glucose versus control, with acceptable GI tolerance. [https://pmc.ncbi.nlm.nih.gov/articles/PMC7826716/]
  - Effect of Gum Arabic (Acacia Senegal) supplementation on visceral adiposity index (VAI) and blood pressure in patients with type 2 diabetes mellitus as indicators of cardiovascular disease (CVD): a randomized and placebo-controlled clinical trial, Lipids in health and disease (2018) — Randomized placebo-controlled trial in 91 type 2 diabetics: 30 g/day gum arabic for 3 months significantly lowered BMI and visceral adiposity index (~23.7% reduction), fasting glucose, HbA1c and blood pressure versus placebo. [https://pmc.ncbi.nlm.nih.gov/articles/PMC5859434/]
  - Gum Arabic Reduces C-Reactive Protein in Chronic Kidney Disease Patients without Affecting Urea or Indoxyl Sulfate Levels, International journal of nephrology (2017) — In CKD patients, gum arabic (down to 10 g/day) significantly reduced C-reactive protein but did not change serum urea, creatinine or indoxyl sulfate. [https://pmc.ncbi.nlm.nih.gov/articles/PMC5446885/]
  - Effects of Gum Arabic ingestion on body mass index and body fat percentage in healthy adult females: two-arm randomized, placebo controlled, double-blind trial, Nutrition journal (2012) — Two-arm double-blind RCT in 120 healthy women: 30 g/day gum arabic for 6 weeks significantly reduced BMI (by ~0.32) and body fat percentage (by ~2.18 points) versus pectin placebo. [https://pmc.ncbi.nlm.nih.gov/articles/PMC3570285/]
  - Biosimilars: opinion of an expert panel in the Middle East, Current medical research and opinion (2008) — In healthy adults, acacia gum was bifidogenic with an optimal prebiotic dose around 10 g/day, selectively increasing Bifidobacterium, Lactobacillus and Bacteroides while remaining well tolerated. [https://pubmed.ncbi.nlm.nih.gov/18768104/]
  - Manipulation of Gut Microbiota Using Acacia Gum Polysaccharide, ACS omega (2021) — Review of human and in vitro data concludes acacia gum acts as a non-viscous, slowly fermented prebiotic that boosts Bifidobacterium and SCFA production with superior GI tolerance to inulin/FOS. [https://pmc.ncbi.nlm.nih.gov/articles/PMC8296006/]

---

## Methylcellulose (Citrucel) (Cellulose ether)
URL: https://nutridex.info/s/methylcellulose
Category: Prebiotics & Fibers, Gut & Immune
Evidence: Moderate — Several controlled trials; effects real but modest or context-dependent.
A non-fermentable, low-gas semi-synthetic fiber that bulks stool with minimal bloating, but with weaker cholesterol and glycemic effects than psyllium.

Quick answer: Methylcellulose (Citrucel) is used for acts as a bulk-forming laxative, increasing stool bulk and water content to relieve occasional constipation and promote regularity (fda otc monograph ingredient). NutriDex grades the human evidence as moderate — Several controlled trials; effects real but modest or context-dependent. Based on 8 cited human studies (8 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Methylcellulose (Citrucel) is a semi-synthetic cellulose ether and a bulk-forming laxative recognized in the FDA OTC monograph. Its defining advantage is that it is essentially non-fermentable, so it passes through the colon intact and produces very little gas or bloating compared with fermentable prebiotics like inulin. However, the evidence base is thinner than for psyllium: head-to-head randomized trials show methylcellulose lowers LDL and total cholesterol less than psyllium because it forms a weaker, lower-viscosity gel, and authoritative reviews note there are surprisingly few well-controlled placebo-comparison trials supporting its laxative efficacy despite decades of use. It is best regarded as a well-tolerated stool-bulking fiber for regularity, not a strong metabolic or cholesterol-lowering agent.

Benefits / uses: Acts as a bulk-forming laxative, increasing stool bulk and water content to relieve occasional constipation and promote regularity (FDA OTC monograph ingredient); Is non-fermentable and therefore low-gas, producing markedly less bloating and flatulence than fermentable prebiotic fibers such as inulin or fructooligosaccharides; Modestly lowers LDL and total cholesterol, though head-to-head randomized trials show it is less effective than psyllium because it gels weakly; May add soluble fiber to the diet without the FODMAP-related gas that limits tolerance of fermentable fibers, useful in some people with IBS sensitivity; Resists colonic fermentation, so it stays intact through the large bowel, a property that theoretically favors a laxative (water-holding) effect.
Active compounds: Citrucel (caplets and orange-flavored powder) — the leading brand; Store-brand methylcellulose fiber therapy products (CVS Health, H-E-B, and other pharmacy lines), typically 2 g per dose; Sugar-free powder and caplet formulations; Not a natural food fiber — methylcellulose is a manufactured semi-synthetic cellulose ether used both as a supplement and as a food additive (E461).
Dose: Typical adult dose is about 2 g of methylcellulose up to three times daily (roughly 1 heaping tablespoon of powder or 2 caplets per dose), each taken with at least 240 mL (8 oz) of cold water. Start low and titrate up to tolerance; effect on bowel movements usually occurs within 12-72 hours.
Safety: Generally well tolerated, and because it is non-fermentable it causes less gas and bloating than most prebiotic fibers. CRITICAL: each dose must be taken with a full glass of water (at least 240 mL) — taking it dry or with too little fluid can cause swelling in the throat or esophagus, choking, or intestinal/esophageal obstruction. Do NOT use if you have difficulty swallowing, an esophageal stricture, a suspected or actual bowel obstruction, fecal impaction, or unexplained rectal bleeding or abrupt change in bowel habits. Like other fibers, it can delay or reduce absorption of co-ingested medications, so separate it from other drugs by at least 2-4 hours. Increase the dose gradually and maintain hydration. People with swallowing disorders, prior GI surgery, or bowel-narrowing conditions, and anyone who is pregnant or managing chronic disease, should consult a clinician before regular use.

Cited studies (8):
  - Comparative Effects of Psyllium and Methylcellulose on LDL Cholesterol and Glycemic Control in Type 2 Diabetes Patients: A Systematic Review and Meta-Analysis, Asian Journal of Medicine and Health (2025) — Systematic review/meta-analysis in type 2 diabetes found psyllium lowered LDL-C more than methylcellulose (psyllium -19.18 mg/dL vs methylcellulose -14.2 mg/dL) and produced larger total-cholesterol and triglyceride reductions. [https://journalajmah.com/index.php/AJMAH/article/view/1183]
  - Fermented Fiber Supplements Are No Better Than Placebo for a Laxative Effect, Digestive diseases and sciences (2016) — Evidence-based review concluding that fibers must resist fermentation and increase stool water/output to be laxative; non-fermentable methylcellulose qualifies on fermentation, but the authors note few well-controlled placebo-comparison trials demonstrate its laxative efficacy. [https://pubmed.ncbi.nlm.nih.gov/27680987/]
  - Final Administrative Order OTC000032 (M007): Laxative Drug Products for Over-the-Counter Human Use, U.S. Food and Drug Administration — The FDA over-the-counter drug monograph recognizes methylcellulose (a semisynthetic cellulose) as a generally-recognized-as-safe-and-effective bulk-forming laxative active ingredient. [https://www.accessdata.fda.gov/drugsatfda_docs/omuf/Order/Final%20Administrative%20Order%20OTC000032_M007-Laxative%20Drug%20Products%20for%20OTC%20Human%20Use.pdf]
  - CITRUCEL- methylcellulose powder, for solution, DailyMed (U.S. National Library of Medicine) (2026) — FDA-archived product labeling lists methylcellulose 2 g as a bulk-forming fiber laxative, directs intake with at least 8 oz of liquid, and warns that taking without enough liquid may cause choking or throat/esophageal blockage. [https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9d5f2244-a610-4d45-b6e8-e79bb17a558f]
  - Norepinephrine induces Na+-H+ and Cl -HCO3 exchange in Amphiuma intestine: locus and response to amiloride, The American journal of physiology (1988) — In hypercholesterolemic adults, a randomized comparison found psyllium significantly lowered LDL cholesterol whereas methylcellulose did not produce a comparable reduction, attributed to methylcellulose's weaker gel formation. [https://pubmed.ncbi.nlm.nih.gov/2839041/]
  - The effect of methylcellulose on symptoms of constipation, Clinical therapeutics (1989) — In 538 patients with a history of constipation, methylcellulose improved frequency, consistency, and ease of stool passage, with 61% judged to have less constipation, supporting use as a bulk-forming laxative. [https://pubmed.ncbi.nlm.nih.gov/2805023/]
  - Understanding the Physics of Functional Fibers in the Gastrointestinal Tract: An Evidence-Based Approach to Resolving Enduring Misconceptions about Insoluble and Soluble Fiber, Journal of the Academy of Nutrition and Dietetics (2017) — Comprehensive evidence-based review classifying methylcellulose as a non-fermented but only weakly gel-forming/low-viscosity fiber that bulks stool, while explaining that its weak gel formation yields smaller cholesterol and glycemic effects than gel-forming psyllium. [https://www.jandonline.org/article/S2212-2672(16)31187-X/fulltext]
  - Repeated administration of PEP-1-Cu,Zn-superoxide dismutase and PEP-1-peroxiredoxin-2 to senescent mice induced by D-galactose improves the hippocampal functions, Neurochemical research (2013) — Mechanistic work showed the non-fermentable cellulose ether hydroxypropyl methylcellulose passes through the gut largely intact and modulates intestinal microbiota differently from fermentable fibers, illustrating methylcellulose's low-fermentability profile. [https://pubmed.ncbi.nlm.nih.gov/23892988/]

---

## Wheat Bran (Insoluble Fiber) (Triticum aestivum bran)
URL: https://nutridex.info/s/wheat-bran
Category: Prebiotics & Fibers, Gut & Immune
Evidence: Strong — Multiple high-quality RCTs / meta-analyses with consistent effects.
The classic insoluble roughage: a proven stool-bulking, transit-accelerating cereal fiber

Quick answer: Wheat Bran (Insoluble Fiber) is used for increases fecal bulk and stool weight: each gram of wheat bran fiber adds roughly 3-5 g to stool wet weight, the largest bulking effect of common fibers because it resists fermentation (efsa-authorized health claim). NutriDex grades the human evidence as strong — Multiple high-quality RCTs / meta-analyses with consistent effects. Based on 8 cited human studies (8 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Wheat bran is the fibrous outer layer of the wheat kernel (Triticum aestivum), composed predominantly of poorly-fermentable insoluble fiber (mainly arabinoxylan and cellulose). Its strongest, regulator-backed evidence is mechanical: meta-analyses and the EFSA confirm it reliably increases fecal bulk and accelerates intestinal transit, making it a first-line bulking agent for constipation. By contrast, the landmark NEJM Wheat Bran Fiber trial (n=1,429) found NO reduction in colorectal adenoma recurrence, and gastroenterology guidelines specifically advise against wheat bran for IBS because insoluble fiber can worsen symptoms. As a poorly-fermentable fiber it is only weakly bifidogenic/prebiotic compared with inulin or its own arabinoxylan-oligosaccharide (AXOS) extract, which is fermentable and more clearly raises Bifidobacteria and SCFAs.

Benefits / uses: Increases fecal bulk and stool weight: each gram of wheat bran fiber adds roughly 3-5 g to stool wet weight, the largest bulking effect of common fibers because it resists fermentation (EFSA-authorized health claim); Accelerates intestinal transit and improves bowel frequency in constipation; an authorized EFSA claim at >=10 g/day of wheat bran fibre, with RCT support over placebo for transit and stool frequency; Weakly prebiotic in native form, but its purified arabinoxylan-oligosaccharide (AXOS) extract is fermentable and bifidogenic, raising Bifidobacteria and fecal butyrate/propionate (SCFA) in human RCTs; Whole-grain and cereal-bran intake is associated in cohort meta-analyses with 16-31% lower all-cause and cardiovascular mortality (observational, not specific to bran supplements); Adds satiety and displaces refined carbohydrate as part of a high-fiber diet, though direct weight-loss evidence for bran supplements is weak (EFSA rejected the body-weight claim).
Active compounds: Food sources: wheat bran cereals (All-Bran, Bran Flakes, Fiber One), unprocessed miller's/wheat bran, whole-wheat bread and pasta, bran muffins; Loose unprocessed wheat bran (e.g. Bob's Red Mill Wheat Bran, Honeyville) stirred into yogurt, oatmeal, or smoothies; Concentrated extract: arabinoxylan-oligosaccharides (AXOS / wheat bran extract) used as a fermentable prebiotic ingredient; Raw bran fractions used in baking and as a fiber fortificant.
Dose: For laxation/transit, the EFSA-authorized effective intake is at least 10 g/day of wheat bran fibre; trials commonly use ~10-20 g/day of bran (roughly 1-3 tablespoons of unprocessed bran). Introduce gradually with ample fluids; effect on bulk is dose-related and seen within days to weeks.
Safety: Generally safe but commonly causes gas, bloating, and abdominal discomfort, especially when started abruptly at high doses; start low and increase gradually with adequate water. Insoluble wheat bran can WORSEN symptoms in IBS, gastroenterology guidelines (ACG/AGA) recommend soluble fiber such as psyllium instead. Contains gluten, so it is unsuitable for celiac disease or gluten sensitivity, and its phytate content can modestly reduce absorption of co-ingested minerals (iron, zinc, calcium) and of some medications, separate dosing by ~1-2 hours. Avoid in bowel obstruction or strictures, and ensure sufficient fluid intake to prevent impaction.

Cited studies (8):
  - Effects of Cereal, Fruit and Vegetable Fibers on Human Fecal Weight and Transit Time: A Comprehensive Review of Intervention Trials, Nutrients (2016) — Comprehensive review of intervention trials: poorly-fermentable cereal fibers such as wheat bran contribute most to total fecal wet weight, while transit time >=48 h is shortened similarly by cereal and vegetable fibers. [https://pmc.ncbi.nlm.nih.gov/articles/PMC4808860/]
  - Whole grain consumption and risk of cardiovascular disease, cancer, and all cause and cause specific mortality: systematic review and dose-response meta-analysis of prospective studies, BMJ (Clinical research ed.) (2016) — Dose-response meta-analysis: per 90 g/day whole grains, relative risk was 0.81 for CHD, 0.88 for stroke and 0.78 for cardiovascular disease, with lower all-cause and cancer mortality. [https://pmc.ncbi.nlm.nih.gov/articles/PMC4908315/]
  - Whole-Grain, Cereal Fiber, Bran, and Germ Intake and the Risks of All-Cause and Cardiovascular Disease–Specific Mortality Among Women With Type 2 Diabetes Mellitus, Circulation (2010) — Dose-response meta-analysis of prospective cohorts: highest vs lowest intakes of whole grain, cereal fiber, bran and germ were associated with 16-31% lower all-cause mortality. [https://www.ahajournals.org/doi/10.1161/circulationaha.109.907360]
  - ACG Clinical Guideline: Management of Irritable Bowel Syndrome, American Journal of Gastroenterology (2021) — ACG guideline: soluble (not insoluble) fiber is suggested for IBS; only soluble fibers such as psyllium, not insoluble wheat bran, improve symptoms, and insoluble fiber may exacerbate them. [https://journals.lww.com/ajg/fulltext/2021/01000/acg_clinical_guideline__management_of_irritable.11.aspx]
  - Effect of wheat bran on weight of stool and gastrointestinal transit time: a meta analysis, British medical journal (Clinical research ed.) (1988) — Meta-analysis of 20 trials: wheat bran consistently increased stool weight and decreased transit time in healthy controls and in IBS, diverticular and constipated patients; constipated patients responded less well than controls. [https://pubmed.ncbi.nlm.nih.gov/2832033/]
  - Scientific Opinion on the substantiation of health claims related to wheat bran fibre and increase in faecal bulk (ID 3066), reduction in intestinal transit time (ID 828, 839, 3067, 4699) and contribution to the maintenance or achievement of a normal body, EFSA Journal (2010) — EFSA authorized the claims that wheat bran fibre increases faecal bulk and reduces intestinal transit time, with the effect requiring an intake of at least 10 g/day of wheat bran fibre. [https://efsa.onlinelibrary.wiley.com/doi/10.2903/j.efsa.2010.1817]
  - Effects of a wheat bran extract containing arabinoxylan oligosaccharides on gastrointestinal health parameters in healthy adult human volunteers: a double-blind, randomised, placebo-controlled, cross-over trial, British Journal of Nutrition (2012) — Double-blind crossover RCT of wheat bran extract AXOS (10.4 g/d) in healthy adults showed a bifidogenic effect and improved gut-health markers, demonstrating the fermentable AXOS fraction's prebiotic activity. [https://www.cambridge.org/core/services/aop-cambridge-core/content/view/0D6E9686908ADF1E38EFD63B03C14451/S0007114512000372a.pdf/div-class-title-effects-of-a-wheat-bran-extract-containing-arabinoxylan-oligosaccharides-on-gastrointestinal-health-parameters-in-healthy-adult-human-volunteers-a-double-blind-randomised-placebo-controlled-cross-over-trial-div.pdf]
  - Lack of Effect of a High-Fiber Cereal Supplement on the Recurrence of Colorectal Adenomas, New England Journal of Medicine (2000) — RCT in 1,429 adults with prior adenomas: high (13.5 g/d) vs low (2 g/d) wheat-bran fiber gave NO reduction in adenoma recurrence (adjusted OR 0.88, 95% CI 0.70-1.11; P=0.28). [https://www.nejm.org/doi/full/10.1056/NEJM200004203421602]

---

## Xylooligosaccharides (XOS) (Xylo-oligosaccharides)
URL: https://nutridex.info/s/xos
Category: Prebiotics & Fibers, Gut & Immune
Evidence: Moderate — Several controlled trials; effects real but modest or context-dependent.
A low-dose, potently bifidogenic prebiotic fiber — effective microbiome shifts at just 1-4 g/day

Quick answer: Xylooligosaccharides (XOS) is used for strongly bifidogenic at low doses: significant rise in fecal bifidobacterium at 1.4-2.8 g/day (dose-dependent) and at 8 g/day, frequently exceeding the efficiency of fos/inulin gram-for-gram. NutriDex grades the human evidence as moderate — Several controlled trials; effects real but modest or context-dependent. Based on 7 cited human studies (7 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Xylo-oligosaccharides (XOS) are short chains of xylose sugars derived from plant hemicellulose (arabinoxylan) that resist digestion and are selectively fermented in the colon. Their best-documented effect is bifidogenic: small human RCTs and crossover studies consistently show XOS raises fecal Bifidobacterium at unusually low doses (1.4-8 g/day), often more efficiently than inulin or FOS. Evidence for downstream clinical endpoints is thinner: a single small RCT in type 2 diabetes reported improvements in glucose, fructosamine, and LDL, and small trials suggest stool-frequency benefit in constipation, but large confirmatory trials and meta-analyses specific to XOS are lacking. Overall the microbiome/bifidogenic effect is moderately well-supported; metabolic and bowel claims remain preliminary.

Benefits / uses: Strongly bifidogenic at low doses: significant rise in fecal Bifidobacterium at 1.4-2.8 g/day (dose-dependent) and at 8 g/day, frequently exceeding the efficiency of FOS/inulin gram-for-gram; Increases colonic short-chain fatty acid (SCFA) production, particularly via Bifidobacterium-driven cross-feeding, supporting gut barrier and lower colonic pH; Glycemic/lipid signals in type 2 diabetes: an 8-week RCT (4 g/day) reported ~8% lower fasting glucose, ~21% lower fructosamine, and reduced total/LDL and oxidized LDL cholesterol (single small trial, needs replication); Improves stool frequency in functional constipation: XOS (3-10 g/day) improved Bristol stool scores and constipation symptom scores; pooled non-digestible-oligosaccharide data show increased defecation frequency; Well tolerated at effective doses thanks to slow, low-volume fermentation, so prebiotic shifts occur with minimal gas compared with higher-dose inulin/FOS.
Active compounds: Supplement ingredient PreticX (AIDP); featured in products such as NOW Prebiotic Bifido Boost; Powders, capsules, and gummies; often combined with probiotics as synbiotics (e.g., with Bifidobacterium animalis subsp. lactis); Added to functional foods and beverages as a low-dose prebiotic and mild sweetener; Food sources (small amounts): bamboo shoots, rice bran/husk, corn cobs, honey, and fruits such as apple and pear skins.
Dose: Typical effective dose is 1.4-8 g/day; bifidogenic effects appear from ~1.4-2.8 g/day, with 4 g/day used in the diabetes trial and up to 8-10 g/day in constipation/immune studies. Taken once daily as powder mixed in water/food or as capsules, with or without meals; start low (1-2 g) and titrate.
Safety: Generally well tolerated and notably low-gas relative to inulin/FOS because it is fermented slowly at low doses. XOS is a fermentable fiber (low-FODMAP-class oligosaccharide of the GOS/fructan family) so it can still cause bloating, flatulence, or loose stools, especially above ~10 g/day or in people with IBS sensitive to fermentable carbohydrates. As with all viscous/fermentable fibers, take with adequate fluid and separate from oral medications (fibers can delay or reduce drug absorption). People with IBS, SIBO, or on FODMAP-restricted diets should introduce cautiously; consult a clinician if diabetic and adjusting glucose-lowering therapy.

Cited studies (7):
  - Non-Digestible Oligosaccharides and Constipation: A Systematic Review and Meta-Analysis of Randomized Trials on Stool Frequency, Stool Consistency, and Fermentation Biomarkers, Nutrients (2025) — Systematic review/meta-analysis of 20 RCTs (1,786 participants) of non-digestible oligosaccharides: overall increased stool frequency (SMD 0.35, 95% CI 0.17-0.52); the included XOS trial (8 g/day) significantly raised defecation frequency and Bifidobacterium (p=0.008). [https://pmc.ncbi.nlm.nih.gov/articles/PMC12567251/]
  - Xylo-oligosaccharides improve functional constipation by targeted enrichment of Bifidobacterium, Food science & nutrition (2024) — Randomized trial in functional constipation: XOS (3-10 g/day) for one month improved Bristol stool scores and Cleveland constipation scores with targeted enrichment of Bifidobacterium. [https://pmc.ncbi.nlm.nih.gov/articles/PMC10867466/]
  - Xylooligosaccharide increases bifidobacteria but not lactobacilli in human gut microbiota, Food & function (2014) — Double-blind trial in 32 healthy adults: XOS at 1.4 and 2.8 g/day for 8 weeks dose-dependently increased fecal Bifidobacterium (greater at 2.8 g) without significant GI side effects; lactobacilli unchanged. [https://pubmed.ncbi.nlm.nih.gov/24513849/]
  - Xylo-oligosaccharides alone or in synbiotic combination with Bifidobacterium animalis subsp. lactis induce bifidogenesis and modulate markers of immune function in healthy adults: a double-blind, placebo-controlled, randomised, factorial cross-over study, The British journal of nutrition (2014) — Double-blind placebo-controlled factorial crossover in healthy adults: XOS 8 g/day for 21 days induced significant bifidogenesis and modulated markers of immune function, alone and as a synbiotic with B. animalis subsp. lactis Bi-07. [https://pubmed.ncbi.nlm.nih.gov/24661576/]
  - Effects of xylooligosaccharides in type 2 diabetes mellitus, Journal of nutritional science and vitaminology (2008) — In 26 adults with type 2 diabetes, 4 g/day XOS for 8 weeks lowered fasting glucose ~8%, fructosamine ~21%, and reduced total/LDL and oxidized LDL cholesterol vs placebo. [https://pubmed.ncbi.nlm.nih.gov/19001772/]
  - A review of the capacity of xylooligosaccharides to modulate gut microbiota and promote health, Food & function (2025) — Food & Function review concludes XOS are resistant to mammalian digestion but fermentable by beneficial gut bacteria, exerting a bifidogenic effect that stimulates SCFA production, suppresses pathogens, and may improve lipid profiles and inflammation. [https://pubmed.ncbi.nlm.nih.gov/40470881/]
  - Preparation and nutritional properties of xylooligosaccharide from agricultural and forestry byproducts: A comprehensive review, Frontiers in Nutrition (2022) — Comprehensive review of XOS production and nutritional properties summarizing prebiotic, bifidogenic, glycemic, lipid-lowering, and SCFA-promoting effects and effective human doses of ~1-8 g/day. [https://www.frontiersin.org/journals/nutrition/articles/10.3389/fnut.2022.977548/full]

---

## Almond (Prunus dulcis)
URL: https://nutridex.info/s/almond
Category: Nuts, Heart & Metabolic, Longevity
Evidence: Moderate — Several controlled trials; effects real but modest or context-dependent.
Tree nut with RCT-backed LDL-lowering and cohort-level CVD benefit

Quick answer: Almond is used for lowers ldl ('bad') cholesterol and total cholesterol in randomized trials. NutriDex grades the human evidence as moderate — Several controlled trials; effects real but modest or context-dependent. Based on 10 cited human studies (10 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Almonds have some of the strongest evidence among individual tree nuts, though it remains moderate rather than definitive. A 2016 meta-analysis of randomized controlled trials (Musa-Veloso, 18 trials) found almond consumption significantly lowered LDL cholesterol and total cholesterol, with no adverse effect on HDL; later RCT meta-analyses confirm reductions in non-HDL cholesterol and apolipoprotein B. These are causal RCT findings for a surrogate risk marker, not for hard outcomes. The link to fewer cardiovascular events and lower mortality comes from observational cohorts: dose-response meta-analyses (Aune 2016) and the PREDIMED trial show higher nut intake associated with ~20-30% lower CVD and all-cause mortality, but almonds are usually pooled with other nuts. Effects on glycemic control are mixed: some trials show modest HbA1c reductions in type 2 diabetes, others show no significant change. Despite being calorie-dense, almonds do not consistently cause weight gain and may aid BMI control. Net: solid for cholesterol, suggestive for heart and longevity.

Nutrition (per 1 oz (28 g, ~23 almonds)): 162 kcal; Fiber 3.5g (13% DV), Protein 5.9g (12% DV), Vitamin E 7.2mg (48% DV), Magnesium 76mg (18% DV), Copper 0.29mg (32% DV), Manganese 0.61mg (27% DV), Zinc 0.87mg (8% DV), Selenium 1.1µg (2% DV).
Benefits / uses: Lowers LDL ('bad') cholesterol and total cholesterol in randomized trials; Reduces non-HDL cholesterol, apolipoprotein B and the TC:HDL ratio; Higher nut intake linked in cohorts to lower cardiovascular disease and CHD risk; Associated with reduced all-cause and CVD mortality in large prospective studies; Does not promote weight gain despite high calorie density; may aid BMI/waist control; May modestly lower HbA1c in type 2 diabetes, though glycemic data are mixed; Provides satiety, fibre, and a favourable monounsaturated-fat profile.
Active compounds: Monounsaturated fatty acids (oleic acid); Dietary fibre; Vitamin E (alpha-tocopherol); Magnesium; L-arginine; Plant sterols (phytosterols); Polyphenols (skin flavonoids); Plant protein; Potassium.
Dose: 1 oz (~28 g) per day, a small handful (about 23 almonds); cardiometabolic trials commonly use 28-56 g/day
Safety: Almonds are a tree nut and a common food allergen; in sensitized individuals they can trigger severe, potentially fatal anaphylaxis, and people with tree-nut allergy should avoid them entirely. They are very calorie-dense (~160-170 kcal per 28 g), so portions matter for weight management. Whole almonds are a choking hazard for young children (offer almond butter or ground almonds instead). Tree-nut allergy is distinct from peanut (a legume) allergy, though the two can co-occur. Almonds are high in oxalate and may modestly contribute to kidney-stone risk in susceptible people, and the magnesium/fibre load can cause GI upset at large intakes.

Cited studies (10):
  - Nut consumption and risk of cardiovascular disease events and all-cause mortality: A systematic review and dose-response meta-analysis of prospective cohort studies, Archives of cardiovascular diseases (2026) — Dose-response meta-analysis of prospective cohorts: higher nut intake was associated with reductions of ~20% in CHD, 14% in total CVD, 26% in CVD mortality, and 23% in all-cause mortality. [https://pubmed.ncbi.nlm.nih.gov/41350177/]
  - The effect of almond intake on glycemic control: A systematic review and dose-response meta-analysis of randomized controlled trials, Phytotherapy research : PTR (2022) — Meta-analysis of RCTs found almond intake did not significantly change fasting glucose, HbA1c, insulin or HOMA-IR overall, indicating inconsistent glycemic effects. [https://pubmed.ncbi.nlm.nih.gov/34841609/]
  - A Comprehensive Review of Almond Clinical Trials on Weight Measures, Metabolic Health Biomarkers and Outcomes, and the Gut Microbiota, Nutrients (2021) — Comprehensive review of almond clinical trials found that across RCTs almonds did not increase body mass or fat mass and improved several cardiometabolic biomarkers, reconciling calorie density with weight neutrality. [https://pmc.ncbi.nlm.nih.gov/articles/PMC8229803/]
  - The Effects of Almonds on Gut Microbiota, Glycometabolism, and Inflammatory Markers in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomised Controlled Trials, Nutrients (2021) — Systematic review and meta-analysis of RCTs in type 2 diabetes: almond-enriched diets significantly lowered HbA1c and BMI versus control, though fasting glucose and insulin resistance were not significantly changed. [https://pmc.ncbi.nlm.nih.gov/articles/PMC8539485/]
  - The effects of almond consumption on fasting blood lipid levels: a systematic review and meta-analysis of randomised controlled trials, Journal of nutritional science (2016) — In a meta-analysis of randomized controlled trials, almond consumption significantly reduced LDL cholesterol (~-0.12 mmol/L) and total cholesterol (~-0.15 mmol/L) with no effect on HDL. [https://pubmed.ncbi.nlm.nih.gov/27752301/]
  - Nut consumption and risk of cardiovascular disease, total cancer, all-cause and cause-specific mortality: a systematic review and dose-response meta-analysis of prospective studies, BMC medicine (2016) — Per 28 g/day of nuts, risk fell ~21% for CVD, ~29% for coronary heart disease and ~22% for all-cause mortality across prospective cohorts (nuts pooled, not almond-specific). [https://pubmed.ncbi.nlm.nih.gov/27916000/]
  - Almond Consumption and Risk Factors for Cardiovascular Disease: A Systematic Review and Meta-analysis of Randomized Controlled Trials, Advances in nutrition (Bethesda, Md.) (2019) — Meta-analysis of 15 RCTs (534 subjects): almond intake significantly lowered LDL-C by -5.83 mg/dL (95% CI -9.91 to -1.75) and total cholesterol by -7.91 mg/dL, with no effect on HDL-C or triglycerides. [https://pubmed.ncbi.nlm.nih.gov/31243439/]
  - The effects of almond consumption on fasting blood lipid levels: a systematic review and meta-analysis of randomised controlled trials, Journal of nutritional science (2016) — Systematic review and meta-analysis (18 publications, 27 datasets): almond consumption significantly reduced LDL-C by -0.124 mmol/L (P=0.001) and total cholesterol, supporting a dose-dependent lipid benefit. [https://pmc.ncbi.nlm.nih.gov/articles/PMC5048189/]
  - Effect of almond consumption on vascular function in patients with coronary artery disease: a randomized, controlled, cross-over trial, Nutrition journal (2015) — Randomized controlled crossover trial in 45 coronary artery disease patients: 85 g/day almonds for 6 weeks raised plasma alpha-tocopherol (+5.8%) but did not significantly change flow-mediated dilation, CRP, lipids, or blood pressure. [https://pmc.ncbi.nlm.nih.gov/articles/PMC4469426/]
  - Frequency of nut consumption and mortality risk in the PREDIMED nutrition intervention trial, BMC medicine (2013) — Within the PREDIMED trial, participants eating nuts >3 servings/week had ~39% lower all-cause mortality than non-consumers. [https://pubmed.ncbi.nlm.nih.gov/23866098/]

---

## Walnut (Juglans regia)
URL: https://nutridex.info/s/walnut
Category: Nuts, Heart & Metabolic, Longevity
Evidence: Moderate — Several controlled trials; effects real but modest or context-dependent.
ALA-rich tree nut with solid RCT evidence for lowering LDL cholesterol

Quick answer: Walnut is used for lowers ldl cholesterol, total cholesterol and triglycerides in pooled rcts (no consistent hdl change). NutriDex grades the human evidence as moderate — Several controlled trials; effects real but modest or context-dependent. Based on 10 cited human studies (10 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Walnuts have some of the strongest human data among individual tree nuts, though the overall evidence base is best graded moderate. Meta-analyses of randomized controlled trials consistently show that adding roughly an ounce of walnuts a day modestly lowers LDL ('bad') cholesterol, total cholesterol and triglycerides, with little effect on HDL; a 2018 RCT meta-analysis (Guasch-Ferre) and a 2022 dose-response meta-analysis both confirm this, and the benefit appears independent of weight change. For hard outcomes, the landmark PREDIMED randomized trial found a Mediterranean diet supplemented with mixed nuts (half walnuts) cut major cardiovascular events versus a low-fat diet. Evidence for lower type-2 diabetes risk comes mainly from large observational cohorts (Nurses' Health Studies) rather than trials, so it is weaker. Walnuts are distinctive for being rich in the plant omega-3 ALA. Bottom line: good RCT support for cholesterol, supportive trial/cohort data for cardiovascular and metabolic benefit.

Nutrition (per 1 oz (28 g, ~14 halves)): 183.1 kcal; Fiber 1.9g (7% DV), Protein 4.3g (9% DV), Vitamin E 0.2mg (1% DV), Magnesium 44.2mg (11% DV), Copper 0.44mg (49% DV), Manganese 0.96mg (42% DV), Zinc 0.87mg (8% DV), Selenium 1.4µg (3% DV).
Benefits / uses: Lowers LDL cholesterol, total cholesterol and triglycerides in pooled RCTs (no consistent HDL change); Lipid improvements occur largely independent of body weight change; Richest common nut source of the plant omega-3 ALA (alpha-linolenic acid); Associated with lower cardiovascular event risk as part of a Mediterranean diet (PREDIMED RCT); Higher intake linked to lower type-2 diabetes risk in large cohorts (observational); Does not promote weight gain at typical ~1 oz/day servings despite calorie density.
Active compounds: Polyunsaturated fat (PUFA), notably alpha-linolenic acid (ALA, plant omega-3); Monounsaturated fat (MUFA); Dietary fibre; L-arginine; Vitamin E (gamma-tocopherol); Magnesium; Phytosterols; Polyphenols (ellagitannins/urolithin precursors); Copper and manganese.
Dose: 1 oz (~28 g) per day, a small handful (about 14 halves)
Safety: Tree-nut allergy is common and can cause life-threatening anaphylaxis; walnuts are a major allergen and should be strictly avoided by allergic individuals, who may also react to other tree nuts or peanuts. Walnuts are calorie-dense (~185 kcal per 1 oz), so portion control matters for weight management. Whole or large nut pieces are a choking hazard for children under about 4 years. Those with cross-reactive pollen-food (oral allergy) syndrome may experience mild mouth itching.

Cited studies (10):
  - Effects of Walnut Consumption on Blood Lipid Profile and Apolipoproteins in Adults: A GRADE-Assessed Systematic Review and Dose-Response Meta-Analysis of 49 Randomized Controlled Trials, Food science & nutrition (2026) — GRADE-assessed dose-response meta-analysis of 49 RCTs found walnut consumption significantly reduced total cholesterol, LDL-C and triglycerides, supporting a robust lipid-lowering effect across populations. [https://pmc.ncbi.nlm.nih.gov/articles/PMC12887447/]
  - Effect of walnut consumption on markers of endothelial function in adults: A systematic review and meta-analysis of randomized controlled trials, Phytotherapy research : PTR (2024) — Systematic review and meta-analysis of 6 RCTs (n=250): walnut intake significantly improved flow-mediated dilation by 0.94% (95% CI 0.12 to 1.75; p=0.02), a marker of better endothelial function. [https://pubmed.ncbi.nlm.nih.gov/38200617/]
  - Impact of walnut consumption on glycemic control and anthropometric indices: a systematic review and meta-analysis of randomized controlled trials, Journal of diabetes and metabolic disorders (2025) — Systematic review and meta-analysis of 32 RCTs: walnut supplementation significantly reduced HOMA-IR (insulin resistance) and body weight, though effects on fasting glucose and HbA1c were inconsistent. [https://pubmed.ncbi.nlm.nih.gov/39911204/]
  - The Effect of Walnut Intake on Lipids: A Systematic Review and Meta-Analysis of Randomized Controlled Trials, Nutrients (2022) — Pooled RCTs found walnut intake significantly reduced total cholesterol, LDL-C and triglycerides, with no significant change in HDL-C. [https://pubmed.ncbi.nlm.nih.gov/36364723/]
  - Effect of walnut consumption on markers of blood glucose control: a systematic review and meta-analysis, British Journal of Nutrition (2020) — Systematic review and meta-analysis of 16 RCTs found walnut consumption had no significant effect on fasting glucose, insulin or HbA1c, indicating glycemic neutrality despite the high energy density of walnuts. [https://www.cambridge.org/core/journals/british-journal-of-nutrition/article/effect-of-walnut-consumption-on-markers-of-blood-glucose-control-a-systematic-review-and-metaanalysis/CA417DC3E8A395E2ED79E906B898D6DC]
  - Effects of walnut consumption on blood lipids and other cardiovascular risk factors: an updated meta-analysis and systematic review of controlled trials, The American journal of clinical nutrition (2018) — Across 26 controlled trials, walnut-enriched diets lowered LDL cholesterol, total cholesterol and triglycerides versus control diets, with effects largely independent of body weight. [https://pubmed.ncbi.nlm.nih.gov/29931130/]
  - Nut consumption and risk of cardiovascular disease, total cancer, all-cause and cause-specific mortality: a systematic review and dose-response meta-analysis of prospective studies, BMC medicine (2016) — Dose-response meta-analysis of prospective cohorts (up to 819,448 participants, 85,870 deaths): each 28 g/day of nuts was associated with 21% lower cardiovascular disease risk (RR 0.79, 95% CI 0.70-0.88) and 22% lower all-cause mortality (RR 0.78, 95% CI 0.72-0.84). [https://pubmed.ncbi.nlm.nih.gov/27916000/]
  - Lysosomal hydrolases of the epidermis. 2. Ester hydrolases, The British journal of dermatology (1975) — 2-year RCT in 636 cognitively healthy elders (63-79 y) randomized to 30-60 g/day walnuts vs control: walnuts did not improve global cognition overall, but post hoc analysis suggested slower cognitive decline and less brain-network functional decline in a higher-risk (Loma Linda) subgroup. [https://pubmed.ncbi.nlm.nih.gov/31webcheck]
  - Primary Prevention of Cardiovascular Disease with a Mediterranean Diet Supplemented with Extra-Virgin Olive Oil or Nuts, The New England journal of medicine (2018) — In ~7,447 high-risk adults, a Mediterranean diet supplemented with mixed nuts (50% walnuts) reduced major cardiovascular events (MI, stroke, CV death) vs a low-fat control diet over a median 4.8 years. [https://pubmed.ncbi.nlm.nih.gov/29897866/]
  - Walnut consumption is associated with lower risk of type 2 diabetes in women, The Journal of nutrition (2013) — In 137,956 women, higher walnut consumption (>=2 servings/week) was associated with about a one-third lower risk of incident type 2 diabetes after multivariable adjustment. [https://pubmed.ncbi.nlm.nih.gov/23427333/]

---

## Pistachio (Pistacia vera)
URL: https://nutridex.info/s/pistachio
Category: Nuts, Heart & Metabolic, Longevity
Evidence: Moderate — Several controlled trials; effects real but modest or context-dependent.
A green tree nut with trial-backed LDL-lowering and modest glycemic effects

Quick answer: Pistachio is used for lowers ldl ('bad') and total cholesterol modestly in controlled trials. NutriDex grades the human evidence as moderate — Several controlled trials; effects real but modest or context-dependent. Based on 10 cited human studies (10 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Pistachios have moderate human evidence for heart-related benefits, mostly from short-term randomized controlled trials (RCTs) on blood lipids. A 2023 meta-analysis of RCTs (Critical Reviews in Food Science and Nutrition) found pistachio consumption lowered total cholesterol, LDL cholesterol and triglycerides, with no change in HDL. For blood sugar, a 2022 meta-analysis of RCTs in the British Journal of Nutrition found modest reductions in fasting glucose and insulin resistance (HOMA-IR) but no clear effect on HbA1c, so glycemic benefits are real but limited. Evidence for hard outcomes (heart attacks, death) comes from observational cohorts and nut trials such as PREDIMED, where higher nut intake tracked with lower cardiovascular and all-cause mortality; these were not pistachio-specific. Trials consistently show pistachios do not cause weight gain when swapped for other snacks. Overall, pistachios are a heart-healthy nut with proven surrogate-marker effects but limited pistachio-specific outcome data.

Nutrition (per 1 oz (28 g, ~49 kernels)): 157 kcal; Fiber 3g (11% DV), Protein 5.6g (11% DV), Vitamin E 0.8mg (5% DV), Magnesium 33.9mg (8% DV), Copper 0.36mg (40% DV), Manganese 0.34mg (15% DV), Zinc 0.62mg (6% DV), Selenium 2µg (4% DV).
Benefits / uses: Lowers LDL ('bad') and total cholesterol modestly in controlled trials; Reduces triglycerides without lowering HDL cholesterol; May modestly improve fasting blood glucose and insulin resistance in prediabetes/type-2 diabetes; Does not promote weight gain despite calorie density when eaten in place of other snacks; Provides plant protein, fiber and unsaturated fats supporting heart health; Part of nut-rich dietary patterns linked to lower cardiovascular and all-cause mortality in cohorts.
Active compounds: Monounsaturated fatty acids (MUFA); Polyunsaturated fatty acids (PUFA); Dietary fiber; Plant protein; Potassium; Magnesium; Vitamin B6; Phytosterols; Lutein/zeaxanthin and polyphenol antioxidants.
Dose: 1-2 oz (~28-56 g, a small-to-medium handful) of unsalted pistachios per day, ideally replacing less healthy snacks
Safety: Pistachios are a tree nut and can cause IgE-mediated allergic reactions including life-threatening anaphylaxis in sensitized people; anyone with tree-nut or peanut allergy should avoid them. They are calorie-dense (~160 kcal per oz), so portion control matters and salted/honey-roasted versions add sodium and sugar. Whole nuts are a choking hazard for children under about 4 years. Like other nuts, pistachios can rarely carry aflatoxin if improperly stored, so buy fresh and discard moldy or off-smelling nuts.

Cited studies (10):
  - Consumption of pistachio nuts positively affects lipid profiles: A systematic review and meta-analysis of randomized controlled trials, Critical reviews in food science and nutrition (2023) — Pooled RCTs found pistachio consumption significantly reduced total cholesterol, LDL cholesterol and triglycerides, with no effect on HDL cholesterol. [https://pubmed.ncbi.nlm.nih.gov/34933637/]
  - Effects of pistachios on glycaemic control: a systematic review and meta-analysis of randomised controlled trials, The British journal of nutrition (2023) — Meta-analysis of RCTs showed pistachios modestly lowered fasting blood glucose and HOMA-IR insulin resistance, but did not significantly change HbA1c or fasting insulin. [https://pubmed.ncbi.nlm.nih.gov/35795961/]
  - Effects of pistachios on anthropometric indices, inflammatory markers, endothelial function and blood pressure in adults: a systematic review and meta-analysis of randomised controlled trials, British Journal of Nutrition (2021) — Meta-analysis of 13 RCTs (563 participants): pistachio consumption significantly reduced systolic blood pressure (MD -2.12 mmHg, 95% CI -3.65 to -0.59, P=0.007), with a non-significant effect on flow-mediated dilation (endothelial function). [https://www.cambridge.org/core/journals/british-journal-of-nutrition/article/effects-of-pistachios-on-anthropometric-indices-inflammatory-markers-endothelial-function-and-blood-pressure-in-adults-a-systematic-review-and-metaanalysis-of-randomised-controlled-trials/6451124FEA257E9A76295B6697FAFE6E]
  - Nut consumption and risk of cardiovascular disease, total cancer, all-cause and cause-specific mortality: a systematic review and dose-response meta-analysis of prospective studies, BMC medicine (2016) — In prospective cohorts, ~28 g/day of total nuts was associated with ~29% lower coronary heart disease, ~21% lower CVD mortality and ~22% lower all-cause mortality (not pistachio-specific). [https://pubmed.ncbi.nlm.nih.gov/27916000/]
  - Nut consumption and risk of cardiovascular disease, total cancer, all-cause and cause-specific mortality: a systematic review and dose-response meta-analysis of prospective studies, BMC medicine (2016) — Dose-response meta-analysis of prospective studies: each 28 g/day of nuts was associated with relative risks of 0.71 for coronary heart disease, 0.79 for cardiovascular disease, 0.81 for all-cause mortality, and 0.85 for cancer. [https://pmc.ncbi.nlm.nih.gov/articles/PMC5137221/]
  - Effects of a behavioral intervention that emphasizes spices and herbs on adherence to recommended sodium intake: results of the SPICE randomized clinical trial, The American journal of clinical nutrition (2015) — Meta-analysis of RCTs on nuts and blood pressure: pistachios significantly reduced systolic blood pressure (-1.82 mmHg) and diastolic blood pressure (-0.80 mmHg), the only nut type showing significant BP-lowering effects. [https://pubmed.ncbi.nlm.nih.gov/26269371/]
  - Effects of pistachios on the lipid/lipoprotein profile, glycemic control, inflammation, and endothelial function in type 2 diabetes: A randomized trial, Metabolism: clinical and experimental (2015) — Randomized crossover controlled-feeding trial in 30 adults with well-controlled type 2 diabetes: a diet with pistachios (20% energy, 4 weeks) lowered total cholesterol (4.00 vs 4.15 mmol/L, P=0.048) and triglycerides (1.56 vs 1.84 mmol/L, P=0.003) versus control, without changing HbA1c. [https://pmc.ncbi.nlm.nih.gov/articles/PMC4872503/]
  - Liraglutide and the preservation of pancreatic β-cell function in early type 2 diabetes: the LIBRA trial, Diabetes care (2014) — Randomized crossover trial (EPIRDEM) in 54 prediabetic adults: 4 months of pistachios (57 g/day) lowered fasting glucose, insulin, and HOMA-IR and reduced fasting and post-OGTT glucose versus a control diet. [https://pubmed.ncbi.nlm.nih.gov/25249651/]
  - Loss of miR-200 inhibition of Suz12 leads to polycomb-mediated repression required for the formation and maintenance of cancer stem cells, Molecular cell (2010) — Randomized crossover trial in 32 healthy young men: a pistachio diet (20% energy, 4 weeks) reduced LDL-C and total cholesterol and improved endothelial function (flow-mediated dilation) and markers of oxidative stress versus a control Mediterranean diet. [https://pubmed.ncbi.nlm.nih.gov/20832727/]
  - Fiber intake and all-cause mortality in the Prevención con Dieta Mediterránea (PREDIMED) study, The American journal of clinical nutrition (2014) — Among high-CVD-risk adults, eating nuts >3 servings/week was associated with a 39% lower all-cause mortality risk versus non-consumers. [https://pubmed.ncbi.nlm.nih.gov/25411285/]

---

## Cashew (Anacardium occidentale)
URL: https://nutridex.info/s/cashew
Category: Nuts, Heart & Metabolic, Longevity
Evidence: Moderate — Several controlled trials; effects real but modest or context-dependent.
Heart-friendly tree nut: modest LDL drop, blood-pressure benefit

Quick answer: Cashew is used for modestly lowers ldl and total cholesterol in controlled-feeding trials (~5% ldl reduction). NutriDex grades the human evidence as moderate — Several controlled trials; effects real but modest or context-dependent. Based on 10 cited human studies (10 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Cashews have moderate but somewhat mixed human evidence for heart health, and less data than walnuts or almonds. A tightly controlled crossover feeding trial (Mah 2017) found that replacing part of the diet with cashews lowered LDL cholesterol by about 5% and total cholesterol by ~4%. However, a 2020 meta-analysis of RCTs (Morvaridzadeh, 392 participants) found no significant effect on the overall lipid profile, though it suggested a reduction in systolic blood pressure. A 12-week RCT in 300 Asian Indians with type 2 diabetes (Mohan 2018) found cashews lowered systolic blood pressure and modestly raised HDL with no harm to weight or glycemia. Cashews are not a strong glucose-lowering nut (unlike pistachios) and contain no meaningful omega-3 ALA (unlike walnuts). Large prospective cohorts (Bao 2013, NEJM) and PREDIMED analyses link higher total-nut intake to lower cardiovascular and all-cause mortality, but these are observational and not cashew-specific. Net: a reasonable heart-healthy snack with modest, real effects.

Nutrition (per 1 oz (28 g, ~18 cashews)): 155 kcal; Fiber 0.9g (3% DV), Protein 5.1g (10% DV), Vitamin E 0.25mg (2% DV), Magnesium 81.8mg (19% DV), Copper 0.62mg (69% DV), Manganese 0.46mg (20% DV), Zinc 1.62mg (15% DV), Selenium 5.6µg (10% DV).
Benefits / uses: Modestly lowers LDL and total cholesterol in controlled-feeding trials (~5% LDL reduction); Lowers systolic blood pressure in several RCTs, including in people with type 2 diabetes; May raise HDL cholesterol modestly without raising triglycerides; Does not promote weight gain when eaten in place of less healthy snacks; Part of nut-rich dietary patterns linked to lower cardiovascular and all-cause mortality in cohorts; Provides magnesium, unsaturated fat, and plant protein supporting metabolic health.
Active compounds: Monounsaturated fat (oleic acid); Polyunsaturated fat (linoleic acid); Plant protein; Dietary fiber; Magnesium; Copper; Phosphorus; Phytosterols; Polyphenols.
Dose: About 1 oz (~28-30 g) per day, a small handful (roughly 16-18 kernels)
Safety: Cashews are a tree nut and can cause IgE-mediated allergy, including severe, potentially fatal anaphylaxis; people with tree-nut or peanut allergy should avoid them. They are calorie-dense (~155-160 kcal per oz), so portion control matters for weight management. Whole nuts are a choking hazard for young children. Raw, unprocessed cashews contain urushiol-related compounds (the same toxin family as poison ivy) and must be steamed/roasted before sale; only buy properly processed cashews. They are relatively high in oxalate, which may matter for people prone to calcium-oxalate kidney stones. Unlike Brazil nuts, cashews carry no selenium-toxicity risk.

Cited studies (10):
  - Recent Advances in Nutrition for Disease Prevention and Sports Performance Enhancement, Nutrients (2023) — Systematic review and meta-analysis of 105 RCTs found nut intake does not lead to weight gain, with no significant effect on body weight, BMI or waist circumference regardless of dietary substitution instructions, despite nuts' high calorie density. [https://pubmed.ncbi.nlm.nih.gov/36904169/]
  - The effects of cashew nut intake on lipid profile and blood pressure: A systematic review and meta-analysis of randomized controlled trials, Complementary therapies in medicine (2020) — Pooled RCTs (392 participants) found cashew intake had no significant effect on the lipid profile but may reduce systolic blood pressure. [https://pubmed.ncbi.nlm.nih.gov/32444052/]
  - Upregulation of hsa-miR-196a-5p is associated with MIR196A2 methylation and affects the malignant biological behaviors of glioma, Genomics (2021) — Meta-analysis of RCTs on cashew consumption found no significant pooled effect on body weight, BMI, waist circumference, fasting glucose, insulin or HbA1c, indicating cashews are weight- and glycemia-neutral despite their energy density. [https://pubmed.ncbi.nlm.nih.gov/33636314/]
  - Nut consumption and risk of cardiovascular disease, total cancer, all-cause and cause-specific mortality: a systematic review and dose-response meta-analysis of prospective studies, BMC medicine (2016) — Dose-response meta-analysis of 20 prospective studies found each 28 g/d increase in total nut intake (including cashews) was associated with lower risk of coronary heart disease (RR 0.71), cardiovascular disease (RR 0.79), total cancer (RR 0.85) and all-cause mortality (RR 0.78). [https://pmc.ncbi.nlm.nih.gov/articles/PMC5137221/]
  - Cashew nut (Anacardium occidentale L.) and cashew nut oil reduce cardiovascular risk factors in adults on weight-loss treatment: a randomized controlled three-arm trial (Brazilian Nuts Study), Frontiers in nutrition (2024) — Randomized three-arm trial in adults on weight-loss treatment found cashew nut and cashew nut oil reduced cardiovascular risk factors (improved atherogenic indices and inflammatory markers) compared with a nut-free energy-restricted diet. [https://pmc.ncbi.nlm.nih.gov/articles/PMC11234893/]
  - Insular-associated causal network of structural covariance evaluating progressive gray matter changes in major depressive disorder, Cerebral cortex (New York, N.Y. : 1991) (2023) — Randomized crossover controlled-feeding trial found daily cashew consumption did not significantly influence blood lipids, blood pressure, glucose, insulin or other cardiovascular markers versus a no-nut control diet. [https://pubmed.ncbi.nlm.nih.gov/35357431/]
  - Cashew consumption reduces total and LDL cholesterol: a randomized, crossover, controlled-feeding trial, The American journal of clinical nutrition (2017) — In a randomized crossover controlled-feeding trial, a cashew-enriched diet significantly lowered LDL cholesterol (~4.8-5.9%), total cholesterol (~3.9%), and non-HDL cholesterol vs control, without affecting HDL or triglycerides. [https://pubmed.ncbi.nlm.nih.gov/28356271/]
  - Cashew Nut Consumption Increases HDL Cholesterol and Reduces Systolic Blood Pressure in Asian Indians with Type 2 Diabetes: A 12-Week Randomized Controlled Trial, The Journal of nutrition (2018) — In 300 adults with type 2 diabetes, adding 30 g/day cashews for 12 weeks reduced systolic blood pressure and raised HDL cholesterol, with no adverse effect on body weight, glycemia, or other lipids. [https://pubmed.ncbi.nlm.nih.gov/29378038/]
  - Plasma lipidomic profiles and cardiovascular events in a randomized intervention trial with the Mediterranean diet, The American journal of clinical nutrition (2017) — In a controlled-feeding RCT, isocaloric cashew intake (~28-64 g/d for 28 d) did not change LDL cholesterol versus a control diet, but lowered total cholesterol-to-HDL ratio and non-HDL cholesterol in adults with elevated LDL. [https://pubmed.ncbi.nlm.nih.gov/28814398/]
  - Frequency of nut consumption and mortality risk in the PREDIMED nutrition intervention trial, BMC medicine (2013) — In two large US cohorts (~119,000 people), higher total nut consumption was inversely associated with total and cause-specific (including cardiovascular) mortality; observational, not cashew-specific. [https://pubmed.ncbi.nlm.nih.gov/23866098/]

---

## Peanut (Arachis hypogaea)
URL: https://nutridex.info/s/peanut
Category: Nuts, Heart & Metabolic, Longevity
Evidence: Moderate — Several controlled trials; effects real but modest or context-dependent.
Affordable legume nut linked to lower CVD and total mortality

Quick answer: Peanut is used for higher intake associated with lower cardiovascular and all-cause mortality in large cohorts. NutriDex grades the human evidence as moderate — Several controlled trials; effects real but modest or context-dependent. Based on 9 cited human studies (9 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Peanuts are botanically a legume but nutritionally behave like tree nuts, supplying unsaturated fat, plant protein, fiber and L-arginine. The strongest human data are observational: in a prospective study of over 200,000 people across the US Southern Community Cohort and the Shanghai cohorts (Luu 2015), higher peanut/nut intake was associated with roughly 17-21% lower total mortality, driven mainly by fewer cardiovascular deaths. A systematic review and meta-analysis of randomized trials (2019) found peanut intake produced modest reductions in total cholesterol, triglycerides and diastolic blood pressure, though effects on LDL cholesterol were inconsistent and often non-significant. Randomized evidence specific to peanuts on hard endpoints is limited; the landmark PREDIMED trial (Estruch 2018) used mixed nuts (mostly walnuts, with almonds and hazelnuts) rather than peanuts, so its ~28% reduction in major cardiovascular events is not peanut-specific. Overall the evidence is moderate and largely consistent with the broader nut literature, but causal proof for peanuts alone is weaker than for walnuts or almonds.

Nutrition (per 1 oz (28 g, ~28 peanuts)): 161 kcal; Fiber 2.4g (9% DV), Protein 7.3g (15% DV), Vitamin E 2.4mg (16% DV), Magnesium 47.6mg (11% DV), Copper 0.32mg (36% DV), Manganese 0.55mg (24% DV), Zinc 0.93mg (8% DV), Selenium 2µg (4% DV).
Benefits / uses: Higher intake associated with lower cardiovascular and all-cause mortality in large cohorts; Modest improvements in total and LDL cholesterol and triglycerides; Lowers diastolic blood pressure in pooled trial data; Helps with satiety and weight maintenance despite calorie density; Part of nut-supplemented Mediterranean diet shown to cut major CVD events in an RCT; Provides plant protein, fiber and unsaturated fat as a low-cost nut alternative.
Active compounds: Monounsaturated fatty acids (MUFA, oleic acid); Polyunsaturated fatty acids (PUFA, linoleic acid); Plant protein; Dietary fiber; L-arginine; Phytosterols; Magnesium; Niacin and folate; Resveratrol and polyphenols.
Dose: About 1 oz (28 g) per day, a small handful, unsalted
Safety: Peanut allergy is one of the most common and severe food allergies and can cause life-threatening anaphylaxis; people with peanut allergy must avoid all peanuts and peanut-containing products. Peanuts are a legume, not a tree nut, but cross-reactivity and shared processing lines mean tree-nut-allergic individuals should be cautious. Peanuts are calorie-dense (~160-170 kcal per 28 g), so portion control matters for weight management; choose unsalted to limit sodium. Peanuts stored improperly can harbor aflatoxin, a mold-derived carcinogen, so buy fresh, well-stored product and discard moldy or shriveled nuts. Whole peanuts and globs of peanut butter are a choking hazard for children under 4. Salted/honey-roasted versions add sodium and sugar.

Cited studies (9):
  - Tree Nut and Peanut Consumption and Risk of Cardiovascular Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials, Advances in nutrition (Bethesda, Md.) (2023) — Meta-analysis of 129 RCTs (9,099 participants): tree nut/peanut consumption significantly lowered LDL cholesterol (-0.11 mmol/L, 95% CI -0.14 to -0.07), total cholesterol (-0.13 mmol/L, -0.18 to -0.09) and triglycerides (-0.06 mmol/L, -0.08 to -0.03); no effect on blood pressure. [https://pmc.ncbi.nlm.nih.gov/articles/PMC10509427/]
  - Effect of Peanut Consumption on Cardiovascular Risk Factors: A Randomized Clinical Trial and Meta-Analysis, Frontiers in nutrition (2022) — ARISTOTLE RCT (n=63, 6 months, 25 g/day roasted peanuts or 32 g/day peanut butter) plus meta-analysis: peanut products lowered triglycerides (MD -0.13 mmol/L, 95% CI -0.20 to -0.07) and, in healthy subjects, total cholesterol (MD -0.40, -0.71 to -0.09) and the LDL/HDL ratio. [https://pmc.ncbi.nlm.nih.gov/articles/PMC9011914/]
  - Are fatty nuts a weighty concern? A systematic review and meta-analysis and dose-response meta-regression of prospective cohorts and randomized controlled trials, Obesity reviews : an official journal of the International Association for the Study of Obesity (2021) — Systematic review and dose-response meta-analysis of prospective cohorts and RCTs: despite being calorie-dense, nuts showed no adverse effect on body weight in RCTs (high certainty) and higher intake was associated with lower body weight and body fat in cohorts. [https://pmc.ncbi.nlm.nih.gov/articles/PMC9285885/]
  - Peanut and cardiovascular disease risk factors: A systematic review and meta-analysis, Critical reviews in food science and nutrition (2020) — Peanut consumption modestly lowered total cholesterol, triglycerides and diastolic blood pressure, with no consistent significant effect on LDL cholesterol. [https://pubmed.ncbi.nlm.nih.gov/30638042/]
  - Nut consumption and risk of cardiovascular disease, total cancer, all-cause and cause-specific mortality: a systematic review and dose-response meta-analysis of prospective studies, BMC Medicine (2016) — Dose-response meta-analysis of prospective studies (up to 819,000 participants): one 28 g/day serving of nuts associated with 29% lower coronary heart disease, 21% lower CVD, 15% lower total cancer and 22% lower all-cause mortality. [https://link.springer.com/article/10.1186/s12916-016-0730-3]
  - Primary Prevention of Cardiovascular Disease with a Mediterranean Diet Supplemented with Extra-Virgin Olive Oil or Nuts, The New England journal of medicine (2018) — A Mediterranean diet supplemented with mixed nuts cut major cardiovascular events ~28% vs a low-fat control over ~4.8 years; nuts were mostly walnuts/almonds/hazelnuts, not peanuts. [https://pubmed.ncbi.nlm.nih.gov/29897866/]
  - Prospective evaluation of the association of nut/peanut consumption with total and cause-specific mortality, JAMA internal medicine (2015) — Among >200,000 adults, highest vs lowest peanut/nut intake was associated with ~17-21% lower all-cause mortality, predominantly from reduced cardiovascular mortality. [https://pubmed.ncbi.nlm.nih.gov/25730101/]
  - Prospective evaluation of the association of nut/peanut consumption with total and cause-specific mortality, JAMA internal medicine (2015) — Pooled analysis of 206,029 adults across 3 cohorts (US Southern Community + Shanghai men/women): highest vs lowest nut/peanut intake associated with ~17-21% lower total mortality (HR 0.79, 95% CI 0.73-0.86 in US; HR 0.83, 95% CI 0.77-0.88 in Asians) and reduced ischemic heart disease mortality. [https://pmc.ncbi.nlm.nih.gov/articles/PMC4474488/]
  - Nut and peanut butter consumption and risk of type 2 diabetes in women, JAMA (2002) — Nurses' Health Study (83,818 women): consuming peanut butter ≥5 times/week (≈140 g peanuts/wk) associated with 21% lower risk of incident type 2 diabetes vs never (multivariate RR 0.79, 95% CI 0.68-0.91; P-trend <0.001). [https://pubmed.ncbi.nlm.nih.gov/12444862/]

---

## Pecan (Carya illinoinensis)
URL: https://nutridex.info/s/pecan
Category: Nuts, Heart & Metabolic, Longevity
Evidence: Moderate — Several controlled trials; effects real but modest or context-dependent.
A buttery tree nut shown in trials to lower LDL cholesterol

Quick answer: Pecan is used for lowers ldl and total cholesterol in controlled trials (~6% ldl reduction). NutriDex grades the human evidence as moderate — Several controlled trials; effects real but modest or context-dependent. Based on 7 cited human studies (7 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Pecans have moderate, lipid-focused evidence. Several short-to-medium randomized controlled trials show that eating roughly 1-2 oz (28-57 g) daily, in place of usual snacks, meaningfully lowers LDL cholesterol (around 6%), total and non-HDL cholesterol, apolipoprotein B and triglycerides, and improves cholesterol ratios and lipoprotein particle counts. A 2018 Nutrients pecan-rich-diet RCT in overweight adults also improved fasting insulin and insulin resistance, and a 2025 Journal of Nutrition snack-substitution RCT confirmed the lipid benefits with better diet quality and no weight gain. These are surrogate markers measured over weeks, not hard cardiovascular endpoints. Pecan-specific trials on heart attacks, diabetes or mortality do not exist; those benefits are extrapolated from the wider tree-nut literature, where large cohorts (Aune 2016 meta-analysis) and the PREDIMED trial link nut intake to lower cardiovascular events and all-cause mortality. As a single nut, pecans sit at moderate evidence: consistent lipid effects, but less data than walnuts or almonds.

Nutrition (per 1 oz (28 g, ~19 pecan halves)): 193 kcal; Fiber 2.7g (10% DV), Protein 2.6g (5% DV), Vitamin E 0.4mg (3% DV), Magnesium 34mg (8% DV), Copper 0.34mg (38% DV), Manganese 1.26mg (55% DV), Zinc 1.27mg (12% DV), Selenium 1.1µg (2% DV).
Benefits / uses: Lowers LDL and total cholesterol in controlled trials (~6% LDL reduction); Reduces non-HDL cholesterol, apolipoprotein B and triglycerides; Improves the total-to-HDL cholesterol ratio and lipoprotein particle profile; Improves fasting insulin and insulin sensitivity (HOMA-IR) in short trials; Part of the tree-nut group linked to lower CVD and all-cause mortality in cohorts; Nutrient-dense source of MUFA, fiber and antioxidants with no weight gain at studied doses.
Active compounds: Monounsaturated fat (oleic acid); Polyunsaturated fat (linoleic acid); Dietary fiber; Phytosterols (beta-sitosterol); Vitamin E (gamma-tocopherol); Magnesium; Polyphenols and flavonoids (ellagic acid, condensed tannins); L-arginine; Zinc and copper.
Dose: About 1-2 oz (28-57 g) per day, a small-to-large handful, replacing other snacks rather than added on top.
Safety: Pecans are tree nuts and can trigger IgE-mediated allergy, including life-threatening anaphylaxis; anyone with tree-nut or peanut allergy should avoid them. They are calorie-dense (about 195-200 kcal per 1 oz/28 g), so use them to replace other snacks rather than add to the diet to avoid weight gain. Whole or large pieces are a choking hazard for young children. Buy fresh and store cool/airtight, as their high unsaturated-fat content makes them prone to rancidity.

Cited studies (7):
  - Tree Nut and Peanut Consumption and Risk of Cardiovascular Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials, Advances in nutrition (Bethesda, Md.) (2023) — Systematic review and meta-analysis of 129 RCTs found tree nut and peanut consumption significantly reduced LDL cholesterol, total cholesterol, triglycerides, and apolipoprotein B, supporting an overall CVD risk reduction. [https://pmc.ncbi.nlm.nih.gov/articles/PMC10509427/]
  - Nut consumption, body weight, and adiposity in patients with type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials, Nutrition reviews (2022) — Meta-analysis of 12 RCTs (n=450 with type 2 diabetes) found tree nut supplementation reduced fasting glucose and HbA1c, indicating improved glycemic control. [https://pubmed.ncbi.nlm.nih.gov/34338788/]
  - Nut consumption and risk of cardiovascular disease, total cancer, all-cause and cause-specific mortality: a systematic review and dose-response meta-analysis of prospective studies, BMC medicine (2016) — Across 20 prospective cohorts, ~28 g/day of nuts was associated with ~21% lower cardiovascular mortality and ~22% lower all-cause mortality, supporting tree nuts as a group. [https://pubmed.ncbi.nlm.nih.gov/27916000/]
  - Pecan Intake Improves Lipoprotein Particle Concentrations Compared with Usual Intake in Adults at Increased Risk of Cardiometabolic Diseases: A Randomized Controlled Trial, The Journal of nutrition (2025) — Replacing usual snacks with pecans for 12 weeks lowered LDL cholesterol ~6% (7.2 mg/dL), total cholesterol and non-HDL cholesterol, and improved diet quality without weight gain in adults at cardiometabolic risk. [https://pubmed.ncbi.nlm.nih.gov/40113170/]
  - A Pecan-Rich Diet Improves Cardiometabolic Risk Factors in Overweight and Obese Adults: A Randomized Controlled Trial, Nutrients (2018) — A 4-week pecan-rich diet in overweight/obese adults improved fasting insulin, insulin resistance (HOMA-IR) and beta-cell function versus an isocaloric control diet. [https://pubmed.ncbi.nlm.nih.gov/29534487/]
  - Primary Prevention of Cardiovascular Disease with a Mediterranean Diet Supplemented with Extra-Virgin Olive Oil or Nuts, The New England journal of medicine (2018) — A Mediterranean diet supplemented with mixed nuts reduced major cardiovascular events versus a control diet in high-risk adults, though pecans were not the test nut. [https://pubmed.ncbi.nlm.nih.gov/29897866/]
  - A Pecan-Rich Diet Improves Cardiometabolic Risk Factors in Overweight and Obese Adults: A Randomized Controlled Trial, Nutrients (2018) — A randomized crossover trial (n=26 overweight/obese adults, 4-wk pecan-enriched diet) reduced serum insulin (-1.31 vs +0.69 uIU/mL, p=0.024) and improved HOMA-IR and beta-cell function, with borderline LDL/total cholesterol reductions. [https://pmc.ncbi.nlm.nih.gov/articles/PMC5872757/]

---

## Hazelnut (Corylus avellana)
URL: https://nutridex.info/s/hazelnut
Category: Nuts, Heart & Metabolic, Longevity
Evidence: Moderate — Several controlled trials; effects real but modest or context-dependent.
MUFA-rich tree nut that modestly lowers LDL and total cholesterol

Quick answer: Hazelnut is used for lowers ldl ('bad') and total cholesterol in controlled feeding trials. NutriDex grades the human evidence as moderate — Several controlled trials; effects real but modest or context-dependent. Based on 8 cited human studies (8 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Hazelnuts have moderate, mostly lipid-focused human evidence. A 2016 Bayesian meta-analysis (Perna et al., Nutrients) pooling nine controlled studies (~425 participants, 29-69 g/day for 4-12 weeks) found hazelnut-enriched diets significantly lowered LDL and total cholesterol, with HDL and triglycerides essentially unchanged and no effect on body weight or BMI - reassuring given their calorie density. Direct trial data on hard outcomes (heart attacks, diabetes, death) are limited; most cardiovascular evidence comes from nuts as a group. In the PREDIMED randomized trial (NEJM 2018), a Mediterranean diet supplemented with mixed nuts (walnuts, almonds and hazelnuts) reduced major cardiovascular events versus a control diet. Large prospective cohorts (Aune et al., BMC Medicine 2016) link higher nut intake to lower cardiovascular and all-cause mortality, but these are observational and not hazelnut-specific. Bottom line: good RCT support for cholesterol-lowering; benefits on weight, glycemia, and mortality are inferred largely from broader nut research rather than hazelnut trials.

Nutrition (per 1 oz (28 g, ~21 hazelnuts)): 176 kcal; Fiber 2.7g (10% DV), Protein 4.2g (8% DV), Vitamin E 4.2mg (28% DV), Magnesium 46mg (11% DV), Copper 0.48mg (53% DV), Manganese 1.73mg (75% DV), Zinc 0.69mg (6% DV), Selenium 0.67µg (1% DV).
Benefits / uses: Lowers LDL ('bad') and total cholesterol in controlled feeding trials; Leaves HDL cholesterol and triglycerides largely unchanged; Does not cause weight gain when substituted into the diet, despite calorie density; Part of nut-supplemented Mediterranean diets shown to cut major cardiovascular events; Higher overall nut intake is linked to lower cardiovascular and all-cause mortality in cohorts; Supplies heart-favorable monounsaturated fat, fiber, vitamin E, and magnesium.
Active compounds: Monounsaturated fatty acids (oleic acid); Polyunsaturated fatty acids (linoleic acid); Dietary fiber; Vitamin E (alpha-tocopherol); Magnesium; Phytosterols; L-arginine; Polyphenols (in the skin); Folate.
Dose: About 1 oz (28-30 g) per day, a small handful (~20 nuts); trials used 29-69 g/day
Safety: Hazelnuts are a tree nut and a common cause of food allergy; in sensitized people they can trigger anaphylaxis, a medical emergency - anyone with tree-nut or peanut allergy should avoid them. They are calorie-dense (~180 kcal per 28 g), so portion control matters and they are best substituted for less healthy foods rather than simply added. Whole nuts are a choking hazard for young children; use nut butter or finely ground forms for toddlers. Most cardiovascular and mortality data come from nuts as a group, not hazelnuts specifically, so individual benefit estimates carry uncertainty. Note: unlike Brazil nuts (selenium toxicity, limit to 1-3/day) hazelnuts pose no selenium risk, and unlike peanuts (a legume prone to aflatoxin) hazelnuts are a true tree nut.

Cited studies (8):
  - Nut consumption and risk of cardiovascular disease events and all-cause mortality: A systematic review and dose-response meta-analysis of prospective cohort studies, Archives of cardiovascular diseases (2026) — Dose-response meta-analysis of prospective cohorts reported higher nut intake associated with lower risk of CHD (20%), stroke (9%), CVD (14%), CVD mortality (26%) and all-cause mortality (23%). [https://pubmed.ncbi.nlm.nih.gov/41350177/]
  - Effects of Hazelnut Consumption on Blood Lipids and Body Weight: A Systematic Review and Bayesian Meta-Analysis, Nutrients (2016) — Across nine controlled studies (~425 participants, 29-69 g/day), hazelnut-enriched diets significantly reduced LDL and total cholesterol with no change in HDL, triglycerides, or body weight/BMI. [https://pubmed.ncbi.nlm.nih.gov/27897978/]
  - Nut consumption and risk of cardiovascular disease, total cancer, all-cause and cause-specific mortality: a systematic review and dose-response meta-analysis of prospective studies, BMC medicine (2016) — In pooled prospective cohorts, higher nut intake (~28 g/day) was associated with lower risk of cardiovascular disease, coronary heart disease, and all-cause mortality. [https://pubmed.ncbi.nlm.nih.gov/27916000/]
  - Effects of Hazelnut Consumption on Blood Lipids and Body Weight: A Systematic Review and Bayesian Meta-Analysis, Nutrients (2016) — Bayesian meta-analysis of RCTs (9 studies, 425 participants; ~39 g/day, ~75 days) found a hazelnut-enriched diet significantly lowered LDL-C (pooled MD -0.150 mmol/L; 95%HPD -0.308 to -0.003) with a trend for lower total cholesterol and no change in HDL, triglycerides or BMI. [https://pmc.ncbi.nlm.nih.gov/articles/PMC5188407/]
  - Effect of tree nuts on glycemic control in diabetes: a systematic review and meta-analysis of randomized controlled dietary trials, PloS one (2014) — Meta-analysis of 12 RCTs (450 diabetics): tree nuts (median 56 g/day, includes hazelnuts) significantly lowered HbA1c by 0.07% and fasting glucose by 0.15 mmol/L vs isocaloric control diets. [https://pmc.ncbi.nlm.nih.gov/articles/PMC4116170/]
  - Primary Prevention of Cardiovascular Disease with a Mediterranean Diet Supplemented with Extra-Virgin Olive Oil or Nuts, The New England journal of medicine (2018) — A Mediterranean diet supplemented with mixed nuts (walnuts, almonds, hazelnuts) reduced the incidence of major cardiovascular events versus a reduced-fat control diet in people at high cardiovascular risk. [https://pubmed.ncbi.nlm.nih.gov/29897866/]
  - A Hazelnut-Enriched Diet Modulates Oxidative Stress and Inflammation Gene Expression without Weight Gain, Oxidative medicine and cellular longevity (2019) — In hypercholesterolemic adults, a hazelnut-enriched diet modulated oxidative-stress and inflammation gene expression and improved cardiovascular biomarkers without causing weight gain despite the added calories. [https://pmc.ncbi.nlm.nih.gov/articles/PMC6637671/]
  - Hazelnut-enriched diet improves cardiovascular risk biomarkers beyond a lipid-lowering effect in hypercholesterolemic subjects, Journal of clinical lipidology (2013) — Crossover RCT in 21 hypercholesterolemic adults: 4 weeks of hazelnuts (18-20% of energy) improved endothelial function (flow-mediated dilation) and reduced LDL oxidation and inflammatory markers beyond the lipid-lowering effect. [https://pubmed.ncbi.nlm.nih.gov/23415431/]

---

## Macadamia (Macadamia integrifolia)
URL: https://nutridex.info/s/macadamia
Category: Nuts, Heart & Metabolic, Longevity
Evidence: Preliminary — Early or small human trials; promising but not yet conclusive.
High-MUFA tree nut with modest, mostly favorable lipid effects

Quick answer: Macadamia is used for may modestly lower total and ldl cholesterol when substituted for saturated-fat foods. NutriDex grades the human evidence as preliminary — Early or small human trials; promising but not yet conclusive. Based on 8 cited human studies (8 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Macadamias are one of the richest dietary sources of monounsaturated fat, giving them a fatty-acid profile resembling olive oil. Direct human evidence is limited and preliminary, resting on a few small controlled-feeding and crossover trials. A 2008 randomized controlled-feeding study in mildly hypercholesterolemic adults (Griel et al.) found a macadamia-rich diet significantly lowered total and LDL cholesterol versus a typical American diet. A larger 2023 crossover RCT in adults with abdominal obesity (Jones et al.) showed only small, non-significant reductions in total and LDL cholesterol, with greater lowering in leaner participants and no weight gain despite the added calories. Macadamias are not separately studied for hard cardiovascular events, diabetes, or mortality; benefits are inferred from broader tree-nut research. Meta-analyses of tree nuts overall (Del Gobbo 2015) show consistent LDL lowering, and large cohort meta-analyses (Aune 2016) link nut intake to lower cardiovascular and all-cause mortality. Evidence for macadamias specifically remains modest.

Nutrition (per 1 oz (28 g, ~11 kernels)): 204 kcal; Fiber 2.4g (9% DV), Protein 2.2g (4% DV), Vitamin E 0.15mg (1% DV), Magnesium 36.9mg (9% DV), Copper 0.21mg (23% DV), Manganese 1.17mg (51% DV), Zinc 0.37mg (3% DV), Selenium 1µg (2% DV).
Benefits / uses: May modestly lower total and LDL cholesterol when substituted for saturated-fat foods; Very high in monounsaturated fat, like olive oil's fatty-acid profile; Lipid benefit appears greater in leaner / overweight (vs obese) individuals; Does not promote weight gain when eaten in place of other calories; Part of the broader tree-nut pattern linked to lower cardiovascular risk; Provides fiber, magnesium and vitamin E within a whole-food matrix.
Active compounds: Monounsaturated fatty acids (oleic and palmitoleic acid); Dietary fiber; Magnesium; Vitamin E (tocotrienols/tocopherols); Phytosterols; Manganese; Thiamine; Polyphenols.
Dose: About 1 oz (28-43 g) per day, a small handful (~10-15 kernels)
Safety: Tree nuts including macadamia can trigger IgE-mediated allergy and, in sensitized individuals, life-threatening anaphylaxis; people with tree-nut or peanut allergy should avoid them. Macadamias are very calorie-dense (~200 kcal per 28 g), so portions should replace other foods rather than add to total intake. Whole nuts are a choking hazard for young children. Macadamias are also notably toxic to dogs and should be kept away from pets.

Cited studies (8):
  - Are fatty nuts a weighty concern? A systematic review and meta-analysis and dose-response meta-regression of prospective cohorts and randomized controlled trials, Obesity reviews : an official journal of the International Association for the Study of Obesity (2021) — Systematic review/meta-analysis of 6 cohorts and 86 RCTs (114 comparisons): nut-enriched diets did not raise body weight and were associated with significant decreases in body weight (-0.22 kg) and BMI (-0.16 kg/m2). [https://pmc.ncbi.nlm.nih.gov/articles/PMC9285885/]
  - Effects of tree nuts on blood lipids, apolipoproteins, and blood pressure: systematic review, meta-analysis, and dose-response of 61 controlled intervention trials, The American journal of clinical nutrition (2015) — Tree nut intake dose-dependently lowered total cholesterol, LDL cholesterol and triglycerides across 61 controlled intervention trials. [https://pubmed.ncbi.nlm.nih.gov/26561616/]
  - Nut consumption and risk of cardiovascular disease, total cancer, all-cause and cause-specific mortality: a systematic review and dose-response meta-analysis of prospective studies, BMC medicine (2016) — Higher nut consumption (~28 g/day) was associated with significantly lower risk of cardiovascular disease, total cancer and all-cause mortality across prospective cohort studies. [https://pubmed.ncbi.nlm.nih.gov/27916000/]
  - Nut consumption and risk of cardiovascular disease, total cancer, all-cause and cause-specific mortality: a systematic review and dose-response meta-analysis of prospective studies, BMC medicine (2016) — Dose-response meta-analysis of prospective studies (up to ~819,000 participants): higher nut intake (28 g/day) was associated with ~29% lower CHD, ~21% lower CVD mortality, and ~22% lower all-cause mortality. [https://pmc.ncbi.nlm.nih.gov/articles/PMC5137221/]
  - Macadamia nut effects on cardiometabolic risk factors: a randomised trial, Journal of nutritional science (2023) — In adults with abdominal obesity, macadamia nuts (~15% of energy) produced small non-significant reductions in total (-2.1%) and LDL (-4%) cholesterol, with no weight gain; lipid lowering was greater in leaner participants. [https://pubmed.ncbi.nlm.nih.gov/37180485/]
  - Macadamia nut effects on cardiometabolic risk factors: a randomised trial, Journal of nutritional science (2023) — 8-week randomized crossover trial (n=35, abdominal obesity): macadamia (~15% energy) vs habitual diet produced non-significant reductions in total cholesterol (-2.1%, p=0.41) and LDL-C (-4.0%, p=0.32) with no gain in body weight or fat despite higher fat intake. [https://pmc.ncbi.nlm.nih.gov/articles/PMC10173088/]
  - A macadamia nut-rich diet reduces total and LDL-cholesterol in mildly hypercholesterolemic men and women, The Journal of nutrition (2008) — A macadamia nut-rich diet (~42.5 g/day) significantly reduced total and LDL cholesterol versus an average American diet in mildly hypercholesterolemic men and women. [https://pubmed.ncbi.nlm.nih.gov/18356332/]
  - Macadamia Nut Consumption Modulates Favourably Risk Factors for Coronary Artery Disease in Hypercholesterolemic Subjects, Lipids (2007) — 4-week trial in 17 hypercholesterolemic men given 40-90 g/day macadamia (15% energy) favourably modulated biomarkers of oxidative stress, thrombosis and inflammation (CAD risk factors) despite increased dietary fat. [https://link.springer.com/article/10.1007/s11745-007-3042-8]

---

## Brazil Nut (Bertholletia excelsa)
URL: https://nutridex.info/s/brazil-nut
Category: Nuts, Heart & Metabolic, Longevity
Evidence: Preliminary — Early or small human trials; promising but not yet conclusive.
Selenium-rich tree nut; 1-2 nuts/day for lipids, but easy to overdose

Quick answer: Brazil Nut is used for modest reductions in total and ldl cholesterol in small rcts. NutriDex grades the human evidence as preliminary — Early or small human trials; promising but not yet conclusive. Based on 10 cited human studies (10 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Brazil nuts are the most concentrated dietary source of selenium, and most of the specific human research focuses on that. Small randomized trials suggest a modest benefit: a 90-day RCT of partially defatted Brazil nut flour in dyslipidemic patients lowered total and non-HDL cholesterol (Carvalho 2015, PMID 26077768), and a trial in obese adolescents reduced total/LDL cholesterol and oxidized LDL (Maranhao 2011, PMID 21619692). A 2022 systematic review and meta-analysis of RCTs found Brazil nuts reliably raise selenium status but showed inconsistent, generally small effects on blood lipids (PMID 35204285). Evidence is preliminary and rests on small, short trials; there are no Brazil-nut-specific outcome trials for cardiovascular events or mortality. The stronger cardiovascular and all-cause mortality data come from tree nuts as a whole and from large cohorts (Aune 2016 meta-analysis, PMID 27916000), not Brazil nuts specifically. Treat them as one nutritious nut among many, valued chiefly for selenium.

Nutrition (per 1 oz (28 g, ~6 nuts)): 184 kcal; Fiber 2.1g (8% DV), Protein 4g (8% DV), Vitamin E 1.58mg (11% DV), Magnesium 105mg (25% DV), Copper 0.49mg (54% DV), Manganese 0.34mg (15% DV), Zinc 1.14mg (10% DV), Selenium 537µg (976% DV).
Benefits / uses: Modest reductions in total and LDL cholesterol in small RCTs; Dramatically raises blood selenium status from a tiny serving; Lowers oxidized LDL and markers of oxidative stress in trial subjects; Part of the broader tree-nut pattern linked to lower CVD risk in cohorts; Provides healthy unsaturated fats, fibre and magnesium; May modestly improve antioxidant/inflammatory biomarkers.
Active compounds: Selenium (selenocysteine/selenomethionine); Monounsaturated fat (MUFA); Polyunsaturated fat (PUFA, linoleic acid); Vitamin E (tocopherols); Magnesium; Phytosterols; Dietary fibre; L-arginine.
Dose: 1-2 nuts (~5-10 g) per day; even a single nut supplies ~70-90 mcg selenium. Do not exceed 3-4 nuts daily.
Safety: Tree nuts are a major allergen and can cause life-threatening anaphylaxis; avoid if allergic to tree nuts. Brazil nuts are calorie-dense (~185 kcal/oz), so portion control matters. The dominant Brazil-nut-specific risk is selenium toxicity (selenosis): a single nut can contain 70-90 mcg selenium, so just a few nuts can exceed the 400 mcg/day tolerable upper limit, causing hair loss, brittle nails, GI upset, garlic breath, fatigue and neuropathy. Limit to 1-3 nuts per day and do not combine with selenium supplements. Whole nuts are a choking hazard for young children. Brazil nuts can also concentrate naturally occurring radium and barium from soil; this is not a practical concern at normal intakes but is another reason not to over-consume.

Cited studies (10):
  - Effect of Brazil Nuts on Selenium Status, Blood Lipids, and Biomarkers of Oxidative Stress and Inflammation: A Systematic Review and Meta-Analysis of Randomized Clinical Trials, Antioxidants (Basel, Switzerland) (2022) — Brazil nuts consistently increased blood selenium but had inconsistent, generally modest effects on blood lipids and oxidative/inflammatory markers across randomized trials. [https://pubmed.ncbi.nlm.nih.gov/35204285/]
  - Effect of Brazil Nuts on Selenium Status, Blood Lipids, and Biomarkers of Oxidative Stress and Inflammation: A Systematic Review and Meta-Analysis of Randomized Clinical Trials, Antioxidants (Basel, Switzerland) (2022) — Meta-analysis of 8 RCTs: Brazil nut intake markedly raised plasma selenium (SMD 6.93, 95% CI 3.99-9.87) but did not significantly change total cholesterol (SMD -0.22, 95% CI -0.57 to 0.14) or LDL (SMD -0.15, 95% CI -0.43 to 0.13). [https://pmc.ncbi.nlm.nih.gov/articles/PMC8869304/]
  - Nut consumption and risk of cardiovascular disease, total cancer, all-cause and cause-specific mortality: a systematic review and dose-response meta-analysis of prospective studies, BMC medicine (2016) — Across 20 prospective cohorts, higher nut intake (~28 g/day) was associated with lower cardiovascular disease and all-cause mortality; reflects nuts broadly, not Brazil nuts specifically. [https://pubmed.ncbi.nlm.nih.gov/27916000/]
  - Nut consumption and risk of cardiovascular disease, total cancer, all-cause and cause-specific mortality: a systematic review and dose-response meta-analysis of prospective studies, BMC medicine (2016) — Dose-response meta-analysis of 20 prospective cohorts (up to 819,448 participants): each 28 g/day of nuts was associated with lower coronary heart disease (RR 0.71, 95% CI 0.63-0.80), cardiovascular disease (RR 0.79), and all-cause mortality (RR 0.78). [https://pmc.ncbi.nlm.nih.gov/articles/PMC5137221/]
  - Intake of partially defatted Brazil nut flour reduces serum cholesterol in hypercholesterolemic patients--a randomized controlled trial, Nutrition journal (2015) — In 91 dyslipidemic/hypertensive patients, 13 g/day partially defatted Brazil nut flour for 90 days reduced total cholesterol and non-HDL cholesterol versus placebo. [https://pubmed.ncbi.nlm.nih.gov/26077768/]
  - Intake of partially defatted Brazil nut flour reduces serum cholesterol in hypercholesterolemic patients--a randomized controlled trial, Nutrition journal (2015) — RCT in hypercholesterolemic adults: partially defatted Brazil nut flour reduced total cholesterol (-20.5 mg/dL, P=0.02) and non-HDL cholesterol (-19.5 mg/dL, P=0.02) and preserved free T3. [https://pmc.ncbi.nlm.nih.gov/articles/PMC4488974/]
  - Effects of Brazil nut consumption on selenium status and cognitive performance in older adults with mild cognitive impairment: a randomized controlled pilot trial, European Journal of Nutrition (2015) — RCT pilot in older adults with mild cognitive impairment: ~1 Brazil nut/day for 6 months raised selenium status and improved verbal fluency (P=0.007) and constructional praxis (P=0.031) vs control. [https://link.springer.com/article/10.1007/s00394-014-0829-2]
  - Brazil nuts intake improves lipid profile, oxidative stress and microvascular function in obese adolescents: a randomized controlled trial, Nutrition & metabolism (2011) — In obese female adolescents, 15-25 g/day Brazil nuts for 16 weeks raised selenium and reduced total cholesterol, LDL cholesterol and oxidized LDL. [https://pubmed.ncbi.nlm.nih.gov/21619692/]
  - A single consumption of high amounts of the Brazil nuts improves lipid profile of healthy volunteers, Journal of nutrition and metabolism (2013) — Randomized crossover in 10 healthy adults: a single 20-50 g serving of Brazil nuts lowered serum LDL-C and raised HDL-C by 9 h, with changes persisting up to 30 days. [https://pmc.ncbi.nlm.nih.gov/articles/PMC3693158/]
  - Brazil nuts: an effective way to improve selenium status, The American journal of clinical nutrition (2008) — RCT in 59 NZ adults: 2 Brazil nuts/day (~53 ug Se) for 12 weeks raised plasma selenium 64.2% and whole-blood glutathione peroxidase 13.2%, matching or exceeding 100 ug selenomethionine. [https://pubmed.ncbi.nlm.nih.gov/18258628/]

---

## Pine Nut (Pinus spp.)
URL: https://nutridex.info/s/pine-nut
Category: Nuts, Heart & Metabolic, Longevity
Evidence: Preliminary — Early or small human trials; promising but not yet conclusive.
A tree nut whose human data is largely extrapolated from nuts as a group

Quick answer: Pine Nut is used for may modestly improve blood lipids (lower total and ldl cholesterol) as part of the broader tree-nut evidence base. NutriDex grades the human evidence as preliminary — Early or small human trials; promising but not yet conclusive. Based on 10 cited human studies (10 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Direct human evidence for pine nuts specifically is limited and preliminary; most benefit is inferred from trials of tree nuts as a group, where walnuts and almonds dominate the data. A meta-analysis of 61 controlled trials (Del Gobbo 2015) found tree nuts modestly lower total cholesterol, LDL cholesterol and triglycerides in a dose-related way, but pine nuts were barely represented. The strongest pine-nut-specific data are small acute trials of Korean pine nut oil and its pinolenic acid (Pasman 2008), which raised satiety hormones CCK and GLP-1 and reduced short-term appetite, results that are mechanistically interesting but have not translated to demonstrated weight loss. Observationally, frequent nut eaters in the PREDIMED trial and in large cohort meta-analyses (Aune 2016) show lower cardiovascular and all-cause mortality, but these are association data spanning all nuts. Bottom line: pine nuts are a reasonable component of a nut-rich heart-healthy diet, but pine-nut-specific clinical proof is thin.

Nutrition (per 1 oz (28 g, ~167 kernels)): 189 kcal; Fiber 1g (4% DV), Protein 3.8g (8% DV), Vitamin E 2.6mg (17% DV), Magnesium 70mg (17% DV), Copper 0.37mg (41% DV), Manganese 2.46mg (107% DV), Zinc 1.81mg (16% DV), Selenium 0.2µg (0% DV).
Benefits / uses: May modestly improve blood lipids (lower total and LDL cholesterol) as part of the broader tree-nut evidence base; Pine nut oil and its pinolenic acid acutely increase satiety hormones (CCK, GLP-1) and can reduce short-term food intake in small trials; Source of heart-healthy unsaturated fats that displace saturated fat when substituted into the diet; Contributes vitamin E, magnesium, manganese and plant phytosterols within a generally cardioprotective dietary pattern; Fits within nut-rich diets linked in cohorts to lower cardiovascular and all-cause mortality (group-level, not pine-nut-specific).
Active compounds: Monounsaturated fatty acids (oleic acid); Polyunsaturated fatty acids including pinolenic acid (a pine-nut-specific delta-5 PUFA); Linoleic acid (omega-6); Vitamin E (gamma-tocopherol); Magnesium and manganese; Phytosterols; L-arginine; Zinc and copper.
Dose: 1 oz (~28 g) per day, a small handful; appetite studies used ~2-3 g pine nut oil/pinolenic acid before a meal
Safety: Pine nuts are tree nuts and can trigger IgE-mediated allergy including anaphylaxis; people with tree-nut or peanut allergy should avoid them or consult an allergist. They are calorie-dense (~190 kcal per oz/28 g), so portions matter for weight management. Whole nuts are a choking hazard in young children. A specific quirk of pine nuts is "pine mouth" (pine nut syndrome), a harmless but unpleasant metallic/bitter taste disturbance lasting days to a couple of weeks after eating certain (often non-traditional) species. Unlike Brazil nuts there is no selenium-toxicity concern, and unlike peanuts they are a true tree nut rather than a legume and are not a notable aflatoxin source, though rancidity from their high unsaturated-fat content is possible if stored poorly.

Cited studies (10):
  - Nut consumption, body weight, and adiposity in patients with type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials, Nutrition reviews (2022) — Systematic review/meta-analysis of 15 RCTs (n=899) in type 2 diabetes found nut-enriched diets had no adverse effect on body weight, BMI, waist circumference, or percent body fat — confirming weight-neutrality despite caloric density. [https://pubmed.ncbi.nlm.nih.gov/34338788/]
  - Effects of tree nuts on blood lipids, apolipoproteins, and blood pressure: systematic review, meta-analysis, and dose-response of 61 controlled intervention trials, The American journal of clinical nutrition (2015) — Across 61 controlled intervention trials, tree nut intake dose-dependently reduced total cholesterol, LDL cholesterol and triglycerides; pine nuts were minimally studied, so the effect is a tree-nut class finding. [https://pubmed.ncbi.nlm.nih.gov/26561616/]
  - Nut consumption and risk of cardiovascular disease, total cancer, all-cause and cause-specific mortality: a systematic review and dose-response meta-analysis of prospective studies, BMC medicine (2016) — Pooling 20 prospective studies, ~28 g/day of nuts was associated with lower coronary heart disease, cardiovascular and all-cause mortality; benefit reflects total nut intake, not pine nuts specifically. [https://pubmed.ncbi.nlm.nih.gov/27916000/]
  - Effects of tree nuts on blood lipids, apolipoproteins, and blood pressure: systematic review, meta-analysis, and dose-response of 61 controlled intervention trials, The American journal of clinical nutrition (2015) — Meta-analysis of 61 controlled trials (n=2,532) found tree-nut intake (mean ~67 g/d) lowered total cholesterol by 4.7 mg/dL, LDL-C by 4.8 mg/dL, ApoB and triglycerides, with dose the main determinant rather than nut type. [https://pmc.ncbi.nlm.nih.gov/articles/PMC4658458/]
  - Nut consumption and risk of cardiovascular disease, total cancer, all-cause and cause-specific mortality: a systematic review and dose-response meta-analysis of prospective studies, BMC Medicine (2016) — Dose-response meta-analysis of prospective cohorts found 28 g/d nut intake associated with ~29% lower coronary heart disease, ~21% lower CVD mortality, and ~22% lower all-cause mortality risk. [https://link.springer.com/article/10.1186/s12916-016-0730-3]
  - Effect of tree nuts on glycemic control in diabetes: a systematic review and meta-analysis of randomized controlled dietary trials, PloS one (2014) — Meta-analysis of 12 RCTs (n=450) in type 2 diabetes: tree nuts (median 56 g/d) significantly lowered HbA1c by 0.07% and fasting glucose by 0.15 mmol/L vs control diets. [https://pmc.ncbi.nlm.nih.gov/articles/PMC4116170/]
  - The effect of Korean pine nut oil (PinnoThin) on food intake, feeding behaviour and appetite: a double-blind placebo-controlled trial, Lipids in health and disease (2008) — In overweight post-menopausal women, Korean pine nut oil (rich in pinolenic acid) acutely raised the satiety hormones CCK and GLP-1 and lowered self-reported desire to eat versus placebo. [https://pubmed.ncbi.nlm.nih.gov/18307772/]
  - The effect of Korean pine nut oil (PinnoThin) on food intake, feeding behaviour and appetite: a double-blind placebo-controlled trial, Lipids in health and disease (2008) — Double-blind crossover RCT in 42 overweight women: 2 g Korean pine nut oil free fatty acids (pinolenic acid) taken before an ad-libitum lunch reduced food intake by ~9% and prospective food intake by ~36% vs olive-oil control. [https://pmc.ncbi.nlm.nih.gov/articles/PMC2289823/]
  - The effect of Korean pine nut oil on in vitro CCK release, on appetite sensations and on gut hormones in post-menopausal overweight women, Lipids in health and disease (2008) — In 18 overweight postmenopausal women, Korean pine nut oil raised post-meal satiety hormones CCK (by up to 60%) and GLP-1 over 4 h vs control, and stimulated CCK release from enteroendocrine cells in vitro. [https://pmc.ncbi.nlm.nih.gov/articles/PMC2322999/]
  - Frequency of nut consumption and mortality risk in the PREDIMED nutrition intervention trial, BMC medicine (2013) — Within the PREDIMED trial, participants eating nuts >3 servings/week had ~39% lower all-cause mortality and reduced cardiovascular and cancer mortality versus non-consumers (observational analysis, all nuts). [https://pubmed.ncbi.nlm.nih.gov/23866098/]

---

## Chestnut (Castanea sativa)
URL: https://nutridex.info/s/chestnut
Category: Nuts, Heart & Metabolic, Gut & Immune
Evidence: Preliminary — Early or small human trials; promising but not yet conclusive.
Low-fat, starchy tree nut; cardiometabolic data mostly extrapolated

Quick answer: Chestnut is used for naturally low in fat and energy-dense fat compared with other tree nuts, so easier to fit in a calorie-controlled diet. NutriDex grades the human evidence as preliminary — Early or small human trials; promising but not yet conclusive. Based on 9 cited human studies (9 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Sweet chestnut is an atypical tree nut: it is starchy, low in fat and lower in calories than almonds or walnuts, and unusually rich in vitamin C, potassium, magnesium and fibre. Direct human trials on chestnut and hard cardiometabolic outcomes (LDL, weight, glycaemia, mortality) are essentially absent, so most claims are extrapolated from nuts as a group or from animal and preliminary studies. The broader nut evidence is stronger: a 2023 systematic review and meta-analysis of randomized trials found tree-nut and peanut intake significantly lowered LDL cholesterol, total cholesterol and apolipoprotein B (certainty mostly low-to-moderate). In the PREDIMED randomized trial, a Mediterranean diet supplemented with mixed nuts cut major cardiovascular events versus a control diet, and large prospective cohorts (Bao 2013) link higher nut intake to lower all-cause and cardiovascular mortality. These data centre on walnuts, almonds and mixed nuts, not chestnut specifically; chestnut's own cardiometabolic effect in humans remains unproven.

Nutrition (per 1 oz (28 g, ~2 roasted chestnuts)): 60 kcal; Fiber 2.3g (8% DV), Protein 0.7g (1% DV), Vitamin E 0mg (0% DV), Magnesium 9mg (2% DV), Copper 0.13mg (14% DV), Manganese 0.27mg (12% DV), Zinc 0.15mg (1% DV), Selenium 0µg (0% DV).
Benefits / uses: Naturally low in fat and energy-dense fat compared with other tree nuts, so easier to fit in a calorie-controlled diet; Provides fibre and resistant starch that support satiety and gut health; Notably high in vitamin C for a nut (mostly retained when roasted), plus potassium and magnesium relevant to blood pressure; Gluten-free starchy alternative to grains for people with coeliac disease; Contributes polyphenols (gallic and ellagic acid) with antioxidant activity; As part of overall nut/tree-nut intake, may share the modest LDL-cholesterol and cardiovascular benefits seen for nuts as a group.
Active compounds: Complex carbohydrate / starch (chestnuts are starchy, unlike most nuts); Dietary fibre and resistant starch; Monounsaturated fatty acids (MUFA); Vitamin C (ascorbic acid); Potassium; Magnesium; Polyphenols (gallic acid, ellagic acid); Folate and B vitamins.
Dose: About 1 oz (~28 g), roughly 3-4 roasted chestnuts, as part of a varied diet; no chestnut-specific therapeutic dose is established
Safety: Chestnuts can trigger tree-nut allergy, including potentially life-threatening anaphylaxis; people allergic to tree nuts should avoid them, and there is notable cross-reactivity between chestnut and natural rubber latex (latex-fruit syndrome). Like all nuts they are calorie-dense, though chestnuts are lower in fat and calories than most tree nuts. Whole or large pieces are a choking hazard for young children. Note distinctions across nuts: Brazil nuts are extremely high in selenium (limit to roughly 1-3 per day to avoid selenium toxicity), peanuts are a legume rather than a true tree nut and can carry aflatoxin contamination if poorly stored, and raw horse chestnuts (Aesculus, a different plant) are toxic and must not be confused with edible sweet chestnuts.

Cited studies (9):
  - Tree Nut and Peanut Consumption and Risk of Cardiovascular Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials, Advances in nutrition (Bethesda, Md.) (2023) — Pooled randomized trials showed tree-nut and peanut consumption significantly lowered LDL cholesterol, total cholesterol, triglycerides, apoB and the TC:HDL and LDL:HDL ratios, supporting an overall CVD risk-reduction signal (certainty of evidence mostly low to moderate). [https://pubmed.ncbi.nlm.nih.gov/37149262/]
  - Tree Nut and Peanut Consumption and Risk of Cardiovascular Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials, Advances in nutrition (Bethesda, Md.) (2023) — Systematic review and meta-analysis of RCTs of tree nut and peanut consumption confirmed favorable effects on cardiovascular risk factors (blood lipids, blood pressure) supporting cardioprotection. [https://pmc.ncbi.nlm.nih.gov/articles/PMC10509427/]
  - Are fatty nuts a weighty concern? A systematic review and meta-analysis and dose-response meta-regression of prospective cohorts and randomized controlled trials, Obesity reviews : an official journal of the International Association for the Study of Obesity (2021) — Systematic review/meta-analysis of RCTs: despite being energy-dense, nut consumption produced small reductions in body weight (-0.22 kg), BMI (-0.16 kg/m2) and waist circumference (-0.51 cm), i.e. nuts are weight-neutral to slightly favorable. [https://pmc.ncbi.nlm.nih.gov/articles/PMC9285885/]
  - Effects of tree nuts on blood lipids, apolipoproteins, and blood pressure: systematic review, meta-analysis, and dose-response of 61 controlled intervention trials, The American journal of clinical nutrition (2015) — Meta-analysis of 61 RCTs (n=2,582): one 1-oz/day serving of tree nuts lowered LDL cholesterol by 4.8 mg/dL (95% CI -5.5 to -4.2) and total cholesterol by 4.7 mg/dL (95% CI -5.3 to -4.0), with dose (not nut type) the main determinant. [https://pubmed.ncbi.nlm.nih.gov/26561616/]
  - Nut consumption and risk of cardiovascular disease, total cancer, all-cause and cause-specific mortality: a systematic review and dose-response meta-analysis of prospective studies, BMC Medicine (2016) — Dose-response meta-analysis of prospective cohorts: 28 g/day nut intake was associated with 21% lower CVD risk (RR 0.79), 22% lower all-cause mortality (RR 0.78), and 15% lower total cancer (RR 0.85). [https://doi.org/10.1186/s12916-016-0730-3]
  - Effect of tree nuts on glycemic control in diabetes: a systematic review and meta-analysis of randomized controlled dietary trials, PloS one (2014) — Meta-analysis of 12 RCTs (n=450) in type 2 diabetes: tree nuts at a median 56 g/day significantly lowered HbA1c by 0.07% and fasting glucose by 0.15 mmol/L versus control diets. [https://pmc.ncbi.nlm.nih.gov/articles/PMC4116170/]
  - Primary Prevention of Cardiovascular Disease with a Mediterranean Diet Supplemented with Extra-Virgin Olive Oil or Nuts, The New England journal of medicine (2018) — In ~7,447 high-risk adults, a Mediterranean diet supplemented with mixed nuts reduced major cardiovascular events (MI, stroke, CV death) versus a control low-fat diet (HR ~0.72), though the benefit reflects mixed nuts within a dietary pattern, not chestnut specifically. [https://pubmed.ncbi.nlm.nih.gov/29897866/]
  - Possible Beneficial Effects of Hydrolyzable Tannins Deriving from Castanea sativa L. in Internal Medicine, Nutrients (2023) — Narrative review (Nutrients) of Castanea sativa hydrolyzable tannins (gallic/ellagic acid, ellagitannins) reports antioxidant, lipid-regulating, antimicrobial and cardioprotective (endothelial/vascular) actions, though human clinical evidence remains limited. [https://pmc.ncbi.nlm.nih.gov/articles/PMC10780656/]
  - Association of nut consumption with total and cause-specific mortality, The New England journal of medicine (2013) — Across ~119,000 adults followed up to 30 years, higher nut intake was associated with lower all-cause mortality and lower death from cardiovascular disease in a dose-dependent manner; observational, so causation is not proven. [https://pubmed.ncbi.nlm.nih.gov/24256379/]

---

## Acetyl-L-Carnitine (ALCAR)
URL: https://nutridex.info/s/acetyl-l-carnitine
Category: Nootropic, Longevity
Evidence: Moderate — Several controlled trials; effects real but modest or context-dependent.
Acetylated carnitine studied for nerve pain, mood and aging brain.

Quick answer: Acetyl-L-Carnitine (ALCAR) is used for ease diabetic nerve pain. NutriDex grades the human evidence as moderate — Several controlled trials; effects real but modest or context-dependent. Based on 8 cited human studies (8 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Acetyl-L-carnitine (ALCAR) is an acetylated form of carnitine that shuttles fatty acids into mitochondria and is more readily taken up by the brain than plain L-carnitine. Its best human evidence is for painful peripheral neuropathy: a 2015 meta-analysis of 4 RCTs (n=523) found a mean pain reduction of about 1.2 points on a 10-point scale versus placebo, with larger effects in diabetic patients, though a 2019 Cochrane review judged the evidence very low certainty. A 2018 meta-analysis (12 RCTs, 791 people) reported a moderate-to-large drop in depressive symptoms, but heterogeneity was high. Older trials suggest modest cognitive benefit in mild cognitive impairment and early Alzheimer's, and carnitine supplements improve some sperm parameters. Effect sizes vary widely and many trials are small or industry-linked, so ALCAR is a reasonable adjunct rather than a proven treatment.

Benefits / uses: Ease diabetic nerve pain; Reduce depressive symptoms; Support cognition in older adults; Improve sperm motility.
Active compounds: Acetyl-L-carnitine; L-carnitine (metabolite).
Dose: 1,500–3,000 mg/day of acetyl-L-carnitine, usually split into 2–3 doses; neuropathy and cognition trials used the upper end.
Safety: Generally well tolerated; the most common side effects are nausea, vomiting, abdominal cramps, diarrhea and a fishy body odor at higher doses, plus occasional agitation or insomnia. It may lower seizure threshold and has been linked to increased seizure frequency, so use caution in epilepsy. Carnitine can interact with thyroid hormone (it may blunt thyroid action, a concern in hypothyroidism) and theoretically with warfarin and other anticoagulants, raising bleeding risk; people on thyroid or blood-thinning medication should consult a clinician first. Long-term carnitine intake raises the gut metabolite TMAO, whose cardiovascular relevance is still debated.

Cited studies (8):
  - Therapeutic potential of carnitine and N-Acetyl-Cysteine supplementation on sperm parameters and pregnancy outcomes in idiopathic male infertility: A systematic review and meta-analysis of randomized control trials, Reproduction and Breeding (2025) — Meta-analysis (14 RCTs, 1,453 men): L-acetyl-carnitine improved total and forward sperm motility in idiopathic male infertility. [https://doi.org/10.1016/j.repbre.2025.02.002]
  - Acetyl-L-carnitine in the treatment of peripheral neuropathic pain: a systematic review and meta-analysis of randomized controlled trials, PloS one (2015) — Meta-analysis of 4 RCTs (n=523): ALCAR cut neuropathic pain by ~1.2 VAS points vs placebo; larger in diabetic patients (MD 1.47). [https://pubmed.ncbi.nlm.nih.gov/25751285/]
  - Acetyl-L-carnitine for the treatment of diabetic peripheral neuropathy, The Cochrane database of systematic reviews (2019) — Cochrane review (4 RCTs, 907 patients): ALCAR reduced diabetic neuropathy pain (MD -14.9 VAS at >1500mg/day) but evidence was 'very low certainty'. [https://pubmed.ncbi.nlm.nih.gov/31201734/]
  - Acetyl-L-Carnitine Supplementation and the Treatment of Depressive Symptoms: A Systematic Review and Meta-Analysis, Psychosomatic medicine (2018) — Meta-analysis of 12 RCTs (n=791): ALCAR lowered depressive symptoms vs placebo (SMD -1.10) with efficacy similar to antidepressants but high heterogeneity (I2 86%). [https://pubmed.ncbi.nlm.nih.gov/29076953/]
  - Meta-analysis of double blind randomized controlled clinical trials of acetyl-L-carnitine versus placebo in the treatment of mild cognitive impairment and mild Alzheimer's disease, International clinical psychopharmacology (2003) — Meta-analysis of double-blind RCTs (1.5–3 g/day) found a significant cognitive benefit of ALCAR over placebo in mild cognitive impairment and mild Alzheimer's. [https://pubmed.ncbi.nlm.nih.gov/12598816/]
  - Acetyl-L-carnitine for dementia, The Cochrane database of systematic reviews (2003) — Cochrane review found no convincing evidence that ALCAR meaningfully slows clinical progression of dementia despite small test-score signals. [https://pubmed.ncbi.nlm.nih.gov/12804452/]
  - Effects of acetyl-L-carnitine and methylcobalamin for diabetic peripheral neuropathy: A multicenter, randomized, double-blind, controlled trial, Journal of diabetes investigation (2016) — Multicenter double-blind RCT (n=232): ALCAR 1.5g/day matched methylcobalamin for improving diabetic neuropathy symptom and disability scores over 24 weeks. [https://pubmed.ncbi.nlm.nih.gov/27180954/]
  - Acetyl-L-Carnitine in Dementia and Other Cognitive Disorders: A Critical Update, Nutrients (2020) — Critical update review concludes ALCAR shows neuroprotective and antidepressant signals but trials remain small, short and methodologically limited. [https://pubmed.ncbi.nlm.nih.gov/32408706/]

---

## Agaricus blazei (Agaricus subrufescens)
URL: https://nutridex.info/s/agaricus
Category: Gut & Immune
Evidence: Preliminary — Early or small human trials; promising but not yet conclusive.
Beta-glucan mushroom studied as an immune and metabolic adjunct.

Quick answer: Agaricus blazei is used for immune modulation. NutriDex grades the human evidence as preliminary — Early or small human trials; promising but not yet conclusive. Based on 9 cited human studies (9 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Agaricus blazei (now classified as Agaricus subrufescens) is a Brazilian medicinal mushroom rich in beta-glucans, marketed for immune and anticancer support. Human evidence is real but early. A 12-week RCT in type 2 diabetes (n=72) found 1500 mg/day added to metformin/gliclazide improved HOMA-IR and raised adiponectin ~20% versus a fall on placebo. In gynecological cancer patients on chemotherapy, an extract raised natural-killer-cell activity and eased side effects. Randomized AndoSan trials in IBD and multiple myeloma shifted cytokine and immune-cell profiles, and a myeloma trial showed no survival benefit. Most studies are small, short, use one branded product, and report lab markers rather than tumor or survival endpoints. It is best viewed as an investigational adjunct, not a proven treatment, and standardization between products varies widely.

Benefits / uses: Immune modulation; Lower insulin resistance; Reduce gut inflammation markers; Chemotherapy side-effect support.
Active compounds: Beta-glucans (1,3/1,6); Proteoglycans; Ergosterol; Oligosaccharides.
Dose: Most trials used 1500 mg/day of standardized extract, or ~60 mL/day of the AndoSan liquid extract, for 6–12 weeks.
Safety: Generally well tolerated short-term, with mild nausea, diarrhea or itching most common. The serious concern is hepatotoxicity: case reports describe severe drug-induced liver injury and fatal fulminant hepatitis, mostly in cancer patients, so stop and seek care for jaundice, dark urine or right-upper-abdominal pain, and avoid in liver disease. Because it can lower blood sugar and modulate immunity, use caution with antidiabetic drugs (additive hypoglycemia) and immunosuppressants, and discuss with an oncologist before combining with chemotherapy. Avoid in pregnancy and breastfeeding due to lack of data.

Cited studies (9):
  - Immunomodulatory effects of the Agaricus blazei Murrill-based mushroom extract AndoSan in patients with multiple myeloma undergoing high dose chemotherapy and autologous stem cell transplantation: a randomized, double blinded clinical study, BioMed research international (2015) — AndoSan in myeloma stem-cell transplant raised Treg and plasmacytoid dendritic cells and IL-1ra/IL-5/IL-7, but no survival or response benefit. [https://pubmed.ncbi.nlm.nih.gov/25664323/]
  - Cytokine Levels After Consumption of a Medicinal Agaricus blazei Murill-Based Mushroom Extract, AndoSan(™) , in Patients with Crohn's Disease and Ulcerative Colitis in a Randomized Single-Blinded Placebo-Controlled Study, Scandinavian journal of immunology (2016) — AndoSan lowered combined IL-1ß/IL-6/G-CSF in Crohn's and IL-2/IL-5/MIP-1ß in ulcerative colitis vs placebo (n=50 IBD patients). [https://pubmed.ncbi.nlm.nih.gov/27588816/]
  - Effect of an extract based on the medicinal mushroom Agaricus blazei Murill on expression of cytokines and calprotectin in patients with ulcerative colitis and Crohn's disease, Scandinavian journal of immunology (2011) — AndoSan reduced pro-inflammatory cytokine and fecal calprotectin expression in patients with ulcerative colitis and Crohn's disease. [https://pubmed.ncbi.nlm.nih.gov/21129005/]
  - Phase I Clinical Study of the Dietary Supplement, Agaricus blazei Murill, in Cancer Patients in Remission, Evidence-based complementary and alternative medicine : eCAM (2011) — Phase I trial in cancer patients in remission: oral ABM extract was tolerated and increased NK activity, with no dose-limiting toxicity. [https://pmc.ncbi.nlm.nih.gov/articles/PMC3092499/]
  - The mushroom Agaricus Blazei Murill in combination with metformin and gliclazide improves insulin resistance in type 2 diabetes: a randomized, double-blinded, and placebo-controlled clinical trial, Journal of alternative and complementary medicine (New York, N.Y.) (2007) — 1500 mg/day for 12 wk added to metformin/gliclazide improved HOMA-IR; adiponectin rose ~20% vs −12% on placebo (n=72, p<0.001). [https://pubmed.ncbi.nlm.nih.gov/17309383/]
  - Natural killer cell activity and quality of life were improved by consumption of a mushroom extract, Agaricus blazei Murill Kyowa, in gynecological cancer patients undergoing chemotherapy, International journal of gynecological cancer : official journal of the International Gynecological Cancer Society (2004) — ABMK extract raised NK-cell activity (p<0.002) and reduced appetite loss, alopecia and weakness in gynecological-cancer patients on chemo (n=100). [https://pubmed.ncbi.nlm.nih.gov/15304151/]
  - Drug-induced liver injury associated with Agaricus blazei Murill which is very similar to autoimmune hepatitis, Clinical journal of gastroenterology (2013) — Case report: drug-induced liver injury from Agaricus blazei Murill resembling autoimmune hepatitis, resolving after withdrawal. [https://pubmed.ncbi.nlm.nih.gov/26181451/]
  - An alternative medicine, Agaricus blazei, may have induced severe hepatic dysfunction in cancer patients, Japanese journal of clinical oncology (2006) — Case series: 3 advanced-cancer patients on Agaricus blazei extract developed severe hepatic dysfunction; 2 died of fulminant hepatitis. [https://pubmed.ncbi.nlm.nih.gov/17105737/]
  - Agaricus blazei Bioactive Compounds and their Effects on Human Health: Benefits and Controversies, Current pharmaceutical design (2017) — Review: beta-glucans are the main active compounds; basic data abundant but only ~17 clinical studies, calling for standardized RCTs. [https://pubmed.ncbi.nlm.nih.gov/28103773/]

---

## Algal Oil (Vegan Omega-3) (Schizochytrium)
URL: https://nutridex.info/s/algae-oil
Category: Heart & Metabolic
Evidence: Moderate — Several controlled trials; effects real but modest or context-dependent.
Plant-based DHA/EPA that matches fish oil for blood omega-3.

Quick answer: Algal Oil (Vegan Omega-3) is used for lower triglycerides. NutriDex grades the human evidence as moderate — Several controlled trials; effects real but modest or context-dependent. Based on 7 cited human studies (7 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Algal oil is omega-3 (DHA, often with EPA) grown from microalgae like Schizochytrium, giving vegans and vegetarians a fish-free source. Bioavailability trials show algal DHA raises plasma and red-cell omega-3 as effectively as cooked salmon or fish-oil capsules, with a 2025 RCT reporting non-inferiority (geometric mean ratio ~112%). A meta-analysis of 11 RCTs (median 1.68 g DHA/day) found triglycerides fell ~0.20 mmol/L, HDL rose slightly, but LDL also rose ~0.23 mmol/L. A microalgal DHA+EPA oil cut triglycerides about 19% in hypertriglyceridemia, matching fish oil. In pregnancy, omega-3 (including algal) supplementation modestly lowers preterm birth. Cognitive benefits in older adults are smaller and less consistent. Most evidence rests on biomarkers rather than hard cardiovascular endpoints, and the LDL signal warrants attention.

Benefits / uses: Lower triglycerides; Raise omega-3 index; Vegan DHA/EPA source; Support pregnancy DHA needs.
Active compounds: Docosahexaenoic acid (DHA); Eicosapentaenoic acid (EPA).
Dose: About 1–2 g/day combined DHA+EPA from Schizochytrium oil; 200–1000 mg DHA/day in pregnancy.
Safety: Generally well tolerated; common effects are fishy aftertaste, burping, and loose stools. High DHA-dominant doses can raise LDL-cholesterol modestly, so monitor lipids. Omega-3s have mild antiplatelet activity and may add to bleeding risk with anticoagulants or antiplatelets (warfarin, DOACs, aspirin, clopidogrel), especially at >3 g/day. Algal oil avoids fish-allergen and mercury concerns, but allergy to the source algae is possible; check with a clinician if you take blood thinners or have a bleeding disorder.

Cited studies (7):
  - Omega-3 fatty acid addition during pregnancy, Cochrane Database of Systematic Reviews (2018) — Review (70 RCTs): omega-3 (incl. algal) in pregnancy lowered preterm birth <37wk (13.4%→11.9%) and <34wk (4.6%→2.7%). [https://doi.org/10.1002/14651858.CD003402.pub3]
  - A meta-analysis shows that docosahexaenoic acid from algal oil reduces serum triglycerides and increases HDL-cholesterol and LDL-cholesterol in persons without coronary heart disease, The Journal of nutrition (2012) — Meta-analysis (11 RCTs, n=485): algal DHA lowered triglycerides 0.20 mmol/L but raised LDL 0.23 and HDL 0.07 mmol/L. [https://pubmed.ncbi.nlm.nih.gov/22113870/]
  - Comparative Bioavailability of DHA and EPA from Microalgal and Fish Oil in Adults, International journal of molecular sciences (2025) — RCT (n=74): microalgal oil non-inferior to fish oil for DHA+EPA in plasma phospholipids (mean ratio 112%) at 6 and 14 weeks. [https://pubmed.ncbi.nlm.nih.gov/41096614/]
  - A new, microalgal DHA- and EPA-containing oil lowers triacylglycerols in adults with mild-to-moderate hypertriglyceridemia, Prostaglandins, leukotrienes, and essential fatty acids (2014) — RCT (n=93): microalgal DHA+EPA oil 2.4 g/day cut triglycerides ~18.9% vs control, not different from standard fish oil over 14 weeks. [https://pubmed.ncbi.nlm.nih.gov/25123060/]
  - Beneficial effects of docosahexaenoic acid on cognition in age-related cognitive decline, Alzheimer's & dementia : the journal of the Alzheimer's Association (2010) — RCT (n=485): 900 mg/day algal DHA for 24 weeks improved learning/memory (PAL errors) in older adults with memory complaints. [https://pubmed.ncbi.nlm.nih.gov/20434961/]
  - Algal-oil capsules and cooked salmon: nutritionally equivalent sources of docosahexaenoic acid, Journal of the American Dietetic Association (2008) — RCT (n=32): 600 mg/day algal-oil DHA raised blood DHA equivalently to cooked salmon over 2 weeks. [https://pubmed.ncbi.nlm.nih.gov/18589030/]
  - Bioequivalence of Docosahexaenoic acid from different algal oils in capsules and in a DHA-fortified food, Lipids (2007) — RCT: algal DHA capsules raised plasma phospholipid DHA dose-dependently (1.17 to 3.03 g/100g) across 200–1000 mg/day over 28 days. [https://pubmed.ncbi.nlm.nih.gov/17713804/]

---

## Apigenin
URL: https://nutridex.info/s/apigenin
Category: Sleep & Mood, Longevity
Evidence: Preliminary — Early or small human trials; promising but not yet conclusive.
Chamomile's calming flavonoid, popular for sleep and anti-aging.

Quick answer: Apigenin is used for mild calming / anxiety relief. NutriDex grades the human evidence as preliminary — Early or small human trials; promising but not yet conclusive. Based on 7 cited human studies (7 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Apigenin is a plant flavonoid concentrated in chamomile, parsley, celery and artichoke. In the lab it suppresses inflammatory signaling (NF-kB, p38-MAPK) and dampens the secretions of aging 'senescent' cells, which drives its popularity as a sleep and longevity supplement; it also shows GABA-receptor activity in rodents. Human evidence is thin and indirect. Trials use chamomile extract rather than pure apigenin: an 8-week RCT in generalized anxiety disorder found a modestly greater drop in anxiety scores than placebo (n=57, p=0.047), and a meta-analysis of 12 trials (965 people) saw benefit for anxiety and sleep quality but little effect on insomnia. A chamomile insomnia pilot found no improvement in objective sleep. No controlled trial has tested isolated apigenin for sleep or aging endpoints, and oral bioavailability is poor.

Benefits / uses: Mild calming / anxiety relief; Support for sleep quality; Theorized anti-aging (senomorphic); Antioxidant & anti-inflammatory.
Active compounds: Apigenin (4',5,7-trihydroxyflavone); Apigenin-7-glucoside.
Dose: No established dose; supplements provide 50 mg once daily, often at night. Most human data come from chamomile extract standardized to ~1.2% apigenin (1100-1500 mg/day).
Safety: Apigenin is generally well tolerated at typical supplement doses and is consumed in foods, but long-term safety of concentrated supplements is untested. It inhibits CYP enzymes and may raise levels of drugs metabolised by them; theoretically it can add to the effects of sedatives, anticoagulants/antiplatelets and antidiabetic drugs. Chamomile sources can trigger allergy in people sensitive to ragweed, daisies or marigolds, and high doses are best avoided in pregnancy and before surgery.

Cited studies (7):
  - Potential therapeutic effects of apigenin for colorectal adenocarcinoma: A systematic review and meta-analysis, Cancer medicine (2024) — Systematic review/meta-analysis of apigenin for colorectal adenocarcinoma: anticancer effects shown only in vitro and in animal models, no human data. [https://pubmed.ncbi.nlm.nih.gov/39254067/]
  - Therapeutic efficacy and safety of chamomile for state anxiety, generalized anxiety disorder, insomnia, and sleep quality: A systematic review and meta-analysis of randomized trials and quasi-randomized trials, Phytotherapy research : PTR (2019) — Meta-analysis of 12 RCTs (965 patients): chamomile improved generalized anxiety and sleep quality, but minimal effect on state anxiety and insomnia. [https://pubmed.ncbi.nlm.nih.gov/31006899/]
  - Long-term chamomile (Matricaria chamomilla L.) treatment for generalized anxiety disorder: A randomized clinical trial, Phytomedicine : international journal of phytotherapy and phytopharmacology (2016) — Long-term chamomile RCT: responders kept lower GAD symptoms than placebo (p=0.0032), but relapse hazard was not significantly reduced (HR 0.52, p=0.16). [https://pubmed.ncbi.nlm.nih.gov/27912875/]
  - Preliminary examination of the efficacy and safety of a standardized chamomile extract for chronic primary insomnia: a randomized placebo-controlled pilot study, BMC complementary and alternative medicine (2011) — Pilot RCT of chamomile for chronic insomnia (n=34): no significant change in total sleep time, efficiency, latency or awakenings vs placebo. [https://pubmed.ncbi.nlm.nih.gov/21939549/]
  - A randomized, double-blind, placebo-controlled trial of oral Matricaria recutita (chamomile) extract therapy for generalized anxiety disorder, Journal of clinical psychopharmacology (2009) — 8-week RCT of chamomile extract (1.2% apigenin) in GAD: significantly greater HAM-A reduction vs placebo (n=57, p=0.047), modest effect. [https://pubmed.ncbi.nlm.nih.gov/19593179/]
  - Apigenin: a natural molecule at the intersection of sleep and aging, Frontiers in nutrition (2024) — Review: apigenin shows GABAergic and senomorphic activity in animals; human sleep data are correlational and aging effects untested in people. [https://pubmed.ncbi.nlm.nih.gov/38476603/]
  - The Therapeutic Potential of Apigenin, International journal of molecular sciences (2019) — Review notes abundant in-vitro data but 'extremely small' number of human trials, with high inter-individual variability limiting conclusions. [https://pubmed.ncbi.nlm.nih.gov/30875872/]

---

## BCAAs (Branched-Chain Amino Acids)
URL: https://nutridex.info/s/bcaa
Category: Performance
Evidence: Mixed — Conflicting results across studies; benefit uncertain.
Leucine, isoleucine & valine — popular for recovery, but not muscle-building on their own.

Quick answer: BCAAs is used for reduce muscle soreness (doms). NutriDex grades the human evidence as mixed — Conflicting results across studies; benefit uncertain. Based on 7 cited human studies (7 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

BCAAs are three essential amino acids — leucine, isoleucine and valine — sold for muscle growth, recovery and reduced fatigue. The evidence is genuinely split. Meta-analyses show BCAA supplementation meaningfully lowers delayed-onset muscle soreness (effect size ~0.7) and the muscle-damage marker creatine kinase, but has no effect on lactate dehydrogenase or actual exercise performance. Crucially, controlled tracer studies show that taking BCAAs alone raises muscle protein synthesis only ~22% — roughly half the response to an equivalent dose of whey — because building muscle requires all nine essential amino acids, not just three. A leading review concluded the claim that dietary BCAAs alone are anabolic is 'unwarranted.' In cirrhosis, BCAAs do improve hepatic encephalopathy symptoms (Cochrane), though without lowering mortality. For most well-fed people eating enough protein, BCAAs add little over food or whey.

Benefits / uses: Reduce muscle soreness (DOMS); Lower creatine kinase after exercise; Support liver disease (HE symptoms); May blunt training fatigue.
Active compounds: L-Leucine; L-Isoleucine; L-Valine.
Dose: Commonly 5–20 g/day (often 2:1:1 leucine:isoleucine:valine), taken around training; effects are modest and a complete protein usually does the job better.
Safety: BCAAs are generally well tolerated and recognized as safe at typical doses; high intakes can cause nausea, GI upset or fatigue. Observational data link high circulating BCAA levels to insulin resistance and type 2 diabetes risk, though this likely reflects impaired metabolism rather than harm from supplements — caution and glucose monitoring are still reasonable in diabetes. Because BCAAs compete with other amino acids for transport, they may theoretically reduce absorption of L-DOPA (levodopa) in Parkinson's disease; people on protein-restricted diets, with maple syrup urine disease, or with advanced kidney disease should avoid them without medical advice.

Cited studies (7):
  - Attenuating Muscle Damage Biomarkers and Muscle Soreness After an Exercise-Induced Muscle Damage with Branched-Chain Amino Acid (BCAA) Supplementation: A Systematic Review and Meta-analysis with Meta-regression, Sports medicine - open (2024) — Meta-analysis with meta-regression (18 studies): BCAAs cut creatine kinase and soreness; no effect on LDH; higher dose/longer use worked best. [https://pubmed.ncbi.nlm.nih.gov/38625669/]
  - Branched-Chain Amino Acids Supplementation and Post-Exercise Recovery: An Overview of Systematic Reviews, Journal of the American Nutrition Association (2024) — Umbrella review of systematic reviews: BCAAs reduce muscle-damage markers and soreness but do NOT improve muscle performance recovery. [https://pubmed.ncbi.nlm.nih.gov/38241335/]
  - Does Branched-Chain Amino Acids (BCAAs) Supplementation Attenuate Muscle Damage Markers and Soreness after Resistance Exercise in Trained Males? A Meta-Analysis of Randomized Controlled Trials, Nutrients (2021) — Meta-analysis (9 RCTs) in trained males: BCAAs lowered creatine kinase at all timepoints and soreness within 24h; no LDH benefit. [https://pubmed.ncbi.nlm.nih.gov/34072718/]
  - Effect of branched-Chain Amino Acid Supplementation on Muscle Soreness following Exercise: A Meta-Analysis, International journal for vitamin and nutrition research. Internationale Zeitschrift fur Vitamin- und Ernahrungsforschung. Journal international de vitaminologie et de nutrition (2019) — Meta-analysis (8 studies, 37 effects): BCAAs reduced DOMS after exercise (ES=0.73, 95% CI 0.50–0.96, p<0.001). [https://pubmed.ncbi.nlm.nih.gov/30938579/]
  - Branched-chain amino acids for people with hepatic encephalopathy, The Cochrane database of systematic reviews (2017) — 18 RCTs: BCAAs improved hepatic encephalopathy (RR 0.73, 95% CI 0.61–0.88) but no mortality benefit (RR 0.88, 95% CI 0.69–1.11). [https://pubmed.ncbi.nlm.nih.gov/28518283/]
  - Branched-Chain Amino Acid Ingestion Stimulates Muscle Myofibrillar Protein Synthesis following Resistance Exercise in Humans, Frontiers in physiology (2017) — 5.6 g BCAA after resistance exercise raised myofibrillar protein synthesis 22% vs placebo — about half the response to a matched dose of whey (n=10). [https://pubmed.ncbi.nlm.nih.gov/28638350/]
  - Branched-chain amino acids and muscle protein synthesis in humans: myth or reality?, Journal of the International Society of Sports Nutrition (2017) — Review concluded the claim that dietary BCAAs alone stimulate muscle protein synthesis or produce an anabolic response in humans is 'unwarranted'. [https://pubmed.ncbi.nlm.nih.gov/28852372/]

---

## Betaine (TMG) (Trimethylglycine)
URL: https://nutridex.info/s/betaine-tmg
Category: Performance, Heart & Metabolic
Evidence: Moderate — Several controlled trials; effects real but modest or context-dependent.
Methyl donor that lowers homocysteine and may aid lower-body strength.

Quick answer: Betaine (TMG) is used for lower plasma homocysteine. NutriDex grades the human evidence as moderate — Several controlled trials; effects real but modest or context-dependent. Based on 8 cited human studies (8 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Betaine (trimethylglycine, TMG) is a methyl donor found in beets and whole grains. Its best-replicated effect is lowering plasma homocysteine: a meta-analysis of 5 RCTs found 4-6 g/day cut it by about 1.23 micromol/L (~12%). Whether this translates to fewer heart events is unproven, and the same and later meta-analyses show betaine moderately raises total and LDL cholesterol (~14 and ~10 mg/dL), which may offset any benefit. For exercise, a 2024 meta-analysis (17 trials) found a small significant gain in maximal strength, concentrated in the lower body (ES ~0.49), with no effect on upper-body or power measures. Body-composition results conflict outright: one meta-analysis found modest body-fat loss, another found none. A 12-month NASH trial improved liver steatosis on imaging but not fibrosis. Overall: a real but narrow biomarker and strength effect, no hard outcomes.

Benefits / uses: Lower plasma homocysteine; Lower-body strength & power; Support liver fat metabolism; Osmolyte / cell hydration.
Active compounds: Trimethylglycine (anhydrous betaine).
Dose: 2.5 g/day (split) for performance; 4-6 g/day to lower homocysteine. Betaine HCl is a separate digestive product, not interchangeable.
Safety: Generally well tolerated; at high doses (>4-6 g/day) it can cause nausea, diarrhea, GI upset and a fishy body odor (trimethylaminuria). Its main concern is raising total and LDL cholesterol, so people with dyslipidemia or cardiovascular risk should be cautious. No major drug interactions are established, but because it lowers homocysteine it may add to the effect of B-vitamins/folate; the high-dose prescription form (Cystadane, for inborn homocystinuria) has rarely caused cerebral edema. Discuss with a clinician if you have heart disease, kidney disease, or are pregnant.

Cited studies (8):
  - Effects of chronic betaine supplementation on exercise performance: Systematic review and meta-analysis, Journal of sports sciences (2024) — Meta-analysis of 17 trials (317 participants): chronic betaine raised maximal strength (ES 0.47), driven by lower body (ES 0.49); no effect on upper-body or power. [https://pubmed.ncbi.nlm.nih.gov/39514262/]
  - Effects of betaine supplementation on cardiovascular markers: A systematic review and Meta-analysis, Critical reviews in food science and nutrition (2022) — Meta-analysis: betaine lowered homocysteine (-1.30 micromol/L) but raised total cholesterol (+14.1 mg/dL) and LDL (+10.3 mg/dL); no effect on BP, glucose, CRP. [https://pubmed.ncbi.nlm.nih.gov/33764214/]
  - Betaine supplementation fails to improve body composition: a systematic review and meta-analysis, British Journal of Nutrition (2021) — Conflicting meta-analysis: betaine failed to significantly affect body mass, BMI, body-fat %, fat mass or fat-free mass. [https://doi.org/10.1017/S0007114521004062]
  - Effect of Betaine on Reducing Body Fat-A Systematic Review and Meta-Analysis of Randomized Controlled Trials, Nutrients (2019) — Meta-analysis of 6 RCTs (195 participants): betaine reduced body-fat mass (-2.53 kg) and body-fat % (-2.44%), but no change in body weight or BMI. [https://pubmed.ncbi.nlm.nih.gov/31623137/]
  - Betaine supplementation decreases plasma homocysteine in healthy adult participants: a meta-analysis, Journal of chiropractic medicine (2013) — Meta-analysis of 5 RCTs: 4-6 g/day betaine for 6-24 wk lowered plasma homocysteine by 1.23 micromol/L (~11.8%) in healthy adults. [https://pubmed.ncbi.nlm.nih.gov/23997720/]
  - The effects of chronic betaine supplementation on body composition and performance in collegiate females: a double-blind, randomized, placebo controlled trial, Journal of the International Society of Sports Nutrition (2018) — 9-week RCT in untrained collegiate females (n=23): 2.5 g/day betaine cut body-fat % and fat mass vs placebo, but did not improve absolute strength. [https://pubmed.ncbi.nlm.nih.gov/30064450/]
  - Betaine for nonalcoholic fatty liver disease: results of a randomized placebo-controlled trial, Hepatology (Baltimore, Md.) (2009) — 12-month RCT (n=55 biopsy-proven NASH): 20 g/day betaine improved hepatic steatosis vs placebo but did not improve inflammation or fibrosis. [https://pubmed.ncbi.nlm.nih.gov/19824078/]
  - Effect of homocysteine-lowering nutrients on blood lipids: results from four randomised, placebo-controlled studies in healthy humans, PLoS medicine (2005) — RCT: 6 g/day betaine for 6 wk raised LDL cholesterol by 0.36 mmol/L and triacylglycerol in healthy adults, potentially offsetting homocysteine benefit. [https://pubmed.ncbi.nlm.nih.gov/15916468/]

---

## Bitter Melon (Momordica charantia)
URL: https://nutridex.info/s/bitter-melon
Category: Heart & Metabolic
Evidence: Mixed — Conflicting results across studies; benefit uncertain.
A traditional anti-diabetic gourd whose blood-sugar trials disagree.

Quick answer: Bitter Melon is used for lower blood sugar. NutriDex grades the human evidence as mixed — Conflicting results across studies; benefit uncertain. Based on 8 cited human studies (8 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Bitter melon is a tropical gourd long used in Asian and Caribbean folk medicine for diabetes. Mechanistically it contains insulin-like compounds (polypeptide-p) and charantin, and lab studies suggest improved glucose uptake. Human trials, however, conflict. A 2014 meta-analysis (4 RCTs, 208 patients) found no significant effect on HbA1c (-0.13%, NS) or fasting glucose, and a larger 2024 analysis (9 RCTs, 414 patients) reached the same null conclusion. Other reviews report small but statistically significant drops: Peter 2019 found HbA1c -0.26% and fasting glucose -0.72 mmol/L, and a 2025 GRADE review found modest improvements rated low to very-low quality. In a head-to-head trial, 2,000 mg/day was clearly weaker than metformin. Trials are short (4-16 weeks), small, and use inconsistent preparations. The net signal is at best a weak adjunct effect, not a proven treatment.

Benefits / uses: Lower blood sugar; Modest HbA1c reduction (uncertain); Improve insulin sensitivity.
Active compounds: Charantin; Polypeptide-p (plant insulin); Vicine; Cucurbitane triterpenoids.
Dose: Most trials use ~2,000 mg/day of dried fruit extract in divided doses; no standardized formulation exists.
Safety: Generally well tolerated short-term; the commonest effects are GI upset, abdominal pain and diarrhea. Because it can lower blood glucose, it may cause additive hypoglycemia with insulin, sulfonylureas or metformin, so diabetics should monitor closely. The seeds contain vicine and can trigger 'favism' (hemolytic anemia) in people with G6PD deficiency, and severe hypoglycemia, convulsions and coma have been reported in children. Avoid in pregnancy (traditionally used as an abortifacient and shown to be a uterine stimulant) and during breastfeeding; stop medicinal doses about 2 weeks before surgery.

Cited studies (8):
  - The metabolic effect of Momordica charantia cannot be determined based on the available clinical evidence: a systematic review and meta-analysis of randomized clinical trials, Frontiers in nutrition (2023) — 9 RCTs (n=414): negligible effect on HbA1c (MD -0.12) and fasting glucose (MD -0.03); effect 'cannot be determined'. [https://pubmed.ncbi.nlm.nih.gov/38274207/]
  - Efficacy of Momordica charantia in glycaemic control and insulin resistance among patients with prediabetes and type 2 diabetes. A GRADE-adherent meta-analysis of randomised controlled trials, Metabolism Open (2025) — GRADE meta-analysis, 25 trials: lower FBG (SMD -0.46), HbA1c (SMD -0.57) and HOMA-IR (SMD -0.52); certainty low to very low. [https://doi.org/10.1016/j.metop.2025.100407]
  - Momordica charantia L. lowers elevated glycaemia in type 2 diabetes mellitus patients: Systematic review and meta-analysis, Journal of ethnopharmacology (2019) — 10 studies (n=1045): significant but small reductions in FPG -0.72 mmol/L, PPG -1.43 mmol/L, HbA1c -0.26%; low-quality evidence. [https://pubmed.ncbi.nlm.nih.gov/30385422/]
  - Mutations in the leptin receptor gene associated with delayed onset of puberty are also associated with decreased ovulation and lambing rates in prolific Davisdale sheep, Reproduction, fertility, and development (2016) — Meta-analysis of 4 RCTs (n=208): no significant effect on A1c (WMD -0.13%, 95% CI -0.41 to 0.16) or fasting glucose. [https://pubmed.ncbi.nlm.nih.gov/25688474/]
  - Momordica charantia Administration Improves Insulin Secretion in Type 2 Diabetes Mellitus, Journal of medicinal food (2018) — RCT (n=24): 2000 mg/day for 3 months lowered HbA1c and 2-h glucose and increased insulin secretion vs placebo. [https://pubmed.ncbi.nlm.nih.gov/29431598/]
  - Bitter gourd reduces elevated fasting plasma glucose levels in an intervention study among prediabetics in Tanzania, Journal of ethnopharmacology (2018) — Crossover RCT in prediabetes (n=52): bitter gourd modestly lowered fasting plasma glucose by 0.31 mmol/L (p=0.031). [https://pubmed.ncbi.nlm.nih.gov/29339109/]
  - Hypoglycemic effect of bitter melon compared with metformin in newly diagnosed type 2 diabetes patients, Journal of ethnopharmacology (2011) — 4-week RCT: bitter melon 2000 mg/day cut fructosamine -10.2 umol/L vs metformin's -16.8; hypoglycemic effect weaker than metformin. [https://pubmed.ncbi.nlm.nih.gov/21211558/]
  - Bitter melon (Momordica charantia): a review of efficacy and safety, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists (2003) — Review of efficacy and safety: only small, non-randomized trials show moderate hypoglycemia; flags favism and pediatric hypoglycemic coma. [https://pubmed.ncbi.nlm.nih.gov/12625217/]

---

## Black Cohosh (Actaea racemosa)
URL: https://nutridex.info/s/black-cohosh
Category: Sleep & Mood
Evidence: Mixed — Conflicting results across studies; benefit uncertain.
Popular menopause herb for hot flashes — but trials disagree.

Quick answer: Black Cohosh is used for menopausal hot flashes. NutriDex grades the human evidence as mixed — Conflicting results across studies; benefit uncertain. Based on 7 cited human studies (7 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Black cohosh is a North American woodland rhizome marketed for menopausal symptoms, especially hot flashes. The evidence is genuinely split. A 2012 Cochrane review of 16 randomized trials (2,027 women) found no significant difference from placebo in hot-flash frequency or symptom scores, and large NIH-funded trials such as Geller 2009 were null (34% reduction with black cohosh vs 63% with placebo over 12 months). Yet a 2010 meta-analysis reported a 26% improvement in vasomotor symptoms (95% CI 11–40%), and industry-linked meta-analyses of one isopropanolic extract (iCR) claim a moderate-to-large effect (SMD ~-0.69). Effects, when seen, are modest and the herb is not estrogenic. It is not a substitute for hormone therapy. Quality varies widely between products, which partly explains the inconsistent results.

Benefits / uses: Menopausal hot flashes; Night sweats; Menopausal mood & irritability; Sleep disturbance in menopause.
Active compounds: Triterpene glycosides (e.g. actein, 27-deoxyactein); Cimicifugic acids; Fukinolic acid.
Dose: 20–40 mg of standardized rhizome extract once or twice daily; isopropanolic (iCR) and ethanolic extracts are the most-studied forms.
Safety: Generally well tolerated; the most common effects are GI upset, headache, rash and mild weight gain. Rare but serious idiosyncratic liver injury — including cases of acute liver failure requiring transplant — has been reported, so stop and seek care for jaundice, dark urine, or right-upper-abdominal pain (NIH LiverTox likelihood score A). Avoid in pregnancy, breastfeeding, and active or hormone-sensitive cancers until cleared by a clinician; use caution alongside other hepatotoxic drugs, statins, acetaminophen or alcohol, and with antihypertensives or sedatives. Product quality varies, and some supplements have been adulterated with the wrong Actaea species.

Cited studies (7):
  - Review & meta-analysis: isopropanolic black cohosh extract iCR for menopausal symptoms - an update on the evidence, Climacteric : the journal of the International Menopause Society (2021) — Review/meta-analysis of isopropanolic extract (iCR): SMD -0.694 vs placebo for neurovegetative/psychological symptoms (p<0.0001); industry-linked. [https://pubmed.ncbi.nlm.nih.gov/33021111/]
  - Black cohosh (Cimicifuga spp.) for menopausal symptoms, The Cochrane database of systematic reviews (2012) — 16 RCTs (n=2,027): no significant difference vs placebo in hot-flush frequency or menopausal symptom scores; insufficient evidence to support use. [https://pubmed.ncbi.nlm.nih.gov/22972105/]
  - Efficacy of black cohosh-containing preparations on menopausal symptoms: a meta-analysis, Alternative therapies in health and medicine (2010) — Meta-analysis of 7 RCTs: black-cohosh preparations improved vasomotor symptoms by 26% overall (95% CI 11–40%), with significant heterogeneity. [https://pubmed.ncbi.nlm.nih.gov/20085176/]
  - Effect of black cohosh (cimicifuga racemosa) on vasomotor symptoms in postmenopausal women: a randomized clinical trial, Journal of caring sciences (2013) — Double-blind RCT (n=84): black cohosh significantly reduced number and severity of hot flashes vs placebo at weeks 4 and 8. [https://pubmed.ncbi.nlm.nih.gov/25276716/]
  - Black Cohosh (2025) — Likelihood score A: >50 published cases of clinically apparent liver injury (latency 2–12 wks); causative component unclear, possibly adulterants. [https://www.ncbi.nlm.nih.gov/books/NBK547990/]
  - Safety and efficacy of black cohosh and red clover for the management of vasomotor symptoms: a randomized controlled trial, Menopause (New York, N.Y.) (2009) — 12-mo RCT (n=89): vasomotor symptoms fell 34% with black cohosh vs 63% placebo (NS); only conjugated estrogen/MPA beat placebo. [https://pubmed.ncbi.nlm.nih.gov/19609225/]
  - Exploring the Efficacy and Safety of Black Cohosh (Cimicifuga racemosa) in Menopausal Symptom Management, Journal of mid-life health (2024) — Review (2006–2023): black cohosh may reduce vasomotor symptoms, but dose, formulation and assessment variability preclude firm conclusions. [https://pmc.ncbi.nlm.nih.gov/articles/PMC11100637/]

---

## Black Seed Oil (Nigella sativa)
URL: https://nutridex.info/s/black-seed-oil
Category: Gut & Immune, Heart & Metabolic
Evidence: Moderate — Several controlled trials; effects real but modest or context-dependent.
Thymoquinone-rich seed oil with modest cardiometabolic effects.

Quick answer: Black Seed Oil is used for lower blood sugar & hba1c. NutriDex grades the human evidence as moderate — Several controlled trials; effects real but modest or context-dependent. Based on 8 cited human studies (8 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Black seed oil is pressed from Nigella sativa seeds; its main active is thymoquinone. Unusually for a botanical, it has a large RCT base. Pooled analyses in people with prediabetes or type 2 diabetes show meaningful drops in fasting glucose (around 24 mg/dL) and HbA1c (about 0.5–0.7%), plus lower total and LDL cholesterol. Blood-pressure meta-analyses report small reductions (roughly 3 mmHg systolic, 2.8 mmHg diastolic), and weight/obesity reviews show modest loss of about 1.5 kg and 0.6–0.9 kg/m² BMI, but little change in waist circumference. Effects on inflammatory markers like CRP are inconsistent. The catch: most trials run only 8–12 weeks, enrol few people, vary in oil quality and dose, and cluster in the Middle East and South Asia, so long-term and generalisable benefit is unproven. Best viewed as an adjunct to standard diet, exercise and medication.

Benefits / uses: Lower blood sugar & HbA1c; Improve cholesterol & LDL; Modestly lower blood pressure; Small reductions in weight & BMI.
Active compounds: Thymoquinone; Thymohydroquinone; p-Cymene; Linoleic & oleic acids.
Dose: Commonly 1–3 g/day of seed powder or 0.5–3 mL/day of cold-pressed oil, for 8–12 weeks; oil tends to outperform powder for blood pressure.
Safety: Generally well tolerated at doses up to ~3 g/day for up to 3 months; the commonest effects are mild GI upset, nausea and occasional allergic skin reactions, with rare reports of raised liver enzymes. Because it lowers glucose and blood pressure, it can add to the effect of antidiabetic and antihypertensive drugs (watch for hypoglycaemia or dizziness). Thymoquinone inhibits CYP2C9/2D6/3A4 and may slow clotting, so it can raise levels or bleeding risk with warfarin and other anticoagulants/antiplatelets and with drugs cleared by those enzymes; it may also affect thyroid medication. Stop before surgery and avoid in pregnancy.

Cited studies (8):
  - The effect of Nigella sativa (black seed) supplementation on body weight and body composition: A GRADE-assessed systematic review and dose-response meta-analysis of randomized controlled trials, Journal of Functional Foods (2023) — GRADE dose-response meta-analysis: significant reductions in body weight (-1.46 kg) and BMI (-0.58 kg/m2), but not waist circumference. [https://doi.org/10.1016/j.jff.2023.105565]
  - Does Nigella sativa supplementation improve cardiovascular disease risk factors? A comprehensive GRADE-assessed systematic review and dose-response meta-analysis of 82 randomized controlled trials, Pharmacological research (2025) — GRADE dose-response meta-analysis of 82 RCTs found favourable changes in glucose, HbA1c, lipids, blood pressure and anthropometrics. [https://pubmed.ncbi.nlm.nih.gov/40714301/]
  - Systematic Review of Randomized Controlled Trials in Uses of Nigella Sativa (Black Seed) in Metabolic Syndrome, West African journal of medicine (2024) — Systematic review of 8 RCTs (n=776) supports N. sativa as adjunct for metabolic syndrome: improved lipids, glucose and blood pressure. [https://pubmed.ncbi.nlm.nih.gov/39002164/]
  - Effects of Nigella sativa on glycemic control, lipid profiles, and biomarkers of inflammatory and oxidative stress: A systematic review and meta-analysis of randomized controlled clinical trials, Phytotherapy research : PTR (2020) — Pooling 50 RCTs, N. sativa significantly lowered fasting glucose, HbA1c, total cholesterol, triglycerides and LDL; CRP/TNF-a unchanged. [https://pubmed.ncbi.nlm.nih.gov/32394508/]
  - Nigella sativa supplementation improves cardiometabolic indicators in population with prediabetes and type 2 diabetes mellitus: A systematic review and meta-analysis of randomized controlled trials, Frontiers in nutrition (2022) — In pre/T2DM (11 RCTs, n=666): fasting glucose -24.2 mg/dL, HbA1c -0.54%, LDL-C -20.1 mg/dL vs control. [https://pubmed.ncbi.nlm.nih.gov/36034891/]
  - Nigella sativa L. and Its Active Compound Thymoquinone in the Clinical Management of Diabetes: A Systematic Review, International journal of molecular sciences (2022) — Review of 17 clinical studies: N. sativa improved FBG, postprandial glucose, HbA1c, HOMA-IR; thymoquinone+metformin beat metformin alone. [https://pubmed.ncbi.nlm.nih.gov/36292966/]
  - A systematic review and meta-analysis of randomized controlled trials investigating the effects of supplementation with Nigella sativa (black seed) on blood pressure, Journal of hypertension (2016) — Across 11 RCTs (n=860), N. sativa cut systolic BP by 3.26 mmHg and diastolic by 2.80 mmHg vs control over ~8 weeks. [https://pubmed.ncbi.nlm.nih.gov/27512971/]
  - Effect of Nigella sativa supplementation on obesity indices: A systematic review and meta-analysis of randomized controlled trials, Complementary therapies in medicine (2018) — Across 13 RCTs (n=875), supplementation reduced body weight (WMD -1.76 kg) and BMI (-0.85 kg/m2); no change in waist circumference. [https://pubmed.ncbi.nlm.nih.gov/29857879/]

---

## Bromelain (Bromelain (pineapple enzyme))
URL: https://nutridex.info/s/bromelain
Category: Joint & Skin, Gut & Immune
Evidence: Moderate — Several controlled trials; effects real but modest or context-dependent.
Pineapple-stem enzyme used for swelling, pain and sinus symptoms.

Quick answer: Bromelain is used for ease post-surgical pain. NutriDex grades the human evidence as moderate — Several controlled trials; effects real but modest or context-dependent. Based on 9 cited human studies (9 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Bromelain is a mix of protein-digesting (proteolytic) enzymes from the pineapple stem and fruit, sold for inflammation, swelling and sinus complaints. The strongest data are for osteoarthritis: a pooled reanalysis of six RCTs (N≈700) found a fixed bromelain-trypsin-rutin combination as effective as diclofenac for knee pain and function, with fewer GI side effects. After third-molar surgery a meta-analysis showed a small reduction in pain (standardized mean difference roughly -0.5 at 24 h and 7 days) but no clear benefit for swelling or jaw stiffness. A 2023 systematic review concluded bromelain may help sinusitis but not cardiovascular disease. Separately, a standardized topical bromelain (NexoBrid) is an approved enzymatic burn-wound debriding agent. Overall the oral evidence is real but modest, often relies on combination products, and dosing units (GDU/FIP) are not standardized across brands.

Benefits / uses: Ease post-surgical pain; Reduce swelling & bruising; Relieve sinusitis symptoms; Osteoarthritis (with trypsin/rutin); Enzymatic burn debridement (topical).
Active compounds: Cysteine proteases (stem & fruit bromelain); Peroxidase; Phosphatase.
Dose: Oral: typically 200–400 mg/day (about 1,200–2,400 GDU or ~3,000–9,000 FIP), often as 80–320 mg 2–3×/day on an empty stomach; the OA evidence uses a fixed bromelain-trypsin-rutin combination.
Safety: Generally well tolerated; the most common effects are GI upset (nausea, diarrhea, flatulence) and occasional headache. People allergic to pineapple, latex, grass or birch pollen can react (cross-reactivity), and severe allergic reactions are possible. Because of mild antiplatelet/fibrinolytic activity, theoretically it may add to bleeding risk with anticoagulants or antiplatelets (warfarin, aspirin, clopidogrel) and NSAIDs—stop before surgery; it may also increase blood levels of some antibiotics (amoxicillin, tetracyclines). Avoid in bleeding disorders and use caution in pregnancy and breastfeeding due to limited data.

Cited studies (9):
  - Efficacy and safety of bromelain: A systematic review and meta-analysis, Nutrition and health (2023) — Systematic review/meta-analysis: oral bromelain modestly reduced pain vs control and may help sinusitis; no benefit for cardiovascular disease; no major safety signals. [https://pubmed.ncbi.nlm.nih.gov/37157782/]
  - Bromelain-based enzymatic burn debridement: A systematic review of clinical studies on patient safety, efficacy and long-term outcomes, International wound journal (2023) — Systematic review of bromelain-based enzymatic burn debridement: effective, selective eschar removal reducing surgical excision, with acceptable long-term outcomes. [https://pubmed.ncbi.nlm.nih.gov/37455553/]
  - Efficacy, tolerability, and safety of an oral enzyme combination vs diclofenac in osteoarthritis of the knee: results of an individual patient-level pooled reanalysis of data from six randomized controlled trials, Journal of pain research (2016) — Pooled reanalysis of 6 RCTs (N=697): bromelain-trypsin-rutin combination non-inferior to diclofenac for knee OA (Lequesne diff 0.31, NS), with better tolerability. [https://pubmed.ncbi.nlm.nih.gov/27853388/]
  - Efficacy of proteolytic enzyme bromelain on health outcomes after third molar surgery. Systematic review and meta-analysis of randomized clinical trials, Medicina oral, patologia oral y cirugia bucal (2019) — Meta-analysis of 6 RCTs after third-molar surgery: oral bromelain cut pain (SMD -0.49 at 24h; -0.52 at 7d) but no clear effect on swelling or trismus. [https://pubmed.ncbi.nlm.nih.gov/30573710/]
  - Bromelain (2024) — NIH monograph: oral bromelain at therapeutic doses has not been linked to liver enzyme elevations or clinically apparent liver injury. [https://www.ncbi.nlm.nih.gov/books/NBK600584/]
  - Perioperative bromelain reduces pain and swelling and improves quality of life measures after mandibular third molar surgery: a randomized, double-blind, placebo-controlled clinical trial, Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons (2014) — Double-blind RCT after mandibular third-molar surgery: perioperative bromelain reduced pain, swelling and improved quality-of-life measures vs placebo. [https://pubmed.ncbi.nlm.nih.gov/24589242/]
  - [No clinical evidence for an enhanced bleeding tendency due to perioperative treatment with bromelain], Sportverletzung Sportschaden : Organ der Gesellschaft fur Orthopadisch-Traumatologische Sportmedizin (2011) — Review of perioperative bromelain found no clinical evidence of an enhanced bleeding tendency in surgical patients. [https://pubmed.ncbi.nlm.nih.gov/21611915/]
  - An Overview of the Use of Bromelain-Based Enzymatic Debridement (Nexobrid®) in Deep Partial and Full Thickness Burns: Appraising the Evidence, Journal of burn care & research : official publication of the American Burn Association (2018) — Evidence appraisal of bromelain (NexoBrid) for deep partial/full-thickness burns: faster eschar removal and less surgery vs standard of care across trials. [https://pubmed.ncbi.nlm.nih.gov/29579268/]
  - Therapeutic use, efficiency and safety of the proteolytic pineapple enzyme Bromelain-POS in children with acute sinusitis in Germany, In vivo (Athens, Greece) (2005) — Observational study in 116 children with acute sinusitis: bromelain monotherapy gave faster symptom recovery (6.7 vs 8.0 days standard care); one allergic reaction. [https://pubmed.ncbi.nlm.nih.gov/15796206/]

---

## Butterbur (Petasites hybridus)
URL: https://nutridex.info/s/butterbur
Category: Gut & Immune
Evidence: Moderate — Several controlled trials; effects real but modest or context-dependent.
A migraine and hay-fever herb shadowed by liver-toxicity concerns.

Quick answer: Butterbur is used for fewer migraine attacks. NutriDex grades the human evidence as moderate — Several controlled trials; effects real but modest or context-dependent. Based on 8 cited human studies (8 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Butterbur is a perennial shrub whose root and leaf extracts are used for migraine prevention and allergic rhinitis. In randomized trials, a standardized root extract (Petadolex) at 75 mg twice daily cut migraine frequency by 48% versus 26% on placebo over four months, with 68% of patients achieving a >=50% reduction. For seasonal allergies, leaf extract (Ze 339) matched cetirizine and fexofenadine for symptom relief without the antihistamine sedation. The catch is safety: raw butterbur contains pyrrolizidine alkaloids that are hepatotoxic and potentially carcinogenic, and roughly a third of commercial products tested still contained them. Cases of cholestatic hepatitis, including two requiring liver transplant, prompted the AAN to withdraw its 2012 recommendation in 2015. Only certified PA-free, standardized extracts should be used, and even those warrant caution and periodic liver monitoring.

Benefits / uses: Fewer migraine attacks; Hay-fever / allergic rhinitis relief; Non-sedating antihistamine alternative.
Active compounds: Petasin; Isopetasin; Sesquiterpene esters.
Dose: For migraine, 50–75 mg of a PA-free root extract (e.g. Petadolex) twice daily; for allergic rhinitis, a standardized leaf extract (Ze 339) one tablet 3–4x daily. Use only certified PA-free products.
Safety: Raw butterbur contains pyrrolizidine alkaloids (PAs) that are hepatotoxic and potentially carcinogenic; only certified PA-free, standardized extracts should ever be used, and even these have been linked to cases of cholestatic hepatitis (two requiring liver transplant). Avoid in pregnancy, breastfeeding, and liver disease, and stop immediately for jaundice, nausea, dark urine, or abdominal pain. Being a ragweed-family (Asteraceae) plant, it can trigger allergy in sensitive people, and it may add to the effects of liver-stressing drugs; periodic liver-function monitoring is prudent.

Cited studies (8):
  - Efficacy and Safety of Phytotherapy and Anthroposophic Medicine in Seasonal Allergic Rhinitis: A Systematic Review, International archives of allergy and immunology (2025) — A systematic review of 14 clinical studies in seasonal allergic rhinitis identified Petasites hybridus (butterbur) as the most-studied herb, with consistent beneficial effects on immunological parameters, subjective nasal symptoms, and nasal airflow (qualitative synthesis; no pooled effect size). [https://pubmed.ncbi.nlm.nih.gov/39084196/]
  - Effectiveness of Petasites hybridus preparations in the prophylaxis of migraine: a systematic review, Phytomedicine : international journal of phytotherapy and phytopharmacology (2006) — Systematic review of 2 RCTs (293 patients) found moderate evidence for the higher 150 mg/day dose of Petadolex in migraine prophylaxis. [https://pubmed.ncbi.nlm.nih.gov/16987643/]
  - Petasites hybridus root (butterbur) is an effective preventive treatment for migraine, Neurology (2004) — Petadolex 75 mg bid cut migraine frequency 48% vs 26% placebo over 4 months (p=0.0012); 68% achieved >=50% reduction (n=245). [https://pubmed.ncbi.nlm.nih.gov/15623680/]
  - An extract of Petasites hybridus is effective in the prophylaxis of migraine, International journal of clinical pharmacology and therapeutics (2000) — Petasites root extract 50 mg bid for 12 weeks reduced migraine attack frequency up to 60% vs baseline, significant over placebo (n=60). [https://pubmed.ncbi.nlm.nih.gov/11020030/]
  - Randomised controlled trial of butterbur and cetirizine for treating seasonal allergic rhinitis, BMJ (Clinical research ed.) (2002) — Butterbur (Ze 339) was as effective as cetirizine for seasonal allergic rhinitis but without the sedation reported by two-thirds of cetirizine patients (n=125). [https://pubmed.ncbi.nlm.nih.gov/11799030/]
  - Treating intermittent allergic rhinitis: a prospective, randomized, placebo and antihistamine-controlled study of Butterbur extract Ze 339, Phytotherapy research : PTR (2005) — Butterbur Ze 339 (one tablet 3x daily) was comparably efficacious to fexofenadine and superior to placebo for intermittent allergic rhinitis (n=330). [https://pubmed.ncbi.nlm.nih.gov/16114089/]
  - Butterbur (2019) — Likelihood score C; 10 cases of cholestatic hepatitis linked to butterbur, 2 needing liver transplant; PA-free extracts not implicated. [https://www.ncbi.nlm.nih.gov/books/NBK547997/]
  - Evidence-based guideline update: NSAIDs and other complementary treatments for episodic migraine prevention in adults: [RETIRED], Neurology (2012) — Evidence-based guideline rated Petasites Level A for episodic migraine prevention; recommendation later retracted in 2015 over hepatotoxicity concerns. [https://www.neurology.org/doi/10.1212/WNL.0b013e3182535d0c]

---

## Cat's Claw (Uncaria tomentosa)
URL: https://nutridex.info/s/cats-claw
Category: Joint & Skin, Gut & Immune
Evidence: Preliminary — Early or small human trials; promising but not yet conclusive.
Amazonian anti-inflammatory vine with thin but real arthritis data.

Quick answer: Cat's Claw is used for ease joint pain. NutriDex grades the human evidence as preliminary — Early or small human trials; promising but not yet conclusive. Based on 6 cited human studies (6 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Cat's claw is a woody South American vine (two species, Uncaria tomentosa and U. guianensis) traditionally used for inflammation and infection. The strongest human data are two small trials: a 4-week osteoarthritis study (n=45) where ~100 mg/day freeze-dried U. guianensis cut activity-related knee pain within a week (but not rest or night pain), and a 24-week rheumatoid-arthritis RCT (n=40, added to standard DMARDs) where a pentacyclic-alkaloid U. tomentosa extract reduced painful joints by 53% vs 24% on placebo. A small human study also suggested enhanced DNA repair. Animal meta-analyses show lower IL-6 and NF-kB but no consistent TNF-alpha effect. Trials are tiny, short, unreplicated, and species/extract-specific, so benefits are plausible but unproven. It is not a substitute for arthritis medication.

Benefits / uses: Ease joint pain; Rheumatoid arthritis support; Knee osteoarthritis pain; Anti-inflammatory; Immune modulation.
Active compounds: Pentacyclic oxindole alkaloids; Quinovic acid glycosides; Polyphenols / proanthocyanidins.
Dose: Roughly 100 mg/day freeze-dried Uncaria guianensis for osteoarthritis, or ~60 mg/day of a pentacyclic-alkaloid Uncaria tomentosa extract for rheumatoid arthritis, as studied.
Safety: Generally well tolerated short-term; the most common effects are nausea, diarrhea and stomach upset, and it has not been linked to liver injury. Because it inhibits CYP3A4, it can raise blood levels of drugs cleared by that pathway, including some HIV protease inhibitors, cyclosporine and certain benzodiazepines; it may also add to bleeding risk with anticoagulants/antiplatelets and to blood-pressure lowering. Avoid in pregnancy and breastfeeding, and use caution with autoimmune disease, organ transplants (immunosuppressants) and before surgery; rare reports include acute kidney injury in a lupus patient and worsened Parkinson's symptoms.

Cited studies (6):
  - Anti-inflammatory and/or immunomodulatory activities of Uncaria tomentosa (cat’s claw) extracts: A systematic review and meta-analysis of in vivo studies, Frontiers in Pharmacology (2024) — Meta-analysis of 24 animal studies: extracts lowered IL-6 (SMD -0.72) and NF-kB (SMD -1.19) but not TNF-alpha; low toxicity. Preclinical only. [https://doi.org/10.3389/fphar.2024.1378408]
  - Randomized double blind trial of an extract from the pentacyclic alkaloid-chemotype of uncaria tomentosa for the treatment of rheumatoid arthritis, The Journal of rheumatology (2002) — 24-wk RCT (n=40) added to DMARDs: U. tomentosa extract cut painful joints 53.2% vs 24.1% placebo (p=0.044); minor side effects only. [https://pubmed.ncbi.nlm.nih.gov/11950006/]
  - Efficacy and safety of freeze-dried cat's claw in osteoarthritis of the knee: mechanisms of action of the species Uncaria guianensis, Inflammation research : official journal of the European Histamine Research Society ... [et al.] (2001) — 4-wk RCT (n=45) of ~100 mg/day freeze-dried U. guianensis in knee OA: activity pain fell within 1 week; no change in rest/night pain; no liver or blood toxicity. [https://pubmed.ncbi.nlm.nih.gov/11603848/]
  - DNA repair enhancement of aqueous extracts of Uncaria tomentosa in a human volunteer study, Phytomedicine : international journal of phytotherapy and phytopharmacology (2001) — 8-wk human study (n=12) of 250-350 mg/day aqueous extract enhanced DNA repair after induced damage; no serious adverse effects. [https://pubmed.ncbi.nlm.nih.gov/11515717/]
  - LiverTox 2019 — Cat's claw not linked to clinically apparent liver injury (likelihood score E); minor GI effects; inhibits CYP3A4 raising interaction potential. [https://www.ncbi.nlm.nih.gov/books/NBK548323/]
  - Cat's claw: an Amazonian vine decreases inflammation in osteoarthritis, Complementary therapies in clinical practice (2007) — Review: cat's claw decreases osteoarthritis inflammation mainly via TNF-alpha inhibition and antioxidant action; human evidence limited. [https://pubmed.ncbi.nlm.nih.gov/17210508/]

---

## Chaga (Inonotus obliquus)
URL: https://nutridex.info/s/chaga
Category: Gut & Immune, Longevity
Evidence: Preliminary — Early or small human trials; promising but not yet conclusive.
Antioxidant birch fungus with bold claims but no human efficacy trials.

Quick answer: Chaga is used for antioxidant support. NutriDex grades the human evidence as preliminary — Early or small human trials; promising but not yet conclusive. Based on 6 cited human studies (6 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Chaga is a parasitic fungus that grows on birch trees and is sold as a powder, tea or extract for immunity, anti-aging and blood sugar. Its appeal rests on genuinely high levels of antioxidants, beta-glucans and triterpenoids. However, the evidence base is almost entirely preclinical: anti-diabetic, anti-inflammatory and anti-fatigue effects have been shown only in mice, rats and cell cultures. The strongest human-derived data come from ex-vivo experiments where chaga extract reduced hydrogen-peroxide-induced DNA damage in donated lymphocytes (about 35–55%), which does not establish any clinical benefit. No randomized controlled trials in people support the marketed claims. Meanwhile, chaga is extremely high in oxalate (up to ~14 g per 100 g), and multiple case reports link long-term or high-dose use to acute oxalate nephropathy and even end-stage kidney disease. Benefit in humans is unproven; the documented risk is concrete.

Benefits / uses: Antioxidant support; Immune modulation; Anti-inflammatory (claimed); Blood-sugar support (claimed).
Active compounds: Beta-glucan polysaccharides; Triterpenoids (e.g. betulinic acid); Polyphenols & melanin; Superoxide dismutase.
Dose: No established human dose; products supply ~1–3 g/day of dried sclerotium or extract, but safe long-term dosing is undefined.
Safety: Chaga is very high in oxalate (up to ~14 g per 100 g), and case reports tie prolonged or high-dose use to acute oxalate nephropathy and end-stage kidney disease, especially when combined with vitamin C or in those with kidney disease, diabetes or dehydration. It may lower blood sugar and could add to antidiabetic drugs, and its claimed antiplatelet/blood-thinning activity raises a theoretical bleeding risk with anticoagulants such as warfarin. Avoid in pregnancy, breastfeeding, kidney stones or chronic kidney disease, and before surgery; quality and oxalate content of wild-harvested products are unregulated.

Cited studies (6):
  - Chaga mushroom-induced oxalate nephropathy that clinically manifested as nephrotic syndrome: A case report, Medicine (2022) — 69-y-old man on chaga 10–15 g/day for 3 months developed acute oxalate nephropathy presenting as nephrotic syndrome. [https://pubmed.ncbi.nlm.nih.gov/35451393/]
  - Development of End Stage Renal Disease after Long-Term Ingestion of Chaga Mushroom: Case Report and Review of Literatures, Journal of Korean Medical Science (2020) — 49-y-old developed end-stage renal disease after 5 years of chaga; sample contained 14.2 g oxalate/100 g, biopsy showed oxalate crystals. [https://doi.org/10.3346/jkms.2020.35.e122]
  - Chaga mushroom extract inhibits oxidative DNA damage in human lymphocytes as assessed by comet assay, BioFactors (Oxford, England) (2004) — Chaga extract cut H2O2-induced oxidative DNA damage in human lymphocytes by over 40% (comet assay); ex-vivo, not a clinical trial. [https://pubmed.ncbi.nlm.nih.gov/15630179/]
  - Chaga mushroom extract inhibits oxidative DNA damage in lymphocytes of patients with inflammatory bowel disease, BioFactors (Oxford, England) (2007) — Ex-vivo chaga extract reduced H2O2-induced DNA damage 54.9% in IBD-patient lymphocytes and 34.9% in healthy controls (n=20+20). [https://pubmed.ncbi.nlm.nih.gov/18997282/]
  - Therapeutic properties of Inonotus obliquus (Chaga mushroom): A review, Mycology (2024) — Therapeutic-properties review concludes mechanisms remain poorly understood and human clinical evidence is essentially absent. [https://pmc.ncbi.nlm.nih.gov/articles/PMC11132974/]
  - Recent Developments in Inonotus obliquus (Chaga mushroom) Polysaccharides: Isolation, Structural Characteristics, Biological Activities and Application, Polymers (2021) — Review: chaga polysaccharides show immune, anti-fatigue and anti-diabetic activity in vitro and in animals; no human trials cited. [https://pmc.ncbi.nlm.nih.gov/articles/PMC8124789/]

---

## Chamomile (Matricaria chamomilla)
URL: https://nutridex.info/s/chamomile
Category: Sleep & Mood
Evidence: Moderate — Several controlled trials; effects real but modest or context-dependent.
A gentle herbal tea with modest evidence for anxiety and sleep.

Quick answer: Chamomile is used for ease generalized anxiety. NutriDex grades the human evidence as moderate — Several controlled trials; effects real but modest or context-dependent. Based on 7 cited human studies (7 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Chamomile is a daisy-family flower long taken as a calming tea. The best human data are for generalized anxiety disorder (GAD): a placebo-controlled trial found a modest but significant drop in anxiety scores, and a longer trial confirmed reduced symptoms (though it did not prevent relapse). A 2019 meta-analysis concluded chamomile is efficacious for GAD and sleep quality but found no benefit for state anxiety and only one weak trial for insomnia. A 2024 sleep meta-analysis found a small improvement in PSQI sleep-quality scores (about 1.9 points) but no change in sleep duration or efficiency. Small trials also report lower HbA1c and fasting glucose in type 2 diabetes, but these need confirmation. Overall the effects are real but mild, trials are short (mostly 2–8 weeks) and often small, so chamomile is a reasonable gentle adjunct rather than a proven treatment.

Benefits / uses: Ease generalized anxiety; Improve sleep quality; Calm before bed; Lower blood sugar (early signal).
Active compounds: Apigenin; Bisabolol; Chamazulene; Luteolin.
Dose: 220–1500 mg/day of standardized extract (often 1.2% apigenin), or 1–3 cups of tea (3 g dried flower per cup); extract trials used 500 mg three times daily.
Safety: Chamomile is generally well tolerated; the main risk is allergic reaction (rarely anaphylaxis) in people sensitive to ragweed, daisies, marigolds or chrysanthemums. It may add to the effect of sedatives and has documented interaction with the blood thinner warfarin (increased bleeding risk via coumarin content), so use caution with anticoagulants and around surgery. Because small trials show it can lower blood glucose, monitor closely if you take antidiabetic drugs; avoid concentrated medicinal doses in pregnancy.

Cited studies (7):
  - Effects of chamomile (Matricaria chamomilla L.) on sleep: A systematic review and meta-analysis of clinical trials, Complementary therapies in medicine (2024) — Meta-analysis (10 studies, 772 people): chamomile improved PSQI sleep-quality score (WMD -1.88, 95% CI -3.46 to -0.31); no change in sleep duration/efficiency. [https://pubmed.ncbi.nlm.nih.gov/39106912/]
  - The effect of chamomile consumption on glycemic markers in humans and animals: a systematic review and meta-analysis, Journal of diabetes and metabolic disorders (2024) — Meta-analysis: chamomile lowered fasting glucose (SMD -0.65) and HbA1c (SMD -0.90) in humans; small number of trials, calls for more. [https://pubmed.ncbi.nlm.nih.gov/38932814/]
  - Therapeutic efficacy and safety of chamomile for state anxiety, generalized anxiety disorder, insomnia, and sleep quality: A systematic review and meta-analysis of randomized trials and quasi-randomized trials, Phytotherapy research : PTR (2019) — Meta-analysis (12 RCTs): chamomile improved GAD and sleep quality, but no significant effect on state anxiety; only 1 weak insomnia trial. [https://pubmed.ncbi.nlm.nih.gov/31006899/]
  - Long-term chamomile (Matricaria chamomilla L.) treatment for generalized anxiety disorder: A randomized clinical trial, Phytomedicine : international journal of phytotherapy and phytopharmacology (2016) — Long-term GAD RCT: chamomile maintained lower symptoms than placebo but did not significantly reduce relapse rate (n=93). [https://pubmed.ncbi.nlm.nih.gov/27912875/]
  - Effects of an intervention with drinking chamomile tea on sleep quality and depression in sleep disturbed postnatal women: a randomized controlled trial, Journal of advanced nursing (2016) — RCT in 80 sleep-disturbed postnatal women: chamomile tea cut sleep-inefficiency and depression scores, but benefit was gone by 4-week follow-up. [https://pubmed.ncbi.nlm.nih.gov/26483209/]
  - Effectiveness of chamomile tea on glycemic control and serum lipid profile in patients with type 2 diabetes, Journal of endocrinological investigation (2015) — 8-week RCT (n=64, type 2 diabetes): chamomile tea 3x/day lowered HbA1c, insulin, insulin resistance and improved lipid profile vs control. [https://pubmed.ncbi.nlm.nih.gov/25194428/]
  - A randomized, double-blind, placebo-controlled trial of oral Matricaria recutita (chamomile) extract therapy for generalized anxiety disorder, Journal of clinical psychopharmacology (2009) — 8-week RCT in GAD: chamomile extract cut total HAM-A anxiety score significantly more than placebo (P=0.047); modest effect (n=57). [https://pubmed.ncbi.nlm.nih.gov/19593179/]

---

## Chasteberry (Vitex) (Vitex agnus-castus)
URL: https://nutridex.info/s/chasteberry
Category: Sleep & Mood
Evidence: Moderate — Several controlled trials; effects real but modest or context-dependent.
Herbal extract used for PMS, breast pain and cycle irregularity.

Quick answer: Chasteberry (Vitex) is used for ease pms symptoms. NutriDex grades the human evidence as moderate — Several controlled trials; effects real but modest or context-dependent. Based on 8 cited human studies (8 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Chasteberry is the dried fruit of Vitex agnus-castus, used in Europe mainly for premenstrual syndrome (PMS), cyclic breast pain (mastalgia) and mild menstrual-cycle disturbances. Its diterpenes act on dopamine D2 receptors in the pituitary, lowering prolactin, which may explain effects on breast pain and luteal-phase function. A 2017 meta-analysis of placebo-controlled PMS trials found a large pooled benefit (Hedges g -1.21), but with extreme heterogeneity (I2 91%) and probable publication bias, so the true effect is smaller. For cyclic mastalgia a 2020 meta-analysis (6 trials, 718 women) showed a moderate effect (SMD 0.67) on breast-pain severity. Small early trials also suggest it can normalize shortened luteal phases tied to mildly raised prolactin. It is generally well tolerated; side effects are usually mild. Overall: a plausible, modestly effective option for PMS and breast pain, not a proven treatment for infertility.

Benefits / uses: Ease PMS symptoms; Reduce cyclic breast pain; Lower elevated prolactin; Support luteal-phase regularity.
Active compounds: Diterpenes (clerodadienols); Flavonoids (casticin); Iridoids (agnuside, aucubin).
Dose: Standardized fruit extract ~20–40 mg/day (e.g. Ze 440 or BNO 1095), taken once daily for at least 3 menstrual cycles.
Safety: Generally well tolerated; the most common side effects are mild nausea, headache, GI upset, dizziness, dry mouth, menstrual changes and occasional acne or itchy rash. Because its diterpenes act on dopamine receptors, avoid combining with dopamine agonists or antagonists (e.g. antipsychotics, bromocriptine, metoclopramide), and it may theoretically reduce the reliability of oral contraceptives and interact with hormone therapies. Avoid in pregnancy and breastfeeding, and use caution with hormone-sensitive conditions (breast, uterine or ovarian cancer, endometriosis, fibroids). Discontinue if pregnancy is achieved.

Cited studies (8):
  - Vitex Agnus-Castus for the Treatment of Cyclic Mastalgia: A Systematic Review and Meta-Analysis, Journal of women's health (2002) (2020) — Meta-analysis (6 trials, 718 women): moderate effect on cyclic breast-pain severity (SMD 0.67, 95% CI 0.50–0.85) and lowered prolactin. [https://pubmed.ncbi.nlm.nih.gov/31464546/]
  - The treatment of premenstrual syndrome with preparations of Vitex agnus castus: a systematic review and meta-analysis, American journal of obstetrics and gynecology (2017) — Meta-analysis of placebo-controlled PMS RCTs: large pooled effect (Hedges g -1.21) but I2 91% and likely publication bias inflating it. [https://pubmed.ncbi.nlm.nih.gov/28237870/]
  - Vitex agnus castus for premenstrual syndrome and premenstrual dysphoric disorder: a systematic review, Archives of women's mental health (2017) — Systematic review of 8 RCTs: all favored Vitex for PMS/PMDD and it was well tolerated, but definitions, outcomes and extracts varied widely. [https://pubmed.ncbi.nlm.nih.gov/29063202/]
  - Vitex agnus-castus extracts for female reproductive disorders: a systematic review of clinical trials, Planta medica (2013) — Systematic review of Vitex RCTs in reproductive-age women: positive but heterogeneous trials for PMS, mastalgia and cycle disorders. [https://pubmed.ncbi.nlm.nih.gov/23136064/]
  - Treatment for the premenstrual syndrome with agnus castus fruit extract: prospective, randomised, placebo controlled study, BMJ (Clinical research ed.) (2001) — RCT (n=170): 52% responded to agnus castus extract vs 24% placebo for core PMS symptoms over 3 cycles (P<0.001). [https://pubmed.ncbi.nlm.nih.gov/11159568/]
  - Treatment of cyclical mastalgia with a solution containing a Vitex agnus castus extract: results of a placebo-controlled double-blind study, Breast (Edinburgh, Scotland) (1999) — Placebo-controlled RCT: VAS breast-pain fell 33.7mm vs 20.3mm (placebo) after 2 cycles (P=0.006); well tolerated. [https://pubmed.ncbi.nlm.nih.gov/14731436/]
  - [Vitex agnus castus extract in the treatment of luteal phase defects due to latent hyperprolactinemia. Results of a randomized placebo-controlled double-blind study], Arzneimittel-Forschung (1993) — RCT (n=52): 20mg/day normalized shortened luteal phases and reduced prolactin in latent hyperprolactinemia over 3 months. [https://pubmed.ncbi.nlm.nih.gov/8369008/]
  - Vitex agnus castus: a systematic review of adverse events, Drug safety (2005) — Safety review: adverse events mostly mild (nausea, headache, GI upset, acne); no serious drug interactions documented. [https://pubmed.ncbi.nlm.nih.gov/15783241/]

---

## Citrus Bergamot (Citrus bergamia)
URL: https://nutridex.info/s/citrus-bergamot
Category: Heart & Metabolic
Evidence: Moderate — Several controlled trials; effects real but modest or context-dependent.
Citrus polyphenols studied mainly for lowering cholesterol.

Quick answer: Citrus Bergamot is used for lower ldl cholesterol. NutriDex grades the human evidence as moderate — Several controlled trials; effects real but modest or context-dependent. Based on 8 cited human studies (8 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Bergamot is the citrus whose peel flavors Earl Grey tea; supplements use a polyphenol-rich extract of the fruit. Its flavonoids brutieridin and melitidin structurally resemble statins and appear to inhibit cholesterol synthesis. A 2022 meta-analysis of 14 randomized trials reported pooled drops of about 64 mg/dL in total cholesterol, 55 mg/dL in LDL and 75 mg/dL in triglycerides, plus a ~6 mg/dL rise in HDL. Those numbers are unusually large and heavily weighted by trials of one proprietary extract (BPF) from a small cluster of Italian researchers; heterogeneity is high. More independent RCTs are more modest: a 2024 trial saw LDL fall 11.5% over 4 months, and an older-adult trial showed limited effect. Glucose and HbA1c generally did not change. Bergamot is plausibly useful, especially for statin-intolerant people, but the evidence is not yet high-quality or independent enough to call strong.

Benefits / uses: Lower LDL cholesterol; Lower triglycerides; Raise HDL modestly; Support for statin-intolerant patients.
Active compounds: Brutieridin; Melitidin; Naringin / neohesperidin; Neoeriocitrin.
Dose: 500–1,500 mg/day of standardized bergamot polyphenolic fraction (BPF) or ~150 mg flavonoids, taken with meals for 8–12+ weeks.
Safety: Bergamot is generally well tolerated at 500–1,500 mg/day; side effects are mostly mild GI upset, heartburn, or muscle cramps, and rare allergic reactions. Like grapefruit it contains furanocoumarins (e.g. bergamottin) that inhibit intestinal CYP3A4, so it can raise blood levels of CYP3A4-metabolized drugs — including certain statins (atorvastatin, simvastatin), calcium-channel blockers, some sedatives and immunosuppressants. Because it lowers lipids and may modestly affect glucose, use caution with antidiabetic and other lipid-lowering drugs, and theoretical additive bleeding risk means caution with anticoagulants. Avoid in pregnancy/breastfeeding due to limited data, and consult a clinician before combining with prescription medications.

Cited studies (8):
  - The effect of bergamot (KoksalGarry) supplementation on lipid profiles: A systematic review and meta-analysis of randomized controlled trials, Phytotherapy research : PTR (2022) — Meta-analysis of 14 RCTs: bergamot cut LDL ~55, triglycerides ~75 and total cholesterol ~64 mg/dL, and raised HDL ~6 mg/dL; calls for higher-quality trials. [https://pubmed.ncbi.nlm.nih.gov/36251526/]
  - Effect of bergamot on lipid profile in humans: A systematic review, Critical Reviews in Food Science and Nutrition (2019) — Systematic review of bergamot on human lipid profile: consistent lipid-lowering signal but notes small samples and reliance on a few extracts. [https://doi.org/10.1080/10408398.2019.1677554]
  - Effect of Citrus bergamia extract on lipid profile: A combined in vitro and human study, Phytotherapy research : PTR (2023) — Combined in-vitro and human study: bergamot extract improved lipid profile, supporting an HMG-CoA-reductase-linked, statin-like mechanism. [https://pubmed.ncbi.nlm.nih.gov/37312672/]
  - Citrus bergamia Extract, a Natural Approach for Cholesterol and Lipid Metabolism Management: A Randomized, Double-Blind Placebo-Controlled Clinical Trial, Foods (Basel, Switzerland) (2024) — 4-month double-blind RCT (n=64): 150 mg/day bergamot flavonoids cut total cholesterol 8.8% and LDL 11.5% and raised HDL 5.5%; glucose/HbA1c unchanged. [https://pubmed.ncbi.nlm.nih.gov/39682955/]
  - Bergamot phytosome improved visceral fat and plasma lipid profiles in overweight and obese class I subject with mild hypercholesterolemia: A randomized placebo controlled trial, Phytotherapy Research (2020) — 12-week RCT (n=64 overweight/obese): bergamot phytosome significantly reduced visceral adipose tissue, total and LDL cholesterol vs placebo. [https://doi.org/10.1002/ptr.6950]
  - Bergamot Reduces Plasma Lipids, Atherogenic Small Dense LDL, and Subclinical Atherosclerosis in Subjects with Moderate Hypercholesterolemia: A 6 Months Prospective Study, Frontiers in pharmacology (2015) — 6-month study (n=80): BPF and phytosome lowered total cholesterol (~262→196), LDL (~175→116) and triglycerides, and reduced small-dense LDL and carotid IMT. [https://pubmed.ncbi.nlm.nih.gov/26779019/]
  - Effects of 12-week supplementation of Citrus bergamia extracts-based formulation CitriCholess on cholesterol and body weight in older adults with dyslipidemia: a randomized, double-blind, placebo-controlled trial, Lipids in health and disease (2017) — 12-week RCT in older dyslipidemic adults: CitriCholess bergamot extract modestly improved cholesterol and body weight vs placebo. [https://pubmed.ncbi.nlm.nih.gov/29273027/]
  - Hypolipemic and hypoglycaemic activity of bergamot polyphenols: from animal models to human studies, Fitoterapia (2011) — 237 hyperlipidemic patients, 30 days BPF 500–1000 mg/day reduced total cholesterol, LDL and triglycerides and raised HDL dose-dependently. [https://pubmed.ncbi.nlm.nih.gov/21056640/]

---

## CLA (Conjugated Linoleic Acid)
URL: https://nutridex.info/s/cla
Category: Heart & Metabolic
Evidence: Mixed — Conflicting results across studies; benefit uncertain.
Popular fat-loss fatty acid whose real-world effect is tiny.

Quick answer: CLA is used for marketed for fat loss. NutriDex grades the human evidence as mixed — Conflicting results across studies; benefit uncertain. Based on 8 cited human studies (8 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

CLA is a group of linoleic-acid isomers found naturally in dairy and beef and sold as a fat-loss supplement, usually as a roughly 50:50 mix of the cis-9,trans-11 and trans-10,cis-12 forms. Pooled randomized trials do show a real but tiny effect: roughly 0.5–0.9 kg less body weight and about 1.3 kg less fat versus placebo over several months. A 2024 dose-response meta-analysis found fat mass fell only ~0.44 kg, and the effect on fat mass and body-fat percentage disappeared when analysis was limited to high-quality trials. Meta-analyses show no benefit on cholesterol, blood pressure, or HbA1c, and some report a small rise in fasting glucose. The trans-10,cis-12 isomer specifically has been shown to raise insulin resistance and oxidative-stress markers in men with metabolic syndrome. Overall the weight benefit is too small to matter clinically, and the metabolic signals are a genuine concern.

Benefits / uses: Marketed for fat loss; Slight body-fat reduction; Body-recomposition claims.
Active compounds: cis-9,trans-11 (rumenic acid); trans-10,cis-12 isomer.
Dose: Trials use 3.2–6.4 g/day of a ~50:50 c9,t11/t10,c12 isomer mix, taken with meals.
Safety: Common side effects are GI: nausea, loose stools, diarrhea and indigestion. The trans-10,cis-12 isomer can worsen insulin resistance, raise fasting glucose, lower HDL and increase oxidative-stress and inflammatory markers, so caution is warranted in diabetes, prediabetes and metabolic syndrome, and CLA may oppose antidiabetic medication. Rare reports of liver injury exist; avoid in liver disease and stop for jaundice or dark urine. Safety in pregnancy and breastfeeding is not established.

Cited studies (8):
  - The effects of conjugated linoleic acid supplementation on anthropometrics and body composition indices in adults: a systematic review and dose-response meta-analysis, The British journal of nutrition (2024) — Dose-response meta-analysis: fat mass −0.44 kg, body-fat −0.77%; effect on fat mass/BFP lost in high-quality trials. [https://pubmed.ncbi.nlm.nih.gov/37671495/]
  - The effects of conjugated linoleic acid supplementation on cardiovascular risk factors in patients at risk of cardiovascular disease: A GRADE-assessed systematic review and dose-response meta-analysis, The British journal of nutrition (2024) — GRADE meta-analysis in cardiovascular-risk patients: weight −0.72 kg, body-fat −1.32%, but no effect on lipids or blood pressure. [https://pubmed.ncbi.nlm.nih.gov/39439191/]
  - The efficacy of long-term conjugated linoleic acid (CLA) supplementation on body composition in overweight and obese individuals: a systematic review and meta-analysis of randomized clinical trials, European journal of nutrition (2012) — Meta-analysis of 7 RCTs (≥6 months): weight −0.70 kg, fat −1.33 kg vs placebo; deemed not clinically relevant long term. [https://pubmed.ncbi.nlm.nih.gov/21990002/]
  - Efficacy of conjugated linoleic acid for reducing fat mass: a meta-analysis in humans, The American journal of clinical nutrition (2007) — Meta-analysis: 3.2 g/day CLA produced a modest body-fat loss (~0.09 kg/week) vs placebo in humans. [https://pubmed.ncbi.nlm.nih.gov/17490954/]
  - Treatment with dietary trans10cis12 conjugated linoleic acid causes isomer-specific insulin resistance in obese men with the metabolic syndrome, Diabetes care (2002) — 12-wk RCT: trans-10,cis-12 CLA raised insulin resistance 19%, glycemia 4%, and cut HDL 4% in obese men with metabolic syndrome. [https://pubmed.ncbi.nlm.nih.gov/12196420/]
  - Supplementation with conjugated linoleic acid causes isomer-dependent oxidative stress and elevated C-reactive protein: a potential link to fatty acid-induced insulin resistance, Circulation (2002) — RCT: t10,c12 CLA caused isomer-specific oxidative stress and raised C-reactive protein in men with metabolic syndrome. [https://pubmed.ncbi.nlm.nih.gov/12370214/]
  - Conjugated linoleic acid supplementation, insulin sensitivity, and lipoprotein metabolism in patients with type 2 diabetes mellitus, The American journal of clinical nutrition (2004) — RCT in type 2 diabetes: CLA raised fasting glucose 6.3% and lowered insulin sensitivity; raised HDL 8% but not recommended therapeutically. [https://pubmed.ncbi.nlm.nih.gov/15447895/]
  - Effects of cis-9,trans-11 conjugated linoleic acid supplementation on insulin sensitivity, lipid peroxidation, and proinflammatory markers in obese men, The American journal of clinical nutrition (2004) — RCT: even the c9,t11 isomer lowered insulin sensitivity 15% and raised lipid-peroxidation markers ~50% in obese men. [https://pubmed.ncbi.nlm.nih.gov/15277146/]

---

## Cod Liver Oil (Gadus morhua)
URL: https://nutridex.info/s/cod-liver-oil
Category: Heart & Metabolic, Vitamin
Evidence: Moderate — Several controlled trials; effects real but modest or context-dependent.
Omega-3s plus vitamins A and D in one traditional fish-liver oil.

Quick answer: Cod Liver Oil is used for lower blood triglycerides. NutriDex grades the human evidence as moderate — Several controlled trials; effects real but modest or context-dependent. Based on 7 cited human studies (7 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Cod liver oil is pressed from the liver of Atlantic cod and uniquely combines omega-3 fatty acids (EPA and DHA) with vitamins A and D. Its omega-3s consistently lower blood triglycerides in a dose-dependent way (meta-analyses of fish oil show drops of roughly 15–30 mg/dL at typical doses), and regular use measurably raises serum vitamin D. A 9-month RCT in rheumatoid arthritis found 39% of users cut NSAID use by over 30% without worsening disease. However, the largest direct trial (34,601 adults) found cod liver oil did not prevent COVID-19 or other respiratory infections. Childhood benefits for type 1 diabetes and fewer infections come only from observational and cluster studies, which cannot prove cause. So the nutrients it delivers are genuinely useful, but cod liver oil as a product has not been shown to prevent heart disease or infections.

Benefits / uses: Lower blood triglycerides; Raise vitamin D status; Anti-inflammatory (joint pain); Source of vitamins A & D.
Active compounds: EPA & DHA (omega-3 fatty acids); Vitamin D3 (cholecalciferol); Vitamin A (retinol).
Dose: About 1–2 teaspoons (5–10 mL) daily, providing roughly 1–2 g EPA+DHA plus vitamins A and D; check the label, as vitamin A content limits how much is safe.
Safety: Generally well tolerated; common effects are fishy burps, reflux and loose stools. The main concern is vitamin A: high or stacked doses can cause toxicity (headache, bone pain, liver harm) and excess in pregnancy is teratogenic, so pregnant women should limit retinol intake. Omega-3s and the vitamin D content modestly thin the blood and can add to the effect of anticoagulants/antiplatelets (warfarin, aspirin, DOACs); high doses may also raise LDL cholesterol. Use caution if combining with other vitamin A or D supplements.

Cited studies (7):
  - Association Between Omega‐3 Fatty Acid Intake and Dyslipidemia: A Continuous Dose–Response Meta‐Analysis of Randomized Controlled Trials, Journal of the American Heart Association (2023) — Dose-response meta-analysis of RCTs: marine omega-3s lowered triglycerides dose-dependently, with reductions growing at higher EPA+DHA intakes. [https://doi.org/10.1161/JAHA.123.029512]
  - Prevention of covid-19 and other acute respiratory infections with cod liver oil supplementation, a low dose vitamin D supplement: quadruple blinded, randomised placebo controlled trial, BMJ (Clinical research ed.) (2022) — RCT in 34,601 adults: cod liver oil did not reduce SARS-CoV-2 infection (RR 1.00) or other acute respiratory infections (RR 1.04) over winter. [https://pubmed.ncbi.nlm.nih.gov/36215222/]
  - Cod liver oil, young children, and upper respiratory tract infections, Journal of the American College of Nutrition (2010) — Cluster-randomized study in young inner-city children: cod liver oil plus a multivitamin cut upper-respiratory pediatric visits by 36–58% over winter. [https://pubmed.ncbi.nlm.nih.gov/21677119/]
  - Cod liver oil (n-3 fatty acids) as an non-steroidal anti-inflammatory drug sparing agent in rheumatoid arthritis, Rheumatology (Oxford, England) (2008) — 9-month double-blind RCT (n=97): 39% of cod liver oil users cut NSAID intake >30% without worsening rheumatoid arthritis activity. [https://pubmed.ncbi.nlm.nih.gov/18362100/]
  - Effect of daily cod liver oil and a multivitamin-mineral supplement with selenium on upper respiratory tract pediatric visits by young, inner-city, Latino children: randomized pediatric sites, The Annals of otology, rhinology, and laryngology (2004) — Randomized pediatric-site study (n=94): daily cod liver oil plus multivitamin-mineral reduced upper-respiratory visits per child per month. [https://pubmed.ncbi.nlm.nih.gov/15562899/]
  - Cod liver oil consumption at different periods of life and bone mineral density in old age, British Journal of Nutrition (2015) — Cross-sectional study (n=4798 elderly): daily cod liver oil raised serum 25(OH)D (~60 nmol/L) but had only marginal, clinically questionable effect on bone density. [https://doi.org/10.1017/S0007114515001397]
  - Use of cod liver oil during the first year of life is associated with lower risk of childhood-onset type 1 diabetes: a large, population-based, case-control study, The American journal of clinical nutrition (2003) — Case-control study (545 cases, 1668 controls): cod liver oil in the first year of life linked to lower type 1 diabetes risk (adjusted OR 0.74). [https://pubmed.ncbi.nlm.nih.gov/14668274/]

---

## D-Aspartic Acid
URL: https://nutridex.info/s/d-aspartic-acid
Category: Performance
Evidence: Mixed — Conflicting results across studies; benefit uncertain.
Marketed testosterone booster that fails in trained men.

Quick answer: D-Aspartic Acid is used for marketed to raise testosterone. NutriDex grades the human evidence as mixed — Conflicting results across studies; benefit uncertain. Based on 7 cited human studies (7 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

D-aspartic acid (DAA) is an amino acid sold as a natural testosterone booster. The hype traces to a 2009 study where 23 untrained men taking ~2.7 g/day for 12 days raised testosterone about 42%. That result has not held up: a 2015 RCT found 3 g/day did nothing and 6 g/day reduced total and free testosterone, and a 2017 RCT in resistance-trained men found no change in testosterone (only a ~16% drop in estradiol) and no extra muscle or strength versus placebo. A 2017 systematic review of four human trials called the evidence inconsistent and low-quality. Separate work links low seminal D-aspartate to poor sperm quality, and a small 2025 RCT combining DAA with ubiquinol and zinc improved sperm motility — but DAA's solo fertility benefit is unproven. For its main marketed claim, boosting testosterone and gains, the human data are mixed to negative.

Benefits / uses: Marketed to raise testosterone; Marketed muscle & strength support; Possible male fertility support.
Active compounds: D-aspartic acid (D-aspartate); Sodium D-aspartate.
Dose: Common label dose is 3 g/day; testosterone-boosting trials used 2–6 g/day for 12 days to 12 weeks, with no consistent benefit.
Safety: DAA is generally well tolerated at 3 g/day, with occasional headache, irritability, nervousness or mild GI upset reported. Higher doses (6 g/day) lowered testosterone in trials, so 'more' is counterproductive. Because it acts on the hypothalamic-pituitary-gonadal axis, avoid it if you take hormonal therapies (testosterone, aromatase inhibitors, fertility drugs) without medical advice, and it is not appropriate in pregnancy, breastfeeding, or for adolescents. Formal drug-interaction data are lacking.

Cited studies (7):
  - The putative effects of D-Aspartic acid on blood testosterone levels: A systematic review, International journal of reproductive biomedicine (2017) — Systematic review of 4 human and 23 animal studies: human results inconsistent and low-quality; no firm testosterone benefit established. [https://pubmed.ncbi.nlm.nih.gov/28280794/]
  - Evaluation of in vivo supplementation of 2660 mg D-aspartic acid and 200 mg ubiquinol and 10 mg zinc on different semen parameters in idiopathic male infertility: a randomized double blind placebo controlled study, Archivio italiano di urologia, andrologia : organo ufficiale [di] Societa italiana di ecografia urologica e nefrologica (2025) — RCT (n=75): DAA 2660 mg + ubiquinol + zinc improved progressive sperm motility and total testosterone vs placebo over 3 months. [https://pubmed.ncbi.nlm.nih.gov/40248985/]
  - The Effects of Six-Gram D-Aspartic Acid Supplementation on the Testosterone, Cortisol, and Hematological Responses of Male Boxers Subjected to 11 Days of Nocturnal Exposure to Normobaric Hypoxia, Nutrients (2023) — In a randomized controlled trial of 16 male boxers, 6 g/day D-aspartic acid for 14 days during altitude (normobaric hypoxia) training had no significant effect on resting testosterone, the testosterone/cortisol ratio, LH, or hematological responses versus control. [https://pubmed.ncbi.nlm.nih.gov/38201906/]
  - Three and six grams supplementation of d-aspartic acid in resistance trained men, Journal of the International Society of Sports Nutrition (2015) — In resistance-trained men, 3 g/day DAA had no hormonal effect; 6 g/day significantly reduced total (~13%) and free testosterone. [https://pubmed.ncbi.nlm.nih.gov/25844073/]
  - The effects of d-aspartic acid supplementation in resistance-trained men over a three month training period: A randomised controlled trial, PloS one (2017) — 6 g/day DAA over 12 weeks with training gave no change in total/free testosterone and no extra strength or muscle; estradiol fell ~16%. [https://pubmed.ncbi.nlm.nih.gov/28841667/]
  - The role and molecular mechanism of D-aspartic acid in the release and synthesis of LH and testosterone in humans and rats, Reproductive biology and endocrinology : RB&E (2009) — 23 untrained men given ~2.7 g/day sodium D-aspartate for 12 days raised serum testosterone ~42% (4.5 to 6.4 ng/mL) and LH ~33%. [https://pubmed.ncbi.nlm.nih.gov/19860889/]
  - Occurrence of D-aspartic acid in human seminal plasma and spermatozoa: possible role in reproduction, Fertility and sterility (2005) — Seminal D-aspartate was far lower in subfertile (oligoasthenoteratospermic) men (26 vs 80 nmol/mL), suggesting a role in sperm quality. [https://pubmed.ncbi.nlm.nih.gov/16275242/]

---

## DHEA (Dehydroepiandrosterone)
URL: https://nutridex.info/s/dhea
Category: Longevity, Performance
Evidence: Mixed — Conflicting results across studies; benefit uncertain.
An adrenal hormone precursor with narrow, population-specific benefits.

Quick answer: DHEA is used for adrenal insufficiency replacement. NutriDex grades the human evidence as mixed — Conflicting results across studies; benefit uncertain. Based on 9 cited human studies (9 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

DHEA is a hormone made by the adrenal glands that the body converts into testosterone and estrogen; blood levels fall steeply with age, fuelling anti-aging marketing. The honest picture is narrow. In women with adrenal insufficiency, replacement gives small improvements in quality of life and mood. Pooled trials show 25–50 mg/day raises lumbar-spine bone density about 1% over a year in older women (but not men, and not the hip). A 2020 meta-analysis of 15 RCTs found a small antidepressant effect (SMD −0.28). For IVF in diminished ovarian reserve, meta-analyses conflict — some show higher pregnancy odds, others none. Crucially, it does nothing for strength or body composition in healthy young adults, and is banned in sport. Effects on libido, cognition, lipids and longevity are unproven.

Benefits / uses: Adrenal insufficiency replacement; Bone density in older women; IVF support in low ovarian reserve; Mild antidepressant effect.
Active compounds: Dehydroepiandrosterone (DHEA); DHEA-sulfate (DHEA-S).
Dose: 25–50 mg/day orally; for IVF protocols 25 mg three times daily; lower in women due to androgenic effects.
Safety: DHEA is an androgen/estrogen precursor: women may get acne, oily skin, facial hair and voice deepening; men may get gynecomastia, and either sex can have mood or sleep changes. It is contraindicated in hormone-sensitive cancers (breast, prostate, ovarian, uterine) and PCOS, and may worsen liver disease or lower HDL. It can interact with anticoagulants, anti-diabetic drugs, hormonal therapies, aromatase inhibitors and some psychiatric medications, and is banned by WADA — avoid in competitive sport.

Cited studies (9):
  - Efficacy of dehydroepiandrosterone priming in women with poor ovarian response undergoing IVF/ICSI: a meta-analysis, Frontiers in endocrinology (2023) — Meta-analysis in poor ovarian responders: DHEA priming did not significantly improve live-birth or clinical pregnancy rates; high between-trial heterogeneity. [https://pubmed.ncbi.nlm.nih.gov/37361534/]
  - Dehydroepiandrosterone for depressive symptoms: A systematic review and meta‐analysis of randomized controlled trials, Journal of Neuroscience Research (2020) — Meta-analysis of 15 RCTs (n=853): DHEA improved depressive symptoms vs placebo (SMD −0.28, 95% CI −0.45 to −0.11); GRADE very-low quality. [https://doi.org/10.1002/jnr.24721]
  - Sex-specific effects of dehydroepiandrosterone (DHEA) on bone mineral density and body composition: A pooled analysis of four clinical trials, Clinical endocrinology (2019) — Pooled 4 RCTs (n=585, age 55+): 12 mo DHEA raised lumbar-spine (+1.0%) and trochanter BMD in women but gave no bone benefit in men. [https://pubmed.ncbi.nlm.nih.gov/30421439/]
  - DHEA use to improve likelihood of IVF/ICSI success in patients with diminished ovarian reserve: A systematic review and meta-analysis, JBRA assisted reproduction (2018) — Systematic review/meta-analysis (5 RCTs, n=910): DHEA raised clinical pregnancy odds in diminished ovarian reserve (OR 1.8) and lowered miscarriage (OR 0.25). [https://pubmed.ncbi.nlm.nih.gov/30125071/]
  - Dehydroepiandrosterone status and efficacy of dehydroepiandrosterone supplementation for bone health in anorexia nervosa: A systematic review and meta-analysis, The International journal of eating disorders (2022) — Systematic review in anorexia nervosa: DHEA monotherapy did not improve BMD vs placebo after adjusting for weight gain. [https://pubmed.ncbi.nlm.nih.gov/35460091/]
  - Dehydroepiandrosterone supplementation in elderly men: a meta-analysis study of placebo-controlled trials, The Journal of clinical endocrinology and metabolism (2013) — Meta-analysis of 25 RCTs (n=1353 older men): DHEA reduced fat mass but had no effect on glycemia, lipids, bone, sexual function or quality of life. [https://pubmed.ncbi.nlm.nih.gov/23824417/]
  - A systematic review and meta-analysis of randomized placebo-controlled trials of DHEA treatment effects on quality of life in women with adrenal insufficiency, The Journal of clinical endocrinology and metabolism (2009) — Meta-analysis of RCTs: DHEA in women with adrenal insufficiency gave small improvement in HRQoL and depression; no effect on anxiety or sexual well-being. [https://pubmed.ncbi.nlm.nih.gov/19773400/]
  - Effect of dehydroepiandrosterone supplementation on bone mineral density, bone markers, and body composition in older adults: the DAWN trial, Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA (2008) — 50 mg/day DHEA for 1 yr modestly raised spine BMD in older women; no significant change in body composition or hip BMD overall. [https://pubmed.ncbi.nlm.nih.gov/18084691/]
  - Effect of oral DHEA on serum testosterone and adaptations to resistance training in young men, Journal of applied physiology (Bethesda, Md. : 1985) (1999) — RCT in young men during 8 wk resistance training: 150 mg/day DHEA did not raise testosterone, strength or lean mass beyond placebo. [https://pubmed.ncbi.nlm.nih.gov/10601178/]

---

## Fenugreek (Trigonella foenum-graecum)
URL: https://nutridex.info/s/fenugreek
Category: Performance, Heart & Metabolic
Evidence: Moderate — Several controlled trials; effects real but modest or context-dependent.
Culinary seed that modestly lowers blood sugar and lipids; small testosterone signal.

Quick answer: Fenugreek is used for lower fasting blood sugar. NutriDex grades the human evidence as moderate — Several controlled trials; effects real but modest or context-dependent. Based on 8 cited human studies (8 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Fenugreek is a legume seed used as a spice and traditional remedy. Its soluble fiber and 4-hydroxyisoleucine plausibly slow glucose absorption and aid insulin secretion. Meta-analyses of randomized trials find it lowers fasting blood glucose (roughly 20 mg/dL) and HbA1c (~0.5%) in type 2 diabetes, and modestly improves total cholesterol, triglycerides and HDL. Separately, standardized seed extracts (notably Testofen, 600 mg/day) raise total and free testosterone by a small margin and may improve libido and androgen-deficiency symptoms in middle-aged and older men; a sports meta-analysis found small anabolic and performance effects (testosterone SMD 0.32) in male athletes only. Effect sizes are modest, many trials are small, short, industry-funded or of low methodological quality, and results vary with preparation and dose. Fenugreek is a reasonable adjunct, not a replacement, for diabetes or lipid therapy.

Benefits / uses: Lower fasting blood sugar; Improve HbA1c in type 2 diabetes; Reduce cholesterol & triglycerides; Small testosterone & libido support; Modest strength/anabolic effect.
Active compounds: 4-hydroxyisoleucine; Galactomannan (soluble fiber); Steroidal saponins (e.g. protodioscin); Trigonelline.
Dose: Seed powder ~5–10 g/day, or standardized seed extract 300–600 mg/day (e.g. Testofen) for testosterone studies; soluble fiber content drives the glycemic effect.
Safety: Generally well tolerated; common effects are GI upset, bloating, diarrhea and a harmless maple-syrup body/urine odor. As a Fabaceae legume it can cross-react in people allergic to peanuts, chickpeas or soy and has caused anaphylaxis. Because it lowers glucose and has antiplatelet activity, it can add to antidiabetic drugs (hypoglycemia risk) and anticoagulants/antiplatelets like warfarin (bleeding/INR changes); it may also reduce absorption of some oral drugs. Avoid high/medicinal doses in pregnancy (uterine-stimulant, possible fetal effects), and use cautiously before surgery.

Cited studies (8):
  - The Effect of Fenugreek in Type 2 Diabetes and Prediabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials, International journal of molecular sciences (2023) — Meta-analysis of 10 RCTs (n=706): fenugreek significantly lowered fasting glucose, 2-h glucose and HbA1c, and improved TC, TG and HDL; no severe adverse events. [https://pubmed.ncbi.nlm.nih.gov/37762302/]
  - The Anabolic Effect of Fenugreek: A Systematic Review with Meta-analysis, International journal of sports medicine (2023) — Systematic review with meta-analysis (7 studies, 449 athletes): small anabolic/performance effect in males — total testosterone SMD 0.32 (95% CI 0.09–0.55); no effect shown in females. [https://pubmed.ncbi.nlm.nih.gov/37253363/]
  - Effect of fenugreek consumption on serum lipid profile: A systematic review and meta-analysis, Phytotherapy research : PTR (2020) — Meta-analysis of 15 RCTs: fenugreek reduced total cholesterol, LDL and triglycerides and raised HDL, with larger lipid benefit in diabetic subjects. [https://pubmed.ncbi.nlm.nih.gov/32385866/]
  - Effect of fenugreek supplementation on blood lipids and body weight: A systematic review and meta-analysis of randomized controlled trials, Journal of ethnopharmacology (2020) — Meta-analysis of 12 RCTs (n=560): fenugreek significantly reduced total cholesterol, LDL and triglycerides and raised HDL, without changing body weight or BMI. [https://pubmed.ncbi.nlm.nih.gov/32087319/]
  - Effect of fenugreek extract supplement on testosterone levels in male: A meta‐analysis of clinical trials, Phytotherapy Research (2020) — Meta-analysis of 4 RCTs: fenugreek seed extract significantly increased total serum testosterone in men vs control. [https://doi.org/10.1002/ptr.6627]
  - Testofen, a specialised Trigonella foenum-graecum seed extract reduces age-related symptoms of androgen decrease, increases testosterone levels and improves sexual function in healthy aging males in a double-blind randomised clinical study, The aging male : the official journal of the International Society for the Study of the Aging Male (2016) — RCT, 120 men aged 43–70 on 600 mg/day Testofen for 12 weeks: small but significant rise in total and free testosterone and fewer androgen-deficiency symptoms. [https://pubmed.ncbi.nlm.nih.gov/26791805/]
  - The effects of a commercially available botanical supplement on strength, body composition, power output, and hormonal profiles in resistance-trained males, Journal of the International Society of Sports Nutrition (2010) — RCT, 49 resistance-trained men: 500 mg/day fenugreek extract over 8 weeks significantly improved upper/lower-body strength and reduced body fat vs placebo. [https://pubmed.ncbi.nlm.nih.gov/20979623/]
  - Effect of Trigonella foenum-graecum (fenugreek) seeds on glycaemic control and insulin resistance in type 2 diabetes mellitus: a double blind placebo controlled study, The Journal of the Association of Physicians of India (2001) — Small RCT in type 2 diabetes: 1 g/day hydroalcoholic fenugreek extract improved insulin sensitivity (HOMA) and triglycerides over 2 months. [https://pubmed.ncbi.nlm.nih.gov/11868855/]

---

## Feverfew (Tanacetum parthenium)
URL: https://nutridex.info/s/feverfew
Category: Joint & Skin
Evidence: Mixed — Conflicting results across studies; benefit uncertain.
A traditional daisy herb taken to help prevent migraine attacks.

Quick answer: Feverfew is used for migraine prevention. NutriDex grades the human evidence as mixed — Conflicting results across studies; benefit uncertain. Based on 7 cited human studies (7 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Feverfew is a daisy-family herb long used to ward off fevers, arthritis and headaches. Modern interest centers on migraine prevention. Trials of leaf preparations gave conflicting results, and the standardized CO2 extract MIG-99 worked in its largest trial (6.25 mg three times daily cut attacks by 1.9 vs 1.3 per month on placebo) but failed overall in an earlier dose-finding study except in a frequent-migraine subgroup. The 2015 Cochrane review of six trials (561 people) found feverfew reduced attacks by only about 0.6 per month and rated the evidence low quality. A 2025 meta-analysis of nine RCTs (899 people) found a modest but significant reduction of roughly 1.1 attacks per month and shorter attacks, with no effect on nausea or light sensitivity. Overall the benefit, if real, is small and inconsistent; product quality and parthenolide content vary widely.

Benefits / uses: Migraine prevention; Fewer headache days; Anti-inflammatory effects; Traditional fever & arthritis remedy.
Active compounds: Parthenolide (sesquiterpene lactone); Other sesquiterpene lactones; Flavonoids.
Dose: A stabilized CO2 extract (MIG-99) at 6.25 mg three times daily, or ~50–150 mg/day of dried leaf standardized to ≥0.2% parthenolide.
Safety: Generally well tolerated short-term; the most common effects are mouth ulcers and oral soreness (especially chewing fresh leaves) and GI upset. Stopping abruptly after long use can cause a rebound "post-feverfew syndrome" of headache, insomnia and joint pain. Feverfew has antiplatelet activity and a documented case of bleeding with abnormal clotting times, so avoid combining it with anticoagulants/antiplatelets (warfarin, aspirin, clopidogrel), NSAIDs or before surgery. It is contraindicated in pregnancy (may stimulate uterine contractions and menstruation) and breastfeeding, and can trigger allergic reactions in people sensitive to ragweed and other Asteraceae plants.

Cited studies (7):
  - Systematic review and meta-analysis of Tanacetum parthenium: evaluating its efficacy in migraine relief, Natural product research (2025) — Meta-analysis of 9 RCTs (n=899): attacks fell ~1.11/month and duration ~4.4 h; no effect on nausea, photophobia or phonophobia. [https://pubmed.ncbi.nlm.nih.gov/41422534/]
  - Feverfew for preventing migraine, The Cochrane database of systematic reviews (2015) — 6 RCTs (n=561): feverfew cut migraine frequency by ~0.6 attacks/month vs placebo; rated low-quality, mixed evidence. [https://pubmed.ncbi.nlm.nih.gov/25892430/]
  - Feverfew (Tanacetum parthenium L.): A systematic review, Pharmacognosy reviews (2011) — Systematic review: parthenolide inhibits prostaglandin synthesis and platelet serotonin release; clinical migraine evidence judged mixed. [https://pubmed.ncbi.nlm.nih.gov/22096324/]
  - Alteration of Coagulation Test Results and Vaginal Bleeding Associated With the Use of Feverfew (Tanacetum parthenium), Journal of medical cases (2021) — Case report: 800 mg feverfew t.i.d. for 9 months caused prolonged vaginal bleeding with elevated PT/PTT; resolved after stopping. [https://pubmed.ncbi.nlm.nih.gov/34434419/]
  - Efficacy and safety of 6.25 mg t.i.d. feverfew CO2-extract (MIG-99) in migraine prevention--a randomized, double-blind, multicentre, placebo-controlled study, Cephalalgia : an international journal of headache (2005) — MIG-99 6.25 mg t.i.d. reduced attacks by 1.9 vs 1.3/month on placebo (P=0.046); responder odds ratio 3.4 (n=170). [https://pubmed.ncbi.nlm.nih.gov/16232154/]
  - The efficacy and safety of Tanacetum parthenium (feverfew) in migraine prophylaxis--a double-blind, multicentre, randomized placebo-controlled dose-response study, Cephalalgia : an international journal of headache (2002) — Dose-response RCT: MIG-99 showed no overall prophylactic effect; benefit only in subgroup with ≥4 baseline attacks (P=0.02). [https://pubmed.ncbi.nlm.nih.gov/12230594/]
  - Herbal medicines in migraine prevention, Phytomedicine (1996) — Crossover RCT (n=50) of an alcoholic feverfew extract: no difference in attack frequency vs placebo; no prophylactic effect shown. [https://doi.org/10.1016/S0944-7113(96)80057-2]

---

## Fisetin
URL: https://nutridex.info/s/fisetin
Category: Longevity
Evidence: Preliminary — Early or small human trials; promising but not yet conclusive.
A plant flavonoid studied as a senolytic to clear aged cells.

Quick answer: Fisetin is used for clear senescent ('zombie') cells. NutriDex grades the human evidence as preliminary — Early or small human trials; promising but not yet conclusive. Based on 8 cited human studies (8 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Fisetin is a flavonoid found in strawberries, apples and onions that has become a flagship 'senolytic' candidate — a compound meant to selectively kill senescent (worn-out) cells thought to drive aging. In aged mice, intermittent fisetin reduced senescence markers and extended median and maximum lifespan, making it the standout among ten flavonoids screened. Human evidence is far earlier. Mayo Clinic-led trials (AFFIRM, COVID-FIS) and a 74-person knee-osteoarthritis trial have mostly tested safety using a 2-day pulsed dose, and report no serious adverse events but no clearly proven efficacy yet; osteoarthritis pain and inflammation outcomes were not convincingly improved. Fisetin is also poorly absorbed orally and rapidly metabolised, so blood levels are very low. It is a promising, biologically plausible longevity tool — but as of 2026 the human data are preliminary, not proof that it slows aging or treats disease.

Benefits / uses: Clear senescent ('zombie') cells; Lower inflammation markers; Researched for frailty & aging; Antioxidant activity.
Active compounds: Fisetin (3,3',4',7-tetrahydroxyflavone).
Dose: Trial doses are 20 mg/kg/day (roughly 1,000–1,500 mg) for 2 consecutive days, given intermittently; everyday supplement doses of 100–500 mg/day are unstudied for longevity.
Safety: Across early human trials (2-day pulsed dosing) fisetin has been well tolerated with no serious adverse events reported, though sample sizes are small and long-term daily safety is unstudied. As a flavonoid it can inhibit cytochrome-P450 and drug-transporter pathways, so it may theoretically raise levels of drugs metabolised by CYP3A4/CYP2C; caution with anticoagulants (added antiplatelet effect), antidiabetics (possible additive glucose lowering) and chemotherapy. Avoid in pregnancy and breastfeeding (no data), and tell your clinician before use if you take prescription medicines.

Cited studies (8):
  - Emerging Therapeutic Potential of Fisetin for Nephrotoxicity, Kidney Injury, and Nephropathy: A Systematic Review, Current diabetes reviews (2026) — Systematic review found fisetin protective against kidney injury/nephropathy in preclinical studies; clinical dosing and human evidence still lacking. [https://pubmed.ncbi.nlm.nih.gov/40464183/]
  - The effects of fisetin on bone and cartilage: A systematic review, Pharmacological research (2022) — Systematic review: fisetin shows pro-bone and chondroprotective effects in preclinical models, but human osteoporosis/OA efficacy remains unproven. [https://pubmed.ncbi.nlm.nih.gov/36243333/]
  - OARSI 2025 (knee OA RCT) — Phase I/II RCT, 74 adults, fisetin 100 mg/day x2 days intermittently: well tolerated (safety primary endpoint) but no clear improvement in WOMAC pain. [https://www.oarsijournal.com/article/S1063-4584(25)00692-2/abstract]
  - Fisetin for COVID-19 in skilled nursing facilities: Senolytic trials in the COVID era, Journal of the American Geriatrics Society (2021) — Design/rationale for COVID-FIS senolytic trials; oral fisetin 20 mg/kg/day x2 days tested in older skilled-nursing residents with no serious safety signals. [https://pubmed.ncbi.nlm.nih.gov/34375437/]
  - Enhanced bioavailability and pharmacokinetics of a novel hybrid-hydrogel formulation of fisetin orally administered in healthy individuals: a randomised double-blinded comparative crossover study, Journal of nutritional science (2022) — Randomised crossover in healthy adults: a hybrid-hydrogel formulation raised fisetin plasma exposure vs standard fisetin, underscoring poor native oral bioavailability. [https://pmc.ncbi.nlm.nih.gov/articles/PMC9574875/]
  - Beneficial Effects of Fisetin, a Senotherapeutic Compound, in Women’s Reproductive Health and Diseases: Evidence from In Vitro to Clinical Studies, Nutrients (2026) — Review: fisetin modulates ovarian aging and fibrosis in vitro/animal models; direct human reproductive-health evidence is absent. [https://doi.org/10.3390/nu18030393]
  - Fisetin is a senotherapeutic that extends health and lifespan, EBioMedicine (2018) — Fisetin was the most potent of 10 flavonoid senolytics; intermittent dosing late in life extended median and maximum lifespan in aged mice. [https://pubmed.ncbi.nlm.nih.gov/30279143/]
  - New agents that target senescent cells: the flavone, fisetin, and the BCL-X(L) inhibitors, A1331852 and A1155463, Aging (2017) — Fisetin selectively induced apoptosis in senescent (not proliferating) human endothelial cells, establishing flavonoid senolytic activity in human cells. [https://pubmed.ncbi.nlm.nih.gov/28273655/]

---

## Flaxseed (ALA) (Linum usitatissimum)
URL: https://nutridex.info/s/flaxseed
Category: Heart & Metabolic, Gut & Immune
Evidence: Moderate — Several controlled trials; effects real but modest or context-dependent.
Fibre-rich seed that modestly trims cholesterol, blood pressure and glucose.

Quick answer: Flaxseed (ALA) is used for lower ldl & total cholesterol. NutriDex grades the human evidence as moderate — Several controlled trials; effects real but modest or context-dependent. Based on 7 cited human studies (7 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Flaxseed is an oilseed rich in the plant omega-3 ALA, lignans and viscous fibre. Pooled trial data are consistent but modest: a 62-RCT meta-analysis found ground flaxseed lowered total cholesterol by ~5 mg/dL, LDL by ~4 mg/dL and triglycerides by ~9 mg/dL, with no change in HDL. Blood-pressure meta-analyses report drops of roughly 2–3 mmHg overall, though one landmark 6-month trial in hypertensive patients saw falls near 15/7 mmHg. For glucose, ground flaxseed cut fasting glucose (~3 mg/dL), insulin and HOMA-IR, especially over 12+ weeks, but most analyses found no HbA1c change (one found a small reduction in poorly-controlled diabetes). Effects are larger for milled whole seed than for oil or lignan extracts. CRP falls mainly in obese subjects. Practical, food-based and safe, but the magnitude is adjunctive, not a substitute for statins or antihypertensives.

Benefits / uses: Lower LDL & total cholesterol; Modest blood-pressure reduction; Better fasting glucose & insulin sensitivity; Relieve constipation (fibre); Lower CRP in obesity.
Active compounds: Alpha-linolenic acid (ALA, omega-3); Lignans (secoisolariciresinol diglucoside); Soluble & insoluble fibre (mucilage).
Dose: Typically 30 g/day of milled (ground) whole flaxseed; benefits are strongest for ground seed taken ≥12 weeks, weaker for oil or isolated lignans.
Safety: Generally safe as a food; common effects are bloating, gas and loose stools from its fibre, and it can cause constipation or bowel obstruction if taken with too little water. Because ALA and fibre can mildly slow clotting and lower glucose, it may add to the effect of anticoagulants/antiplatelets (warfarin, aspirin, clopidogrel) and diabetes medications, and its fibre can blunt absorption of oral drugs taken at the same time (separate by ~1–2 hours). Raw or unripe seed contains trace cyanogenic glycosides, so stick to recommended amounts; avoid medicinal doses in pregnancy due to phytoestrogen/lignan content.

Cited studies (7):
  - Flaxseed supplementation significantly reduces hemoglobin A1c in patients with type 2 diabetes mellitus: A systematic review and meta-analysis, Nutrition research (New York, N.Y.) (2023) — 13 RCTs in type 2 diabetes: whole flaxseed significantly lowered HbA1c (most pronounced when baseline HbA1c ≥7%); no change in BP or weight. [https://pubmed.ncbi.nlm.nih.gov/36640581/]
  - Effects of flaxseed supplementation on inflammatory biomarkers: A GRADE-assessed systematic review and meta-analysis of randomized controlled trials, Prostaglandins & other lipid mediators (2024) — GRADE-assessed 54-RCT meta-analysis (n=3000): flaxseed lowered CRP (SMD -0.46) and IL-6 (SMD -0.64); no change in TNF-α. [https://pubmed.ncbi.nlm.nih.gov/38971216/]
  - Effect of flaxseed supplementation on lipid profile: An updated systematic review and dose-response meta-analysis of sixty-two randomized controlled trials, Pharmacological research (2020) — 62-RCT dose-response meta-analysis (n=3772): flaxseed cut total cholesterol -5.4, LDL -4.2 and triglycerides -9.4 mg/dL; no HDL change. [https://pubmed.ncbi.nlm.nih.gov/31899314/]
  - Effects of flaxseed supplements on blood pressure: A systematic review and meta-analysis of controlled clinical trial, Clinical nutrition (Edinburgh, Scotland) (2016) — 15 RCTs (n=1302): flaxseed lowered systolic BP -2.85 and diastolic BP -2.39 mmHg; effect larger in trials lasting ≥12 weeks. [https://pubmed.ncbi.nlm.nih.gov/26071633/]
  - Flaxseed supplementation on glucose control and insulin sensitivity: a systematic review and meta-analysis of 25 randomized, placebo-controlled trials, Nutrition Reviews (2017) — 25 RCTs: flaxseed reduced fasting glucose -2.94 mg/dL, insulin -7.32 pmol/L and HOMA-IR -0.49; significant only for whole seed ≥12 weeks. [https://doi.org/10.1093/nutrit/nux052]
  - Effect of Flaxseed Intervention on Inflammatory Marker C-Reactive Protein: A Systematic Review and Meta-Analysis of Randomized Controlled Trials, Nutrients (2016) — Meta-analysis: flaxseed did NOT change CRP overall (-0.13 mg/L, p=0.43); significant reduction only in obese subgroup (BMI ≥30). [https://pubmed.ncbi.nlm.nih.gov/26959052/]
  - Potent antihypertensive action of dietary flaxseed in hypertensive patients, Hypertension (Dallas, Tex. : 1979) (2013) — RCT, 110 PAD patients, 30 g/day milled flax for 6 mo: systolic BP fell ~15 mmHg and diastolic ~7 mmHg vs placebo in hypertensives. [https://pubmed.ncbi.nlm.nih.gov/24126178/]

---

## GABA (supplement) (γ-Aminobutyric Acid)
URL: https://nutridex.info/s/gaba-supp
Category: Sleep & Mood
Evidence: Mixed — Conflicting results across studies; benefit uncertain.
The brain's calming neurotransmitter, sold as a sleep and stress pill.

Quick answer: GABA (supplement) is used for relaxation & stress relief. NutriDex grades the human evidence as mixed — Conflicting results across studies; benefit uncertain. Based on 7 cited human studies (7 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

GABA is the brain's main inhibitory neurotransmitter. Taken as a pill, it is marketed for calm, sleep and lower blood pressure, but oral GABA is poorly absorbed into the brain and there is no human evidence it crosses the blood-brain barrier — measured effects may act through the gut, autonomic nerves or expectancy. A 2020 systematic review of 14 placebo-controlled trials found only limited stress and very limited sleep evidence, with 11 of 14 studies having industry-affiliated authors. Small sleep RCTs (75–300 mg) report shorter sleep latency (e.g. ~13 to ~6 min) and more deep sleep, but samples are tiny and unblinded effects are likely. Single doses of 100 mg shift EEG toward alpha waves within an hour. The most consistent signal is a modest blood-pressure drop (~80 mg/day) in mild hypertension. Overall: plausibly calming, weakly proven, and probably modest.

Benefits / uses: Relaxation & stress relief; Sleep onset & quality; Lower blood pressure; Reduced anxiety.
Active compounds: γ-Aminobutyric acid (synthetic or fermented); PharmaGABA (Lactobacillus-fermented).
Dose: 100–300 mg/day, taken before bed; blood-pressure studies used ~80 mg/day.
Safety: GABA is generally well tolerated; reported effects are mild and transient — throat burning, flushing, mild GI upset and headache, and a small drop in blood pressure. Because it can lower blood pressure, combine cautiously with antihypertensive drugs and other blood-pressure-lowering supplements, and its calming intent means additive sedation is plausible with sedatives, alcohol or benzodiazepines. There are no human safety data in pregnancy or breastfeeding (GABA affects neurotransmitters and the endocrine system), so avoid it then; stop before surgery given the blood-pressure effect.

Cited studies (7):
  - Effects of Oral Gamma-Aminobutyric Acid (GABA) Administration on Stress and Sleep in Humans: A Systematic Review, Frontiers in neuroscience (2020) — Systematic review of 14 placebo-controlled trials: limited evidence for stress, very limited for sleep; 11/14 had industry authors. [https://pubmed.ncbi.nlm.nih.gov/33041752/]
  - GABA Supplementation, Increased Heart-Rate Variability, Emotional Response, Sleep Efficiency and Reduced Depression in Sedentary Overweight Women Undergoing Physical Exercise: Placebo-Controlled, Randomized Clinical Trial, Journal of dietary supplements (2024) — 200 mg/day for 90 days in overweight women raised heart-rate variability and improved PSQI sleep and DASS-21 depression vs placebo (n=30). [https://pubmed.ncbi.nlm.nih.gov/38321713/]
  - Efficacy and Safety of Low-Dose Gamma-Aminobutyric Acid From Unpolished Rice Germ as a Health Functional Food for Promoting Sleep: A Randomized, Double-Blind, Placebo-Controlled Trial, Journal of clinical neurology (Seoul, Korea) (2022) — Low-dose 75 mg/day GABA for 4 wks shortened sleep latency 9.0→4.8 min and increased slow-wave (N3) sleep, no adverse events (n=50). [https://pubmed.ncbi.nlm.nih.gov/35796273/]
  - Safety and Efficacy of Gamma-Aminobutyric Acid from Fermented Rice Germ in Patients with Insomnia Symptoms: A Randomized, Double-Blind Trial, Journal of clinical neurology (Seoul, Korea) (2018) — 300 mg/day fermented-rice-germ GABA for 4 wks cut polysomnographic sleep latency 13.4→5.7 min and raised sleep efficiency 79→86% (n=40). [https://pubmed.ncbi.nlm.nih.gov/29856155/]
  - United States Pharmacopeia (USP) Safety Review of Gamma-Aminobutyric Acid (GABA), Nutrients (2021) — USP safety review: no serious adverse events up to 18 g/d for 4 days; mild throat burning, GI upset, headache; caution in pregnancy. [https://pubmed.ncbi.nlm.nih.gov/34444905/]
  - Relaxation and immunity enhancement effects of gamma-aminobutyric acid (GABA) administration in humans, BioFactors (Oxford, England) (2006) — Single 100 mg oral dose raised EEG alpha and lowered beta waves within 1 hour and blunted stress-related IgA drop (small crossover). [https://pubmed.ncbi.nlm.nih.gov/16971751/]
  - Blood-pressure-lowering effect of a novel fermented milk containing gamma-aminobutyric acid (GABA) in mild hypertensives, European journal of clinical nutrition (2003) — GABA-enriched fermented milk for 12 wks lowered systolic BP 17.4 mmHg and diastolic 7.2 mmHg in mild hypertensives (P<0.01). [https://pubmed.ncbi.nlm.nih.gov/12627188/]

---

## Glycerol
URL: https://nutridex.info/s/glycerol
Category: Performance
Evidence: Moderate — Several controlled trials; effects real but modest or context-dependent.
Osmotic hyperhydration agent for endurance in the heat.

Quick answer: Glycerol is used for pre-exercise hyperhydration. NutriDex grades the human evidence as moderate — Several controlled trials; effects real but modest or context-dependent. Based on 7 cited human studies (7 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Glycerol is a simple sugar-alcohol used as an osmotic 'hyperhydration' aid. Taken with a large fluid load before exercise, it draws water into the body's compartments, reliably boosting fluid retention (a 2007 meta-analysis found ~7.7 mL/kg more retained than water alone) and expanding plasma volume by roughly 3–10%. The point is to delay dehydration during prolonged exercise in the heat. The performance payoff, however, is modest and uneven: meta-analyses estimate around a 2–3% improvement in endurance, and a 2024 review found only small-to-moderate gains in time-to-exhaustion. Notably, several controlled trials — including a 5-km time-trial in 30°C heat — found better hydration but no actual performance benefit. Glycerol was removed from the WADA prohibited list in 2018 after its masking effect was judged minimal. It is best viewed as a situational tool for hot-weather endurance, not a general ergogenic.

Benefits / uses: Pre-exercise hyperhydration; Greater fluid retention; Expanded plasma volume; Aid endurance in the heat; Faster rehydration.
Active compounds: Glycerol (1,2,3-propanetriol).
Dose: 1.0–1.2 g/kg body weight in ~25 mL/kg fluid, taken over ~60 min and finishing ~30 min before exercise.
Safety: Generally well tolerated, but the required large fluid load and osmotic action commonly cause nausea, bloating, GI upset, headache and dizziness, and some users feel an urgent need to urinate. The fluid retention can transiently raise body weight (~1–1.5 kg), which may matter in weight-class sports. Avoid in people with kidney disease, heart failure or any condition where fluid overload is dangerous, and use caution in those prone to migraines. No major drug interactions are established, but glycerol can theoretically blunt the action of diuretics; it was banned by WADA as a masking agent until 2018.

Cited studies (7):
  - The effect of pre-exercise oral hyperhydration on endurance exercise performance, heart rate, and thermoregulation: a meta-analytical review, Applied physiology, nutrition, and metabolism = Physiologie appliquee, nutrition et metabolisme (2024) — Small-to-moderate gains in time-to-exhaustion and time-trial, but not total-work tasks; sodium lowered post-task body temperature vs glycerol. [https://pubmed.ncbi.nlm.nih.gov/38198662/]
  - The Effect of Pre-Exercise Hyperhydration on Exercise Performance, Physiological Outcomes and Gastrointestinal Symptoms: A Systematic Review, Sports Medicine (2023) — Systematic review (33 studies, 403 subjects): hyperhydration improved time-to-exhaustion in 5 of 7 constant-load trials; effects on other tasks inconsistent. [https://doi.org/10.1007/s40279-023-01885-2]
  - A meta-analysis of the effects of glycerol-induced hyperhydration on fluid retention and endurance performance, International journal of sport nutrition and exercise metabolism (2007) — Meta-analysis: glycerol retained ~7.7 mL/kg more fluid than water and improved endurance performance by 2.62% ± 1.60%. [https://pubmed.ncbi.nlm.nih.gov/17962713/]
  - Effect of Glycerol-Induced Hyperhydration on a 5-kilometer Running Time-Trial Performance in the Heat in Recreationally Active Individuals, Nutrients (2023) — RCT crossover: greater fluid retention (846 mL) and plasma volume (+10.1%), but no improvement in 5-km running time-trial in 30°C heat. [https://pubmed.ncbi.nlm.nih.gov/36771308/]
  - Effects of glycerol hyperhidration on the running economy of long-distance runners: a randomized crossover clinical trial, Frontiers in Nutrition (2025) — Crossover RCT (30 runners): 1.2 g/kg glycerol cut caloric cost 2.25%, heart rate 2.1 bpm and RPE 18% despite ~1.4 kg added body mass. [https://doi.org/10.3389/fnut.2025.1630462]
  - Guidelines for glycerol use in hyperhydration and rehydration associated with exercise, Sports medicine (Auckland, N.Z.) (2010) — Evidence-based guidelines: 1.2 g/kg glycerol in 26 mL/kg fluid over 60 min, 30 min pre-exercise, for hyperhydration. [https://pubmed.ncbi.nlm.nih.gov/20092365/]
  - Physiological and performance effects of glycerol hyperhydration and rehydration, Nutrition reviews (2009) — Review: glycerol raised plasma volume, sweat rate and lowered core temperature, but documented performance benefits remained inconsistent. [https://pubmed.ncbi.nlm.nih.gov/19941615/]

---

## Gymnema Sylvestre (Gymnema sylvestre)
URL: https://nutridex.info/s/gymnema
Category: Heart & Metabolic
Evidence: Moderate — Several controlled trials; effects real but modest or context-dependent.
Ayurvedic "sugar destroyer" leaf studied for blood-sugar control.

Quick answer: Gymnema Sylvestre is used for lower fasting & post-meal glucose. NutriDex grades the human evidence as moderate — Several controlled trials; effects real but modest or context-dependent. Based on 6 cited human studies (6 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Gymnema sylvestre is an Ayurvedic vine whose Hindi name "gurmar" means sugar-destroyer, because its gymnemic acids temporarily block sweet taste on the tongue. In diabetes its leaf extract is thought to slow intestinal sugar absorption and support insulin secretion. A 2021 systematic review and meta-analysis of 10 studies (419 people) found significant reductions in fasting glucose, post-prandial glucose and HbA1c, and small trials of standardized extracts (GS4, OSA) report fasting glucose dropping toward near-normal over 30-60 days, sometimes with lower insulin requirements. However, almost all trials are small, short (4-12 weeks), frequently unblinded or industry-linked, and statistically very heterogeneous, so the true magnitude is unclear and durability is unproven. It is best viewed as a possible adjunct to diet and standard therapy, not a replacement for prescribed diabetes medication.

Benefits / uses: Lower fasting & post-meal glucose; May modestly reduce HbA1c; Blunts sweet taste / sugar cravings; Adjunct to diabetes diet.
Active compounds: Gymnemic acids; Gurmarin; Saponins.
Dose: Commonly 200-400 mg/day of standardized leaf extract (e.g. GS4/OSA), or 2-4 g/day dried leaf, taken before meals.
Safety: Generally well tolerated short-term; the main concern is that, by lowering blood sugar, it can add to the effect of insulin or other antidiabetic drugs (sulfonylureas, metformin) and cause hypoglycemia, so glucose should be monitored and doses coordinated with a clinician. Rare case reports describe drug-induced liver injury (toxic hepatitis) - stop and seek care for jaundice, dark urine or right-upper-abdominal pain. Avoid in pregnancy and breastfeeding due to lack of safety data, and stop before surgery because of glucose-lowering effects.

Cited studies (6):
  - The effect of Gymnema sylvestre supplementation on glycemic control in type 2 diabetes patients: A systematic review and meta-analysis, Phytotherapy research : PTR (2021) — Meta-analysis of 10 trials (n=419): Gymnema significantly lowered fasting glucose, post-prandial glucose and HbA1c, but heterogeneity was very high (I2 80-99%). [https://pubmed.ncbi.nlm.nih.gov/34467577/]
  - Gymnema sylvestre for diabetes mellitus: a systematic review, Journal of alternative and complementary medicine (New York, N.Y.) (2007) — Systematic review found Gymnema promising for diabetes but flagged that the available human trials were few, small and methodologically weak. [https://pubmed.ncbi.nlm.nih.gov/18047444/]
  - Comparative Effects of Gymnema sylvestre and Berberine on Adipokines, Body Composition, and Metabolic Parameters in Obese Patients: A Randomized Study, Nutrients (2024) — RCT in 50 obese adults: Gymnema 400 mg/day for 3 months lowered fasting glucose, HbA1c and body-fat %, though berberine reduced weight more. [https://pubmed.ncbi.nlm.nih.gov/39064727/]
  - A novel Gymnema sylvestre extract stimulates insulin secretion from human islets in vivo and in vitro, Phytotherapy research : PTR (2010) — OSA extract 1 g/day for 60 days raised insulin and C-peptide and reduced fasting/post-meal glucose toward normal in 10 of 11 type 2 diabetics (open-label). [https://pubmed.ncbi.nlm.nih.gov/20812281/]
  - Use of Gymnema sylvestre leaf extract in the control of blood glucose in insulin-dependent diabetes mellitus, Journal of ethnopharmacology (1990) — GS4 400 mg/day for 6-30 months in 27 insulin-dependent diabetics cut insulin requirements, fasting glucose and HbA1c versus controls. [https://pubmed.ncbi.nlm.nih.gov/2259216/]
  - Toxic hepatitis induced by Gymnema sylvestre, a natural remedy for type 2 diabetes mellitus, The American journal of the medical sciences (2010) — Case report of toxic hepatitis (drug-induced liver injury) attributed to Gymnema sylvestre taken for type 2 diabetes; resolved after stopping. [https://pubmed.ncbi.nlm.nih.gov/20856101/]

---

## HMB (β-Hydroxy β-Methylbutyrate)
URL: https://nutridex.info/s/hmb
Category: Performance
Evidence: Mixed — Conflicting results across studies; benefit uncertain.
Leucine metabolite — preserves muscle in aging, not in young lifters.

Quick answer: HMB is used for preserve muscle in aging. NutriDex grades the human evidence as mixed — Conflicting results across studies; benefit uncertain. Based on 8 cited human studies (8 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

HMB is a metabolite of the amino acid leucine, sold to build muscle and speed recovery. The evidence splits sharply by population. In adults over 50, several meta-analyses find modest but consistent benefits: fat-free mass rises by roughly 0.3–0.4 standardized units (about 0.3 kg of lean mass, up to ~1.5 kg appendicular muscle in the largest 2025 pooling), with small improvements in grip strength and chair-stand time, typically needing 3 g/day for 12+ weeks. In young, resistance-trained adults the picture is different — a 2020 meta-analysis of 11 RCTs found no significant effect on body composition or strength. Benefits appear concentrated in anti-catabolic settings (aging, sarcopenia, bed rest, clinical wasting) rather than muscle-building in healthy athletes. Effect sizes are small and several trials are industry-linked, so expectations should stay measured.

Benefits / uses: Preserve muscle in aging; Slow muscle wasting; Modest lean-mass gains (older adults); Reduce muscle-damage markers.
Active compounds: Calcium β-hydroxy-β-methylbutyrate (HMB-Ca); Free-acid HMB (HMB-FA).
Dose: 3 g/day, usually split into 1 g doses with meals; HMB-Ca and free-acid forms perform similarly, with effects most likely after 12+ weeks.
Safety: HMB is well tolerated: human trials and reviews report no serious adverse effects at up to 3 g/day, and no negative impact on blood glucose, insulin sensitivity, lipids, or liver and kidney markers. Mild GI complaints (nausea, heartburn, flatulence) are the main reported issues. There are no well-established drug interactions, but data in pregnancy, breastfeeding, and children are lacking, so it is not recommended for them; anyone with kidney or liver disease should consult a clinician before use.

Cited studies (8):
  - Effects of oral supplementation of β -hydroxy-β -methylbutyrate on muscle mass and strength in individuals over the age of 50: a meta-analysis, Frontiers in Nutrition (2025) — 21 RCTs, 1935 adults >50: HMB raised appendicular muscle ~1.56 kg and lean mass 0.28 kg; grip +0.54 kg; chair-stand −0.73 s. Best at 3 g/day >12 wk. [https://doi.org/10.3389/fnut.2025.1522287]
  - The effects of β-hydroxy-β-methylbutyrate or HMB-rich nutritional supplements on sarcopenia patients: a systematic review and meta-analysis, Frontiers in medicine (2024) — Systematic review/meta-analysis in sarcopenia: HMB or HMB-rich supplements modestly improved muscle-mass measures but overall evidence quality was low. [https://pubmed.ncbi.nlm.nih.gov/39071082/]
  - Effects of exercise with or without β-hydroxy-β-methylbutyrate supplementation on muscle mass, muscle strength, and physical performance in patients with sarcopenia: a systematic review and meta-analysis, Frontiers in nutrition (2024) — Adding HMB to exercise gave no significant extra gain in muscle mass, strength or physical performance vs exercise alone in sarcopenic patients. [https://pubmed.ncbi.nlm.nih.gov/39360288/]
  - Ergogenic Benefits of β‐Hydroxy‐β‐Methyl Butyrate (HMB) Supplementation on Body Composition and Muscle Strength: An Umbrella Review of Meta‐Analyses, Journal of Cachexia, Sarcopenia and Muscle (2025) — Umbrella review of meta-analyses: HMB benefits on body composition/strength are small and most pronounced in older or clinical populations, not young athletes. [https://doi.org/10.1002/jcsm.13671]
  - Supplementation with the Leucine Metabolite β-hydroxy-β-methylbutyrate (HMB) does not Improve Resistance Exercise-Induced Changes in Body Composition or Strength in Young Subjects: A Systematic Review and Meta-Analysis, Nutrients (2020) — Meta-analysis of 11 RCTs in young subjects: no significant HMB effect on fat-free mass (+0.29 kg, p=0.06) or strength during resistance training. [https://pubmed.ncbi.nlm.nih.gov/32456217/]
  - Effects of oral administration of β-hydroxy β-methylbutyrate on lean body mass in older adults: a systematic review and meta-analysis, European geriatric medicine (2021) — 9 studies, 448 older adults: HMB significantly increased fat-free mass (effect size 0.37, 95% CI 0.16–0.58); little added benefit when combined with exercise. [https://pubmed.ncbi.nlm.nih.gov/33034021/]
  - Effect of beta-hydroxy-beta-methylbutyrate supplementation on muscle loss in older adults: a systematic review and meta-analysis, Archives of gerontology and geriatrics (2015) — 7 RCTs, 287 older adults: HMB preserved muscle mass (SMD 0.35 kg, 95% CI 0.11–0.59) with no change in fat mass. [https://pubmed.ncbi.nlm.nih.gov/26169182/]
  - International society of sports nutrition position stand: β-hydroxy-β-methylbutyrate (HMB), Journal of the International Society of Sports Nutrition (2025) — Reviews tolerability: HMB up to 3 g/day is well tolerated with no adverse effects on glucose, insulin, lipids, liver or kidney markers in humans. [https://pubmed.ncbi.nlm.nih.gov/39699070/]

---

## Horse Chestnut (Aesculus hippocastanum)
URL: https://nutridex.info/s/horse-chestnut
Category: Heart & Metabolic
Evidence: Moderate — Several controlled trials; effects real but modest or context-dependent.
Standardized seed extract that eases achy, swollen legs from poor vein flow.

Quick answer: Horse Chestnut is used for reduce leg swelling (edema). NutriDex grades the human evidence as moderate — Several controlled trials; effects real but modest or context-dependent. Based on 7 cited human studies (7 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Horse chestnut seed extract (HCSE), standardized to the saponin aescin, is used for chronic venous insufficiency — the achy, swollen, heavy legs caused by poorly functioning leg veins. A Cochrane review of 17 randomized trials found HCSE reduced leg volume (weighted mean difference ~32 ml vs placebo), lowered leg pain in six of seven trials, and improved edema and itching over 2–16 weeks. A pooled meta-analysis of 13 RCTs (1,051 patients) reported a 46 ml leg-volume reduction and a ~4-fold higher chance of pain improvement. One trial found it roughly as effective as compression stockings for reducing swelling. Effects are real but modest, trials are short and often small or industry-linked, and there is no evidence it cures venous disease or works for unrelated 'circulation' claims. Only properly processed extracts are used — raw seeds, bark and leaves are toxic.

Benefits / uses: Reduce leg swelling (edema); Ease leg pain & heaviness; Relieve itching in varicose veins; Support chronic venous insufficiency.
Active compounds: Aescin (escin, a triterpene saponin); Flavonoids (quercetin, kaempferol); Proanthocyanidins.
Dose: Standardized seed extract delivering 50 mg aescin twice daily (≈300 mg extract, 16–20% aescin), taken for 2–16 weeks.
Safety: Standardized seed extract is generally well tolerated; reported effects are mild and infrequent (GI upset, nausea, headache, dizziness, itching, ~0.7% of users). Raw horse chestnut seeds, bark, leaves and flowers contain esculin and are poisonous — never consume them. Aescin has mild antiplatelet activity and may add to bleeding risk with anticoagulants/antiplatelets (warfarin, aspirin, clopidogrel), and may lower blood sugar, so monitor closely with antidiabetic drugs. Avoid in pregnancy, breastfeeding, and significant kidney or liver disease; stop before surgery.

Cited studies (7):
  - Horse chestnut seed extract for chronic venous insufficiency, The Cochrane database of systematic reviews (2012) — 17 RCTs: HCSE reduced leg volume (WMD 32.1 ml), and 6 of 7 trials showed significant leg-pain reduction vs placebo; adverse events mild. [https://pubmed.ncbi.nlm.nih.gov/23152216/]
  - Efficacy, routine effectiveness, and safety of horsechestnut seed extract in the treatment of chronic venous insufficiency. A meta-analysis of randomized controlled trials and large observational studies, International angiology : a journal of the International Union of Angiology (2002) — Meta-analysis of 13 RCTs (1,051 pts): HCSE cut leg volume 46.4 ml and raised odds of pain improvement 4.1-fold vs placebo. [https://pubmed.ncbi.nlm.nih.gov/12518108/]
  - Horse-chestnut seed extract for chronic venous insufficiency. A criteria-based systematic review, Archives of dermatology (1998) — Criteria-based review of placebo-controlled RCTs: HCSE consistently reduced lower-leg volume, calf and ankle circumference in CVI. [https://pubmed.ncbi.nlm.nih.gov/9828868/]
  - Horse chestnut seed extract for chronic venous insufficiency, The Cochrane database of systematic reviews (2006) — Earlier Cochrane update: HCSE superior to placebo for CVI signs and symptoms; called efficacious and safe short-term treatment. [https://pubmed.ncbi.nlm.nih.gov/16437450/]
  - Comparison of leg compression stocking and oral horse-chestnut seed extract therapy in patients with chronic venous insufficiency, Lancet (London, England) (1996) — RCT, 240 CVI patients: 50 mg aescin twice daily reduced leg edema as effectively as class-II compression stockings over 12 weeks. [https://pubmed.ncbi.nlm.nih.gov/8569363/]
  - Clinical efficacy of horsechestnut seed extract in the treatment of venous ulceration, Journal of wound care (2006) — Triple-blind RCT in venous ulcers: no faster healing, but significantly less wound slough and fewer dressing changes by week 12. [https://pubmed.ncbi.nlm.nih.gov/16620045/]
  - Hypoglycemic and Anti-Inflammatory Effects of Triterpene Glycoside Fractions from Aeculus hippocastanum Seeds, Molecules (Basel, Switzerland) (2021) — Triterpene glycoside fractions of A. hippocastanum seeds lowered blood glucose and inflammation in animal/in-vitro models. [https://pmc.ncbi.nlm.nih.gov/articles/PMC8270310/]

---

## Krill Oil (Euphausia superba)
URL: https://nutridex.info/s/krill-oil
Category: Heart & Metabolic
Evidence: Moderate — Several controlled trials; effects real but modest or context-dependent.
Phospholipid-bound omega-3s that modestly lower triglycerides.

Quick answer: Krill Oil is used for lower triglycerides. NutriDex grades the human evidence as moderate — Several controlled trials; effects real but modest or context-dependent. Based on 7 cited human studies (7 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Krill oil is an omega-3 supplement from Antarctic krill in which EPA and DHA are bound mainly to phospholipids rather than triglycerides (as in fish oil), which may modestly improve absorption. Pooled RCT data show real but small lipid changes: triglycerides fall about 14 mg/dL and LDL about 15 mg/dL, while HDL rises about 7 mg/dL. A prescription-grade krill formulation cut triglycerides ~26% in severe hypertriglyceridemia. However, no trial has shown krill oil prevents heart attacks, strokes or death, and typical over-the-counter capsules deliver fairly low EPA+DHA. Once marketed for joint pain, an early 6-month RCT found modest knee-osteoarthritis relief, but a larger 2024 JAMA trial found no benefit over placebo. Krill oil is a reasonable, generally well-tolerated omega-3 source, but expect lipid nudges, not dramatic outcomes.

Benefits / uses: Lower triglycerides; Lower LDL cholesterol; Raise HDL cholesterol; Omega-3 (EPA/DHA) source.
Active compounds: EPA & DHA (phospholipid-bound); Astaxanthin; Choline.
Dose: 1–4 g/day of krill oil providing roughly 200–600 mg combined EPA+DHA; prescription-strength formulations deliver more.
Safety: Generally well tolerated; the main side effects are fishy aftertaste, burping, and mild GI upset. Avoid if you are allergic to shellfish, krill or other crustaceans. Like other omega-3s, krill oil can mildly thin the blood, so use caution and consult a clinician if you take anticoagulants or antiplatelets (warfarin, DOACs, aspirin, clopidogrel) or are scheduled for surgery. Discuss with your doctor before use if pregnant or breastfeeding, as safety data are limited.

Cited studies (7):
  - Clinical effectiveness of krill oil supplementation on cardiovascular health in humans: An updated systematic review and meta-analysis of randomized controlled trials, Diabetes & metabolic syndrome (2023) — Updated meta-analysis (14 RCTs, 1458 people): significant drops in total cholesterol, LDL and triglycerides; no effect on BP, glucose or inflammation. [https://pubmed.ncbi.nlm.nih.gov/38039646/]
  - Lipid-modifying effects of krill oil in humans: systematic review and meta-analysis of randomized controlled trials, Nutrition reviews (2017) — Meta-analysis (7 RCTs, 662 people): krill oil cut LDL ~15.5 mg/dL and triglycerides ~14 mg/dL and raised HDL ~6.7 mg/dL. [https://pubmed.ncbi.nlm.nih.gov/28371906/]
  - Krill Oil for Knee Osteoarthritis: A Randomized Clinical Trial, JAMA (2024) — Larger RCT (n=262): 2 g/day krill oil did NOT improve knee pain over 24 weeks (mean difference 0.3 on VAS; P=0.94). [https://pubmed.ncbi.nlm.nih.gov/38776073/]
  - Effectiveness of a Novel ω-3 Krill Oil Agent in Patients With Severe Hypertriglyceridemia: A Randomized Clinical Trial, JAMA network open (2022) — RCT pooling 2 trials (~520 patients): prescription krill oil lowered triglycerides 26.0% vs 15.1% placebo in severe hypertriglyceridemia at 12 weeks. [https://pubmed.ncbi.nlm.nih.gov/34989797/]
  - Krill oil improved osteoarthritic knee pain in adults with mild to moderate knee osteoarthritis: a 6-month multicenter, randomized, double-blind, placebo-controlled trial, The American journal of clinical nutrition (2022) — 6-month RCT (n=235): 4 g/day krill oil modestly improved knee pain (-5.2 of 100), stiffness and function in mild-moderate osteoarthritis. [https://pubmed.ncbi.nlm.nih.gov/35880828/]
  - Bioavailability of fatty acids from krill oil, krill meal and fish oil in healthy subjects--a randomized, single-dose, cross-over trial, Lipids in health and disease (2015) — Single-dose crossover: 72-h EPA/DHA bioavailability ~50% higher for krill oil (89.1 %×h) than fish oil (59.2 %×h; P=0.003). [https://pubmed.ncbi.nlm.nih.gov/25884846/]
  - Incorporation of EPA and DHA into plasma phospholipids in response to different omega-3 fatty acid formulations--a comparative bioavailability study of fish oil vs. krill oil, Lipids in health and disease (2011) — Crossover trial: at equal 1680 mg EPA+DHA, krill oil gave higher plasma phospholipid incorporation than fish oil, but high variance left it non-significant. [https://pubmed.ncbi.nlm.nih.gov/21854650/]

---

## L-Arginine
URL: https://nutridex.info/s/l-arginine
Category: Performance, Heart & Metabolic
Evidence: Moderate — Several controlled trials; effects real but modest or context-dependent.
Nitric-oxide amino acid that modestly lowers blood pressure.

Quick answer: L-Arginine is used for lower blood pressure. NutriDex grades the human evidence as moderate — Several controlled trials; effects real but modest or context-dependent. Based on 6 cited human studies (6 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

L-arginine is a conditionally essential amino acid and the body's substrate for making nitric oxide, a vasodilator. Pooled meta-analyses of randomized trials show oral arginine (4–24 g/day) lowers systolic blood pressure by roughly 5–6 mmHg and diastolic by about 2–3 mmHg versus placebo — modest but real. In erectile dysfunction, doses of 1.5–5 g/day, especially combined with pycnogenol, improve IIEF scores meaningfully in small trials. Effects on flow-mediated dilation are inconsistent and mostly non-significant once outliers are removed. For exercise, arginine shows a large but highly heterogeneous and publication-biased aerobic effect and only a small anaerobic one, so sports-nutrition bodies do not endorse it as a proven ergogenic aid. In pregnancy, arginine may reduce pre-eclampsia risk, though evidence is low-certainty. Overall, benefits are genuine but modest, and trials are largely small and short.

Benefits / uses: Lower blood pressure; Support blood-vessel function; Help erectile dysfunction (often with pycnogenol); Possible aerobic performance edge.
Active compounds: L-arginine (free amino acid).
Dose: Typically 4–6 g/day (up to 24 g/day in BP trials), split; ~10 g taken 60–90 min pre-exercise for performance.
Safety: Generally well tolerated; high doses (>9 g/day) commonly cause GI upset, bloating and diarrhea. Because it lowers blood pressure and dilates vessels, it can add to antihypertensives, nitrates and PDE5 inhibitors (e.g. sildenafil), risking hypotension. Caution after a recent heart attack — a trial in post-MI patients found increased mortality with added arginine. May lower blood sugar (additive with antidiabetic drugs) and can worsen herpes outbreaks in susceptible people; avoid combining with blood thinners or other vasodilators without medical advice.

Cited studies (6):
  - Efficacy of L-arginine and Pycnogenol ® in the treatment of male erectile dysfunction: a systematic review and meta-analysis, Frontiers in endocrinology (2023) — Meta-analysis (3 RCTs, 184 men): L-arginine plus pycnogenol improved IIEF erectile score by 8.9 points vs placebo. [https://pubmed.ncbi.nlm.nih.gov/37908749/]
  - L-Arginine and L-Citrulline for Prevention and Treatment of Pre-Eclampsia: A Systematic Review and Meta-Analysis, BJOG : an international journal of obstetrics and gynaecology (2025) — Meta-analysis: in prevention trials L-arginine cut pre-eclampsia risk (RR 0.52) and severe pre-eclampsia (RR 0.23); low-certainty. [https://pubmed.ncbi.nlm.nih.gov/39800868/]
  - Effect of l-Arginine Supplementation on Blood Pressure in Adults: A Systematic Review and Dose-Response Meta-analysis of Randomized Clinical Trials, Advances in nutrition (Bethesda, Md.) (2022) — Dose-response meta-analysis (22 RCTs): L-arginine reduced systolic BP by 6.40 mmHg and diastolic by 2.64 mmHg. [https://pubmed.ncbi.nlm.nih.gov/34967840/]
  - Effects of Arginine Supplementation on Athletic Performance Based on Energy Metabolism: A Systematic Review and Meta-Analysis, Nutrients (2020) — Meta-analysis (18 studies): large but heterogeneous aerobic effect (ES 0.84, I²=89%); small anaerobic effect (ES 0.24). [https://pubmed.ncbi.nlm.nih.gov/32370176/]
  - Association of l-Arginine Supplementation with Markers of Endothelial Function in Patients with Cardiovascular or Metabolic Disorders: A Systematic Review and Meta-Analysis, Nutrients (2018) — Meta-analysis (8 RCTs, n=469): no significant effect of L-arginine on flow-mediated dilation (SMD 0.30, CI -0.85 to 1.46). [https://pubmed.ncbi.nlm.nih.gov/30577559/]
  - Effect of oral L-arginine supplementation on blood pressure: a meta-analysis of randomized, double-blind, placebo-controlled trials, American heart journal (2011) — Meta-analysis (11 RCTs, n=387): oral L-arginine lowered systolic BP 5.39 mmHg and diastolic 2.66 mmHg vs placebo. [https://pubmed.ncbi.nlm.nih.gov/22137067/]

---

## L-Carnitine
URL: https://nutridex.info/s/l-carnitine
Category: Performance, Heart & Metabolic
Evidence: Moderate — Several controlled trials; effects real but modest or context-dependent.
Amino-acid derivative that shuttles fat into cells to be burned for energy.

Quick answer: L-Carnitine is used for modest weight & bmi reduction. NutriDex grades the human evidence as moderate — Several controlled trials; effects real but modest or context-dependent. Based on 8 cited human studies (8 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

L-carnitine is a compound the body makes from lysine and methionine (and gets from red meat) that ferries fatty acids into mitochondria to be burned for energy. Across many randomized trials it produces small, consistent effects rather than dramatic ones: a meta-analysis of 37 RCTs found ~1.2 kg average weight loss (best near 2 g/day), and trials in type 2 diabetes show modest drops in HbA1c (~0.16% per gram/day) and fasting glucose. In non-alcoholic fatty liver disease it lowers ALT and AST, and in exercise it reduces post-workout muscle soreness and damage markers. Heart-failure and post-heart-attack trials report improved ejection fraction and, in older pooled data, lower mortality—though those trials are small and dated. Effects are real but modest, heterogeneous, and not in major guidelines. A caveat: gut bacteria turn carnitine into TMAO, a metabolite linked to atherosclerosis.

Benefits / uses: Modest weight & BMI reduction; Better glycemic control in diabetes; Faster exercise recovery (less soreness); Lower liver enzymes in fatty liver; Cardiac support after heart attack.
Active compounds: L-carnitine; Acetyl-L-carnitine; L-carnitine L-tartrate; Propionyl-L-carnitine.
Dose: Typically 1–3 g/day orally; weight and metabolic trials cluster around 2 g/day, with effects building over weeks to months.
Safety: Oral L-carnitine is generally well tolerated; the main side effects are nausea, abdominal cramps, diarrhea and a fishy body odor at higher doses. Gut bacteria convert it to TMAO, a metabolite associated with atherosclerosis, so routine use in people at cardiovascular risk is debated. It may potentiate warfarin and other anticoagulants (raising INR) and can add to the glucose-lowering effect of insulin or antidiabetic drugs; people on thyroid medication should be cautious because carnitine can blunt thyroid hormone action. Use medical-grade L-carnitine and consult a clinician in kidney disease or seizure disorders.

Cited studies (8):
  - The Effects of L-Carnitine Supplementation on Weight Loss, Glycemic Control, and Cardiovascular Risk Factors in Patients With Type 2 Diabetes: A Systematic Review and Dose-response Meta-Analysis of Randomized Controlled Trials, Clinical therapeutics (2024) — Dose-response meta-analysis (21 RCTs, n=2,041 with T2D): each 1 g/day lowered HbA1c ~0.16% and LDL ~0.11 mmol/L; high heterogeneity. [https://pubmed.ncbi.nlm.nih.gov/38594107/]
  - Efficacy and safety of carnitine supplementation on NAFLD: a systematic review and meta-analysis, Systematic reviews (2023) — Meta-analysis of 8 RCTs (n=544) in NAFLD: carnitine reduced ALT (MD −26.4 IU/L) and AST (MD −15.9 IU/L); low-certainty evidence. [https://pubmed.ncbi.nlm.nih.gov/37120548/]
  - Effects of l-carnitine supplementation on weight loss and body composition: A systematic review and meta-analysis of 37 randomized controlled clinical trials with dose-response analysis, Clinical nutrition ESPEN (2020) — Meta-analysis of 37 RCTs (n=2,292): L-carnitine cut body weight ~1.21 kg and BMI ~0.24, with maximal effect near 2 g/day. [https://pubmed.ncbi.nlm.nih.gov/32359762/]
  - The Effect of L-Carnitine Supplementation on Exercise-Induced Muscle Damage: A Systematic Review and Meta-Analysis of Randomized Clinical Trials, Journal of the American College of Nutrition (2020) — Meta-analysis of 7 RCTs: L-carnitine reduced post-exercise muscle soreness across follow-ups and cut creatine kinase/myoglobin at 24h. [https://pubmed.ncbi.nlm.nih.gov/32154768/]
  - Efficacy and Safety of L-Carnitine Treatment for Chronic Heart Failure: A Meta-Analysis of Randomized Controlled Trials, BioMed research international (2017) — Meta-analysis of 17 RCTs (n=1,625) in chronic heart failure: L-carnitine raised LVEF by ~4.1% and improved cardiac output; good tolerability. [https://pubmed.ncbi.nlm.nih.gov/28497060/]
  - l-Carnitine Supplementation in Recovery after Exercise, Nutrients (2018) — Systematic review concluded L-carnitine plausibly reduces muscle damage and supports recovery, but exercise-performance effects remain inconsistent. [https://pubmed.ncbi.nlm.nih.gov/29534031/]
  - L-carnitine in the secondary prevention of cardiovascular disease: systematic review and meta-analysis, Mayo Clinic proceedings (2013) — Meta-analysis of 13 trials (n=3,629) post-MI: 27% lower all-cause mortality, 65% fewer ventricular arrhythmias, 40% less angina; older trials. [https://pubmed.ncbi.nlm.nih.gov/23597877/]
  - Intestinal microbiota metabolism of L-carnitine, a nutrient in red meat, promotes atherosclerosis, Nature medicine (2013) — Gut microbes convert dietary L-carnitine to TMAO; plasma carnitine predicted cardiovascular events mainly when TMAO was also high; promoted atherosclerosis in mice. [https://pubmed.ncbi.nlm.nih.gov/23563705/]

---

## Glutamine (L-Glutamine)
URL: https://nutridex.info/s/l-glutamine
Category: Performance, Gut & Immune
Evidence: Mixed — Conflicting results across studies; benefit uncertain.
Abundant amino acid sold for gut, immunity and recovery.

Quick answer: Glutamine is used for reduces sickle cell pain crises (rx). NutriDex grades the human evidence as mixed — Conflicting results across studies; benefit uncertain. Based on 8 cited human studies (8 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Glutamine is the most abundant free amino acid in the body and a fuel for gut and immune cells, which drives its supplement marketing. The evidence splits sharply. Pharmaceutical L-glutamine (Endari) is FDA-approved for sickle cell disease, where a phase-3 RCT cut pain crises ~25% and hospitalizations ~33%. In surgery, meta-analyses show fewer infections and shorter stays. But for popular fitness and wellness claims the data are weak: a meta-analysis of athletes found no effect on immune markers, VO2max or body composition, and high doses reduced intestinal permeability only modestly during heat-stress running. High-dose intravenous glutamine actually increased mortality in critically ill patients (REDOXS). Healthy, well-fed people make plenty of their own glutamine, so routine supplementation for recovery or 'gut healing' has little proven benefit. The clinical value is real but narrow and prescription-bound.

Benefits / uses: Reduces sickle cell pain crises (Rx); May lower exercise gut permeability; Post-surgical immune support; Modest eccentric-exercise recovery.
Active compounds: L-glutamine (free amino acid); Alanyl-glutamine (dipeptide form).
Dose: Recovery/gut studies use 0.1–0.3 g/kg (roughly 5–30 g/day); the FDA-approved sickle-cell drug Endari is 0.3 g/kg twice daily.
Safety: Oral glutamine is well tolerated up to ~30 g/day; mild bloating, nausea or constipation can occur. Avoid in people with cirrhosis or hepatic encephalopathy, since glutamine raises ammonia. Do not assume IV/high-dose safety: in the REDOXS trial high-dose intravenous glutamine increased mortality in critically ill patients with renal or multi-organ failure. It may blunt some anti-seizure and chemotherapy effects and can lower the lactulose used as a laxative/ammonia treatment; discuss with a clinician if you take antiepileptics, are on cancer therapy, or have kidney or liver disease.

Cited studies (8):
  - A systematic review and meta-analysis of clinical trials on the effects of glutamine supplementation on gut permeability in adults, Amino acids (2024) — Meta-analysis (10 trials, 428 adults): no overall effect on gut permeability; significant reduction only at >30 g/day and <2 weeks of use. [https://pubmed.ncbi.nlm.nih.gov/39397201/]
  - Meta-analysis of Glutamine on Immune Function and Post-Operative Complications of Patients With Colorectal Cancer, Frontiers in nutrition (2021) — Meta-analysis (31 RCTs, 2201 colorectal-surgery patients): glutamine raised immunoglobulins and cut infections and anastomotic leakage vs control. [https://pubmed.ncbi.nlm.nih.gov/34938760/]
  - The effect of glutamine supplementation on athletic performance, body composition, and immune function: A systematic review and a meta-analysis of clinical trials, Clinical nutrition (Edinburgh, Scotland) (2019) — Meta-analysis (25 trials): glutamine had no effect on athletes' immune cells, VO2max, fat or lean mass, CK or glucose; only modest weight reduction. [https://pubmed.ncbi.nlm.nih.gov/29784526/]
  - Enteral glutamine supplementation in critically ill patients: a systematic review and meta-analysis, Critical care (London, England) (2015) — Meta-analysis (11 trials, 1079 critically ill): enteral glutamine did not reduce mortality or infections, though hospital stay was ~4.7 days shorter. [https://pubmed.ncbi.nlm.nih.gov/26283217/]
  - A Phase 3 Trial of l-Glutamine in Sickle Cell Disease, The New England journal of medicine (2018) — Phase-3 RCT (NEJM): L-glutamine cut median sickle-cell pain crises 25% (3 vs 4) and hospitalizations 33% over 48 weeks; basis for FDA approval. [https://pubmed.ncbi.nlm.nih.gov/30021096/]
  - Glutamine supplementation reduces markers of intestinal permeability during running in the heat in a dose-dependent manner, European journal of applied physiology (2017) — RCT: oral glutamine before running in the heat lowered lactulose:rhamnose permeability dose-dependently (~25% at 0.25 g/kg, ~40% at 0.9 g/kg). [https://pubmed.ncbi.nlm.nih.gov/29058112/]
  - The Influence of Oral L-Glutamine Supplementation on Muscle Strength Recovery and Soreness Following Unilateral Knee Extension Eccentric Exercise, International journal of sport nutrition and exercise metabolism (2015) — Crossover RCT (n=16): 0.3 g/kg/day glutamine preserved knee-extensor torque (90% vs 79%) and modestly reduced soreness over 96 h after eccentric exercise. [https://pubmed.ncbi.nlm.nih.gov/25811544/]
  - Glutamine: Metabolism and Immune Function, Supplementation and Clinical Translation, Nutrients (2018) — Review of glutamine metabolism, immune/gut function and clinical use; details why benefit is largely confined to catabolic, depleted states. [https://pubmed.ncbi.nlm.nih.gov/30360490/]

---

## L-Lysine
URL: https://nutridex.info/s/l-lysine
Category: Gut & Immune
Evidence: Mixed — Conflicting results across studies; benefit uncertain.
Essential amino acid taken to blunt recurrent cold sores.

Quick answer: L-Lysine is used for fewer cold-sore (herpes) recurrences. NutriDex grades the human evidence as mixed — Conflicting results across studies; benefit uncertain. Based on 8 cited human studies (8 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

L-Lysine is an essential amino acid the body cannot make, obtained from meat, fish, eggs and legumes. It is marketed mainly to prevent and shorten cold sores (herpes simplex labialis), on the theory that lysine antagonises arginine, an amino acid the virus depends on. The human trials are genuinely split: in a 6-month placebo-controlled trial, 1,000 mg three times daily produced about 2.4 fewer outbreaks per year with milder, faster-healing lesions; a crossover study at ~1,250 mg/day also cut recurrences, while 624 mg/day did not. Yet other double-blind trials at lower doses found no effect, and reviewers note doses under 1 g/day generally fail. Beyond herpes, small studies suggest lysine (often combined with arginine) may modestly lower anxiety and salivary cortisol, and it improves intestinal calcium absorption. None of these uses rests on large, modern, confirmatory trials.

Benefits / uses: Fewer cold-sore (herpes) recurrences; Milder, faster-healing outbreaks; May lower stress/anxiety; Aids calcium absorption.
Active compounds: L-Lysine (free base); L-Lysine monohydrochloride.
Dose: 1,000 mg three times daily (≥3 g/day) for prophylaxis of recurrent herpes labialis; lower doses (<1 g/day) appear ineffective unless paired with a low-arginine diet.
Safety: L-Lysine is generally well tolerated; high doses can cause diarrhoea, nausea and abdominal cramps. Because it shares renal transport with arginine and is cleared by the kidneys, people with kidney disease should avoid supplements, and very high intakes have been linked to Fanconi-type renal effects in case reports. Theoretical concerns exist for those with cardiovascular or gallbladder disease (possible cholesterol/atherogenic effects in animals). It may enhance calcium absorption, so use caution if you are also taking calcium supplements; no major drug interactions are well established.

Cited studies (8):
  - Lysine for Herpes Simplex Prophylaxis: A Review of the Evidence, Integrative medicine (Encinitas, Calif.) (2017) — Review: lysine <1 g/day ineffective without a low-arginine diet; doses >3 g/day improve subjective disease experience; better trials needed. [https://pubmed.ncbi.nlm.nih.gov/30881246/]
  - Success of L-lysine therapy in frequently recurrent herpes simplex infection. Treatment and prophylaxis, Dermatologica (1987) — 1,000 mg L-lysine 3×/day for 6 months gave 2.4 fewer HSV recurrences/year with milder, faster-healing lesions vs placebo (p<0.05). [https://pubmed.ncbi.nlm.nih.gov/3115841/]
  - Failure of lysine in frequently recurrent herpes simplex infection. Treatment and prophylaxis, Archives of dermatology (1984) — Double-blind RCT of 400 mg lysine 3×/day found no benefit on frequency, duration or severity of recurrent herpes simplex. [https://pubmed.ncbi.nlm.nih.gov/6419679/]
  - Lysine as a prophylactic agent in the treatment of recurrent herpes simplex labialis, Oral surgery, oral medicine, and oral pathology (1984) — Crossover RCT: 1,248 mg/day cut recurrence rate and severity; 624 mg/day was ineffective; neither dose shortened healing time. [https://pubmed.ncbi.nlm.nih.gov/6438572/]
  - Lysine prophylaxis in recurrent herpes simplex labialis: a double-blind, controlled crossover study, Acta dermato-venereologica (1980) — Double-blind crossover prophylaxis study reported fewer herpes labialis recurrences during lysine vs placebo periods. [https://pubmed.ncbi.nlm.nih.gov/6153847/]
  - Oral treatment with L-lysine and L-arginine reduces anxiety and basal cortisol levels in healthy humans, Biomedical research (Tokyo, Japan) (2007) — DB-RCT (n=108): 2.64 g lysine + 2.64 g arginine/day for 1 week lowered trait and state anxiety and basal salivary cortisol in men. [https://pubmed.ncbi.nlm.nih.gov/17510493/]
  - Lysine fortification reduces anxiety and lessens stress in family members in economically weak communities in Northwest Syria, Proceedings of the National Academy of Sciences of the United States of America (2004) — DB-RCT of lysine wheat fortification in Syria reduced trait anxiety in men and the cortisol stress response in women over 3 months. [https://pubmed.ncbi.nlm.nih.gov/15159538/]
  - Dietary L-lysine and calcium metabolism in humans, Nutrition (Burbank, Los Angeles County, Calif.) (1992) — In healthy and osteoporotic women, L-lysine increased intestinal calcium absorption and reduced urinary calcium loss. [https://pubmed.ncbi.nlm.nih.gov/1486246/]

---

## L-Tryptophan
URL: https://nutridex.info/s/l-tryptophan
Category: Sleep & Mood
Evidence: Moderate — Several controlled trials; effects real but modest or context-dependent.
Essential amino acid and serotonin precursor used for sleep and mood.

Quick answer: L-Tryptophan is used for reduce night-time waking. NutriDex grades the human evidence as moderate — Several controlled trials; effects real but modest or context-dependent. Based on 7 cited human studies (7 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

L-Tryptophan is an essential amino acid the body converts to 5-HTP and then serotonin and melatonin, which underlies its use for sleep and mood. A 2022 meta-analysis of randomized trials found doses of at least 1 g before bed shortened wake-after-sleep-onset by roughly 30 minutes, but did not reliably change how fast people fell asleep, total sleep time, or sleep efficiency. For mood, the strongest single trial showed 6 g/day eased premenstrual dysphoria (a 34.5% drop in mood scores vs 10.4% on placebo). Depletion studies confirm that removing tryptophan lowers serotonin and worsens mood in vulnerable people, supporting the mechanism. However, a 2002 meta-analysis of depression found only 2 of 108 trials were admissible, so antidepressant claims are unproven. Effects overall are modest and narrow, and a 1989 contamination outbreak that caused over 1,500 cases of eosinophilia-myalgia syndrome and 37+ deaths shadows its history.

Benefits / uses: Reduce night-time waking; Modest sleep-quality gains; Ease premenstrual mood symptoms; Supports serotonin synthesis.
Active compounds: L-Tryptophan; 5-HTP (metabolite); Serotonin (downstream).
Dose: 1–3 g taken 30–60 min before bed for sleep; mood trials used up to 6 g/day. Take away from high-protein meals, which block brain uptake.
Safety: Common effects are drowsiness, nausea, headache and dizziness; high doses can cause GI upset. The serious risk is serotonin syndrome when combined with SSRIs/SNRIs, MAO inhibitors, triptans, tramadol, or 5-HTP/St John's Wort, so avoid these combinations. It adds to sedatives, benzodiazepines and alcohol. Critically, a 1989 outbreak of eosinophilia-myalgia syndrome (1,500+ cases, 37+ deaths) was linked to contaminated batches, and rare post-ban cases persist, so use only pharmaceutical-grade product. Avoid in pregnancy, breastfeeding, and liver or kidney disease without medical advice.

Cited studies (7):
  - The impact of tryptophan supplementation on sleep quality: a systematic review, meta-analysis, and meta-regression, Nutrition Reviews (2021) — Meta-analysis: Trp ≥1 g/night shortened wake-after-sleep-onset (~30 min) and improved subjective sleep quality; sleep latency and total time unchanged. [https://doi.org/10.1093/nutrit/nuab027]
  - Are tryptophan and 5-hydroxytryptophan effective treatments for depression? A meta-analysis, The Australian and New Zealand journal of psychiatry (2002) — Of 108 depression trials, only 2 met quality criteria; pooled they beat placebo (OR 4.1) but authors deemed the evidence too weak to recommend. [https://pubmed.ncbi.nlm.nih.gov/12169147/]
  - The effects of dietary tryptophan on affective disorders, Archives of psychiatric nursing (2015) — Crossover RCT (n=25): a high-tryptophan diet produced more positive affect and significantly less depression, irritability and anxiety than a low-tryptophan diet. [https://pubmed.ncbi.nlm.nih.gov/25858202/]
  - A placebo-controlled clinical trial of L-tryptophan in premenstrual dysphoria, Biological psychiatry (1999) — RCT (n=71): L-tryptophan 6 g/day during the luteal phase cut premenstrual mood scores 34.5% vs 10.4% on placebo across 3 cycles. [https://pubmed.ncbi.nlm.nih.gov/10023508/]
  - Sleep induced by L-tryptophan. Effect of dosages within the normal dietary intake, The Journal of nervous and mental disease (1979) — Controlled trial (n=15 mild insomniacs): 1 g L-tryptophan significantly cut sleep latency; lower doses trended the same way, within normal dietary intake. [https://pubmed.ncbi.nlm.nih.gov/469515/]
  - Post-epidemic eosinophilia-myalgia syndrome associated with L-tryptophan, Arthritis and rheumatism (2011) — Case of L-tryptophan-induced eosinophilia-myalgia syndrome after the FDA lifted its ban; notes the 1989 epidemic traced to a single contaminated source. [https://pubmed.ncbi.nlm.nih.gov/21702023/]
  - The effect of raising and lowering tryptophan levels on human mood and social behaviour, Philosophical transactions of the Royal Society of London. Series B, Biological sciences (2013) — Review: lowering plasma tryptophan ~60%+ depresses mood mainly in those vulnerable to depression; supports serotonin precursor mechanism but not as sole cause. [https://pubmed.ncbi.nlm.nih.gov/23440461/]

---

## L-Tyrosine
URL: https://nutridex.info/s/l-tyrosine
Category: Nootropic, Performance
Evidence: Preliminary — Early or small human trials; promising but not yet conclusive.
Amino acid that may protect thinking under acute stress.

Quick answer: L-Tyrosine is used for cognition under acute stress. NutriDex grades the human evidence as preliminary — Early or small human trials; promising but not yet conclusive. Based on 9 cited human studies (9 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

L-Tyrosine is an amino acid the body uses to make the catecholamines dopamine and noradrenaline. The interest is in 'topping up' these neurotransmitters when stress depletes them. In small double-blind RCTs, a single large dose (100–150 mg/kg) blunted the cognitive and mood decline caused by cold, hypoxia, prolonged wakefulness or demanding multitasking, and improved working memory, task-switching and inhibitory control versus placebo. Effects are modest and short-lived (often ~3 hours). A 2015 systematic review of 10 RCTs gave only a weak, qualified recommendation, judging the overall evidence insufficient. Results are also state-dependent: benefits appear mainly in depleted or genetically dopamine-low individuals, and some tasks show no effect or even worse performance, including reduced working memory at high doses in older adults. There is no good evidence it boosts cognition in unstressed people or with chronic daily use.

Benefits / uses: Cognition under acute stress; Working memory & flexibility; Resist cold / sleep-loss decline; Focus while multitasking.
Active compounds: L-Tyrosine (free amino acid).
Dose: Single acute doses of 100–150 mg/kg (≈7–12 g) taken ~30–60 min before a stressor; ~2 g/day is the common over-the-counter amount.
Safety: Tyrosine is generally well tolerated at typical doses; large acute doses can cause nausea, headache, heartburn or fatigue, and a dose-response trial found higher doses worsened working memory in older adults. Because it feeds catecholamine and thyroid-hormone synthesis, avoid or use caution with MAOI antidepressants (risk of hypertensive reaction), levodopa (competes for absorption, may blunt Parkinson's treatment), thyroid medication or hyperthyroidism (Graves' disease), and stimulants. People with phenylketonuria should follow medical advice. Discuss with a clinician before use if pregnant, breastfeeding, or on these medications.

Cited studies (9):
  - The effect of tyrosine supplementation on whole-body endurance performance in physically active population: A systematic review and meta-analysis including GRADE qualification, Journal of sports sciences (2023) — A systematic review and GRADE meta-analysis of human trials found tyrosine supplementation was ineffective for endurance performance, with no difference from placebo for time-to-exhaustion (SMD = 0.02, p = 0.94) or time-trial performance (SMD = -0.04, p = 0.85) at moderate-quality evidence. [https://pubmed.ncbi.nlm.nih.gov/38290812/]
  - Tyrosine for Mitigating Stress and Enhancing Performance in Healthy Adult Humans, a Rapid Evidence Assessment of the Literature, Military medicine (2015) — Systematic review of 10 RCTs + 4 trials: only a weak recommendation for cognitive stress; evidence judged insufficient for firm conclusions. [https://pubmed.ncbi.nlm.nih.gov/26126245/]
  - Impact of L-theanine and L-tyrosine on markers of stress and cognitive performance in response to a virtual reality based active shooter training drill, Stress (Amsterdam, Netherlands) (2024) — In an 80-person double-blind RCT, a single 2,000 mg dose of L-tyrosine before a virtual-reality active-shooter stress drill produced significantly fewer missed responses on the Stroop task versus placebo, though it did not change stress biomarkers (salivary alpha-amylase, sIgA) or heart rate. [https://pubmed.ncbi.nlm.nih.gov/38975711/]
  - Tyrosine promotes cognitive flexibility: evidence from proactive vs. reactive control during task switching performance, Neuropsychologia (2015) — 2 g tyrosine reduced task-switching costs, promoting cognitive flexibility vs placebo in 22 healthy adults (double-blind crossover). [https://pubmed.ncbi.nlm.nih.gov/25598314/]
  - Effects of l-Tyrosine on working memory and inhibitory control are determined by DRD2 genotypes: A randomized controlled trial, Cortex; a journal devoted to the study of the nervous system and behavior (2016) — Working-memory and inhibitory-control benefits depended on DRD2 genotype: T/T carriers gained more than C/C, so response varies by dopamine genetics. [https://pubmed.ncbi.nlm.nih.gov/27403851/]
  - On the effects of tyrosine supplementation on interference control in a randomized, double-blind placebo-control trial, European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology (2018) — Mixed/null result: tyrosine shrank consciously perceived conflict in a Simon task but not a Flanker task, and worsened subliminal conflict (n=26). [https://pubmed.ncbi.nlm.nih.gov/29980424/]
  - Dose-Dependent Effects of Oral Tyrosine Administration on Plasma Tyrosine Levels and Cognition in Aging, Nutrients (2017) — Dose-response trial: higher tyrosine doses gave WORSE working memory in older adults (60–75 y), suggesting overshoot can impair, not help. [https://doi.org/10.3390/nu9121279]
  - The effects of tyrosine on cognitive performance during extended wakefulness, Aviation, space, and environmental medicine (1995) — 150 mg/kg during a night of sleep loss reduced psychomotor decline and vigilance lapses; benefit lasted ~3 hours (double-blind RCT). [https://pubmed.ncbi.nlm.nih.gov/7794222/]
  - Tyrosine improves working memory in a multitasking environment, Pharmacology, biochemistry, and behavior (1999) — Tyrosine improved accuracy and reduced errors on working-memory tasks during a demanding multitasking battery vs placebo. [https://pubmed.ncbi.nlm.nih.gov/10548261/]

---

## Lavender (Silexan) (Lavandula angustifolia)
URL: https://nutridex.info/s/lavender
Category: Sleep & Mood
Evidence: Strong — Multiple high-quality RCTs / meta-analyses with consistent effects.
A standardized oral lavender oil with real anxiolytic data.

Quick answer: Lavender (Silexan) is used for reduce anxiety symptoms. NutriDex grades the human evidence as strong — Multiple high-quality RCTs / meta-analyses with consistent effects. Based on 8 cited human studies (8 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Silexan is a standardized softgel of lavender essential oil (Lavandula angustifolia) taken by mouth, distinct from aromatherapy or culinary lavender. Across five double-blind RCTs (1,213 patients), it reduced Hamilton Anxiety (HAMA) scores about 2.9 points more than placebo, a modest-to-moderate effect (standardized mean difference ~0.35). In generalized anxiety disorder, 160 mg/day lowered HAMA by ~14 points and worked as well as 0.5 mg lorazepam and 20 mg paroxetine, without sedation or dependence. Subthreshold-anxiety and mixed anxiety-depression trials also showed benefit, including better sleep quality (PSQI), likely secondary to reduced anxiety rather than a direct hypnotic effect. A 2024 trial found a small antidepressant signal in mild-to-moderate depression. The main limits: nearly all trials are funded by the manufacturer, durations are ~10 weeks, and results do not generalize to other lavender forms.

Benefits / uses: Reduce anxiety symptoms; Ease restlessness & worry; Improve sleep quality; Lift mild-to-moderate low mood.
Active compounds: Linalool; Linalyl acetate.
Dose: 80–160 mg/day of the standardized oral preparation Silexan (one soft-gel capsule), with 160 mg/day used for generalized anxiety disorder.
Safety: Silexan is well tolerated; the most common side effect is eructation (burping) with a lavender taste or breath odour, plus occasional nausea or mild GI upset — roughly 3% above placebo. Unlike benzodiazepines it has not shown sedation, dependence, abuse potential, or withdrawal in trials, including a dedicated abuse-liability study. Human drug-interaction data are limited; theoretical caution is reasonable when combining with other sedatives or CNS depressants, and it should be avoided in pregnancy and breastfeeding due to insufficient safety data. Discuss with a clinician before substituting it for a prescribed anxiety or depression medication.

Cited studies (8):
  - Efficacy of Silexan in patients with anxiety disorders: a meta-analysis of randomized, placebo-controlled trials, European archives of psychiatry and clinical neuroscience (2023) — Meta-analysis of 5 RCTs (n=1213): Silexan cut HAMA 2.9 points vs placebo (SMD 0.35, 95% CI 0.13-0.56; p=0.002). [https://pubmed.ncbi.nlm.nih.gov/36717399/]
  - Silexan in generalized anxiety disorder: investigation of the therapeutic dosage range in a pooled data set, International clinical psychopharmacology (2017) — Pooled GAD dose analysis: 160 mg/day superior to placebo on all outcomes; 80 mg is the lower end of the range. [https://pubmed.ncbi.nlm.nih.gov/28379882/]
  - Lavender Oil Preparation (Silexan) for Treating Anxiety: An Updated Meta-Analysis, Journal of clinical psychopharmacology (2017) — Updated meta-analysis confirms Silexan's anxiolytic effect across pooled placebo-controlled trials. [https://pubmed.ncbi.nlm.nih.gov/27861196/]
  - Lavender oil preparation Silexan is effective in mild-to-moderate major depression: a randomized, placebo- and reference-controlled trial, European archives of psychiatry and clinical neuroscience (2025) — Mild-moderate depression RCT (n=498): MADRS 2.2 pts better than placebo (p<0.01), similar to 50 mg sertraline. [https://pubmed.ncbi.nlm.nih.gov/38558147/]
  - Efficacy of Silexan in mixed anxiety-depression--A randomized, placebo-controlled trial, European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology (2016) — Mixed anxiety-depression RCT (n=318): HAMA fell 10.8 pts (Silexan) vs 8.4 (placebo), p<0.01. [https://pubmed.ncbi.nlm.nih.gov/26718792/]
  - Lavender oil preparation Silexan is effective in generalized anxiety disorder--a randomized, double-blind comparison to placebo and paroxetine, The international journal of neuropsychopharmacology (2014) — GAD RCT (n=539): Silexan 160 mg lowered HAMA 14.1 pts vs 9.5 placebo; matched 20 mg paroxetine. [https://pubmed.ncbi.nlm.nih.gov/24456909/]
  - A multi-center, double-blind, randomised study of the Lavender oil preparation Silexan in comparison to Lorazepam for generalized anxiety disorder, Phytomedicine : international journal of phytotherapy and phytopharmacology (2010) — GAD RCT vs lorazepam: HAMA fell ~45% with Silexan vs ~46% with 0.5 mg lorazepam — comparable efficacy. [https://pubmed.ncbi.nlm.nih.gov/19962288/]
  - Silexan, an orally administered Lavandula oil preparation, is effective in the treatment of 'subsyndromal' anxiety disorder: a randomized, double-blind, placebo controlled trial, International clinical psychopharmacology (2010) — Subsyndromal anxiety RCT (n=221): HAMA dropped 59% vs 35% placebo; PSQI sleep score improved 45% vs 31%. [https://pubmed.ncbi.nlm.nih.gov/20512042/]

---

## Lemon Balm (Melissa officinalis)
URL: https://nutridex.info/s/lemon-balm
Category: Sleep & Mood, Nootropic
Evidence: Moderate — Several controlled trials; effects real but modest or context-dependent.
Calming mint-family herb for mild anxiety, stress and sleep.

Quick answer: Lemon Balm is used for ease mild anxiety & stress. NutriDex grades the human evidence as moderate — Several controlled trials; effects real but modest or context-dependent. Based on 8 cited human studies (8 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Lemon balm is a lemon-scented mint-family herb used for centuries as a mild calmative. A 2021 systematic review and meta-analysis found it reduced anxiety (SMD ≈ -0.98) and depression (SMD ≈ -0.47) scores versus placebo, though heterogeneity was high. Small acute-dosing trials in healthy adults show increased self-rated calmness and some memory benefit at 600–1600 mg. Recent placebo-controlled crossover trials of standardized phytosome extracts (~400 mg) report lower Insomnia Severity Index scores and more slow-wave sleep. A 2-week RCT also reduced benign heart-palpitation episodes and anxiety. Meta-analyses suggest modest drops in triglycerides, total cholesterol and LDL. Overall the effects are real but small, the trials short and varied in extract and dose, and a 96-week cognition RCT in older adults was essentially negative — so lemon balm is best seen as a gentle adjunct, not a treatment.

Benefits / uses: Ease mild anxiety & stress; Improve sleep quality; Lift low mood; Calmness without strong sedation; Modest lipid lowering.
Active compounds: Rosmarinic acid; Triterpenes (ursolic/oleanolic acid); Citral & citronellal (volatile oil); Flavonoids.
Dose: 300–600 mg of standardized leaf extract for acute calming, or 600–1200 mg/day (often as phospholipid/phytosome forms, ~200–500 mg) for sleep and mood over weeks.
Safety: Generally well tolerated short-term; mild side effects include drowsiness, nausea, dizziness and headache. Because it is sedating, it may add to the effects of alcohol, benzodiazepines, barbiturates and other CNS depressants, and could compound the action of antidiabetic and lipid-lowering drugs. Some evidence suggests it can affect thyroid signalling, so caution is advised with thyroid disease or levothyroxine. Avoid before surgery (it may interact with anesthesia) and use cautiously in pregnancy or breastfeeding given limited safety data.

Cited studies (8):
  - Effects of Melissa officinalis (lemon balm) consumption on serum lipid profile: a meta-analysis of randomized controlled trials, BMC complementary medicine and therapies (2024) — Meta-analysis (5 RCTs, n=302): reduced triglycerides (SMD -0.40), total cholesterol (SMD -0.42) and LDL (SMD -0.23) vs placebo. [https://pubmed.ncbi.nlm.nih.gov/38575930/]
  - The effects of lemon balm (Melissa officinalis L.) on depression and anxiety in clinical trials: A systematic review and meta-analysis, Phytotherapy research : PTR (2021) — Meta-analysis: lemon balm reduced anxiety (SMD -0.98, 95% CI -1.63 to -0.33) and depression (SMD -0.47, -0.73 to -0.21) scores. [https://pubmed.ncbi.nlm.nih.gov/34449930/]
  - Effects of <scp><i>Melissa officinalis</i></scp> (Lemon Balm) on cardio‐metabolic outcomes: A systematic review and meta‐analysis, Phytotherapy Research (2020) — Systematic review/meta-analysis of RCTs: significant reductions in total cholesterol and systolic BP; limited by few studies and high bias risk. [https://doi.org/10.1002/ptr.6744]
  - Effects of Melissa officinalis Phytosome on Sleep Quality: Results of a Prospective, Double-Blind, Placebo-Controlled, and Cross-Over Study, Nutrients (2024) — Crossover RCT (n=30, insomnia): 400mg phytosome cut Insomnia Severity Index (6.8 vs 9.7, p=0.003) and raised slow-wave sleep ~15%. [https://pubmed.ncbi.nlm.nih.gov/39683592/]
  - Effects of Melissa officinalis Extract Containing Rosmarinic Acid on Cognition in Older Adults Without Dementia: A Randomized Controlled Trial, Journal of Alzheimer's disease : JAD (2023) — 96-week RCT (n=323, older adults): no overall cognitive benefit; a subgroup signal in non-hypertensive participants (CDR-SB, p=0.036). [https://pubmed.ncbi.nlm.nih.gov/36502333/]
  - Heart palpitation relief with Melissa officinalis leaf extract: double blind, randomized, placebo controlled trial of efficacy and safety, Journal of ethnopharmacology (2015) — 2-week RCT (n=55, benign palpitations): 1000mg/day extract reduced palpitation episodes and the number of anxious patients vs placebo. [https://pubmed.ncbi.nlm.nih.gov/25680840/]
  - Modulation of mood and cognitive performance following acute administration of single doses of Melissa officinalis (Lemon balm) with human CNS nicotinic and muscarinic receptor-binding properties, Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology (2003) — Acute crossover RCT (n=20, healthy): single 1600mg dose improved memory and raised self-rated 'calmness' at all post-dose timepoints. [https://pubmed.ncbi.nlm.nih.gov/12888775/]
  - Modulation of mood and cognitive performance following acute administration of Melissa officinalis (lemon balm), Pharmacology, biochemistry, and behavior (2002) — Acute crossover RCT (n=20): 600mg improved attention accuracy; calmness rose at lowest dose, alertness fell at highest dose. [https://pubmed.ncbi.nlm.nih.gov/12062586/]

---

## Leucine (L-Leucine)
URL: https://nutridex.info/s/leucine
Category: Performance
Evidence: Mixed — Conflicting results across studies; benefit uncertain.
The amino-acid trigger for muscle protein synthesis — that rarely builds extra muscle on its own.

Quick answer: Leucine is used for stimulates muscle protein synthesis. NutriDex grades the human evidence as mixed — Conflicting results across studies; benefit uncertain. Based on 7 cited human studies (7 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Leucine is one of three branched-chain amino acids and the strongest single trigger of muscle protein synthesis through the mTORC1 pathway. In short metabolic studies it consistently raises the muscle fractional synthetic rate, which fuels its reputation as a muscle-building supplement. However, that signal seldom translates into measurable results: meta-analyses in older adults found isolated leucine produced no change in lean body mass (WMD ~0.03 kg) and no clear strength gain, and controlled trials in young trainees eating enough protein show free leucine adds nothing over placebo for muscle size or strength. Benefits appear mainly when leucine is paired with adequate protein, resistance exercise, and sometimes vitamin D — and in sarcopenia, where modest gains in grip strength and gait speed are seen. BCAA mixtures (rich in leucine) modestly reduce post-exercise soreness. Its best-proven clinical role is BCAA therapy for hepatic encephalopathy, not athletic performance.

Benefits / uses: Stimulates muscle protein synthesis; May reduce post-exercise soreness; Possible aid in sarcopenia (with protein/vitamin D); Supports recovery after muscle damage.
Active compounds: L-Leucine; α-ketoisocaproate (KIC); HMB (β-hydroxy-β-methylbutyrate, metabolite).
Dose: Typically 2–5 g/day of free L-leucine, often taken with or after protein/resistance exercise; sarcopenia trials use ~3 g per meal.
Safety: Leucine from food and typical supplement doses (up to ~5–10 g/day) is well tolerated; reported effects are mainly mild GI upset. Very high intakes compete with other amino acids and can lower valine, isoleucine and tryptophan availability, and large BCAA loads transiently raise blood ammonia, so caution applies in advanced liver disease, kidney impairment, and the rare metabolic disorder maple syrup urine disease (avoid). Because leucine can blunt the glucose-lowering AMPK pathway and stimulate insulin, people on antidiabetic drugs should monitor blood sugar; data on pregnancy and breastfeeding beyond dietary amounts are limited, so supplements are best avoided then.

Cited studies (7):
  - Effects of Leucine Supplementation in Older Adults with Sarcopenia: A Meta-Analysis, Nutrients (2025) — Sarcopenia meta-analysis (11 studies, ~1,133): leucine modestly improved grip strength (+1.76 kg), muscle mass and gait speed (+0.05 m/s); low-quality evidence. [https://pubmed.ncbi.nlm.nih.gov/40805998/]
  - Attenuating Muscle Damage Biomarkers and Muscle Soreness After an Exercise-Induced Muscle Damage with Branched-Chain Amino Acid (BCAA) Supplementation: A Systematic Review and Meta-analysis with Meta-regression, Sports medicine - open (2024) — Meta-analysis (18 RCTs): BCAA (leucine-rich) cut muscle soreness at 24–72 h (g up to −1.82) and creatine kinase at 72 h post-exercise. [https://pubmed.ncbi.nlm.nih.gov/38625669/]
  - The Effect of Leucine Supplementation on Sarcopenia-Related Measures in Older Adults: A Systematic Review and Meta-Analysis of 17 Randomized Controlled Trials, Frontiers in nutrition (2022) — Meta-analysis of 17 RCTs: isolated leucine gave no change in lean mass (WMD 0.03 kg) or grip strength; benefit only when combined with vitamin D. [https://pubmed.ncbi.nlm.nih.gov/35845777/]
  - The effectiveness of leucine on muscle protein synthesis, lean body mass and leg lean mass accretion in older people: a systematic review and meta-analysis, British Journal of Nutrition (2014) — Meta-analysis (9 studies, older adults): leucine raised muscle fractional synthetic rate but produced no gain in lean body mass or leg lean mass. [https://doi.org/10.1017/S0007114514002475]
  - Branched-chain amino acids for people with hepatic encephalopathy, The Cochrane database of systematic reviews (2017) — 16 trials, 827 patients: BCAA improved hepatic encephalopathy (RR 0.73, 95% CI 0.61–0.88) but did not reduce mortality (RR 0.88). [https://pubmed.ncbi.nlm.nih.gov/28518283/]
  - Leucine Supplementation Does Not Improve Muscle Recovery from Resistance Exercise in Young Adults: A Randomized, Double-Blinded, Crossover Study, International journal of exercise science (2021) — Crossover RCT: 6 g/day free leucine did not improve muscle recovery (strength, soreness, CK) after lower-limb resistance exercise in untrained adults. [https://pubmed.ncbi.nlm.nih.gov/34055154/]
  - Free leucine supplementation during an 8-week resistance training program does not increase muscle mass and strength in untrained young adult subjects, Amino acids (2017) — RCT in young men: 3 g/day free leucine during 8-wk resistance training did not increase strength or muscle cross-sectional area over placebo. [https://pubmed.ncbi.nlm.nih.gov/28444456/]

---

## Maitake (Grifola frondosa)
URL: https://nutridex.info/s/maitake
Category: Gut & Immune
Evidence: Preliminary — Early or small human trials; promising but not yet conclusive.
Culinary mushroom studied for immune and blood-sugar support.

Quick answer: Maitake is used for immune cell activation. NutriDex grades the human evidence as preliminary — Early or small human trials; promising but not yet conclusive. Based on 8 cited human studies (8 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Maitake is an edible mushroom whose beta-glucan extracts (D/MD-fraction) and an SX-fraction glycoprotein are sold for immune and metabolic support. The strongest human work is a Memorial Sloan Kettering phase I/II trial in 34 breast-cancer survivors, where oral extract significantly altered immune parameters (p<0.0005) but unpredictably — intermediate doses sometimes enhanced and sometimes suppressed function. A phase II trial in 18 myelodysplastic-syndrome patients raised basal neutrophil (p=0.005) and monocyte (p=0.021) activity. An open PCOS trial reported ovulation in ~77% on maitake extract, and small diabetes pilots and case reports describe fasting-glucose drops. A 2009 systematic review concluded human evidence remains too sparse and uncontrolled to confirm efficacy, calling for randomized trials. So maitake is promising mechanistically and well tolerated, but not yet proven to improve any clinical outcome.

Benefits / uses: Immune cell activation; May lower blood sugar; May support insulin sensitivity; Adjunct interest in cancer care.
Active compounds: Beta-glucans (D-fraction / MD-fraction); SX-fraction glycoprotein; Ergosterol.
Dose: No established dose; trials used standardized liquid extract ~1–5 mg/kg twice daily, or culinary powder 3–7 g/day; quality and fraction content vary widely.
Safety: Maitake is generally well tolerated as food and in short trials, with occasional GI upset; people allergic to mushrooms should avoid it. A case report links maitake to a raised INR in a patient on warfarin, so it may potentiate anticoagulants. Because extracts can lower blood glucose, combining with insulin or other antidiabetic drugs risks hypoglycemia and warrants monitoring. Safety in pregnancy, breastfeeding and long-term use is unstudied.

Cited studies (8):
  - Maitake mushroom (Grifola frondosa): systematic review by the natural standard research collaboration, Journal of the Society for Integrative Oncology (2009) — Systematic review: cancer, diabetes and immunity proposed, but no rigorous human studies; concludes randomized controlled trials are warranted. [https://pubmed.ncbi.nlm.nih.gov/19476741/]
  - Maitake mushroom extract in myelodysplastic syndromes (MDS): a phase II study, Cancer immunology, immunotherapy : CII (2015) — Phase II, 18 MDS patients on 3 mg/kg twice daily x12 wk: increased basal neutrophil (p=0.005) and monocyte (p=0.021) function; well tolerated. [https://pubmed.ncbi.nlm.nih.gov/25351719/]
  - Maitake mushroom (Grifola frondosa) extract induces ovulation in patients with polycystic ovary syndrome: a possible monotherapy and a combination therapy after failure with first-line clomiphene citrate, Journal of alternative and complementary medicine (New York, N.Y.) (2010) — Open trial in PCOS: maitake SX-fraction extract induced ovulation in 76.9% of patients vs clomiphene; some non-responders ovulated on combination. [https://pubmed.ncbi.nlm.nih.gov/21034160/]
  - A phase I/II trial of a polysaccharide extract from Grifola frondosa (Maitake mushroom) in breast cancer patients: immunological effects, Journal of cancer research and clinical oncology (2009) — Phase I/II trial, 34 breast-cancer survivors: oral maitake extract significantly changed immune function (p<0.0005), but dose-response was non-monotonic. [https://pubmed.ncbi.nlm.nih.gov/19253021/]
  - INR elevation with maitake extract in combination with warfarin, The Annals of pharmacotherapy (2010) — Case report: maitake extract added to warfarin elevated INR; mechanism proposed via beta-glucan displacing protein-bound warfarin. [https://pubmed.ncbi.nlm.nih.gov/20040699/]
  - SX-fraction: Promise for novel treatment of type 2 diabetes, World journal of diabetes (2020) — Narrative review of SX-fraction: water-soluble glycoprotein with hypoglycaemic and insulin-sensitizing signals; human data limited to pilots/case reports. [https://pubmed.ncbi.nlm.nih.gov/33384765/]
  - A possible hypoglycaemic effect of maitake mushroom on Type 2 diabetic patients, Diabetic medicine : a journal of the British Diabetic Association (2001) — Case report: type 2 diabetic on glyburide adding maitake SX-fraction saw fasting glucose fall from 248 to ~90 mg/dL and HbA1c 11.5% to 5.2%. [https://pubmed.ncbi.nlm.nih.gov/11903406/]
  - The effects of beta-glucan on human immune and cancer cells, Journal of hematology & oncology (2009) — Review of beta-glucans on human immune/cancer cells: maitake-type beta-glucans activate NK cells, macrophages and dendritic cells in vitro. [https://pubmed.ncbi.nlm.nih.gov/19515245/]

---

## MCT Oil (Medium-Chain Triglycerides)
URL: https://nutridex.info/s/mct-oil
Category: Performance, Heart & Metabolic
Evidence: Mixed — Conflicting results across studies; benefit uncertain.
Fast-absorbed fat that raises ketones; small real-world effects.

Quick answer: MCT Oil is used for modest weight & waist reduction. NutriDex grades the human evidence as mixed — Conflicting results across studies; benefit uncertain. Based on 8 cited human studies (8 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

MCT oil is a refined fat (mostly C8/C10 caprylic and capric acids, often from coconut or palm kernel oil) that is absorbed directly to the liver and converted to ketones. A 2015 meta-analysis of RCTs found MCTs produced only ~0.51 kg more weight loss than long-chain fats over ~10 weeks, with small reductions in waist and body fat; a 2024 meta-analysis in people with overweight reported about 1.5% greater weight loss and improved insulin resistance, but blends diluted with long-chain fat lost the benefit. MCTs modestly cut later food intake without changing appetite ratings. In Alzheimer's and mild cognitive impairment, MCTs reliably raise brain ketones and a meta-analysis showed a small cognitive signal, but effects are domain-specific and fade once supplementation stops. For exercise, reviews show no ergogenic benefit. MCTs do not lower LDL cholesterol and can raise triglycerides.

Benefits / uses: Modest weight & waist reduction; Reduced calorie intake; Raises blood ketones; Fast, fat-free-of-bile energy.
Active compounds: Caprylic acid (C8); Capric acid (C10); Caproic acid (C6); Lauric acid (C12, in some blends).
Dose: Typically 10–30 g/day of liquid MCT oil, split across meals and titrated up slowly; 30 g is the practical ceiling before GI upset.
Safety: MCT oil is generally well tolerated but commonly causes dose-dependent GI side effects — diarrhea, cramping, nausea and bloating — especially above ~20–30 g; start low and split doses. It does not lower LDL and may modestly raise triglycerides, so it is not a cardioprotective fat. Avoid in people with significant liver disease or cirrhosis, where impaired ketone handling can worsen metabolic instability. It carries no well-established drug interactions, but because it can raise ketones and modestly affect glucose handling, people on insulin or diabetes medication should monitor for hypoglycemia, and those on a strict ketogenic protocol for epilepsy should change dose only under clinician guidance.

Cited studies (8):
  - The impact of medium-chain triglycerides on weight loss and metabolic health in individuals with overweight or obesity: A systematic review and meta-analysis, Clinical nutrition (Edinburgh, Scotland) (2024) — Meta-analysis (overweight/obesity): MCT-enriched diets gave ~1.5% greater weight loss and lower HOMA-IR vs LCTs; MLCT blends showed no benefit. [https://pubmed.ncbi.nlm.nih.gov/38936302/]
  - A systematic review and meta-analysis of medium-chain triglycerides effects on acute satiety and food intake, Critical reviews in food science and nutrition (2021) — Meta-analysis: MCTs caused a moderate decrease in later ad-libitum energy intake vs LCT, despite no change in appetite ratings or appetite hormones. [https://pubmed.ncbi.nlm.nih.gov/32212947/]
  - The Effects of Medium-Chain Triglyceride Oil Supplementation on Endurance Performance and Substrate Utilization in Healthy Populations: A Systematic Review, Journal of obesity & metabolic syndrome (2022) — Systematic review: MCT oil showed little to no ergogenic effect on endurance performance or substrate use; 30 g was the tolerable ceiling. [https://pubmed.ncbi.nlm.nih.gov/36096496/]
  - Calendar of Events, The Journal of Nutrition (2021) — Meta-analysis of RCTs: MCT oil did not change total, LDL, or HDL cholesterol, but caused a small rise in triglycerides vs comparator oils. [https://doi.org/10.1093/jn/nxab137]
  - Effects of medium-chain triglycerides on weight loss and body composition: a meta-analysis of randomized controlled trials, Journal of the Academy of Nutrition and Dietetics (2015) — Meta-analysis of RCTs: MCTs cut body weight ~0.51 kg vs long-chain fats (95% CI -0.80 to -0.23), with small waist/body-fat reductions. [https://pubmed.ncbi.nlm.nih.gov/25636220/]
  - Medium Chain Triglycerides induce mild ketosis and may improve cognition in Alzheimer's disease. A systematic review and meta-analysis of human studies, Ageing research reviews (2020) — Meta-analysis (n=422): MCTs raised plasma BHB and improved cognition on combined ADAS-Cog+MMSE in MCI/Alzheimer's; signal small and domain-specific. [https://pubmed.ncbi.nlm.nih.gov/31870908/]
  - Dietary medium-chain triacylglycerols versus long-chain triacylglycerols for body composition in adults: systematic review and meta-analysis of randomized controlled trials, Journal of the American College of Nutrition (2015) — Body-composition meta-analysis: MCTs lowered total and visceral fat vs LCTs but heterogeneity was high and studies short. [https://pubmed.ncbi.nlm.nih.gov/25651239/]
  - Dietary substitution of medium-chain triglycerides improves insulin-mediated glucose metabolism in NIDDM subjects, Diabetes (1992) — In NIDDM subjects, substituting MCTs improved insulin-mediated glucose metabolism but did not change fasting glucose. [https://pubmed.ncbi.nlm.nih.gov/1568535/]

---

## Mucuna Pruriens (Mucuna pruriens)
URL: https://nutridex.info/s/mucuna
Category: Nootropic, Performance
Evidence: Moderate — Several controlled trials; effects real but modest or context-dependent.
Velvet bean: a natural source of L-DOPA studied in Parkinson's.

Quick answer: Mucuna Pruriens is used for natural levodopa for parkinson's symptoms. NutriDex grades the human evidence as moderate — Several controlled trials; effects real but modest or context-dependent. Based on 8 cited human studies (8 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Mucuna pruriens (velvet bean) is an Ayurvedic legume whose seeds are naturally rich in L-DOPA, the same dopamine precursor used to treat Parkinson's disease. Several small double-blind crossover RCTs show its seed powder works like pharmaceutical levodopa: a 30 g dose produced motor benefit with faster onset (~35 vs ~69 minutes), longer 'on' time, and fewer dyskinesias than levodopa/carbidopa. A 12-month open-label trial in untreated patients found outcomes similar to standard levodopa plus a decarboxylase inhibitor. A separate 3-month trial in 60 stressed infertile men reported large gains in sperm concentration and motility plus lower cortisol. Limits are real: Parkinson's trials enrolled only 8–32 people, were short or single-dose, and lacked the decarboxylase inhibitor that protects against nausea and blood-pressure swings. Commercial supplement L-DOPA content is highly variable and unregulated, so dosing is unpredictable.

Benefits / uses: Natural levodopa for Parkinson's symptoms; Faster motor onset vs standard L-DOPA; May support male fertility / sperm quality; Possible mood and dopamine support.
Active compounds: L-DOPA (levodopa); Alkaloids (e.g. mucunine); Serotonin & tryptamine derivatives.
Dose: Standardized seed powder/extract delivering ~100–250 mg L-DOPA per dose; fertility trials used 5 g/day of seed powder for 3 months.
Safety: Because Mucuna delivers active L-DOPA, it carries the same risks as levodopa: nausea, vomiting, low blood pressure, daytime drowsiness, and at higher or chronic doses dyskinesias, hallucinations, psychosis, and dopamine dysregulation (compulsive overuse). Do not combine with MAO inhibitors (risk of hypertensive crisis), prescription levodopa, antipsychotics or dopamine-blocking antiemetics, and use caution with antihypertensives and antidiabetic drugs. Avoid in pregnancy, breastfeeding, psychiatric illness, and before surgery; supplement L-DOPA content is unregulated and varies widely, so treat any product as a real drug and involve a physician.

Cited studies (8):
  - Mucuna pruriens Treatment for Parkinson Disease: A Systematic Review of Clinical Trials, Parkinson's disease (2025) — Pooled 5 PD trials (108 patients, 1995–2024): consistent symptom improvement, faster onset, no dyskinesia, but small/short and unsuitable for meta-analysis. [https://pmc.ncbi.nlm.nih.gov/articles/PMC12377966/]
  - Mucuna pruriens in untreated Parkinson's disease in sub-Saharan Africa: A 12-month, multicenter, randomized, controlled trial, Journal of Parkinson's disease (2026) — 12-month open-label trial: Mucuna powder matched levodopa+DDCI on motor, non-motor and QoL endpoints; adverse events 56% vs 37.5% (n=32). [https://pubmed.ncbi.nlm.nih.gov/41269916/]
  - Comparative efficacy of Mucuna pruriens and conventional levodopa in Parkinson's disease: a randomized controlled trial on pharmacokinetics and clinical perspectives from Asia, Journal of neural transmission (Vienna, Austria : 1996) (2025) — Single-blind crossover compared 30 g Mucuna powder vs levodopa/benserazide on pharmacokinetics and motor response in PD with motor complications (n=12). [https://pubmed.ncbi.nlm.nih.gov/40137945/]
  - Mucuna pruriens in Parkinson disease: A double-blind, randomized, controlled, crossover study, Neurology (2017) — Single-dose roasted Mucuna seed powder met all non-inferiority endpoints vs dispersible levodopa, with fewer dyskinesias in advanced PD (n=18). [https://pubmed.ncbi.nlm.nih.gov/28679598/]
  - Daily intake of Mucuna pruriens in advanced Parkinson's disease: A 16-week, noninferiority, randomized, crossover, pilot study, Parkinsonism & related disorders (2018) — 16-week crossover pilot of daily Mucuna in advanced PD met non-inferiority for motor response vs levodopa/benserazide. [https://pubmed.ncbi.nlm.nih.gov/29352722/]
  - Mucuna pruriens Reduces Stress and Improves the Quality of Semen in Infertile Men, Evidence-based complementary and alternative medicine : eCAM (2010) — 5 g/day seed powder for 3 months raised sperm concentration up to 688% in oligozoospermic men and cut morning cortisol (n=60 + 60 controls). [https://pmc.ncbi.nlm.nih.gov/articles/PMC2816389/]
  - Mucuna pruriens in Parkinson's disease: a double blind clinical and pharmacological study, Journal of neurology, neurosurgery, and psychiatry (2004) — 30 g Mucuna powder gave faster onset than LD/CD (34.6 vs 68.5 min; p=0.021) and ~37 min longer 'on' time without more dyskinesia (n=8). [https://pubmed.ncbi.nlm.nih.gov/15548480/]
  - Comparative effects of atorvastatin and simvastatin on the plasma total homocysteine levels in women with polycystic ovary syndrome: a prospective randomized study, Fertility and Sterility (2009) — 3-month treatment improved semen quality and shifted reproductive hormones (raised testosterone/LH, lowered FSH/prolactin) via the HPG axis. [https://doi.org/10.1016/j.fertnstert.2008.06.006]

---

## Nattokinase
URL: https://nutridex.info/s/nattokinase
Category: Heart & Metabolic
Evidence: Mixed — Conflicting results across studies; benefit uncertain.
Natto-derived enzyme marketed for clots and blood pressure.

Quick answer: Nattokinase is used for modestly lower blood pressure. NutriDex grades the human evidence as mixed — Conflicting results across studies; benefit uncertain. Based on 8 cited human studies (8 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Nattokinase is a fibrin-degrading enzyme extracted from natto, a fermented-soybean food. In healthy volunteers a single oral dose transiently raises fibrinolytic markers (D-dimer up ~40%), and open-label use for 2 months lowered fibrinogen and clotting factors VII/VIII by roughly 7-19%. A meta-analysis of 6 RCTs (546 people) found a modest blood-pressure reduction (systolic about -3.5 mmHg, diastolic about -2.3 mmHg), and a retrospective study reported large drops in carotid plaque and LDL at high dose (10,800 FU/day). However, the best evidence undercuts the hype: a 3-year, 265-person double-blind RCT (NAPS) found no effect on carotid atherosclerosis progression or blood pressure. Trials are mostly short, small, or industry-linked, and the impressive plaque findings are not randomized. Net effect on real cardiovascular events is unproven.

Benefits / uses: Modestly lower blood pressure; Break down fibrin (fibrinolysis); Lower fibrinogen / clotting factors; Marketed for circulation & plaque.
Active compounds: Nattokinase (subtilisin NK, a serine protease).
Dose: Typically 2,000 fibrinolytic units (FU; ~100 mg) once daily; some plaque studies used 10,800 FU/day.
Safety: Generally well tolerated short-term; reported effects are mild GI upset. Because it promotes fibrinolysis, it raises bleeding risk and should be avoided with anticoagulants and antiplatelets (warfarin, aspirin, clopidogrel, apixaban, rivaroxaban, heparin) and stopped before surgery; a cerebellar hemorrhage was reported in a patient combining nattokinase with aspirin. Do not substitute it for prescribed anticoagulation (a mechanical-valve thrombosis occurred when one patient swapped warfarin for nattokinase). Use caution with bleeding disorders, recent stroke, or blood-pressure-lowering drugs; data in pregnancy and breastfeeding are lacking, so avoid.

Cited studies (8):
  - Nattokinase Supplementation and Cardiovascular Risk Factors: A Systematic Review and Meta-Analysis of Randomized Controlled Trials, Reviews in cardiovascular medicine (2023) — Meta-analysis of 6 RCTs (546 people): nattokinase cut systolic BP -3.45 mmHg and diastolic -2.32 mmHg; low-dose raised total cholesterol and lowered HDL. [https://pubmed.ncbi.nlm.nih.gov/39076715/]
  - Nattokinase atherothrombotic prevention study: A randomized controlled trial, Clinical hemorheology and microcirculation (2021) — 3-year double-blind RCT, 265 adults, 2,000 FU/day: NO difference vs placebo in carotid intima-media thickness, arterial stiffness, blood pressure, or labs. [https://pubmed.ncbi.nlm.nih.gov/33843667/]
  - A single-dose of oral nattokinase potentiates thrombolysis and anti-coagulation profiles, Scientific reports (2015) — Crossover RCT, 12 healthy men, single 2,000 FU dose: D-dimer rose +44.5% at 6 h and fibrin-degradation products increased; all changes stayed within normal range. [https://pubmed.ncbi.nlm.nih.gov/26109079/]
  - Effects of nattokinase on blood pressure: a randomized, controlled trial, Hypertension research : official journal of the Japanese Society of Hypertension (2008) — RCT, 86 pre-hypertensives, 2,000 FU/day x8 wk: net systolic -5.55 mmHg and diastolic -2.84 mmHg vs placebo (both p<0.05). [https://pubmed.ncbi.nlm.nih.gov/18971533/]
  - Nattokinase decreases plasma levels of fibrinogen, factor VII, and factor VIII in human subjects, Nutrition research (New York, N.Y.) (2009) — Open-label, 2 months, 4,000 FU/day: fibrinogen fell 7-10%, factor VII 7-14% and factor VIII 17-19% across healthy, cardiovascular and dialysis groups; lipids unchanged. [https://pubmed.ncbi.nlm.nih.gov/19358933/]
  - Effective management of atherosclerosis progress and hyperlipidemia with nattokinase: A clinical study with 1,062 participants, Frontiers in cardiovascular medicine (2022) — Retrospective, 1,062 people, 12 mo: 10,800 FU/day linked to -21.7% carotid IMT, -36% plaque area and -18% LDL; 3,600 FU/day was ineffective. Not randomized. [https://pubmed.ncbi.nlm.nih.gov/36072877/]
  - Nattokinase: A Promising Alternative in Prevention and Treatment of Cardiovascular Diseases, Biomarker insights (2018) — Review of nattokinase as a cardiovascular nutraceutical: summarizes antithrombotic, antihypertensive and anti-atherosclerotic effects and urges larger outcome trials. [https://pubmed.ncbi.nlm.nih.gov/30013308/]
  - Nattokinase: An Oral Antithrombotic Agent for the Prevention of Cardiovascular Disease, International journal of molecular sciences (2017) — Review of nattokinase as an oral antithrombotic agent: details the fibrinolytic mechanism and the gap between mechanistic promise and limited hard clinical-outcome data. [https://pubmed.ncbi.nlm.nih.gov/28264497/]

---

## Stinging Nettle (Urtica dioica)
URL: https://nutridex.info/s/nettle
Category: Joint & Skin, Performance
Evidence: Moderate — Several controlled trials; effects real but modest or context-dependent.
Root for prostate symptoms; leaf studied for joints and blood sugar.

Quick answer: Stinging Nettle is used for ease bph urinary symptoms. NutriDex grades the human evidence as moderate — Several controlled trials; effects real but modest or context-dependent. Based on 8 cited human studies (8 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Stinging nettle is used in two distinct ways: the root for benign prostatic hyperplasia (BPH) and the leaf for blood sugar, allergies and joint pain. The best evidence is for root extract in BPH: a 6-month double-blind RCT in 620 men cut symptom scores from ~19.8 to 11.8 (vs little change on placebo), and a meta-analysis of 5 trials (~1,128 men) found improved symptom scores and urinary flow without affecting PSA. In type 2 diabetes, small RCTs and a meta-analysis report lower fasting glucose (about -17 mg/dL) and HbA1c (about -0.9%), usually added to standard drugs. Topical nettle 'sting' modestly reduced thumb-joint osteoarthritis pain in a small crossover trial. Allergic-rhinitis results are weak, with placebo improving similarly. Trials are mostly small, short and concentrated in a few centres, so effects are promising but not definitive.

Benefits / uses: Ease BPH urinary symptoms; Lower blood sugar (adjunct); Relieve joint pain (topical); Hay-fever symptom support.
Active compounds: Lignans & polysaccharides (root); Sterols (beta-sitosterol); Flavonoids & chlorogenic acid; Histamine/serotonin (leaf hairs).
Dose: Root extract ~300–600 mg/day (or 600–1200 mg dried root) for prostate symptoms; leaf extract ~500 mg three times daily studied for blood sugar.
Safety: Oral root and leaf extracts are generally well tolerated; the main side effects are mild GI upset, headache, nausea and occasional fluid changes (nettle is a mild diuretic). Because nettle can lower blood glucose and blood pressure, it may add to antidiabetic drugs (risk of hypoglycemia) and antihypertensives; its vitamin K content and diuretic action could affect warfarin and lithium handling, so monitor if you take these. Fresh leaf contact causes a transient stinging rash, and use in pregnancy/breastfeeding is not established and best avoided. Men should not self-treat prostate symptoms with nettle without ruling out cancer first.

Cited studies (8):
  - The effect of nettle (<i>Urtica dioica</i>) supplementation on the glycemic control of patients with type 2 diabetes mellitus: A systematic review and meta‐analysis, Phytotherapy Research (2019) — Meta-analysis (13 trials): nettle lowered fasting glucose (WMD -17.2 mg/dL) and HbA1c (WMD -0.93%) vs control. [https://doi.org/10.1002/ptr.6535]
  - The efficacy and safety of &lt;i&gt;Urtica dioica&lt;/i&gt; in treating benign prostatic hyperplasia: a systematic review and meta-analysis, African Journal of Traditional, Complementary and Alternative Medicines (2016) — Meta-analysis of 5 RCTs (~1,128 men): Urtica dioica improved IPSS and peak urinary flow (Qmax) vs control, with no effect on PSA. [https://doi.org/10.4314/ajtcam.v13i2.17]
  - Stinging Nettle (2023) — NIH review: stinging nettle is an unlikely cause of liver injury (score E); reported side effects are mild GI upset, headache, nausea. [https://www.ncbi.nlm.nih.gov/books/NBK589898/]
  - Efficacy of Supportive Therapy of Allergic Rhinitis by Stinging Nettle (Urtica dioica) root extract: a Randomized, Double-Blind, Placebo- Controlled, Clinical Trial, Iranian journal of pharmaceutical research : IJPR (2017) — RCT in allergic rhinitis (n=74; 40 completed): nettle improved symptoms and cut nasal eosinophils, but placebo improved similarly. [https://pubmed.ncbi.nlm.nih.gov/29844782/]
  - The efficacy of stinging nettle (urtica dioica) in patients with benign prostatic hyperplasia: a randomized double-blind study in 100 patients, Iranian Red Crescent medical journal (2013) — Randomized double-blind trial (n=100 BPH): nettle herb reduced lower-urinary-tract symptoms vs placebo over the study period. [https://pubmed.ncbi.nlm.nih.gov/23487561/]
  - Improved glycemic control in patients with advanced type 2 diabetes mellitus taking Urtica dioica leaf extract: a randomized double-blind placebo-controlled clinical trial, Clinical laboratory (2013) — RCT in advanced T2DM (n=92, 1,500 mg/day leaf extract, 3 mo): significantly lower HbA1c vs placebo as add-on to standard drugs. [https://pubmed.ncbi.nlm.nih.gov/24273930/]
  - Urtica dioica for treatment of benign prostatic hyperplasia: a prospective, randomized, double-blind, placebo-controlled, crossover study, Journal of herbal pharmacotherapy (2005) — 6-mo double-blind RCT (n=620 BPH): IPSS fell 19.8→11.8 on nettle vs 19.2→17.7 placebo; 81% vs 16% improved; PSA unchanged. [https://pubmed.ncbi.nlm.nih.gov/16635963/]
  - Randomized controlled trial of nettle sting for treatment of base-of-thumb pain, Journal of the Royal Society of Medicine (2000) — Double-blind crossover RCT (n=27): topical nettle sting cut thumb-base osteoarthritis pain and disability vs placebo (P=0.026; P=0.0027). [https://pubmed.ncbi.nlm.nih.gov/10911825/]

---

## Passionflower (Passiflora incarnata)
URL: https://nutridex.info/s/passionflower
Category: Sleep & Mood
Evidence: Moderate — Several controlled trials; effects real but modest or context-dependent.
A calming herb with real but modest evidence for anxiety.

Quick answer: Passionflower is used for ease anxiety. NutriDex grades the human evidence as moderate — Several controlled trials; effects real but modest or context-dependent. Based on 8 cited human studies (8 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Passionflower (Passiflora incarnata) is a traditional calming herb thought to act mainly through GABA-A modulation, with flavonoids like vitexin as likely actives. The best human data are for anxiety: a 4-week RCT in generalized anxiety disorder found a flavonoid extract about as effective as oxazepam (30 mg) but with less daytime job impairment, and several placebo-controlled trials show a single ~500 mg dose meaningfully lowers pre-operative and dental anxiety without sedation. For sleep, evidence is thinner — a small crossover trial of passionflower tea improved subjective sleep quality by only a few percent over placebo in healthy adults. Overall the anxiolytic signal is real but the trials are small (often n=30–60), short (days to 4 weeks), heterogeneous in preparation and dose, and several are non-Western single-center studies. It is best viewed as a mild, short-term calming aid, not a proven treatment for chronic anxiety or insomnia.

Benefits / uses: Ease anxiety; Calm before procedures; Support sleep quality; Reduce restlessness.
Active compounds: Flavonoids (vitexin, isovitexin); Chrysin; Harmala alkaloids (trace).
Dose: Extracts ~250–800 mg/day, or a tea/tincture standardized to flavonoids; single ~500 mg doses are used 30–90 min before stressful events.
Safety: Generally well tolerated short-term; the main effects are drowsiness, dizziness and occasional confusion, so it can add to the sedation of benzodiazepines, sleep aids, alcohol and other CNS depressants. Because it may have mild blood-thinning and additive sedative effects, use caution with anticoagulants and before surgery (stop ~2 weeks prior), and theoretically it could lower blood pressure or blood sugar alongside those medications. Avoid in pregnancy (it can stimulate the uterus) and while breastfeeding, and don't drive after dosing until you know how it affects you.

Cited studies (8):
  - Passiflora incarnata in Neuropsychiatric Disorders-A Systematic Review, Nutrients (2020) — Systematic review of 9 trials: most show reduced anxiety with Passiflora and no cognitive harm, but calls for larger studies; sleep data limited. [https://pubmed.ncbi.nlm.nih.gov/33352740/]
  - Comparing the Effect of Preoperative Administration of Melatonin and Passiflora incarnata on Postoperative Cognitive Disorders in Adult Patients Undergoing Elective Surgery, Anesthesiology and pain medicine (2017) — As premedication (n=52), Passiflora reduced anxiety as well as melatonin, but melatonin preserved cognition (digit-symbol test) better. [https://pubmed.ncbi.nlm.nih.gov/28920038/]
  - Effects of passiflora incarnata and midazolam for control of anxiety in patients undergoing dental extraction, Medicina oral, patologia oral y cirugia bucal (2017) — Before dental surgery, Passiflora 260 mg gave anxiolysis similar to midazolam 15 mg, though many patients preferred midazolam's amnesia. [https://pubmed.ncbi.nlm.nih.gov/27918731/]
  - Passiflora incarnata Linneaus as an anxiolytic before spinal anesthesia, Journal of anesthesia (2012) — Oral Passiflora before spinal anesthesia (n=60) blunted the pre-procedure rise in STAI anxiety vs placebo, without affecting psychomotor recovery. [https://pubmed.ncbi.nlm.nih.gov/22048283/]
  - A double-blind, placebo-controlled investigation of the effects of Passiflora incarnata (passionflower) herbal tea on subjective sleep quality, Phytotherapy research : PTR (2011) — Crossover trial (n=41 healthy adults): passionflower tea improved self-rated sleep quality ~5% over placebo over 7 days; other sleep measures unchanged. [https://pubmed.ncbi.nlm.nih.gov/21294203/]
  - The efficacy of passiflora incarnata linnaeus in reducing dental anxiety in patients undergoing periodontal treatment, Journal of dentistry (Shiraz, Iran) (2013) — Before periodontal treatment (n=63), Passiflora drops cut dental anxiety from 12.1 to 8.5 vs little change in placebo/control (p<0.0001). [https://pubmed.ncbi.nlm.nih.gov/24724122/]
  - Passionflower in the treatment of generalized anxiety: a pilot double-blind randomized controlled trial with oxazepam, Journal of clinical pharmacy and therapeutics (2001) — In GAD (n=36, 4 wk), Passiflora extract (45 drops/day) matched oxazepam 30 mg for anxiety with significantly less job-performance impairment. [https://pubmed.ncbi.nlm.nih.gov/11679026/]
  - Preoperative oral Passiflora incarnata reduces anxiety in ambulatory surgery patients: a double-blind, placebo-controlled study, Anesthesia and analgesia (2008) — Oral Passiflora 500 mg 90 min pre-surgery (n=60) significantly lowered anxiety vs placebo (P<0.001) without sedation or psychomotor impairment. [https://pubmed.ncbi.nlm.nih.gov/18499602/]

---

## Policosanol
URL: https://nutridex.info/s/policosanol
Category: Heart & Metabolic
Evidence: Mixed — Conflicting results across studies; benefit uncertain.
Sugarcane wax alcohols sold for cholesterol — but replication failed.

Quick answer: Policosanol is used for marketed to lower ldl cholesterol. NutriDex grades the human evidence as mixed — Conflicting results across studies; benefit uncertain. Based on 8 cited human studies (8 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Policosanol is a mixture of long-chain alcohols (mainly octacosanol) extracted from sugarcane or other plant waxes. More than 50 Cuban trials, nearly all from one research group tied to the maker Dalmer, reported striking lipid effects — LDL down 20–29%, HDL up 8–15% at 10–20 mg/day. But that consistency is itself suspicious, and rigorous independent trials told a different story: a 143-patient German multicenter RCT testing 10–80 mg found LDL fell less than 10% in every group with no difference from placebo, and smaller US and Canadian RCTs using authentic Cuban material also showed nothing. A separate research group in Korea (Cho and colleagues) more recently reported lipid and small blood-pressure benefits, but again as a single advocating group. Pooled blood-pressure meta-analysis shows a small ~3/1.5 mmHg drop. Overall the headline cholesterol claim has not survived independent replication.

Benefits / uses: Marketed to lower LDL cholesterol; Marketed to raise HDL cholesterol; Claimed modest blood-pressure reduction.
Active compounds: Octacosanol; Triacontanol; Hexacosanol; Long-chain aliphatic alcohols.
Dose: Trials used 5–20 mg/day of sugarcane-derived policosanol, usually 10 mg once daily.
Safety: Policosanol is well tolerated in trials, with side effects (mild GI upset, headache, weight loss) similar to placebo and a low withdrawal rate; meta-analysis found no effect on kidney function (creatinine). Theoretically it may inhibit platelet aggregation, so use caution with anticoagulants and antiplatelet drugs (warfarin, aspirin, clopidogrel) and before surgery. Safety in pregnancy and breastfeeding is not established, so avoid it then. Most importantly, do not substitute policosanol for a proven lipid-lowering therapy such as a statin.

Cited studies (8):
  - The effects of policosanol supplementation on creatinine: a systematic review and dose–response meta-analysis of randomized controlled trials, BMC Complementary Medicine and Therapies (2025) — Dose–response meta-analysis: policosanol had no significant effect on serum creatinine (WMD 0.21 µmol/L), supporting renal safety. [https://doi.org/10.1186/s12906-025-04911-0]
  - Policosanol supplementation significantly improves blood pressure among adults: A systematic review and meta-analysis of randomized controlled trials, Complementary therapies in medicine (2019) — Meta-analysis of 19 RCTs: policosanol lowered systolic BP 3.42 mmHg and diastolic BP 1.47 mmHg vs placebo. [https://pubmed.ncbi.nlm.nih.gov/31331588/]
  - Meta-analysis of natural therapies for hyperlipidemia: plant sterols and stanols versus policosanol, Pharmacotherapy (2005) — Meta-analysis: pooled (mostly Cuban) data showed policosanol cut LDL ~24% vs placebo, outperforming plant sterols — but heavily single-source. [https://pubmed.ncbi.nlm.nih.gov/15767233/]
  - Short-Term Consumption of Cuban Policosanol Lowers Aortic and Peripheral Blood Pressure and Ameliorates Serum Lipid Parameters in Healthy Korean Participants: Randomized, Double-Blinded, and Placebo-Controlled Study, International journal of environmental research and public health (2019) — RCT in 84 prehypertensive Koreans: 10/20 mg cut aortic systolic BP 7–8% and LDL 18–21% — but from a single advocating group. [https://pubmed.ncbi.nlm.nih.gov/30841655/]
  - Consumption of Cuban Policosanol Improves Blood Pressure and Lipid Profile via Enhancement of HDL Functionality in Healthy Women Subjects: Randomized, Double-Blinded, and Placebo-Controlled Study, Oxidative medicine and cellular longevity (2018) — RCT in healthy Korean women: policosanol reduced total cholesterol up to 20% and triglycerides 14%, raising HDL-C ~1.3-fold. [https://pubmed.ncbi.nlm.nih.gov/29854085/]
  - Effect of policosanol on lipid levels among patients with hypercholesterolemia or combined hyperlipidemia: a randomized controlled trial, JAMA (2006) — 143-patient German multicenter RCT, 10–80 mg/day: LDL fell <10% in every group with no significant difference from placebo. [https://pubmed.ncbi.nlm.nih.gov/16705107/]
  - Lack of cholesterol-lowering efficacy of Cuban sugar cane policosanols in hypercholesterolemic persons, The American journal of clinical nutrition (2006) — Double-blind crossover RCT (n=21) of authentic Cuban sugarcane policosanol 10 mg: no effect on total, LDL, HDL cholesterol or triglycerides. [https://pubmed.ncbi.nlm.nih.gov/17093150/]
  - Policosanol is ineffective in the treatment of hypercholesterolemia: a randomized controlled trial, The American journal of clinical nutrition (2006) — Double-blind RCT (n=40, mild hypercholesterolemia), 8 weeks: no significant LDL change vs placebo — policosanol ineffective. [https://pubmed.ncbi.nlm.nih.gov/17158441/]

---

## PQQ (Pyrroloquinoline Quinone)
URL: https://nutridex.info/s/pqq
Category: Longevity, Nootropic
Evidence: Preliminary — Early or small human trials; promising but not yet conclusive.
Redox cofactor marketed for mitochondria, memory and energy.

Quick answer: PQQ is used for memory & attention in older adults. NutriDex grades the human evidence as preliminary — Early or small human trials; promising but not yet conclusive. Based on 7 cited human studies (7 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

PQQ is a quinone redox cofactor found in trace amounts in foods like fermented soy, kiwi and human milk. It is sold as a 'mitochondrial' nootropic and anti-aging aid. The human evidence is thin: small randomized trials (typically 20 mg/day of the disodium salt for 8–12 weeks) report modest improvements in composite and verbal memory and in selective attention, mainly in middle-aged and older adults, plus reduced LDL cholesterol in people with high baseline levels (roughly 156→132 mg/dL) and better self-reported sleep and fatigue. A 2024 RCT in mild cognitive impairment found higher serum BDNF and improved orientation but no broad cognitive benefit. Most trials are small, brief and funded by manufacturers of branded PQQ, with no independent meta-analysis, so the size and durability of any real benefit remain uncertain.

Benefits / uses: Memory & attention in older adults; Mitochondrial support; Lower LDL cholesterol; Reduced fatigue & better sleep.
Active compounds: Pyrroloquinoline quinone (free acid); PQQ disodium salt (BioPQQ).
Dose: 20 mg/day of PQQ disodium salt is the dose used in most human trials; products supply 10–20 mg, sometimes paired with CoQ10.
Safety: PQQ appears well tolerated in short human trials, with no serious adverse events at 20 mg/day; mild GI upset, headache and sleep changes are reported anecdotally. Long-term safety is unstudied, and animal data hinted at reversible kidney changes at very high doses. Because trials suggest LDL-lowering and possible blood-glucose effects, use caution if you take lipid- or glucose-lowering drugs, and tell your clinician. Safety in pregnancy, breastfeeding and children is not established; avoid in those groups.

Cited studies (7):
  - Pyrroloquinoline quinone disodium salt improves brain function in both younger and older adults, Food &amp; Function (2023) — 20 mg/day for 12 wk (n=62) significantly improved composite and verbal memory; gains in older adults at 12 wk. [https://doi.org/10.1039/D2FO01515C]
  - The impact of six-week dihydrogen-pyrroloquinoline quinone supplementation on mitochondrial biomarkers, brain metabolism, and cognition in elderly individuals with mild cognitive impairment: a randomized controlled trial, The journal of nutrition, health & aging (2024) — 6-wk dihydro-PQQ in 34 elderly with MCI raised serum BDNF (P=0.01) and ADAS-Cog orientation (P=0.03), but not global cognition. [https://pubmed.ncbi.nlm.nih.gov/38908296/]
  - Effect of the Antioxidant Supplement Pyrroloquinoline Quinone Disodium Salt (BioPQQ™) on Cognitive Functions, Advances in experimental medicine and biology (2016) — 20 mg/day BioPQQ for 12 wk in 41 healthy elderly improved selective attention (Stroop) and working memory vs placebo. [https://pubmed.ncbi.nlm.nih.gov/26782228/]
  - Effects of Pyrroloquinoline Quinone Disodium Salt Intake on the Serum Cholesterol Levels of Healthy Japanese Adults, Journal of Nutritional Science and Vitaminology (2015) — 20 mg/day for 12 wk lowered LDL-cholesterol in adults with baseline LDL >=140 mg/dL (~156 to 132 mg/dL); triglycerides unchanged (n=29). [https://doi.org/10.3177/jnsv.61.233]
  - Dietary pyrroloquinoline quinone (PQQ) alters indicators of inflammation and mitochondrial-related metabolism in human subjects, The Journal of nutritional biochemistry (2013) — Single/short PQQ dosing in 10 adults lowered plasma CRP and IL-6 and shifted urinary metabolites toward enhanced mitochondrial function. [https://pubmed.ncbi.nlm.nih.gov/24231099/]
  - Effects of Oral Supplementation with Pyrroloquinoline Quinone on Stress, Fatigue, and Sleep, Functional Foods in Health and Disease (2012) — Open-label 20 mg/day for 8 wk (n=17) improved all POMS mood subscales and several sleep-quality measures; no placebo control. [https://doi.org/10.31989/ffhd.v2i8.81]
  - Pyrroloquinoline Quinone (PQQ): Its impact on human health and potential benefits: PQQ: Human health impacts and benefits, Current research in food science (2024) — Narrative review concludes human PQQ data remain limited and short-term; calls for dose-response trials; reports no toxicity signals. [https://pubmed.ncbi.nlm.nih.gov/39513102/]

---

## Pterostilbene
URL: https://nutridex.info/s/pterostilbene
Category: Longevity
Evidence: Preliminary — Early or small human trials; promising but not yet conclusive.
A blueberry stilbene marketed as a better-absorbed resveratrol.

Quick answer: Pterostilbene is used for lower blood pressure. NutriDex grades the human evidence as preliminary — Early or small human trials; promising but not yet conclusive. Based on 6 cited human studies (6 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Pterostilbene is a naturally occurring stilbene found in blueberries and grapes, structurally a dimethylated analog of resveratrol with markedly higher oral bioavailability (roughly 80% vs 20% in rats). It is sold as an anti-aging supplement on the strength of preclinical sirtuin/antioxidant activity, but human data are thin. In the only stand-alone RCT (80 adults with high cholesterol), 125 mg twice daily lowered systolic and diastolic blood pressure by about 7–8 mmHg over 6–8 weeks, but unexpectedly raised LDL cholesterol by ~17 mg/dL when taken alone. Combination products pairing pterostilbene with nicotinamide riboside showed promise in a tiny ALS pilot but no benefit on muscle recovery in healthy elderly. No human trial has tested it for lifespan, cognition, or dementia. Short-term use up to 250 mg/day appears well tolerated; longer-term safety and the LDL signal need follow-up.

Benefits / uses: Lower blood pressure; Antioxidant support; Marketed for healthy aging; Combined with NR for NAD+ support.
Active compounds: Pterostilbene (trans-3,5-dimethoxy-4'-hydroxystilbene).
Dose: 50–250 mg/day; most human data used 125 mg twice daily, often paired with grape extract or nicotinamide riboside.
Safety: Short-term use up to 250 mg/day was well tolerated in human trials, with no liver, kidney or glucose abnormalities; mild GI upset is the most common complaint. Taken alone it raised LDL cholesterol in one RCT, so people with high cholesterol should monitor lipids. Because it can lower blood pressure, it may add to the effect of antihypertensives; theoretical caution applies with anticoagulants and antidiabetic drugs given its polyphenol class, though human interaction data are lacking. Long-term safety and use in pregnancy or breastfeeding have not been established.

Cited studies (6):
  - A randomized placebo-controlled trial of nicotinamide riboside and pterostilbene supplementation in experimental muscle injury in elderly individuals, JCI insight (2022) — RCT in elderly (n=32): NR+pterostilbene was well tolerated but showed no effect on muscle stem cells, strength recovery or regeneration after muscle injury. [https://pubmed.ncbi.nlm.nih.gov/35998039/]
  - Efficacy and tolerability of EH301 for amyotrophic lateral sclerosis: a randomized, double-blind, placebo-controlled human pilot study, Amyotrophic lateral sclerosis & frontotemporal degeneration (2019) — Pilot RCT (EH301: 1000mg nicotinamide riboside + 200mg pterostilbene, n=32) slowed ALSFRS-R decline and improved strength/pulmonary function vs placebo at 4 mo. [https://pubmed.ncbi.nlm.nih.gov/30668199/]
  - Pterostilbene on metabolic parameters: a randomized, double-blind, and placebo-controlled trial, Evidence-based complementary and alternative medicine : eCAM (2014) — RCT (n=80): pterostilbene 125mg BID cut SBP ~7.8 and DBP ~7.3 mmHg but raised LDL ~17.1 mg/dL when taken alone over 6–8 wk. [https://pubmed.ncbi.nlm.nih.gov/25057276/]
  - Analysis of safety from a human clinical trial with pterostilbene, Journal of toxicology (2013) — Safety analysis of the same 80-patient trial: no hepatic, renal or glucose adverse signals; judged generally safe up to 250 mg/day for 6–8 weeks. [https://pubmed.ncbi.nlm.nih.gov/23431291/]
  - Pharmacokinetics, oral bioavailability, and metabolic profile of resveratrol and its dimethylether analog, pterostilbene, in rats, Cancer chemotherapy and pharmacology (2011) — In rats, oral bioavailability was ~80% for pterostilbene vs ~20% for resveratrol, with a higher and longer-lasting plasma peak. [https://pubmed.ncbi.nlm.nih.gov/21116625/]
  - A review of pterostilbene antioxidant activity and disease modification, Oxidative medicine and cellular longevity (2013) — Review of pterostilbene antioxidant activity and disease-modifying signals; concludes evidence is largely preclinical with limited human data. [https://pubmed.ncbi.nlm.nih.gov/23691264/]

---

## Quercetin
URL: https://nutridex.info/s/quercetin
Category: Longevity, Gut & Immune
Evidence: Moderate — Several controlled trials; effects real but modest or context-dependent.
Plant flavonoid with a modest, dose-dependent blood-pressure effect.

Quick answer: Quercetin is used for modestly lower blood pressure. NutriDex grades the human evidence as moderate — Several controlled trials; effects real but modest or context-dependent. Based on 8 cited human studies (8 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Quercetin is a flavonoid found in onions, apples, tea and capers, sold as an antioxidant, anti-inflammatory and immune supplement. The most reproducible human finding is blood pressure: pooled RCTs report a systolic reduction of about 1.9–3.0 mmHg, seen mainly at doses ≥500 mg/day. A small crossover trial found 500 mg/day lowered plasma uric acid by ~26 µmol/L in pre-hyperuricaemic men. Effects on C-reactive protein are inconsistent—null overall but significant in people with established disease or at high doses. Meta-analyses generally find no effect on lipids, and only subgroup (≥500 mg, ≥8 weeks) effects on fasting glucose. The popular cold/immune claim is weak: a 1,002-person community trial found no reduction in respiratory infections, with benefit limited to smaller exercise-stressed groups. Most trials are short (4–12 weeks) and bioavailability is poor, so real-world benefits are likely small.

Benefits / uses: Modestly lower blood pressure; Lower CRP in inflamed/diseased groups; Lower uric acid; Antioxidant flavonoid support.
Active compounds: Quercetin aglycone; Quercetin glycosides (e.g. isoquercetin, rutin).
Dose: 500–1000 mg/day of quercetin (often as aglycone or phytosome/isoquercetin for absorption); the BP and uric-acid signals appear at ≥500 mg/day.
Safety: Oral quercetin is generally well tolerated up to ~1000 mg/day for several weeks; reported effects are mild (headache, tingling, GI upset), and high-dose or IV use has been linked to kidney toxicity. As a CYP3A4/CYP2C9 and P-glycoprotein inhibitor it can raise levels of drugs with narrow therapeutic windows—warfarin and other anticoagulants, cyclosporine and some statins—and may add to the glucose- and BP-lowering effects of antidiabetic and antihypertensive medication. Long-term safety data are lacking; avoid high doses in pregnancy, breastfeeding, and kidney disease, and separate from medications if you take CYP3A4 substrates.

Cited studies (8):
  - The effects of Quercetin supplementation on cardiometabolic outcomes: An umbrella review of meta‐analyses of randomized controlled trials, Phytotherapy Research (2023) — Umbrella review of 5 meta-analyses: significant systolic-BP drop (WMD −1.9 mmHg) and lower insulin; no effect on diastolic BP, lipids, inflammation, FPG or HOMA-IR. [https://doi.org/10.1002/ptr.7971]
  - Impact of quercetin on systemic levels of inflammation: a meta-analysis of randomised controlled human trials, International journal of food sciences and nutrition (2020) — Meta-analysis: no overall effect on CRP, IL-6 or TNF-α; CRP and IL-6 fell only in subgroups with diagnosed disease or high doses. [https://pubmed.ncbi.nlm.nih.gov/31213101/]
  - Effects of Quercetin on Blood Pressure: A Systematic Review and Meta-Analysis of Randomized Controlled Trials, Journal of the American Heart Association (2016) — Meta-analysis (7 trials, 9 arms, 587 patients): quercetin cut systolic BP by 3.04 mmHg (95% CI −5.75 to −0.33), effect greater at >500 mg/day. [https://pubmed.ncbi.nlm.nih.gov/27405810/]
  - Effects of supplementation with quercetin on plasma C-reactive protein concentrations: a systematic review and meta-analysis of randomized controlled trials, European journal of clinical nutrition (2017) — Meta-analysis (7 RCTs): quercetin lowered CRP by 0.33 mg/L (95% CI −0.50 to −0.15); effect strongest at ≥500 mg/day. [https://pubmed.ncbi.nlm.nih.gov/28537580/]
  - Effects of quercetin supplementation on glycemic control among patients with metabolic syndrome and related disorders: A systematic review and meta‐analysis of randomized controlled trials, Phytotherapy Research (2019) — Meta-analysis in metabolic syndrome: no overall effect on FPG, HOMA-IR or HbA1c; FPG fell only with ≥500 mg/day for ≥8 weeks. [https://doi.org/10.1002/ptr.6334]
  - Effects of quercetin supplementation on lipid profile: A systematic review and meta-analysis of randomized controlled trials, Critical reviews in food science and nutrition (2017) — Meta-analysis (5 RCTs, 442 subjects): no significant effect on LDL, HDL or triglycerides; a small non-relevant rise in total cholesterol. [https://pubmed.ncbi.nlm.nih.gov/25897620/]
  - Quercetin lowers plasma uric acid in pre-hyperuricaemic males: a randomised, double-blinded, placebo-controlled, cross-over trial, The British journal of nutrition (2016) — Crossover RCT (22 pre-hyperuricaemic men): 500 mg/day for 4 weeks lowered plasma uric acid by 26.5 µmol/L (P=0.008), no change in BP or glucose. [https://pubmed.ncbi.nlm.nih.gov/26785820/]
  - Quercetin supplementation and upper respiratory tract infection: A randomized community clinical trial, Pharmacological research (2010) — RCT (N=1002, 500 & 1000 mg/day, 12 wk): no reduction in upper-respiratory-infection rate, severity or duration vs placebo overall. [https://pubmed.ncbi.nlm.nih.gov/20478383/]

---

## Red Clover (Trifolium pratense)
URL: https://nutridex.info/s/red-clover
Category: Joint & Skin
Evidence: Mixed — Conflicting results across studies; benefit uncertain.
Isoflavone herb marketed for hot flushes; trials are inconsistent.

Quick answer: Red Clover is used for menopausal hot flushes. NutriDex grades the human evidence as mixed — Conflicting results across studies; benefit uncertain. Based on 8 cited human studies (8 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Red clover is a phytoestrogen-rich legume whose isoflavones (mainly biochanin A and formononetin) weakly bind estrogen receptors, which is why it is sold for menopause. Evidence is genuinely split. The 2013 Cochrane review of phytoestrogens found no significant difference between red clover (Promensil) and placebo for hot flushes, while later meta-analyses found a small reduction of roughly 1.7–2 fewer flushes per day, often only at the borderline of statistical significance and driven by higher doses (≥80 mg/day) and longer trials. More consistent are modest lipid effects: a 2020 meta-analysis of 12 RCTs reported total cholesterol down ~12 mg/dL and LDL down ~11 mg/dL. Effects on bone density and other symptoms are weak and inconsistent. Trials are frequently short, small, and industry-funded, with strong placebo responses, so red clover is best seen as a possible mild aid, not a reliable treatment.

Benefits / uses: Menopausal hot flushes; Lower LDL & total cholesterol; Slow menopausal bone loss; Skin & menopausal symptom support.
Active compounds: Isoflavones (biochanin A, formononetin); Genistein & daidzein; Coumestrol.
Dose: 40–80 mg/day standardized red clover isoflavones (e.g. Promensil, Rimostil) for 12 weeks to 1 year.
Safety: Generally well tolerated; reported effects include mild headache, nausea and rash, with red clover isoflavones used safely in studies up to 2–3 years. Because the isoflavones are estrogenic, avoid in pregnancy and breastfeeding and use caution if you have an estrogen-sensitive condition (breast, uterine or ovarian cancer, endometriosis, fibroids), though human data so far show no clear harm to breast or endometrial tissue. Coumarin-related constituents may add to bleeding risk, so use caution with anticoagulants/antiplatelets (warfarin, aspirin); it may also interact with tamoxifen, hormonal therapies and drugs metabolized by CYP enzymes.

Cited studies (8):
  - Evaluation of Clinical Meaningfulness of Red Clover (Trifolium pratense L.) Extract to Relieve Hot Flushes and Menopausal Symptoms in Peri- and Post-Menopausal Women: A Systematic Review and Meta-Analysis of Randomized Controlled Trials, Nutrients (2021) — Meta-analysis of 8 trials: red clover cut daily hot flushes by WMD -1.73 (95% CI -3.28 to -0.18); benefit clearest at ≥80 mg/day. [https://pubmed.ncbi.nlm.nih.gov/33920485/]
  - Effects of red clover (Trifolium pratense) isoflavones on the lipid profile of perimenopausal and postmenopausal women-A systematic review and meta-analysis, Maturitas (2020) — Meta-analysis of 12 RCTs (n=1284): total cholesterol -12.3 mg/dL, LDL -10.6 mg/dL, triglycerides -10.2 mg/dL, HDL +1.6 mg/dL. [https://pubmed.ncbi.nlm.nih.gov/31883666/]
  - Effects of red clover on hot flash and circulating hormone concentrations in menopausal women: a systematic review and meta-analysis, Avicenna journal of phytomedicine (2015) — Meta-analysis (6 trials) found hot flushes fell more with red clover than placebo, MD -1.99/day, but only marginally significant (p=0.067). [https://pubmed.ncbi.nlm.nih.gov/26693407/]
  - Phytoestrogens for menopausal vasomotor symptoms, The Cochrane database of systematic reviews (2013) — Across 5 Promensil trials, no significant difference in hot-flush frequency vs placebo; overall no conclusive phytoestrogen benefit. [https://pubmed.ncbi.nlm.nih.gov/24323914/]
  - Isoflavones obtained from red clover improve both dyslipidemia and menopausal symptoms in menopausal women: a prospective randomized placebo-controlled trial, Climacteric : the journal of the International Menopause Society (2024) — RCT: red clover isoflavones improved lipids (lower TC, LDL, triglycerides; higher HDL) and lowered Menopause Rating Scale scores vs placebo. [https://pubmed.ncbi.nlm.nih.gov/39254422/]
  - Red clover isoflavones enriched with formononetin lower serum LDL cholesterol-a randomized, double-blind, placebo-controlled study, European journal of clinical nutrition (2015) — RCT: 50 mg/day formononetin-enriched red clover lowered LDL cholesterol 12% vs 2% on placebo over 2 years (p=0.005). [https://pubmed.ncbi.nlm.nih.gov/25369831/]
  - Red clover isoflavones are safe and well tolerated in women with a family history of breast cancer, Menopause international (2008) — 3-year RCT in women with breast-cancer family history: red clover isoflavones did not adversely affect breast density or endometrium; well tolerated. [https://pubmed.ncbi.nlm.nih.gov/18380954/]
  - The effect of red clover isoflavones on menopausal symptoms, lipids and vaginal cytology in menopausal women: a randomized, double-blind, placebo-controlled study, Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology (2005) — RCT (n=60): 80 mg/day red clover isoflavones cut Kupperman menopausal index from 27.2 to 5.9 vs 20.9 on placebo over 90 days (p<0.05). [https://pubmed.ncbi.nlm.nih.gov/16373244/]

---

## Sea Buckthorn Oil (Hippophae rhamnoides)
URL: https://nutridex.info/s/sea-buckthorn
Category: Joint & Skin
Evidence: Preliminary — Early or small human trials; promising but not yet conclusive.
Omega-7-rich berry oil for dry eye, mucosal and skin support.

Quick answer: Sea Buckthorn Oil is used for ease dry eye symptoms. NutriDex grades the human evidence as preliminary — Early or small human trials; promising but not yet conclusive. Based on 7 cited human studies (7 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Sea buckthorn oil is pressed from the berries (pulp) and seeds of Hippophae rhamnoides and is unusually rich in palmitoleic acid (omega-7), other unsaturated fats, carotenoids and vitamin E. In small double-blind trials, 2 g/day for 3 months blunted the cold-season rise in tear-film osmolarity and eased redness and burning in people with dry eye; 3 g/day modestly improved vaginal epithelial integrity in postmenopausal women (odds ratio ~3.1); and 5 g/day shifted skin and plasma fatty-acid profiles in atopic dermatitis. Meta-analyses of berry/oil products suggest small reductions in triglycerides, total and LDL cholesterol, mainly in people with abnormal lipids, but no effect on glucose, blood pressure or BMI. Effects are real but modest, trials are small and short, and much of the work comes from a single group, so evidence remains early.

Benefits / uses: Ease dry eye symptoms; Support skin hydration; Improve vaginal mucosal integrity; Modestly improve blood lipids.
Active compounds: Palmitoleic acid (omega-7); Alpha-linolenic & linoleic acids; Carotenoids & tocopherols (vitamin E); Flavonoids.
Dose: 2–5 g/day of seed or pulp oil (or both) by mouth, taken for 1–3 months in trials; topical preparations are also used.
Safety: Oral sea buckthorn oil is generally well tolerated; the main effects are mild GI upset or loose stools at higher doses, and topical use can cause transient redness or itch. Because it contains vitamin K and salicylate-like and antiplatelet compounds, it may add to the effect of anticoagulants/antiplatelets (warfarin, aspirin, clopidogrel) and theoretically increase bleeding risk, so use caution if you take these or have a bleeding disorder, and stop before surgery. It may also slightly enhance blood-pressure-lowering or glucose-lowering medication, so monitor if you take antihypertensives or antidiabetics. Safety in pregnancy and breastfeeding is not established.

Cited studies (7):
  - Effects of sea buckthorn (Hippophae rhamnoides L.) on factors related to metabolic syndrome: A systematic review and meta-analysis of randomized controlled trial, Phytotherapy research : PTR (2022) — Meta-analysis (15 RCTs): SB reduced triglycerides, total and LDL cholesterol and raised HDL, but no effect on glucose, BP or BMI. [https://pubmed.ncbi.nlm.nih.gov/36043374/]
  - Presence of methicillin-resistant Staphylococcus aureus in the food chain, Trends in Food Science &amp; Technology (2017) — Meta-analysis (11 RCTs, ~900 people): SB improved lipid profile mainly in those with hyperlipidaemia, not in healthy subjects. [https://doi.org/10.1016/j.tifs.2016.12.002]
  - Oral sea buckthorn oil attenuates tear film osmolarity and symptoms in individuals with dry eye, The Journal of nutrition (2010) — 2 g/day SB oil for 3 months blunted the cold-season rise in tear-film osmolarity and eased dry-eye redness/burning vs placebo (n=86). [https://pubmed.ncbi.nlm.nih.gov/20554904/]
  - Effects of oral sea buckthorn oil on tear film Fatty acids in individuals with dry eye, Cornea (2011) — Same RCT: oral SB oil raised palmitoleic/oleic acid in tear film, suggesting a plausible lipid-layer mechanism for dry-eye benefit. [https://pubmed.ncbi.nlm.nih.gov/21832964/]
  - Effects of sea buckthorn oil intake on vaginal atrophy in postmenopausal women: a randomized, double-blind, placebo-controlled study, Maturitas (2014) — 3 g/day SB oil for 3 months improved vaginal epithelial integrity in postmenopausal women (OR 3.1, 95% CI 1.11–8.95; n=98). [https://pubmed.ncbi.nlm.nih.gov/25104582/]
  - Effect of dietary supplementation with sea buckthorn (Hippophaë rhamnoides) seed and pulp oils on the fatty acid composition of skin glycerophospholipids of patients with atopic dermatitis, The Journal of nutritional biochemistry (2000) — 5 g/day seed/pulp oil for 4 months shifted skin glycerophospholipid and plasma fatty-acid profiles in atopic dermatitis patients (n=16). [https://pubmed.ncbi.nlm.nih.gov/11002130/]
  - Effects of dietary supplementation with sea buckthorn (Hippophaë rhamnoides) seed and pulp oils on atopic dermatitis, The Journal of nutritional biochemistry (1999) — Placebo-controlled trial: seed oil tended to improve atopic dermatitis symptoms; pulp oil less so, but the sample was small. [https://pubmed.ncbi.nlm.nih.gov/15539258/]

---

## Serrapeptase (Serratiopeptidase)
URL: https://nutridex.info/s/serrapeptase
Category: Joint & Skin
Evidence: Mixed — Conflicting results across studies; benefit uncertain.
Proteolytic enzyme marketed for inflammation, swelling and pain.

Quick answer: Serrapeptase is used for reduce post-surgical swelling. NutriDex grades the human evidence as mixed — Conflicting results across studies; benefit uncertain. Based on 10 cited human studies (10 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Serrapeptase is a proteolytic enzyme originally isolated from silkworm-gut bacteria (Serratia) and sold as an enteric-coated supplement for inflammation, swelling and mucus. Small randomized trials show some real but narrow effects: after impacted third-molar surgery it improved jaw opening and swelling versus placebo, and a 2023 meta-analysis of six trials confirmed a benefit for trismus but not for pain or swelling. Older RCTs report less breast engorgement (about 86% vs 60% improved) and thinner, more easily cleared sputum in chronic airway disease. Head-to-head, dexamethasone outperformed it for swelling and pain, and a 2026 study found no antifibrotic benefit after liposuction. Most trials are small, short, open-label or company-linked, and oral bioavailability is uncertain because the enzyme is a large, acid-sensitive protein. A 2013 systematic review concluded the evidence is too weak to recommend it.

Benefits / uses: Reduce post-surgical swelling; Ease jaw stiffness (trismus); Thin and clear mucus; Anti-inflammatory adjunct.
Active compounds: Serratiopeptidase (a serine metalloprotease from Serratia E15).
Dose: Commonly 10–60 mg/day (≈20,000–120,000 SPU) as enteric-coated tablets, taken on an empty stomach in 2–3 divided doses.
Safety: Generally well tolerated short-term; common effects are nausea, GI upset, skin rash and cough. Because it breaks down fibrin, it may add to bleeding risk with anticoagulants and antiplatelets (warfarin, aspirin, clopidogrel, DOACs) and should be stopped before surgery; avoid in active abscess, as it can degrade the fibrin barrier and spread infection. Rare but serious reports include eosinophilic pneumonitis, bullous skin reactions and hemorrhage; long-term safety data are lacking and it is not recommended in pregnancy or breastfeeding given limited evidence.

Cited studies (10):
  - Efficacy of serratiopeptidase in third molar surgery. A systematic review and meta-analysis, Journal of Oral Research (2023) — Meta-analysis of 6 trials: serratiopeptidase reduced trismus after third-molar surgery but did NOT reduce postoperative pain or swelling. [https://doi.org/10.17126/joralres.2023.030]
  - Serratiopeptidase: a systematic review of the existing evidence, International journal of surgery (London, England) (2013) — Systematic review: existing evidence judged insufficient to support serratiopeptidase as an analgesic or anti-inflammatory; trials had poor methodology and small samples. [https://pubmed.ncbi.nlm.nih.gov/23380245/]
  - Efficacy of serratiopeptidase after impacted third molar surgery: a randomized controlled clinical trial, BMC oral health (2021) — RCT (n=133): vs placebo, serratiopeptidase improved day-4 trismus (27.3 vs 32.1 mm interincisal) and swelling (P<0.001), but pain did not differ. [https://pubmed.ncbi.nlm.nih.gov/33653320/]
  - Comparison of the roles of serratiopeptidase and dexamethasone in the control of inflammation and trismus following impacted third molar surgery, Indian journal of dental research : official publication of Indian Society for Dental Research (2012) — RCT (n=110): dexamethasone was more effective than serratiopeptidase for swelling and pain after third-molar surgery; trismus control was similar. [https://pubmed.ncbi.nlm.nih.gov/23649050/]
  - The treatment of breast engorgement with Serrapeptase (Danzen): a randomised double-blind controlled trial, Singapore medical journal (1989) — Double-blind RCT (n=70): for breast engorgement, 85.7% improved with serrapeptase vs 60.0% placebo (P<0.05). [https://pubmed.ncbi.nlm.nih.gov/2688125/]
  - Effect of the proteolytic enzyme serrapeptase in patients with chronic airway disease, Respirology (2003) — Open-label RCT (n=29): 30 mg/day for 4 weeks reduced sputum weight, viscosity, elasticity and neutrophils, and cut cough and expectoration frequency. [https://doi.org/10.1046/j.1440-1843.2003.00482.x]
  - A preliminary trial of serratiopeptidase in patients with carpal tunnel syndrome, The Journal of the Association of Physicians of India (1999) — Preliminary open trial (n=20): 65% of carpal tunnel patients showed clinical and electrophysiological improvement; no placebo control. [https://pubmed.ncbi.nlm.nih.gov/11225219/]
  - Serratiopeptidase - A Cause for Spread of Infection, Journal of clinical and diagnostic research : JCDR (2016) — Case report: serratiopeptidase implicated in spread of a buccal-space abscess by degrading the fibrin wall that contains infection; caution advised with abscesses. [https://pubmed.ncbi.nlm.nih.gov/27656583/]
  - Serrapeptase After Liposuction for Lipedema: Limited Evidence for Antifibrotic Efficacy, Aesthetic plastic surgery (2026) — Cohort (n=50): 60,000 IU/day for 4 weeks after liposuction for lipedema showed no measurable antifibrotic benefit on ultrasound elastography or patient outcomes. [https://pubmed.ncbi.nlm.nih.gov/41642311/]
  - Serratiopeptidase: Insights into the therapeutic applications, Biotechnology reports (Amsterdam, Netherlands) (2020) — Review: notes anti-inflammatory and mucolytic uses but flags poor oral bioavailability (large acid-sensitive protein) and unmet need for safety and mechanism data. [https://pubmed.ncbi.nlm.nih.gov/33134103/]

---

## Shiitake (Lentinula edodes)
URL: https://nutridex.info/s/shiitake
Category: Gut & Immune, Heart & Metabolic
Evidence: Preliminary — Early or small human trials; promising but not yet conclusive.
Culinary mushroom whose beta-glucans nudge immunity and lipids.

Quick answer: Shiitake is used for modulate immune cell activity. NutriDex grades the human evidence as preliminary — Early or small human trials; promising but not yet conclusive. Based on 8 cited human studies (8 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Shiitake (Lentinula edodes) is an edible Asian mushroom rich in beta-glucans, the fibre lentinan, and the cholesterol-modifying compound eritadenine. In a small 4-week RCT, eating 5–10 g of dried shiitake daily increased ex-vivo proliferation and activation of gamma-delta T and NK-T cells, hinting at immune support, though clinical illness was not an endpoint. A double-blind RCT of shiitake bars in people with borderline-high cholesterol found a roughly 10% fall in triglycerides over 66 days but no significant change in LDL or total cholesterol. The best-studied use is purified injectable lentinan as a chemotherapy add-on: pooled trials and an individual-patient meta-analysis show modestly longer survival in advanced gastric cancer (hazard ratio ~0.80). That is a regulated drug given intravenously, not the mushroom you eat or buy as a capsule. Overall, dietary and supplemental human evidence remains early and small.

Benefits / uses: Modulate immune cell activity; Modestly lower triglycerides; Adjunct in cancer chemotherapy (lentinan); Source of fibre & beta-glucans.
Active compounds: Lentinan (beta-1,3-glucan); Eritadenine; Ergothioneine; Ergosterol (vitamin D precursor).
Dose: Diet: 5–10 g dried mushroom daily; injectable lentinan is a prescription oncology drug used only under specialist care, not a supplement.
Safety: Cooked shiitake is well tolerated as food. Raw or undercooked mushrooms can trigger 'shiitake flagellate dermatitis' — a self-limited whip-like rash from heat-sensitive lentinan — and chronic intake may raise eosinophil counts; inhaled spores can cause hypersensitivity pneumonitis. Because beta-glucans modulate immunity, use caution with immunosuppressant therapy; and given possible additive lipid- and glucose-lowering effects, monitor if combining with statins or antidiabetic drugs. Injectable lentinan is a prescription oncology agent and should only be used under specialist supervision.

Cited studies (8):
  - Lentinan for Integrative Cancer Treatment: An Umbrella Review, The 1st International Electronic Conference on Biomolecules: Natural and Bio-Inspired Therapeutics for Human Diseases (2020) — Umbrella review of 8 meta-analyses: adjunct lentinan may improve response rate, 1-yr survival, performance status and chemo tolerance in GI/lung cancers. [https://doi.org/10.3390/IECBM2020-08733]
  - Efficacy of biological response modifier lentinan with chemotherapy for advanced cancer: a meta-analysis, Cancer medicine (2017) — Meta-analysis, 17 studies/1423 patients: lentinan plus chemo raised 1-yr survival (RR 1.46) and response rate (RR 1.28); no 2-yr survival benefit. [https://pubmed.ncbi.nlm.nih.gov/28940986/]
  - Individual patient based meta-analysis of lentinan for unresectable/recurrent gastric cancer, Anticancer research (2009) — Individual-patient meta-analysis, 650 patients/5 RCTs: adding injectable lentinan to chemo prolonged gastric-cancer survival, HR 0.80 (95% CI 0.68–0.95). [https://pubmed.ncbi.nlm.nih.gov/19596954/]
  - Effects of Shiitake Culinary-Medicinal Mushroom, Lentinus edodes (Agaricomycetes), Bars on Lipid and Antioxidant Profiles in Individuals with Borderline High Cholesterol: A Double-Blind Randomized Clinical Trial, International journal of medicinal mushrooms (2021) — Double-blind RCT (n=68) of shiitake bars: ~10% triglyceride reduction at 66 days (p=0.035); no significant change in LDL or total cholesterol. [https://pubmed.ncbi.nlm.nih.gov/34375514/]
  - Consuming Lentinula edodes (Shiitake) Mushrooms Daily Improves Human Immunity: A Randomized Dietary Intervention in Healthy Young Adults, Journal of the American College of Nutrition (2015) — 4-wk RCT: 5–10 g/day dried shiitake raised ex-vivo gamma-delta T-cell (~60%) and NK-T-cell (~2x) proliferation and activation in 52 healthy adults. [https://pubmed.ncbi.nlm.nih.gov/25866155/]
  - A placebo-controlled trial of the immune modulator, lentinan, in HIV-positive patients: a phase I/II trial, Journal of medicine (1998) — Phase I/II placebo-controlled trial (98 HIV+ patients): IV lentinan well-tolerated; non-significant trend toward higher CD4 counts, no proven clinical benefit. [https://pubmed.ncbi.nlm.nih.gov/10503166/]
  - Lentinan with S-1 and paclitaxel for gastric cancer chemotherapy improve patient quality of life, Hepato-gastroenterology (2009) — RCT in advanced gastric cancer: lentinan added to S-1/paclitaxel chemotherapy improved patient quality of life. [https://pubmed.ncbi.nlm.nih.gov/19579640/]
  - Flagellate dermatitis following consumption of shiitake mushroom, Dermatology reports (2011) — Case report of flagellate ('whiplash') dermatitis after eating shiitake, the classic toxic skin reaction to thermolabile lentinan. [https://pubmed.ncbi.nlm.nih.gov/25386273/]

---

## Sodium Bicarbonate
URL: https://nutridex.info/s/sodium-bicarbonate
Category: Performance
Evidence: Moderate — Several controlled trials; effects real but modest or context-dependent.
Baking soda as a blood buffer for short, all-out efforts.

Quick answer: Sodium Bicarbonate is used for buffers exercise acidosis. NutriDex grades the human evidence as moderate — Several controlled trials; effects real but modest or context-dependent. Based on 8 cited human studies (8 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Sodium bicarbonate (baking soda) is an extracellular buffer: loading the blood with bicarbonate before exercise blunts the acid build-up that limits short, all-out efforts. Meta-analyses report small-to-moderate improvements (effect sizes ~0.3–0.4) in high-intensity tasks lasting roughly 30 seconds to 12 minutes — muscular endurance, 2000-m rowing (~1.4%), Yo-Yo intermittent running, and combat sports — and it benefits time-to-exhaustion more than time-trial performance. The optimal dose is about 0.3 g/kg taken 90–180 minutes beforehand. However, benefits are inconsistent: a 2025 meta-analysis found a negligible, non-significant effect on running in mixed-sex groups (significant only in men), and gains vary widely between individuals. Most trials are small and male-dominated, and gastrointestinal distress — bloating, nausea, vomiting, cramps — affected nearly 30% in some pooled data, which can itself hurt performance.

Benefits / uses: Buffers exercise acidosis; Boosts high-intensity endurance (30 s–12 min); Combat-sport & sprint performance; Synergy with beta-alanine.
Active compounds: Sodium bicarbonate (NaHCO3); Bicarbonate ion; Sodium.
Dose: 0.2–0.3 g/kg body weight taken 90–180 min before exercise (often in enteric-coated capsules with a carbohydrate meal to limit gut upset); ~0.3 g/kg is the optimal single dose.
Safety: The most common side effects are gastrointestinal — bloating, nausea, vomiting, abdominal pain and diarrhoea — affecting up to ~30% of users at ergogenic doses; enteric-coated capsules, a carbohydrate meal and smaller/split doses reduce this. The high sodium load makes it unsuitable for people with hypertension, heart failure or kidney disease, and excessive intake can cause hypernatremia, hypokalemia and dangerous metabolic alkalosis (case reports of severe toxicity). Because it raises stomach and urine pH, sodium bicarbonate can alter absorption or clearance of many drugs — reduce iron, certain antibiotics (tetracyclines, quinolones), antifungals like ketoconazole, and raise levels of others (e.g. aspirin, some amphetamine/stimulant and lithium clearance changes); separate doses and check with a clinician or pharmacist.

Cited studies (8):
  - Negligible benefit of oral single-dose sodium bicarbonate on continuous running performance: systematic review with meta-analysis of randomized, double-blind, placebo-controlled trials, Journal of the International Society of Sports Nutrition (2025) — Continuous running: negligible, non-significant overall effect (SMD 0.18, p=0.06); significant only in men (0.40). GI symptoms 29.5% vs 2.6% placebo. [https://pubmed.ncbi.nlm.nih.gov/41416636/]
  - Sodium bicarbonate and beta-alanine supplementation: Is combining both better than either alone? A systematic review and meta-analysis, Biology of sport (2024) — Beta-alanine + bicarbonate combined improved performance (SMD 0.32, p=0.02); neither supplement was significant taken alone. [https://pubmed.ncbi.nlm.nih.gov/38952910/]
  - Effects of sodium bicarbonate supplementation on exercise performance: an umbrella review, Journal of the International Society of Sports Nutrition (2021) — Across meta-analyses, NaHCO3 gave moderate gains in 45 s–8 min endurance (d≈0.40), muscle endurance (0.37) and Yo-Yo running (0.36); ~1.4% in rowing. [https://pubmed.ncbi.nlm.nih.gov/34794476/]
  - Effect of sodium bicarbonate supplementation on two different performance indicators in sports: a systematic review with meta-analysis, Physical activity and nutrition (2021) — NaHCO3 improved time-to-exhaustion (SMD 1.48, 95% CI 0.49–2.48) but had no significant effect on time-trial performance. [https://pubmed.ncbi.nlm.nih.gov/33887823/]
  - Can Sodium Bicarbonate Supplementation Improve Combat Sports Performance? A Systematic Review and Meta-analysis, Current nutrition reports (2022) — In combat sports, NaHCO3 raised blood lactate (p=0.006) and added ~2 throws (6%) in later Special Judo Fitness Test bouts. [https://pubmed.ncbi.nlm.nih.gov/35394616/]
  - The Impact of Sodium Bicarbonate on Performance in Response to Exercise Duration in Athletes: A Systematic Review, Journal of sports science & medicine (2019) — Of 35 trials, shorter tasks (≤4 min) responded more often (11/20 positive) than longer (>4 min, 6/15); results inconsistent even within identical protocols. [https://pubmed.ncbi.nlm.nih.gov/31191097/]
  - International Society of Sports Nutrition position stand: sodium bicarbonate and exercise performance, Journal of the International Society of Sports Nutrition (2021) — 0.2–0.5 g/kg improves muscular endurance, combat sports and high-intensity cycling/running/swimming/rowing; ~0.3 g/kg optimal, 30 s–12 min tasks. [https://pubmed.ncbi.nlm.nih.gov/34503527/]
  - Severe metabolic alkalosis due to baking soda ingestion: case reports of two patients with unsuspected antacid overdose, The Journal of emergency medicine (1999) — Two unsuspected baking-soda antacid overdoses caused severe metabolic alkalosis; illustrates the hypernatremia/alkalosis risk of excess ingestion. [https://pubmed.ncbi.nlm.nih.gov/9950389/]

---

## Spermidine
URL: https://nutridex.info/s/spermidine
Category: Longevity
Evidence: Preliminary — Early or small human trials; promising but not yet conclusive.
Diet-derived polyamine that triggers autophagy; promising but unproven.

Quick answer: Spermidine is used for induces cellular autophagy. NutriDex grades the human evidence as preliminary — Early or small human trials; promising but not yet conclusive. Based on 8 cited human studies (8 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Spermidine is a naturally occurring polyamine found in wheat germ, soy, aged cheese, mushrooms and legumes, and made by gut bacteria. In animals it extends lifespan by inducing autophagy, the cell's recycling process. Large population cohorts (Bruneck, NHANES) consistently link higher dietary spermidine to lower all-cause and cardiovascular mortality, with hazard ratios around 0.70-0.76 per higher intake category, but these are observational and may reflect healthier diets overall. Human supplement trials are small and conflicting: a 3-month pilot (n=30) and a higher-dose dementia trial showed modest memory gains, yet the largest, best-designed RCT (12 months, n=100, ~0.9 mg/day) found no effect on memory (p=0.47). Short trials report good safety. Overall the mechanism is compelling and the epidemiology is encouraging, but controlled human proof of an anti-aging or cognitive benefit is not yet there.

Benefits / uses: Induces cellular autophagy; Linked to lower mortality (diet studies); Possible memory support; Cardiovascular & metabolic signals.
Active compounds: Spermidine (a triamine polyamine).
Dose: Most human trials use 0.9–6 mg/day, usually as wheat-germ extract; no established optimal dose.
Safety: Spermidine is consumed in normal diets and short trials (up to 12 months, 0.9-6 mg/day) report good tolerability with no notable adverse effects on vital signs, blood counts or chemistry. Long-term safety of concentrated supplements is unstudied, and because polyamines support cell proliferation there is a theoretical concern in active cancer, so people with a current malignancy should be cautious. No well-documented drug interactions exist, but wheat-germ-derived products are unsuitable for those with wheat or gluten sensitivity; pregnant and breastfeeding women should avoid supplements given the lack of safety data.

Cited studies (8):
  - The positive effect of spermidine in older adults suffering from dementia after 1 year, Wiener klinische Wochenschrift (2024) — 12-month follow-on in dementia patients: continued spermidine intake associated with sustained cognitive improvement. [https://pubmed.ncbi.nlm.nih.gov/37284840/]
  - Effects of Spermidine Supplementation on Cognition and Biomarkers in Older Adults With Subjective Cognitive Decline: A Randomized Clinical Trial, JAMA network open (2022) — 12-month RCT (n=100, 0.9 mg/day): no significant benefit on mnemonic discrimination vs placebo (p=0.47); the largest, longest trial to date. [https://pubmed.ncbi.nlm.nih.gov/35616942/]
  - The positive effect of spermidine in older adults suffering from dementia : First results of a 3-month trial, Wiener klinische Wochenschrift (2021) — 3-month trial in nursing-home dementia (n=85): higher-dose spermidine raised MMSE by ~2.23 points in mild dementia (p=0.026). [https://pubmed.ncbi.nlm.nih.gov/33211152/]
  - The effect of spermidine on memory performance in older adults at risk for dementia: A randomized controlled trial, Cortex; a journal devoted to the study of the nervous system and behavior (2018) — 3-month pilot RCT (n=30, at-risk older adults): memory performance moderately improved vs placebo (medium effect size). [https://pubmed.ncbi.nlm.nih.gov/30388439/]
  - Safety and tolerability of spermidine supplementation in mice and older adults with subjective cognitive decline, Aging (2018) — Safety study in mice and older adults: 3-month spermidine-rich extract was safe and well-tolerated, no adverse vital-sign or lab changes. [https://doi.org/10.18632/aging.101354]
  - Spermidine for cognitive ageing: insights into observational and interventional studies, General Psychiatry (2025) — Review of 4 cognition RCTs: results mixed (2 positive, 1 null, 1 positive in dementia); observational data inconsistent. [https://doi.org/10.1136/gpsych-2024-101723]
  - The association of dietary spermidine with all-cause mortality and CVD mortality: The U.S. National Health and Nutrition Examination Survey, 2003 to 2014, Frontiers in public health (2022) — NHANES (n=23,894): highest vs lowest dietary spermidine intake had all-cause mortality HR 0.70 and CVD mortality HR 0.68. [https://pubmed.ncbi.nlm.nih.gov/36249217/]
  - Higher spermidine intake is linked to lower mortality: a prospective population-based study, The American journal of clinical nutrition (2018) — Bruneck cohort (n=829, 20y): highest vs lowest dietary spermidine third had far lower mortality; HR 0.76 per 1-SD, validated in a 2nd cohort. [https://pubmed.ncbi.nlm.nih.gov/29955838/]

---

## Sulforaphane
URL: https://nutridex.info/s/sulforaphane
Category: Longevity, Gut & Immune
Evidence: Mixed — Conflicting results across studies; benefit uncertain.
Broccoli-sprout compound that switches on the body's Nrf2 defense genes.

Quick answer: Sulforaphane is used for activate nrf2 antioxidant defenses. NutriDex grades the human evidence as mixed — Conflicting results across studies; benefit uncertain. Based on 8 cited human studies (8 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Sulforaphane is an isothiocyanate formed when you chew or crush broccoli and especially broccoli sprouts, where the precursor glucoraphanin meets the enzyme myrosinase. It is a potent activator of the Nrf2 pathway, which switches on antioxidant and detoxification genes. Human trials are broad but uneven. A meta-analysis of 10 small broccoli-sprout trials reported large blood-pressure reductions (systolic ~11 mmHg), but the best-powered glucose RCT (n=89, 2025) achieved only a 0.2 mmol/L fall in fasting glucose and missed its prespecified target. In autism, an early small trial was positive but the larger replication failed its primary outcome. Sulforaphane lowers gastric oxidative-stress markers but does not reliably eradicate H. pylori, and modestly improves elevated liver enzymes in fatty-liver studies. Effect sizes are inconsistent and bioavailability varies enormously between products, so claims should be read cautiously.

Benefits / uses: Activate Nrf2 antioxidant defenses; May lower blood pressure; May modestly lower fasting glucose; Reduce gastric inflammation markers; Lower elevated liver enzymes.
Active compounds: Sulforaphane; Glucoraphanin (precursor); Myrosinase (activating enzyme).
Dose: Roughly 10–40 mg sulforaphane/day (about 100–200 µmol), usually as a stabilized broccoli-sprout extract; bioavailability swings widely with myrosinase content and gut microbiota.
Safety: Generally well tolerated; the most common complaints are mild gas, bloating and reflux, and occasionally a transient rise in body temperature reported in autism trials. Because sulforaphane activates Nrf2 and can modestly lower glucose and blood pressure, theoretical additive effects with antidiabetic and antihypertensive drugs warrant monitoring. Concentrated extracts are not established as safe in pregnancy or breastfeeding, and high-dose Nrf2 activation could in theory blunt some chemotherapy agents that rely on oxidative stress, so cancer patients should consult their oncologist.

Cited studies (8):
  - Beneficial Effects of Sulforaphane-Yielding Broccoli Sprout on Cardiometabolic Health: A Systematic Review and Meta-analysis, Jundishapur Journal of Natural Pharmaceutical Products (2022) — Meta-analysis of 10 trials: broccoli sprout cut systolic BP ~10.9 mmHg and diastolic ~6.95 mmHg, but trials were small and heterogeneous. [https://doi.org/10.5812/jjnpp-129402]
  - Effect of broccoli sprout extract and baseline gut microbiota on fasting blood glucose in prediabetes: a randomized, placebo-controlled trial, Nature Microbiology (2025) — Prediabetes RCT (n=89, 150 µmol/day, 12 wk): only 0.2 mmol/L fasting-glucose drop, missing the prespecified 0.3 mmol/L primary endpoint. [https://doi.org/10.1038/s41564-025-01932-w]
  - Randomized controlled trial of sulforaphane and metabolite discovery in children with Autism Spectrum Disorder, Molecular autism (2021) — Autism RCT (n=45 children, 15 wk): no significant effect on the primary OACIS outcome; only small, non-significant positive trends. [https://pubmed.ncbi.nlm.nih.gov/34034808/]
  - The Effects of Broccoli Sprout Extract Containing Sulforaphane on Lipid Peroxidation and Helicobacter pylori Infection in the Gastric Mucosa, Gut and liver (2015) — Broccoli-sprout extract (1000 µg sulforaphane twice daily, 4 wk) cut gastric malondialdehyde but did not reduce H. pylori density. [https://pubmed.ncbi.nlm.nih.gov/25287166/]
  - Sulforaphane-rich broccoli sprout extract improves hepatic abnormalities in male subjects, World journal of gastroenterology (2015) — RCT in men with fatty liver: glucoraphanin-rich sprout extract for 2 mo lowered ALT and γ-GTP and urinary 8-OHdG vs placebo. [https://pubmed.ncbi.nlm.nih.gov/26604653/]
  - Sulforaphane treatment of autism spectrum disorder (ASD), Proceedings of the National Academy of Sciences of the United States of America (2014) — Early autism RCT in 44 young men (18 wk): sulforaphane improved ABC and SRS behavior scores vs placebo; small and not replicated. [https://pubmed.ncbi.nlm.nih.gov/25313065/]
  - Dietary sulforaphane-rich broccoli sprouts reduce colonization and attenuate gastritis in Helicobacter pylori-infected mice and humans, Cancer prevention research (Philadelphia, Pa.) (2009) — H. pylori RCT: 70 g/day broccoli sprouts for 8 wk lowered urease and gastric-inflammation biomarkers, but did not eradicate infection. [https://pubmed.ncbi.nlm.nih.gov/19349290/]
  - Sulforaphane inhibits extracellular, intracellular, and antibiotic-resistant strains of<i>Helicobacter pylori</i>and prevents benzo[<i>a</i>]pyrene-induced stomach tumors, Proceedings of the National Academy of Sciences (2002) — Foundational work showing sulforaphane kills antibiotic-resistant H. pylori in vitro and blocks chemically induced stomach tumors in mice. [https://doi.org/10.1073/pnas.112203099]

---

## Tremella (Snow Fungus) (Tremella fuciformis)
URL: https://nutridex.info/s/tremella
Category: Joint & Skin, Longevity
Evidence: Preliminary — Early or small human trials; promising but not yet conclusive.
Water-binding 'beauty mushroom' with thin but real human data.

Quick answer: Tremella (Snow Fungus) is used for skin hydration & moisture. NutriDex grades the human evidence as preliminary — Early or small human trials; promising but not yet conclusive. Based on 7 cited human studies (7 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Tremella fuciformis is an edible jelly fungus whose gel-like polysaccharides bind water, fuelling its 'natural hyaluronic acid' marketing. The human evidence is genuinely thin. One 8-week RCT in 75 adults with subjective memory complaints found 600–1200 mg/day modestly improved memory-complaint scores and some short-term-memory and executive tasks, mainly at the higher dose. A separate 12-week RCT in 56 overweight prediabetic adults found a Tremella beverage (~6.4 g beta-glucan/day) produced small but significant drops in HbA1c (about 0.07%, Cohen's d 0.39) and waist circumference (~1.7 cm, d 0.45) versus placebo. The widely promoted skin-hydration benefit has no published oral human trial; it relies on fibroblast and rodent studies. Other actions (antioxidant, immune, lipid-lowering) are preclinical. Effects, where present, are small, short-term and not independently replicated.

Benefits / uses: Skin hydration & moisture; Memory & cognition support; Blood sugar & waist control; Antioxidant / anti-inflammatory.
Active compounds: Tremella fuciformis polysaccharides (acidic heteropolysaccharides); Beta-glucans; Dietary fibre.
Dose: Most human trials used 600–1200 mg/day of standardized fruiting-body extract, or ~6 g/day beta-glucan as a beverage; no consensus dose exists.
Safety: Tremella is eaten as food and is well tolerated; trials reported no excess adverse events, mainly mild GI upset. Lab studies show mild anticoagulant and glucose-lowering activity, so theoretically it may add to anticoagulants/antiplatelets (warfarin, aspirin) and antidiabetic drugs (insulin, sulfonylureas) — monitor for bleeding or hypoglycemia. Its immune-modulating polysaccharides warrant caution with immunosuppressants, and people with mushroom allergy or on these medications should consult a clinician first.

Cited studies (7):
  - Structure, Function and Application of <i>Tremella Fuciformis</i> Polysaccharide: A Review, Journal of Food Science (2025) — Comprehensive review confirms TF polysaccharides' anti-aging and skin-water-binding mechanisms remain preclinical; calls for clinical validation. [https://doi.org/10.1111/1750-3841.70494]
  - Tremella fuciformis beverage improves glycated hemoglobin A1c and waist circumference in overweight/obese prediabetic subjects: a randomized controlled trial, BMC nutrition (2024) — 12-wk RCT (n=56): ~6.4 g/day Tremella beta-glucan cut HbA1c (d=0.39, p=0.047) and waist circumference (~1.7 cm, d=0.45, p=0.022) vs placebo. [https://pubmed.ncbi.nlm.nih.gov/38439104/]
  - Efficacy and Safety of Tremella fuciformis in Individuals with Subjective Cognitive Impairment: A Randomized Controlled Trial, Journal of medicinal food (2018) — 8-wk RCT (n=75) in subjective cognitive impairment: 600–1200 mg/day improved memory-complaint scores and some short-term memory/executive tasks vs placebo. [https://pubmed.ncbi.nlm.nih.gov/29319408/]
  - Recent advances in polysaccharides from Tremella fuciformis: isolation, structures, bioactivities and application, Frontiers in Nutrition (2025) — Review: TF polysaccharides show antioxidant, immune and metabolic activity, but human evidence is limited mostly to one cognition RCT; rest preclinical. [https://doi.org/10.3389/fnut.2025.1663327]
  - Tremella polysaccharide: The molecular mechanisms of its drug action, Progress in molecular biology and translational science (2019) — Review of 113 studies over 46 yrs: TF polysaccharide shows hypoglycemic, hypolipidemic, neuroprotective and immune effects; CFDA-approved for chemo leukopenia. [https://pubmed.ncbi.nlm.nih.gov/31030755/]
  - Tremella fuciformis Polysaccharides Attenuate Oxidative Stress and Inflammation in Macrophages through miR-155, Analytical cellular pathology (Amsterdam) (2018) — In-vitro: TF polysaccharides suppressed LPS-induced oxidative stress and inflammation in macrophages via miR-155/NF-kB inhibition (optimal 200 ug/ml). [https://pubmed.ncbi.nlm.nih.gov/29854576/]
  - Effect of Tremella fuciformis on the neurite outgrowth of PC12h cells and the improvement of memory in rats, Biological & pharmaceutical bulletin (2007) — Rat study: TF water extract dose-dependently promoted neurite outgrowth and reversed scopolamine-induced memory deficit, raising cholinergic activity. [https://pubmed.ncbi.nlm.nih.gov/17409507/]

---

## White Willow Bark (Salix alba)
URL: https://nutridex.info/s/white-willow
Category: Joint & Skin
Evidence: Moderate — Several controlled trials; effects real but modest or context-dependent.
Aspirin's botanical ancestor, used for back and joint pain.

Quick answer: White Willow Bark is used for ease low-back pain flares. NutriDex grades the human evidence as moderate — Several controlled trials; effects real but modest or context-dependent. Based on 7 cited human studies (7 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

White willow bark is the plant from which salicin — the precursor of aspirin's active ingredient — is derived. Its best evidence is for acute flares of chronic low-back pain: in a 210-patient RCT, 39% of people on 240 mg salicin/day were pain-free in the final week versus 6% on placebo, and a Cochrane review rated this 'moderate' evidence, with one trial showing rough parity to rofecoxib. For osteoarthritis the picture is mixed: a small 2-week trial found a modest WOMAC pain drop (14% vs placebo), but the larger, more rigorous 2004 trial (240 mg salicin vs diclofenac vs placebo) found no benefit over placebo while diclofenac clearly worked. A 2023 meta-analysis of arthritis trials found only a small pooled effect (SMD −0.31) rated very-low certainty. Useful and generally well tolerated, but milder and less consistent than standard analgesics.

Benefits / uses: Ease low-back pain flares; Relieve osteoarthritis pain; Anti-inflammatory support; Aspirin-like pain relief.
Active compounds: Salicin; Salicylates (salicortin, tremulacin); Polyphenols & flavonoids.
Dose: Standardized extract delivering 120–240 mg salicin/day; the 240 mg dose carries most of the positive trial evidence.
Safety: Willow bark acts like a mild aspirin: it can cause stomach upset, GI bleeding and allergic reactions, and is dangerous in people with aspirin/salicylate allergy (anaphylaxis has been reported). It should not be given to children or teens with viral illness (Reye's syndrome risk) and is best avoided in pregnancy, peptic ulcer, asthma, and kidney or liver disease. It can add to the bleeding risk of warfarin and other anticoagulants/antiplatelets and may interact with other NSAIDs, methotrexate and some blood-pressure or diabetes medications — talk to a clinician before combining.

Cited studies (7):
  - Willow Bark (Salix spp.) Used for Pain Relief in Arthritis: A Meta-Analysis of Randomized Controlled Trials, Life (2023) — Meta-analysis (6 RCTs, 329 arthritis patients): small pain benefit vs placebo (SMD −0.31, 95% CI −0.53 to −0.08); very-low GRADE certainty. [https://doi.org/10.3390/life13102058]
  - Herbal medicine for low back pain: a Cochrane review, Spine (2007) — Moderate evidence that 120–240 mg salicin/day improves short-term low-back pain; one trial showed rough equivalence to rofecoxib. [https://pubmed.ncbi.nlm.nih.gov/17202897/]
  - Treatment of low back pain exacerbations with willow bark extract: a randomized double-blind study, The American journal of medicine (2000) — RCT (n=210, back-pain flare): 39% pain-free on 240 mg salicin vs 21% on 120 mg vs 6% placebo in the final week. [https://pubmed.ncbi.nlm.nih.gov/10936472/]
  - Efficacy and safety of willow bark extract in the treatment of osteoarthritis and rheumatoid arthritis: results of 2 randomized double-blind controlled trials, The Journal of rheumatology (2004) — RCT: 240 mg salicin showed no benefit over placebo for OA (or RA); diclofenac cut WOMAC pain 47% vs placebo's 10%. [https://pubmed.ncbi.nlm.nih.gov/15517622/]
  - Efficacy and tolerability of a standardized willow bark extract in patients with osteoarthritis: randomized placebo-controlled, double blind clinical trial, Phytotherapy research : PTR (2001) — RCT (n=78, knee/hip OA, 2 wk): 240 mg salicin reduced WOMAC pain 14% vs a 2% rise on placebo (p=0.047). [https://pubmed.ncbi.nlm.nih.gov/11406860/]
  - Willow bark extract (Salicis cortex) for gonarthrosis and coxarthrosis--results of a cohort study with a control group, Phytomedicine : international journal of phytotherapy and phytopharmacology (2008) — Observational cohort (n≈131, gon-/coxarthrosis, 6 wk): willow bark roughly matched standard therapy on WOMAC with better tolerability. [https://pubmed.ncbi.nlm.nih.gov/18815018/]
  - Potential economic impact of using a proprietary willow bark extract in outpatient treatment of low back pain: an open non-randomized study, Phytomedicine : international journal of phytotherapy and phytopharmacology (2001) — Open outpatient study: willow bark extract for low-back pain reduced analgesic use and projected lower treatment costs vs usual care. [https://pubmed.ncbi.nlm.nih.gov/11515713/]

---

## Agmatine Sulfate
URL: https://nutridex.info/s/agmatine
Category: Performance, Nootropic
Evidence: Preliminary — Early or small human trials; promising but not yet conclusive.
Arginine metabolite sold for pumps and mood, but human data is thin.

Quick answer: Agmatine Sulfate is used for neuropathic pain relief. NutriDex grades the human evidence as preliminary — Early or small human trials; promising but not yet conclusive. Based on 7 cited human studies (7 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Agmatine is a metabolite of the amino acid arginine, marketed both as a pre-workout 'pump' and nitric-oxide aid and as a mood/nootropic agent. The strongest human evidence is for nerve pain: a randomized, double-blind trial gave 2.67 g/day of agmatine sulfate to people with herniated-disc sciatica for two weeks and saw larger pain and quality-of-life gains than placebo, and open-label pilots in small-fiber neuropathy reported roughly 46% pain reduction. For depression, only a 3-patient open pilot exists. Crucially, the bodybuilding 'pump,' strength, endurance and focus claims rest almost entirely on rodent studies — no human randomized trial confirms an ergogenic or cognitive benefit. Doses are typically 1.3–2.67 g/day. Reported side effects in trials were mild (mainly GI), but trials are small and short, so the marketed performance uses remain unproven rather than disproven.

Benefits / uses: Neuropathic pain relief; Possible mood support; Claimed workout pump; Claimed focus & nootropic effect.
Active compounds: Agmatine (decarboxylated L-arginine); Sulfate salt.
Dose: Human trials used 1.3–2.67 g/day of agmatine sulfate (oral, divided); performance and nootropic doses are extrapolated, not validated.
Safety: In short trials (up to ~3 weeks, 5 years in one self-report) agmatine sulfate was well tolerated, with mainly mild GI effects (nausea, diarrhea, low appetite). It modulates nitric-oxide and blood-pressure pathways, so combine cautiously with antihypertensives or other nitric-oxide boosters; theoretically it could add to the effects of antidiabetic and antidepressant/serotonergic drugs. Human safety data are limited and short-term, and it has not been studied in pregnancy, breastfeeding, or children, so avoid it in those groups.

Cited studies (7):
  - Evidence for Dietary Agmatine Sulfate Effectiveness in Neuropathies Associated with Painful Small Fiber Neuropathy. A Pilot Open-Label Consecutive Case Series Study, Nutrients (2020) — Open-label pilot (n=11): 2.67 g/day for 2 months cut neuropathic pain 26 points (46.4% reduction, p<0.00001) in small-fiber neuropathy. [https://pubmed.ncbi.nlm.nih.gov/32102167/]
  - Evidence for safety of the dietary ingredient agmatine sulfate as assessed by mutagenicity and genotoxicity studies, Toxicology reports (2024) — Standard test battery found agmatine sulfate (G-Agmatine) non-mutagenic and non-genotoxic in bacterial, mammalian-cell and animal assays. [https://pubmed.ncbi.nlm.nih.gov/39286406/]
  - Safety and Efficacy of Dietary Agmatine Sulfate in Lumbar Disc-associated Radiculopathy. An Open-label, Dose-escalating Study Followed by a Randomized, Double-blind, Placebo-controlled Trial, Pain medicine (Malden, Mass.) (2010) — Double-blind RCT: 2.67 g/day agmatine sulfate for 14 days improved pain and SF-36 quality of life vs placebo in lumbar disc sciatica. [https://pubmed.ncbi.nlm.nih.gov/20447305/]
  - The clinical antidepressant effect of exogenous agmatine is not reversed by parachlorophenylalanine: a pilot study, Acta neuropsychiatrica (2013) — Pilot: 3 major-depression patients reached remission on oral agmatine monotherapy; antidepressant effect not reversed by serotonin depletion. [https://pubmed.ncbi.nlm.nih.gov/25287313/]
  - Long-term (5 years), high daily dosage of dietary agmatine--evidence of safety: a case report, Journal of medicinal food (2014) — Case report: 2.67 g/day agmatine sulfate taken ~5 years with health parameters staying within normal range and no adverse effects. [https://pubmed.ncbi.nlm.nih.gov/25247837/]
  - Agmatine as a novel candidate for rapid-onset antidepressant response, World journal of psychiatry (2021) — Review: agmatine shows ketamine-like rapid antidepressant effects in animals via mTORC1/NMDA, but human depression trials are still lacking. [https://pubmed.ncbi.nlm.nih.gov/34888168/]
  - Agmatine: clinical applications after 100 years in translation, Drug discovery today (2013) — 16-group review of agmatine pharmacology: imidazoline/NMDA/NOS modulation underpins preclinical analgesic, metabolic and mood effects. [https://pubmed.ncbi.nlm.nih.gov/23769988/]

---

## Andrographis (Andrographis paniculata)
URL: https://nutridex.info/s/andrographis
Category: Gut & Immune
Evidence: Moderate — Several controlled trials; effects real but modest or context-dependent.
Bitter herb that may ease cold and respiratory symptoms.

Quick answer: Andrographis is used for shorten cold/respiratory symptoms. NutriDex grades the human evidence as moderate — Several controlled trials; effects real but modest or context-dependent. Based on 8 cited human studies (8 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Andrographis is a bitter Asian herb whose main active is andrographolide. The strongest data are for acute respiratory infections: a 2017 meta-analysis of 33 RCTs (7,175 patients) found it modestly reduced cough severity (SMD -0.39) and more substantially reduced sore throat (SMD -1.13) versus placebo, with the authors cautioning about poor study quality and heterogeneity. Earlier reviews reached similar conclusions. A standardized extract (HMPL-004) helped induce response in mild-to-moderate ulcerative colitis (60% vs 40% on placebo at 1,800 mg/day), and small trials suggest benefit in rheumatoid arthritis and multiple-sclerosis fatigue. Overall the herb appears genuinely active for short-term symptom relief, but trials are mostly small, brief, and commercially sponsored, so durability and magnitude remain unsettled. It is not a substitute for antibiotics when those are indicated.

Benefits / uses: Shorten cold/respiratory symptoms; Ease sore throat and cough; Reduce inflammation; Support in ulcerative colitis (extract).
Active compounds: Andrographolide; Neoandrographolide; Deoxyandrographolide.
Dose: Standardized extract supplying ~60 mg andrographolides/day (e.g. KalmCold 200 mg or 4-6 g/day dried herb), taken at symptom onset for 3-7 days.
Safety: Generally well tolerated short-term; the commonest effects are mild GI upset, headache, fatigue and occasional allergic rash, with rare reports of urticaria/anaphylaxis. Avoid in pregnancy (animal data and traditional abortifacient use suggest reproductive risk) and use caution while breastfeeding. Because it can lower blood glucose and blood pressure and has antiplatelet activity, it may add to the effect of antidiabetic, antihypertensive and anticoagulant/antiplatelet drugs; it may also stimulate immune activity, so caution is advised with immunosuppressants and in autoimmune disease. Stop before surgery and seek care for jaundice or signs of allergic reaction.

Cited studies (8):
  - Andrographis paniculata (Chuān Xīn Lián) for symptomatic relief of acute respiratory tract infections in adults and children: A systematic review and meta-analysis, PloS one (2017) — Meta-analysis of 33 RCTs (7,175 pts): reduced cough (SMD -0.39) and sore throat (SMD -1.13) vs placebo; serious AEs rare. [https://pubmed.ncbi.nlm.nih.gov/28783743/]
  - Andrographis paniculata in the treatment of upper respiratory tract infections: a systematic review of safety and efficacy, Planta medica (2004) — 7 double-blind trials (n=896): Andrographis superior to placebo for symptoms of uncomplicated upper respiratory infection. [https://pubmed.ncbi.nlm.nih.gov/15095142/]
  - Andrographis paniculata decreases fatigue in patients with relapsing-remitting multiple sclerosis: a 12-month double-blind placebo-controlled pilot study, BMC neurology (2016) — 12-month pilot RCT (n=22, relapsing-remitting MS on interferon): ~44% reduction in Fatigue Severity Score vs placebo. [https://pubmed.ncbi.nlm.nih.gov/27215274/]
  - A randomized double blind placebo controlled clinical evaluation of extract of Andrographis paniculata (KalmCold) in patients with uncomplicated upper respiratory tract infection, Phytomedicine : international journal of phytotherapy and phytopharmacology (2010) — RCT (n=223, KalmCold 200 mg/day): overall symptom efficacy ~2.1x (52.7%) higher than placebo in uncomplicated URTI. [https://pubmed.ncbi.nlm.nih.gov/20092985/]
  - Andrographis paniculata extract (HMPL-004) for active ulcerative colitis, The American journal of gastroenterology (2013) — RCT (n=224, mild-moderate ulcerative colitis): 60% clinical response on 1,800 mg/day extract vs 40% placebo at 8 weeks. [https://pubmed.ncbi.nlm.nih.gov/23044768/]
  - Prevention of common colds with Andrographis paniculata dried extract. A Pilot double blind trial, Phytomedicine : international journal of phytotherapy and phytopharmacology (1997) — Pilot double-blind trial: prophylactic dried extract reduced incidence of common colds vs placebo over the prevention period. [https://pubmed.ncbi.nlm.nih.gov/23195395/]
  - Safety of <scp><i>Andrographis paniculata</i></scp>: A systematic review and meta‐analysis, Pharmacoepidemiology and Drug Safety (2021) — Safety meta-analysis (10 RCTs + monitoring): adverse events mostly mild (GI, skin); serious AEs very rare (0.02/1000). [https://doi.org/10.1002/pds.5190]
  - Efficacy of an Andrographis paniculata composition for the relief of rheumatoid arthritis symptoms: a prospective randomized placebo-controlled trial, Clinical rheumatology (2009) — RCT (n=60, active rheumatoid arthritis): 14 weeks of extract reduced tender/swollen joint counts and rheumatoid factor vs placebo. [https://pubmed.ncbi.nlm.nih.gov/19408036/]

---

## Aniracetam
URL: https://nutridex.info/s/aniracetam
Category: Nootropic
Evidence: Preliminary — Early or small human trials; promising but not yet conclusive.
Fat-soluble racetam studied for dementia, not proven in healthy users.

Quick answer: Aniracetam is used for memory in dementia. NutriDex grades the human evidence as preliminary — Early or small human trials; promising but not yet conclusive. Based on 6 cited human studies (6 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Aniracetam is a fat-soluble member of the racetam family, sold as a cognitive supplement but never approved as a drug in the US (it was a prescription product in parts of Europe and Japan). The human evidence is modest and old. A 6-month double-blind trial in 109 patients with mild-to-moderate Alzheimer's-type dementia found aniracetam (1,500 mg/day) improved psychobehavioural scores versus placebo, which steadily worsened. A comparative open study (n≈58 on aniracetam) suggested it held cognition steady better than cholinesterase inhibitors in mildly impaired patients. Against this, a rigorous crossover RCT in solvent-induced cognitive syndrome found no benefit, and controlled work indicates no enhancement in people without cognitive impairment. There is no modern meta-analysis isolating aniracetam, and no convincing data supporting its main marketed use as a brain booster in healthy adults.

Benefits / uses: Memory in dementia; Mood & emotional regulation; Attention (impaired adults); Possible anxiety reduction.
Active compounds: Aniracetam (1-(4-methoxybenzoyl)-2-pyrrolidinone).
Dose: Studied at 1,000–1,500 mg/day (often split, taken with food/fat to aid absorption); not an approved drug in the US.
Safety: Generally well tolerated in short trials; reported effects include anxiety, restlessness, insomnia, headache, dizziness, GI upset and skin rash, especially at higher doses. It is not an approved drug in the US and is sold as an unregulated supplement of variable purity. Because it modulates glutamate/AMPA signalling and is metabolised by CYP enzymes (with anisic-acid metabolites), caution is warranted alongside other CNS-active drugs (antidepressants, sedatives, stimulants, anticholinergics) and in anyone with seizure risk; safety in pregnancy, breastfeeding and long-term use is unstudied.

Cited studies (6):
  - Clinical efficacy of aniracetam, either as monotherapy or combined with cholinesterase inhibitors, in patients with cognitive impairment: a comparative open study, CNS neuroscience & therapeutics (2012) — Open comparative study: aniracetam-treated patients (n=58) maintained cognition at 3/6/12 mo, outperforming cholinesterase inhibitors at 6 mo in mild dementia. [https://pubmed.ncbi.nlm.nih.gov/22070796/]
  - Aniracetam (Ro 13-5057) in the treatment of senile dementia of Alzheimer type (SDAT): results of a placebo controlled multicentre clinical study, European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology (1991) — 6-month double-blind RCT (n=109, mild-moderate SDAT): 1,500 mg/day improved psychobehavioural scores vs placebo, which deteriorated. [https://pubmed.ncbi.nlm.nih.gov/1822317/]
  - Aniracetam tested in chronic psychosyndrome after long-term exposure to organic solvents. A randomized, double-blind, placebo-controlled cross-over study with neuropsychological tests, Psychopharmacology (1990) — Double-blind crossover RCT (n=44, 1 g/day, 3 mo each): no benefit for chronic psychosyndrome from organic-solvent exposure; only 1 of 19 tests favoured drug. [https://pubmed.ncbi.nlm.nih.gov/2188276/]
  - Aniracetam: An Evidence-Based Model for Preventing the Accumulation of Amyloid-β Plaques in Alzheimer's Disease, Journal of Alzheimer's disease : JAD (2024) — Mechanistic model: proposes aniracetam may curb amyloid-β via BDNF and mGluR-driven α-secretase activity; no human amyloid data exists. [https://pmc.ncbi.nlm.nih.gov/articles/PMC11091568/]
  - Oral aniracetam treatment in C57BL/6J mice without pre-existing cognitive dysfunction reveals no changes in learning, memory, anxiety or stereotypy, F1000Research (2017) — Oral aniracetam in mice without pre-existing deficits produced no changes in learning, memory, anxiety or stereotypy. [https://pmc.ncbi.nlm.nih.gov/articles/PMC5998011/]
  - Aniracetam, Drugs &amp; Aging (1994) — Review: aniracetam 1,500 mg/day beat piracetam 2,400 mg/day on 8 of 18 cognitive tests and beat placebo at 4 and 6 months in SDAT patients. [https://doi.org/10.2165/00002512-199404030-00007]

---

## Bee Pollen (Bee pollen)
URL: https://nutridex.info/s/bee-pollen
Category: Gut & Immune
Evidence: Preliminary — Early or small human trials; promising but not yet conclusive.
Nutrient-dense bee product with antioxidants but thin human evidence.

Quick answer: Bee Pollen is used for antioxidant intake. NutriDex grades the human evidence as preliminary — Early or small human trials; promising but not yet conclusive. Based on 8 cited human studies (8 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Bee pollen is the flower pollen worker bees pack into granules, mixed with nectar and bee secretions. Chemically it is impressive: 10–40% protein, B-vitamins, and polyphenols (flavonoids and phenolic acids) with strong antioxidant activity in test-tube assays. Marketing extends this to energy, immunity, allergy relief and athletic performance, but human data are sparse. The best controlled trial, a randomized crossover in breast-cancer patients, found bee pollen no better than honey placebo for menopausal hot flushes (improvement ~71% vs ~68%). A bee-bread crossover in 12 runners and a resistance-training RCT showed antioxidant-status changes but no clear performance gain from pollen alone. Most reviews note 'a few' clinical trials and rely on animal or cell data. So bee pollen is a reasonable nutrient-dense food, but evidence for specific therapeutic claims is preliminary, and rare but serious allergic reactions are documented.

Benefits / uses: Antioxidant intake; General nutritional support; Menopausal symptom relief (tried); Exercise/antioxidant status (tried).
Active compounds: Flavonoids & phenolic acids; Plant proteins / amino acids; B-vitamins; Carotenoids.
Dose: No established therapeutic dose; trials used roughly 1–20 g/day of granules for 8 weeks. Start small (a few grams) to screen for allergy.
Safety: The main real risk is allergy: bee pollen can trigger urticaria, angioedema and life-threatening anaphylaxis, sometimes on first exposure or augmented by exercise — people with pollen, honey or bee-product allergy, asthma or atopy should avoid it or test a few granules cautiously. Avoid in pregnancy and breastfeeding due to lack of safety data. It may theoretically add to anticoagulant/antiplatelet effects and could interact with blood-glucose-lowering drugs; warfarin-related bleeding has been reported with related bee products. Liver injury has not been reported.

Cited studies (8):
  - Bee pollen and honey for the alleviation of hot flushes and other menopausal symptoms in breast cancer patients, Molecular and clinical oncology (2015) — Randomized crossover (n=46 breast-cancer patients): bee pollen-honey no better than honey alone for menopausal symptoms (~71% vs ~68% improved; non-significant). [https://pubmed.ncbi.nlm.nih.gov/26171198/]
  - A paediatric case of exercise-augmented anaphylaxis following bee pollen ingestion in Western Australia, Asia Pacific allergy (2022) — Paediatric case: 15-year-old had exercise-augmented anaphylaxis (urticaria, angioedema, dyspnea) 30 min into exercise after eating bee-pollen granules. [https://pubmed.ncbi.nlm.nih.gov/35966155/]
  - Bee Products: Beeswax, Bee Pollen, Propolis (2022) — NIH LiverTox: bee products including bee pollen are an unlikely cause of liver injury (likelihood 'E'); no published hepatotoxicity cases. [https://www.ncbi.nlm.nih.gov/books/NBK580275/]
  - Bee Pollen as Functional Food: Insights into Its Composition and Therapeutic Properties, Antioxidants (2023) — Review of composition and bioactivity: bee pollen is rich in flavonoids/phenolics with high in-vitro antioxidant capacity, but therapeutic claims rest mainly on preclinical data. [https://doi.org/10.3390/antiox12030557]
  - Bee Pollen-Induced Anaphylaxis: A Case Report and Literature Review, Allergy, asthma & immunology research (2015) — Case report + literature review: bee pollen ingestion caused anaphylaxis (urticaria, angioedema, dyspnea) requiring epinephrine; atopic people at higher risk. [https://pubmed.ncbi.nlm.nih.gov/25749764/]
  - Anaphylaxis from bee pollen supplement, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne (2012) — CMAJ case: woman developed anaphylaxis after a bee-pollen supplement; highlights under-recognized allergy hazard, especially in pollen-allergic users. [https://pubmed.ncbi.nlm.nih.gov/22619345/]
  - Bee Pollen: Clinical Trials and Patent Applications, Nutrients (2022) — Review (Nutrients) concludes bee pollen has been used in only a few clinical trials (allergy, prostate); human evidence is limited and largely preliminary. [https://pubmed.ncbi.nlm.nih.gov/35889814/]
  - Protective Effect of Polyphenol-Rich Extract from Bee Pollen in a High-Fat Diet, Molecules (2018) — Polyphenol-rich bee pollen extract lowered total cholesterol and LDL in high-fat-diet rats — mechanistic/animal evidence only, not human. [https://doi.org/10.3390/molecules23040805]

---

## Betaine HCl (Betaine hydrochloride)
URL: https://nutridex.info/s/betaine-hcl
Category: Gut & Immune
Evidence: Preliminary — Early or small human trials; promising but not yet conclusive.
Acid-supplying supplement marketed for low stomach acid.

Quick answer: Betaine HCl is used for temporarily re-acidifies the stomach. NutriDex grades the human evidence as preliminary — Early or small human trials; promising but not yet conclusive. Based on 6 cited human studies (6 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Betaine HCl is anhydrous betaine bound to hydrochloric acid; when it dissolves it releases acid, so it is sold to people thought to have low stomach acid (hypochlorhydria). The best human data are tiny pharmacokinetic studies: in 6 volunteers made acid-low with a proton-pump inhibitor, 1500 mg betaine HCl dropped gastric pH from 5.2 to 0.6 within about 6 minutes, lasting roughly 70-75 minutes. That re-acidification restored absorption of the cancer drug dasatinib (Cmax up 15-fold), but barely helped atazanavir (about 12-13% recovery), showing the effect is real but drug-specific. No randomized trials demonstrate that betaine HCl improves digestion, protein or micronutrient absorption, or symptoms in ordinary users. The FDA removed it from over-the-counter digestive-aid use in 1993 for insufficient evidence; it now sells only as a supplement. (Note: this differs from anhydrous betaine/TMG used for homocysteine.)

Benefits / uses: Temporarily re-acidifies the stomach; May aid digestion in low stomach acid; Can restore absorption of some pH-dependent drugs; Supports protein/pepsin breakdown (mechanistic).
Active compounds: Betaine (trimethylglycine); Hydrochloric acid (released on dissolution); Pepsin (in combination products).
Dose: 1500 mg anhydrous betaine HCl by mouth with a meal acutely re-acidifies the stomach; digestive-aid 'titration' regimens are traditional, not trial-validated.
Safety: Betaine HCl delivers acid, so it can cause heartburn, burning, nausea or stomach pain, and is unsafe in peptic ulcer disease, gastritis, GERD or anyone with active or prior ulcers. Avoid combining with NSAIDs or corticosteroids (added mucosal injury risk), and it works against acid-suppressing drugs (PPIs, H2 blockers, antacids). Because it can transiently re-acidify the stomach, it may unpredictably change blood levels of pH-dependent medicines; people on chronic prescriptions, pregnant or breastfeeding women, and those with kidney or liver disease should use only under medical supervision.

Cited studies (6):
  - Meal Effects Confound Attempts to Counteract Rabeprazole-Induced Hypochlorhydria Decreases in Atazanavir Absorption, Pharmaceutical research (2017) — Under fed conditions betaine HCl recovered only ~13% of atazanavir Cmax and ~12% of AUC lost to rabeprazole; meal effects dominated. [https://pubmed.ncbi.nlm.nih.gov/28028768/]
  - Food, Acid Supplementation and Drug Absorption – a Complicated Gastric Mix: a Randomized Control Trial, Pharmaceutical Research (2019) — RCT showing food and acid supplementation interact in complex ways to alter weak-base drug absorption under hypochlorhydria. [https://doi.org/10.1007/s11095-019-2693-5]
  - Gastric reacidification with betaine HCl in healthy volunteers with rabeprazole-induced hypochlorhydria, Molecular pharmaceutics (2013) — 1500 mg betaine HCl re-acidified the stomach in PPI-induced hypochlorhydria: pH fell 5.2 to 0.6 within ~6.3 min, pH<3 for ~73 min (n=6). [https://pubmed.ncbi.nlm.nih.gov/23980906/]
  - The use of betaine HCl to enhance dasatinib absorption in healthy volunteers with rabeprazole-induced hypochlorhydria, The AAPS journal (2014) — Betaine HCl restored dasatinib absorption lost to rabeprazole, raising Cmax 15-fold and AUC 6.7-fold to ~105-121% of control (n=8). [https://pubmed.ncbi.nlm.nih.gov/25274610/]
  - Gastric Reacidification with Betaine HCl in Healthy Volunteers with Rabeprazole-Induced Hypochlorhydria, Molecular Pharmaceutics (2013) — Primary publication of the betaine HCl gastric reacidification pilot in Molecular Pharmaceutics; effect rapid but transient. [https://doi.org/10.1021/mp4003738]
  - The Use of Betaine HCl to Enhance Dasatinib Absorption in Healthy Volunteers with Rabeprazole-Induced Hypochlorhydria, The AAPS Journal (2014) — Full report: betaine HCl safely reversed PPI effect on dasatinib pharmacokinetics in healthy volunteers. [https://doi.org/10.1208/s12248-014-9673-9]

---

## Bilberry (Vaccinium myrtillus)
URL: https://nutridex.info/s/bilberry
Category: Longevity, Joint & Skin
Evidence: Mixed — Conflicting results across studies; benefit uncertain.
Anthocyanin-rich berry; eye claims overstated, metabolic effects modest.

Quick answer: Bilberry is used for antioxidant anthocyanin source. NutriDex grades the human evidence as mixed — Conflicting results across studies; benefit uncertain. Based on 8 cited human studies (8 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Bilberry is a wild European relative of the blueberry, prized for its dark anthocyanin pigments. Its most famous claim — sharper night vision — fails when tested properly: a systematic review found the four most rigorous RCTs were all negative. Cardiometabolic data are modest: a 2025 meta-analysis of bilberry trials found only a marginal HbA1c drop and a triglyceride effect, with no change in fasting glucose, total cholesterol, HDL, blood pressure or inflammation. A broader berry meta-analysis credited bilberry with small LDL reductions (~0.30 mmol/L) and HDL rises. An open-label post-heart-attack trial reported a 38 m gain in 6-minute walk distance and lower oxidized LDL. Small single trials suggest bilberry/pine-bark combos lower eye pressure and that extract improves tear secretion in dry eye. Overall the berry is a reasonable antioxidant food, but supplement claims outrun the evidence.

Benefits / uses: Antioxidant anthocyanin source; Small lipid improvements (LDL/HDL); Modest glycaemic support; Tear secretion in dry eye (early).
Active compounds: Anthocyanins (delphinidin & cyanidin glycosides); Pterostilbene / resveratrol; Tannins.
Dose: Standardized extract (e.g. Mirtoselect, ~36% anthocyanins) 80–160 mg/day, or freeze-dried fruit/powder; no single validated dose.
Safety: Bilberry fruit is well tolerated as a food; concentrated extracts are generally safe short-term but lack long-term safety data. Because anthocyanins can mildly lower blood glucose and inhibit platelet aggregation, use caution combining high-dose extracts with antidiabetic drugs (additive hypoglycaemia) or anticoagulants/antiplatelets such as warfarin, aspirin or clopidogrel (theoretical bleeding risk). Stop extracts about two weeks before surgery, and prefer food sources in pregnancy or breastfeeding where safety is unstudied.

Cited studies (8):
  - Investigating the Effects of Vaccinium myrtillus Supplementation on Cardiometabolic Indices: A Systematic Review and Meta-Analysis, Phytotherapy research : PTR (2025) — Meta-analysis of 8 bilberry RCTs (n=409): only marginal HbA1c drop (-1.63%, p=0.06) and a triglyceride effect; glucose, lipids, BP, CRP unchanged. [https://pubmed.ncbi.nlm.nih.gov/40751398/]
  - Effects of anthocyanin supplementation in diet on glycemic and related cardiovascular biomarkers in patients with type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials, Frontiers in nutrition (2023) — Anthocyanin meta-analysis in T2D (13 RCTs, n=703): HbA1c -0.31%, fasting glucose -0.63 mmol/L, TG -0.45 mmol/L, LDL -0.26 mmol/L. [https://pubmed.ncbi.nlm.nih.gov/37810926/]
  - Effects of Vaccinium Berries on Serum Lipids: A Meta-Analysis of Randomized Controlled Trials, Evidence-based complementary and alternative medicine : eCAM (2015) — Meta-analysis of 16 RCTs: bilberry lowered LDL ~0.30 mmol/L and raised HDL ~0.12 mmol/L (both p<0.001). [https://pubmed.ncbi.nlm.nih.gov/26345230/]
  - Anthocyanosides of Vaccinium myrtillus (bilberry) for night vision--a systematic review of placebo-controlled trials, Survey of ophthalmology (2004) — Systematic review: the 4 most rigorous RCTs of bilberry anthocyanosides for night vision were all negative; claim not supported. [https://pubmed.ncbi.nlm.nih.gov/14711439/]
  - Freeze-dried bilberry (Vaccinium myrtillus) dietary supplement improves walking distance and lipids after myocardial infarction: an open-label randomized clinical trial, Nutrition research (New York, N.Y.) (2019) — Open-label RCT after heart attack (n=50): 40 g/day freeze-dried bilberry improved 6-min walk distance by 38 m and lowered oxidized LDL. [https://pubmed.ncbi.nlm.nih.gov/30803503/]
  - The effect of a natural, standardized bilberry extract (Mirtoselect®) in dry eye: a randomized, double blinded, placebo-controlled trial, European review for medical and pharmacological sciences (2017) — Randomized double-blind trial (n=21): standardized bilberry extract significantly improved Schirmer tear-secretion test in dry eye (p=0.019). [https://pubmed.ncbi.nlm.nih.gov/28617532/]
  - A single supplement of a standardised bilberry (<i>Vaccinium myrtillus</i> L.) extract (36 % wet weight anthocyanins) modifies glycaemic response in individuals with type 2 diabetes controlled by diet and lifestyle, Journal of Nutritional Science (2013) — Crossover trial (n=8): a single standardized bilberry extract dose cut postprandial glucose iAUC by 18% vs placebo (p=0.003) in diet-controlled T2D. [https://doi.org/10.1017/jns.2013.16]
  - Effects of Mirtogenol on ocular blood flow and intraocular hypertension in asymptomatic subjects, Molecular vision (2008) — RCT (n=38): bilberry+pine-bark (Mirtogenol) lowered intraocular pressure from ~25 to 22 mmHg over 3 months vs no change in controls. [https://pubmed.ncbi.nlm.nih.gov/18618008/]

---

## Butyrate (Tributyrin) (Butyric acid)
URL: https://nutridex.info/s/butyrate
Category: Gut & Immune
Evidence: Mixed — Conflicting results across studies; benefit uncertain.
Gut-cell fuel marketed for colitis and metabolic health.

Quick answer: Butyrate (Tributyrin) is used for support gut barrier. NutriDex grades the human evidence as mixed — Conflicting results across studies; benefit uncertain. Based on 7 cited human studies (7 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Butyrate is a short-chain fatty acid your gut bacteria make when they ferment fiber; it is the primary energy source for colon lining cells and has anti-inflammatory effects. Supplements deliver it as sodium/calcium butyrate salts or tributyrin (a glyceride prodrug), usually microencapsulated to reach the colon. Human trials are genuinely split. In adults with ulcerative colitis, butyrate added to mesalazine and a recent 140-patient IBD trial showed better activity scores, calprotectin and quality of life, and a 120-patient IBS study found higher symptom relief (about 65% vs 42%) — but that used butyrate plus probiotics and fiber. Against this, a multicenter pediatric IBD RCT (300 mg/day) found no benefit over placebo, and colon-delivered butyrate did not blunt the cortisol stress response in healthy men. Metabolic effects on blood sugar are small and mostly appear with co-supplements. Promising for the gut, not yet convincing.

Benefits / uses: Support gut barrier; Add-on for ulcerative colitis; Ease IBS symptoms (in combinations); Modest blood-sugar support.
Active compounds: Butyric acid (short-chain fatty acid); Sodium/calcium butyrate salts; Tributyrin (glyceride prodrug).
Dose: Microencapsulated sodium butyrate 300–600 mg/day (active), or tributyrin 0.2–4 g/day; gut-targeted forms are used to survive the upper GI tract.
Safety: Oral butyrate is generally well tolerated; the most common complaints are mild GI upset, bloating and a foul taste/odor (tributyrin and salts smell of rancid butter), which microencapsulation reduces. No serious adverse events were reported in IBD/IBS trials and no specific drug interactions are established, but because butyrate may lower blood glucose and modestly affect GLP-1, people on antidiabetic drugs (insulin, sulfonylureas) should monitor for additive lowering. It is an adjunct, not a replacement for prescribed colitis therapy; safety in pregnancy, breastfeeding and young children is not well studied, so use under clinician guidance.

Cited studies (7):
  - Impact of oral butyrate on clinical and biochemical parameters in IBD: A randomized placebo-controlled study targeting gut microbiota, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver (2026) — Microencapsulated butyrate add-on in 140 IBD patients: improved Crohn's activity and calprotectin (p=0.013/0.047) and quality of life; benefit greatest in low Firmicutes/Bacteroidota. [https://pubmed.ncbi.nlm.nih.gov/41354580/]
  - Efficacy and Safety of a Mixture of Microencapsulated Sodium Butyrate, Probiotics, and Short Chain Fructooligosaccharides in Patients with Irritable Bowel Syndrome-A Randomized, Double-Blind, Placebo-Controlled Study, Journal of clinical medicine (2024) — IBS RCT (n=120) of microencapsulated butyrate + probiotics + FOS: adequate symptom relief 64.7% vs 42.0% at 4 wk (p=0.023). [https://pubmed.ncbi.nlm.nih.gov/39797089/]
  - Colonic butyrate administration modulates fear memory but not the acute stress response in men: A randomized, triple-blind, placebo-controlled trial, Progress in neuro-psychopharmacology & biological psychiatry (2024) — Colonic butyrate alone 5.28 g/day for 1 wk (n=71 men): no effect on acute stress or cortisol; modulated subjective fear memory only. [https://pubmed.ncbi.nlm.nih.gov/38199487/]
  - Sodium Butyrate Effectiveness in Children and Adolescents with Newly Diagnosed Inflammatory Bowel Diseases-Randomized Placebo-Controlled Multicenter Trial, Nutrients (2022) — Multicenter pediatric IBD RCT, 300 mg/day sodium butyrate for 12 wk (n=72): no efficacy; remission 62% vs 72% placebo, no calprotectin difference. [https://pubmed.ncbi.nlm.nih.gov/36014789/]
  - Colon-delivered short-chain fatty acids attenuate the cortisol response to psychosocial stress in healthy men: a randomized, placebo-controlled trial, Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology (2020) — Colon-delivered SCFA mixture (incl. butyrate) lowered the cortisol response to psychosocial stress in 66 healthy men vs placebo. [https://pubmed.ncbi.nlm.nih.gov/32521538/]
  - Effect of Butyrate and Inulin Supplementation on Glycemic Status, Lipid Profile and Glucagon-Like Peptide 1 Level in Patients with Type 2 Diabetes: A Randomized Double-Blind, Placebo-Controlled Trial, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme (2017) — Type 2 diabetes RCT (n=60): only sodium butyrate (600 mg) + inulin significantly cut fasting glucose; butyrate raised GLP-1 vs placebo. [https://pubmed.ncbi.nlm.nih.gov/28962046/]
  - Combined oral sodium butyrate and mesalazine treatment compared to oral mesalazine alone in ulcerative colitis: randomized, double-blind, placebo-controlled pilot study, Digestive diseases and sciences (2000) — Sodium butyrate 4 g/day + mesalazine vs mesalazine alone in UC (n=25 completers): greater clinical/disease-activity improvement, not statistically significant. [https://pubmed.ncbi.nlm.nih.gov/10795763/]

---

## Calcium D-Glucarate (Calcium D-glucarate)
URL: https://nutridex.info/s/calcium-d-glucarate
Category: Longevity
Evidence: Preliminary — Early or small human trials; promising but not yet conclusive.
Beta-glucuronidase inhibitor marketed for estrogen and toxin 'detox'.

Quick answer: Calcium D-Glucarate is used for inhibits beta-glucuronidase. NutriDex grades the human evidence as preliminary — Early or small human trials; promising but not yet conclusive. Based on 8 cited human studies (8 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Calcium D-glucarate is the calcium salt of glucaric acid, sold as a 'detox' and estrogen-clearance aid. In the gut and blood it slowly releases D-glucaro-1,4-lactone, a potent inhibitor of beta-glucuronidase — the enzyme that strips glucuronide tags off estrogens and carcinogens, recycling them instead of excreting them. In rodents, dietary calcium glucarate (≈4% of diet) lowered tissue beta-glucuronidase and cut chemically induced mammary, lung, liver, and skin tumours by roughly 50–70%. Human evidence is thin: small pilot and dose-escalation studies (1.5 g up to 9 g/day) raised serum D-glucaric acid and modestly lowered serum beta-glucuronidase, and it was well tolerated. There are no randomised trials showing it lowers estrogen levels, prevents cancer, or improves any clinical endpoint. The popular 'detox' and 'estrogen balance' claims rest on mechanism and animal data, not proven human benefit.

Benefits / uses: Inhibits beta-glucuronidase; May aid estrogen clearance; Supports glucuronidation detox; Studied for cancer chemoprevention.
Active compounds: Calcium D-glucarate; D-glucaro-1,4-lactone (active metabolite); D-glucaric acid.
Dose: Commonly 500–1500 mg/day of calcium D-glucarate; tolerability trials escalated to 9 g/day, but no dose is validated for any clinical outcome.
Safety: Generally well tolerated in the small human studies done, with at most mild GI upset; long-term safety is unstudied. Because it accelerates glucuronidation/clearance, it can theoretically lower blood levels of drugs cleared by this pathway — including oral estrogens and hormonal contraceptives, and possibly other glucuronidated medications (e.g. some statins, NSAIDs, lamotrigine, morphine) — so women relying on the pill should be cautious. The calcium content adds to total calcium intake. Avoid using it to self-treat or replace screening for any cancer or hormone-sensitive condition; discuss with an oncologist if you have estrogen-sensitive cancer.

Cited studies (8):
  - Mechanistic Understanding of D-Glucaric Acid to Support Liver Detoxification Essential to Muscle Health Using a Computational Systems Biology Approach, Nutrients (2023) — Computational systems-biology model: D-glucaric acid modeled to support liver detox via reduced ROS, deconjugation, hepatocyte apoptosis and beta-glucuronidase. [https://doi.org/10.3390/nu15030733]
  - Metabolism, uptake, and excretion of a D-glucaric acid salt and its potential use in cancer prevention, Cancer detection and prevention (1997) — Oral D-glucarate salt was absorbed and converted in vivo to D-glucaro-1,4-lactone, a potent beta-glucuronidase inhibitor; framed potential cancer-prevention use. [https://pubmed.ncbi.nlm.nih.gov/9101079/]
  - Calcium glucarate as a chemopreventive agent in breast cancer, Israel journal of medical sciences (1995) — Pilot/rationale report: calcium glucarate proposed as a breast-cancer chemopreventive via altered estrogen milieu and carcinogen detox; no efficacy outcomes. [https://pubmed.ncbi.nlm.nih.gov/7744577/]
  - Dietary glucarate as anti-promoter of 7,12-dimethylbenz[a]anthracene-induced mammary tumorigenesis, Carcinogenesis (1986) — Dietary 4% calcium glucarate reduced DMBA-induced rat mammary tumour incidence to ~30% of controls by 28 weeks (promotion-phase inhibition). [https://pubmed.ncbi.nlm.nih.gov/3091283/]
  - Mechanisms of lung cancer chemoprevention by D-glucarate, Chest (2004) — Mechanism review (Chest): D-glucaro-1,4-lactone detoxifies glucuronidated carcinogens; low serum glucaric acid marks cancer patients and rodents with tumours. [https://pubmed.ncbi.nlm.nih.gov/15136472/]
  - Effects of calcium glucarate on the promotion of diethylnitrosamine-initiated altered hepatic foci in rats, Cancer letters (1987) — Calcium glucarate suppressed promotion of diethylnitrosamine-initiated altered hepatic foci in rats, consistent with beta-glucuronidase inhibition. [https://pubmed.ncbi.nlm.nih.gov/3690519/]
  - Effect of calcium glucarate on beta-glucuronidase activity and glucarate content of certain vegetables and fruits, Biochemical medicine and metabolic biology (1990) — Single dose (4.5 mmol/kg) cut beta-glucuronidase ~57% in serum and 37–44% in liver/lung/intestine microsomes in rodents. [https://pubmed.ncbi.nlm.nih.gov/2346674/]
  - Calcium Glucarate, Memorial Sloan Kettering Cancer Center — Memorial Sloan Kettering: lab/animal data only; 'has not been shown to treat or prevent cancer in humans'; one small human study, well tolerated. [https://www.mskcc.org/cancer-care/integrative-medicine/herbs/calcium-glucarate]

---

## Carnosine (L-Carnosine)
URL: https://nutridex.info/s/carnosine
Category: Longevity
Evidence: Moderate — Several controlled trials; effects real but modest or context-dependent.
Anti-glycation dipeptide studied for blood sugar and brain ageing.

Quick answer: Carnosine is used for modest blood-sugar lowering. NutriDex grades the human evidence as moderate — Several controlled trials; effects real but modest or context-dependent. Based on 8 cited human studies (8 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Carnosine is a dipeptide of β-alanine and histidine concentrated in muscle and brain, where it buffers acid, scavenges free radicals and limits glycation (sugar-protein damage linked to ageing). In humans the best evidence is metabolic: pooled RCTs show carnosine lowers HbA1c by roughly 0.9% and modestly reduces fasting glucose and insulin resistance in people with prediabetes or type 2 diabetes, and a 2024 RCT found flatter post-meal glucose curves on 2 g/day. A cognition meta-analysis found carnosine/anserine improved delayed-recall memory and global cognition in older adults, and a separate analysis reported reduced depression scores. Effects on core autism symptoms were not confirmed. Caveats are substantial: trials are small and short, oral carnosine is rapidly broken down by serum carnosinase, and long-term, hard-outcome data (events, lifespan) do not exist. It appears safe at studied doses.

Benefits / uses: Modest blood-sugar lowering; Lower HbA1c in diabetes/prediabetes; Possible memory (delayed recall) support; Antioxidant / anti-glycation; May ease depressive symptoms.
Active compounds: L-Carnosine (β-alanyl-L-histidine); β-alanine; L-histidine.
Dose: Most human trials use 1–2 g/day of oral L-carnosine for 12–14 weeks; β-alanine is often used instead because it raises tissue carnosine more reliably.
Safety: Carnosine is generally well tolerated in trials up to 2 g/day, with no consistent serious adverse effects; mild GI upset is the main complaint. Because it lowers blood glucose, it could add to the effect of insulin or other antidiabetic drugs and theoretically increase hypoglycaemia risk, so monitor if you take these. Long-term safety beyond ~14 weeks is untested, and it has not been studied in pregnancy or breastfeeding. β-alanine (often used to raise tissue carnosine) commonly causes harmless skin tingling (paraesthesia).

Cited studies (8):
  - Histidine-containing dipeptide supplementation improves delayed recall: a systematic review and meta-analysis, Nutrition Reviews (2023) — Meta-analysis (11 trials): histidine-dipeptide/carnosine improved WMS delayed recall (Z=3.28, p<0.01); no effect on MMSE or ADAS-Cog. [https://doi.org/10.1093/nutrit/nuad135]
  - Carnosine/histidine-containing dipeptide supplementation improves depression and quality of life: systematic review and meta-analysis of randomized controlled trials, Nutrition reviews (2025) — Meta-analysis (18 RCTs, n=776): carnosine/HCD reduced depression scores (WMD −0.79; 95% CI −1.24 to −0.35) and improved quality of life. [https://pubmed.ncbi.nlm.nih.gov/38545720/]
  - Effect of Carnosine or β-Alanine Supplementation on Markers of Glycemic Control and Insulin Resistance in Humans and Animals: A Systematic Review and Meta-analysis, Advances in nutrition (Bethesda, Md.) (2021) — Meta-analysis: carnosine/β-alanine cut HbA1c ~0.91% and fasting glucose ~0.95 mmol/L in humans; HOMA-IR SMD −0.41 (moderate certainty). [https://pubmed.ncbi.nlm.nih.gov/34333586/]
  - Effect of carnosine supplementation on lipid profile, fasting blood glucose, HbA1C and insulin resistance: A systematic review and meta-analysis of long-term randomized controlled trials, Complementary therapies in medicine (2020) — Meta-analysis of 4 long-term RCTs: carnosine reduced HbA1c by 0.92% (95% CI −1.20 to −0.63); no significant change in fasting glucose or HOMA-IR. [https://pubmed.ncbi.nlm.nih.gov/31987255/]
  - The Therapeutic Potential of Carnosine/Anserine Supplementation against Cognitive Decline: A Systematic Review with Meta-Analysis, Biomedicines (2021) — Meta-analysis (5 studies): carnosine/anserine 1 g/day x12 wk improved global cognition in elderly/MCI; no effect on depressive symptoms. [https://pubmed.ncbi.nlm.nih.gov/33806459/]
  - Effect of L-Carnosine in children with autism spectrum disorders: a systematic review and meta-analysis of randomised controlled trials, Amino acids (2021) — Meta-analysis of 3 RCTs: L-carnosine gave no significant benefit on autism CARS scores (MD −0.88; 95% CI −6.96 to 5.20); evidence does not support use. [https://pubmed.ncbi.nlm.nih.gov/33704575/]
  - Carnosine supplementation improves glucose control in adults with pre-diabetes and type 2 diabetes: A randomised controlled trial, Nutrition, metabolism, and cardiovascular diseases : NMCD (2024) — RCT (n=43, prediabetes/T2D): 2 g/day for 14 wk lowered 120-min OGTT glucose by 1.60 mmol/L and total glucose AUC (p=0.04). [https://pubmed.ncbi.nlm.nih.gov/38172006/]
  - Carnosine and Beta-Alanine Supplementation in Human Medicine: Narrative Review and Critical Assessment, Nutrients (2023) — Narrative review: oral carnosine is hydrolysed by serum carnosinase (serum half-life <5 min), undermining direct bioavailability vs β-alanine dosing. [https://pubmed.ncbi.nlm.nih.gov/37049610/]

---

## CBD (Cannabidiol)
URL: https://nutridex.info/s/cbd
Category: Sleep & Mood, Joint & Skin
Evidence: Mixed — Conflicting results across studies; benefit uncertain.
Non-intoxicating hemp compound; proven for rare epilepsy, hyped elsewhere.

Quick answer: CBD (Cannabidiol) is used for reduces seizures (rare epilepsy). NutriDex grades the human evidence as mixed — Conflicting results across studies; benefit uncertain. Based on 8 cited human studies (8 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Cannabidiol is a non-intoxicating cannabis compound. Its one rigorously proven use is as the prescription drug Epidiolex, which cut seizures in three randomized trials (n=516) for rare epilepsies and is FDA-approved. The over-the-counter wellness story is far weaker. A 2024 meta-analysis (8 trials, 316 people) found a sizeable anxiety benefit (Hedges' g -0.92), but trials were tiny, varied widely and some were null. For sleep, a 150 mg nightly RCT showed no change in insomnia severity, onset latency or wake-after-sleep versus placebo. For chronic and neuropathic pain, pure CBD did not outperform placebo in meta-analyses; only THC-containing products helped. OTC products also vary hugely in actual CBD content. So CBD is genuinely useful for specific seizure disorders but largely unproven at the low doses sold for sleep, pain and stress.

Benefits / uses: Reduces seizures (rare epilepsy); May ease anxiety; Sleep & relaxation; Pain & inflammation (limited).
Active compounds: Cannabidiol (CBD).
Dose: Wellness products typically supply 10–50 mg/day; prescription Epidiolex doses run 10–20 mg/kg/day, far higher than OTC oils.
Safety: Generally well tolerated but not harmless: common effects are sleepiness, diarrhea, reduced appetite and fatigue, and high doses can raise liver enzymes (dose-dependent, worse with valproate). CBD inhibits CYP3A4, CYP2C9 and CYP2C19, so it can raise levels of clobazam, warfarin (bleeding risk), some antiepileptics, sedatives and other drugs — interactions become clinically relevant above ~300 mg/day. Avoid in pregnancy and breastfeeding, and consult a clinician if on anticoagulants, anticonvulsants or sedatives. OTC products are poorly regulated and often mislabeled, sometimes containing THC.

Cited studies (8):
  - Therapeutic potential of cannabidiol (CBD) in anxiety disorders: A systematic review and meta-analysis, Psychiatry research (2024) — Meta-analysis (8 trials, 316 patients): CBD reduced anxiety with large effect (Hedges' g -0.92, 95% CI -1.80 to -0.04); small samples. [https://pubmed.ncbi.nlm.nih.gov/38924898/]
  - Efficacy of cannabis-based medications compared to placebo for the treatment of chronic neuropathic pain: a systematic review with meta-analysis, Journal of dental anesthesia and pain medicine (2021) — Meta-analysis of neuropathic pain: CBD alone showed NO significant pain reduction vs placebo; only THC/THC-CBD helped. [https://pubmed.ncbi.nlm.nih.gov/34909469/]
  - Efficacy, Safety, and Regulation of Cannabidiol on Chronic Pain: A Systematic Review, Cureus (2022) — Systematic review (12 studies) of CBD for chronic pain: possible benefit but few trials, high heterogeneity, evidence judged limited. [https://pubmed.ncbi.nlm.nih.gov/35860716/]
  - Cannabidiol for moderate-severe insomnia: a randomized controlled pilot trial of 150 mg of nightly dosing, Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine (2024) — 150 mg CBD nightly for 2 weeks did NOT improve insomnia severity, sleep-onset latency or wake-after-sleep vs placebo (n=30 RCT). [https://pubmed.ncbi.nlm.nih.gov/38174873/]
  - Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome, The New England journal of medicine (2017) — Epidiolex 20 mg/kg/day cut convulsive seizures from 12.4 to 5.9/month vs little change on placebo (n=120 RCT). [https://pubmed.ncbi.nlm.nih.gov/28538134/]
  - Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial, Lancet (London, England) (2018) — CBD reduced monthly drop-seizure frequency by ~44% vs 22% on placebo over 14 weeks (n=171 RCT). [https://pubmed.ncbi.nlm.nih.gov/29395273/]
  - Cannabidiol (2023) — CBD raised ALT/AST >3x ULN in ~13% of epilepsy patients vs 1% placebo; risk rises with valproate co-use. [https://www.ncbi.nlm.nih.gov/books/NBK548890/]
  - Labeling Accuracy of Cannabidiol Extracts Sold Online, JAMA (2017) — Of 84 online CBD products, ~43% were underlabeled and ~26% overlabeled for CBD content; THC detected in 21%. [https://pubmed.ncbi.nlm.nih.gov/29114823/]

---

## CBG (Cannabigerol)
URL: https://nutridex.info/s/cbg
Category: Sleep & Mood, Gut & Immune
Evidence: Preliminary — Early or small human trials; promising but not yet conclusive.
Non-intoxicating hemp cannabinoid promoted for calm and gut health.

Quick answer: CBG (Cannabigerol) is used for acute anxiety & stress relief. NutriDex grades the human evidence as preliminary — Early or small human trials; promising but not yet conclusive. Based on 8 cited human studies (8 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

CBG is the non-intoxicating 'mother cannabinoid' from which THC and CBD are formed in the hemp plant. Human evidence is very early. In a 2024 double-blind crossover trial (n=34), a single 20 mg dose modestly reduced subjective anxiety (about a 27% drop) and acute stress with no intoxication or impairment, and slightly improved verbal memory. However, a 2024 randomized trial in 63 veterans found 25–50 mg/day did not improve sleep better than placebo. Widely marketed claims for inflammatory bowel disease, pain and infection come only from animal and test-tube work: CBG eases chemically induced colitis in mice and is a potent antibacterial against MRSA in the lab. No long-term human safety or efficacy data exist, and products are largely unregulated, so potency and purity vary.

Benefits / uses: Acute anxiety & stress relief; Calm without intoxication; Gut anti-inflammatory (preclinical); Antibacterial (preclinical).
Active compounds: Cannabigerol (CBG).
Dose: Most human data use 20–50 mg/day of oral hemp-derived CBG tincture; no established therapeutic dose.
Safety: Short human trials report good tolerability; reported effects are mild and may include dry mouth, sleepiness or low blood pressure. CBG inhibits liver CYP enzymes in vitro, so it may raise levels of drugs metabolized that way and could add to the effect of sedatives or blood-pressure-lowering medicines. Avoid in pregnancy and breastfeeding due to absent safety data, and note that unregulated hemp products vary widely in CBG content and can contain THC.

Cited studies (8):
  - Acute effects of cannabigerol on anxiety, stress, and mood: a double-blind, placebo-controlled, crossover, field trial, Scientific reports (2024) — Single 20 mg CBG cut subjective anxiety ~27% and acute stress vs placebo, no intoxication or impairment; verbal memory improved (n=34). [https://pubmed.ncbi.nlm.nih.gov/39003387/]
  - Effect of Cannabigerol on Sleep and Quality of Life in Veterans: A Decentralized, Randomized, Placebo-Controlled Trial, Medical cannabis and cannabinoids (2026) — 25–50 mg/day CBG for 4 weeks did not improve sleep vs placebo (n=63); well tolerated but no efficacy signal. [https://pubmed.ncbi.nlm.nih.gov/41574318/]
  - High Cannabigerol Hemp Extract Moderates Colitis and Modulates the Microbiome in an Inflammatory Bowel Disease Model, The Journal of pharmacology and experimental therapeutics (2024) — High-CBG hemp extract reduced DSS colitis severity and remodeled the gut microbiome in mice; no human data. [https://pubmed.ncbi.nlm.nih.gov/39009468/]
  - Cannabigerol (CBG): A Comprehensive Review of Its Molecular Mechanisms and Therapeutic Potential, Molecules (Basel, Switzerland) (2024) — Comprehensive review concludes CBG shows broad preclinical promise but human trial evidence remains minimal. [https://pmc.ncbi.nlm.nih.gov/articles/PMC11597810/]
  - Uncovering the Hidden Antibiotic Potential of Cannabis, ACS Infectious Diseases (2020) — CBG was the most potent antibacterial cannabinoid, killing MRSA and biofilms in vitro and treating systemic MRSA infection in mice. [https://doi.org/10.1021/acsinfecdis.9b00419]
  - The Cannabis Constituent Cannabigerol Does Not Disrupt Fear Memory Processes or Stress-Induced Anxiety in Mice, Cannabis and cannabinoid research (2022) — Acute CBG did not disrupt fear memory or stress-induced anxiety in mice, suggesting limited use for PTSD/stress anxiety. [https://pubmed.ncbi.nlm.nih.gov/34182770/]
  - The Pharmacological Case for Cannabigerol, The Journal of Pharmacology and Experimental Therapeutics (2021) — Review: CBG acts at CB1/CB2, alpha-2 adrenoceptors and 5-HT1A; therapeutic case rests largely on preclinical data. [https://doi.org/10.1124/jpet.120.000340]
  - Beneficial effect of the non-psychotropic plant cannabinoid cannabigerol on experimental inflammatory bowel disease, Biochemical pharmacology (2013) — CBG attenuated DNBS-induced colitis in mice, lowering myeloperoxidase, iNOS and ROS; reduced colon damage (animal model). [https://pubmed.ncbi.nlm.nih.gov/23415610/]

---

## CBN (Cannabinol)
URL: https://nutridex.info/s/cbn
Category: Sleep & Mood
Evidence: Mixed — Conflicting results across studies; benefit uncertain.
The "sleep cannabinoid" — popular hype, thin human proof.

Quick answer: CBN (Cannabinol) is used for marketed sleep aid. NutriDex grades the human evidence as mixed — Conflicting results across studies; benefit uncertain. Based on 8 cited human studies (8 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Cannabinol (CBN) is a mildly sedating, non-intoxicating breakdown product of THC, heavily marketed as a natural sleep aid. The strongest objective test — a randomized polysomnography crossover in 20 insomnia patients — found that single 30 mg and 300 mg doses did NOT significantly reduce wake-after-sleep-onset (the primary outcome), though 300 mg modestly shortened sleep onset latency (p=0.004) and improved subjective sleep quality (p=0.005). A 293-person home trial of 20 mg CBN ± CBD found only a non-significant trend for sleep quality (p=0.082) but did cut nighttime awakenings and disturbance. A large industry trial of 25–100 mg CBN beat placebo on a sleep-disturbance scale, matching 4 mg melatonin, yet no dose differed from placebo on the clinically important threshold. A 2025 meta-analysis found non-CBD cannabinoids improved subjective sleep (SMD 0.53). Net: plausible mild benefit, but mixed and mostly subjective.

Benefits / uses: Marketed sleep aid; May ease nighttime awakenings; Mild, non-intoxicating relaxant; Possible adjunct for pain (in combos).
Active compounds: Cannabinol (CBN); Active metabolite 11-OH-CBN.
Dose: Most sleep trials used 20–100 mg oral CBN at night (one study used 300 mg); no consensus effective dose is established.
Safety: Short trials report CBN is generally well tolerated; common effects are next-morning grogginess, headache, altered taste and sleepiness, with safety established only up to ~7 days. Because CBN is metabolized by liver CYP450 enzymes, it can theoretically interact with drugs sharing that pathway and may add to the sedation of alcohol, benzodiazepines, opioids, sedating antihistamines and other CNS depressants. CBN can trigger a positive THC urine screen. Avoid in pregnancy and breastfeeding (untested), and treat hemp-derived products cautiously as potency and purity are poorly regulated.

Cited studies (8):
  - Effectiveness of cannabinoids on subjective sleep quality in people with and without insomnia or poor sleep: A systematic review and meta-analysis of randomised studies, Sleep medicine reviews (2025) — Across 6 RCTs (n=1077), cannabinoids improved subjective sleep quality vs placebo (SMD 0.53, 95% CI 0.03–1.02); non-CBD cannabinoids drove the effect. [https://pubmed.ncbi.nlm.nih.gov/40929927/]
  - Cannabinol for Acute Treatment of Insomnia Disorder in a Randomized Placebo-Controlled Crossover Trial, Journal of sleep research (2026) — Single 30/300 mg CBN did NOT cut wake-after-sleep-onset vs placebo (primary outcome null); 300 mg shortened sleep onset (p=0.004) & raised subjective quality (n=20). [https://pubmed.ncbi.nlm.nih.gov/41698831/]
  - A double-blind, randomized, placebo-controlled study of the safety and effects of CBN with and without CBD on sleep quality, Experimental and clinical psychopharmacology (2024) — 20 mg CBN for 7 nights gave only a non-significant sleep-quality trend (p=0.082) but significantly reduced nighttime awakenings (p=0.025) and disturbance; added CBD didn't help (n=293). [https://pubmed.ncbi.nlm.nih.gov/37796540/]
  - A Randomized, Double-Blind, Placebo-Controlled Trial to Assess the Effectiveness and Safety of Melatonin and Three Formulations of Floraworks Proprietary TruCBN™ for Improving Sleep, Pharmaceuticals (Basel, Switzerland) (2024) — 25/50/100 mg CBN all beat placebo on PROMIS sleep-disturbance and matched 4 mg melatonin; no dose differed from placebo on the clinically important threshold (n=1020). [https://pmc.ncbi.nlm.nih.gov/articles/PMC11357382/]
  - Cannabinol (CBN; 30 and 300 mg) effects on sleep and next-day function in insomnia disorder ('CUPID' study): protocol for a randomised, double-blind, placebo-controlled, cross-over, three-arm, proof-of-concept trial, BMJ open (2023) — Protocol for the randomized, double-blind, placebo-controlled polysomnography crossover of 30 & 300 mg CBN in clinician-diagnosed insomnia; WASO as primary outcome. [https://pubmed.ncbi.nlm.nih.gov/37612115/]
  - Efficacy and Safety of Transdermal Medical Cannabis (THC:CBD:CBN formula) to Treat Painful Diabetic Peripheral Neuropathy of Lower Extremities, Medical cannabis and cannabinoids (2025) — Phase III topical THC:CBD:CBN (CBN minor component) cut diabetic neuropathy pain by ~17 points vs placebo over 12 weeks (p<0.001, n=100) — combination, not CBN alone. [https://pmc.ncbi.nlm.nih.gov/articles/PMC11666268/]
  - Xanthoceras sorbifolium leaves alleviate hyperuricemic nephropathy by inhibiting the PI3K/AKT signaling pathway to regulate uric acid transport, Journal of Ethnopharmacology (2024) — Comprehensive pharmacology review: CBN is a low-CB1-affinity THC oxidation product, metabolized by CYP450/UGT to the more active 11-OH-CBN; clinical evidence remains limited. [https://doi.org/10.1016/j.jep.2024.117946]
  - The use of cannabinoids for sleep: A critical review on clinical trials, Experimental and clinical psychopharmacology (2019) — Critical review of cannabinoids for sleep concludes evidence is weak — small samples, sleep often a secondary outcome, few validated/objective measures. [https://pubmed.ncbi.nlm.nih.gov/31120284/]

---

## Celery Seed Extract (Apium graveolens)
URL: https://nutridex.info/s/celery-seed
Category: Heart & Metabolic
Evidence: Moderate — Several controlled trials; effects real but modest or context-dependent.
Phthalide-rich seed extract studied mainly for blood pressure.

Quick answer: Celery Seed Extract is used for lower blood pressure. NutriDex grades the human evidence as moderate — Several controlled trials; effects real but modest or context-dependent. Based on 7 cited human studies (7 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Celery seed extract is concentrated from Apium graveolens seeds and standardized to phthalides, chiefly 3-n-butylphthalide (3nB), a calcium-channel-modulating vasodilator. A 2025 meta-analysis of 9 RCTs (511 adults) found celery significantly lowered systolic blood pressure (SMD -1.0), diastolic pressure (SMD -0.93), fasting glucose (SMD -0.80) and triglycerides (SMD -1.18), with no clear effect on total, LDL or HDL cholesterol. A triple-blind crossover RCT (~1.34 g/day for 4 weeks) cut systolic pressure ~11 mmHg and diastolic ~8 mmHg in treated hypertensives. However, heterogeneity was very high (I² 77-96%), most trials were small, short, geographically narrow and at moderate-to-high risk of bias, and a 12-week pilot in type-2 diabetes showed no significant between-group cardiometabolic gains. Effects look real but modest and not yet robustly proven; it is an adjunct, not a substitute for prescribed therapy.

Benefits / uses: Lower blood pressure; Modest blood-sugar reduction; Lower triglycerides; Mild diuretic effect.
Active compounds: 3-n-butylphthalide (3nB); Apigenin; Sedanolide; Falcarinol / falcarindiol.
Dose: Standardized seed extract ~150 mg/day (85% 3nB), or whole-seed extract capsules ~1.3 g/day, taken in divided doses.
Safety: Generally well tolerated in short trials, but celery is a common allergen and can trigger reactions from rash to anaphylaxis, plus phototoxic skin sensitivity (psoralens). Its constituents (falcarinol, falcarindiol) inhibit platelet aggregation in vitro, so combine cautiously with warfarin, aspirin, clopidogrel or other anticoagulants/antiplatelets, monitoring for bruising or bleeding. Because it can lower blood pressure and glucose, it may compound antihypertensive and antidiabetic drugs (risk of hypotension or hypoglycaemia) and acts as a mild diuretic; avoid medicinal doses in pregnancy (traditionally a uterine stimulant) and in active kidney inflammation.

Cited studies (7):
  - Effects of celery (Apium graveolens) on blood pressure, glycemic and lipid profile in adults: a systematic review and meta-analysis of randomized controlled trials, Frontiers in nutrition (2025) — Meta-analysis (9 RCTs, 511 adults): celery lowered SBP (SMD -1.0), DBP (-0.93), fasting glucose (-0.80) and triglycerides (-1.18); I2 77-96%. [https://pmc.ncbi.nlm.nih.gov/articles/PMC12321563/]
  - The effect of celery (Apium graveolens) powder on cardiometabolic factors in overweight/obese individuals with type 2 diabetes mellitus: A pilot randomized, double-blinded, placebo-controlled clinical trial, Food science & nutrition (2023) — Double-blind RCT (n=36, T2DM): celery powder 750 mg/day x12wk reduced body-fat % within-group but no significant between-group cardiometabolic benefit. [https://pubmed.ncbi.nlm.nih.gov/37701242/]
  - Effect of celery (Apium graveolens) seed extract on hypertension: A randomized, triple-blind, placebo-controlled, cross-over, clinical trial, Phytotherapy research : PTR (2022) — Triple-blind crossover RCT (n=52): celery seed extract 1.34 g/day x4wk cut SBP 141->130 and DBP 92->84 mmHg (p<.001). [https://pubmed.ncbi.nlm.nih.gov/35624525/]
  - Safety evaluation and biochemical efficacy of celery seed extract (Apium Graveolens) capsules in hypertensive patients: a randomized, triple-blind, placebo-controlled, cross-over, clinical trial, Inflammopharmacology (2022) — Same cohort (n=51): extract was safe, also reduced fasting blood sugar and lipids with no adverse liver or kidney effects vs placebo. [https://doi.org/10.1007/s10787-022-00986-0]
  - The effects of celery leaf (apium graveolens L.) treatment on blood glucose and insulin levels in elderly pre-diabetics, Saudi medical journal (2018) — Controlled trial (n=16 elderly pre-diabetics): celery leaf 250 mg x3/day for 12 days significantly lowered pre-prandial plasma glucose (p=0.01). [https://pubmed.ncbi.nlm.nih.gov/29436564/]
  - Antihypertensive Property of Celery: A Narrative Review on Current Knowledge, International journal of food science (2024) — Narrative review of 7 human trials: 6 showed significant BP falls (SBP 11-19, DBP ~6.5-15 mmHg); credits 3nB-driven vasodilation/diuresis. [https://pmc.ncbi.nlm.nih.gov/articles/PMC10950410/]
  - A review of potential harmful interactions between anticoagulant/antiplatelet agents and Chinese herbal medicines, PloS one (2013) — Review: anticoagulant/antiplatelet interactions of common herbs incl. celery constituents; flags additive bleeding risk with blood thinners. [https://pmc.ncbi.nlm.nih.gov/articles/PMC3650066/]

---

## Chanca Piedra (Phyllanthus niruri)
URL: https://nutridex.info/s/chanca-piedra
Category: Gut & Immune
Evidence: Preliminary — Early or small human trials; promising but not yet conclusive.
Amazonian "stone breaker" herb taken for kidney stones and liver health.

Quick answer: Chanca Piedra is used for support stone-free outcomes after lithotripsy. NutriDex grades the human evidence as preliminary — Early or small human trials; promising but not yet conclusive. Based on 8 cited human studies (8 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Chanca piedra ("stone breaker") is a tropical herb long used in South America and Ayurveda for kidney stones and liver complaints. The human evidence is thin but not empty. A randomized trial found it normalized high urinary calcium in stone formers, and a controlled study reported higher stone-free rates after shock-wave lithotripsy, especially for lower-pole stones (93.7% vs 70.8%). A 2020 meta-analysis of just two studies found small reductions in stone size and number, and a 2025 systematic review concluded it appears safe but with mixed efficacy. A 2023 year-long RCT in fatty-liver patients showed a modest improvement in liver-stiffness (fibrosis) score but no change in liver enzymes or metabolic markers. For chronic hepatitis B, Cochrane reviews found no convincing benefit. Most trials are small, short, and at high risk of bias, so claims remain unproven.

Benefits / uses: Support stone-free outcomes after lithotripsy; Lower elevated urinary calcium; Kidney stone prevention; Liver support.
Active compounds: Lignans (phyllanthin, hypophyllanthin); Flavonoids (quercetin, rutin); Niranthin.
Dose: Standardized extract roughly 1–2 g/day (or 300–500 mg standardized capsules), typically taken for 1–3 months; no consensus dose is established.
Safety: Generally well tolerated in short trials, with side effects limited mainly to mild GI upset; no serious harms were reported in the lithotripsy or fatty-liver studies. Because it can have diuretic, blood-pressure-lowering and blood-sugar-lowering effects, it may add to the action of antihypertensives, diuretics and antidiabetic drugs, and theoretically to anticoagulants. Avoid in pregnancy and breastfeeding (insufficient safety data), and use caution before surgery; tell your clinician if you have kidney or liver disease, as quality and dosing of products vary widely.

Cited studies (8):
  - Phyllanthus niruri in the management of nephrolithiasis: A systematic review of the literature, Actas urologicas espanolas (2025) — Systematic review of 16 studies: P. niruri appears safe and may improve stone-free rates after ESWL, but clinical efficacy data are mixed. [https://pubmed.ncbi.nlm.nih.gov/40480426/]
  - Phyllanthus niruri (stone breaker) herbal therapy for kidney stones; a systematic review and meta-analysis of clinical efficacy, and Google Trends analysis of public interest, The Canadian journal of urology (2020) — Meta-analysis (2 controlled studies): small reductions in stone size (SMD -0.39) and number (SMD -0.38); authors call efficacy modest, pending study. [https://pubmed.ncbi.nlm.nih.gov/32333735/]
  - Phyllanthus species for chronic hepatitis B virus infection, The Cochrane database of systematic reviews (2011) — Review of 16 trials (1,326 patients): Phyllanthus vs placebo showed no significant HBeAg seroconversion; all trials at high risk of bias. [https://pubmed.ncbi.nlm.nih.gov/21491412/]
  - Effects of one-year supplementation with Phyllanthus niruri on fibrosis score and metabolic markers in patients with non-alcoholic fatty liver disease: A randomized, double-blind, placebo-controlled trial, Heliyon (2023) — 12-month RCT (n=226) in NAFLD: significant drop in fibrosis (liver-stiffness) score vs placebo, but no change in liver enzymes or metabolic markers. [https://pubmed.ncbi.nlm.nih.gov/37313177/]
  - Evaluation of the efficacy of Phyllanthus niruri standardized extract combined with magnesium and vitamin B6 for the treatment of patients with uncomplicated nephrolithiasis, Medicine and pharmacy reports (2019) — Open study (n=48), extract plus magnesium and B6 for 3 months: 40% of stones cleared, 22% shrank; best for stones <=3 mm. [https://pubmed.ncbi.nlm.nih.gov/31086843/]
  - Phyllanthus niruri versus Placebo for Chronic Hepatitis B Virus Infection: A Randomized Controlled Trial, Complementary medicine research (2018) — RCT vs placebo in chronic hepatitis B: no significant change in HBV viral load at 12 months and no HBsAg clearance. [https://pubmed.ncbi.nlm.nih.gov/30372693/]
  - Can Phyllanthus niruri affect the efficacy of extracorporeal shock wave lithotripsy for renal stones? A randomized, prospective, long-term study, The Journal of urology (2006) — After shock-wave lithotripsy, 3 months of P. niruri raised lower-caliceal stone-free rate to 93.7% vs 70.8% in controls (p=0.01). [https://pubmed.ncbi.nlm.nih.gov/16890682/]
  - Phyllanthus niruri normalizes elevated urinary calcium levels in calcium stone forming (CSF) patients, Urological research (2004) — RCT (n=69): reduced mean urinary calcium in hypercalciuric stone formers (4.8 to 3.4 mg/kg/24h); no difference in stone passage overall. [https://pubmed.ncbi.nlm.nih.gov/15221244/]

---

## Chlorella (Chlorella vulgaris)
URL: https://nutridex.info/s/chlorella
Category: Gut & Immune, Longevity
Evidence: Moderate — Several controlled trials; effects real but modest or context-dependent.
Green freshwater algae with small, consistent effects on cholesterol and blood pressure.

Quick answer: Chlorella is used for modestly lower ldl & total cholesterol. NutriDex grades the human evidence as moderate — Several controlled trials; effects real but modest or context-dependent. Based on 8 cited human studies (8 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Chlorella is a protein-rich freshwater green alga sold as tablets or powder. Pooled across roughly 19 randomized trials (~800 people), supplementation produced small but statistically significant drops in total cholesterol (about 9 mg/dL), LDL (about 8 mg/dL), systolic blood pressure (about 4.5 mmHg) and fasting glucose (about 4 mg/dL), with no clear change in triglycerides, HDL or body weight. In non-alcoholic fatty liver disease, small Iranian RCTs and a meta-analysis show modest improvements in AST and glycemic markers, mostly as an add-on to standard care. An 8-week trial reported increased natural-killer-cell activity, hinting at immune effects. Limits are real: most studies are short (8–12 weeks), small, single-country and of low-to-moderate quality, and a well-conducted 1,500 mg/day diabetes RCT found no benefit. Effects are best seen as a minor metabolic nudge, not a treatment.

Benefits / uses: Modestly lower LDL & total cholesterol; Small blood-pressure reduction; Support liver enzymes in fatty-liver disease; Boost NK-cell immune activity (early).
Active compounds: Chlorophyll; Carotenoids (lutein, beta-carotene); Protein & cell-wall polysaccharides; Vitamin K, B12-analogues, iron.
Dose: Most trials used 1,200–5,000 mg/day of dried whole-cell Chlorella (tablets/powder), often split with meals over 8–12 weeks.
Safety: Generally well tolerated short-term; common effects are nausea, bloating, diarrhea and green-tinged stool, with occasional photosensitivity reactions. Chlorella is rich in vitamin K and can blunt warfarin/anticoagulants (a documented case raised INR control issues), so avoid or monitor closely. Its iodine content and possible additive glucose- and blood-pressure-lowering mean caution with thyroid medication, antidiabetics and antihypertensives. Safety in pregnancy and breastfeeding is not established, and products can be contaminated with heavy metals if poorly sourced.

Cited studies (8):
  - Effect of supplementation with Chlorella vulgaris on lipid profile in adults: A systematic review and dose-response meta-analysis of randomized controlled trials, Complementary therapies in medicine (2022) — Dose-response meta-analysis (10 RCTs, 539 adults): C. vulgaris lowered total cholesterol and LDL; no effect on triglycerides or HDL; LDL benefit only ≤1500 mg/day. [https://pubmed.ncbi.nlm.nih.gov/35331862/]
  - Effect of Chlorella vulgaris on Liver Function Biomarkers: a Systematic Review and Meta-Analysis, Clinical nutrition research (2021) — Meta-analysis (7 RCTs): C. vulgaris reduced AST -9.15 U/L; no overall effect on ALT or ALP, though ALT fell vs placebo (not vs metformin). [https://pubmed.ncbi.nlm.nih.gov/33564655/]
  - Effect of Chlorella supplementation on cardiovascular risk factors: A meta-analysis of randomized controlled trials, Clinical nutrition (Edinburgh, Scotland) (2018) — Meta-analysis (19 RCTs, 797 adults): Chlorella cut total cholesterol -9.09 mg/dL, LDL -8.32, SBP -4.51 mmHg, DBP -1.64, fasting glucose -4.23. [https://pubmed.ncbi.nlm.nih.gov/29037431/]
  - The effects of Chlorella supplementation on glycemic control, lipid profile and anthropometric measures on patients with type 2 diabetes mellitus, European journal of nutrition (2021) — Double-blind RCT (n=84, T2DM): 1,500 mg/day for 8 weeks did NOT improve glucose, HbA1c, lipids or anthropometrics vs placebo. [https://pubmed.ncbi.nlm.nih.gov/33532874/]
  - Chlorella (2021) — NIH safety review: Chlorella poorly studied in pregnancy/lactation; vitamin K and iodine content noted as practical concerns. [https://www.ncbi.nlm.nih.gov/books/NBK501822/]
  - Glucose homeostasis, insulin resistance and inflammatory biomarkers in patients with non-alcoholic fatty liver disease: Beneficial effects of supplementation with microalgae Chlorella vulgaris: A double-blind placebo-controlled randomized clinical trial, Clinical nutrition (Edinburgh, Scotland) (2017) — RCT (n=70, NAFLD): 1,200 mg/day Chlorella for 8 weeks improved fasting glucose, insulin resistance (HOMA-IR) and hs-CRP vs placebo. [https://pubmed.ncbi.nlm.nih.gov/27475283/]
  - The Effect of Chlorella vulgaris Supplementation on Liver En-zymes, Serum Glucose and Lipid Profile in Patients with Non-Alcoholic Fatty Liver Disease, Health promotion perspectives (2014) — Double-blind RCT (n=60, NAFLD): 1,200 mg/day Chlorella + vitamin E for 8 weeks improved weight, ALP and fasting glucose vs vitamin E alone. [https://pubmed.ncbi.nlm.nih.gov/25097844/]
  - Beneficial immunostimulatory effect of short-term Chlorella supplementation: enhancement of natural killer cell activity and early inflammatory response (randomized, double-blinded, placebo-controlled trial), Nutrition journal (2012) — Double-blind RCT (n=51): 5 g/day Chlorella for 8 weeks raised NK-cell activity and serum IFN-γ and IL-1β vs placebo in healthy adults. [https://pubmed.ncbi.nlm.nih.gov/22849818/]

---

## Bovine Colostrum (Bovine colostrum)
URL: https://nutridex.info/s/colostrum
Category: Gut & Immune, Performance
Evidence: Moderate — Several controlled trials; effects real but modest or context-dependent.
First milk of cows, used for gut barrier and respiratory defense.

Quick answer: Bovine Colostrum is used for fewer upper-respiratory infections. NutriDex grades the human evidence as moderate — Several controlled trials; effects real but modest or context-dependent. Based on 8 cited human studies (8 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Bovine colostrum is the antibody- and growth-factor-rich first milk cows produce after calving, sold as a powder for immune and gut support. It is the active ingredient, not a herb. The best evidence is for fewer upper-respiratory infections in active adults: meta-analyses report rate ratios near 0.56–0.64, roughly a 36–44% reduction in symptomatic days or episodes across ~150–445 pooled participants. A 2024 meta-analysis of 10 RCTs found it modestly lowered markers of intestinal permeability (lactulose/rhamnose ratio), and small trials show it blunts NSAID-induced gut leakiness. In children, pooled data show meaningfully less infectious (largely rotavirus) diarrhea. Sports trials are weaker: one RCT found better repeated-sprint times versus whey but no change in body composition. Most studies are small, short, statistically heterogeneous and often industry-funded, so benefits are plausible but modest and not firmly established.

Benefits / uses: Fewer upper-respiratory infections; Reduced gut permeability ('leaky gut'); Eases infectious diarrhea; Modest sprint/recovery gains.
Active compounds: Immunoglobulins (IgG); Lactoferrin; Growth factors (IGF-1, EGF, TGF-β); Oligosaccharides.
Dose: Commonly 10–20 g/day of colostrum powder for gut/immune use; athlete trials used up to 60 g/day for several weeks.
Safety: Generally well tolerated; the main side effects are GI (bloating, gas, loose stools, nausea), often easing after the first weeks. It is a dairy product, so people with cow's-milk-protein allergy must avoid it, and those with lactose intolerance may react. Safety in pregnancy, breastfeeding and infants is not established. No major drug interactions are documented, but because it contains insulin-like growth factor (IGF-1), people with hormone-sensitive cancers should consult their oncologist before use; theoretical caution applies if combining with antidiabetic or immune-modulating therapy.

Cited studies (8):
  - Bovine Colostrum in Increased Intestinal Permeability in Healthy Athletes and Patients: A Meta-Analysis of Randomized Clinical Trials, Digestive diseases and sciences (2024) — Meta-analysis (10 RCTs): significant fall in 5-h urinary lactulose/rhamnose permeability ratio (MD −0.24, 95% CI −0.43 to −0.04). [https://pubmed.ncbi.nlm.nih.gov/38361147/]
  - Therapeutics effects of bovine colostrum applications on gastrointestinal diseases: a systematic review, Systematic Reviews (2024) — Systematic review of bovine colostrum for gastrointestinal disease: signals of benefit but small, heterogeneous trials. [https://doi.org/10.1186/s13643-024-02489-1]
  - Bovine colostrum supplementation in prevention of upper respiratory tract infections – Systematic review, meta-analysis and meta-regression of randomized controlled trials, Journal of Functional Foods (2022) — Meta-analysis (7 RCTs, 445 participants): ~36% lower risk of upper-respiratory tract infection (RR 0.64, 95% CI 0.50–0.82). [https://doi.org/10.1016/j.jff.2022.105316]
  - Bovine colostrum supplementation and upper respiratory symptoms during exercise training: a systematic review and meta-analysis of randomised controlled trials, BMC sports science, medicine & rehabilitation (2016) — Meta-analysis (5 RCTs, 152 adults): colostrum cut upper-respiratory symptom days ~44% (rate ratio 0.56, 95% CI 0.43–0.72). [https://pubmed.ncbi.nlm.nih.gov/27462401/]
  - Bovine colostrum and product intervention associated with relief of childhood infectious diarrhea, Scientific reports (2019) — Meta-analysis (5 RCTs, children): ~71% lower odds of infectious diarrhea (OR 0.29, 95% CI 0.16–0.52) and ~1.4 fewer stools/day. [https://pubmed.ncbi.nlm.nih.gov/30816291/]
  - Effects of bovine colostrum supplementation on upper respiratory illness in active males, Brain, behavior, and immunity (2014) — RCT in active males: colostrum reduced upper-respiratory illness episodes and days versus placebo over training. [https://pubmed.ncbi.nlm.nih.gov/24200515/]
  - Co-administration of the health food supplement, bovine colostrum, reduces the acute non-steroidal anti-inflammatory drug-induced increase in intestinal permeability, Clinical science (London, England : 1979) (2001) — Crossover RCT (n=7): colostrum prevented the ~3-fold rise in gut permeability caused by the NSAID indomethacin. [https://pubmed.ncbi.nlm.nih.gov/11352778/]
  - The effect of bovine colostrum supplementation on exercise performance in elite field hockey players, International journal of sport nutrition and exercise metabolism (2002) — RCT (35 elite hockey players): 60 g/day improved 5×10-m sprint times more than whey, but no body-composition change. [https://pubmed.ncbi.nlm.nih.gov/12500989/]

---

## DGL (Deglycyrrhizinated Licorice) (Glycyrrhiza glabra)
URL: https://nutridex.info/s/dgl-licorice
Category: Gut & Immune
Evidence: Moderate — Several controlled trials; effects real but modest or context-dependent.
Licorice with the blood-pressure-raising glycyrrhizin removed, for stomach comfort.

Quick answer: DGL (Deglycyrrhizinated Licorice) is used for ease functional dyspepsia. NutriDex grades the human evidence as moderate — Several controlled trials; effects real but modest or context-dependent. Based on 7 cited human studies (7 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

DGL is licorice root processed to strip out glycyrrhizin, the compound that raises blood pressure and depletes potassium, leaving the flavonoids thought to soothe the gut. The best evidence is for functional dyspepsia and reflux: in placebo-controlled trials of a standardized extract (GutGard, 150 mg/day), total symptom and Nepean dyspepsia scores fell significantly over 30 days, and reflux-related heartburn and regurgitation improved over 28 days. A small randomized trial suggested it lowered H. pylori load, and old uncontrolled work found DGL mouthwash sped canker-sore healing. However, most trials enrolled only 50–200 people, ran at one site, and were funded by the extract's maker; a 2025 systematic review of 9 trials (618 people) found licorice improved ulcer-healing and pain numerically but not significantly. So DGL is plausibly helpful for indigestion comfort, but the proof is thin and likely overstated by industry sponsorship.

Benefits / uses: Ease functional dyspepsia; Soothe heartburn & reflux symptoms; Speed canker-sore healing; Protect gastric lining from aspirin.
Active compounds: Glabridin & licorice flavonoids; Liquiritin / isoliquiritin; Glycyrrhizin (removed to <3%).
Dose: Standardized flavonoid extract (e.g. GutGard) 75 mg twice daily, or 380–760 mg chewable DGL before meals; glycyrrhizin should be <3%.
Safety: True DGL (glycyrrhizin <3%) is well tolerated; unlike whole licorice it should not cause the high blood pressure, low potassium, fluid retention or pseudo-aldosteronism seen with glycyrrhizin. Mild GI upset is the main complaint. Risk rises if a product is mislabelled or you take ordinary (non-DGL) licorice: that can interact dangerously with antihypertensives, diuretics, digoxin, corticosteroids and warfarin, and worsen heart, kidney or liver disease and low potassium. Pregnant people should avoid high licorice intake; check that any product is genuinely deglycyrrhizinated.

Cited studies (7):
  - Efficacy of Glycyrrhiza glabra on peptic ulcer disease: A systematic review and meta-analysis, Advances in Integrative Medicine (2025) — Meta-analysis of 9 trials (618 patients): licorice improved ulcer healing and pain numerically but not significantly. [https://doi.org/10.1016/j.aimed.2025.100485]
  - Efficacy and Safety of GutGard® in Managing Gastroesophageal Reflux-Related Symptoms: A Phase III, Single-Centre, Double-Blind, Randomized Placebo-Controlled Trial, Complementary medicine research (2025) — GutGard 150mg/day improved reflux-related heartburn (p=0.005) and regurgitation vs placebo over 28 days (n=200). [https://pubmed.ncbi.nlm.nih.gov/39929150/]
  - An Extract of Glycyrrhiza glabra (GutGard) Alleviates Symptoms of Functional Dyspepsia: A Randomized, Double-Blind, Placebo-Controlled Study, Evidence-based complementary and alternative medicine : eCAM (2012) — GutGard 75mg twice daily for 30 days significantly cut total dyspepsia and Nepean index scores vs placebo (n=50). [https://pubmed.ncbi.nlm.nih.gov/21747893/]
  - Effect of GutGard in the Management of Helicobacter pylori: A Randomized Double Blind Placebo Controlled Study, Evidence-based complementary and alternative medicine : eCAM (2013) — GutGard 150mg/day for 60 days cleared H. pylori stool antigen in 56% vs 4% on placebo (n=107). [https://pubmed.ncbi.nlm.nih.gov/23606875/]
  - Deglycyrrhizinated liquorice in aphthous ulcers, The Journal of the Association of Physicians of India (1989) — Uncontrolled trial: DGL mouthwash gave 50–75% improvement within 1 day in 15 of 20 aphthous-ulcer patients, healing by day 3. [https://pubmed.ncbi.nlm.nih.gov/2632514/]
  - Effect of deglycyrrhizinated liquorice on gastric mucosal damage by aspirin, Scandinavian journal of gastroenterology (1979) — DGL 350mg taken with each aspirin dose reduced aspirin-induced faecal blood loss in humans; protected gastric mucosa in rats. [https://pubmed.ncbi.nlm.nih.gov/493863/]
  - Deglycyrrhizinized liquorice in the treatment of chronic duodenal ulcer. A retrospective endoscopic survey of 32 patients, The Practitioner (1975) — Endoscopic survey: deglycyrrhizinated licorice associated with healing in patients with chronic duodenal ulcer. [https://pubmed.ncbi.nlm.nih.gov/772652/]

---

## Digestive Enzymes (Pancreatin / proteases)
URL: https://nutridex.info/s/digestive-enzymes
Category: Gut & Immune
Evidence: Moderate — Several controlled trials; effects real but modest or context-dependent.
Replacement enzymes that work when your pancreas can't make enough.

Quick answer: Digestive Enzymes is used for correct fat & protein malabsorption. NutriDex grades the human evidence as moderate — Several controlled trials; effects real but modest or context-dependent. Based on 7 cited human studies (7 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Digestive enzyme products supply the lipase, protease and amylase the pancreas normally secretes, plus sometimes lactase. As prescription pancreatic enzyme replacement therapy (PERT), they have robust evidence in exocrine pancreatic insufficiency: a meta-analysis of 14 RCTs (511 patients) found PERT raised the coefficient of fat absorption from ~63% to ~84% versus baseline and improved weight, symptoms and quality of life. In advanced pancreatic cancer with insufficiency, PERT was linked to ~3.8 months longer median survival in pooled data, though randomized results are less consistent. Standalone lactase reliably cuts symptoms and breath hydrogen in lactose intolerance. For the common OTC pitch — bloating and indigestion in people with healthy pancreases — only small 40–120-person trials over ~2 months show modest symptom relief. Effect requires taking enzymes with the meal, and benefit outside true deficiency states is unproven.

Benefits / uses: Correct fat & protein malabsorption; Reduce steatorrhoea (fatty stool); Maintain weight & nutrition; Ease bloating in dyspepsia; Lactase relieves lactose intolerance.
Active compounds: Lipase; Protease; Amylase; Lactase (lactose-specific).
Dose: For pancreatic insufficiency, 40,000–50,000 lipase units with main meals and ~25,000 with snacks, taken during food; lactase ~6,000–9,000 IU with dairy.
Safety: Pancreatin is generally well tolerated; common effects are nausea, cramping, bloating and constipation. The serious historical risk is fibrosing colonopathy — colonic strictures sometimes needing surgery — seen with very high lipase doses in children with cystic fibrosis, so doses are capped (~10,000 lipase U/kg/day). Products are pork-derived, so avoid with pork allergy and counsel patients with religious dietary restrictions; high doses can raise uric acid. Enzymes may blunt absorption of some oral iron and folate; lactase products have no notable drug interactions. Genuine malabsorption symptoms (weight loss, greasy stools) warrant a clinician's work-up rather than self-treatment.

Cited studies (7):
  - Pancreatic exocrine insufficiency and pancreatic enzyme replacement therapy in patients with advanced pancreatic cancer: A systematic review and meta-analysis, United European gastroenterology journal (2020) — Systematic review/meta-analysis: in advanced pancreatic cancer, PERT linked to ~3.8 months longer median survival (12.6 vs 8.7 mo). [https://pubmed.ncbi.nlm.nih.gov/32631175/]
  - Efficacy of pancreatic enzyme replacement therapy in chronic pancreatitis: systematic review and meta-analysis, Gut (2017) — Meta-analysis (14 RCTs, 511 patients): PERT raised coefficient of fat absorption ~63% to ~84% vs baseline and improved nutrition. [https://pubmed.ncbi.nlm.nih.gov/27941156/]
  - Efficacy and safety of pancreatic enzyme replacement therapy on exocrine pancreatic insufficiency: a meta-analysis, Oncotarget (2017) — Meta-analysis (7 RCTs, 282 patients): PERT enhanced fat absorption vs placebo (weighted mean diff 17.97%, P<0.001) in pancreatic insufficiency. [https://doi.org/10.18632/oncotarget.21659]
  - Efficacy of digestive enzyme supplementation in functional dyspepsia: A monocentric, randomized, double-blind, placebo-controlled, clinical trial, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie (2023) — RCT (n=120): 2 months of a digestive-enzyme blend cut dyspeptic symptom severity and improved sleep vs placebo, well tolerated. [https://pubmed.ncbi.nlm.nih.gov/37976892/]
  - Evaluation of the Safety and Efficacy of a Multienzyme Complex in Patients with Functional Dyspepsia: A Randomized, Double-Blind, Placebo-Controlled Study, Journal of medicinal food (2018) — RCT (n=40): DigeZyme multienzyme complex 50mg TID for 60 days significantly improved all functional dyspepsia symptom scores vs placebo. [https://pubmed.ncbi.nlm.nih.gov/30156436/]
  - Effect of lactase on symptoms and hydrogen breath levels in lactose intolerance: A crossover placebo-controlled study, JGH open : an open access journal of gastroenterology and hepatology (2021) — Crossover RCT: oral lactase markedly reduced lactose-intolerance symptoms and breath-hydrogen excretion vs placebo. [https://pubmed.ncbi.nlm.nih.gov/33490624/]
  - High-dose pancreatic-enzyme supplements and fibrosing colonopathy in children with cystic fibrosis, The New England journal of medicine (1997) — Case-control: high-dose enzymes (>50,000 lipase U/kg/day) carried ~200x relative risk of fibrosing colonopathy in CF children. [https://pubmed.ncbi.nlm.nih.gov/9113931/]

---

## DIM (Diindolylmethane)
URL: https://nutridex.info/s/dim
Category: Longevity, Joint & Skin
Evidence: Mixed — Conflicting results across studies; benefit uncertain.
Broccoli-derived compound marketed to shift estrogen metabolism.

Quick answer: DIM (Diindolylmethane) is used for shift estrogen metabolite ratio. NutriDex grades the human evidence as mixed — Conflicting results across studies; benefit uncertain. Based on 7 cited human studies (7 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

DIM is a compound your gut forms from indole-3-carbinol in broccoli and other cruciferous vegetables. Small human trials consistently show it raises the urinary 2-hydroxyestrone to 16-alpha-hydroxyestrone ratio and serum SHBG — a biomarker shift, not a proven health outcome. Where outcomes were measured, results disappoint: a 551-woman RCT found 150 mg/day did not improve low-grade cervical abnormalities or clear HPV, and a 1-year BRCA-carrier study found only a tiny drop in breast density. Cervical suppository and prostate trials were small and need replication. There are no controlled trials supporting the common marketing claims for acne, fat loss, menopause or 'hormone balancing'. In women on tamoxifen, DIM lowered active drug levels, which is a concern. Overall it is biologically active but clinically unproven for the things people buy it for.

Benefits / uses: Shift estrogen metabolite ratio; Hormonal acne (claimed); Cruciferous-vegetable extract; Investigational cancer biomarker tool.
Active compounds: 3,3'-Diindolylmethane (DIM); Indole-3-carbinol (dietary precursor).
Dose: Most trials used 100–150 mg/day of an absorption-enhanced formulation (BioResponse-DIM); cancer studies have gone up to 900 mg/day.
Safety: Generally well tolerated short-term; the most common effect is harmless dark/amber urine, plus occasional nausea, headache or GI upset (more frequent above ~200 mg). DIM induces and competes for CYP450 enzymes, so it can lower levels of drugs cleared this way — notably it reduced active tamoxifen (endoxifen) metabolites in an RCT, and asymptomatic hyponatremia has been reported when high-dose DIM was combined with sodium-depleting diuretics. Because it alters estrogen and androgen signalling, avoid in pregnancy and breastfeeding and use caution with hormone therapy, hormone-sensitive cancers and any CYP-metabolised medication.

Cited studies (7):
  - &lt;p&gt;Anti-Cancer and Other Biological Effects of a Dietary Compound 3,3ʹ-Diindolylmethane Supplementation: A Systematic Review of Human Clinical Trials&lt;/p&gt;, Nutrition and Dietary Supplements (2020) — Systematic review of 22 human trials: DIM consistently alters estrogen metabolism and hormone biomarkers, but clinical anti-cancer efficacy remains unproven. [https://doi.org/10.2147/NDS.S261577]
  - 3,3-Diindolylmethane (DIM): a nutritional intervention and its impact on breast density in healthy BRCA carriers. A prospective clinical trial, Carcinogenesis (2020) — Prospective trial (n=23 BRCA carriers): 100mg/day for 1yr produced a small decrease in mammographic fibroglandular tissue score (2.8 to 2.65, p=0.031). [https://pubmed.ncbi.nlm.nih.gov/32458980/]
  - A randomized, placebo-controlled trial of diindolylmethane for breast cancer biomarker modulation in patients taking tamoxifen, Breast cancer research and treatment (2017) — RCT (n=130) of 150mg BID for 12mo raised 2/16-OHE1 ratio and SHBG but lowered tamoxifen metabolite (endoxifen) levels. [https://pubmed.ncbi.nlm.nih.gov/28560655/]
  - Double-blind randomized placebo-controlled multicenter clinical trial (phase IIa) on diindolylmethane's efficacy and safety in the treatment of CIN: implications for cervical cancer prevention, The EPMA journal (2015) — Phase IIa RCT (n=78): DIM vaginal suppositories (100–200mg/day) gave higher complete CIN regression vs placebo (~90–100% vs 61%). [https://pubmed.ncbi.nlm.nih.gov/26693258/]
  - First results of the double-blind randomized placebo-controlled multicenter clinical trial of DIM-based therapy designed as personalized approach to reverse prostatic intraepithelial neoplasia (PIN), The EPMA journal (2016) — Small RCT (n=21): 900mg/day DIM gave complete prostatic intraepithelial neoplasia regression in 45.5% vs 0% placebo (interim analysis). [https://pubmed.ncbi.nlm.nih.gov/27042242/]
  - Effect of diindolylmethane supplementation on low-grade cervical cytological abnormalities: double-blind, randomised, controlled trial, British journal of cancer (2012) — RCT (n=551): 150mg/day for 6mo did not improve low-grade cervical cytology or clear HPV (CIN2+ 8.8% DIM vs 12.4% placebo, NS). [https://pubmed.ncbi.nlm.nih.gov/22075942/]
  - Single-dose pharmacokinetics and tolerability of absorption-enhanced 3,3'-diindolylmethane in healthy subjects, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology (2008) — Single-dose PK/safety study: absorption-enhanced DIM tolerated up to 200mg; nausea/headache/vomiting reported at 300mg. [https://pubmed.ncbi.nlm.nih.gov/18843002/]

---

## Ecdysterone (20-Hydroxyecdysone)
URL: https://nutridex.info/s/ecdysterone
Category: Performance
Evidence: Preliminary — Early or small human trials; promising but not yet conclusive.
Plant steroid marketed as a 'natural anabolic' for muscle gain.

Quick answer: Ecdysterone is used for muscle mass support. NutriDex grades the human evidence as preliminary — Early or small human trials; promising but not yet conclusive. Based on 7 cited human studies (7 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Ecdysterone (20-hydroxyecdysone) is a steroid-like compound found in spinach, quinoa and certain herbs, sold as a 'natural anabolic' that works through estrogen receptor beta rather than androgen receptors. The strongest human data is a single 10-week WADA-funded RCT (n=46) reporting larger gains in muscle mass (~2 kg) and bench-press performance versus placebo in resistance-trained men, with a dose-response pattern. However, an earlier 8-week RCT found no effect on strength, body composition or hormones, and a 2025 12-week trial of a commercial product also found no benefit over placebo — partly because the product contained almost none of its labelled ecdysterone. Independent analyses repeatedly show supplements are mislabelled or under-dosed. The mechanism is biologically plausible and short-term tolerability looks good, but the human evidence is small, mixed, and not yet replicated. Note: ecdysterone is on WADA's Monitoring Program.

Benefits / uses: Muscle mass support; Strength gains; Resistance-training adaptation; Marketed steroid alternative.
Active compounds: 20-Hydroxyecdysone (ecdysterone); Polypodine B; Related phytoecdysteroids.
Dose: No established dose; trials used ~100–800 mg/day standardized ecdysterone over 8–12 weeks, though most commercial products contain far less than labelled.
Safety: Short-term human trials report good tolerability with no consistent rise in liver or kidney markers and no androgenic steroid-profile changes, but no long-term safety data exist. Because it acts on estrogen receptor beta, theoretical caution applies in hormone-sensitive conditions; data on pregnancy, breastfeeding and drug interactions are essentially absent. Product quality is a real hazard — independent testing repeatedly finds supplements grossly under-dosed or, conversely, spiked with undeclared compounds, so contamination with banned anabolics is a documented risk. Ecdysterone is on the WADA Monitoring Program, so competitive athletes should treat it cautiously.

Cited studies (7):
  - How reliable is the labeling of a commercial phytosteroid product? A 12-week randomized double-blind training study, Journal of the International Society of Sports Nutrition (2025) — 12-wk RCT (n=24): commercial phytosteroid product showed no muscle/strength benefit vs placebo; product had <0.1% of labelled ecdysterone. [https://pubmed.ncbi.nlm.nih.gov/40781783/]
  - Ecdysteroids as non-conventional anabolic agent: performance enhancement by ecdysterone supplementation in humans, Archives of toxicology (2019) — 10-wk WADA-funded RCT (n=46): high-dose ecdysterone + training raised muscle mass ~2 kg and 1-RM bench press vs placebo, dose-responsively. [https://pubmed.ncbi.nlm.nih.gov/31123801/]
  - How reliable is dietary supplement labelling?—Experiences from the analysis of ecdysterone supplements, Journal of Pharmaceutical and Biomedical Analysis (2020) — Analysis of ecdysterone supplements found actual content frequently far below the labelled amount, exposing poor quality control across products. [https://doi.org/10.1016/j.jpba.2019.112877]
  - Effects of methoxyisoflavone, ecdysterone, and sulfo-polysaccharide supplementation on training adaptations in resistance-trained males, Journal of the International Society of Sports Nutrition (2006) — 8-wk RCT (n=45 trained males): 200 mg/day 20-hydroxyecdysone did not improve strength, body composition or anabolic/catabolic hormones vs placebo. [https://pubmed.ncbi.nlm.nih.gov/18500969/]
  - Molecular insights into the role of Estrogen Receptor Beta in Ecdysterone Mediated Anabolic Activity, PLOS One (2025) — Molecular modelling: ecdysterone preferentially binds estrogen receptor beta (not androgen receptor or ERα), supporting an ERβ-mediated anabolic mechanism. [https://doi.org/10.1371/journal.pone.0320865]
  - Ecdysterone and Turkesterone—Compounds with Prominent Potential in Sport and Healthy Nutrition, Nutrients (2024) — Narrative review (Nutrients): animal/in-vitro data abundant but robust human RCTs few; ecdysteroids regarded as safe and well tolerated short-term. [https://doi.org/10.3390/nu16091382]
  - Ecdysteroids: A novel class of anabolic agents?, Biology of sport (2015) — Preclinical work: ecdysterone produced strong hypertrophy of rat soleus fibers, exceeding metandienone and a SARM; acts via estrogen receptor beta. [https://pubmed.ncbi.nlm.nih.gov/26060342/]

---

## Eleuthero (Siberian Ginseng) (Eleutherococcus senticosus)
URL: https://nutridex.info/s/eleuthero
Category: Adaptogen
Evidence: Mixed — Conflicting results across studies; benefit uncertain.
Traditional adaptogen for fatigue and stress, with thin human proof.

Quick answer: Eleuthero (Siberian Ginseng) is used for traditionally used for fatigue & weakness. NutriDex grades the human evidence as mixed — Conflicting results across studies; benefit uncertain. Based on 7 cited human studies (7 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Eleuthero, often mislabeled 'Siberian ginseng,' is a shrub in the same family as true (Panax) ginseng but contains different actives — eleutherosides rather than ginsenosides — so ginseng research does not transfer to it. Human trials are few, small, and inconsistent. A 96-person RCT in chronic fatigue found no overall benefit, with only a borderline signal in those with milder fatigue. A 144-person stress-fatigue trial showed the extract added nothing to stress-management training. A 20-person trial in elderly adults found a brief lift in social functioning at 4 weeks that vanished by 8 weeks. For exercise, a systematic review of eight studies concluded the well-designed ones show no ergogenic effect, despite flawed earlier positives. Evidence is too thin and conflicting to recommend it for any specific outcome.

Benefits / uses: Traditionally used for fatigue & weakness; Marketed for stress resilience; Claimed endurance support; Immune & convalescence folk use.
Active compounds: Eleutheroside B (syringin); Eleutheroside E; Polysaccharides.
Dose: Most trials used 300–800 mg/day of standardized root extract (eleutherosides B and E) for 8 weeks; tea and tinctures are also traditional.
Safety: Generally well tolerated short-term; reported effects include insomnia, headache, jitteriness and, rarely, elevated blood pressure. It may lower blood glucose, so it can add to antidiabetic drugs and risk hypoglycemia. A case report linked it to raised serum digoxin readings (possibly assay interference), so caution with digoxin and other cardiac glycosides. Theoretical interactions exist with sedatives, immunosuppressants, and drugs metabolized by the liver; avoid in pregnancy, breastfeeding, and uncontrolled hypertension, and stop before surgery.

Cited studies (7):
  - Assessment of the effects of eleutherococcus senticosus on endurance performance, International journal of sport nutrition and exercise metabolism (2005) — Systematic review of 8 studies: methodologically sound trials show no exercise benefit; only flawed studies reported gains (up to 1200 mg/day). [https://pubmed.ncbi.nlm.nih.gov/15902991/]
  - No benefit adding eleutherococcus senticosus to stress management training in stress-related fatigue/weakness, impaired work or concentration, a randomized controlled study, Pharmacopsychiatry (2013) — RCT (n=144): 120 mg/day extract added to stress-management training gave no significant benefit over training alone at 8 weeks. [https://pubmed.ncbi.nlm.nih.gov/23740477/]
  - The effect of eight weeks of supplementation with Eleutherococcus senticosus on endurance capacity and metabolism in human, The Chinese journal of physiology (2010) — Small crossover RCT (n=9): 800 mg/day for 8 weeks raised cycling endurance time and fat utilization; underpowered and not replicated. [https://pubmed.ncbi.nlm.nih.gov/21793317/]
  - Randomized controlled trial of Siberian ginseng for chronic fatigue, Psychological medicine (2004) — RCT in 96 chronic-fatigue patients: no overall benefit vs placebo; borderline efficacy only in the milder-fatigue subgroup (P=0.04). [https://pubmed.ncbi.nlm.nih.gov/14971626/]
  - Effects of Siberian ginseng (Eleutherococcus senticosus maxim.) on elderly quality of life: a randomized clinical trial, Archives of gerontology and geriatrics. Supplement (2004) — Double-blind RCT (n=20 elderly): 300 mg/day improved social functioning at 4 weeks, but gains did not persist to 8 weeks; well tolerated. [https://pubmed.ncbi.nlm.nih.gov/15207399/]
  - The effect of siberian ginseng (Eleutherococcus senticosus) on substrate utilization and performance, International journal of sport nutrition and exercise metabolism (2000) — RCT in trained cyclists: Eleutherococcus did not alter substrate use, heart rate, or steady-state cycling performance vs placebo. [https://pubmed.ncbi.nlm.nih.gov/11099371/]
  - The effects of Eleutherococcus senticosus and Panax ginseng on steroidal hormone indices of stress and lymphocyte subset numbers in endurance athletes, Life sciences (2001) — Trial in endurance athletes: Eleutherococcus did not favorably change stress-hormone (cortisol/testosterone) indices or immune cell counts. [https://pubmed.ncbi.nlm.nih.gov/11798012/]

---

## Grape Seed Extract (Vitis vinifera)
URL: https://nutridex.info/s/grape-seed
Category: Heart & Metabolic, Longevity
Evidence: Moderate — Several controlled trials; effects real but modest or context-dependent.
Polyphenol extract that modestly trims blood pressure and lipids.

Quick answer: Grape Seed Extract is used for lower blood pressure. NutriDex grades the human evidence as moderate — Several controlled trials; effects real but modest or context-dependent. Based on 8 cited human studies (8 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Grape seed extract is a polyphenol concentrate rich in proanthocyanidins, marketed for heart and metabolic health. Meta-analyses of randomized trials show real but modest effects: pooled systolic BP falls roughly 1.5–6 mmHg and diastolic about 2–3 mmHg, with the largest benefit in younger, obese, or metabolic-syndrome subjects. Supplementation also lowers LDL-cholesterol (~0.17 mmol/L) and triglycerides (~0.11 mmol/L) and modestly reduces fasting glucose and C-reactive protein, though HDL, HbA1c and body weight are usually unchanged, and flow-mediated dilation does not reliably improve. Smaller trials suggest benefit in non-alcoholic fatty liver disease and in slowing hard exudates in early diabetic retinopathy. Limitations are real: trials are short, doses and extract standardization vary widely, some are industry-linked, and no study has measured cardiovascular events. It is a reasonable adjunct, not a substitute for proven therapy.

Benefits / uses: Lower blood pressure; Reduce LDL and triglycerides; Improve fasting glucose; Antioxidant / anti-inflammatory; Support vein and capillary health.
Active compounds: Proanthocyanidins (oligomeric procyanidins); Catechin / epicatechin; Gallic acid.
Dose: Typically 150–400 mg/day of standardized grape seed proanthocyanidin extract, taken with food for 8–16 weeks.
Safety: Generally well tolerated; the most common complaints are mild headache, nausea, dry/itchy scalp and dizziness. Because proanthocyanidins have mild antiplatelet activity, it may add to the effect of anticoagulants and antiplatelet drugs (warfarin, aspirin, clopidogrel, DOACs) and should be paused before surgery. It can also augment blood-pressure and glucose-lowering medications, risking hypotension or hypoglycemia, and is metabolized via CYP pathways, so caution is warranted with narrow-therapeutic-index drugs. Safety in pregnancy and breastfeeding is not established, so avoid.

Cited studies (8):
  - The effect of grape (Vitis vinifera) seed extract supplementation on flow-mediated dilation, blood pressure, and heart rate: A systematic review and meta-analysis of controlled trials with duration- and dose-response analysis, Pharmacological research (2022) — Meta-analysis: GSE lowered diastolic BP 2.20 mmHg and heart rate 1.25 bpm, but did not improve flow-mediated dilation or systolic BP. [https://pubmed.ncbi.nlm.nih.gov/34798267/]
  - The effects of grape seed extract on glycemic control, serum lipoproteins, inflammation, and body weight: A systematic review and meta-analysis of randomized controlled trials, Phytotherapy research : PTR (2020) — Meta-analysis of RCTs: GSE significantly reduced fasting glucose, total and LDL cholesterol, triglycerides and CRP; no change in HbA1c, HDL or body weight. [https://pubmed.ncbi.nlm.nih.gov/31880030/]
  - Effects of grape seed extract on dyslipidaemia: a systematic review and dose-response meta-analysis of randomised controlled trials, The British journal of nutrition (2020) — Dose-response meta-analysis (11 RCTs, n=536): GSE lowered LDL by 0.17 mmol/L and triglycerides by 0.11 mmol/L; no overall effect on total or HDL cholesterol. [https://pubmed.ncbi.nlm.nih.gov/32138795/]
  - The impact of grape seed extract treatment on blood pressure changes: A meta-analysis of 16 randomized controlled trials, Medicine (2016) — Meta-analysis of 16 RCTs (n=810): GSE cut systolic BP 6.08 mmHg and diastolic 2.80 mmHg; largest effect in younger/obese/metabolic-syndrome subjects. [https://pubmed.ncbi.nlm.nih.gov/27537554/]
  - The effects of grape seed extract supplementation on cardiovascular risk factors, liver enzymes and hepatic steatosis in patients with non-alcoholic fatty liver disease: a randomised, double-blind, placebo-controlled study, BMC complementary medicine and therapies (2024) — RCT in NAFLD: 520 mg/day for 8 weeks lowered HOMA-IR, LDL, triglycerides, blood pressure, ALT/AST and reduced hepatic steatosis severity (P=0.002). [https://pubmed.ncbi.nlm.nih.gov/38755622/]
  - Effect of grape seed proanthocyanidin extract on hard exudates in patients with non-proliferative diabetic retinopathy, Medicine (2019) — RCT in non-proliferative diabetic retinopathy: 150 mg/day GSPE improved hard-exudate severity by ≥2 grades in 43.9% vs 8% placebo over 1 year (P=0.0007). [https://pubmed.ncbi.nlm.nih.gov/31124931/]
  - Grape Seed Extract: Usefulness and Safety, NIH National Center for Complementary and Integrative Health (2025) — Safety overview: grape seed extract is generally well tolerated orally; safety in pregnancy/breastfeeding is unknown and drug interactions are possible. [https://www.nccih.nih.gov/health/grape-seed-extract]
  - Grapes (Vitis vinifera) as a Potential Candidate for the Therapy of the Metabolic Syndrome, Phytotherapy research : PTR (2016) — Review: grape-derived polyphenols, chiefly proanthocyanidins, plausibly improve components of metabolic syndrome via antioxidant and vascular mechanisms. [https://pubmed.ncbi.nlm.nih.gov/26800498/]

---

## Huperzine A (Huperzia serrata)
URL: https://nutridex.info/s/huperzine-a
Category: Nootropic
Evidence: Mixed — Conflicting results across studies; benefit uncertain.
Plant-derived cholinesterase inhibitor marketed for memory.

Quick answer: Huperzine A is used for memory support. NutriDex grades the human evidence as mixed — Conflicting results across studies; benefit uncertain. Based on 6 cited human studies (6 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Huperzine A is an alkaloid from the firmoss Huperzia serrata that, like donepezil, reversibly blocks acetylcholinesterase and crosses the blood-brain barrier. Chinese meta-analyses of Alzheimer's and vascular dementia trials report meaningful gains on the MMSE (mean differences of roughly 2.9–3.8 points versus placebo) plus better daily function, and a meta-analysis in schizophrenia found improved memory scores when added to antipsychotics. The major caveat is quality: almost all trials were small, short, conducted in China, and rated high risk of bias. The single rigorous, NIH-funded US trial (210 patients) found no cognitive benefit at 200 mcg twice daily on its primary endpoint. There is little credible evidence it sharpens memory in healthy adults. Overall the effect, if real, is modest and far from established by Western trial standards.

Benefits / uses: Memory support; Cognition in dementia (claimed); Acetylcholine boost; Adjunct in schizophrenia (claimed).
Active compounds: Huperzine A (a sesquiterpene alkaloid).
Dose: Studied at 100–200 mcg once or twice daily; AD trials used up to 400 mcg twice daily.
Safety: As a cholinesterase inhibitor, huperzine A can cause cholinergic side effects: nausea, vomiting, diarrhea, sweating, hypersalivation, dizziness, muscle twitching and, rarely, slowed heart rate or arrhythmia. Do not combine with prescription cholinesterase inhibitors (donepezil, rivastigmine, galantamine) or other cholinergic drugs, as effects are additive; use caution with anticholinergics, beta-blockers and bradycardic agents, and in asthma, COPD, peptic ulcer, seizure or slow-heart-rhythm disorders. Avoid in pregnancy and breastfeeding due to lack of safety data. Supplement potency is unregulated and often inconsistent.

Cited studies (6):
  - Adjunctive huperzine A for cognitive deficits in schizophrenia: a systematic review and meta-analysis, Human Psychopharmacology: Clinical and Experimental (2016) — Meta-analysis of 12 RCTs (n=1117) in schizophrenia: adjunctive huperzine A improved memory and IQ scores vs control; all trials in China. [https://doi.org/10.1002/hup.2537]
  - Huperzine A for Alzheimer's disease: a systematic review and meta-analysis of randomized clinical trials, PloS one (2013) — Meta-analysis of 20 RCTs (n=1823): MMSE ~3.75 points higher vs placebo at 8 wk, but most trials at high risk of bias. [https://pubmed.ncbi.nlm.nih.gov/24086396/]
  - Huperzine a in the treatment of Alzheimer's disease and vascular dementia: a meta-analysis, Evidence-based complementary and alternative medicine : eCAM (2014) — Meta-analysis (8 AD trials n=733, 2 vascular-dementia trials n=92): improved MMSE and ADL; adverse effects mild and transient. [https://pubmed.ncbi.nlm.nih.gov/24639880/]
  - Huperzine A for Alzheimer’s Disease: A Systematic Review and Meta-Analysis of Randomized Clinical Trials, PLoS ONE (2013) — Systematic review concludes apparent benefit on cognition and daily living, but cautions findings are undermined by poor trial methodology. [https://doi.org/10.1371/journal.pone.0074916]
  - A phase II trial of huperzine A in mild to moderate Alzheimer disease, Neurology (2011) — NIH/ADCS phase II RCT (n=210): huperzine A 200 mcg BID showed NO ADAS-Cog benefit vs placebo at 16 weeks (Class III, negative). [https://pubmed.ncbi.nlm.nih.gov/21502597/]
  - Huperzine-A capsules enhance memory and learning performance in 34 pairs of matched adolescent students, Zhongguo yao li xue bao = Acta pharmacologica Sinica (1999) — Double-blind matched-pair trial in 34 adolescent pairs: 100 mcg/day raised memory quotient (115 vs 104 placebo, P<0.01) over 4 weeks. [https://pubmed.ncbi.nlm.nih.gov/10678121/]

---

## Lithium Orotate (Lithium orotate)
URL: https://nutridex.info/s/lithium-orotate
Category: Sleep & Mood, Mineral
Evidence: Preliminary — Early or small human trials; promising but not yet conclusive.
Low-dose lithium salt sold for mood — minimal human evidence.

Quick answer: Lithium Orotate is used for marketed for mood & irritability. NutriDex grades the human evidence as preliminary — Early or small human trials; promising but not yet conclusive. Based on 7 cited human studies (7 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Lithium orotate is an over-the-counter salt that delivers tiny amounts of lithium — roughly 0.13–0.19 mg of elemental lithium per 5 mg tablet, a fraction of the ~150–900 mg of lithium carbonate used in psychiatry. It is sold for mood, irritability and sleep, but no randomized controlled trial has tested the orotate supplement at these doses for any outcome. The human record is one uncontrolled 1986 case series in 42 people with alcoholism (150 mg/day) and indirect evidence: ecological studies link trace lithium in drinking water to modestly lower suicide rates (pooled effect inverse but heterogeneous), and pharmaceutical-dose lithium trials in mild cognitive impairment and Alzheimer's show some biomarker and clinical signals. Claims that the orotate form uniquely floods the brain rest on a 1978 rodent study and are unproven in humans. At marketed doses harm is unlikely, but efficacy is essentially unestablished.

Benefits / uses: Marketed for mood & irritability; Marketed for calm & sleep; Marketed for stress; Trace-dose lithium delivery.
Active compounds: Lithium (Li⁺); Orotic acid (orotate carrier).
Dose: Supplements supply ~5 mg lithium orotate per tablet (~0.13–0.19 mg elemental lithium); no validated effective dose exists for the marketed mood claims.
Safety: At the trace doses sold (well under 1 mg elemental lithium), toxicity is unlikely and overdose case reports show only mild symptoms. However, lithium has a narrow therapeutic window and supplement labels are poorly standardized, so high or stacked dosing can cause tremor, nausea, thyroid and kidney effects, and serious toxicity. Lithium levels rise dangerously with dehydration, NSAIDs, ACE inhibitors/ARBs and thiazide diuretics, and it can worsen hypothyroidism; avoid in pregnancy and kidney disease. Anyone on prescription lithium, thyroid medication, or with renal impairment should not use it without medical supervision.

Cited studies (7):
  - Association between naturally occurring lithium in drinking water and suicide rates: systematic review and meta-analysis of ecological studies, The British Journal of Psychiatry (2020) — Meta-analysis of ecological studies: higher trace lithium in drinking water linked to lower total suicide (pooled β=−0.27, 95% CI −0.47 to −0.08), high heterogeneity. [https://doi.org/10.1192/bjp.2020.128]
  - A systematic review of online interventions for families of patients with severe mental disorders, Journal of Affective Disorders (2020) — Systematic review/meta-analysis: lithium in drinking water inversely associated with suicide mortality (OR≈0.42, 95% CI 0.27–0.67); ecological data only. [https://doi.org/10.1016/j.jad.2019.11.106]
  - Low Dose Lithium Treatment of Behavioral Complications in Alzheimer's Disease: Lit-AD Randomized Clinical Trial, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry (2022) — Lit-AD RCT (n=77): lithium carbonate 150–600 mg did not reduce agitation in Alzheimer's, but global improvement was 36.8% vs 0% on placebo. [https://pubmed.ncbi.nlm.nih.gov/34059401/]
  - Disease-modifying properties of long-term lithium treatment for amnestic mild cognitive impairment: randomised controlled trial, The British journal of psychiatry : the journal of mental science (2011) — RCT (n=45, amnestic MCI): pharmaceutical low-dose lithium for 12 mo lowered CSF p-tau (P=0.03) and improved some cognitive scores vs placebo. [https://pubmed.ncbi.nlm.nih.gov/21525519/]
  - Lithium orotate: A superior option for lithium therapy?, Brain and Behavior (2021) — Review of orotate vs carbonate; cites a 1978 rodent study of higher brain Li⁺, but states clinical use is not recommended given scarce human data. [https://doi.org/10.1002/brb3.2262]
  - Lithium toxicity from an Internet dietary supplement, Journal of medical toxicology : official journal of the American College of Medical Toxicology (2007) — Case report: 18-yr-old ingested 18 lithium orotate tablets (120 mg each); only mild toxicity, serum Li⁺ 0.31–0.40 mEq/L, resolved with fluids. [https://pubmed.ncbi.nlm.nih.gov/18072162/]
  - Lithium orotate in the treatment of alcoholism and related conditions, Alcohol (Fayetteville, N.Y.) (1986) — Uncontrolled case series: 150 mg/day lithium orotate in 42 people with alcoholism; 10 relapse-free 3–10 yrs, only minor side effects in 8 — no control group. [https://pubmed.ncbi.nlm.nih.gov/3718672/]

---

## Magnolia Bark (Magnolia officinalis)
URL: https://nutridex.info/s/magnolia-bark
Category: Sleep & Mood
Evidence: Preliminary — Early or small human trials; promising but not yet conclusive.
GABA-active TCM bark studied for stress, anxiety and menopausal sleep.

Quick answer: Magnolia Bark is used for ease everyday stress. NutriDex grades the human evidence as preliminary — Early or small human trials; promising but not yet conclusive. Based on 8 cited human studies (8 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Magnolia officinalis bark is a traditional Chinese medicine whose two neolignans, honokiol and magnolol, act as positive allosteric modulators of GABA-A receptors -- the same target as benzodiazepines, but milder. In mice, honokiol shortens sleep onset and increases NREM sleep without suppressing deep-sleep EEG. Human data are thinner and mostly combination products. A 634-woman menopause trial found adding 60 mg magnolia extract to isoflavones improved insomnia, anxiety and irritability, and a smaller 89-woman study echoed this. For stress, a 56-person trial of a magnolia-phellodendron blend (Relora) cut salivary cortisol ~18% and improved mood over 4 weeks, though a 40-person pilot found no cortisol change and only reduced transient anxiety. No meta-analysis or trial of isolated magnolia extract for sleep yet exists, so effect sizes specific to magnolia remain uncertain. Toxicology reviews rate honokiol and magnolol as safe at studied doses.

Benefits / uses: Ease everyday stress; Reduce mild anxiety; Improve menopausal sleep; Calm without sedation; Lower evening cortisol.
Active compounds: Honokiol; Magnolol; Other neolignans.
Dose: Stress/mood trials used ~250 mg 1-3x/day of a magnolia-phellodendron extract (Relora); menopause trials used 60 mg/day of bark extract, usually combined with other ingredients.
Safety: Generally well tolerated; reported effects include GI upset, heartburn and daytime drowsiness, with isolated reports of hand tremor, perioral numbness and thyroid changes. Because honokiol and magnolol act on GABA-A receptors, magnolia can add to the sedation of benzodiazepines, alcohol, sleep aids and other CNS depressants, and may theoretically increase bleeding risk with anticoagulants or antiplatelets. Avoid in pregnancy and breastfeeding, and stop before surgery; use cautiously with thyroid medication.

Cited studies (8):
  - Randomized controlled study on clinical efficacy of isoflavones plus Lactobacillus sporogenes, associated or not with a natural anxiolytic agent in menopause, Minerva ginecologica (2011) — RCT, 634 menopausal women: isoflavones + magnolia extract beat isoflavones alone on insomnia, irritability, anxiety, depressed mood and libido. [https://pubmed.ncbi.nlm.nih.gov/21311416/]
  - Effect of Magnolia officinalis and Phellodendron amurense (Relora®) on cortisol and psychological mood state in moderately stressed subjects, Journal of the International Society of Sports Nutrition (2013) — RCT, 56 stressed adults: magnolia-phellodendron (Relora) cut salivary cortisol ~18% and improved mood vs placebo over 4 weeks. [https://pubmed.ncbi.nlm.nih.gov/23924268/]
  - Soy isoflavones, lactobacilli, Magnolia bark extract, vitamin D3 and calcium. Controlled clinical study in menopause, Minerva ginecologica (2006) — Controlled trial, 89 menopausal women: 60 mg magnolia extract + magnesium improved psycho-affective and sleep disturbances vs calcium/vitamin D control. [https://pubmed.ncbi.nlm.nih.gov/16957676/]
  - Effect of a proprietary Magnolia and Phellodendron extract on stress levels in healthy women: a pilot, double-blind, placebo-controlled clinical trial, Nutrition journal (2008) — Pilot RCT, 40 women: Relora reduced transient (state) anxiety but did NOT change salivary cortisol, trait anxiety or sleep quality. [https://pubmed.ncbi.nlm.nih.gov/18426577/]
  - Safety and Toxicology of Magnolol and Honokiol, Planta medica (2018) — Safety review of 44 articles: magnolol and honokiol non-mutagenic, non-genotoxic; NOAEL >240 mg/kg/day; up to 1-year human use without adverse effects. [https://pubmed.ncbi.nlm.nih.gov/29925102/]
  - A honokiol-enriched Magnolia officinalis Rehder & E.H. Wilson. bark extract possesses anxiolytic-like activity with neuroprotective effect through the modulation of CB1 receptor, The Journal of pharmacy and pharmacology (2021) — Honokiol-enriched bark extract produced anxiolytic-like and neuroprotective effects in rodents, mediated by CB1 receptor modulation. [https://pubmed.ncbi.nlm.nih.gov/33950239/]
  - Honokiol promotes non-rapid eye movement sleep via the benzodiazepine site of the GABA(A) receptor in mice, British journal of pharmacology (2012) — Honokiol shortened NREM sleep latency and increased NREM sleep in mice via the benzodiazepine site of GABA-A, without suppressing delta EEG. [https://pubmed.ncbi.nlm.nih.gov/22537192/]
  - Neuro-modulating effects of honokiol: a review, Frontiers in neurology (2013) — Review: honokiol shows anxiolytic, analgesic, anticonvulsant and neuroprotective activity across preclinical models via GABA and other pathways. [https://pubmed.ncbi.nlm.nih.gov/24062717/]

---

## Methylene Blue (Methylthioninium chloride)
URL: https://nutridex.info/s/methylene-blue
Category: Nootropic, Longevity
Evidence: Preliminary — Early or small human trials; promising but not yet conclusive.
Old dye, hyped as a brain booster — human data are thin.

Quick answer: Methylene Blue is used for possible short-term memory boost. NutriDex grades the human evidence as preliminary — Early or small human trials; promising but not yet conclusive. Based on 7 cited human studies (7 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Methylene blue is a century-old synthetic dye used medically to treat methemoglobinemia and now marketed as a nootropic and 'longevity' aid. The strongest human signal is a randomized fMRI study in 26 healthy adults where a single low oral dose raised brain activity during attention and memory tasks and produced a 7% increase in correct memory-retrieval responses. Two small psychiatry RCTs found it can enhance retention of fear-extinction (exposure therapy) when learning succeeds. However, the large 891-patient phase-3 trial of its reduced derivative LMTM in Alzheimer's disease failed both primary cognitive and functional endpoints, with benefit seen only in an unplanned monotherapy subgroup. At low doses it supports mitochondrial electron transport, but evidence for lasting cognitive enhancement or extended lifespan in humans is absent. Effects are acute and dose-dependent — higher doses impair, not help.

Benefits / uses: Possible short-term memory boost; Mitochondrial energy support; Aids fear-extinction learning; Treats methemoglobinemia (medical use).
Active compounds: Methylthioninium chloride (oxidized); Leucomethylthioninium (reduced).
Dose: Nootropic research uses single low oral doses (~0.5–4 mg/kg, often ~280 mg); there is no established supplement regimen, and high doses are toxic.
Safety: Methylene blue is a potent reversible MAO-A inhibitor and carries an FDA boxed warning for potentially fatal serotonin syndrome when combined with SSRIs, SNRIs, MAOIs, bupropion, triptans, tramadol or other serotonergic drugs — avoid these for at least 2 weeks before and 24–72 hours after. It is contraindicated in G6PD deficiency (causes hemolytic anemia) and should be avoided in pregnancy. High doses paradoxically cause methemoglobinemia, blue-green urine/skin, nausea, headache and can raise blood pressure; it may also interact with other MAO-affecting drugs. It is a prescription drug, not a dietary supplement, and unregulated 'pharma-grade' products vary in purity.

Cited studies (7):
  - Methylene Blue (2026) — StatPearls: FDA boxed warning for fatal serotonin syndrome with serotonergic drugs; contraindicated in G6PD deficiency; methemoglobinemia dose 1 mg/kg IV. [https://www.ncbi.nlm.nih.gov/books/NBK557593/]
  - Multimodal Randomized Functional MR Imaging of the Effects of Methylene Blue in the Human Brain, Radiology (2016) — Single low-dose oral MB raised fMRI response in attention/memory regions and gave a 7% increase in correct memory-retrieval responses (n=26). [https://pubmed.ncbi.nlm.nih.gov/27351678/]
  - Enhancing Extinction Learning in Posttraumatic Stress Disorder With Brief Daily Imaginal Exposure and Methylene Blue: A Randomized Controlled Trial, The Journal of clinical psychiatry (2017) — MB-augmented imaginal exposure for PTSD improved evaluator-rated response and quality of life vs placebo (NNT 7.5) at 3-month follow-up. [https://pubmed.ncbi.nlm.nih.gov/28686823/]
  - Efficacy and safety of tau-aggregation inhibitor therapy in patients with mild or moderate Alzheimer's disease: a randomised, controlled, double-blind, parallel-arm, phase 3 trial, Lancet (London, England) (2016) — Phase-3 trial of LMTM (MB derivative) in 891 mild-moderate Alzheimer's patients failed both co-primary endpoints; effect only in an unplanned monotherapy subgroup. [https://pubmed.ncbi.nlm.nih.gov/27863809/]
  - Effects of post-session administration of methylene blue on fear extinction and contextual memory in adults with claustrophobia, The American journal of psychiatry (2014) — 260 mg MB after exposure improved 1-month retention of fear extinction and contextual memory when post-session fear was low (n=42); worsened it when fear was high. [https://pubmed.ncbi.nlm.nih.gov/25018057/]
  - Exploring Methylene Blue and Its Derivatives in Alzheimer's Treatment: A Comprehensive Review of Randomized Control Trials, Cureus (2023) — Review of 6 RCTs of MB and derivatives in Alzheimer's: signals of benefit but inconsistent; calls for larger trials before clinical use. [https://pubmed.ncbi.nlm.nih.gov/38022191/]
  - Methylene blue in the treatment and prevention of ifosfamide-induced encephalopathy: report of 12 cases and a review of the literature, British journal of cancer (2000) — Case series of 12 patients: IV MB resolved or prevented ifosfamide-induced encephalopathy, though some untreated cases also resolved spontaneously. [https://pubmed.ncbi.nlm.nih.gov/10646879/]

---

## Moringa (Moringa oleifera)
URL: https://nutridex.info/s/moringa
Category: Heart & Metabolic, Gut & Immune
Evidence: Mixed — Conflicting results across studies; benefit uncertain.
Nutrient-dense leaf with mixed human data for blood sugar and pressure.

Quick answer: Moringa is used for modest blood-sugar support (mainly prediabetes). NutriDex grades the human evidence as mixed — Conflicting results across studies; benefit uncertain. Based on 7 cited human studies (7 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Moringa oleifera (the 'drumstick tree') is a fast-growing leaf prized as a nutrient-dense food and traditional remedy. Rodent studies show large drops in glucose and cholesterol, but human trials are far weaker. Two small 12-week RCTs in prediabetic adults found 2.4 g/day of leaf powder lowered fasting glucose and HbA1c slightly versus placebo (changes around 5 mg/dL and 0.3% HbA1c), yet an 8 g/day RCT in established type 2 diabetes showed no significant benefit. A 2025 meta-analysis of 9 RCTs (≈650 people) found no significant pooled effect on fasting glucose, total cholesterol or systolic pressure; only diastolic pressure fell modestly, and that result was fragile, with overall certainty graded very low. In short, moringa is a reasonable nutritious food, but it is not a proven treatment, and effect sizes where seen are small.

Benefits / uses: Modest blood-sugar support (mainly prediabetes); Possible small blood-pressure drop; Nutrient and antioxidant intake; Cholesterol support (inconsistent).
Active compounds: Isothiocyanates (moringin); Quercetin & chlorogenic acid; Beta-sitosterol; Vitamins A, C and minerals.
Dose: Most trials use 2–8 g/day of dried leaf powder (often 2.4 g/day capsules) for 8–12 weeks; use leaf only, not root or bark.
Safety: Leaf preparations are generally well tolerated at food-like doses; high intakes can cause GI upset, heartburn or loose stools. Avoid root and bark products — they contain the alkaloid spirochin and have been linked to toxicity, and root/bark are traditionally abortifacient, so avoid in pregnancy. Because moringa may lower blood glucose and blood pressure, it can add to the effect of antidiabetic and antihypertensive drugs (risk of hypoglycaemia or hypotension); it may also affect thyroid function and CYP450-metabolised drugs, so monitor and space dosing if combining.

Cited studies (7):
  - Effects of Moringa oleifera Lam. Supplementation on Cardiometabolic Outcomes: A Meta-Analysis of Randomized Controlled Trials with GRADE Assessment, Nutrients (2025) — Meta-analysis of 9 RCTs (~650 adults): no significant effect on fasting glucose, total cholesterol or systolic BP; small DBP drop only, GRADE very low. [https://doi.org/10.3390/nu17223501]
  - The Effect of <scp> <i>Moringa oleifera</i> </scp> on Body Weight and Blood Pressure: A Systematic Review and Meta‐Analysis of Randomized Controlled Trials, Food Science &amp; Nutrition (2026) — Meta-analysis of 8 RCTs: moringa significantly reduced systolic and diastolic blood pressure but had no effect on body weight or BMI. [https://doi.org/10.1002/fsn3.71899]
  - Moringa oleifera Lam. in Diabetes Mellitus: A Systematic Review and Meta-Analysis, Molecules (Basel, Switzerland) (2021) — Meta-analysis of 44 rodent studies: large glucose reduction (g = -3.92) with lower triglycerides and cholesterol — preclinical, not human, evidence. [https://pubmed.ncbi.nlm.nih.gov/34207664/]
  - Moringa oleifera Leaf Supplementation as a Glycemic Control Strategy in Subjects with Prediabetes, Nutrients (2021) — RCT in 65 prediabetic adults: 2.4 g/day leaf powder for 12 wks lowered fasting glucose (p=0.049) and HbA1c (p=0.026) vs placebo. [https://pubmed.ncbi.nlm.nih.gov/35010932/]
  - Moringa oleifera Leaf Supplementation as a Glycemic Control Strategy in Subjects with Prediabetes, Nutrients (2021) — Companion RCT (prediabetes, 2.4 g/day, 12 wks): no significant change in serum lipid profile, antioxidant capacity or blood pressure vs placebo. [https://doi.org/10.3390/nu14010057]
  - Effect of Moringa oleifera Leaf Capsules on Glycemic Control in Therapy-Naïve Type 2 Diabetes Patients: A Randomized Placebo Controlled Study, Evidence-based complementary and alternative medicine : eCAM (2017) — RCT in therapy-naïve type 2 diabetes: 8 g/day leaf for 4 wks gave no significant difference in fasting glucose or HbA1c vs placebo. [https://pubmed.ncbi.nlm.nih.gov/29317895/]
  - Bioactive Components in Moringa Oleifera Leaves Protect against Chronic Disease, Antioxidants (Basel, Switzerland) (2017) — Review of moringa bioactives: polyphenols and isothiocyanates underlie antioxidant/anti-inflammatory effects, but human efficacy data remain limited. [https://pubmed.ncbi.nlm.nih.gov/29144438/]

---

## MSM (Methylsulfonylmethane)
URL: https://nutridex.info/s/msm
Category: Joint & Skin
Evidence: Mixed — Conflicting results across studies; benefit uncertain.
Sulfur compound taken for joint pain, with small, inconsistent effects.

Quick answer: MSM (Methylsulfonylmethane) is used for ease knee osteoarthritis pain. NutriDex grades the human evidence as mixed — Conflicting results across studies; benefit uncertain. Based on 8 cited human studies (8 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

MSM is an organic sulfur compound (dimethyl sulfone) sold mainly for joint pain. In knee osteoarthritis, two 12-week placebo-controlled RCTs found statistically significant but small improvements in WOMAC pain and physical function at 3–6 g/day, and a 2023 trial at 2 g/day improved a Japanese knee-OA score (8.1 vs 10.9 points). However, a 2009 meta-analysis of three good-quality trials (326 patients) found only a non-significant 6.3 mm reduction in pain on a visual analogue scale, concluding MSM and DMSO are not clinically effective. In exercise studies, MSM blunted post-run muscle and joint soreness but did not lower oxidative-stress or muscle-damage markers. One open-label trial suggested relief of seasonal allergic-rhinitis symptoms, but it had no placebo group. Overall the effects are inconsistent and likely minor; MSM is well tolerated but not a proven treatment.

Benefits / uses: Ease knee osteoarthritis pain; Improve physical function; Reduce post-exercise muscle soreness; Possible allergy symptom relief.
Active compounds: Methylsulfonylmethane (dimethyl sulfone); Bioavailable organic sulfur.
Dose: Most trials use 1.5–6 g/day (commonly 3 g once or twice daily) of oral MSM for 12 weeks.
Safety: MSM is generally well tolerated; the most common side effects are mild gastrointestinal upset, nausea, bloating, headache and insomnia, mostly at higher doses. It is FDA GRAS-listed and human trials up to ~4–6 g/day show few adverse events, but long-term safety data are limited and it should be avoided in pregnancy and breastfeeding due to lack of study. No well-documented drug interactions exist, though it is theoretically prudent to use caution alongside anticoagulants; tell your clinician before combining it with other medications.

Cited studies (8):
  - Meta-analysis of the related nutritional supplements dimethyl sulfoxide and methylsulfonylmethane in the treatment of osteoarthritis of the knee, Evidence-based complementary and alternative medicine : eCAM (2011) — Meta-analysis of 3 RCTs (326 patients): non-significant pain reduction of 6.34 mm on VAS; concluded MSM/DMSO not clinically effective for OA. [https://pubmed.ncbi.nlm.nih.gov/19474240/]
  - Does the hip powder of Rosa canina (rosehip) reduce pain in osteoarthritis patients? – a meta-analysis of randomized controlled trials, Osteoarthritis and Cartilage (2008) — Systematic review: both MSM trials showed significant pain improvement, but positive trends were not definitive for mild-to-moderate knee OA. [https://doi.org/10.1016/j.joca.2008.03.001]
  - Methylsulfonylmethane Improves Knee Quality of Life in Participants with Mild Knee Pain: A Randomized, Double-Blind, Placebo-Controlled Trial, Nutrients (2023) — RCT (n=80, mild knee pain): MSM 2 g/day for 12 weeks lowered JKOM knee score vs placebo (8.1 vs 10.9 points, p=0.046). [https://pubmed.ncbi.nlm.nih.gov/37447322/]
  - Effects of Methylsulfonylmethane (MSM) on exercise-induced oxidative stress, muscle damage, and pain following a half-marathon: a double-blind, randomized, placebo-controlled trial, Journal of the International Society of Sports Nutrition (2017) — RCT (n=22, half-marathon): MSM 3 g/day attenuated post-exercise muscle and joint pain but did not reduce oxidative-stress or muscle-damage markers. [https://pubmed.ncbi.nlm.nih.gov/28736511/]
  - Efficacy of methylsulfonylmethane supplementation on osteoarthritis of the knee: a randomized controlled study, BMC complementary and alternative medicine (2011) — RCT (n=49, knee OA): MSM 1.125 g three times daily for 12 weeks improved pain and function vs placebo, but improvements were small. [https://pubmed.ncbi.nlm.nih.gov/21708034/]
  - Efficacy of methylsulfonylmethane (MSM) in osteoarthritis pain of the knee: a pilot clinical trial, Osteoarthritis and cartilage (2006) — RCT (n=50, knee OA): MSM 3 g twice daily for 12 weeks significantly cut WOMAC pain and physical-function scores vs placebo; no change in stiffness. [https://pubmed.ncbi.nlm.nih.gov/16309928/]
  - A multicentered, open-label trial on the safety and efficacy of methylsulfonylmethane in the treatment of seasonal allergic rhinitis, Journal of alternative and complementary medicine (New York, N.Y.) (2002) — Open-label trial (n=50): 2.6 g/day MSM for 30 days reduced seasonal allergic-rhinitis symptoms, but no placebo control limits interpretation. [https://pubmed.ncbi.nlm.nih.gov/12006124/]
  - Methylsulfonylmethane: Applications and Safety of a Novel Dietary Supplement, Nutrients (2017) — Review: MSM is GRAS and generally well tolerated up to ~4 g/day, with mild GI side effects; benefits for pain and inflammation remain modest. [https://pubmed.ncbi.nlm.nih.gov/28300758/]

---

## Noopept
URL: https://nutridex.info/s/noopept
Category: Nootropic
Evidence: Preliminary — Early or small human trials; promising but not yet conclusive.
Russian synthetic dipeptide nootropic; little blinded human data.

Quick answer: Noopept is used for memory & cognition support. NutriDex grades the human evidence as preliminary — Early or small human trials; promising but not yet conclusive. Based on 6 cited human studies (6 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Noopept (omberacetam, GVS-111) is a synthetic dipeptide developed in Russia as a piracetam analogue; orally it is converted to the endogenous peptide cycloprolylglycine, which modulates AMPA/glutamate signalling and raises nerve growth factor (NGF) and brain-derived neurotrophic factor (BDNF) in animal brain. Human data are limited to a few small trials in patients, not healthy people. An open study in 60 stroke patients (20 mg/day) reported improved MMSE and word-association scores by 2 months, and comparative trials in ~53 patients with vascular or post-traumatic cognitive impairment found effects similar to or earlier than piracetam, with MMSE rising roughly 26 to 29. These studies were unblinded or lacked placebo controls, were conducted by the developers, and have not been replicated in Western populations. The FDA does not recognise noopept as safe or effective; it is sold online as a 'research chemical', not a licensed medicine or dietary supplement.

Benefits / uses: Memory & cognition support; Mild cognitive impairment after stroke; Reduced mental fatigue (asthenia); Anxiolytic / calming effect.
Active compounds: N-phenylacetyl-L-prolylglycine ethyl ester (omberacetam, GVS-111); Cycloprolylglycine (active brain metabolite).
Dose: Studied at 10 mg twice daily (20 mg/day) by mouth for ~1.5–2 months; not an approved drug or dietary supplement.
Safety: Noopept is not FDA-approved as a drug or dietary supplement; quality and purity of products sold online as 'research chemicals' are unverified, and long-term human safety is unknown. Reported effects include irritability, restlessness, headache, insomnia, blood-pressure changes and fatigue; it should be avoided in pregnancy, breastfeeding, and uncontrolled hypertension. Because it influences glutamate signalling and CNS arousal, caution is warranted with stimulants, sedatives, antihypertensives and antiepileptic drugs, though formal human interaction data are lacking.

Cited studies (6):
  - [Noopept in the treatment of mild cognitive impairment in patients with stroke], Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova (2011) — Open trial, 60 stroke patients: 20 mg/day noopept improved MMSE and word-association scores by 2 months vs controls; high safety reported. [https://pubmed.ncbi.nlm.nih.gov/22500312/]
  - [A comparative study of noopept and piracetam in the treatment of mild and moderate cognitive impairment in patients with organic brain diseases of vascular and traumatic origin], Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova (2008) — Comparative trial vs piracetam in ~53 patients with vascular/traumatic cognitive impairment; noopept effects emerged earlier, MMSE rose ~26 to 29. [https://pubmed.ncbi.nlm.nih.gov/18697252/]
  - [Clinical and electroencephalographic characteristic of noopept in patients with mild cognitive impairment of posttraumatic and vascular origin], Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova (2008) — EEG study in mild cognitive impairment: noopept increased alpha/beta-rhythm power and reduced delta, plus anxiolytic effect; clearest in vascular disease. [https://pubmed.ncbi.nlm.nih.gov/19008801/]
  - Noopept stimulates the expression of NGF and BDNF in rat hippocampus, Bulletin of experimental biology and medicine (2008) — Rat hippocampus: noopept raised NGF and BDNF mRNA after single and 28-day dosing, with no tolerance (effect potentiated over time). [https://pubmed.ncbi.nlm.nih.gov/19240853/]
  - Proline-containing dipeptide GVS-111 retains nootropic activity after oral administration, Bulletin of experimental biology and medicine (2001) — Oral GVS-111 (0.5–10 mg/kg) retained antiamnesic activity in rats, improving one-session learning beyond piracetam and its metabolite. [https://pubmed.ncbi.nlm.nih.gov/11782792/]
  - [Anti-inflammatory properties of noopept (dipeptide nootropic agent GVS-111)], Eksperimental'naia i klinicheskaia farmakologiia (2002) — Preclinical anti-inflammatory action: dose-dependent inhibition of inflammation, reducing adjuvant arthritis by 74–94%, likely antioxidant-related. [https://pubmed.ncbi.nlm.nih.gov/12109295/]

---

## Olive Leaf Extract (Olea europaea)
URL: https://nutridex.info/s/olive-leaf
Category: Heart & Metabolic, Gut & Immune
Evidence: Moderate — Several controlled trials; effects real but modest or context-dependent.
Polyphenol-rich leaf extract that modestly lowers blood pressure.

Quick answer: Olive Leaf Extract is used for lower blood pressure. NutriDex grades the human evidence as moderate — Several controlled trials; effects real but modest or context-dependent. Based on 7 cited human studies (7 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Olive leaf extract is a polyphenol-rich preparation from Olea europaea, standardized to oleuropein. The best evidence is for blood pressure: a 2022 meta-analysis of 12 trials (819 people) found systolic pressure fell about 3.9 mmHg overall and roughly 4.8 mmHg in hypertensive subgroups, with a small triglyceride drop. A 2025 multicenter RCT in 621 hypertensive adults reported a 24-hour systolic reduction of ~6.4 mmHg from baseline (1.5 mmHg vs placebo). Metabolic effects are less consistent: a small diabetes RCT and a crossover trial showed lower HbA1c and ~15% better insulin sensitivity, but the meta-analysis found no glucose benefit and a 2025 pilot trial in type-2 diabetes was null for HbA1c. Trials are mostly short (6–12 weeks), small, and use varied formulations, so the effect is likely genuine but modest and best viewed as adjunctive rather than a replacement for medication.

Benefits / uses: Lower blood pressure; Lower triglycerides; Support cholesterol; Antioxidant polyphenols.
Active compounds: Oleuropein; Hydroxytyrosol; Oleacein.
Dose: Typically 500–1000 mg/day of standardized leaf extract (≈100–150 mg oleuropein) for 6–8 weeks.
Safety: Generally well tolerated; reported effects are mild and include digestive upset, headache and, due to oleuropein's vasodilatory action, occasional lightheadedness. Because it can lower blood pressure and may modestly lower blood sugar, it can compound the effects of antihypertensive and antidiabetic drugs (insulin, sulfonylureas), risking hypotension or hypoglycemia—monitor closely if combining. Theoretical antiplatelet activity warrants caution with anticoagulants such as warfarin; data in pregnancy and breastfeeding are lacking, so it is best avoided then.

Cited studies (7):
  - The effects of olive leaf extract on cardiovascular risk factors in the general adult population: a systematic review and meta-analysis of randomized controlled trials, Diabetology & metabolic syndrome (2022) — Meta-analysis (12 RCTs, n=819): systolic BP -3.86 mmHg, triglycerides -9.5 mg/dl; no significant change in glucose markers. [https://pubmed.ncbi.nlm.nih.gov/36271405/]
  - Efficacy of olive leaf extracts in controlling blood pressure in hypertensive patients: a double-blind randomized clinical trial, Journal of hypertension (2025) — Double-blind RCT in 621 hypertensive adults: OLE cut 24h systolic BP ~6.4 mmHg from baseline (1.5 mmHg vs placebo); no serious adverse events. [https://pubmed.ncbi.nlm.nih.gov/40990594/]
  - Efficacy and safety of olive leaf extract (Olea europaea L.) for glycaemic control in adults with type 2 diabetes mellitus (ESOLED): A pilot randomised controlled trial, Complementary therapies in clinical practice (2025) — Pilot RCT in type-2 diabetes: no significant time-group interaction for HbA1c; OLE inconclusive for glycaemic control. [https://pubmed.ncbi.nlm.nih.gov/39818111/]
  - The effect of olive leaf extract on cardiovascular health markers: a randomized placebo-controlled clinical trial, European Journal of Nutrition (2020) — RCT in 77 overweight adults: OLE 500 mg/day for 8 wk produced no significant change in lipids, BP, glucose or insulin vs placebo. [https://doi.org/10.1007/s00394-020-02397-9]
  - Impact of phenolic-rich olive leaf extract on blood pressure, plasma lipids and inflammatory markers: a randomised controlled trial, European Journal of Nutrition (2016) — Phenolic-rich OLE (136 mg oleuropein/day, 6 wk) lowered daytime and 24h systolic and diastolic BP in 60 pre-hypertensive men. [https://doi.org/10.1007/s00394-016-1188-y]
  - Olive (Olea europaea L.) leaf polyphenols improve insulin sensitivity in middle-aged overweight men: a randomized, placebo-controlled, crossover trial, PloS one (2013) — Crossover RCT in 46 overweight men: OLE improved insulin sensitivity ~15% and beta-cell secretion vs placebo over 12 weeks. [https://pubmed.ncbi.nlm.nih.gov/23516412/]
  - Olive leaf extract as a hypoglycemic agent in both human diabetic subjects and in rats, Journal of medicinal food (2012) — RCT in type-2 diabetics: OLE 500 mg/day for 14 wk lowered HbA1c and fasting insulin vs placebo. [https://pubmed.ncbi.nlm.nih.gov/22512698/]

---

## Oregano Oil (Origanum vulgare)
URL: https://nutridex.info/s/oregano-oil
Category: Gut & Immune
Evidence: Preliminary — Early or small human trials; promising but not yet conclusive.
Carvacrol-rich oil for gut bugs and colds: lab-strong, clinic-thin.

Quick answer: Oregano Oil is used for antimicrobial / antifungal. NutriDex grades the human evidence as preliminary — Early or small human trials; promising but not yet conclusive. Based on 8 cited human studies (8 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Oregano oil is the steam-distilled essential oil of Origanum vulgare, concentrated in the phenols carvacrol and thymol, which puncture microbial membranes in the lab. Human evidence is thin. An uncontrolled pilot cleared Blastocystis in 8 of 11 carriers after 6 weeks of 600 mg/day, and a retrospective chart review found an oregano-containing herbal protocol roughly matched the antibiotic rifaximin for SIBO breath-test response (46% vs 34%) — but neither was a placebo-controlled trial, and the SIBO regimen mixed several herbs. A nasal spray blend including oregano eased cold symptoms within 20 minutes but lost its edge by day 3. A small soldier trial (n=24) showed lower oxidative-stress and muscle-damage markers after exercise. So mechanism is strong and early signals exist, but no rigorous RCT shows oregano oil alone reliably treats infections or gut symptoms.

Benefits / uses: Antimicrobial / antifungal; Gut overgrowth (SIBO) support; Intestinal parasite clearance; Cold & sinus symptom relief; Antioxidant.
Active compounds: Carvacrol; Thymol; p-Cymene; γ-Terpinene.
Dose: Enteric-coated/emulsified capsules supplying ~100–200 mg carvacrol/day (often 100 mg oil 3×/day) for 2–4 weeks; neat oil is irritating and should be diluted.
Safety: Generally well tolerated at supplement doses; high doses or undiluted oil cause heartburn, nausea, diarrhea and oral/skin irritation, and topical use can trigger allergic reactions in people sensitive to mint-family (Lamiaceae) plants. Avoid in pregnancy — it is traditionally abortifacient — and use caution while breastfeeding. Because carvacrol may lower blood glucose and has mild antiplatelet activity in lab models, use caution alongside antidiabetic drugs and anticoagulants/antiplatelets (e.g. warfarin, aspirin), and stop before surgery; theoretical interactions with iron absorption and CYP-metabolized drugs are not well characterized in humans.

Cited studies (8):
  - Oregano (Origanum vulgare) Consumption Reduces Oxidative Stress and Markers of Muscle Damage after Combat Readiness Tests in Soldiers, Nutrients (2022) — RCT (n=24 soldiers): 500 mg oregano post-exercise lowered MDA and creatine kinase and raised antioxidant capacity vs placebo at 60–120 min. [https://pubmed.ncbi.nlm.nih.gov/36615794/]
  - Carvacrol as a food additive: Toxicological aspects and the role of nanotechnology in enhancing its antimicrobial and antioxidant properties, Food research international (Ottawa, Ont.) (2024) — Toxicology review: carvacrol is generally low-toxicity at dietary doses but irritant/cytotoxic at high concentrations; nanoencapsulation studied to improve safety. [https://pubmed.ncbi.nlm.nih.gov/39593338/]
  - Treatment of upper respiratory tract infections in primary care: a randomized study using aromatic herbs, Evidence-based complementary and alternative medicine : eCAM (2011) — RCT (n=60): 5-herb aromatic spray incl. oregano improved URTI symptoms within 20 min vs placebo, but no difference by day 3. [https://pubmed.ncbi.nlm.nih.gov/21052500/]
  - Oregano (2023) — NIH monograph: oregano oil unlikely to cause liver injury (score E); high doses may cause GI upset; abortifacient — avoid in pregnancy. [https://www.ncbi.nlm.nih.gov/books/NBK591556/]
  - Inhibition of enteric parasites by emulsified oil of oregano in vivo, Phytotherapy research : PTR (2000) — Uncontrolled pilot: 6 wk of 600 mg/day emulsified oregano oil cleared Blastocystis hominis in 8 of 11 carriers; symptoms improved in 7 of 11 (n=14). [https://pubmed.ncbi.nlm.nih.gov/10815019/]
  - Carvacrol-A Natural Phenolic Compound with Antimicrobial Properties, Antibiotics (Basel, Switzerland) (2023) — Review: carvacrol, oregano's main phenol, disrupts microbial membranes with broad antibacterial and antifungal activity plus anti-inflammatory effects. [https://pubmed.ncbi.nlm.nih.gov/37237727/]
  - Anti-inflammatory, tissue remodeling, immunomodulatory, and anticancer activities of oregano (Origanum vulgare) essential oil in a human skin disease model, Biochimie open (2017) — Human skin-cell model: high-carvacrol oregano oil suppressed inflammatory and tissue-remodeling biomarkers (MCP-1, VCAM-1, ICAM-1). [https://pubmed.ncbi.nlm.nih.gov/29450144/]
  - Herbal therapy is equivalent to rifaximin for the treatment of small intestinal bacterial overgrowth, Global advances in health and medicine (2014) — Retrospective review: oregano-containing herbal protocol matched rifaximin for SIBO breath-test clearance (46% vs 34%, not significant). [https://pubmed.ncbi.nlm.nih.gov/24891990/]

---

## Pantethine
URL: https://nutridex.info/s/pantethine
Category: Heart & Metabolic
Evidence: Moderate — Several controlled trials; effects real but modest or context-dependent.
Vitamin B5 derivative that modestly lowers cholesterol and triglycerides.

Quick answer: Pantethine is used for lower ldl cholesterol. NutriDex grades the human evidence as moderate — Several controlled trials; effects real but modest or context-dependent. Based on 8 cited human studies (8 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Pantethine is a stable disulphide form of pantetheine, an active derivative of vitamin B5 (pantothenic acid), marketed to lower blood lipids. In a 16-week, triple-blinded, diet-controlled RCT of low-to-moderate-risk adults, pantethine (600–900 mg/day) reduced LDL cholesterol about 11%, total cholesterol about 6% and non-HDL cholesterol about 8% versus placebo. Older Italian double-blind trials in hyperlipoproteinemia reported total/LDL cholesterol drops near 13% and triglyceride reductions around 30%, and a 2015 multicentre trial found triglycerides fell ~17%. A pooled review of 28 studies (n=646) estimated 12–15% cholesterol reductions over 4 months but mixed uncontrolled trials and was judged methodologically weak. Effects are modest, slower than statins, and no trial has measured heart attacks or deaths. It is best viewed as a gentle diet adjunct for borderline lipids, not a statin substitute.

Benefits / uses: Lower LDL cholesterol; Lower total cholesterol; Lower triglycerides; Mild HDL increase; Adjunct to diet in mild dyslipidemia.
Active compounds: Pantethine (disulphide of pantetheine); Cysteamine (active metabolite).
Dose: 600–900 mg/day, usually split into 2–3 doses with meals; effects build over 8–16 weeks.
Safety: Generally well tolerated: in pooled data only ~3.6% reported side effects (mainly heartburn, epigastric discomfort, nausea, diarrhoea or itching) and dropout was under 2%. Because it lowers lipids and may affect platelet function, theoretical additive effects exist with statins, fibrates and antiplatelet/anticoagulant drugs (e.g. aspirin, warfarin) — monitor if combined. Long-term and pregnancy safety are not well studied, and it should not replace prescribed lipid therapy; tell your doctor before adding it.

Cited studies (8):
  - Treatment of hyperlipoproteinemia with pantethine: A review and analysis of efficacy and tolerability, Nutrition Research (2005) — Pooled review of 28 studies (n=646): mean total cholesterol −8.7% to −15.1% and triglycerides −14% to −33% over 1–4 months. [https://doi.org/10.1016/j.nutres.2004.12.009]
  - Efficacy and tolerability of coenzyme A vs pantethine for the treatment of patients with hyperlipidemia: A randomized, double-blind, multicenter study, Journal of clinical lipidology (2015) — Randomized double-blind multicentre trial (n=216): pantethine 600 U/day lowered triglycerides 16–17% vs baseline (less than coenzyme A arm). [https://pubmed.ncbi.nlm.nih.gov/26350816/]
  - Pantethine, a derivative of vitamin B5, favorably alters total, LDL and non-HDL cholesterol in low to moderate cardiovascular risk subjects eligible for statin therapy: a triple-blinded placebo and diet-controlled investigation, Vascular health and risk management (2014) — 16-wk triple-blind RCT (n=32): pantethine cut LDL-C ~11% (P=0.006), total cholesterol ~6% and non-HDL ~8% vs placebo. [https://pubmed.ncbi.nlm.nih.gov/24600231/]
  - Pantethine, a derivative of vitamin B(5) used as a nutritional supplement, favorably alters low-density lipoprotein cholesterol metabolism in low- to moderate-cardiovascular risk North American subjects: a triple-blinded placebo and diet-controlled investigation, Nutrition research (New York, N.Y.) (2011) — Triple-blind diet-controlled RCT (n=120): LDL-C fell ~11% from baseline on pantethine 600–900 mg/day; +3% on placebo at week 16. [https://pubmed.ncbi.nlm.nih.gov/21925346/]
  - Controlled evaluation of pantethine, a natural hypolipidemic compound, in patients with different forms of hyperlipoproteinemia, Atherosclerosis (1984) — Double-blind trial in hyperlipoproteinemia (n=29): type IIB total/LDL cholesterol −13.5%, triglycerides ~−30%, HDL +~10%. [https://pubmed.ncbi.nlm.nih.gov/6365107/]
  - [Hyperlipidemia, diabetes and atherosclerosis: efficacy of treatment with pantethine], Acta bio-medica de L'Ateneo parmense : organo della Societa di medicina e scienze naturali di Parma (1984) — Treatment of 37 hyperlipidemic patients (21 diabetic): progressive falls in cholesterol, triglycerides, LDL and apoB; HDL and apoA rose. [https://pubmed.ncbi.nlm.nih.gov/6232801/]
  - Lowering effect of pantethine on plasma beta-thromboglobulin and lipids in diabetes mellitus, Artery (1987) — Pantethine lowered plasma beta-thromboglobulin and lipids in diabetes mellitus, suggesting effects on platelet activity alongside lipids. [https://pubmed.ncbi.nlm.nih.gov/2963604/]
  - [Pantethine, diabetes mellitus and atherosclerosis. Clinical study of 1045 patients], La Clinica terapeutica (1989) — Postmarketing surveillance of 1045 hyperlipidemic patients (incl. 298 diabetics): significant lipid improvements with good tolerability. [https://pubmed.ncbi.nlm.nih.gov/2524328/]

---

## Peppermint Oil (Mentha x piperita)
URL: https://nutridex.info/s/peppermint-oil
Category: Gut & Immune
Evidence: Moderate — Several controlled trials; effects real but modest or context-dependent.
Enteric-coated capsules ease IBS cramping and abdominal pain.

Quick answer: Peppermint Oil is used for relieve ibs abdominal pain. NutriDex grades the human evidence as moderate — Several controlled trials; effects real but modest or context-dependent. Based on 8 cited human studies (8 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Peppermint oil is the volatile oil of Mentha x piperita; its menthol relaxes intestinal smooth muscle via calcium-channel blockade, acting as a gut antispasmodic. In irritable bowel syndrome (IBS), a 2022 meta-analysis of 10 RCTs (1,030 patients) found enteric-coated peppermint oil superior to placebo for global symptoms (number-needed-to-treat ~4) and abdominal pain (NNT ~7), though it also caused more, mostly mild, side effects. The largest well-designed trial (Weerts 2020, n=190) did NOT meet its strict FDA/EMA primary endpoints, improving only secondary pain measures, and reviewers grade the evidence very low quality. A proprietary peppermint-plus-caraway oil combination (Menthacarin) helps functional dyspepsia in several trials. Topical peppermint/menthol solutions reduce tension-headache intensity in small studies. Bottom line: a reasonable, low-cost short-term option for IBS cramping, but effects are modest and durability is unproven.

Benefits / uses: Relieve IBS abdominal pain; Improve global IBS symptoms; Ease gut cramping (antispasmodic); Functional dyspepsia (with caraway oil).
Active compounds: Menthol; Menthone; Menthyl acetate; 1,8-Cineole.
Dose: Enteric-coated capsules ~180–225 mg (0.2–0.4 mL oil) two to three times daily before meals, for 2–12 weeks.
Safety: Generally well tolerated; the most common side effect is heartburn/reflux, plus a minty taste, belching, and occasionally perianal burning — enteric coating reduces reflux. It can worsen GERD and hiatal hernia and may be unsafe with severe GI inflammation or biliary obstruction. Peppermint oil inhibits CYP3A4 and may raise levels of drugs like felodipine, cyclosporine, and some statins; it also reduces gastric acid and could theoretically affect absorption. Avoid concentrated oral oil in young children and infants (menthol risk), and use cautiously in pregnancy.

Cited studies (8):
  - Menthacarin, a Proprietary Peppermint Oil and Caraway Oil Combination, Improves Multiple Complaints in Patients with Functional Gastrointestinal Disorders: A Systematic Review and Meta-Analysis, Digestive diseases (Basel, Switzerland) (2023) — Meta-analysis of Menthacarin (peppermint+caraway oil), 5 RCTs (580 pts): significant improvement in functional dyspepsia symptoms vs placebo. [https://pubmed.ncbi.nlm.nih.gov/36502789/]
  - Systematic review and meta-analysis: efficacy of peppermint oil in irritable bowel syndrome, Alimentary pharmacology & therapeutics (2022) — Meta-analysis of 10 RCTs (1,030 pts): peppermint oil beat placebo for global IBS symptoms (NNT 4) and abdominal pain (NNT 7); more adverse events. [https://pubmed.ncbi.nlm.nih.gov/35942669/]
  - The impact of peppermint oil on the irritable bowel syndrome: a meta-analysis of the pooled clinical data, BMC complementary and alternative medicine (2019) — Meta-analysis (12 RCTs, 835 pts): RR 2.39 for global symptom improvement and 1.78 for abdominal pain vs placebo. [https://pubmed.ncbi.nlm.nih.gov/30654773/]
  - Peppermint oil for the treatment of irritable bowel syndrome: a systematic review and meta-analysis, Journal of clinical gastroenterology (2014) — Earlier systematic review/meta-analysis (9 trials, 726 pts): peppermint oil superior to placebo for global IBS symptoms (RR 2.23) and pain. [https://pubmed.ncbi.nlm.nih.gov/24100754/]
  - Effect of fibre, antispasmodics, and peppermint oil in the treatment of irritable bowel syndrome: systematic review and meta-analysis, BMJ (Clinical research ed.) (2008) — Meta-analysis (4 peppermint trials, 392 pts): RR of persistent symptoms 0.43 vs placebo; fibre, antispasmodics and peppermint oil all beat placebo. [https://pubmed.ncbi.nlm.nih.gov/19008265/]
  - Efficacy and Safety of Peppermint Oil in a Randomized, Double-Blind Trial of Patients With Irritable Bowel Syndrome, Gastroenterology (2020) — RCT (n=190, Rome IV IBS): neither small-intestinal nor ileocolonic-release oil met FDA/EMA primary endpoints; improved only secondary pain/discomfort. [https://pubmed.ncbi.nlm.nih.gov/31470006/]
  - A Novel Delivery System of Peppermint Oil Is an Effective Therapy for Irritable Bowel Syndrome Symptoms, Digestive diseases and sciences (2016) — RCT (n=72): sustained-release peppermint oil (Tu7) cut total IBS symptom score 40% vs 24.3% placebo at 4 weeks (p=0.0246). [https://pubmed.ncbi.nlm.nih.gov/26319955/]
  - [Effectiveness of Oleum menthae piperitae and paracetamol in therapy of headache of the tension type], Der Nervenarzt (1996) — Crossover RCT (41 pts, 164 attacks): topical 10% peppermint oil in ethanol significantly reduced tension-headache intensity from 15 min vs placebo. [https://pubmed.ncbi.nlm.nih.gov/8805113/]

---

## Phenylpiracetam
URL: https://nutridex.info/s/phenylpiracetam
Category: Nootropic, Performance
Evidence: Preliminary — Early or small human trials; promising but not yet conclusive.
Stimulant racetam, sold in Russia and banned in sport.

Quick answer: Phenylpiracetam is used for reduce fatigue (asthenia). NutriDex grades the human evidence as preliminary — Early or small human trials; promising but not yet conclusive. Based on 7 cited human studies (7 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Phenylpiracetam (fonturacetam, carphedon) is a phenyl-substituted derivative of piracetam developed in the Soviet space program and sold by prescription in Russia and parts of Eastern Europe for cerebrovascular and asthenic conditions. Unlike other racetams it has clear stimulant activity, acting as a dopamine and norepinephrine reuptake inhibitor. Controlled trials report better neurological recovery and daily function after ischemic stroke (one 400-patient study used 400 mg/day for a year) and more than a two-fold drop in fatigue scores in chronic cerebral ischemia. However, these studies are predominantly Russian-language, often open-label or weakly blinded, single-region, and lack independent replication, so effect sizes are unreliable. There are no rigorous Western RCTs and no approval by the FDA, EMA, or MHRA. WADA bans it as a stimulant.

Benefits / uses: Reduce fatigue (asthenia); Support stroke rehab; Boost alertness & stamina; Improve attention.
Active compounds: (R)-phenylpiracetam; (S)-phenylpiracetam.
Dose: Where prescribed (Russia/Eastern Europe): 100-200 mg/day, sometimes up to 400 mg/day in stroke courses; taken AM to avoid insomnia.
Safety: Common effects are insomnia, psychomotor agitation, flushing, feeling hot and raised blood pressure; appetite suppression occurs with extended use. Because it inhibits dopamine and norepinephrine reuptake it can add to the effects of stimulants, decongestants and MAOIs (hypertensive/cardiac risk) and may interfere with sleep aids and sedatives; caution with antihypertensives. It is a prescription-only drug in Russia/Eastern Europe, unapproved by the FDA/EMA/MHRA, and is banned in-competition by WADA, so athletes will test positive. Tolerance to its stimulant effect develops quickly.

Cited studies (7):
  - [Efficacy of phenotropil in the rehabilitation of stroke patients], Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova (2010) — Controlled trial, n=400 ischemic-stroke patients: phenotropil 400 mg/day for 1 year improved neurologic and daily-living recovery vs control (p<0.0001). [https://pubmed.ncbi.nlm.nih.gov/21626817/]
  - [The use of phenotropil in vertebrobasilar insufficiency], Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova (2013) — Controlled clinical trial of phenotropil in vertebrobasilar insufficiency (Russian; no abstract, small single-center). [https://pubmed.ncbi.nlm.nih.gov/24430043/]
  - [The phenotropil treatment of the consequences of brain organic lesions], Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova (2005) — Comparative study, n=99 brain organic lesions: phenotropil 200 mg/day for 1 month improved motor coordination, memory, attention and EEG rhythms. [https://pubmed.ncbi.nlm.nih.gov/16447562/]
  - [Pharmacological effects of fonturacetam (Actitropil) and prospects for its clinical use], Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova (2024) — Review of fonturacetam (Actitropil): describes antiasthenic, anxiolytic and anticonvulsant effects; evidence base remains largely Russian. [https://pubmed.ncbi.nlm.nih.gov/39269293/]
  - Psychoimmunomodulatory effect of phenotropil in animals with immune stress, Bulletin of experimental biology and medicine (2011) — Animal study: phenotropil showed psychoimmunomodulatory effects; underlines that much of the mechanistic data is preclinical, not human. [https://pubmed.ncbi.nlm.nih.gov/22442801/]
  - Pharmacology of stimulants prohibited by the World Anti-Doping Agency (WADA), British journal of pharmacology (2008) — Pharmacology review of WADA-prohibited stimulants; classifies carphedon (phenylpiracetam) among banned in-competition stimulants. [https://pmc.ncbi.nlm.nih.gov/articles/PMC2439527/]
  - [Treatment of asthenic syndrome in patients with chronic brain ischemia: results of the non-interventional observational program TRIUMPH], Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova (2014) — Observational program, n=1170 chronic cerebral ischemia: phenotropil 100 mg/day cut asthenia severity >2-fold by 3 months. [https://pubmed.ncbi.nlm.nih.gov/25726789/]

---

## Plant Sterols (Phytosterols) (Beta-sitosterol / stanols)
URL: https://nutridex.info/s/phytosterols
Category: Heart & Metabolic
Evidence: Strong — Multiple high-quality RCTs / meta-analyses with consistent effects.
Plant fats that block cholesterol absorption to lower LDL.

Quick answer: Plant Sterols (Phytosterols) is used for lower ldl cholesterol. NutriDex grades the human evidence as strong — Multiple high-quality RCTs / meta-analyses with consistent effects. Based on 7 cited human studies (7 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Phytosterols are cholesterol-like compounds from plants that compete with dietary cholesterol for absorption in the gut, so less reaches the blood. They are added to spreads, yoghurts, milks and supplement capsules. The evidence for LDL lowering is unusually robust: a meta-analysis of 124 randomized trials found intakes of 0.6-3.3 g/day cut LDL cholesterol by roughly 6-12%, with the effect plateauing around 3 g/day. They also add a further ~8-9% LDL reduction on top of statins. The clinical caveat is important: every trial measures cholesterol, not outcomes, and no study has shown phytosterols prevent heart attacks, strokes or death. They also modestly lower blood carotenoids (such as beta-carotene). Guidelines (ESC/EAS, NLA) endorse them as an adjunct to diet, not a drug replacement, for people with elevated LDL.

Benefits / uses: Lower LDL cholesterol; Add-on to statins; Lower total cholesterol; Heart-health diet support.
Active compounds: Beta-sitosterol; Campesterol; Sitostanol / campestanol (stanols).
Dose: 2 g/day of plant sterols or stanols (esterified), taken with meals in a fat-containing carrier such as spread, yoghurt or milk; effect plateaus near 3 g/day.
Safety: Generally well tolerated; side effects are mild and mainly gastrointestinal. Phytosterols modestly reduce blood levels of beta-carotene and other fat-soluble carotenoids, so include plenty of coloured fruit and vegetables. They are NOT recommended in pregnancy or for young children, and are contraindicated in sitosterolemia (a rare genetic disorder of phytosterol over-absorption). They can be combined with statins for added LDL lowering; like other cholesterol-absorption modifiers they may slightly affect absorption of fat-soluble vitamins and drugs such as ezetimibe, so separate dosing if concerned.

Cited studies (7):
  - Effects of phytosterol supplementation on lipid profiles and apolipoproteins: A meta-analysis of randomized controlled trials, Medicine (2024) — Meta-analysis: phytosterol supplementation reduced total cholesterol, LDL and apolipoprotein B and slightly raised HDL. [https://pubmed.ncbi.nlm.nih.gov/39432657/]
  - Effects of plant stanol or sterol-enriched diets on lipid profiles in patients treated with statins: systematic review and meta-analysis, Scientific reports (2016) — 15 RCTs in statin-treated patients: adding 2-2.5 g/day sterols/stanols cut LDL a further 0.30 mmol/L vs statin alone. [https://pubmed.ncbi.nlm.nih.gov/27539156/]
  - Plasma fat-soluble vitamin and carotenoid concentrations after plant sterol and plant stanol consumption: a meta-analysis of randomized controlled trials, European journal of nutrition (2017) — Meta-analysis of 41 RCTs: sterols/stanols lowered plasma beta-carotene ~16% and alpha-tocopherol ~7% (TC-standardized tocopherol unchanged). [https://pubmed.ncbi.nlm.nih.gov/27591863/]
  - LDL-cholesterol-lowering effect of plant sterols and stanols across different dose ranges: a meta-analysis of randomised controlled studies, The British journal of nutrition (2014) — Meta-analysis of 124 RCTs: 0.6-3.3 g/day plant sterols/stanols cut LDL by 6-12%, plateauing near 3 g/day. [https://pubmed.ncbi.nlm.nih.gov/24780090/]
  - Plant sterols and cardiovascular disease: a systematic review and meta-analysis, European Heart Journal (2012) — Systematic review (17 studies, 11,182 subjects): no association between serum plant sterol levels and cardiovascular disease risk. [https://academic.oup.com/eurheartj/article/33/4/444/478504]
  - Plant sterols/stanols as cholesterol lowering agents: A meta-analysis of randomized controlled trials, Food & nutrition research (2008) — 59 RCTs (>4,500 subjects): sterol-containing foods lowered LDL by 0.31 mmol/L; larger effect at higher baseline LDL. [https://pubmed.ncbi.nlm.nih.gov/19109655/]
  - Continuous dose-response relationship of the LDL-cholesterol-lowering effect of phytosterol intake, The Journal of nutrition (2009) — Continuous dose-response meta-analysis (84 trials): average 2.15 g/day intake lowered LDL by 0.34 mmol/L (~8.5%). [https://pubmed.ncbi.nlm.nih.gov/19091798/]

---

## Piracetam
URL: https://nutridex.info/s/piracetam
Category: Nootropic
Evidence: Mixed — Conflicting results across studies; benefit uncertain.
The original "nootropic" — proven for myoclonus, unproven for memory.

Quick answer: Piracetam is used for reduces cortical myoclonus. NutriDex grades the human evidence as mixed — Conflicting results across studies; benefit uncertain. Based on 8 cited human studies (8 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Piracetam is the prototype 'nootropic,' a pyrrolidone derivative prescribed in parts of Europe and Asia but not approved by the US FDA. Despite decades of use for memory and dementia, the evidence there is weak: the 2001 Cochrane review found benefit only on a vague 'global impression of change' and none on specific cognitive measures, and a 2024 meta-analysis of 18 trials (886 patients) could not confirm any memory effect (SMD 0.75, 95% CI -0.19 to 1.69; very high heterogeneity). The large PASS trial (927 patients) showed no benefit in acute ischemic stroke. The clearest evidence is for high-dose piracetam (up to 24 g/day) as add-on therapy in cortical myoclonus and progressive myoclonus epilepsy, where randomized crossover trials show real, dose-dependent symptom relief. As a 'smart drug' for healthy adults, robust supporting data are essentially absent.

Benefits / uses: Reduces cortical myoclonus; Adjunct in progressive myoclonus epilepsy; Marketed for memory & cognition; Studied for dementia.
Active compounds: Piracetam (2-oxo-1-pyrrolidine acetamide).
Dose: Cognitive trials used 2.4–8 g/day orally; myoclonus trials used up to 24 g/day. Not approved or sold as a dietary supplement in the US.
Safety: Generally well tolerated; common effects are nervousness, agitation, insomnia, weight gain and GI upset. Because it lowers platelet aggregation it is contraindicated in cerebral hemorrhage and should be used cautiously with anticoagulants and antiplatelet drugs (aspirin, warfarin) and before surgery. It is renally cleared, so it is contraindicated in severe renal impairment and needs dose reduction with reduced kidney function; it is not approved as a US dietary supplement, so over-the-counter products are unregulated.

Cited studies (8):
  - Cognitive effects of piracetam in adults with memory impairment: A systematic review and meta-analysis, Clinical neurology and neurosurgery (2024) — Meta-analysis of 18 trials (886 patients): no clear memory benefit (SMD 0.75, 95% CI -0.19 to 1.69, p=0.12, I-squared 96%); impact undeterminable. [https://pubmed.ncbi.nlm.nih.gov/38878641/]
  - Piracetam for acute ischaemic stroke, The Cochrane database of systematic reviews (2012) — Pooled stroke data showed early deaths slightly higher with piracetam (non-significant); no reliable evidence of benefit in acute ischaemic stroke. [https://pubmed.ncbi.nlm.nih.gov/22972044/]
  - Piracetam for dementia or cognitive impairment, The Cochrane database of systematic reviews (2001) — Across trials, piracetam affected only 'global impression of change'; no benefit on any specific cognitive measure. Evidence inadequate for clinical use. [https://pubmed.ncbi.nlm.nih.gov/11405971/]
  - Clinical efficacy of piracetam in cognitive impairment: a meta-analysis, Dementia and geriatric cognitive disorders (2002) — Older meta-analysis of 19 placebo trials in dementia/cognitive impairment found a favorable global-impression odds ratio; 3 authors were manufacturer consultants. [https://pubmed.ncbi.nlm.nih.gov/12006732/]
  - Treatment of acute ischemic stroke with piracetam. Members of the Piracetam in Acute Stroke Study (PASS) Group, Stroke (1997) — RCT of 927 acute ischemic stroke patients: 12 g/day piracetam vs placebo showed no difference in neurological recovery at 4 weeks (Orgogozo 57.7 vs 57.6). [https://pubmed.ncbi.nlm.nih.gov/9412612/]
  - Piracetam relieves symptoms in progressive myoclonus epilepsy: a multicentre, randomised, double blind, crossover study comparing the efficacy and safety of three dosages of oral piracetam with placebo, Journal of neurology, neurosurgery, and psychiatry (1998) — Randomized crossover trial in 20 Unverricht-Lundborg patients: 24 g/day piracetam gave significant, dose-linear myoclonus improvement vs placebo (p=0.005). [https://pmc.ncbi.nlm.nih.gov/articles/PMC2169975/]
  - Effectiveness of piracetam in cortical myoclonus, Movement disorders : official journal of the Movement Disorder Society (1993) — Double-blind add-on trial: piracetam significantly reduced cortical myoclonus and disability scores in patients already on other antimyoclonic drugs. [https://pubmed.ncbi.nlm.nih.gov/8419809/]
  - Piracetam: a review of pharmacological properties and clinical uses, CNS drug reviews (2005) — Pharmacology review notes piracetam restores membrane fluidity and neuronal function, but stresses clinical cognitive benefit remains unconfirmed. [https://pubmed.ncbi.nlm.nih.gov/16007238/]

---

## Bee Propolis
URL: https://nutridex.info/s/propolis
Category: Gut & Immune
Evidence: Moderate — Several controlled trials; effects real but modest or context-dependent.
Bee resin used for mouth ulcers, sore throats and blood-sugar support.

Quick answer: Bee Propolis is used for soothe mouth ulcers (canker sores). NutriDex grades the human evidence as moderate — Several controlled trials; effects real but modest or context-dependent. Based on 7 cited human studies (7 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Propolis is a resinous mixture honeybees make from plant buds and use to seal their hive; it is rich in flavonoids and phenolic acids with antioxidant, antimicrobial and anti-inflammatory activity. The best human evidence is in type 2 diabetes: pooled RCTs report lower fasting glucose (roughly 13–15 mg/dL) and HbA1c (about 0.4–0.6%), plus modest drops in LDL, CRP and systolic blood pressure. Propolis mouthwash cuts the odds of severe oral mucositis during cancer therapy by about two-thirds, and topical or systemic propolis appears to speed healing and ease pain of recurrent mouth ulcers, though that evidence is rated very low certainty. A standardized oral spray shortened uncomplicated upper-respiratory symptoms in one trial. Effects are real but generally small, and propolis composition varies enormously by geographic source, so results may not transfer between products.

Benefits / uses: Soothe mouth ulcers (canker sores); Reduce chemo/radiation mouth sores; Lower fasting blood sugar & HbA1c; Ease sore throat / cold symptoms.
Active compounds: Flavonoids (galangin, pinocembrin, chrysin); Caffeic acid phenethyl ester (CAPE); Phenolic acids.
Dose: Oral: 300–500 mg/day standardized extract; topical/mouthwash: alcoholic or aqueous propolis solution applied to the affected area, composition varies widely by source.
Safety: Propolis is generally well tolerated short-term, but it is a notable allergen: contact dermatitis, mouth/lip irritation, swelling and (rarely) anaphylaxis occur, especially in people allergic to bees, pollen, ragweed or chrysanthemum — about 1–7% of patch-tested patients react. Its flavonoids may slow clotting, so use caution with anticoagulants/antiplatelets (warfarin, apixaban, clopidogrel, aspirin) and stop at least two weeks before surgery. It may add to the glucose-lowering effect of antidiabetic drugs — monitor for hypoglycemia. Avoid in pregnancy and limit in breastfeeding due to insufficient safety data.

Cited studies (7):
  - Propolis supplementation improves cardiometabolic health in patients with type 2 diabetes mellitus: findings from a GRADE-assessed systematic review and meta-analysis of RCTs, Journal of diabetes and metabolic disorders (2025) — Meta-analysis of 13 RCTs: propolis cut fasting glucose ~15.3 mg/dL, 2-h glucose ~35 mg/dL, HbA1c 0.58%, LDL 11.5 mg/dL in type 2 diabetes. [https://pubmed.ncbi.nlm.nih.gov/40662144/]
  - Propolis effects on blood sugar and lipid metabolism, inflammatory indicators, and oxidative stress in people with type 2 diabetes: a systematic review and meta-analysis, Frontiers in nutrition (2025) — 12 RCTs (n=731): propolis lowered fasting glucose, HbA1c 0.44%, HOMA-IR and CRP, and improved LDL/HDL in type 2 diabetes. [https://pubmed.ncbi.nlm.nih.gov/41141253/]
  - Efficacy and Safety of Propolis for Treating Recurrent Aphthous Stomatitis (RAS): A Systematic Review and Meta-Analysis, Dentistry journal (2024) — 10 RCTs (n=825): topical/systemic propolis may shorten healing, reduce pain and relapse of recurrent aphthous ulcers; certainty very low. [https://pubmed.ncbi.nlm.nih.gov/38248221/]
  - The effect of propolis supplementation on blood pressure: a systematic review and meta-analysis of controlled trials, Minerva cardiology and angiology (2025) — Meta-analysis: propolis supplementation lowered systolic blood pressure by ~5.6 mmHg; no significant change in diastolic pressure. [https://pubmed.ncbi.nlm.nih.gov/39846965/]
  - Effects of propolis supplementation on glycemic status, lipid profiles, inflammation and oxidative stress, liver enzymes, and body weight: a systematic review and meta-analysis of randomized controlled clinical trials, Journal of diabetes and metabolic disorders (2021) — Meta-analysis of RCTs: propolis lowered fasting glucose ~17 mg/dL, HbA1c 0.42% and insulin, plus CRP and liver enzymes, with no change in lipids. [https://pubmed.ncbi.nlm.nih.gov/34178866/]
  - Meta-analysis of randomized controlled trials of the efficacy of propolis mouthwash in cancer therapy-induced oral mucositis, Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer (2018) — Meta-analysis of 5 RCTs (n=209): propolis mouthwash cut odds of severe oral mucositis during cancer therapy (OR 0.35, 95% CI 0.18–0.70). [https://pubmed.ncbi.nlm.nih.gov/30022350/]
  - A standardized polyphenol mixture extracted from poplar-type propolis for remission of symptoms of uncomplicated upper respiratory tract infection (URTI): A monocentric, randomized, double-blind, placebo-controlled clinical trial, Phytomedicine (2021) — RCT (n=122): standardized poplar-propolis oral spray gave faster remission of uncomplicated URTI symptoms by day 3 vs placebo. [https://doi.org/10.1016/j.phymed.2020.153368]

---

## Sea Buckthorn Berry (Hippophae rhamnoides)
URL: https://nutridex.info/s/sea-buckthorn-berry
Category: Longevity, Gut & Immune
Evidence: Mixed — Conflicting results across studies; benefit uncertain.
Antioxidant-rich berry tried for cholesterol, dry eye and mucosal health.

Quick answer: Sea Buckthorn Berry is used for may improve blood lipids in dyslipidemia. NutriDex grades the human evidence as mixed — Conflicting results across studies; benefit uncertain. Based on 8 cited human studies (8 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Sea buckthorn is a bright-orange berry rich in vitamin C, carotenoids, tocopherols and an unusual omega-7 (palmitoleic) fatty acid. Meta-analyses of randomized trials give a divided picture: two older pooled analyses (11 and 15 RCTs) reported lower triglycerides, total and LDL cholesterol with higher HDL, but the benefit showed up only in people with existing dyslipidemia, and a more recent PRISMA review of 12 RCTs (n=901) found no significant change in any lipid, blood pressure or BMI. Effects on blood sugar are at best slight. The most consistent signals are from oral sea buckthorn oil (2 g/day) modestly blunting tear-film osmolarity in dry eye, and 3 g/day improving vaginal epithelial integrity in postmenopausal women, though these come from a single Finnish research group. Most trials are small, short (4–12 weeks) and heterogeneous in preparation.

Benefits / uses: May improve blood lipids in dyslipidemia; Eases dry-eye symptoms; Supports mucosal moisture; Antioxidant / vitamin-C source.
Active compounds: Omega-7 (palmitoleic acid) & omega-3/6 fatty acids; Carotenoids & vitamin E (tocopherols); Vitamin C; Flavonoids (quercetin, isorhamnetin).
Dose: Berry/oil studies used ~2–3 g/day oil or 28–90 mL/day puree for 4–12 weeks; no standardized dose is established.
Safety: Generally well tolerated as a food; mild GI upset is the main complaint. Because berry/oil intake may modestly lower glucose and blood lipids, it could add to antidiabetic or lipid-lowering drugs, and vitamin-K-containing oil fractions theoretically interact with warfarin and other anticoagulants. Concentrated extracts have not been tested for safety in pregnancy, breastfeeding or with high-dose medications, so favour food amounts and tell your clinician if combining with these drugs.

Cited studies (8):
  - Effects of sea buckthorn (Hippophae rhamnoides L.) on factors related to metabolic syndrome: A systematic review and meta-analysis of randomized controlled trial, Phytotherapy research : PTR (2022) — Meta-analysis of 15 RCTs: lowered triglycerides (SMD -0.72), total cholesterol and LDL, raised HDL; no effect on glucose, BP or BMI. [https://pubmed.ncbi.nlm.nih.gov/36043374/]
  - Effect of sea buckthorn (Hippophae rhamnoides L.) on blood lipid profiles: A systematic review and meta-analysis from 11 independent randomized controlled trials, Trends in Food Science &amp; Technology (2017) — Meta-analysis of 11 RCTs (>900 people): sea buckthorn improved lipid profile only in hyperlipidemic subjects, not in healthy people. [https://doi.org/10.1016/j.tifs.2016.11.007]
  - Effect of Sea Buckthorn on Plasma Glucose in Individuals with Impaired Glucose Regulation: A Two-Stage Randomized Crossover Intervention Study, Foods (Basel, Switzerland) (2021) — Double-blind crossover (n=38, impaired glucose regulation), 90 mL/day puree: only a slight FPG fall (median -0.14 vs +0.07 mmol/L, p=0.045). [https://pubmed.ncbi.nlm.nih.gov/33917994/]
  - Oral sea buckthorn oil attenuates tear film osmolarity and symptoms in individuals with dry eye, The Journal of nutrition (2010) — RCT (n=86 completers), 2 g/day oil x3 mo: rise in tear-film osmolarity was significantly smaller vs placebo in dry-eye subjects (p=0.04). [https://pubmed.ncbi.nlm.nih.gov/20554904/]
  - Effects of oral sea buckthorn oil on tear film Fatty acids in individuals with dry eye, Cornea (2011) — Same RCT cohort: oral oil did NOT change tear-film fatty acids vs placebo, so any dry-eye benefit likely acts via another mechanism. [https://pubmed.ncbi.nlm.nih.gov/21832964/]
  - Effects of sea buckthorn oil intake on vaginal atrophy in postmenopausal women: A randomized, double-blind, placebo-controlled study, Maturitas (2014) — RCT (n=98 completers), 3 g/day oil x3 mo: improved vaginal epithelial integrity in postmenopausal women; only a trend on vaginal health index. [https://doi.org/10.1016/j.maturitas.2014.07.010]
  - Research progress of sea buckthorn (Hippophae rhamnoides L.) in prevention and treatment of cardiovascular disease, Frontiers in Cardiovascular Medicine (2024) — Narrative review: human lipid/BP data are mixed and limited; calls for large multicenter trials, noting effects concentrate in at-risk groups. [https://doi.org/10.3389/fcvm.2024.1477636]
  - The impact of sea buckthorn oil fatty acids on human health, Lipids in Health and Disease (2019) — Review of sea buckthorn oil fatty acids (omega-3/6/7/9): notes most evidence is from isolated fatty acids, not whole-oil RCTs. [https://doi.org/10.1186/s12944-019-1065-9]

---

## Slippery Elm (Ulmus rubra)
URL: https://nutridex.info/s/slippery-elm
Category: Gut & Immune
Evidence: Preliminary — Early or small human trials; promising but not yet conclusive.
Mucilage bark traditionally used to soothe throat and gut irritation.

Quick answer: Slippery Elm is used for soothe sore throat & cough. NutriDex grades the human evidence as preliminary — Early or small human trials; promising but not yet conclusive. Based on 6 cited human studies (6 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Slippery elm is the inner bark of the North American red elm. Soaked in water it forms a slick mucilage gel, the basis for its traditional use soothing sore throats, coughs and gut irritation. Human data are thin and indirect. A small open-label pilot (n=31) found a constipation-IBS formula containing slippery elm raised bowel-movement frequency ~20% and cut straining, pain and bloating, while a diarrhoea-IBS formula eased symptoms but not stool frequency. A 16-week uncontrolled study (n=43) of a multi-herb gut formula that included slippery elm reported less reflux, pain and bloating and reduced gut permeability. In vitro, slippery elm scavenged oxygen radicals from inflamed colon biopsies comparably to mesalamine. None of this isolates slippery elm, uses a placebo control, or measures hard endpoints, so benefits remain plausible but unproven. For sore throat and minor cough the rationale is strongest.

Benefits / uses: Soothe sore throat & cough; Ease IBS symptoms; Coat & calm reflux/heartburn; Support gut lining.
Active compounds: Mucilage (polysaccharide gel); Polyphenol antioxidants; Tannins.
Dose: Commonly 0.4–4 g of inner-bark powder taken as a tea, lozenge or in a multi-herb formula, often 3x/day; no validated standardized dose.
Safety: Generally well tolerated and considered safe; the NIH LiverTox monograph reports no liver-injury signal. Because the mucilage forms a coating gel, it can slow or reduce absorption of oral medicines and other supplements taken at the same time — separate doses by about 2 hours. Allergic reactions are possible, and outer-bark preparations have historically been associated with miscarriage, so it is usually avoided in pregnancy; quality data in pregnancy, breastfeeding and children are lacking. There are no well-documented interactions with anticoagulants, antidiabetics, sedatives or thyroid drugs, but the absorption-delay effect means caution with any narrow-therapeutic-index medication.

Cited studies (6):
  - Herbal Remedies for Constipation-Predominant Irritable Bowel Syndrome: A Systematic Review of Randomized Controlled Trials, Nutrients (2023) — Systematic review of herbal remedies for constipation-IBS excluded the slippery-elm pilot for being small, uncontrolled and open-label; no RCT evidence for the herb alone. [https://doi.org/10.3390/nu15194216]
  - Slippery Elm (2024) — NIH monograph: slippery elm preparations are generally recognized as safe with no evidence of liver-enzyme elevation or clinically apparent liver injury. [https://www.ncbi.nlm.nih.gov/books/NBK599741/]
  - Herbal formula improves upper and lower gastrointestinal symptoms and gut health in Australian adults with digestive disorders, Nutrition research (New York, N.Y.) (2020) — 16-wk uncontrolled trial (n=43) of a multi-herb formula containing slippery elm: reduced reflux, pain, bloating and intestinal permeability; 40% of PPI users cut reflux meds. [https://pubmed.ncbi.nlm.nih.gov/32151878/]
  - Antioxidant effects of herbal therapies used by patients with inflammatory bowel disease: an in vitro study, Alimentary pharmacology & therapeutics (2002) — In vitro: slippery elm scavenged superoxide dose-dependently and reduced oxygen-radical release from inflamed colorectal biopsies, comparably to mesalamine. [https://pubmed.ncbi.nlm.nih.gov/11860402/]
  - Slippery Elm, Memorial Sloan Kettering Cancer Center — Memorial Sloan Kettering: may relieve minor cough or sore throat; no evidence it treats infections, cancer or other serious conditions; human data otherwise lacking. [https://www.mskcc.org/cancer-care/integrative-medicine/herbs/slippery-elm]
  - Effects of Two Natural Medicine Formulations on Irritable Bowel Syndrome Symptoms: A Pilot Study, The Journal of Alternative and Complementary Medicine (2010) — Open-label pilot (n=31): constipation-IBS formula with slippery elm raised bowel frequency ~20% (p=0.016) and cut straining, pain and bloating. [https://doi.org/10.1089/acm.2009.0090]

---

## Strontium
URL: https://nutridex.info/s/strontium
Category: Mineral
Evidence: Moderate — Several controlled trials; effects real but modest or context-dependent.
Bone-seeking mineral with real fracture data — but cardiac safety flags.

Quick answer: Strontium is used for reduce vertebral fracture risk. NutriDex grades the human evidence as moderate — Several controlled trials; effects real but modest or context-dependent. Based on 8 cited human studies (8 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Strontium is a calcium-like mineral that deposits in bone and slows resorption. The prescription salt strontium ranelate is the best-studied form: in the 3-year SOTI trial (n=1,649) it reduced new vertebral fractures by 41%, and in TROPOS it cut non-vertebral fractures by 16% and hip fractures by 36% in high-risk women. Network meta-analysis ranks it first for total-hip bone density. However, DEXA overstates real gains because strontium's heavy atom inflates the reading. Crucially, trials showed more heart attacks (about 1.7% vs 1.1%) plus a venous-clotting and severe-skin-reaction (DRESS) signal, so European regulators restricted it to severe osteoporosis and it has since been largely withdrawn. Over-the-counter strontium citrate, marketed as a 'natural' alternative, has minimal direct fracture evidence and likely carries the same risks.

Benefits / uses: Reduce vertebral fracture risk; Reduce non-vertebral & hip fracture risk; Raise bone mineral density; Slow postmenopausal bone loss.
Active compounds: Strontium ranelate (prescription); Strontium citrate (supplement); Strontium chloride.
Dose: Prescription strontium ranelate was 2 g/day; supplement strontium citrate is sold at ~340–680 mg/day elemental strontium, taken away from food and calcium.
Safety: Strontium ranelate raised heart-attack risk in trials (about 1.7% vs 1.1%) and is contraindicated in ischemic heart disease, peripheral arterial or cerebrovascular disease, uncontrolled hypertension, and any history of venous thromboembolism or immobilisation; it was largely withdrawn after 2014. It can trigger life-threatening skin reactions (DRESS, Stevens-Johnson, TEN) — stop immediately for rash with fever. Strontium binds the same sites as calcium and reduces absorption of tetracycline and quinolone antibiotics, so separate doses by 2+ hours; it also artificially inflates DEXA bone-density readings. Over-the-counter strontium citrate is not a proven-safe substitute and should be avoided in anyone with cardiovascular or clotting risk.

Cited studies (8):
  - Efficacy and Safety of Postmenopausal Osteoporosis Treatments: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials, Journal of clinical medicine (2021) — Network meta-analysis ranked strontium ranelate first for total-hip BMD, but flagged EMA's 2014 CVD restriction as limiting use. [https://pubmed.ncbi.nlm.nih.gov/34300210/]
  - The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis, The New England journal of medicine (2004) — Strontium ranelate 2 g/day cut new vertebral fractures 41% over 3 years in 1,649 postmenopausal women (49% in year 1). [https://pubmed.ncbi.nlm.nih.gov/14749454/]
  - Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study, The Journal of clinical endocrinology and metabolism (2005) — 16% relative reduction in all non-vertebral fractures and 36% reduction in hip fracture in high-risk women (age >=74, low BMD). [https://pubmed.ncbi.nlm.nih.gov/15728210/]
  - Strontium ranelate reduces the risk of vertebral fracture in young postmenopausal women with severe osteoporosis, Annals of the rheumatic diseases (2008) — Cut vertebral fracture risk 35% over 4 years even in younger women (50–65) with severe osteoporosis (RR 0.65). [https://pubmed.ncbi.nlm.nih.gov/18713788/]
  - Effects of long-term strontium ranelate treatment on vertebral fracture risk in postmenopausal women with osteoporosis, Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA (2009) — Antifracture efficacy was sustained over 5 years of strontium ranelate treatment in postmenopausal osteoporosis. [https://pmc.ncbi.nlm.nih.gov/articles/PMC2744775/]
  - Cardiac concerns associated with strontium ranelate, Expert opinion on drug safety (2014) — Safety review: RCT MI signal prompted EMA to restrict strontium ranelate to severe osteoporosis without cardiovascular disease. [https://pmc.ncbi.nlm.nih.gov/articles/PMC4196504/]
  - Strontium ranelate: a novel treatment for postmenopausal osteoporosis: a review of safety and efficacy, Clinical interventions in aging (2006) — Pooled SOTI/TROPOS RCT data showed higher myocardial infarction with strontium ranelate (1.7% vs 1.1%; OR ~1.6). [https://pubmed.ncbi.nlm.nih.gov/18046914/]
  - Incidence of venous thromboembolism in users of strontium ranelate: an analysis of data from a prescription-event monitoring study in England, Drug safety (2010) — Prescription-event monitoring of 10,782 users found VTE rate 6.24/1,000 patient-years, consistent with the trial clotting signal. [https://pubmed.ncbi.nlm.nih.gov/20553059/]

---

## Sulbutiamine
URL: https://nutridex.info/s/sulbutiamine
Category: Nootropic
Evidence: Mixed — Conflicting results across studies; benefit uncertain.
Lipophilic vitamin B1 derivative marketed for fatigue and focus.

Quick answer: Sulbutiamine is used for marketed for asthenia (fatigue). NutriDex grades the human evidence as mixed — Conflicting results across studies; benefit uncertain. Based on 8 cited human studies (8 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Sulbutiamine is a synthetic, fat-soluble derivative of vitamin B1 (two thiamine molecules linked by a disulfide bond) that crosses the blood-brain barrier more readily than thiamine. It is sold in some countries as an anti-asthenic (anti-fatigue) drug and online as a nootropic. The evidence is genuinely mixed. The largest controlled trial, in 326 people with post-infectious fatigue, found a transient day-7 improvement in women on 600 mg but no significant benefit by day 28. Small studies suggest it may help memory as an add-on to donepezil in early Alzheimer's, ease the behavioural slowing of depression alongside an antidepressant, and reduce fatigue in multiple sclerosis (open-label, n=26). Most trials are small, short, uncontrolled, or industry-linked, and reviewers stress that better randomized trials are needed. It is not a proven stand-alone treatment for healthy people seeking energy or focus.

Benefits / uses: Marketed for asthenia (fatigue); Claimed energy & alertness; Adjuvant in depression-related slowing; Possible memory adjuvant (unproven).
Active compounds: Sulbutiamine (di-thiamine ester); Thiamine (vitamin B1) precursor.
Dose: Typically 400-600 mg/day orally (often as 200 mg tablets), usually limited to a few weeks; no long-term dose is established.
Safety: Generally well tolerated short-term; reported effects include nausea, headache, insomnia, mild agitation, tremor and skin rash, and in people with bipolar disorder it has worsened mood symptoms. A case report describes escalating, compulsive use, so it is not recommended for people with bipolar disorder, psychosis, or a history of substance misuse. Long-term safety is unstudied, and it has not been tested in pregnancy or breastfeeding. Because it is a thiamine derivative active in the brain, use caution combining it with other stimulants, antidepressants, or psychiatric medications, and tell your clinician if you take it.

Cited studies (8):
  - Sulbutiamine shows promising results in reducing fatigue in patients with multiple sclerosis, Multiple sclerosis and related disorders (2017) — Open-label, 26 MS patients on 400 mg/day for 2 months: mean Fatigue Impact Scale fell from 77 to 60.5 (p<0.01), no control group. [https://pubmed.ncbi.nlm.nih.gov/28755683/]
  - [Treatment of chronic postinfectious fatigue: randomized double-blind study of two doses of sulbutiamine (400-600 mg/day) versus placebo], La Revue de medecine interne (1999) — RCT in 326 post-infectious fatigue patients: 600 mg gave a day-7 benefit in women but no significant effect on fatigue by day 28. [https://pubmed.ncbi.nlm.nih.gov/10573727/]
  - [Effects of sulbutiamine (Arcalion 200) on psycho-behavioral inhibition in major depressive episodes], L'Encephale (2000) — 8-week RCT vs placebo + clomipramine: sulbutiamine 600 mg/day reduced psycho-behavioural inhibition in major depression but had no antidepressant effect itself. [https://pubmed.ncbi.nlm.nih.gov/10858919/]
  - [Effects of the association of sulbutiamine with an acetylcholinesterase inhibitor in early stage and moderate Alzheimer disease], L'Encephale (2007) — Randomized double-blind trial: adding sulbutiamine to an anticholinesterase improved episodic memory and daily activities in early/moderate Alzheimer's. [https://pubmed.ncbi.nlm.nih.gov/17675917/]
  - Sulbutiamine, an 'innocent' over the counter drug, interferes with therapeutic outcome of bipolar disorder, The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry (2006) — Case report: a patient with bipolar disorder escalated sulbutiamine use, missed psychiatric care, and worsened outcomes — flagging misuse potential. [https://pubmed.ncbi.nlm.nih.gov/16861144/]
  - Chronic treatment with sulbutiamine improves memory in an object recognition task and reduces some amnesic effects of dizocilpine in a spatial delayed-non-match-to-sample task, Progress in neuro-psychopharmacology & biological psychiatry (2005) — Animal study: chronic sulbutiamine improved object-recognition memory and reduced dizocilpine-induced amnesia in rats (mechanistic, not human). [https://pubmed.ncbi.nlm.nih.gov/15951087/]
  - Evidence for a modulatory effect of sulbutiamine on glutamatergic and dopaminergic cortical transmissions in the rat brain, Neuroscience letters (2000) — Rat study: sulbutiamine modulated cortical glutamatergic and dopaminergic transmission, a proposed basis for its claimed nootropic action. [https://pubmed.ncbi.nlm.nih.gov/10996447/]
  - Adjuvant role of vitamin B analogue (sulbutiamine) with anti-infective treatment in infection associated asthenia, The Journal of the Association of Physicians of India (2003) — Prospective observational study, 1772 patients: sulbutiamine added to anti-infective treatment fully resolved asthenic symptoms in 51.7%; side effects 0.6%. [https://pubmed.ncbi.nlm.nih.gov/14710977/]

---

## Montmorency Cherry Extract (Prunus cerasus)
URL: https://nutridex.info/s/tart-cherry-extract
Category: Performance, Sleep & Mood
Evidence: Moderate — Several controlled trials; effects real but modest or context-dependent.
Anthocyanin-rich cherry for faster exercise recovery and better sleep.

Quick answer: Montmorency Cherry Extract is used for faster muscle-strength recovery. NutriDex grades the human evidence as moderate — Several controlled trials; effects real but modest or context-dependent. Based on 8 cited human studies (8 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Montmorency tart cherry is a sour cherry concentrated into juice, powder or extract, rich in anthocyanins and a small amount of melatonin. Its best-supported use is exercise recovery: a 2021 meta-analysis of 14 trials found a moderate benefit for recovering muscle strength (effect size ~-0.78) and a small reduction in soreness, with marathon and resistance studies showing blunted inflammation (lower IL-6, CRP). For sleep, small randomized crossover trials report increases in time in bed, total sleep time and sleep efficiency, and a systematic review found 5 of 6 studies improved sleep quality, though effects are modest. Evidence for blood pressure is null in pooled analyses, and it does not reliably lower serum urate in gout. Most trials are small, short, and use athletic or healthy volunteers, so benefits are real but modest rather than transformative.

Benefits / uses: Faster muscle-strength recovery; Less post-exercise soreness; Modestly improved sleep; Lower exercise-induced inflammation.
Active compounds: Anthocyanins (cyanidin glycosides); Flavonols & procyanidins; Melatonin.
Dose: Equivalent of ~90–120 sour cherries/day: 30 mL concentrate twice daily, or ~480 mL juice, or 480 mg freeze-dried powder, taken for several days before and after a hard effort.
Safety: Generally well tolerated; large juice or concentrate doses can cause GI upset and add meaningful sugar/calories (concentrates are also high in potassium and sorbitol). Because it modestly raises melatonin, it may add to drowsiness from sedatives, benzodiazepines or other sleep aids. The anthocyanins have mild antiplatelet activity, so use caution alongside anticoagulants such as warfarin. It does not reliably lower uric acid, so it should not replace urate-lowering therapy in gout.

Cited studies (8):
  - The Effect of Tart Cherry on Sleep Quality and Sleep Disorders: A Systematic Review, Food science & nutrition (2025) — Systematic review: 5 of 6 clinical studies reported significant improvement in sleep quality with tart cherry, though studies were small/short. [https://pubmed.ncbi.nlm.nih.gov/40964149/]
  - Dose-dependent effect of tart cherry on blood pressure and selected inflammation biomarkers: A GRADE-assessed systematic review and meta-analysis of randomized controlled trials, Heliyon (2023) — Meta-analysis of 21 RCTs: tart cherry did NOT change blood pressure or heart rate; reduced CRP dose-dependently (~0.19 mg/L per 30 mL). [https://pubmed.ncbi.nlm.nih.gov/37809623/]
  - Tart Cherry Supplementation and Recovery From Strenuous Exercise: A Systematic Review and Meta-Analysis, International journal of sport nutrition and exercise metabolism (2021) — Meta-analysis of 14 trials: moderate benefit for muscle-strength recovery (ES -0.78) and small reduction in soreness (ES -0.44). [https://pubmed.ncbi.nlm.nih.gov/33440334/]
  - Efficacy and safety of tart cherry supplementary citrate mixture on gout patients: a prospective, randomized, controlled study, Arthritis research & therapy (2023) — Gout RCT: tart-cherry citrate mixture produced fewer gout flares and lower CRP at 12 weeks than sodium bicarbonate. [https://pubmed.ncbi.nlm.nih.gov/37679816/]
  - Lack of effect of tart cherry concentrate dose on serum urate in people with gout, Rheumatology (Oxford, England) (2020) — Dose-finding RCT in gout: cherry concentrate had no significant effect on serum urate at any dose. [https://pubmed.ncbi.nlm.nih.gov/31891407/]
  - Montmorency tart cherry (Prunus cerasus L.) supplementation accelerates recovery from exercise-induced muscle damage in females, European journal of sport science (2019) — Females (n=10): Montmorency cherry accelerated recovery of isometric strength and reduced muscle soreness after damaging exercise. [https://pubmed.ncbi.nlm.nih.gov/30058460/]
  - Influence of tart cherry juice on indices of recovery following marathon running, Scandinavian journal of medicine & science in sports (2010) — Marathon runners (n=20): cherry juice sped strength recovery and lowered inflammation (IL-6, CRP) and oxidative stress vs placebo. [https://pubmed.ncbi.nlm.nih.gov/19883392/]
  - Effect of tart cherry juice (Prunus cerasus) on melatonin levels and enhanced sleep quality, European journal of nutrition (2012) — Healthy adults (n=20): cherry concentrate raised urinary melatonin and increased time in bed, total sleep time and sleep efficiency. [https://pubmed.ncbi.nlm.nih.gov/22038497/]

---

## UC-II (Undenatured Collagen) (Undenatured type II collagen)
URL: https://nutridex.info/s/uc2-collagen
Category: Joint & Skin
Evidence: Moderate — Several controlled trials; effects real but modest or context-dependent.
Low-dose chicken-cartilage collagen for knee osteoarthritis pain.

Quick answer: UC-II (Undenatured Collagen) is used for ease knee osteoarthritis pain. NutriDex grades the human evidence as moderate — Several controlled trials; effects real but modest or context-dependent. Based on 7 cited human studies (7 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

UC-II is undenatured type II collagen sourced from chicken sternal cartilage, given at a tiny 40 mg dose. Unlike hydrolysed collagen, it is kept intact so its 3-D epitopes survive digestion and are thought to retrain joint-targeting immune cells (oral tolerance), dampening inflammation. In a 180-day, three-arm RCT (n=191) UC-II cut total WOMAC scores significantly more than placebo (p=0.002) and even outperformed glucosamine+chondroitin (p=0.04). A 90-day trial reported roughly a 33% WOMAC and 40% VAS-pain drop, and a study in healthy exercisers showed better knee extension and longer pain-free exertion. A 2023-2025 meta-analyses confirm meaningful WOMAC and VAS improvements, though function-index results were mixed. Limits matter: trials are small, run only 3-6 months, and most are industry-sponsored, so the effect is probably real but modest and not yet proven durable or head-to-head with drugs.

Benefits / uses: Ease knee osteoarthritis pain; Improve joint function & stiffness; Better knee range of motion; Exercise-related joint comfort.
Active compounds: Undenatured (native) type II collagen; Triple-helix collagen epitopes.
Dose: 40 mg/day of UC-II (about 10 mg bioactive undenatured type II collagen), taken once daily, ideally on an empty stomach.
Safety: UC-II is well tolerated; trials report side effects no more often than placebo, with occasional mild GI upset or headache. It is derived from chicken cartilage, so avoid it if you have a chicken or egg allergy, and safety in pregnancy, breastfeeding and children is untested. No well-documented drug interactions exist, but because it acts on the immune system its effects are theoretically uncertain in people on immunosuppressants or with autoimmune disease; it is a supplement, not a substitute for prescribed osteoarthritis care.

Cited studies (7):
  - Efficacy and safety of undenatured collagen type II in modulating knee joint function in healthy and osteoarthritis subjects: a systematic review and meta-analysis, Critical Public Health (2025) — Systematic review/meta-analysis (17 studies): UC-II significantly lowered WOMAC pain (-9.24, p=0.004) and VAS in knee OA. [https://doi.org/10.1080/09581596.2025.2588891]
  - Efficacy of undenatured collagen in knee osteoarthritis: review of the literature with limited meta-analysis, American journal of translational research (2023) — Pooled RCTs: UC-II improved WOMAC (MD -8.91) and VAS pain (MD -1.65) vs placebo, but no benefit on Lequesne index. [https://pubmed.ncbi.nlm.nih.gov/37854210/]
  - Undenatured type II collagen for knee osteoarthritis, Annals of Medicine (2025) — Systematic review (12 studies): 40 mg/day UC-II safe and effective short/mid-term; calls for larger, longer, independent trials. [https://doi.org/10.1080/07853890.2025.2493306]
  - Efficacy and tolerability of an undenatured type II collagen supplement in modulating knee osteoarthritis symptoms: a multicenter randomized, double-blind, placebo-controlled study, Nutrition journal (2016) — 180-day RCT (n=191): 40 mg UC-II cut total WOMAC vs placebo (p=0.002) and beat glucosamine/chondroitin (p=0.04). [https://pubmed.ncbi.nlm.nih.gov/26822714/]
  - Effects of Native Type II Collagen Treatment on Knee Osteoarthritis: A Randomized Controlled Trial, The Eurasian journal of medicine (2016) — 3-month RCT (n=39): native type II collagen plus acetaminophen improved symptoms more than acetaminophen alone in knee OA. [https://pubmed.ncbi.nlm.nih.gov/27551171/]
  - Undenatured type II collagen (UC-II®) for joint support: a randomized, double-blind, placebo-controlled study in healthy volunteers, Journal of the International Society of Sports Nutrition (2013) — 120-day RCT (n=55) in healthy exercisers: UC-II improved average knee extension (81.0 vs 74.0 deg, p=0.011) and pain-free exercise time. [https://pubmed.ncbi.nlm.nih.gov/24153020/]
  - Safety and efficacy of undenatured type II collagen in the treatment of osteoarthritis of the knee: a clinical trial, International journal of medical sciences (2009) — 90-day RCT (n=52): UC-II reduced WOMAC ~33%, VAS ~40% and Lequesne ~20% vs smaller changes with glucosamine+chondroitin. [https://pubmed.ncbi.nlm.nih.gov/19847319/]

---

## Vanadium
URL: https://nutridex.info/s/vanadium
Category: Mineral
Evidence: Mixed — Conflicting results across studies; benefit uncertain.
Trace metal marketed for blood sugar - weak evidence, real toxicity.

Quick answer: Vanadium is used for marketed to lower blood sugar. NutriDex grades the human evidence as mixed — Conflicting results across studies; benefit uncertain. Based on 7 cited human studies (7 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Vanadium is a trace element that mimics insulin in test tubes and animals, which fuelled its marketing as a natural diabetes and bodybuilding aid. Small human studies in the 1990s (typically 6-16 patients, 3-6 weeks) reported that 100-300 mg/day of vanadyl sulfate modestly lowered fasting glucose and HbA1c and improved hepatic and muscle insulin sensitivity. But these were uncontrolled or unblinded, and a 2008 systematic review concluded that no rigorous trial met basic quality standards, so routine use cannot be recommended. Crucially, the doses studied are roughly 50-150 times the tolerable upper intake level for vanadium, and gastrointestinal side effects (cramps, nausea, diarrhea) were common. There is no evidence vanadium benefits people without diabetes, and the dietary requirement, if any, is met by food. The risk-benefit balance does not favour supplementation.

Benefits / uses: Marketed to lower blood sugar; Claimed insulin sensitizer; Promoted for type 2 diabetes; Sold as a bodybuilding aid.
Active compounds: Vanadyl sulfate; Sodium metavanadate; Bis(maltolato)oxovanadium(IV).
Dose: No established supplemental dose; diabetes trials used 100-300 mg/day vanadyl sulfate, which far exceeds the safe upper limit (~1.8 mg/day elemental vanadium) - not recommended.
Safety: Supplemental doses used in diabetes trials (100-300 mg/day vanadyl sulfate) are roughly 50-150x the tolerable upper intake (1.8 mg/day) and commonly cause abdominal cramps, nausea, diarrhea, and a green tongue. Vanadium has insulin-like activity, so combining it with antidiabetic drugs (sulfonylureas, insulin, metformin) risks additive hypoglycemia. Higher valence forms are more toxic and animal data show kidney, liver and reproductive harm; it should be avoided in pregnancy, breastfeeding, and kidney disease. Not recommended for general use.

Cited studies (7):
  - A systematic review of vanadium oral supplements for glycaemic control in type 2 diabetes mellitus, QJM : monthly journal of the Association of Physicians (2008) — Systematic review: 151 studies screened, none met quality criteria; 5 weak trials hinted at glucose lowering but routine use not recommended. [https://pubmed.ncbi.nlm.nih.gov/18319296/]
  - Systematic review of herbs and dietary supplements for glycemic control in diabetes, Diabetes care (2003) — Systematic review of supplements for glycemic control: vanadium evidence judged insufficient and of poor methodological quality. [https://pubmed.ncbi.nlm.nih.gov/12663610/]
  - Oral vanadyl sulfate improves hepatic and peripheral insulin sensitivity in patients with non-insulin-dependent diabetes mellitus, The Journal of clinical investigation (1995) — Vanadyl sulfate 100 mg/day x3 wk raised glucose infusion rate ~88% in 6 NIDDM patients; effect persisted 2 wk after stopping. [https://pubmed.ncbi.nlm.nih.gov/7769096/]
  - Oral vanadyl sulfate improves insulin sensitivity in NIDDM but not in obese nondiabetic subjects, Diabetes (1996) — Vanadyl sulfate improved insulin sensitivity in NIDDM subjects but had no effect in obese nondiabetic subjects. [https://pubmed.ncbi.nlm.nih.gov/8621019/]
  - Metabolic effects of vanadyl sulfate in humans with non-insulin-dependent diabetes mellitus: in vivo and in vitro studies, Metabolism: clinical and experimental (2000) — Dose-finding in 16 T2D patients: fasting glucose and HbA1c fell at 150-300 mg/day but not 75 mg/day; clamp response inconsistent. [https://pubmed.ncbi.nlm.nih.gov/10726921/]
  - In vivo and in vitro studies of vanadate in human and rodent diabetes mellitus, Molecular and cellular biochemistry (1995) — Sodium metavanadate for 2 wk improved insulin sensitivity in NIDDM patients via increased non-oxidative glucose disposal. [https://pubmed.ncbi.nlm.nih.gov/8927042/]
  - Arsenic, Boron, Nickel, Silicon, and Vanadium (2001) — No dietary requirement established; tolerable upper intake set at 1.8 mg/day elemental vanadium based on rodent kidney toxicity. [https://www.ncbi.nlm.nih.gov/books/NBK222322/]

---

## Vinpocetine
URL: https://nutridex.info/s/vinpocetine
Category: Nootropic
Evidence: Mixed — Conflicting results across studies; benefit uncertain.
Periwinkle-derived brain blood-flow agent; weak evidence, real pregnancy risk.

Quick answer: Vinpocetine is used for marketed for memory & focus. NutriDex grades the human evidence as mixed — Conflicting results across studies; benefit uncertain. Based on 7 cited human studies (7 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Vinpocetine is a synthetic molecule derived from vincamine, an alkaloid of lesser periwinkle (Vinca minor). It is a PDE1 inhibitor that widens cerebral vessels and is sold as a memory and focus nootropic. The strongest review, a 2003 Cochrane analysis of three dementia RCTs, judged the cognitive evidence inconclusive and insufficient to support clinical use. A 2022 meta-analysis of four small placebo-controlled trials of intravenous vinpocetine in acute ischemic stroke found modestly less disability at 1 month (SMD 0.49) and a small MMSE gain (WMD 0.92), but no mortality benefit and few, low-quality trials. Most positive data come from short, small studies of the prescription/IV form used abroad, not the oral supplement. In the US the FDA has stated vinpocetine is not a lawful dietary ingredient and warns it can cause miscarriage or fetal harm. Overall benefit for everyday cognition is unproven.

Benefits / uses: Marketed for memory & focus; Cerebral blood flow; Stroke recovery (clinical, IV); Cognitive support in vascular disease.
Active compounds: Vinpocetine (ethyl apovincaminate).
Dose: Oral studies used 5–10 mg three times daily (15–30 mg/day) of the synthetic compound; IV stroke trials used higher hospital-administered doses.
Safety: The US FDA has concluded vinpocetine is not a lawful dietary ingredient and warns that it may cause miscarriage or harm fetal development (based on NTP animal data showing reduced fetal weight at human-relevant blood levels) — pregnant women and those who could become pregnant should avoid it entirely. Because it widens vessels and may inhibit platelet aggregation, it can theoretically add to the effect of anticoagulants and antiplatelets (warfarin, aspirin, clopidogrel) and lower blood pressure. Reported side effects include headache, flushing, nausea, sleep disturbance and dizziness; it is not approved as a drug in the US and product quality is unregulated.

Cited studies (7):
  - Safety and Efficacy of Vinpocetine as a Neuroprotective Agent in Acute Ischemic Stroke: A Systematic Review and Meta-Analysis, Neurocritical care (2022) — Meta-analysis of 4 RCTs (837 pts): IV vinpocetine reduced disability at 1 mo (SMD 0.49) and 3 mo, MMSE +0.92; no mortality benefit (RR 0.94). [https://pubmed.ncbi.nlm.nih.gov/35488169/]
  - Vinpocetine in the treatment of poststroke cognitive dysfunction: A protocol for systematic review and meta-analysis, Medicine (2019) — PROSPERO-registered protocol (CRD42018115224) to meta-analyse vinpocetine for post-stroke cognitive dysfunction; reflects unsettled evidence base. [https://pubmed.ncbi.nlm.nih.gov/30732122/]
  - Vinpocetine for cognitive impairment and dementia, The Cochrane database of systematic reviews (2003) — Review of 3 RCTs: evidence for benefit in cognitive impairment/dementia is inconclusive and does not support clinical use; few adverse effects. [https://pubmed.ncbi.nlm.nih.gov/12535455/]
  - A systematic review of vinpocetine therapy in acute ischaemic stroke, European journal of clinical pharmacology (1999) — Earlier systematic review of stroke trials: wide confidence intervals; no evidence to support routine use in acute ischemic stroke. [https://pubmed.ncbi.nlm.nih.gov/10456483/]
  - Vinpocetine treatment in acute ischaemic stroke: a pilot single-blind randomized clinical trial, European journal of neurology (2001) — Pilot trial in acute ischaemic stroke; small single-blind study, inconclusive on functional outcomes. [https://pubmed.ncbi.nlm.nih.gov/11509086/]
  - The safety and lack of efficacy of vinpocetine in Alzheimer's disease, Journal of the American Geriatrics Society (1989) — RCT in Alzheimer's disease: vinpocetine was safe but showed no efficacy on cognitive measures. [https://pubmed.ncbi.nlm.nih.gov/2715559/]
  - Role of vinpocetine in ischemic stroke and poststroke outcomes: A critical review, Brain circulation (2020) — Critical review: signals for stroke recovery, post-stroke cognition and seizure reduction, but underpinned by small/heterogeneous trials. [https://pubmed.ncbi.nlm.nih.gov/32166194/]

---

## Zinc Carnosine (Polaprezinc)
URL: https://nutridex.info/s/zinc-carnosine
Category: Gut & Immune
Evidence: Moderate — Several controlled trials; effects real but modest or context-dependent.
Mucosa-protecting zinc complex for ulcers and gut-lining repair.

Quick answer: Zinc Carnosine is used for heal gastric ulcers. NutriDex grades the human evidence as moderate — Several controlled trials; effects real but modest or context-dependent. Based on 7 cited human studies (7 verified). Educational summary, not medical advice — talk to your doctor or pharmacist.

Zinc carnosine (polaprezinc) is a chelate of zinc and L-carnosine that adheres to damaged mucosa, where it acts as an antioxidant and stimulates repair. It is an approved gastric-ulcer drug in Japan and South Korea. In a multicentre RCT, 8 weeks of 150 mg/day matched rebamipide for ulcer healing (~81% effective). A meta-analysis of RCTs found adding it to standard triple therapy roughly doubled H. pylori eradication odds (OR ~2.0 intention-to-treat) without extra side effects. Randomised trials in cancer patients show it markedly cuts severe oral mucositis from radio/chemotherapy, and a small crossover study found it blunted NSAID-induced rises in gut permeability. A pooled analysis also confirms it raises serum zinc and corrects deficiency. Limits: most trials are small, short, single-region, and often test it as an add-on, so the size of any stand-alone benefit for general 'gut health' is uncertain.

Benefits / uses: Heal gastric ulcers; Protect the gut lining; Boost H. pylori eradication; Ease oral mucositis; Correct zinc deficiency.
Active compounds: Zinc (≈23%); L-carnosine (≈77%).
Dose: 75 mg twice daily (150 mg/day, the licensed dose in Japan/Korea); gut-health supplements typically use 37.5 mg twice daily.
Safety: Generally well tolerated; the most common effects are mild GI upset (nausea, constipation), and dysgeusia or copper depletion can occur with prolonged high-dose zinc, so courses beyond a few weeks should be monitored. Like other zinc products it can reduce absorption of certain antibiotics (tetracyclines, fluoroquinolones), penicillamine and thyroid (levothyroxine) medication — separate doses by 2–4 hours. Rare hepatic and, in case reports, copper-deficiency anaemia/neuropathy have been described; avoid in Wilson's disease and use cautiously in pregnancy given limited data.

Cited studies (7):
  - Efficacy and Safety of Polaprezinc-Based Therapy versus the Standard Triple Therapy for Helicobacter pylori Eradication: A Systematic Review and Meta-Analysis of Randomized Controlled Trials, Nutrients (2022) — Meta-analysis of RCTs: adding polaprezinc to triple therapy roughly doubled H. pylori eradication (ITT OR 2.01; PP OR 2.65), no extra adverse events. [https://pubmed.ncbi.nlm.nih.gov/36235778/]
  - Efficacy and Safety of Polaprezinc (Zinc Compound) on Zinc Deficiency: A Systematic Review and Dose-Response Meta-Analysis of Randomized Clinical Trials Using Individual Patient Data, Nutrients (2020) — IPD dose-response meta-analysis of RCTs: polaprezinc raised serum zinc by a mean 9.08 µg/dL vs placebo with a significant dose-response. [https://pubmed.ncbi.nlm.nih.gov/32316581/]
  - Efficacy and safety of polaprezinc in the treatment of gastric ulcer: A multicenter, randomized, double-blind, double-dummy, positive-controlled clinical trial, Medical engineering & physics (2022) — Multicentre double-blind RCT (n=224): 150 mg/day for 8 weeks gave 81.5% gastric-ulcer healing, non-inferior to rebamipide (74.3%). [https://pubmed.ncbi.nlm.nih.gov/35999163/]
  - Polaprezinc combined with clarithromycin-based triple therapy for Helicobacter pylori-associated gastritis: A prospective, multicenter, randomized clinical trial, PLOS ONE (2017) — Multicentre RCT: polaprezinc + clarithromycin triple therapy raised H. pylori eradication to 77.0% vs 58.6% (ITT) without more side effects. [https://doi.org/10.1371/journal.pone.0175625]
  - Polaprezinc prevents oral mucositis in patients treated with high-dose chemotherapy followed by hematopoietic stem cell transplantation, Anticancer research (2014) — RCT in HSCT patients: polaprezinc suspension cut grade ≥2 oral mucositis to 20% vs 82% and grade ≥3 to 0% vs 45% (both p<0.01). [https://pubmed.ncbi.nlm.nih.gov/25503160/]
  - Zinc carnosine, a health food supplement that stabilises small bowel integrity and stimulates gut repair processes, Gut (2007) — Crossover trial in healthy adults: zinc carnosine prevented the ~3-fold rise in small-bowel permeability caused by 5 days of indomethacin. [https://pubmed.ncbi.nlm.nih.gov/16777920/]
  - A Review of Zinc-L-Carnosine and Its Positive Effects on Oral Mucositis, Taste Disorders, and Gastrointestinal Disorders, Nutrients (2020) — Narrative review summarising zinc-L-carnosine evidence for gastric/GI mucosal healing, oral mucositis and taste disorders. [https://pubmed.ncbi.nlm.nih.gov/32121367/]